PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E				Magrassi, L; Conti, L; Lanterna, A; Zuccato, C; Marchionni, M; Cassini, P; Arienta, C; Cattaneo, E			Shc3 affects human high-grade astrocytomas survival	ONCOGENE			English	Article						Shc; brain tumors; signal transduction; neuro-oncology; growth control; gliomas	GROWTH-FACTOR RECEPTOR; ANAPLASTIC LYMPHOMA KINASE; CELL-LINE; NEUROTROPHIC FACTOR; GLIOBLASTOMA CELLS; ADAPTER PROTEINS; HUMAN BRAIN; GENE; ACTIVATION; PATHWAY	A selective switch from expression of Shc1 gene to Shc3 occurs with maturation of neuronal precursors into postmitotic neurons. Previous studies showed that in the embryo, Shc1 is maximally expressed in dividing CNS stem cells while it is silenced in mature neurons, where it is replaced by Shc3. Under normal conditions Shc3 is never expressed by glial cells. We now show that in human astrocytomas and glioblastomas, the normal pattern of expression of Shc1/Shc3 is totally subverted, both proteins being present at the same time and in the same cells. Our data indicate that Shc3 is maximally expressed, together with Shc1, in glioblastoma, a highly proliferative tumor with little, if any, indication of neuronal differentiation. In primary cultures of glioblastoma, tumor cells maintain Shc1 expression but downregulate Shc3. Analysis of the phosphorylation status of Shc3 in human glioblastoma tumor samples in vivo indicates that it is tyrosine phosphorylated. Finally, we found that the expression of truncated variants of Shc3 with dominant-negative effects in human high-grade glioma cells that maintain Shc3 expression in vitro leads to a decreased Akt posphorylation and increased apoptosis, thus resulting in impaired survival of the transfected cells. These data suggest that Shc molecules play an important role in glioblastoma cell growth and survival.	Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy; CNR, IGM, I-27100 Pavia, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy; Osped Riuniti Bergamo, Dept Neurosurg, I-24100 Bergamo, Italy; Univ Milano Bicocca, Dept Neurosci & Biomed Technol, Monza, Italy	IRCCS Fondazione San Matteo; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Ospedali Riuniti di Bergamo; University of Milano-Bicocca	Magrassi, L (corresponding author), Univ Pavia, Dipartimento Chirurg, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy.	magrassi@igm.cnr.it	Conti, Luciano/H-4184-2012; Magrassi, Lorenzo/AAJ-3105-2020	Conti, Luciano/0000-0002-2050-9846; lanterna, luigi andrea/0000-0001-9484-4834; CATTANEO, ELENA/0000-0002-0755-4917; Magrassi, Lorenzo/0000-0002-8308-2720; ZUCCATO, CHIARA/0000-0003-1771-3392				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Cattaneo E, 1998, ANTICANCER RES, V18, P2381; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Hecker TP, 2004, ONCOGENE, V23, P3962, DOI 10.1038/sj.onc.1207541; Hecker TP, 2002, CANCER RES, V62, P2699; Lemkine GF, 1999, J DRUG TARGET, V7, P305, DOI 10.3109/10611869909085513; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NIKKHAH G, 1992, J NEURO-ONCOL, V13, P1, DOI 10.1007/BF00172941; Nishiguchi M, 2003, NEUROCHEM INT, V42, P493, DOI 10.1016/S0197-0186(02)00139-0; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pore N, 2003, CANCER RES, V63, P236; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rubenstein M, 2001, MED ONCOL, V18, P121, DOI 10.1385/MO:18:2:121; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Su JD, 2003, CANCER RES, V63, P3585; Trinei M, 2000, CANCER RES, V60, P793; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Wiesenhofer B, 2000, ACTA NEUROPATHOL, V99, P131, DOI 10.1007/PL00007416	29	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5198	5206		10.1038/sj.onc.1208708	http://dx.doi.org/10.1038/sj.onc.1208708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870690				2022-12-25	WOS:000230964600006
J	Rogers, SC; Khalatbari, A; Gapper, PW; Frenneaux, MP; James, PE				Rogers, SC; Khalatbari, A; Gapper, PW; Frenneaux, MP; James, PE			Detection of human red blood cell-bound nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSOTHIOL FORMATION; HEMOGLOBIN; NO; NITROSOHEMOGLOBIN; DEOXYHEMOGLOBIN; NITROSOALBUMIN; FLOW; OXYHEMOGLOBIN; CHEMISTRY; TRANSPORT	Major disparities in reported levels of basal human nitric oxide metabolites have resulted in a recent literature focusing almost exclusively on methods. We chose to analyze triiodide chemiluminescence, drawn by the prospect of identifying why the most commonly employed assay in nitric oxide biology typically yielded lower metabolite values, compared with several other techniques. We found that the sensitivity of triiodide was greatly affected by the auto-capture of nitric oxide by deoxygenated cell-free heme in the reaction chamber. Potential contaminants and signal losses were also associated with standard sample purification procedures and the chemistry involved in nitrite removal. To inhibit heme nitric oxide auto-capture, we added potassium ferricyanide to the triiodide reagent, reasoning this would provide a more complete detection of any liberated nitric oxide. From human venous blood samples, we established nitric oxide levels ranging from 0.000178 to 0.00024 mol nitric oxide/mol hemoglobin. We went on to find significantly elevated nitric oxide levels in venous blood taken from diabetic patients in comparison to healthy controls (p<0.0001). We concluded that the lack of signals reported of late by several groups using triiodide chemiluminescence for the detection of hemoglobin-bound nitric oxide may not represent levels on the border of assay sensitivity but rather underestimated values because of methodological limitations. We therefore stress the need for assay systems to be developed that differentiate between individual nitric oxide metabolite species and overcome the limitations we outline, allowing accurate conclusions to be drawn regarding physiological nitric oxide metabolite levels.	Cardiff Univ, Sch Med, Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, Wales; Univ Birmingham, Sch Med, Dept Cardiovasc Med, Birmingham B15 2TT, W Midlands, England	Cardiff University; University of Birmingham	James, PE (corresponding author), Cardiff Univ, Sch Med, Wales Heart Res Inst, Dept Cardiol, Heath Pk, Cardiff CF14 4XN, Wales.	Jamespp@Cardiff.ac.uk		Rogers, Stephen/0000-0003-1139-4730				Bryan NS, 2004, NITRIC OXIDE-BIOL CH, V10, P221, DOI 10.1016/j.niox.2004.04.008; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; COSBY K, 2003, NAT MED; Datta B, 2004, CIRCULATION, V109, P1339, DOI 10.1161/01.CIR.0000124450.07016.1D; Dejam A, 2003, FREE RADICAL BIO MED, V35, P1551, DOI 10.1016/j.freeradbiomed.2003.09.009; Dicks AP, 1996, J CHEM SOC PERK T 2, P481, DOI 10.1039/p29960000481; Doctor A, 2005, P NATL ACAD SCI USA, V102, P5709, DOI 10.1073/pnas.0407490102; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Foster MW, 2005, HYPERTENSION, V45, P15, DOI 10.1161/01.HYP.0000150160.41992.71; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Giustarini D, 2004, TRENDS PHARMACOL SCI, V25, P311, DOI 10.1016/j.tips.2004.04.009; Giustarini D, 2003, CLIN CHIM ACTA, V330, P85, DOI 10.1016/S0009-8981(03)00046-9; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Gladwin MT, 2004, CIRC RES, V94, P851, DOI 10.1161/01.RES.0000126697.64381.37; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Herold S, 2003, J BIOL CHEM, V278, P6623, DOI 10.1074/jbc.M210275200; James PE, 2004, CIRC RES, V94, P976, DOI 10.1161/01.RES.0000122044.21787.01; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; Luchsinger BP, 2005, J INORG BIOCHEM, V99, P912, DOI 10.1016/j.jinorgbio.2004.12.010; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; Milsom AB, 2002, DIABETOLOGIA, V45, P1515, DOI 10.1007/s00125-002-0956-9; Moore KP, 2002, METHOD ENZYMOL, V359, P256; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Rassaf T, 2004, FREE RADICAL BIO MED, V36, P413, DOI 10.1016/j.freeradbiomed.2003.11.011; Rassaf T, 2003, NAT MED, V9, P481, DOI 10.1038/nm0503-481; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; Robinson JM, 2005, AM J RESP CELL MOL, V32, P257, DOI 10.1165/rcmb.F292; Rossi R, 2001, CIRC RES, V89; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Tsikas D, 1999, J CHROMATOGR B, V726, P13, DOI 10.1016/S0378-4347(99)00058-4; Tsikas D, 2003, NITRIC OXIDE-BIOL CH, V9, P53, DOI 10.1016/S1089-8603(03)00044-2; Tsikas D, 2002, CIRC RES, V90, pE39; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112	48	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26720	26728		10.1074/jbc.M501179200	http://dx.doi.org/10.1074/jbc.M501179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15879596	hybrid			2022-12-25	WOS:000230589500012
J	Kim, S; Ahn, T; Park, C				Kim, S; Ahn, T; Park, C			The Pro(335)-> Leu polymorphism of type 3 inositol 1,4,5-trisphosphate receptor found in mouse inbred lines results in functional change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRISPHOSPHATE RECEPTOR; LIGAND-BINDING; CALCIUM SENSOR; CA2+; ISOFORMS; IP3; CALMODULIN; EXPRESSION; INSP(3); CELLS	Inositol 1,4,5-trisphosphate receptor (IP3R) is an intracellular Ca2+ channel involved in various cellular signaling. Type 3 IP3R (IP(3)R3) retains ligand-gated Ca2+ channel properties differing from other subtypes in terms of IP3-binding affinity and regulation of its channel activity by effector molecules. In this study, we found the natural Pro(335) -> Leu polymorphism of mouse IP(3)R3 between BALB/c and C57BL/6J. We investigated the functional differences between Pro(335)IP(3)R3 and Leu(335)IP(3)R3 with purified receptors reconstituted into proteoliposomes as well as with soluble ligand binding domains. Pro335IP(3)R3 exhibited significantly higher IP3-binding affinity and IP3-induced Ca2+ release than those of Leu335IP(3)R3 in both forms of the receptor. Moreover, the polymorphic change caused differences in the effect of external Ca2+ on IP3-induced Ca2+ release. The Pro335 3 Leu substitution alters the conformation of soluble ligand binding domain as revealed by intrinsic fluorescence and circular dichroism spectra with or without Ca2+. The results indicate that the polymorphism of IP(3)R3 causes changes in receptor function, presumably affecting intracellular Ca2+ signaling.	Chonnam Natl Univ, Coll Vet Med, Dept Biochem, Kwangju 500757, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon, South Korea	Chonnam National University; Korea Advanced Institute of Science & Technology (KAIST)	Ahn, T (corresponding author), Chonnam Natl Univ, Coll Vet Med, Dept Biochem, Kwangju 500757, South Korea.	thahn@chonam.ac.kr; ckpark@kaist.ac.kr	Park, Chankyu/C-1936-2011					BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; DeSmedt H, 1997, BIOCHEM J, V322, P575; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; Iwai M, 2005, J BIOL CHEM, V280, P10305, DOI 10.1074/jbc.M413824200; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; Kim S, 2002, BEHAV PROCESS, V60, P181, DOI 10.1016/S0376-6357(02)00085-2; KOLCHENS S, 1993, CHEM PHYS LIPIDS, V65, P1, DOI 10.1016/0009-3084(93)90076-F; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Tu HP, 2005, BIOPHYS J, V88, P1056, DOI 10.1529/biophysj.104.049601; Tu HP, 2003, BIOPHYS J, V85, P290, DOI 10.1016/S0006-3495(03)74474-9; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Vanlingen S, 2000, BIOCHEM J, V346, P275, DOI 10.1042/0264-6021:3460275; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	40	2	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26024	26031		10.1074/jbc.M501777200	http://dx.doi.org/10.1074/jbc.M501777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15890645	hybrid			2022-12-25	WOS:000230386800011
J	Pineau, B; Mathieu, C; Gerard-Hirne, C; De Paepe, R; Chetrit, P				Pineau, B; Mathieu, C; Gerard-Hirne, C; De Paepe, R; Chetrit, P			Targeting the NAD7 subunit to mitochondria restores a functional complex I and a wild type phenotype in the Nicotiana sylvestris CMS II mutant lacking nad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENCODED SUBUNITS; RESPIRATORY-CHAIN; UBIQUINONE OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE; ALTERNATIVE OXIDASE; NEUROSPORA-CRASSA; PROTEIN COMPLEXES; GENE; YEAST; SUPERCOMPLEXES	The mitochondrial DNA of the Nicotiana sylvestris CMSII mutant carries a 72-kb deletion comprising the single copy nad7 gene that encodes the NAD7 subunit of the respiratory complex I (NADH-ubiquinone oxidoreductase). CMSII plants lack rotenone-sensitive complex I activity and are impaired in physiological and phenotypical traits. To check whether these changes directly result from the deletion of nad7, we constructed CMS transgenic plants ( termed as CMSnad7) carrying an edited nad7 cDNA fused to the CAMV S-35 promoter and to a mitochondrial targeting sequence. The nad7 sequence was transcribed and translated and the NAD7 protein directed to mitochondria in CMSnad7 transgenic plants, which recovered both wild type morphology and growth features. Blue-native/SDS gel electrophoresis and enzymatic assays showed that, whereas fully assembled complex I was absent from CMSII mitochondria, a functional complex was present in CMSnad7 mitochondria. Furthermore, a supercomplex involving complex I and complex III was present in CMSnad7 as in the wild type. Taken together, these data demonstrate that lack of complex I in CMSII was indeed the direct consequence of the absence of nad7. Hence, NAD7 is a key element for complex assembly in plants. These results also show that allotopic expression from the nucleus can fully complement the lack of a mitochondrial-encoded complex I gene.	Univ Paris 11, CNRS, Inst Biotechnol Plantes, Lab Mitochondries & Metab,UMR 8618, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Chetrit, P (corresponding author), Univ Paris 11, CNRS, Inst Biotechnol Plantes, Lab Mitochondries & Metab,UMR 8618, F-91405 Orsay, France.	chetrit@ibp.u-psud.fr	mathieu, chantal/ABD-5505-2021	mathieu, chantal/0000-0002-4055-5233				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Adams KL, 2003, MOL PHYLOGENET EVOL, V29, P380, DOI 10.1016/S1055-7903(03)00194-5; Ambard-Bretteville F, 2003, BIOCHEM BIOPH RES CO, V311, P966, DOI 10.1016/j.bbrc.2003.10.099; Antonicka H, 2003, J BIOL CHEM, V278, P43081, DOI 10.1074/jbc.M304998200; Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Brangeon J, 2000, PLANT J, V21, P269, DOI 10.1046/j.1365-313x.2000.00679.x; Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2; CHETRIT P, 1992, CURR GENET, V21, P131, DOI 10.1007/BF00318472; Chevallet M, 2003, BBA-BIOENERGETICS, V1557, P51, DOI 10.1016/S0005-2728(02)00398-5; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; DOUCE R, 1973, BIOCHIM BIOPHYS ACTA, V292, P105, DOI 10.1016/0005-2728(73)90255-7; Duarte M, 2000, GENETICS, V156, P607; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Gutierres S, 1999, EUR J BIOCHEM, V261, P361, DOI 10.1046/j.1432-1327.1999.00310.x; Gutierres S, 1997, P NATL ACAD SCI USA, V94, P3436, DOI 10.1073/pnas.94.7.3436; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Karpova OV, 1999, PLANT J, V17, P511, DOI 10.1046/j.1365-313X.1999.00401.x; Karpova OV, 2002, PLANT CELL, V14, P3271, DOI 10.1105/tpc.005603; Kerscher SJ, 2000, BBA-BIOENERGETICS, V1459, P274, DOI 10.1016/S0005-2728(00)00162-6; Kobayashi Y, 1997, MOL GEN GENET, V256, P589, DOI 10.1007/PL00008616; Kruft V, 2001, PLANT PHYSIOL, V127, P1694, DOI 10.1104/pp.010474; LAW RHP, 1988, FEBS LETT, V236, P501, DOI 10.1016/0014-5793(88)80086-3; Lelandais C, 1998, GENETICS, V150, P873; Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3; LETERME S, 1993, PLANT PHYSIOL, V102, P435, DOI 10.1104/pp.102.2.435; LI XQ, 1988, CURR GENET, V13, P261, DOI 10.1007/BF00387773; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; Marques I, 2005, BBA-BIOENERGETICS, V1707, P211, DOI 10.1016/j.bbabio.2004.12.003; Michalecka AM, 2004, PLANT J, V37, P415, DOI 10.1046/j.1365-313X.2003.01970.x; Moller IM, 2002, TRENDS PLANT SCI, V7, P235, DOI 10.1016/S1360-1385(02)02281-1; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pineau B, 2001, PLANT PHYSIOL BIOCH, V39, P73, DOI 10.1016/S0981-9428(00)01215-8; PLA M, 1995, MOL GEN GENET, V248, P79, DOI 10.1007/BF02456616; RASMUSSON AG, 1991, PHYSIOL PLANTARUM, V83, P357, DOI 10.1111/j.1399-3054.1991.tb00106.x; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; Sabar M, 2000, PLANT PHYSIOL, V124, P1239, DOI 10.1104/pp.124.3.1239; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schulte U, 1995, METHOD ENZYMOL, V260, P3, DOI 10.1016/0076-6879(95)60126-0; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071; Videira A, 2002, BBA-BIOENERGETICS, V1555, P187, DOI 10.1016/S0005-2728(02)00276-1; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; Vogel R, 2004, CURR OPIN NEUROL, V17, P179, DOI 10.1097/00019052-200404000-00016; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Yadava N, 2004, J BIOL CHEM, V279, P12406, DOI 10.1074/jbc.M313588200; Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	72	64	68	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25994	26001		10.1074/jbc.M500508200	http://dx.doi.org/10.1074/jbc.M500508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15849190	hybrid			2022-12-25	WOS:000230386800007
J	Britton, FC; Wang, GL; Huang, ZM; Ye, LD; Horowitz, B; Hume, JR; Duan, DY				Britton, FC; Wang, GL; Huang, ZM; Ye, LD; Horowitz, B; Hume, JR; Duan, DY			Functional characterization of novel alternatively spliced ClC-2 chloride channel variants in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT ATRIAL MYOCYTES; REGULATED CL-CURRENTS; ELECTROPHYSIOLOGICAL RESPONSE; INWARD RECTIFIER; VOLTAGE; CIC-2; CLONING; IDENTIFICATION; SELECTIVITY; EXPRESSION	A novel volume- regulated hyperpolarization- activated chloride inward rectifier channel ( Cl. ir) was identified in mammalian heart. To investigate whether ClC- 2 is the gene encoding Cl. ir channels in heart, ClC- 2 cDNAs cloned from rat ( rClC- 2) and guinea pig ( gpClC- 2) hearts were functionally characterized. When expressed in NIH/ 3T3 cells, full- length rClC- 2 yielded inwardly rectifying whole- cell currents with very slow activation kinetics ( time constants > 1.7 s) upon hyperpolarization under hypotonic condition. The single- channel rClC- 2 currents had a unitary slope conductance of 3.9 +/- 0.2 picosiemens. A novel variant with an in- frame deletion at the beginning of exon 15 that leads to a deletion of 45 bp ( corresponding to 15 amino acids in alpha- helices O and P, rClC- 2 Delta(509 - 523)) was identified in rat heart. The relative transcriptional expression levels of full- length rClC- 2 and rClC- 2(Delta 509 - 523) in rat heart were 0.018 +/- 0.003 and 0.028 +/- 0.006 arbitrary units, respectively, relative to glyceraldehyde- 3- phosphate dehydrogenase ( n = 5, p = nonsignificant). A similar partial exon 15 skipping with a deletion of 105 bp ( 35 amino acids in alpha- helices O - Q, rClC- 2(Delta 509 - 543)) was also identified in guinea pig heart. Expression of both rClC- 2(Delta 509 - 523) and gpClC2(Delta 509 - 543) resulted in functional channels with phenotypic activation kinetics and many properties identical to those of endogenous Cl. ir channels in native rat and guinea pig cardiac myocytes, respectively. Intracellular dialysis of anti- ClC- 2 antibody inhibited expressed ClC- 2 channels and endogenous Cl. ir currents in native rat and guinea pig cardiac myocytes. These results demonstrate that novel deletion variants of ClC- 2 due to partial exon 15 skipping may be expressed normally in heart and contribute to the formation of endogenous Cl. ir channels in native cardiac cells.	Univ Nevada, Sch Med, Dept Pharmacol, Reno, NV 89557 USA; Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA; Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Duan, DY (corresponding author), Univ Nevada, Sch Med, Dept Pharmacol, Manville Med Bldg,Rm 9,1664 N Virginia St,MS 318, Reno, NV 89557 USA.	dduan@med.unr.edu	Britton, Fiona/Q-5338-2016	Britton, Fiona/0000-0002-3834-9940	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063914] Funding Source: NIH RePORTER; NCRR NIH HHS [P-20 RR-15581] Funding Source: Medline; NHLBI NIH HHS [HL63914] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arreola J, 2002, J PHYSIOL-LONDON, V541, P103, DOI 10.1113/jphysiol.2002.016485; Britton FC, 2002, J PHYSIOL-LONDON, V539, P107, DOI 10.1113/jphysiol.2001.013170; Britton FC, 2000, AM J PHYSIOL-HEART C, V279, pH2225, DOI 10.1152/ajpheart.2000.279.5.H2225; Chu SJ, 1996, NUCLEIC ACIDS RES, V24, P3453, DOI 10.1093/nar/24.17.3453; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; CID LP, 1995, HUM MOL GENET, V4, P407, DOI 10.1093/hmg/4.3.407; Cid LP, 2000, AM J PHYSIOL-CELL PH, V279, pC1198, DOI 10.1152/ajpcell.2000.279.4.C1198; Denton J, 2004, J PHYSIOL-LONDON, V555, P97, DOI 10.1113/jphysiol.2003.053165; Duan D, 2000, CIRC RES, V86, pE63, DOI 10.1161/01.RES.86.4.e63; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; DUAN D, 1995, CIRC RES, V77, P379, DOI 10.1161/01.RES.77.2.379; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; Duan DY, 2005, ACTA PHARMACOL SIN, V26, P265, DOI 10.1111/j.1745-7254.2005.00061.x; DUAN DY, 1992, AM J PHYSIOL, V263, pH1967, DOI 10.1152/ajpheart.1992.263.6.H1967; Duffield M, 2003, J GEN PHYSIOL, V121, P149, DOI 10.1085/jgp.20028741; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; Estevez R, 2002, CURR OPIN STRUC BIOL, V12, P531, DOI 10.1016/S0959-440X(02)00358-5; Fahlke C, 2001, AM J PHYSIOL-RENAL, V280, pF748, DOI 10.1152/ajprenal.2001.280.5.F748; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; FURUKAWA T, 1995, FEBS LETT, V375, P56, DOI 10.1016/0014-5793(95)01178-H; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hume JR, 2000, PHYSIOL REV, V80, P31, DOI 10.1152/physrev.2000.80.1.31; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Komukai K, 2002, AM J PHYSIOL-HEART C, V283, pH715, DOI 10.1152/ajpheart.01000.2001; Komukai K, 2002, AM J PHYSIOL-HEART C, V283, pH412, DOI 10.1152/ajpheart.01042.2001; Loewen ME, 2000, BBA-GENE STRUCT EXPR, V1493, P284, DOI 10.1016/S0167-4781(00)00181-0; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nagasaki M, 2000, J PHYSIOL-LONDON, V523, P705, DOI 10.1111/j.1469-7793.2000.00705.x; Nobile M, 2000, FEBS LETT, V479, P10, DOI 10.1016/S0014-5793(00)01876-7; Park K, 1998, J MEMBRANE BIOL, V163, P87, DOI 10.1007/s002329900373; Pedersen SF, 2002, J PHYSIOL-LONDON, V541, P779, DOI 10.1113/jphysiol.2002.018887; Stroffekova K, 1998, AM J PHYSIOL-CELL PH, V275, pC1113, DOI 10.1152/ajpcell.1998.275.4.C1113; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Varela D, 2002, J PHYSIOL-LONDON, V544, P363, DOI 10.1113/jphysiol.2002.026096; Weinreich F, 2001, J BIOL CHEM, V276, P2347, DOI 10.1074/jbc.M005733200	43	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25871	25880		10.1074/jbc.M502826200	http://dx.doi.org/10.1074/jbc.M502826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883157	hybrid			2022-12-25	WOS:000230207900068
J	Lypowy, J; Chen, IY; Abdellatif, M				Lypowy, J; Chen, IY; Abdellatif, M			An alliance between Ras GTPase-activating protein, filamin C, and Ras GTPase-activating protein SH3 domain-binding protein regulates myocyte growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; TYROSINE PHOSPHORYLATION; CARDIAC-HYPERTROPHY; TARGETS FILAMIN; KINASE; GAP; ACTIN; COMPLEX	We have previously reported that Ras GTPase-activating protein (RasGAP) is involved in a pathway that regulates total cellular mRNA and protein synthesis in cardiac myocytes. A yeast two-hybrid screen resulted in identification of filamin C (FLN-C) as one of its targets. Knockdown of RasGAP or FLN-C, or severing their interaction, resulted in down-regulation of the RNA polymerase II kinase, cyclin-dependent kinase 7 (Cdk7). This appeared to be provoked by the release of cdk7 mRNA from RasGAP SH3 domain-binding protein, G3BP, and its subsequent degradation. In parallel, myocyte growth was also inhibited. On the other hand, overexpression of RasGAP induced a Cdk7- and FLN-C-dependent growth. Thus, we propose that the physical interaction between RasGAP and FLN-C facilitates an interaction between G3BP and cdk7 mRNA. This results in stabilization of cdk7 mRNA, an increase in its protein, which is required for cell growth.	Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Lypowy, J (corresponding author), Univ Med & Dent New Jersey, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA.	abdellma@umdnj.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057970] Funding Source: NIH RePORTER; NHLBI NIH HHS [2R01-HL057970-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; Flusberg DA, 2001, MOL BIOL CELL, V12, P3087, DOI 10.1091/mbc.12.10.3087; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Graham F L, 1992, Biotechnology, V20, P363; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Parker F, 1996, MOL CELL BIOL, V16, P2561; Pinhero R, 2004, EUR J BIOCHEM, V271, P1004, DOI 10.1111/j.1432-1033.2004.04002.x; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Schwartz BE, 2003, MOL CELL BIOL, V23, P6876, DOI 10.1128/MCB.23.19.6876-6886.2003; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200	52	42	44	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25717	25728		10.1074/jbc.M414266200	http://dx.doi.org/10.1074/jbc.M414266200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886195	hybrid			2022-12-25	WOS:000230207900052
J	Mercer, SE; Ewton, DZ; Deng, XB; Lim, S; Mazur, TR; Friedman, E				Mercer, SE; Ewton, DZ; Deng, XB; Lim, S; Mazur, TR; Friedman, E			Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CYCLIN-DEPENDENT KINASE; SKELETAL-MUSCLE DIFFERENTIATION; CYTOPLASMIC P21(CIP1/WAF1); DNA-REPLICATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEAR ACCUMULATION; CELL-SURVIVAL; CANCER-CELLS; DYRK FAMILY	The kinase Mirk/ dyrk1B is essential for the differentiation of C2C12 myoblasts. Mirk reinforces the G(0)/ G(1) arrest state in which differentiation occurs by directly phosphorylating and stabilizing p27(Kip1) and destabilizing cyclin D1. We now demonstrate that Mirk is antiapoptotic in myoblasts. Knockdown of endogenous Mirk by RNA interference activated caspase 3 and decreased myoblast survival by 75%, whereas transient overexpression of Mirk increased cell survival. Mirk exerts its anti- apoptotic effects during muscle differentiation at least in part through effects on the cell cycle inhibitor and pro- survival molecule p21(Cip1). Overexpression and RNA interference experiments demonstrated that Mirk phosphorylates p21 within its nuclear localization domain at Ser- 153 causing a portion of the typically nuclear p21 to localize in the cytoplasm. Phosphomimetic GFP- p21- S153D was pancellular in both cycling C2C12 myoblasts and NIH3T3 cells. Endogenous Mirk in myotubes and overexpressed Mirk in NIH3T3 cells were able to cause the pancellular localization of wild- type GFPp21 but not the nonphosphorylatable mutant GFP- p21S153A. Translocation to the cytoplasm enables p21 to block apoptosis through inhibitory interaction with pro- apoptotic molecules. Phosphomimetic p21- S153D was more effective than wild- type p21 in blocking the activation of caspase 3. Transient expression of p21S153D also increased myoblast viability in colony forming assays, whereas the p21- S153A mutant had no effect. This Mirk- dependent change in p21 intracellular localization is a natural part of myoblast differentiation. Endogenous p21 localized exclusively to the nuclei of proliferating myoblasts but was also found in the cytoplasm of post- mitotic multinucleated myotubes and adult human skeletal myofibers.	SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), SUNY Upstate Med Univ, Dept Pathol, 750 E Adams St, Syracuse, NY 13210 USA.	friedmae@upstate.edu		Lim, Seunghwan/0000-0001-8920-0890	NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA67405, R01 CA067405-09, R01 CA067405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng XB, 2005, J BIOL CHEM, V280, P4894, DOI 10.1074/jbc.M411894200; Deng XB, 2004, J BIOL CHEM, V279, P22498, DOI 10.1074/jbc.M400479200; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dong Y, 2004, CELL SIGNAL, V16, P263, DOI 10.1016/S0898-6568(03)00136-0; DOTTO G, 2000, BIOCHIM BIOPHYS ACTA, V31, pM43; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; GUO K, 1995, MOL CELL BIOL, V15, P3823; HARPER JW, 1993, CELL, V75, P805; Hawke TJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1019, DOI 10.1152/ajpcell.00055.2003; Heliez C, 2003, ONCOGENE, V22, P3260, DOI 10.1038/sj.onc.1206409; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leder S, 2003, BIOCHEM J, V372, P881, DOI 10.1042/BJ20030182; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lee K.-M., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P273; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Prall OWJ, 2001, J BIOL CHEM, V276, P45433, DOI 10.1074/jbc.M104752200; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SCHERR CJ, 1995, GENE DEV, V9, P1149; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; SHERMAN MY, 1993, P NATL ACAD SCI USA, V90, P8648, DOI 10.1073/pnas.90.18.8648; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Taminato A, 2002, MOL BIOL CELL, V13, P2266, DOI 10.1091/mbc.01-11-0555; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Tanaka H, 2004, NEUROSCIENCE, V127, P155, DOI 10.1016/j.neuroscience.2004.05.010; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG J, 1996, SCIENCE, V273, P369; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200; Zou YL, 2003, J BIOL CHEM, V278, P49573, DOI 10.1074/jbc.M307556200	55	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25788	25801		10.1074/jbc.M413594200	http://dx.doi.org/10.1074/jbc.M413594200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15851482	Green Accepted, hybrid			2022-12-25	WOS:000230207900060
J	Radtke, S; Haan, S; Jorissen, A; Hermanns, HM; Diefenbach, S; Smyczek, T; Schmitz-VandeLeur, H; Heinrich, PC; Behrmann, I; Haan, C				Radtke, S; Haan, S; Jorissen, A; Hermanns, HM; Diefenbach, S; Smyczek, T; Schmitz-VandeLeur, H; Heinrich, PC; Behrmann, I; Haan, C			The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; ONCOSTATIN-M-RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; JANUS KINASE-1; PEPTIDE; BINDING; INTERLEUKIN-6; TRANSDUCTION; COMPLEX	The presence of a Src homology 2 ( SH2) domain sequence similarity in the sequence of Janus kinases ( Jaks) has been discussed since the first descriptions of these enzymes. We performed an in depth study to determine the function of the Jak1 SH2 domain. We investigated the functionality of the Jak1 SH2 domain by stably reconstituting Jak1- defective human fibrosarcoma cells U4C with endogenous amounts of Jak1 in which the crucial arginine residue Arg(466) within the SH2 domain has been replaced by lysine. This mutant still binds to the receptor subunits gp130 and OSMR. Moreover, the SH2 R466K mutation does not affect the subcellular distribution of Jak1 as assessed by cell fractionation and confocal microscopy of cells expressing endogenous levels of non- tagged or a yellow fluorescent protein ( YFP)- tagged Jak1- R466K, respectively. Likewise, the signaling capacity of Jak1 was not affected by this point mutation. However, we found that the SH2 domain is structurally important for cytokine receptor binding and surface expression of the OSMR.	Uniklin Aachen, Inst Biochem, D-52074 Aachen, Germany; Univ Luxembourg, Fac Sci Technol & Commun, Lab Biol & Physiol Integree, L-1511 Luxembourg, Luxembourg	RWTH Aachen University; RWTH Aachen University Hospital; University of Luxembourg	Haan, S (corresponding author), Uniklin Aachen, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	serge.haan@rwth-aachen.de; claude.haan@uni.lu		Behrmann, Iris/0000-0003-3688-3645				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BERNARDS A, 1991, ONCOGENE, V6, P1185; Bork P, 1996, METHOD ENZYMOL, V266, P162; Breeze AL, 1996, EMBO J, V15, P3579, DOI 10.1002/j.1460-2075.1996.tb00727.x; Charifson PS, 1997, BIOCHEMISTRY-US, V36, P6283, DOI 10.1021/bi970019n; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Giese B, 2003, J BIOL CHEM, V278, P39205, DOI 10.1074/jbc.M303347200; GILMER T, 1994, J BIOL CHEM, V269, P31711; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; HARPUR AG, 1992, ONCOGENE, V7, P1347; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Nam HJ, 1996, STRUCTURE, V4, P1105, DOI 10.1016/S0969-2126(96)00116-5; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; Stoica B, 1998, J IMMUNOL, V160, P1059; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; XU RX, 1995, BIOCHEMISTRY-US, V34, P2107, DOI 10.1021/bi00007a003; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297	38	60	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25760	25768		10.1074/jbc.M500822200	http://dx.doi.org/10.1074/jbc.M500822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15894543	hybrid			2022-12-25	WOS:000230207900057
J	Adams, B; Musiyenko, A; Kumar, R; Barik, S				Adams, B; Musiyenko, A; Kumar, R; Barik, S			A novel class of dual-family immunophilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PLASMODIUM-FALCIPARUM; CYCLOSPORINE-A; CATALYTIC DOMAINS; FK506-BINDING PROTEIN; CHAPERONE ACTIVITIES; TOXOPLASMA-GONDII; MALARIA PARASITE; CALCINEURIN; CYCLOPHILIN	Immunophilins are protein chaperones with peptidylprolyl isomerase activity that belong to one of two large families, the cyclosporin- binding cyclophilins ( CyPs) and the FK506- binding proteins ( FKBPs). Each family displays characteristic and conserved sequence features that differ between the two families. We report a novel group of dual- family immunophilins that contain both CyP and FKBP domains for which we propose the name FCBP ( FK506- and cyclosporin- binding protein). The FCBP of Toxoplasma gondii, a protozoan parasite, contained N- terminal FKBP and C- terminal CyP domains joined by tetratricopeptide repeats. Structure function analysis revealed that both domains were functional and exhibited family- specific drug sensitivity. The individual domains of FCBP inhibited calcineurin ( protein phosphatase 2B) in the presence of the appropriate drugs. In binding studies, FCBP recruited calcineurin in the presence of FK506 and a putative target of rapamycin homolog in the presence of rapamycin. Two additional FCBP sequences in Flavobacterium and one in Treponema ( spirochete) were also identified in which the CyP and FKBP domains were in the reverse order. T. gondii growth was inhibited by cyclosporin and FK506 in a moderately synergistic manner. The knockdown of FCBP by RNA interference revealed its essentiality for T. gondii growth. Clearly, the FCBPs are novel chaperones and potential targets of multiple immunosuppressant drugs.	Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA	University of South Alabama	Barik, S (corresponding author), Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA.	sbarik@jaguar1.usouthal.edu			NIAID NIH HHS [R01 AI045803-05, R01 AI045803, AI045803] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045803] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Anouti F, 2002, ANTISENSE NUCLEIC A, V12, P275, DOI 10.1089/108729002320351593; Ben Mamoun C, 1998, J BIOL CHEM, V273, P11241, DOI 10.1074/jbc.273.18.11241; Blankenship Jill R, 2003, Curr Opin Investig Drugs, V4, P192; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Feske S, 2003, BIOCHEM BIOPH RES CO, V311, P1117, DOI 10.1016/j.bbrc.2003.09.174; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HOFFMANN K, 1995, EUR J BIOCHEM, V229, P188, DOI 10.1111/j.1432-1033.1995.tb20454.x; Howard MB, 2004, J BACTERIOL, V186, P1297, DOI 10.1128/JB.186.5.1297-1303.2004; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Kumar R, 2005, MOL BIOCHEM PARASIT, V141, P163, DOI 10.1016/j.molbiopara.2005.02.007; Kumar R, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-6; Kumar R, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-30; Kumar Rajinder, 2002, Malar J, V1, P5, DOI 10.1186/1475-2875-1-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; McBride MJ, 2004, J BACTERIOL, V186, P2295, DOI 10.1128/JB.186.8.2295-2302.2004; McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Monaghan P, 2005, MOL BIOCHEM PARASIT, V139, P185, DOI 10.1016/j.molbiopara.2004.10.007; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Royer W, 2002, BIOCHEM J, V366, P921, DOI 10.1042/bj20011764; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; Suzuki Y, 2004, EUR J BIOCHEM, V271, P1372, DOI 10.1111/j.1432-1033.2004.04049.x; Tanaka T, 2001, J BIOL CHEM, V276, P35629, DOI 10.1074/jbc.M105919200; Ward BK, 2002, J BIOL CHEM, V277, P40799, DOI 10.1074/jbc.M207097200; Wu BL, 2004, P NATL ACAD SCI USA, V101, P8348, DOI 10.1073/pnas.0305969101	36	45	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24308	24314		10.1074/jbc.M500990200	http://dx.doi.org/10.1074/jbc.M500990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15845546	Green Accepted, hybrid			2022-12-25	WOS:000230114000003
J	Iizuka, Y; Yokomizo, T; Terawaki, K; Komine, M; Tamaki, K; Shimizu, T				Iizuka, Y; Yokomizo, T; Terawaki, K; Komine, M; Tamaki, K; Shimizu, T			Characterization of a mouse second leukotriene b4 receptor, mBLT2 - BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; B-4 RECEPTOR; MOLECULAR-CLONING; MEDIATES CHEMOTAXIS; GROWTH-FACTOR; HUMAN SKIN; T-CELLS; HYDROLASE; MICE; 5-LIPOXYGENASE	Leukotriene B4 (LTB4) is a potent chemoattractant and activator for granulocytes and macrophages and is considered to be an inflammatory mediator. Two G-protein-coupled receptors for LTB4, BLT1 and BLT2, have been cloned from human and shown to be high and low affinity LTB4 receptors, respectively. To reveal the biological roles of BLT2 using mouse disease models, we cloned and characterized mouse BLT2. Chinese hamster ovary cells stably expressing mouse BLT2 exhibited specific binding to LTB4, LTB4-induced calcium mobilization, inhibition of adenylyl cyclase, and phosphorylation of extracellular signal-regulated kinase. We found that Compound A (4'-{[pentanoyl (phenyl) amino] methyl}1, 1'-biphenyl-2-carboxylic acid) was a BLT2-selective agonist and induced Ca2+ mobilization and phosphorylation of extracellular signal-regulated kinase through BLT2, whereas it had no effect on BLT1. 12-epi LTB4 exhibited a partial agonistic activity against mBLT1 and mBLT2, whereas 6-trans-12-epi LTB4 did not. Northern blot analysis showed that mouse BLT2 is expressed highly in small intestine and skin in contrast to the ubiquitous expression of human BLT2. By in situ hybridization and the reverse transcriptase polymerase chain reaction, we demonstrated that mouse BLT2 is expressed in follicular and interfollicular keratinocytes. Compound A, LTB4, and 12-epi LTB4 all induced phosphorylation of extracellular signal-regulated kinase in primary mouse keratinocytes. Furthermore, Compound A and LTB4 induced chemotaxis in primary mouse keratinocytes. These data suggest the presence of functional BLT2 in primary keratinocytes.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Dermatol, Tokyo 1130033, Japan; PRESTO, Japan Sci & Technol Agcy, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	yokomizo-tky@umin.ac.jp	Shimizu, Takao/AAV-7052-2021; Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553				Andoh T, 2004, J INVEST DERMATOL, V123, P196, DOI 10.1111/j.0022-202X.2004.22704.x; Andoh T, 2001, J INVEST DERMATOL, V117, P1621, DOI 10.1046/j.0022-202x.2001.01585.x; Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Cole AT, 1996, GUT, V39, P248, DOI 10.1136/gut.39.2.248; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Grone A, 2002, VET IMMUNOL IMMUNOP, V88, P1, DOI 10.1016/S0165-2427(02)00136-8; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; HUSSAIN H, 1994, AM J PHYSIOL, V266, P243; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Iversen L, 1996, ACTA DERM-VENEREOL, V76, P424; Iversen L, 1997, SKIN PHARMACOL, V10, P169, DOI 10.1159/000211501; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; Kamohara M, 2000, J BIOL CHEM, V275, P27000; Kato K, 2000, J EXP MED, V192, P413, DOI 10.1084/jem.192.3.413; KRIEG P, 1995, MOL CARCINOGEN, V14, P118, DOI 10.1002/mc.2940140208; Lindsay MA, 1998, J LEUKOCYTE BIOL, V64, P555, DOI 10.1002/jlb.64.4.555; MACKENZIE RH, 1990, DIS MARKERS, V8, P137; Marshall J, 2000, J IMMUNOL, V164, P2084, DOI 10.4049/jimmunol.164.4.2084; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MINAMI M, 1987, J BIOL CHEM, V262, P13873; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Wang SK, 2000, J BIOL CHEM, V275, P40686, DOI 10.1074/jbc.M004512200; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Yamasaki K, 2003, J INVEST DERMATOL, V120, P1030, DOI 10.1046/j.1523-1747.2003.12239.x; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200	43	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24816	24823		10.1074/jbc.M413257200	http://dx.doi.org/10.1074/jbc.M413257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866883	hybrid			2022-12-25	WOS:000230114000064
J	Kamata, T; Handa, M; Sato, Y; Ikeda, Y; Aiso, S				Kamata, T; Handa, M; Sato, Y; Ikeda, Y; Aiso, S			Membrane-proximal alpha/beta stalk interactions differentially regulate integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; CALCIUM-BINDING DOMAIN; INSIDE-OUT ACTIVATION; LIGAND-BINDING; CONFORMATIONAL-CHANGES; EXTRACELLULAR SEGMENT; PLATELET-AGGREGATION; ALPHA(IIB) SUBUNIT; CRYSTAL-STRUCTURE; DIVALENT-CATIONS	The affinity of integrin-ligand interaction is regulated extracellularly by divalent cations and intracellularly by inside-out signaling. We report here that the extracellular, membrane-proximal alpha/beta stalk interactions not only regulate cation-induced integrin activation but also play critical roles in propagating inside-out signaling. Two closely related integrins, alpha IIb beta 3 and alpha V beta 3, share high structural homology and bind to similar ligands in an RGD-dependent manner. Despite these structural and functional similarities, they exhibit distinct responses to Mn2+. Although alpha V beta 3 showed robust ligand binding in the presence of Mn2+, alpha IIb beta 3 showed a limited increase but failed to achieve full activation. Swapping alpha stalk regions between alpha IIb and alpha V revealed that the alpha stalk, but not the ligand-binding head region, was responsible for the difference. A series of alpha IIb/alpha V domain-swapping chimeras were constructed to identify the responsible domain. Surprisingly, the minimum component required to render alpha IIb beta 3 susceptible to Mn2+ activation was the alpha V calf-2 domain, which does not contain any divalent cation-binding sites. The calf-2 domain makes interface with beta epidermal growth factor 4 and beta tail domain in three-dimensional structure. The effect of calf-2 domain swapping was partially reproduced by mutating the specific amino acid residues in the calf-2/epidermal growth factor 4-beta tail domain interface. When this interface was constrained by an artificially introduced disulfide bridge, the Mn2+-induced alpha V beta 3-fibrinogen interaction was significantly impaired. Notably, a similar disulfide bridge completely abrogated fibrinogen binding to alpha IIb beta 3 when alpha IIb beta 3 was activated by cytoplasmic tail truncation to mimic inside-out signaling. Thus, disruption/formation of the membrane-proximal alpha/beta stalk interface may act as an on/off switch that triggers integrin-mediated bidirectional signaling.	Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Transfus Med & Cell Therapy, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University	Kamata, T (corresponding author), Keio Univ, Sch Med, Dept Anat, Shinjuku Ku, 3S1,35 Shinanomachi, Tokyo 1608582, Japan.	kamata@sc.itc.keio.ac.jp	Handa, Makoto/B-1121-2014					AZUMA H, 1989, THROMB HAEMOSTASIS, V62, P984; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2004, J BIOL CHEM, V279, P32435, DOI 10.1074/jbc.M404387200; Delwel GO, 1996, J BIOL CHEM, V271, P7293, DOI 10.1074/jbc.271.13.7293; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Fujimoto TT, 2003, J BIOL CHEM, V278, P26655, DOI 10.1074/jbc.M302194200; Gidwitz S, 2000, J BIOL CHEM, V275, P6680, DOI 10.1074/jbc.275.9.6680; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2004, BIOCHEM J, V378, P1079, DOI 10.1042/BJ20031701; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Pujades C, 1997, MOL BIOL CELL, V8, P2647, DOI 10.1091/mbc.8.12.2647; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; RENESTO P, 1993, BLOOD, V82, P139, DOI 10.1182/blood.V82.1.139.bloodjournal821139; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1994, J BIOL CHEM, V269, P960; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, J THROMB HAEMOST, V1, P1642, DOI 10.1046/j.1538-7836.2003.00277.x; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; YLANNE J, 1988, BLOOD, V72, P1478	54	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24775	24783		10.1074/jbc.M409548200	http://dx.doi.org/10.1074/jbc.M409548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863495	hybrid			2022-12-25	WOS:000230114000060
J	Nogaj, LA; Beale, SI				Nogaj, LA; Beale, SI			Physical and kinetic interactions between glutamyl-tRNA reductase and glutamate-1-semialdehyde aminotransferase of Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINIC-ACID; GREENING BARLEY LEAVES; CHLOROPHYLL BIOSYNTHESIS; 1-SEMIALDEHYDE AMINOTRANSFERASE; SYNTHESIZING ENZYMES; NEGATIVE REGULATOR; ACTIVE-SITE; SUBSTRATE; PURIFICATION; PROTEIN	In plants, algae, and most bacteria, the heme and chlorophyll precursor 5- aminolevulinic acid ( ALA) is formed from glutamate in a three- step process. First, glutamate is ligated to its cognate tRNA by glutamyl- tRNA synthetase. Activated glutamate is then converted to a glutamate 1- semialdehyde ( GSA) by glutamyl- tRNA reductase ( GTR) in an NADPH- dependent reaction. Subsequently, GSA is rearranged to ALA by glutamate- 1- semialdehyde aminotransferase ( GSAT). The intermediate GSA is highly unstable under physiological conditions. We have used purified recombinant GTR and GSAT from the unicellular alga Chlamydomonas reinhardtii to show that GTR and GSAT form a physical and functional complex that allows channeling of GSA between the enzymes. Co- immunoprecipitation and sucrose gradient ultracentrifugation results indicate that recombinant GTR and GSAT enzymes specifically interact. In vivo cross- linking results support the in vitro results and demonstrate that GTR and GSAT are components of a high molecular mass complex in C. reinhardtii cells. In a coupled enzyme assay containing GTR and wild- type GSAT, addition of inactive mutant GSAT inhibited ALA formation from glutamyl- tRNA. Mutant GSAT did not inhibit ALA formation from GSA by wild- type GSAT. These results suggest that there is competition between wild- type and mutant GSAT for binding to GTR and channeling GSA from GTR to GSAT. Further evidence supporting kinetic interaction of GTR and GSAT is the observation that both wild- type and mutant GSAT stimulate glutamyl-tRNA-dependent NADPH oxidation by GTR.	Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Brown University	Beale, SI (corresponding author), Brown Univ, Div Biol & Med, Box G-J4, Providence, RI 02912 USA.	sib@brown.edu						BATKE J, 1989, TRENDS BIOCHEM SCI, V14, P481, DOI 10.1016/0968-0004(89)90179-5; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEALE SI, 1975, P NATL ACAD SCI USA, V72, P2719, DOI 10.1073/pnas.72.7.2719; BEALE SI, 1990, PLANT PHYSIOL, V93, P1273, DOI 10.1104/pp.93.4.1273; Beale SI, 1999, PHOTOSYNTH RES, V60, P43, DOI 10.1023/A:1006297731456; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUYANT P, 1987, CARLSBERG RES COMMUN, V52, P99, DOI 10.1007/BF02910432; EASTERBY JS, 1981, BIOCHEM J, V199, P155, DOI 10.1042/bj1990155; FALCIATORE A, 2002, GENE DEV, V19, P176; FERREIRA GC, 1988, J BIOL CHEM, V263, P3835; Geck MK, 1999, BIOCHEMISTRY-US, V38, P8032, DOI 10.1021/bi983029c; GORCHEIN A, 1972, BIOCHEM J, V127, P97, DOI 10.1042/bj1270097; GOUGH SP, 1989, CARLSBERG RES COMMUN, V54, P99, DOI 10.1007/BF02908302; GRIMM B, 1992, EUR J BIOCHEM, V206, P579, DOI 10.1111/j.1432-1033.1992.tb16962.x; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HIGUCHI M, 1975, ANN NY ACAD SCI, V244, P401, DOI 10.1111/j.1749-6632.1975.tb41545.x; Hinchigeri SB, 1997, FEBS LETT, V407, P337, DOI 10.1016/S0014-5793(97)00371-2; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HUANG DD, 1984, SCIENCE, V225, P1482, DOI 10.1126/science.6206568; JAHN D, 1992, FEBS LETT, V314, P77, DOI 10.1016/0014-5793(92)81465-X; James CL, 2002, BIOCHEMISTRY-US, V41, P3726, DOI 10.1021/bi0159074; KANNANGARA CG, 1984, CARLSBERG RES COMMUN, V49, P417, DOI 10.1007/BF02907783; KELETI T, 1978, CURR TOP CELL REGUL, V29, P1; Kim WJ, 2002, J BIOL CHEM, V277, P30264, DOI 10.1074/jbc.M202517200; Kim WJ, 2001, NUCLEIC ACIDS RES, V29, P1724, DOI 10.1093/nar/29.8.1724; MATHEWS CK, 1982, P NATL ACAD SCI-BIOL, V79, P302, DOI 10.1073/pnas.79.2.302; MATTERS GL, 1994, PLANT MOL BIOL, V24, P617, DOI 10.1007/BF00023558; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; Meskauskiene R, 2002, FEBS LETT, V532, P27, DOI 10.1016/S0014-5793(02)03617-7; Meskauskiene R, 2001, P NATL ACAD SCI USA, V98, P12826, DOI 10.1073/pnas.221252798; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; ONEILL GP, 1990, J BACTERIOL, V172, P6363, DOI 10.1128/jb.172.11.6363-6371.1990; RUDOLPH J, 1995, BIOCHEMISTRY-US, V34, P2241, DOI 10.1021/bi00007a019; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA A, 2005, IN PRESS PLANT MOL B; URATA G, 1963, J BIOL CHEM, V238, P811; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG WY, 1984, PLANT PHYSIOL, V74, P569, DOI 10.1104/pp.74.3.569	41	43	47	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24301	24307		10.1074/jbc.M502483200	http://dx.doi.org/10.1074/jbc.M502483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15890644	hybrid			2022-12-25	WOS:000230114000002
J	Pelletier, B; Trott, A; Morano, KA; Labbe, S				Pelletier, B; Trott, A; Morano, KA; Labbe, S			Functional characterization of the iron-regulatory transcription factor Fep1 from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-METAL TRANSPORT; SACCHAROMYCES-CEREVISIAE; SIDEROPHORE BIOSYNTHESIS; GATA FACTOR; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; GENE-EXPRESSION; USTILAGO-MAYDIS; ZINC FINGERS; COILED COILS	In response to excess iron, Schizosaccharomyces pombe cells repress transcription of genes encoding components involved in iron uptake through the Fep1 transcription factor. Fep1 mediates this control by interacting with the consensus sequence 5'-(A/T) GATAA-3', found in iron-dependent promoters. In this report, we show that Fep1 localizes to the nucleus under both iron-replete and iron-starved conditions. The Fep1 DNA binding domain (amino acids 1-241) contains two GATA-type zinc finger motifs. Although we determine that the Fep1 C-terminal zinc finger (ZF2) is essential for DNA binding, we show that the N-terminal zinc finger (ZF1) enhances DNA binding affinity similar to 5-fold. Between the two zinc finger motifs of Fep1 resides an invariant amino acid sequence, denoted the Cys-rich region (amino acids 68-94), in which four highly conserved Cys residues are found. Cells harboring mutant alleles in which two or more of the conserved Cys residues were substituted by alanine exhibited elevated fio1(+) mRNA levels. We determine that the dissociation constant for the resulting complex between each of the Cys mutants and the sequence 5'-(A/T) GATAA-3' reflects a much lower affinity that correlates with failure to repress fio1(+) gene expression. Deletion analysis identified two heptad repeats (amino acids 522-536) within the C-terminal region of Fep1 that are necessary and sufficient to mediate Fep1 dimerization. Moreover, mutations that impair dimerization also negatively affect transcriptional repression. Together these findings reveal several novel features of Fep1, a non-canonical GATA factor required for iron homeostasis.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Sherbrooke; University of Texas System	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca		Morano, Kevin/0000-0002-5992-0253; Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; Askwith C, 1997, J BIOL CHEM, V272, P401; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Beutler E, 2004, SCIENCE, V306, P2051, DOI 10.1126/science.1107224; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Fashena SJ, 2000, GENE, V250, P1, DOI 10.1016/S0378-1119(00)00182-7; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FOX KR, 1987, BIOCHEM J, V243, P847, DOI 10.1042/bj2430847; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Haas H, 1999, J BIOL CHEM, V274, P4613, DOI 10.1074/jbc.274.8.4613; Haas H, 1997, J BIOL CHEM, V272, P22576, DOI 10.1074/jbc.272.36.22576; Haas H, 2003, APPL MICROBIOL BIOT, V62, P316, DOI 10.1007/s00253-003-1335-2; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Harrison KA, 2002, BIOCHEMISTRY-US, V41, P15288, DOI 10.1021/bi0204995; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; KEENEY JB, 1994, GENETICS, V136, P849; Kim J, 1998, GENETICS, V149, P795; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lan CY, 2004, MOL MICROBIOL, V53, P1451, DOI 10.1111/j.1365-2958.2004.04214.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17, DOI 10.1128/.61.1.17-32.1997; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; Miller JH., 1972, EXPT MOL GENETICS; Oberegger H, 2002, BIOCHEM SOC T, V30, P781, DOI 10.1042/bst0300781; Oberegger H, 2001, MOL MICROBIOL, V41, P1077, DOI 10.1046/j.1365-2958.2001.02586.x; Pelletier B, 2003, NUCLEIC ACIDS RES, V31, P4332, DOI 10.1093/nar/gkg647; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Puig S, 2005, CELL, V120, P99, DOI 10.1016/j.cell.2004.11.032; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Scazzocchio C, 2000, CURR OPIN MICROBIOL, V3, P126, DOI 10.1016/S1369-5274(00)00063-1; Schrettl M, 2004, BIOMETALS, V17, P647, DOI 10.1007/s10534-004-1230-z; Siam R, 2004, METHODS, V33, P189, DOI 10.1016/j.ymeth.2003.11.013; Svetlov VV, 1998, J BACTERIOL, V180, P5682, DOI 10.1128/JB.180.21.5682-5688.1998; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhou LW, 1999, BIOCHEMISTRY-US, V38, P4335, DOI 10.1021/bi982543f; Znaidi S, 2004, J BIOL CHEM, V279, P9462, DOI 10.1074/jbc.M312787200	56	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25146	25161		10.1074/jbc.M502947200	http://dx.doi.org/10.1074/jbc.M502947200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866870	hybrid			2022-12-25	WOS:000230114000099
J	Tse, SML; Mason, D; Botelho, RJ; Chiu, B; Reyland, M; Hanada, K; Inman, RD; Grinstein, S				Tse, SML; Mason, D; Botelho, RJ; Chiu, B; Reyland, M; Hanada, K; Inman, RD; Grinstein, S			Accumulation of diacylglycerol in the Chlamydia inclusion vacuole - Possible role in the inhibition of host cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHORBOL ESTER BINDING; PKC-DELTA; SPHINGOLIPID BIOSYNTHESIS; GOLGI-APPARATUS; INFECTED CELLS; ACTIVATION; PHOSPHORYLATION; KERATINOCYTES; TRANSLOCATION	Intracellular pathogens have developed strategies to survive for extended periods inside their host cells. These include avoidance of host microbicidal effectors, often by sequestration in a protected subcompartment of the host cell. In some cases, the parasites exert also an antiapoptotic effect that prolongs the life of the infected host cell. Chlamydia utilizes both strategies, but the underlying molecular mechanisms are incompletely understood. Comparatively, little is known regarding the effects that Chlamydia exerts on the metabolism and distribution of the host cell lipids. The expression of fluorescently tagged C1 domains revealed that diacylglycerol is greatly accumulated in the immediate vicinity of Chlamydia inclusion vacuoles. The concentrated diacylglycerol recruits protein kinase C delta (PKC delta), a proapoptotic effector, to the immediate vicinity of the vacuole. PKC delta normally exerts its pro-apoptotic effects at the mitochondria and in the nucleus. We speculate that Chlamydia antagonizes the pro-apoptotic effect of PKC delta by sequestering the enzyme on the inclusion vacuole away from its conventional target sites. Accordingly, we found that the ectopic expression of a catalytic fragment of PKC delta that cannot be recruited by the vacuole, because it lacks a functional C1 domain, overcame the anti-apoptotic effect of the bacteria. The scavenging of pro-apoptotic factors may provide a novel mechanism whereby pathogens promote their own survival by extending the life of the host cells they infect.	Hosp Sick Children, Dept Cell Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Div Rheumatol, Dept Med, Toronto, ON M5T 2S8, Canada; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Boulder, CO 80309 USA; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Toyama 1620011, Japan; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Institute of Infectious Diseases (NIID); University of Toronto	Grinstein, S (corresponding author), Hosp Sick Children, Dept Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca	Botelho, Roberto J/B-9145-2013	Botelho, Roberto J/0000-0002-7820-0999; Hanada, Kentaro/0000-0003-1383-2781; Mason, David/0000-0002-8773-5274; Inman, Robert/0000-0002-4750-1422				Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Dean D, 2001, INFECT IMMUN, V69, P2442, DOI 10.1128/IAI.69.4.2442-2447.2001; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Li LW, 1999, MOL CELL BIOL, V19, P8547; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Perego C, 2002, BIOCHEM BIOPH RES CO, V294, P127, DOI 10.1016/S0006-291X(02)00448-5; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schultz A, 2004, J BIOL CHEM, V279, P31750, DOI 10.1074/jbc.M313017200; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Sweeney DA, 2002, J BIOL CHEM, V277, P3030, DOI 10.1074/jbc.M104639200	33	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25210	25215		10.1074/jbc.M501980200	http://dx.doi.org/10.1074/jbc.M501980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863503	hybrid			2022-12-25	WOS:000230114000106
J	Tagawa, H; Kizuka, Y; Ikeda, T; Itoh, S; Kawasaki, N; Kurihara, H; Onozato, ML; Tojo, A; Sakai, T; Kawasaki, T; Oka, S				Tagawa, H; Kizuka, Y; Ikeda, T; Itoh, S; Kawasaki, N; Kurihara, H; Onozato, ML; Tojo, A; Sakai, T; Kawasaki, T; Oka, S			A non-sulfated form of the HNK-1 carbohydrate is expressed in mouse kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; MYELIN GLYCOPROTEIN P0; NERVOUS-SYSTEM; RAT-KIDNEY; MONOCLONAL-ANTIBODIES; MICE DEFICIENT; EPITOPE HNK-1; BRUSH-BORDER; AMINO-ACIDS; N-GLYCANS	The HNK-1 carbohydrate, which is recognized by anti-HNK-1 antibody, is well known to be expressed predominantly in the nervous system. The characteristic structural feature of the HNK-1 carbohydrate is 3-sulfo-glucuronyl residues attached to lactosamine structures (Gal beta 1-4GlcNAc) on glycoproteins and glycolipids. The biosynthesis of the HNK-1 carbohydrate is regulated mainly by two glucuronyltransferases (GlcAT-P and GlcAT-S) and a sulfotransferase. In this study, we found that GlcAT-S mRNA was expressed at higher levels in the kidney than in the brain, but that both GlcAT-P and HNK-1 sulfotransferase mRNAs, which were expressed at high levels in the brain, were not detected in the kidney. These results suggested that the HNK-1 carbohydrate without sulfate (non-sulfated HNK-1 carbohydrate) is expressed in the kidney. We substantiated this hypothesis using two different monoclonal antibodies: one (anti-HNK-1 antibody) requires sulfate on glucuronyl residues for its binding, and the other (antibody M6749) does not. Western blot analyses of mouse kidney revealed that two major bands (80 and 140 kDa) were detected with antibody M6749, but not with anti-HNK-1 antibody. The 80- and 140-kDa band materials were identified as meprin alpha and CD13/aminopeptidase N, respectively. We also confirmed the presence of the non-sulfated HNK-1 carbohydrate on N-linked oligosaccharides by multistage tandem mass spectrometry. Immunofluorescence staining with antibody M6749 revealed that the non-sulfated HNK-1 carbohydrate was expressed predominantly on the apical membranes of the proximal tubules in the cortex and was also detected in the thin ascending limb in the inner medulla. This is the first study indicating the presence of the non-sulfated HNK-1 carbohydrate being synthesized by GlcAT-S in the kidney. The results presented here constitute novel knowledge concerning the function of the HNK-1 carbohydrate.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Sankyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Japan Sci & Technol Corp, Kyoto 6068501, Japan; Natl Inst Hlth Sci, Div Biol Chem & Biol, Tokyo 1588501, Japan; Juntendo Univ, Sch Med, Dept Anat, Tokyo 1138421, Japan; Univ Tokyo, Div Nephrol & Endocrinol, Tokyo 1138655, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; National Institute of Health Sciences - Japan; Juntendo University; University of Tokyo	Oka, S (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Sankyo Ku, Kyoto 6068501, Japan.	shogo@pharm.kyoto-u.ac.jp		Kizuka, Yasuhiko/0000-0002-3181-9743				ABO T, 1981, J IMMUNOL, V127, P1024; Agre P, 2000, J AM SOC NEPHROL, V11, P764, DOI 10.1681/ASN.V114764; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FASTH A, 1986, AM J PATHOL, V125, P555; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Gallego RG, 2001, J BIOL CHEM, V276, P30834, DOI 10.1074/jbc.M101013200; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JIANG WP, 1992, J BIOL CHEM, V267, P9185; Kadowaki T, 2000, J BIOL CHEM, V275, P25577, DOI 10.1074/jbc.M003521200; Kakuda S, 2005, GLYCOBIOLOGY, V15, P203, DOI 10.1093/glycob/cwi001; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; OBATA K, 1988, NEUROSCI RES, V6, P131, DOI 10.1016/0168-0102(88)90015-6; OKA S, 1992, J BIOL CHEM, V267, P22711; OLBRICHT CJ, 1986, AM J PHYSIOL, V250, P1055; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Pfaff IL, 1999, J AM SOC NEPHROL, V10, P1861; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Senn C, 2002, MOL CELL NEUROSCI, V20, P712, DOI 10.1006/mcne.2002.1142; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TAUC M, 1988, J HISTOCHEM CYTOCHEM, V36, P523, DOI 10.1177/36.5.2895788; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Vandewalle A, 1997, AM J PHYSIOL-RENAL, V272, pF678, DOI 10.1152/ajprenal.1997.272.5.F678; Villa JP, 2003, J BIOL CHEM, V278, P42545, DOI 10.1074/jbc.M303718200; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Wuhrer M, 2003, BIOCHIMIE, V85, P207, DOI 10.1016/S0300-9084(03)00043-9; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200; Yamamoto S, 2002, J BIOCHEM, V131, P337, DOI 10.1093/oxfordjournals.jbchem.a003108; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	39	33	33	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23876	23883		10.1074/jbc.M501728200	http://dx.doi.org/10.1074/jbc.M501728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843379	hybrid			2022-12-25	WOS:000229880000061
J	Chen, EI; Florens, L; Axelrod, FT; Monosov, E; Barbas, CF; Yates, JR; Felding-Habermann, B; Smith, JW				Chen, EI; Florens, L; Axelrod, FT; Monosov, E; Barbas, CF; Yates, JR; Felding-Habermann, B; Smith, JW			Maspin alters the carcinoma proteome	FASEB JOURNAL			English	Article						cancer proteomics; MudPIT; tumor suppressor; metastasis; protein profiling	MAJOR HISTOCOMPATIBILITY COMPLEX; MASS-SPECTRAL DATA; MULTICATALYTIC PROTEINASE; PLASMINOGEN-ACTIVATOR; PEPTIDASE ACTIVITIES; TUMOR PROGRESSION; SUBUNIT PATTERN; BREAST-CANCER; PROTEASOME; EXPRESSION	Maspin, a member of the serine protease inhibitor (serpin) family, is a tumor suppressor in breast and prostate cancer. To address molecular mechanisms underlying maspin's activity, we restored its expression in invasive carcinoma cells and analyzed the resulting changes by shotgun proteomics. Using a mass spectrometry-based multidimensional proteomic method, we observed changes to the expression of similar to 27% of the detectable proteome. In particular, we noted changes to the expression of proteins that regulate cytoskeletal architecture, cell death, and protein turnover. In each case, changes in protein expression were accompanied by measurable changes in tumor cell phenotype. Thus, maspin-expressing cells exhibit a more prominent actin cytoskeleton, a reduced invasive capacity, an increased rate of spontaneous apoptosis, and an altered proteasome function. These observations reveal for the first time the far reaching effects of maspin on multiple protein networks and a new hypothesis of maspin function based on the regulation of proteasome function.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, Canc Res Ctr, Program Cell Adhes, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Scripps Research Institute	Chen, EI (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	emilyc@scripps.edu		Florens, Laurence/0000-0002-9310-6650	NCI NIH HHS [CA30199, CA95458, CA69306, 5 R01 CA086258, CA82713] Funding Source: Medline; NCRR NIH HHS [M01 RR00833, U54 RR020843-01, M01 RR0083] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07695] Funding Source: Medline; NIAID NIH HHS [R21AI53781] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA095458, P01CA082713, R01CA086258, R01CA069306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833, U54RR020843, M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053781] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Bennett RG, 2000, ENDOCRINOLOGY, V141, P2508, DOI 10.1210/en.141.7.2508; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CARDOZO C, 1995, J BIOL CHEM, V270, P22645, DOI 10.1074/jbc.270.38.22645; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hojo T, 2001, CANCER LETT, V171, P103, DOI 10.1016/S0304-3835(01)00569-9; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maass N, 2001, J PATHOL, V195, P321; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; McGowen R, 2000, CANCER RES, V60, P4771; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319; Ngamkitidechakul C, 2003, J BIOL CHEM, V278, P31796, DOI 10.1074/jbc.M302408200; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PARISH RW, 1987, J CELL SCI, P181; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PRICE JE, 1990, CANCER RES, V50, P717; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sadygov RG, 2003, ANAL CHEM, V75, P3792, DOI 10.1021/ac034157w; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Sood AK, 2002, CLIN CANCER RES, V8, P2924; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Van den Eynde BJ, 2001, CURR OPIN IMMUNOL, V13, P147, DOI 10.1016/S0952-7915(00)00197-7; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	56	30	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1123	+		10.1096/fj.04-2970fje	http://dx.doi.org/10.1096/fj.04-2970fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857880				2022-12-25	WOS:000228865300005
J	Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA				Abraham, N; Ma, MC; Snow, JW; Miners, MJ; Herndier, BG; Goldsmith, MA			Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas	ONCOGENE			English	Article						cytokine; cytokine receptors; transcription factors; haploinsufficiency; lymphoma development	SEVERE COMBINED IMMUNODEFICIENCY; LYMPHOBLASTIC-LEUKEMIA CELLS; HEMATOPOIETIC STEM-CELLS; INTERLEUKIN-7 RECEPTOR; T-CELLS; IN-VIVO; CYCLE PROGRESSION; SEXUAL-DIMORPHISM; GENE-EXPRESSION; TRANSGENIC MICE	The requirement for receptor components and the signalling effector, signal transducer and activator of transcription (STAT) 5A/5B, was assessed genetically in a lymphoma development model induced by interleukin-7 (IL-7). This growth factor for T- and B-cell progenitors and mature lymphocytes activates survival and proliferative pathways including Bcl-2, phosphatidylinositol-3 kinase and STAT5. Overexpression of IL-7 in vivo causes early mortality from lymphoma development. Mice overexpressing IL-7 that were heterozygous for the IL-7R alpha subunit showed improved survival compared to wild-type mice. In addition, STAT5A/5B(+/-) compound heterozygous mice with one targeted allele each of STAT5A and STAT5B showed striking amelioration of IL-7-induced mortality and disease development. STAT5A/5B(+/-) compound heterozygous mice were otherwise normal in stem cell and lymphocyte development and cellularity. Lower STAT5 protein levels accompanied the reduction in STAT5A/5B copy number, which suggests that STAT5 haploinsufficiency is a modifier of IL-7 signal strength.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of British Columbia; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Francisco	Abraham, N (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	ninan@interchange.ubc.ca	Abraham, Ninan/K-5572-2012	Abraham, Ninan/0000-0002-2747-1246	NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENJAMIN D, 1994, J IMMUNOL, V152, P4749; Bradley HL, 2002, BLOOD, V100, P3983, DOI 10.1182/blood-2002-05-1602; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DADI HK, 1993, J CLIN INVEST, V92, P1559, DOI 10.1172/JCI116736; DALLOUL A, 1992, J CLIN INVEST, V90, P1054, DOI 10.1172/JCI115920; Danilovich N, 2002, BIOL REPROD, V67, P361, DOI 10.1095/biolreprod67.2.361; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; FISHER AG, 1993, LEUKEMIA, V7, pS66; FRISHMAN J, 1993, J EXP MED, V177, P955, DOI 10.1084/jem.177.4.955; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Hofmeister R, 1999, CYTOKINE GROWTH F R, V10, P41, DOI 10.1016/S1359-6101(98)00025-2; Jegalian AG, 2002, BLOOD, V99, P2603, DOI 10.1182/blood.V99.7.2603; Kang JS, 2004, J IMMUNOL, V173, P2307, DOI 10.4049/jimmunol.173.4.2307; Kemkemer R, 2002, P NATL ACAD SCI USA, V99, P13783, DOI 10.1073/pnas.212386999; Kieslinger M, 2000, GENE DEV, V14, P232; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Qin JZ, 2001, J INVEST DERMATOL, V117, P583, DOI 10.1046/j.0022-202x.2001.01436.x; Qin JZ, 2001, BLOOD, V98, P2778, DOI 10.1182/blood.V98.9.2778; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Seidman JG, 2002, J CLIN INVEST, V109, P451, DOI 10.1172/JC1200215043; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shelburne CP, 2002, MOL IMMUNOL, V38, P1187, DOI 10.1016/S0161-5890(02)00061-5; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Socolovsky M, 1998, P NATL ACAD SCI USA, V95, P6573, DOI 10.1073/pnas.95.12.6573; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; vanderPlas DC, 1996, LEUKEMIA, V10, P1317; VENKITARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168, DOI 10.1002/eji.1830240935; Williams IR, 1997, J IMMUNOL, V159, P3044; Zamorano J, 1998, J IMMUNOL, V160, P3502	53	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5252	5257		10.1038/sj.onc.1208726	http://dx.doi.org/10.1038/sj.onc.1208726			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15870688				2022-12-25	WOS:000230964600012
J	Ghosh, M; Meiss, G; Pingoud, A; London, RE; Pedersen, LC				Ghosh, M; Meiss, G; Pingoud, A; London, RE; Pedersen, LC			Structural insights into the mechanism of Nuclease A, a beta beta alpha metal nuclease from Anabaena	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERRATIA-MARCESCENS ENDONUCLEASE; SUGAR-NONSPECIFIC NUCLEASE; DNA-BINDING; EXTRACELLULAR NUCLEASE; PERIPLASMIC NUCLEASE; ACTIVE-SITE; AMINO-ACIDS; CLEAVAGE; IDENTIFICATION; VII	Nuclease A (NucA) is a nonspecific endonuclease from Anabaena sp. capable of degrading single- and double-stranded DNA and RNA in the presence of divalent metal ions. We have determined the structure of the Delta(2-24), D121A mutant of NucA in the presence of Zn2+ and Mn2+ (PDB code 1ZM8). The mutations were introduced to remove the N-terminal signal peptide and to reduce the activity of the nonspecific nuclease, thereby reducing its toxicity to the Escherichia coli expression system. NucA contains a beta beta alpha metal finger motif and a hydrated Mn2+ ion at the active site. Unexpectedly, NucA was found to contain additional metal binding sites similar to 26 angstrom apart from the catalytic metal binding site. A structural comparison between NucA and the closest analog for which structural data exist, the Serratia nuclease, indicates several interesting differences. First, NucA is a monomer rather than a dimer. Second, there is an unexpected structural homology between the N-terminal segments despite a poorly conserved sequence, which in Serratia includes a cysteine bridge thought to play a regulatory role. In addition, although a sequence alignment had suggested that NucA lacks a proposed catalytic residue corresponding to Arg(57) in Serratia, the structure determined here indicates that Arg(93) in NucA is positioned to fulfill this role. Based on comparison with DNA-bound nuclease structures of the beta beta alpha metal finger nuclease family and available mutational data on NucA, we propose that His(124) acts as a catalytic base, and Arg(93) participates in the catalysis possibly through stabilization of the transition state.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; Univ Giessen, Inst Biochem, FB08, D-35392 Giessen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Justus Liebig University Giessen	London, RE (corresponding author), NIEHS, Struct Biol Lab, MR 01,111 Alexnder Dr,Box 12233, Res Triangle Pk, NC 27709 USA.	london@niehs.nih.gov	Pedersen, Lars/C-6173-2019; London, Robert E/F-7990-2019	Pedersen, Lars/0000-0002-4488-4077; London, Robert E/0000-0001-9108-8463	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050147, ZIAES050147] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALL TK, 1992, NUCLEIC ACIDS RES, V20, P4971, DOI 10.1093/nar/20.19.4971; BALL TK, 1987, GENE, V57, P183, DOI 10.1016/0378-1119(87)90121-1; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Benedik MJ, 1998, FEMS MICROBIOL LETT, V165, P1; Birkenbihl RP, 1998, EMBO J, V17, P4527, DOI 10.1093/emboj/17.15.4527; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COTE J, 1989, J BIOL CHEM, V264, P3301; DOHERTY AJ, 1995, J MOL BIOL, V251, P366, DOI 10.1006/jmbi.1995.0440; FILIMONOVA M N, 1981, Biokhimiya, V46, P1660; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Franke I, 1999, J BIOL CHEM, V274, P825, DOI 10.1074/jbc.274.2.825; Franke I, 1998, FEBS LETT, V425, P517, DOI 10.1016/S0014-5793(98)00279-8; Friedhoff P, 1999, FEBS LETT, V443, P209, DOI 10.1016/S0014-5793(98)01660-3; Friedhoff P, 1999, NAT STRUCT BIOL, V6, P112; FRIEDHOFF P, 1994, NUCLEIC ACIDS RES, V22, P3280, DOI 10.1093/nar/22.16.3280; Friedhoff P, 1996, EUR J BIOCHEM, V241, P572, DOI 10.1111/j.1432-1033.1996.00572.x; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; Golz S, 1997, EUR J BIOCHEM, V245, P573, DOI 10.1111/j.1432-1033.1997.00573.x; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hsia KC, 2004, STRUCTURE, V12, P205, DOI 10.1016/j.str.2004.01.004; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirby TW, 2002, J MOL BIOL, V320, P771, DOI 10.1016/S0022-2836(02)00460-6; Kleanthous C, 2001, TRENDS BIOCHEM SCI, V26, P624, DOI 10.1016/S0968-0004(01)01941-7; Kuhlmann UC, 1999, FEBS LETT, V463, P1, DOI 10.1016/S0014-5793(99)01499-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Mannino SJ, 1999, BIOCHEMISTRY-US, V38, P16178, DOI 10.1021/bi991452v; Mate MJ, 2004, J BIOL CHEM, V279, P34763, DOI 10.1074/jbc.M403719200; MEISS G, 1995, BIOCHEMISTRY-US, V34, P11979, DOI 10.1021/bi00037a040; Meiss G, 2000, J MOL BIOL, V297, P521, DOI 10.1006/jmbi.2000.3586; Meiss G, 1999, J MOL BIOL, V288, P377, DOI 10.1006/jmbi.1999.2694; Meiss G, 1998, EUR J BIOCHEM, V251, P924, DOI 10.1046/j.1432-1327.1998.2510924.x; Miller MD, 1999, J MOL BIOL, V288, P975, DOI 10.1006/jmbi.1999.2729; Miller MD, 1996, PROTEIN SCI, V5, P24; MUROPASTOR AM, 1992, MOL MICROBIOL, V6, P3021, DOI 10.1111/j.1365-2958.1992.tb01760.x; MuroPastor AM, 1997, J MOL BIOL, V268, P589, DOI 10.1006/jmbi.1997.0985; NESTLE M, 1969, J BIOL CHEM, V244, P5213; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pommer AJ, 2001, J MOL BIOL, V314, P735, DOI 10.1006/jmbi.2001.5189; PUYET A, 1990, J MOL BIOL, V213, P727, DOI 10.1016/S0022-2836(05)80259-1; Raaijmakers H, 2001, J MOL BIOL, V308, P311, DOI 10.1006/jmbi.2001.4592; Saravanan M, 2004, NUCLEIC ACIDS RES, V32, P6129, DOI 10.1093/nar/gkh951; Schafer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069; Shen BW, 2004, J MOL BIOL, V342, P43, DOI 10.1016/j.jmb.2004.07.032; Shlyapnikov SV, 2000, ACTA CRYSTALLOGR D, V56, P567, DOI 10.1107/S090744490000322X; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; Walker DC, 2002, NUCLEIC ACIDS RES, V30, P3225, DOI 10.1093/nar/gkf420; Woo EJ, 2004, MOL CELL, V14, P531, DOI 10.1016/S1097-2765(04)00258-8; Wu SI, 2001, APPL ENVIRON MICROB, V67, P82, DOI 10.1128/AEM.67.1.82-88.2001	54	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27990	27997		10.1074/jbc.M501798200	http://dx.doi.org/10.1074/jbc.M501798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15897201	hybrid			2022-12-25	WOS:000230678600061
J	Kitzing, K; Fitzpatrick, TB; Wilken, C; Sawa, J; Bourenkov, GP; Macheroux, P; Clausen, T				Kitzing, K; Fitzpatrick, TB; Wilken, C; Sawa, J; Bourenkov, GP; Macheroux, P; Clausen, T			The 1.3 A crystal structure of the flavoprotein YqjM reveals a novel class of Old Yellow Enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; PROTEIN CRYSTALLOGRAPHY; STRUCTURE REFINEMENT; OXIDATIVE STRESS; REACTIVITY; REDUCTASE; BINDING; RESOLUTION; HOMOLOG; PROGRAM	Here we report the crystal structure of YqjM, a homolog of Old Yellow Enzyme (OYE) that is involved in the oxidative stress response of Bacillus subtilis. In addition to the oxidized and reduced enzyme form, the structures of complexes with p-hydroxybenzaldehyde and pnitrophenol, respectively, were solved. As for other OYE family members, YqjM folds into a (alpha/beta) (8)-barrel and has one molecule of flavin mononucleotide bound non-covalently at the COOH termini of the beta-sheet. Most of the interactions that control the electronic properties of the flavin mononucleotide cofactor are conserved within the OYE family. However, in contrast to all members of the OYE family characterized to date, YqjM exhibits several unique structural features. For example, the enzyme exists as a homotetramer that is assembled as a dimer of catalytically dependent dimers. Moreover, the protein displays a shared active site architecture where an arginine finger (Arg(336)) at the COOH terminus of one monomer extends into the active site of the adjacent monomer and is directly involved in substrate recognition. Another remarkable difference in the binding of the ligand in YqjM is represented by the contribution of the NH2-terminal Tyr(28) instead of a COOH-terminal tyrosine in OYE and its homologs. The structural information led to a specific data base search from which a new class of OYE oxidoreductases was identified that exhibits a strict conservation of active site residues, which are critical for this subfamily, most notably Cys(26), Tyr(28), Lys(109), and Arg(336). Therefore, YqjM is the first representative of a new bacterial subfamily of OYE homologs.	Res Inst Mol Pathol, A-1030 Vienna, Austria; ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland; Max Planck Arbeitsgrp Strukturelle Mol Biol, Deutsch Elektronen Synchrotron, D-22603 Hamburg, Germany; Graz Tech Univ, Inst Biochem, A-8010 Graz, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Graz University of Technology	Kitzing, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	kitzingk@gmx.net; clausen@imp.univie.ac.at	Macheroux, Peter/AAB-5157-2019; Bourenkov, Gleb P/C-7794-2017	Macheroux, Peter/0000-0002-0242-454X; Bourenkov, Gleb P/0000-0002-2617-5920; Clausen, Tim/0000-0003-1582-6924				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Breithaupt C, 2001, STRUCTURE, V9, P419, DOI 10.1016/S0969-2126(01)00602-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fitzpatrick TB, 2004, PROTEIN EXPRES PURIF, V36, P280, DOI 10.1016/j.pep.2004.04.012; Fitzpatrick TB, 2003, J BIOL CHEM, V278, P19891, DOI 10.1074/jbc.M211778200; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Haarer BK, 2004, MOL BIOL CELL, V15, P4522, DOI 10.1091/mbc.E04-06-0445; Hasford JJ, 1997, J ORG CHEM, V62, P5244, DOI 10.1021/jo9703865; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Malone TE, 2005, PROTEINS, V58, P243, DOI 10.1002/prot.20162; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; SIMONDSEN RP, 1980, MOL CELL BIOCHEM, V33, P13; STOTT K, 1993, J BIOL CHEM, V268, P6097; Theorell H, 1935, BIOCHEM Z, V275, P344; THEORELL H, 1954, ACTA CHEM SCAND, V8, P1104, DOI 10.3891/acta.chem.scand.08-1104c; THEORELL H, 1954, ARK KEMI, V7, P205; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; WARBURG O, 1932, NATURWISSENSCHAFTEN, V20, P688; Xu D, 1999, P NATL ACAD SCI USA, V96, P3556, DOI 10.1073/pnas.96.7.3556	33	104	117	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27904	27913		10.1074/jbc.M502587200	http://dx.doi.org/10.1074/jbc.M502587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15890652	hybrid, Green Published			2022-12-25	WOS:000230678600053
J	Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA				Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA			Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome	ONCOGENE			English	Article						microarray; Werner syndrome; DNA damage; aging	REPLICATIVE SENESCENCE; CALORIC RESTRICTION; 4-NITROQUINOLINE 1-OXIDE; SACCHAROMYCES-CEREVISIAE; SYNDROME FIBROBLASTS; ADAPTIVE RESPONSE; OXIDATIVE STRESS; CELL-LINES; LIFE-SPAN; REPAIR	The accumulation of DNA damage and mutations is considered a major cause of cancer and aging. While it is known that DNA damage can affect changes in gene expression, transcriptional regulation after DNA damage is poorly understood. We characterized the expression of 6912 genes in human primary. broblasts after exposure to three different kinds of cellular stress that introduces DNA damage: 4- nitroquinoline-1-oxide (4NQO), gamma-irradiation, or UV-irradiation. Each type of stress elicited damage specific gene expression changes of up to 10-fold. A total of 85 genes had similar changes in expression of 3-40- fold after all three kinds of stress. We examined transcription in cells from young and old individuals and from patients with Werner syndrome (WS), a segmental progeroid condition with a high incidence of cancer, and found various age-associated transcriptional changes depending upon the type of cellular stress. Compared to young individuals, both WS and old individuals had similarly aberrant transcriptional responses to gamma- and UV-irradiation, suggesting a role for Werner protein in stress- induced gene expression. Our results suggest that aberrant DNA damage-induced gene regulation may contribute to the aging process and the premature aging in WS.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus, Denmark; NIA, Gene Express & Genom Unit, Baltimore, MD 21224 USA; Univ Aarhus, Inst Human Genet, DK-8000 Aarhus, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Kyng, Kasper/AAA-5339-2019	Kyng, Kasper/0000-0001-7940-1656; Stevnsner, Tinna/0000-0003-1007-0427; Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; COLLIER IE, 1982, MECH AGEING DEV, V19, P141, DOI 10.1016/0047-6374(82)90005-7; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; LAMBERT B, 1979, CANCER RES, V39, P2792; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Moggs JG, 2003, TOXICOL LETT, V140, P149, DOI 10.1016/S0378-4274(02)00501-5; Moradas-Ferreira P, 2000, REDOX REP, V5, P277, DOI 10.1179/135100000101535816; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nakura J, 2000, CELL MOL LIFE SCI, V57, P716, DOI 10.1007/s000180050036; Nantel A, 2002, MOL BIOL CELL, V13, P3452, DOI 10.1091/mbc.E02-05-0272; NIEDERMULLER H, 1985, MECH AGEING DEV, V29, P221, DOI 10.1016/0047-6374(85)90064-8; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Ostermeier GC, 2002, LANCET, V360, P772, DOI 10.1016/S0140-6736(02)09899-9; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 1999, HUM GENET, V105, P132, DOI 10.1007/s004390051075; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Smith L, 2003, HUM MOL GENET, V12, pR1, DOI 10.1093/hmg/ddg053; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Volkert MR, 2001, CURR OPIN MICROBIOL, V4, P178, DOI 10.1016/S1369-5274(00)00186-7; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; Welle S, 2002, EXP GERONTOL, V37, P583, DOI 10.1016/S0531-5565(01)00231-5; Welle S, 2001, PHYSIOL GENOMICS, V5, P67, DOI 10.1152/physiolgenomics.2001.5.2.67; Xu GG, 2000, MUTAT RES-DNA REPAIR, V459, P195, DOI 10.1016/S0921-8777(99)00069-5; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Zahn RK, 2000, MECH AGEING DEV, V119, P101, DOI 10.1016/S0047-6374(00)00170-6; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	58	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5026	5042		10.1038/sj.onc.1208692	http://dx.doi.org/10.1038/sj.onc.1208692			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897889				2022-12-25	WOS:000230816900003
J	Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M				Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M			TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38 MAPK-dependent pathway	ONCOGENE			English	Article						p38 MAP kinase; c-jun; Ah receptor; dioxin; cross-talk; TCDD	GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; GENE-EXPRESSION; HEPATOMA-CELLS; CROSS-TALK; KAPPA-B; ACTIVATION; AP-1; TOXICITY	The aryl hydrocarbon receptor (AhR) has a fundamental role during postnatal liver development and is essential for mediating dioxin toxicity. However, the genetic programs mediating, both, the toxic and physiological effects downstream of the transcription factor AhR are in major parts unknown. We have identified the proto-oncogene c-jun as a novel target gene of AhR. Induction of c-jun depends on activation of p38-mitogen-activated protein kinase (MAPK) by an AhR-dependent mechanism. None of the kinases that are known to phosphorylate p38-MAPK is activated by AhR. Neither the dephosphorylation rate of p38-MAPK is reduced. Furthermore, increased p38-MAPK phosphorylation in response to dioxins does not require ongoing transcription. These findings establish activating 'cross-talk' with MAPK signaling as a novel principle of AhR action, which is apparently independent of the AhR's function as a DNA-binding transcriptional activator.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Univ Karlsruhe, Dept Food Chem & Toxicol, D-76128 Karlsruhe, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Toxicol, D-85764 Neuherberg, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weiss, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherster 67, D-55131 Mainz, Germany.	weissca@uni-mainz.de; martin.goettlicher@gsf.de	Oesch, Franz/AAA-8746-2020; Göttlicher, Martin/M-7342-2014; Weiss, Carsten/I-1811-2013	Göttlicher, Martin/0000-0003-0619-2181; Weiss, Carsten/0000-0002-5380-3208				Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; ENAN E, 1995, BIOCHEM PHARMACOL, V49, P249, DOI 10.1016/S0006-2952(94)00430-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Noselli S, 2000, SCIENCE, V290, P68, DOI 10.1126/science.290.5489.68; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDENHEUVEL JP, 1993, ENVIRON HEALTH PERSP, V100, P189, DOI 10.1289/ehp.93100189; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weiss C, 2004, CELL CYCLE, V3, P111; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; ZUGERMAN C, 1990, DERMATOL CLIN, V8, P209, DOI 10.1016/S0733-8635(18)30553-9	45	77	82	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4975	4983		10.1038/sj.onc.1208679	http://dx.doi.org/10.1038/sj.onc.1208679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897893				2022-12-25	WOS:000230646500010
J	Li, CS; Zienkiewicz, J; Hawiger, J				Li, CS; Zienkiewicz, J; Hawiger, J			Interactive sites in the MyD88 toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1 beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACCESSORY PROTEIN; TOLL-LIKE RECEPTORS; SWISS-MODEL; TIR DOMAIN; KAPPA-B; INTERLEUKIN-1; IRAK; FAMILY; ADAPTERS; COMPLEX	Myeloid differentiation factor MyD88 is the essential adaptor protein that integrates and transduces intracellular signals generated by multiple Toll-like receptors including receptor complex for interleukin (IL) 1 beta, a key inflammatory cytokine. IL1 beta receptor complex interacts with MyD88 via the Toll/IL1 receptor (TIR) domain. Here we report structure-function studies that help define the MyD88 TIR domain binding sites involved in IL1 beta-induced protein-protein interactions. The MyD88 TIR domain, employed as a dominant negative inhibitor of IL1 beta signaling to screen MyD88 TIR mutants, lost its suppressing activity upon truncation of its Box 3. Accordingly, mutations of Box 3 residues 285-286 reversed the dominant negative effect of the MyD88 TIR domain on IL1 beta-induced and NF kappa B-dependent reporter gene activity and IL6 production. Moreover, mutations of residues 171 in helix alpha A, 195-197 in Box 2, and 275 in beta E-strand had similar functional effects. Strikingly, only mutations of residues 195-197 eliminated the TIR-TIR interaction of MyD88 and IL1 receptor accessory protein (IL1RAcP), whereas substitution of neighboring canonical Pro(200) by His was without effect. Mutations in Box 2 and 3 prevented homotypic MyD88 oligomerization via TIR domain. Based on this structure-function analysis, a three-dimensional docking model of TIR-TIR interaction between MyD88 and IL1RAcP was developed.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 1161 21st Ave S,A-5321 MCN, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu			NCI NIH HHS [2P30CA68485] Funding Source: Medline; NHLBI NIH HHS [P01 HL068744, HL62356, HL68744, HL69542, R01 HL069452, R01 HL062356] Funding Source: Medline; NIDDK NIH HHS [5P30DK058404-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, R43HL069542, R01HL062356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200; Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Radons J, 2002, J BIOL CHEM, V277, P16456, DOI 10.1074/jbc.M201000200; Radons JR, 2003, J BIOL CHEM, V278, P49145, DOI 10.1074/jbc.M306077200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Tao X, 2002, BIOCHEM BIOPH RES CO, V299, P216, DOI 10.1016/S0006-291X(02)02581-0; VANNIER E, 1994, J BIOL CHEM, V269, P9952; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006	27	93	101	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26152	26159		10.1074/jbc.M503262200	http://dx.doi.org/10.1074/jbc.M503262200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15849357	hybrid			2022-12-25	WOS:000230386800028
J	Karlsson, M; Ekeroth, J; Elwing, H; Carlsson, U				Karlsson, M; Ekeroth, J; Elwing, H; Carlsson, U			Reduction of irreversible protein adsorption on solid surfaces by protein engineering for increased stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARBONIC-ANHYDRASE; INDUCED CONFORMATIONAL-CHANGES; REVERSED-PHASE CHROMATOGRAPHY; SELF-ASSEMBLED MONOLAYERS; MOLTEN-GLOBULE; SILICA NANOPARTICLES; LYSOZYME; SITE; AGGREGATION; VARIANTS	The influence of protein stability on the adsorption and desorption behavior to surfaces with fundamentally different properties (negatively charged, positively charged, hydrophilic, and hydrophobic) was examined by surface plasmon resonance measurements. Three engineered variants of human carbonic anhydrase II were used that have unchanged surface properties but large differences in stability. The orientation and conformational state of the adsorbed protein could be elucidated by taking all of the following properties of the protein variants into account: stability, unfolding, adsorption, and desorption behavior. Regardless of the nature of the surface, there were correlation between (i) the protein stability and kinetics of adsorption, with an increased amplitude of the first kinetic phase of adsorption with increasing stability; (ii) the protein stability and the extent of maximally adsorbed protein to the actual surface, with an increased amount of adsorbed protein with increasing stability; (iii) the protein stability and the amount of protein desorbed upon washing with buffer, with an increased elutability of the adsorbed protein with increased stability. All of the above correlations could be explained by the rate of denaturation and the conformational state of the adsorbed protein. In conclusion, protein engineering for increased stability can be used as a strategy to decrease irreversible adsorption on surfaces at a liquid-solid interface.	Linkoping Univ, Dept Chem, IFM, SE-58183 Linkoping, Sweden; Univ Gothenburg, Dept Cell & Mol Biol, SE-40530 Gothenburg, Sweden	Linkoping University; University of Gothenburg	Elwing, H (corresponding author), Linkoping Univ, Dept Chem, IFM, SE-58183 Linkoping, Sweden.	ucn@ifm.liu.se		Karlsson, Martin/0000-0002-6681-4897				Ball V, 1996, LANGMUIR, V12, P1614, DOI 10.1021/la950735v; Billsten P, 1997, FEBS LETT, V402, P67, DOI 10.1016/S0014-5793(96)01431-7; Bower CK, 1999, BIOTECHNOL BIOENG, V64, P373, DOI 10.1002/(SICI)1097-0290(19990805)64:3<373::AID-BIT14>3.0.CO;2-J; Burkett SL, 2001, LANGMUIR, V17, P5059, DOI 10.1021/la010156s; Carignano MA, 2000, COLLOID SURFACE B, V18, P169, DOI 10.1016/S0927-7765(99)00146-0; Chapman RG, 2000, J AM CHEM SOC, V122, P8303, DOI 10.1021/ja000774f; Ekeroth J, 2002, LANGMUIR, V18, P7923, DOI 10.1021/la026131q; Ekeroth J, 2002, J COLLOID INTERF SCI, V254, P322, DOI 10.1006/jcis.2002.8576; Engel MFM, 2002, J BIOL CHEM, V277, P10922, DOI 10.1074/jbc.M106005200; Hammarstrom P, 1999, J BIOL CHEM, V274, P32897, DOI 10.1074/jbc.274.46.32897; Hlady V, 1996, CURR OPIN BIOTECH, V7, P72, DOI 10.1016/S0958-1669(96)80098-X; Hook F, 2001, ANAL CHEM, V73, P5796, DOI 10.1021/ac0106501; JONSSON M, 1968, ACTA CHEM SCAND, V22, P712, DOI 10.3891/acta.chem.scand.22-0712; Karlsson M, 2005, BIOPHYS J, V88, P3536, DOI 10.1529/biophysj.104.054809; Karlsson M, 2000, LANGMUIR, V16, P8470, DOI 10.1021/la0002738; Karlsson M, 2005, BIOCHEMISTRY-US, V44, P3487, DOI 10.1021/bi048610p; Karlsson M, 2004, BIOCHEMISTRY-US, V43, P6803, DOI 10.1021/bi049709z; Malmsten M, 1998, J COLLOID INTERF SCI, V207, P186, DOI 10.1006/jcis.1998.5763; Malmsten M, 1998, J COLLOID INTERF SCI, V204, P104, DOI 10.1006/jcis.1998.5568; MARTENSSON LG, 1992, BIOCHIM BIOPHYS ACTA, V1118, P179; MARTENSSON LG, 1993, BIOCHEMISTRY-US, V32, P224, DOI 10.1021/bi00052a029; Martensson LG, 2002, BIOCHEMISTRY-US, V41, P15867, DOI 10.1021/bi020433+; Matheis W, 2001, VACCINE, V20, P67, DOI 10.1016/S0264-410X(01)00317-6; MCGUIRE J, 1995, J COLLOID INTERF SCI, V170, P182, DOI 10.1006/jcis.1995.1087; Mcleod AG, 2000, HAEMOPHILIA, V6, P89; McNay JLM, 2001, BIOTECHNOL BIOENG, V76, P233, DOI 10.1002/bit.10016; McNay JLM, 2001, BIOTECHNOL BIOENG, V76, P224, DOI 10.1002/bit.10015; Moulin AM, 1999, LANGMUIR, V15, P8776, DOI 10.1021/la990416u; Nakanishi K, 2001, J BIOSCI BIOENG, V91, P233, DOI 10.1016/S1389-1723(01)80127-4; NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4; Ostuni E, 2001, LANGMUIR, V17, P5605, DOI 10.1021/la010384m; Petrash S, 2001, LANGMUIR, V17, P7645, DOI 10.1021/la011192u; PTITSYN OB, 1995, PHILOS T ROY SOC B, V348, P35, DOI 10.1098/rstb.1995.0043; RAMSDEN JJ, 1995, J AM CHEM SOC, V117, P8511, DOI 10.1021/ja00138a003; Roque ACA, 2004, BIOTECHNOL PROGR, V20, P639, DOI 10.1021/bp030070k; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Stuart MAC, 1998, SURF SCI SERIES, V75, P1; Tzannis ST, 1996, P NATL ACAD SCI USA, V93, P5460, DOI 10.1073/pnas.93.11.5460; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Valimaa L, 2004, ANAL BIOCHEM, V331, P376, DOI 10.1016/j.ab.2004.04.003; Valiokas R, 1999, LANGMUIR, V15, P3390, DOI 10.1021/la981647o; Wendorf JR, 2004, BIOTECHNOL BIOENG, V87, P565, DOI 10.1002/bit.20132; Wertz CF, 2002, LANGMUIR, V18, P1190, DOI 10.1021/la0108813; Wisniewski N, 2000, COLLOID SURFACE B, V18, P197, DOI 10.1016/S0927-7765(99)00148-4	44	67	70	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25558	25564		10.1074/jbc.M503665200	http://dx.doi.org/10.1074/jbc.M503665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15857836	hybrid			2022-12-25	WOS:000230207900033
J	Karnell, FG; Brezski, RJ; King, LB; Silverman, MA; Monroe, JG				Karnell, FG; Brezski, RJ; King, LB; Silverman, MA; Monroe, JG			Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ANTIGEN(HI); LIPID RAFTS; INTRACELLULAR CHOLESTEROL; NEGATIVE SELECTION; PLASMA-MEMBRANE; CUTTING EDGE; IMMATURE; ACTIVATION; HYPOTHESIS; APOPTOSIS	Recent studies argue for an important role for cholesterol in maintaining plasma membrane heterogeneity and influencing a variety of cellular processes, including signaling, adhesion, and permeability. Here, we document that tolerance-sensitive transitional immature B cells maintain significantly lower membrane unesterified cholesterol levels than mature-stage splenic B cells. In addition, the relatively low level of cholesterol in transitional immature B cells impairs compartmentalization of their B cell receptor (BCR) into cholesterol-enriched domains following BCR aggregation and reduces their ability to sustain certain aspects of BCR signaling as compared with mature B cells. These studies establish an unexpected difference in the lipid composition of peripheral transitional immature and mature B cells and point to a determining role for development-associated differences in cholesterol content for the differential responses of these B cells to BCR engagement.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Monroe, JG (corresponding author), Univ Penn, Dept Pathol & Lab Med, 421 Curie Blvd,BRB2-3,Rm 311, Philadelphia, PA 19104 USA.	monroej@mail.med.upenn.edu		Brezski, Randall/0000-0003-4028-4741	NIAID NIH HHS [AI055428, AI32592, T32 AI055428, AI43620] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043620, R01AI032592, T32AI055428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cheng PC, 2001, SEMIN IMMUNOL, V13, P107, DOI 10.1006/smim.2000.0302; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JB, 2003, J IMMUNOL, V171, P1758, DOI 10.4049/jimmunol.171.4.1758; Chung JB, 2001, J IMMUNOL, V166, P736, DOI 10.4049/jimmunol.166.2.736; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Dykstra ML, 2001, TRAFFIC, V2, P160, DOI 10.1034/j.1600-0854.2001.020302.x; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Fielding CJ, 1997, J LIPID RES, V38, P1503; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; HASSALL DG, 1995, CYTOMETRY, V21, P352, DOI 10.1002/cyto.990210407; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; KATZENSTEIN IP, 1974, J ANTIBIOT, V27, P943, DOI 10.7164/antibiotics.27.943; King LB, 1999, J IMMUNOL, V162, P2655; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; Kouskoff V, 1998, J EXP MED, V188, P1453, DOI 10.1084/jem.188.8.1453; Kovesdi D, 2004, CELL SIGNAL, V16, P881, DOI 10.1016/S0898-6568(04)00016-6; Kovesdi D, 2002, CELL SIGNAL, V14, P563, DOI 10.1016/S0898-6568(01)00274-1; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; LANGE Y, 1991, J LIPID RES, V32, P329; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MULLER CP, 1984, CYTOMETRY, V5, P42, DOI 10.1002/cyto.990050108; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; NORVELL A, 1995, J IMMUNOL, V154, P4404; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Sarmay G, 2002, ANN NY ACAD SCI, V973, P181, DOI 10.1111/j.1749-6632.2002.tb04629.x; SEVERS NJ, 1982, CELL TISSUE RES, V224, P613; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shogomori H, 2003, BIOL CHEM, V384, P1259, DOI 10.1515/BC.2003.139; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823	41	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25621	25628		10.1074/jbc.M503162200	http://dx.doi.org/10.1074/jbc.M503162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878848	hybrid			2022-12-25	WOS:000230207900041
J	Lopez-Montero, I; Rodriguez, N; Cribier, S; Pohl, A; Velez, M; Devaux, PF				Lopez-Montero, I; Rodriguez, N; Cribier, S; Pohl, A; Velez, M; Devaux, PF			Rapid transbilayer movement of ceramides in phospholipid vesicles and in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-LABELED LIPIDS; UNILAMELLAR VESICLES; SHAPE CHANGES; PHOSPHATIDYLCHOLINE MEMBRANES; ENDOPLASMIC-RETICULUM; BIOLOGICAL-MEMBRANES; GIANT LIPOSOMES; ASYMMETRY; TRANSPORT; RAFTS	The transbilayer diffusion of unlabeled ceramides with different acyl chains ( C-6- Cer, C-10- Cer, and C-16- Cer) was investigated in giant unilamellar vesicles ( GUVs) and in human erythrocytes. Incorporation of a very small percentage of ceramides ( similar to 0.1% of total lipids) to the external leaflet of egg phosphatidylcholine GUVs suffices to trigger a shape change from prolate to pear shape vesicle. By observing the reversibility of this shape change the transmembrane diffusion of lipids was inferred. We found a half- time for unlabeled ceramide flip- flop below 1 min at 37 degrees C. The rapid diffusion of ceramides in a phosphatidylcholine bilayer was confirmed by flip- flop experiments with a spin- labeled ceramide analogue incorporated into large unilamellar vesicles. Shape change experiments were also carried out with human erythrocytes to determine the trans- membrane diffusion of unlabeled ceramides into a biological membrane. Addition of exogenous ceramides to the external leaflet of human erythrocytes did not trigger echinocyte formation immediately as one would anticipate from an asymmetrical accumulation of new amphiphiles in the outer leaflet but only after similar to 15 min of incubation at 20 degrees C in the presence of an excess of ceramide. We interpret these data as being indicative of a rapid ceramide equilibration between both erythrocyte leaflets as indicated also by electron spin resonance spectroscopy with a spin- labeled ceramide. The late appearance of echinocytes could reveal a progressive trapping of a fraction of the ceramide molecules in the outer erythrocytes leaflet. Thus, we cannot exclude the trapping of ceramides into plasma membrane domains.	Inst Biol Phys Chim, F-75005 Paris, France; C16 Univ Autonoma Madrid, Inst Ciencia Mat Nicolas Cabrera, E-28049 Madrid, Spain		Devaux, PF (corresponding author), Inst Biol Phys Chim, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	Philippe.Devaux@ibpc.fr	Velez, Marisela/F-2900-2013; López-Montero, Iván/A-5263-2017	Velez, Marisela/0000-0002-9424-510X; López-Montero, Iván/0000-0001-8131-6063; Cribier, Sophie/0000-0001-7727-645X				ANGUELOVA MI, 1986, FARADAY DISCUSS, V81, P303; Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; BAUGMAR T, 2003, NATURE, V425, P821; BELLEAU B, 1968, J AM CHEM SOC, V90, P1652; BERNDL K, 1990, EUROPHYS LETT, V13, P659, DOI 10.1209/0295-5075/13/7/015; BESSIS M, 1972, NOUV REV FR HEMATOL, V12, P721; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; Contreras FX, 2003, J BIOL CHEM, V278, P37169, DOI 10.1074/jbc.M303206200; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; Devaux PF, 2004, TRAFFIC, V5, P241, DOI 10.1111/j.1600-0854.2004.0170.x; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; FARGE E, 1993, J PHYS CHEM-US, V97, P2958, DOI 10.1021/j100114a022; Fellmann P, 1994, Methods Mol Biol, V27, P161; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hsueh YW, 2002, BIOPHYS J, V82, P3089, DOI 10.1016/S0006-3495(02)75650-6; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; Li RX, 1999, J BIOL CHEM, V274, P21121, DOI 10.1074/jbc.274.30.21121; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; MIAO L, 1994, PHYS REV E, V49, P5389, DOI 10.1103/PhysRevE.49.5389; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; NEEDHAM D, 1995, ANN BIOMED ENG, V23, P287, DOI 10.1007/BF02584429; SAMUEL NKP, 1985, J AM CHEM SOC, V107, P42, DOI 10.1021/ja00287a008; SCHWICHTENHOVEL C, 1992, BIOCHIM BIOPHYS ACTA, V1111, P35, DOI 10.1016/0005-2736(92)90271-M; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Tanaka T, 2004, LANGMUIR, V20, P9526, DOI 10.1021/la049481g; Traikia M, 2000, EUR BIOPHYS J BIOPHY, V29, P184, DOI 10.1007/s002490000077; Traikia M, 2002, BIOPHYS J, V83, P1443, DOI 10.1016/S0006-3495(02)73915-5; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; VANHELVOORT A, 1995, FEBS LETT, V369, P18, DOI 10.1016/0014-5793(95)00616-H; ZIMMERMANN P, 1988, LIEBIGS ANN CHEM, P663	45	112	115	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25811	25819		10.1074/jbc.M412052200	http://dx.doi.org/10.1074/jbc.M412052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883154	hybrid			2022-12-25	WOS:000230207900062
J	Mitra, K; Rangaraj, N; Shivaji, S				Mitra, K; Rangaraj, N; Shivaji, S			Novelty of the pyruvate metabolic enzyme dihydrolipoamide dehydrogenase in spermatozoa - Correlation of its localization, tyrosine phosphorylation, and activity during sperm capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR OXIDATIVE-PHOSPHORYLATION; PORIN-BINDING DOMAIN; ACROSOME REACTION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MITOCHONDRIAL INHERITANCE; LIPOAMIDE DEHYDROGENASE; DIFFERENTIAL RELEASE; LIPOYL DEHYDROGENASE; HAMSTER SPERMATOZOA; SIGNALING PATHWAYS	Spermatozoa are cells distinctly different from other somatic cells of the body, capacitation being one of the unique phenomena manifested by this gamete. We have shown earlier that dihydrolipoamide dehydrogenase, a post- pyruvate metabolic enzyme, undergoes capacitation dependent tyrosine phosphorylation, and the functioning of the enzyme is required for hyperactivation ( enhanced motility) and acrosome reaction of hamster spermatozoa ( Mitra, K., and Shivaji, S. ( 2004) Biol. Reprod. 70, 887 - 899). In this report we have investigated the localization of this mitochondrial enzyme in spermatozoa revealing non- canonical extra- mitochondrial localization of the enzyme in mammalian spermatozoa. In hamster spermatozoa, dihydrolipoamide dehydrogenase along with its host complex, the pyruvate dehydrogenase complex, are localized in the acrosome and in the principal piece of the sperm flagella. The localization of dihydrolipoamide dehydrogenase, however, appears to be in the mitochondria in the spermatocytes, but in spermatids it appears to show a juxtanuclear localization ( like Golgi). The capacitation- dependent time course of tyrosine phosphorylation of dihydrolipoamide dehydrogenase appears to be different in the principal piece of the flagella and the acrosome in hamster spermatozoa. Activity assays of this bi- directional enzyme suggest a strong correlation between the tyrosine phosphorylation and the bi- directional enzyme activity. This is the first report of a direct correlation of the localization, tyrosine phosphorylation, and activity of the important metabolic enzyme, dihydrolipoamide dehydrogenase, implicating dual involvement and regulation of the enzyme during sperm capacitation.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Shivaji, S (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	shivas@ccmb.res.in		shivaji, sisinthy/0000-0003-0376-4658				AUSTIN CR, 1952, NATURE, V170, P326, DOI 10.1038/170326a0; BABA T, 1989, J BIOL CHEM, V264, P11920; Bajpai M, 2003, ARCH ANDROLOGY, V49, P229, DOI 10.1080/01485010390196715; BAVISTER BD, 1989, GAMETE RES, V23, P139, DOI 10.1002/mrd.1120230202; Bhushan B, 2002, BIOCHEM BIOPH RES CO, V296, P779, DOI 10.1016/S0006-291X(02)00874-4; BLANCO A, 1980, JOHNS HOPKINS MED J, V146, P231; Boue F, 1996, BIOL REPROD, V54, P1009, DOI 10.1095/biolreprod54.5.1009; Bronson R, 2000, MOL HUM REPROD, V6, P977, DOI 10.1093/molehr/6.11.977; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; CALVIN J, 1978, EUR J BIOCHEM, V89, P315, DOI 10.1111/j.1432-1033.1978.tb20929.x; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0; COWAN AE, 1986, J CELL BIOL, V103, P1289, DOI 10.1083/jcb.103.4.1289; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; deLamirande E, 1997, MOL HUM REPROD, V3, P175, DOI 10.1093/molehr/3.3.175; Devi KU, 2000, ANDROLOGIA, V32, P95, DOI 10.1046/j.1439-0272.2000.00331.x; El-Maghrabi MR, 2001, CURR OPIN CLIN NUTR, V4, P411, DOI 10.1097/00075197-200109000-00012; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Foster JA, 1997, J BIOL CHEM, V272, P12714, DOI 10.1074/jbc.272.19.12714; Gaudreault C, 2001, BIOL REPROD, V65, P79, DOI 10.1095/biolreprod65.1.79; Gazaryan IG, 2002, J BIOL CHEM, V277, P10064, DOI 10.1074/jbc.M108264200; Goldberg E, 1975, Methods Enzymol, V41, P318; GOLDBERG E, 1977, SCIENCE, V196, P1010, DOI 10.1126/science.193188; Grace KS, 2002, BIOL REPROD, V66, P823, DOI 10.1095/biolreprod66.3.823; Hinsch KD, 2004, J BIOL CHEM, V279, P15281, DOI 10.1074/jbc.M313433200; HUANG KP, 1980, J BIOL CHEM, V255, P3141; Igamberdiev AU, 2004, FEBS LETT, V568, P146, DOI 10.1016/j.febslet.2004.05.024; Jaiswal BS, 1999, MOL HUM REPROD, V5, P214, DOI 10.1093/molehr/5.3.214; Jha KN, 2003, CELL MOL BIOL, V49, P329; Jha KN, 2002, MOL REPROD DEV, V61, P258, DOI 10.1002/mrd.1155; Johnson MT, 1997, P NATL ACAD SCI USA, V94, P14512, DOI 10.1073/pnas.94.26.14512; Kang-Decker N, 2001, SCIENCE, V294, P1531, DOI 10.1126/science.1063665; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; Kim KS, 2003, DEV BIOL, V264, P141, DOI 10.1016/j.ydbio.2003.08.006; Kim KS, 2001, BIOL REPROD, V64, P148, DOI 10.1095/biolreprod64.1.148; KIM YB, 1964, REV MOD PHYS, V36, P43, DOI 10.1103/RevModPhys.36.43; KOPF GS, 1991, MAMMALIAN SPERM ACRO, P153; Kulanand J, 2001, ANDROLOGIA, V33, P95, DOI 10.1046/j.1439-0272.2001.00410.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; Luconi M, 2004, J CELL SCI, V117, P1235, DOI 10.1242/jcs.00931; LUSTY CJ, 1963, J BIOL CHEM, V238, P3443; Mahony MC, 1999, BIOL REPROD, V60, P1239, DOI 10.1095/biolreprod60.5.1239; MASSEY V, 1961, BIOCHIM BIOPHYS ACTA, V48, P33, DOI 10.1016/0006-3002(61)90512-1; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; Meinhardt A, 1999, HUM REPROD UPDATE, V5, P108, DOI 10.1093/humupd/5.2.108; MEINHARDT A, 1995, BIOL REPROD, V52, P798, DOI 10.1095/biolreprod52.4.798; Miething A, 1998, Adv Anat Embryol Cell Biol, V140, P1; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; Mitra K, 2004, BIOL REPROD, V70, P887, DOI 10.1095/biolreprod.103.022780; Moran JF, 2002, PLANT PHYSIOL, V128, P300, DOI 10.1104/pp.010505; MORI C, 1993, BIOL REPROD, V49, P191, DOI 10.1095/biolreprod49.2.191; MORTON BE, 1967, BIOCHEMISTRY-US, V6, P43, DOI 10.1021/bi00853a009; MORTON BE, 1967, BIOCHEMISTRY-US, V6, P50, DOI 10.1021/bi00853a010; Narisawa S, 2002, MOL CELL BIOL, V22, P5554, DOI 10.1128/MCB.22.15.5554-5562.2002; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSON GE, 1988, BIOL REPROD, V39, P1145, DOI 10.1095/biolreprod39.5.1145; PATEL MS, 1995, METHOD ENZYMOL, V252, P186; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Petrat F, 2003, J BIOL CHEM, V278, P46403, DOI 10.1074/jbc.M305291200; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; PILKIS SJ, 1980, J BIOL CHEM, V255, P2770; Ramalho-Santos J, 2002, BIOL REPROD, V67, P1043, DOI 10.1095/biolreprod67.4.1043; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Si YM, 1999, BIOL REPROD, V61, P240, DOI 10.1095/biolreprod61.1.240; Smith AW, 2002, MOL MICROBIOL, V44, P431, DOI 10.1046/j.1365-2958.2002.02883.x; STOREY BT, 1975, FERTIL STERIL, V26, P1257; Sutovsky P, 2000, BIOL REPROD, V63, P582, DOI 10.1095/biolreprod63.2.582; Thompson WE, 2003, BIOL REPROD, V69, P254, DOI 10.1095/biolreprod.102.010975; Tomes CN, 2004, DEV BIOL, V265, P399, DOI 10.1016/j.ydbio.2003.09.032; Travis AJ, 1998, MOL BIOL CELL, V9, P263, DOI 10.1091/mbc.9.2.263; Travis AJ, 2001, J BIOL CHEM, V276, P7630, DOI 10.1074/jbc.M006217200; Urner F, 2003, REPRODUCTION, V125, P17, DOI 10.1530/rep.0.1250017; Urner F, 2001, BIOL REPROD, V64, P1350, DOI 10.1095/biolreprod64.5.1350; VANDOP C, 1977, J BIOL CHEM, V252, P1303; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; Visconti PE, 1998, J ANDROL, V19, P242; Westhoff D, 1997, J CELL SCI, V110, P1821; WILKINSON KD, 1981, J BIOL CHEM, V256, P2307; Yanagimachi R., 1994, P189; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899	83	33	37	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25743	25753		10.1074/jbc.M500310200	http://dx.doi.org/10.1074/jbc.M500310200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888450	hybrid			2022-12-25	WOS:000230207900055
J	Pelisch, F; Blaustein, M; Kornblihtt, AR; Srebrow, A				Pelisch, F; Blaustein, M; Kornblihtt, AR; Srebrow, A			Cross-talk between signaling pathways regulates alternative splicing - A novel role for JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; PRE-MESSENGER-RNA; METALLOPROTEINASE GENE-EXPRESSION; MAMMARY EPITHELIAL-CELLS; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; SUBCELLULAR-DISTRIBUTION; CYCLE PROGRESSION; FIBRONECTIN	The regulation of alternative splicing by extracellular signals represents a key event in the control of gene expression. There is increasing evidence showing that many extracellular cues regulate alternative splicing. Nevertheless, the broad picture regarding the role of different signaling pathways and their interaction remains incomplete. Using the fibronectin gene as a model, we show that a laminin- rich basement membrane regulates the alternative splicing of two out of three regions of the transcript ( extra domain I and type III connecting segment) in mammary epithelial cells, through a non- stress c- Jun N- terminal kinase ( JNK) signaling pathway. We propose that dephosphorylation of the extracellular signal- regulated kinase is involved in this regulatory process. Furthermore, the laminin- rich basement membrane blocks the effect of a mammary mesenchymal cell- conditioned medium, which stimulates the inclusion of extra domain I and type III connecting segment through a phosphatidylinositol3-kinase-dependent cascade, indicating that JNK signaling can inhibit the phosphatidylinositol 3- kinase- mediated splicing regulation. These results implicate JNK in the regulation of alternative splicing and provide new evidence on how extracellular stimuli are converted into changes in splicing patterns, strengthening the view that the control of alternative splicing is as complex and relevant as transcriptional control, together accounting for the spatiotemporal requirements of gene expression.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis Biol Mol & Celular,Inst Fisiol Biol Mol, Consejo Nacl Invest Cient & Tecn,Lab Fisiol & Bio, RA-1428 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Srebrow, A (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fis Biol Mol & Celular,Inst Fisiol Biol Mol, Consejo Nacl Invest Cient & Tecn,Lab Fisiol & Bio, Pabellon 2, RA-1428 Buenos Aires, DF, Argentina.	asrebrow@fbmc.fcen.uba.ar	Pelisch, Federico/C-3815-2011; Blaustein, Matías/ABF-7951-2020; Pelisch, Federico/H-9219-2013	Blaustein, Matías/0000-0001-6309-6888; Pelisch, Federico/0000-0003-4575-1492; Kornblihtt, Alberto/0000-0003-4322-0831				Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Bissell MJ, 1999, CANCER RES, V59, p1757S; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blaustein M, 2004, J BIOL CHEM, V279, P21029, DOI 10.1074/jbc.M314260200; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Lynch KW, 2000, MOL CELL BIOL, V20, P70, DOI 10.1128/MCB.20.1.70-80.2000; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; Shimao Y, 1999, INT J CANCER, V82, P449, DOI 10.1002/(SICI)1097-0215(19990730)82:3<449::AID-IJC20>3.0.CO;2-H; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Shomron N, 2005, J CELL SCI, V118, P1151, DOI 10.1242/jcs.01720; Srebrow A, 2002, FEBS LETT, V514, P285, DOI 10.1016/S0014-5793(02)02382-7; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xia Y, 2004, BIOCHEM PHARMACOL, V68, P997, DOI 10.1016/j.bcp.2004.05.028; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	57	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25461	25469		10.1074/jbc.M412007200	http://dx.doi.org/10.1074/jbc.M412007200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886203	hybrid			2022-12-25	WOS:000230207900020
J	Shen, DX; Dalton, TP; Nebert, DW; Shertzer, HG				Shen, DX; Dalton, TP; Nebert, DW; Shertzer, HG			Glutathione redox state regulates mitochondrial reactive oxygen production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; HALOGENATED AROMATIC-HYDROCARBONS; OXIDATIVE STRESS-RESPONSE; MOUSE-LIVER MICROSOMES; SUBCHRONIC EXPOSURE; MAMMALIAN-CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; REPAIR ENDONUCLEASES; BASE MODIFICATIONS; REDUCTIVE STRESS	Oxidative stress induced by 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD; dioxin) is poorly understood. Following one dose of TCDD (5 mu g/kg body weight), mitochondrial succinate- dependent production of superoxide and H2O2 in mouse liver doubled at 7-28 days, then subsided by day 56; concomitantly, levels of GSH and GSSG increased in both cytosol and mitochondria. Cytosol displayed a typical oxidative stress response, consisting of diminished GSH relative to GSSG, decreased potential to reduce protein-SSG mixed disulfide bonds (type 1 thiol redox switch) or protein-SS-protein disulfide bonds ( type 2 thiol redox switch), and a +10 mV change in GSSG/2GSH reduction potential. In contrast, mitochondria showed a rise in reduction state, consisting of increased GSH relative to GSSG, increases in type 1 and type 2 thiol redox switches, and a -25 mV change in GSSG/2GSH reduction potential. Comparing Ahr(-/-) knock-out and wild-type mice, we found that TCDD-induced thiol changes in both cytosol and mitochondria were dependent on the aromatic hydrocarbon receptor (AHR). GSH was rapidly taken up by mitochondria and stimulated succinate- dependent H2O2 production. A linear dependence of H2O2 production on the reduction potential for GSSG/2GSH exists between -150 and -300mV. The TCDD-stimulated increase in succinate-dependent and thiol-stimulated production of reactive oxygen paralleled a four-fold increase in formamidopyrimidine DNA N-glycosylase (FPG)-sensitive cleavage sites in mitochondrial DNA, compared with a two-fold increase in nuclear DNA. These results suggest that TCDD produces an AHR-dependent oxidative stress in mitochondria, with concomitant mitochondrial DNA damage mediated, at least in part, by an increase in the mitochondrial thiol reduction state.	Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Shertzer, HG (corresponding author), Dept Environm Hlth, 3223 Eden Ave, Cincinnati, OH 45267 USA.	shertzhg@ucmail.uc.edu			NIEHS NIH HHS [P30 ES06096, R01 ES08147, R01 ES10133, R01 ES12463] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012463, R01ES010133, P30ES006096, R01ES008147] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Carretero J, 2000, FREE RADICAL BIO MED, V29, P913, DOI 10.1016/S0891-5849(00)00392-0; CASH WD, 1965, J BIOL CHEM, V240, P3450; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Coll O, 2003, HEPATOLOGY, V38, P692, DOI 10.1053/jhep.2003.50351; Collins AR, 2000, FREE RADICAL RES, V32, P333, DOI 10.1080/10715760000300331; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 2003, CURR MED CHEM, V10, P1473, DOI 10.2174/0929867033457197; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; Dalton TP, 2002, CHEM-BIOL INTERACT, V141, P77, DOI 10.1016/S0009-2797(02)00067-4; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DeVito MJ, 1997, TOXICOL APPL PHARM, V147, P267, DOI 10.1006/taap.1997.8261; Dufer M, 2001, MOL PHARMACOL, V60, P873; DUN J, 2003, ARCH BIOCHEM BIOPHYS, V419, P198; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; GEBICKI JM, 1964, J BIOL CHEM, V239, P631; Granville DJ, 2003, CURR MED CHEM, V10, P1527, DOI 10.2174/0929867033457214; Grav HJ, 2003, J BIOL CHEM, V278, P30525, DOI 10.1074/jbc.M303382200; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hartwig A, 1996, TOXICOL LETT, V88, P85, DOI 10.1016/0378-4274(96)03722-8; Hassoun EA, 2000, TOXICOLOGY, V145, P103, DOI 10.1016/S0300-483X(99)00221-8; Hassoun EA, 1998, TOXICOL SCI, V42, P23, DOI 10.1006/toxs.1997.2411; Hoffmann S, 2004, FREE RADICAL BIO MED, V36, P765, DOI 10.1016/j.freeradbiomed.2003.12.019; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; Ip SP, 1996, FREE RADICAL BIO MED, V21, P709, DOI 10.1016/0891-5849(96)00179-7; Jacobson J, 2002, J CELL SCI, V115, P1175; James AM, 2004, ARCH BIOCHEM BIOPHYS, V423, P47, DOI 10.1016/j.abb.2003.12.025; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; KERKVLIET NI, 1990, FUND APPL TOXICOL, V14, P532, DOI 10.1016/0272-0590(90)90257-K; Khan S, 1997, BIOCHEM BIOPH RES CO, V238, P320, DOI 10.1006/bbrc.1997.7281; Khan S, 1999, CLIN BIOCHEM, V32, P585, DOI 10.1016/S0009-9120(99)00059-4; Koshkin V, 2004, J BIOL CHEM, V279, P41368, DOI 10.1074/jbc.M406914200; Krokan HE, 1997, BIOCHEM J, V325, P1; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Lash LH, 1998, TOXICOLOGY, V130, P1, DOI 10.1016/S0300-483X(98)00093-6; LEHNINGE.AL, 1967, J BIOL CHEM, V242, P2098; Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484; Miwa S, 2003, BIOCHEM SOC T, V31, P1300; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NIKNAHAD H, 1995, CHEM-BIOL INTERACT, V98, P27, DOI 10.1016/0009-2797(95)03631-U; Nishimura N, 2001, LIFE SCI, V69, P1291, DOI 10.1016/S0024-3205(01)01212-7; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Pflaum M, 1998, FREE RADICAL RES, V29, P585, DOI 10.1080/10715769800300631; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REICHARD JF, 2005, NONLINEARITY BIOL TO; SCHNELLMANN RG, 1988, KIDNEY INT, V34, P229, DOI 10.1038/ki.1988.169; Senft AP, 2002, FREE RADICAL BIO MED, V33, P1268, DOI 10.1016/S0891-5849(02)01014-6; Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498; Senft AP, 2002, TOXICOL APPL PHARM, V178, P15, DOI 10.1006/taap.2001.9314; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Shertzer HG, 1998, BIOCHEM BIOPH RES CO, V253, P44, DOI 10.1006/bbrc.1998.9753; Shertzer HG, 2004, FREE RADICAL BIO MED, V36, P618, DOI 10.1016/j.freeradbiomed.2003.11.014; SHERTZER HG, 1976, J BIOL CHEM, V251, P2446; Shertzer HG, 2004, FREE RADICAL BIO MED, V36, P605, DOI 10.1016/j.freeradbiomed.2003.11.013; Slezak BP, 2000, TOXICOL SCI, V54, P390, DOI 10.1093/toxsci/54.2.390; STOHS SJ, 1991, ADV EXP MED BIOL, V283, P827; STOHS SJ, 1990, FREE RADICAL BIO MED, V9, P79, DOI 10.1016/0891-5849(90)90052-K; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Thornton AS, 2001, MUTAT RES-FUND MOL M, V478, P45, DOI 10.1016/S0027-5107(01)00105-1; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; vanBirgelen APJM, 1996, TOXICOL APPL PHARM, V138, P98, DOI 10.1006/taap.1996.0103; Vendemiale G, 1996, BIOCHEM PHARMACOL, V52, P1147, DOI 10.1016/0006-2952(96)00414-5; Vezina CM, 2004, ENVIRON HEALTH PERSP, V112, P1636, DOI 10.1289/txg.7253; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Williamson JR, 1999, DIABETES RES CLIN PR, V45, P81; Zoccarato F, 2004, J BIOL CHEM, V279, P4166, DOI 10.1074/jbc.M308143200; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	85	107	112	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25305	25312		10.1074/jbc.M500095200	http://dx.doi.org/10.1074/jbc.M500095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883162	hybrid			2022-12-25	WOS:000230207900002
J	Fang, JG; Lu, J; Holmgren, A				Fang, JG; Lu, J; Holmgren, A			Thioredoxin reductase is irreversibly modified by curcumin - A novel molecular mechanism for its anticancer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN BREAST-CANCER; BCL-X-L; MAMMALIAN THIOREDOXIN; CELL-CYCLE; CHEMOPREVENTIVE AGENT; OXIDATIVE STRESS; DIETARY CURCUMIN; GENE-EXPRESSION; DOWN-REGULATION	The thioredoxin reductase (TrxR) isoenzymes, TrxR1 in cytosol or nucleus and TrxR2 in mitochondria, are essential mammalian selenocysteine (Sec)-containing flavoenzymes with a -Gly-Cys-Sec-Gly active site. TrxRs are the only enzymes catalyzing the NADPH-dependent reduction of the active site disulfide in thioredoxins (Trxs), which play essential roles in substrate reductions, defense against oxidative stress, and redox regulation by thiol redox control. TrxRs have been found to be overexpressed by a number of human tumors. Curcumin, which is consumed daily by millions of people, is a polyphenol derived from the plant Curcuma longa. This phytochemical has well known anticancer and antiangiogenic properties. In this study we report that rat TrxR1 activity in Trx-dependent disulfide reduction was inhibited by curcumin. The IC50 value for the enzyme was 3.6 mu M after incubation at room temperature for 2 h in vitro. The inhibition occurred with enzyme only in the presence of NADPH and persisted after removal of curcumin. By using mass spectrometry and blotting analysis, we proved that this irreversible inhibition by curcumin was caused by alkylation of both residues in the catalytically active site (Cys(496)/Sec(497)) of the enzyme. However, the curcumin-modified enzyme showed a strongly induced NADPH oxidase activity to produce reactive oxygen species. Inhibition of TrxR by curcumin added to cultured HeLa cells was also observed with an IC50 of around 15 mu M. Modification of TrxR by curcumin provides a possible mechanistic explanation for its cancer preventive activity, shifting the enzyme from an antioxidant to a prooxidant.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	Arne.Holmgren@mbb.ki.se	Lu, Jun/E-9701-2017; Fang, Jianguo/K-8058-2016	Lu, Jun/0000-0002-1699-8835; 				Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Awasthi S, 2000, CHEM-BIOL INTERACT, V128, P19, DOI 10.1016/S0009-2797(00)00185-X; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Cheng AL, 2001, ANTICANCER RES, V21, P2895; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Das KC, 2000, BIOCHEM BIOPH RES CO, V277, P443, DOI 10.1006/bbrc.2000.3689; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Elattar TMA, 2000, ANTICANCER RES, V20, P1733; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; HAINAUT P, 1993, CANCER RES, V53, P4469; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; Hasmeda M, 1996, PHYTOCHEMISTRY, V42, P599, DOI 10.1016/0031-9422(96)00091-X; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; HUANG MT, 1994, CANCER RES, V54, P5841; HUANG MT, 1988, CANCER RES, V48, P5941; Ireson CR, 2002, CANCER EPIDEM BIOMAR, V11, P105; Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702; Kang JH, 2005, BIOCHEM PHARMACOL, V69, P1205, DOI 10.1016/j.bcp.2005.01.014; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kim JR, 2004, FEBS LETT, V567, P189, DOI 10.1016/j.febslet.2004.04.055; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; Lin JK, 2000, BIOFACTORS, V13, P153, DOI 10.1002/biof.5520130125; Liu XW, 2004, BIOL CHEM, V385, P633, DOI 10.1515/BC.2004.078; MATSUDA M, 1991, J IMMUNOL, V147, P3837; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; Moos PJ, 2004, CARCINOGENESIS, V25, P1611, DOI 10.1093/carcin/bgh163; Naidu KA, 2002, MOL CELL BIOCHEM, V229, P19, DOI 10.1023/A:1017930708099; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535; Ramsewak RS, 2000, PHYTOMEDICINE, V7, P303, DOI 10.1016/S0944-7113(00)80048-3; REDDY S, 1994, FEBS LETT, V341, P19, DOI 10.1016/0014-5793(94)80232-7; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sharma RA, 2001, CLIN CANCER RES, V7, P1894; Somasundaram S, 2002, CANCER RES, V62, P3868; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Syng-ai C, 2004, MOL CANCER THER, V3, P1101; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Tanaka H, 1999, VITAM HORM, V57, P153; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tsvetkov P, 2005, P NATL ACAD SCI USA, V102, P5535, DOI 10.1073/pnas.0501828102; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Vasko MR, 2005, DNA REPAIR, V4, P367, DOI 10.1016/j.dnarep.2004.11.006; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	69	416	430	3	68	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25284	25290		10.1074/jbc.M414645200	http://dx.doi.org/10.1074/jbc.M414645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15879598	hybrid			2022-12-25	WOS:000230114000115
J	Zhao, RX; Xing, S; Li, Z; Fu, XQ; Li, QS; Krantz, SB; Zhao, ZHJ				Zhao, RX; Xing, S; Li, Z; Fu, XQ; Li, QS; Krantz, SB; Zhao, ZHJ			Identification of an acquired JAK2 mutation in Polycythemia vera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; KINASE SUPERFAMILY; ERYTHROPOIETIN; PERSPECTIVE; ACTIVATION; PATHWAY	Polycythemia vera (PV) is a human clonal hematological disorder. The molecular etiology of the disease has not been identified. PV hematopoietic progenitor cells exhibit hypersensitivity to growth factors and cytokines, suggesting possible abnormalities in protein-tyrosine kinases and phosphatases. By sequencing the entire coding regions of cDNAs of candidate enzymes, we identified a G:C -> T:A point mutation of the JAK2 tyrosine kinase in 20 of 24 PV blood samples but none in 12 normal samples. The mutation has varying degrees of heterozygosity and is apparently acquired. It changes conserved Va(l617) to Phe in the pseudokinase domain of JAK2 that is known to have an inhibitory role. The mutant JAK2 has enhanced kinase activity, and when over-expressed together with the erythropoietin receptor in cells, it caused hyperactivation of erythropoietin-induced cell signaling. This gain-of-function mutation of JAK may explain the hypersensitivity of PV progenitor cells to growth factors and cytokines. Our study thus defines a molecular defect of PV.	Vanderbilt Univ, Div Hematol Oncol, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Jilin Univ, Coll Life Sci, Edmond H Fischer Signal Transduct Lab, Changchun 130023, Peoples R China	Vanderbilt University; Jilin University	Zhao, ZHJ (corresponding author), 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	joe.zhao@vanderbilt.edu	li, zhe/B-6882-2011	Xing, Shu/0000-0001-5449-4497	NCI NIH HHS [P30 CA068485] Funding Source: Medline; NHLBI NIH HHS [HL076309, R01 HL076309-01, R01 HL076309] Funding Source: Medline; NIDDK NIH HHS [DK-15555] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bench AJ, 1998, BAILLIERE CLIN HAEM, V11, P819, DOI 10.1016/S0950-3536(98)80041-3; Dai CH, 2005, EXP HEMATOL, V33, P152, DOI 10.1016/j.exphem.2004.10.017; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Green AR, 1996, LANCET, V347, P844, DOI 10.1016/S0140-6736(96)91338-0; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; KRANTZ SB, 1991, BLOOD, V77, P419; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Prchal J F, 1999, Curr Opin Hematol, V6, P100, DOI 10.1097/00062752-199903000-00008; Roder S, 2001, EXP HEMATOL, V29, P694, DOI 10.1016/S0301-472X(01)00637-3; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; Spivak JL, 2002, BLOOD, V100, P4272, DOI 10.1182/blood-2001-12-0349; Sui XW, 1997, BLOOD, V90, P651, DOI 10.1182/blood.V90.2.651.651_651_657; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Ward AC, 2000, BLOOD, V95, P19; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xu MJ, 2003, BLOOD, V102, P4354, DOI 10.1182/blood-2003-04-1308	32	473	507	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22788	22792		10.1074/jbc.C500138200	http://dx.doi.org/10.1074/jbc.C500138200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15863514	Green Accepted, hybrid			2022-12-25	WOS:000229741800029
J	Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK				Lu, M; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Jing, YK			Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells	ONCOGENE			English	Article						cellular retinoic acid binding protein; retinoic acid receptor; breast cancer; estrogen receptor	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY-CARCINOMA; GROWTH-INHIBITION; RAR-ALPHA; 9-CIS-RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; HUMAN SKIN; VITAMIN-A; IN-VITRO	Human breast cancer cell lines expressing the estrogen receptor alpha (ER alpha), all-trans-retinoic acid (ATRA) receptor alpha (RAR alpha) and cellular retinoic acid binding protein II (CRABPII) genes are sensitive to ATRA-mediated growth inhibition. To study the relationship among ER alpha, RAR alpha and CRABPII expression, the protein levels of each member were compared in five breast cancer cell lines (T47D, MCF-7, ZR-75-1, Hs587T and MDA-MB-231 cells) and two immortalized nontumorigenic breast epithelial cell lines (MTSV1.7 and MCF-10A). ER alpha, RAR alpha and CRABPII proteins were detected in T47D, MCF-7 and ZR-75-1 cells but not in other tested cell lines. RAR alpha and CRABPII proteins were either reduced or undetectable in T47D/C4:2W and MCF-7/ADR cells with lost expression of ER alpha. Estradiol increased and antiestrogens (tamoxifen and ICI 164,384) downregulated the expression of both RAR alpha and CRABPII proteins in T47D and MCF-7 cells. RAR alpha antagonist Ro-41-5253 inhibited CRABPII expression, but not RAR alpha expression in estradiol-treated T47D and MCF-7 cells. Suppression of ER alpha by small interfering RNA (siRNA) reduced RAR alpha and CRABPII gene expression and siRNA suppression of RAR alpha reduced CRABPII expression while having no effect on ER alpha in T47D cells. Transient transfection of either RAR alpha or ER alpha expression vectors increased CRABPII expression in MDA-MB-231 cells but only RAR alpha, not ER alpha, activated hCRABPII promoter reporter. These results indicate that there is a gene activation pathway in which ERa drives RAR alpha transcription and RAR alpha drives CRABPII transcription in ER alpha-positive human breast cancer cells.	Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo, Japan	Icahn School of Medicine at Mount Sinai; Showa University	Jing, YK (corresponding author), Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [NIH CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054273, R01CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1994, CANCER RES, V54, P4614; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; ASTROM A, 1992, J BIOL CHEM, V267, P25251; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Bucco RA, 1997, BIOCHEMISTRY-US, V36, P4009, DOI 10.1021/bi962094o; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DAWSON MI, 1995, CANCER RES, V55, P4446; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Delva L, 1999, MOL CELL BIOL, V19, P7158; Di W, 1998, J INVEST DERMATOL, V111, P1109, DOI 10.1046/j.1523-1747.1998.00455.x; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; Gottardis MM, 1996, CANCER RES, V56, P5566; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JIANG SY, 1992, MOL ENDOCRINOL, V6, P2167, DOI 10.1210/me.6.12.2167; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; Li XH, 2003, J BIOL CHEM, V278, P35819, DOI 10.1074/jbc.M302551200; Lin XH, 2003, CANCER RES, V63, P498; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; Mangelsdorf David J., 1994, P319; Manor D, 2003, CANCER RES, V63, P4426; Nakagawa S, 2003, MOL CARCINOGEN, V38, P106, DOI 10.1002/mc.10150; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Ong David E., 1994, P283; Pasquali D, 1997, EUR J ENDOCRINOL, V137, P410, DOI 10.1530/eje.0.1370410; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; RISHI AK, 1995, CANCER RES, V55, P4999; ROMAN SD, 1992, CANCER RES, V52, P2236; ROMAN SD, 1993, CANCER RES, V53, P5940; Rosenauer A, 1998, CANCER RES, V58, P5110; ROSS AC, 1993, J AM DIET ASSOC, V93, P1285, DOI 10.1016/0002-8223(93)91956-Q; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Schneider SM, 2000, CANCER RES, V60, P5479; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P146, DOI 10.1111/1523-1747.ep12616781; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Widschwendter M, 1997, INT J CANCER, V71, P497; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QF, 2002, BREAST CANCER RES TR, V76, P167, DOI 10.1023/A:1020576606004; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264	53	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4362	4369		10.1038/sj.onc.1208661	http://dx.doi.org/10.1038/sj.onc.1208661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15870697				2022-12-25	WOS:000229976900005
J	Menard, C; Horvitz, HR; Cannon, S				Menard, C; Horvitz, HR; Cannon, S			Chimeric mutations in the M2 segment of the 5-hydroxytryptamine-gated chloride channel MOD-1 define a minimal determinant of anion/cation permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; NEURONAL NICOTINIC RECEPTOR; GATED ION CHANNELS; GLYCINE RECEPTOR; STRUCTURAL DETERMINANTS; CHARGE SELECTIVITY; XENOPUS-OOCYTES; MOLECULAR-BASIS; AMINO-ACIDS; DOMAIN	The ionic selectivity of ligand-gated ion channels (LGICs) determines whether receptor activation produces an excitatory or inhibitory response. The determinants of anion/cation selectivity were investigated for a new member of the LGIC superfamily, MOD-1, a serotonin-gated chloride channel cloned from the nematode Caenorhabditis elegans. In common with other anionic LGICs ( glycine receptors and GABA(A) receptors), the selectivity triple mutant in the pore-forming M2 segment ( proline insertion, Ala -> Glu substitution at the central ring, and Thr -> Val at the hydrophobic ring) converted the selectivity of MOD-1 from anionic to cationic. Unlike other LGICs, however, this mutant in MOD-1 was highly selective for K+ over other cations. Subsets of this selectivity triple mutant were studied to define the minimal change required for conversion from anion-permeable to cation-permeable. The double mutant at the central ring of charge (Delta Pro-269/A270E) produced a non-selective cation channel. Charge reversal at the central ring alone (A270E) was sufficient to convert MOD-1 to cation-permeable. These results refine the determinants of ion-charge selectivity in LGICs and demonstrate the critical role of the central ring of charge formed by the M2 segments.	CNRS, Ctr Rech Biochem Macromol, FRE2593, F-34293 Montpellier, France; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA	Centre National de la Recherche Scientifique (CNRS); Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Menard, C (corresponding author), CNRS, Ctr Rech Biochem Macromol, FRE2593, 1919 Route Mende, F-34293 Montpellier, France.	menard@crbm.cnrs.fr	Cannon, Stephen/V-5343-2019	Cannon, Stephen/0000-0001-8428-3690				Adcock C, 1998, BIOCHEM SOC T, V26, pS300, DOI 10.1042/bst026s300; BARNARD EA, 1992, ADV BIOCHEM PSYCHOPH, V47, P17; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; COHEN BN, 1992, J GEN PHYSIOL, V99, P545, DOI 10.1085/jgp.99.4.545; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GOLDIN AL, 1991, METHOD CELL BIOL, V36, P487; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HILLE B, 1992, IONIC CHANNELS EXICT; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Saul B, 1999, J NEUROSCI, V19, P869; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; WANG F, 1992, P ROY SOC B-BIOL SCI, V250, P11, DOI 10.1098/rspb.1992.0124; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030	38	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27502	27507		10.1074/jbc.M501624200	http://dx.doi.org/10.1074/jbc.M501624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15878844	hybrid			2022-12-25	WOS:000230678600005
J	Barbier, GG; Campbell, WH				Barbier, GG; Campbell, WH			Viscosity effects on eukaryotic nitrate reductase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; CYTOCHROME-B REDUCTASE; SULFITE OXIDASE; CRYSTAL-STRUCTURE; SQUASH NADH; CORN; FRAGMENT; MUTANT; EXPRESSION; APOENZYME	Rate-limiting processes of catalysis by eukaryotic molybdenum-containing nitrate reductase (NaR, EC 1.7.1.1-3) were investigated using two viscosogens ( glycerol and sucrose) and observing their impact on NAD(P) H: NaR activity of corn leaf NaR and recombinant Arabidopsis and yeast NaR. Holo-NaR has two "hinge" sequences between stably folded regions housing its internal electron carriers: 1) Hinge 1 between the molybdenum-containing nitrate reducing module and cytochrome b domain containing heme and 2) Hinge 2 between cytochrome b and cytochrome b reductase (CbR) module containing FAD. Solution viscosity negatively impacted the activity of these holo-NaR forms, which suggests that the rate-limiting events in catalysis were likely to involve large conformational changes that restrict or "gate" internal electron-proton transfers (IET). Little effect of viscosity was observed on recombinant CbR module and methyl viologen nitrate reduction by holo-NaR, suggesting that these activities involved no large conformational changes. To determine whether Hinge 2 is involved in gating the first step in IET, the effects of viscosogen on cytochrome c and ferricyanide reductase activities of holo-NaR and ferricyanide reductase activity of the recombinant molybdenum reductase module ( CbR, Hinge 2, and cytochrome b) were analyzed. Solution viscosity negatively impacted these partial activities, as if Hinge 2 were involved in gating IET in both enzyme forms. We concluded that both Hinges 1 and 2 appear to be involved in gating IET steps by restricting the movement of the cytochrome b domain relative to the larger nitrate-reducing and electron-donating modules of NaR.	Nitrate Eliminat Co Inc, Lake Linden, MI 49945 USA; Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA	Michigan Technological University	Campbell, WH (corresponding author), Nitrate Eliminat Co Inc, Lake Linden, MI 49945 USA.	bill@nitrate.com		Campbell, Wilbur/0000-0001-6432-7537	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM056598] Funding Source: NIH RePORTER; NIGMS NIH HHS [R44GM56598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVILA J, 1995, FEBS LETT, V366, P137, DOI 10.1016/0014-5793(95)00511-7; Barbier GG, 2004, PROTEIN EXPRES PURIF, V37, P61, DOI 10.1016/j.pep.2004.05.021; BLACKOW SC, 1987, BIOCHEMISTRY-US, V27, P1158; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; Fischer K, 2005, PLANT CELL, V17, P1167, DOI 10.1105/tpc.104.029694; GUTFREUND H, 1995, KINETICS LIFE SCI RE, P231; Heimann S, 2000, BIOCHEMISTRY-US, V39, P2692, DOI 10.1021/bi9921992; Hille R, 1997, J BIOL INORG CHEM, V2, P804, DOI 10.1007/s007750050199; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1989, PLANT MOL BIOL, V13, P233, DOI 10.1007/BF00016141; Jas GS, 2001, J PHYS CHEM B, V105, P261, DOI 10.1021/jp0022048; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; LU GG, 1994, STRUCTURE, V2, P809, DOI 10.1016/S0969-2126(94)00082-4; MacKintosh C, 2001, CELL MOL LIFE SCI, V58, P205, DOI 10.1007/PL00000848; MENDEL RR, 1979, MOL GEN GENET, V177, P145, DOI 10.1007/BF00267264; Mertens JA, 2000, PLANT PHYSIOL, V123, P743, DOI 10.1104/pp.123.2.743; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; PELSY F, 1991, GENETICS, V127, P199; QUIN L, 1992, BIOCHEMISTRY-US, V33, P12592; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; SHARP RE, 1994, BIOCHEMISTRY-US, V33, P5115, DOI 10.1021/bi00183a015; Shiraishi N, 1998, ARCH BIOCHEM BIOPHYS, V358, P104, DOI 10.1006/abbi.1998.0827; Skipper L, 2001, J BIOL CHEM, V276, P26995, DOI 10.1074/jbc.M100356200; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135; Sutherland W, 1905, PHILOS MAG, V9, P781, DOI 10.1080/14786440509463331	31	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26049	26054		10.1074/jbc.M409694200	http://dx.doi.org/10.1074/jbc.M409694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15897195	hybrid			2022-12-25	WOS:000230386800014
J	Corson, TW; Huang, A; Tsao, MS; Gallie, BL				Corson, TW; Huang, A; Tsao, MS; Gallie, BL			KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers	ONCOGENE			English	Article						retinoblastoma; breast cancer; lung cancer; medulloblastoma; kinesin; chromosome 1	KINESIN-RELATED PROTEIN; RETINOBLASTOMA; GENE; MOUSE; KLP38B; AMPLIFICATION; ORGANIZATION; ABERRATIONS; IMBALANCES; PARALLEL	Gain of chromosome 1q31-1q32 is seen in > 50% of retinoblastoma and is common in other tumors. To de. ne the minimal 1q region of gain, we determined genomic copy number by quantitative multiplex PCR of 14 sequence tagged sites (STSs) spanning 1q25.3-1q41. The most frequently gained STS at 1q32.1 (71%; 39 of 55 retinoblastoma) defined a 3.06Mbp minimal region of gain between flanking markers, containing 14 genes. Of these, only KIF14, a putative chromokinesin, was over-expressed in various cancers by real-time RT-PCR. KIF14 mRNA was expressed in 20/ 22 retinoblastoma samples 100-1000-fold higher than in retina (t-test P = 0.00002); cell lines (n = 10) had higher levels than tumors (n = 12) (P = 0.009). KIF14 protein was overexpressed in retinoblastoma tumors and breast cancer cell lines by immunoblot. KIF14 was expressed in 4/4 breast cancer cell lines 31-92-fold higher than in normal breast tissue, in 5/5 medulloblastoma cell lines 22-79-fold higher than in fetal brain, and in 10/22 primary lung tumors 3-34-fold higher than in normal lung. Patients with lung tumors that overexpress KIF14 showed a trend toward decreased survival. KIF14 may thus be important in oncogenesis, and has promise as a prognostic indicator and therapeutic target.	Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Canc Res Program, Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1LS, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Gallie, BL (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Room 8-415,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	gallie@attglobal.net	Tsao, Ming Sound/AFQ-7332-2022; Corson, Timothy W./B-6851-2009; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Corson, Timothy W./0000-0002-1402-7875; Gallie, Brenda/0000-0002-9697-9211				Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Bertuzzi S, 1999, MECH DEVELOP, V81, P193, DOI 10.1016/S0925-4773(98)00233-0; Blackhall FH, 2004, LUNG CANCER, V46, P197, DOI 10.1016/j.lungcan.2004.04.002; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeBonis S, 2004, MOL CANCER THER, V3, P1079; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Gallie BL, 1999, CANCER RES, V59, p1731S; GALLIE BL, 1999, HUMAN CELL CULTURE, V2, P361; Hackett CS, 2003, CANCER RES, V63, P5266; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2002, CANCER RES, V62, P2675; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Leizerman I, 2004, CELL MOL LIFE SCI, V61, P2060, DOI 10.1007/s00018-004-4074-3; LEROY H, 1993, GENE CHROMOSOME CANC, V6, P156; Levesque AA, 2003, MOL BIOL CELL, V14, P3541, DOI 10.1091/mbc.E03-02-0082; Lillington DM, 2002, BRIT J CANCER, V87, P779, DOI 10.1038/sj.bjc.6600532; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Marchong MN, 2004, MOL CANCER RES, V2, P495; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nomura N, 1994, DNA Res, V1, P251, DOI 10.1093/dnares/1.5.251; Ohkura H, 1997, J CELL SCI, V110, P945; OLIVEROS O, 1995, CANCER GENET CYTOGEN, V82, P155, DOI 10.1016/0165-4608(94)00212-T; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Retaux S, 1999, J NEUROSCI, V19, P783; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Ruden DM, 1997, DEV BIOL, V191, P284, DOI 10.1006/dbio.1997.8726; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sargent LM, 2002, CANCER RES, V62, P1152; Schreiner B, 2003, GENE CHROMOSOME CANC, V38, P240, DOI 10.1002/gcc.10285; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VANBERLO RJ, 1990, CANCER RES, V50, P3416; Yan RT, 1997, GENE, V189, P263, DOI 10.1016/S0378-1119(96)00860-8	44	140	146	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4741	4753		10.1038/sj.onc.1208641	http://dx.doi.org/10.1038/sj.onc.1208641			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897902				2022-12-25	WOS:000230477900001
J	Deschenes-Furry, J; Belanger, G; Mwanjewe, J; Lunde, JA; Parks, RJ; Perrone-Bizzozero, N; Jasmin, BJ				Deschenes-Furry, J; Belanger, G; Mwanjewe, J; Lunde, JA; Parks, RJ; Perrone-Bizzozero, N; Jasmin, BJ			The RNA-binding protein HuR binds to acetylcholinesterase transcripts and regulates their expression in differentiating skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-43 MESSENGER-RNA; TISSUE-SPECIFIC EXPRESSION; NERVE GROWTH-FACTOR; VERTEBRATE NEUROMUSCULAR-JUNCTION; PC12 CELLS; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; NEURITE OUTGROWTH; MAMMALIAN ACETYLCHOLINESTERASE	During myogenic differentiation, acetylcholinesterase (AChE) transcript levels are known to increase dramatically. Although this increase can be attributed in part to increased transcriptional activity, posttranscriptional mechanisms have also been implicated in the high levels of AChE mRNA in myotubes. In this study, we observed that transfection of a luciferase reporter construct containing the full-length AChE 3'-untranslated region ( UTR) resulted in significantly higher (5-fold) luciferase activity in differentiated myotubes versus myoblasts. RNA-electrophoretic mobility shift assays (REMSAs) performed with a full-length AChE 3'-UTR probe and the AU-rich element revealed that the intensity of RNA-binding protein complexes increased as myogenic differentiation proceeded. Using several complementary approaches including supershift REMSA, mRNA-binding protein pull-down assays, and immunoprecipitation followed by reverse transcription-PCR, we found that the mRNA-stabilizing protein HuR interacts directly with AChE transcripts. Stable overexpression of HuR in C2C12 cells increased the expression of endogenous AChE transcripts as well as that of the luciferase reporter construct containing the AChE 3'-UTR. In vitro stability assays performed with protein extracts from these cells versus controls resulted in a slower rate of AChE mRNA decay. The down-regulation of HuR expression mediated through small interfering RNA further confirmed the role of HuR in the regulation of AChE mRNA levels. Taken together, these studies demonstrate that HuR interacts with the AChE 3'-UTR to regulate posttranscriptionally the expression of AChE mRNA during myogenic differentiation.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Med, Fac Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Biochem, Fac Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Microbiol & Immunol, Fac Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON K1H 8L6, Canada; Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON, Canada; Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of New Mexico	Jasmin, BJ (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jasmin@uottawa.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030255, R29NS030255] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-30255] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Alvarez A, 1998, J NEUROSCI, V18, P3213; Anderson KD, 2000, J NEUROCHEM, V75, P1103, DOI 10.1046/j.1471-4159.2000.0751103.x; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Beckel-Mitchener AC, 2002, J BIOL CHEM, V277, P27996, DOI 10.1074/jbc.M201982200; BOUDREAULARIVIERE, 2000, J NEUROCHEM, V74, P2250; BOUDREAULARIVIERE, 1996, NEUROSCIENCE, V73, P613; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; CRESNAR B, 1994, J NEUROSCI RES, V38, P294, DOI 10.1002/jnr.490380307; Cuadrado A, 2003, J NEUROCHEM, V86, P763, DOI 10.1046/j.1471-4159.2003.01877.x; Deschenes-Furry J, 2003, J BIOL CHEM, V278, P5710, DOI 10.1074/jbc.M209383200; Dobashi Y, 1998, BIOCHEM BIOPH RES CO, V244, P226, DOI 10.1006/bbrc.1998.8247; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; Engel AG, 1999, ARCH NEUROL-CHICAGO, V56, P163, DOI 10.1001/archneur.56.2.163; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; FERNANDEZ HL, 1984, NEUROSCI LETT, V44, P187, DOI 10.1016/0304-3940(84)90079-X; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; FORSTER E, 1993, NEUROSCI LETT, V155, P216, DOI 10.1016/0304-3940(93)90711-S; Freyssenet D, 1999, AM J PHYSIOL-ENDOC M, V277, pE26, DOI 10.1152/ajpendo.1999.277.1.E26; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gramolini AO, 1999, NUCLEIC ACIDS RES, V27, P3603, DOI 10.1093/nar/27.17.3603; Gramolini AO, 2001, J CELL BIOL, V154, P1173, DOI 10.1083/jcb.200101108; GRUBIC Z, 1995, NEURON, V14, P317, DOI 10.1016/0896-6273(95)90288-0; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Irwin N, 2002, P NATL ACAD SCI USA, V99, P12427, DOI 10.1073/pnas.152457399; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Legay C, 1999, J NEUROSCI, V19, P8252; Legay C, 2000, MICROSC RES TECHNIQ, V49, P56, DOI 10.1002/(SICI)1097-0029(20000401)49:1<56::AID-JEMT7>3.0.CO;2-R; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; LUO ZG, 1994, J BIOL CHEM, V269, P27216; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Misquitta CM, 2001, MOL CELL BIOCHEM, V224, P53, DOI 10.1023/A:1011982932645; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Ng Philip, 2002, Methods Mol Med, V69, P389; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Perrone-Bizzozero N, 2002, J NEUROSCI RES, V68, P121, DOI 10.1002/jnr.10175; PRIVES JM, 1974, P NATL ACAD SCI USA, V71, P3208, DOI 10.1073/pnas.71.8.3208; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Rotundo RL, 2003, J NEUROCYTOL, V32, P743, DOI 10.1023/B:NEUR.0000020621.58197.d4; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Tang KC, 2002, AM J PHYSIOL-HEART C, V283, pH1497, DOI 10.1152/ajpheart.00813.2001; ULRICH J, 1990, ACTA NEUROPATHOL, V80, P624, DOI 10.1007/BF00307630; VALLETTE FM, 1987, DEV BIOL, V120, P77, DOI 10.1016/0012-1606(87)90105-9; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; VIGNY M, 1976, J NEUROCHEM, V27, P1347, DOI 10.1111/j.1471-4159.1976.tb02614.x; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zhao ZQ, 2000, NUCLEIC ACIDS RES, V28, P2695, DOI 10.1093/nar/28.14.2695	77	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25361	25368		10.1074/jbc.M410929200	http://dx.doi.org/10.1074/jbc.M410929200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878846	hybrid			2022-12-25	WOS:000230207900008
J	Guimaraes, BG; Souchon, H; Honore, N; Saint-Joanis, B; Brosch, R; Shepard, W; Cole, ST; Alzari, PM				Guimaraes, BG; Souchon, H; Honore, N; Saint-Joanis, B; Brosch, R; Shepard, W; Cole, ST; Alzari, PM			Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE GENE; CRYSTAL-STRUCTURE; ISONIAZID RESISTANCE; ANTIOXIDANT DEFENSE; 2-CYS PEROXIREDOXIN; REDUCTASE; OLIGOMERIZATION; PEROXYNITRITE; GENERATION; BACTERIAL	The peroxiredoxin AhpC from Mycobacterium tuberculosis ( MtAhpC) is the foremost element of a NADH- dependent peroxidase and peroxynitrite reductase system, where it directly reduces peroxides and peroxynitrite and is in turn reduced by AhpD and other proteins. Overexpression of MtAhpC in isoniazid- resistant strains of M. tuberculosis harboring mutations in the catalase/ peroxidase katG gene provides antioxidant protection and may substitute for the lost enzyme activities. We report here the crystal structure of oxidized MtAhpC trapped in an intermediate oligomeric state of its catalytic cycle. The overall structure folds into a ring- shaped hexamer of dimers instead of the usual pentamer of dimers observed in other reduced peroxiredoxins. Although the general structure of the functional dimer is similar to that of other 2- Cys peroxiredoxins, the alpha- helix containing the peroxidatic cysteine Cys(61) undergoes a unique rigid- body movement to allow the formation of the disulfide bridge with the resolving cysteine Cys(174). This conformational rearrangement creates a large internal cavity enclosing the active site, which might be exploited for the design of inhibitors that could block the catalytic cycle. Structural and mutagenesis evidence points to a model for the electron transfer pathway in MtAhpC that accounts for the unusual involvement of three cysteine residues in catalysis and suggests a mechanism by which MtAhpC can specifically interact with different redox partners.	Inst Pasteur, CNR, Unite Biochim Struct, URA 2185, F-75724 Paris, France; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; European Synchrotron Radiation Facility (ESRF)	Alzari, PM (corresponding author), Inst Pasteur, CNR, Unite Biochim Struct, URA 2185, 25 Rue Dr Roux, F-75724 Paris, France.	alzari@pasteur.fr	Brosch, Roland/AAZ-3850-2021; Brosch, Roland/ABB-4108-2021; Guimarães, Beatriz Gomes/Z-6242-2019; Guimarães, Beatriz G/D-3858-2014	Brosch, Roland/0000-0003-2587-3863; Guimarães, Beatriz Gomes/0000-0002-8546-2460; Shepard, William/0000-0002-5724-1193; Alzari, Pedro/0000-0002-4233-1903				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Chauhan R, 2002, BIOCHEM J, V367, P255, DOI 10.1042/BJ20020545; Chauhan R, 2001, BIOCHEM J, V354, P209, DOI 10.1042/0264-6021:3540209; Chen L, 1998, MOL CELL, V1, P795, DOI 10.1016/S1097-2765(00)80079-9; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koshkin A, 2004, ANTIMICROB AGENTS CH, V48, P2424, DOI 10.1128/AAC.48.7.2424-2430.2004; Koshkin A, 2004, ARCH BIOCHEM BIOPHYS, V427, P41, DOI 10.1016/j.abb.2004.04.017; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Manca C, 1999, INFECT IMMUN, V67, P74, DOI 10.1128/IAI.67.1.74-79.1999; Master SS, 2002, MICROBIOL-SGM, V148, P3139, DOI 10.1099/00221287-148-10-3139; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nunn CM, 2002, J BIOL CHEM, V277, P20033, DOI 10.1074/jbc.M200864200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SHERMAN DR, 1995, P NATL ACAD SCI USA, V92, P6625, DOI 10.1073/pnas.92.14.6625; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhang Y, 1996, P NATL ACAD SCI USA, V93, P13212, DOI 10.1073/pnas.93.23.13212; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	39	78	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25735	25742		10.1074/jbc.M503076200	http://dx.doi.org/10.1074/jbc.M503076200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886207	Green Published, hybrid			2022-12-25	WOS:000230207900054
J	Pan, PY; Cai, Q; Lin, L; Lu, PH; Duan, SM; Sheng, ZH				Pan, PY; Cai, Q; Lin, L; Lu, PH; Duan, SM; Sheng, ZH			SNAP-29-mediated modulation of synaptic transmission in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SHORT-TERM PLASTICITY; NEUROTRANSMITTER RELEASE; CALCIUM-CHANNELS; N-TYPE; PRESYNAPTIC PROTEINS; CENTRAL SYNAPSES; NERVE-TERMINALS; ALPHA-SNAP; IN-VITRO	Identifying the molecules that regulate both the recycling of synaptic vesicles and the SNARE components required for fusion is critical for elucidating the molecular mechanisms underlying synaptic plasticity. SNAP- 29 was initially isolated as a syntaxin- binding and ubiquitously expressed protein. Previous studies have suggested that SNAP- 29 inhibits SNARE complex disassembly, thereby reducing synaptic transmission in cultured superior cervical ganglion neurons in an activity-dependent manner. However, the role of SNAP- 29 in regulating synaptic vesicle recycling and short- term plasticity in the central nervous system remains unclear. In the present study, we examined the effect of SNAP- 29 on synaptic transmission in cultured hippocampal neurons by dual patch clamp whole- cell recording, FM dye imaging, and immunocytochemistry. Our results demonstrated that exogenous expression of SNAP- 29 in presynaptic neurons significantly decreased the efficiency of synaptic transmission after repetitive firing within a few minutes under low and moderate frequency stimulations ( 0.1 and 1 Hz). In contrast, SNAP- 29 did not affect the density of synapses and basal synaptic transmission. Whereas neurotransmitter release was unaffected during intensive stimulation, recovery after synaptic depression was impaired by SNAP- 29. Furthermore, knockdown of SNAP- 29 expression in neurons by small interfering RNA increased the efficiency of synaptic transmission during repetitive firing. These findings suggest that SNAP- 29 acts as a negative modulator for neurotransmitter release, probably by slowing recycling of the SNARE- based fusion machinery and synaptic vesicle turnover.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Shanghai 200031, Peoples R China; Shanghai Med Univ 2, Dept Neurobiol, Shanghai 200025, Peoples R China; NINDS, Synapt Funct Unit, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Duan, SM (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China.	shumin@ion.ac.cn; shengz@ninds.nih.gov		Pan, Pingyue/0000-0002-2805-6810	Intramural NIH HHS Funding Source: Medline; NINDS NIH HHS [Z01 NS002946-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002946] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Calakos N, 2004, NEURON, V42, P889, DOI 10.1016/j.neuron.2004.05.014; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Degtiar VE, 2000, J NEUROSCI, V20, P4355, DOI 10.1523/JNEUROSCI.20-12-04355.2000; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; GALLI T, 2001, SCI STKE, V88, pRE1; Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Hohenstein AC, 2001, BIOCHEM BIOPH RES CO, V285, P167, DOI 10.1006/bbrc.2001.5141; Kawasaki F, 1998, J NEUROSCI, V18, P10241; Lao GF, 2000, NEURON, V25, P191, DOI 10.1016/S0896-6273(00)80882-X; Littleton JT, 2001, P NATL ACAD SCI USA, V98, P12233, DOI 10.1073/pnas.221450198; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Sanyal S, 2001, NEUROSCI LETT, V311, P21, DOI 10.1016/S0304-3940(01)02125-5; Schikorski T, 2001, NAT NEUROSCI, V4, P391, DOI 10.1038/86042; Schikorski T, 1997, J NEUROSCI, V17, P5858; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Sippy T, 2003, NAT NEUROSCI, V6, P1031, DOI 10.1038/nn1117; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Su QN, 2001, P NATL ACAD SCI USA, V98, P14038, DOI 10.1073/pnas.251532398; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thakur P, 2004, J NEUROSCI, V24, P6476, DOI 10.1523/JNEUROSCI.0590-04.2004; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Waters J, 2002, J PHYSIOL-LONDON, V541, P811, DOI 10.1113/jphysiol.2001.013485; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	50	57	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25769	25779		10.1074/jbc.M502356200	http://dx.doi.org/10.1074/jbc.M502356200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890653	hybrid, Green Accepted			2022-12-25	WOS:000230207900058
J	Golubkov, VS; Boyd, S; Savinov, AY; Chekanov, AV; Osterman, AL; Remacle, A; Rozanov, DV; Doxsey, SJ; Strongin, AY				Golubkov, VS; Boyd, S; Savinov, AY; Chekanov, AV; Osterman, AL; Remacle, A; Rozanov, DV; Doxsey, SJ; Strongin, AY			Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-MATRIX METALLOPROTEINASE; RAPID TRAFFICKING; CENTROSOME; PERICENTRIN; CANCER; FURIN; ACTIVATION; ANEUPLOIDY; PROTEINS; COMPLEX	Elevated expression of membrane type-1 matrix metalloproteinase (MT1-MMP) is closely associated with malignancies. There is a consensus among scientists that cell surface-associated MT1-MMP is a key player in pericellular proteolytic events. Now we have identified an intracellular, hitherto unknown, function of MT1-MMP. We demonstrated that MT1-MMP is trafficked along the tubulin cytoskeleton. A fraction of cellular MT1-MMP accumulates in the centrosomal compartment. MT1-MMP targets an integral centrosomal protein, pericentrin. Pericentrin is known to be essential to the normal functioning of centrosomes and to mitotic spindle formation. Expression of MT1-MMP stimulates mitotic spindle aberrations and aneuploidy in nonmalignant cells. Volumes of data indicate that chromosome instability is an early event of carcinogenesis. In agreement, the presence of MT1-MMP activity correlates with degraded pericentrin in tumor biopsies, whereas normal tissues exhibit intact pericentrin. We believe that our data show a novel proteolytic pathway to chromatin instability and elucidate the close association of MT1-MMP with malignant transformation.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Monash Univ, Sch Comp Sci & Software Engn, Melbourne, Vic 3800, Australia; Univ Massachusetts, Sch Med, Worcester, MA 01605 USA	Sanford Burnham Prebys Medical Discovery Institute; Monash University; University of Massachusetts System; University of Massachusetts Worcester	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Boyd, Sarah E/I-9047-2012; Golubkov, Vladislav/L-6828-2017	Strongin, Alex/0000-0003-3765-3016; Boyd, Sarah/0000-0002-7264-8602	NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Boyd SE, 2004, 2004 IEEE COMPUTATIONAL SYSTEMS BIOINFORMATICS CONFERENCE, PROCEEDINGS, P372; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 2002, CANCER RES, V62, P580; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Duesberg P, 2004, IUBMB LIFE, V56, P65, DOI 10.1080/15216540410001667902; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Flory MR, 2003, GENOMICS, V82, P401, DOI 10.1016/S0888-7543(03)00119-8; Golldack D, 2002, J BIOL CHEM, V277, P5541, DOI 10.1074/jbc.M106197200; Ha HY, 2001, CANCER RES, V61, P984; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Honda S, 2004, J BIOL CHEM, V279, P10615, DOI 10.1074/jbc.M308841200; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hwang IK, 2004, BBA-PROTEINS PROTEOM, V1702, P79, DOI 10.1016/j.bbapap.2004.08.001; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jurczyk A, 2004, J CELL BIOL, V166, P637, DOI 10.1083/jcb.200405023; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Kwan JA, 2004, FASEB J, V18, P690, DOI 10.1096/fj.02-1202fje; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2004, BIOL CHEM, V385, P493, DOI 10.1515/BC.2004.058; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Peden AA, 2004, MOL BIOL CELL, V15, P3530, DOI 10.1091/mbc.E03-12-0918; Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Schnaeker EM, 2004, CANCER RES, V64, P8924, DOI 10.1158/0008-5472.CAN-04-0324; Soulie P, 2005, ONCOGENE, V24, P1689, DOI 10.1038/sj.onc.1208360; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Urena JM, 1999, J CELL SCI, V112, P773; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang Q, 2004, DNA CELL BIOL, V23, P475, DOI 10.1089/1044549041562276; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	68	81	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25079	25086		10.1074/jbc.M502779200	http://dx.doi.org/10.1074/jbc.M502779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878869	hybrid			2022-12-25	WOS:000230114000091
J	Goudet, C; Kniazeff, J; Hlavackova, V; Malhaire, F; Maurel, D; Acher, F; Blahos, J; Prezeau, L; Pin, JP				Goudet, C; Kniazeff, J; Hlavackova, V; Malhaire, F; Maurel, D; Acher, F; Blahos, J; Prezeau, L; Pin, JP			Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HEPTAHELICAL DOMAIN; GABA(B) RECEPTOR; ACTIVATION MECHANISM; SUBUNITS; ORGANIZATION; DIMERIZATION; RHODOPSIN; FAMILY; ROLES	The recent discovery of positive allosteric modulators (PAMs) for G-protein-coupled receptors open new possibilities to control a number of physiological and pathological processes. Understanding the mechanism of action of such compounds will provide new information on the activation process of these important receptors. Within the last 10 years, a number of studies indicate that G-protein-coupled receptors can form dimers, but the functional significance of this phenomenon remains elusive. Here we used the metabotropic glutamate receptors as a model, because these receptors, for which PAMs have been identified, are constitutive dimers. We used the quality control system of the GABA(B) receptor to generate metabotropic glutamate receptor dimers in which a single subunit binds a PAM. We show that one PAM/dimer is sufficient to enhance receptor activity. Such a potentiation can still be observed if the subunit unable to bind the PAM is also made unable to activate G-proteins. However, the PAM acts as a non- competitive antagonist when it binds in the subunit that cannot activate G-proteins. These data are consistent with a single heptahelical domain reaching the active state per dimer during receptor activation.	Univ Montpellier 2, Univ Montpellier 1,CNRS UMR5203, Inst Genom Fonctionnelle,INSERM U661, Dept Pharmacol Mol, F-34094 Montpellier, France; Acad Sci Czech Republ, Inst Expt Med, Dept Mol Pharmacol, Prague 14220 4, Czech Republic; Cis Bio Int, F-30204 Bagnols Sur Ceze, France; Univ Paris 05, CNRS UMR8601, Lab Pharmacol & Toxicol Chem & Biochem, F-75270 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Czech Academy of Sciences; Institute of Experimental Medicine of the Czech Academy of Sciences; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite	Pin, JP (corresponding author), Univ Montpellier 2, Univ Montpellier 1,CNRS UMR5203, Inst Genom Fonctionnelle,INSERM U661, Dept Pharmacol Mol, 141 Rue Cardonille, F-34094 Montpellier, France.	jppin@igf.cnrs.fr	Goudet, Cyril/AAE-3415-2020; Pin, Jean-Philippe/Y-6668-2019; Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Goudet, Cyril/0000-0002-8255-3535; Pin, Jean-Philippe/0000-0002-1423-345X; Kniazeff, Julie/0000-0002-0426-0999; Maurel, Damien/0000-0003-1281-0871; MALHAIRE, Fanny/0000-0001-5930-9879; Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Fourgeaud L, 2003, J BIOL CHEM, V278, P12222, DOI 10.1074/jbc.M205663200; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Havlickova M, 2003, J BIOL CHEM, V278, P35063, DOI 10.1074/jbc.M306555200; Hlavackova V, 2005, EMBO J, V24, P499, DOI 10.1038/sj.emboj.7600557; Jensen AA, 2004, EUR J PHARM SCI, V21, P407, DOI 10.1016/j.ejps.2003.11.007; JOLIDON S, 2001, Patent No. 20020022648; Kew JNC, 2004, PHARMACOL THERAPEUT, V104, P233, DOI 10.1016/j.pharmthera.2004.08.010; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2004, NAT STRUCT MOL BIOL, V11, P706, DOI 10.1038/nsmb794; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013; May LT, 2003, CURR OPIN PHARMACOL, V3, P551, DOI 10.1016/S1471-4892(03)00107-3; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; O'Brien JA, 2003, MOL PHARMACOL, V64, P731, DOI 10.1124/mol.64.3.731; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Schaffhauser H, 2003, MOL PHARMACOL, V64, P798, DOI 10.1124/mol.64.4.798; Shoback DM, 2003, J CLIN ENDOCR METAB, V88, P5644, DOI 10.1210/jc.2002-021597; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101	40	107	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24380	24385		10.1074/jbc.M502642200	http://dx.doi.org/10.1074/jbc.M502642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863499	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000230114000012
J	Palmitessa, A; Hess, HA; Bany, IA; Kim, YM; Koelle, MR; Benovic, JL				Palmitessa, A; Hess, HA; Bany, IA; Kim, YM; Koelle, MR; Benovic, JL			Caenorhabditus elegans arrestin regulates neural G protein signaling and olfactory adaptation and recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; C-ELEGANS; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; CLATHRIN; ENDOCYTOSIS; ADAPTER; GENE; RHODOPSIN; DOMAIN	Although regulation of G protein-coupled receptor signaling by receptor kinases and arrestins is a well established biochemical process, the physiological significance of such regulation remains poorly understood. To better understand the in vivo consequences of arrestin function, we have examined the function of the sole arrestin in Caenorhabditis elegans (ARR-1). ARR-1 is primarily expressed in the nervous system, including the HSN neuron and various chemosensory neurons involved in detecting soluble and volatile odorants. arr-1 null mutants exhibit normal chemotaxis but have significant defects in olfactory adaptation and recovery to volatile odorants. In contrast, adaptation is enhanced in animals overexpressing ARR-1. Both the adaptation and recovery defects of arr-1 mutants are rescued by transgenic expression of wild-type ARR-1, whereas expression of a C-terminally truncated ARR-1 effectively rescues only the adaptation defect. A potential mechanistic basis for these findings is revealed by in vitro studies demonstrating that wild-type ARR-1 binds proteins of the endocytic machinery and promotes receptor endocytosis, whereas C-terminally truncated ARR-1 does not. These results demonstrate that ARR-1 functions to regulate chemosensory signaling, enabling organisms to adapt to a variety of environmental cues, and provide an in vivo link between arrestin, receptor endocytosis, and temporal recovery from adaptation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Jefferson University; Yale University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu	Kim, You-Me/I-5553-2013	Kim, You-Me/0000-0001-8780-704X	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R37GM047417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036918] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM47417] Funding Source: Medline; NINDS NIH HHS [NS36918] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Bargmann C. I., 1997, C ELEGANS, P717; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BRENNER S, 1974, GENETICS, V77, P71; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; Colbert HA, 1997, J NEUROSCI, V17, P8259; Conner DA, 1997, CIRC RES, V81, P1021; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896-6273(04)00252-1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; L'Etoile ND, 2002, NEURON, V36, P1079, DOI 10.1016/S0896-6273(02)01066-8; L'Etoile ND, 2000, NEURON, V25, P575, DOI 10.1016/S0896-6273(00)81061-2; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Moresco JJ, 2004, J NEUROSCI, V24, P8522, DOI 10.1523/JNEUROSCI.1915-04.2004; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Roman G, 2000, GENETICS, V155, P1281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Wilkie TM, 2000, CURR BIOL, V10, pR853, DOI 10.1016/S0960-9822(00)00823-X; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200	55	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24649	24662		10.1074/jbc.M502637200	http://dx.doi.org/10.1074/jbc.M502637200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878875	hybrid			2022-12-25	WOS:000230114000045
J	Suzuki, T; Okada, Y; Semba, S; Orba, Y; Yamanouchi, S; Endo, S; Tanaka, S; Fujita, T; Kuroda, S; Nagashima, K; Sawa, H				Suzuki, T; Okada, Y; Semba, S; Orba, Y; Yamanouchi, S; Endo, S; Tanaka, S; Fujita, T; Kuroda, S; Nagashima, K; Sawa, H			Identification of FEZ1 as a protein that interacts with JC virus agnoprotein and microtubules - Role of agnoprotein-induced dissociation of FEZ1 from microtubules in viral propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; FAST AXONAL-TRANSPORT; MAJOR CAPSID PROTEIN; LARGE T-ANTIGEN; HUMAN POLYOMAVIRUS; AUXILIARY PROTEINS; GLIAL-CELLS; TYPE-1 VPU; KINESIN; EXPRESSION	The human polyomavirus JC virus (JCV) is the causative agent of a fatal demyelinating disease, progressive multifocal leukoencephalopathy, and encodes six major proteins, including agnoprotein. Agnoprotein colocalizes with microtubules in JCV-infected cells, but its function is not fully understood. We have now identified fasciculation and elongation protein zeta 1 (FEZ1) as a protein that interacted with JCV agnoprotein in a yeast two-hybrid screen of a human brain cDNA library. An in vitro binding assay showed that agnoprotein interacted directly with FEZ1 and microtubules. A microtubule co-sedimentation assay revealed that FEZ1 also associates with microtubules and that agnoprotein induces the dissociation of FEZ1 from microtubules. Agnoprotein inhibited the promotion by FEZ1 of neurite outgrowth in PC12 cells. Conversely, overexpression of FEZ1 suppressed JCV protein expression and intracellular trafficking in JCV-infected cells. These results suggest that FEZ1 promotes neurite extension through its interaction with microtubules, and that agnoprotein facilitates JCV propagation by inducing the dissociation of FEZ1 from microtubules.	Hokkaido Univ, Res Ctr Zoonosis Control, Dept Mol Biol & Diag, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Century Ctr Excellence Program Zoonosis Control, Sapporo, Hokkaido 0608638, Japan; Japan Sci & Technol Agcy, Sch Med Core Res Evolut Sci & Technol, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan; Osaka Univ, Inst Sci & Ind Res Sanken, Dept Struct Mol Biol, Osaka 5670047, Japan	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST); Osaka University	Sawa, H (corresponding author), Hokkaido Univ, Res Ctr Zoonosis Control, Dept Mol Biol & Diag, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	h-sawa@patho2.med.hokudai.ac.jp	FUJITA, Toshitsugu/ABH-5101-2020; Sawa, Hirofumi/AAW-8816-2021; Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/F-6954-2012; Suzuki, Tadaki/ABH-2661-2020; Orba, Yasuko/F-6888-2012	FUJITA, Toshitsugu/0000-0002-9536-9999; Sawa, Hirofumi/0000-0003-2569-2755; 				Ashok A, 2003, J VIROL, V77, P1347, DOI 10.1128/JVI.77.2.1347-1356.2003; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CARSWELL S, 1986, J VIROL, V60, P415, DOI 10.1128/JVI.60.2.415-422.1986; CARSWELL S, 1986, J VIROL, V60, P1055, DOI 10.1128/JVI.60.3.1055-1061.1986; CLAYSON ET, 1989, J VIROL, V63, P2278, DOI 10.1128/JVI.63.5.2278-2288.1989; Cohen EA, 1996, CURR TOP MICROBIOL, V214, P219; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Diefenbach RJ, 2002, J VIROL, V76, P3282, DOI 10.1128/JVI.76.7.3282-3291.2002; Endo S, 2003, J NEUROVIROL, V9, P10, DOI 10.1080/13550280390195333; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Fujita T, 2004, BIOCHEM BIOPH RES CO, V313, P738, DOI 10.1016/j.bbrc.2003.12.006; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; Gindhart JG, 2003, MOL BIOL CELL, V14, P3356, DOI 10.1091/mbc.E02-12-0800; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; Harris M, 1999, CURR BIOL, V9, pR459, DOI 10.1016/S0960-9822(99)80282-6; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; HOUJONG MHJ, 1987, J VIROL, V61, P937, DOI 10.1128/JVI.61.3.937-939.1987; Komagome R, 2002, J VIROL, V76, P12992, DOI 10.1128/JVI.76.24.12992-13000.2002; Kuroda S, 1999, J CELL BIOL, V144, P403, DOI 10.1083/jcb.144.3.403; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; MICHAUD G, 1989, J MOL BIOL, V209, P667, DOI 10.1016/0022-2836(89)90599-8; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Nakata T, 2003, J CELL BIOL, V162, P1045, DOI 10.1083/jcb.200302175; NOMURA S, 1983, J VIROL, V45, P428, DOI 10.1128/JVI.45.1.428-433.1983; NUKUZUMA S, 1995, J MED VIROL, V47, P370, DOI 10.1002/jmv.1890470413; Okada Y, 2002, ACTA NEUROPATHOL, V104, P130, DOI 10.1007/s00401-002-0526-8; Okada Y, 2001, J NEUROVIROL, V7, P302; Okada Y, 2000, J BIOL CHEM, V275, P17016, DOI 10.1074/jbc.275.22.17016; Orba Y, 2004, J VIROL, V78, P7270, DOI 10.1128/JVI.78.13.7270-7273.2004; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Qu QM, 2004, J BIOL CHEM, V279, P27735, DOI 10.1074/jbc.M310827200; RESNICK J, 1986, J VIROL, V60, P1098, DOI 10.1128/JVI.60.3.1098-1106.1986; RESSETAR HG, 1990, LAB INVEST, V62, P287; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Safak R, 1999, MOL CELL BIOL, V19, P2712; Setou M, 2004, J NEUROBIOL, V58, P201, DOI 10.1002/neu.10324; Shinohara T, 1997, VIROLOGY, V228, P269, DOI 10.1006/viro.1996.8409; Shishido-Hara Y, 2000, J VIROL, V74, P1840, DOI 10.1128/JVI.74.4.1840-1853.2000; Stebbings H, 2001, INT REV CYTOL, V211, P1, DOI 10.1016/S0074-7696(01)11016-8; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; Suzuki S, 2001, VIROLOGY, V286, P100, DOI 10.1006/viro.2001.0972; Takakuwa H, 2001, GENES CELLS, V6, P955, DOI 10.1046/j.1365-2443.2001.00475.x; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	53	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24948	24956		10.1074/jbc.M411499200	http://dx.doi.org/10.1074/jbc.M411499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15843383	hybrid			2022-12-25	WOS:000230114000079
J	Trakul, N; Menard, RE; Schade, GR; Qian, ZH; Rosner, MR				Trakul, N; Menard, RE; Schade, GR; Qian, ZH; Rosner, MR			Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CELLS; PATHWAY; PHOSPHORYLATION; ERK; SUPPRESSION; MECHANISM; MODULATION; EXPRESSION; SPROUTY1; CASCADE	Raf kinase inhibitory protein (RKIP; also known as phosphatidylethanolamine-binding protein or PEBP) is a modulator of the Raf/MAPK signaling cascade and a suppressor of metastatic cancer. Here, we show that RKIP inhibits MAPK by regulating Raf-1 activation; specifically, RKIP acts subsequent to Raf-1 membrane recruitment, prevents association of Raf-1 and p21-activated kinase (PAK), and blocks phosphorylation of the Raf-1 kinase domain by PAK and Src family kinases. Mutation of the PAK and Src phosphorylation sites on Raf-1 to aspartate, a phosphate mimic, prevented RKIP association with or inhibition of Raf-1 signaling. Interestingly, although RKIP can interact with B-Raf, RKIP depletion had no effect on activation of B-Raf. Because c-Raf-1 and B-Raf are both required for maximal MAPK stimulation by epidermal growth factor in neuronal and epithelial cell lines, we determined whether RKIP significantly affects MAPK signaling. In fact, RKIP depletion increased not only the amplitude but also the sensitivity of MAPK and DNA synthesis to epidermal growth factor stimulation by up to an order of magnitude. These results indicate that selective modulation of c-Raf-1 but not B-Raf activation by RKIP can limit the dynamic range of the MAPK signaling response to growth factors and may play a critical role in growth and development.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 5841 S Maryland Ave,MC6027, Chicago, IL 60637 USA.	m-rosner@uchicago.edu			NATIONAL CANCER INSTITUTE [T32CA009594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033858] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA09594] Funding Source: Medline; NINDS NIH HHS [NS33858] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Brightman FA, 2000, FEBS LETT, V482, P169, DOI 10.1016/S0014-5793(00)02037-8; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corbit KC, 2000, MOL CELL BIOL, V20, P5392, DOI 10.1128/MCB.20.15.5392-5403.2000; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Gross I, 2003, J BIOL CHEM, V278, P41420, DOI 10.1074/jbc.M306425200; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Trakul N, 2005, CELL RES, V15, P19, DOI 10.1038/sj.cr.7290258; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yamada S, 2004, BIOCHEM BIOPH RES CO, V314, P1113, DOI 10.1016/j.bbrc.2004.01.009; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151	30	101	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24931	24940		10.1074/jbc.M413929200	http://dx.doi.org/10.1074/jbc.M413929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15886202	hybrid			2022-12-25	WOS:000230114000077
J	Uter, NT; Sovulj, IG; Perona, JJ				Uter, NT; Sovulj, IG; Perona, JJ			Amino acid-dependent transfer RNA affinity in a class I aminoacyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; RECOGNITION; SPECIFICITY; MECHANISM; EVOLUTION; IDENTITY; BINDING; ATP	Steady-state and transient kinetic analyses of glutaminyl-tRNA synthetase ( GlnRS) reveal that the enzyme discriminates against noncognate glutamate at multiple steps during the overall aminoacylation reaction. A major portion of the selectivity arises in the amino acid activation portion of the reaction, whereas the discrimination in the overall two-step reaction arises from very weak binding of noncognate glutamate. Further transient kinetics experiments showed that tRNAGln binds to GlnRS similar to 60-fold weaker when noncognate glutamate is present and that glutamate reduces the association rate of tRNA with the enzyme by 100-fold. These findings demonstrate that amino acid and tRNA binding are interdependent and reveal an important additional source of specificity in the aminoacylation reaction. Crystal structures of the GlnRS(.)tRNA complex bound to either amino acid have previously shown that glutamine and glutamate bind in distinct positions in the active site, providing a structural basis for the amino acid-dependent modulation of tRNA affinity. Together with other crystallographic data showing that ligand binding is essential to assembly of the GlnRS active site, these findings suggest a model for specificity generation in which required induced-fit rearrangements are significantly modulated by the identities of the bound substrates.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Perona, JJ (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	perona@chem.ucsb.edu			NIGMS NIH HHS [GM63713] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063713] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agou F, 1998, BIOCHEMISTRY-US, V37, P11309, DOI 10.1021/bi9805590; AVIS JM, 1993, BIOCHEMISTRY-US, V32, P5312, DOI 10.1021/bi00071a005; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; Beuning PJ, 1999, BIOPOLYMERS, V52, P1; BHATTACHARYYA T, 1993, BIOCHEMISTRY-US, V32, P9268, DOI 10.1021/bi00087a002; Brown JR, 1999, J MOL EVOL, V49, P485, DOI 10.1007/PL00006571; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Hendrickson TL, 2003, MOL B INT U, P34; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 1996, P NATL ACAD SCI USA, V93, P6953, DOI 10.1073/pnas.93.14.6953; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; JOHNSON KA, 1991, ENZYMES, V20, P1; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Mandal AK, 1998, PROTEIN SCI, V7, P1046; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nissan TA, 2000, RNA, V6, P1585, DOI 10.1017/S1355838200001126; Ogle JM, 2003, TRENDS BIOCHEM SCI, V28, P259, DOI 10.1016/S0968-0004(03)00066-5; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; PERONA JJ, 1990, THESIS YALE U; Post CB, 1995, BIOCHEMISTRY-US, V34, P15881, DOI 10.1021/bi00049a001; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; Rose I A, 1980, Methods Enzymol, V64, P47; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sekine S, 2003, EMBO J, V22, P676, DOI 10.1093/emboj/cdg053; Sherlin LD, 2003, STRUCTURE, V11, P591, DOI 10.1016/S0969-2126(03)00074-1; Sherlin LD, 2001, RNA, V7, P1671; Siatecka M, 1998, EUR J BIOCHEM, V256, P80, DOI 10.1046/j.1432-1327.1998.2560080.x; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; TEMPEST DW, 1970, J GEN MICROBIOL, V64, P171, DOI 10.1099/00221287-64-2-171; Uter NT, 2004, P NATL ACAD SCI USA, V101, P14396, DOI 10.1073/pnas.0404017101; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799	36	48	49	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23966	23977		10.1074/jbc.M414259200	http://dx.doi.org/10.1074/jbc.M414259200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845537	hybrid			2022-12-25	WOS:000229880000071
J	Liu, K; Zhang, XP; Lester, RL; Dickson, RC				Liu, K; Zhang, XP; Lester, RL; Dickson, RC			The sphingoid long chain base phytosphingosine activates AGC-type protein kinases in Saccharomyces cerevisiae including Ypk1, Ypk2, and Sch9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STRESS RESPONSE; DOCKING-SITE; HYDROPHOBIC MOTIF; COUPLED RECEPTOR; GLOBAL ANALYSIS; BINDING POCKET; CELL-GROWTH; YEAST; PDK1; GENE	The Pkh1 protein kinase of Saccharomyces cerevisiae, a homolog of the mammalian 3-phosphoinositide-dependent kinase (PDK1), regulates downstream AGC-type protein kinases including Ypk1/2 and Pkc1, which control cell wall integrity, growth, and other processes. Phytosphingosine (PHS), a sphingoid long chain base, is hypothesized to be a lipid activator of Pkh1 and thereby controls the activity of Ypk1/2. Here we present biochemical evidence supporting this hypothesis, and in addition we demonstrate that PHS also stimulates autophosphorylation and activation of Ypk1/2. Greatest stimulation of Ypk1/2 phosphorylation and activity are achieved by inclusion of both PHS and Pkh1 in an in vitro kinase reaction. We also demonstrate for the first time that Pkh1 phosphorylates the Sch9 protein kinase in vitro and that such phosphorylation is stimulated by PHS. This is the first biochemical demonstration of Sch9 activators, and the results further support roles for long chain bases in heat stress resistance in addition to implying roles in chronological aging and cell size determination, since Sch9 functions in these processes. Thus, our data support a model in which PHS, rather than simply being an upstream activator of Pkh1, also activates kinases that are downstream targets of Pkh1 including Ypk1/2 and Sch9.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	bobd@uky.edu	Liu, Ke/D-3380-2015	Liu, Ke/0000-0002-4683-9325	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG024377, R01AG024377] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020171] Funding Source: Medline; NIA NIH HHS [AG 024377] Funding Source: Medline; NIGMS NIH HHS [GM 41302] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; CHEN P, 1993, MOL GEN GENET, V236, P443, DOI 10.1007/BF00277146; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Friant S, 2000, EMBO J, V19, P2834, DOI 10.1093/emboj/19.12.2834; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; Lorenz MC, 2000, GENETICS, V154, P609; Martinez MJ, 2004, MOL BIOL CELL, V15, P5295, DOI 10.1091/mbc.E03-11-0856; MAURER RA, 1988, DNA-J MOLEC CELL BIO, V7, P469, DOI 10.1089/dna.1.1988.7.469; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Morano KA, 1999, EMBO J, V18, P5953, DOI 10.1093/emboj/18.21.5953; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Prusty R, 2004, MOL GENET GENOMICS, V272, P264, DOI 10.1007/s00438-004-1049-x; Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Sasaki T, 2000, MOL GEN GENET, V262, P940, DOI 10.1007/PL00008662; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmitz HP, 2003, CURR GENET, V43, P245, DOI 10.1007/s00294-003-0403-6; Scholes DT, 2001, GENETICS, V159, P1449; Silber J, 2004, BIOCHEM BIOPH RES CO, V321, P823, DOI 10.1016/j.bbrc.2004.07.031; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2004, J BIOL CHEM, V279, P22030, DOI 10.1074/jbc.M400299200	58	93	103	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22679	22687		10.1074/jbc.M502972200	http://dx.doi.org/10.1074/jbc.M502972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840588	hybrid			2022-12-25	WOS:000229741800017
J	Zhou, SH; Lechpammer, S; Greenberger, JS; Glowacki, J				Zhou, SH; Lechpammer, S; Greenberger, JS; Glowacki, J			Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INDUCIBLE FACTOR-I; ADIPOCYTE DIFFERENTIATION; FACTOR-BETA; GENE-EXPRESSION; TGF-BETA; S6 KINASE; TRANSCRIPTION; ADIPOGENESIS; INDUCTION	Although hypoxia and transforming growth factor-beta (TGF-beta) inhibit differentiation of adipocytes from pre-adipocytes and bone marrow-derived cells in several species, the relationship between hypoxia and TGF-beta signaling in adipocytogenesis is unknown. In this study, we evaluated the mechanisms of inhibition of adipocyte differentiation by hypoxia and TGF-beta in human and murine marrow stromal cells (MSCs) and the role of TGF beta/Smad signaling in the inhibition of adipocytogenesis by hypoxia. Both hypoxia-mimetic deferoxamine mesylate (DFO) and TGF-beta 1 inhibited adipocyte differentiation (1.0% versus the control at 15 mu M DFO and 1.4% versus the control at 1 ng/ml TGF-beta 1) and adipocyte gene expression (peroxisome proliferator-activated receptor-gamma 2 and lipoprotein lipase) in human MSCs after 21 days of treatment. Hypoxia (2% O-2) and DFO (but not TGF-beta 1) increased hypoxia-inducible factor-1 alpha as shown by Western blotting. Macroarrays and Western and Northern blot analyses showed that hypoxia activated the TGF-beta/Smad signaling pathway and that both hypoxia and TGF-beta 1 modulated adipocyte differentiation pathways such as the insulin-, peroxisome proliferator-activated receptor-gamma-, phosphatidylinositol 3-kinase, and MAPK-associated signaling pathways. Studies with mouse marrow stromal cell lines derived from Smad3(+/+) or Smad3(+/+) mice revealed that the TGF-beta type I receptor (ALK-5) and its intracellular signaling molecule Smad3 were necessary for the inhibition of adipocyte differentiation by both TGF-beta and hypoxia-mimetic DFO. Thus, the TGF-beta/Smad signaling pathway is required for hypoxia-mediated inhibition of adipocyte differentiation in MSCs.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA; Univ Pittsburgh, Med Ctr, Dept Radiat Oncol, Pittsburgh, PA 15213 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Glowacki, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.	jglowacki@rics.bwh.harvard.edu	Zhou, Shuanhu/Q-7137-2019; Zhou, Shuanhu/AAW-4405-2021	Zhou, Shuanhu/0000-0003-4745-5347	NIAMS NIH HHS [AR45870] Funding Source: Medline; NIA NIH HHS [R01 AG025015, AG 025015] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025015] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akman HO, 2001, BLOOD, V98, P3324, DOI 10.1182/blood.V98.12.3324; Aubert J, 1999, CELL MOL LIFE SCI, V56, P538, DOI 10.1007/s000180050450; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Carriere A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Entingh AJ, 2003, J BIOL CHEM, V278, P33377, DOI 10.1074/jbc.M303056200; Epperly MW, 2005, EXP HEMATOL, V33, P353, DOI 10.1016/j.exphem.2004.11.010; Falanga V, 2002, J CELL PHYSIOL, V191, P42, DOI 10.1002/jcp.10065; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; Hausman GJ, 2004, J ANIM SCI, V82, P925; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jiang Z, 2003, BIOCHEM BIOPH RES CO, V309, P961, DOI 10.1016/j.bbrc.2003.08.102; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531-5565(02)00014-1; Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Li WQ, 2004, FREE RADICAL BIO MED, V37, P196, DOI 10.1016/j.freeradbiomed.2004.04.028; Locklin RM, 1999, CELL BIOL INT, V23, P185, DOI 10.1006/cbir.1998.0338; LOMEDE K, 2003, INT J OBESITY, V27, P1187; Loskutoff DJ, 2000, ANN NY ACAD SCI, V902, P272; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Meriane M, 2002, BIOL CELL, V94, P535, DOI 10.1016/S0248-4900(02)00023-0; Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Persaud SJ, 2002, FEBS LETT, V510, P225, DOI 10.1016/S0014-5793(01)03268-9; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rosen ED, 2002, ANN NY ACAD SCI, V979, P143, DOI 10.1111/j.1749-6632.2002.tb04875.x; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Saed GM, 2002, AM J REPROD IMMUNOL, V48, P387, DOI 10.1034/j.1600-0897.2002.01090.x; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Sawada Y, 1996, MOL ENDOCRINOL, V10, P1238, DOI 10.1210/me.10.10.1238; Schiller PC, 2001, J BIOL CHEM, V276, P14133, DOI 10.1074/jbc.M011055200; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shemirani B, 2002, ORAL ONCOL, V38, P251, DOI 10.1016/S1368-8375(01)00052-5; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Xia XM, 1999, J CELL PHYSIOL, V178, P9, DOI 10.1002/(SICI)1097-4652(199901)178:1<9::AID-JCP2>3.0.CO;2-#; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; Yoo BC, 2004, INT J CANCER, V108, P532, DOI 10.1002/ijc.11604; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629; Zhou SH, 2004, J BONE MINER RES, V19, P1732, DOI 10.1359/JBMR.040702; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239	67	77	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22688	22696		10.1074/jbc.M412953200	http://dx.doi.org/10.1074/jbc.M412953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845540	hybrid, Green Accepted			2022-12-25	WOS:000229741800018
J	Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L; Swaby, LA; Huang, H; Sasazuki, T; Shirasawa, S; Augenlicht, L			Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis	ONCOGENE			English	Article						Ras; 5-FU; colon cancer; gelsolin	ADVANCED COLORECTAL-CANCER; C-MYC; KI-RAS; INTERFERON ALPHA-2A; GELSOLIN EXPRESSION; CARCINOMA CELLS; PHASE-III; P53; 5-FLUOROURACIL; OVEREXPRESSION	Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FU-induced apoptosis. These data therefore demonstrate that Ras mutations increase sensitivity to 5-FU-induced apoptosis at least in part through the negative regulation of gelsolin expression. Our data indicate that Ras mutations promote apoptosis in response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U01CA088104, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA 88104, P30 CA 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal B, 1999, CLIN CANCER RES, V5, P2223; Ahnen DJ, 1998, CANCER RES, V58, P1149; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Arango D, 2003, BRIT J CANCER, V89, P1757, DOI 10.1038/sj.bjc.6601338; Arango D, 2001, CANCER RES, V61, P4910; Augenlicht LH, 1997, CANCER RES, V57, P1769; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BENZ C, 1982, CANCER RES, V42, P2081; BERTINO JR, 1983, SEMIN ONCOL, V10, P2; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Greco FA, 1996, J CLIN ONCOL, V14, P2674, DOI 10.1200/JCO.1996.14.10.2674; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Huang YC, 2000, CANCER RES, V60, P3200; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JONES DV, 1995, CANCER-AM CANCER SOC, V76, P1709, DOI 10.1002/1097-0142(19951115)76:10<1709::AID-CNCR2820761006>3.0.CO;2-5; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Mariadason JM, 2003, CANCER RES, V63, P8791; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; MARSONI S, 1995, LANCET, V345, P1582; Maxwell PJ, 2003, CANCER RES, V63, P4602; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NADAL JC, 1988, BIOMED PHARMACOTHER, V42, P387; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Sheng HM, 2001, CANCER RES, V61, P2670; Shieh DB, 1999, CANCER-AM CANCER SOC, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Tseng YS, 2003, EXP CELL RES, V288, P403, DOI 10.1016/S0014-4827(03)00225-8; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolmark N, 1998, J NATL CANCER I, V90, P1810, DOI 10.1093/jnci/90.23.1810; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	50	33	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3932	3941		10.1038/sj.onc.1208552	http://dx.doi.org/10.1038/sj.onc.1208552			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856030				2022-12-25	WOS:000229435300009
J	Wang, YA; Zhang, ZQ; Lubet, R; You, M				Wang, YA; Zhang, ZQ; Lubet, R; You, M			Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf	ONCOGENE			English	Article						tobacco smoke; A/J mice; transgene; lung tumorigenesis; K-ras; p53; Ink4a/Arf	CIGARETTE-SMOKE; P16(INK4A) INACTIVATION; PROTEIN ACCUMULATION; ONCOGENE ACTIVATION; CANCER; TUMORS; MUTATIONS; MOUSE; GENE; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	A/J mice with genetic alterations in K-ras, p53, or Ink4a/Arf were employed to investigate whether mice carrying these germline mutations would be susceptible to tobacco smoke-induced lung tumorigenesis. Transgenic mice of both genders and their wild-type littermates were exposed to environmental cigarette smoke for 6 months, followed by recovery in air for 5 months. A significant increase of lung tumor multiplicity was observed in K-ras, p53, or Ink4a/Arf mutant mice when compared with wild-type mice. Furthermore, an additive effect was observed between the mice with a mutant p53 transgene and an Ink4A/Arf deletion during tobacco smoke-induced lung tumorigenesis. Sequence analysis of the K-ras gene indicated that the mutations had occurred at either codon 12/13 or 61 in both spontaneously occurring (air control) and tobacco smoke-induced lung tumors. K-ras mutations were found in 62% of the tumors from air-control animals and 83% in those exposed to tobacco smoke. The mutation spectrum found in tumors from mice exposed to tobacco smoke is somewhat similar to that in tumors from air-control mice. In addition, we identified three novel mutations at codon 12: GGT (Gly)-> TTT (Phe), ATT (Ile), and CTT (Leu). These findings provide evidence that K-ras, p53, and Ink4a/Arf mutations play a role in tobacco smoke-related lung carcinogenesis. The similarity of the mutation spectra in the K-ras oncogene observed in tobacco smoke-induced tumors, as compared to spontaneous tumors, suggests that tobacco smoke enhances lung tumorigenesis primarily through promoting spontaneously occurring K-ras mutations.	Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Rockville, MD 20892 USA	Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Siteman Canc Ctr, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554, N01CN-35117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; CARBONE D, 1992, AM J MED, V93, P13; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; CHIBA I, 1990, ONCOGENE, V5, P1603; D'Agostini F, 2001, INT J ONCOL, V18, P607; De Flora S, 2003, CANCER RES, V63, P793; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; FONTANINI G, 1994, J PATHOL, V174, P23, DOI 10.1002/path.1711740105; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HERZOG CR, 1993, MOL CARCINOGEN, V8, P202, DOI 10.1002/mc.2940080311; Hursting SD, 2001, TOXICOL PATHOL, V29, P137, DOI 10.1080/019262301301418946; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Hwang SJ, 2003, HUM GENET, V113, P238, DOI 10.1007/s00439-003-0968-7; Kamb A, 1994, Nat Genet, V8, P23; Kinoshita I, 1996, CANCER RES, V56, P5557; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARCHETTI A, 1993, CANCER RES, V53, P4665; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; MERLO A, 1995, NAT MED, V1, P692; MINNA JD, 1993, CHEST S, V103, P449; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, P27; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SOZZI G, 1992, CANCER RES, V52, P6079; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; TOP B, 1995, INT J CANCER, V64, P83, DOI 10.1002/ijc.2910640203; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wang Y, 2003, CANCER RES, V63, P4389; WIETHEGE T, 1995, J CANCER RES CLIN, V121, P371, DOI 10.1007/BF01225691; Witschi H, 2002, TOXICOL SCI, V68, P322, DOI 10.1093/toxsci/68.2.322; WITSCHI H, 1995, FUND APPL TOXICOL, V26, P32, DOI 10.1006/faat.1995.1072; Witschi H, 2000, EXP LUNG RES, V26, P743, DOI 10.1080/01902140150216792; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhang ZQ, 2002, CANCER RES, V62, P3024	46	31	32	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3042	3049		10.1038/sj.onc.1208390	http://dx.doi.org/10.1038/sj.onc.1208390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846305				2022-12-25	WOS:000228649500013
J	Waghray, M; Cui, ZB; Horowitz, JC; Subramanian, IM; Martinez, FJ; Toews, GB; Thannickal, VJ				Waghray, M; Cui, ZB; Horowitz, JC; Subramanian, IM; Martinez, FJ; Toews, GB; Thannickal, VJ			Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts	FASEB JOURNAL			English	Article						TGF-1 beta fibrosis; oxidative stress; tissue repair; apoptosis	TRANSFORMING GROWTH-FACTOR-BETA-1; UP-REGULATION; MEDIATED APOPTOSIS; LUNG FIBROBLASTS; MESSENGER-RNA; FAS LIGAND; EXPRESSION; TYROSINE; BETA; TRANSFORMING-GROWTH-FACTOR-BETA-1	Cell-cell signaling roles for reactive oxygen species (ROS) generated in response to growth factors/ cytokines in nonphagocytic cells are not well defined. In this study, we show that fibroblasts isolated from lungs of patients with idiopathic pulmonary fibrosis (IPF) generate extracellular hydrogen peroxide (H2O2) in response to the multifunctional cytokine, transforming growth factor beta 1 (TGF-beta 1). In contrast, TGF-beta 1 stimulation of small airway epithelial cells (SAECs) does not result in detectable levels of extracellular H2O2. IPF fibroblasts independently stimulated with TGF-beta 1 induce loss of viability and death of overlying SAECs when cocultured in a compartmentalized Transwell system. These effects on SAECs are inhibited by the addition of catalase to the coculture system or by the selective enzymatic blockade of H2O2 production by IPF fibroblasts. IPF fibroblasts heterogeneously express alpha-smooth muscle actin stress fibers, a marker of myofibroblast differentiation. Cellular localization of H2O2 by a fluorescent-labeling strategy demonstrated that extracellular secretion of H2O2 is specific to the myofibroblast phenotype. Thus, myofibroblast secretion of H2O2 functions as a diffusible death signal for lung epithelial cells. This novel mechanism for intercellular ROS signaling may be important in physiological/ pathophysiological processes characterized by regenerating epithelial cells and activated myofibroblasts.	Univ Michigan, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thannickal, VJ (corresponding author), Univ Michigan, Med Ctr, Dept Med, Div Pulm & Crit Care Med, 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	vjt@umich.edu	Horowitz, Jeffrey/AAY-7238-2021	Horowitz, Jeffrey/0000-0002-1505-2837	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL074024, R01HL067967] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Geiser T, 2004, AM J PHYSIOL-LUNG C, V287, pL448, DOI 10.1152/ajplung.00177.2003; Goldkorn T, 1998, J CELL SCI, V111, P3209; Hagimoto N, 2002, J IMMUNOL, V168, P6470, DOI 10.4049/jimmunol.168.12.6470; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Jiang Z, 2003, BIOCHEM BIOPH RES CO, V309, P961, DOI 10.1016/j.bbrc.2003.08.102; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Krysko O, 2004, APOPTOSIS, V9, P495, DOI 10.1023/B:APPT.0000031452.75162.75; Kuwano K, 2002, LAB INVEST, V82, P1695, DOI 10.1097/01.LAB.0000045084.81853.76; Kuwano K, 1999, AM J RESP CELL MOL, V20, P53, DOI 10.1165/ajrcmb.20.1.2941; Larios JM, 2001, J BIOL CHEM, V276, P17437, DOI 10.1074/jbc.M100426200; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li WQ, 2004, FREE RADICAL BIO MED, V37, P196, DOI 10.1016/j.freeradbiomed.2004.04.028; Maeyama T, 2001, EUR RESPIR J, V17, P180, DOI 10.1183/09031936.01.17201800; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Uhal BD, 2003, EUR RESPIR J, V22, p7S, DOI 10.1183/09031936.03.00000303; Uhal Bruce D., 1998, American Journal of Physiology, V275, pL1192; Wang RG, 1999, AM J PHYSIOL-LUNG C, V277, pL1158, DOI 10.1152/ajplung.1999.277.6.L1158; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974	34	190	205	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					854	+		10.1096/fj.04-2882fje	http://dx.doi.org/10.1096/fj.04-2882fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15857893	Green Published			2022-12-25	WOS:000227591900012
J	Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA				Spinola, M; Galvan, A; Pignatiello, C; Conti, B; Pastorino, U; Nicander, B; Paroni, R; Dragani, TA			Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer	ONCOGENE			English	Article						lung cancer; disease models; tumor suppressor genes; nonsense suppressor	TRANSFER-RNA MODIFICATION; ESCHERICHIA-COLI K-12; SELENOCYSTEINE INCORPORATION; SELENOPROTEIN SYNTHESIS; MIAA GENE; ISOPENTENYLADENOSINE; TRANSLATION; ENZYME; MITOCHONDRIAL; ARABIDOPSIS	tRNA-isopentenyltransferase (tRNA-IPT) catalyses the addition of N-6-isopentenyladenosine (i(6)A) on residue 37 of tRNA molecules that bind codons starting with uridine. Post-transcriptional modifications of tRNA molecules have been demonstrated to be essential in maintaining the correct reading frame of the translational machinery, thus improving fidelity and efficiency of protein synthesis. We show here that the human tRNA-isopentenyltransferase (TRIT1) gene encodes a complex pattern of mRNA variants through alternative splicing in both normal and tumor lung tissue and that the nonsense suppressor activity of tRNA-IPT is maintained only in the full-length mRNA isoform, as revealed by gene complementation in yeast. Expression of the full-length transcript was down-regulated 6-14-fold in lung adenocarcinomas as compared to normal lung tissue. A549 lung cancer cells transfected to express the functional TRIT1 gene formed significantly smaller colonies with reduced scattering on the edges and had only limited ability to induce tumors in nude mice. Our findings raise the possibility of TRIT1 as a candidate lung tumor suppressor.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Thorac Surg, I-20133 Milan, Italy; Swedish Univ Agr Sci, Dept Plant Biol, Uppsala, Sweden; Univ Milan, San Paolo Hosp, Dept Med Surg & Dent Sci, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Swedish University of Agricultural Sciences; San Paolo-Polo Universitaria Hospital; University of Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	PARONI, RITA/C-2955-2012; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017; PARONI, RITA/AAC-6265-2020	PARONI, RITA/0000-0002-3186-8860; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902; PARONI, RITA/0000-0002-3186-8860				Berry MJ, 2001, BIOFACTORS, V14, P17, DOI 10.1002/biof.5520140104; Bjork GR, 1999, FEBS LETT, V452, P47, DOI 10.1016/S0014-5793(99)00528-1; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; DIAZ I, 1987, MOL GEN GENET, V208, P373, DOI 10.1007/BF00328126; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DIRHEIMER G, 1995, BIOCHIMIE, V77, P99, DOI 10.1016/0300-9084(96)88111-9; GEHRKE CW, 1982, J CHROMATOGR, V230, P297, DOI 10.1016/S0378-4347(00)80479-X; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; Lemieux J, 2001, GENETICS, V159, P147; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; PERSSON BC, 1994, BIOCHIMIE, V76, P1152, DOI 10.1016/0300-9084(94)90044-2; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Sakakibara H, 2002, J PLANT GROWTH REGUL, V21, P17, DOI 10.1007/s003440010043; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; Warner GJ, 2000, J BIOL CHEM, V275, P28110	25	69	73	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5502	5509		10.1038/sj.onc.1208687	http://dx.doi.org/10.1038/sj.onc.1208687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15870694				2022-12-25	WOS:000231222300010
J	Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M				Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M			All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo	ONCOGENE			English	Article						Wilms tumor; nephroblastoma; retinoic acid; ATRA; TGF beta	TISSUE GROWTH-FACTOR; COLORECTAL-CANCER; TGF-BETA; NEUROBLASTOMA; CARCINOMA; PROGRESSION; DEHYDROGENASE/REDUCTASE; DIFFERENTIATION; ADENOCARCINOMA; PROLIFERATION	Wilms tumor is one of the most frequent neoplasias in children. Our previous microarray screening in a large series of Wilms tumors revealed several candidate genes that are deregulated in advanced tumors and are part of the retinoic acid signaling pathway. To investigate whether retinoic acid could be employed as a novel therapeutic agent in these tumors, we treated cultured Wilms tumor cells with different concentrations of all-trans retinoic acid (ATRA) and assessed gene expression changes by real-time RT-PCR as well as microarray analysis. Several genes like RARRES1, RARRES3, CTGF, CKS2, CCNA2, IGFBP3, UBE2C, CCL2 or ITM2B that were previously found to be deregulated in advanced tumors exhibited opposite expression changes after ATRA treatment. In addition to enhanced retinoid signaling, the transforming growth factor-beta (TGF beta) pathway was strongly activated by ATRA treatment of Wilms tumor cells. Both the retinoic acid and the TGFbeta pathway mediate inhibition of cell growth. These findings represent the first molecular evidence of a potential benefit from ATRA treatment in Wilms tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Univ Mainz, Dept Mol Genet, D-6500 Mainz, Germany; Univ Saarland, Dept Paediat Oncol & Haematol, Childrens Hosp, Saarland, Germany	University of Wurzburg; Philipps University Marburg; Johannes Gutenberg University of Mainz; Saarland University	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	gessler@biozentrum.uni-wuerzburg.de	Graf, Norbert/H-1328-2011	Graf, Norbert/0000-0002-2248-323X; Eilers, Martin/0000-0002-0376-6533; Gessler, Manfred/0000-0002-7915-6045				Adamson PC, 1997, J CLIN ONCOL, V15, P3330, DOI 10.1200/JCO.1997.15.11.3330; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Burrow CR, 2000, PEDIATR NEPHROL, V14, P240, DOI 10.1007/s004670050049; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Cerignoli F, 2002, CANCER RES, V62, P1196; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Farias EF, 2002, CELL GROWTH DIFFER, V13, P335; Fleischer A, 2002, ONCOGENE, V21, P3181, DOI 10.1038/sj.onc.1205464; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; Kastner P, 1997, DEVELOPMENT, V124, P313; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Li P, 2004, J PEDIATR SURG, V39, P1512, DOI 10.1016/j.jpedsurg.2004.06.011; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; Petridou E, 2001, ONCOLOGY-BASEL, V60, P252, DOI 10.1159/000055326; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Shyu RY, 2003, BRIT J CANCER, V89, P146, DOI 10.1038/sj.bjc.6601049; Sriuranpong V, 2004, CLIN CANCER RES, V10, P4944, DOI 10.1158/1078-0432.CCR-03-0757; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Xie W, 2002, CANCER RES, V62, P497; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zirn B, 2005, CANCER LETT, V220, P115, DOI 10.1016/j.canlet.2004.08.001	36	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5246	5251		10.1038/sj.onc.1208725	http://dx.doi.org/10.1038/sj.onc.1208725			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897880				2022-12-25	WOS:000230964600011
J	Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP				Rugo, RE; Almeida, KH; Hendricks, CA; Jonnalagadda, VS; Engelward, BP			A single acute exposure to a chemotherapeutic agent induces hyper-recombination in distantly descendant cells and in their neighbors	ONCOGENE			English	Article						genetic instability; homologous recombination; persistent; bystander; DNA damage	INDUCED GENOMIC INSTABILITY; SISTER-CHROMATID EXCHANGES; MITOTIC HOMOLOGOUS RECOMBINATION; EMBRYONIC STEM-CELLS; DOUBLE-STRAND BREAKS; VERY-LOW FLUENCES; ALPHA-PARTICLES; IONIZING-RADIATION; MAMMALIAN-CELLS; MITOMYCIN-C	Homologous recombination can induce tumorigenic sequence rearrangements. Here, we show that persistent hyper-recombination can be induced following exposure to a bifunctional alkylating agent, mitomycin C (MMC), and that the progeny of exposed cells induce a hyperrecombination phenotype in unexposed neighboring cells. Residual damage cannot be the cause of delayed recombination events, since recombination is observed after drug and template damage are diluted over a millionfold. Furthermore, not only do progeny of MMC-exposed cells induce recombination in unexposed cells ( bystanders), but these bystanders can in turn induce recombination in their unexposed neighbors. Thus, a signal to induce homologous recombination can be passed from cell to cell. Although the underlying molecular mechanism is not yet known, these studies reveal that cells suffer consequences of damage long after exposure, and that can signal unexposed neighboring cells to respond similarly. Thus, a single acute exposure to a chemotherapeutic agent can cause long-term changes in genomic stability. If the results of these studies of mouse embryonic stem (ES) cells are generally applicable to many cell types, these results suggest that a relatively small number of cells could potentially induce a tissue-wide increase in the risk of de novo homologous recombination events.	MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Engelward, BP (corresponding author), MIT, Biol Engn Div, 77 Mass Ave,56-631, Cambridge, MA 02139 USA.	bevin@mit.edu			NCI NIH HHS [R01 CA079827, CA84740, R21 CA084740] Funding Source: Medline; NIEHS NIH HHS [P30 ES002109, P30-ES02109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084740, R01CA079827, R33CA084740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; Auerbach Charlotte, 1946, PROC ROY SOC EDINBURGH, V62B, P211; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Bishop AJR, 2000, HUM MOL GENET, V9, P2427, DOI 10.1093/hmg/9.16.2427; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Brennan RJ, 2001, RADIAT RES, V155, P768, DOI 10.1667/0033-7587(2001)155[0768:PGIITY]2.0.CO;2; Camenisch G, 1996, NUCLEIC ACIDS RES, V24, P3707, DOI 10.1093/nar/24.19.3707; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gupta PK, 1997, CANCER RES, V57, P1188; Helleday T, 2003, MUTAT RES-FUND MOL M, V532, P103, DOI 10.1016/j.mrfmmm.2003.08.013; Hendricks CA, 2003, P NATL ACAD SCI USA, V100, P6325, DOI 10.1073/pnas.1232231100; Huang L, 2004, MOL CELL BIOL, V24, P5060, DOI 10.1128/MCB.24.11.5060-5068.2004; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; Iyer R, 2000, CANCER RES, V60, P1290; JONNALAGADDA V, 2005, IN PRESS DNA REPAIR; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lehnert BE, 1997, CANCER RES, V57, P2164; Limoli CL, 1998, CANCER RES, V58, P3712; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; LIULEE VW, 1984, MUTAT RES, V127, P139, DOI 10.1016/0027-5107(84)90015-0; LOEB LA, 1991, CANCER RES, V51, P3075; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; MORLEY AA, 1990, CANCER RES, V50, P4584; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; NAGASAWA H, 1991, RADIAT RES, V126, P280, DOI 10.2307/3577917; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; OHTSURU M, 1980, CANCER RES, V40, P477; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Sasaki MS, 2004, CYTOGENET GENOME RES, V104, P28, DOI 10.1159/000077463; Schmid CW, 1996, PROG NUCLEIC ACID RE, V53, P283, DOI 10.1016/S0079-6603(08)60148-8; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; STETKA DG, 1978, MUTAT RES, V51, P383, DOI 10.1016/0027-5107(78)90126-4; Suzuki K, 2003, CANCER RES, V63, P936; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	57	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5016	5025		10.1038/sj.onc.1208690	http://dx.doi.org/10.1038/sj.onc.1208690			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856014				2022-12-25	WOS:000230816900002
J	Fryer, JD; DeMattos, RB; McCormick, LM; O'Dell, MA; Spinner, ML; Bales, KR; Paul, SM; Sullivan, PM; Parsadanian, M; Bu, GJ; Holtzman, DM				Fryer, JD; DeMattos, RB; McCormick, LM; O'Dell, MA; Spinner, ML; Bales, KR; Paul, SM; Sullivan, PM; Parsadanian, M; Bu, GJ; Holtzman, DM			The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA METABOLISM; ALZHEIMERS-DISEASE; MOUSE MODEL; PRECURSOR PROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; LDL RECEPTOR; DEPOSITION; FIBROBLASTS; CHOLESTEROL; BIOLOGY	Apolipoprotein E ( apoE), a chaperone for the amyloid beta( A beta) peptide, regulates the deposition and structure of A beta that deposits in the brain in Alzheimer disease ( AD). The primary apoE receptor that regulates levels of apoE in the brain is unknown. We report that the low density lipoprotein receptor ( LDLR) regulates the cellular uptake and central nervous system levels of astrocyte- derived apoE. Cells lacking LDLR were unable to appreciably endocytose astrocyte- secreted apoE- containing lipoprotein particles. Moreover, cells overexpressing LDLR showed a dramatic increase in apoE endocytosis and degradation. We also found that LDLR knock- out ( Ldlr (-/-)) mice had a significant, similar to 50% increase in the level of apoE in the cerebrospinal fluid and extracellular pools of the brain. However, when the PDAPP mouse model of AD was bred onto an Ldlr (-/-) background, we did not observe a significant change in brain A beta levels either before or after the onset of A beta deposition. Interestingly, human APOE3 or APOE4 ( but not APOE2) knock- in mice bred on an Ldlr (-/-) background had a 210% and 380% increase, respectively, in the level of apoE in cerebrospinal fluid. These results demonstrate that central nervous system levels of both human and murine apoE are directly regulated by LDLR. Although the increase in murine apoE caused by LDLR deficiency was not sufficient to affect A beta levels or deposition by 10 months of age in PDAPP mice, it remains a possibility that the increase in human apoE3 and apoE4 levels caused by LDLR deficiency will affect this process and could hold promise for therapeutic targets in AD.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Hope Ctr Neurol Diorders, St Louis, MO 63110 USA; Eli Lilly & Co, Neurosci Discovery Res, Lilly Res Labs, Indianapolis, IN 46285 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46285 USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46285 USA; Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Bryan Alzheimers Dis Res Ctr, Durham, NC 27710 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; Duke University	Holtzman, DM (corresponding author), Washington Univ, Sch Med, Dept Neurol, Campus Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	holtzman@wustl.edu	Paul, Steve/ABE-5400-2020		NIA NIH HHS [P50 AG05681, AG13956, AG11355] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG011355, R01AG013956, R37AG013956, P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALES KL, 2002, SOC NEUR ABSTR; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIBSON JC, 1987, ARTERIOSCLEROSIS, V7, P401, DOI 10.1161/01.ATV.7.4.401; Hock B J Jr, 2001, Trends Genet, V17, pS7, DOI 10.1016/S0168-9525(01)02449-0; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KAJINAMI K, 1992, CLIN CHIM ACTA, V211, P93, DOI 10.1016/0009-8981(92)90108-3; Knouff C, 2004, BBA-MOL CELL BIOL L, V1684, P8, DOI 10.1016/j.bbalip.2004.03.004; KRUL ES, 1988, J LIPID RES, V29, P1309; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Quan G, 2003, DEV BRAIN RES, V146, P87, DOI 10.1016/j.devbrainres.2003.09.015; Reblin T, 1997, J LIPID RES, V38, P2103; SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Van Uden E, 2002, J NEUROSCI, V22, P9298; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Zerbinatti CV, 2004, P NATL ACAD SCI USA, V101, P1075, DOI 10.1073/pnas.0305803101	39	112	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25754	25759		10.1074/jbc.M502143200	http://dx.doi.org/10.1074/jbc.M502143200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888448	hybrid			2022-12-25	WOS:000230207900056
J	Kutuzov, MA; Andreeva, AV; Voyno-Yasenetskaya, TA				Kutuzov, MA; Andreeva, AV; Voyno-Yasenetskaya, TA			Regulation of apoptosis signal-regulating kinase 1 (ASK1) by polyamine levels via protein phosphatase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SERINE/THREONINE PHOSPHATASE; TETRATRICOPEPTIDE REPEAT; APOPTOSIS; IDENTIFICATION; BINDING; ACTIVATION; DOMAIN; SUBUNIT; CHANNEL; GROWTH	Recent evidence has implicated the protein phosphatase PP5 in a variety of signaling pathways. Whereas several proteins have been identified that interact with PP5 and regulate its activity, a possibility of its regulation by second messengers remains speculative. Activation of PP5 in vitro by polyunsaturated fatty acids (e. g. arachidonic acid) and fatty acyl-CoA esters (e. g. arachidonoyl-CoA) has been reported. We report here that PP5 is strongly inhibited by micromolar concentrations of a natural polyamine spermine. This inhibition was observed both in assays with a low molecular weight substrate p-nitrophenyl phosphate as well as phosphocasein and apoptosis signal-regulating kinase 1 (ASK1), thought to be a physiological substrate of PP5. Furthermore, a decrease in polyamine levels in COS-7 cells induced by alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, led to accelerated dephosphorylation of oxidative stress-activated ASK1. This effect was suppressed by okadaic acid and by siRNA-mediated PP5 depletion, indicating that the effect of polyamine levels on ASK1 dephosphorylation was mediated by PP5. In line with the decreased ASK1 activation, polyamine depletion in COS-7 cells abrogated oxidative stress-induced activation of caspase-3, which executes ASK1-induced apoptosis, as well as caspase-3 activation induced by ASK1 overexpression, but had no effect on basal caspase-3 activity. These results implicate polyamines, emerging intracellular signaling molecules, as potential physiological regulators of PP5. Our findings also suggest a novel mechanism of the antiapoptotic action of a decrease in polyamine levels via de- inhibition of PP5 and accelerated dephosphorylation and deactivation of ASK1.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, 835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Kutuzov, Mikhail/0000-0003-3386-4350	NHLBI NIH HHS [R01 HL074948-01A1, HL06078] Funding Source: Medline; NIGMS NIH HHS [R01 GM056159-01A2, R01 GM065160, R55 GM056159, R01 GM065160-03, GM65160, R01 GM056159, GM56159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056159, R55GM056159, R01GM065160] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman CD, 2002, NEURON, V34, P623, DOI 10.1016/S0896-6273(02)00674-8; Andreeva Alexandra V., 2001, Molecular Cell Biology Research Communications, V4, P345, DOI 10.1006/mcbr.2001.0302; Andreeva AV, 1999, CELL SIGNAL, V11, P555, DOI 10.1016/S0898-6568(99)00032-7; Andreeva AV, 2001, MOL BIOL EVOL, V18, P448, DOI 10.1093/oxfordjournals.molbev.a003823; BECKER W, 1994, J BIOL CHEM, V269, P22586; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BHATTACHARYA S, 2004, AM J PHYSIOL-GASTR L, V286, pG4796; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; CORNWELL T, 1986, J CYCLIC NUCL PROT, V11, P373; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; EKMAN P, 1993, ANAL BIOCHEM, V214, P138, DOI 10.1006/abio.1993.1468; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Gong CX, 2004, J NEUROCHEM, V88, P298, DOI 10.1046/j.1471-4159.2003.02147.x; Guo DL, 2003, J GEN PHYSIOL, V122, P485, DOI 10.1085/jgp.200308890; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; KIUCHI K, 1987, BIOCHEM BIOPH RES CO, V148, P1460, DOI 10.1016/S0006-291X(87)80296-6; Kono Y, 2002, GENES CELLS, V7, P821, DOI 10.1046/j.1365-2443.2002.00562.x; Kutuzov MA, 1998, FEBS LETT, V440, P147, DOI 10.1016/S0014-5793(98)01428-8; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Moller SG, 2003, PLANT CELL, V15, P1111, DOI 10.1105/tpc.008649; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nilsson BO, 2002, ACTA PHYSIOL SCAND, V176, P33, DOI 10.1046/j.1365-201X.2002.01013.x; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Ramsey AJ, 2002, BIOCHEMISTRY-US, V41, P5625, DOI 10.1021/bi016090h; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; SINGH SS, 1995, LIFE SCI, V57, P685, DOI 10.1016/0024-3205(95)00320-6; Sjoholm A, 2000, PANCREAS, V20, P32; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; SWARD K, 1995, AM J PHYSIOL-CELL PH, V269, pC563, DOI 10.1152/ajpcell.1995.269.3.C563; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Thomas T, 2002, ONCOL RES, V13, P123; Tomsig JL, 2003, J BIOL CHEM, V278, P10048, DOI 10.1074/jbc.M212632200; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zhou GF, 2004, J BIOL CHEM, V279, P46595, DOI 10.1074/jbc.M408320200; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	62	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25388	25395		10.1074/jbc.M413202200	http://dx.doi.org/10.1074/jbc.M413202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890660	Green Accepted, hybrid			2022-12-25	WOS:000230207900012
J	Brown, MA; Zhao, QH; Baker, KA; Naik, C; Chen, C; Pukac, L; Singh, M; Tsareva, T; Parice, Y; Mahoney, A; Roschke, V; Sanyal, I; Choe, S				Brown, MA; Zhao, QH; Baker, KA; Naik, C; Chen, C; Pukac, L; Singh, M; Tsareva, T; Parice, Y; Mahoney, A; Roschke, V; Sanyal, I; Choe, S			Crystal structure of BMP-9 and functional interactions with pro-region and receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-9; MOLECULAR RECOGNITION; SEQUENCE ALIGNMENT; I RECEPTORS; BETA; ACTIVATION; DOMAIN; GENE; EXPRESSION; MEMBRANE	Bone morphogenetic proteins (BMPs), a subset of the transforming growth factor (TGF)-beta superfamily, regulate a diverse array of cellular functions during development and in the adult. BMP-9 (also known as growth and differentiation factor (GDF)-2) potently induces osteogenesis and chondrogenesis, has been implicated in the differentiation of cholinergic neurons, and may help regulate glucose metabolism. We have determined the structure of BMP-9 to 2.3 angstrom and examined the differences between our model and existing crystal structures of other BMPs, both in isolation and in complex with their receptors. TGF-beta ligands are translated as precursors, with pro-regions that generally dissociate after cleavage from the ligand, but in some cases (including GDF-8 and TGF-beta 1, -2, and -3), the pro-region remains associated after secretion from the cell and inhibits binding of the ligand to its receptor. Although the pro-region of BMP-9 remains tightly associated after secretion, we find, in several cell-based assays, that the activities of BMP-9 and BMP-9(.)pro-region complex were equivalent. Activin receptor-like kinase 1 (ALK-1), an orphan receptor in the TGF-beta family, was also identified as a potential receptor for BMP-9 based on surface plasmon resonance studies (BIAcore) and the ability of soluble ALK-1 to block the activity of BMP-9(.)pro-region complex in cell-based assays.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Salk Institute; University of California System; University of California San Diego; GlaxoSmithKline; Human Genome Sciences Inc	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	choe@salk.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agrotis A, 2000, FEBS LETT, V467, P128, DOI 10.1016/S0014-5793(00)01132-7; Allan DW, 2003, CELL, V113, P73, DOI 10.1016/S0092-8674(03)00204-6; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Constam DB, 1999, J CELL BIOL, V144, P139, DOI 10.1083/jcb.144.1.139; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Haramoto Y, 2004, DEV BIOL, V265, P155, DOI 10.1016/j.ydbio.2003.09.015; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Jiang MS, 2004, BIOCHEM BIOPH RES CO, V315, P525, DOI 10.1016/j.bbrc.2004.01.085; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Li JZ, 2003, GENE THER, V10, P1735, DOI 10.1038/sj.gt.3302075; Lopez-Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313; Majumdar MK, 2001, J CELL PHYSIOL, V189, P275, DOI 10.1002/jcp.10025; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miller AF, 2000, J BIOL CHEM, V275, P17937, DOI 10.1074/jbc.275.24.17937; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sebald W, 2004, BIOL CHEM, V385, P697, DOI 10.1515/BC.2004.086; Sebald W, 2003, TRENDS BIOCHEM SCI, V28, P518, DOI 10.1016/j.tibs.2003.08.001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thies RS, 2001, GROWTH FACTORS, V18, P251; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; Wozney JM, 2002, SPINE, V27, pS2, DOI 10.1097/00007632-200208151-00002; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamamoto Y, 2004, NATURWISSENSCHAFTEN, V91, P519, DOI 10.1007/s00114-004-0575-z; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; 1994, ACTA CRYSTALLGOR SD, V50, P760	46	228	247	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25111	25118		10.1074/jbc.M503328200	http://dx.doi.org/10.1074/jbc.M503328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851468	hybrid			2022-12-25	WOS:000230114000095
J	Degryse, B; Resnati, M; Czekay, RP; Loskutoff, DJ; Blasi, F				Degryse, B; Resnati, M; Czekay, RP; Loskutoff, DJ; Blasi, F			Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity - Generation of a new integrin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SMOOTH-MUSCLE-CELLS; CYTOSKELETON REORGANIZATION; HUMAN CARCINOMA; DEFICIENT MICE; IN-VIVO; MIGRATION; BINDING; VITRONECTIN; ADHESION	We investigated the interaction between the urokinase receptor (uPAR) and the integrin alpha v beta 3. Vitronectin (VN) induces cell migration by binding to alpha v beta 3, but expression of the uPAR boosts its efficacy. Thus, uPAR may regulate VN-induced cell migration by interacting laterally with alpha v beta 3. In contrast, cells expressing a uPAR mutant lacking domain 2 do not migrate in response to VN. This effect is overcome by D2A, a synthetic peptide derived from the sequence of domain 2. In addition, D2A has chemotactic activity that requires alpha v beta 3 and activates alpha v beta 3-dependent signaling pathways such as the Janus kinase/Stat pathway. Moreover, D2A disrupts uPAR-alpha v beta 3 and uPAR-alpha 5 beta 1 co-immunoprecipitation, indicating that it can bind both of these integrins. We also identify the chemotactically active epitope harbored by peptide D2A. Mutating two glutamic acids into two alanines generates peptide D2A-Ala, which lacks chemotactic activity but inhibits VN-, FN-, and collagen-dependent cell migration. In fact, the GEEG peptide has potent chemotactic activity, and the GAAG sequence has inhibitory capacities. In summary, we have identified an integrin-interacting sequence located in domain 2 of uPAR, which is also a new chemotactic epitope that can activate alpha v beta 3-dependent signaling pathways and stimulate cell migration. This sequence thus plays a pivotal role in the regulation of uPAR-integrin interactions. Moreover, we describe a novel, very potent inhibitor of integrin-dependent cell migration.	Univ Vita Salute San Raffaele, DIBIT, Dept Mol Biol & Funct Genom, I-20132 Milan, Italy; Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Vita-Salute San Raffaele University; Scripps Research Institute	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, DIBIT, Dept Mol Biol & Funct Genom, Via Olgettina 58, I-20132 Milan, Italy.	blasi.francesco@hsr.it	Massimo, Resnati/AAN-5854-2020	Massimo, Resnati/0000-0002-4804-4569; Blasi, Francesco/0000-0001-9406-1784	NHLBI NIH HHS [HL 31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; APPELLA E, 1987, J BIOL CHEM, V262, P4437; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chavakis T, 2002, BIOCHEM SOC T, V30, P168, DOI 10.1042/BST0300168; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Degryse B, 2003, FEBS LETT, V553, P11, DOI 10.1016/S0014-5793(03)01027-5; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Degryse Bernard, 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P237, DOI 10.2174/1568014033483734; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; Gyetko MR, 2000, J IMMUNOL, V165, P1513, DOI 10.4049/jimmunol.165.3.1513; Gyetko MR, 2001, J IMMUNOL, V167, P5539, DOI 10.4049/jimmunol.167.10.5539; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Kiian I, 2003, THROMB HAEMOSTASIS, V89, P904; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; LLINAS P, 2005, IN PRESS EMBO J; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riittinen L, 1996, FEBS LETT, V381, P1, DOI 10.1016/0014-5793(96)00033-6; Rijneveld AW, 2002, J IMMUNOL, V168, P3507, DOI 10.4049/jimmunol.168.7.3507; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393	61	95	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24792	24803		10.1074/jbc.M413954200	http://dx.doi.org/10.1074/jbc.M413954200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863511	hybrid			2022-12-25	WOS:000230114000062
J	Klotzsche, M; Berens, C; Hillen, W				Klotzsche, M; Berens, C; Hillen, W			A peptide triggers allostery in Tet repressor by binding to a unique site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CONFORMATIONAL-CHANGES; ANTIBIOTIC-RESISTANCE; TETRACYCLINE COMPLEX; PROTEIN RECOGNITION; INTERACTION DOMAINS; INTERACTION NETWORK; GENETIC SELECTION; CRYSTAL-STRUCTURE; INDUCTION	Regulatory proteins often communicate with each other to manage various cellular processes. Such interactions mostly rely on the recognition of small peptide motifs. The activity of other regulatory proteins depends on small molecular weight effectors and allostery. We demonstrate the in vivo regulation of the tetracycline-dependent Tet repressor by an oligopeptide fused to the N or C terminus of thioredoxin A. The binding site of the peptide overlaps but is not identical with the tetracycline binding site. Several TetR mutants that are non-inducible by tetracycline also respond to the peptide. This demonstrates for the first time the conversion of a small molecular weight effector-dependent regulator to a protein-protein contact-dependent potential member of designed signaling chains.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Inst Mikrobiol Biochem & Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Hillen, W (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Inst Mikrobiol Biochem & Genet, Staudtstr 5, D-91058 Erlangen, Germany.	whillen@biologie.uni-erlangen.de						ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BAUMEISTER R, 1992, PROTEINS, V14, P168, DOI 10.1002/prot.340140204; Berens C, 1997, J BIOL CHEM, V272, P6936, DOI 10.1074/jbc.272.11.6936; Berens Christian, 2004, Genet Eng (N Y), V26, P255; Castagnoli L, 2004, FEBS LETT, V567, P74, DOI 10.1016/j.febslet.2004.03.116; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; DEGENKOLB J, 1991, ANTIMICROB AGENTS CH, V35, P1591, DOI 10.1128/AAC.35.8.1591; Dover LG, 2004, J MOL BIOL, V340, P1095, DOI 10.1016/j.jmb.2004.06.003; Ettner N, 1996, J CHROMATOGR A, V742, P95, DOI 10.1016/0021-9673(96)00232-4; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Grkovic S, 2003, BIOCHEMISTRY-US, V42, P15226, DOI 10.1021/bi035447+; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Kintrup M, 2000, EUR J BIOCHEM, V267, P821, DOI 10.1046/j.1432-1327.2000.01063.x; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Krueger C, 2003, NUCLEIC ACIDS RES, V31, P3050, DOI 10.1093/nar/gkg421; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lu HC, 2004, NUCLEIC ACIDS RES, V32, P4804, DOI 10.1093/nar/gkh814; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Miller JH., 1972, EXPT MOL GENETICS; MULLER G, 1995, NAT STRUCT BIOL, V2, P693, DOI 10.1038/nsb0895-693; Natsume R, 2004, J MOL BIOL, V336, P409, DOI 10.1016/j.jmb.2003.12.040; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Park SH, 2000, NAT BIOTECHNOL, V18, P847, DOI 10.1038/78451; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pawson T, 2002, FEBS LETT, V513, P2, DOI 10.1016/S0014-5793(01)03292-6; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Schirmer F, 1997, J BACTERIOL, V179, P1329, DOI 10.1128/jb.179.4.1329-1336.1997; Schnappinger D, 1999, J BIOL CHEM, V274, P6405, DOI 10.1074/jbc.274.10.6405; Schnappinger D, 1998, EMBO J, V17, P535, DOI 10.1093/emboj/17.2.535; Scholz O, 2000, BIOCHEMISTRY-US, V39, P10914, DOI 10.1021/bi001018p; Scholz O, 2003, J MOL BIOL, V329, P217, DOI 10.1016/S0022-2836(03)00427-3; Scholz O, 2001, J MOL BIOL, V310, P979, DOI 10.1006/jmbi.2001.4820; Schubert P, 2004, EUR J BIOCHEM, V271, P2144, DOI 10.1111/j.1432-1033.2004.04130.x; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; TAKAHASHI M, 1991, ANAL BIOCHEM, V199, P197, DOI 10.1016/0003-2697(91)90089-C; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Vergani B, 2000, BIOCHEMISTRY-US, V39, P2759, DOI 10.1021/bi9912591; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24591	24599		10.1074/jbc.M501872200	http://dx.doi.org/10.1074/jbc.M501872200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870072	hybrid			2022-12-25	WOS:000230114000038
J	Kuusk, S; Sedman, T; Joers, P; Sedman, J				Kuusk, S; Sedman, T; Joers, P; Sedman, J			Hmi1p from Saccharomyces cerevisiae mitochondria is a structure-specific DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; REPLICATION FORKS; BINDING; PROTEIN; PCRA; MUTATION; RECOMBINATION; PURIFICATION; MECHANISM; TWINKLE	Hmi1p is a Saccharomyces cerevisiae mitochondrial DNA helicase that is essential for the maintenance of functional mitochondrial DNA. Hmi1p belongs to the superfamily 1 of helicases and is a close homologue of bacterial PcrA and Rep helicases. We have overexpressed and purified recombinant Hmi1p from Escherichia coli and describe here the biochemical characteristics of its DNA helicase activities. Among nucleotide cofactors, the DNA unwinding by Hmi1p was found to occur efficiently only in the presence of ATP and dATP. Hmi1p could unwind only the DNA substrates with a 3'- single- stranded overhang. The length of the 3'- overhang needed for efficient targeting of the helicase to the substrate depended on the substrate structure. For substrates consisting of duplex DNA with a 3'- singlestranded DNA overhang, at least a 19- nt 3'- overhang was needed. In the case of forked substrates with both 3 and 5'- overhangs, a 9- nt 3'- overhang was sufficient provided that the 5'- overhang was also 9 nt in length. In flap- structured substrates mimicking the chain displacement structures in DNA recombination process, only a 5- nt 3'- single- stranded DNA tail was required for efficient unwinding by Hmi1p. These data indicate that Hmi1p may be targeted to a specific 3'- flap structure, suggesting its possible role in DNA recombination.	Univ Tartu, Dept Gen & Microbial Biochem, Inst Mol & Cell Biol, EE-51014 Tartu, Estonia	University of Tartu	Sedman, J (corresponding author), Univ Tartu, Dept Gen & Microbial Biochem, Inst Mol & Cell Biol, Vanemuise 46, EE-51014 Tartu, Estonia.	jsedman@ebc.ee	Sedman, Juhan/H-1820-2011	Joers, Priit/0000-0002-9248-1774; Sedman, Juhan/0000-0003-2081-1452				Anand SP, 2004, NUCLEIC ACIDS RES, V32, P3190, DOI 10.1093/nar/gkh641; Bessler JB, 2001, TRENDS CELL BIOL, V11, P60, DOI 10.1016/S0962-8924(00)01877-8; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuusk Silja, 2002, Methods Mol Biol, V197, P303, DOI 10.1385/1-59259-284-8:303; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; LANE HED, 1975, J MOL BIOL, V97, P99; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MALESZKA R, 1991, EMBO J, V10, P3923, DOI 10.1002/j.1460-2075.1991.tb04962.x; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; O'Rourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; Sedman T, 2000, MOL CELL BIOL, V20, P1816, DOI 10.1128/MCB.20.5.1816-1824.2000; Sedman T, 2005, CURR GENET, V47, P213, DOI 10.1007/s00294-005-0566-4; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Tuteja N, 2004, EUR J BIOCHEM, V271, P1849, DOI 10.1111/j.1432-1033.2004.04094.x; Van Komen S, 2003, J BIOL CHEM, V278, P44331, DOI 10.1074/jbc.M307256200; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Williamson D, 2002, NAT REV GENET, V3, P475, DOI 10.1038/nrg814; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	35	14	14	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24322	24329		10.1074/jbc.M500354200	http://dx.doi.org/10.1074/jbc.M500354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855170	hybrid			2022-12-25	WOS:000230114000005
J	Nishino, T; Okamoto, K; Kawaguchi, Y; Hori, H; Matsumura, T; Eger, BT; Pai, EF; Nishino, T				Nishino, T; Okamoto, K; Kawaguchi, Y; Hori, H; Matsumura, T; Eger, BT; Pai, EF; Nishino, T			Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase - Identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-CAPSULATUS; MOLYBDENUM ENZYMES; O-2-DEPENDENT TYPE; DEPENDENT TYPE; OXIDOREDUCTASE; PURIFICATION; FORMS; NAD; FLUORODINITROBENZENE; PROTEIN	Mammalian xanthine dehydrogenase can be converted to xanthine oxidase by modification of cysteine residues or by proteolysis of the enzyme polypeptide chain. Here we present evidence that the Cys(535) and Cys(992) residues of rat liver enzyme are indeed involved in the rapid conversion from the dehydrogenase to the oxidase. The purified mutants C535A and/or C992R were significantly resistant to conversion by incubation with 4,4'-dithiodipyridine, whereas the recombinant wildtype enzyme converted readily to the oxidase type, indicating that these residues are responsible for the rapid conversion. The C535A/C992R mutant, however, converted very slowly during prolonged incubation with 4,4'-dithiodipyridine, and this slow conversion was blocked by the addition of NADH, suggesting that another cysteine couple located near the NAD(+) binding site is responsible for the slower conversion. On the other hand, the C535A/C992R/C1316S and C535A/C992R/C1324S mutants were completely resistant to conversion, even on prolonged incubation with 4,4'-dithiodipyridine, indicating that Cys(1316) and Cys(1324) are responsible for the slow conversion. The crystal structure of the C535A/C992R/C1324S mutant was determined in its demolybdo form, confirming its dehydrogenase conformation.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Toronto, Ontario Canc Inst, Hlth Network,Div Mol & Struct Biol, Dept Biochem, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Hlth Network,Div Mol & Struct Biol, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Hlth Network,Div Mol & Struct Biol, Dept Mol & Med Genet, Toronto, ON M5G 2M9, Canada	Nippon Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Nishino, T (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	nishino@nms.ac.jp	Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013	Pai, Emil/0000-0002-1162-7242; Kawaguchi, Yuko/0000-0002-5366-2847				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DELLACORTE E, 1968, BIOCHEM J, V108, P349; ENROTH T, 2000, P NATL ACAD SCI USA, P10723; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HUNT J, 1992, J BIOL CHEM, V267, P21476; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; JONSON JL, 1974, J BIOL CHEM, V249, P5056; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuwabara Y, 2003, P NATL ACAD SCI USA, V100, P8170, DOI 10.1073/pnas.1431485100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; McManaman JL, 2002, J BIOL CHEM, V277, P21261, DOI 10.1074/jbc.M200828200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; Nishino T, 1997, J BIOL CHEM, V272, P29859, DOI 10.1074/jbc.272.47.29859; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; Nishino T, 2002, J BIOCHEM, V132, P597, DOI 10.1093/oxfordjournals.jbchem.a003262; NISHINO T, 1982, J BIOL CHEM, V257, P7348; OLSON JS, 1974, J BIOL CHEM, V249, P4363; Rasmussen JT, 2000, J DAIRY SCI, V83, P499, DOI 10.3168/jds.S0022-0302(00)74909-5; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P10015; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; STRIPE F, 1969, J BIOL CHEM, V244, P3855; Summers MD, 1987, TEXAS AGR EXPT STATI; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; VIRLARD J, 1990, J VIROL, V64, P37; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4	32	112	114	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24888	24894		10.1074/jbc.M501830200	http://dx.doi.org/10.1074/jbc.M501830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878860	hybrid			2022-12-25	WOS:000230114000072
J	Shi, ZH; Chak, KF; Yuan, HS				Shi, ZH; Chak, KF; Yuan, HS			Identification of an essential cleavage site in ColE7 required for import and killing of cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; OUTER-MEMBRANE; DNASE DOMAIN; BINDING; PROTEIN; TRANSLOCATION; MECHANISMS; COLICIN-E3; TRANSPORT	Colicin E7 ( ColE7), a nuclease toxin released from Escherichia coli, kills susceptible bacteria under environmental stress. Nuclease colicins are processed during translocation with only the cytotoxic nuclease domains traversing the inner membrane to cleave tRNA, rRNA, or DNA in the cytoplasm of target cells. In this study, we show that the E. coli periplasmic extract cleaves ColE7 between Lys(446) and Arg(447) in the presence or absence of its inhibitor Im7 protein. Several residues near cleavage sites were mutated, but only mutants of Arg447 completely lost in vivo cell-killing activity. Both the full-length and the nuclease domain of Arg(447) mutants retained their nuclease activities, indicating that failure to kill cells was not a consequence of damage to the endonuclease activity of the enzyme. Moreover, the R447E ColE7 mutant was not cleaved at its 447 site by periplasmic extracts or transported into the cytoplasm of target cells. Collectively, these results suggest that ColE7 is cleaved at Arg(447) during translocation and that cleavage is an essential step for ColE7 import into the cytoplasm of target cells and its cell-killing activity. Conserved basic residues aligned with Arg(447) have also been found in other nuclease colicins, implying that the processing at this position may be common to other colicins during translocation.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Yuan, HS (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	hanna@sinica.edu.tw	Chia, linda/B-3406-2011; Yuan, Hanna S./AAA-4005-2021	Yuan, Hanna S./0000-0001-9671-6967				Barnard TJ, 2001, MOL MICROBIOL, V41, P527, DOI 10.1046/j.1365-2958.2001.02473.x; Cao Z, 2002, BIOCHIMIE, V84, P399, DOI 10.1016/S0300-9084(02)01455-4; CHAK KF, 1991, J GEN MICROBIOL, V137, P91, DOI 10.1099/00221287-137-1-91; de Zamaroczy M, 2001, MOL CELL, V8, P159, DOI 10.1016/S1097-2765(01)00276-3; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Gillor O, 2004, ADV APPL MICROBIOL, V54, P129, DOI 10.1016/S0065-2164(04)54005-4; Hilsenbeck JL, 2004, MOL MICROBIOL, V51, P711, DOI 10.1111/j.1365-2958.2003.03884.x; Hsia KC, 2005, CURR OPIN STRUC BIOL, V15, P126, DOI 10.1016/j.sbi.2005.01.015; James R, 2002, BIOCHIMIE, V84, P381, DOI 10.1016/S0300-9084(02)01450-5; Ko TP, 1999, STRUCT FOLD DES, V7, P91, DOI 10.1016/S0969-2126(99)80012-4; Kurisu G, 2003, NAT STRUCT BIOL, V10, P948, DOI 10.1038/nsb997; Lazzaroni JC, 2002, BIOCHIMIE, V84, P391, DOI 10.1016/S0300-9084(02)01419-0; Liao CC, 2001, BIOCHEM BIOPH RES CO, V284, P556, DOI 10.1006/bbrc.2001.5016; Masaki H, 2002, BIOCHIMIE, V84, P433, DOI 10.1016/S0300-9084(02)01425-6; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; RILEY MA, 2002, BIOCHIMIE PARIS, V84, P365; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Sui MJ, 2002, PROTEIN SCI, V11, P2947, DOI 10.1110/ps.0220602; THOMAS JA, 1993, J BACTERIOL, V175, P548, DOI 10.1128/JB.175.2.548-552.1993; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Zakharov SD, 2004, FRONT BIOSCI-LANDMRK, V9, P1311, DOI 10.2741/1334; Zakharov SD, 2002, BBA-BIOMEMBRANES, V1565, P333, DOI 10.1016/S0005-2736(02)00579-5	24	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24663	24668		10.1074/jbc.M501216200	http://dx.doi.org/10.1074/jbc.M501216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15857830	hybrid			2022-12-25	WOS:000230114000046
J	Yu, PB; Beppu, H; Kawai, N; Li, E; Bloch, KD				Yu, PB; Beppu, H; Kawai, N; Li, E; Bloch, KD			Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC PROTEIN-1; FUNCTIONAL-ANALYSIS; ACTIVIN RECEPTOR; IN-VIVO; BETA; EXPRESSION; ACTIVATION; HYPERTENSION; MUTATIONS; CLONING	Bone morphogenetic protein (BMP) ligands signal by binding the BMP type II receptor (BMPR2) or the activin type II receptors (ActRIIa and ActRIIb) in conjunction with type I receptors to activate SMADs 1, 5, and 8, as well as members of the mitogen- activated protein kinase family. Loss-of-function mutations in Bmpr2 have been implicated in tumorigenesis and in the etiology of primary pulmonary hypertension. Because several different type II receptors are known to recognize BMP ligands, the specific contribution of BMPR2 to BMP signaling is not defined. Here we report that the ablation of Bmpr2 in pulmonary artery smooth muscle cells, using an ex vivo conditional knock-out (Cre-lox) approach, as well as small interfering RNA specific for Bmpr2, does not abolish BMP signaling. Disruption of Bmpr2 leads to diminished signaling by BMP2 and BMP4 and augmented signaling by BMP6 and BMP7. Using small interfering RNAs to inhibit the expression of other BMP receptors, we found that wild-type cells transduce BMP signals via BMPR2, whereas BMPR2-deficient cells transduce BMP signals via ActRIIa in conjunction with a set of type I receptors distinct from those utilized by BMPR2. These findings suggest that disruption of Bmpr2 leads to the net gain of signaling by some, but not all, BMP ligands via the activation of ActRIIa.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Novartis Inst Biomed Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Novartis	Yu, PB (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Navy Yard,149 13th St,4100A, Charlestown, MA 02129 USA.	pbyu@partners.org	Yu, Paul B./J-7540-2019	Yu, Paul B./0000-0003-2145-4944	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352, T32HL007208, K08HL079943] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL079943, K08 HL079943-01A1, T32-HL007208, HL074352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson C, 2002, CIRCULATION, V105, P1672, DOI 10.1161/01.CIR.0000012754.72951.3D; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; Beppu H, 2005, GENESIS, V41, P133, DOI 10.1002/gene.20099; Beppu H, 2004, AM J PHYSIOL-LUNG C, V287, pL1241, DOI 10.1152/ajplung.00239.2004; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; Dorai H, 2000, J CELL PHYSIOL, V184, P37, DOI 10.1002/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M; Dorai H, 2001, J BONE JOINT SURG AM, V83A, pS70; Ebisawa T, 1999, J CELL SCI, V112, P3519; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Forrest ST, 2004, CIRC RES, V95, P557, DOI 10.1161/01.RES.0000142735.67542.5a; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Hall AK, 2004, J NEUROSCI RES, V76, P1, DOI 10.1002/jnr.20019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 2004, ONCOGENE, V23, P7651, DOI 10.1038/sj.onc.1207924; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; King KE, 2003, J BIOL CHEM, V278, P11661, DOI 10.1074/jbc.M211337200; Knaus P, 2001, BIOL CHEM, V382, P1189, DOI 10.1515/BC.2001.149; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kumar MS, 2003, CIRC RES, V92, P840, DOI 10.1161/01.RES.0000069031.55281.7C; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; LIU F, 1995, MOL CELL BIOL, V15, P3479; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Loscalzo J, 2001, NEW ENGL J MED, V345, P367, DOI 10.1056/NEJM200108023450511; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; Nishihara A, 2002, MOL BIOL CELL, V13, P3055, DOI 10.1091/mbc.E02-02-0063; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; Takata M, 2001, AM J PHYSIOL-LUNG C, V280, pL272, DOI 10.1152/ajplung.2001.280.2.L272; Takeda M, 2004, ENDOCRINOLOGY, V145, P4344, DOI 10.1210/en.2004-0234; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang S, 2003, AM J PHYSIOL-LUNG C, V285, pL740, DOI 10.1152/ajplung.00284.2002	57	158	167	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24443	24450		10.1074/jbc.M502825200	http://dx.doi.org/10.1074/jbc.M502825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15883158	hybrid			2022-12-25	WOS:000230114000020
J	Garg, P; Stith, CM; Majka, J; Burgers, PMJ				Garg, P; Stith, CM; Majka, J; Burgers, PMJ			Proliferating cell nuclear antigen promotes translesion synthesis by DNA polymerase zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; THYMINE-THYMINE DIMER; ABASIC SITES; REV1 PROTEIN; POL-ETA; IN-VIVO; YEAST; DELTA; PCNA; BYPASS	DNA polymerase zeta (Pol zeta), a heterodimer of Rev3 and Rev7, is essential for DNA damage provoked mutagenesis in eukaryotes. DNA polymerases that function in a processive complex with the replication clamp proliferating cell nuclear antigen ( PCNA) have been shown to possess a close match to the consensus PCNA-binding motif QxxLxxFF. This consensus motif is lacking in either subunit of Pol zeta, yet its activity is stimulated by PCNA. In particular, translesion synthesis of UV damage-containing DNA is dramatically stimulated by PCNA such that translesion synthesis rates are comparable with replication rates by Pol zeta on undamaged DNA. PCNA also stimulated translesion synthesis of a model abasic site by Pol zeta. Efficient PCNA stimulation required that PCNA was prevented from sliding off the damage-containing model oligonucleotide template-primer through the use of biotin-streptavidin bumpers or other blocks. Under those experimental conditions, facile bypass of the abasic site was also detected by DNA polymerase delta or eta (Rad30). The yeast DNA damage checkpoint clamp, consisting of Rad17, Mec3, and Ddc1, and an ortholog of human 9-1-1, has been implicated in damage-induced mutagenesis. However, this checkpoint clamp did not stimulate translesion synthesis by Pol zeta or by DNA polymerase delta.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [R01 GM032431, GM32431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gibbs PEM, 2005, GENETICS, V169, P575, DOI 10.1534/genetics.104.034611; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang ME, 2002, GENETICS, V160, P1409; Johansson E, 2004, J BIOL CHEM, V279, P1907, DOI 10.1074/jbc.M310362200; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Lu XQ, 2002, J BIOL CHEM, V277, P24340, DOI 10.1074/jbc.M200065200; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Otsuka C, 2002, NUCLEIC ACIDS RES, V30, P5129, DOI 10.1093/nar/gkf666; Paulovich AG, 1998, GENETICS, V150, P75; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; RAHN RO, 1971, BIOCHIM BIOPHYS ACTA, V247, P197, DOI 10.1016/0005-2787(71)90670-8; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; Vidal AE, 2004, J BIOL CHEM, V279, P48360, DOI 10.1074/jbc.M406511200; Wang WS, 2004, P NATL ACAD SCI USA, V101, P16762, DOI 10.1073/pnas.0407686101; Woodgate R, 2001, MUTAT RES-DNA REPAIR, V485, P83, DOI 10.1016/S0921-8777(00)00076-8; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647	37	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23446	23450		10.1074/jbc.C500173200	http://dx.doi.org/10.1074/jbc.C500173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15879599	hybrid			2022-12-25	WOS:000229880000007
J	Takahashi, Y; Li, LL; Kamiryo, M; Asteriou, T; Moustakas, A; Yamashita, H; Heldin, P				Takahashi, Y; Li, LL; Kamiryo, M; Asteriou, T; Moustakas, A; Yamashita, H; Heldin, P			Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ANGIOGENIC OLIGOSACCHARIDES; ORNITHINE-DECARBOXYLASE; EXTRACELLULAR-MATRIX; TUBE FORMATION; TUMOR-GROWTH; EXPRESSION; DEGRADATION; CD44; INHIBITOR	Hyaluronan is a glycosaminoglycan of the extracellular matrix. In tumors and during chronic inflammatory diseases, hyaluronan is degraded to smaller fragments, which are known to stimulate endothelial cell differentiation. In this study, we have compared the molecular mechanisms through which hyaluronan dodecasaccharides (HA12), and the known angiogenic factor, fibroblast growth factor 2 (FGF-2), induce capillary endothelial cell sprouting in a three-dimensional collagen gel. The gene expression profiles of unstimulated and HA12- or FGF-2-stimulated endothelial cells were compared using a microarray analysis approach. The data revealed that both FGF-2 and HA12 promoted endothelial cell morphogenesis in a process depending on the expression of ornithine decarboxylase (Odc) and ornithine decarboxylase antizyme inhibitor (Oazi) genes. Among the genes selectively up-regulated in response to HA12 was the chemokine CXCL1/GRO1 gene. The notion that the induction of CXCL1/GRO1 is of importance for HA12-induced endothelial cell sprouting was supported by the fact that morphogenesis was inhibited by antibodies specifically neutralizing the CXCL1/GRO1 protein product. HA12- stimulated endothelial cell differentiation was exerted via binding to CD44 since it was inhibited by antibodies blocking CD44 function. Our data show that hyaluronan fragments and FGF-2 affect endothelial cell morphogenesis by the induction of overlapping but also by distinct sets of genes.	Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, S-75123 Uppsala, Sweden; Yamagata Univ, Sch Med, Dept Ophthalmol, Yamagata 9909585, Japan	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University; Yamagata University	Heldin, P (corresponding author), Uppsala Univ, Biomed Ctr, Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	Paraskevi.Heldin@imbim.uu.se			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abdullah KM, 1999, ENDOCRINE, V10, P35, DOI 10.1385/ENDO:10:1:35; AMANUMA K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P336, DOI 10.1016/S0167-4889(97)90009-4; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Auvinen M, 1997, CANCER RES, V57, P3016; Berthelsen J, 1998, GENOMICS, V47, P323, DOI 10.1006/geno.1997.5086; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Ge Yimin, 2003, Lab Hematol, V9, P67; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hasan RN, 2003, ARTERIOSCL THROM VAS, V23, P988, DOI 10.1161/01.ATV.0000071351.07784.19; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Hawkins CL, 1998, FREE RADICAL BIO MED, V24, P1396, DOI 10.1016/S0891-5849(98)00009-4; Heldin P, 2003, BRAZ J MED BIOL RES, V36, P967, DOI 10.1590/S0100-879X2003000800002; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Jacobson A, 2002, INT J CANCER, V102, P212, DOI 10.1002/ijc.10683; Jonsdottir GA, 2004, CURR BIOL, V14, P1604, DOI 10.1016/j.cub.2004.08.055; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; Lokeshwar VB, 1996, CANCER RES, V56, P651; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; LUBBERT M, 1991, LEUKEMIA, V5, P361; Lui HM, 2003, MOL CANCER RES, V1, P508; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Montesano R, 1996, LAB INVEST, V75, P249; Muckian C, 2002, BLOOD, V100, P1220, DOI 10.1182/blood-2002-01-0283; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Nemoto T, 2002, BLOOD, V99, P1478, DOI 10.1182/blood.V99.4.1478; Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; SATO Y, 1991, BIOCHEM BIOPH RES CO, V180, P1098, DOI 10.1016/S0006-291X(05)81179-9; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; SATTAR A, 1992, SEMIN ARTH RHEUM, V21, P43; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Slevin M, 2002, J BIOL CHEM, V277, P41046, DOI 10.1074/jbc.M109443200; Slevin M, 1998, LAB INVEST, V78, P987; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Weston GC, 2002, MOL HUM REPROD, V8, P855, DOI 10.1093/molehr/8.9.855; White E. S., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P403, DOI 10.2174/1568011024606406; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125; Zeng Q, 2000, J CELL SCI, V113, P471; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	54	107	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24195	24204		10.1074/jbc.M411913200	http://dx.doi.org/10.1074/jbc.M411913200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843382	hybrid			2022-12-25	WOS:000229880000095
J	Wang, J; Feng, H; Huang, XQ; Xiang, H; Mao, YW; Liu, JP; Yan, Q; Liu, WB; Liu, Y; Deng, M; Gong, LL; Sun, SM; Luo, C; Liu, SJ; Zhang, XJ; Liu, Y; Li, DWC				Wang, J; Feng, H; Huang, XQ; Xiang, H; Mao, YW; Liu, JP; Yan, Q; Liu, WB; Liu, Y; Deng, M; Gong, LL; Sun, SM; Luo, C; Liu, SJ; Zhang, XJ; Liu, Y; Li, DWC			Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; HUMAN-DIPLOID FIBROBLASTS; CATALYTIC SUBUNIT GENE; GROWTH-FACTOR; LIFE-SPAN; PHOSPHATIDYLINOSITOL-3 KINASE; P53 PROTEIN; MAP KINASE; EXPRESSION; APOPTOSIS	Telomerase is a specialized reverse transcriptase that extends telomeres of eukaryotic chromosomes. The functional telomerase complex contains a telomerase reverse transcriptase catalytic subunit and a telomerase template RNA. We have previously demonstrated that human telomerase reverse transcriptase (hTERT) catalytic subunit is functionally compatible with a telomerase template RNA from rabbit. In this study, we show that hTERT is also functionally compatible with a telomerase template RNA from bovine. Introduction of hTERT into bovine lens epithelial cells (BLECs) provides the transfected cells telomerase activity. The expressed hTERT in BLECs supports normal growth of the transfected cells for 108 population doublings so far, and these cells are still extremely healthy in both morphology and growth. In contrast, the vector-transfected cells display growth crisis after 20 population doublings. These cells run into cellular senescence due to shortening of the telomeres and also commit differentiation as indicated by the accumulation of the differentiation markers, beta-crystallin and filensin. hTERT prevents the occurrence of both events. By synthesizing new telomere, hTERT prevents replicative senescence, and through regulation of MEK/ERK, protein kinase C, and protein kinase A and eventual suppression of the MEK/ERK signaling pathway, hTERT inhibits differentiation of BLECs. Our finding that hTERT can suppress RAS/RAF/MEK/ERK signaling pathway to prevent differentiation provides a novel mechanism to explain how hTERT regulates cell differentiation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ 08084 USA	University of Minnesota System; Hunan Normal University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwcli@hi.umn.edu	Yan, Qin/F-5161-2012; Yan, Qin/K-3539-2013; Gong, Lili/F-8452-2014; Deng, Mi/K-8699-2012	Yan, Qin/0000-0002-6344-6398; Gong, Lili/0000-0002-6533-5333; Deng, Mi/0000-0003-4291-0144; Mao, Yingwei/0000-0001-7339-1565; xiang, hua/0000-0003-0369-1225	NEI NIH HHS [EY15765, R01 EY015765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Cui WW, 2004, J BIOL CHEM, V279, P11088, DOI 10.1074/jbc.M312414200; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Gong XH, 2001, INVEST OPHTH VIS SCI, V42, P539; Govindarajan V, 2001, DEVELOPMENT, V128, P1617; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henning KA, 1998, P NATL ACAD SCI USA, V95, P5667, DOI 10.1073/pnas.95.10.5667; Huang XQ, 2005, INVEST OPHTH VIS SCI, V46, P2503, DOI 10.1167/iovs.05-0154; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMPE PD, 1986, EUR J BIOCHEM, V156, P351, DOI 10.1111/j.1432-1033.1986.tb09590.x; Le ACN, 2001, J CELL BIOL, V154, P197, DOI 10.1083/jcb.200101057; Le ACN, 2001, DEV BIOL, V233, P394, DOI 10.1006/dbio.2001.0194; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P5259, DOI 10.1167/iovs.03-0296; Lin DB, 2003, INVEST OPHTH VIS SCI, V44, P1160, DOI 10.1167/iovs.02-0737; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lovicu FJ, 2001, DEVELOPMENT, V128, P5075; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; MATSUMURA T, 1979, J GERONTOL, V34, P328, DOI 10.1093/geronj/34.3.328; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; O'Reilly Marc, 1999, Current Opinion in Structural Biology, V9, P56, DOI 10.1016/S0959-440X(99)80008-6; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pardue ML, 1999, CHROMOSOMA, V108, P73, DOI 10.1007/s004120050354; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1306; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wagner LM, 2001, MOL VIS, V7, P57; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1990, TRENDS GENET, V6, P12, DOI 10.1016/0168-9525(90)90043-6; Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168; Zatechka DS, 2002, EXP EYE RES, V75, P177, DOI 10.1006/exer.2002.2018; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhou JZ, 2003, J BIOL CHEM, V278, P5388, DOI 10.1074/jbc.M209695200	100	29	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22776	22787		10.1074/jbc.M500032200	http://dx.doi.org/10.1074/jbc.M500032200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849192	hybrid			2022-12-25	WOS:000229741800028
J	Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H				Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H			The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappa B activation induced via interaction between Akt and I kappa B kinase-beta in breast cancer cells	ONCOGENE			English	Article						breast cancer; fibroblast growth factor; apoptosis; proteomics; signaling	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; DEPENDENT PATHWAY; SURVIVAL; TARGET; PROLIFERATION; PROGRESSION; METASTASIS; MODULATION	Fibroblast growth factor-2 (FGF-2) is known for its mitogenic and motogenic effects on breast cancer cells. Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells. The use of pharmacological inhibitors (PD98059, wortmannin, LY294002, SN50) and transfection with negative dominants (I kappa Bm, p110(PI3K (phosphoinositide 3-kinase))*Delta K, AktND) or small interfering RNA targeted against Akt indicated that PI3K/Akt and nuclear factor-kappa B (NF-kappa B), but not p42/p44 MAP-kinases, were required to stimulate FGF-2 antiapoptotic activity. The activation of NF-kappa B was dependent on PI3K/Akt, and using a combination of approaches based on immunoprecipitation, Western blotting and proteomics (two-dimensional electrophoresis and mass spectrometry), we identified the beta form of I kappa B kinase (IKK beta) as a target of Akt signaling. The selective disruption of IKK beta using small interfering RNA induced a potent inhibition of Akt-mediated activation of NF-kappa B and cell survival, indicating the functional involvement of IKK beta in FGF-2 antiapoptotic signaling. Together, these results demonstrate Akt/IKK beta interaction in NF-kappa B pathways, thereby emphasizing the potential of these proteins as therapeutic targets in breast cancer.	INSERM, ERI8, UPRESEA 1033, F-59655 Villeneuve Dascq, France; Univ Sci & Tech Lille Flandres Artois, IFR118, CNRS, UMR 8576, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), INSERM, ERI8, UPRESEA 1033, Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; VANDERMOERE, Franck/0000-0001-5724-7037; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manetti F, 2003, CURR PHARM DESIGN, V9, P567, DOI 10.2174/1381612033391487; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ornitz DM, 2001, GENOME BIOL, V2; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Polnaszek N, 2003, CANCER RES, V63, P5754; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TAKEI Y, 1994, CLIN CHEM, V40, P1980; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2000, FEBS LETT, V478, P209, DOI 10.1016/S0014-5793(00)01855-X; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; Zhang LR, 1999, CANCER RES, V59, P5023	41	84	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5482	5491		10.1038/sj.onc.1208713	http://dx.doi.org/10.1038/sj.onc.1208713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856005				2022-12-25	WOS:000231222300008
J	Jiang, H; Rao, KS; Yee, VC; Kraus, JP				Jiang, H; Rao, KS; Yee, VC; Kraus, JP			Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; COENZYME-A CARBOXYLASE; BETA-SUBUNIT; PCCB GENE; MYCOBACTERIUM-SMEGMATIS; ACIDEMIA PATIENTS; MUTATIONS; TRANSCARBOXYLASE; FIBROBLASTS	Propionyl-CoA carboxylase (PCC) is a biotin-dependent mitochondrial enzyme that catalyzes the conversion of propionyl-CoA to D-methylmalonyl-CoA. PCC consists of two heterologous subunits, alpha PCC and beta PCC, which are encoded by the nuclear PCCA and PCCB genes, respectively. Deficiency of PCC results in a metabolic disorder, propionic acidemia, which is sufficiently severe to cause neonatal death. We have purified three PCCs containing pathogenic mutations in the beta subunit (R165W, E168K, and R410W) and one PCCB polymorphism (A497V) to homogeneity to elucidate the potential structural and functional effects of these substitutions. We observed no significant difference in Km values for propionyl-CoA between wild- type and the variant enzymes, which indicated that these substitutions had no effect on the affinity of the enzyme for this substrate. Furthermore, the kinetic studies indicated that mutation R410W was not involved in propionyl-CoA binding in contrast to a previous report. The three mutant PCCs had half the catalytic efficiency of wild- type PCC as judged by the k(cat)/K-m ratios. No significant differences have been observed in molecular mass or secondary structure among these enzymes. However, the variant PCCs were less thermostable than the wild- type. Following incubation at 47 degrees C, blue native-PAGE revealed a lower oligomeric form (alpha(2)beta(2)) in the three mutants not detectable in wildtype and the polymorphism. Interestingly, the lower oligomeric form was also observed in the corresponding crude Escherichia coli extracts. Our biochemical data and the structural analysis using a beta PCC homology model indicate that the pathogenic nature of these mutations is more likely to be due to a lack of assembly rather than disruption of catalysis. The strong favorable effect of the co-expressed chaperone proteins on PCC folding, assembly, and activity suggest that propionic acidemia may be amenable to chaperone therapy.	Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Case Western Reserve University	Kraus, JP (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Mail Stop 8313,POB 6511, Aurora, CO 80045 USA.	jan.kraus@uchsc.edu			NICHD NIH HHS [P01HD08315] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD008315] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Campeau E, 2001, MOL GENET METAB, V74, P238, DOI 10.1006/mgme.2001.3210; Chloupkova M, 2002, HUM MUTAT, V19, P629, DOI 10.1002/humu.10085; Chloupkova M, 2000, MOL GENET METAB, V71, P623, DOI 10.1006/mgme.2000.3097; Clavero S, 2002, BBA-MOL BASIS DIS, V1588, P119, DOI 10.1016/S0925-4439(02)00155-2; Corydon TJ, 1998, J BIOL CHEM, V273, P13065, DOI 10.1074/jbc.273.21.13065; Diacovich L, 2004, BIOCHEMISTRY-US, V43, P14027, DOI 10.1021/bi049065v; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Fenton WA, 2001, METABOLIC MOL BASES, P2165; Gamez A, 2000, J BIOL CHEM, V275, P29737, DOI 10.1074/jbc.M003231200; GRAVEL RA, 1994, AM J HUM GENET, V55, P51; HAASE FC, 1984, EUR J BIOCHEM, V140, P147, DOI 10.1111/j.1432-1033.1984.tb08078.x; HAASE FC, 1982, J BIOL CHEM, V257, P1994; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALOUSEK F, 1980, J BIOL CHEM, V255, P60; Kelson TL, 1996, HUM MOL GENET, V5, P331, DOI 10.1093/hmg/5.3.331; Kim SN, 2002, MOL GENET METAB, V77, P209, DOI 10.1016/S1096-7192(02)00139-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1994, GENOMICS, V19, P500, DOI 10.1006/geno.1994.1099; LAMHONWAH AM, 1990, GENOMICS, V8, P249, DOI 10.1016/0888-7543(90)90279-4; LAMHONWAH AM, 1987, AM J HUM GENET, V41, P1124; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Muro S, 2000, J INHERIT METAB DIS, V23, P300, DOI 10.1023/A:1005617420460; Muro S, 2001, MOL GENET METAB, V74, P476, DOI 10.1006/mgme.2001.3254; OHURA T, 1989, AM J HUM GENET, V45, P33; OHURA T, 1993, J INHERIT METAB DIS, V16, P863, DOI 10.1007/BF00714279; PACE CN, 1997, PROTEIN STRUCTURE PR, P229; Perez B, 2003, MOL GENET METAB, V78, P59, DOI 10.1016/S1096-7192(02)00197-X; Perez-Cerda C, 2003, BBA-MOL BASIS DIS, V1638, P43, DOI 10.1016/S0925-4439(03)00039-5; POTO EM, 1977, BIOCHEMISTRY-US, V16, P1949, DOI 10.1021/bi00628a030; Ravn K, 2000, AM J HUM GENET, V67, P203, DOI 10.1086/302971; Rodriguez-Pombo P, 1998, AM J HUM GENET, V63, P360, DOI 10.1086/301970; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; STANKOVICS J, 1993, AM J HUM GENET, V52, P144; TAHARA T, 1993, J INHERIT METAB DIS, V16, P353, DOI 10.1007/BF00710282; THORNTON CG, 1993, J BACTERIOL, V175, P5301, DOI 10.1128/JB.175.17.5301-5308.1993; Ugarte M, 1999, HUM MUTAT, V14, P275, DOI 10.1002/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N; WOOD HG, 1977, J BIOL CHEM, V252, P1490; WRIGLEY NG, 1977, J BIOL CHEM, V252, P1500	45	34	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27719	27727		10.1074/jbc.M413281200	http://dx.doi.org/10.1074/jbc.M413281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15890657	hybrid			2022-12-25	WOS:000230678600031
J	Lee, JA; Suh, DC; Kang, JE; Kim, MH; Park, H; Lee, MN; Kim, JM; Jeon, BN; Roh, HE; Yu, MY; Choi, KY; Kim, KY; Hur, MW				Lee, JA; Suh, DC; Kang, JE; Kim, MH; Park, H; Lee, MN; Kim, JM; Jeon, BN; Roh, HE; Yu, MY; Choi, KY; Kim, KY; Hur, MW			Transcriptional activity of Sp1 is regulated by molecular interactions between the zinc finger DNA binding domain and the inhibitory domain with corepressors, and this interaction is modulated by MEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; FUNCTIONAL-ANALYSIS; GENE-TRANSCRIPTION; ACTIVATION DOMAINS; MINIMAL PROMOTER; KINASE PATHWAY; ELEMENT; PROTEIN; PHOSPHORYLATION	Sp1 activates the transcription of many cellular and viral genes with the GC-box in either the proximal promoter or the enhancer. Sp1 is composed of several functional domains, such as the inhibitory domain ( ID), two serine/threonine-rich domains, two glutamine-rich domains, three C2H2-type zinc finger DNA binding domains (ZFDBD), and a C-terminal D domain. The ZDDBD is the most highly conserved domain among the Sp-family transcription factors and plays a critical role in GC-box recognition. In this study, we investigated the protein-protein interactions occurring at the Sp1ZFDBD and the Sp1ID, and the molecular mechanisms controlling the interaction. Our results found that Sp1ZFDBD and Sp1ID repressed transcription once they were targeted to the proximal promoter of the pGal4 UAS reporter fusion gene system, suggesting molecular interaction with the repressor molecules. Indeed, mammalian two-hybrid assays, GST fusion protein pull-down assays, and co-immunoprecipitation assays showed that Sp1ZFDBD and Sp1ID are able to interact with corepressor proteins such as SMRT, NcoR, and BCoR. The molecular interactions appear to be regulated by MAP kinase/Erk kinase kinase (MEK). The molecular interactions between Sp1ID and the corepressor might explain the role of Sp1 as a repressor under certain circumstances. The siRNA-induced degradation of the core-pressors resulted in an up-regulation of Sp1-dependent transcription. The cellular context of the corepressors and the regulation of molecular interaction between corepressors and Sp1ZFDBD or Sp1ID might be important in controlling Sp1 activity.	Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol,BK21 Project Med Sci, Seoul 120752, South Korea; PoChon CHA Univ, Coll Med, Dept Biochem, SeongNam 463836, Kyungki, South Korea; Yonsei Univ, Dept Biotechnol, Seoul 120752, South Korea; Ewha Womans Univ, Dept Sci Biol, Seoul 120752, South Korea	Yonsei University; Pochon Cha University; Yonsei University; Ewha Womans University	Hur, MW (corresponding author), Yonsei Univ, Sch Med, Inst Genet Sci, Dept Biochem & Mol Biol,BK21 Project Med Sci, 134 ShinChon Dong, Seoul 120752, South Korea.	mwhur2@yumc.yonsei.ac.kr		Hur, Man-Wook/0000-0002-3416-1334				Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Huynh KD, 2000, GENE DEV, V14, P1810; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li N, 1998, J BIOL CHEM, V273, P16104, DOI 10.1074/jbc.273.26.16104; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Moon SK, 2004, BIOCHEM BIOPH RES CO, V316, P605, DOI 10.1016/j.bbrc.2004.02.096; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Ogra Y, 2001, J BIOL CHEM, V276, P16534, DOI 10.1074/jbc.M100570200; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; SUSKE G, 1999, UNPUB GENE AMST, V238, P291; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Zaid A, 2001, EUR J BIOCHEM, V268, P5497, DOI 10.1046/j.0014-2956.2001.02453.x; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001	45	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28061	28071		10.1074/jbc.M414134200	http://dx.doi.org/10.1074/jbc.M414134200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15878880	hybrid			2022-12-25	WOS:000230678600069
J	Chen, M; O'Connor, KL				Chen, M; O'Connor, KL			Integrin alpha 6 beta 4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells	ONCOGENE			English	Article						integrin; chemotaxis; gene transcription; nuclear factor of activated T-cells ( NFAT)	LYSOPHOSPHOLIPASE-D ACTIVITY; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL REGULATION; CHEMOTACTIC MIGRATION; LAMELLAE FORMATION; CANCER CELLS; INVASION; RECEPTOR; PROTEIN; KINASE	In advanced breast carcinomas, the alpha 6 beta 4 integrin is associated with a migratory and invasive phenotype. In our current study, we show that expression of the a6b4 integrin in MDA- MB- 435 breast carcinoma cells leads to increased expression of the autocrine motility factor autotaxin, as determined by Affymetrix gene chip, realtime quantitative RT-PCR and immunoblot analyses. We further demonstrate that increased autotaxin secretion from integrin a6b4 expressing cells acts to enhance chemotaxis through its ability to convert lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA) and accounts for 80% of the motogenic activity of the conditioned medium. We determine that integrin alpha 6 beta 4dependent overexpression of autotaxin in MDA- MB- 435 cells is mediated by NFAT1, but not NFAT5, through the use of siRNAs that specifically target autotaxin, integrin beta 4, NFAT1 and NFAT5. Finally, we show by electrophoretic mobility shift assays that two consensus NFAT binding sites found in the autotaxin promoter strongly and specifically bind NFAT1 from integrin a6b4 expressing cells. In summary, we find that the a6b4 integrin potentiates autotaxin expression through the upregulation and activation of NFAT1. The se observations highlight for the first time a mechanism by which NFAT transcription factors can facilitate an invasive and motile phenotype downstream of integrin a6b4 signaling.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	O'Connor, KL (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	kloconno@utmb.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734				Bachelder RE, 2003, CANCER RES, V63, P5230; Bachelder RE, 2002, CANCER RES, V62, P7203; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; Chao C, 1996, CANCER RES, V56, P4811; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Kawagoe H, 1997, CANCER RES, V57, P2516; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Mainiero F, 2003, EUR J IMMUNOL, V33, P3038, DOI 10.1002/eji.200323931; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nam SW, 2001, CANCER RES, V61, P6938; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tani T, 1997, AM J PATHOL, V151, P1289; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	33	97	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5125	5130		10.1038/sj.onc.1208729	http://dx.doi.org/10.1038/sj.onc.1208729			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897878				2022-12-25	WOS:000230816900012
J	Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL				Cheng, N; Bhowmick, NA; Chytil, A; Gorksa, AE; Brown, KA; Muraoka, R; Arteaga, CL; Neilson, EG; Hayward, SW; Moses, HL			Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks	ONCOGENE			English	Article						TGF-beta; TGF-beta receptor type II; mammary gland; tumor-stromal interactions; tumor progression; subrenal grafting	MACROPHAGE-STIMULATING PROTEIN; TUMOR-STROMAL INTERACTIONS; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; EPITHELIAL INTERACTIONS; FACTOR/SCATTER FACTOR; EXTRACELLULAR-MATRIX; GLAND DEVELOPMENT; TYROSINE KINASE; REACTIVE STROMA	Stromal fibroblasts regulate epithelial cell behavior through direct and indirect cell-cell interactions. To clarify the role of TGF-beta signaling in stromal. broblasts during mammary development and tumorigenesis, we conditionally knocked out the TGF-beta type II receptor gene in mouse mammary. broblasts (Tgfbr2(fspKO)). Tgfbr2(fspKO) mice exhibit defective mammary ductal development, characterized in part by increased ductal epithelial cell turnover associated with an increase in stromal. fibroblast abundance. Tgfbr2(fspKO) mammary. broblasts transplanted with mammary carcinoma cells promote growth and invasion, which is associated with increased activating phosphorylation of the receptors: erbB1, erbB2, RON, and c- Met. Furthermore, the increased receptor phosphorylation correlates with increased secretion of the cognate ligands by Tgfbr2(fspKO). broblasts. Treatment of tumor cells with. fibroblast-conditioned medium leads to increased tumor cell proliferation and motility, which are blocked by addition of pharmacologic inhibitors of TGF-alpha signaling or neutralizing antibodies to macrophage-stimulating protein (MSP), HGF, or c- Met. These studies characterize a significant role for stromal TGF-beta signaling in mammary tissue homeostasis and mammary tumor progression via regulation of TGF-alpha, MSP, and HGF signaling pathways.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Urol Surg, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, 691 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	Hal.Moses@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019; Thomson, Axel/A-7893-2013	Bhowmick, Neil/0000-0001-8747-5989; Hayward, Simon/0000-0002-6059-6550	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA085492, R01CA102162, T32CA009592, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085492, R01 CA108646-01, P30 CA068485, R01 CA102162, CA102162, P30 CA68485, CA85492, R01 CA108646, T32 CA009592] Funding Source: Medline; NIAMS NIH HHS [AR41943, P30 AR041943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bitzer M, 2000, GENE DEV, V14, P187; Bottinger EP, 1997, CANCER RES, V57, P5564; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Cardiff RD, 2001, VET PATHOL, V38, P357, DOI 10.1354/vp.38-4-357; Cardiff RD, 2001, MICROSC RES TECHNIQ, V52, P224, DOI 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.3.CO;2-1; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065; CUNHA G, 2000, METHODS MAMMARY GLAN; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Daniel CW, 2001, ADV EXP MED BIOL, V501, P61; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hagedorn HG, 2001, INT J ONCOL, V18, P669; Haslam SZ, 2003, BREAST CANCER RES, V5, P208, DOI 10.1186/bcr615; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Joseph H, 1999, MOL BIOL CELL, V10, P1221, DOI 10.1091/mbc.10.4.1221; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Leonard E J, 1979, Adv Exp Med Biol, V121B, P181; LEONARD JE, 1987, CANCER RES, V47, P2899; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu YH, 2004, AM J PHYSIOL-RENAL, V287, pF7, DOI 10.1152/ajprenal.00451.2003; Maglione JE, 2001, CANCER RES, V61, P8298; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Moinfar F, 2000, CANCER RES, V60, P2562; Moulder SL, 2001, CANCER RES, V61, P8887; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; SAKAKURA T, 1981, J NATL CANCER I, V66, P953; SCHOR AM, 1994, INT J CANCER, V59, P25, DOI 10.1002/ijc.2910590107; Shekhar MPV, 2001, CANCER RES, V61, P1320; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Simian M, 2001, DEVELOPMENT, V128, P3117; SKEEL A, 1994, J IMMUNOL, V152, P4618; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Sun LZ, 2004, FRONT BIOSCI, V9, P1925, DOI 10.2741/1382; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tolstonog GV, 2001, DNA CELL BIOL, V20, P509, DOI 10.1089/104454901317094945; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wakeling AE, 2002, CANCER RES, V62, P5749; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2002, SCAND J IMMUNOL, V56, P545, DOI 10.1046/j.1365-3083.2002.01177.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	66	211	220	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5053	5068		10.1038/sj.onc.1208685	http://dx.doi.org/10.1038/sj.onc.1208685			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856015	Green Accepted			2022-12-25	WOS:000230816900005
J	Zhang, W; Campbell, HA; King, SC; Dowhan, W				Zhang, W; Campbell, HA; King, SC; Dowhan, W			Phospholipids as determinants of membrane protein topology - Phosphatidylethanolamine is required for the proper topological organization of the gamma-aminobutyric acid permease (GabP) of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT SPECIFICITY RATIO; 4-AMINOBUTYRATE TRANSPORTER; LACTOSE PERMEASE; CYSTEINE; MECHANISM; SUPERFAMILY; SUBUNIT; SYSTEM	Evidence is accumulating that the topological organization and hence function of some membrane proteins are not solely determined by the amino acid sequence of the protein but are also influenced by the lipid composition of the membrane. The gamma-aminobutyric acid ( GABA) permease (GabP) of Escherichia coli has been found in this study to be affected both topologically and kinetically by membrane lipids. Using single cysteine accessibility methods with viable E. coli strains of natural lipid composition and those lacking phosphatidylethanolamine ( PE), we have shown that the N-terminal hairpin of GabP is inverted relative to the membrane in PE-lacking cells, with a hinge point in transmembrane domain III. The rate of GABA transport is reduced by more than 99% in PE-lacking cells. The Michaelis constant for GABA transport is not greatly affected nor is the dependence of transport on energy. However, "transport specificity ratio" analysis demonstrated a clear transition state stability difference for GABA and nipecotic acid between the protein in PE-containing and PE-lacking cells. The patterns of observed effects are similar to those seen with the phenylalanine transporter of E. coli (Zhang, W., Bogdanov, M. Pi, J. Pittard, A. J., and Dowhan, W. ( 2003) J. Biol. Chem. 278, 50128-50135), also an amino acid/polyamine/organocation family member but quite distinct from those observed with lactose permease ( Bogdanov, M., Heacock, P. N., and Dowhan, W. ( 2002) EMBO J. 21, 2107-2116), a major facilitator superfamily member. Therefore, by extending the studies of similarities and differences in lipid responses among and between family groups, we may identify elements within the proteins that facilitate lipid responsiveness.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA	University of Texas System; Oregon Health & Science University	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St,Suite 6,200, Houston, TX 77030 USA.	William.Dowhan@uth.tmc.edu		Adams, Heidi/0000-0001-7563-3126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038226] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20487, GM071128] Funding Source: Medline; NINDS NIH HHS [NS38226] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; CHEN CC, 1984, J BIOL CHEM, V259, P150; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Dowhan W, 2004, BBA-BIOMEMBRANES, V1666, P19, DOI 10.1016/j.bbamem.2004.04.010; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Hu LA, 1998, J BIOL CHEM, V273, P20162, DOI 10.1074/jbc.273.32.20162; Hu LA, 1998, BIOCHEM J, V336, P69, DOI 10.1042/bj3360069; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JACKSON RW, 1965, J BACTERIOL, V90, P1420, DOI 10.1128/JB.90.5.1420-1425.1965; KING SC, 1995, J BIOL CHEM, V270, P19893, DOI 10.1074/jbc.270.34.19893; King SC, 2003, BIOCHEM J, V376, P633, DOI 10.1042/BJ20030594; King Steven C., 2004, BMC Biochemistry, V5, P16, DOI 10.1186/1471-2091-5-16; Linton KJ, 2002, MOL MEMBR BIOL, V19, P51, DOI 10.1080/09687680110103622; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Motulsky H, 1999, ANAL DATA GRAPHPAD P, P174; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pi J, 1996, J BACTERIOL, V178, P2650, DOI 10.1128/jb.178.9.2650-2655.1996; Rutz C, 1999, J BIOL CHEM, V274, P33757, DOI 10.1074/jbc.274.47.33757; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; von Heijne G, 1994, Subcell Biochem, V22, P1; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Wikstrom M, 2004, J BIOL CHEM, V279, P10484, DOI 10.1074/jbc.M310183200; Zhang W, 2003, J BIOL CHEM, V278, P50128, DOI 10.1074/jbc.M309840200	35	82	87	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26032	26038		10.1074/jbc.M504929200	http://dx.doi.org/10.1074/jbc.M504929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15890647	hybrid			2022-12-25	WOS:000230386800012
J	Ayrapetov, MK; Nam, NH; Ye, GF; Kumar, A; Parang, K; Sun, GQ				Ayrapetov, MK; Nam, NH; Ye, GF; Kumar, A; Parang, K; Sun, GQ			Functional diversity of Csk, Chk, and Src SH2 domains due to a single residue variation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BREAST-CANCER CELLS; HOMOLOGOUS KINASE; GROWTH-FACTOR; BINDING; SPECIFICITY; ACTIVATION; RECEPTOR; PHOSPHORYLATION; PURIFICATION	The C- terminal Src kinase ( Csk) family of protein tyrosine kinases contains two members: Csk and Csk homologous kinase ( Chk). Both phosphorylate and inactivate Src family kinases. Recent reports suggest that the Src homology ( SH) 2 domains of Csk and Chk may bind to different phosphoproteins, which provides a basis for different cellular functions for Csk and Chk. To verify and characterize such a functional divergence, we compared the binding properties of the Csk, Chk, and Src SH2 domains and investigated the structural basis for the functional divergence. First, the study demonstrated striking functional differences between the Csk and Chk SH2 domains and revealed functional similarities between the Chk and Src SH2 domains. Second, structural analysis and mutagenic studies revealed that the functional differences among the three SH2 domains were largely controlled by one residue, Glu(127) in Csk, Ile(167) in Chk, and Lys(200) in Src. Mutating these residues in the Csk or Chk SH2 domain to the Src counterpart resulted in dramatic gain of function similar to Src SH2 domain, whereas mutating Lys200 in Src SH2 domain to Glu ( the Csk counterpart) resulted in loss of Src SH2 function. Third, a single point mutation of E127K rendered Csk responsive to activation by a Src SH2 domain ligand. Finally, the optimal phosphopeptide sequence for the Chk SH2 domain was determined. These results provide a compelling explanation for the functional differences between two homologous protein tyrosine kinases and reveal a new structure- function relationship for the SH2 domains.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA; Univ Rhode Isl, Dept Biomed Sci, Kingston, RI 02881 USA	University of Rhode Island; University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Hall,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu	Parang, Keykavous/ABC-1584-2021; Kumar, Anil/F-8777-2011; Parang, Keykavous/F-9236-2010; Kumar, Anil/V-8315-2019; Ye, Guofeng/B-2441-2009; Boothapati, Anil Kumar/HHS-1813-2022; KUMAR, ANIL/ACD-8340-2022	Parang, Keykavous/0000-0001-8600-0893; Kumar, Anil/0000-0003-4699-3178; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P20 RR16457] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; Ayrapetov MK, 2003, PROTEIN EXPRES PURIF, V29, P148, DOI 10.1016/S1046-5928(02)006980-8; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Bradshaw JM, 1999, BIOCHEMISTRY-US, V38, P5147, DOI 10.1021/bi982974y; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Catipovic B, 1996, Lijec Vjesn, V118, P264; Catipovic B, 1996, J BIOL CHEM, V271, P9698, DOI 10.1074/jbc.271.16.9698; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Dittmar T, 2002, FASEB J, V16, P1823, DOI 10.1096/fj.02-0096fje; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Grgurevich S, 1999, BIOCHEM BIOPH RES CO, V256, P668, DOI 10.1006/bbrc.1999.0398; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kim S, 2002, J BIOL CHEM, V277, P36465, DOI 10.1074/jbc.M206018200; Kimber MS, 2000, MOL CELL, V5, P1043, DOI 10.1016/S1097-2765(00)80269-5; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; Lin XF, 2005, BIOCHEMISTRY-US, V44, P1561, DOI 10.1021/bi048142j; Lynch BA, 1997, ANAL BIOCHEM, V247, P77, DOI 10.1006/abio.1997.2042; McShan GD, 2002, INT J ONCOL, V21, P197; Muller K, 1996, J BIOL CHEM, V271, P16500; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1991, J BIOL CHEM, V266, P24249; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pfrepper KI, 2001, EUR J IMMUNOL, V31, P1825, DOI 10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Sheinerman FB, 2003, J MOL BIOL, V334, P823, DOI 10.1016/j.jmb.2003.09.075; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; SUN GQ, 1995, ANAL BIOCHEM, V231, P458, DOI 10.1006/abio.1995.0081; Szustakowski JD, 2000, PROTEINS, V38, P428, DOI 10.1002/(SICI)1097-0134(20000301)38:4<428::AID-PROT8>3.0.CO;2-N; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	47	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25780	25787		10.1074/jbc.M504022200	http://dx.doi.org/10.1074/jbc.M504022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890649	hybrid			2022-12-25	WOS:000230207900059
J	Beard, M; Satoh, A; Shorter, J; Warren, G				Beard, M; Satoh, A; Shorter, J; Warren, G			A cryptic Rab1-binding site in the p115 tethering protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MATRIX PROTEIN; COILED-COIL PROTEINS; CIS-GOLGI; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; VESICLE DOCKING; AFFINITY-CHROMATOGRAPHY; VESICULAR TRANSPORT; COPII VESICLES; REQUIRES USO1P	Small GTPases and coiled- coil proteins of the golgin family help to tether COPI vesicles to Golgi membranes. At the cis- side of the Golgi, the Rab1 GTPase binds directly to each of three coiled- coil proteins: p115, GM130, and as now shown, Giantin. Rab1 binds to a coiled- coil region within the tail domain of p115 and this binding is inhibited by the C- terminal, acidic domain of p115. Furthermore, GM130 and Giantin bind to the acidic domain of p115 and stimulate p115 binding to Rab1, suggesting that p115 binding to Rab1 is regulated. Regulation of this interaction by proteins such as GM130 and Giantin may control the membrane recruitment of p115 by Rab1.	Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Whitehead Inst, Lindquist Lab, Cambridge, MA 02142 USA	Ludwig Institute for Cancer Research; Yale University; Columbia University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Warren, G (corresponding author), Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	graham.warren@yale.edu	Satoh, Ayano/B-2423-2011; Shorter, James/ABE-7307-2020; Shorter, James/E-8207-2011	Satoh, Ayano/0000-0003-3736-1283; Shorter, James/0000-0001-5269-8533; 				Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Christoforidis S, 2001, METHOD ENZYMOL, V329, P120; Cullis DN, 2002, J BIOL CHEM, V277, P49158, DOI 10.1074/jbc.M206316200; Diao A, 2003, J CELL BIOL, V160, P201, DOI 10.1083/jcb.200207045; Dirac-Svejstrup AB, 2000, J CELL BIOL, V150, P475, DOI 10.1083/jcb.150.3.475; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Jackson CL, 2003, CURR BIOL, V13, pR174, DOI 10.1016/S0960-9822(03)00116-7; Kondylis V, 2003, J CELL BIOL, V162, P185, DOI 10.1083/jcb.200301136; Lesa GM, 2000, J BIOL CHEM, V275, P2831, DOI 10.1074/jbc.275.4.2831; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; Lowe M, 2000, CURR BIOL, V10, pR407, DOI 10.1016/S0960-9822(00)00505-4; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Mayer A, 2001, TRENDS BIOCHEM SCI, V26, P717, DOI 10.1016/S0968-0004(01)01984-3; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Pfeffer S, 2001, MOL CELL, V8, P729, DOI 10.1016/S1097-2765(01)00371-9; Puthenveedu MA, 2004, P NATL ACAD SCI USA, V101, P1253, DOI 10.1073/pnas.0306373101; Puthenveedu MA, 2001, J CELL BIOL, V155, P227, DOI 10.1083/jcb.200105005; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Short B, 2002, CURR BIOL, V12, P1792, DOI 10.1016/S0960-9822(02)01221-6; Short B, 2001, J CELL BIOL, V155, P877, DOI 10.1083/jcb.200108079; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; Sollner TH, 2002, DEV CELL, V2, P377, DOI 10.1016/S1534-5807(02)00161-2; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Valsdottir R, 2001, FEBS LETT, V508, P201, DOI 10.1016/S0014-5793(01)02993-3; Vasile E, 2003, TRAFFIC, V4, P254, DOI 10.1034/j.1600-0854.2003.00080.x; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weide T, 2001, EMBO REP, V2, P336, DOI 10.1093/embo-reports/kve065; Whyte JRC, 2002, J CELL SCI, V115, P2627; Yamakawa H, 1996, J STRUCT BIOL, V116, P356, DOI 10.1006/jsbi.1996.0053; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	60	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25840	25848		10.1074/jbc.M503925200	http://dx.doi.org/10.1074/jbc.M503925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878873	hybrid			2022-12-25	WOS:000230207900065
J	Carlson, EC; Liu, CY; Chikama, TI; Hayashi, Y; Kao, CWC; Birk, DE; Funderburgh, JL; Jester, JV; Kao, WWY				Carlson, EC; Liu, CY; Chikama, TI; Hayashi, Y; Kao, CWC; Birk, DE; Funderburgh, JL; Jester, JV; Kao, WWY			Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; VIVO CONFOCAL MICROSCOPY; HUMAN BREAST-CARCINOMA; COLLAGEN FIBRILLOGENESIS; DEFICIENT MICE; IN-VIVO; DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; TRANSGENIC MICE	Lumican is an extracellular matrix glycoprotein widely distributed in mammalian connective tissues. Corneal lumican modified with keratan sulfate constitutes one of the major proteoglycans of the stroma. Lumican-null mice exhibit altered collagen fibril organization and loss of corneal transparency. A closely related protein, keratocan, carries the remaining keratan sulfate of the cornea, but keratocan-null mice exhibit a less severe corneal phenotype. In the current study, we examined the effect of lumican overexpression in corneas of wild type mice. These mice showed no alteration in collagen organization or transparency but had increased keratocan expression at both protein and mRNA levels. Corneas of lumican-null mice showed decreased keratocan. This coupling of keratocan expression with lumican also was observed after intrastromal injection of a lumican expression minigene into the corneal stroma of Lum(-/-) mice. Small interfering RNA knockdown of lumican in vitro reduced keratocan expression, whereas co-injection of a lumican-expressing minigene with a beta-galactosidase reporter driven by the keratocan promoter demonstrated an increase of keratocan transcriptional activity in response to lumican expression in Lum(-/-) corneas in vivo. These observations demonstrate that lumican has a novel regulatory role in keratocan expression at the transcriptional level. Such results help provide an explanation for the differences in severity of corneal manifestation found in Lum(-/-) and Kera(-/-) mice. The results also suggest a critical level of small proteoglycans to be essential for collagen organization but that overabundance is not detrimental to extracellular matrix morphogenesis.	Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Ophthalmol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Pharmacol & Cell Biol, Miami, FL 33136 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA	University System of Ohio; University of Cincinnati; Bascom Palmer Eye Institute; University of Miami; University of Miami; University of Miami; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kao, WWY (corresponding author), Univ Cincinnati, Dept Ophthalmol, 3223 Eden Ave, Cincinnati, OH 45267 USA.	Winston.Kao@uc.edu	Birk, David/I-4072-2012; Chikama, Taiichiro/P-8371-2016	Birk, David/0000-0002-4865-9088; Chikama, Taiichiro/0000-0003-4001-678X; Liu, Chia-yang/0000-0002-8398-5516; Jester, James/0000-0002-9246-0981	NEI NIH HHS [EY13215, EY05129, R01 EY011845, EY09368, R01 EY009368-13, R01 EY012486, R01 EY009368, EY12486, P30 EY008098, EY08098, R01 EY005129, EY11845] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009368, R01EY005129, R01EY012486, P30EY008098, R01EY013215, R01EY011845] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Austin BA, 2002, INVEST OPHTH VIS SCI, V43, P1695; BIRK DE, 1984, J CELL BIOL, V99, P2024, DOI 10.1083/jcb.99.6.2024; Carlson EC, 2004, INVEST OPHTH VIS SCI, V45, P2194, DOI 10.1167/iovs.03-1224; Carlson EC, 2003, BIOCHEM J, V369, P461, DOI 10.1042/BJ20020593; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Doane KJ, 1996, EXP EYE RES, V62, P271; Duca L, 2004, CRIT REV ONCOL HEMAT, V49, P235, DOI 10.1016/j.critrevonc.2003.09.007; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; Funderburgh JL, 2003, J BIOL CHEM, V278, P45629, DOI 10.1074/jbc.M303292200; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; Funderburgh JL, 1997, INVEST OPHTH VIS SCI, V38, P1159; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Jester JV, 1999, METHOD ENZYMOL, V307, P230; Jester JV, 2001, VISION RES, V41, P1283, DOI 10.1016/S0042-6989(00)00222-4; Kao WWY, 2002, GLYCOCONJUGATE J, V19, P275, DOI 10.1023/A:1025396316169; KRULL NB, 1992, FEBS LETT, V312, P47, DOI 10.1016/0014-5793(92)81407-D; Leygue E, 2000, J PATHOL, V192, P313; Leygue E, 1998, CANCER RES, V58, P1348; Li HF, 1997, CURR EYE RES, V16, P214, DOI 10.1076/ceyr.16.3.214.15412; Li J, 2000, INVEST OPHTH VIS SCI, V41, P2945; Liu CY, 2003, J BIOL CHEM, V278, P21672, DOI 10.1074/jbc.M301169200; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Liu CY, 2000, GENE, V250, P85, DOI 10.1016/S0378-1119(00)00165-7; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Lu YP, 2002, PATHOL INT, V52, P519, DOI 10.1046/j.1440-1827.2002.01384.x; Meek KM, 2003, MATRIX BIOL, V22, P467, DOI 10.1016/S0945-053X(03)00081-7; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; PING LY, 2002, J PATHOL, V196, P324; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Saika S, 2003, INVEST OPHTH VIS SCI, V44, P2094, DOI 10.1167/iovs.02-1059; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Stechschulte SU, 2001, INVEST OPHTH VIS SCI, V42, P1975; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Tran KT, 2004, WOUND REPAIR REGEN, V12, P262, DOI 10.1111/j.1067-1927.2004.012302.x; Troup S, 2003, CLIN CANCER RES, V9, P207; Vij N, 2004, EXP EYE RES, V78, P957, DOI 10.1016/j.exer.2003.12.006; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wilda M, 2000, J BONE MINER RES, V15, P2187, DOI 10.1359/jbmr.2000.15.11.2187; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	52	109	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25541	25547		10.1074/jbc.M500249200	http://dx.doi.org/10.1074/jbc.M500249200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15849191	hybrid, Green Accepted			2022-12-25	WOS:000230207900031
J	Chen, P; Sun, CX; Liu, JN				Chen, P; Sun, CX; Liu, JN			A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin (alpha)(IIb)beta(3) inhibits platelet aggregation and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GPIIB-IIIA; MYOCARDIAL-INFARCTION; IIB/IIIA ANTAGONISTS; FIBRINOGEN BINDING; ACTIVATION; DOMAIN; AFFINITY; RECEPTOR; ALPHA(IIB)BETA(3)	Activation or ligand binding induces conformational changes in alpha(IIb)beta(3), resulting in exposure of neoepitopes named ligand-induced binding sites. We reported here a novel monoclonal antibody developed by using Chinese hamster ovary (CHO) cells expressing an activated alpha(IIb)beta(3) mutant (CHO alpha(IIb)beta(3)Delta 717) as the immunogen. This IgG(2b)kappa named 3C7 was specific for the complex of alpha(IIb)beta(3) as demonstrated by flow cytometry, immunoprecipitation, and EDTA chelating. The binding of 3C7 to platelets increased significantly when platelets were activated by ADP/thrombin or occupied by RGDS peptides, fibrinogen, or PAC-1, suggesting that 3C7 was an antiligand-induced binding site antibody. The antibody failed to bind to the CHO cells expressing another alpha(IIb)beta(3) mutant (beta(3)Y178A) suggesting that the Cys(177) - Cys(184) loop of beta(3) was likely the epitope for 3C7. 3C7 inhibited platelet aggregation, which was initiated by ADP or thrombin in a dose- dependent manner (IC(50)s of 5.6 and 0.05 mu g/ml, respectively). The antibody also inhibited platelet adhesion to immobilized fibrinogen but not to fibronectin or collagen. These findings suggested that 3C7 was a potent antagonist of integrin alpha(IIb)beta(3) and a potential anti-thrombotic agent.	Nanjing Univ, Inst Mol Med, Nanjing 210093, Peoples R China; Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China	Nanjing University; Nanjing University	Liu, JN (corresponding author), Nanjing Univ, Inst Mol Med, 22 Hankou Rd, Nanjing 210093, Peoples R China.	jnliu@verizon.net						ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; Bednar RA, 1998, J PHARMACOL EXP THER, V285, P1317; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blankenship JC, 1999, AM HEART J, V138, pS287, DOI 10.1053/hj.1999.v138.a100461; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Braunwald E, 1998, EUR HEART J, V19, pD22; Calzada MJ, 2002, J BIOL CHEM, V277, P39899, DOI 10.1074/jbc.M205886200; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Dorsam RT, 2004, J CLIN INVEST, V113, P340, DOI 10.1172/JCI200420986; DUPERRAY A, 1989, BLOOD, V74, P1603; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jacobin MJ, 2002, J IMMUNOL, V168, P2035, DOI 10.4049/jimmunol.168.4.2035; JENNINGS LK, 1985, BLOOD, V65, P1112; Joseph JE, 1997, BLOOD REV, V11, P178, DOI 10.1016/S0268-960X(97)90018-7; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lefkovits J, 1996, EUR HEART J, V17, P9; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; Mazurov AV, 1996, FEBS LETT, V391, P84, DOI 10.1016/0014-5793(96)00709-0; Miao H, 2002, J CELL SCI, V115, P2199; NIIYA K, 1987, BLOOD, V70, P475; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; PRAMMER KV, 1994, RECEPTOR, V4, P93; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Scarborough RM, 1999, CIRCULATION, V100, P437, DOI 10.1161/01.CIR.100.4.437; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHADLE PJ, 1982, J CELL BIOL, V95, P361, DOI 10.1083/jcb.95.1.361; SHATTIL SJ, 1985, BLOOD, V66, P92; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Tam SH, 1998, CIRCULATION, V98, P1085, DOI 10.1161/01.CIR.98.11.1085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	46	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25403	25408		10.1074/jbc.M500462200	http://dx.doi.org/10.1074/jbc.M500462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890654	hybrid			2022-12-25	WOS:000230207900014
J	Hirai, MY; Klein, M; Fujikawa, Y; Yano, M; Goodenowe, DB; Yamazaki, Y; Kanaya, S; Nakamura, Y; Kitayama, M; Suzuki, H; Sakurai, N; Shibata, D; Tokuhisa, J; Reichelt, M; Gershenzon, J; Papenbrock, J; Saito, K				Hirai, MY; Klein, M; Fujikawa, Y; Yano, M; Goodenowe, DB; Yamazaki, Y; Kanaya, S; Nakamura, Y; Kitayama, M; Suzuki, H; Sakurai, N; Shibata, D; Tokuhisa, J; Reichelt, M; Gershenzon, J; Papenbrock, J; Saito, K			Elucidation of gene-to-gene and metabolite-to-gene networks in Arabidopsis by integration of metabolomics and transcriptomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMICS; GLUCOSINOLATE BIOSYNTHESIS; THALIANA; SULFOTRANSFERASES; EXPRESSION; REGULATOR; REVEALS; LYASE	Since the completion of genome sequences of model organisms, functional identification of unknown genes has become a principal challenge in biology. Postgenomics sciences such as transcriptomics, proteomics, and metabolomics are expected to discover gene functions. This report outlines the elucidation of gene-to-gene and metabolite-to-gene networks via integration of metabolomics with transcriptomics and presents a strategy for the identification of novel gene functions. Metabolomics and transcriptomics data of Arabidopsis grown under sulfur deficiency were combined and analyzed by batch-learning self-organizing mapping. A group of metabolites/genes regulated by the same mechanism clustered together. The metabolism of glucosinolates was shown to be coordinately regulated. Three uncharacterized putative sulfotransferase genes clustering together with known glucosinolate biosynthesis genes were candidates for involvement in biosynthesis. In vitro enzymatic assays of the recombinant gene products confirmed their functions as desulfoglucosinolate sulfotransferases. Several genes involved in sulfur assimilation clustered with O-acetylserine, which is considered a positive regulator of these genes. The genes involved in anthocyanin biosynthesis clustered with the gene encoding a transcriptional factor that up-regulates specifically anthocyanin biosynthesis genes. These results suggested that regulatory metabolites and transcriptional factor genes can be identified by this approach, based on the assumption that they cluster with the downstream genes they regulate. This strategy is applicable not only to plant but also to other organisms for functional elucidation of unknown genes.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Chiba 2638522, Japan; RIKEN, Plant Sci Ctr, Kanagawa 2300045, Japan; Leibniz Univ Hannover, Inst Bot, D-30419 Hannover, Germany; Phenomenome Discoveries Inc, Saskatoon, SK S7N 4L8, Canada; Nara Inst Sci & Technol, Dept Bioinformat & Genom, Grad Sch Informat Sci, Nara 6300101, Japan; Kazusa DNA Res Inst, Chiba 2920818, Japan; Max Planck Inst Chem Ecol, D-07745 Jena, Germany	Chiba University; RIKEN; Leibniz University Hannover; Nara Institute of Science & Technology; Kazusa DNA Research Institute; Max Planck Society	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Chiba 2638522, Japan.	ksaito@faculty.chiba-u.jp	Saito, Kazuki/D-2670-2009; Suzuki, Hideyuki/J-7571-2016; Hirai, Masami Y/D-5319-2009; Tokuhisa, James G/B-5664-2008; Gershenzon, Jonathan/K-1331-2013	Saito, Kazuki/0000-0001-6310-5342; Hirai, Masami Y/0000-0003-0802-6208; Tokuhisa, James G/0000-0002-3834-5149; Gershenzon, Jonathan/0000-0002-1812-1551				Abe T, 2003, GENOME RES, V13, P693, DOI 10.1101/gr.634603; Aharoni A, 2000, PLANT CELL, V12, P647, DOI 10.1105/tpc.12.5.647; Bino RJ, 2004, TRENDS PLANT SCI, V9, P418, DOI 10.1016/j.tplants.2004.07.004; Borevitz JO, 2000, PLANT CELL, V12, P2383, DOI 10.1105/tpc.12.12.2383; Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248; Field B, 2004, PLANT PHYSIOL, V135, P828, DOI 10.1104/pp.104.039347; GLENDENING TM, 1990, PLANT PHYSIOL, V94, P811, DOI 10.1104/pp.94.2.811; Goossens A, 2003, P NATL ACAD SCI USA, V100, P8595, DOI 10.1073/pnas.1032967100; Graser G, 2000, ARCH BIOCHEM BIOPHYS, V378, P411, DOI 10.1006/abbi.2000.1812; Graser G, 2001, PHYTOCHEMISTRY, V57, P23, DOI 10.1016/S0031-9422(00)00501-X; Grubb CD, 2004, PLANT J, V40, P893, DOI 10.1111/j.1365-313X.2004.02261.x; Guterman I, 2002, PLANT CELL, V14, P2325, DOI 10.1105/tpc.005207; Hirai MY, 2004, P NATL ACAD SCI USA, V101, P10205, DOI 10.1073/pnas.0403218101; Hirai MY, 2003, PLANT J, V33, P651, DOI 10.1046/j.1365-313X.2003.01658.x; Jones PR, 2003, J BIOL CHEM, V278, P10291, DOI 10.1074/jbc.M212207200; Kanaya S, 2001, GENE, V276, P89, DOI 10.1016/S0378-1119(01)00673-4; Klein M, 2004, J EXP BOT, V55, P1809, DOI 10.1093/jxb/erh183; Kutz A, 2002, PLANT J, V30, P95, DOI 10.1046/j.1365-313X.2002.01271.x; Maruyama-Nakashita A, 2003, PLANT PHYSIOL, V132, P597, DOI 10.1104/pp.102.019802; Mellon FA, 2002, ANAL BIOCHEM, V306, P83, DOI 10.1006/abio.2002.5677; Mercke P, 2004, PLANT PHYSIOL, V135, P2012, DOI 10.1104/pp.104.048116; Mikkelsen MD, 2004, PLANT J, V37, P770, DOI 10.1111/j.1365-313X.2004.02002.x; Mikkelsen MD, 2002, AMINO ACIDS, V22, P279, DOI 10.1007/s007260200014; Nikiforova V, 2003, PLANT J, V33, P633, DOI 10.1046/j.1365-313X.2003.01657.x; Petersen BL, 2001, PLANTA, V212, P612, DOI 10.1007/s004250000429; Piotrowski M, 2004, J BIOL CHEM, V279, P50717, DOI 10.1074/jbc.M407681200; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; Tohge T, 2005, PLANT J, V42, P218, DOI 10.1111/j.1365-313X.2005.02371.x; Urbanczyk-Wochniak E, 2003, EMBO REP, V4, P989, DOI 10.1038/sj.embor.embor944; Weckwerth W, 2004, P NATL ACAD SCI USA, V101, P7809, DOI 10.1073/pnas.0303415101; Wittstock U, 2002, CURR OPIN PLANT BIOL, V5, P300, DOI 10.1016/S1369-5266(02)00264-9; Wittstock U, 2002, TRENDS PLANT SCI, V7, P263, DOI 10.1016/S1360-1385(02)02273-2	33	361	395	5	95	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25590	25595		10.1074/jbc.M502332200	http://dx.doi.org/10.1074/jbc.M502332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15866872	hybrid			2022-12-25	WOS:000230207900037
J	Travaglini-Allocatelli, C; Gianni, S; Dubey, VK; Borgia, A; Di Matteo, A; Bonivento, D; Cutruzzola, F; Bren, KL; Brunori, M				Travaglini-Allocatelli, C; Gianni, S; Dubey, VK; Borgia, A; Di Matteo, A; Bonivento, D; Cutruzzola, F; Bren, KL; Brunori, M			An obligatory intermediate in the folding pathway of cytochrome c(552) from Hydrogenobacter thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; PSEUDOMONAS-AERUGINOSA; PROTEIN; MECHANISM; KINETICS; CONSERVATION; SPECTROSCOPY; DYNAMICS; HEME; IM7	The folding mechanism of many proteins involves the population of partially organized structures en route to the native state. Identification and characterization of these intermediates is particularly difficult, as they are often only transiently populated and may play different mechanistic roles, being either on- pathway productive species or off- pathway kinetic traps. Following different spectroscopic probes, and employing state- of- the- art kinetic analysis, we present evidence that the folding mechanism of the thermostable cytochrome c(552) from Hydrogenobacter thermophilus does involve the presence of an elusive, yet compact, on- pathway intermediate. Characterization of the folding mechanism of this cytochrome c is particularly interesting for the purpose of comparative folding studies, because H. thermophilus cytochrome c552 shares high sequence identity and structural homology with its homologue from the mesophilic bacterium Pseudomonas aeruginosa cytochrome c(551), which refolds through a broad energy barrier without the accumulation of intermediates. Analysis of the folding kinetics and correlation with the three- dimensional structure add new evidence for the validity of a consensus folding mechanism in the cytochrome c family.	Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy; CNR, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Rochester, Dept Chem, Rochester, NY 14627 USA	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Fondazione Cenci Bolognetti; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Rochester	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	Dubey, Vikash Kumar/B-3542-2008; gianni, stefano/C-8536-2009; Borgia, Alessandro/AAF-9203-2019; Cutruzzola', Francesca/G-4052-2011; Di Matteo, Adele/AAC-8338-2019	Dubey, Vikash Kumar/0000-0002-4281-2504; Borgia, Alessandro/0000-0002-4701-8967; Cutruzzola', Francesca/0000-0002-4621-2135; Di Matteo, Adele/0000-0002-5921-7365; Bren, Kara/0000-0002-8082-3634; Gianni, Stefano/0000-0003-1653-1925; Dubey, Vikash Kumar/0000-0002-3870-2660; Brunori, Maurizio/0000-0002-7795-1635; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama S, 2002, P NATL ACAD SCI USA, V99, P1329, DOI 10.1073/pnas.012458999; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Callender R, 2002, CURR OPIN STRUC BIOL, V12, P628, DOI 10.1016/S0959-440X(02)00370-6; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; Daggett V, 2003, NAT REV MOL CELL BIO, V4, P497, DOI 10.1038/nrm1126; Daggett V, 2003, TRENDS BIOCHEM SCI, V28, P18, DOI 10.1016/S0968-0004(02)00012-9; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Gianni S, 2003, P NATL ACAD SCI USA, V100, P13286, DOI 10.1073/pnas.1835776100; Gianni S, 2001, J MOL BIOL, V309, P1177, DOI 10.1006/jmbi.2001.4728; Grantcharova VP, 1998, NAT STRUCT BIOL, V5, P714, DOI 10.1038/1412; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; Hasegawa J, 2000, J BIOL CHEM, V275, P37824, DOI 10.1074/jbc.M005861200; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; Jemth P, 2004, P NATL ACAD SCI USA, V101, P6450, DOI 10.1073/pnas.0401732101; Karan EF, 2002, J BIOL INORG CHEM, V7, P260, DOI 10.1007/s007750100292; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9026; Kragelund BB, 1999, NAT STRUCT BIOL, V6, P594; Krantz BA, 2002, J MOL BIOL, V324, P359, DOI 10.1016/S0022-2836(02)01029-X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martinez JC, 1999, NAT STRUCT BIOL, V6, P1010; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; McCallister EL, 2000, NAT STRUCT BIOL, V7, P669, DOI 10.1038/77971; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nishimura C, 2000, NAT STRUCT BIOL, V7, P679, DOI 10.1038/77985; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; Sauder JM, 1998, FOLD DES, V3, P293, DOI 10.1016/S1359-0278(98)00040-6; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Travaglini-Allocatelli C, 2004, TRENDS BIOCHEM SCI, V29, P535, DOI 10.1016/j.tibs.2004.08.004; Travaglini-Allocatelli C, 2003, J BIOL CHEM, V278, P41136, DOI 10.1074/jbc.M303990200; TRAVAGLINIALLOCATE, 1999, J MOL BIOL, V289, P1459; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200	41	64	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25729	25734		10.1074/jbc.M502628200	http://dx.doi.org/10.1074/jbc.M502628200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883159	hybrid			2022-12-25	WOS:000230207900053
J	Gargiulo, L; Longanesi-Cattani, I; Bifulco, K; Franco, P; Raiola, R; Campiglia, P; Grieco, P; Peluso, G; Stoppelli, MP; Carriero, MV				Gargiulo, L; Longanesi-Cattani, I; Bifulco, K; Franco, P; Raiola, R; Campiglia, P; Grieco, P; Peluso, G; Stoppelli, MP; Carriero, MV			Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; CELL-MIGRATION; IN-VITRO; BINDING; CANCER; CLEAVAGE; SYSTEM; UPAR; REORGANIZATION; IDENTIFICATION	The urokinase-type plasminogen activator receptor (uPAR) sustains cell migration through its capacity to promote pericellular proteolysis, regulate integrin function, and mediate chemotactic signaling in response to urokinase. We have characterized the early signaling events triggered by the Ser-Arg-Ser-Arg-Tyr (SRSRY) chemotactic uPAR sequence. Cell exposure to SRSRY peptide promotes directional migration on vitronectin-coated filters, regardless of uPAR expression, in a specific and dose-dependent manner, with maximal effect at a concentration level as low as 10 nM. A similar concentration profile is observed in a quantitative analysis of SRSRY-dependent cytoskeletal rearrangements, mostly consisting of filamentous structures localized in a single cell region. SRSRY analogues with alanine substitutions fail to drive F-actin formation and cell migration, indicating a critical role for each amino acid residue. As with ligand-dependent uPAR signaling, SRSRY stimulates protein kinase C activity and results in ERK1/2 phosphorylation. The involvement of the high affinity N-formyl-Met-Leu-Phe receptor (FPR) in this process is indicated by the finding that 100 nM N-formyl-Met-Leu-Phe inhibits binding of D2D3 to the cell surface, as well as SRSRY-stimulated cell migration and F-actin polarization. Moreover, cell exposure to SRSRY promotes FPR-dependent vitronectin release and increased uPAR center dot alpha v beta 5 vitronectin receptor physical association, indicating that alpha v beta 5 activity is regulated by the SRSRY uPAR sequence via FPR. Finally, we provide evidence that alpha v beta 5 is required for SRSRY-dependent ERK1/2 phosphorylation, whereas it is not required for protein kinase C activation. The data indicate that the ability of uPAR to stimulate cell migration and cytoskeletal rearrangements is retained by the SRSRY peptide alone and that it is supported by cross-talk between FPR and alpha v beta 5.	NCI, Dept Expt Oncol, I-80131 Naples, Italy; Int Inst Genet & Biophys, I-80125 Naples, Italy; Univ Naples Federico II, Dept Pharmaceut Chem & Toxicol, I-80131 Naples, Italy	IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Naples Federico II	Carriero, MV (corresponding author), NCI, Dept Expt Oncol, Via M Semmola, I-80131 Naples, Italy.	mariolina.carriero@fondazionepascale.it	Campiglia, Pietro/J-5625-2018; Franco, Paola/O-5897-2015; Grieco, Paolo/AAB-9034-2019; Carriero, Maria Vincenza/K-1240-2018	Franco, Paola/0000-0002-3289-7284; Grieco, Paolo/0000-0002-6854-8123; Carriero, Maria Vincenza/0000-0002-9768-2997; Campiglia, Pietro/0000-0002-1069-2181; Gargiulo, Lucia/0000-0001-9401-9439				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bae YS, 2003, MOL PHARMACOL, V64, P841, DOI 10.1124/mol.64.4.841; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Carriero MV, 1999, CANCER RES, V59, P5307; Carriero MV, 1997, CLIN CANCER RES, V3, P1299; Carriero MV, 2002, BIOL CHEM, V383, P107, DOI 10.1515/BC.2002.011; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; DELVECCHIO S, 1993, CANCER RES, V53, P3198; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Franco P, 1997, J CELL BIOL, V137, P779, DOI 10.1083/jcb.137.3.779; Furlan F, 2004, J CELL SCI, V117, P2909, DOI 10.1242/jcs.01149; Gellert GC, 2004, BIOCHEM BIOPH RES CO, V315, P1025, DOI 10.1016/j.bbrc.2004.01.163; Hoyer-Hansen G, 2001, BIOCHEM J, V358, P673, DOI 10.1042/0264-6021:3580673; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Kutsuna H, 2004, AM J PHYSIOL-CELL PH, V286, pC55, DOI 10.1152/ajpcell.00131.2003; Montuori N, 2002, J BIOL CHEM, V277, P46932, DOI 10.1074/jbc.M207494200; Mustjoki S, 2000, CANCER RES, V60, P7126; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Sidenius N, 2000, FEBS LETT, V475, P52, DOI 10.1016/S0014-5793(00)01624-0; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Sier CFM, 1999, LAB INVEST, V79, P717; Simon DI, 2000, J BIOL CHEM, V275, P10228, DOI 10.1074/jbc.275.14.10228; Spisani S, 2005, FEBS J, V272, P883, DOI 10.1111/j.1742-4658.2004.04497.x; Stewart JM, 1984, SOLID PHASE PEPTIDE; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wilcox-Adelman SA, 2000, CELL ADHES COMMUN, V7, P477, DOI 10.3109/15419060009040305; Zhang F, 2003, J CELL BIOL, V163, P177, DOI 10.1083/jcb.200304065	40	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25225	25232		10.1074/jbc.M412605200	http://dx.doi.org/10.1074/jbc.M412605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866865	hybrid			2022-12-25	WOS:000230114000108
J	Girnita, L; Shenoy, SK; Sehat, B; Vasilcanu, R; Girnita, A; Lefkowitz, RJ; Larsson, O				Girnita, L; Shenoy, SK; Sehat, B; Vasilcanu, R; Girnita, A; Lefkowitz, RJ; Larsson, O			beta-arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; BETA(2)-ADRENERGIC RECEPTOR; CELL-GROWTH; PROTEIN; P53; GENE; BETA-ARRESTIN-2; DEGRADATION; INHIBITION; EXPRESSION	The insulin-like growth factor-1 receptor ( IGF-1R) plays important roles in physiological growth and aging as well as promoting several crucial functions in cancer cells. However, the molecular mechanisms involved in expression and down- regulation of IGF-1R are still poorly understood. Here we provide evidence that beta-arrestin, otherwise known to be involved in the regulation of G protein- coupled receptors, serves as an adaptor to bring the oncoprotein E3 ubiquitin ligase MDM2 to the IGF-1R. In this way, beta-arrestin acts as a crucial component in the ubiquitination and down-regulation of the receptor. Both MDM2 and beta-arrestin co-immunoprecipitated with the IGF-1R. The beta-arrestin isoform 1 appeared to be more strongly associated with the receptor than isoform 2, and in a molecular context it was 4-fold more efficient in inducing polyubiquitination of IGF-1R, a reaction that required the presence of beta-arrestin and MDM2. Ligand stimulation accelerated IGF-1R ubiquitination. In mouse P6 cells (overexpressing human IGF-1R) absence of beta-arrestin 1, but not of beta-arrestin 2, blocked ubiquitination of IGF-1R. Conversely, in the two studied human melanoma cell lines both beta-arrestin isoforms seemed to be involved in IGF-1R ubiquitination. However, because depletion of beta-arrestin 1 almost completely eliminated degradation, and IGF-1 induced down-regulation of the receptor in these cells, whereas beta-arrestin 2 only had a partial effect, beta-arrestin 1 seems to the more important isoform in affecting the expression of IGF-1R. To our knowledge this is the first study demonstrating a defined molecular role of beta-arrestin with direct relevance to cell growth and cancer.	Karolinska Hosp, Ctr Canc, Dept Oncol & Pathol, Div Cellular & Mol Tumor Pathol, SE-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Duke University; Howard Hughes Medical Institute; Duke University	Larsson, O (corresponding author), Karolinska Hosp, Ctr Canc, Dept Oncol & Pathol, Div Cellular & Mol Tumor Pathol, R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Shenoy, Sudha/AAN-4075-2021; 高, 雨莉/HGU-8187-2022; Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008; Lefkowitz, Robert/AAW-2649-2021	Shenoy, Sudha/0000-0002-2565-4663; Girnita, Leonard/0000-0003-0280-9500; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037, HL 70631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BASERGA R, 1995, CANCER RES, V55, P249; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dupont Joelle, 2003, Birth Defects Research, V69, P257, DOI 10.1002/bdrc.10022; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2002, J CELL SCI, V115, P455; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Shan YX, 2003, J BIOL CHEM, V278, P45492, DOI 10.1074/jbc.M304498200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318	39	125	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24412	24419		10.1074/jbc.M501129200	http://dx.doi.org/10.1074/jbc.M501129200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878855	hybrid			2022-12-25	WOS:000230114000016
J	Glaros, EN; Kim, WS; Quinn, CM; Wong, J; Gelissen, I; Jessup, W; Garner, B				Glaros, EN; Kim, WS; Quinn, CM; Wong, J; Gelissen, I; Jessup, W; Garner, B			Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER A1; APOLIPOPROTEIN-E GENE; LIVER-X-RECEPTOR; PLASMA-MEMBRANE; PROTEIN-KINASE; LIPID EFFLUX; FOAM CELL; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS	Cellular glycosphingolipid (GSL) storage is known to promote cholesterol accumulation. Although physical interactions between GSLs and cholesterol are thought to cause intracellular cholesterol "trapping," it is not known whether cholesterol homeostatic mechanisms are also impaired under these conditions. ApoA-I-mediated cholesterol efflux via ABCA1 (ATP-binding cassette transporter A1) is a key regulator of cellular cholesterol balance. Here, we show that apoA-I-mediated cholesterol efflux was inhibited ( by up to 53% over 8 h) when fibroblasts were treated with lactosylceramide or the glucocerebrosidase inhibitor conduritol B epoxide. Furthermore, apoA-I-mediated cholesterol efflux from fibroblasts derived from patients with genetic GSL storage diseases ( Fabry disease, Sandhoff disease, and GM1 gangliosidosis) was impaired compared with control cells. Conversely, apoA-I-mediated cholesterol efflux from fibroblasts and cholesterol-loaded macrophage foam cells was dose-dependently stimulated ( by up to 6-fold over 8 h) by the GSL synthesis inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol ( PDMP). Unexpectedly, a structurally unrelated GSL synthesis inhibitor, N-butyldeoxynojirimycin, was unable to stimulate apoA-I-mediated cholesterol efflux despite achieving similar GSL depletion. PDMP was found to up-regulate ABCA1 mRNA and protein expression, thereby identifying a contributing mechanism for the observed acceleration of cholesterol efflux to apoA-I. This study reveals a novel defect in cellular cholesterol homeostasis induced by GSL storage and identifies PDMP as a new agent for enhancing cholesterol efflux via the ABCA1/apoA-I pathway.	Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Garner, B (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Sydney, NSW 2052, Australia.	brett.garner@unsw.edu.au						BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Blom TS, 2001, BIOCHEMISTRY-US, V40, P14635, DOI 10.1021/bi0156714; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BRECKENRIDGE WC, 1975, LIPIDS, V10, P256, DOI 10.1007/BF02532490; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; Cenarro A, 1999, LANCET, V353, P642, DOI 10.1016/S0140-6736(99)00188-9; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; FIELDING CJ, 1982, J BIOL CHEM, V257, P955; Garner B, 2002, J LIPID RES, V43, P205; Garner B, 2001, J BIOL CHEM, V276, P22200, DOI 10.1074/jbc.M102150200; Garner B, 1997, FREE RADICAL RES, V27, P487, DOI 10.3109/10715769709065788; GARNER B, 1994, BIOCHEM J, V301, P421, DOI 10.1042/bj3010421; Garner B, 2002, BIOCHEM BIOPH RES CO, V290, P1361, DOI 10.1006/bbrc.2002.6356; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Higgins CF, 2004, NAT STRUCT MOL BIOL, V11, P918, DOI 10.1038/nsmb836; Ito J, 2000, J LIPID RES, V41, P894; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Liu SM, 2003, J LIPID RES, V44, P1156, DOI 10.1194/jlr.M200464-JLR200; Lusa S, 2001, J CELL SCI, V114, P1893; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; McGovern MM, 2004, J PEDIATR-US, V145, P77, DOI 10.1016/j.jpeds.2004.02.048; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Ohvo H, 1997, BBA-LIPID LIPID MET, V1349, P131, DOI 10.1016/S0005-2760(97)00126-4; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Quinn CM, 2004, BIOCHEM J, V378, P753, DOI 10.1042/BJ20031352; Rader DJ, 2003, AM J CARDIOL, V92, p42J, DOI 10.1016/S0002-9149(03)00615-5; Radin N S, 1981, Methods Enzymol, V72, P673; RADIN NS, 1993, ADV LIPID RES, V26, P183; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Roosbeek S, 2004, J BIOL CHEM, V279, P37779, DOI 10.1074/jbc.M401821200; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Vruchte DT, 2004, J BIOL CHEM, V279, P26167, DOI 10.1074/jbc.M311591200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wing DR, 2001, ANAL BIOCHEM, V298, P207, DOI 10.1006/abio.2001.5393; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Wong J, 2004, ARTERIOSCL THROM VAS, V24, P2365, DOI 10.1161/01.ATV.0000148707.93054.7d; Yamauchi Y, 2004, J LIPID RES, V45, P1943, DOI 10.1194/jlr.M400264-JLR200; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	62	55	61	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24515	24523		10.1074/jbc.M413862200	http://dx.doi.org/10.1074/jbc.M413862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15890646	hybrid			2022-12-25	WOS:000230114000028
J	Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W				Krepulat, F; Lohler, J; Heinlein, C; Hermannstadter, A; Tolstonog, GV; Deppert, W			Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice	ONCOGENE			English	Article						transgenic mice; whey acidic protein ( WAP) promoter; mutant p53; mammary carcinoma; SV40 T- antigen; epigenetics	LARGE T-ANTIGEN; PROTEIN GENE PROMOTER; MATRIX-ATTACHMENT REGIONS; BREAST-CANCER PATIENTS; MAMMARY-GLAND; VALPROIC ACID; MOUSE MODEL; CELL-DIFFERENTIATION; TUMOR-SUPPRESSOR; HYBRID GENE	We describe the construction and phenotypic characterization of 23 whey acidic protein (WAP)-mutp53 transgenic mouse lines. The mutp53-expressing lines showed a mosaic expression pattern for the transgenes, leading to a heterogeneous yet mouse line-specific expression pattern for mutp53 upon induction. Only fewlines were obtained, in which the majority of the induced mammary epithelial cells expressed the mutp53 transgene, most of the transgenic lines did not express mutp53, or expressed the transgene in less than 2% of the induced mammary epithelial cells. Hormone requirements for mutp53 transgene expression from the WAP-promoter differed in high and lowexpressing lines, being low in high expressing lines, and even lower in multiparous mutp53 mice, where persistent expression of the transgene occurred. Repeated induction of mutp53 expression through repeated parturition resulted in the formation of expanding mutp53-expressing foci within the mammary alveolar epithelium. The data suggest that epigenetic mechanisms play a role in modulating the expression of the mutp53 transgene. To support this idea, we crossed a nonexpressing WAP-mutp53 line with a strongly SV40 T-antigen-expressing WAP-T mouse line. In the bitransgenic mice, T-antigen-induced chromatin remodeling led to re-expression of epigenetically silenced mutp53 transgene(s). In these mice, mutp53 expression was much more variable compared to SV40 T-antigen expression, and seemed to depend on the coexpression of SV40 T-antigen. Mutp53 expression in this system thus resembles the situation in many human tumors, where one can observe a heterogeneous expression of mutp53, despite a homogeneous distribution of the p53 mutation in the tumor cells.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartoli A, 2003, PHARMACOL RES, V48, P111, DOI 10.1016/S1043-6618(03)00079-3; Borresen-Dale AL, 2003, HUM MUTAT, V21, P292, DOI 10.1002/humu.10174; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BURDON T, 1991, J BIOL CHEM, V266, P6909; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; DEPPERT W, 1979, J VIROL, V31, P522, DOI 10.1128/JVI.31.2.522-536.1979; Deppert W, 2000, J CELL BIOCHEM, P115; Ebina M, 2001, ONCOGENE, V20, P2579, DOI 10.1038/sj.onc.1204351; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FELIX CA, 1993, ONCOGENE, V8, P1203; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOH HS, 1995, CANCER RES, V55, P5217; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Hanash S, 2004, NAT REV CANCER, V4, P638, DOI 10.1038/nrc1414; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; HOGAN B, 1986, MANIPULATING MOUSE E; HORIO Y, 1994, ONCOGENE, V9, P1231; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Jiao JF, 2003, J VIROL, V77, P12720, DOI 10.1128/JVI.77.23.12720-12728.2003; Klawitz I, 2001, INT J ONCOL, V19, P1325; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KRNACIK MJ, 1995, J BIOL CHEM, V270, P11119, DOI 10.1074/jbc.270.19.11119; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lazar H, 2000, INT J CANCER, V85, P578, DOI 10.1002/(SICI)1097-0215(20000215)85:4<578::AID-IJC21>3.0.CO;2-S; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; LI S, 1994, J BIOL CHEM, V269, P14235; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MCKNIGHT RA, 1995, TRANSGENIC RES, V4, P39, DOI 10.1007/BF01976500; McKnight RA, 1996, MOL REPROD DEV, V44, P179, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;179::AID-MRD6&gt;3.0.CO;2-K; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHIRMBECK R, 1991, J VIROL, V65, P2578, DOI 10.1128/JVI.65.5.2578-2588.1991; SCHMITT MK, 1987, VIROLOGY, V156, P268, DOI 10.1016/0042-6822(87)90407-7; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; Seinsoth S, 2003, EMBO REP, V4, P263, DOI 10.1038/sj.embor.embor770; Sherr CJ, 2000, CANCER RES, V60, P3689; Sigal A, 2000, CANCER RES, V60, P6788; Simmons DT, 2004, NUCLEIC ACIDS RES, V32, P1103, DOI 10.1093/nar/gkh236; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; TIEMANN F, 1994, ONCOGENE, V9, P1907; Tolstonog GV, 2000, DNA CELL BIOL, V19, P647, DOI 10.1089/10445490050199054; TZENG YJ, 1993, ONCOGENE, V8, P1965; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Zgouras D, 2004, BIOCHEM BIOPH RES CO, V316, P693, DOI 10.1016/j.bbrc.2004.02.105; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou Q, 2002, BREAST CANCER RES TR, V75, P107, DOI 10.1023/A:1019698807564	64	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4645	4659		10.1038/sj.onc.1208557	http://dx.doi.org/10.1038/sj.onc.1208557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870706				2022-12-25	WOS:000230304500004
J	Ondrovicova, G; Liu, T; Singh, K; Tian, B; Li, H; Gakh, O; Perecko, D; Janata, J; Granot, Z; Orly, J; Kutejova, E; Suzuki, CK				Ondrovicova, G; Liu, T; Singh, K; Tian, B; Li, H; Gakh, O; Perecko, D; Janata, J; Granot, Z; Orly, J; Kutejova, E; Suzuki, CK			Cleavage site selection within a folded substrate by the ATP-dependent lon protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROCESSING PEPTIDASE; PARAPLEGIN-RELATED GENE; DEGRADATION MACHINE; CLPP PROTEASE; ALPHA-SUBUNIT; AAA PROTEASES; PIM1 PROTEASE; DNA-BINDING; PROTEINS; PROTEOLYSIS	Mechanistic studies of ATP-dependent proteolysis demonstrate that substrate unfolding is a prerequisite for processive peptide bond hydrolysis. We show that mitochondrial Lon also degrades folded proteins and initiates substrate cleavage non-processively. Two mitochondrial substrates with known or homology-derived three-dimensional structures were used: the mitochondrial processing peptidase alpha-subunit (MPP alpha) and the steroidogenic acute regulatory protein (StAR). Peptides generated during a time course of Lon-mediated proteolysis were identified and mapped within the primary, secondary, and tertiary structure of the substrate. Initiating cleavages occurred preferentially between hydrophobic amino acids located within highly charged environments at the surface of the folded protein. Subsequent cleavages proceeded sequentially along the primary polypeptide sequence. We propose that Lon recognizes specific surface determinants or folds, initiates proteolysis at solvent-accessible sites, and generates unfolded polypeptides that are then processively degraded.	Slovak Acad Sci, Inst Mol Biol, Bratislava 84551, Slovakia; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Slovak Academy of Sciences; Rutgers State University New Brunswick; Rutgers State University Medical Center; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Hebrew University of Jerusalem	Kutejova, E (corresponding author), Slovak Acad Sci, Inst Mol Biol, Dubravska Cesta 21, Bratislava 84551, Slovakia.	Eva.Kutejova@savba.sk; suzukick@umdnj.edu	Kutejova, Eva/AAI-2544-2021; Kutejova, Eva/K-6550-2014; Janata, Jiri/K-4554-2014	Kutejova, Eva/0000-0002-0973-679X; Kutejova, Eva/0000-0002-0973-679X; Janata, Jiri/0000-0002-4582-2062; Tian, Bin/0000-0001-8903-8256; Li, Hong/0000-0001-5731-5335				Ahnert P, 2000, EMBO J, V19, P3418, DOI 10.1093/emboj/19.13.3418; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Botos I, 2004, J BIOL CHEM, V279, P8140, DOI 10.1074/jbc.M312243200; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Coppola M, 2000, GENOMICS, V66, P48, DOI 10.1006/geno.2000.6136; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Gakh O, 2001, ARCH BIOCHEM BIOPHYS, V385, P392, DOI 10.1006/abbi.2000.2167; GELI V, 1990, J BIOL CHEM, V265, P19216; Gonzalez M, 1998, GENE DEV, V12, P3889, DOI 10.1101/gad.12.24.3889; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Janata J, 2004, BIOCHEM BIOPH RES CO, V316, P211, DOI 10.1016/j.bbrc.2004.02.025; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Neuwald AF, 1999, GENOME RES, P927; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Prakash S, 2004, TRENDS BIOCHEM SCI, V29, P593, DOI 10.1016/j.tibs.2004.09.011; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Strauss JF, 2003, MOL CELL ENDOCRINOL, V202, P59, DOI 10.1016/S0303-7207(03)00063-7; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; Varshavsky A, 2003, NAT CELL BIOL, V5, P373, DOI 10.1038/ncb0503-373; Varshavsky A, 2000, Harvey Lect, V96, P93; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Withey JH, 2003, ANNU REV MICROBIOL, V57, P101, DOI 10.1146/annurev.micro.57.030502.090945	60	86	95	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25103	25110		10.1074/jbc.M502796200	http://dx.doi.org/10.1074/jbc.M502796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870080	hybrid			2022-12-25	WOS:000230114000094
J	Philipova, R; Larman, MG; Leckie, CP; Harrison, PK; Groigno, L; Whitaker, M				Philipova, R; Larman, MG; Leckie, CP; Harrison, PK; Groigno, L; Whitaker, M			Inhibiting MAP kinase activity prevents calcium transients and mitosis entry in early sea urchin embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; NUCLEAR-ENVELOPE BREAKDOWN; INTRACELLULAR FREE CALCIUM; XENOPUS EGG EXTRACTS; CELL-CYCLE CONTROL; CHROMOSOME CONDENSATION; MAMMALIAN-CELLS; TYROSINE PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; MITOTIC PROGRESSION	A transient calcium increase triggers nuclear envelope breakdown (mitosis entry) in sea urchin embryos. Cdk1/cyclin B kinase activation is also known to be required for mitosis entry. More recently, MAP kinase activity has also been shown to increase during mitosis. In sea urchin embryos, both kinases show a similar activation profile, peaking at the time of mitosis entry. We tested whether the activity of both kinases is required for mitosis entry and whether either kinase controls mitotic calcium signals. We found that reducing the activity of either mitotic kinase prevents nuclear envelope breakdown, despite the presence of a calcium transient, when cdk1/cyclin B kinase activity is alone inhibited. When MAP kinase activity alone was inhibited, the calcium signal was absent, suggesting that MAP kinase activity is required to generate the calcium transient that triggers nuclear envelope breakdown. However, increasing intracellular free calcium by microinjection of calcium buffers or InsP(3) while MAP kinase was inhibited did not itself induce nuclear envelope breakdown, indicating that additional MAP kinase-regulated events are necessary. After MAP kinase inhibition early in the cell cycle, the early events of the cell cycle (pronuclear migration/fusion and DNA synthesis) were unaffected, but chromosome condensation and spindle assembly are prevented. These data indicate that in sea urchin embryos, MAP kinase activity is part of a signaling complex alongside two components previously shown to be essential for entry into mitosis: the calcium transient and the increase in cdk1/cyclinB kinase activity.	Univ Newcastle Upon Tyne, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	michael.whitaker@ncl.ac.uk			Wellcome Trust [080374] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, ONCOGENE, V8, P2015; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Becchetti A, 1997, DEVELOPMENT, V124, P1099; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; Carroll DJ, 2000, DEV BIOL, V217, P179, DOI 10.1006/dbio.1999.9526; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Chiri S, 1998, J CELL SCI, V111, P2519; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DOCOMMUN B, 1991, EMBO J, V11, P3311; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EDGECOMBE M, 1991, EMBO J, V10, P3769, DOI 10.1002/j.1460-2075.1991.tb04946.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HOSHI M, 1992, EUR J BIOCHEM, V203, P43, DOI 10.1111/j.1432-1033.1992.tb19825.x; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Kono T, 1996, J CELL BIOL, V132, P915, DOI 10.1083/jcb.132.5.915; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kumano M, 2001, DEV BIOL, V236, P244, DOI 10.1006/dbio.2001.0328; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LARSSON N, 1995, J BIOL CHEM, V270, P14174; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LEWIS T, 1995, J CELL SCI, V108, P2885; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MOUDRIANAKIS EN, 1993, COLD SPRING HARB SYM, V58, P273, DOI 10.1101/SQB.1993.058.01.032; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; NISHIOKA D, 1984, CELL BIOL INT REP, V8, P337, DOI 10.1016/0309-1651(84)90161-9; Olsen MK, 1998, J CELL PHYSIOL, V176, P525, DOI 10.1002/(SICI)1097-4652(199809)176:3<525::AID-JCP9>3.0.CO;2-Q; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Philipova R, 2005, DEVELOPMENT, V132, P579, DOI 10.1242/dev.01607; Philipova R, 1998, J CELL SCI, V111, P2497; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SCHATTEN G, 1982, J CELL BIOL, V94, P455, DOI 10.1083/jcb.94.2.455; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Shearer J, 1999, DEVELOPMENT, V126, P2273; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STRAIGHT AF, SCIENCE, V299, P1743; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; Swanson CA, 1997, P NATL ACAD SCI USA, V94, P1194, DOI 10.1073/pnas.94.4.1194; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; WANG XM, 1997, J CELL BIOL, V137; Whitaker M, 2001, SEMIN CELL DEV BIOL, V12, P53, DOI 10.1006/scdb.2000.0217; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yue JB, 2004, CURR BIOL, V14, P1581, DOI 10.1016/j.cub.2004.08.056	80	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24957	24967		10.1074/jbc.M414437200	http://dx.doi.org/10.1074/jbc.M414437200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15843380	Green Accepted, hybrid			2022-12-25	WOS:000230114000080
J	Pradhan, A; Liu, YC				Pradhan, A; Liu, YC			A multifunctional domain of the calcium-responsive transactivator (CREST) that inhibits dendritic growth in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; PROTEINS; GENES; SYT	The calcium-responsive transactivator ( CREST) is targeted to nuclear bodies and is required for the normal development of neuronal dendritic trees. Here we report the identification of a multifunctional domain (MFD) of CREST that is involved in transcription trans-activation, nuclear body targeting, and dimerization. MFD is located near the C terminus of CREST from amino acid 251 to 322 and is required and sufficient for CREST homodimerization. When fused with a GAL4 DNA-binding domain, MFD was effective in transcription transactivation of a luciferase reporter system. A C-terminal 339-401 amino acid sequence of CREST was shown to contain a nuclear localization signal (NLS), which was able to direct a yellow fluorescence protein (YFP) to nucleus. A CREST deletion mutant containing both the MFD and NLS, which spanned the C-terminal amino acid sequence 251-401, was able to target YFP to the nucleus and nuclear bodies. However, MFD alone failed to target YFP and was largely cytosolic. The addition of a SV40 NLS to MFD domain restored nuclear body targeting. When YFP-MFD was expressed in cultured rat embryonic cortical neurons, it was effective in inhibiting depolarization-induced dendritic growth, suggesting that CREST dimerization may be necessary for its function in neuronal dendritic development.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Liu, YC (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, POB 26901, Oklahoma City, OK 73190 USA.	yuechueng-liu@ouhsc.edu						Aizawa H, 2004, SCIENCE, V303, P197, DOI 10.1126/science.1089845; BROWN PH, 1993, ONCOGENE, V8, P877; Gorbunova YV, 2002, NATURE, V418, P93, DOI 10.1038/nature00835; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Kandel ER, 2001, BIOSCIENCE REP, V21, P565, DOI 10.1023/A:1014775008533; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1994, J NEUROSCI, V14, P5807; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Pham TA, 2001, NEURON, V31, P409, DOI 10.1016/S0896-6273(01)00381-6; Pradhan A, 2004, NEUROSCI LETT, V370, P191, DOI 10.1016/j.neulet.2004.08.062; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	15	6	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24738	24743		10.1074/jbc.M504018200	http://dx.doi.org/10.1074/jbc.M504018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866867	hybrid			2022-12-25	WOS:000230114000055
J	Rodda, DJ; Chew, JL; Lim, LH; Loh, YH; Wang, B; Ng, HH; Robson, P				Rodda, DJ; Chew, JL; Lim, LH; Loh, YH; Wang, B; Ng, HH; Robson, P			Transcriptional regulation of Nanog by Oct4 and Sox2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; MOUSE DEVELOPMENT; SELF-RENEWAL; ES CELLS; PLURIPOTENCY; EXPRESSION; COMPLEX; GENE; OCT-3/4; IDENTIFICATION	Nanog, Sox2, and Oct4 are transcription factors all essential to maintaining the pluripotent embryonic stem cell phenotype. Through a cooperative interaction, Sox2 and Oct4 have previously been described to drive pluripotent-specific expression of a number of genes. We now extend the list of Sox2-Oct4 target genes to include Nanog. Within the Nanog proximal promoter, we identify a composite sox-oct cis-regulatory element essential for Nanog pluripotent transcription. This element is conserved over 250 million years of cumulative evolution within the eutherian mammals. A Nanog proximal promoter-EGFP ( enhanced green fluorescent protein) reporter transgene recapitulates endogenous Nanog mRNA expression in embryonic stem cells and their differentiated derivatives. Sox2 and Oct4 interaction with the Nanog promoter was confirmed through mutagenesis and in vitro binding assays. Electrophoretic mobility shift assays indicate that the Sox2-Oct4 heterodimer forms more efficiently on the composite element within Nanog than the similar element within Fgf4. Using chromatin immunoprecipitation, we show that Oct4 and Sox2 bind to the Nanog promoter in living mouse and human embryonic stem cells. Furthermore, by specific knockdown of Oct4 and Sox2 mRNA by RNA interference in embryonic stem cells, we provide genetic evidence for a link between Oct4, Sox2, and the Nanog promoter. These studies extend the understanding of the pluripotent genetic regulatory network within which the Sox2-Oct4 complex are at the top of the regulatory hierarchy.	Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Robson, P (corresponding author), Genome Inst Singapore, Gene Regulat Lab, 60 Biopolis St 02-01,Genome Bldg, Singapore 138672, Singapore.	robsonp@gis.a-star.edu.sg	Robson, Paul/A-3464-2009; Ng, Huck Hui/A-1135-2009; Loh, Yuin-Han/E-1096-2014	Robson, Paul/0000-0002-0191-3958; Loh, Yuin-Han/0000-0002-4715-6454				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHEW JL, 2005, IN PRESS MOL CELL BI; CHISHOLM JC, 1985, J EMBRYOL EXP MORPH, V86, P311; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Hart AH, 2004, DEV DYNAM, V230, P187, DOI 10.1002/dvdy.20034; Hatano S, 2005, MECH DEVELOP, V122, P67, DOI 10.1016/j.mod.2004.08.008; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; ROSSANT J, 1980, DEV BIOL, V76, P475, DOI 10.1016/0012-1606(80)90395-4; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Wang SH, 2003, GENE EXPR PATTERNS, V3, P99, DOI 10.1016/S1567-133X(03)00005-X; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	28	793	852	2	78	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24731	24737		10.1074/jbc.M502573200	http://dx.doi.org/10.1074/jbc.M502573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15860457	hybrid			2022-12-25	WOS:000230114000054
J	Sung, JY; Park, SM; Lee, CH; Um, JW; Lee, HJ; Kim, J; Oh, YJ; Lee, ST; Paik, SR; Chung, KC				Sung, JY; Park, SM; Lee, CH; Um, JW; Lee, HJ; Kim, J; Oh, YJ; Lee, ST; Paik, SR; Chung, KC			Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; PRECURSOR PROTEIN; BRAIN; EXPRESSION; MUTATION; MMP-9; ACTIVATION; INHIBITOR; NITRATION	Although alpha-synuclein is the main structural component of the insoluble filaments that form Lewy bodies in Parkinson disease (PD), its physiological function and exact role in neuronal death remain poorly understood. In the present study, we examined the possible functional relationship between alpha-synuclein and several forms of matrix metalloproteinases ( MMPs) in the human dopaminergic neuroblastoma (SK-N-BE) cell line. When SK-N-BE cells were transiently transfected with alpha-synuclein, it was secreted into the extracellular culture media, concomitantly with a significant decrease in cell viability. Also the addition of nitric oxide-generating compounds to the cells caused the secreted alpha-synuclein to be digested, producing a small fragment whose size was similar to that of the fragment generated during the incubation of alpha-synuclein with various MMPs in vitro. Among several forms of MMPs, alpha-synuclein was cleaved most efficiently by MMP-3, and MALDI-TOF mass spectra analysis showed that alpha-synuclein is cleaved from its C-terminal end with at least four cleavage sites within the non-A beta component of AD amyloid sequence. Compared with the intact form, the protein aggregation of alpha-synuclein was remarkably facilitated in the presence of the proteolytic fragments, and the fragment-induced aggregates showed more toxic effect on cell viability. Moreover, the levels of MMP-3 were also found to be increased significantly in the rat PD brain model produced by the cerebral injection of 6-hydroxydopamine into the substantia nigra. The present study suggests that the extracellularly secreted alpha-synuclein could be processed via the activation of MMP-3 in a selective manner.	Seoul Natl Univ, Coll Engn, Sch Chem & Biol Engn, Seoul 151744, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Seoul National University (SNU); Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Rockefeller University	Paik, SR (corresponding author), Seoul Natl Univ, Coll Engn, Sch Chem & Biol Engn, Seoul 151744, South Korea.	srpaik@snu.ac.kr; kchung@yonsei.ac.kr		Lee, Seung-Taek/0000-0001-7300-9784				Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; FOLLETT MJ, 1963, J SCI FOOD AGR, V14, P138, DOI 10.1002/jsfa.2740140302; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jia TL, 1999, CANCER RES, V59, P742; Jo Y, 1999, J BIOCHEM MOL BIOL, V32, P60; Kim J, 1997, MOL CELLS, V7, P78; Kim SJ, 2003, J BIOL CHEM, V278, P41890, DOI 10.1074/jbc.M306017200; Koo HM, 2002, MOL CELLS, V13, P118; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Leake A, 2000, NEUROSCI LETT, V291, P201, DOI 10.1016/S0304-3940(00)01418-X; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; Monji A, 1998, BRAIN RES, V796, P171, DOI 10.1016/S0006-8993(98)00342-4; MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15, DOI 10.1006/bbrc.1995.1003; NAKAJO S, 1994, MOL BRAIN RES, V27, P81, DOI 10.1016/0169-328X(94)90187-2; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RIES C, 1995, BIOL CHEM H-S, V376, P345; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Surgucheva IG, 2003, ARCH BIOCHEM BIOPHYS, V410, P167, DOI 10.1016/S0003-9861(02)00664-1; Tamura T, 1996, ENDOCRINOLOGY, V137, P3729, DOI 10.1210/en.137.9.3729; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; UNGERSTEDT U, 1970, Brain Research, V24, P485, DOI 10.1016/0006-8993(70)90187-3; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; Yoshiyama Y, 2000, ACTA NEUROPATHOL, V99, P91, DOI 10.1007/PL00007428	55	186	191	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25216	25224		10.1074/jbc.M503341200	http://dx.doi.org/10.1074/jbc.M503341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863497	hybrid			2022-12-25	WOS:000230114000107
J	Ambrosio, C; Molinari, P; Fanelli, F; Chuman, Y; Sbraccia, M; Ugur, O; Costa, T				Ambrosio, C; Molinari, P; Fanelli, F; Chuman, Y; Sbraccia, M; Ugur, O; Costa, T			Different structural requirements for the constitutive and the agonist-induced activities of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA FUSION PROTEINS; ADRENERGIC-RECEPTOR; LIGAND-BINDING; ACTIVATION; SERINE; RHODOPSIN; RESIDUES; EFFICACY; AFFINITY; THREONINE	We converted Ser-207, located in helix 5 of the beta(2)-adrenergic receptor, into all other natural amino acids. To quantify receptor activation as a receptor number-independent parameter and directly related to G(s) activation, we expressed the mutants in a G alpha(s)-tethered form. GTP exchange in such constructs is restricted to the fused alpha-subunit and is a linear function of the receptor concentration. Except S207R, all other mutants were expressed to a suitable level for investigation. All mutations reduced the binding affinities of the catechol agonists, epinephrine and isoproterenol, and the extent of reduction was unrelated to the residue ability to form hydrogen bonds. Instead, both enhancements and reductions of affinity were observed for the partial agonist halostachin and the antagonist pindolol. The mutations also enhanced and diminished ligand-induced receptor activation, but the effects were strictly ligand-specific. Polar residues such as Asp and His exalted the activation by full agonists but suppressed that induced by the partial agonists halostachin and dichloroisoproterenol. In contrast, hydrophobic residues such as Ile and Val augmented partial agonist activation. Only Ile and Lys produced a significant increase of constitutive activity. The effects on binding and activity were not correlated, nor did such parameters show any clear correlation with up to 78 descriptors of amino acid physicochemical properties. Our data question the idea that Ser-207 is exposed to the polar crevice in the unbound receptor. They also suggest that the active receptor form induced by a full agonist might be substantially different from that caused by constitutive activation.	Ist Super Sanita, Dept Pharmacol, I-00161 Rome, Italy; Univ Modena, Dulbecco Telethon Inst, I-41100 Modena, Italy; Univ Modena, Dept Chem, I-41100 Modena, Italy; Kyushu Univ, Dept Chem, Lab Struct Funct Biochem, Fukuoka, Japan; Ankara Univ, Dept Pharmacol, TR-06339 Ankara, Turkey	Istituto Superiore di Sanita (ISS); Fondazione Telethon; Dulbecco Telethon Institute (DTI); Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Kyushu University; Ankara University	Costa, T (corresponding author), Ist Super Sanita, Dept Pharmacol, Viale Regina Elena 229, I-00161 Rome, Italy.	tomcosta@iss.it	Ugur, Özlem/J-3169-2019; costa, tommaso/AAD-3714-2019; Fanelli, Francesca/O-8807-2014; ambrosio, caterina/M-7952-2017	Ugur, Özlem/0000-0002-5404-5242; costa, tommaso/0000-0002-8729-3357; Fanelli, Francesca/0000-0002-7620-6895; ambrosio, caterina/0000-0002-0807-9003; molinari, paola/0000-0002-8454-0121; Chuman, Yoshiro/0000-0003-4995-3542	Telethon [TCP00068] Funding Source: Medline	Telethon(Fondazione Telethon)		Ambrosio C, 2000, MOL PHARMACOL, V57, P198; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHARTON M, 1990, PROG PHYS ORG CHEM, V18, P163; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Del Carmine R, 2004, MOL PHARMACOL, V66, P356, DOI 10.1124/mol.66.2.356; Del Carmine R, 2002, BRIT J PHARMACOL, V135, P1715, DOI 10.1038/sj.bjp.0704622; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Deupi X, 2004, BIOPHYS J, V86, P105, DOI 10.1016/S0006-3495(04)74088-6; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; ERIKSSON L, 1988, QUANT STRUCT-ACT REL, V7, P144, DOI 10.1002/qsar.19880070305; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Kenakin T, 2002, TRENDS PHARMACOL SCI, V23, P275, DOI 10.1016/S0165-6147(02)02036-9; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Lazaridis T, 2003, PROTEINS, V52, P176, DOI 10.1002/prot.10410; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; MANAVALAN P, 1978, NATURE, V275, P673, DOI 10.1038/275673a0; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Molinari P, 2003, J BIOL CHEM, V278, P15778, DOI 10.1074/jbc.M300731200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NODA K, 1994, J BIOL CHEM, V269, P6743; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sato T, 1999, BRIT J PHARMACOL, V128, P272, DOI 10.1038/sj.bjp.0702813; Seeber M, 2003, J CHEM INF COMP SCI, V43, P1520, DOI 10.1021/ci034069c; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	42	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23464	23474		10.1074/jbc.M502901200	http://dx.doi.org/10.1074/jbc.M502901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845544	hybrid			2022-12-25	WOS:000229880000009
J	Ben-Shlomo, A; Wawrowsky, KA; Proekt, I; Wolkenfeld, NM; Ren, SG; Taylor, J; Culler, MD; Melmed, S				Ben-Shlomo, A; Wawrowsky, KA; Proekt, I; Wolkenfeld, NM; Ren, SG; Taylor, J; Culler, MD; Melmed, S			Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LINE ATT-20; ANTERIOR-PITUITARY-CELLS; GROWTH-HORMONE; INTRACELLULAR CALCIUM; PHARMACOLOGICAL CHARACTERIZATION; CA2+ OSCILLATIONS; ADENYLATE-CYCLASE; CYTOSOLIC CA-2+; TUMOR CELLS; COS-7 CELLS	Somatostatin inhibits adrenocorticotropin ( ACTH) secretion from pituitary tumor cells. To assess the contribution of somatostatin receptor subtype 5 (SST5) to somatostatin receptor subtype 2 ( SST2) action in these cells, we assessed multipathway responses to novel highly monoreceptor-selective peptide agonists and multireceptor agonists, including octreotide and somatostatin-28. Octreotide and somatostatin-28 cell membrane binding affinities correlated with their respective SST2-selective peptide ligand. Although octreotide had similar inhibiting potency (picomolar) for cAMP accumulation and ACTH secretion as an SST2-selective agonist, somatostatin-28 exhibited a higher potency (femtomolar). Baseline spontaneous calcium oscillations assessed by fluorescent confocal microscopy revealed two distinct effects: SST2 activation reduced oscillations at femtomolar concentrations reflected by high inhibiting potency of averaged normalized oscillation amplitude, whereas SST5 activation induces brief oscillation pauses and increased oscillation amplitude. Octreotide exhibits an integrated effect of both receptors; however, somatostatin-28 exhibited a complex response with two separate inhibitory potencies. SST2 internalization was visualized with SST2-selective agonist at lower concentrations than for octreotide or somatostatin-28, whereas SST5 did not internalize. Using monoreceptor-selective peptide agonists, the results indicate that, in AtT-20 cells, SST5 regulates the dominant SST2 action, attenuating SST2 effects on intracellular calcium oscillation and internalization. This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors.	Univ Calif Los Angeles, Cedars Sinai Res Inst, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA; Biomeasure Inc, Milford, MA 01757 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ben-Shlomo, A (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Rm 2015, Los Angeles, CA 90048 USA.	Melmed@csmc.edu	Ben-Shlomo, Anat/AAH-6009-2021	Culler, Michael D./0000-0001-5168-8739				ADLER M, 1989, CELL CALCIUM, V10, P467, DOI 10.1016/0143-4160(89)90024-9; Bonnefont X, 2000, ENDOCRINOLOGY, V141, P868, DOI 10.1210/en.141.3.868; Boudin H, 2000, J NEUROSCI, V20, P5932, DOI 10.1523/JNEUROSCI.20-16-05932.2000; Cervia D, 2003, BRIT J PHARMACOL, V139, P109, DOI 10.1038/sj.bjp.0705235; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; Chen CR, 2001, J BIOL CHEM, V276, P14767, DOI 10.1074/jbc.M008001200; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Feuerbach D, 2000, NEUROPHARMACOLOGY, V39, P1451, DOI 10.1016/S0028-3908(00)00063-0; Fiekers JF, 1996, CELL CALCIUM, V19, P327, DOI 10.1016/S0143-4160(96)90073-1; Filipsson K, 1998, REGUL PEPTIDES, V74, P167, DOI 10.1016/S0167-0115(98)00037-8; GILL DL, 2004, SCI STKE, pPE39, DOI DOI 10.1126/ST5E.2432004PE39; Goddard H, 2000, P NATL ACAD SCI USA, V97, P1932, DOI 10.1073/pnas.020516397; HEIMAN ML, 1985, AM J PHYSIOL, V249, pE380, DOI 10.1152/ajpendo.1985.249.4.E380; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Hofland LJ, 2004, FRONT HORM RES, V32, P235; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; JOHANSSON O, 1987, MED BIOL, V65, P57; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; Kiang JG, 1997, EUR J PHARMACOL, V329, P237, DOI 10.1016/S0014-2999(97)00165-9; Knight MM, 2003, AM J PHYSIOL-CELL PH, V284, pC1083, DOI 10.1152/ajpcell.00276.2002; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3916, DOI 10.1210/en.136.9.3916; Kwiecien R, 1998, NEUROENDOCRINOLOGY, V68, P135, DOI 10.1159/000054360; Labeur M., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P335, DOI 10.2174/1568008043339703; LAMBERTS SW, 1989, NEUROENDOCRINOLOGY, V50, P44, DOI 10.1159/000125200; LITVIN Y, 1986, ENDOCRINOLOGY, V119, P737, DOI 10.1210/endo-119-2-737; Liu QS, 2001, J BIOL CHEM, V276, P3709, DOI 10.1074/jbc.M008873200; Martin MT, 2004, NEUROGASTROENT MOTIL, V16, P175, DOI 10.1111/j.1365-2982.2004.00518.x; MASUMOTO N, 1995, CELL CALCIUM, V18, P223, DOI 10.1016/0143-4160(95)90067-5; Maturana A, 2002, J BIOL CHEM, V277, P39713, DOI 10.1074/jbc.M200464200; Mezer A, 2004, J NEUROSCI, V24, P8838, DOI 10.1523/JNEUROSCI.2815-04.2004; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Murray F, 2001, J CARDIOVASC PHARM, V37, P324, DOI 10.1097/00005344-200103000-00011; Nieman Lynnette K, 2002, Pituitary, V5, P77, DOI 10.1023/A:1022308429992; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; Ren SG, 2003, J CLIN ENDOCR METAB, V88, P4239, DOI 10.1210/jc.2003-030303; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; Sarret P, 1999, J BIOL CHEM, V274, P19294, DOI 10.1074/jbc.274.27.19294; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; Schonbrunn A, 1999, ANN ONCOL, V10, pS17, DOI 10.1093/annonc/10.suppl_2.S17; Shimon I, 1997, J CLIN INVEST, V99, P789, DOI 10.1172/JCI119225; Shimon I, 1997, J CLIN INVEST, V100, P2386, DOI 10.1172/JCI119779; Siehler S, 1999, N-S ARCH PHARMACOL, V360, P488, DOI 10.1007/s002109900141; SPADA A, 1990, J CLIN ENDOCR METAB, V70, P1262, DOI 10.1210/jcem-70-5-1262; SRIKANT CB, 1985, ENDOCRINOLOGY, V117, P271, DOI 10.1210/endo-117-1-271; Stroh T, 2000, ENDOCRINOLOGY, V141, P354, DOI 10.1210/en.141.1.354; Strowski MZ, 2002, NEUROENDOCRINOLOGY, V75, P339, DOI 10.1159/000059430; SURPRENANT A, 1982, J CELL BIOL, V95, P559, DOI 10.1083/jcb.95.2.559; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Tallent M, 1996, NEUROSCIENCE, V71, P1073, DOI 10.1016/0306-4522(95)00510-2; Tallent M, 1996, NEUROSCIENCE, V73, P855, DOI 10.1016/0306-4522(96)00079-6; Thomas P, 2001, PFLUG ARCH EUR J PHY, V441, P816, DOI 10.1007/s004240000488; Tse A, 2000, J PHYSIOL-LONDON, V528, P79, DOI 10.1111/j.1469-7793.2000.00079.x; Tulipano G, 2002, ENDOCRINOLOGY, V143, P1218, DOI 10.1210/en.143.4.1218; Viollet C, 2000, EUR J NEUROSCI, V12, P3761, DOI 10.1046/j.1460-9568.2000.00249.x; Weckbecker G, 2003, NAT REV DRUG DISCOV, V2, P999, DOI 10.1038/nrd1255; Zheng H, 1997, MOL ENDOCRINOL, V11, P1709, DOI 10.1210/me.11.11.1709	58	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24011	24021		10.1074/jbc.M501998200	http://dx.doi.org/10.1074/jbc.M501998200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15857828	hybrid			2022-12-25	WOS:000229880000075
J	Cashikar, AG; Duennwald, M; Lindquist, SL				Cashikar, AG; Duennwald, M; Lindquist, SL			A chaperone pathway in protein disaggregation - Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; MULTICHAPERONE NETWORK; HUNTINGTIN; THERMOTOLERANCE; TEMPERATURE; TRANSPORT; UBIQUITIN; TOXICITY; DISEASE	Cellular protein folding is challenged by environmental stress and aging, which lead to aberrant protein conformations and aggregation. One way to antagonize the detrimental consequences of protein misfolding is to reactivate vital proteins from aggregates. In the yeast Saccharomyces cerevisiae, Hsp104 facilitates disaggregation and reactivates aggregated proteins with assistance from Hsp70 (Ssa1) and Hsp40 (Ydj1). The small heat shock proteins, Hsp26 and Hsp42, also function in the recovery of misfolded proteins and prevent aggregation in vitro, but their in vivo roles in protein homeostasis remain elusive. We observed that after a sublethal heat shock, a majority of Hsp26 becomes insoluble. Its return to the soluble state during recovery depends on the presence of Hsp104. Further, cells lacking Hsp26 are impaired in the disaggregation of an easily assayed heat-aggregated reporter protein, luciferase. In vitro, Hsp104, Ssa1, and Ydj1 reactivate luciferase: Hsp26 co-aggregates 20-fold more efficiently than luciferase aggregates alone. Small Hsps also facilitate the Hsp104-mediated solubilization of polyglutamine in yeast. Thus, Hsp26 renders aggregates more accessible to Hsp104/Ssa1/Ydj1. Small Hsps partially suppress toxicity, even in the absence of Hsp104, potentially by sequestering polyglutamine from toxic interactions with other proteins. Hence, Hsp26 plays an important role in pathways that defend cells against environmental stress and the types of protein misfolding seen in neurodegenerative disease.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Lindquist, SL (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	Lindquist_admin@wi.mit.edu	Cashikar, Anil G/F-5968-2011	Cashikar, Anil/0000-0002-3671-684X	NIGMS NIH HHS [R01 GM025874, R37 GM025874, R37 GM25874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck M, 2004, J MOL BIOL, V343, P445, DOI 10.1016/j.jmb.2004.08.048; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; Haslbeck M, 2005, J BIOL CHEM, V280, P23861, DOI 10.1074/jbc.M502697200; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Morrow G, 2003, SEMIN CELL DEV BIOL, V14, P291, DOI 10.1016/j.semcdb.2003.09.023; Mosser DD, 2004, BIOCHEMISTRY-US, V43, P8107, DOI 10.1021/bi0493766; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; STEGE GJJ, 1995, J CELL PHYSIOL, V164, P579, DOI 10.1002/jcp.1041640316; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Weibezahn J, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-1; Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137	36	229	237	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23869	23875		10.1074/jbc.M502854200	http://dx.doi.org/10.1074/jbc.M502854200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845535	Green Accepted, hybrid			2022-12-25	WOS:000229880000060
J	Kennell, JA; MacDougald, OA				Kennell, JA; MacDougald, OA			Wnt signaling inhibits adipogenesis through beta-catenin-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; ADIPOCYTE DIFFERENTIATION; FRIZZLED RECEPTORS; GENE-EXPRESSION; CYCLIN D1; PATHWAY; CALCINEURIN; SPECIFICITY; ACTIVATION; BINDING	Wnt signaling has been reported to block apoptosis and regulate differentiation of mesenchymal progenitors through inhibition of glycogen synthase kinase 3 and stabilization of beta-catenin. The effects of Wnt in preadipocytes may be mediated through Frizzled (Fz) 1 and/ or Fz2 as these Wnt receptors are expressed in preadipocytes and their expression declines upon induction of differentiation. We ectopically expressed constitutively active chimeras between Wnt8 and Fz1 or Fz2 in preadipocytes and mesenchymal precursor cells. Our results indicated that activated Fz1 increases stability of beta-catenin, inhibits apoptosis, induces osteoblastogenesis, and inhibits adipogenesis. Although activated Fz2 does not influence apoptosis or osteoblastogenesis, it inhibits adipogenesis through a mechanism independent of beta-catenin. An important mediator of the beta-catenin-independent pathway appears to be calcineurin because inhibitors of this serine/threonine phosphatase partially rescue the block to adipogenesis caused by Wnt3a or activated Fz2. These data supported a model in which Wnt signaling inhibits adipogenesis through both beta-catenin-dependent and beta-catenin-independent mechanisms.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, 1301 E Catherine Rd, Ann Arbor, MI 48109 USA.	macdouga@umich.edu		MacDougald, Ormond/0000-0001-6907-7960; Kennell, Jennifer/0000-0001-9793-6259	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51563] Funding Source: Medline; NIGMS NIH HHS [T32-GM08322, T32 GM008322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Huang HC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-7-234; Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272-1282.2005; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Liu JQ, 2004, J BIOL CHEM, V279, P24493, DOI [10.1074/jbc.M402920200, 10.1074/jbc.M407050200]; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; Preece A., 1972, MANUAL HISTOLOGIC TE; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411	51	200	222	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24004	24010		10.1074/jbc.M501080200	http://dx.doi.org/10.1074/jbc.M501080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849360	hybrid			2022-12-25	WOS:000229880000074
J	Krampert, M; Kuenzle, S; Thai, SNM; Lee, N; Iruela-Arispe, ML; Werner, S				Krampert, M; Kuenzle, S; Thai, SNM; Lee, N; Iruela-Arispe, ML; Werner, S			ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM CULTURE; EPIDERMAL DIFFERENTIATION; EXTRACELLULAR-MATRIX; PROTEOLYTIC CLEAVAGE; EXPRESSION; GROWTH; KERATINOCYTES; VERSICAN; FAMILY; REPAIR	The metalloproteinase ADAMTS1 ( a disintegrin and metalloproteinase with thrombospondin motifs) is induced under inflammatory conditions, and it is also a potent inhibitor of angiogenesis. Due to these properties, we speculated about the role of ADAMTS1 in cutaneous wound repair. Here we have shown up-regulation of ADAMTS1 expression in wounds of normal and particularly of healing-impaired genetically diabetic mice. Immunofluorescence staining identified macrophages as the source of ADAMTS1 in early wounds, whereas keratinocytes and fibroblasts produce this protein at later stages of wound healing. The distribution of ADAMTS1 in the normal and wounded epidermis, its regulation in cultured keratinocytes, as well as the skin phenotype of ADAMTS1 knock-out mice suggests a role of this metalloproteinase in keratinocyte differentiation. Furthermore, we provide evidence for a novel dual function of ADAMTS1 in fibroblast migration; although low concentrations of this protein stimulate fibroblast migration via its proteolytic activity, high concentrations inhibit this process because of binding to fibroblast growth factor-2 and subsequent inhibition of its promotogenic activity. Similar effects were also observed with endothelial cells. Taken together, our results suggest a role of ADAMTS1 in keratinocyte differentiation and migration of fibroblasts and endothelial cells in healing skin wounds.	ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Los Angeles	Werner, S (corresponding author), ETH, Inst Cell Biol, Dept Biol, HPM D42, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch	Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Werner, Sabine/0000-0001-7397-8710	NCI NIH HHS [CA 077420] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Caldelari R, 2000, J INVEST DERMATOL, V114, P1064, DOI 10.1046/j.1523-1747.2000.00960-4.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK RAF, 1996, WOUND REPAIR OVERVIE, P3; COLEMAN DL, 1982, DIABETES, V31, P830, DOI 10.2337/diabetes.31.9.830; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Greenhalgh DG, 2003, METH MOLEC MED, V78, P181; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; Hart TC, 1999, J MED GENET, V36, P881; INKI P, 1994, EUR J CELL BIOL, V63, P43; Kim SY, 1998, EXP MOL MED, V30, P257, DOI 10.1038/emm.1998.38; Kondo H, 2000, BIOCHEM BIOPH RES CO, V272, P648, DOI 10.1006/bbrc.2000.2790; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Lundqvist K, 2001, BRIT J DERMATOL, V144, P254, DOI 10.1046/j.1365-2133.2001.04009.x; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Sasaki M, 2001, MOL BRAIN RES, V89, P158, DOI 10.1016/S0169-328X(01)00046-8; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Thai SNM, 2002, MECH DEVELOP, V115, P181, DOI 10.1016/S0925-4773(02)00115-6; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Watkinson A, 1999, ARCH DERMATOL RES, V291, P260, DOI 10.1007/s004030050406; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yuan W, 2002, NEUROSCIENCE, V114, P1091, DOI 10.1016/S0306-4522(02)00347-0; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	45	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23844	23852		10.1074/jbc.M412212200	http://dx.doi.org/10.1074/jbc.M412212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843381	hybrid			2022-12-25	WOS:000229880000057
J	Wang, W; Li, G; Clancy, JP; Kirk, KL				Wang, W; Li, G; Clancy, JP; Kirk, KL			Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; R-DOMAIN; DELTA-F508; CURCUMIN; PHOSPHORYLATION; MUTATION; RESCUE; SITES	Cystic fibrosis (CF) is caused by mutations that disrupt the surface localization and/or gating of the CF transmembrane conductance regulator ( CFTR) chloride channel. The most common CF mutant is Delta F508-CFTR, which inefficiently traffics to the surfaces of most cells. The Delta F508 mutation may also disrupt the opening of CFTR channels once they reach the cell surface, but the extent of this gating defect is unclear. Here, we describe potent activators of wild-type and Delta F508-CFTR channels that are structurally related to 5-nitro-2-(3-phenylpropylamino) benzoate (NPPB), a negatively charged pore blocker that we show to have mixed agonistic activity ( channel activation plus voltage-dependent pore block). These CFTR agonists include 1) an uncharged NPPB analog that stimulates channel opening at submicromolar concentrations without blocking the pore and 2) curcumin, a dietary compound recently reported to augment Delta F508-CFTR function in mice by an unknown mechanism. The uncharged NPPB analog enhanced the activities of wild-type and Delta F508-CFTR channels both in excised membrane patches and in intact epithelial monolayers. This compound increased the open probabilities of Delta F508-CFTR channels in excised membrane patches by 10-15-fold under conditions in which wildtype channels were already maximally active. Our results support the emerging view that CFTR channel activity is substantially reduced by the Delta F508 mutation and that effective CF therapies may require the use of channel openers to activate mutant CFTR channels at the cell surface.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kirk, KL (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 982B MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.	klkirk@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056796] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56796] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berger AL, 2005, J BIOL CHEM, V280, P5221, DOI 10.1074/jbc.M412972200; Bock A, 2001, BIOCHEMISTRY-US, V40, P3273, DOI 10.1021/bi002167a; Chappe V, 2003, J PHYSIOL-LONDON, V548, P39, DOI 10.1113/jphysiol.2002.035790; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; Hentchel-Franks K, 2004, AM J RESP CELL MOL, V31, P140, DOI 10.1165/rcmb.2004-0012OC; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; Riordan JR, 1999, AM J HUM GENET, V64, P1499, DOI 10.1086/302429; Schultz BD, 1999, J MEMBRANE BIOL, V170, P51, DOI 10.1007/s002329900537; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Song YL, 2004, J BIOL CHEM, V279, P40629, DOI 10.1074/jbc.M407308200; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; Walsh KB, 1999, BRIT J PHARMACOL, V127, P369, DOI 10.1038/sj.bjp.0702562; Wang F, 1998, J GEN PHYSIOL, V111, P477, DOI 10.1085/jgp.111.3.477; Wang F, 2000, J PHYSIOL-LONDON, V524, P637, DOI 10.1111/j.1469-7793.2000.00637.x; Wang W, 2005, J GEN PHYSIOL, V125, P127, DOI 10.1085/jgp.200409115; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yang H, 2003, J BIOL CHEM, V278, P35079, DOI 10.1074/jbc.M303098200; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	29	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23622	23630		10.1074/jbc.M503118200	http://dx.doi.org/10.1074/jbc.M503118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15857825	hybrid			2022-12-25	WOS:000229880000028
J	Rim, JS; Mynatt, RL; Gawronska-Kozak, B				Rim, JS; Mynatt, RL; Gawronska-Kozak, B			Mesenchymal stem cells from the outer ear: a novel adult stem cell model system for the study of adipogenesis	FASEB JOURNAL			English	Article						clone; adipocyte differentiation; chondrogenesis; osteogenesis	HUMAN ADIPOSE-TISSUE; ADIPOCYTE DIFFERENTIATION; GENE-EXPRESSION; STROMAL CELLS; PPAR-GAMMA; WHITE FAT; ALPHA; PROLIFERATION; MACROSIALIN; METABOLISM	Adipocytes arise from multipotent stem cells of mesodermal origin, which also give rise to the muscle, bone, and cartilage lineages. However, signals and early molecular events that commit multipotent stem cells into the adipocyte lineage are not well established mainly due to lack of an adequate model system. We have identified a novel source of adult stem cells from the external murine ears referred to here as an ear mesenchymal stem cells (EMSC). EMSC have been isolated from several standard and mutant strains of mice. They are self-renewing, clonogenic, and multipotent, since they give rise to osteocytes, chondrocytes, and adipocytes. The in vitro characterization of EMSC indicates very facile adipogenic differentiation. Morphological, histochemical, and molecular analysis after the induction of differentiation showed that EMSC maintain adipogenic potentials up to fifth passage. A comparison of EMSC to the stromal-vascular (S-V) fraction of fat depots, under identical culture conditions (isobutyl-methylxanthine, dexamethasone, and insulin), revealed much more robust and consistent adipogenesis in EMSC than in the S-V fraction. In summary, we show that EMSC can provide a novel, easily obtainable, primary culture model for the study of adipogenesis.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Gawronska-Kozak, B (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	kozakB@pbrc.edu	Mynatt, Randall L/N-1980-2017; Gawronska-Kozak, Barbara/A-2980-2017	Mynatt, Randall L/0000-0003-4399-0019; Gawronska-Kozak, Barbara/0000-0002-2006-8534	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK072476] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; Bennett CN, 2003, BIOCHEM BIOPH RES CO, V302, P12, DOI 10.1016/S0006-291X(03)00092-5; Boone C, 2000, J ANIM SCI, V78, P885; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Caserta F, 2001, AM J PHYSIOL-ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238; Castro-Munozledo F, 2003, EXP CELL RES, V284, P163, DOI 10.1016/S0014-4827(02)00036-8; Cho YC, 2004, J CELL BIOCHEM, V91, P336, DOI 10.1002/jcb.10743; Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111; Dani C, 1997, J CELL SCI, V110, P1279; Dani C, 1999, CELLS TISSUES ORGANS, V165, P173, DOI 10.1159/000016697; Davis KE, 2004, J BIOL CHEM, V279, P42453, DOI 10.1074/jbc.M402197200; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Gawronska-Kozak B, 2004, TISSUE ENG, V10, P1251, DOI 10.1089/ten.2004.10.1251; Gimble JM, 1998, CRIT REV EUKAR GENE, V8, P141, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.30; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Muraglia A, 2000, J CELL SCI, V113, P1161; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 2002, NAT BIOTECHNOL, V20, P791, DOI 10.1038/nbt0802-791; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ryden M, 2003, BIOCHEM BIOPH RES CO, V311, P391, DOI 10.1016/j.bbrc.2003.10.010; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Sen A, 2001, J CELL BIOCHEM, V81, P312, DOI 10.1002/1097-4644(20010501)81:2<312::AID-JCB1046>3.0.CO;2-Q; Sewter CP, 2002, DIABETES, V51, P718, DOI 10.2337/diabetes.51.3.718; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Smith SR, 2003, DIABETES, V52, P2914, DOI 10.2337/diabetes.52.12.2914; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Tchoukalova YD, 2004, AM J PHYSIOL-REG I, V287, pR1132, DOI 10.1152/ajpregu.00337.2004; Tchoukalova YD, 2000, OBES RES, V8, P664, DOI 10.1038/oby.2000.85; van Harmelen V, 2004, METABOLISM, V53, P632, DOI 10.1016/j.metabol.2003.11.012; Weyer C, 2000, DIABETOLOGIA, V43, P1498, DOI 10.1007/s001250051560; Wolfrum C, 2003, J CLIN INVEST, V112, P345, DOI 10.1172/JCI18698; Yajima Y, 2003, ENDOCRINOLOGY, V144, P2559, DOI 10.1210/en.2002-220894; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Young HE, 2001, ANAT RECORD, V263, P350, DOI 10.1002/ar.1112; Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	56	57	65	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1205	+		10.1096/fj.04-3204fje	http://dx.doi.org/10.1096/fj.04-3204fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857881				2022-12-25	WOS:000228865300004
J	Mun, HC; Culverston, EL; Franks, AH; Collyer, CA; Clifton-Bligh, RJ; Conigrave, AD				Mun, HC; Culverston, EL; Franks, AH; Collyer, CA; Clifton-Bligh, RJ; Conigrave, AD			A double mutation in the extracellular Ca2+-sensing receptor's Venus flytrap domain that selectively disables L-amino acid sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; CALCIMIMETIC COMPOUND; ACTIVATING MUTATIONS; GLUTAMATE; RECOGNITION	The extracellular Ca2+-sensing receptor is activated allosterically by L-amino acids, and recent molecular analysis indicates that amino acids are likely to bind in the receptor's Venus flytrap domain. In the current study we set out to identify residues in the VFT domain that specifically support amino acid binding and/or amino acid-dependent receptor activation. Herein we describe two mutations of the Ca2+-sensing receptor (CaR) Venus Flytrap domain, T145A and S170T, that specifically impair amino acid sensing, leaving Ca2+ sensing intact, as determined by receptor-dependent activation of intracellular Ca2+ mobilization in fura-2-loaded HEK293 cells. With respect to the wild-type CaR, T145A and S170T exhibited reduced sensitivity to L-Phe, and T145A also exhibited markedly impaired L/D selectivity. When combined, the double mutant T145A/S170T exhibited normal or near-normal sensitivity to extracellular Ca2+ but was resistant to L-Phe at concentrations up to 100 mM. We conclude that T145A/S170T selectively disables L-amino acid sensing and that the Ca2+ and L-amino acid-sensing functions of the CaR can be dissociated.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Dept Endocrinol, St Leonards, NSW 2065, Australia	University of Sydney; Royal North Shore Hospital	Conigrave, AD (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.	a.conigrave@mmb.usyd.edu.au		Clifton-Bligh, Roderick/0000-0002-1545-0368; Conigrave, Arthur/0000-0002-7232-3891				Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bradbury RA, 1996, J ENDOCRINOL, V149, P135, DOI 10.1677/joe.0.1490135; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Conigrave AD, 2000, TRENDS PHARMACOL SCI, V21, P401, DOI 10.1016/S0165-6147(00)01546-7; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Conigrave AD, 2004, J BIOL CHEM, V279, P38151, DOI 10.1074/jbc.M406373200; Conigrave AD, 2002, EUR J CLIN NUTR, V56, P1072, DOI 10.1038/sj.ejcn.1601463; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Mun HC, 2004, J BIOL CHEM, V279, P51739, DOI 10.1074/jbc.M406164/200; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Reyes-Cruz G, 2001, J BIOL CHEM, V276, P32145, DOI 10.1074/jbc.M102977200; Tan YM, 2003, J CLIN ENDOCR METAB, V88, P605, DOI 10.1210/jc.2002-020081; Tsuchiya D, 2002, P NATL ACAD SCI USA, V99, P2660, DOI 10.1073/pnas.052708599; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200	21	51	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 12	2005	280	32					29067	29072		10.1074/jbc.M500002200	http://dx.doi.org/10.1074/jbc.M500002200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	952QT	15888439	hybrid			2022-12-25	WOS:000231021300032
J	Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S				Fujimoto, M; Kitazawa, R; Maeda, S; Kitazawa, S			Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression	ONCOGENE			English	Article						TrkA; non-CpG islands; methylation; AP-1; pancreatic cancer	NERVE GROWTH-FACTOR; PANCREATIC DUCTAL ADENOCARCINOMA; DNA-METHYLATION; PERINEURAL INVASION; NEUROTROPHIN RECEPTOR; CPG METHYLATION; BINDING; PROLIFERATION; NEUROBLASTOMAS; REPRESSION	Nerve growth factor and its high-affinity receptor TrkA are thought to be involved in the progression of various cancers. This study investigated the mechanism that regulates aberrant or increased TrkA expression in various cancer cell lines and in the course of pancreatic cancer progression. W e found that the negative cis-acting AP-1-like sequence TGAGCGA was located in the 5'-untranslated region of the TrkA gene. Sodium bisulfite mapping revealed that steady-state TrkA expression correlated positively with the accumulation of methylated CpG around the AP-1-like site. Electrophoretic mobility shift assay showed that the AP-1- like site was bound mainly by c-Jun homodimers; the binding was directly blocked by Sss I methylase-induced methylation or by an excess of oligonucleotides containing consensus AP-1 sequences. Consequently, activation of TrkA gene expression by methylation was considered to be caused by the direct interference of c-Jun binding to the negatively regulating AP-1- like site. Further more, the accumulation of methylated CpG around the AP-1- like site was also observed with increased TrkA immunohistochemical staining in cases of advanced pancreatic adenocarcinoma with extensive perineural invasion. Unlike global methylation at CpG islands that leads to gene silencing, specific methylation at non-CpG islands would play a crucial epigenetic role in the versatility and plasticity of TrkA expression during cancer progression.	Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kitazawa, S (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Pathol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kitazawa@med.kobe-u.ac.jp	Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356				Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brellier F, 2004, CANCER RES, V64, P2699, DOI 10.1158/0008-5472.CAN-03-3477; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Eberhart CG, 2001, J NEUROPATH EXP NEUR, V60, P462, DOI 10.1093/jnen/60.5.462; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; George DJ, 1998, PROSTATE, V36, P172, DOI 10.1002/(SICI)1097-0045(19980801)36:3<172::AID-PROS5>3.0.CO;2-J; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Indo Y, 1997, JPN J HUM GENET, V42, P343, DOI 10.1007/BF02766957; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kitazawa S, 2000, LAB INVEST, V80, P275, DOI 10.1038/labinvest.3780031; Kondo T, 2004, J BONE MINER RES, V19, P1411, DOI 10.1359/JBMR.040604; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; Sakamoto Y, 2001, ONCOL REP, V8, P477; Schneider MB, 2001, J HISTOCHEM CYTOCHEM, V49, P1205, DOI 10.1177/002215540104901002; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Yi SQ, 2003, PANCREAS, V27, P225, DOI 10.1097/00006676-200310000-00005; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003; Zhu ZW, 2002, MOL CARCINOGEN, V35, P138, DOI 10.1002/mc.10083; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	36	22	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 28	2005	24	32					5108	5118		10.1038/sj.onc.1208697	http://dx.doi.org/10.1038/sj.onc.1208697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870692				2022-12-25	WOS:000230816900010
J	Hatters, DM; Peters-Libeu, CA; Weisgraber, KH				Hatters, DM; Peters-Libeu, CA; Weisgraber, KH			Engineering conformational destabilization into mouse apolipoprotein E - A model for a unique property of human apolipoprotein E4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PEPTIDE DEPOSITION; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; DOMAIN INTERACTION; E ISOFORMS; MOLTEN GLOBULE; E GENOTYPE; PROTEIN; ASSOCIATION; ALLELE	Apolipoprotein (apo) E4 is a major risk factor for Alzheimer and cardiovascular diseases. ApoE4 differs from the two other common isoforms (apoE2 and apoE3) by its lower resistance to denaturation and greater propensity to form partially folded intermediates. As a first step to determine the importance of stability differences in vivo, we reengineered a partially humanized variant of the amino-terminal domain of mouse apoE (T61R mouse apoE) to acquire a destabilized conformation like that of apoE4. For this process, we determined the crystal structure of wild-type mouse apoE, which, like apoE4, forms a four-helix bundle, and identified two structural differences in the turn between helices 2 and 3 and in the middle of helix 3 as potentially destabilizing sites. Introducing mutations G83T and N113G at these sites destabilized the mouse apoE conformation. The mutant mouse apoE more rapidly remodeled phospholipid than T61R mouse apoE, which supports the hypothesis that a destabilized conformation promotes apoE4 lipid binding.	Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weisgraber, KH (corresponding author), Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	kweisgraber@gladstone.ucsf.edu		Hatters, Danny/0000-0002-9965-2847	NATIONAL INSTITUTE ON AGING [R01AG020235, P01AG022074] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG20235, P01 AG022074] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Brendza RP, 2002, MOL PSYCHIATR, V7, P132, DOI 10.1038/sj.mp.4001006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buttini M, 2002, J NEUROSCI, V22, P10539; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dolev I, 2004, P NATL ACAD SCI USA, V101, P13909, DOI 10.1073/pnas.0404458101; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Pace C N, 1986, Methods Enzymol, V131, P266; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Saito H, 2003, J BIOL CHEM, V278, P40723, DOI 10.1074/jbc.M304814200; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Weers PMM, 2003, BIOPHYS CHEM, V100, P481, DOI 10.1016/S0301-4622(02)00300-9; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200	51	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26477	26482		10.1074/jbc.M503910200	http://dx.doi.org/10.1074/jbc.M503910200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15890642	hybrid			2022-12-25	WOS:000230386800063
J	Mayo, LD; Seo, YR; Jackson, MW; Smith, ML; Guzman, JR; Korgaonkar, CK; Donner, DB				Mayo, LD; Seo, YR; Jackson, MW; Smith, ML; Guzman, JR; Korgaonkar, CK; Donner, DB			Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN KINASE-2; DRUG-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; PHOSPHATASE-ACTIVITY; TRANSCRIPTION FACTOR; ONCOPROTEIN MDM2; COWDEN-DISEASE; ORAL ETOPOSIDE; BREAST-CANCER	The capacity of DNA damaging agents to induce apoptosis is regulated by target gene induction by p53. We found that p53 targeted MDM2 in cells in which DNA repair was occurring, but persistent DNA damage induced by chemotherapy led p53 to selectively target PTEN. High dose chemotherapy induced the phosphorylation of p53 on serine 46, whereas low dose chemotherapy did not. A nonphosphorylatable serine 46 to alanine p53 mutant (S46A) targeted the MDM2 promoter in preference to that for PTEN. A serine 46 to aspartate mutant (S46D, a phosphorylation mimic) targeted PTEN in preference to MDM2. These observations show that phosphorylation of serine 46 in p53 is sufficient for it to induce the PTEN (phosphatase and tensin homolog deleted on chromosome ten) tumor suppressor protein in preference to MDM2. S46A induced significantly less cell death than the S46D in cells. The phosphorylation-induced change of p53 promoter targeting suppresses the induction of MDM2 and the formation of the autoregulatory feedback loop. Induction of PTEN by p53 followed by expression of PTEN inhibits AKT-induced translocation of MDM2 into the nucleus and sustains p53 function. The protection of p53 from MDM2 by PTEN and the damage-induced activation of PTEN by phosphorylated p53 leads to the formation of an apoptotic amplification cycle in which p53 and PTEN coordinately increase cellular apoptosis.	Case Western Reserve Univ, Case Comprenens Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprenens Canc Ctr, Dept Pharmacol, Cleveland, OH 44106 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44159 USA	Case Western Reserve University; Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cleveland Clinic Foundation	Donner, DB (corresponding author), Case Western Reserve Univ, Case Comprenens Canc Ctr, Dept Radiat Oncol, Cleveland, OH 44106 USA.	ddonner@iupui.edu		Rivera Guzman, Javier/0000-0001-9004-6739	NATIONAL CANCER INSTITUTE [R01CA073023, R55CA067891, R01CA067891] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67891, CA 73023] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Braybrooke JP, 2003, CLIN CANCER RES, V9, P4682; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARK PI, 1994, J CLIN ONCOL, V12, P1427, DOI 10.1200/JCO.1994.12.7.1427; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huigsloot M, 2001, BIOCHEM PHARMACOL, V62, P1087, DOI 10.1016/S0006-2952(01)00755-9; Joel SP, 1996, J CLIN ONCOL, V14, P1903, DOI 10.1200/JCO.1996.14.6.1903; JOEL SP, 1995, CANCER CHEMOTH PHARM, V37, P125; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WM, 2002, EUR J CANCER, V38, P842, DOI 10.1016/S0959-8049(02)00016-3; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McCoy MA, 2003, P NATL ACAD SCI USA, V100, P1645, DOI 10.1073/pnas.0334477100; MILLWARD MJ, 1995, CANCER CHEMOTH PHARM, V37, P161; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	73	123	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25953	25959		10.1074/jbc.M503026200	http://dx.doi.org/10.1074/jbc.M503026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15843377	hybrid			2022-12-25	WOS:000230386800003
J	Ford, B; Skowronek, K; Boykevisch, S; Bar-Sagi, DB; Nassar, N				Ford, B; Skowronek, K; Boykevisch, S; Bar-Sagi, DB; Nassar, N			Structure of the G60A mutant of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ONCOGENIC RAS; ALA MUTATION; GTP; ACTIVATION; P21; EFFECTORS; PROTEINS	Substituting alanine for glycine at position 60 in v-H-Ras generated a dominant negative mutant that completely abolished the ability of v-H-Ras to transform NIH 3T3 cells and to induce germinal vesicle breakdown in Xenopus oocytes. The crystal structure of the GppNp-bound form of RasG60A unexpectedly shows that the switch regions adopt an open conformation reminiscent of the structure of the nucleotide-free form of Ras in complex with Sos. Critical residues that normally stabilize the guanine nucleotide and the Mg2+ ion have moved considerably. Sos binds to RasG60A but is unable to catalyze nucleotide exchange. Our data suggest that the dominant negative effect observed for RasG60A center dot GTP could result from the sequestering of Sos in a non-productive Ras-GTP-guanine nucleotide exchange factor ternary complex.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Nassar, N (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Basic Sci Tower, Stony Brook, NY 11794 USA.	nicolas.nassar@sunysb.edu		Ford, Bradley/0000-0002-7871-7955; Bar-Sagi, Dafna/0000-0003-2597-8948	NIDDK NIH HHS [T32-DK07521-16] Funding Source: Medline; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian Mohammad Reza, 2002, Methods Mol Biol, V189, P45; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Hall BE, 2002, P NATL ACAD SCI USA, V99, P12138, DOI 10.1073/pnas.192453199; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; HUBBARD SJ, 1993, NACCESS COMPUTE PROG; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Sung YJ, 1996, J BIOL CHEM, V271, P30537, DOI 10.1074/jbc.271.48.30537; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925	39	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25697	25705		10.1074/jbc.M502240200	http://dx.doi.org/10.1074/jbc.M502240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878843	hybrid			2022-12-25	WOS:000230207900050
J	Kuwata, H; Nonaka, T; Murakami, M; Kudo, I				Kuwata, H; Nonaka, T; Murakami, M; Kudo, I			Search of factors that intermediate cytokine-induced group IIA phospholipase A(2) expression through the cytosolic phospholipase A(2)- and 12/15-lipoxygenase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; NF-KAPPA-B; GROUP-V; GENE-EXPRESSION; A(2) GENE; OXIDATIVE STRESS; GROWTH-FACTOR; NITRIC-OXIDE; CELLS; ACTIVATION	Inducible expression of group IIA secretory phospholipase A(2) ( sPLA(2)- IIA) by interleukin- 1 beta( IL- 1 beta) and tumor necrosis factor- alpha( TNF alpha) is under the control of group IVA cytosolic PLA(2)alpha and 12/ 15- lipoxygenase ( 12/ 15- LOX) in rat fibroblastic 3Y1 cells. We show here that this cytokine induction of sPLA2- IIA mRNA requires de novo protein synthesis. By means of cDNA array analysis, we found that the level of the CXC chemokine MIP- 2 ( macrophage inflammatory protein- 2) was significantly elevated in 12/ 15- LOX- transfected cells compared with control cells. IL-1 beta/ TNF alpha- stimulated induction of endogenous MIP- 2 preceded that of sPLA2- IIA, and exogenous MIP- 2 induced sPLA2- IIA dose- dependently. Moreover, a MIP- 2- specific antisense oligonucleotide and small interfering RNA attenuated the IL- 1 beta/ TNF alpha- induced expression of sPLA(2)-IIA, suggesting that MIP- 2 is an absolute intermediate requirement for optimal induction of sPLA2- IIA. In addition, the expression of c- jun and fra- 1, which are components of the transcription factor AP- 1, was elevated in 12/ 15- LOX- transfected cells, in which cytokine- dependent binding of AP- 1 to the sPLA2- IIA promoter was increased significantly. Conversely, the receptors for transforming growth factor-beta and platelet- derived growth factor, which contributed to down- regulation of sPLA2- IIA expression, were decreased following 12/ 15- LOX overexpression. Taken together, 12/ 15- LOX- dependent up- regulation of sPLA2- IIA expression may result from the interplay between accelerated MIP- 2 signaling, AP- 1 activation, and attenuated transforming growth factor-beta and platelet- derived growth factor signaling.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kudo@pharm.showa-u.ac.jp	Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Andreani M, 2000, BBA-MOL CELL BIOL L, V1488, P149, DOI 10.1016/S1388-1981(00)00117-7; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Beck S, 2003, J BIOL CHEM, V278, P29799, DOI 10.1074/jbc.M211763200; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Couturier C, 2000, ARTERIOSCL THROM VAS, V20, P2559, DOI 10.1161/01.ATV.20.12.2559; CROWL RM, 1991, J BIOL CHEM, V266, P2647; Diab A, 1999, INFECT IMMUN, V67, P2590, DOI 10.1128/IAI.67.5.2590-2601.1999; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Guidet B, 1996, INFECTION, V24, P103, DOI 10.1007/BF01713312; Hall DA, 1999, BRIT J PHARMACOL, V126, P810, DOI 10.1038/sj.bjp.0702329; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; Jaramillo M, 2005, J IMMUNOL, V174, P475, DOI 10.4049/jimmunol.174.1.475; Jaramillo M, 2002, J IMMUNOL, V169, P7026, DOI 10.4049/jimmunol.169.12.7026; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuhn H, 2002, PROSTAG OTH LIPID M, V68-9, P263, DOI 10.1016/S0090-6980(02)00035-7; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Kuwata H, 2004, BBA-MOL CELL BIOL L, V1686, P15, DOI 10.1016/j.bbalip.2004.07.002; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Menschikowski M, 1995, ATHEROSCLEROSIS, V118, P173, DOI 10.1016/0021-9150(95)05604-1; Mira JP, 1997, J BIOL CHEM, V272, P10474; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; Pawliczak R, 2004, J BIOL CHEM, V279, P48550, DOI 10.1074/jbc.M408926200; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Rangan GK, 1999, AM J PHYSIOL-RENAL, V277, pF779, DOI 10.1152/ajprenal.1999.277.5.F779; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Schachtrup C, 2004, BIOCHEM J, V382, P239, DOI 10.1042/BJ20031340; Scholz-Pedretti K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133611; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Shappell SB, 2001, CANCER RES, V61, P497; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shi MM, 1999, IMMUNOLOGY, V97, P309; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Uozumi N, 2002, PROSTAG OTH LIPID M, V68-9, P59, DOI 10.1016/S0090-6980(02)00021-7; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Walker G, 1998, BBA-LIPID LIPID MET, V1391, P213, DOI 10.1016/S0005-2760(97)00204-X; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	58	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25830	25839		10.1074/jbc.M500168200	http://dx.doi.org/10.1074/jbc.M500168200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878884	hybrid			2022-12-25	WOS:000230207900064
J	Ruan, BF; Soll, D				Ruan, BF; Soll, D			The bacterial YbaK protein is a Cys-tRNA(Pro) and Cys-tRNA(Cys) deacylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNAS; ESCHERICHIA-COLI; ACID; SYNTHETASE; MECHANISM; SELECTION; DOMAIN	Bacterial prolyl- tRNA synthetases and some smaller paralogs, YbaK and ProX, can hydrolyze misacylated Cys- tRNA(Pro) or Ala- tRNA(Pro). To assess the significance of this quality control editing reaction in vivo, we tested Escherichia coli ybaK for its ability to suppress the E. coli thymidylate synthase thyA: 146CCA missense mutant strain, which requires Cys- tRNAPro for growth in the absence of thymine. Missense suppression was observed in a ybaK deletion background, suggesting that YbaK functions as a Cys- tRNAPro deacylase in vivo. In vitro studies with the full set of 20 E. coli aminoacyltRNAs revealed that the Haemophilus influenzae and E. coli YbaK proteins are moderately general aminoacyltRNA deacylases that preferentially hydrolyze CystRNAPro and Cys- tRNACys and are also weak deacylases that cleave Gly- tRNA, Ala- tRNA, Ser- tRNA, Pro- tRNA, and Met- tRNA. The ProX protein acted as an aminoacyltRNA deacylase that cleaves preferentially Ala- tRNA and Gly- tRNA. The potential of H. influenzae YbaK to hydrolyze in vivo correctly charged Cys- tRNACys was tested in E. coli strain X2913 ( ybaK (+)). Overexpression of H. influenzae ybaK decreased the in vivo ratio of CystRNA(Cys) to tRNACys from 65 to 35% and reduced the growth rate of strain X2913 by 30% in LB medium. These data suggest that YbaK- mediated hydrolysis of aminoacyltRNA can influence cell growth.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu						Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; An SG, 2004, J BIOL CHEM, V279, P42359, DOI 10.1074/jbc.C400304200; Bacher JM, 2005, P NATL ACAD SCI USA, V102, P1697, DOI 10.1073/pnas.0409064102; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; BUMSTED RM, 1968, J BIOL CHEM, V243, P779; Choi H, 2003, RNA, V9, P386, DOI 10.1261/rna.2139703; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DeVito JA, 2002, NAT BIOTECHNOL, V20, P478, DOI 10.1038/nbt0502-478; Dittmar KA, 2005, EMBO REP, V6, P151, DOI 10.1038/sj.embor.7400341; Dock-Bregeon AC, 2004, MOL CELL, V16, P375, DOI 10.1016/S1097-2765(04)00591-X; GOLDMAN E, 1990, MOL MICROBIOL, V4, P2035, DOI 10.1111/j.1365-2958.1990.tb00563.x; GOULD RM, 1968, J BIOL CHEM, V243, P3096; Hendrickson TL, 2003, MOL B INT U, P34; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2004, GENE DEV, V18, P731, DOI 10.1101/gad.1187404; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; KAPLANSKY DA, 1982, J BIOL CHEM, V257, P5722; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; Min B, 2003, J BACTERIOL, V185, P3524, DOI 10.1128/JB.185.12.3524-3526.2003; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Rigden DJ, 2004, RNA, V10, P1845, DOI 10.1261/rna.7115404; Ruan BF, 2004, J BACTERIOL, V186, P8, DOI 10.1128/JB.186.1.8-14.2004; Schauer S, 2002, J BIOL CHEM, V277, P48657, DOI 10.1074/jbc.M206924200; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y	33	64	72	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25887	25891		10.1074/jbc.M502174200	http://dx.doi.org/10.1074/jbc.M502174200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886196	hybrid			2022-12-25	WOS:000230207900069
J	Sigoillot, FD; Kotsis, DH; Serre, V; Sigoillot, SM; Evans, DR; Guy, HI				Sigoillot, FD; Kotsis, DH; Serre, V; Sigoillot, SM; Evans, DR; Guy, HI			Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; CARBAMOYL-PHOSPHATE SYNTHETASE; EHRLICH ASCITES-CARCINOMA; HAMSTER-CELLS; MAMMALIAN-CELLS; DEPENDENT REGULATION; INITIAL STEPS; RAT-LIVER; ENZYMES; LOCATION	CAD is a multifunctional protein that initiates and regulates mammalian de novo pyrimidine biosynthesis. The activation of the pathway required for cell proliferation is a consequence of the phosphorylation of CAD Thr-456 by mitogen-activated protein (MAP) kinase. Although most of the CAD in the cell was cytosolic, cell fractionation and fluorescence microscopy showed that Thr(P)-456 CAD was primarily localized within the nucleus in association with insoluble nuclear substructures, including the nuclear matrix. CAD in resting cells was cytosolic and unphosphorylated. Upon epidermal growth factor stimulation, CAD moved to the nucleus, and Thr-456 was found to be phosphorylated. Mutation of the CAD Thr-456 and inhibitor studies showed that nuclear import is not mediated by MAP kinase phosphorylation. Two fluorescent CAD constructs, NLS-CAD and NES-CAD, were prepared that incorporated strong nuclear import and export signals, respectively. NLS-CAD was exclusively nuclear and extensively phosphorylated. In contrast, NES-CAD was confined to the cytoplasm, and Thr-456 remained unphosphorylated. Although alternative explanations can be envisioned, it is likely that phosphorylation occurs within the nucleus where much of the activated MAP kinase is localized. Trapping CAD in the nucleus had a minimal effect on pyrimidine metabolism. In contrast, when CAD was excluded from the nucleus, the rate of pyrimidine biosynthesis, the nucleotide pools, and the growth rate were reduced by 21, 36, and 60%, respectively. Thus, the nuclear import of CAD appears to promote optimal cell growth. UMP synthase, the bifunctional protein that catalyzes the last two steps in the pathway, was also found in both the cytoplasm and nucleus.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 07, F-75743 Paris, France	Wayne State University; UDICE-French Research Universities; Universite Paris Cite	Sigoillot, FD (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	hguy@cmb.biosci.wayne.edu		Sigoillot, Frederic/0000-0002-8695-4838	NIGMS NIH HHS [GM47399, GM/CA60371, R01 GM060371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399, R01GM060371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angeletti PC, 1998, J VIROL, V72, P2896, DOI 10.1128/JVI.72.4.2896-2904.1998; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; Carrey EA, 2002, REPRODUCTION, V123, P757, DOI 10.1530/rep.0.1230757; CHAPARIAN MG, 1988, FASEB J, V2, P2982, DOI 10.1096/fasebj.2.14.2903106; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dzeja PP, 2002, P NATL ACAD SCI USA, V99, P10156, DOI 10.1073/pnas.152259999; Evans DR, 2004, J BIOL CHEM, V279, P33035, DOI 10.1074/jbc.R400007200; Fairbanks LD, 1999, J CHROMATOGR B, V732, P487, DOI 10.1016/S0378-4347(99)00303-5; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HUISMAN WH, 1979, J BIOL CHEM, V254, P2595; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Loffler M, 1996, HISTOCHEM CELL BIOL, V105, P119, DOI 10.1007/BF01696151; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MATTOON JR, 1967, METHOD ENZYMOL, V10, P135; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; PATTERSON D, 1977, SOMAT CELL GENET, V3, P483, DOI 10.1007/BF01539120; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; Sigoillot FD, 2004, INT J CANCER, V109, P491, DOI 10.1002/ijc.11717; Sigoillot FD, 2003, J BIOL CHEM, V278, P3403, DOI 10.1074/jbc.M211078200; Sigoillot FD, 2002, J BIOL CHEM, V277, P15745, DOI 10.1074/jbc.M201112200; Sigoillot FD, 2002, J BIOL CHEM, V277, P24809, DOI 10.1074/jbc.M203512200; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TUBO RA, 1987, J BIOL CHEM, V262, P5857; VANDERWALLE CF, 1996, PHARM SCI, V2, P59; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	39	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25611	25620		10.1074/jbc.M504581200	http://dx.doi.org/10.1074/jbc.M504581200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890648	hybrid			2022-12-25	WOS:000230207900040
J	Yang, CH; Murti, A; Valentine, WJ; Du, ZY; Pfeffer, LM				Yang, CH; Murti, A; Valentine, WJ; Du, ZY; Pfeffer, LM			Interferon alpha activates NF-kappa B in JAK1-deficient cells through a TYK2-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; COMPLEMENTS DEFECTS; SIGNALING PATHWAY; TYROSINE KINASE; DAUDI CELLS; RECEPTOR; STAT3; TRANSCRIPTION; INDUCTION	In addition to activating members of the STAT transcription factor family, interferon alpha/beta( IFN alpha/beta) activates the NF- kappa B transcription factor. To determine the role of the Janus tyrosine kinase ( JAK)- STAT pathway in NF-kappa B activation by IFN, we examined NF- kappa B activation in JAK1- deficient mutant human fibrosarcoma cells. In wild- type fibrosarcoma cells ( 2fTGH), IFN activates STAT1, STAT2, and STAT3, as well as NF- kappa B complexes comprised of p50 and p65. In contrast, in JAK1- deficient cells, IFN induces NF- kappa B activation and NF-kappa B dependent gene transcription but does not activate these STAT proteins and has no effect on STAT- dependent gene transcription. Expression of a catalytically inactive TYK2 tyrosine kinase in JAK1- deficient cells, as well as in the highly IFN- sensitive Daudi lymphoblastoid cell line, abrogates NF- kappa B activation by IFN. Moreover, IFN does not promote NF- kappa B activation in TYK2- deficient mutant fibrosarcoma cells. Our results demonstrate a dichotomy between the classical JAK- STAT pathway and the NF- kappa B signaling pathway. In the IFN signaling pathway leading to STAT activation, both JAK1 and TYK2 are essential, whereas NF- kappa B activation requires only TYK2.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Univ Tennessee, Inst Canc, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, 930 Madison Ave,Rm 530, Memphis, TN 38163 USA.	lpfeffer@utmem.edu		Pfeffer, Lawrence/0000-0003-2809-1234	NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER; NCI NIH HHS [CA73753, R01 CA073753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FALTYNEK CR, 1989, J BIOL CHEM, V264, P14305; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; LARNER AC, 1986, J BIOL CHEM, V261, P453; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; Schindler C, 1998, TRENDS CELL BIOL, V8, P97, DOI 10.1016/S0962-8924(98)01233-1; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397	23	28	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25849	25853		10.1074/jbc.M413721200	http://dx.doi.org/10.1074/jbc.M413721200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883164	hybrid, Green Accepted			2022-12-25	WOS:000230207900066
J	Zhang, B; Kaufman, RJ; Ginsburg, D				Zhang, B; Kaufman, RJ; Ginsburg, D			LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; GOLGI INTERMEDIATE COMPARTMENT; ENDOPLASMIC-RETICULUM; LEGUMINOUS LECTINS; TRANSPORT VESICLES; CRYSTAL-STRUCTURE; FACTORS V; ER; PROTEIN; ERGIC-53	Mutations in LMAN1 (ERGIC-53) and MCFD2 are the causes of a human genetic disorder, combined deficiency of coagulation factor V and factor VIII. LMAN1 is a type 1 transmembrane protein with homology to mannose-binding lectins. MCFD2 is a soluble EF-hand-containing protein that is retained in the endoplasmic reticulum through its interaction with LMAN1. We showed that endogenous LMAN1 and MCFD2 are present primarily in complex with each other with a 1:1 stoichiometry, although MCFD2 is not required for oligomerization of LMAN1. Using a cross-linking-immunoprecipitation assay, we detected a specific interaction of both LMAN1 and MCFD2 with factor VIII, with the B domain as the most likely site of interaction. We also present evidence that this interaction is independent of the glycosylation state of factor VIII but requires native calcium concentration in the endoplasmic reticulum. The interaction of MCFD2 with factor VIII appeared to be independent of LMAN1-MCFD2 complex formation. These results suggest that LMAN1 and MCFD2 form a cargo receptor complex and that the primary sorting signals residing in the B domain direct the binding of factor VIII to LMAN1-MCFD2 through calcium-dependent protein-protein interactions. MCFD2 may function to specifically recruit factor V and factor VIII to sites of transport vesicle budding within the endoplasmic reticulum lumen.	Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Ginsburg, D (corresponding author), Univ Michigan, Life Sci Inst, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	ginsburg@umich.edu	Zhang, Bin/B-8102-2012		NHLBI NIH HHS [P01 HL057346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; APPENZELLERHERZ.C, 1999, MOL BIOL CELL, V1, P330; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bouw G, 2004, MOL BIOL CELL, V15, P1244, DOI 10.1091/mbc.E03-08-0600; Carney GE, 2003, GENETICS, V164, P173; Cunningham MA, 2003, J THROMB HAEMOST, V1, P2360, DOI 10.1046/j.1538-7836.2003.00415.x; Davidson CJ, 2003, J THROMB HAEMOST, V1, P1487, DOI 10.1046/j.1538-7836.2003.00334.x; Denzel A, 2000, CURR BIOL, V10, P55, DOI 10.1016/S0960-9822(99)00266-3; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KANE WH, 1988, BLOOD, V71, P539; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Martin-Bermudo MD, 2000, J CELL SCI, V113, P3715; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Miao HZ, 2004, BLOOD, V103, P3412, DOI 10.1182/blood-2003-10-3591; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2004, NAT CELL BIOL, V6, P1189, DOI 10.1038/ncb1195; Pezzati R, 1997, MOL BIOL CELL, V8, P1501, DOI 10.1091/mbc.8.8.1501; Pipe SW, 2004, SEMIN THROMB HEMOST, V30, P227, DOI 10.1055/s-2004-825636; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1993, BLOOD, V81, P2925; Prout M, 1997, GENETICS, V146, P275; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; Toda H, 2003, J BIOL CHEM, V278, P35491, DOI 10.1074/jbc.M305342200; Velloso LM, 2003, J MOL BIOL, V334, P845, DOI 10.1016/j.jmb.2003.10.031; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	41	102	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25881	25886		10.1074/jbc.M502160200	http://dx.doi.org/10.1074/jbc.M502160200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886209	hybrid			2022-12-25	WOS:000230207900079
J	Liu, JG; Guan, XQ; Ma, XJ				Liu, JG; Guan, XQ; Ma, XJ			Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon gamma-induced RANTES/CC15 expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; INFLAMMATORY PROTEIN 1-ALPHA; NECROSIS-FACTOR-ALPHA; NATURAL-KILLER-CELLS; P40 GENE PROMOTER; CHEMOKINE GENE; FACTOR IRF-1; FACTOR-I; T-CELLS; IDENTIFICATION	Interferon regulatory factor 1 ( IRF- 1) is an important transcription factor in interferon gamma( IFN gamma)- mediated signaling in the development and function of NK cells and cytotoxic T lymphocytes. RANTES ( regulated on activation normal T cell expressed and secreted; CCL5) is a member of the CC chemokine family of proteins, which is strongly chemoattractant for several important immune cell types in host defense against infectious agents and cancer. However, the role of IFN gamma and IRF- 1 in the regulation of RANTES gene expression and their operative mechanisms in macrophages have not been established. We report here that RANTES expression in IRF1- null mice, primarily in macrophages, in response to carcinogenic stimulation in vivo and in vitro and to IFN gamma but not to lipopolysaccharide in vitro, was markedly decreased. As a result, RANTES- mediated chemoattraction of CCR5(+) target cells was also severely impaired. Adenovirus- mediated gene transduction of IRF- 1 in primary macrophages resulted in enhanced RANTES expression. The IFN gamma and IRF1 response element was localized to a TTTTC motif at - 147 to - 143 of the mouse RANTES promoter, to which endogenous or recombinant IRF- 1 can physically bind in vitro and in vivo. This study uncovers a novel IFN gamma induced pathway in RANTES expression mediated by IRF- 1 in macrophages and elucidates an important host defense mechanism against neoplastic transformation.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Ma, XJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10021 USA.	xim2002@med.cornell.edu						Andoh A, 2002, J IMMUNOL, V169, P1683, DOI 10.4049/jimmunol.169.4.1683; Casola A, 2002, AM J PHYSIOL-LUNG C, V283, pL1280, DOI 10.1152/ajplung.00162.2002; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Erickson L, 2004, TRANSPL IMMUNOL, V13, P169, DOI 10.1016/j.trim.2004.06.003; Genin P, 2000, J IMMUNOL, V164, P5352, DOI 10.4049/jimmunol.164.10.5352; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Kutubuddin M, 1999, BLOOD, V93, P643, DOI 10.1182/blood.V93.2.643.402k24_643_654; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu JG, 2004, J IMMUNOL, V173, P1184, DOI 10.4049/jimmunol.173.2.1184; Liu JG, 2003, J EXP MED, V198, P1265, DOI 10.1084/jem.20030026; Lohoff M, 2000, J EXP MED, V192, P325, DOI 10.1084/jem.192.3.325; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Melchjorsen J, 2002, J VIROL, V76, P2780, DOI 10.1128/JVI.76.6.2780-2788.2002; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; Miyagishi R, 1997, J NEUROIMMUNOL, V77, P17, DOI 10.1016/S0165-5728(97)00040-4; Miyamoto NG, 2000, J NEUROIMMUNOL, V105, P78, DOI 10.1016/S0165-5728(00)00195-8; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Moriuchi H, 1997, J IMMUNOL, V158, P3483; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Nelson PJ, 1996, J IMMUNOL, V157, P1139; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Ortiz BD, 1996, MOL CELL BIOL, V16, P202; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sin JI, 2000, J VIROL, V74, P11173, DOI 10.1128/JVI.74.23.11173-11180.2000; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623	39	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24347	24355		10.1074/jbc.M500973200	http://dx.doi.org/10.1074/jbc.M500973200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15860458	hybrid			2022-12-25	WOS:000230114000008
J	Mukrasch, MD; Biernat, J; von Bergen, M; Griesinger, C; Mandelkow, E; Zweckstetter, M				Mukrasch, MD; Biernat, J; von Bergen, M; Griesinger, C; Mandelkow, E; Zweckstetter, M			Sites of tau important for aggregation populate beta-structure and bind to microtubules and polyanions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN-TAU; ALZHEIMERS-DISEASE; UNFOLDED PROTEINS; CHEMICAL-SHIFTS; NMR; DOMAIN; PHOSPHORYLATION; ASSIGNMENT; MUTATIONS	The aggregation of the microtubule-associated tau protein and formation of "neurofibrillary tangles" is one of the hallmarks of Alzheimer disease. The mechanisms underlying the structural transition of innocuous, natively unfolded tau to neurotoxic forms and the detailed mechanisms of binding to microtubules are largely unknown. Here we report the high-resolution characterization of the repeat domain of soluble tau using multidimensional NMR spectroscopy. NMR secondary chemical shifts detect residual beta-structure for 8-10 residues at the beginning of repeats R2-R4. These regions correspond to sequence motifs known to form the core of the cross-beta-structure of tau-paired helical filaments. Chemical shift perturbation studies show that polyanions, which promote paired helical filament aggregation, as well as microtubules interact with tau through positive charges near the ends of the repeats and through the beta-forming motifs at the beginning of repeats 2 and 3. The high degree of similarity between the binding of polyanions and microtubules supports the hypothesis that stable microtubules prevent paired helical filament formation by blocking the tau-polyanion interaction sites, which are crucial for paired helical filament formation.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Zweckstetter, M (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzwecks@gwdg.de	von Bergen, Martin/D-7960-2011	von Bergen, Martin/0000-0003-2732-2977; Zweckstetter, Markus/0000-0002-2536-6581				Barghorn S, 2002, BIOCHEMISTRY-US, V41, P14885, DOI 10.1021/bi026469j; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Buee Luc, 2002, Journal de la Societe de Biologie, V196, P103; Craik D J, 1997, Methods Mol Biol, V60, P195; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Downing KH, 1999, CELL STRUCT FUNCT, V24, P269; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Eliezer D, 2005, BIOCHEMISTRY-US, V44, P1026, DOI 10.1021/bi048953n; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Goux WJ, 2004, J BIOL CHEM, V279, P26868, DOI 10.1074/jbc.M402379200; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; Hiraoka S, 2004, BIOCHEM BIOPH RES CO, V315, P659, DOI 10.1016/j.bbrc.2004.01.107; Jung YS, 2004, J BIOMOL NMR, V30, P11, DOI 10.1023/B:JNMR.0000042954.99056.ad; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; Minoura K, 2004, EUR J BIOCHEM, V271, P545, DOI 10.1046/j.1432-1033.2003.03956.x; Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422; Perez M, 1996, J NEUROCHEM, V67, P1183; Santarella RA, 2004, J MOL BIOL, V339, P539, DOI 10.1016/j.jmb.2004.04.008; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Smet C, 2004, CHEMBIOCHEM, V5, P1639, DOI 10.1002/cbic.200400145; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, MOL BIOL CELL, V11, p363A; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Zweckstetter M, 2001, J AM CHEM SOC, V123, P9490, DOI 10.1021/ja016496h	39	231	239	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24978	24986		10.1074/jbc.M501565200	http://dx.doi.org/10.1074/jbc.M501565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855160	hybrid			2022-12-25	WOS:000230114000082
J	Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R				Zhang, S; Wang, GZ; Liu, D; Bao, ZZ; Fernig, DG; Rudland, PS; Barraclough, R			The C-terminal region of S100A4 is important for its metastasis-inducing properties	ONCOGENE			English	Article						S100A4; breast cancer; metastasis; calcium; EF-hand	CALCIUM-BINDING PROTEIN; PROGNOSTIC-SIGNIFICANCE; IN-VITRO; NONMUSCLE MYOSIN; ESCHERICHIA-COLI; BREAST-CANCER; EXPRESSION; P9KA; MTS1; GENE	The EF-hand protein, S100A4, binds calcium ions and interacts specifically in vitro with protein targets. Elevated levels of S100A4 have been shown to produce a metastatic phenotype in independent models of breast cancer. The presence of S100A4 in the carcinoma cells of patients with different carcinomas is associated with reduced patient survival. In order to identify the region of the S100A4 molecule that is responsible for its metastasis-inducing properties, specific mutant S100A4 genes and proteins have been produced which contain targeted mutations to the two calcium-binding sites and a deletion of the last 15 amino-acid residues of the protein. The ability of the mutant proteins to bind to a potential specific target in vitro, nonmuscle myosin heavy chain, is correlated with their ability to cause motile, invasive and metastatic phenotypes. Mutation of the C-EF hand of S100A4 virtually abolished calcium binding, and motility/invasion in vitro, abolished interaction with a molecular target, and reduced metastasis induction by 2.5-3-fold. However, deletion of the last 15 amino acids of S100A4 reduced motility/invasion, target binding and metastasis-induction to similar extents as the C-EF-hand mutant, but reduced calcium binding by only 26%. The results suggest that the ability to interact with protein target(s) is important in S100A4-induced metastasis.	Univ Liverpool, Canc & Polio Res Fund Labs, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Canc & Polio Res Fund Labs, Biosci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.	brb@liv.ac.uk	Barraclough, Roger/AAH-6516-2020; Fernig, David G/A-3590-2008; Barraclough, Dong/V-4230-2019; Barraclough, Dong/E-2205-2012	Fernig, David G/0000-0003-4875-4293; Barraclough, Dong/0000-0001-8440-0623; Barraclough, Roger/0000-0002-7203-1194				Ambartsumian N, 1999, INVAS METAST, V18, P96; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; Chen HL, 2003, BIOCHEM BIOPH RES CO, V308, P408, DOI 10.1016/S0006-291X(03)01310-X; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; Davies MPA, 1996, ONCOGENE, V13, P1631; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jenkinson SR, 2004, BRIT J CANCER, V90, P253, DOI 10.1038/sj.bjc.6601483; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kimura K, 2000, INT J ONCOL, V16, P1125; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kriajevska M, 2002, J BIOL CHEM, V277, P5229, DOI 10.1074/jbc.M110976200; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Nakamura T, 2002, INT J ONCOL, V20, P937; Ninomiya I, 2001, INT J ONCOL, V18, P715; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rudland PS, 2000, CANCER RES, V60, P1595; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER B, 1996, GUIDEBOOK CALCIUM BI, P132; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; Zhang S, 2005, EUR BIOPHYS J BIOPHY, V34, P19, DOI 10.1007/s00249-004-0428-x	42	33	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4401	4411		10.1038/sj.onc.1208663	http://dx.doi.org/10.1038/sj.onc.1208663			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856021				2022-12-25	WOS:000229976900009
J	Schildknecht, S; Bachschmid, M; Ullrich, V				Schildknecht, S; Bachschmid, M; Ullrich, V			Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells	FASEB JOURNAL			English	Article						cyclooxygenase; prostanoid pathways	PROSTAGLANDIN-H SYNTHASE-1; NITRIC-OXIDE SYNTHASE; BOVINE CORONARY-ARTERIES; ENDOTHELIAL-CELLS; CYCLOOXYGENASE ACTIVITIES; HYDROPEROXIDE REDUCTION; SIMULTANEOUS GENERATION; TYROSINE NITRATION; REACTION-KINETICS; VESICULAR GLAND	Endotoxin-treated vascular smooth muscle cells (VSMCs) were recently shown to release high amounts of prostacyclin (PGI(2)) dependent on the induction of prostaglandin endoperoxide synthase-2 (PGHS-2). In contrast to endothelial PGI(2)-synthase, for which nitration and inhibition by peroxynitrite was reported, addition of SIN-I as a peroxynitrite-generating system did not cause inhibition but rather doubled PGI(2) release by VSMC. The hypothesis of peroxynitrite supplementing an unsaturated peroxide tone for PGHS-2 was supported by H2O2 exerting the same effect. Studies performed with purified PGHS-2 revealed maximal elevation of enzyme activity in the presence of equimolar concentrations of (NO)-N-center dot and O-center dot(2)-, which together form peroxynitrite, while excessive production of either one radical was inhibitory. Most importantly, 6-keto-PGF(1 alpha) formation by intact VSMC depended on a nearly equimolar generation of (NO)-N-center dot and center dot O-2(-) for providing the endogenous peroxide tone. These findings, together with the observation that an excess of exogenously added (NO)-N-center dot, as well as uric acid as a scavenger of peroxynitrite potently reduced PGI(2) release, underlined the role of peroxynitrite as the dominating and rate-limiting intracellular mediator of peroxide tone in VSMC. The results allow us to postulate a new cross-talk between the (NO)-N-center dot and the prostanoid pathways with a crucial role for peroxynitrite in providing the peroxide tone for a continuous activation of PGHS-2.	Univ Konstanz, Fak Biol, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Dept Biol, Fach X910 Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de		Bachschmid, Markus Michael/0000-0002-0748-5528				Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Daiber A, 2002, J BIOL CHEM, V277, P11882, DOI 10.1074/jbc.M111988200; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DONI MG, 1988, EUR J PHARMACOL, V151, P19; EGAN RW, 1976, J BIOL CHEM, V251, P7329; FU JY, 1990, J BIOL CHEM, V265, P16737; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HALUSHKA PV, 1985, CRIT CARE MED, V13, P451, DOI 10.1097/00003246-198506000-00001; HEMLER M, 1976, J BIOL CHEM, V251, P5575; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Lu GQ, 1999, J BIOL CHEM, V274, P16162, DOI 10.1074/jbc.274.23.16162; Margalit A, 1998, AM J PHYSIOL-REG I, V274, pR294, DOI 10.1152/ajpregu.1998.274.2.R294; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MATTHEWS JS, 1995, BBA-MOL CELL RES, V1269, P237, DOI 10.1016/0167-4889(95)00125-X; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MONCADA S, 1976, PROSTAGLANDINS, V12, P715, DOI 10.1016/0090-6980(76)90048-4; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Sato Y, 2004, J BIOL CHEM, V279, P8827, DOI 10.1074/jbc.M310327200; Schildknecht S, 2005, BIOCHEM BIOPH RES CO, V327, P43, DOI 10.1016/j.bbrc.2004.11.132; Schildknecht S, 2004, FASEB J, V18, P757, DOI 10.1096/fj.03-0609fje; Schmidt P, 2003, J BIOL CHEM, V278, P12813, DOI 10.1074/jbc.M208080200; Schwarz PM, 1999, ARTERIOSCL THROM VAS, V19, P2584, DOI 10.1161/01.ATV.19.11.2584; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Song I, 2001, BIOCHEM BIOPH RES CO, V289, P869, DOI 10.1006/bbrc.2001.6071; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; TSAI AL, 1994, ARCH BIOCHEM BIOPHYS, V313, P367, DOI 10.1006/abbi.1994.1400; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Upmacis RK, 1999, BIOCHEMISTRY-US, V38, P12505, DOI 10.1021/bi983049e; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weaver JA, 2001, FREE RADICAL BIO MED, V30, P299, DOI 10.1016/S0891-5849(00)00466-4; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231; ZEHETGRUBER M, 1993, LIFE SCI, V52, P1397, DOI 10.1016/0024-3205(93)90063-9; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	62	40	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1169	+		10.1096/fj.04-3465fje	http://dx.doi.org/10.1096/fj.04-3465fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15878931				2022-12-25	WOS:000229602600018
J	Sun, XL; Wang, YX; Qing, H; Christensen, MA; Liu, YQ; Zhou, WH; Tong, YG; Xiao, CY; Huang, Y; Zhang, SZ; Liu, XH; Song, WH				Sun, XL; Wang, YX; Qing, H; Christensen, MA; Liu, YQ; Zhou, WH; Tong, YG; Xiao, CY; Huang, Y; Zhang, SZ; Liu, XH; Song, WH			Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes	FASEB JOURNAL			English	Article						secretase; amyloid beta; transcription; promoter; Alzheimer's disease	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; FACTOR-BINDING SITES; ASPARTYL PROTEASE; CORTICAL-NEURONS; ALPHA-SECRETASE; KNOCKOUT MICE; DOWN-SYNDROME; HUMAN BRAIN; IN-VITRO	Amyloid beta protein (A beta) is the principal component of neuritic plaques in Alzheiirner's disease (AD). A beta is derived from beta amyloid precursor protein (APP) by beta- and gamma-secretases. Beta-site APP cleaving enzyme 1 (BACE1) has been identified as the major beta-secretase. BACE2 is the homolog of BACE1. The BACE2 gene is on chromosome 21 and has been implicated in the pathogenesis of AD. However, the function of BACE2 in A beta generation is controversial. Some studies have shown that BACE2 cleaved APP at the beta-site whereas other studies showed it cleaved around the alpha-secretase site. To elucidate the involvement of BACE2 in AD pathogenesis, we compared BACE2 and BACE1 gene regulation and their functions in A beta generation. We cloned and functionally characterized the human BACE2 promoter. The BACE2 gene is controlled by a TATA-less promoter. Though Sp1 can regulate both BACE1 and BACE2 genes, comparative sequence analysis and transcription factor prediction showed little similarity between the two promoters. BACE1 increased APP cleavage at the beta-site and A beta production whereas BACE2 did not. Overexpression of BACE2 significantly increased sAPP levels in conditioned media but markedly reduced A beta production. Knockdown of BACE2 resulted in increased APP C83. Our data indicate that despite being homologous in amino acid sequence, BACE2 and BACE1 have distinct functions and transcriptional regulation. BACE2 is not a beta-secretase, but processes APP within the A beta domain at a site downstream of the alpha-secretase cleavage site. Our data argue against BACE2 being involved in the formation of neuritic plaques in AD.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Grad Program Neurosci, Vancouver, BC V6T 1Z3, Canada; Sichuan Univ, W China Hosp, Dept Psychiat, Chengdu, Sichuan, Peoples R China; Sichuan Univ, W China Hosp, Dept Med Genet, Chengdu, Sichuan, Peoples R China; Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China	University of British Columbia; University of British Columbia; Sichuan University; Sichuan University; Sichuan University	Song, WH (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	weihong@interchange.ubc.ca	Song, Weihong/O-7623-2017	Song, Weihong/0000-0001-9928-889X; Tong, Yigang/0000-0002-8503-8045				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Andrau D, 2003, J BIOL CHEM, V278, P25859, DOI 10.1074/jbc.M302622200; Barath P, 2004, EUR J BIOCHEM, V271, P1781, DOI 10.1111/j.1432-1033.2004.04090.x; Basi G, 2003, J BIOL CHEM, V278, P31512, DOI 10.1074/jbc.M300169200; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DHooge R, 1996, NEUROREPORT, V7, P2807, DOI 10.1097/00001756-199611040-00080; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Freiman RN, 2002, SCIENCE, V296, P2149, DOI 10.1126/science.1073845; Garcia-Martinez J, 2004, MOL CELL, V15, P303, DOI 10.1016/j.molcel.2004.06.004; Ge YW, 2004, FASEB J, V18, P1037, DOI 10.1096/fj.03-1379fje; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lott IT, 2001, MENT RETARD DEV D R, V7, P172, DOI 10.1002/mrdd.1025; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Murphy T, 2001, NEUROREPORT, V12, P631, DOI 10.1097/00001756-200103050-00040; Nowotny P, 2001, NEUROREPORT, V12, P1799, DOI 10.1097/00001756-200107030-00008; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Osada S, 1997, J BIOCHEM, V121, P355; Ovcharenko I, 2004, GENOME RES, V14, P472, DOI 10.1101/gr.2129504; Parks CL, 1996, J BIOL CHEM, V271, P4417; Pham NL, 2004, ARTERIOSCL THROM VAS, V24, P982, DOI 10.1161/01.ATV.0000126679.70877.d0; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Przyborski SA, 2003, STEM CELLS, V21, P459; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Ryu H, 2003, J NEUROSCI, V23, P3597; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Sullivan AA, 2003, MOL ENDOCRINOL, V17, P2125, DOI 10.1210/me.2002-0430; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang GX, 2004, MOL GENET GENOMICS, V271, P468, DOI 10.1007/s00438-004-0998-4; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	56	107	115	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					739	749		10.1096/fj.04-3426com	http://dx.doi.org/10.1096/fj.04-3426com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857888				2022-12-25	WOS:000229602600030
J	Andi, B; West, AH; Cook, PF				Andi, B; West, AH; Cook, PF			Regulatory mechanism of histidine-tagged homocitrate synthase from Saccharomyces cerevisiae - I. Kinetic studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMINOADIPATE PATHWAY; LYSINE BIOSYNTHESIS; YEAST; METABOLISM; ISOENZYME; ENZYME; FUNGI	Homocitrate synthase (HCS) catalyzes one of the regulated steps of the alpha-aminoadipate pathway for lysine biosynthesis in fungi. The kinetic mechanism of regulation of HCS from Saccharomyces cerevisiae by Na+ and the feedback inhibitor lysine was studied by measuring the initial rate in the absence and presence of the effectors. The data suggest that Na+ is an activator at low concentrations and an inhibitor at high concentrations and that these effects occur as a result of the monovalent ion binding to two different sites in the free enzyme. Inhibition and activation by Na+ can occur simultaneously, with the net rate of the enzyme determined by Na+/K-iNa+ and Na+/ K-act, where K-iNa(+) and K-act are the inhibition and activation constants, respectively. The inhibition by Na+ was eliminated at high concentrations of acetyl-CoA, the second substrate bound, but the activation remained. Fluorescence binding studies indicated that lysine bound with high affinity to its binding site as an inhibitor. The inhibition by lysine was competitive versus alpha-ketoglutarate and linear in the physiological range of lysine concentrations up to 5 mM. The effects of Na+ and lysine were independent of one another. A model is developed for regulation of HCS that takes into account all of the effects discussed above.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu		Andi, Babak/0000-0002-7666-639X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 071417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andi B, 2005, J BIOL CHEM, V280, P31633, DOI 10.1074/jbc.M502847200; Andi B, 2004, BIOCHEMISTRY-US, V43, P11790, DOI 10.1021/bi048766p; Andi B, 2004, ARCH BIOCHEM BIOPHYS, V421, P243, DOI 10.1016/j.abb.2003.11.005; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BHATTACHARJEE JK, 1992, EVOLUTION METABOLIC, P47; Chen SP, 1997, J BIOL CHEM, V272, P10839; COOK PF, 1982, BIOCHEMISTRY-US, V21, P113, DOI 10.1021/bi00530a020; Feller A, 1999, EUR J BIOCHEM, V261, P163, DOI 10.1046/j.1432-1327.1999.00262.x; Feller A, 1997, YEAST, V13, P1337, DOI 10.1002/(SICI)1097-0061(199711)13:14<1337::AID-YEA186>3.0.CO;2-O; GAILLARDIN CM, 1976, BIOCHIM BIOPHYS ACTA, V422, P390, DOI 10.1016/0005-2744(76)90150-9; Giuseppin MLF, 2000, METAB ENG, V2, P14, DOI 10.1006/mben.1999.0134; Hans MA, 2003, BIOTECHNOL BIOENG, V82, P143, DOI 10.1002/bit.10553; Hans MA, 2001, APPL MICROBIOL BIOT, V56, P776, DOI 10.1007/s002530100708; JAKLITSCH WM, 1990, BIOCHEM J, V269, P247, DOI 10.1042/bj2690247; Johansson E, 2000, STRUCTURE, V8, P1037, DOI 10.1016/S0969-2126(00)00512-8; Liu WS, 2004, BIOCHEMISTRY-US, V43, P4998, DOI 10.1021/bi035854l; Ramos F, 1996, YEAST, V12, P1315, DOI 10.1002/(SICI)1097-0061(199610)12:13<1315::AID-YEA20>3.3.CO;2-H; TERSCHURE EG, 1995, J BACTERIOL, V177, P6672, DOI 10.1128/jb.177.22.6672-6675.1995; TRACY JW, 1975, P NATL ACAD SCI USA, V72, P1802, DOI 10.1073/pnas.72.5.1802; UMBARGER HE, 1987, ANNU REV BIOCHEM, V47, P532; VOGEL HJ, 1960, BIOCHIM BIOPHYS ACTA, V41, P172, DOI 10.1016/0006-3002(60)90392-9; WOEHL EU, 1995, COORDIN CHEM REV, V144, P147, DOI 10.1016/0010-8545(94)08001-8; Wulandari AP, 2002, FEBS LETT, V522, P35, DOI 10.1016/S0014-5793(02)02877-6; Zabriskie TM, 2000, NAT PROD REP, V17, P85, DOI 10.1039/a801345d	24	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31624	31632		10.1074/jbc.M502846200	http://dx.doi.org/10.1074/jbc.M502846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15897192	hybrid			2022-12-25	WOS:000231665200037
J	Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ				Aouacheria, A; Navratil, V; Wen, WY; Jiang, M; Mouchiroud, D; Gautier, C; Gouy, M; Zhang, MJ			In silico whole-genome scanning of cancer-associated nonsynonymous SNPs and molecular characterization of a dynein light chain tumour variant	ONCOGENE			English	Article						single-nucleotide polymorphism; DNCL1; cancer genomics; cancer association study; dynein light chain; expressed sequence tags	SINGLE-NUCLEOTIDE POLYMORPHISMS; ACID SUBSTITUTION VARIANTS; INITIATION-FACTORS EIF-4E; AFFECT PROTEIN FUNCTION; NITRIC-OXIDE SYNTHASE; DNA-REPAIR GENES; SEQUENCE VARIATION; STRUCTURAL BASIS; MOTOR COMPLEX; CELL-ADHESION	Last decade has led to the accumulation of large amounts of data on cancer genetics, opening an unprecedented access to the mapping of cancer genes in the human genome. Single-nucleotide polymorphisms ( SNPs), the most common form of DNA variation in humans, emerge as an invaluable tool for cancer association studies. These genotypic markers can be used to assay how alleles of candidate genes correlate with the malignant phenotype, and may provide new clues into the genetic modi. cations that characterize cancer onset. In this cancer-oriented study, we detail an SNP mining strategy based on the analysis of expressed sequence tags among publicly available databases. Our whole-genome approach provides a comprehensive and unbiased description of nonsynonymous SNPs ( nsSNPs) in tumoral versus normal tissues. To gain further insights into the possible relationships between genetic variation and altered phenotype, locations of a subset of nsSNPs were mapped onto protein domains known to be critical for protein function. Computational methods were also used to predict the potential impact of these cancer-associated nsSNPs on protein structure and function. We illustrate our approach through the detailed biochemical and structural characterization of a previously unknown cancer-associated mutation ( G79C) affecting the 8 kDa dynein light chain ( DNCL1).	Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Hong Kong University of Science & Technology	Aouacheria, A (corresponding author), Univ Lyon 1, CNRS, UMR 5558, Lab Biometr & Biol Evolut, F-69622 Villeurbanne, France.	aouacher@biomserv.univ-lyon1.fr	navratil, vincent/C-4193-2008	Zhang, Mingjie/0000-0001-9404-0190; navratil, vincent/0000-0001-9974-1877				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bassen R, 2000, B CANCER, V87, P703; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Buetow KH, 2001, P NATL ACAD SCI USA, V98, P581, DOI 10.1073/pnas.021506298; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; Chakravarti A, 1998, NAT GENET, V19, P216, DOI 10.1038/885; Chasman D, 2001, J MOL BIOL, V307, P683, DOI 10.1006/jmbi.2001.4510; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Dick T, 1996, MOL CELL BIOL, V16, P1966; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iida A, 2002, J HUM GENET, V47, P285, DOI 10.1007/s100380200041; Imyanitov EN, 2004, CANCER LETT, V204, P3, DOI 10.1016/j.canlet.2003.09.026; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mohrenweiser HW, 2002, CANCER EPIDEM BIOMAR, V11, P1054; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ng PC, 2002, GENOME RES, V12, P436, DOI 10.1101/gr.212802; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Phillis R, 1996, DEVELOPMENT, V122, P2955; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qiu P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-4; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sajantila A, 1999, EUR J HUM GENET, V7, P263, DOI 10.1038/sj.ejhg.5200257; Sass PM, 1998, CANCER INVEST, V16, P322, DOI 10.3109/07357909809084652; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Stitziel NO, 2003, J MOL BIOL, V327, P1021, DOI 10.1016/S0022-2836(03)00240-7; Strausberg RL, 2003, NAT REV GENET, V4, P409, DOI 10.1038/nrg1085; Sunyaev S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591; Sunyaev S, 2001, CURR OPIN STRUC BIOL, V11, P125, DOI 10.1016/S0959-440X(00)00175-5; Turk V, 2004, CANCER CELL, V5, P409, DOI 10.1016/S1535-6108(04)00117-5; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Wall Steven J., 2003, Cancer Research, V63, P4750; Wang WN, 2003, J BIOL CHEM, V278, P41491, DOI 10.1074/jbc.M307118200; Wang Z, 2001, HUM MUTAT, V17, P263, DOI 10.1002/humu.22; Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016	63	15	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6133	6142		10.1038/sj.onc.1208745	http://dx.doi.org/10.1038/sj.onc.1208745			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897869				2022-12-25	WOS:000231718100007
J	Al Masri, A; Gendler, SJ				Al Masri, A; Gendler, SJ			Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis	ONCOGENE			English	Article						mucin; oncogene; transgenic mice; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; INTERCELLULAR-ADHESION MOLECULE-1; MIDDLE T-ANTIGEN; BREAST-CANCER; BETA-CATENIN; TYROSINE KINASE; FOCAL ADHESIONS; CELL-ADHESION; STAT PROTEINS; V-SRC	MUC1 is an integral membrane mucin glycoprotein that is normally expressed on the apical surface of most simple, secretory epithelia and hematopoietic cells. Overexpression of aberrantly glycosylated MUC1 is a hallmark of many carcinomas including 90% of breast carcinomas. MUC1 has been shown to bind to c-Src tyrosine kinase in vitro, whereby c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif. c-Src is an extensively studied nonreceptor tyrosine kinase implicated in mammary tumorigenesis. Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice crossed onto a Muc1 null background exhibited a significant delay in tumor progression. c-Src has been shown to interact with PyV MT, and to play an integral and indispensable role in MMTV-PyV MT-induced mammary tumorigenesis. Here, we determine the effect of Muc1 expression on c-Src activation and signaling. Examination of MMTV-PyV MT glands on a wild-type or Muc1 null background demonstrates that Muc1 expression promotes c-Src signaling by influencing its association with known substrates such as the p85 subunit of phosphatidylinositol 3-kinase and beta-catenin. These findings may provide a mechanism for the delay in tumor progression that is observed in the absence of Muc1.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu			NCI NIH HHS [R01CA64389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; FREUND R, 1992, AM J PATHOL, V141, P1409; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kam JL, 1998, CANCER RES, V58, P5577; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; MOCKENSTURMGARD.M, 1998, P AM ASSOC CANC RES, V39, pA375; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PANDEY P, 1995, CANCER RES, V55, P4000; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rowse GJ, 1998, CANCER RES, V58, P315; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZOTTER S, 1988, Cancer Reviews, V11-12, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	56	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5799	5808		10.1038/sj.onc.1208738	http://dx.doi.org/10.1038/sj.onc.1208738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897873				2022-12-25	WOS:000231590400002
J	Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C				Ruiz-Vela, A; Piqueras, R; Carvalho-Pinto, C; Gomez, L; Yaniz-Galende, E; Moreno-Ortiz, MC; Bernad, A; Harshman, K; Martinez, C			ZAP-70 upregulation in transformed B cells after early pre-BI cell transplant into NOD/SCID mice	ONCOGENE			English	Article						pre-B cells; microarray; lineage; NOD/SCID; transplant	CHRONIC LYMPHOCYTIC-LEUKEMIA; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION; CD19; PHENOTYPE; PROTEINS	Understanding of the signal transduction pathways that lead to B cell development is of extreme interest to learn how alterations in these pathways might initiate malignant transformation. Long- term cultured early pre-BI cells can differentiate into IgM(+) B cells after transplant into NOD/SCID mice, offering the possibility to explore checkpoints in B cell development. Using DNA microarray and Western blot analysis of IgM(+)B cells vs parental early pre-BI cells, we demonstrated that zetaassociated protein 70 (ZAP-70) is upregulated in our B cell differentiation model. Unlike parental ZAP-70(-) early pre-BI cells, ZAP-70(+) IgM B cells exhibited a transformed phenotype, as indicated by BCL-6 expression, a high Ki-67 proliferation index, resistance to IL-7 deprivation-induced apoptosis, and an increased repopulation rate in NOD/SCID mice. These data show the characterization and generation of a novel murine leukemia model with many similarities to human ZAP70(+) B cell chronic lymphocytic leukemia.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Ruiz-Vela, A (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	aruiz@cnb.uam.es	Bernad, Antonio/P-8573-2017; Carla, Carvalho-Pinto Eponina/GXG-7917-2022	Carla, Carvalho-Pinto Eponina/0000-0002-1815-8418; Ruiz-Vela, Antonio/0000-0002-4410-6208; Bernad, Antonio/0000-0003-0620-9668				Astsaturov IA, 1997, LEUKEMIA LYMPHOMA, V26, P337, DOI 10.3109/10428199709051783; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; CORDONE I, 1992, LEUKEMIA, V6, P902; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hunte BE, 1998, EUR J IMMUNOL, V28, P3850; Ibrahim S, 2001, BLOOD, V98, P181, DOI 10.1182/blood.V98.1.181; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSTO P, 1990, HAEMATOLOGICA, V75, P583; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; O'Riordan M, 2000, IMMUNOL REV, V175, P94, DOI 10.1034/j.1600-065X.2000.017503.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; RANHEIM EA, 1995, BLOOD, V85, P3556, DOI 10.1182/blood.V85.12.3556.bloodjournal85123556; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	27	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5119	5124		10.1038/sj.onc.1208706	http://dx.doi.org/10.1038/sj.onc.1208706			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856008				2022-12-25	WOS:000230816900011
J	Guo, F; Gabor, J; Cen, S; Hu, K; Mouland, AJ; Kleiman, L				Guo, F; Gabor, J; Cen, S; Hu, K; Mouland, AJ; Kleiman, L			Inhibition of cellular HIV-1 protease activity by lysy1-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSFER-RNA SYNTHETASE; PRIMER TRANSFER-RNAS; WILD-TYPE; TRNA(LYS) INCORPORATION; VIRAL INFECTIVITY; LIVING CELLS; GAG; PR160GAG-POL; PARTICLES	During early assembly of human immunodeficiency virus type 1 (HIV-1), an assembly complex is formed, the components of which include genomic RNA, Gag, Gag-Pol, tRNALys, and lysyl tRNA synthetase (LysRS). Directly increasing or decreasing cellular expression of LysRS results in corresponding changes in viral infectivity and in the viral concentrations of LysRS, tRNALys, and, surprisingly, reverse transcriptase (RT). Since altering the cellular expression of LysRS does not lead to a change in the incorporation of the RT precursor protein, GagPol, in protease-negative HIV-1, we propose that the altered viral content of RT resulting from alterations in cellular LysRS concentration results from the ability of LysRS to inhibit premature activation of GagPol viral protease within the complex. Supporting this hypothesis, we find that increases and decreases in cellular LysRS expression are accompanied by 5-8-fold increases and 5-fold decreases, respectively, in the cytoplasmic proteolysis of Gag and GagPol to mature viral proteins. Using a novel bioluminescence resonance energy transfer assay to directly measure HIV-1 protease activity in vivo also indicates that the overexpression of LysRS in the cell reduces viral protease activity.	Lady Davis Inst Med Res, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol & Microbiol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Kleiman, L (corresponding author), Lady Davis Inst Med Res, Jewish Gen Hosp, 3755 Cote St,Catherine Rd, Montreal, PQ H3T 1E2, Canada.	lawrence.kleiman@mcgill.ca		Guo, Fei/0000-0003-3500-1006				Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Cen S, 2004, J VIROL, V78, P1595, DOI 10.1128/JVI.78.3.1595-1601.2004; Cen S, 2002, J VIROL, V76, P13111, DOI 10.1128/JVI.76.24.13111-13115.2002; Chatel-Chaix L, 2004, MOL CELL BIOL, V24, P2637, DOI 10.1128/MCB.24.7.2637-2648.2004; Gabor J, 2002, J VIROL, V76, P9096, DOI 10.1128/JVI.76.18.9096-9102.2002; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Guo F, 2003, J VIROL, V77, P9817, DOI 10.1128/JVI.77.18.9817-9822.2003; Halwani R, 2004, J VIROL, V78, P7553, DOI 10.1128/JVI.78.14.7553-7564.2004; HU K, 2005, IN PRESS J VIROL MET; HUANG Y, 1994, J VIROL, V68, P7676, DOI 10.1128/JVI.68.12.7676-7683.1994; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; Khorchid A, 2002, J VIROL, V76, P4131, DOI 10.1128/JVI.76.8.4131-4137.2002; Khorchid A, 2000, J MOL BIOL, V299, P17, DOI 10.1006/jmbi.2000.3709; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Pettit SC, 2004, J VIROL, V78, P8477, DOI 10.1128/JVI.78.16.8477-8485.2004; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SMITH AJ, 1990, J VIROL, V64, P2743, DOI 10.1128/JVI.64.6.2743-2750.1990; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; SRINIVASAKUMAR N, 1995, J VIROL, V69, P6106, DOI 10.1128/JVI.69.10.6106-6114.1995; Swanstrom R., 1997, P263; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222	25	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26018	26023		10.1074/jbc.M502454200	http://dx.doi.org/10.1074/jbc.M502454200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888436	hybrid			2022-12-25	WOS:000230386800010
J	Bobofchak, KM; Pineda, AO; Mathews, FS; Di Cera, E				Bobofchak, KM; Pineda, AO; Mathews, FS; Di Cera, E			Energetic and structural consequences of perturbing Gly-193 in the oxyanion hole of serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE STABILIZATION; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; NA+ BINDING; THROMBIN; CHYMOTRYPSIN; MECHANISM; ENZYME; PROTEINASES	The oxyanion hole of serine proteases is formed by the backbone N atoms of the catalytic Ser-195 and Gly-193 and engages the backbone O atom of the P1 residue of substrate in an important H-bonding interaction. The energetic contribution of this interaction in the ground and transition states is presently unknown. Measurements of the individual rate constants defining the catalytic mechanism of substrate hydrolysis for wild-type thrombin and trypsin and their G193A and G193P mutants reveal that Gly-193 is required for optimal substrate binding and acylation. Crystal structures of the G193A and G193P mutants of thrombin bound to the active site inhibitor H-D-Phe-Pro-Arg-CH2Cl document the extent of perturbation induced by the replacement of Gly-193. The Ala mutant weakens the H-bonding interaction of the N atom of residue 193, whereas the Pro substitution abrogates it altogether with additional small shifts of the protein backbone. From the kinetic and structural data, we estimate that the H-bonding interaction in the oxyanion hole contributes a stabilization of the ground and transition states of > 1.5 kcal/mol but < 3.0 kcal/mol. These results shed light on a basic aspect of the enzyme-substrate interaction in the entire family of trypsin-like serine proteases.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			NHLBI NIH HHS [HL49413, HL73813, HL58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R29HL049413, R01HL049413, R01HL058141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; BARNES WM, 2003, PCR PRIMER LAB MANUA, P441; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; Braud S, 2000, J BIOL CHEM, V275, P1823, DOI 10.1074/jbc.275.3.1823; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; Carlos JL, 2000, BIOCHEMISTRY-US, V39, P7276, DOI 10.1021/bi000301l; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Ordentlich A, 1998, J BIOL CHEM, V273, P19509, DOI 10.1074/jbc.273.31.19509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parry MAA, 1998, STRUCT FOLD DES, V6, P1195, DOI 10.1016/S0969-2126(98)00119-1; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Schmidt AE, 2004, J BIOL CHEM, V279, P29485, DOI 10.1074/jbc.M402971200; STOLL VS, 1990, METHOD ENZYMOL, V182, P24; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; van Holde KE, 2002, BIOPHYS CHEM, V101, P249, DOI 10.1016/S0301-4622(02)00176-X; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	32	47	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25644	25650		10.1074/jbc.M503499200	http://dx.doi.org/10.1074/jbc.M503499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890651	hybrid			2022-12-25	WOS:000230207900044
J	Cao, X; Kambe, F; Lu, XL; Kobayashi, N; Ohmori, S; Seo, H				Cao, X; Kambe, F; Lu, XL; Kobayashi, N; Ohmori, S; Seo, H			Glutathionylation of two cysteine residues in paired domain regulates DNA binding activity of Pax-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID FRTL-5 CELLS; NF-KAPPA-B; REDOX REGULATION; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; REPAIR ENZYME; CYCLIC-AMP; REF-1	We reported that the first two cysteine residues out of three present in paired domain (PD), a DNA-binding domain, are responsible for redox regulation of Pax-8 DNA binding activity. We show that glutathionylation of these cysteines has a regulatory role in PD binding. Wild-type PD and its mutants with substitution of cysteine to serine were synthesized and named CCC, CSS, SCS, SSC, and SSS according to the positions of substituted cysteines. They were incubated in a buffer containing various ratios of GSH/GSSG and subjected to gel shift assay. Binding of CCC, CSS, and SCS was impaired with decreasing GSH/GSSG ratio, whereas that of SSC and SSS was not affected. Because [(3)H]glutathione was incorporated into CCC, CSS, and SCS, but not into SSC and SSS, the binding impairment was ascribed to glutathionylation of the redox-reactive cysteines. This oxidative inactivation of PD binding was reversed by a reductant dithiothreitol and by redox factor (Ref)-1 in vitro. To explore the glutathionylation in cells, Chinese hamster ovary cells overexpressing CSS and SCS were labeled with [(35)S]cysteine in the presence of cycloheximide. Immunoprecipitation with an antibody against PD revealed that treatment of the cells with an oxidant diamide induced the (35)S incorporation into both mutants, suggesting the PD glutathionylation in cells. Since the two cysteine residues in PD are conserved in all Pax members, this novel posttranslational modification of PD would provide a new insight into molecular basis for modulation of Pax function.	Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 4648601, Japan	Nagoya University	Kambe, F (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adaptat, Nagoya, Aichi 4648601, Japan.	kambe@riem.nagoya-u.ac.jp		Lu, Xiuli/0000-0003-4267-1112				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Cao X, 2002, BIOCHEM BIOPH RES CO, V297, P288, DOI 10.1016/S0006-291X(02)02196-4; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hothersall JS, 1997, BIOCHEM J, V322, P477, DOI 10.1042/bj3220477; Humphries KM, 2002, J BIOL CHEM, V277, P43505, DOI 10.1074/jbc.M207088200; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Iseki A, 2000, ENDOCRINOLOGY, V141, P4373, DOI 10.1210/en.141.12.4373; KAMBE F, 1992, MOL ENDOCRINOL, V6, P443, DOI 10.1210/me.6.3.443; Kambe F, 1996, J ENDOCRINOL, V150, P287, DOI 10.1677/joe.0.1500287; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Lonigro R, 2000, ENDOCRINOLOGY, V141, P901, DOI 10.1210/en.141.3.901; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Musallam L, 2004, J CELL PHYSIOL, V198, P62, DOI 10.1002/jcp.10389; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Poleev A, 1997, EUR J BIOCHEM, V247, P860, DOI 10.1111/j.1432-1033.1997.00860.x; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; Tell G, 2000, J MOL ENDOCRINOL, V24, P383, DOI 10.1677/jme.0.0240383; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; Vilain C, 2001, J CLIN ENDOCR METAB, V86, P234, DOI 10.1210/jc.86.1.234; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	44	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25901	25906		10.1074/jbc.M411443200	http://dx.doi.org/10.1074/jbc.M411443200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888455	hybrid			2022-12-25	WOS:000230207900080
J	Corvey, C; Koetter, P; Beckhaus, T; Hack, J; Hofmann, S; Hampel, M; Stein, T; Karas, M; Entian, KD				Corvey, C; Koetter, P; Beckhaus, T; Hack, J; Hofmann, S; Hampel, M; Stein, T; Karas, M; Entian, KD			Carbon source-dependent assembly of the Snf1p kinase complex in Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HAPLOID INVASIVE GROWTH; SACCHAROMYCES-CEREVISIAE; YEAST SNF1; CATABOLITE REPRESSION; GLUCOSE REPRESSION; SUBCELLULAR-LOCALIZATION; BETA-SUBUNITS; GENE; TRANSFORMATION	The Snf1p/AMP-activated kinases are involved in transcriptional, metabolic, and developmental regulation in response to stress. In Saccharomyces cerevisiae, Snf1p (Cat1p) is one of the key regulators of carbohydrate metabolism, and cat1 (snf1) mutants fail to grow with non-fermentable carbon sources. In Candida albicans, Snf1p is an essential protein and cells depend on a functional Snf1 kinase even with glucose as carbon source. We investigated the CaSnf1p complex after tandem affinity purification and mass spectrometric analysis and show that the complex composition changes with the carbon source provided. Three subunits were identified, one of which was named CaSnf4p because of its homology to the ScSnf4 protein and the respective CaSNF4 gene could complement a S. cerevisiae snf4 mutant. The other two proteins revealed similarities to the S. cerevisiae kinase beta subunits ScGal83p, ScSip2p, and ScSip1p. Both genes complemented the scaffold function in a S. cerevisiae gal83,sip1,sip2 triple deletion mutant and were named according to their scaffold function as CaKIS1p and CaKIS2p. Matrix-assisted laser desorption ionization peptide mass fingerprint analysis indicated that CaKis2p is N-terminal myristoylated and the incorporation of CaKis2p in the Snf1p complex was reduced when compared with cells grown with glucose as a carbon source. To verify the different complex assemblies, a stable isotope labeling technique (iTraq (TM)) was employed, confirming a 3-fold decrease of CaKis2p with ethanol. Yeast two-hybrid analysis confirmed the interaction partners, and these results showed an activator domain for the CaKis2 protein that has not been reported for S. cerevisiae scaffold subunits.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Microbiol, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Corvey, C (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	corvey@iachem.uni-frankfurt.de; koetter@em.uni-frankfurt.de	Hack, Sandra/F-1833-2011; Entian, Karl-Dieter/D-3080-2011					Aivaliotis M, 2004, ELECTROPHORESIS, V25, P3468, DOI 10.1002/elps.200406079; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Ashrafi K, 2000, GENE DEV, V14, P1872; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Coligan JE, 1995, CURRENT PROTOCOLS PR; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Cullen PJ, 2000, P NATL ACAD SCI USA, V97, P13619, DOI 10.1073/pnas.240345197; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Enloe B, 2000, J BACTERIOL, V182, P5730, DOI 10.1128/JB.182.20.5730-5736.2000; ENTIAN KD, 1982, J BACTERIOL, V151, P1123, DOI 10.1128/JB.151.3.1123-1128.1982; ENTIAN KD, 1977, MOL GEN GENET, V156, P99, DOI 10.1007/BF00272258; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hedbacker K, 2004, MOL CELL BIOL, V24, P1836, DOI 10.1128/MCB.24.5.1836-1843.2004; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; HUBBARD EJA, 1992, GENETICS, V130, P71; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kanai T, 1999, ARCH MICROBIOL, V172, P256, DOI 10.1007/s002030050768; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kuchin S, 2003, BIOCHEM SOC T, V31, P175, DOI 10.1042/bst0310175; LAEMMLI UK, 1970, NATURE, V227, P685; Lin SS, 2003, J BIOL CHEM, V278, P13390, DOI 10.1074/jbc.M212818200; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MILLER JH, 1992, SHORT COURSE BACTERI, P71; NEIGEBORN L, 1984, GENETICS, V108, P845; ODDS FC, 1988, CANDIDA CANDIDOSIS, P279; Petter R, 1997, INFECT IMMUN, V65, P4909, DOI 10.1128/IAI.65.12.4909-4917.1997; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Purnapatre K, 2002, GENES CELLS, V7, P675, DOI 10.1046/j.1365-2443.2002.00551.x; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; SCHULLER HJ, 1988, GENE, V67, P247; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Uhl MA, 2003, EMBO J, V22, P2668, DOI 10.1093/emboj/cdg256; Vincent O, 2001, GENE DEV, V15, P1104, DOI 10.1101/gad.879301; Vyas VK, 2003, MOL CELL BIOL, V23, P1341, DOI 10.1128/MCB.23.4.1341-1348.2003; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	52	42	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25323	25330		10.1074/jbc.M503719200	http://dx.doi.org/10.1074/jbc.M503719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890650	hybrid			2022-12-25	WOS:000230207900004
J	Begon, DY; Delacroix, L; Vernimmen, D; Jackers, P; Winkler, R				Begon, DY; Delacroix, L; Vernimmen, D; Jackers, P; Winkler, R			Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; BINDING-SITES; RETINOBLASTOMA PROTEIN; SIGNALING NETWORK; FACTOR YY1; OVEREXPRESSION; REGULATOR; HER2; IDENTIFICATION	Overexpression of the ERBB2 oncogene is observed in about 30% of breast cancers and is generally correlated with a poor prognosis. Previous results from our and other laboratories indicated that elevated transcriptional activity contributes significantly to the overexpression of ERBB2 mRNA in mammary adenocarcinoma cell lines. Activator protein 2 (AP-2) transcription factors account for this overexpression through two recognition sequences located 215 and 500 bp upstream from the transcription start site. Furthermore, AP-2 transcription factors are highly expressed in cancer cell lines overexpressing ERBB2. In this report, we examined the cooperative effect of Yin Yang 1 (YY1) on AP-2-induced activation of ERBB2 promoter activity. We detected high levels of YY1 transcription factor in mammary cancer cell lines. Notably, we showed that YY1 enhances AP-2 alpha transcriptional activation of the ERBB2 promoter through an AP-2 site both in HepG2 and in HCT116 cells, whereas a carboxyl- terminal- truncated form of YY1 cannot. Moreover, we demonstrated the interaction between endogenous AP-2 and YY1 factors in the BT-474 mammary adenocarcinoma cell line. In addition, inhibition of endogenous YY1 protein by an antisense decreased the transcription of an AP-2-responsive ERBB2 reporter plasmid in BT-474 breast cancer cells. Finally, we detected in vivo AP-2 and YY1 occupancy of the ERBB2 proximal promoter in chromatin immunoprecipitation assays. Our data thus provide evidence that YY1 cooperates with AP2 to stimulate ERBB2 promoter activity through the AP-2 binding sites.	Univ Liege, Expt Canc Res Ctr, Ctr Biomed Integrat Genoproteom, Mol Oncol Lab, B-4000 Liege, Belgium; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, MRC Mol Haematol Unit, Oxford OX3 9DS, England	University of Liege; University of Oxford	Winkler, R (corresponding author), Univ Liege, Expt Canc Res Ctr, Ctr Biomed Integrat Genoproteom, Mol Oncol Lab, B-4000 Liege, Belgium.	rwinkler@ulg.ac.be		Delacroix, Laurence/0000-0003-3440-5359				Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; Bushmeyer SM, 1998, J CELL BIOCHEM, V68, P484, DOI 10.1002/(SICI)1097-4644(19980315)68:4<484::AID-JCB8>3.3.CO;2-F; Cheng C, 2002, INT J BIOCHEM CELL B, V34, P78, DOI 10.1016/S1357-2725(01)00098-X; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gilles C, 1999, J CELL SCI, V112, P4615; Grooteclaes M, 1999, CANCER RES, V59, P2527; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Jackers P, 2004, J BIOL CHEM, V279, P52183, DOI 10.1074/jbc.M407489200; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim J, 2003, HUM MOL GENET, V12, P233, DOI 10.1093/hmg/ddg028; Klapper LN, 2000, ADV CANCER RES, V77, P25; LEE TC, 1994, ONCOGENE, V9, P1047; Menard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425; Neve RM, 2002, ONCOGENE, V21, P3934, DOI 10.1038/sj.onc.1205503; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; PASLEAU F, 1993, ONCOGENE, V8, P849; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; Raval-Pandya M, 2001, MOL ENDOCRINOL, V15, P1035, DOI 10.1210/me.15.6.1035; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Turner BC, 1998, CANCER RES, V58, P5466; Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238; Wu F, 2001, J BIOL CHEM, V276, P28, DOI 10.1074/jbc.M006074200; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	44	77	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24428	24434		10.1074/jbc.M503790200	http://dx.doi.org/10.1074/jbc.M503790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870067	hybrid, Green Submitted			2022-12-25	WOS:000230114000018
J	Chintharlapalli, S; Burghardt, R; Papineni, S; Ramaiah, S; Yoon, K; Safe, S				Chintharlapalli, S; Burghardt, R; Papineni, S; Ramaiah, S; Yoon, K; Safe, S			Activation of Nur77 by selected 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes induces apoptosis through nuclear pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN STEROID-RECEPTOR; OVARIAN-CARCINOMA CELLS; MAMMARY-TUMOR GROWTH; BREAST-CANCER CELLS; COACTIVATOR RECRUITMENT; HORMONE RECEPTORS; GENE-EXPRESSION; IN-VIVO; NGFI-B; SUPERFAMILY	Nur77 is an orphan receptor and a member of the nerve growth factor-I-B subfamily of the nuclear receptor family of transcription factors. Based on the results of transactivation assays in pancreatic and other cancer cell lines, we have now identified for the first time Nur77 agonists typified by 1,1-bis(3-indolyl)-1-(p-anisyl)methane that activate GAL4-Nur77 chimeras expressing wildtype and the ligand binding domain (E/F) of Nur77. In Panc-28 pancreatic cancer cells, Nur77 agonists activate the nuclear receptor, and downstream responses include decreased cell survival and induction of cell death pathways, including tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) and poly(ADP-ribose) polymerase ( PARP) cleavage. Moreover, the transactivation and apoptotic responses are also induced in other pancreatic, prostate, and breast cancer cells that express Nur77. In Panc-28 cells, small inhibitory RNA for Nur77 reverses ligand-dependent transactivation and induction of TRAIL and PARP cleavage. Nur77 agonists also inhibit tumor growth in vivo in athymic mice bearing Panc-28 cell xenografts. These results identify compounds that activate Nur77 through the ligand binding domain and show that ligand-dependent activation of Nur77 through nuclear pathways in cancer cells induces cell death and these compounds are a novel class of anticancer agents.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU,Vet Res Bldg 409, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Burghardt, Robert C./AAF-4847-2021	Burghardt, Robert C./0000-0003-1021-8444	NCI NIH HHS [P20CA10193, CA108718] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benoit G, 2004, TRENDS CELL BIOL, V14, P369, DOI 10.1016/j.tcb.2004.05.007; CALNAN BJ, 1995, IMMUNITY, V3, P273; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Chintharlapalli S, 2004, CANCER RES, V64, P5994, DOI 10.1158/0008-5472.CAN-04-0399; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; He YW, 2002, J LEUKOCYTE BIOL, V72, P440; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Kim SO, 2003, J EXP MED, V197, P1441, DOI 10.1084/jem.20021842; Kuang AA, 1999, EUR J IMMUNOL, V29, P3722, DOI 10.1002/(SICI)1521-4141(199911)29:11<3722::AID-IMMU3722>3.0.CO;2-N; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; McDougal A, 2000, CANCER LETT, V151, P169, DOI 10.1016/S0304-3835(99)00406-1; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mohan R, 2003, CURR TOP MED CHEM, V3, P1637, DOI 10.2174/1568026033451709; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Qin CH, 2004, MOL CANCER THER, V3, P247; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; Shin HJ, 2004, CARCINOGENESIS, V25, P1467, DOI 10.1093/carcin/bgh135; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sohn YC, 2001, J BIOL CHEM, V276, P43734, DOI 10.1074/jbc.M107208200; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wilson AJ, 2003, CANCER RES, V63, P5401; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116	44	130	137	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24903	24914		10.1074/jbc.M500107200	http://dx.doi.org/10.1074/jbc.M500107200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15871945	hybrid			2022-12-25	WOS:000230114000074
J	Kruse, ML; Arlt, A; Sieke, A; Grohmann, F; Grossmann, M; Minkenberg, J; Folsch, UR; Schafer, H				Kruse, ML; Arlt, A; Sieke, A; Grohmann, F; Grossmann, M; Minkenberg, J; Folsch, UR; Schafer, H			Immediate early gene X1 (IEX-1) is organized in subnuclear structures and partially co-localizes with promyelocytic leukemia protein in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EARLY-RESPONSE GENE; ONCOGENIC DOMAINS PODS; NUCLEAR-BODY FORMATION; P53 TUMOR-SUPPRESSOR; TARGET GENE; EPITHELIAL-CELLS; IN-VIVO; PML; APOPTOSIS	Immediate early gene X1 (IEX-1) represents a stress response gene involved in growth control and modulation of apoptosis. Here, we report a detailed analysis of IEX-1 with respect to its intracellular localization. By means of confocal laser scanning microscopy, a green fluorescent protein-IEX-1 fusion protein transfected into HeLa cells, as well as endogenous IEX-1, could be detected in distinct subnuclear structures. This particular subnuclear localization of IEX-1 was not observed with a green fluorescent protein-IEX-1 fusion protein lacking a putative nuclear localization sequence, along with a decreased effect on apoptosis. Double immunofluorescence staining revealed a partial co-localization of endogenous promyelocytic leukemia protein (PML) and IEX-1 in these subnuclear structures. Nuclear localization of IEX-1 is also enhanced upon treatment of cells with leptomycin B, an inhibitor of the nuclear exporter CRM1. These observations indicate that IEX-1 is specifically shuttled to and from the nucleus. Overexpression experiments using PML isoforms III and IV revealed distinct intranuclear interaction of IEX-1 and PML. Coprecipitation experiments showed physical interaction between IEX-1 and PML. The close structural relation of IEX-1-containing nuclear subdomains and PML nuclear bodies suggests a function of IEX-1 related to the multiple functions of these unique subnuclear regions, particularly during stress response and growth control.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Arlt A, 2004, LEUKEMIA, V18, P1646, DOI 10.1038/sj.leu.2403481; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CHARLES CH, 1993, ONCOGENE, V8, P797; De Keulenaer GW, 2002, CIRC RES, V90, P690, DOI 10.1161/01.RES.0000012922.40318.05; Dilley WG, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-9; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Everett RD, 1999, J CELL SCI, V112, P4581; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Im HJ, 2002, ONCOGENE, V21, P3706, DOI 10.1038/sj.onc.1205450; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LAVAU C, 1995, ONCOGENE, V11, P871; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Osawa Y, 2003, J IMMUNOL, V170, P4053, DOI 10.4049/jimmunol.170.8.4053; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Ruthardt M, 1998, ONCOGENE, V16, P1945, DOI 10.1038/sj.onc.1201722; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, SCIENCE, V279, P1547; WIE X, 2003, J BIOL CHEM, V278, P29288; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	56	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24849	24856		10.1074/jbc.M501571200	http://dx.doi.org/10.1074/jbc.M501571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855159	hybrid			2022-12-25	WOS:000230114000067
J	Wang, ZY; Wen, XH; Ablonczy, Z; Crouch, RK; Makino, CL; Lem, J				Wang, ZY; Wen, XH; Ablonczy, Z; Crouch, RK; Makino, CL; Lem, J			Enhanced shutoff of phototransduction in transgenic mice expressing palmitoylation-deficient rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; MASS-SPECTROMETRIC ANALYSIS; DEPENDENT PROTEIN-KINASE; IN-VIVO; BOVINE RHODOPSIN; BETA(2)-ADRENERGIC RECEPTOR; MULTIPLE PHOSPHORYLATION; CYSTEINE RESIDUES; ROD; OPSIN	Palmitoylation is a reversible, post- translational modification observed in a number of G- protein- coupled receptors. To gain a better understanding of its role in visual transduction, we produced transgenic knock- in mice that expressed a palmitoylation- deficient rhodopsin (Palm (-/-)). The mutant rhodopsin was expressed at wild- type levels and showed normal cellular localization to rod outer segments, indicating that neither rhodopsin stability nor its intracellular trafficking were compromised. But Palm (-/-) rods had briefer flash responses and reduced sensitivity to flashes and to steps of light. Upon exposure to light, rhodopsin became phosphorylated at a faster rate in mutant than in wild- type retinas. Since quench of rhodopsin begins with its phosphorylation, these results suggest that palmitoylation may modulate rod photoreceptor sensitivity by permitting rhodopsin to remain active for a longer period.	Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Tufts Univ, Sch Med, Tufts Ctr Vis Res, Dept Ophthalmol,Program Genet, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Medical University of South Carolina; Tufts University	Lem, J (corresponding author), Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 5045, Boston, MA 02111 USA.	Jlem@Tufts-NEMC.org	Makino, Clint Lawrence/H-8428-2019	Makino, Clint Lawrence/0000-0002-6005-9069	NATIONAL EYE INSTITUTE [P30EY014104, R01EY004939, F32EY013912, R29EY011358, R24EY014799, R01EY011358, P30EY013078, R01EY012008] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012008-04, F2EY13912A, R24 EY014799, R01 EY004939, EY12008, P30 EY013078, R01 EY011358, P30 EY14104, R01 EY012008, EY04939, EY11358, P30 EY014104, EY014799, EY13078, R29 EY011358, F32 EY013912, R01 EY012008-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; Ablonczy Z, 2001, ANAL CHEM, V73, P4774, DOI 10.1021/ac015563n; Adams RA, 2003, BIOCHEM J, V374, P537, DOI 10.1042/BJ20030408; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DONOSO LA, 1985, INVEST OPHTH VIS SCI, V26, P561; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Fukushima Y, 2001, BBA-MOL CELL RES, V1539, P181, DOI 10.1016/S0167-4889(01)00104-5; GORODOVIKOVA EN, 1993, FEBS LETT, V335, P277, DOI 10.1016/0014-5793(93)80746-H; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Langen R, 1999, BIOCHEMISTRY-US, V38, P7918, DOI 10.1021/bi990010g; Lee KA, 2002, PROTEIN SCI, V11, P862, DOI 10.1110/ps.3870102; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Ma JX, 2001, NEURON, V32, P451, DOI 10.1016/S0896-6273(01)00482-2; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Moffett S, 2001, J NEUROCHEM, V76, P269, DOI 10.1046/j.1471-4159.2001.00005.x; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; Nikonov S, 1998, J GEN PHYSIOL, V111, P7, DOI 10.1085/jgp.111.1.7; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; PEPPERBERG DR, 1992, EXP EYE RES, V54, P369, DOI 10.1016/0014-4835(92)90049-X; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Tachibanaki S, 2001, P NATL ACAD SCI USA, V98, P14044, DOI 10.1073/pnas.241396898; Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	51	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24293	24300		10.1074/jbc.M502588200	http://dx.doi.org/10.1074/jbc.M502588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851469	Green Accepted, hybrid			2022-12-25	WOS:000230114000001
J	Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J				Ceballos, E; Munoz-Alonso, MJ; Berwanger, B; Acosta, JC; Hernandez, R; Krause, M; Hartmann, O; Eilers, M; Leon, J			Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes	ONCOGENE			English	Article						c-Myc; p53; apoptosis; microarrays; chaperones; ARF	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR P53; HEAT-SHOCK PROTEINS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; DNA-DAMAGE; IN-VIVO; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTOR; NEGATIVE REGULATION	We have previously demonstrated that c-Myc impairs p53-mediated apoptosis in K562 human leukemia cells, which lack ARF. To investigate the mechanisms by which c-Myc protects from p53-mediated apoptosis, we used K562 cells that conditionally express c-Myc and harbor a temperature-sensitive allele of p53. Gene expression profiles of cells expressing wild-type conformation p53 in the presence of either uninduced or induced c-Myc were analysed by cDNA microarrays. The results show that multiple p53 target genes are downregulated when c-Myc is present, including p21(WAF1), MDM2, PERP, NOXA, GADD45, DDB2, PIR121 and p53R2. Also, a number of genes that are upregulated by c-Myc in cells expressing wild-type conformation p53 encode chaperones related to cell death protection as HSP105, HSP90 and HSP27. Both downregulation of p53 target genes and upregulation of chaperones could explain the inhibition of apoptosis observed in K562 cells with ectopic c-Myc. Myc-mediated impairment of p53 transactivation was not restricted to K562 cells, but it was reproduced in a panel of human cancer cell lines derived from different tissues. Our data suggest that elevated levels of Myc counteract p53 activity in human tumor cells that lack ARF. This mechanism could contribute to explain the c- Myc deregulation frequently found in cancer.	Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Cantabria, CSIC, Unidad Biomed, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain; Univ Marburg, IMT, Inst Mol Biol & Tumor Res, Marburg, Germany; Hosp Univ Marques Valdecilla, Urol Serv, Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Philipps University Marburg; Hospital Universitario Marques de Valdecilla (HUMV)	Leon, J (corresponding author), Univ Cantabria, CSIC, Dept Mol Biol, Grp Biol Mol Canc,Fac Med, Santander 39011, Spain.	leonj@unican.es	Acosta, Juan/AAE-6320-2021; Leon, Javier/K-4615-2014	Acosta, Juan/0000-0002-7989-7329; Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1998, CELL DEATH DIFFER, V5, P148, DOI 10.1038/sj.cdd.4400325; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bearss DJ, 2002, CANCER RES, V62, P2077; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Chang CC, 2000, AM J CLIN PATHOL, V113, P512, DOI 10.1309/YHFE-R65B-D3LK-3GGV; CHANG H, 1994, BLOOD, V83, P452; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Lewis JL, 2001, BLOOD, V97, P2604, DOI 10.1182/blood.V97.9.2604; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mauleon I, 2004, MOL CARCINOGEN, V39, P85, DOI 10.1002/mc.20000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Motwani M, 2002, CANCER RES, V62, P3950; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pierzchalski P, 1997, EXP CELL RES, V234, P57, DOI 10.1006/excr.1997.3604; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strutt H, 1999, METH MOL B, V119, P455; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	84	33	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4559	4571		10.1038/sj.onc.1208652	http://dx.doi.org/10.1038/sj.onc.1208652			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856024	Bronze			2022-12-25	WOS:000230157100009
J	Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I				Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I			Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta 1 in hepatocytes	ONCOGENE			English	Article						apoptosis; TGF-beta; Akt; EGFR; c-Src; hepatocytes	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; FETAL HEPATOCYTES; CELL SURVIVAL; APOPTOSIS; METASTASIS; ACTIVATION; KINASE	Transforming growth factor beta1 (TGF-beta 1) belongs to a family of polypeptide factors, whose cytostatic and apoptotic functions help restrain the growth of mammalian cells. Although solid data established the role of TGF-beta's as suppressor factors in tumorigenic processes, in the context of an advanced stage of disease, TGF-beta's could also play a pro-oncogenic role. We have previously shown that TGF-beta 1 induces both pro- and antiapoptotic signals in foetal rat hepatocytes. In this work, we have focused on its antiapoptotic mechanism. We show that TGF-beta 1 activates the epidermal growth factor receptor ( EGFR) and phosphorylates c-Src. EGFR is required for Akt activation. Blocking EGFR signalling amplifies the apoptotic response to TGF-beta 1. TGF-beta 1 induced a rapid activation of the tumour necrosis factor-alpha-converting enzyme (TACE/ADAM ( a disintegrin and metalloprotease) 17). Inhibitors of TACE considerably attenuated Akt activation, which suggests that TGF-beta 1 activates EGF signalling in hepatocytes by promoting shedding of EGF-like ligands. The activation of c-Src by TGF-beta 1 is EGFR dependent and is required for full Akt phosphorylation and cell survival. Inhibition of EGFR does not block the epithelial-mesenchymal transition (EMT) induced by TGF-beta 1 in hepatocytes, which indicates that activation of EGFR plays an essential role in impairing apoptosis, but it is dispensable for the EMT process.	IDIBELL, Inst Recerca Oncol, Barcelona 08907, Spain; Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Complutense University of Madrid	Fabregat, I (corresponding author), IDIBELL, Inst Recerca Oncol, Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	ifabregat@iro.es	Murillo, Miguel/C-6964-2008; Fernández, Margarita/H-9077-2015; Sánchez, Aránzazu/H-7810-2015; Fabregat, Isabel/H-7038-2015	Fernández, Margarita/0000-0001-7207-2028; Sánchez, Aránzazu/0000-0001-9145-6633; Fabregat, Isabel/0000-0003-0136-8440				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; Arteaga CL, 2004, CANCER CELL, V5, P525, DOI 10.1016/j.ccr.2004.05.028; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Gotzmann J, 2002, J CELL SCI, V115, P1189; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KARI C, 2003, CANCER CELL, V5, P525; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Park SS, 2004, ONCOGENE, V23, P6272, DOI 10.1038/sj.onc.1207856; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sanchez A, 1999, EXP CELL RES, V252, P281, DOI 10.1006/excr.1999.4624; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001	42	125	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4580	4587		10.1038/sj.onc.1208664	http://dx.doi.org/10.1038/sj.onc.1208664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856020				2022-12-25	WOS:000230157100011
J	Buzza, MS; Zamurs, L; Sun, JR; Bird, CH; Smith, AI; Trapani, JA; Froelich, CJ; Nice, EC; Bird, PI				Buzza, MS; Zamurs, L; Sun, JR; Bird, CH; Smith, AI; Trapani, JA; Froelich, CJ; Nice, EC; Bird, PI			Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ARTICULAR CHONDROCYTES; GRANULE-MEDIATED APOPTOSIS; TIME-LAPSE MICROCINEMATOGRAPHY; CYTOTOXIC T-LYMPHOCYTES; SYNOVIAL-FLUID; TARGET-CELLS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; CYTOSOLIC DELIVERY	Human granzyme B (GrB) released from cytotoxic lymphocytes plays a key role in the induction of target cell apoptosis when internalized in the presence of perforin. Here we demonstrate that GrB also possesses a potent extracellular matrix remodeling activity. Both native and recombinant GrB caused detachment of immortalized and transformed cell lines, primary endothelial cells, and chondrocytes. Cell detachment by GrB induced endothelial cell death (anoikis). GrB also inhibited tumor cell spreading, migration, and invasion in vitro. Investigation into the underlying mechanism revealed that GrB efficiently cleaves three proteins involved in extracellular matrix structure and function: vitronectin, fibronectin, and laminin. In vitronectin, GrB cleaves after an Arg-Lys-Asp (RGD) motif, which is part of the integrin-binding site found in matrix proteins. We propose that targeting of the integrin-extracellular matrix interface by GrB may allow perforin-independent killing of target cells via anoikis, restrict motility of tumor cells, facilitate lymphocyte migration, or directly reduce virus infectivity. It may also contribute to tissue destruction in diseases in which extracellular GrB is evident, such as rheumatoid arthritis and atherosclerosis.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Melbourne Tumor Biol Branch, Ludwig Inst Canc Res, Parkville, Vic 3052, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 8006, Australia; Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA	Monash University; Ludwig Institute for Cancer Research; Peter Maccallum Cancer Center	Bird, PI (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	phil.bird@med.monash.edu.au	Nice, Edouard C/B-1026-2011	Bird, Phillip/0000-0002-6695-606X; Smith, Ian/0000-0002-4143-2892; Trapani, Joseph/0000-0003-0983-1532				Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Amirahmadi SF, 2004, IMMUNOL CELL BIOL, V82, P427, DOI 10.1111/j.0818-9641.2004.01267.x; Barilla ML, 2000, SEMIN ARTHRITIS RHEU, V29, P252, DOI 10.1016/S0049-0172(00)80012-8; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Browne KA, 1999, MOL CELL BIOL, V19, P8604; BURGESS AW, 1982, P NATL ACAD SCI-BIOL, V79, P5753, DOI 10.1073/pnas.79.19.5753; Buzza MS, 2001, CELL IMMUNOL, V210, P21, DOI 10.1006/cimm.2001.1806; CARNEMOLLA B, 1984, ARTHRITIS RHEUM, V27, P913, DOI 10.1002/art.1780270811; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; Champliaud MF, 2000, EXP CELL RES, V259, P326, DOI 10.1006/excr.2000.4980; Choy JC, 2003, MODERN PATHOL, V16, P460, DOI 10.1097/01.MP.0000067424.12280.BC; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; CLEMMENSEN I, 1982, ARTHRITIS RHEUM, V25, P25, DOI 10.1002/art.1780250104; De Arcangelis A, 2001, INT J CANCER, V94, P44, DOI 10.1002/ijc.1444; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; Doucey MA, 2003, J BIOL CHEM, V278, P26983, DOI 10.1074/jbc.M302709200; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; FROELICH CJ, 1993, J IMMUNOL, V151, P7161; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; Gahring LC, 2001, J IMMUNOL, V166, P1433, DOI 10.4049/jimmunol.166.3.1433; Galvin JP, 1999, J IMMUNOL, V162, P5345; Gechtman Z, 1997, BIOCHEM J, V325, P339, DOI 10.1042/bj3250339; GOLDBERG RL, 1984, J CELL BIOL, V99, P2114, DOI 10.1083/jcb.99.6.2114; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; HELD W, 1990, INT IMMUNOL, V2, P57, DOI 10.1093/intimm/2.1.57; Hermsen CC, 2003, CLIN EXP IMMUNOL, V132, P467, DOI 10.1046/j.1365-2249.2003.02160.x; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Horiuchi K, 2003, J RHEUMATOL, V30, P1799; Hu SX, 2003, BRIT J CANCER, V89, P135, DOI 10.1038/sj.bjc.6601051; ISAAZ S, 1995, EUR J IMMUNOL, V25, P1071, DOI 10.1002/eji.1830250432; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Lauw FN, 2000, J INFECT DIS, V182, P206, DOI 10.1086/315642; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MASON PW, 1994, P NATL ACAD SCI USA, V91, P1932, DOI 10.1073/pnas.91.5.1932; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Pouliot N, 2000, EXP CELL RES, V261, P360, DOI 10.1006/excr.2000.5065; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; Pulai JI, 2002, ARTHRITIS RHEUM, V46, P1528, DOI 10.1002/art.10334; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; Rissoan MC, 2002, BLOOD, V100, P3295, DOI 10.1182/blood-2002-02-0638; Romberger DJ, 1997, INT J BIOCHEM CELL B, V29, P939, DOI 10.1016/S1357-2725(96)00172-0; Ronday HK, 2001, RHEUMATOLOGY, V40, P55, DOI 10.1093/rheumatology/40.1.55; ROTHSTEIN TL, 1978, J IMMUNOL, V121, P1652; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SANDERSON CJ, 1976, PROC R SOC SER B-BIO, V192, P241, DOI 10.1098/rspb.1976.0011; Sasson R, 2003, FASEB J, V17, P1256, DOI 10.1096/fj.02-0740com; SAYERS TJ, 1992, J IMMUNOL, V148, P292; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; SIMON MM, 1988, BIOL CHEM H-S, V369, P107; SIMON MM, 1991, IMMUNOLOGY, V73, P117; Smeets TJM, 2001, ANN RHEUM DIS, V60, P561, DOI 10.1136/ard.60.6.561; Sower LE, 1996, J IMMUNOL, V156, P2585; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Sun J, 2001, J BIOL CHEM, V276, P15177, DOI 10.1074/jbc.M006645200; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; TAKAHASHI K, 1991, EUR J IMMUNOL, V21, P1559, DOI 10.1002/eji.1830210634; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; Trapani JA, 2003, CURR OPIN IMMUNOL, V15, P533, DOI 10.1016/S0952-7915(03)00107-9; Tremble P M, 1992, Matrix Suppl, V1, P212; Triantafilou K, 2001, CRIT REV IMMUNOL, V21, P311; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wowk ME, 2004, MICROBES INFECT, V6, P752, DOI 10.1016/j.micinf.2004.03.008; Xu B, 2001, TRANSPLANTATION, V71, P1137, DOI 10.1097/00007890-200104270-00022; Zamurs L, 2003, BIOMED CHROMATOGR, V17, P201, DOI 10.1002/bmc.248; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116	96	185	201	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23549	23558		10.1074/jbc.M412001200	http://dx.doi.org/10.1074/jbc.M412001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843372	hybrid			2022-12-25	WOS:000229880000019
J	Egusa, H; Schweizer, FE; Wang, CC; Matsuka, Y; Nishimura, I				Egusa, H; Schweizer, FE; Wang, CC; Matsuka, Y; Nishimura, I			Neuronal differentiation of bone marrow-derived stromal stem cells involves suppression of discordant phenotypes through gene silencing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; EXTRACELLULAR-MATRIX; PURKINJE NEURONS; CARDIAC-MUSCLE; EXPRESSION; SKELETAL; COLONY; BRAIN; MICE; HEMATOPOIESIS	Tissue engineering involves the construction of transplantable tissues in which bone marrow aspirates may serve as an accessible source of autogenous multipotential mesenchymal stem cells. Increasing reports indicate that the lineage restriction of adult mesenchymal stem cells may be less established than previously believed, and stem cell-based therapeutics await the establishment of an efficient protocol capable of achieving a prescribed phenotype differentiation. We have investigated how adult mouse bone marrow-derived stromal cells (BMSCs) are guided to neurogenic and osteogenic phenotypes. Naive BMSCs were found surprisingly active in expression of a wide range of mRNAs and proteins, including those normally reported in terminally differentiated neuronal cells and osteoblasts. The naive BMSCs were found to exhibit voltage-dependent membrane currents similar to the neuronally guided BMSCs, although with smaller amplitudes. Once BMSCs were exposed to the osteogenic culture condition, the neuronal characteristics quickly disappeared. Our data suggest that the loss of discordant phenotypes during BMSC differentiation cannot be explained by the selection and elimination of unfit cells from the whole BMSC population. The percent ratio of live to dead BMSCs examined did not change during the first 8-10 days in either neurogenic or osteogenic differentiation media, and cell detachment was estimated at < 1%. However, during this period, bone-associated extracellular matrix genes were selectively down-regulated in neuronally guided BMSCs. These data indicate that the suppression of discordant phenotypes of differentiating adult stem cells is achieved, at least in part, by silencing of superfluous gene clusters.	Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Hosp Dent, Los Angeles, CA 90095 USA; Osaka Univ, Grad Sch Dent, Dept Fixed Prosthodont, Suita, Osaka 5650871, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Biomed Engn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Diov Oral Biol & Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Osaka University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Nishimura, I (corresponding author), Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat, Box 951668,CHS B3-087, Los Angeles, CA 90095 USA.	ichiron@dent.ucla.edu	Egusa, Hiroshi/AFT-9694-2022	Egusa, Hiroshi/0000-0002-0200-8132; Matsuka, Yoshizo/0000-0003-1069-2605	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014529] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR014529] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; Bonnet D, 2003, CLIN EXP MED, V3, P140, DOI 10.1007/s10238-003-0017-9; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Fraser JK, 2004, INT J BIOCHEM CELL B, V36, P658, DOI 10.1016/j.biocel.2003.10.018; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Fukada S, 2002, J CELL SCI, V115, P1285; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hung SC, 2002, STEM CELLS, V20, P522, DOI 10.1634/stemcells.20-6-522; Hunziker E, 2000, BIOCHEM BIOPH RES CO, V271, P116, DOI 10.1006/bbrc.2000.2611; Iida K, 2002, CRIT REV ORAL BIOL M, V13, P35, DOI 10.1177/154411130201300105; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Jones SE, 1998, BIOCHEM BIOPH RES CO, V252, P236, DOI 10.1006/bbrc.1998.9631; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756-200207020-00023; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kuznetsov SA, 1997, BRIT J HAEMATOL, V97, P561, DOI 10.1046/j.1365-2141.1997.902904.x; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Muraglia A, 2000, J CELL SCI, V113, P1161; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Prockop DJ, 2000, BIOCHEM SOC T, V28, P341, DOI 10.1042/0300-5127:0280341; Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756-3282(97)00276-7; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Schena FP, 2003, J NEPHROL, V16, pS1; Serreze DV, 2004, J IMMUNOL, V172, P871, DOI 10.4049/jimmunol.172.2.871; Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301; Shortman K, 1990, Semin Immunol, V2, P3; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Song Shijie, 2002, Methods Mol Biol, V198, P79; Stanic AK, 2004, J IMMUNOL, V172, P2265, DOI 10.4049/jimmunol.172.4.2265; Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279; Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432-0436.2004.07207003.x; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; vanInzen WG, 1996, BBA-MOL CELL RES, V1312, P21, DOI 10.1016/0167-4889(96)00011-0; Wakabayashi T, 1999, BIOTECHNIQUES, V26, P302, DOI 10.2144/99262st04; Walde SSI, 2002, LIFE SCI, V71, P1681, DOI 10.1016/S0024-3205(02)01918-5; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Wieczorek G, 2003, CELL TISSUE RES, V311, P227, DOI 10.1007/s00441-002-0671-3; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375	65	56	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23691	23697		10.1074/jbc.M413796200	http://dx.doi.org/10.1074/jbc.M413796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855172	hybrid			2022-12-25	WOS:000229880000037
J	Bates, S; MacCallum, DM; Bertram, G; Munro, CA; Hughes, HB; Buurman, ET; Brown, AJP; Odds, FC; Gow, NAR				Bates, S; MacCallum, DM; Bertram, G; Munro, CA; Hughes, HB; Buurman, ET; Brown, AJP; Odds, FC; Gow, NAR			Candida albicans Pmr1p, a secretory pathway P-type Ca2+/Mn2+-ATPase, is required for glycosylation and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; SACCHAROMYCES-CEREVISIAE; PROTEIN MANNOSYLTRANSFERASE; MANNOSE PYROPHOSPHORYLASE; MOLECULAR ANALYSIS; ACID-PHOSPHATASE; GOLGI; GENE; ADHESION; MUTANTS	The cell surface of Candida albicans is the immediate point of contact with the host. The outer layer of the cell wall is enriched in highly glycosylated mannoproteins that are implicated in many aspects of the host-fungus interaction. Glycosylation of cell wall proteins is initiated in the endoplasmic reticulum and then elaborated in the Golgi as the protein passes through the secretory pathway. Golgi-bound mannosyltransferases require Mn2(+) as an essential cofactor. In Saccharomyces cerevisiae, the P-type ATPase Pmr1p transports Ca2+ and Mn2+ ions into the Golgi. To determine the effect of a gross defect in glycosylation on host-fungus interactions of C. albicans, we disrupted the PMR1 homolog, CaPMR1. This mutation would simultaneously inhibit many Golgi-located, Mn2+-dependent mannosyltransferases. The Capmr1 Delta null mutant was viable in vitro and had no growth defect even on media containing low Ca2+/Mn2+ ion concentrations. However, cells grown in these media progressively lost viability upon entering stationary phase. Phosphomannan was almost completely absent, and O-mannan was severely truncated in the null mutant. A defect in N-linked outer chain glycosylation was also apparent, demonstrated by the underglycosylation of surface acid phosphatase. Consistent with the glycosylation defect, the null mutant had a weakened cell wall, exemplified by hypersensitivity to Calcofluor white, Congo red, and hygromycin B and constitutive activation of the cell integrity pathway. In a murine model of systemic infection, the null mutant was severely attenuated in virulence. These results demonstrate the importance of glycosylation for cell wall structure and virulence of C. albicans.	Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Gow, NAR (corresponding author), Univ Aberdeen, Inst Med Sci, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.	n.gow@abdn.ac.uk	Brown, Alistair J.P./B-6627-2014; MacCallum, Donna M./D-7897-2011; Munro, Carol A/A-5175-2011; GOW, Neil/AAS-5323-2021	MacCallum, Donna M./0000-0003-4833-0378; GOW, Neil/0000-0002-2776-5850; Brown, Alistair JP/0000-0003-1406-4251; Bates, Steven/0000-0003-0489-5705; Munro, Carol/0000-0003-0761-1755	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; Blankenship JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003; Brand A, 2004, EUKARYOT CELL, V3, P900, DOI 10.1128/EC.3.4.900-909.2004; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Buurman ET, 1998, P NATL ACAD SCI USA, V95, P7670, DOI 10.1073/pnas.95.13.7670; Calderone RA., 2002, CANDIDA CANDIDIASIS; Calderone Richard, 2002, P67; Calderone Richard A., 1993, Trends in Microbiology, V1, P55, DOI 10.1016/0966-842X(93)90033-N; Chauhan Neeraj, 2002, P159; Cortes JCG, 2004, EUKARYOT CELL, V3, P1124, DOI 10.1128/EC.3.5.1124-1135.2004; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; FONZI WA, 1993, GENETICS, V134, P717; Fukazawa Y, 1997, J MED VET MYCOL, V35, P87; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Harmsen MM, 1996, APPL MICROBIOL BIOT, V46, P365, DOI 10.1007/s002530050831; Herrero AB, 2002, EUKARYOT CELL, V1, P420, DOI 10.1128/EC.1.3.420-431.2002; Hobson RP, 2004, J BIOL CHEM, V279, P39628, DOI 10.1074/jbc.M405003200; Hwang CS, 2003, MOL MICROBIOL, V47, P1029, DOI 10.1046/j.1365-2958.2003.03353.x; KANIKENNULAT C, 1995, GENETICS, V140, P933; Klis FM, 2001, MED MYCOL, V39, P1, DOI 10.1080/744118876; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Martinez P, 2004, MOL MICROBIOL, V51, P371, DOI 10.1046/j.1365-2958.2003.03845.x; MOIR DT, 1987, GENE, V56, P209, DOI 10.1016/0378-1119(87)90138-7; Munro CA, 2005, J BIOL CHEM, V280, P1051, DOI 10.1074/jbc.M411413200; Munro CA, 2003, FUNGAL GENET BIOL, V40, P146, DOI 10.1016/S1087-1845(03)00083-5; Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4&lt;325::AID-YEA538&gt;3.0.CO;2-#; National Committee for Clinical Laboratory Standards, 2002, REF METH BROTH DIL A; Nishikawa A, 2002, J BACTERIOL, V184, P29, DOI 10.1128/JB.184.1.29-42.2002; ODDS FC, 1988, J ANTIMICROB CHEMOTH, V22, P473, DOI 10.1093/jac/22.4.473; ODDS FC, 1973, J BACTERIOL, V114, P257, DOI 10.1128/JB.114.1.257-266.1973; Odds FC., 1988, CANDIDA CANDIDOSIS; Pappas PG, 2003, CLIN INFECT DIS, V37, P634, DOI 10.1086/376906; Poster JB, 1996, J BIOL CHEM, V271, P3837; Prill SKH, 2005, MOL MICROBIOL, V55, P546, DOI 10.1111/j.1365-2958.2004.04401.x; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Romani Luigina, 2002, P223; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sandven Per, 2000, Revista Iberoamericana de Micologia, V17, P73; SCHWEINGRUBER AM, 1986, EUR J BIOCHEM, V158, P133, DOI 10.1111/j.1432-1033.1986.tb09730.x; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; Sohn YS, 1998, J BACTERIOL, V180, P6736, DOI 10.1128/JB.180.24.6736-6742.1998; Sorin A, 1997, J BIOL CHEM, V272, P9895; Southard SB, 1999, J BACTERIOL, V181, P7439, DOI 10.1128/JB.181.24.7439-7448.1999; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Sundstrom P, 2002, CELL MICROBIOL, V4, P461, DOI 10.1046/j.1462-5822.2002.00206.x; Timpel C, 2000, J BACTERIOL, V182, P3063, DOI 10.1128/JB.182.11.3063-3071.2000; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; Trinel PA, 1997, FEBS LETT, V416, P203, DOI 10.1016/S0014-5793(97)01205-2; Uccelletti D, 2004, J BIOTECHNOL, V109, P93, DOI 10.1016/j.jbiotec.2003.10.037; VIDEBAEK A, 1953, J GERONTOL, V8, P63; Wang YY, 1998, INFECT IMMUN, V66, P1384, DOI 10.1128/IAI.66.4.1384-1391.1998; Warit S, 1998, MICROBIOL-UK, V144, P2417, DOI 10.1099/00221287-144-9-2417; Warit S, 2000, MOL MICROBIOL, V36, P1156, DOI 10.1046/j.1365-2958.2000.01944.x	62	139	151	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23408	23415		10.1074/jbc.M502162200	http://dx.doi.org/10.1074/jbc.M502162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15843378	hybrid			2022-12-25	WOS:000229741800101
J	Jorgensen, SB; Wojtaszewski, JFP; Viollet, B; Andreelli, F; Birk, JB; Hellsten, Y; Schjerling, P; Vaulont, S; Neufer, PD; Richter, EA; Pilegaard, H				Jorgensen, SB; Wojtaszewski, JFP; Viollet, B; Andreelli, F; Birk, JB; Hellsten, Y; Schjerling, P; Vaulont, S; Neufer, PD; Richter, EA; Pilegaard, H			Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle	FASEB JOURNAL			English	Article						gene transcription; mRNA; AICAR; PGC-1 alpha; PDK4; adenosine nucleotides; inosine monophosphate	5'-AMP-ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE; ACETYL-COA CARBOXYLASE; GLUCOSE-TRANSPORT; FIBER-TYPE; TRANSCRIPTIONAL ACTIVATION; MITOCHONDRIAL BIOGENESIS; SUBSTRATE-SPECIFICITY; ENERGY DEPRIVATION; PHYSICAL-ACTIVITY	We tested the hypothesis that 5'AMP-activated protein kinase (AMPK) plays an important role in regulating the acute, exercise-induced activation of metabolic genes in skeletal muscle, which were dissected from whole-body alpha 2- and alpha 1-AMPK knockout (KO) and wild-type (WT) mice at rest, after treadmill running (90 min), and in recovery. Running increased alpha 1-AMPK kinase activity, phosphorylation (P) of AMPK, and acetyl-CoA carboxylase (ACC)beta in alpha 2-WT and alpha 2-KO muscles and increased alpha 2-AMPK kinase activity in alpha 2-WT. In alpha 2-KO muscles, AMPK-P and ACC beta-P were markedly lower compared with alpha 2-WT. However, in alpha 1-WT and alpha 1-KO muscles, AMPK-P and ACC beta-P levels were identical at rest and increased similarly during exercise in the two genotypes. The alpha 2-KO decreased peroxisome-proliferator-activated receptor 7 coactivator (PGC)-1 alpha, uncoupling protein-3 (UCP3), and hexokinase II (HKII) transcription at rest but did not affect exercise-induced transcription. Exercise increased the mRNA content of PGC-1 alpha, Forkhead box class O (FOXO)1, HKII, and pyruvate dehydrogenase kinase 4 (PDK4) similarly in alpha 2-WT and alpha 2-KO mice, whereas glucose transporter GLUT 4, carnitine palmitoyltransferase I (CPTI), lipoprotein lipase, and UCP3 mRNA were unchanged by exercise in both genotypes. CPTI mRNA was lower in alpha 2-KO muscles than in alpha 2-WT muscles at all time-points. In alpha 1-WT and alpha 1-KO muscles, running increased the mRNA content of PGC-1 alpha and FOXO1 similarly. The alpha 2-KO was associated with lower muscle adenosine 5'-triphosphate content, and the inosine monophosphate content increased substantially at the end of exercise only in alpha 2-KO muscles. In addition, subcutaneous injection of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) increased the mRNA content of PGC-1 alpha, HKII, FOXO1, PDK4, and UCP3, and alpha 2-KO abolished the AICAR-induced increases in PGC-1 alpha and HKII mRNA. In conclusion, KO of the alpha 2- but not the alpha 1-AMPK isoform markedly diminished AMPK activation during running. Nevertheless, exercise-induced activation of the investigated genes in mouse skeletal muscle was not impaired in alpha- or alpha 2-AMPK KO muscles. Although it cannot be ruled out that activation of the remaining alpha-isoform is sufficient to increase gene activation during exercise, the present data do not support an essential role of AMPK in regulating exercise-induced gene activation in skeletal muscle.	Univ Copenhagen, Inst Exercise & Sport Sci, Dept Human Physiol, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol & Physiol, Copenhagen, Denmark; Rigshosp, Dept Mol Muscle Biol, DK-2100 Copenhagen, Denmark; Univ Paris 05, Dept Genet Dev & Mol Pathol, CNRS, INSERM,Inst Cochin, Paris, France; Yale Univ, John B Pierce Lab, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Yale University; The John B Pierce Laboratory, Inc	Jorgensen, SB (corresponding author), Univ Copenhagen, Inst Exercise & Sport Sci, Dept Human Physiol, Copenhagen Muscle Res Ctr, 13 Univ Pk, DK-2100 Copenhagen, Denmark.	SBJorgensen@ifi.ku.dk	Vaulont, Sophie/O-6732-2017; Birk, Jesper B/D-3523-2015; Schjerling, Peter/F-6194-2011; Viollet, Benoit/O-6927-2017; Pilegaard, Henriette/M-2315-2014; Wojtaszewski, Jørgen FP/P-6583-2014; Richter, Erik A./Y-8131-2019; Viollet, Benoit/N-2397-2019; Hellsten, Ylva/B-3420-2015	Birk, Jesper B/0000-0001-9775-4789; Schjerling, Peter/0000-0001-7138-3211; Viollet, Benoit/0000-0002-0121-0224; Pilegaard, Henriette/0000-0002-1071-0327; Wojtaszewski, Jørgen FP/0000-0001-9785-6830; Richter, Erik A./0000-0002-6850-3056; Viollet, Benoit/0000-0002-0121-0224; Hellsten, Ylva/0000-0002-2435-9558; wojtaszewski, jorgen/0000-0001-8185-3408				Ai H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1291, DOI 10.1152/ajpendo.00167.2001; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; Aschenbach WG, 2004, SPORTS MED, V34, P91, DOI 10.2165/00007256-200434020-00003; Baldwin KM, 2002, AM J PHYS MED REHAB, V81, pS40, DOI 10.1097/00002060-200211001-00006; Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340; Buhl ES, 2001, DIABETES, V50, P12, DOI 10.2337/diabetes.50.1.12; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fluck M, 2000, J APPL PHYSIOL, V88, P352, DOI 10.1152/jappl.2000.88.1.352; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Holmes BF, 2004, AM J PHYSIOL-ENDOC M, V287, pE739, DOI 10.1152/ajpendo.00080.2004; Jones TE, 2003, AM J PHYSIOL-ENDOC M, V284, pE96, DOI 10.1152/ajpendo.00316.2002; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Kamei Y, 2003, FEBS LETT, V536, P232, DOI 10.1016/S0014-5793(03)00062-0; Kiens B, 2004, J APPL PHYSIOL, V97, P1209, DOI 10.1152/japplphysiol.01278.2003; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Longnus SL, 2003, AM J PHYSIOL-REG I, V284, pR936, DOI 10.1152/ajpregu.00319.2002; MacLean PS, 2002, BIOCHEM BIOPH RES CO, V292, P409, DOI 10.1006/bbrc.2002.6654; McGee SL, 2004, DIABETES, V53, P1208, DOI 10.2337/diabetes.53.5.1208; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Neufer PD, 1996, AM J PHYSIOL-CELL PH, V271, pC1828; NEUFER PD, 1993, AM J PHYSIOL, V265, pC1597; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; PASSONNEAU JV, 1967, ANAL BIOCHEM, V19, P315, DOI 10.1016/0003-2697(67)90167-4; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2002, J PHYSIOL-LONDON, V541, P261, DOI 10.1113/jphysiol.2002.016832; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Rose AJ, 2003, J PHYSIOL-LONDON, V553, P303, DOI 10.1113/jphysiol.2003.054171; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Seip RL, 1997, AM J PHYSIOL-ENDOC M, V272, pE255; Shang J, 2004, J BIOL CHEM, V279, P12076, DOI 10.1074/jbc.M400431200; Stoppani J, 2002, AM J PHYSIOL-ENDOC M, V283, pE1239, DOI 10.1152/ajpendo.00278.2002; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; TULLSON PC, 1990, AM J PHYSIOL, V258, pC258, DOI 10.1152/ajpcell.1990.258.2.C258; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Wojtaszewski JFP, 2003, BIOCHEM SOC T, V31, P1290; Wojtaszewski JFP, 2000, J PHYSIOL-LONDON, V528, P221, DOI 10.1111/j.1469-7793.2000.t01-1-00221.x; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Wright DC, 2004, DIABETES, V53, P330, DOI 10.2337/diabetes.53.2.330; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	57	223	234	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1146	+		10.1096/fj.04-3144fje	http://dx.doi.org/10.1096/fj.04-3144fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15878932				2022-12-25	WOS:000229602600017
J	Riz, I; Hawley, RG				Riz, I; Hawley, RG			G(1)/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia	ONCOGENE			English	Review						T-cell acute lymphoblastic leukemia; HOX11 oncogene; oligonucleotide microarrays; G1/S transcriptional networks	PROTEIN PHOSPHATASE 2A; CREB-BINDING PROTEIN; SV40 SMALL T; NF-KAPPA-B; C-MYC; HOMEOBOX GENE; BETA-CATENIN; PRE-TCR; THYMOCYTE DIFFERENTIATION; ACETYLTRANSFERASE COMPLEX	The HOX11/TLXI homeobox gene is aberrantly expressed in a subset of T-cell acute lymphoblastic leukemia (T-ALL). Here, we employed oligonucleotide microarrays to compare the expression profiles of the K3P and Sil leukemic cell lines originating from patients with HOX11+ T-ALL to that of Jurkat cells, which originated from a distinct subtype of T-ALL (TAL1(+)). To distinguish potential HOX11 target genes from those characteristic of the stage of HOX11 leukemic arrest, we also performed gene expression analysis on Jurkat cells, genetically engineered to express exogenous HOX11. The resulting HOX11 gene expression signature, which was validated for representative signaling pathways by transient transfection of reporter constructs, was characterized by elevated expression of transcriptional programs involved in cell proliferation, including those regulated by E2F, c-Myc and cAMP response element-binding protein. We subsequently showed that ectopic HOX11 expression resulted in hyperphosphorylation of the retinoblastoma protein (Rb), which correlated with inhibition of the major Rb serine/threonine phosphatase PP1. HOX11 also inhibited PP2A serine/threonine phosphatase activity concomitant with stimulation of the AKT/PKB signaling cascade. These results suggest that transcriptional deregulation of G(1)/S growth-control genes, mediated in large part through blockade of PP1/PP2A phosphatase activity, plays an important role in HOX11 pathobiology.	George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	George Washington University	Hawley, RG (corresponding author), George Washington Univ, Med Ctr, Dept Anat & Cell Biol, 2300 Eye St,NW, Washington, DC 20037 USA.	rghawley@gwu.edu		Hawley, Robert/0000-0003-3512-5818	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016209] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NCRR NIH HHS [R24RR16209, R24 RR016209] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305, R01 HL066305-05, R01HL66305, R01HL65519, R01 HL065519, R01 HL066305-04] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cohen PTW, 2002, J CELL SCI, V115, P241; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; Du J, 2002, NUCLEIC ACIDS RES, V30, P5465, DOI 10.1093/nar/gkf678; DUBE ID, 1991, BLOOD, V78, P2996; Ebert BL, 2004, BLOOD, V104, P923, DOI 10.1182/blood-2004-01-0274; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Goodman RH, 2000, GENE DEV, V14, P1553; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Grady GC, 2004, J IMMUNOL, V173, P1802, DOI 10.4049/jimmunol.173.3.1802; Greene WK, 1998, MOL CELL BIOL, V18, P7030, DOI 10.1128/MCB.18.12.7030; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Luo Q, 2004, ONCOGENE, V23, P1088, DOI 10.1038/sj.onc.1207225; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Owens BM, 2004, METH MOLEC MED, V105, P311; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Ramezani A, 2003, BLOOD, V101, P4717, DOI 10.1182/blood-2002-09-2991; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RIZ I, 2003, APPL GENOMICS PROTEO, V1, P95; Rudenko A, 2003, EMBO REP, V4, P59, DOI 10.1038/sj.embor.embor712; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trop S, 2001, BLOOD, V97, P2269, DOI 10.1182/blood.V97.8.2269; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VON LM, 1992, MOL CELL BIOL, V12, P3346; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yalcin A, 2003, J NEUROCHEM, V84, P397, DOI 10.1046/j.1471-4159.2003.01540.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	102	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5561	5575		10.1038/sj.onc.1208727	http://dx.doi.org/10.1038/sj.onc.1208727			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897879	Green Accepted			2022-12-25	WOS:000231296100004
J	Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH				Yoo, E; Kim, BU; Lee, SY; Cho, CH; Chung, JH; Lee, CH			53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage	ONCOGENE			English	Article						53BP1; replication protein A; camptothecin	DOUBLE-STRAND BREAKS; BINDING PROTEIN; ATAXIA-TELANGIECTASIA; P34 SUBUNIT; HELA-CELLS; PHOSPHORYLATION; CHECKPOINT; KINASE; CAMPTOTHECIN; SENSITIVITY	p53-binding protein 1 (53BP1) acts as an 'adaptor/mediator' for transducing DNA damage signals, especially following detection of DNA double-strand breaks. In an effort to broaden our understanding of the protein network surrounding 53BP1, we isolated possible 53BP1 binding partners by co-immunoprecipitation, and identified them via tandem mass spectrometric analysis. The 53BP1-associated proteins included RPA1 and RPA2, two components of the replication protein A (RPA) complex. The presence of RPA components in the immunoprecipitates was confirmed by immunoblotting, and we found that the association between 53BP1 and RPA2 was disrupted following DNA damage induced by treatment with camptothecin, a topoisomerase I inhibitor. To investigate the functional meaning of the 53BP1 and RPA interaction, we established U2OS osteosarcoma cell lines stably expressing dominant-negative fragments of 53BP1. We found that camptothecin-induced RPA2 phosphorylation was inhibited in these cells, and also following 53BP1 knockdown by siRNA transfection. On the cellular level, camptothecin-induced apoptosis was augmented in the dominant-negative cell lines, resulting in increased chemosensitivity to this drug. Taken together, these results suggest that 53BP1 is involved in DNA damage-induced RPA2 hyperphosphorylation, and inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.	Natl Canc Ctr, Res Inst, Gyeonggi 411769, South Korea; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Cancer Center - Korea (NCC); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lee, CH (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu Dong, Gyeonggi 411769, South Korea.	chlee@ncc.re.kr						Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fedier A, 2003, INT J ONCOL, V22, P1169; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HY, 2001, CANCER RES, V61, P8554; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	35	30	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5423	5430		10.1038/sj.onc.1208710	http://dx.doi.org/10.1038/sj.onc.1208710			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856006				2022-12-25	WOS:000231222300003
J	Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK				Korkola, JE; Houldsworth, J; Dobrzynski, D; Olshen, AB; Reuter, VE; Bosl, GJ; Chaganti, RSK			Gene expression-based classification of nonseminomatous male germ cell tumors	ONCOGENE			English	Article						testicular germ cell tumors; expression microarray; histologic classification	CARCINOMA-CELLS; DIFFERENTIATION; IDENTIFICATION; ENDODERM; PATTERNS; ANTIGENS; CLONING; CANCER	Male adult germ cell tumors (GCTs) comprise two major histologic groups: seminomas and nonseminomas. Non-seminomatous GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (YS), and choriocarcinoma (CC) on the basis of the lineage differentiation that they exhibit. NSGCTs frequently present as mixed tumors consisting of two or more histological subtypes, often limiting correlative studies of clinical and molecular features to histology. We sought to develop a molecular classifier that could predict the predominant histologic subtype within mixed NSGCT tumor samples. The expression profiles of 84 NSGCTs ( 42 pure and 42 mixed) and normal age- matched testes were obtained using Affymetrix microarrays. Using prediction analysis for microarrays, we identified 146 transcripts that classified the histology of pure NSGCTs samples with 93% accuracy. When applied to mixed NSGCTs, the classifier predicted a histology that was consistent with one of the reported components in 93% of cases. Among the predictive transcripts were CGB ( high in CC), LCN2 (high in T), BMP2 (high in YS), and POU5F1 (high in EC). Thus, the expression-based classifier accurately assigned a single predominant histology to mixed NSGCTs, and identified transcripts differentially expressed between histologic components with relevance to NSGCT differentiation.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Rm K618, New York, NY 10021 USA.	chagantr@mskcc.org		, James/0000-0002-0030-6216; Bosl, George/0000-0002-7842-6584				BO M, 1992, J BIOL CHEM, V267, P3179; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Brinkmann U, 1999, CANCER RES, V59, P1445; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; COOPER S, 1988, DEVELOPMENT, V104, P565; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Looijenga LHJ, 2003, CANCER RES, V63, P2244; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MOSTOFI FK, 2000, COMPREHENSIVE TXB GE; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	21	49	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5101	5107		10.1038/sj.onc.1208694	http://dx.doi.org/10.1038/sj.onc.1208694			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870693				2022-12-25	WOS:000230816900009
J	Laize, V; Martel, P; Viegas, CSB; Price, PA; Cancela, ML				Laize, V; Martel, P; Viegas, CSB; Price, PA; Cancela, ML			Evolution of matrix and bone gamma-carboxyglutamic acid proteins in vertebrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISH SPARUS-AURATA; MULTIPLE SEQUENCE ALIGNMENT; OSTEOCALCIN-DEFICIENT MICE; GLA-PROTEIN; XENOPUS-LAEVIS; MOLECULAR-CLONING; TELEOST FISH; GLUTAMYL CARBOXYLASE; CALCIFIED CARTILAGE; TISSUE DISTRIBUTION	The evolution of calcified tissues is a defining feature in vertebrate evolution. Investigating the evolution of proteins involved in tissue calcification should help elucidate how calcified tissues have evolved. The purpose of this study was to collect and compare sequences of matrix and bone gamma-carboxyglutamic acid proteins (MGP and BGP, respectively) to identify common features and determine the evolutionary relationship between MGP and BGP. Thirteen cDNAs and genes were cloned using standard methods or reconstructed through the use of comparative genomics and data mining. These sequences were compared with available annotated sequences (a total of 48 complete or nearly complete sequences, 28 BGPs and 20 MGPs) have been identified across 32 different species (representing most classes of vertebrates), and evolutionarily conserved features in both MGP and BGP were analyzed using bioinformatic tools and the Tree-Puzzle software. We propose that: 1) MGP and BGP genes originated from two genome duplications that occurred around 500 and 400 million years ago before jawless and jawed fish evolved, respectively; 2) MGP appeared first concomitantly with the emergence of cartilaginous structures, and BGP appeared thereafter along with bony structures; and 3) BGP derives from MGP. We also propose a highly specific pattern definition for the Gla domain of BGP and MGP.	Univ Algarve, Ctr Ciencias Mar CCMAR, P-8005139 Faro, Portugal; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Algarve, Ctr Biomed Mol & Estrutural, P-8005139 Faro, Portugal; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	Universidade do Algarve; Universidade Nova de Lisboa; Universidade do Algarve; University of California System; University of California San Diego	Laize, V (corresponding author), Univ Algarve, Ctr Ciencias Mar CCMAR, Campus Gambelas, P-8005139 Faro, Portugal.	vlaize@ualg.pt	Martel, Paulo J/AFV-2568-2022; Martel, Paulo J/K-4704-2013; Viegas, Carla CSB/N-6695-2014; Cancela, M. Leonor/F-4665-2012; Laizé, Vincent/B-4463-2008; Viegas, Carla/N-6314-2019	Martel, Paulo J/0000-0001-8237-1267; Martel, Paulo J/0000-0001-8237-1267; Viegas, Carla CSB/0000-0002-5765-3665; Cancela, M. Leonor/0000-0003-3114-6662; Laizé, Vincent/0000-0001-9565-9198; Viegas, Carla/0000-0002-5765-3665				Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Cancela ML, 2001, J BONE MINER RES, V16, P1611, DOI 10.1359/jbmr.2001.16.9.1611; CANCELA ML, 1992, ENDOCRINOLOGY, V130, P102, DOI 10.1210/en.130.1.102; CANCELA ML, 1995, INT J PEPT PROT RES, V46, P419, DOI 10.1111/j.1399-3011.1995.tb01076.x; Cancela ML, 1997, J CELL PHYSIOL, V171, P125, DOI 10.1002/(SICI)1097-4652(199705)171:2<125::AID-JCP2>3.3.CO;2-9; Conceicao N, 2002, EUR J BIOCHEM, V269, P1947, DOI 10.1046/j.1432-1033.2002.02846.x; Cotton JA, 2002, P ROY SOC B-BIOL SCI, V269, P1555, DOI 10.1098/rspb.2002.2074; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P121; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Dowd TL, 2003, BIOCHEMISTRY-US, V42, P7769, DOI 10.1021/bi034470s; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Farzaneh-Far A, 2000, BIOCHEM BIOPH RES CO, V277, P736, DOI 10.1006/bbrc.2000.3747; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; FRASER JD, 1990, CALCIFIED TISSUE INT, V46, P270, DOI 10.1007/BF02555007; FRASER JD, 1988, J BIOL CHEM, V263, P11033; Frazao C, 2005, BIOCHEMISTRY-US, V44, P1234, DOI 10.1021/bi048336z; GRISHIN NV, 1995, J MOL EVOL, V41, P675; Gu X, 2002, NAT GENET, V31, P205, DOI 10.1038/ng902; HALE JE, 1991, J BIOL CHEM, V266, P21145; Hardie DC, 2002, J HISTOCHEM CYTOCHEM, V50, P735, DOI 10.1177/002215540205000601; Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079; KING K, 1978, BIOCHIM BIOPHYS ACTA, V542, P542, DOI 10.1016/0304-4165(78)90384-7; Kirfel J, 1997, P NATL ACAD SCI USA, V94, P2227, DOI 10.1073/pnas.94.6.2227; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; KUMAR S, 2000, MOL EVOLUTION PHYLOG, P24; Lamatsch DK, 2000, CYTOMETRY, V39, P91, DOI 10.1002/(SICI)1097-0320(20000201)39:2<91::AID-CYTO1>3.0.CO;2-4; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; LUO GB, 1995, J BONE MINER RES, V10, P325; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Meier M, 2001, EUR RESPIR J, V17, P566, DOI 10.1183/09031936.01.17305660; Munroe PB, 1999, NAT GENET, V21, P142, DOI 10.1038/5102; Murshed M, 2004, J CELL BIOL, V165, P625, DOI 10.1083/jcb.200402046; Nishimoto SK, 2003, J BIOL CHEM, V278, P11843, DOI 10.1074/jbc.M211449200; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; ORTIZDELGADO JB, 2005, IN PRESS HISTOCHEM C; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; Pinto JP, 2003, BONE, V32, P201, DOI 10.1016/S8756-3282(02)00981-X; Pinto JP, 2001, GENE, V270, P77, DOI 10.1016/S0378-1119(01)00426-7; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1994, PROTEIN SCI, V3, P822; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; RICE JS, 1994, J BONE MINER RES, V9, P567; Schinke T, 2000, NEPHROL DIAL TRANSPL, V15, P1272, DOI 10.1093/ndt/15.9.1272; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Simes DC, 2003, J BONE MINER RES, V18, P244, DOI 10.1359/jbmr.2003.18.2.244; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; TAJIMA F, 1993, GENETICS, V135, P599; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Viegas CSB, 2002, GENE, V289, P97, DOI 10.1016/S0378-1119(02)00480-8; VOLK T, 1992, DEVELOPMENT, V116, P721; Wajih N, 2004, J BIOL CHEM, V279, P43052, DOI 10.1074/jbc.M407180200; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	59	33	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26659	26668		10.1074/jbc.M500257200	http://dx.doi.org/10.1074/jbc.M500257200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15849363	hybrid, Green Published			2022-12-25	WOS:000230589500006
J	St-Jean, M; Lafrance-Vanasse, J; Liotard, B; Sygusch, J				St-Jean, M; Lafrance-Vanasse, J; Liotard, B; Sygusch, J			High resolution reaction intermediates of rabbit muscle fructose-1,6-bisphosphate aldolase - Substrate cleavage and induced fit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 1,6-BISPHOSPHATE ALDOLASE; SCHIFF-BASE FORMATION; CRYSTAL-STRUCTURE; ACTIVE-SITE; MECHANISTIC IMPLICATIONS; CARBINOLAMINE FORMATION; DIPHOSPHATE ALDOLASE; BINDING; COMPLEXES; RESIDUE	Crystal structures were determined to 1.8 angstrom resolution of the glycolytic enzyme fructose-1,6-bis(phosphate) aldolase trapped in complex with its substrate and a competitive inhibitor, mannitol-1,6-bis(phosphate). The enzyme substrate complex corresponded to the postulated Schiff base intermediate and has reaction geometry consistent with incipient C-3-C-4 bond cleavage catalyzed by Glu-187, which is adjacent to the Schiff base forming Lys-229. Atom arrangement about the cleaved bond in the reaction intermediate mimics a pericyclic transition state occurring in nonenzymatic aldol condensations. Lys-146 hydrogen-bonds the substrate C-4 hydroxyl and assists substrate cleavage by stabilizing the developing negative charge on the C-4 hydroxyl during proton abstraction. Mannitol-1,6-bis(phosphate) forms a noncovalent complex in the active site whose binding geometry mimics the covalent carbinolamine precursor. Glu-187 hydrogen-bonds the C-2 hydroxyl of the inhibitor in the enzyme complex, substantiating a proton transfer role by Glu-187 in catalyzing the conversion of the carbinolamine intermediate to Schiff base. Modeling of the acyclic substrate configuration into the active site shows Glu-187, in acid form, hydrogen-bonding both substrate C-2 carbonyl and C-4 hydroxyl, thereby aligning the substrate ketose for nucleophilic attack by Lys-229. The multifunctional role of Glu-187 epitomizes a canonical mechanistic feature conserved in Schiff base-forming aldolases catalyzing carbohydrate metabolism. Trapping of tagatose-1,6-bis(phosphate), a diastereoisomer of fructose 1,6-bis(phosphate), displayed stereospecific discrimination and reduced ketohexose binding specificity. Each ligand induces homologous conformational changes in two adjacent alpha-helical regions that promote phosphate binding in the active site.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA	Universite de Montreal; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory	Sygusch, J (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Jurgen.Sygusch@UMontreal.CA	Lafrance-Vanasse, Julien/B-1952-2009; Lafrance-Vanasse, Julien/ABG-9263-2020	Lafrance-Vanasse, Julien/0000-0001-8807-6277; Sygusch, Jurgen/0000-0002-6629-2128				Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; ANAI M, 1973, ARCH BIOCHEM BIOPHYS, V156, P712, DOI 10.1016/0003-9861(73)90324-X; AVIGAD G, 1972, ARCH BIOCHEM BIOPHYS, V153, P337, DOI 10.1016/0003-9861(72)90454-7; BISSETT DL, 1980, J BIOL CHEM, V255, P8750; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; Blonski C, 1997, BIOCHEM J, V323, P71, DOI 10.1042/bj3230071; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; Dalby A, 1999, PROTEIN SCI, V8, P291; DeLano WL, 2004, PYMOL MOL GRAPHICS S; DIAMOND R, 1992, PROTEIN SCI, V1, P1279, DOI 10.1002/pro.5560011006; DIIASIO A, 1977, FEBS LETT, V73, P244, DOI 10.1016/0014-5793(77)80990-3; DUBOIS JE, 1972, TETRAHEDRON, V28, P1653, DOI 10.1016/0040-4020(72)88047-5; GINSBURG A, 1966, BIOCHEMISTRY-US, V5, P2623, DOI 10.1021/bi00872a021; GRAZI E, 1962, BIOCHEM BIOPH RES CO, V9, P38, DOI 10.1016/0006-291X(62)90083-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARTMAN FC, 1976, J BIOL CHEM, V251, P3057; HARTMAN FC, 1965, BIOCHEMISTRY-US, V4, P1068, DOI 10.1021/bi00882a014; HEATHCOCK CH, 1980, J ORG CHEM, V45, P1066, DOI 10.1021/jo01294a030; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; JEFFREY GA, 1994, HYDROGEN BONDING BIO, P48; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Jia J, 1997, PROTEIN SCI, V6, P119; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUO DJ, 1985, BIOCHEMISTRY-US, V24, P3947, DOI 10.1021/bi00336a022; LAI CY, 1965, J BIOL CHEM, V240, P1347; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lorentzen E, 2005, BIOCHEMISTRY-US, V44, P4222, DOI 10.1021/bi048192o; Lorentzen E, 2003, J BIOL CHEM, V278, P47253, DOI 10.1074/jbc.M305922200; Maurady A, 2002, J BIOL CHEM, V277, P9474, DOI 10.1074/jbc.M107600200; MIDELFORT CF, 1976, BIOCHEMISTRY-US, V15, P2178, DOI 10.1021/bi00655a023; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; Morris AJ, 1996, PROTEIN ENG, V9, P61, DOI 10.1093/protein/9.1.61; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENHOET EE, 1971, J BIOL CHEM, V246, P318; RACKER E, 1947, J BIOL CHEM, V167, P843; RAY BD, 1983, J AM CHEM SOC, V105, P3731, DOI 10.1021/ja00349a075; Ringe D, 2003, BIOPHYS CHEM, V105, P667, DOI 10.1016/S0301-4622(03)00096-6; ROSE IA, 1958, J BIOL CHEM, V231, P315; ROSE IA, 1985, BIOCHEMISTRY-US, V24, P3952, DOI 10.1021/bi00336a023; SAYER JM, 1974, J AM CHEM SOC, V96, P7998, DOI 10.1021/ja00833a027; Schorken U, 2001, EUR J BIOCHEM, V268, P2408, DOI 10.1046/j.1432-1327.2001.02128.x; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; ZIMMERMAN HE, 1957, J AM CHEM SOC, V79, P1920, DOI 10.1021/ja01565a041	47	53	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27262	27270		10.1074/jbc.M502413200	http://dx.doi.org/10.1074/jbc.M502413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15870069	hybrid			2022-12-25	WOS:000230589500075
J	Piccoli, C; Ria, R; Scrima, R; Cela, O; D'Aprile, A; Boffoli, D; Falzetti, F; Tabilio, A; Capitanio, N				Piccoli, C; Ria, R; Scrima, R; Cela, O; D'Aprile, A; Boffoli, D; Falzetti, F; Tabilio, A; Capitanio, N			Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells - Novel evidence of the occurrence of NAD(P)H oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; BONE-MARROW-CELLS; NADPH-OXIDASE; PERIPHERAL-BLOOD; OXIDATIVE STRESS; ACTIVATION; PHOSPHORYLATION; CHAIN; SUBPOPULATIONS; MOBILIZATION	This study was aimed to characterize the mitochondrial and extra-mitochondrial oxygen consuming reactions in human CD34(+) hematopoietic stem cells. Cell samples were collected by apheresis following pre-conditioning by granulocyte colony-stimulating factor and isolated by anti-CD34 positive immunoselection. Polarographic analysis of the CN-sensitive endogenous cell respiration revealed a low mitochondrial oxygen consumption rate. Differential absorbance spectrometry on whole cell lysate and two-dimensional blue native-PAGE analysis of mitoplast proteins confirmed a low amount of mitochondrial respiratory chain complexes thus qualifying the hematopoietic stem cell as a poor oxidative phosphorylating cell type. Confocal microscopy imaging showed, however, that the intracellular content of mitochondria was not homogeneously distributed in the CD34(+) hematopoietic stem cell sample displaying a clear inverse correlation of their density with the expression of the CD34 commitment marker. About half of the endogenous oxygen consumption was extra-mitochondrial and completely inhibitable by enzymatic scavengers of reactive oxygen species and by diphenylene iodinium. By spectral analysis, flow cytometry, reverse transcriptase-PCR, immunocytochemistry, and immunoprecipitation it was shown that the extra-mitochondrial oxygen consumption was contributed by the NOX2 and NOX4 isoforms of the O-2(radical anion) producer plasma membrane NAD(P) H oxidase with low constitutive activity. A model is proposed suggesting for the NAD( P) H oxidase a role of O-2 sensor and/or ROS source serving as redox messengers in the activation of intracellular signaling pathways leading ( or contributing) to mitochondriogenesis, cell survival, and differentiation in hematopoietic stem cells.	Univ Foggia, Dept Biomed Sci, I-71100 Foggia, Italy; Univ Perugia, Dept Clin & Expt Med, Hematol & Clin Immunol Sect, I-06100 Perugia, Italy	University of Foggia; University of Perugia	Capitanio, N (corresponding author), Univ Foggia, Dept Biomed Sci, Viale L Pinto OO RR, I-71100 Foggia, Italy.	n.cap@unifg.it	Ria, Roberto/I-4263-2015	Ria, Roberto/0000-0002-1515-0090				Alessandri G, 2004, ANN NY ACAD SCI, V1015, P271, DOI 10.1196/annals.1302.023; Asahara T, 2000, GENE THER, V7, P451, DOI 10.1038/sj.gt.3301142; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Bonnet D, 2002, J PATHOL, V197, P430, DOI 10.1002/path.1153; Brandes RP, 2005, CARDIOVASC RES, V65, P16, DOI 10.1016/j.cardiores.2004.08.007; Brunori M, 2004, BBA-BIOENERGETICS, V1655, P365, DOI 10.1016/j.bbabio.2003.06.008; Bunting KD, 2003, BIOL CELL, V95, P563, DOI 10.1016/j.biolcel.2003.10.001; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Capaldi RA, 2002, BBA-BIOENERGETICS, V1555, P192, DOI 10.1016/S0005-2728(02)00277-3; Carcamo JM, 2002, BLOOD, V99, P3205, DOI 10.1182/blood.V99.9.3205; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chow DC, 2001, BIOPHYS J, V81, P675, DOI 10.1016/S0006-3495(01)75732-3; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; COX JA, 1987, J IMMUNOL, V138, P1884; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Danet GH, 2003, J CLIN INVEST, V112, P126, DOI 10.1172/JCI200317669; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; DRACH D, 1992, BLOOD, V80, P2729; ElBenna J, 1996, J BIOL CHEM, V271, P6374; Finkel T, 2001, IUBMB LIFE, V52, P3, DOI 10.1080/15216540252774694; FLORIS R, 1994, EUR J BIOCHEM, V222, P677, DOI 10.1111/j.1432-1033.1994.tb18912.x; Fritsch G, 1996, BONE MARROW TRANSPL, V17, P169; GABIG TG, 1979, BLOOD, V53, P1133; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Gross S, 1997, EUR J HAEMATOL, V59, P318; Haddad JJ, 2004, BIOCHEM BIOPH RES CO, V316, P969, DOI 10.1016/j.bbrc.2004.02.162; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; Heike T, 2004, INT J HEMATOL, V79, P7, DOI 10.1007/BF02983527; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Jetmore A, 2002, BLOOD, V99, P1585, DOI 10.1182/blood.V99.5.1585; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kim MJ, 1998, BLOOD, V91, P4106, DOI 10.1182/blood.V91.11.4106.411k40_4106_4117; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; Laloi C, 2004, CURR OPIN PLANT BIOL, V7, P323, DOI 10.1016/j.pbi.2004.03.005; Lanza F, 2001, J BIOL REG HOMEOS AG, V15, P1; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1007/BF02254978; LEE NK, 2005, BLOOD; LEUSCH MW, 2004, CURR TOP DEV BIOL, V60, P127; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101; North JA, 1996, ANAL BIOCHEM, V233, P115, DOI 10.1006/abio.1996.0015; Pazianos G, 2003, BIOTECHNIQUES, V35, P1240, DOI 10.2144/03356ss03; Polytarchou C, 2005, EUR J PHARMACOL, V510, P31, DOI 10.1016/j.ejphar.2005.01.004; Porwol T, 2001, RESP PHYSIOL, V128, P331, DOI 10.1016/S0034-5687(01)00310-3; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Saretzki G, 2004, STEM CELLS, V22, P962, DOI 10.1634/stemcells.22-6-962; Sattler M, 1999, BLOOD, V93, P2928; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032; Sauer H, 2000, FEBS LETT, V476, P218, DOI 10.1016/S0014-5793(00)01747-6; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Shao DM, 2003, FEBS LETT, V550, P101, DOI 10.1016/S0014-5793(03)00845-7; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; Steidl U, 2003, ANN NY ACAD SCI, V996, P89, DOI 10.1111/j.1749-6632.2003.tb03237.x; Swartz HM, 2003, ADV EXP MED BIOL, V530, P1; Tabilio A, 1997, J HEMATOTHER, V6, P227, DOI 10.1089/scd.1.1997.6.227; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Uchida N, 1997, BLOOD, V89, P465, DOI 10.1182/blood.V89.2.465; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	73	151	159	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26467	26476		10.1074/jbc.M500047200	http://dx.doi.org/10.1074/jbc.M500047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15883163	hybrid			2022-12-25	WOS:000230386800062
J	Hocevar, BA; Prunier, C; Howe, PH				Hocevar, BA; Prunier, C; Howe, PH			Disabled-2 (Dab2) mediates transforming growth factor beta (TGF beta)-stimulated fibronectin synthesis through TGF beta-activated kinase 1 and activation of the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; C-JUN; KINASE CASCADE; CYTOSOLIC ADAPTER; SIGNALING PATHWAY; BINDING PROTEIN; TAK1; SMAD; EXPRESSION; FAMILY	The multifunctional cytokine transforming growth factor beta ( TGF beta) exerts many of its effects through its regulation of extracellular matrix components, including fibronectin ( FN). Although expression of both TGF beta and FN are essential for embryonic development and wound healing in the adult, overexpression leads to excessive deposition of extracellular matrix observed in many fibroproliferative disorders. We previously have demonstrated that TGF beta- stimulated FN induction requires activation of the c- Jun N- terminal kinase ( JNK) pathway; however, the signaling molecules that link the TGF beta receptors to the JNK pathway remain unknown. We show here that the cytosolic adaptor protein disabled2 ( Dab2) directly stimulates JNK activity, whereas stable small interfering RNA- mediated ablation of Dab2 in NIH3T3 mouse fibroblasts and A10 rat aortic smooth muscle cells demonstrates that its expression is required for TGF beta- mediated FN induction. We demonstrate that TGF beta treatment stimulates the association of Dab2 with the mitogen- activated protein kinase kinase kinase, TAK1. Attenuation of cellular TAK1 levels by transient double- stranded RNA oligonucleotide transfection as well as overexpression of kinase- deficient TAK1 leads to abrogation of TGF beta- stimulated FN induction. Furthermore, cell migration, another JNK- dependent response, is attenuated in NIH3T3- siDab2- expressing clones. We, therefore, delineate a signaling pathway proceeding from the TGF beta receptors to Dab2 and TAK1, leading to TGF beta- stimulated JNK activation, FN expression, and cell migration.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC-1, Cleveland, OH 44195 USA.	howep@ccf.org	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273	NCI NIH HHS [CA80095, CA55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R01CA080095, R29CA055536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOWLUS CL, 1991, J BIOL CHEM, V266, P1122; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEAN DC, 1988, J CELL BIOL, V106, P2159, DOI 10.1083/jcb.106.6.2159; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Mihaly J, 2001, MECH DEVELOP, V102, P67, DOI 10.1016/S0925-4773(01)00285-4; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Ono K, 2003, BIOCHEM BIOPH RES CO, V307, P332, DOI 10.1016/S0006-291X(03)01207-5; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Utsugi M, 2003, AM J RESP CELL MOL, V28, P754, DOI 10.1165/rcmb.4892; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Weston CR, 2003, GENE DEV, V17, P1271, DOI 10.1101/gad.1087303; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhang L, 2003, EMBO J, V22, P4443, DOI 10.1093/emboj/cdg440; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	70	86	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25920	25927		10.1074/jbc.M501150200	http://dx.doi.org/10.1074/jbc.M501150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15894542	hybrid			2022-12-25	WOS:000230207900073
J	Soulet, F; Bailly, K; Roga, S; Lavigne, AC; Amalric, F; Bouche, G				Soulet, F; Bailly, K; Roga, S; Lavigne, AC; Amalric, F; Bouche, G			Exogenously added fibroblast growth factor 2 (FGF-2) to NIH3T3 cells interacts with nuclear ribosomal S6 kinase 2 (RSK2) in a cell cycle-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RIBOSOMAL S6 KINASE; HISTONE H3; PROTEIN KINASE-1; FACTOR-2; PHOSPHORYLATION; TRANSCRIPTION; LOCALIZATION; ACTIVATION; GENE	Fibroblast growth factor 2 (FGF-2) has been detected in the nuclei of many tissues and cell lines. Here we demonstrate that FGF-2 added exogenously to NIH3T3 cells enters the nucleus and interacts with the nuclear active 90-kDa ribosomal S6 kinase 2 (RSK2) in a cell cycle-dependent manner. By using purified proteins, FGF-2 is shown to directly interact through two separate domains with two RSK2 domains on both sides of the hydrophobic motif, namely the NH2-terminal kinase domain (residues 360-381) by amino acid Ser-117 and the COOH-terminal kinase domain (residues 388-400) by amino acids Leu-127 and Lys-128. Moreover, this interaction leads to maintenance of the sustained activation of RSK2 in G(1) phase of the cell cycle. FGF-2 mutants ( FGF-2 S117A, FGF-2 L127A, and FGF-2 K128A) that fail to interact in vitro with RSK2 fail to maintain a sustained RSK2 activity in vivo.	Inst Pharmacol & Biol Struct, Lab Biol Vasc, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bouche, G (corresponding author), Inst Pharmacol & Biol Struct, Lab Biol Vasc, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	Gerard.Bouche@ipbs.fr	Lavigne, Anne-Claire/O-8805-2015					Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; Bossard C, 2003, NAT CELL BIOL, V5, P433, DOI 10.1038/ncb979; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Claus P, 2003, J BIOL CHEM, V278, P479, DOI 10.1074/jbc.M206056200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Facchiano A, 2003, J BIOL CHEM, V278, P8751, DOI 10.1074/jbc.M209936200; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Hu YF, 2004, J BIOL CHEM, V279, P29325, DOI 10.1074/jbc.M311144200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Olsnes S, 2003, PHYSIOL REV, V83, P163, DOI 10.1152/physrev.00021.2002; Peng H, 2002, J NEUROCHEM, V81, P506, DOI 10.1046/j.1471-4159.2002.00833.x; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sheng Z, 2004, J BIOL CHEM, V279, P40153, DOI 10.1074/jbc.M400123200; Skjerpen CS, 2002, EMBO J, V21, P4058, DOI 10.1093/emboj/cdf402; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4	37	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25604	25610		10.1074/jbc.M500232200	http://dx.doi.org/10.1074/jbc.M500232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15879597	Green Published, hybrid			2022-12-25	WOS:000230207900039
J	Meyer, DK; Fischer, C; Becker, U; Gottsching, I; Boutillier, S; Baermann, C; Schmidt, G; Klugbauer, N; Leemhuis, J				Meyer, DK; Fischer, C; Becker, U; Gottsching, I; Boutillier, S; Baermann, C; Schmidt, G; Klugbauer, N; Leemhuis, J			Pituitary adenylyl cyclase-activating polypeptide 38 reduces astroglial proliferation by inhibiting the GTPase RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CYCLIN D1 EXPRESSION; CELL-CYCLE; PROTEIN-KINASE; BINDING-SITES; PROENKEPHALIN GENE; MAMMALIAN-CELLS; CEREBRAL-CORTEX; PACAP RECEPTOR; IN-VITRO	Pituitary adenylyl cyclase-activating polypeptide 38 (PACAP38) plays an important role in the proliferation and differentiation of neural cells. In the present study, we have investigated how PACAP38 inhibits the proliferation of cultured neocortical astroglial cells. When applied to synchronized cells during the G(1) phase of the cell cycle, PACAP38 diminished the subsequent nuclear uptake of bromodeoxyuridine. When applied for 2 days, it reduced the cell number. PACAP38 did not exert its antiproliferative effect by activating protein kinase A. It also did not reduce the activity of mitogen-activated protein kinases essential for G(1) phase progression. Instead, PACAP38 acted on a member of the Rho family of small GTPases. It reduced the activity of RhoA as was shown with a Rhotekin pull-down assay. The decrease in endogenous RhoA activity induced by treatment of the cells with C3 exotoxin or by expression of dominant negative RhoA also reduced the nuclear uptake of bromodeoxyuridine. In contrast, expression of constitutively active RhoA prevented the effect of PACAP38. Our data show a novel signal transduction pathway by which the neuropeptide influences cell proliferation.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxicol, Zentrum Neurowissenschaften, D-79104 Freiburg, Germany	University of Freiburg	Meyer, DK (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxicol, Zentrum Neurowissenschaften, Albert Str 25, D-79104 Freiburg, Germany.	dieter.meyer@pharmakol.uni-freiburg.de						ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carey RG, 2002, J NEUROSCI, V22, P1583, DOI 10.1523/JNEUROSCI.22-05-01583.2002; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; DAY RN, 1989, J BIOL CHEM, V264, P431; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Diviani D, 2004, EMBO J, V23, P2811, DOI 10.1038/sj.emboj.7600287; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hansel DE, 2001, J NEUROSCI, V21, P4625, DOI 10.1523/JNEUROSCI.21-13-04625.2001; Hansen LK, 1999, J CELL SCI, V112, P2971; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hildebrand B, 1996, J NEUROCHEM, V66, P1860; Hill JM, 1999, NEUROSCIENCE, V93, P783, DOI 10.1016/S0306-4522(99)00155-4; Hirai A, 1997, J BIOL CHEM, V272, P13; Hoffmann C, 2004, J BIOL CHEM, V279, P16026, DOI 10.1074/jbc.M313556200; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Just L, 2000, GLIA, V30, P242, DOI 10.1002/(SICI)1098-1136(200005)30:3<242::AID-GLIA4>3.0.CO;2-V; Le Gallic L, 2004, MOL CELL BIOL, V24, P1206, DOI 10.1128/MCB.24.3.1206-1218.2004; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; Lee M, 2001, J NEUROSCI, V21, P3849, DOI 10.1523/JNEUROSCI.21-11-03849.2001; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; McCulloch DA, 2001, MOL PHARMACOL, V59, P1523, DOI 10.1124/mol.59.6.1523; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Nicot A, 2001, P NATL ACAD SCI USA, V98, P4758, DOI 10.1073/pnas.071465398; Nicot A, 2002, J NEUROSCI, V22, P9244; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Olenik C, 1999, MOL BRAIN RES, V70, P9, DOI 10.1016/S0169-328X(99)00121-7; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pielen A, 2004, GRAEF ARCH CLIN EXP, V242, P240, DOI 10.1007/s00417-004-0872-4; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Skoglosa Y, 1999, MOL BRAIN RES, V65, P1, DOI 10.1016/S0169-328X(98)00294-0; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Suh JH, 2001, NAT NEUROSCI, V4, P123, DOI 10.1038/83936; TATSUNO I, 1991, PEPTIDES, V12, P617, DOI 10.1016/0196-9781(91)90110-B; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TISCHLER AS, 1995, NEUROSCI LETT, V189, P135, DOI 10.1016/0304-3940(95)11472-9; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Welsh CF, 2004, BREAST CANCER RES TR, V84, P33, DOI 10.1023/B:BREA.0000018425.31633.07; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zhou CJ, 1999, NEUROSCIENCE, V93, P375, DOI 10.1016/S0306-4522(99)00108-6; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zupan V, 1998, J NEUROCHEM, V70, P2165	71	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25258	25266		10.1074/jbc.M501630200	http://dx.doi.org/10.1074/jbc.M501630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870074	hybrid			2022-12-25	WOS:000230114000112
J	Qin, JZ; Qian, YC; Yao, JH; Grace, C; Li, XX				Qin, JZ; Qian, YC; Yao, JH; Grace, C; Li, XX			SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR; NF-KAPPA-B; INTERLEUKIN-1 RECEPTOR; NEGATIVE REGULATOR; KINASE COMPLEX; IMMUNE CELLS; IL-1; ACTIVATION; MEMBER; IRAK	The Toll-interleukin-1 receptor (TIR) domain-containing orphan receptor SIGIRR (single immunoglobulin interleukin-1 receptor-related protein) acts as a negative regulator of interleukin (IL)-1 and lipopolysaccharide (LPS) signaling. Endogenous SIGIRR transiently interacted with IL-1 receptor and the receptor-proximal signaling components (MyD88, IRAK, and tumor necrosis factor receptor-associated factor 6) upon IL-1 stimulation, indicating that SIGIRR interacts with the IL-1 receptor complex in a ligand-dependent manner. Similar interaction was also observed between SIGIRR and Toll-like receptor 4 receptor complex upon LPS stimulation. To identify the domains of SIGIRR required for its interaction with the Toll-like receptor 4 and IL-1 receptor complexes, several SIGIRR deletion mutants were generated, including Delta N (lacking the extracellular immunoglobulin (Ig) domain with deletion of amino acids 1-119), Delta C ( lacking the C-terminal domain with deletion of amino acids 313-410), and Delta TIR (lacking the TIR domain with deletion of amino acids 161-313). Whereas both the extracellular Ig domain and the intracellular TIR domains are important for SIGIRR to inhibit IL-1 signaling, only the TIR domain is necessary for SIGIRR to inhibit LPS signaling. The extracellular Ig domain exerts its inhibitory role in IL-1 signaling by interfering with the heterodimerization of IL-1 receptor and IL-1RAcP, whereas the intracellular TIR domain inhibits both IL-1 and LPS signaling by attenuating the recruitment of receptor-proximal signaling components to the receptor. These results indicate that SIGIRR inhibits IL-1 and LPS signaling pathways through differential mechanisms.	Cleveland Clin Fdn, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chuang TH, 2004, NAT IMMUNOL, V5, P495, DOI 10.1038/ni1066; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Garlanda C, 2004, P NATL ACAD SCI USA, V101, P3522, DOI 10.1073/pnas.0308680101; Hardy MP, 2004, J BIOL CHEM, V279, P27699, DOI 10.1074/jbc.M403068200; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	56	167	182	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25233	25241		10.1074/jbc.M501363200	http://dx.doi.org/10.1074/jbc.M501363200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866876	hybrid			2022-12-25	WOS:000230114000109
J	Combs, TP; Nagajyothi; Mukherjee, NS; de Almeida, CJG; Jelicks, LA; Schubert, W; Lin, Y; Jayabalan, DS; Zhao, DZ; Braunstein, VL; Landskroner-Eiger, S; Cordero, A; Factor, SM; Weiss, LM; Lisanti, MP; Tanowitz, HB; Scherer, PE				Combs, TP; Nagajyothi; Mukherjee, NS; de Almeida, CJG; Jelicks, LA; Schubert, W; Lin, Y; Jayabalan, DS; Zhao, DZ; Braunstein, VL; Landskroner-Eiger, S; Cordero, A; Factor, SM; Weiss, LM; Lisanti, MP; Tanowitz, HB; Scherer, PE			The adipocyte as an important target cell for Trypanosoma cruzi infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAGAS-DISEASE; FALCIPARUM-MALARIA; INSULIN-RESPONSE; GLUCOSE; HYPERINSULINEMIA; HYPOGLYCEMIA; BRUCEI; MICE; ADIPONECTIN; ENDOTOXEMIA	Adipose tissue plays an active role in normal metabolic homeostasis as well as in the development of human disease. Beyond its obvious role as a depot for triglycerides, adipose tissue controls energy expenditure through secretion of several factors. Little attention has been given to the role of adipocytes in the pathogenesis of Chagas disease and the associated metabolic alterations. Our previous studies have indicated that hyperglycemia significantly increases parasitemia and mortality in mice infected with Trypanosoma cruzi. We determined the consequences of adipocyte infection in vitro and in vivo. Cultured 3T3-L1 adipocytes can be infected with high efficiency. Electron micrographs of infected cells revealed a large number of intracellular parasites that cluster around lipid droplets. Furthermore, infected adipocytes exhibited changes in expression levels of a number of different adipocyte-specific or adipocyte-enriched proteins. The adipocyte is therefore an important target cell during acute Chagas disease. Infection of adipocytes by T. cruzi profoundly influences the pattern of adipokines. During chronic infection, adipocytes may represent an important long-term reservoir for parasites from which relapse of infection can occur. We have demonstrated that acute infection has a unique metabolic profile with a high degree of local inflammation in adipose tissue, hypoadiponectinemia, hypoglycemia, and hypoinsulinemia but with relatively normal glucose disposal during an oral glucose tolerance test.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Jelicks, Linda/L-9740-2019; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Jelicks, Linda/0000-0002-6438-1792; 	FOGARTY INTERNATIONAL CENTER [D43TW007129] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R03EY014935] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012770, R21AI062730, R21AI012770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758, F32DK061228] Funding Source: NIH RePORTER; FIC NIH HHS [D43TW007129] Funding Source: Medline; NEI NIH HHS [R03 EY014935-01] Funding Source: Medline; NHLBI NIH HHS [R01-HL073163-01] Funding Source: Medline; NIAID NIH HHS [AI-062730, AI-52739, AI-12770] Funding Source: Medline; NIDDK NIH HHS [DK61228, R01-DK55758] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOLE BO, 1985, EXP PARASITOL, V60, P342, DOI 10.1016/0014-4894(85)90040-2; BARR SC, 1991, AM J VET RES, V52, P2033; Buckner FS, 1999, INFECT IMMUN, V67, P403, DOI 10.1128/IAI.67.1.403-409.1999; Cummings KL, 2003, MOL BIOCHEM PARASIT, V129, P53, DOI 10.1016/S0166-6851(03)00093-8; dos Santos V M, 1999, Rev Soc Bras Med Trop, V32, P489; ELASED K, 1994, INFECT IMMUN, V62, P5157, DOI 10.1128/IAI.62.11.5157-5160.1994; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; GUARIENTO ME, 1993, BRAZ J MED BIOL RES, V26, P491; Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000; Keller P, 2003, CLIN EXP IMMUNOL, V134, P107, DOI 10.1046/j.1365-2249.2003.02264.x; Kirchhoff LV, 2004, FRONT BIOSCI-LANDMRK, V9, P706, DOI 10.2741/1255; Krogh-Madsen R, 2004, AM J PHYSIOL-ENDOC M, V286, pE766, DOI 10.1152/ajpendo.00468.2003; Lenzi IL, 1996, EXP PARASITOL, V84, P16, DOI 10.1006/expr.1996.0086; MISEK DE, 1992, J BIOL CHEM, V267, P16266; MISEK DE, 1994, ENDOCRINOLOGY, V135, P1869, DOI 10.1210/en.135.5.1869; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477, DOI 10.1128/JCM.27.7.1477-1482.1989; Mynarcik DC, 2002, JAIDS-J ACQ IMM DEF, V31, P514, DOI 10.1097/00126334-200212150-00009; OLIVEIRA LCM, 1993, BRAZ J MED BIOL RES, V26, P1187; PHILLIPS RE, 1993, Q J MED, V86, P233; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rusavy Z, 2004, CRIT CARE, V8, pR213, DOI 10.1186/cc2868; TANOWITZ HB, 1988, T ROY SOC TROP MED H, V82, P90, DOI 10.1016/0035-9203(88)90272-6; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; Tetaud E, 1997, BIOCHEM J, V325, P569, DOI 10.1042/bj3250569; Vaidian Anil K, 2004, Kinetoplastid Biol Dis, V3, P2, DOI 10.1186/1475-9292-3-2; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201	27	145	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24085	24094		10.1074/jbc.M412802200	http://dx.doi.org/10.1074/jbc.M412802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843370	hybrid			2022-12-25	WOS:000229880000082
J	Yu, IM; Gustafson, CLT; Diao, JB; Burgner, JW; Li, ZH; Zhang, JQ; Chen, J				Yu, IM; Gustafson, CLT; Diao, JB; Burgner, JW; Li, ZH; Zhang, JQ; Chen, J			Recombinant severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein forms a dimer through its c-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; SIZE-DISTRIBUTION ANALYSIS; MURINE CORONAVIRUS; SELF-ASSOCIATION; SPIKE PROTEIN; N PROTEIN; SEQUENCE; PARTICLES; ULTRACENTRIFUGATION; IDENTIFICATION	The causative agent of severe acute respiratory syndrome (SARS) is the SARS-associated coronavirus, SARS-CoV. The viral nucleocapsid (N) protein plays an essential role in viral RNA packaging. In this study, recombinant SARS-CoV N protein was shown to be dimeric by analytical ultracentrifugation, size exclusion chromatography coupled with light scattering, and chemical cross-linking. Dimeric N proteins self-associate into tetramers and higher molecular weight oligomers at high concentrations. The dimerization domain of N was mapped through studies of the oligomeric states of several truncated mutants. Although mutants consisting of residues 1-210 and 1-284 fold as monomers, constructs consisting of residues 211-422 and 285-422 efficiently form dimers. When in excess, the truncated construct 285-422 inhibits the homodimerization of full-length N protein by forming a heterodimer with the full-length N protein. These results suggest that the N protein oligomerization involves the C-terminal residues 285-422, and this region is a good target for mutagenic studies to disrupt N protein self-association and virion assembly.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA; Zhongshan Univ, State Key Lab Biocontrol, Guangzhou, Peoples R China	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sun Yat Sen University	Chen, J (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.	chenjue@purdue.edu						Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004; BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988; Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165; Cologna R, 2000, VIROLOGY, V277, P235, DOI 10.1006/viro.2000.0611; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074; He RT, 2003, BIOCHEM BIOPH RES CO, V311, P870, DOI 10.1016/j.bbrc.2003.10.075; Huang QL, 2004, BIOCHEMISTRY-US, V43, P6059, DOI 10.1021/bi036155b; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; MASTERS PS, 1992, ARCH VIROL, V125, P141, DOI 10.1007/BF01309634; Molenkamp R, 1997, VIROLOGY, V239, P78, DOI 10.1006/viro.1997.8867; Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009; Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000; Narayanan K, 2003, VIRUS RES, V98, P131, DOI 10.1016/j.virusres.2003.08.021; Nelson GW, 2000, J GEN VIROL, V81, P181, DOI 10.1099/0022-1317-81-1-181; NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975; PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J; PENG D, 1995, J VIROL, V69, P5475, DOI 10.1128/JVI.69.9.5475-5484.1995; ROBBINS SG, 1986, VIROLOGY, V150, P402, DOI 10.1016/0042-6822(86)90305-3; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; STOHLMAN SA, 1979, J VIROL, V32, P672, DOI 10.1128/JVI.32.2.672-675.1979; STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988; Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102; Surjit M, 2004, BIOCHEM BIOPH RES CO, V317, P1030, DOI 10.1016/j.bbrc.2004.03.154; Tahara SM, 1998, ADV EXP MED BIOL, V440, P313; Tellinghuisen TL, 1999, J VIROL, V73, P5309, DOI 10.1128/JVI.73.7.5309-5319.1999; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; WILBUR SM, 1986, BIOCHEM BIOPH RES CO, V141, P7, DOI 10.1016/S0006-291X(86)80326-6; Wolf BP, 1998, ANAL BIOCHEM, V260, P117, DOI 10.1006/abio.1998.2695; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200	37	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23280	23286		10.1074/jbc.M501015200	http://dx.doi.org/10.1074/jbc.M501015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849181	hybrid, Green Published			2022-12-25	WOS:000229741800086
J	Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL				Stonecypher, MS; Byer, SJ; Grizzle, WE; Carroll, SL			Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						ErbB receptors; neuregulin-1; neurofibromatosis; malignant peripheral nerve sheath tumor; neurofibroma	GROWTH-FACTOR RECEPTOR; POINT MUTATION; NEUROFIBROMATOSIS TYPE-1; SUPPRESSOR MUTATIONS; NEU ONCOGENE; TRANSFORMATION; PATHOGENESIS; EXPRESSION; DELETIONS; GENE	Patients with neurofibromatosis type 1 develop aggressive Schwann cell neoplasms known as malignant peripheral nerve sheath tumors (MPNSTs). Although tumor suppressor gene mutations play an important role in MPNST pathogenesis, it is likely that dysregulated signaling by as yet unidentified growth factors also contributes to the formation of these sarcomas. To test the hypothesis that neuregulin-1 (NRG-1) growth factors promote mitogenesis in MPNSTs, we examined the expression and action of NRG-1 in human MPNSTs and neurofibromas, the benign precursor lesions from which MPNSTs arise. Multiple alpha and beta transmembrane precursors from the class II and III NRG-1 subfamilies are present in both tumor types. Neoplastic Schwann cells within these neoplasms variably express the erbB kinases mediating NRG-1 responses (erbB2, erbB3 and/or erbB4). Human MPNST cell lines (Mash-1, YST-1, NMS-2 and NMS-2PC cells) similarly coexpress multiple NRG-1 isoforms and erbB receptors. These MPNST lines are NRG-1 responsive and demonstrate constitutive erbB phosphorylation. Treatment with PD168393 and PD158780, two structurally and mechanistically distinct erbB inhibitors, abolishes erbB phosphorylation and reduces DNA synthesis in these lines. These findings suggest that autocrine and/or paracrine NRG-1/erbB signaling promotes neoplastic Schwann cell proliferation and may be an important therapeutic target in neurofibromas and MPNSTs.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Sci Training Program, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Carroll, SL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, 1720 7th Ave S,SC843, Birmingham, AL 35294 USA.	carroll@path.uab.edu		Carroll, Steven/0000-0001-6714-4373	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048353] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS048353] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bao JX, 2003, J CELL BIOL, V161, P1133, DOI 10.1083/jcb.200212085; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carroll SL, 2005, J NEUROPATH EXP NEUR, V64, P1; Carroll SL, 2004, J NEUROPATH EXP NEUR, V63, P1115, DOI 10.1093/jnen/63.11.1115; Carroll SL, 1997, J NEUROSCI, V17, P1642; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; Endo H, 2002, BRIT J DERMATOL, V147, P821, DOI 10.1046/j.1365-2133.2002.49279.x; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Ferner RE, 2002, CURR OPIN NEUROL, V15, P679, DOI 10.1097/00019052-200212000-00004; Ferner RE, 2002, CANCER RES, V62, P1573; Frohnert PW, 2003, J NEUROPATH EXP NEUR, V62, P520, DOI 10.1093/jnen/62.5.520; Frohnert PW, 2003, GLIA, V43, P104, DOI 10.1002/glia.10232; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; Kourea HP, 1999, AM J PATHOL, V155, P1885, DOI 10.1016/S0002-9440(10)65508-3; Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO;2-N; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Li HZ, 2002, CANCER RES, V62, P4507; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; METHENY LJ, 1995, J NEUROPATH EXP NEUR, V54, P753, DOI 10.1097/00005072-199511000-00001; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NAGASHIMA Y, 1990, VIRCHOWS ARCH B, V59, P321, DOI 10.1007/BF02899420; Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Parada LF, 2000, BBA-REV CANCER, V1471, pM13, DOI 10.1016/S0304-419X(00)00014-7; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Perry A, 2001, AM J PATHOL, V159, P57, DOI 10.1016/S0002-9440(10)61673-2; Rahmatullah M, 1998, MOL CELL BIOL, V18, P6245, DOI 10.1128/MCB.18.11.6245; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Tucker T, 2002, CLIN GENET, V62, P345, DOI 10.1034/j.1399-0004.2002.620501.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wakatsuki S, 2004, J NEUROCHEM, V89, P119, DOI 10.1046/j.1471-4159.2003.02303.x; Wallace MR, 2000, GENE CHROMOSOME CANC, V27, P117, DOI 10.1002/(SICI)1098-2264(200002)27:2<117::AID-GCC1>3.0.CO;2-H; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	62	59	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5589	5605		10.1038/sj.onc.1208730	http://dx.doi.org/10.1038/sj.onc.1208730			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897877				2022-12-25	WOS:000231296100006
J	Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV				Varga, AE; Stourman, NV; Zheng, Q; Safina, AF; Quan, L; Li, XR; Sossey-Alaoui, K; Bakin, AV			Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta	ONCOGENE			English	Article						metastasis; TGF-beta; tropomyosin; Smad; DNA methylation	GROWTH-FACTOR-BETA; RAS-TRANSFORMED FIBROBLASTS; ACTIVATED PROTEIN-KINASE; ALPHA 2(I) COLLAGEN; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; MESENCHYMAL TRANSDIFFERENTIATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; CANCER-CELLS	Loss of actin stress fibers has been associated with cell transformation and metastasis. TGF-beta induction of stress fibers in epithelial cells requires high molecular weight tropomyosins encoded by TPM1 and TPM2 genes. Here, we investigated the mechanism underlying the failure of TGF-beta to induce stress fibers and inhibit cell migration in metastatic cells. RT-PCR analysis in carcinoma cell lines revealed a significant reduction in TPM1 transcripts in metastatic MDA-MB-231, MDA-MB-435 and SW620 cell lines. Treatment of these cells with demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) increased mRNA levels of TPM1 with no effect on TPM2. Importantly, 5-aza-dC treatment of MDA-MB-231 cells restored TGF-beta induction of TPM1 and formation of stress fibers. Forced expression of TPM1 by using Tet- Off system increased stress fibers in MDA-MB-231 cells and reduced cell migration. A potential CpG island spanning the TPM1 proximal promoter, exon 1, and the beginning of intron 1 was identified. Bisulfite sequencing showed significant cytosine methylation in metastatic cell lines that correlated with a reduced expression of TPM1. Together these results suggest that epigenetic suppression of TPM1 may alter TGF-beta tumor suppressor function and contribute to metastatic properties of tumor cells.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org	Quan, Lei/GXN-1280-2022	Bakin, Andrei/0000-0002-7728-1969; Quan, Lei/0000-0002-6572-0530	NATIONAL CANCER INSTITUTE [R01CA095263] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bakin AV, 2002, J CELL SCI, V115, P3193; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GAGOS S, 1995, ANTICANCER RES, V15, P369; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249; Masuda A, 1996, ONCOGENE, V12, P2081; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Park IK, 2000, BBA-GENE STRUCT EXPR, V1490, P302, DOI 10.1016/S0167-4781(99)00246-8; Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Piek E, 1999, J CELL SCI, V112, P4557; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Robbins J, 1998, CIRC RES, V82, P134; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Saito H, 2000, ANTICANCER RES, V20, P4489; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Temm-Grove CJ, 1998, CELL MOTIL CYTOSKEL, V40, P393, DOI 10.1002/(SICI)1097-0169(1998)40:4<393::AID-CM7>3.0.CO;2-C; Varga AE, 2004, NEOPLASIA, V6, P128, DOI 10.1593/neo.03337; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang FL, 1996, CANCER RES, V56, P3634; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	53	61	65	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5043	5052		10.1038/sj.onc.1208688	http://dx.doi.org/10.1038/sj.onc.1208688			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897890				2022-12-25	WOS:000230816900004
J	Sandalova, T; Michaelsson, J; Harris, RA; Odeberg, J; Schneider, G; Karres, K; Achour, A				Sandalova, T; Michaelsson, J; Harris, RA; Odeberg, J; Schneider, G; Karres, K; Achour, A			A structural basis for CD8(+) T cell-dependent recognition of non-homologous peptide ligands - Implications for molecular mimicry in autoreactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOMENINGITIS VIRUS ESCAPE; CLASS-II MOLECULE; SELF-PEPTIDES; ANTIGEN RECOGNITION; CRYSTAL-STRUCTURE; CROSS-REACTIVITY; VIRAL PEPTIDES; RECEPTOR; COMPLEX; MHC	Molecular mimicry of self-epitopes by viral antigens is one possible pathogenic mechanism underlying induction of autoimmunity. A self-epitope, mDBM, derived from mouse dopamine beta-mono-oxygenase (KALYDYAPI) sharing 44% sequence identity with the lymphocytic choriomeningitis virus-derived immunodominant epitope gp33 (KAVYNFATC/ M), has previously been identified as a cross-reactive self-ligand, presentation of which results in autoimmunity. A rat peptide homologue, rDBM (KALYNYAPI, 56% identity to gp33), which displayed similar properties to mDBM, has also been identified. We herein report the crystal structure of H-2D(b)center dot rDBM and a comparison with the crystal structures of the cross-reactive H-2D(b)center dot gp33 and non- cross- reactive H-2D(b)center dot gp33 (V3L) escape variant (KALYNFATM, 88% identity to gp33). Despite the large sequence disparity, rDBM and gp33 peptides are presented in nearly identical manners by H-2D(b), with a striking juxtaposition of the central sections of both peptides from residues p3 to p7. The structural similarity provides H-2D(b) in complex with either a virus-derived or a dopamine beta-mono-oxygenase-derived peptide with a shared antigenic identity that conserves the positioning of the heavy chain and peptide residues that interact with the T cell receptor (TCR). This stands in contrast to the structure of H-2D(b) center dot gp33 (V3L), in which a single conserved mutation, also present in rDBM, induces large movements of both the peptide backbone and the side chains that interact with the TCR. The TCR-interacting surfaces of the H-2D(b) center dot rDBM and H-2D(b) center dot gp33 major histocompatibility complexes are very similar with regard to shape, topology, and charge distribution, providing a structural basis for CD8 T cell activation by molecular mimicry and potential subsequent development of autoreactivity.	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Strateg Res Ctr IRIS Studies Integrated Recognit, SE-17177 Stockholm, Sweden; Karolinska Univ Hosp Solna, Ctr Mol Med, SE-17177 Stockholm, Sweden; Royal Sch Technol, Dept Biochem, SE-10044 Stockholm, Sweden; Karolinska Univ Hosp Huddinge, Dept Med, Ctr Infect Med, S-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Swedish Foundation for Strategic Research; Karolinska Institutet; Karolinska University Hospital; Royal Institute of Technology; Karolinska Institutet; Karolinska University Hospital	Achour, A (corresponding author), Karolinska Univ Hosp Huddinge, Dept Med F59, Ctr Infect Med, S-14186 Stockholm, Sweden.	adnane.achour@medhs.ki.se	Odeberg, Jacob/I-8314-2016; Odeberg, Jacob O/O-3336-2014; Harris, Robert A./I-6234-2019	Odeberg, Jacob/0000-0003-0996-1644; Odeberg, Jacob O/0000-0003-0996-1644; Harris, Robert A./0000-0003-4990-509X; Sandalova, Tatyana/0000-0002-7694-6420; Achour, Adnane/0000-0003-0432-710X; Schneider, Gunter/0000-0003-0622-5713				Abdul-Majid KB, 2003, J NEUROIMMUNOL, V141, P10, DOI 10.1016/S0165-5728(03)00210-8; Achour A, 2002, IMMUNITY, V17, P757, DOI 10.1016/S1074-7613(02)00478-8; AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; ANDERSON DC, 1988, SCIENCE, V242, P259, DOI 10.1126/science.2459778; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bachmann MF, 1998, EUR J IMMUNOL, V28, P3110; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Bankovich AJ, 2003, IMMUNITY, V18, P7, DOI 10.1016/S1074-7613(02)00517-4; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buslepp J, 2003, IMMUNITY, V19, P595, DOI 10.1016/S1074-7613(03)00269-3; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; Fiorillo MT, 2005, J BIOL CHEM, V280, P2962, DOI 10.1074/jbc.M410807200; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; HAGERTY DT, 1995, J IMMUNOL, V155, P2993; Hemmer B, 1998, J IMMUNOL, V160, P3631; Hennecke J, 2002, J EXP MED, V195, P571, DOI 10.1084/jem.20011194; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; Horwitz MS, 1999, IMMUNOL REV, V169, P241, DOI 10.1111/j.1600-065X.1999.tb01319.x; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Hudrisier D, 2001, J BIOL CHEM, V276, P19396, DOI 10.1074/jbc.M008864200; Hulsmeyer M, 2004, J EXP MED, V199, P271, DOI 10.1084/jem.20031690; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Kohm AP, 2003, TRENDS MICROBIOL, V11, P101, DOI 10.1016/S0966-842X(03)00006-4; Lang HLE, 2002, NAT IMMUNOL, V3, P940, DOI 10.1038/ni835; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; NAKANO T, 1992, BIOCHEM BIOPH RES CO, V189, P590, DOI 10.1016/0006-291X(92)91598-K; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ohteki T, 1999, EUR J IMMUNOL, V29, P2886, DOI 10.1002/(SICI)1521-4141(199909)29:09<2886::AID-IMMU2886>3.0.CO;2-A; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Puglielli MT, 2001, J VIROL, V75, P5099, DOI 10.1128/JVI.75.11.5099-5107.2001; QUARATINO S, 1995, P NATL ACAD SCI USA, V92, P10398, DOI 10.1073/pnas.92.22.10398; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Saibil SD, 2003, EUR J IMMUNOL, V33, P685, DOI 10.1002/eji.200323143; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; Tissot AC, 2000, J MOL BIOL, V302, P873, DOI 10.1006/jmbi.2000.4501; Velloso LM, 2004, J IMMUNOL, V172, P5504, DOI 10.4049/jimmunol.172.9.5504; Vizler C, 1999, IMMUNOL REV, V169, P81; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; WRAITH DC, 1992, J IMMUNOL, V149, P3765; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; Wucherpfennig KW, 2001, J AUTOIMMUN, V16, P293, DOI 10.1006/jaut.2000.0499; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6	68	19	19	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27069	27075		10.1074/jbc.M500927200	http://dx.doi.org/10.1074/jbc.M500927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15845547	hybrid			2022-12-25	WOS:000230589500053
J	Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB				Logan, N; Graham, A; Zhao, XJ; Fisher, R; Maiti, B; Leone, G; La Thangue, NB			E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7	ONCOGENE			English	Article						E2F; cancer; cell cycle; transcription factor	ARABIDOPSIS	E2F is a family of transcription factors implicated in cell cycle control. To understand the role of E2F in controlling cell cycle progression, it is necessary to clarify the breadth of the E2F family. To date, seven E2F subunits have been identified. We report here the characterization of a new E2F subunit, E2F-8, which resembles the organization of E2F-7 in the presence of two separate DNA-binding domains, the integrity of which is required for E2F-8 to bind to DNA. Furthermore, like E2F-7, we find that E2F-8 can repress transcription and delay cell cycle progression. The similarities between E2F-7 and E2F-8 define a new subgroup of the E2F family, and further imply that E2F-7 and E2F-8 may act through overlapping mechanisms in mediating cell cycle control.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Ohio State Univ, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Glasgow; University System of Ohio; Ohio State University	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk			MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vlieghe K, 2005, CURR BIOL, V15, P59, DOI 10.1016/j.cub.2004.12.038; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhao XJ, 2004, J CELL SCI, V117, P6043, DOI 10.1242/jcs.01523; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	17	87	93	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					5000	5004		10.1038/sj.onc.1208703	http://dx.doi.org/10.1038/sj.onc.1208703			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897886				2022-12-25	WOS:000230646500013
J	Chandrasekar, B; Mummidi, S; Valente, AJ; Patel, DN; Bailey, SR; Freeman, GL; Hatano, M; Tokuhisa, T; Jensen, LE				Chandrasekar, B; Mummidi, S; Valente, AJ; Patel, DN; Bailey, SR; Freeman, GL; Hatano, M; Tokuhisa, T; Jensen, LE			The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	77th Scientific Meeting of the American-Heart-Association	NOV 07-10, 2004	New Orleans, LA	Amer Heart Assoc			CORONARY-ARTERY STENOSIS; FACTOR-KAPPA-B; SCAVENGER RECEPTOR; INTERFERON-GAMMA; IFN-GAMMA; TNF-ALPHA; CHEMOKINE; ATHEROSCLEROSIS; IL-18; CXCL16/SR-PSOX	We recently demonstrated that the chemokine CXCL16 is expressed in aortic smooth muscle cells (ASMC) and induces ASMC adhesion and proliferation (Chandrasekar, B., Bysani, S., and Mummidi, S. ( 2004) J. Biol. Chem. 279, 3188 - 3196). Here we reort that interleukin (IL)- 18 positively regulates CXCL16 transcription in rat ASMC. We characterized the cis-regulatory region of CXCL16 and identified a functional activator protein-1 (AP-1) binding motif. Deletion or mutation of this site attenuated IL-18-mediated CXCL16 promoter activity. Gel shift, supershift, and chromatin immunoprecipitation assays confirmed AP-1-dependent CXCL16 expression. CXCL16 promoter-reporter activity was increased by constitutively active c-Fos and c-Jun and decreased by dominant negative or antisense c-Fos and c-Jun. Src kinase inhibitors PP1 and PP2, phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002, Akt inhibitor, the c-Jun N-terminal kinase (JNK) inhibitor SP600125, antisense JNK and dominant negative MyD88, interleukin-1 receptor-associated kinase ( IRAK)- 1, IRAK4, and phosphatidylinositol 3-kinase expression all attenuated IL-18-mediated AP-1 binding and reporter activity, CXCL16 promoter-reporter activity, and CXCL16 expression. Thus IL-18 induced CXCL16 expression via a MyD88 -> IRAK1-IRAK4-TRAF6 ( tumor necrosis factor receptor-associated factor 6) -> c-Src -> PI3K -> Akt -> JNK -> AP-1 pathway. Importantly, IL-18 stimulated ASMC proliferation in a CXCL16-dependent manner. These data provide for the first time a mechanism of IL-18-mediated CXCL16 gene transcription and CXCL16-dependent ASMC proliferation and suggest a role for IL-18-CXCL16 cross-talk in atherogenesis and restenosis following angioplasty.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Chandrasekar, B (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	chandraseka@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; Jensen, Liselotte/0000-0002-0267-8312	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68020] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200; Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185; Chandrasekar B, 2004, J BIOL CHEM, V279, P20221, DOI 10.1074/jbc.M313980200; Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200; Chandrasekar B, 2003, J BIOL CHEM, V278, P4675, DOI 10.1074/jbc.M207006200; Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207; Chandrasekar B, 2003, BIOCHEM BIOPH RES CO, V303, P1152, DOI 10.1016/S0006-291X(03)00496-0; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Gough PJ, 2004, J IMMUNOL, V172, P3678, DOI 10.4049/jimmunol.172.6.3678; Heydtmann M, 2002, GUT, V50, P150, DOI 10.1136/gut.50.2.150; HUE J, 2004, IMMUNOL LETT, V202, P8; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim CH, 2002, BLOOD, V100, P11, DOI 10.1182/blood-2001-12-0196; Lauwerys BR, 1999, CYTOKINE, V11, P822, DOI 10.1006/cyto.1999.0501; Lee JK, 2004, P NATL ACAD SCI USA, V101, P8815, DOI 10.1073/pnas.0402800101; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lundberg GA, 2005, J INTERN MED, V257, P415, DOI 10.1111/j.1365-2796.2005.01469.x; Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; MCBRIDE W, 1988, NEW ENGL J MED, V318, P1734, DOI 10.1056/NEJM198806303182606; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Okada S, 2003, INT IMMUNOL, V15, P1275, DOI 10.1093/intimm/dxg126; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Quercia S, 1996, NEUROSCI LETT, V209, P89, DOI 10.1016/0304-3940(96)12627-6; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schroeder RA, 1998, HEPATOLOGY, V27, P711, DOI 10.1002/hep.510270312; Shashkin P, 2003, ARTERIOSCL THROM VAS, V23, P148, DOI 10.1161/01.ATV.0000043906.61088.4B; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Steffens S, 2004, HERZ, V29, P741, DOI 10.1007/s00059-004-2634-9; Tenger C, 2005, ARTERIOSCL THROM VAS, V25, P791, DOI 10.1161/01.ATV.0000153516.02782.65; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Unutmaz D, 2000, J IMMUNOL, V165, P3284, DOI 10.4049/jimmunol.165.6.3284; Wagsater D, 2004, BIOCHEM BIOPH RES CO, V325, P1187, DOI 10.1016/j.bbrc.2004.10.160; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Wuttge DM, 2004, ARTERIOSCL THROM VAS, V24, P750, DOI 10.1161/01.ATV.0000124102.11472.36; Wyman TH, 2002, J LEUKOCYTE BIOL, V72, P401; Yamauchi R, 2004, ARTERIOSCL THROM VAS, V24, P282, DOI 10.1161/01.ATV.0000114565.42679.c6; Zernecke A, 2005, BASIC RES CARDIOL, V100, P93, DOI 10.1007/s00395-005-0511-6; Zhang SP, 2002, J MOL BIOL, V324, P271, DOI 10.1016/S0022-2836(02)01044-6	53	73	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26263	26277		10.1074/jbc.M502586200	http://dx.doi.org/10.1074/jbc.M502586200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	943WT	15890643	hybrid			2022-12-25	WOS:000230386800042
J	Chen, JL; Peacock, E; Samady, W; Turner, SM; Neese, RA; Hellerstein, MK; Murphy, EJ				Chen, JL; Peacock, E; Samady, W; Turner, SM; Neese, RA; Hellerstein, MK; Murphy, EJ			Physiologic and Pharmacologic factors influencing glyceroneogenic contribution to triacylglyceride glycerol measured by mass isotopomer distribution analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; ADIPOSE-TISSUE; IN-VIVO; DNA-SYNTHESIS; HIGH-PROTEIN; FATTY-ACIDS; GLUCOSE; GLUCONEOGENESIS; THIAZOLIDINEDIONES; METABOLISM	An imbalance between triacylglycerol synthesis and breakdown is necessary for the development of obesity. The direct precursor for triacylglycerol biosynthesis is alpha-glycerol phosphate, which can have glycolytic and glyceroneogenic origins. We present a technique for determining the relative glyceroneogenic contribution to triacylglyceride glycerol by labeling the glycerol moiety with (H2O)-H-2. The number of hydrogen atoms (n) incorporated from H2O into C - H bonds reflects the metabolic source of alpha-glycerol phosphate and can be calculated by combinatorial analysis of the distribution of mass isoto-pomers in triacylglyceride glycerol. Three physiological settings with potential effects on glyceroneogenesis and glycolysis were studied in rodents. Adipose tissue acylglyceride glycerol in mice fed a low carbohydrate diet had significantly higher values of n than in mice fed a high carbohydrate diet, suggesting an increased contribution from glyceroneogenesis of from 17 to 50% on the low carbohydrate diet. Similarly, mice administered rosiglitazone had a significant relative increase in glyceroneogenesis (from 17 to 53%), indicated by an increase in adipose acylglyceride glycerol n. Fructose infusion in overnight fasted rats rapidly lowered plasma triacylglyceride glycerol n, reflecting a decreased contribution from glyceroneogenesis (from 66 to 34%) presumably because of increased glycolytic input. In conclusion, we demonstrate that the number of C - H atoms derived from cellular H2O in triacylglyceride glycerol is an informative indicator of alpha-glycerol phosphate origin and, ultimately, triacylglycerol metabolism. Under certain physiological conditions, glyceroneogenesis can be upregulated in adipose (e. g. low carbohydrate diet) or down-regulated in liver (e. g. fructose infusion). Additionally, stimulation of glyceroneogenesis by rosiglitazone in adipose tissue may be an important factor in the antilipolytic actions of thiazolidinediones.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Murphy, EJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Bldg 30,Rm 3501-K, San Francisco, CA 94110 USA.	smurph@itsa.ucsf.edu		Chen, Jerry/0000-0002-7409-7859	NHLBI NIH HHS [HL65919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; BOTION LM, 1995, HORM METAB RES, V27, P310, DOI 10.1055/s-2007-979967; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Brunengraber DZ, 2003, AM J PHYSIOL-ENDOC M, V285, pE917, DOI 10.1152/ajpendo.00128.2003; Collins ML, 2003, J APPL PHYSIOL, V94, P2203, DOI 10.1152/japplphysiol.00691.2002; Commerford SR, 2002, AM J PHYSIOL-ENDOC M, V283, pE545, DOI 10.1152/ajpendo.00120.2002; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; Duplus E, 2003, BIOCHIMIE, V85, P1257, DOI 10.1016/j.biochi.2003.10.016; FELIG P, 1970, NEW ENGL J MED, V282, P166; FOLCH J, 1957, J BIOL CHEM, V226, P497; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; GORIN E, 1969, EUR J BIOCHEM, V8, P370, DOI 10.1111/j.1432-1033.1969.tb00537.x; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; Jensen MD, 2001, AM J PHYSIOL-ENDOC M, V281, pE998, DOI 10.1152/ajpendo.2001.281.5.E998; Jung HR, 1999, BIOCHEM J, V343, P473, DOI 10.1042/0264-6021:3430473; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Katz J, 1976, Curr Top Cell Regul, V10, P237; LANDAU BR, 1964, J BIOL CHEM, V239, P697; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; Patterson BW, 2002, J LIPID RES, V43, P223; Popkin BM, 2004, NUTR REV, V62, pS140, DOI 10.1111/j.1753-4887.2004.tb00084.x; Previs SF, 1996, J MASS SPECTROM, V31, P639, DOI 10.1002/(SICI)1096-9888(199606)31:6<639::AID-JMS336>3.0.CO;2-S; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; RESHEF L, 1969, J BIOL CHEM, V244, P1994; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; ROGNSTAD R, 1974, EUR J BIOCHEM, V47, P383, DOI 10.1111/j.1432-1033.1974.tb03703.x; Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958; Siler SQ, 1998, J LIPID RES, V39, P2319; Tordjman J, 2003, BIOCHIMIE, V85, P1213, DOI 10.1016/j.biochi.2003.11.010; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; Turner SM, 2003, AM J PHYSIOL-ENDOC M, V285, pE790, DOI 10.1152/ajpendo.00402.2002; van Dijk TH, 2003, ANAL BIOCHEM, V322, P1, DOI 10.1016/j.ab.2003.07.008; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	37	47	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25396	25402		10.1074/jbc.M413948200	http://dx.doi.org/10.1074/jbc.M413948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888453	hybrid			2022-12-25	WOS:000230207900013
J	Ichinose, H; Yoshida, M; Kotake, T; Kuno, A; Igarashi, K; Tsumuraya, Y; Samejima, M; Hirabayashi, J; Kobayashi, H; Kaneko, S				Ichinose, H; Yoshida, M; Kotake, T; Kuno, A; Igarashi, K; Tsumuraya, Y; Samejima, M; Hirabayashi, J; Kobayashi, H; Kaneko, S			An exo-beta-1,3-galactanase having a novel beta-1,3-galactan-binding module from Phanerochaete chrysosporium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING MODULE; FRONTAL AFFINITY-CHROMATOGRAPHY; LIGAND-BINDING; ARABINOGALACTAN-PROTEINS; EXTRACELLULAR-MATRIX; TRICHODERMA-VIRIDE; RECOGNITION; PURIFICATION; REVEALS; OLIGOSACCHARIDES	An exo-beta- 1,3- galactanase gene from Phanerochaete chrysosporium has been cloned, sequenced, and expressed in Pichia pastoris. The complete amino acid sequence of the exo-beta- 1,3- galactanase indicated that the enzyme consists of an N- terminal catalytic module with similarity to glycoside hydrolase family 43 and an additional unknown functional domain similar to carbohydratebinding module family 6 ( CBM6) in the C- terminal region. The molecular mass of the recombinant enzyme was estimated as 55 kDa based on SDS- PAGE. The enzyme showed reactivity only toward beta- 1,3- linked galactosyl oligosaccharides and polysaccharide as substrates but did not hydrolyze beta- 1,4- linked galacto- oligosaccharides, beta- 1,6- linked galacto- oligosaccharides, pectic galactan, larch arabinogalactan, arabinan, gum arabic, debranched arabinan, laminarin, soluble birchwood xylan, or soluble oat spelled xylan. The enzyme also did not hydrolyze beta- 1,3- galactosyl galactosaminide, beta- 1,3- galactosyl glucosaminide, or beta- 1,3- galactosyl arabinofuranoside, suggesting that it specifically cleaves the internal beta- 1,3- linkage of two galactosyl residues. High performance liquid chromatographic analysis of the hydrolysis products showed that the enzyme produced galactose from beta- 1,3- galactan in an exo- acting manner. However, no activity toward p- nitrophenyl beta- galactopyranoside was detected. When incubated with arabinogalactan proteins, the enzyme produced oligosaccharides together with galactose, suggesting that it is able to bypass beta- 1,6- linked galactosyl side chains. The C- terminal CBM6 did not show any affinity for known substrates of CBM6 such as xylan, cellulose, and beta- 1,3- glucan, although it bound beta- 1,3- galactan when analyzed by affinity electrophoresis. Frontal affinity chromatography for the CBM6 moiety using several kinds of terminal galactose-containing oligosaccharides as the analytes clearly indicated that the CBM6 specifically interacted with oligosaccharides containing a beta- 1,3- galactobiose moiety. When the degree of polymerization of galactose oligomers was increased, the binding affinity of the CBM6 showed no marked change.	Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan; Univ Tokyo, Dept Biomat Sci, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Saitama Univ, Fac Sci, Sakura Ku, Urawa, Saitama 3388570, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; University of Tokyo; Saitama University; National Institute of Advanced Industrial Science & Technology (AIST)	Kaneko, S (corresponding author), Natl Food Res Inst, Biol Funct Div, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	sakaneko@nfri.affrc.go.jp	KOTAKE, TOSHIHISA/F-1117-2011; Hirabayashi, Jun/M-3998-2018; Igarashi, Kiyohiko/E-6799-2016; Tsumuraya, Yoichi/C-7903-2012; Kuno, Atsushi/M-2151-2018; Yoshida, Makoto/E-8017-2013	KOTAKE, TOSHIHISA/0000-0002-1110-5006; Hirabayashi, Jun/0000-0002-8571-359X; Igarashi, Kiyohiko/0000-0001-5152-7177; Kuno, Atsushi/0000-0002-6147-6171; 				Boraston AB, 2003, J MOL BIOL, V327, P659, DOI 10.1016/S0022-2836(03)00152-9; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Du H, 1996, TRENDS CELL BIOL, V6, P411, DOI 10.1016/S0962-8924(96)20036-4; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hirabayashi J, 2003, METHOD ENZYMOL, V362, P353; HIRANO H, 1993, ANAL PROTEIN STRUCTU; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P14381, DOI 10.1021/bi961612s; KNOX JP, 1995, FASEB J, V9, P1004, DOI 10.1096/fasebj.9.11.7544308; Kotake T, 2004, BIOCHEM J, V377, P749, DOI 10.1042/bj20031145; KREMER SM, 1992, EUR J BIOCHEM, V205, P133, DOI 10.1111/j.1432-1033.1992.tb16760.x; KUSAKABE I, 1975, NIPPON NOGEIKAGAKU K, V49, P295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Majewska-Sawka A, 2000, PLANT PHYSIOL, V122, P3, DOI 10.1104/pp.122.1.3; Martinez D, 2004, NAT BIOTECHNOL, V22, P695, DOI 10.1038/nbt967; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Nurizzo D, 2002, NAT STRUCT BIOL, V9, P665, DOI 10.1038/nsb835; Okemoto K, 2003, CARBOHYD RES, V338, P219, DOI 10.1016/S0008-6215(02)00405-6; PELLERIN P, 1994, CARBOHYD RES, V264, P281, DOI 10.1016/S0008-6215(05)80012-6; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Schultz C, 1998, TRENDS PLANT SCI, V3, P426, DOI 10.1016/S1360-1385(98)01328-4; SEKIMATA M, 1989, PLANT PHYSIOL, V86, P155; SMALLWOOD M, 1996, MEMBRANES SPECIALIZE; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; TSUMURAYA Y, 1990, J BIOL CHEM, V265, P7207; van Bueren AL, 2005, J BIOL CHEM, V280, P530, DOI 10.1074/jbc.M410113200; van Bueren AL, 2004, J MOL BIOL, V340, P869, DOI 10.1016/j.jbm.2004.05.038	32	69	69	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25820	25829		10.1074/jbc.M501024200	http://dx.doi.org/10.1074/jbc.M501024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15866877	hybrid			2022-12-25	WOS:000230207900063
J	Matsumoto, S; Miyagishi, M; Akashi, H; Nagai, R; Taira, K				Matsumoto, S; Miyagishi, M; Akashi, H; Nagai, R; Taira, K			Analysis of double-stranded RNA-induced apoptosis pathways using interferon-response noninducible small interfering RNA expression vector library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STRESS-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; MAMMALIAN-CELLS; GENE-EXPRESSION; HAIRPIN RNAS; P38 MAPK; PKR; REQUIREMENT; INDUCTION	We have developed an original vector library that allowed us to exploit the phenomenon of RNA interference but also allowed us to avoid the confounding effects of the interferon response. In the present work, we used our library of small interfering RNA expression vectors to examine the genes involved in apoptosis that was induced by double-stranded RNA. To our surprise, screening of our library revealed two novel double-stranded RNA-induced apoptotic pathways, a JNK/SAPK-mediated mitochondrial pathway and an ERK2-related pathway, both of which appeared to be independent of the serine-threonine protein kinase-dependent caspase pathway. We also found that MST2 and protein kinase C alpha both activated the proapoptotic signal mediated by ERK2. The results of our screening analysis suggested the utility of large scale screenings with libraries of small interfering RNA expression vectors.	Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, 21st Century Ctr Excellence Program, Tokyo 1138655, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; University of Tokyo; University of Tokyo	Taira, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Cent 4,1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	makoto-m@chembio.t.u-tokyo.ac.jp; taira@chembio.t.u-tokyo.ac.jp	Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616				Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Dai Y, 2001, CANCER RES, V61, P5106; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gil J, 2002, FEBS LETT, V529, P249, DOI 10.1016/S0014-5793(02)03348-3; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LENGYEL P, 1987, J INTERFERON RES, V7, P511, DOI 10.1089/jir.1987.7.511; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Miyagishi M, 2004, VIRUS RES, V102, P117, DOI 10.1016/j.virusres.2004.01.022; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100	47	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25687	25696		10.1074/jbc.M412784200	http://dx.doi.org/10.1074/jbc.M412784200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15845550	hybrid			2022-12-25	WOS:000230207900049
J	Taille, C; El-Benna, J; Lanone, S; Boczkowski, J; Motterlini, R				Taille, C; El-Benna, J; Lanone, S; Boczkowski, J; Motterlini, R			Mitochondrial respiratory chain and NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTENONE INDUCES APOPTOSIS; OXYGEN SPECIES PRODUCTION; NADPH OXIDASE; HYDROGEN-PEROXIDE; HEME OXYGENASE-1; CELL-PROLIFERATION; ACTIVATION; PHOSPHORYLATION; MOLECULE; GROWTH	Carbon monoxide ( CO), one of the end products of heme oxygenase activity, inhibits smooth muscle proliferation by decreasing ERK1/2 phosphorylation and cyclin D1 expression, a signaling pathway that is known to be modulated by reactive oxygen species (ROS) in airway smooth muscle cells (ASMCs). Two important sources of ROS involved in cell signaling are the membrane NAD( P) H oxidase and the mitochondrial respiratory chain. Thus, that CO could modulate redox signaling in ASMCs by interacting with the heme moiety of NAD(P) H oxidase and/or the respiratory chain is a plausible hypothesis. Here we show that a recently identified carbon monoxide-releasing molecule, [Ru(CO)(3)Cl-2](2) (or CORM-2) 1) inhibits NAD( P) H oxidase cytochrome b(558) activity, 2) increases oxidant production by the mitochondria, and 3) inhibits ASMC proliferation and phosphorylation of the ERK1/2 mitogen-activated protein kinase and expression of cyclin D1, two critical pathways involved in muscle proliferation. No such effects were observed with the negative control (Ru(Me2SO)(4)Cl-2), which does not contain CO groups. Because both diphenylene iodinium or apocynin (inhibitors of NAD(P)H oxidase) and rotenone (a molecule that increases mitochondrial ROS production by blocking the respiratory chain) mimicked the effect of CORM-2 on cyclin D1 expression and ASMC proliferation, the antiproliferative effect of CORM-2 is probably related to inhibition of cytochromes on both NAD( P) H oxidase and the respiratory chain. The involvement of increased mitochondria-derived oxidants is substantiated by the findings showing that the antioxidant N-acetylcysteine partially inhibited the effects of CORM-2. This study provides a new mechanism to explain redox signaling by CO.	Inst Fed Rech 02, Unite 700, Fac Med Xavier Bichat, INSERM, F-75018 Paris, France; Inst Fed Rech 02, Unite 683, Fac Med Xavier Bichat, INSERM, F-75018 Paris, France; Northwick Pk Inst Med Res, Dept Surg Res, Vasc Biol Unit, Harrow HA1 3UJ, Middx, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London	Boczkowski, J (corresponding author), Inst Fed Rech 02, Unite 700, Fac Med Xavier Bichat, INSERM, 16 Rue Henri Huchard, F-75018 Paris, France.	jbb2@bichat.inserm.fr	Lanone, Sophie/I-4042-2016; Motterlini, Roberto/G-2489-2013; Taille, Camille/J-3751-2017; Motterlini, Roberto/Q-1890-2019; Boczkowski, Jorge/S-7474-2018	Lanone, Sophie/0000-0003-2509-8799; Motterlini, Roberto/0000-0003-2684-2612; Motterlini, Roberto/0000-0003-2684-2612; Boczkowski, Jorge/0000-0001-6619-5785				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Alonso JR, 2003, PHARMACOL TOXICOL, V93, P142, DOI 10.1034/j.1600-0773.2003.930306.x; Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Bogoyevitch MA, 2000, J MOL CELL CARDIOL, V32, P1469, DOI 10.1006/jmcc.2000.1187; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Carriere A, 2003, FEBS LETT, V550, P163, DOI 10.1016/S0014-5793(03)00862-7; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Choi BM, 2003, HEPATOLOGY, V37, P810, DOI 10.1053/jhep.2003.50114; Christou H, 2000, CIRC RES, V86, P1224, DOI 10.1161/01.RES.86.12.1224; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Foresti R, 2004, BRIT J PHARMACOL, V142, P453, DOI 10.1038/sj.bjp.0705825; HANCOCK JT, 1991, FREE RADICAL BIO MED, V11, P25, DOI 10.1016/0891-5849(91)90184-5; Horimoto M, 2004, HEPATOLOGY, V39, P386, DOI 10.1002/hep.20047; Johnson FK, 2003, AM J PHYSIOL-REG I, V285, pR536, DOI 10.1152/ajpregu.00624.2002; Kweon SM, 2001, BIOSCIENCE REP, V21, P341, DOI 10.1023/A:1013290316939; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Motterlini R, 2003, CURR PHARM DESIGN, V9, P2525, DOI 10.2174/1381612033453785; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Oldenburg O, 2003, J MOL CELL CARDIOL, V35, P653, DOI 10.1016/S0022-2828(03)00083-X; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2002, ANTIOXID REDOX SIGN, V4, P309, DOI 10.1089/152308602753666361; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Patel HJ, 1999, FASEB J, V13, P1810, DOI 10.1096/fasebj.13.13.1810; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Riganti C, 2004, J BIOL CHEM, V279, P47726, DOI 10.1074/jbc.M406314200; Song RP, 2002, AM J RESP CELL MOL, V27, P603, DOI 10.1165/rcmb.4851; Stanford SJ, 2003, EUR J PHARMACOL, V473, P135, DOI 10.1016/S0014-2999(03)02001-6; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; Thabut G, 2002, J BIOL CHEM, V277, P22814, DOI 10.1074/jbc.M200315200; Watabe M, 2004, J PHARMACOL EXP THER, V311, P948, DOI 10.1124/jpet.104.071381; Young TA, 2002, ARCH BIOCHEM BIOPHYS, V405, P65, DOI 10.1016/S0003-9861(02)00338-7	47	211	220	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25350	25360		10.1074/jbc.M503512200	http://dx.doi.org/10.1074/jbc.M503512200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15863496	hybrid			2022-12-25	WOS:000230207900007
J	Farris, SD; Rubio, ED; Moon, JJ; Gombert, WM; Nelson, BH; Krumm, A				Farris, SD; Rubio, ED; Moon, JJ; Gombert, WM; Nelson, BH; Krumm, A			Transcription-induced chromatin remodeling at the c-myc gene involves the local exchange of histone H2A.Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VIVO; DROSOPHILA-MELANOGASTER; ELONGATION COMPLEX; H3 METHYLATION; NUCLEOSOME; RECRUITMENT; REGIONS; FACT; HETEROCHROMATIN	The post-translational modification of histones and the incorporation of core histone variants play key roles in governing gene expression. Many eukaryotic genes regulate their expression by limiting the escape of RNA polymerase from promoter-proximal pause sites. Here we report that elongating RNA polymerase II complexes encounter distinct chromatin landscapes that are marked by methylation of lysine residues Lys(4), Lys(79), and Lys(36) of histone H3. However, neither histone methylation nor acetylation directly regulates the release of elongation complexes stalled at promoter-proximal pause sites of the c-myc gene. In contrast, transcriptional activation is associated with local displacement of the histone variant H2A.Z within the transcribed region and incorporation of the major histone variant H2A. This result indicates that transcribing RNA polymerase II remodels chromatin in part through coincident displacement of H2A.Z-H2B dimers and incorporation of H2A-H2B dimers. In combination, these results suggest a new model in which the incorporation of H2A.Z into nucleosomes down-regulates transcription; at the same time it may act as a cellular memory for transcriptionally poised gene domains.	Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98104 USA; Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA; British Columbia Canc Agcy, Deeley Res Ctr, Victoria, BC V8R 6V5, Canada	University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; British Columbia Cancer Agency	Krumm, A (corresponding author), Univ Washington, Vet Affairs Med Ctr, 1660 S Columbian Way R 151, Seattle, WA 98108 USA.	akrumm@u.washington.edu	Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Gombert WM, 2003, MOL CELL BIOL, V23, P9338, DOI 10.1128/MCB.23.24.9338-9348.2003; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moon JJ, 2004, J BIOL CHEM, V279, P5520, DOI 10.1074/jbc.M308998200; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Park YJ, 2004, J BIOL CHEM, V279, P24274, DOI 10.1074/jbc.M313152200; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Rangasamy D, 2003, EMBO J, V22, P1599, DOI 10.1093/emboj/cdg160; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Smith MM, 2002, MOL CELL, V9, P1158, DOI 10.1016/S1097-2765(02)00552-X; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; Studitsky VM, 2004, TRENDS BIOCHEM SCI, V29, P127, DOI 10.1016/j.tibs.2004.01.003; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2	42	72	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25298	25303		10.1074/jbc.M501784200	http://dx.doi.org/10.1074/jbc.M501784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878876	hybrid			2022-12-25	WOS:000230114000117
J	Fish, JE; Matouk, CC; Rachlis, A; Lin, S; Tai, SC; D'Abreo, C; Marsden, PA				Fish, JE; Matouk, CC; Rachlis, A; Lin, S; Tai, SC; D'Abreo, C; Marsden, PA			The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO EXPRESSION; RNA-POLYMERASE-II; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; GENE-TRANSCRIPTION; CHROMATIN; PROMOTER; ACETYLATION; H3; BINDING	Expression of endothelial nitric-oxide synthase (eNOS) mRNA is highly restricted to the endothelial cell layer of medium to large sized arterial blood vessels. Here we assessed the chromatin environment of the eNOS gene in expressing and nonexpressing cell types. Within endothelial cells, but not a variety of nonendothelial cells, the nucleosomes that encompassed the eNOS core promoter and proximal downstream coding regions were highly enriched in acetylated histones H3 and H4 and methylated lysine 4 of histone H3. This differentially modified chromatin domain was selectively associated with functionally competent RNA polymerase II complexes. Endothelial cells were particularly enriched in acetylated histone H3 lysine 9, histone H4 lysine 12, and di- and tri-methylated lysine 4 of histone H3 at the core promoter. Histone modifications at this region, which we have previously demonstrated to exhibit cell-specific DNA methylation, were functionally relevant to eNOS expression. Inhibition of histone deacetylase activity by trichostatin A increased acetylation of histones H3 and H4 at the eNOS proximal promoter in nonexpressing cell types and led to increased steady-state eNOS mRNA transcript levels. H3 lysine 4 methylation was also essential for eNOS expression, since treatment of endothelial cells with methylthioadenosine, a known lysine 4 methylation inhibitor, decreased eNOS RNA levels, H3 lysine 4 methylation, and RNA polymerase II loading at the eNOS proximal promoter. Importantly, methylthioadenosine also prevented the trichostatin A-mediated increase in eNOS mRNA transcript levels in nonendothelial cells. Taken together, these findings provide strong evidence that the endothelial cell-specific expression of eNOS is controlled by cell-specific histone modifications.	St Michaels Hosp, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Marsden, PA (corresponding author), St Michaels Hosp, Dept Med Biophys, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Marsden, Philip A/B-1441-2012; Matouk, Charles/AAF-7694-2019; Lin, Steve/H-3723-2013	Lin, Steve/0000-0002-8644-9719; Fish, Jason/0000-0003-0640-7277				Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bitzan MM, 1998, J CLIN INVEST, V101, P372, DOI 10.1172/JCI522; Boutet SC, 2001, BIOCHEM J, V360, P23, DOI 10.1042/0264-6021:3600023; Bream JH, 2004, J BIOL CHEM, V279, P41249, DOI 10.1074/jbc.M401168200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200; Chau CM, 2004, J VIROL, V78, P12308, DOI 10.1128/JVI.78.22.12308-12319.2004; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dong CM, 2002, J NUTR, V132, p2406S, DOI 10.1093/jn/132.8.2406S; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; Edelstein LC, 2005, J BIOL CHEM, V280, P11192, DOI 10.1074/jbc.M412997200; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Fukuchi M, 1999, LAB INVEST, V79, P659; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Guillot PV, 2000, PHYSIOL GENOMICS, V2, P77, DOI 10.1152/physiolgenomics.2000.2.2.77; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Hu JF, 1997, MOL ENDOCRINOL, V11, P1891, DOI 10.1210/me.11.13.1891; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kanno T, 2004, MOL CELL, V13, P33, DOI 10.1016/S1097-2765(03)00482-9; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; Masternak K, 2003, NAT IMMUNOL, V4, P132, DOI 10.1038/ni883; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Oemar BS, 1998, CIRCULATION, V97, P2494, DOI 10.1161/01.CIR.97.25.2494; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Perkins KJ, 2003, FEBS LETT, V538, P168, DOI 10.1016/S0014-5793(03)00175-3; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Ruh MF, 1999, ENDOCRINE, V11, P157, DOI 10.1385/ENDO:11:2:157; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Sandoval J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh091; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sinha A, 2005, BIOCHEM J, V387, P257, DOI 10.1042/BJ20041793; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; Stimson KM, 2002, J BIOL CHEM, V277, P4951, DOI 10.1074/jbc.M109809200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Teichert AM, 2000, AM J PHYSIOL-HEART C, V278, pH1352, DOI 10.1152/ajpheart.2000.278.4.H1352; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wan MM, 2001, HUM MOL GENET, V10, P1085, DOI 10.1093/hmg/10.10.1085; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Weill L, 2003, J VIROL, V77, P2903, DOI 10.1128/JVI.77.5.2903-2914.2003; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Wu J, 2005, MOL CELL BIOL, V25, P1458, DOI 10.1128/MCB.25.4.1458-1474.2005; Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Yin H, 2000, BLOOD, V95, P111, DOI 10.1182/blood.V95.1.111.001k20_111_119; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	80	175	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24824	24838		10.1074/jbc.M502115200	http://dx.doi.org/10.1074/jbc.M502115200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870070	hybrid			2022-12-25	WOS:000230114000065
J	Schmitt, BM; Koepsell, H				Schmitt, BM; Koepsell, H			Alkali cation binding and permeation in the rat organic cation transporter rOCT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TETRAALKYLAMMONIUM COMPOUNDS; SUBSTRATE-BINDING; ELECTROGENIC PROPERTIES; CRYSTAL-STRUCTURES; ANION TRANSPORTER; DEPENDENT CHANGES; LACTOSE PERMEASE; PROXIMAL TUBULE; VOLTAGE-CLAMP; ION-TRANSPORT	Organic cation transporters of the OCT family mediate downhill transport of organic cations, compatible with carrier, pore, or gate-lumen-gate mechanisms. We studied rat OCT2 expressed in Xenopus oocytes by the two-electrode voltage-clamp technique, including membrane capacitance ( Cm) monitoring. Choline, a transported cationic substrate, elicited the expected inward currents but also elicited decreases of Cm. Similar Cm decreases were caused by the non-transported inhibitors tetrabutylammonium ( a cation) and corticosterone (uncharged). Effects on Cm were voltage-dependent, with a maximum at -140 mV. These findings suggest that the empty rOCT2 protein can undergo an electrogenic conformation change, with one conformation highly favored at physiological voltage. Moreover, alkali cations elicited considerable inward currents and inhibited uptake of [C-14] tetraethylammonium with a sequence Cs+ > Rb+ > K+ > Na+ approximate to Li+. Cs+ affected current and capacitance with similar affinity (K-0.5 approximate to 50 mM). Tetraethylammonium inhibited Cs+ currents in a concentration-dependent manner. Conversely, Cs+ inhibited tetraethylammonium uptake by a competitive mechanism. Activation energy of the currents estimated from measurements between 12 C and 32 degrees C was similar to 81 kJ/mol for Cs+ and 39 kJ/mol for tetramethylammonium, compatible with permeation of Cs+ through rOCT2 along the same path as organic substrates and by a mechanism different from simple electrodiffusion. Rationalization of Cs+ selectivity in terms of a pore pointed to a pore diameter of similar to 4 angstrom. Intriguingly, that value matches the known selectivity of rOCT2 for organic compounds. Our data show that selective permeability of rOCT2 is not determined by ligand affinity but might rather be understood in terms of the ion channel concept of a distinct "selectivity filter.".	Univ Wurzburg, Dept Anat & Cell Biol, D-97070 Wurzburg, Germany	University of Wurzburg	Schmitt, BM (corresponding author), Univ Wurzburg, Dept Anat & Cell Biol, Koellikerstr 6, D-97070 Wurzburg, Germany.	bernhard.schmitt@mail.uni-wuerzburg.de						Abramson J, 2004, MOL MEMBR BIOL, V21, P227, DOI 10.1080/09687680410001716862; Arndt P, 2001, AM J PHYSIOL-RENAL, V281, pF454, DOI 10.1152/ajprenal.2001.281.3.F454; Ashida H, 1998, J THEOR BIOL, V195, P219, DOI 10.1006/jtbi.1998.0787; Barendt WM, 2002, J BIOL CHEM, V277, P22491, DOI 10.1074/jbc.M203114200; Bednarczyk D, 2003, MOL PHARMACOL, V63, P489, DOI 10.1124/mol.63.3.489; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; Budiman T, 2000, J BIOL CHEM, V275, P29413, DOI 10.1074/jbc.M004645200; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1998, MOL PHARMACOL, V54, P342, DOI 10.1124/mol.54.2.342; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; DeFelice LJ, 2004, NATURE, V432, P279, DOI 10.1038/432279a; del Moral RG, 1998, EXP NEPHROL, V6, P89; Dresser MJ, 2002, PHARMACEUT RES, V19, P1244, DOI 10.1023/A:1019870831174; Dresser MJ, 2001, J PHARM SCI, V90, P397, DOI 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.3.CO;2-4; Elias CL, 2001, AM J PHYSIOL-CELL PH, V281, pC993, DOI 10.1152/ajpcell.2001.281.3.C993; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Immke D, 1999, J GEN PHYSIOL, V113, P819, DOI 10.1085/jgp.113.6.819; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; Koepsell H, 1998, NEWS PHYSIOL SCI, V13, P11; Koepsell H, 2004, REV PHYSIOL BIOCH P, V150, P36, DOI 10.1007/s10254-003-0017-x; Laio A, 1999, BIOPHYS J, V76, P129, DOI 10.1016/S0006-3495(99)77184-5; LAUGER P, 1981, Q REV BIOPHYS, V14, P513, DOI 10.1017/S003358350000247X; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Luzhkov VB, 2003, FEBS LETT, V554, P159, DOI 10.1016/S0014-5793(03)01117-7; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Naftalin RJ, 1997, BBA-BIOMEMBRANES, V1328, P13, DOI 10.1016/S0005-2736(97)00062-X; Nagel G, 1997, J BIOL CHEM, V272, P31953, DOI 10.1074/jbc.272.51.31953; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PIETRUCK F, 1995, KIDNEY INT, V47, P1647, DOI 10.1038/ki.1995.229; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; QUANDT FN, 1992, J PHARMACOL EXP THER, V260, P1379; RANDLE JCR, 1990, CAN J PHYSIOL PHARM, V68, P1069, DOI 10.1139/y90-161; Schmitt BM, 2002, BIOPHYS J, V82, P1345, DOI 10.1016/S0006-3495(02)75490-8; Schumacher MA, 2003, RES MICROBIOL, V154, P69, DOI 10.1016/S0923-2508(02)00013-X; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Somogyi AA, 1996, J PHARMACOL EXP THER, V278, P31; STARK G, 1971, BIOPHYS J, V11, P981, DOI 10.1016/S0006-3495(71)86272-0; Sweet DH, 1999, AM J PHYSIOL-RENAL, V277, pF890, DOI 10.1152/ajprenal.1999.277.6.F890; Sweet DH, 1999, CELL BIOCHEM BIOPHYS, V31, P89, DOI 10.1007/BF02738157; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; ULLRICH KJ, 1992, PFLUG ARCH EUR J PHY, V420, P29, DOI 10.1007/BF00378638; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Volk C, 2003, MOL PHARMACOL, V64, P1037, DOI 10.1124/mol.64.5.1037; WEISS TF, 1996, CARRIER MEDIATED TRA, V1, P333; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Zhang L, 1999, J PHARMACOL EXP THER, V288, P1192	49	32	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24481	24490		10.1074/jbc.M414550200	http://dx.doi.org/10.1074/jbc.M414550200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878879	hybrid			2022-12-25	WOS:000230114000024
J	Hurley, TD; Stout, S; Miner, E; Zhou, J; Roach, PJ				Hurley, TD; Stout, S; Miner, E; Zhou, J; Roach, PJ			Requirements for catalysis in mammalian glycogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLATING INITIATOR PROTEINS; CRYSTAL-STRUCTURE; BLOOD-GROUP; MECHANISM; ALPHA-1,3-GALACTOSYLTRANSFERASE; BIOSYNTHESIS; TYROSINE-194; BIOGENESIS; COMPLEX; SYSTEM	Glycogenin is a glycosyltransferase that functions as the autocatalytic initiator for the synthesis of glycogen in eukaryotic organisms. Prior structural work identified the determinants responsible for the recognition and binding of UDP-glucose and the catalytic manganese ion and implicated two aspartic acid residues in the reaction mechanism for self-glucosylation. We examined the effects of substituting asparagine and serine for the aspartic acid residues at positions 159 and 162. We also examined whether the truncation of the protein at residue 270 (Delta 270) was compatible with its structural integrity and its functional role as the initiator for glycogen synthesis. The truncated form of the enzyme was indistinguishable from the wild-type enzyme by all measures of activity and could support glycogen accumulation in a glycogenin-deficient yeast strain. Substitution of aspartate 159 by either serine or asparagine eliminated self-glucosylation and reduced trans-glucosylation activity by at least 260-fold but only reduced UDP-glucose hydrolytic activity by 4-14-fold. Substitution of aspartate 162 by either serine or asparagine eliminated self-glucosylation activity and reduced UDP-glucose hydrolytic activity by at least 190-fold. The trans-glucosylation of maltose was reduced to undetectable levels in the asparagine 162 mutant, whereas the serine 162 enzyme showed only an 18-30-fold reduction in its ability to trans-glucosylate maltose. These data support a role for aspartate 162 in the chemical step for the glucosyltransferase reaction and a role for aspartate 159 in binding and activating the acceptor molecule.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063285] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK063285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ALONSO MD, 1995, J BIOL CHEM, V270, P15315, DOI 10.1074/jbc.270.25.15315; ALONSO MD, 1994, FEBS LETT, V352, P222, DOI 10.1016/0014-5793(94)00962-7; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; CHENG C, 1995, MOL CELL BIOL, V15, P6632; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibbons BJ, 2002, J MOL BIOL, V319, P463, DOI 10.1016/S0022-2836(02)00305-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HARDY TA, 1993, J BIOL CHEM, V268, P23799; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin A, 1999, ARCH BIOCHEM BIOPHYS, V363, P163, DOI 10.1006/abbi.1998.1073; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minor W, 2000, STRUCTURE, V8, pR105, DOI 10.1016/S0969-2126(00)00139-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; Roach PJ, 2001, HDB PHYSL 7, VII, P609, DOI DOI 10.1002/CPHY.CP070219; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Zhang YN, 2003, BIOCHEMISTRY-US, V42, P13512, DOI 10.1021/bi035430r	41	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23892	23899		10.1074/jbc.M502344200	http://dx.doi.org/10.1074/jbc.M502344200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849187	Green Accepted, hybrid			2022-12-25	WOS:000229880000063
J	Wolters, JC; Abele, R; Tampe, R				Wolters, JC; Abele, R; Tampe, R			Selective and ATP-dependent translocation of peptides by the homodimeric ATP binding cassette transporter TAP-like (ABCB9)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-PROCESSING TAP; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; INSECT CELLS; IN-VIVO; PURIFICATION; PROTEINS; COMPLEX; HYDROLYSIS; EXPRESSION	The transporter associated with antigen processing ( TAP)-like ( TAPL, ABCB9) belongs to the ATP-binding cassette transporter family, which translocates a vast variety of solutes across membranes. The function of this half-size transporter has not yet been determined. Here, we show that TAPL forms a homodimeric complex, which translocates peptides across the membrane. Peptide transport strictly requires ATP hydrolysis. The transport follows Michaelis-Menten kinetics with low affinity and high capacity. Different nucleotides bind and energize the transport with a slight predilection for purine bases. The peptide specificity is very broad, ranging from 6-mer up to at least 59-mer peptides with a preference for 23-mers. Peptides are recognized via their backbone, including the free N and C termini as well as side chain interactions. Although related to TAP, TAPL is unique as far as its interaction partners, transport properties, and substrate specificities are concerned, thus excluding that TAPL is part of the peptide-loading complex in the classic route of antigen processing via major histocompatibility complex class I molecules.	Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Abele, R (corresponding author), Goethe Univ Frankfurt, Inst Biochem, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.	abele@em.uni-frankfurt.de; tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dani A, 2004, J CELL SCI, V117, P4219, DOI 10.1242/jcs.01288; DANIEL H, 1991, J BIOL CHEM, V266, P19917; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Fersht A.R, 1997, ENZYME STRUCTURE MEC; Heintke S, 2003, FEBS LETT, V533, P42, DOI 10.1016/S0014-5793(02)03746-8; Horn C, 2003, J MOL BIOL, V334, P403, DOI 10.1016/j.jmb.2003.09.079; Kobayashi A, 2004, BIOL PHARM BULL, V27, P1916, DOI 10.1248/bpb.27.1916; Kobayashi A, 2003, BIOCHEM BIOPH RES CO, V309, P815, DOI 10.1016/j.bbrc.2003.08.081; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; Leveson-Gower DB, 2004, BIOCHEMISTRY-US, V43, P14257, DOI 10.1021/bi0491245; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; Uebel S, 1999, CURR OPIN IMMUNOL, V11, P203, DOI 10.1016/S0952-7915(99)80034-X; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Yamaguchi Y, 1999, FEBS LETT, V457, P231, DOI 10.1016/S0014-5793(99)01042-X; Yan G, 1999, J IMMUNOL, V162, P852; Zhang F, 2000, J BIOL CHEM, V275, P23287, DOI 10.1074/jbc.M001819200	36	55	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23631	23636		10.1074/jbc.M503231200	http://dx.doi.org/10.1074/jbc.M503231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15863492	hybrid			2022-12-25	WOS:000229880000029
J	Kim, KY; Kovacs, M; Kawamoto, S; Sellers, JR; Adelstein, RS				Kim, KY; Kovacs, M; Kawamoto, S; Sellers, JR; Adelstein, RS			Disease-associated mutations and alternative splicing alter the enzymatic and motile activity of nonmuscle myosins II-B and II-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; MOTOR DOMAIN; MECHANISM; ABLATION; LOCALIZATION; MIGRATION; ISOFORMS; FECHTNER; ADHESION; CELLS	Human families with single amino acid mutations in nonmuscle myosin heavy chain (NMHC) II-A (MYH9) and II-C (MYH14) have been described as have mice generated with a point mutation in NMHC II-B (MYH10). These mutations (R702C and N93K in human NMHC II-A, R709C in murine NMHC II-B, and R726S in human NMHC II-C) result in phenotypes affecting kidneys, platelets, and leukocytes (II-A), heart and brain (II-B), and the inner ear (II-C). To better understand the mechanisms underlying these defects, we characterized the in vitro activity of mutated and wild-type baculovirus-expressed heavy meromyosin (HMM) II-B and II-C. We also expressed two alternatively spliced isoforms of NMHC II-C which differ by inclusion/ exclusion of eight amino acids in loop 1, with and without mutations. Comparison of the actin-activated MgATPase activity and in vitro motility shows that mutation of residues Asn-97 and Arg-709 in HMM II-B and the homologous residue Arg-722 (Arg-730 in the alternatively spliced isoform) in HMM II-C decreases both parameters but affects in vitro motility more severely. Analysis of the transient kinetics of the HMM II-B R709C mutant shows an extremely tight affinity of HMM for ADP and a very slow release of ADP from acto-HMM. Although mutations generally decreased HMM activity, the R730S mutation in HMM II-C, unlike the R730C mutation, had no effect on actin-activated MgATPase activity but decreased the rate of in vitro motility by 75% compared with wild type. Insertion of eight amino acids into the HMM II-C heavy chain increases both actin-activated MgATPase activity and in vitro motility.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Adelstein, RS (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202,10 Ctr Dr MSC 1762, Bethesda, MD 20892 USA.	AdelsteR@NHLBI.NIH.gov	Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786, ZIAHL004223, Z01HL004223, Z01HL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Conti MA, 2004, J BIOL CHEM, V279, P41263, DOI 10.1074/jbc.C400352200; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Donaudy F, 2004, AM J HUM GENET, V74, P770, DOI 10.1086/383285; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Franke JD, 2005, BLOOD, V105, P161, DOI 10.1182/blood-2004-06-2067; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Houdusse A, 2000, P NATL ACAD SCI USA, V97, P11238, DOI 10.1073/pnas.200376897; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Kolega J, 2003, MOL BIOL CELL, V14, P4745, DOI 10.1091/mbc.E03-04-0205; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2004, BIOCHEMISTRY-US, V43, P4219, DOI 10.1021/bi036007l; Leal A, 2003, GENE, V312, P165, DOI 10.1016/S0378-1119(03)00613-9; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Ma XF, 2004, MOL BIOL CELL, V15, P2568, DOI 10.1091/mbc.E03-11-0836; MAUPIN P, 1994, J CELL SCI, V107, P3077; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sellers JR, 1999, MYOSIN; Shih WM, 2001, J BIOL CHEM, V276, P19491, DOI 10.1074/jbc.M010887200; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2003, CIRC RES, V93, P330, DOI 10.1161/01.RES.0000089256.00309.CB; TOOTHAKER LE, 1991, BLOOD, V78, P1826; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613	37	91	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22769	22775		10.1074/jbc.M503488200	http://dx.doi.org/10.1074/jbc.M503488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845534	hybrid			2022-12-25	WOS:000229741800027
J	Huang, DR; Wujek, J; Kidd, G; He, TT; Cardona, A; Sasse, ME; Stein, EJ; Kish, J; Tani, M; Charo, IF; Proudfoot, AE; Rollins, BJ; Handel, T; Ransohoff, RM				Huang, DR; Wujek, J; Kidd, G; He, TT; Cardona, A; Sasse, ME; Stein, EJ; Kish, J; Tani, M; Charo, IF; Proudfoot, AE; Rollins, BJ; Handel, T; Ransohoff, RM			Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice	FASEB JOURNAL			English	Article						chemokines; chemokine receptors; transgenic mice; macrophages	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; AMYOTROPHIC-LATERAL-SCLEROSIS; MULTIPLE-SCLEROSIS; CHEMOKINE RECEPTORS; CELL-ACTIVATION; TRANSGENIC MICE; MCP-1; INDUCTION; RESIDENT; RECRUITMENT	Increased central nervous system (CNS) levels of monocyte chemoattractant protein 1 [CC chemokine ligand 2 (CCL2) in the systematic nomenclature] have been reported in chronic neurological diseases such as human immunodeficiency virus type 1-associated dementia, amyotrophic lateral sclerosis, and multiple sclerosis. However, a pathogenic role for CCL2 has not been confirmed, and there is no established model for the effects of chronic CCL2 expression on resident and recruited CNS cells. We report that aged (>6 months) transgenic (tg) mice expressing CCL2 under the control of the human glial fibrillary acidic protein promoter (huGFAP-CCL2(hi) tg(+) mice) manifested encephalopathy with mild perivascular leukocyte infiltration, impaired blood brain barrier function, and increased CD45-immunoreactive microglia, which had morphologic features of activation. huGFAP-CCL2(hi) tg(+) mice lacking CC chemokine receptor 2 (CCR2) were normal, showing that chemokine action via CCR2 was required. Studies of cortical slice preparations using video confocal microscopy showed that microglia in the CNS of huGFAP-CCL2(hi) tg(+) mice were defective in expressing amoeboid morphology. Treatment with mutant CCL2 peptides, a receptor antagonist and an obligate monomer, also suppressed morphological transformation in this assay, indicating a critical role for CCL2 in microglial activation and suggesting that chronic CCL2 exposure desensitized CCR2 on microglia, which in the CNS of huGFAP-CCL2(hi) tg(+) mice, did not up-regulate cell-surface expression of major histocompatibility complex class II, CD11b, CD11c, or CD40, in contrast to recruited perivascular macrophages that expressed enhanced levels of these markers. These results indicate that huGFAP-CCL2(hi) tg(+) mice provide a useful model to study how chronic CNS expression of CCL2 alters microglial function and CNS physiology.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA USA; Serono Pharmaceut Res Inst, Geneva, Switzerland; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02115 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; The J David Gladstone Institutes; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; University of California System; University of California Berkeley	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci NC3, 9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org	Cardona, Astrid E/K-4749-2013	Cardona, Astrid E/0000-0002-5093-8078; Kidd, Grahame/0000-0003-3956-2206	NINDS NIH HHS [3R01 NS32151-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Archelos JJ, 2000, ANN NEUROL, V47, P694, DOI 10.1002/1531-8249(200006)47:6<694::AID-ANA2>3.0.CO;2-W; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Berman JW, 1996, J IMMUNOL, V156, P3017; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Grewal IS, 1997, J IMMUNOL, V159, P401; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Gunn MD, 1997, J IMMUNOL, V158, P376; Henkel JS, 2004, ANN NEUROL, V55, P221, DOI 10.1002/ana.10805; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Huang DR, 2002, J NEUROSCI, V22, P10633; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; HULKOWER K, 1993, J IMMUNOL, V150, P2525; Ichikawa M, 1999, CELL IMMUNOL, V191, P97, DOI 10.1006/cimm.1998.1414; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; Juedes AE, 2001, J IMMUNOL, V166, P5168, DOI 10.4049/jimmunol.166.8.5168; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kajihara N, 2003, CIRCULATION, V108, P213, DOI 10.1161/01.cir.0000087426.18858.3a; Karpus WJ, 1998, J EXP MED, V187, P733, DOI 10.1084/jem.187.5.733; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Rezaie P, 2001, BRAIN RES REV, V35, P55, DOI 10.1016/S0165-0173(01)00042-X; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; Sanders VJ, 1998, AIDS, V12, P1021, DOI 10.1097/00002030-199809000-00008; Santambrogio L, 2001, P NATL ACAD SCI USA, V98, P6295, DOI 10.1073/pnas.111152498; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Simpson J, 2000, J NEUROIMMUNOL, V108, P192, DOI 10.1016/S0165-5728(00)00274-5; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Siveke JT, 1998, J IMMUNOL, V160, P550; Sriram S, 1997, NEUROLOGY, V48, P464, DOI 10.1212/WNL.48.2.464; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Tan J, 1999, SCIENCE, V286, P2352, DOI 10.1126/science.286.5448.2352; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VAN DV, 1999, AM J PATHOL, V154, P45; Wilms H, 2003, J NEUROIMMUNOL, V144, P139, DOI 10.1016/j.jneuroim.2003.08.042; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Yacubova E, 2002, NATURE, V415, P77, DOI 10.1038/415077a; YAMAMOTO M, 2005, IN PRESS AM J PATHOL	63	38	40	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					761	772		10.1096/fj.04-3104com	http://dx.doi.org/10.1096/fj.04-3104com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857890				2022-12-25	WOS:000229602600032
J	Meredith, EJ; Holder, MJ; Chamba, A; Challa, A; Lee, AD; Bunce, CM; Drayson, MT; Pilkington, G; Blakely, RD; Dyer, MJS; Barnes, NM; Gordon, J				Meredith, EJ; Holder, MJ; Chamba, A; Challa, A; Lee, AD; Bunce, CM; Drayson, MT; Pilkington, G; Blakely, RD; Dyer, MJS; Barnes, NM; Gordon, J			The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics	FASEB JOURNAL			English	Article						5-hydroxytryptamine; Burkitt's lymphoma; B cell lymphoma	3,4-METHYLENEDIOXYMETHAMPHETAMINE ECSTASY; LYMPHOMA CELLS; D-FENFLURAMINE; APOPTOSIS; DRUGS; BRAIN; LYMPHOCYTES; MDMA; METHYLENEDIOXYMETHAMPHETAMINE; PHARMACOKINETICS	Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. Concentration and timecourse kinetics for the antiproliferative and proapoptotic activities of the amphetamine derivatives fenfluramine (an appetite suppressant) and 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy") revealed them as being similar to the endogenous indoleamine. A tricyclic antidepressant, clomipramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both being effective in the low micromolar range. A majority of neoplastic clones were sensitive to one or more of the serotonergic compounds. Dysregulated bcl-2 expression, either by t(14; 18)(q32;q21) translocation or its introduction as a constitutively active transgene, provided protection from proapoptotic but not antiproliferative outcomes. These data indicate a potential for SERT as a novel anti-tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself.	Univ Birmingham, Sch Med, Div Immun & Infect, MRC Ctr Immune Regulat,Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; ENT Dept Univ Hosp, Birmingham, W Midlands, England; Univ Birmingham, Div Biosci, Birmingham, W Midlands, England; Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Dept Pharmacol, Nashville, TN USA; Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; Univ Birmingham, Sch Med, Div Neurosci, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Portsmouth; Vanderbilt University; University of Leicester; University of Birmingham	Gordon, J (corresponding author), Univ Birmingham, Sch Med, Div Immun & Infect, MRC Ctr Immune Regulat,Inst Biomed Res, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	j.gordon@bham.ac.uk	Barnes, Nicholas/ABE-6312-2020; Gordon, John/F-6443-2011; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236; Drayson, Mark/0000-0002-1528-7564; Bunce, Chris/0000-0003-4084-8973	NIDA NIH HHS [DA-07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anthony IC, 2003, BRAIN, V126, P1058, DOI 10.1093/brain/awg118; BALDESSARINI, 2001, GOODMAN GILLMANS PHA, P399; Batara JF, 2003, CURR OPIN NEUROL, V16, P671, DOI 10.1097/00019052-200312000-00005; Bauman AL, 2000, J NEUROSCI, V20, P7571; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Belous A R, 2001, Neurosci Behav Physiol, V31, P185, DOI 10.1023/A:1005268425375; Bengel D, 1998, NEUROREPORT, V9, P2989, DOI 10.1097/00001756-199809140-00013; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BOELSTERLI UA, 1987, CELL BIOL TOXICOL, V3, P231, DOI 10.1007/BF00117862; Bolo NR, 2000, NEUROPSYCHOPHARMACOL, V23, P428, DOI 10.1016/S0893-133X(00)00116-0; Bowyer JF, 2003, NEUROTOXICOLOGY, V24, P379, DOI 10.1016/S0161-813X(03)00030-5; Chanan-Khan Asher, 2004, Curr Treat Options Oncol, V5, P261, DOI 10.1007/s11864-004-0017-3; Coiffier B, 1998, BLOOD, V92, P1927; Connor TJ, 2004, IMMUNOLOGY, V111, P357, DOI 10.1111/j.0019-2805.2004.01847.x; Daley E, 2005, BIOCHEM BIOPH RES CO, V328, P623, DOI 10.1016/j.bbrc.2005.01.028; De Letter EA, 2004, FORENSIC SCI INT, V141, P85, DOI 10.1016/j.forsciint.2003.12.015; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Fenton SL, 2003, LEUKEMIA, V17, P568, DOI 10.1038/sj.leu.2402843; Gagro A, 2003, EUR J IMMUNOL, V33, P1889, DOI 10.1002/eji.200323357; Garcia-Repetto R, 2003, FORENSIC SCI INT, V135, P110, DOI 10.1016/S0379-0738(03)00179-8; Glatz K, 2003, J NEUROCHEM, V86, P1072, DOI 10.1046/j.1471-4159.2003.01944.x; Gordon J, 2003, TRENDS IMMUNOL, V24, P438, DOI 10.1016/S1471-4906(03)00176-5; Gordon J, 1996, ADV EXP MED BIOL, V406, P139; Hiemke C, 2000, PHARMACOL THERAPEUT, V85, P11, DOI 10.1016/S0163-7258(99)00048-0; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Ketabi-Kiyanvash N, 2003, ADDICT BIOL, V8, P413, DOI 10.1080/13556210310001646475; Lee SL, 2001, FASEB J, V15, P1324, DOI 10.1096/fj.00-0431fje; McCloskey N, 1999, EUR J IMMUNOL, V29, P3236, DOI 10.1002/(SICI)1521-4141(199910)29:10<3236::AID-IMMU3236>3.0.CO;2-T; Montiel-Duarte C, 2002, BBA-MOL BASIS DIS, V1588, P26, DOI 10.1016/S0925-4439(02)00112-6; Montiel-Duarte C, 2004, BIOCHEM PHARMACOL, V67, P1025, DOI 10.1016/j.bcp.2003.10.020; Mossner R, 2000, NEUROCHEM INT, V36, P197, DOI 10.1016/S0197-0186(99)00122-9; Mossner R, 2001, LIFE SCI, V68, P873, DOI 10.1016/S0024-3205(00)00992-9; NISSBRANDT H, 1991, N-S ARCH PHARMACOL, V344, P16; Pellegrin P, 1997, FEBS LETT, V418, P101, DOI 10.1016/S0014-5793(97)01339-2; Pellegrino TC, 2001, INT IMMUNOPHARMACOL, V1, P665, DOI 10.1016/S1567-5769(00)00051-5; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Racke K, 1996, BEHAV BRAIN RES, V73, P83; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reeve HL, 1999, AM J PHYSIOL-LUNG C, V277, pL662, DOI 10.1152/ajplung.1999.277.3.L662; Rooprai HK, 2003, ACTA NEUROCHIR, V145, P683, DOI 10.1007/s00701-003-0073-7; Rothman RB, 2002, PHARMACOL THERAPEUT, V95, P73, DOI 10.1016/S0163-7258(02)00234-6; SEELIG A, 1994, P NATL ACAD SCI USA, V91, P68, DOI 10.1073/pnas.91.1.68; Serafeim A, 2003, BLOOD, V101, P3212, DOI 10.1182/blood-2002-07-2044; Serafeim A, 2002, BLOOD, V99, P2545, DOI 10.1182/blood.V99.7.2545; Serafeim Adamantios, 2001, Current Opinion in Pharmacology, V1, P398, DOI 10.1016/S1471-4892(01)00069-8; TATE CG, 1994, J BIOL CHEM, V269, P26303; Vivero L E, 1998, J Emerg Med, V16, P197, DOI 10.1016/S0736-4679(97)00289-8; Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6; WEISS J, 2003, J PHARM EXP THER; WILLIAMS CKO, 1983, EUR J CANCER CLIN ON, V19, P741, DOI 10.1016/0277-5379(83)90007-X; Xia ZL, 2000, PROG NEUROBIOL, V60, P501, DOI 10.1016/S0301-0082(99)00036-2; Yang GB, 2004, J NEUROIMMUNOL, V146, P46, DOI 10.1016/j.jneuroim.2003.10.044; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462	53	67	69	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1187	+		10.1096/fj.04-3477fje	http://dx.doi.org/10.1096/fj.04-3477fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870169				2022-12-25	WOS:000229602600021
J	Greco, A; Calle, A; Morfin, F; Thouvenot, D; Cayre, M; Kindbeiter, K; Martin, L; Levillain, O; Diaz, JJ				Greco, A; Calle, A; Morfin, F; Thouvenot, D; Cayre, M; Kindbeiter, K; Martin, L; Levillain, O; Diaz, JJ			S-adenosyl methionine decarboxylase activity is required for the outcome of herpes simplex virus type 1 infection and represents a new potential therapeutic target	FASEB JOURNAL			English	Article						HSV-1; SAMDC	RIBOSOMAL-PROTEIN SYNTHESIS; MESSENGER-RNA; POLYAMINE METABOLISM; TRANSLATIONAL CONTROL; THYMIDINE KINASE; ANTIVIRAL DRUGS; HELA-CELLS; ACCUMULATION; REPLICATION; ACYCLOVIR	All the available antiherpetic drugs are directed against viral proteins. Their extensive clinical use has led to the emergence of resistant viral strains. There is a need for the treatment of herpes infections due to resistant strains, especially for immunocompromised patients. To design new kinds of drugs, we have developed a strategy to identify cellular targets. Herpes simplex virus type I (HSV-1) infection is concomitant to a repression of most host protein synthesis. However, some cellular proteins continue to be efficiently synthesized. We speculated that some of them could determine the outcome of infection. Since two polyamines, spermidine and spermine, are components of the HSV-1 virions, we investigated whether enzymes involved in their synthesis could be required for viral infection. We show that inhibition of S-adenosyl methionine decarboxylase, a key enzyme of the polyamine metabolic pathway, prevents HSV-1 infection. Inhibition of polyamine synthesis prevents infection of culture cells with HSV-1 laboratory strains as well as clinical isolates that are resistant to the conventional antiviral drugs acyclovir and foscarnet. Our data provide the opportunity to develop molecules with a novel mechanism of action for the treatment of herpes infection.	UCBL, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Fac Med Laennec, INSERM, U369, F-69372 Lyon, France; Hospices Civils Lyon, Virol Lab, F-69373 Lyon, France; Lab NMDA, UMR 6156, F-13288 Marseille, France; CEI Lyon 1, Idealp Pharma, F-69603 Villeurbanne, France; Fac Med Laennec, INSERM, U499, F-69372 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm)	Greco, A (corresponding author), UCBL, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	greco@cgmc.univ-lyon1.fr	DIAZ, Jean-Jacques/H-3018-2014; MORFIN, Florence/M-7176-2014; DIAZ, Jean-Jacques/AAT-3846-2021; Morfin, Florence/ABG-5220-2020; Cayre, Myriam/AAG-4614-2021	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; 				Ashley RL, 1999, CLIN MICROBIOL REV, V12, P1; BESSON MT, 1986, COMP BIOCHEM PHYS B, V83, P589, DOI 10.1016/0305-0491(86)90300-7; BIRNBAUM MJ, 1988, INSECT BIOCHEM, V18, P853, DOI 10.1016/0020-1790(88)90110-2; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; Crute JJ, 2002, NAT MED, V8, P386, DOI 10.1038/nm0402-386; Danve C, 2002, J VIROL METHODS, V105, P207, DOI 10.1016/S0166-0934(02)00103-9; DIAZ JJ, 1993, J GEN VIROL, V74, P397, DOI 10.1099/0022-1317-74-3-397; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ESTRIDGE JK, 1989, VIROLOGY, V168, P67, DOI 10.1016/0042-6822(89)90404-2; EVERETT RD, 1985, EMBO J, V4, P1973, DOI 10.1002/j.1460-2075.1985.tb03880.x; Everly DN, 2002, J VIROL, V76, P8560, DOI 10.1128/JVI.76.17.8560-8571.2002; FRANCKE B, 1978, BIOCHEMISTRY-US, V17, P5494, DOI 10.1021/bi00618a026; GIBSON W, 1971, P NATL ACAD SCI USA, V68, P2818, DOI 10.1073/pnas.68.11.2818; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; Greco A, 1997, MOL GEN GENET, V256, P320, DOI 10.1007/s004380050575; Greco A, 2000, ELECTROPHORESIS, V21, P2522, DOI 10.1002/1522-2683(20000701)21:12<2522::AID-ELPS2522>3.3.CO;2-1; HARDWICKE MA, 1994, J VIROL, V68, P4797, DOI 10.1128/JVI.68.8.4797-4810.1994; HILL TJ, 1975, J GEN VIROL, V28, P341, DOI 10.1099/0022-1317-28-3-341; Hossain A, 1997, J GEN VIROL, V78, P3341, DOI 10.1099/0022-1317-78-12-3341; KEMP LM, 1988, VIROLOGY, V166, P258, DOI 10.1016/0042-6822(88)90170-5; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; Khodarev NN, 1999, P NATL ACAD SCI USA, V96, P12062, DOI 10.1073/pnas.96.21.12062; LANGLOIS M, 1986, J BIOL STAND, V14, P201, DOI 10.1016/0092-1157(86)90004-1; LARDER BA, 1985, VIROLOGY, V146, P262, DOI 10.1016/0042-6822(85)90009-1; Laurent AM, 1998, J GEN VIROL, V79, P2765, DOI 10.1099/0022-1317-79-11-2765; MAYMAN BA, 1985, J VIROL, V53, P1; MCCORMICK FP, 1975, J GEN VIROL, V27, P25, DOI 10.1099/0022-1317-27-1-25; Morfin F, 1999, ANTIMICROB AGENTS CH, V43, P2412, DOI 10.1128/AAC.43.10.2412; Morfin F, 2003, J CLIN VIROL, V26, P29, DOI 10.1016/S1386-6532(02)00263-9; MOSCA JD, 1992, J VIROL, V66, P3811, DOI 10.1128/JVI.66.6.3811-3822.1992; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; POHJANPELTO P, 1988, LIFE SCI, V42, P2011, DOI 10.1016/0024-3205(88)90501-2; RAINA A, 1981, MED BIOL, V59, P428; Roizman Bernard, 1993, P11; Schang LM, 2002, J VIROL, V76, P7874, DOI 10.1128/JVI.76.15.7874-7882.2002; Schang LM, 1998, J VIROL, V72, P5626, DOI 10.1128/JVI.72.7.5626-5637.1998; SCHENCK P, 1988, J GEN VIROL, V69, P99, DOI 10.1099/0022-1317-69-1-99; Seiler N, 1970, Methods Biochem Anal, V18, P259, DOI 10.1002/9780470110362.ch5; Simonin D, 1997, J GEN VIROL, V78, P435, DOI 10.1099/0022-1317-78-2-435; SINCLAIR MC, 1994, J GEN VIROL, V75, P1083, DOI 10.1099/0022-1317-75-5-1083; STRAMBI C, 1993, ARCH INSECT BIOCHEM, V24, P203, DOI 10.1002/arch.940240404; STROM T, 1987, J VIROL, V61, P2198, DOI 10.1128/JVI.61.7.2198-2207.1987; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TYMS AS, 1979, BIOCHEM BIOPH RES CO, V86, P312, DOI 10.1016/0006-291X(79)90867-2; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; WARRELL RP, 1983, J CLIN ONCOL, V1, P52, DOI 10.1200/JCO.1983.1.1.52	49	15	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1128	+		10.1096/fj.04-2108fje	http://dx.doi.org/10.1096/fj.04-2108fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15863396				2022-12-25	WOS:000228865300002
J	Cassan, N; Lagoutte, B; Setif, P				Cassan, N; Lagoutte, B; Setif, P			Ferredoxin-NADP(+) reductase - Kinetics of electron transfer, transient intermediates, and catalytic activities studied by flash-absorption spectroscopy with isolated photosystem I and ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; C-TERMINAL TYROSINE; NADP+ REDUCTASE; ANABAENA PCC-7119; COMPLEX-FORMATION; EXTINCTION COEFFICIENTS; REDUCED FERREDOXIN; CRYSTAL-STRUCTURE; OXIDOREDUCTASE; OXIDATION	The electron transfer cascade from photosystem I to NADP(+) was studied at physiological pH by flash-absorption spectroscopy in a Synechocystis PCC6803 reconstituted system comprised of purified photosystem I, ferredoxin, and ferredoxin-NADP(+) reductase. Experiments were conducted with a 34-kDa ferredoxin-NADP(+) reductase homologous to the chloroplast enzyme and a 38-kDa N-terminal extended form. Small differences in kinetic and catalytic properties were found for these two forms, although the largest one has a 3-fold decreased affinity for ferredoxin. The dissociation rate of reduced ferredoxin from photosystem I (800 s(-1)) and the redox potential of the first reduction of ferredoxin-NADP(+) reductase (-380 mV) were determined. In the absence of NADP(+), differential absorption spectra support the existence of a high affinity complex between oxidized ferredoxin and semireduced ferredoxin-NADP(+) reductase. An effective rate of 140-170 s(-1) was also measured for the second reduction of ferredoxin-NADP(+) reductase, this process having a rate constant similar to that of the first reduction. In the presence of NADP(+), the second-order rate constant for the first reduction of ferredoxin-NADP(+) reductase was 20% slower than in its absence, in line with the existence of ternary complexes ( ferredoxin-NADP(+) reductase)-NADP(+)-ferredoxin. A single catalytic turnover was monitored, with 50% NADP(+) being reduced in 8-10 ms using 1.6 mu M photosystem I. In conditions of multiple turnover, we determined initial rates of 360-410 electrons per s and per ferredoxin-NADP(+) reductase for the reoxidation of 3.5 mu M photoreduced ferredoxin. Identical rates were found with photosystem I lacking the PsaE subunit and wild type photosystem I. This suggests that, in contrast with previous proposals, the PsaE subunit is not involved in NADP(+) photoreduction.	CEA Saclay, CNRS, DBJC, SBE,URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol, Serv Bioenerget, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Setif, P (corresponding author), CEA Saclay, CNRS, DBJC, SBE,URA 2096, F-91191 Gif Sur Yvette, France.	pierre.setif@cea.fr	sui, laizhi/G-5629-2010					ABRAMSKY MA, 1956, ARCH BIOCHEM BIOPHYS, V65, P475, DOI 10.1016/0003-9861(56)90207-7; Aliverti A, 2001, BIOCHEMISTRY-US, V40, P14501, DOI 10.1021/bi011224c; Barth P, 1998, BIOCHEMISTRY-US, V37, P16233, DOI 10.1021/bi981379t; Barth P, 2000, J BIOL CHEM, V275, P7030, DOI 10.1074/jbc.275.10.7030; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1984, J BIOL CHEM, V259, P8832; BATIE CJ, 1981, J BIOL CHEM, V256, P7756; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BENDALL DS, 1995, BBA-BIOENERGETICS, V1229, P23, DOI 10.1016/0005-2728(94)00195-B; BHATTACHARYYA AK, 1986, BIOCHEMISTRY-US, V25, P4655, DOI 10.1021/bi00364a030; BOHME H, 1987, BIOCHIM BIOPHYS ACTA, V891, P1, DOI 10.1016/0005-2728(87)90076-4; BOHME H, 1978, EUR J BIOCHEM, V83, P137, DOI 10.1111/j.1432-1033.1978.tb12077.x; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; Carrillo N, 2003, EUR J BIOCHEM, V270, P1900, DOI 10.1046/j.1432-1033.2003.03566.x; Corrado ME, 1996, EUR J BIOCHEM, V239, P662, DOI 10.1111/j.1432-1033.1996.0662u.x; Dorowski A, 2001, J BIOL CHEM, V276, P9253, DOI 10.1074/jbc.M004576200; Faro M, 2002, EUR J BIOCHEM, V269, P2656, DOI 10.1046/j.1432-1033.2002.02925.x; Florin L, 2001, J BIOL CHEM, V276, P6125, DOI 10.1074/jbc.M008470200; FOUST GP, 1969, J BIOL CHEM, V244, P964; GINSBURG S, 1994, PLANT PHYSIOL, V105, P545, DOI 10.1104/pp.105.2.545; Gomez-Lojero C, 2003, BIOCHEMISTRY-US, V42, P13800, DOI 10.1021/bi0346998; Hanke GT, 2004, PLANT PHYSIOL, V134, P255, DOI 10.1104/pp.103.032755; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; Hermoso JA, 2002, J MOL BIOL, V319, P1133, DOI 10.1016/S0022-2836(02)00388-1; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; Hurley JK, 2002, BBA-BIOENERGETICS, V1554, P5, DOI 10.1016/S0005-2728(02)00188-3; Hurley JK, 1996, J AM CHEM SOC, V118, P5526, DOI 10.1021/ja953662a; Joliot P, 2002, P NATL ACAD SCI USA, V99, P10209, DOI 10.1073/pnas.102306999; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Karplus PA, 2004, PHOTOSYNTH RES, V81, P303, DOI 10.1023/B:PRES.0000036884.57303.2e; Knaff D.B., 1996, OXYGENIC PHOTOSYNTHE, V4, P333; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; MASAKI R, 1982, BIOCHIM BIOPHYS ACTA, V700, P101, DOI 10.1016/0167-4838(82)90297-7; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Medina M, 2004, PHOTOSYNTH RES, V79, P113, DOI 10.1023/B:PRES.0000015386.67746.2c; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Muramoto T, 2002, PLANT PHYSIOL, V130, P1958, DOI 10.1104/pp.008128; Nogues I, 2004, BIOCHEMISTRY-US, V43, P6127, DOI 10.1021/bi049858h; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PUEYO JJ, 1991, EUR J BIOCHEM, V202, P1065, DOI 10.1111/j.1432-1033.1991.tb16471.x; PUEYO JJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P367, DOI 10.1016/0003-9861(92)90697-U; Rathinasabapathi B, 1997, P NATL ACAD SCI USA, V94, P3454, DOI 10.1073/pnas.94.7.3454; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHLUCHTER WM, 1992, BIOCHEMISTRY-US, V31, P3092, DOI 10.1021/bi00127a009; Schultz DJ, 2000, PLANT PHYSIOL, V124, P681, DOI 10.1104/pp.124.2.681; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; Setif P, 2001, BBA-BIOENERGETICS, V1507, P161, DOI 10.1016/S0005-2728(01)00205-5; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; Shin M, 1971, METHOD ENZYMOL, V23, P440; SMITH JM, 1981, BIOCHIM BIOPHYS ACTA, V635, P405, DOI 10.1016/0005-2728(81)90038-4; Soriano GM, 2002, J BIOL CHEM, V277, P41865, DOI 10.1074/jbc.M205772200; TAGAWA K, 1968, BIOCHIM BIOPHYS ACTA, V153, P602, DOI 10.1016/0005-2728(68)90188-6; Tejero J, 2003, J BIOL CHEM, V278, P49203, DOI 10.1074/jbc.M307934200; Thomsen-Zieger N, 2004, FEBS LETT, V576, P375, DOI 10.1016/j.febslet.2004.09.042; Tu SL, 2004, J AM CHEM SOC, V126, P8682, DOI 10.1021/ja049280z; van Thor JJ, 1999, EMBO J, V18, P4128, DOI 10.1093/emboj/18.15.4128; van Thor JJ, 2000, BBA-BIOENERGETICS, V1457, P129, DOI 10.1016/S0005-2728(00)00072-4; van Thor JJ, 1999, BIOCHEMISTRY-US, V38, P12735, DOI 10.1021/bi9903502; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; WALKER MC, 1991, ARCH BIOCHEM BIOPHYS, V287, P351, DOI 10.1016/0003-9861(91)90489-6; Weber-Main AM, 1998, ARCH BIOCHEM BIOPHYS, V355, P181, DOI 10.1006/abbi.1998.0743	66	49	51	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25960	25972		10.1074/jbc.M503742200	http://dx.doi.org/10.1074/jbc.M503742200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15894798	hybrid			2022-12-25	WOS:000230386800004
J	Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S				Lewandowski, SA; Thiery, J; Jalil, A; Leclercq, G; Szczylik, C; Chouaib, S			Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity	ONCOGENE			English	Article						estrogen receptor; p53; cell death	TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; ER-BETA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; MAMMARY-GLAND; BAX GENE; BCL-2	We have investigated the effect of estrogen on p53 cellular location and its influence on tumor cell susceptibility to tumor necrosis factor (TNF)-mediated cytotoxic action. For this purpose, we have used the TNF- sensitive human breast adenocarcinoma MCF-7 and its derivative, the TNF- resistant 1001 clone. Our data indicate that although estrogen receptor (ER) a is present in both cell lines, estrogen treatment (1 x 10(-8) M) has an influence only on the MCF- 7 cells and protects these cells from the TNF cytotoxicity. This protective effect is associated with translocation of p53 from the nucleus to the cytoplasm in p53 wild-type MCF-7 and not in p53-mutated 1001 cells. The translocation of p53 in MCF- 7 cells results in a decrease in its transcriptional activity, as revealed by diminished p21(WAF1/CIP1) induction and an altered ratio of Bax and Bcl-2 proteins. The estrogen-induced effects are reversed by the selective estrogen inhibitor 182, 780 (1 x 10(-6) M). Interestingly, transient transfection of MCF-7 cells with ER beta but not ER alpha cDNA encoding plasmid results in retention of p53 in the nucleus, a subsequent potentiation of its transcriptional activity, and in an increased MCF-7 sensitivity to TNF. The estrogen effects on p53 location and transcriptional activity may involve the mdm2 protein since both events were reversed following MCF-7 transfection with plasmid encoding the ARF cDNA. These studies suggest that estrogen-induced MCF-7 cell survival in the presence of TNF requires a transcriptionally active p53 and, more importantly, indicate that introduction of ERb can attenuate the estrogen effects on the p53 protein location, its transcriptional activity and also results in a potentiation of cell sensitivity to TNF-mediated cell death.	Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Military Inst Med, Dept Oncol, PL-00909 Warsaw, Poland; Univ Libre Bruxelles, Inst Jules Bordet, Serv Med Interne, Lab JC Heuson Cancerol Mammaire, B-1000 Brussels, Belgium; Postgrad Sch Mol Med, PL-02093 Warsaw, Poland	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut Jules Bordet; Universite Libre de Bruxelles	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, Cytokines & Immunol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.	chouaib@igr.fr	Lewandowski, Sebastian A./K-2492-2019; Chouaib, Salem/F-7939-2016; THIERY, Jerome/N-2469-2018	Lewandowski, Sebastian A./0000-0002-5935-0211; THIERY, Jerome/0000-0002-0998-3627; JALIL, Abdelali/0000-0003-2710-8735; Guy, LECLERCQ/0000-0001-7231-6563				Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; Berns EMJJ, 2000, CANCER RES, V60, P2155; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown JM, 1999, CANCER RES, V59, P1391; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; Burow ME, 2000, INT J ONCOL, V16, P1179; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; Driggers PH, 2002, TRENDS ENDOCRIN MET, V13, P422, DOI 10.1016/S1043-2760(02)00634-3; Geisler S, 2001, CANCER RES, V61, P2505; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Hyder SM, 1999, BIOCHEM PHARMACOL, V57, P597, DOI 10.1016/S0006-2952(98)00355-4; Kanda N, 2003, J INVEST DERMATOL, V121, P1500, DOI 10.1111/j.1523-1747.2003.12617.x; Kato K, 2002, J BIOL CHEM, V277, P11217, DOI 10.1074/jbc.M107391200; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lilling G, 2000, CANCER LETT, V161, P27, DOI 10.1016/S0304-3835(00)00579-6; Liu G, 1999, BIOCHEM BIOPH RES CO, V264, P359, DOI 10.1006/bbrc.1999.1525; Liu GZ, 2000, CANCER RES, V60, P1810; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Molinari AM, 2000, CANCER RES, V60, P2594; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; OLTVAI ZN, 1993, CELL, V74, P619; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Phelps M, 2003, CANCER RES, V63, P2616; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sudoh N, 2001, CIRCULATION, V103, P724; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thiery J, 2003, J IMMUNOL, V170, P5919, DOI 10.4049/jimmunol.170.12.5919; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Weatherman RV, 2001, J BIOL CHEM, V276, P3827, DOI 10.1074/jbc.M005414200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522	61	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4789	4798		10.1038/sj.onc.1208595	http://dx.doi.org/10.1038/sj.onc.1208595			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870704				2022-12-25	WOS:000230477900005
J	Arnold, JJ; Vignuzzi, M; Stone, JK; Andino, R; Cameron, CE				Arnold, JJ; Vignuzzi, M; Stone, JK; Andino, R; Cameron, CE			Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; I KLENOW FRAGMENT; VESICULAR STOMATITIS-VIRUS; DNA-POLYMERASE; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RIBONUCLEOTIDE INCORPORATION; CHEMICAL MUTAGENESIS; STRUCTURAL BASIS	The kinetic, thermodynamic, and structural basis for fidelity of nucleic acid polymerases remains controversial. An understanding of viral RNA-dependent RNA polymerase (RdRp) fidelity has become a topic of considerable interest as a result of recent experiments that show that a 2-fold increase in fidelity attenuates viral pathogenesis and a 2-fold decrease in fidelity reduces viral fitness. Here we show that a conformational change step preceding phosphoryl transfer is a key fidelity checkpoint for the poliovirus RdRp (3D(pol)). We provide evidence that this conformational change step is orientation of the triphosphate into a conformation suitable for catalysis, suggesting a kinetic and structural model for RdRp fidelity that can be extrapolated to other classes of nucleic acid polymerases. Finally, we show that a site remote from the catalytic center can control this checkpoint, which occurs at the active site. Importantly, similar connections between a remote site and the active site exist in a wide variety of viral RdRps. The capacity for sites remote from the catalytic center to alter fidelity suggests new possibilities for targeting the viral RdRp for antiviral drug development.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu		Vignuzzi, Marco/0000-0002-4400-771X	NIAID NIH HHS [AI45818, N01AI40085, R01 AI045818] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040085, R01AI045818, R21AI040085] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5138, DOI 10.1021/bi035213q; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P2706, DOI 10.1074/jbc.274.5.2706; Artsimovitch I, 2003, SCIENCE, V302, P650, DOI 10.1126/science.1087526; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Castro C, 2005, VIRUS RES, V107, P141, DOI 10.1016/j.virusres.2004.11.004; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; Domingo E, 2005, VIRUS RES, V107, P115, DOI 10.1016/j.virusres.2004.11.001; Domingo E, 2005, VIRUS RES, V107, P129, DOI 10.1016/j.virusres.2004.11.003; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; FERRIN LJ, 1985, BIOCHEMISTRY-US, V24, P6904, DOI 10.1021/bi00345a024; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 2004, BIOCHEMISTRY-US, V43, P5149, DOI 10.1021/bi035429s; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HEINZ BA, 1989, J VIROL, V63, P2476, DOI 10.1128/JVI.63.6.2476-2485.1989; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; KATI WM, 1992, J BIOL CHEM, V267, P25988; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Lee CH, 1997, J VIROL, V71, P3636, DOI 10.1128/JVI.71.5.3636-3640.1997; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Love RA, 2004, STRUCTURE, V12, P1533, DOI 10.1016/j.str.2004.05.024; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MOSSER AG, 1994, J VIROL, V68, P8193, DOI 10.1128/JVI.68.12.8193-8201.1994; MOSSER AG, 1993, J VIROL, V67, P1246, DOI 10.1128/JVI.67.3.1246-1254.1993; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pfeiffer JK, 2003, P NATL ACAD SCI USA, V100, P7289, DOI 10.1073/pnas.1232294100; REARDON JE, 1993, J BIOL CHEM, V268, P8743; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Vignuzzi M, 2005, VIRUS RES, V107, P173, DOI 10.1016/j.virusres.2004.11.007; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5	46	139	146	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25706	25716		10.1074/jbc.M503444200	http://dx.doi.org/10.1074/jbc.M503444200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878882	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000230207900051
J	Chen, YB; Yang, CP; Li, RX; Zeng, R; Zhou, JQ				Chen, YB; Yang, CP; Li, RX; Zeng, R; Zhou, JQ			Def1p is involved in telomere maintenance in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; REPLICATION FORK PROGRESSION; DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; LENGTH MAINTENANCE; MAINTAIN TELOMERES; EST GENES; IN-VITRO; HELICASE; RECOMBINATION	Saccharomyces Rrm3p, a member of Pif1 5'-3' DNA helicase subfamily, helps replication forks traverse protein-DNA complexes, including the telomere. Here we have identified an Rrm3p interaction protein known to be Def1p. In def1 mutants, telomeres were similar to 200-bp shorter than that in wild-type cells. DEF1 is also required for the stable maintenance of mitochondrial DNA, and the telomere shortening phenotype seen in def1 cells is not a secondary consequence of the mitochondrion defect. A combination of DEF1 null mutation with deletion of EST2 or EST3 resulted in an accelerated senescence phenotype, suggesting that Def1p is not involved in the telomerase recruitment pathway. In the absence of telomerase, cells escape senescence by either amplifying Y' regions or TG-telomeric repeats to generate type I or type II survivors, respectively. Only type I survivors were recovered from both def1 Delta est2 Delta and def1 Delta est3 Delta double mutant cells, further suggesting that the function of Def1p in telomere maintenance is specific. Our novel findings of the functions of Def1p in telomere and mitochondria suggested that Def1p plays multiple roles in yeast.	Chinese Acad Sci, Inst Biol Sci, Max Planck Jr Res Grp, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Zhou, JQ (corresponding author), Chinese Acad Sci, Inst Biol Sci, Max Planck Jr Res Grp, State Key Lab Mol Biol, 320 Yue-Yang Rd, Shanghai 200031, Peoples R China.	jqzhou@sibs.ac.cn						Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cervantes RB, 2002, CURR OPIN CELL BIOL, V14, P351, DOI 10.1016/S0955-0674(02)00325-3; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 2000, MOL CELL BIOL, V20, P8397, DOI 10.1128/MCB.20.22.8397-8408.2000; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2003, MOL CELL, V12, P1525, DOI 10.1016/S1097-2765(03)00456-8; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; Le S, 1999, GENETICS, V152, P143; Lendvay TS, 1996, GENETICS, V144, P1399; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Longhese MP, 2000, GENETICS, V155, P1577; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teng SC, 1999, MOL CELL BIOL, V19, P8083; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771; Zhou JQ, 2002, MOL BIOL CELL, V13, P2180, DOI 10.1091/mbc.02-02-0021	52	21	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24784	24791		10.1074/jbc.M413562200	http://dx.doi.org/10.1074/jbc.M413562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863512	hybrid			2022-12-25	WOS:000230114000061
J	Daval, M; Diot-Dupuy, F; Bazin, R; Hainault, I; Viollet, B; Vaulont, S; Hajduch, E; Ferre, P; Foufelle, F				Daval, M; Diot-Dupuy, F; Bazin, R; Hainault, I; Viollet, B; Vaulont, S; Hajduch, E; Ferre, P; Foufelle, F			Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; GLUCOSE; PHOSPHORYLATION; ISOPROTERENOL; METABOLISM; EXPRESSION; CASCADE; AICAR	Despite its importance in terms of energy homeostasis, the role of AMP-activated protein kinase in adipose tissue remains controversial. Initial studies have described an anti-lipolytic role for AMP-activated protein kinase, whereas more recent studies have suggested the converse. Thus we have addressed the role of AMP-activated protein kinase in adipose tissue by modulating AMP-activated protein kinase activity in primary rodent adipocytes using pharmacological activators or by adenoviral expression of dominant negative or constitutively active forms of the kinase. We then studied the effects of AMP-activated protein kinase activity modulation on lipolytic mechanisms. Finally, we analyzed the consequences of a genetic deletion of AMP-activated protein kinase in mouse adipocytes. AMP-activated protein kinase activity in adipocytes is represented mainly by the alpha(1) isoform and is induced by all of the stimuli that increase cAMP in adipocytes, including fasting. When AMP-activated protein kinase activity is increased by 5-aminoimidazole-4-carboxamide-riboside, phenformin, or by the expression of a constitutively active form, isoproterenol-induced lipolysis is strongly reduced. Conversely, when AMP-activated protein kinase activity is decreased either by a dominant negative form or in AMP-activated protein kinase alpha(1) knock-out mice, lipolysis is increased. We present data suggesting that AMP-activated protein kinase acts on hormone-sensitive lipase by blocking its translocation to the lipid droplet. We conclude that, in mature adipocytes, AMP-activated protein kinase activation has a clear anti-lipolytic effect.	Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM, U671, F-75270 Paris, France; Inst Cochin Genet Mol, Fac Med, Dept Genet Dev & Pathol Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Foufelle, F (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM, U671, 15 Rue Ecole Med, F-75270 Paris, France.	foufelle@bhdc.jussieu.fr	Vaulont, Sophie/O-6732-2017; Ferré, Pascal/K-1250-2013; Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019; Hajduch, Eric/B-7332-2008	Ferré, Pascal/0000-0003-0115-7045; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Hajduch, Eric/0000-0002-0125-7751; FOUFELLE, Fabienne/0000-0002-0752-622X				Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Bergeron R, 2001, DIABETES, V50, P1076, DOI 10.2337/diabetes.50.5.1076; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Su CL, 2003, J BIOL CHEM, V278, P43615, DOI 10.1074/jbc.M301809200; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	29	262	282	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25250	25257		10.1074/jbc.M414222200	http://dx.doi.org/10.1074/jbc.M414222200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878856	hybrid			2022-12-25	WOS:000230114000111
J	Felipe, MSS; Andrade, RV; Arraes, FBM; Nicola, AM; Maranhao, AQ; Torres, FAG; Silva-Pereira, I; Poc as-Fonseca, MJ; Campos, EG; Moraes, LMP; Andrade, PA; Tavares, AHFP; Silva, SS; Kyaw, CM; Souza, DP; Network, P; Pereira, M; Jesuino, RSA; Andrade, EV; Parente, JA; Oliveira, GS; Barbosa, MS; Martins, NF; Fachin, AL; Cardoso, RS; Passos, GAS; Almeida, NF; Walter, MEMT; Soares, CMA; Carvalho, MJA; Brigido, MM				Felipe, MSS; Andrade, RV; Arraes, FBM; Nicola, AM; Maranhao, AQ; Torres, FAG; Silva-Pereira, I; Poc as-Fonseca, MJ; Campos, EG; Moraes, LMP; Andrade, PA; Tavares, AHFP; Silva, SS; Kyaw, CM; Souza, DP; Network, P; Pereira, M; Jesuino, RSA; Andrade, EV; Parente, JA; Oliveira, GS; Barbosa, MS; Martins, NF; Fachin, AL; Cardoso, RS; Passos, GAS; Almeida, NF; Walter, MEMT; Soares, CMA; Carvalho, MJA; Brigido, MM			Transcriptional profiles of the human pathogenic fungus Paracoccidioides brasiliensis in mycelium and yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-ALBICANS; MOLECULAR-CLONING; REACTIVE OXYGEN; BINDING-PROTEIN; GENE; IDENTIFICATION; EXPRESSION; ENCODES; CALCINEURIN; DIMORPHISM	Paracoccidioides brasiliensis is the causative agent of paracoccidioidomycosis, a disease that affects 10 million individuals in Latin America. This report depicts the results of the analysis of 6,022 assembled groups from mycelium and yeast phase expressed sequence tags, covering about 80% of the estimated genome of this dimorphic, thermo-regulated fungus. The data provide a comprehensive view of the fungal metabolism, including overexpressed transcripts, stage-specific genes, and also those that are up-or down-regulated as assessed by in silico electronic subtraction and cDNA microarrays. Also, a significant differential expression pattern in mycelium and yeast cells was detected, which was confirmed by Northern blot analysis, providing insights into differential metabolic adaptations. The overall transcriptome analysis provided information about sequences related to the cell cycle, stress response, drug resistance, and signal transduction pathways of the pathogen. Novel P. brasiliensis genes have been identified, probably corresponding to proteins that should be addressed as virulence factor candidates and potential new drug targets.	Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil; Univ Brasilia, Dept Ciencia Computacao, BR-70910900 Brasilia, DF, Brazil; EMBRAPA, Recursos Genet & Biotecnol, BR-70770900 Brasilia, DF, Brazil; Univ Fed Goias, Dept Bioquim, BR-74001970 Goiania, Go, Brazil; Univ Fed Mato Grosse Sul, Dept Computacao & Estat, BR-79070900 Campo Grande, Mississippi, Brazil; Univ Sao Paulo, Dept Genet, BR-14040900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Fac Odontol, BR-14040900 Ribeirao Preto, SP, Brazil	Universidade de Brasilia; Universidade de Brasilia; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA); Universidade Federal de Goias; Universidade Federal de Mato Grosso do Sul; Universidade de Sao Paulo; Universidade de Sao Paulo	Felipe, MSS (corresponding author), Univ Brasilia, Dept Biol Celular, BR-70910900 Brasilia, DF, Brazil.	msueli@unb.br	Parachin, N. S./J-4247-2018; Soares, Celia/N-6395-2014; martins, natalia florencio/AAE-7875-2019; Fachin, Ana L/B-7916-2012; TAVARES, ALDO HENRIQUE/L-5662-2015; Maranhão, Andrea/AAC-3560-2019; DE BASTOS ASCENÇO SOARES, RENATA/G-4330-2019; Mello, Stephano Spano/ABF-9477-2020; Campos, Elida/B-2319-2013; Almeida, João R. M./K-1915-2012; Passos, Geraldo A/A-2899-2008; Passos, Geraldo Aleixo/ABE-3251-2020; Titze-de-Almeida, Simoneide S./Q-3549-2017; Maranhão, Andrea Queiroz/S-8696-2019; Nicola, Andre Moraes/B-3434-2008; TAVARES, ALDO HENRIQUE/AGI-3412-2022; Brigido, Marcelo Macedo/A-1972-2015; Albuquerque, Patricia/H-1403-2011; Silva-Pereira, Ildinete/C-7509-2011; Amaral, Andre/A-7936-2015; Felipe, Maria Sueli/L-6260-2016; Torres, Fernando A.G./D-5651-2012; Walter, Maria Emilia M. T./A-8000-2015; Brigido, Marcelo/H-2718-2019; Maranhão, Andrea Q/L-4474-2013; Almeida, Nalvo/B-5856-2012; Parachin, Nádia Skorupa/I-5494-2012; Arraes, Fabrício B. M./G-9621-2014; SOARES, RENATA BA/B-6423-2011; Bailao, Alexandre/H-1272-2013	Parachin, N. S./0000-0002-5392-4560; Fachin, Ana L/0000-0001-8755-9250; Maranhão, Andrea/0000-0002-1946-7191; DE BASTOS ASCENÇO SOARES, RENATA/0000-0003-1029-325X; Almeida, João R. M./0000-0002-2902-5805; Passos, Geraldo A/0000-0002-4408-140X; Passos, Geraldo Aleixo/0000-0002-4408-140X; Titze-de-Almeida, Simoneide S./0000-0001-6122-054X; Nicola, Andre Moraes/0000-0001-8656-5835; TAVARES, ALDO HENRIQUE/0000-0003-0579-3380; Brigido, Marcelo Macedo/0000-0002-7136-7059; Albuquerque, Patricia/0000-0001-8160-7784; Silva-Pereira, Ildinete/0000-0003-1403-9363; Felipe, Maria Sueli/0000-0003-4347-6853; Torres, Fernando A.G./0000-0002-3650-7271; Walter, Maria Emilia M. T./0000-0001-6822-931X; Brigido, Marcelo/0000-0002-7136-7059; Maranhão, Andrea Q/0000-0002-1946-7191; Parachin, Nádia Skorupa/0000-0002-5392-4560; Arraes, Fabrício B. M./0000-0001-9735-9025; Correa Amaral, Andre/0000-0001-9516-8970; Fernandes, Larissa/0000-0002-2814-7501; Mello, Stephano Spano/0000-0002-2484-086X; Junta, Cristina/0000-0001-7233-3881; Almeida, Nalvo/0000-0001-5615-1746; Sandrin-Garcia, Paula/0000-0003-4641-7429; Pocas-Fonseca, Marcio Jose/0000-0002-4108-5122; Bailao, Alexandre/0000-0001-7754-4047; Moraes, Lidia/0000-0002-4293-304X; De-Souza, Marlene Teixeira/0000-0003-1538-2657; Sandes, Edans/0000-0001-9502-7799; Souza, Diorge/0000-0003-1303-1765				Albuquerque P, 2004, FUNGAL GENET BIOL, V41, P510, DOI 10.1016/j.fgb.2004.01.001; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P44, DOI 10.1093/nar/29.1.44; Audic S, 1997, GENOME RES, V7, P986, DOI 10.1101/gr.7.10.986; Bruckmann A, 2000, MICROBIOL-SGM, V146, P2755, DOI 10.1099/00221287-146-11-2755; Cano MIN, 1998, J CLIN MICROBIOL, V36, P742, DOI 10.1128/JCM.36.3.742-747.1998; Cox GM, 2000, INFECT IMMUN, V68, P443, DOI 10.1128/IAI.68.2.443-448.2000; Cunha AF, 1999, MED MYCOL, V37, P115, DOI 10.1046/j.1365-280X.1999.00211.x; da Silva SP, 1999, MOL MICROBIOL, V31, P1039, DOI 10.1046/j.1365-2958.1999.01236.x; de Almeida SM, 2004, J INFECTION, V48, P193, DOI 10.1016/j.jinf.2003.08.012; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Falkow S, 2004, NAT REV MICROBIOL, V2, P67, DOI 10.1038/nrmicro799; Felipe MSS, 2003, YEAST, V20, P263, DOI 10.1002/yea.964; FRANCO M, 1987, J MED VET MYCOL, V25, P5; Goldman GH, 2003, EUKARYOT CELL, V2, P34, DOI 10.1128/EC.2.1.34-48.2003; Gray CH, 2003, YEAST, V20, P865, DOI 10.1002/yea.1013; Hohmann S, 2002, INT REV CYTOL, V215, P149; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Izacc SMS, 2001, MED MYCOL, V39, P445, DOI 10.1080/714031053; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; Kraus PR, 2003, BIOCHEM BIOPH RES CO, V311, P1151, DOI 10.1016/S0006-291X(03)01528-6; Krishnamurthy S, 1998, FEMS MICROBIOL LETT, V160, P191, DOI 10.1111/j.1574-6968.1998.tb12910.x; Lengeler KB, 2000, MICROBIOL MOL BIOL R, V64, P746, DOI 10.1128/MMBR.64.4.746-785.2000; LOOSE DS, 1983, P NATL ACAD SCI-BIOL, V80, P7659, DOI 10.1073/pnas.80.24.7659; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; Marques ER, 2004, MOL GENET GENOMICS, V271, P667, DOI 10.1007/s00438-004-1016-6; Moradas-Ferreira P, 2000, REDOX REP, V5, P277, DOI 10.1179/135100000101535816; Moreira SFI, 2004, YEAST, V21, P173, DOI 10.1002/yea.1077; Mosch HU, 1999, MOL BIOL CELL, V10, P1325, DOI 10.1091/mbc.10.5.1325; Muhlschlegel FA, 1997, MOL CELL BIOL, V17, P5960; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Onyewu C, 2003, ANTIMICROB AGENTS CH, V47, P956, DOI 10.1128/AAC.47.3.956-964.2003; PARIS S, 1985, MYCOPATHOLOGIA, V92, P115, DOI 10.1007/BF00444093; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perea S, 2002, CLIN INFECT DIS, V35, P1073, DOI 10.1086/344058; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; RESTREPO A, 1981, SABOURAUDIA, V19, P295; Restrepo A, 2001, MED MYCOL, V39, P233, DOI 10.1080/714031028; SALAZAR ME, 1988, INFECT IMMUN, V56, P711, DOI 10.1128/IAI.56.3.711-713.1988; San-Blas G, 2002, MED MYCOL, V40, P225, DOI 10.1080/mmy.40.3.225.242; San-Blas G, 2001, FUNGAL PATHOGENESIS, P205; Sonneborn A, 2000, MOL MICROBIOL, V35, P386, DOI 10.1046/j.1365-2958.2000.01705.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venancio EJ, 2002, MED MYCOL, V40, P45, DOI 10.1080/mmy.40.1.45.51; Wills EA, 2000, EMERG THERAP TARGETS, V4, P1; Xu JR, 2000, FUNGAL GENET BIOL, V31, P137, DOI 10.1006/fgbi.2000.1237	49	139	147	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24706	24714		10.1074/jbc.M500625200	http://dx.doi.org/10.1074/jbc.M500625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15849188	Green Published, hybrid			2022-12-25	WOS:000230114000051
J	Jin, SH; Zhuo, Y; Guo, WN; Field, J				Jin, SH; Zhuo, Y; Guo, WN; Field, J			p21-Activated kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-KINASE; SIGNALING PATHWAY; AGONIST BAD; SURVIVAL; RAS; PAK; ACTIVATION; APOPTOSIS; COUPLES	Raf-1 protects cells from apoptosis, independently of its signals to MEK and ERK, by translocating to the mitochondria where it binds Bcl-2 and displaces BAD. However, the answer to the question of how Raf-1 is normally lured to the mitochondria and becomes activated remains elusive. p21-activated protein kinases (Paks) are serine/threonine protein kinases that phosphorylate Raf-1 at Ser-338 and Ser-339. Here we elucidate the molecular mechanism through which Pak1 signals to BAD through a Raf-1-activated pathway. Upon phosphorylation by Pak1, Raf-1 translocates to mitochondria and phosphorylates BAD at Ser-112. Moreover, the mitochondrial translocation of Raf-1 and the interaction between Raf-1 and Bcl-2 are regulated by Raf-1 phosphorylation at Ser-338/Ser-339. Notably, we show that formation of a Raf-1-Bcl-2 complex coincides with loss of an interaction between Bcl- 2 and BAD. These signals are specific for Pak1, because Src-activated Raf-1 only stimulates the MAP kinase cascade. Thus, our data identify the molecular connections of a Pak1-Raf-1-BAD pathway that is involved in cell survival signaling.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Field, J (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	field@pharm.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048241] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM048241, GM48241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Grana TM, 2002, CANCER RES, V62, P4142; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gupta AK, 2001, CANCER RES, V61, P4278; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hindley A, 2002, J CELL SCI, V115, P1575; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mazumdar A, 2003, FEBS LETT, V535, P6, DOI 10.1016/S0014-5793(02)03846-2; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	45	118	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24698	24705		10.1074/jbc.M413374200	http://dx.doi.org/10.1074/jbc.M413374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15849194	hybrid			2022-12-25	WOS:000230114000050
J	Othumpangat, S; Kashon, M; Joseph, P				Othumpangat, S; Kashon, M; Joseph, P			Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE CELLS; CAP-BINDING PROTEIN; RNA 5' CAP; MESSENGER-RNA; UP-REGULATION; C-MYC; MALIGNANT TRANSFORMATION; RESPONSIVE PROTOONCOGENE; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS	Whether translation initiation factor 4E (eIF4E), the mRNA cap binding and rate-limiting factor required for translation, is a target for cytotoxicity and cell death induced by cadmium, a human carcinogen, was investigated. Exposure of human cell lines, HCT15, PLC/PR/5, HeLa, and Chang, to cadmium chloride resulted in cytotoxicity and cell death, and this was associated with a significant decrease in eIF4E protein levels. Similarly, specific silencing of the expression of the eIF4E gene, caused by a small interfering RNA, resulted in significant cytotoxicity and cell death. On the other hand, overexpression of the eIF4E gene was protective against the cadmium-induced cytotoxicity and cell death. Further studies revealed the absence of alterations in the eIF4E mRNA level in the cadmium-treated cells despite their decreased eIF4E protein level. In addition, exposure of cells to cadmium resulted in enhanced ubiquitination of eIF4E protein while inhibitors of proteasome activity reversed the cadmium-induced decrease of eIF4E protein. Exposure of cells to cadmium, as well as the specific silencing of eIF4E gene, also resulted in decreased cellular levels of cyclin D1, a critical cell cycle and growth regulating gene, suggesting that the observed inhibition of cyclin D1 gene expression in the cadmium-treated cells is most likely due to decreased cellular level of eIF4E. Taken together, our results demonstrate that the exposure of cells to cadmium chloride resulted in cytotoxicity and cell death due to enhanced ubiquitination and consequent proteolysis of eIF4E protein, which in turn diminished cellular levels of critical genes such as cyclin D1.	NIOSH, Mol Carcinogenesis Lab, Toxicol & Mol Biol Branch, CDC, Morgantown, WV 26505 USA; NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Joseph, P (corresponding author), NIOSH, Mol Carcinogenesis Lab, Toxicol & Mol Biol Branch, CDC, 1095 Willowdale Rd,MS 3014, Morgantown, WV 26505 USA.	pcj5@cdc.gov		Othumpangat, Sreekumar/0000-0002-6563-611X				Achanzar WE, 2000, TOXICOL APPL PHARM, V164, P291, DOI 10.1006/taap.1999.8907; Alam J, 2000, J BIOL CHEM, V275, P27694; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; AYLETT BJ, 1979, CHEM BIOCH BIOL CADM; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; GOYER RA, 1994, HDB EXPT PHARM TOXIC; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang CS, 2001, MOL CELL BIOCHEM, V222, P141, DOI 10.1023/A:1017953927347; International Agency for Research on Cancer Monographs, 1993, BERYLLIUM CADMIUM ME, V58, P119; Joseph P, 2004, MOL CELL BIOCHEM, V255, P93, DOI 10.1023/B:MCBI.0000007265.38475.f7; Joseph P, 2001, TOXICOL SCI, V61, P295, DOI 10.1093/toxsci/61.2.295; Joseph P, 2002, CANCER RES, V62, P703; Joseph P, 2002, J BIOL CHEM, V277, P6131, DOI 10.1074/jbc.M109373200; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; Kondoh M, 2002, TOXICOLOGY, V170, P111, DOI 10.1016/S0300-483X(01)00536-4; Lag M, 2002, CELL BIOL TOXICOL, V18, P29, DOI 10.1023/A:1014467112463; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Li W, 2001, J BIOL CHEM, V276, P29111, DOI 10.1074/jbc.C100284200; Lopez E, 2003, BRIT J PHARMACOL, V138, P901, DOI 10.1038/sj.bjp.0705111; Matsuda K, 2003, ARCH ENVIRON HEALTH, V58, P218, DOI 10.3200/AEOH.58.4.218-222; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; POLLA BS, 1995, INFLAMMATION, V19, P363, DOI 10.1007/BF01534393; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stayner L, 1992, Ann Epidemiol, V2, P177, DOI 10.1016/1047-2797(92)90052-R; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Thevenod F, 1999, FASEB J, V13, P1751, DOI 10.1096/fasebj.13.13.1751; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; WAALKES MP, 1992, CRIT REV TOXICOL, V22, P175, DOI 10.3109/10408449209145323; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Yassin AS, 2004, J OCCUP ENVIRON HYG, V1, P324, DOI 10.1080/15459620490445499	46	55	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25162	25169		10.1074/jbc.M414303200	http://dx.doi.org/10.1074/jbc.M414303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878868	hybrid			2022-12-25	WOS:000230114000100
J	Lozach, PY; Burleigh, L; Staropoli, I; Navarro-Sanchez, E; Harriague, J; Virelizier, JL; Rey, FA; Despres, P; Arenzana-Seisdedos, F; Amara, A				Lozach, PY; Burleigh, L; Staropoli, I; Navarro-Sanchez, E; Harriague, J; Virelizier, JL; Rey, FA; Despres, P; Arenzana-Seisdedos, F; Amara, A			Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-TYPE LECTIN; ENVELOPE GLYCOPROTEINS; LANGERHANS CELLS; LIGAND-BINDING; RECEPTOR; TRANS; GLYCOSYLATION; EXPRESSION; PROTEIN	Dengue virus ( DV) is a mosquito-borne flavivirus that causes hemorrhagic fever in humans. In the natural infection, DV is introduced into human skin by an infected mosquito vector where it is believed to target immature dendritic cells (DCs) and Langerhans cells (LCs). We found that DV productively infects DCs but not LCs. We show here that the interactions between DV E protein, the sole mannosylated glycoprotein present on DV particles, and the C-type lectin dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) are essential for DV infection of DCs. Binding of mannosylated N-glycans on DV E protein to DC-SIGN triggers a rapid and efficient internalization of the viral glycoprotein. However, we observed that endocytosis-defective DC-SIGN molecules allow efficient DV replication, indicating that DC-SIGN endocytosis is dispensable for the internalization step in DV entry. Together, these results argue in favor of a mechanism by which DC-SIGN enhances DV entry and infection in cis. We propose that DC-SIGN concentrates mosquito-derived DV particles at the cell surface to allow efficient interaction with an as yet unidentified entry factor that is ultimately responsible for DV internalization and pH-dependent fusion into DCs.	Inst Pasteur, Unite Immunol Virale, F-75724 Paris, France; Inst Pasteur, Unite Postulante Interact Mol Flavivirus Hotes, F-75724 Paris, France; CNRS 2472, INRA 1157, Unite Mixte REch Virol Mol & Struct, F-91198 Gif Sur Yvette, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	Amara, A (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75724 Paris, France.	aamara@pasteur.fr	Amara, Ali/E-8803-2017; AMARA, Ali/ABX-9903-2022; Arenzana-Seisdedos, Fernando/E-5835-2016; Lozach, Pierre-Yves/H-7072-2015; Rey, Felix/B-6497-2012; Burleigh, Laura/B-7860-2010	Lozach, Pierre-Yves/0000-0002-9966-1452; Rey, Felix/0000-0002-9953-7988; Burleigh, Laura/0000-0002-8484-5670; AMARA, Ali/0000-0002-0283-1815; Harriague, Julie/0000-0001-6824-9169				Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Amara A, 2003, J VIROL, V77, P2550, DOI 10.1128/JVI.77.4.2550-2558.2003; Bernhard OK, 2004, J BIOL CHEM, V279, P51828, DOI 10.1074/jbc.M402741200; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHAMBERS TJ, 2003, FLAVIVIRUS PATHOGENE; Chen YC, 1999, J VIROL, V73, P2650, DOI 10.1128/JVI.73.4.2650-2657.1999; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Courageot MP, 2000, J VIROL, V74, P564, DOI 10.1128/JVI.74.1.564-572.2000; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x; JOHNSON AJ, 1994, VIROLOGY, V203, P241, DOI 10.1006/viro.1994.1481; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Nobile C, 2003, J VIROL, V77, P5313, DOI 10.1128/JVI.77.9.5313-5323.2003; Ploquin MJY, 2004, J VIROL, V78, P798, DOI 10.1128/JVI.78.2.798-810.2004; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Snyder GA, 2005, J MOL BIOL, V347, P979, DOI 10.1016/j.jmb.2005.01.063; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841; Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; Valle JRD, 2005, J VIROL, V79, P4557, DOI 10.1128/JVI.79.8.4557-4567.2005; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Weaver SC, 2004, NAT REV MICROBIOL, V2, P789, DOI 10.1038/nrmicro1006; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m	48	188	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23698	23708		10.1074/jbc.M504337200	http://dx.doi.org/10.1074/jbc.M504337200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855154	Green Published, hybrid			2022-12-25	WOS:000229880000038
J	Xu, XQ; Emerald, BS; Goh, ELK; Kannan, N; Miller, LD; Gluckman, PD; Liu, ET; Lobie, PE				Xu, XQ; Emerald, BS; Goh, ELK; Kannan, N; Miller, LD; Gluckman, PD; Liu, ET; Lobie, PE			Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; INTESTINAL TREFOIL FACTOR; CELL-SPECIFIC EXPRESSION; IN-VIVO; SPASMOLYTIC POLYPEPTIDE; PS2 PROTEIN; RAT; PROLACTIN; INSULIN; GH	We have exploited a discrepancy in the oncogenic potential of autocrine and exogenous human growth hormone (hGH) in an attempt to identify molecules that could potentially be involved in oncogenic transformation of the human mammary epithelial cell. Microarray analysis of 19,000 human genes identified a subset of 305 genes in a human mammary carcinoma cell line that were remarkably different in their response to autocrine and exogenous hGH. Autocrine and exogenous hGH also regulated 167 common genes. Semiquantitative reverse transcription-PCR confirmed differential regulation of genes by either autocrine or exogenous hGH. Functional analysis of one of the identified autocrine hGH-regulated genes, TFF3, determined that its expression is sufficient to support anchorage-independent growth of human mammary carcinoma cells. Small interfering RNA-mediated knockdown of TFF3 concordantly abrogated anchorage-independent growth of mammary carcinoma cells and abrogated the ability of autocrine hGH to stimulate oncogenic transformation of immortalized human mammary epithelial cells. Further functional characterization of the identified subset of specifically autocrine hGH regulated genes will delineate additional novel oncogenes for the human mammary epithelial cell.	Univ Auckland, Liggins Inst & Natl Res Ctr Growth & Dev, Auckland 1, New Zealand; Inst Mol & Cell Biol, Singapore 117609, Singapore; Genome Inst, Singapore, Singapore	University of Auckland; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst & Natl Res Ctr Growth & Dev, 2-6 Park Ave,Private Bag 92019, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	David, Starling Emerald Bright/R-6034-2019; Miller, Lance/A-5633-2009; Goh, Eyleen/A-8006-2013; Liu, Edison/C-4141-2008	David, Starling Emerald Bright/0000-0001-6875-2258; Kannan, Nagarajan/0000-0002-8825-2178; Goh, Eyleen/0000-0002-8244-6959; Miller, Lance/0000-0003-3799-2528				BCHINI O, 1991, ENDOCRINOLOGY, V128, P539, DOI 10.1210/endo-128-1-539; Beck S, 1998, INT J MOL MED, V2, P353; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; EKBERG S, 1992, J ENDOCRINOL, V135, P59, DOI 10.1677/joe.0.1350059; ERIKSSON L, 1989, J STEROID BIOCHEM, V33, P413, DOI 10.1016/0022-4731(89)90331-2; Flores-Morales A, 2001, ENDOCRINOLOGY, V142, P3163, DOI 10.1210/en.142.7.3163; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; Garverick HA, 2002, REPRODUCTION, V123, P651, DOI 10.1530/rep.0.1230651; Gillesby BE, 1999, BREAST CANCER RES TR, V56, P253; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; HOSOKAWA M, 1988, RES COMMUN CHEM PATH, V62, P279; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; IZUMI T, 1995, MOL CELL ENDOCRINOL, V112, P95, DOI 10.1016/0303-7207(95)03591-T; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kimura AP, 2004, MOL ENDOCRINOL, V18, P1018, DOI 10.1210/me.2003-0468; KLAPPER DG, 1983, ENDOCRINOLOGY, V112, P2215, DOI 10.1210/endo-112-6-2215; Kleinberg DL, 1997, J MAMMARY GLAND BIOL, V2, P49, DOI 10.1023/A:1026373513521; Lalani EN, 1999, LAB INVEST, V79, P537; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Li HK, 2001, J BONE MINER RES, V16, P1068, DOI 10.1359/jbmr.2001.16.6.1068; Liu ND, 1997, EXP CELL RES, V237, P196, DOI 10.1006/excr.1997.3789; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; Machado JC, 1996, EUR J CANCER, V32A, P1585, DOI 10.1016/0959-8049(96)00116-5; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; May FEB, 1997, J PATHOL, V183, P4; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2003, ENDOCRINOLOGY, V144, P3182, DOI 10.1210/en.2002-221121; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; MULLER W, 1993, J PATHOL, V171, P263, DOI 10.1002/path.1711710406; NAGASAWA H, 1985, EUR J CANCER CLIN ON, V21, P1547, DOI 10.1016/0277-5379(85)90250-0; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Okada S, 2001, TRENDS MOL MED, V7, P126, DOI 10.1016/S1471-4914(01)01933-5; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; Pedersen SB, 1999, J CLIN ENDOCR METAB, V84, P4073, DOI 10.1210/jc.84.11.4073; Pfaffle RW, 1999, ACTA PAEDIATR, V88, P33, DOI 10.1111/j.1651-2227.1999.tb14401.x; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; PORTERFIELD SP, 1979, HORM METAB RES, V11, P444, DOI 10.1055/s-0028-1092757; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Ribatti D, 1998, J SUBMICR CYTOL PATH, V30, P459; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; ROGERS SA, 1994, AM J PHYSIOL, V267, pF208, DOI 10.1152/ajprenal.1994.267.2.F208; SOULE HD, 1990, CANCER RES, V50, P6075; Stavrou S, 2001, ENDOCRIN METAB CLIN, V30, P545, DOI 10.1016/S0889-8529(05)70201-2; Swanson SM, 2002, CARCINOGENESIS, V23, P977, DOI 10.1093/carcin/23.6.977; Swolin D, 1996, J CLIN ENDOCR METAB, V81, P4329, DOI 10.1210/jc.81.12.4329; Thorner MO, 1999, J CLIN ENDOCR METAB, V84, P2098, DOI 10.1210/jc.84.6.2098; Tonner E, 2000, J ENDOCRINOL, V167, P265, DOI 10.1677/joe.0.1670265; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Walden PD, 1998, ENDOCRINOLOGY, V139, P659, DOI 10.1210/en.139.2.659; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xian CJ, 1999, AM J PHYSIOL-GASTR L, V277, pG785, DOI 10.1152/ajpgi.1999.277.4.G785; Zebrowska T, 1997, J PHYSIOL PHARMACOL, V48, P825; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317	71	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23987	24003		10.1074/jbc.M503869200	http://dx.doi.org/10.1074/jbc.M503869200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845533	hybrid			2022-12-25	WOS:000229880000073
J	Nilius, B; Prenen, J; Janssens, A; Owsianik, G; Wang, CB; Zhu, MX; Voets, T				Nilius, B; Prenen, J; Janssens, A; Owsianik, G; Wang, CB; Zhu, MX; Voets, T			The selectivity filter of the cation channel TRPM4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INWARD RECTIFICATION; MOLECULAR-BASIS; SWISS-MODEL; PERMEATION; CELL; BLOCK	Transient receptor potential channel melastatin subfamily (TRPM) 4 and its close homologue, TRPM5, are the only two members of the large transient receptor potential superfamily of cation channels that are impermeable to Ca2+. In this study, we located the TRPM4 selectivity filter and investigated possible structural elements that render it Ca2+-impermeable. Based on homology with known cation channel pores, we identified an acidic stretch of six amino acids in the loop between transmembrane helices TM5 and TM6 ((981)EDMDVA(986)) as a potential selectivity filter. Substitution of this six-amino acid stretch with the selectivity filter of TRPV6 (TIIDGP) resulted in a functional channel that combined the gating hallmarks of TRPM4 (activation by Ca2+, voltage dependence) with TRPV6-like sensitivity to block by extracellular Ca2+ and Mg2+ as well as Ca2+ permeation. Neutralization of Glu(981) resulted in a channel with normal permeability properties but a strongly reduced sensitivity to block by intracellular spermine. Neutralization of Asp(982) yielded a functional channel that exhibited extremely fast desensitization (tau < 5 s), possibly indicating destabilization of the pore. Neutralization of Asp(984) resulted in a non-functional channel with a dominant negative phenotype when coexpressed with wild type TRPM4. Combined neutralization of all three acidic residues resulted in a functional channel whose voltage dependence was shifted toward very positive potentials. Substitution of Gln(977) by a glutamate, the corresponding residue in divalent cation-permeable TRPM channels, altered the monovalent cation permeability sequence and resulted in a pore with moderate Ca2+ permeability. Our findings delineate the selectivity filter of TRPM channels and provide the first insight into the molecular basis of monovalent cation selectivity.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA	KU Leuven; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	bernd.nilius@med.kuleuven.ac.be	Voets, Thomas/AAD-4389-2019; Voets, Thomas/E-2466-2012	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Janssens, Annelies/0000-0002-6735-8248				BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Earley S, 2004, CIRC RES, V95, P922, DOI 10.1161/01.RES.0000147311.54833.03; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guinamard R, 2004, J CARDIOVASC ELECTR, V15, P342, DOI 10.1046/j.1540-8167.2004.03477.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Kurata HT, 2004, J GEN PHYSIOL, V124, P541, DOI 10.1085/jgp.200409159; Launay P, 2004, SCIENCE, V306, P1374, DOI 10.1126/science.1098845; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2005, J BIOL CHEM, V280, P6423, DOI 10.1074/jbc.M411089200; Nilius B, 2004, J PHYSIOL-LONDON, V560, P753, DOI 10.1113/jphysiol.2004.070839; Nilius B, 2004, PFLUG ARCH EUR J PHY, V448, P70, DOI 10.1007/s00424-003-1221-x; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Prawitt D, 2003, P NATL ACAD SCI USA, V100, P15166, DOI 10.1073/pnas.2334624100; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Ullrich ND, 2005, CELL CALCIUM, V37, P267, DOI 10.1016/j.ceca.2004.11.001; Vennekens R, 2001, J PHYSIOL-LONDON, V530, P183, DOI 10.1111/j.1469-7793.2001.0183l.x; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2004, J BIOL CHEM, V279, P15223, DOI 10.1074/jbc.M312076200; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200	30	99	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22899	22906		10.1074/jbc.M501686200	http://dx.doi.org/10.1074/jbc.M501686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845551	Green Published, hybrid			2022-12-25	WOS:000229741800043
J	Kraman, M; McCright, B				Kraman, M; McCright, B			Functional conservation of Notch1 and Notch2 intracellular domains	FASEB JOURNAL			English	Article						ICD; PEST; CSL	ANKYRIN REPEATS; CELL FATE; SEL-10; MICE; MUTATION; PROTEOLYSIS; RECEPTORS; PATHWAYS; DEFECTS; PROTEIN	The Notch receptor is a key component of a highly conserved signaling pathway that regulates cell fate determination during development. In Drosophila, where Notch signaling was first identified and studied, there is only one Notch receptor. In contrast, mammals have four Notch receptor genes, Notch1-4. Notch1 and Notch2 are both required for embryo viability, are widely expressed in mammals, and are structurally conserved. It is presently unknown if these two receptors are functionally redundant or if they have unique capabilities related to differences in their amino acid sequences. In contrast to the rest of the molecule, the amino acid sequences of a large region of the Notch intracellular domain are not highly conserved and thus may be able to interact with distinct transcription factors and mediate the expression of different sets of genes. To determine if the function of this region is conserved, the last 426 amino acids of the Notch2 receptor have been replaced with the corresponding region of Notch1 in mice by using gene targeting. We have determined that even though the amino acid sequences of this region are only 37% identical (137/426), the C-terminal region of the Notch1 intracellular domain can functionally replace that of Notch2 in vivo.	US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	McCright, B (corresponding author), US FDA, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA.	mccright@cber.fda.gov		Kraman, Matthew/0000-0002-5040-0067				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Foltz DR, 2001, BIOCHEM BIOPH RES CO, V286, P484, DOI 10.1006/bbrc.2001.5421; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kile BT, 2003, MAMM GENOME, V14, P81, DOI 10.1007/s00335-002-2160-0; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; McCright B, 2001, DEVELOPMENT, V128, P491; McCright B, 2002, DEVELOPMENT, V129, P1075; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ramain P, 2001, CURR BIOL, V11, P1729, DOI 10.1016/S0960-9822(01)00562-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	32	22	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					1311	+		10.1096/fj.04-3407fje	http://dx.doi.org/10.1096/fj.04-3407fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15897231				2022-12-25	WOS:000229602600012
J	Lu, Z; Rowe, SP; Brennan, BB; Davis, SE; Metzler, RE; Nau, JJ; Majmudar, CY; Mapp, AK; Ansari, AZ				Lu, Z; Rowe, SP; Brennan, BB; Davis, SE; Metzler, RE; Nau, JJ; Majmudar, CY; Mapp, AK; Ansari, AZ			Unraveling the mechanism of a potent transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; PROLINE UTILIZATION PATHWAY; SACCHAROMYCES-CEREVISIAE; GENE ACTIVATION; TRANSACTIVATION DOMAIN; TUMOR-SUPPRESSOR; YEAST; PROTEIN; MEDIATOR; GALACTOSE	Despite their enormous potential as novel research tools and therapeutic agents, artificial transcription factors (ATFs) that up-regulate transcription robustly in vivo remain elusive. In investigating an ATF that does function exceptionally well in vivo, we uncovered an unexpected relationship between transcription function and a binding interaction between the activation domain and an adjacent region of the DNA binding domain. Disruption of this interaction leads to complete loss of function in vivo, even though the activation domain is still able to bind to its target in the transcriptional machinery. We propose that this interaction parallels those between natural activation domains and their regulatory proteins, concealing the activation domain from solvent and the cellular milieu until it binds to its transcriptional machinery target. Inclusion of this property in the future design of ATFs should enhance their efficacy in vivo.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Genome Ctr, Madison, WI 53706 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan	Ansari, AZ (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.	ansari@biochem.wisc.edu	, Dr Anna Mapp/GPX-8261-2022; Ansari, Aseem/AAF-4945-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863, R01GM065330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65330, GM07863] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Ansari AZ, 2002, CURR OPIN CHEM BIOL, V6, P765, DOI 10.1016/S1367-5931(02)00377-0; Ansari AZ, 2002, P NATL ACAD SCI USA, V99, P14706, DOI 10.1073/pnas.232573899; Ansari AZ, 1998, P NATL ACAD SCI USA, V95, P13543, DOI 10.1073/pnas.95.23.13543; Ansari AZ, 2001, CHEM BIOL, V8, P583, DOI 10.1016/S1074-5521(01)00037-0; Ansari AZ, 2001, CURR ORG CHEM, V5, P903, DOI 10.2174/1385272013375139; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Buskirk AR, 2003, CHEM BIOL, V10, P533, DOI 10.1016/S1074-5521(03)00109-1; Chan WC, 2000, FMOC SOLID PHASE PEP; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; des Etages SAG, 2001, MOL MICROBIOL, V40, P890, DOI 10.1046/j.1365-2958.2001.02432.x; desEtages SAG, 1996, GENETICS, V142, P1069; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Frangioni JV, 2000, NAT BIOTECHNOL, V18, P1080, DOI 10.1038/80280; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Han Y, 2000, J BIOL CHEM, V275, P14979, DOI 10.1074/jbc.275.20.14979; Hidalgo P, 2001, GENE DEV, V15, P1007, DOI 10.1101/gad.873901; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Jeong CJ, 2001, BIOCHEMISTRY-US, V40, P9421, DOI 10.1021/bi010011k; KIM M, 1991, J CHROMATOGR, V585, P45, DOI 10.1016/0021-9673(91)85055-K; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Kuznetsova S, 1999, NUCLEIC ACIDS RES, V27, P3995, DOI 10.1093/nar/27.20.3995; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Liu B, 2003, CHEM BIOL, V10, P909, DOI 10.1016/j.chembiol.2003.09.008; Liu QL, 2001, J BIOL CHEM, V276, P6112, DOI 10.1074/jbc.M009519200; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Lu XY, 2000, P NATL ACAD SCI USA, V97, P1988, DOI 10.1073/pnas.040573197; Lu Z, 2002, P NATL ACAD SCI USA, V99, P8591, DOI 10.1073/pnas.092263499; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Mapp AK, 2003, ORG BIOMOL CHEM, V1, P2217, DOI 10.1039/b302656f; Mapp AK, 2000, P NATL ACAD SCI USA, V97, P3930, DOI 10.1073/pnas.97.8.3930; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Ptashne M, 2001, GENES SIGNALS; Saha S, 2003, NUCLEIC ACIDS RES, V31, P1565, DOI 10.1093/nar/gkg227; Sellick CA, 2003, EMBO J, V22, P5147, DOI 10.1093/emboj/cdg480; Sengupta DJ, 1999, RNA, V5, P596, DOI 10.1017/S1355838299002113; SHIN EJ, 1997, THESIS HARVARD U CAM; Sil AK, 1999, MOL CELL BIOL, V19, P7828; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; Wang D, 1999, J BIOL CHEM, V274, P19017, DOI 10.1074/jbc.274.27.19017; Wu ZQ, 2003, J AM CHEM SOC, V125, P12390, DOI 10.1021/ja036685v; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	62	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2005	280	33					29689	29698		10.1074/jbc.M504895200	http://dx.doi.org/10.1074/jbc.M504895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	954SX	15886204	hybrid			2022-12-25	WOS:000231176200039
J	Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T				Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T			Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes	ONCOGENE			English	Article						PEDF; p53; p73; p63; differentiation	ADENOVIRUS-MEDIATED TRANSFER; SPONTANEOUS TUMORS; CDNA MICROARRAY; CANCER-CELLS; P73; P63; APOPTOSIS; NEUROBLASTOMA; ANGIOGENESIS; HOMOLOG	p63 and p73 show a high degree of structural homology to p53 and are members of a family of transcriptional factors that can activate transcription of p53-responsive genes. p53 is mutated in more than 50% of human cancers, whereas p63 and p73 are rarely mutated. Studies of knockout mice also revealed an unexpected functional diversity among the p53 family. To determine how p63 and p73 are involved in tumorigenesis and normal development, we used cDNA microarray to examine 9216 genes in human colorectal cancer cells. We discovered that the expression of pigment epithelium-derived factor (PEDF) was specifically induced by either p63 or p73, but not by p53. We also report here that the PEDF gene contains a response element specific for p63 and p73 in its promoter region and is a direct target of p63 and p73. Collectively, p63 and p73 may be involved in cell fate by inducing PEDF expression.	Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo	Tokino, T (corresponding author), Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Crawford SE, 2001, J CELL SCI, V114, P4421; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	40	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5131	5136		10.1038/sj.onc.1208695	http://dx.doi.org/10.1038/sj.onc.1208695			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856012				2022-12-25	WOS:000230816900013
J	Bukys, MA; Blum, MA; Kim, PY; Brufatto, N; Nesheim, ME; Kalafatis, M				Bukys, MA; Blum, MA; Kim, PY; Brufatto, N; Nesheim, ME; Kalafatis, M			Incorporation of factor Va into prothrombinase is required for coordinated cleavage of prothrombin by factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; ACTIVATED PROTEIN-C; COAGULATION FACTOR-XA; BOVINE FACTOR XA; PHOSPHOLIPID-VESICLES; CRYSTAL-STRUCTURE; ALPHA-THROMBIN; HEAVY-CHAIN; COMPLEX; BINDING	Prothrombin is activated to thrombin by two sequential factor Xa-catalyzed cleavages, at Arg(271) followed by cleavage at Arg(320). Factor Va, along with phospholipid and Ca2+, enhances the rate of the process by 300,000-fold, reverses the order of cleavages, and directs the process through the meizothrombin pathway, characterized by initial cleavage at Arg320. Previous work indicated reduced rates of prothrombin activation with recombinant mutant factor Va defective in factor Xa binding (E323F/Y324F and E330M/V331I, designated factor Va(FF/MI)). The present studies were undertaken to determine whether loss of activity can be attributed to selective loss of efficiency at one or both of the two prothrombin-activating cleavage sites. Kinetic constants for the overall activation of prothrombin by prothrombinase assembled with saturating concentrations of recombinant mutant factor Va were calculated, prothrombin activation was assessed by SDS-PAGE, and rate constants for both cleavages were analyzed from the time course of the concentration of meizothrombin. Prothrombinase assembled with factor Va(FF/MI) had decreased k(cat) for prothrombin activation with K-m remaining unaffected. Prothrombinase assembled with saturating concentrations of factor Va(FF/MI) showed significantly lower rate for cleavage of plasma-derived prothrombin at Arg(320) than prothrombinase assembled with saturating concentrations of wild type factor Va. These results were corroborated by analysis of cleavage of recombinant prothrombin mutants rMz-II (R155A/R284A/R271A) and rP2-II (R155A/R284A/R320A), which can be cleaved only at Arg(320) or Arg(271), respectively. Time courses of these mutants indicated that mutations in the factor Xa binding site of factor Va reduce rates for both bonds. These data indicate that the interaction of factor Xa with the heavy chain of factor Va strongly influences the catalytic activity of the enzyme resulting in increased rates for both prothrombin-activating cleavages.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	University System of Ohio; Cleveland State University; Queens University - Canada; Cleveland Clinic Foundation	Kalafatis, M (corresponding author), Cleveland State Univ, Dept Chem, 2121 Euclid Ave,Sci Bldg SR370, Cleveland, OH 44115 USA.	m.kalafatis@csuohio.edu	Kim, Paul/GYV-3258-2022	Kim, Paul/0000-0003-0943-4924	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073343, P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6, 5R01HL-073343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Brufatto N, 2003, J BIOL CHEM, V278, P6755, DOI 10.1074/jbc.M206413200; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; CAMIRE RM, 1998, BIOCHEMISTRY-US, V37, P20527; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Degen SJF, 1998, CRIT REV EUKAR GENE, V8, P203, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.60; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; DUNWIDDIE CT, 1992, BIOCHEMISTRY-US, V31, P12126, DOI 10.1021/bi00163a022; ESMON CT, 1973, BIOCHIM BIOPHYS ACTA, V310, P289, DOI 10.1016/0005-2795(73)90034-2; ESMON CT, 1974, J BIOL CHEM, V249, P606; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; Kalafatis M, 2001, J BIOL CHEM, V276, P18614, DOI 10.1074/jbc.M007134200; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; Mildvan AS, 2004, BIOCHEMISTRY-US, V43, P14517, DOI 10.1021/bi048052e; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; OWEN WG, 1974, J BIOL CHEM, V249, P594; ROSING J, 1980, J BIOL CHEM, V255, P274; Singh LS, 2003, J BIOL CHEM, V278, P28335, DOI 10.1074/jbc.M300233200; SKRZYPCZAKJANKUN E, 1989, J MOL BIOL, V206, P755, DOI 10.1016/0022-2836(89)90582-2; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	57	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27393	27401		10.1074/jbc.M503435200	http://dx.doi.org/10.1074/jbc.M503435200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15897196	Green Published, hybrid			2022-12-25	WOS:000230589500090
J	Parmar, KM; Nambudiri, V; Dai, GH; Larman, HB; Gimbrone, MA; Garcia-Cardena, G				Parmar, KM; Nambudiri, V; Dai, GH; Larman, HB; Gimbrone, MA; Garcia-Cardena, G			Statins exert endothelial atheroprotective effects via the KLF2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE INHIBITORS; C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; NATRIURETIC PEPTIDE; IN-VITRO; EXPRESSION; INFLAMMATION; CELLS; ATHEROSCLEROSIS	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, statins, have been shown to positively impact vascular function independent of their plasma lipid-lowering action. Several of these beneficial effects involve modulation of gene expression. Here we explored whether the transcription factor Kruppel-like factor 2 (KLF2), a biomechanically activated gene we recently identified as part of the endothelial "atheroprotective phenotype," is regulated by statins and whether this mechanism is important for the non-lipid lowering beneficial effects mediated by these drugs in endothelium. The mRNA levels of KLF2 in human umbilical vein endothelial cells increased in the presence of various statins. KLF2 induction was observed within 8 h after drug treatment and remained elevated for at least 24 h. This statin effect on KLF2 expression was reversed by addition of mevalonate and its downstream metabolite geranygeranyl pyrophosphate. Furthermore, inhibition of protein geranylgeranylation with GGTI-298 significantly induced KLF2 levels, whereas inhibition of farnesylation did not. Statin-mediated KLF2 expression was followed by the up-regulation of several of its downstream transcriptional targets. Using small interfering RNA to block KLF2 expression, we demonstrated that this transcription factor is necessary for the statin-mediated regulation of several pathophysiologically relevant genes. These results strongly implicate KLF2 as a transcriptional regulator of the statin-mediated effects in vascular endothelium and provide a novel mechanism for the well established non-lipid lowering beneficial cardiovascular effects of statins.	Harvard Univ, Sch Med, Dept Pathol, Ctr Excellence Vasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Garcia-Cardena, G (corresponding author), 77 Ave Louis Pasteur,NRB-730C, Boston, MA 02115 USA.	guillermo_garcia-cardena@hms.harvard.edu	Garcia-Cardena, Guillermo/Q-6649-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028, P50HL056985, R01HL076686] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL36028, P50-HL56985, R01-HL076686] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2002, CIRCULATION, V106, P1390, DOI 10.1161/01.CIR.0000028465.52694.9B; Aikawa M, 2001, CIRCULATION, V103, P276; Albert MA, 2003, CIRCULATION, V108, P161, DOI 10.1161/01.CIR.0000080289.72166.CF; Blanco-Colio LM, 2003, CIRCULATION, V108, P1506, DOI 10.1161/01.CIR.0000089086.48617.2B; Bourcier T, 2000, ARTERIOSCL THROM VAS, V20, P556, DOI 10.1161/01.ATV.20.2.556; Chauhan SD, 2003, P NATL ACAD SCI USA, V100, P1426, DOI 10.1073/pnas.0336365100; Dai GH, 2004, P NATL ACAD SCI USA, V101, P14871, DOI 10.1073/pnas.0406073101; Davignon J, 2004, CIRCULATION, V109, P39, DOI 10.1161/01.CIR.0000131517.20177.5a; Davignon J, 2004, CIRCULATION, V109, P27, DOI 10.1161/01.CIR.0000131515.03336.f8; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; Garcia MJ, 2003, METHOD FIND EXP CLIN, V25, P457; Harris MB, 2004, AM J PHYSIOL-HEART C, V287, pH560, DOI 10.1152/ajpheart.00214.2004; Hernandez-Perera O, 1998, J CLIN INVEST, V101, P2711, DOI 10.1172/JCI1500; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2001, AM J CARDIOL, V88, P1306, DOI 10.1016/S0002-9149(01)02095-1; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Masamura K, 2003, ARTERIOSCL THROM VAS, V23, P512, DOI 10.1161/01.ATV.0000060461.64771.F0; McVeigh Gary E, 2003, Curr Diab Rep, V3, P87, DOI 10.1007/s11892-003-0059-0; Morikawa Shigeru, 2004, J Atheroscler Thromb, V11, P62; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; Ohno N, 2002, CIRCULATION, V105, P1623, DOI 10.1161/01.CIR.0000014985.50017.6E; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Qian JY, 2002, CIRC RES, V91, P1063, DOI 10.1161/01.RES.0000043631.25915.E6; Ridker PM, 2004, CIRCULATION, V109, P6, DOI 10.1161/01.CIR.0000133444.17867.56; Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Russo G, 2002, VASC PHARMACOL, V38, P259, DOI 10.1016/S1537-1891(02)00250-1; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Scotland RS, 2005, PHARMACOL THERAPEUT, V105, P85, DOI 10.1016/j.pharmthera.2004.08.011; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Stein E, 1999, AM J CARDIOL, V83, P1433, DOI 10.1016/S0002-9149(99)00120-4	40	171	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26714	26719		10.1074/jbc.C500144200	http://dx.doi.org/10.1074/jbc.C500144200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15878865	hybrid			2022-12-25	WOS:000230589500011
J	Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F				Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F			Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A	ONCOGENE			English	Article						valproic acid; trichostatin A; oestrogen signalling; sirtuin; transcriptional repression	BREAST-CANCER CELLS; HISTONE DEACETYLASE; SODIUM-BUTYRATE; PROTEASOMAL DEGRADATION; DNA METHYLATION; ER-ALPHA; EXPRESSION; EPILEPSY; TARGET; WOMEN	Valproate (VPA) and trichostatin A (TSA), inhibitors of zinc-dependent deacetylase activity, induce reduction in the levels of mRNA encoding oestrogen receptor-alpha (ER alpha), resulting in subsequent clearance of ER alpha protein from breast and ovarian cell lines. Inhibition of oestrogen signalling may account for the endocrine disorders, menstrual abnormalities, osteoporosis and weight gain that occur in a proportion of women treated with VPA for epilepsy or for bipolar mood disorder. Transcriptome pro. ling revealed that VPA and TSA also modulate the expression of, among others, key regulatory components of the cell cycle. Meta-analysis of genes directly responsive to oestrogen indicates that VPA and TSA have a generally antioestrogenic profile in ER alpha positive cells. Concomitant treatment with cycloheximide prevented most of these changes in gene expression, including downregulation of ER alpha mRNA, indicating that a limited number of genes signal a hyperacetylated state within cells. Three members of the NAD-dependent deacetylases, the sirtuins, are upregulated by VPA and by TSA and sirtuin activity contributes to loss of ER alpha expression. However, prolonged inhibition of the sirtuins by sirtinol also induces loss of ER alpha from cells. Mechanistically, we show that VPA invokes reversible promoter shutoff of the ER alpha, pS2 and cyclin D1 promoters, by inducing recruitment of methyl cytosine binding protein 2 (MeCP2) with concomitant exclusion of the maintenance methylase DNMT1. Furthermore, we demonstrate that, in the presence of VPA, local DNA methylation, deacetylation and demethylation of activated histones and recruitment of inhibitory complexes occurs on the pS2 promoter.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Genome Inst Singapore, Singapore 138672, Singapore	European Molecular Biology Laboratory (EMBL); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Reid, G (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	george.reid@embl.de	Liu, Edison/C-4141-2008; Gannon, Frank/G-1194-2015	Lin, Chin-Yo/0000-0002-4461-6216; Reid, George/0000-0002-0298-693X; Benes, Vladimir/0000-0002-0352-2547				Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Clarke M, 1998, LANCET, V351, P1451; Cuzick J, 2002, LANCET, V360, P817; Davis T, 2000, CLIN CANCER RES, V6, P4334; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; Duncan S, 2001, EPILEPSIA, V42, P60, DOI 10.1046/j.1528-1157.2001.042suppl.3060.x; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Green PS, 2000, ANN NY ACAD SCI, V924, P93; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; Kim MS, 2003, CANCER RES, V63, P7291; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KUEBAYASHI J, 2003, BREAST CANC, V10, P112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lombardi G, 2001, MOL CELL ENDOCRINOL, V178, P51, DOI 10.1016/S0303-7207(01)00420-8; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; Luef G, 2002, METABOLISM, V51, P1274, DOI 10.1053/meta.2002.34708; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Munster PN, 2001, CANCER RES, V61, P8492; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NELSON JE, 1992, ANAL BIOCHEM, V207, P197, DOI 10.1016/0003-2697(92)90523-A; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Donovan C, 2002, J CLIN PSYCHIAT, V63, P322, DOI 10.4088/JCP.v63n0409; PARKER MI, 1986, J BIOL CHEM, V261, P2786; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Rattya J, 2001, NEUROLOGY, V57, P440, DOI 10.1212/WNL.57.3.440; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rosano GMC, 2001, INT J FERTIL WOMEN M, V46, P248; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Tran CP, 1998, AM J PHYSIOL-GASTR L, V275, pG85, DOI 10.1152/ajpgi.1998.275.1.G85; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	51	133	136	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 21	2005	24	31					4894	4907		10.1038/sj.onc.1208662	http://dx.doi.org/10.1038/sj.onc.1208662			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15870696				2022-12-25	WOS:000230646500003
J	Ricci, G; De Maria, F; Antonini, G; Turella, P; Bullo, A; Stella, L; Filomeni, G; Federici, G; Caccuri, AM				Ricci, G; De Maria, F; Antonini, G; Turella, P; Bullo, A; Stella, L; Filomeni, G; Federici, G; Caccuri, AM			7-nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases - Mechanism of action of potential anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL PATHWAYS; CELL-LINES; IDENTIFICATION; RAT; SUBSTITUTION; SIMULATION; CONJUGATE; TRANSPORT; DYNAMICS; PROGRAM	Spectroscopic and rapid kinetic experiments were performed to detail the interaction of human glutathione S-transferases GSTA1-1, GSTM2-2, and GSTP1-1 with 6-(7-nitro- 2,1,3-benzoxadiazol-4-ylthio) hexanol ( NBDHEX). This compound is a representative molecule of a new class of 7-nitro- 2,1,3-benzoxadiazole (NBD) derivatives (non-GSH peptidomimetic compounds) that have been designed both to give strong GST inhibition and to accumulate in tumor cells avoiding the extrusion mechanisms mediated by the multidrug resistance protein pumps. We have recently shown that submicromolar amounts of NBDHEX trigger apoptosis in several human tumor cell lines through the dissociation of the JNK (.) GSTP1-1 complex ( Turella, P., Cerella, C., Filomeni, G., Bullo, A., De Maria, F., Ghibelli, L., Ciriolo, M. R., Cianfriglia, M., Mattei, M., Federici, G., Ricci, G., and Caccuri, A. M. ( 2005) Cancer Res. 65, 3751-3761). Results reported in the present study indicated that NBDHEX behaves like a suicide inhibitor for GSTs. It bound to the H-site and was conjugated with GSH forming a sigma complex at the C-4 of the benzoxadiazole ring. This complex was tightly stabilized in the active site of GSTP1-1 and GSTM2-2, whereas in GSTA1-1 the release of the 6- mercapto1-hexanol from the sigma complex was the favored event. Docking studies demonstrated the likely localization of the sigma complex in the GST active sites and provide a structural explanation for its strong stabilization.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Rome Roma Tre, Dept Biol, I-00146 Rome, Italy; IRCCS, Childrens Hosp Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Roma Tre University; IRCCS Bambino Gesu	Caccuri, AM (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	caccuri@uniroma2.it	Stella, Lorenzo/A-7996-2010; CACCURI, ANNA MARIA/AFU-2643-2022	Stella, Lorenzo/0000-0002-5489-7381; CACCURI, ANNA MARIA/0000-0002-3756-4163; Filomeni, Giuseppe/0000-0002-2719-1412; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Antonini G, 1996, BIOCHEM J, V314, P533, DOI 10.1042/bj3140533; BICO P, 1994, BIOCHEM MOL BIOL INT, V33, P887; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; CARMPTON MR, 2002, J CHEM SOC P2, P257; Crampton MR, 2003, ORG BIOMOL CHEM, V1, P3438, DOI 10.1039/b307648m; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; Habig W H, 1981, Methods Enzymol, V77, P398; HENDLER RW, 1994, J BIOCHEM BIOPH METH, V28, P1, DOI 10.1016/0165-022X(94)90061-2; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Schultz M, 1997, ADV DRUG DELIVER REV, V26, P91, DOI 10.1016/S0169-409X(97)00029-X; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tew KD, 1996, MOL PHARMACOL, V50, P149; Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1	34	115	119	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26397	26405		10.1074/jbc.M503295200	http://dx.doi.org/10.1074/jbc.M503295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888444	hybrid			2022-12-25	WOS:000230386800055
J	Briozzo, P; Evrin, C; Meyer, P; Assairi, L; Joly, N; Barzu, O; Gilles, AM				Briozzo, P; Evrin, C; Meyer, P; Assairi, L; Joly, N; Barzu, O; Gilles, AM			Structure of Escherichia coli UMP kinase differs from that of other nucleoside monophosphate kinases and sheds new light on enzyme regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; KEY ENZYME; COMPLEX; BINDING; MUTAGENESIS; FAMILY	Bacterial UMP kinases are essential enzymes involved in the multistep synthesis of nucleoside triphosphates. They are hexamers regulated by the allosteric activator GTP and inhibited by UTP. We solved the crystal structure of Escherichia coli UMP kinase bound to the UMP substrate (2.3 angstrom resolution), the UDP product (2.6 angstrom), or UTP (2.45 angstrom). The monomer fold, unrelated to that of other nucleoside monophosphate kinases, belongs to the carbamate kinase-like superfamily. However, the phosphate acceptor binding cleft and subunit assembly are characteristic of UMP kinase. Interactions with UMP explain the high specificity for this natural substrate. UTP, previously described as an allosteric inhibitor, was unexpectedly found in the phosphate acceptor site, suggesting that it acts as a competitive inhibitor. Site-directed mutagenesis of residues Thr-138 and Asn-140, involved in both uracil recognition and active site interaction within the hexamer, decreased the activation by GTP and inhibition by UTP. These experiments suggest a cross-talk mechanism between enzyme subunits involved in cooperative binding at the phosphate acceptor site and in allosteric regulation by GTP. As bacterial UMP kinases have no counterpart in eukaryotes, the information provided here could help the design of new antibiotics.	INRA, Inst Natl Agron Paris Grignon, Unite Chim Biol, UMR 206, F-78850 Thiverval Grignon, France; Inst Pasteur, CNRS, Unite Genet Genomes Bacteriens, URA 2171, F-75724 Paris, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Ctr Univ Paris Sud, Inst Curie, F-91405 Orsay, France	AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Briozzo, P (corresponding author), INRA, Inst Natl Agron Paris Grignon, Unite Chim Biol, UMR 206, F-78850 Thiverval Grignon, France.	briozzo@grignon.inra.fr; meyer@lebs.cnrs-gif.fr						Bertrand T, 2002, J MOL BIOL, V315, P1099, DOI 10.1006/jmbi.2001.5286; BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briozzo P, 1998, STRUCTURE, V6, P1517, DOI 10.1016/S0969-2126(98)00150-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bucurenci N, 1998, J BACTERIOL, V180, P473, DOI 10.1128/JB.180.3.473-477.1998; Crowe J, 1994, Methods Mol Biol, V31, P371; DELANE WL, 2002, PYMOL MOL GRAPHICS S; Fassy F, 2004, BIOCHEM J, V384, P619, DOI 10.1042/BJ20040440; Gagyi C, 2003, EUR J BIOCHEM, V270, P3196, DOI 10.1046/j.1432-1033.2003.03702.x; Gil-Ortiz F, 2003, J MOL BIOL, V331, P231, DOI 10.1016/S0022-2836(03)00716-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Marco-Marin C, 2005, BBA-PROTEINS PROTEOM, V1747, P271, DOI 10.1016/j.bbapap.2004.11.010; MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140; MUNIER H, 1991, EUR J BIOCHEM, V196, P469, DOI 10.1111/j.1432-1033.1991.tb15838.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWAKI Z, 1993, DENZO FILM PROCESSIN; Picard V, 1997, Methods Mol Biol, V67, P183; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; ROUSSEL A, 1989, SILICON GRAPHICS GEO, V77; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; Serina L, 1996, BIOCHEMISTRY-US, V35, P7003, DOI 10.1021/bi960062v; SMALLSHAW JD, 1992, LIFE SCI ADV, V11, P59; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Tock MR, 2003, EMBO J, V22, P995, DOI 10.1093/emboj/cdg098; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; YAMANAKA K, 1992, J BACTERIOL, V174, P7517, DOI 10.1128/JB.174.23.7517-7526.1992; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	40	45	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25533	25540		10.1074/jbc.M501849200	http://dx.doi.org/10.1074/jbc.M501849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15857829	hybrid			2022-12-25	WOS:000230207900030
J	Vargas, MR; Pehar, M; Cassina, P; Martinez-Palma, L; Thompson, JA; Beckman, JS; Barbeito, L				Vargas, MR; Pehar, M; Cassina, P; Martinez-Palma, L; Thompson, JA; Beckman, JS; Barbeito, L			Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT-RESPONSE ELEMENT; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON APOPTOSIS; NAD(P)H-QUINONE OXIDOREDUCTASE1 GENE; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; EXTRACELLULAR APPEARANCE; REGULATORY MECHANISMS; SUPEROXIDE-DISMUTASE	Fibroblast growth factor-1 (FGF-1) is highly expressed in motor neurons and can be released in response to sublethal cell injury. Because FGF-1 potently activates astroglia and exerts a direct neuroprotection after spinal cord injury or axotomy, we examined whether it regulated the expression of inducible and cytoprotective heme oxygenase-1 (HO-1) enzyme in astrocytes. FGF-1 induced the expression of HO-1 in cultured rat spinal cord astrocytes, which was dependent on FGF receptor activation and prevented by cycloheximide. FGF-1 also induced Nrf2 mRNA and protein levels and prompted its nuclear translocation. HO-1 induction was abolished by transfection of astrocytes with a dominant-negative mutant Nrf2, indicating that FGF-1 regulates HO-1 expression through Nrf2. FGF-1 also modified the expression of other antioxidant genes regulated by Nrf2. Both Nrf2 and HO-1 levels were increased and co-localized with reactive astrocytes in the degenerating lumbar spinal cord of rats expressing the amyotrophic lateral sclerosis-linked SOD1 G93A mutation. Overexpression of Nrf2 in astrocytes increased survival of co-cultured embryonic motor neurons and prevented motor neuron apoptosis mediated by nerve growth factor through p75 neurotrophin receptor. Taken together, these results emphasize the key role of astrocytes in determining motor neuron fate in amyotrophic lateral sclerosis.	Inst Invest Biol Clemente Estable, Dept Neurobiol Celular & Mol, Montevideo 11600, Uruguay; Univ Republica, Fac Med, Dept Histol, Montevideo 11800, Uruguay; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Oregon State Univ, Dept Biochem & Biophys, Linus Pauling Inst, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA	Instituto de Investigaciones Biologicas Clemente Estable Uruguay; Universidad de la Republica, Uruguay; University of Alabama System; University of Alabama Birmingham; Oregon State University	Barbeito, L (corresponding author), Inst Clemente Estable, Av Italia 3318, Montevideo 11600, Uruguay.	lbarb@iibce.edu.uy		Martinez-Palma, Laura/0000-0002-1094-5409; Barbeito, Luis/0000-0002-3047-232X; Vargas, Marcelo/0000-0003-1039-4210	FOGARTY INTERNATIONAL CENTER [R03TW006482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW006482] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Beckman JS, 2001, TRENDS NEUROSCI, V24, pS15, DOI 10.1016/S0166-2236(00)01981-0; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Carreira CM, 2001, GROWTH FACTORS, V18, P277, DOI 10.3109/08977190109029116; Cassina P, 2005, J NEUROCHEM, V93, P38, DOI 10.1111/j.1471-4159.2004.02984.x; Cassina P, 2002, J NEUROSCI RES, V67, P21, DOI 10.1002/jnr.10107; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; CUEVAS P, 1995, NEUROL RES, V17, P396, DOI 10.1080/01616412.1995.11740350; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; Dwyer BE, 1998, EXP NEUROL, V150, P206, DOI 10.1006/exnr.1997.6763; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Fauconneau B, 2002, J NEUROCHEM, V83, P1338, DOI 10.1046/j.1471-4159.2002.01230.x; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Gong PF, 2004, ARCH BIOCHEM BIOPHYS, V432, P252, DOI 10.1016/j.abb.2004.09.024; Henderson C.E., 1995, NERVE CELL CULTURE P, P69; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; KERN JC, 2004, 7063 SOC NEUR; Kitamura Y, 1998, GLIA, V22, P138; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; LAIRD JMA, 1995, NEUROSCIENCE, V65, P209, DOI 10.1016/0306-4522(94)00465-H; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; Mehindate K, 2001, J NEUROCHEM, V77, P1386, DOI 10.1046/j.1471-4159.2001.00354.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Opalenik SR, 1998, ARCH BIOCHEM BIOPHYS, V351, P17, DOI 10.1006/abbi.1997.0566; Ornitz DM, 2001, GENOME BIOL, V2; Panek RL, 1998, J PHARMACOL EXP THER, V286, P569; Pehar M, 2004, J NEUROCHEM, V89, P464, DOI 10.1111/j.1471-4159.2004.02357.x; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P587, DOI 10.1089/15230860260220085; Saneto RP., 1987, NEUROCHEMISTRY PRACT, P27; Sankaranarayanan K, 2004, J BIOL CHEM, V279, P50810, DOI 10.1074/jbc.M404984200; Scapagnini G, 2002, BRAIN RES, V954, P51, DOI 10.1016/S0006-8993(02)03338-3; Schipper HM, 2004, FREE RADICAL BIO MED, V37, P1995, DOI 10.1016/j.freeradbiomed.2004.09.015; Schipper HM, 1999, J NEUROCHEM, V72, P1802, DOI 10.1046/j.1471-4159.1999.0721802.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Takeda A, 2004, ANTIOXID REDOX SIGN, V6, P888, DOI 10.1089/ars.2004.6.888; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; WALICKE PA, 1988, J NEUROSCI, V8, P2618; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	71	115	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25571	25579		10.1074/jbc.M501920200	http://dx.doi.org/10.1074/jbc.M501920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15870071	hybrid			2022-12-25	WOS:000230207900035
J	Gantt, K; Cherry, J; Tenney, R; Karschner, V; Pekala, PH				Gantt, K; Cherry, J; Tenney, R; Karschner, V; Pekala, PH			An early event in adipogenesis, the nuclear selection of the CCAAT enhancer-binding protein beta (C/EBP beta) mRNA by HuR and its translocation to the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; ADIPOCYTE DIFFERENTIATION; 3T3-L1 ADIPOCYTES; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; ADIPOSE-TISSUE; GENE PROMOTER; IN-VIVO; EXPRESSION; STABILITY	HuR is a ligand for nuclear mRNAs containing adenylate-uridylate-rich elements in the 3'-untranslated region. Once bound to the mRNA, HuR is recognized by adapter proteins that then facilitate nuclear export of the complex. In the cytosol, HuR is thought to function to control stability and translation of its ligand message. In the 3T3-L1 cells HuR is constitutively expressed and localized predominantly to the nucleus in the preadipocytes. However, within 30 min of exposure to the differentiation stimulus the HuR content in the cytosol increases, consistent with HuR regulating the availability of relevant mRNAs for translation. Using in vitro RNA gel shifts, we have demonstrated that the CCAAT enhancer-binding protein beta (C/EBP beta) message is a ligand for HuR. Within 2 h of initiation of the differentiation process, HuR complexes containing C/EBP beta mRNA could be isolated from the cytosolic compartment. Importantly, the process appears to be highly selective, as cyclin D1, which contains a putative HuR binding site and is expressed on the same time frame as C/EBP beta, was not found in the immunoprecipitated messenger ribonucleoprotein complexes. The proximity of this event to adipogenic stimuli and the importance of C/EBP beta to the differentiation process have led us to hypothesize a role for HuR in the regulation of the onset of adipogenesis. In support of this hypothesis, small interfering RNA suppression of HuR protein content resulted in an inhibition of C/EBP beta protein expression and an attenuation of the differentiation process.	E Carolina Univ, Brody Sch Med, Dept Biochem & Mol Biol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University	Pekala, PH (corresponding author), E Carolina Univ, Brody Sch Med, Dept Biochem & Mol Biol, 600 Moye Blvd, Greenville, NC 27858 USA.	pekalap@mail.ecu.edu			NIDDK NIH HHS [DK55169] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akamatsu W, 2005, P NATL ACAD SCI USA, V102, P4625, DOI 10.1073/pnas.0407523102; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; COLE KA, 2004, AM J PHYSIOL, V268, pC349; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gantt KR, 2004, BIOCHEM BIOPH RES CO, V313, P619, DOI 10.1016/j.bbrc.2003.11.162; GANTT KR, 2003, P KEYST S RNA TRAFF, P47; Gnudi L, 1996, P NUTR SOC, V55, P191, DOI 10.1079/PNS19960020; Habinowski SA, 2001, BIOCHEM BIOPH RES CO, V286, P852, DOI 10.1006/bbrc.2001.5484; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rosen ED, 2000, GENE DEV, V14, P1293; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Sprott KM, 2002, BIOCHEM J, V365, P181, DOI 10.1042/BJ20020215; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; VAN RLR, 1976, J CLIN INVEST, V58, P699, DOI 10.1172/JCI108516; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24768	24774		10.1074/jbc.M502011200	http://dx.doi.org/10.1074/jbc.M502011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863502	Green Published, hybrid			2022-12-25	WOS:000230114000059
J	Wiederschain, D; Kawai, H; Shilatifard, A; Yuan, ZM				Wiederschain, D; Kawai, H; Shilatifard, A; Yuan, ZM			Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; P53; REARRANGEMENTS; DOMAIN; CELLS; DEACETYLATION; ACETYLATION; DEGRADATION; ACTIVATION; TERMINUS	Chromosomal translocations involving the mixed lineage leukemia ( MLL) gene are often observed in acute leukemias of both myeloid and lymphocytic origin. Expression of MLL fusion proteins is known to induce malignant transformation of normal blood progenitors; however, molecular mechanisms of this process are still poorly understood. In this study we investigated the effect of several frequently detected MLL fusion proteins on p53 transcriptional activity. Our data show that MLL- AF9, MLL- AF10, MLL- ENL, and MLL- ELL substantially down- regulate p53- mediated induction of p21, MDM2, and Bax in response to DNA damage. Furthermore, we identify the reduction in p53 acetylation by p300 as a major mechanism of the inhibitory effect of MLL leukemic fusions. Our data suggest that abrogation of p53 functional activity can be a common feature of MLL fusion- mediated leukemogenesis.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63141 USA	Harvard University; Harvard T.H. Chan School of Public Health; Saint Louis University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Bldg 1,Rm 507,665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu		Kawai, Hidehiko/0000-0003-2213-7166	NCI NIH HHS [R01 CA85679-02] Funding Source: Medline; NIEHS NIH HHS [ES11627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; BOWER M, 1994, BLOOD, V84, P3776, DOI 10.1182/blood.V84.11.3776.bloodjournal84113776; Caslini C, 2000, LEUKEMIA, V14, P1898, DOI 10.1038/sj.leu.2401933; CHEN CS, 1993, BLOOD, V81, P2386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kanda Y, 1998, J BIOL CHEM, V273, P5248, DOI 10.1074/jbc.273.9.5248; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wiederschain D, 2003, MOL CELL BIOL, V23, P4230, DOI 10.1128/MCB.23.12.4230-4246.2003; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286	19	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24315	24321		10.1074/jbc.M412237200	http://dx.doi.org/10.1074/jbc.M412237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851483	hybrid			2022-12-25	WOS:000230114000004
J	Zhao, MY; Soderhall, I; Park, JW; Ma, YG; Osaki, T; Ha, NC; Wu, CF; Soderhall, K; Lee, BL				Zhao, MY; Soderhall, I; Park, JW; Ma, YG; Osaki, T; Ha, NC; Wu, CF; Soderhall, K; Lee, BL			A novel 43-kDa protein as a negative regulatory component of phenoloxidase-induced melanin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; TENEBRIO-MOLITOR LARVAE; PRO-PHENOL-OXIDASE; PROPHENOLOXIDASE-ACTIVATING ENZYME; SERINE-PROTEASE; COLEOPTERAN INSECT; MOLECULAR-CLONING; INNATE IMMUNITY; MANDUCA-SEXTA; DROSOPHILA	The melanization reaction induced by activated phenoloxidase in arthropods is important in the multiple host defense innate immune reactions, leading to the sequestration and killing of invading microorganisms. This reaction ought to be tightly controlled because excessive formation of quinones and systemic hypermelanization are deleterious to the hosts, suggesting that a negative regulator(s) of melanin synthesis may exist in hemolymph. Here, we report the purification and cloning of a cDNA of a novel 43-kDa protein, from the mealworm Tenebrio molitor, which functions as a melanization-inhibiting protein (MIP). The deduced amino acid sequence of 352 residues has no homology to known sequences in protein data bases. When the concentration of the 43-kDa protein was examined by Western blot analysis in a melanin-induced hemolymph prepared by injection of Candida albicans into T. molitor larvae, the 43-kDa protein specifically decreased in the melanin-induced hemolymph compared with control hemolymph. Recombinant MIP expressed in a baculovirus system had an inhibitory effect on melanin synthesis in vitro. RNA interference using a synthetic 445-mer double-stranded RNA of MIP injected into Tenebrio larvae showed that melanin synthesis was markedly induced. These results suggest that this 43-kDa MIP inhibits the formation of melanin and thus is a modulator of the melanization reaction to prevent the insect from excessive melanin synthesis in places where it should be inappropriate.	Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea; Uppsala Univ, Dept Comparat Physiol, Evolut Biol Ctr, SE-75236 Uppsala, Sweden; Shenyang Pharmaceut Univ, Dept Pharmacol, Shenyang 110016, Peoples R China	Pusan National University; Uppsala University; Shenyang Pharmaceutical University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Jie, Ying/AAJ-4697-2021; Soderhall, Irene/AAS-5433-2020	Jie, Ying/0000-0003-4003-2579; Osaki, Tsukasa/0000-0002-9487-3253				Ashida Masaaki, 1998, P135; Briganti S, 2003, PIGM CELL RES, V16, P101, DOI 10.1034/j.1600-0749.2003.00029.x; Cho MY, 1999, EUR J BIOCHEM, V262, P737, DOI 10.1046/j.1432-1327.1999.00416.x; DAQUINAG AC, 1995, P NATL ACAD SCI USA, V92, P2964, DOI 10.1073/pnas.92.7.2964; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Fetchko M, 2002, EMBO J, V21, P1074, DOI 10.1093/emboj/21.5.1074; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Graham LA, 2000, EUR J BIOCHEM, V267, P6452, DOI 10.1046/j.1432-1327.2000.01734.x; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Iwanaga S, 2005, J BIOCHEM MOL BIOL, V38, P128; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Land EJ, 2004, METHOD ENZYMOL, V378, P88; LASPADA AR, 1994, ANN NEUROL, V36, P814, DOI 10.1002/ana.410360604; Lee KM, 2000, EUR J BIOCHEM, V267, P3695, DOI 10.1046/j.1432-1327.2000.01402.x; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liang ZC, 1997, P NATL ACAD SCI USA, V94, P6682, DOI 10.1073/pnas.94.13.6682; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; Seo SY, 2003, J AGR FOOD CHEM, V51, P2837, DOI 10.1021/jf020826f; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; Shimizu K, 2001, LIPIDS, V36, P1321, DOI 10.1007/s11745-001-0847-9; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tsuzuki S, 2001, INSECT BIOCHEM MOLEC, V31, P321, DOI 10.1016/S0965-1748(00)00124-7; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	40	53	56	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24744	24751		10.1074/jbc.M504173200	http://dx.doi.org/10.1074/jbc.M504173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15857824	hybrid			2022-12-25	WOS:000230114000056
J	Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT				Xu, CJ; Shen, GX; Chen, C; Gelinas, C; Kong, ANT			Suppression of NF-kappa B and NF-kappa B-regulated gene expression by sulforaphane and PEITC through I kappa B alpha, IKK pathway in human prostate cancer PC-3 cells	ONCOGENE			English	Article						sulforaphane; phenethyl isothiocyanate; NF-kappa B; I kappa B alpha; IKK	PHENETHYL ISOTHIOCYANATE; TYROSINE PHOSPHORYLATION; INFLAMMATORY STIMULI; SIGNALING PATHWAY; INDUCED APOPTOSIS; POTENT INDUCTION; TERMINAL KINASE; DOWN-REGULATION; UP-REGULATION; ACTIVATION	Recent studies indicate that natural isothiocyanates, such as sulforaphane (SFN) and phenethyl isothiocyanate ( PEITC) possess strong antitumor activities in vitro and in vivo. The nuclear factor kappa B (NF-kappa B) is believed to play an important role in cancer chemoprevention due to its involvement in tumor cell growth, proliferation, angiogenesis, invasion, apoptosis, and survival. In this study, we investigated the effects and the molecular mechanisms of SFN and PEITC on NF-kappa B transcriptional activation and NF-kappa B-regulated gene expression in human prostate cancer PC-3 C4 cells. Treatment with SFN ( 20 and 30 mu M) and PEITC ( 5 and 7.5 mu M) significantly inhibited NF-kappa B transcriptional activity, nuclear transloction of p65, and gene expression of NF-kappa B-regulated VEGF, cylcin D1, and Bcl-X-L in PC- 3 C4 cells. To further elucidate the mechanism, we utilized the dominant-negative mutant of inhibitor of NF-kappa B alpha (I kappa B alpha) (SR-I kappa B alpha). Analogous to treatments with SFN and PEITC, SR-I kappa B alpha also strongly inhibited NF-kappa B transcriptional activity as well as VEGF, cylcin D1, and Bcl-X-L expression. Furthermore, SFN and PEITC also inhibited the basal and UVC-induced phosphorylation of I kappa B alpha and blocked UVC-induced I kappa B alpha degradation in PC-3 C4 cells. In examining the upstream signaling, we found that the dominant-negative mutant of IKK beta (dnIKK beta) possessed inhibitory effects similar to SFN and PEITC on NF-kappa B, VEGF, cylcin D1, Bcl-X-L as well as I kappa B alpha phosphorylation. In addition, treatment with SFN and PEITC potently inhibited phosphorylation of both IKKb and IKK alpha and significantly inhibited the in vitro phosphorylation of I kappa B alpha mediated by IKKb. Taken together, these results suggest that the inhibition of SFN and PEITC on NF-kappa B transcriptional activation as well as NF-kappa B-regulated VEGF, cyclin D1, and Bcl-X-L gene expression is mainly mediated through the inhibition of IKK phosphorylation, particularly IKK beta, and the inhibition of I kappa B alpha phosphorylation and degradation, as well as the decrease of nuclear translocation of p65 in PC-3 cells.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA; Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Kong, ANT (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinghuysen Rd,Room 226, Piscataway, NJ 08854 USA.	kongt@cop.rutgers.edu	Chen, Chi/AAF-5343-2020; Kong, Ah-Ng Tony/AAX-2828-2020; Chen, Chi/B-4618-2008	Chen, Chi/0000-0001-9703-604X; 	NATIONAL CANCER INSTITUTE [R01CA073674, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA54999, R01-CA073674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Bremner P, 2002, J PHARM PHARMACOL, V54, P453, DOI 10.1211/0022357021778637; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Brooks JD, 1999, PROSTATE CANCER P D, V2, pS8, DOI 10.1038/sj.pcan.4500334; Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Chiao JW, 2002, INT J ONCOL, V20, P631; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Gasparian AV, 2002, J CELL SCI, V115, P141; Gasparian AV, 2002, MOL CANCER THER, V1, P1079; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henttu P, 1998, BIOCHEM BIOPH RES CO, V244, P167, DOI 10.1006/bbrc.1998.8238; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Manna SK, 1999, J IMMUNOL, V163, P6800; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586; Singh AV, 2004, CARCINOGENESIS, V25, P83, DOI 10.1093/carcin/bgg178; Srivastava SK, 2004, CARCINOGENESIS, V25, P1701, DOI 10.1093/carcin/bgh179; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Willis MS, 2003, CLIN CHIM ACTA, V330, P57, DOI 10.1016/S0009-8981(03)00048-2; Xiao D, 2002, CANCER RES, V62, P3615	42	252	266	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4486	4495		10.1038/sj.onc.1208656	http://dx.doi.org/10.1038/sj.onc.1208656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856023				2022-12-25	WOS:000230157100002
J	Piantedosi, R; Ghyselinck, N; Blaner, WS; Vogel, S				Piantedosi, R; Ghyselinck, N; Blaner, WS; Vogel, S			Cellular retinol-binding protein type III is needed for retinoid incorporation into milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; VITAMIN-A SUPPLEMENTATION; MAMMARY-GLAND; BREAST-MILK; MOTHERS; ESTERS; ACID; ACYLTRANSFERASE; ESTERIFICATION; LACTATION	The physiologic role(s) of cellular retinol-binding protein (CRBP)-III, an intracellular retinol-binding protein that is expressed solely in heart, muscle, adipose, and mammary tissue, remains to be elucidated. To address this, we have generated and characterized CRBP-III-deficient (CRBP-III-/-) mice. Mice that lack CRBP-III were viable and healthy but displayed a marked impairment in retinoid incorporation into milk. Milk obtained from CRBP-III-/- dams contains significantly less retinyl ester, especially retinyl palmitate, than milk obtained from wild type dams. We demonstrated that retinol bound to CRBP-III is an excellent substrate for lecithin-retinol acyltransferase, the enzyme responsible for catalyzing retinyl ester formation from retinol. Our data indicated that the diminished milk retinyl ester levels arise from impaired utilization of retinol by lecithin-retinol acyltransferase in CRBP-III-/- mice. Interestingly, CRBP-I and CRBP-III each appeared to compensate for the absence of the other, specifically in mammary tissue, adipose tissue, muscle, and heart. For CRBP-III-/- mice, CRBP-I protein levels were markedly elevated in adipose tissue and mammary gland. In addition, in CRBP-I-/- mice, CRBP-III protein levels were elevated in tissues that normally express CRBP-III but were not elevated in other tissues that do not normally express CRBP-III. Our data suggested that CRBP-I and CRBP-III share some physiologic actions within tissues and that each can compensate for the absence of the other to help maintain normal retinoid homeostasis. However, under conditions of high demand for retinoid, such as those experienced during lactation, this compensation was incomplete.	Columbia Univ, Div Prevent Med & Nutr, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire,Coll France, F-67404 Illkirch Graffenstaden, France	Columbia University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Vogel, S (corresponding author), Columbia Univ, Div Prevent Med & Nutr, Dept Med, Coll Phys & Surg, 630 W 168th St,P&S 9-510, New York, NY 10032 USA.	sv98@columbia.edu	GHYSELINCK, Norbert/I-6999-2015	GHYSELINCK, Norbert/0000-0003-4042-6818	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067512, R56DK068437, R01DK052444, R01DK068437] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK068437, DK067512, DK052444] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahl R, 2002, J NUTR, V132, P3243; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Blaner W.S., 1999, HANDB EXP PHARM, P117; Caprioli A, 2004, GENESIS, V40, P139, DOI 10.1002/gene.20075; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; DAVILA ME, 1985, J NUTR, V115, P1033, DOI 10.1093/jn/115.8.1033; E XP, 2002, J BIOL CHEM, V277, P36617, DOI 10.1074/jbc.M205519200; ERIKSSON U, 1984, J BIOL CHEM, V259, P3464; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Green MH, 2001, J NUTR, V131, P1544, DOI 10.1093/jn/131.5.1544; Green MH, 2001, J NUTR, V131, P1279, DOI 10.1093/jn/131.4.1279; GUDAS L, 1994, RETINOIDS, P453; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MORRISON BW, 1994, ONCOGENE, V9, P3417; Muslimatun S, 2001, J NUTR, V131, P2664, DOI 10.1093/jn/131.10.2664; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Ong David E., 1994, P283; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; Rice AL, 1999, J NUTR, V129, P356, DOI 10.1093/jn/129.2.356; Ross AC, 2004, EXP BIOL MED, V229, P46, DOI 10.1177/153537020422900106; ROSS AC, 1985, J NUTR, V115, P1488, DOI 10.1093/jn/115.11.1488; ROSS AC, 1982, J LIPID RES, V23, P133; Roy SK, 1997, EUR J CLIN NUTR, V51, P302, DOI 10.1038/sj.ejcn.1600398; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2002, INVEST OPHTH VIS SCI, V43, P1730; Saari John C., 1994, P351; SOBEL AE, 1950, AMA AM J DIS CHILD, V80, P932; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; SZUTS EZ, 1991, ARCH BIOCHEM BIOPHYS, V287, P297, DOI 10.1016/0003-9861(91)90482-X; TETER BB, 1990, J NUTR, V120, P818, DOI 10.1093/jn/120.8.818; van Bennekum AM, 1999, J LIPID RES, V40, P565; Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; VOGEL S, 1999, HANDB EXP PHARM, V139, P31	40	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24286	24292		10.1074/jbc.M503906200	http://dx.doi.org/10.1074/jbc.M503906200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15870066	hybrid			2022-12-25	WOS:000229880000106
J	Shih, AY; Imbeault, S; Barakauskas, V; Erb, H; Jiang, L; Li, P; Murphy, TH				Shih, AY; Imbeault, S; Barakauskas, V; Erb, H; Jiang, L; Li, P; Murphy, TH			Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; GLUTATHIONE S-TRANSFERASES; OXIDATIVE STRESS; 3-NITROPROPIONIC ACID; NAD(P)H-QUINONE REDUCTASE; INDUCIBLE EXPRESSION; CORTICAL ASTROCYTES; PARKINSONS-DISEASE; GENE-EXPRESSION; ENZYME GENES	NF-E2 related factor (Nrf2) controls a pleiotropic cellular defense, where multiple antioxidant/detoxification pathways are up-regulated in unison. Although small molecule inducers of Nrf2 activity have been reported to protect neurons in vitro, whether similar pathways can be accessed in vivo is not known. We have investigated whether in vivo toxicity of the mitochondrial complex II inhibitor 3-nitropropionic acid (3-NP) can be attenuated by constitutive and inducible Nrf2 activity. The absence of Nrf2 function in Nrf2(-/-) mice resulted in 3-NP hypersensitivity that became apparent with time and increasing dose, causing motor deficits and striatal lesions on a more rapid time scale than identically treated Nrf2(-/-) and Nrf2(-/-) controls. Striatal succinate dehydrogenase activity, the target of 3-NP, was inhibited to the same extent in all genotypes by a single acute dose of 3-NP, suggesting that brain concentrations of 3-NP were similar. Dietary supplementation with the Nrf2 inducer tert-butylhydroquinone attenuated 3-NP toxicity in Nrf2(-/-) mice, but not Nrf2(-/-), confirming the Nrf2-specific action of the inducer in vivo. Increased Nrf2 activity alone was sufficient to protect animals from 3-NP toxicity because intrastriatal adenovirus-mediated Nrf2 overexpression significantly reduced lesion size compared with green fluorescent protein overexpressing controls. In cultured astrocytes, 3-NP was found to increase Nrf2 activity leading to antioxidant response element-dependent gene expression providing a potential mechanism for the increased sensitivity of Nrf2(-/-) animals to 3-NP toxicity in vivo. We conclude that Nrf2 may underlie a feedback system limiting oxidative load during chronic metabolic stress.	Univ British Columbia, Dept Psychiat, Kinsmen Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Murphy, TH (corresponding author), Univ British Columbia, Dept Psychiat, Kinsmen Lab, 4N1-2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	thmurphy@interchange.ubc.ca	Murphy, Timothy/AAW-1975-2021; Murphy, Timothy H/I-4982-2014	Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490; Imbeault, Sophie/0000-0003-1454-9267				Ahlgren-Beckendorf JA, 1999, GLIA, V25, P131, DOI 10.1002/(SICI)1098-1136(19990115)25:2<131::AID-GLIA4>3.0.CO;2-6; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BEAL MF, 1993, J NEUROSCI, V13, P4181; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; BJELKE B, 1995, NEUROREPORT, V6, P1005, DOI 10.1097/00001756-199505090-00014; Brouillet E, 1998, J NEUROCHEM, V70, P794; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Cho HY, 2002, AM J RESP CELL MOL, V26, P42, DOI 10.1165/ajrcmb.26.1.4536; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Di Monte DA, 2002, NEUROTOXICOLOGY, V23, P487, DOI 10.1016/S0161-813X(02)00099-2; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Drukarch B, 1998, FREE RADICAL BIO MED, V25, P217, DOI 10.1016/S0891-5849(98)00050-1; Duffy S, 1998, J NEUROCHEM, V71, P69; Eftekharpour E, 2000, GLIA, V31, P241, DOI 10.1002/1098-1136(200009)31:3<241::AID-GLIA50>3.0.CO;2-9; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; EVERSE J, 1970, SCIENCE, V168, P1236, DOI 10.1126/science.168.3936.1236; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; *FAO WHO, 1975, FAO NUTR M REP SER A, V55, P1; *FAO WHO, 1997, NATL TOXICOL PROGRAM, V459, P1; Ghorayeb I, 2002, NEUROSCIENCE, V115, P533, DOI 10.1016/S0306-4522(02)00401-3; Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jenner P, 2001, TRENDS NEUROSCI, V24, P245, DOI 10.1016/S0166-2236(00)01789-6; Johnson DA, 2002, J NEUROCHEM, V81, P1233, DOI 10.1046/j.1471-4159.2002.00913.x; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kelly VP, 2000, CANCER RES, V60, P957; KENSLER TW, 1993, BASIC LIFE SCI, V61, P127; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McWalter GK, 2004, J NUTR, V134, p3499S, DOI 10.1093/jn/134.12.3499S; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Murphy TH, 2001, J NEUROCHEM, V76, P1670, DOI 10.1046/j.1471-4159.2001.00157.x; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Olsen C, 1999, BRAIN RES, V850, P144, DOI 10.1016/S0006-8993(99)02115-0; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Paxinos G., 2001, MOUSE BRAIN STEROTAX; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; RAHIMTULA AD, 1982, BRIT J CANCER, V45, P935, DOI 10.1038/bjc.1982.146; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reynolds DS, 1998, J NEUROSCI, V18, P10116; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schulz JB, 1995, J NEUROSCI, V15, P8419; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; SHIH AY, 2004, ABSTR VIEW IT PLANN; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102; Talalay P, 1996, BIOCHEM SOC T, V24, P806, DOI 10.1042/bst0240806; Thimmulappa RK, 2002, CANCER RES, V62, P5196; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Walz W, 2000, GLIA, V31, P95, DOI 10.1002/1098-1136(200008)31:2<95::AID-GLIA10>3.0.CO;2-6; Wu LY, 2001, J HYPERTENS, V19, P1819, DOI 10.1097/00004872-200110000-00016; Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101; Zhou FM, 2002, J NEUROBIOL, V53, P590, DOI 10.1002/neu.10150; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200; Zoli M, 1999, TRENDS PHARMACOL SCI, V20, P142, DOI 10.1016/S0165-6147(99)01343-7	82	214	225	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22925	22936		10.1074/jbc.M414635200	http://dx.doi.org/10.1074/jbc.M414635200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840590	hybrid			2022-12-25	WOS:000229741800046
J	Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT				Qiu, HQ; Zappacosta, F; Su, WJ; Annan, RS; Miller, WT			Interaction between Brk kinase and insulin receptor substrate-4	ONCOGENE			English	Article						Brk; tyrosine kinase; IRS-4	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR; GASTROINTESTINAL-TRACT; THERAPEUTIC TARGET; PROTEIN; EXPRESSION; PROLIFERATION; DIFFERENTIATION; IDENTIFICATION	Breast tumor kinase (Brk) is a member of the Frk family of nonreceptor tyrosine kinases that is overexpressed in a high percentage of human breast tumors. The downstream substrates and effectors of Brk remain largely unidentified. In this study, we carried out immunoprecipitation and mass spectrometry experiments to identify new Brk binding partners. One interacting protein was insulin receptor substrate 4 (IRS-4), a member of the IRS family. We confirmed that Brk associates with IRS-4 in resting and insulin-like growth factor 1 (IGF-1)-stimulated HEK 293 cells. The SH3 and SH2 domains of Brk are both involved in the association. The tyrosine phosphorylation of Brk increases after stimulation with IGF-1, and in MCF-7 breast cancer cells we show that the presence of IRS-4 enhances this effect. Finally, we demonstrate that endogenous Brk and IRS-4 interact in A431 human epidermoid carcinoma cells.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; GlaxoSmithKline Pharmaceut, Dept Computat Analyt & Struct Sci, Proteom & Biol Mass Spect Lab, King Of Prussia, PA 19406 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; GlaxoSmithKline	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Karas M, 2001, ENDOCRINOLOGY, V142, P1835, DOI 10.1210/en.142.5.1835; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Llor X, 1999, CLIN CANCER RES, V5, P1767; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Sesti G, 2000, Pharmacogenomics, V1, P343, DOI 10.1517/14622416.1.3.343; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Uchida T, 2000, MOL CELL BIOL, V20, P126, DOI 10.1128/MCB.20.1.126-138.2000; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	34	46	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5656	5664		10.1038/sj.onc.1208721	http://dx.doi.org/10.1038/sj.onc.1208721			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15870689				2022-12-25	WOS:000231296100012
J	Alonso, R; Rodriguez, MC; Pindado, J; Merino, E; Merida, I; Izquierdo, M				Alonso, R; Rodriguez, MC; Pindado, J; Merino, E; Merida, I; Izquierdo, M			Diacylglycerol kinase alpha regulates the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ANTIGEN RECEPTOR; APOPTOSIS; EXPRESSION; MEMBRANE; MICROVESICLES; PATHWAYS; RAS; TRANSMEMBRANE; ATTENUATION	Fas ligand ( FasL) mediates both apoptotic and inflammatory responses in the immune system. FasL function critically depends on the different forms of FasL; soluble Fas ligand lacking the transmembrane and cytoplasmic domains is a poor mediator of apoptosis, whereas full-length, membrane-associated FasL ( mFasL) is pro-apoptotic. mFasL can be released from T lymphocytes, via the secretion of mFasL-bearing exosomes. mFasL in exosomes retains its activity in triggering Fas-dependent apoptosis, providing an alternative mechanism of cell death that does not necessarily imply cell-to-cell contact. Diacylglycerol kinase alpha ( DGK alpha), a diacylglycerol ( DAG)-consuming enzyme, is involved in the attenuation of DAG-derived responses initiated at the plasma membrane that lead to T lymphocyte activation. Here we studied the role of DGK alpha on activation-induced cell death on a T cell line and primary T lymphoblasts. The inhibition of DGK alpha increases the secretion of lethal exosomes bearing mFas ligand and subsequent apoptosis. On the contrary, the overactivation of the DGK alpha pathway inhibits exosome secretion and subsequent apoptosis. DGK alpha was found associated with the trans-Golgi network and late endosomal compartments. Our results support the hypothesis that the DGK alpha effect on apoptosis occurs via the regulation of the release of lethal exosomes by the exocytic pathway, and point out that the spatial orchestration of the different pools of DAG ( plasma membrane and Golgi membranes) by DGK alpha is crucial for the control of cell activation and also for the regulation of the secretion of lethal exosomes, which in turn controls cell death.	Univ Valladolid, Fac Med, CSIC, Inst Biol & Genet Mol, E-47005 Valladolid, Spain; Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Izquierdo, M (corresponding author), Univ Valladolid, Fac Med, CSIC, Inst Biol & Genet Mol, Ramon & Cajal 7, E-47005 Valladolid, Spain.	mizquierdo@iib.uam.es	Izquierdo, Manuel/D-2971-2017; Izquierdo, Manuel/I-4812-2013; Merida, Isabel/A-9713-2014; Izquierdo, Manuel/I-4812-2013	Izquierdo, Manuel/0000-0002-7701-1002; Izquierdo, Manuel/0000-0002-7701-1002; Merida, Isabel/0000-0003-2762-6241; Izquierdo, Manuel/0000-0002-7261-404X				Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Abrahams VM, 2003, CANCER RES, V63, P5573; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Ebinu JO, 2000, BLOOD, V95, P3199; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Hohlbaum AM, 2000, J EXP MED, V191, P1209, DOI 10.1084/jem.191.7.1209; Izquierdo M, 1996, J IMMUNOL, V157, P21; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jodo S, 2001, J BIOL CHEM, V276, P39938, DOI 10.1074/jbc.M107005200; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAYAGAKI N, 1995, J EXP MED, V182, P17777; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Monleon I, 2001, J IMMUNOL, V167, P6736, DOI 10.4049/jimmunol.167.12.6736; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; Teixeiro E, 2002, J BIOL CHEM, V277, P3993, DOI 10.1074/jbc.M107797200; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Wang R, 2001, J IMMUNOL METHODS, V249, P167, DOI 10.1016/S0022-1759(00)00357-4; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958	48	101	105	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28439	28450		10.1074/jbc.M501112200	http://dx.doi.org/10.1074/jbc.M501112200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15870081	hybrid			2022-12-25	WOS:000230857300033
J	Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F				Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F			The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer	ONCOGENE			English	Article						mineral dust; mdig; lung cancer	MESSENGER-RNA; ASBESTOS; EXPRESSION; HAIRLESS; SILICA	Environmental or occupational exposure to mineral dusts, mainly silica and asbestos, is associated with an increased incidence of lung inflammation, fibrosis, and/or cancer. To better understand the molecular events associated with these pulmonary diseases, we attempted to identify genes that are regulated by mineral dusts. Using a differential display reverse transcription polymerase chain reaction technique and mRNAs of alveolar macrophages from both normal individuals and coal miners, we identified a novel mineral dust-induced gene named mdig, which had not been fully characterized. The expression of mdig mRNA was detected in alveolar macrophages from coal miners but not from normal subjects. The inducible expression of mdig could be observed in A549 cells exposed to silica particles in a time-dependent manner. The full-length mdig mRNA was expressed in human lung cancer tissues but was barely detectable in the adjacent normal tissues. In addition, a number of lung cancer cell lines constitutively express mdig. Alternative spliced transcripts of mdig were detected in some lung cancer cell lines. Silencing mdig mRNA expression in A549 lung cancer cells by siRNA-mediated RNA interference inhibits cell proliferation and sensitizes the cells to silica-induced cytotoxicity. These results suggest that the mdig gene may be involved in the regulation of cell growth and possibly the development of cancer.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Mail Stop 2015,1095 Willowdale Rd, Morgantown, WV 26505 USA.	LFD3@cdc.gov	Hu, Ruogu/B-2203-2008; Shi, Xianglin/B-8588-2012; Chen, Fei/A-3056-2008					BRODY AR, 1982, LAB INVEST, V47, P533; *CDC NIOSH, 2003, WORK REL LUNG DIS SU; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298, DOI 10.1164/ajrccm/136.2.298; Kuempel Eileen D., 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P15; LIANG P, 1992, CANCER RES, V52, P6966; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martin RG, 1996, J BACTERIOL, V178, P2216, DOI 10.1128/jb.178.8.2216-2223.1996; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nelson HH, 2002, ONCOGENE, V21, P7284, DOI 10.1038/sj.onc.1205804; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; ROM WN, 1991, AM REV RESPIR DIS, V143, P408, DOI 10.1164/ajrccm/143.2.408; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; WEISSMAN DN, 1986, AM J MED SCI, V292, P187, DOI 10.1097/00000441-198610000-00001	20	58	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4873	4882		10.1038/sj.onc.1208668	http://dx.doi.org/10.1038/sj.onc.1208668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897898				2022-12-25	WOS:000230646500001
J	Molnar, F; Matilainen, M; Carlberg, C				Molnar, F; Matilainen, M; Carlberg, C			Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR-RECEPTOR; VITAMIN-D-3 RECEPTOR; CRYSTAL-STRUCTURE; RETINOIC ACID; ORPHAN RECEPTORS; THYROID-HORMONE; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-BASIS	Lipid homeostasis is controlled by various nuclear receptors (NRs), including the peroxisome proliferator-activated receptors (PPAR alpha, delta, and gamma), which sense lipid levels and regulate their metabolism. Here we demonstrate that human PPARs have a high basal activity and show ligand-independent coactivator (CoA) association comparable with the NR constitutive androstane receptor. Using PPAR gamma as an example, we found that four different amino acid groups contribute to the ligand-independent stabilization of helix 12 of the PPAR ligand-binding domain. These are: (i) Lys(329) and Glu(499), mediating a charge clamp-type stabilization of helix 12 via a CoA bridge; (ii) Glu(352), Arg(425), and Tyr(505), directly stabilizing the helix via salt bridges and hydrogen bonds; (iii) Lys(347) and Asp(503), interacting with each other as well as contacting the CoA; and (iv) His(351), Tyr(355), His(477), and Tyr(501), forming a hydrogen bond network. These amino acids are highly conserved within the PPAR subfamily, suggesting that the same mechanism may apply for all three PPARs. Phylogenetic trees of helix 12 amino acid and nucleotide sequences of all crystallized NRs and all human NRs, respectively, indicated a close relationship of PPARs with constitutive androstane receptor and other constitutive active members of the NR superfamily. Taking together, the ligand-independent tight control of the position of the PPAR helix 12 provides an effective alternative for establishing an interaction with CoA proteins. This leads to high basal activity of PPARs and provides an additional view on PPAR signaling.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.	carlberg@messi.uku.fi	Molnár, Ferdinand/E-2290-2011; Heinaniemi, Merja/AAS-4530-2020; Heinäniemi, Merja/C-5051-2014; Carlberg, Carsten/C-9075-2011	Molnár, Ferdinand/0000-0001-9008-4233; Heinaniemi, Merja/0000-0001-6190-3439; Heinäniemi, Merja/0000-0001-6190-3439; Carlberg, Carsten/0000-0003-2633-0684				Agarwal AK, 2002, J CLIN ENDOCR METAB, V87, P408, DOI 10.1210/jc.87.1.408; Andersin T, 2003, MOL ENDOCRINOL, V17, P234, DOI 10.1210/me.2002-0263; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Brelivet Y, 2004, EMBO REP, V5, P423, DOI 10.1038/sj.embor.7400119; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Dussault I, 2002, MOL CELL BIOL, V22, P5270, DOI 10.1128/MCB.22.15.5270-5280.2002; Frank C, 2004, J BIOL CHEM, V279, P33558, DOI 10.1074/jbc.M403946200; Frederiksen KS, 2004, J LIPID RES, V45, P592, DOI 10.1194/jlr.M300239-JLR200; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gonzalez MM, 2003, MOL ENDOCRINOL, V17, P2028, DOI 10.1210/me.2003-0072; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; Heuvel JPV, 2003, TOXICOL APPL PHARM, V188, P185, DOI 10.1016/S0041-008X(03)00015-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kallen J, 2004, J BIOL CHEM, V279, P14033, DOI 10.1074/jbc.M400302200; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Quack M, 2000, MOL PHARMACOL, V57, P375; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Shan L, 2004, MOL CELL, V16, P907, DOI 10.1016/S1097-2765(04)00728-2; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Stehlin-Gaon C, 2003, NAT STRUCT BIOL, V10, P820, DOI 10.1038/nsb979; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Suino K, 2004, MOL CELL, V16, P893, DOI 10.1016/j.molcel.2004.11.036; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vaisanen S, 2002, J MOL BIOL, V315, P229, DOI 10.1006/jmbi.2001.5225; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walczak R, 2002, J LIPID RES, V43, P177; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xu RX, 2004, MOL CELL, V16, P919, DOI 10.1016/j.molcel.2004.11.042; Yamazaki K, 2002, BIOCHEM BIOPH RES CO, V290, P1114, DOI 10.1006/bbrc.2001.6319; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	70	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26543	26556		10.1074/jbc.M502463200	http://dx.doi.org/10.1074/jbc.M502463200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888456	hybrid			2022-12-25	WOS:000230386800071
J	Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE				Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE			Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development	ONCOGENE			English	Article						LIM domain; mammary gland; alveolar development	TRANSGENIC MICE; ONLY PROTEIN; BINDING PROTEIN; ADULT-MOUSE; CELL-CYCLE; GENE; EXPRESSION; IDENTIFICATION; LEUKEMIA; RBTN2	LMO4, a member of the LIM-only family of zinc-finger proteins, is overexpressed in a significant proportion of breast carcinomas and acts as a negative regulator of mammary epithelial differentiation. To delineate cell types within the developing mouse mammary gland that express Lmo4, we analysed different stages of mammopoiesis by immunohistochemistry. Lmo4 was found to be highly expressed in the proliferating cap cells of the terminal end bud and in the ductal and alveolar luminal cells of the mature mammary gland but was negligible or low in myoepithelial cells. To assess the physiological role of Lmo4 in the mammary gland, we generated conditionally targeted mice lacking Lmo4 in the mammary epithelium during pregnancy. Acute loss of Lmo4 in late pregnancy impaired lobuloalveolar development, accompanied by a two-fold reduction in the percentage of BrdU-positive cells. In contrast, germline loss of Lmo4 did not alter lobuloalveolar development arising from transplanted mammary anlagen, implying the existence of a compensatory mechanism in these knockout mice. Thus, the use of a conditional targeting strategy has revealed that Lmo4 is required for proper development of the mammary gland during pregnancy and indicated that Lmo4 acts as a positive regulator of alveolar epithelial proliferation.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Walter & Eliza Hall Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center	Visvader, JE (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au	Wagner, Kay-Uwe/B-6044-2009	Lindeman, Geoffrey/0000-0001-9386-2416; Wagner, Kay-Uwe/0000-0002-5081-0226				Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bulchand S, 2003, DEV DYNAM, V226, P460, DOI 10.1002/dvdy.10235; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FISCH P, 1992, ONCOGENE, V7, P2389; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MEDINA D, 1990, PROTOPLASMA, V159, P77, DOI 10.1007/BF01322591; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; SUM EY, 2002, J HISTOCHEM CYTOCHEM, V53, P475; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; Visvader JE, 2003, INT J BIOCHEM CELL B, V35, P1034, DOI 10.1016/S1357-2725(03)00030-X; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Vu D, 2003, MOL BRAIN RES, V115, P93, DOI 10.1016/S0169-328X(03)00119-0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	45	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4820	4828		10.1038/sj.onc.1208638	http://dx.doi.org/10.1038/sj.onc.1208638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15856027				2022-12-25	WOS:000230477900009
J	Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF				Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF			An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity	ONCOGENE			English	Article						Bcl-xL; TCTP; apoptosis; protein interaction	HISTAMINE-RELEASING-FACTOR; BCL-2 FAMILY-MEMBERS; CELL-DEATH; IDENTIFICATION; APOPTOSIS; INHIBITION; EXPRESSION; INTERACTS; BCL-X(L); FORTILIN	Bcl-xL plays a critical role in maintaining cell survival. However, the relationship between the potential interaction of Bcl-xL with other cytosolic proteins and the regulation of cell survival remains incompletely defined. We have identified translationally controlled tumor protein (TCTP), a multifunctional protein, as a novel antiapoptotic Bcl-xL-interacting protein. TCTP interacted in vivo and in vitro with Bcl-xL, and their sites have been mapped to an N- terminal region of TCTP and the Bcl-2 homology domain 3 of Bcl-xL. Consistent with a role in maintaining T-cell survival during activation, TCTP was significantly upregulated in murine T cells activated by T-cell antigen receptor (TCR) ligation and CD28 costimulation, which was correlated with the upregulation of Bcl-xL in activated T cells. Moreover, downregulation of TCTP expression by antisense technology in T cells results in the increase of T-cell apoptosis. Furthermore, the N-terminal region of TCTP was required for its ability to inhibit apoptosis. In conclusion, this study has demonstrated that an N-terminal region of a cytosolic protein, TCTP, is required for its binding to Bcl-xL and for its antiapoptotic activity.	Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Univ Houston, Dept Comp Sci, Houston, TX 77204 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston	Yang, XF (corresponding author), Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, 1 Baylor Plaza,BCM 285,Suite 672E, Houston, TX 77030 USA.	xyang1@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NATIONAL CANCER INSTITUTE [P20CA103698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI054514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA103698] Funding Source: Medline; NIAID NIH HHS [K08 AI054514, AI054514] Funding Source: Medline; NIDDK NIH HHS [P30 DK56238, R01 DK056238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ADAMS PD, 2002, PROTEIN PROTEIN INTE, P59; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bangrak P, 2004, J BIOTECHNOL, V108, P219, DOI 10.1016/j.jbiotec.2003.12.007; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Baudet C, 1998, CELL DEATH DIFFER, V5, P116, DOI 10.1038/sj.cdd.4400327; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Diaz JL, 1997, J BIOL CHEM, V272, P11350; EINARSON M, 2002, IDENTIFICATION PROTE; FANG W, 1994, J IMMUNOL, V153, P4388; Gachet Y, 1999, J CELL SCI, V112, P1257; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Graidist P, 2004, J BIOL CHEM, V279, P40868, DOI 10.1074/jbc.M401454200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kang HS, 2001, J IMMUNOL, V166, P6545, DOI 10.4049/jimmunol.166.11.6545; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Shim J, 2002, MOL CELLS, V14, P323; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Vonakis BM, 2003, J IMMUNOL, V171, P3742, DOI 10.4049/jimmunol.171.7.3742; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 2002, MOL IMMUNOL, V39, P45, DOI 10.1016/S0161-5890(02)00049-4; Yang XF, 2001, P NATL ACAD SCI USA, V98, P7492, DOI 10.1073/pnas.131590998; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084; Yoon T, 2000, ARCH BIOCHEM BIOPHYS, V384, P379, DOI 10.1006/abbi.2000.2108; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	55	141	153	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4778	4788		10.1038/sj.onc.1208666	http://dx.doi.org/10.1038/sj.onc.1208666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870695	Green Accepted			2022-12-25	WOS:000230477900004
J	Kumar, P; Meizel, S				Kumar, P; Meizel, S			Nicotinic acetylcholine receptor subunits and associated proteins in human sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN-BINDING; FYN TYROSINE KINASE; PROGESTERONE-INITIATED INCREASE; INTRACELLULAR CALCIUM STORE; ADRENAL CHROMAFFIN CELLS; HUMAN FOLLICULAR-FLUID; ACROSOME REACTION; LIPID RAFTS; MOUSE SPERM; HYPERACTIVATED MOTILITY	We demonstrated previously the involvement of a nicotinic acetylcholine receptor containing an alpha 7 subunit in the human sperm acrosome reaction ( a modified exocytotic event essential to fertilization). Here we report the presence in human sperm of alpha 7, alpha 9, alpha 3, alpha 5, and beta 4 nicotinic acetylcholine receptor subunits and the following proteins known to be associated with the receptor in the somatic cell: rapsyn and the tyrosine kinases c- SRC and FYN. The alpha 7 subunit appears to exist as a homomer in the posterior post- acrosomal and neck regions of sperm and is probably linked to the cytoskeleton via rapsyn. The alpha 3, alpha 5, and beta 4 subunits are present in the sperm flagellar mid- piece of sperm and possibly exist as alpha 3 alpha 5 beta 4 and/ or alpha 3 beta 4 channels. The alpha 9 subunit is present in the sperm mid- piece. We detected the FYN and c- SRC tyrosine kinases in the flagellar mid- piece region. Both co- precipitated only with the nicotinic acetylcholine receptor beta 4 subunit. Immunolocalization with a C- terminal SRC kinase antibody, which recognizes several members of SRC kinase family, detected a SRC kinase co- localized with the alpha 7 subunit in the neck region of sperm. Immunoprecipitation studies with that antibody demonstrated that the alpha 7 subunit is associated with a SRC kinase. Antagonists of tyrosine phosphorylation inhibited the acetylcholine- initiated acrosome reaction, suggesting the involvement of a SRC kinase in the acrosome reaction.	Univ Calif Davis, Sch Med, Dept Human Anat & Cell Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Kumar, P (corresponding author), Univ Calif Davis, Sch Med, Dept Human Anat & Cell Biol, Davis, CA 95616 USA.	pkumar@ucdavis.edu	kumar, priyadarsini/AAG-7494-2019	kumar, priyadarsini/0000-0001-6800-9632	NICHD NIH HHS [HD 33368, 5 T32 HD007131] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007131, R01HD033368] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; Arredondo J, 2002, J CELL BIOL, V159, P325, DOI 10.1083/jcb.200206096; Ashcroft FM, 2000, ION CHANNELS DIS; BACCETTI B, 1995, ZYGOTE, V3, P207, DOI 10.1017/S0967199400002604; Bark SJ, 2000, METHODS, V20, P429, DOI 10.1006/meth.2000.0956; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Bray C, 2002, BIOL REPROD, V67, P782, DOI 10.1095/biolreprod.102.004580; Brener E, 2003, BIOL REPROD, V68, P837, DOI 10.1095/biolreprod.102.009233; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; Broxton NM, 1999, J NEUROCHEM, V72, P1656, DOI 10.1046/j.1471-4159.1999.721656.x; Bruses JL, 2001, J NEUROSCI, V21, P504, DOI 10.1523/JNEUROSCI.21-02-00504.2001; Buckel A, 1998, ANN NY ACAD SCI, V841, P14, DOI 10.1111/j.1749-6632.1998.tb10906.x; Burns AL, 1997, J NEUROSCI, V17, P5016; Chen DN, 1997, J BIOL CHEM, V272, P24024, DOI 10.1074/jbc.272.38.24024; Conroy WG, 1999, J NEUROCHEM, V73, P1399, DOI 10.1046/j.1471-4159.1999.0731399.x; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; Cross NL, 2004, BIOL REPROD, V71, P1367, DOI 10.1095/biolreprod.104.030502; Drisdel RC, 2000, J NEUROSCI, V20, P133, DOI 10.1523/JNEUROSCI.20-01-00133.2000; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Ellison M, 2004, BIOCHEMISTRY-US, V43, P16019, DOI 10.1021/bi048918g; ENG CM, 1991, GENOMICS, V9, P278, DOI 10.1016/0888-7543(91)90253-B; FAWCETT DW, 1975, DEV BIOL, V44, P394, DOI 10.1016/0012-1606(75)90411-X; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Fuhrer C, 1997, EMBO J, V16, P4951, DOI 10.1093/emboj/16.16.4951; Goldsmith JF, 2002, BIOCHEM BIOPH RES CO, V298, P501, DOI 10.1016/S0006-291X(02)02510-X; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harper CV, 2004, J BIOL CHEM, V279, P46315, DOI 10.1074/jbc.M401194200; Herrick SB, 2005, J CELL PHYSIOL, V202, P663, DOI 10.1002/jcp.20172; Ho HC, 2003, BIOL REPROD, V68, P1590, DOI 10.1095/biolreprod.102.011320; Hogg RC, 2003, REV PHYSIOL BIOCH P, V147, P1, DOI 10.1007/s10254-003-0005-1; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kassner PD, 1998, MOL CELL NEUROSCI, V10, P258, DOI 10.1006/mcne.1998.0664; Khiroug SS, 2002, J PHYSIOL-LONDON, V540, P425, DOI 10.1113/jphysiol.2001.013847; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kurokawa M, 2004, REPRODUCTION, V127, P441, DOI 10.1530/rep.1.00128; LAROCHELLE WJ, 1987, J BIOL CHEM, V262, P8190; Leclerc P, 2002, BIOL REPROD, V67, P301, DOI 10.1095/biolreprod67.1.301; Maekawa M, 2002, BIOL REPROD, V66, P211, DOI 10.1095/biolreprod66.1.211; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marchand S, 2002, J NEUROSCI, V22, P8891; MEIZEL S, 1993, MOL REPROD DEV, V34, P457, DOI 10.1002/mrd.1080340416; Meizel S, 2004, BIOL REV, V79, P713, DOI 10.1017/S1464793103006407; Melendrez CS, 1996, BIOCHEM BIOPH RES CO, V223, P675, DOI 10.1006/bbrc.1996.0954; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Mitsui T, 2000, J CELL BIOCHEM, V77, P584, DOI 10.1002/(SICI)1097-4644(20000615)77:4<584::AID-JCB6>3.0.CO;2-U; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; MUSIL LS, 1989, J CELL BIOL, V108, P1833, DOI 10.1083/jcb.108.5.1833; NELSON L, 1976, EXP CELL RES, V101, P221, DOI 10.1016/0014-4827(76)90371-2; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; ORTOFT E, 1995, INT J CANCER, V60, P38, DOI 10.1002/ijc.2910600105; Oshikawa J, 2003, AM J PHYSIOL-CELL PH, V285, pC567, DOI 10.1152/ajpcell.00422.2002; PILLAI MC, 1991, J EXP ZOOL, V258, P384, DOI 10.1002/jez.1402580314; PLACZEK R, 1988, ARCH ANDROLOGY, V21, P1; Rossato M, 2001, MOL HUM REPROD, V7, P119, DOI 10.1093/molehr/7.2.119; Sabeur K, 1996, BIOL REPROD, V54, P993, DOI 10.1095/biolreprod54.5.993; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; Shadan S, 2004, BIOL REPROD, V71, P253, DOI 10.1095/biolreprod.103.026435; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shoop RD, 2000, J NEUROSCI, V20, P4021; Son JH, 2003, BIOL REPROD, V68, P1348, DOI 10.1095/biolreprod.102.011163; Suarez SS, 2003, REPROD DOMEST ANIM, V38, P119, DOI 10.1046/j.1439-0531.2003.00397.x; SWOPE SL, 1995, ANN NY ACAD SCI, V757, P197, DOI 10.1111/j.1749-6632.1995.tb17476.x; Tachikawa E, 2001, NEUROSCI LETT, V312, P161, DOI 10.1016/S0304-3940(01)02211-X; THOMAS P, 1988, GAMETE RES, V20, P397, DOI 10.1002/mrd.1120200402; Traxler P, 1999, J MED CHEM, V42, P1018, DOI 10.1021/jm980551o; Urner F, 2003, REPRODUCTION, V125, P17, DOI 10.1530/rep.0.1250017; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; Wang W, 2000, TOXICOL APPL PHARM, V163, P125, DOI 10.1006/taap.1999.8870; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; Yanagimachi R., 1994, P189; YOUNG RJ, 1991, MOL REPROD DEV, V28, P55, DOI 10.1002/mrd.1080280109; YUDIN AI, 1988, GAMETE RES, V20, P11, DOI 10.1002/mrd.1120200103; ZHAO YH, 1990, ONCOGENE, V5, P1629; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	83	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25928	25935		10.1074/jbc.M502435200	http://dx.doi.org/10.1074/jbc.M502435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15894803	hybrid			2022-12-25	WOS:000230207900074
J	Naude, B; Brzostowski, JA; Kimmel, AR; Wellems, TE				Naude, B; Brzostowski, JA; Kimmel, AR; Wellems, TE			Dictyostelium discoideum expresses a malaria chloroquine resistance mechanism upon transfection with mutant, but not wild-type, Plasmodium falciparum transporter PfCRT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PROTEIN PFCRT; DIGESTIVE VACUOLE; DIHYDROARTEMISININ-PIPERAQUINE; INFECTED ERYTHROCYTES; IN-VITRO; EFFLUX; PH; MUTATIONS; PARASITES; IDENTIFICATION	Chloroquine resistance in Plasmodium falciparum malaria results from mutations in PfCRT, a member of a unique family of transporters present in apicomplexan parasites and Dictyostelium discoideum. Mechanisms that have been proposed to explain chloroquine resistance are difficult to evaluate within malaria parasites. Here we report on the targeted expression of wild-type and mutant forms of PfCRT to acidic vesicles in D. discoideum. We show that wild-type PfCRT has minimal effect on the accumulation of chloroquine by D. discoideum, whereas forms of PfCRT carrying a key charge-loss mutation of lysine 76 (e.g. K76T) enable D. discoideum to expel chloroquine. As in P. falciparum, the chloroquine resistance phenotype conferred on transformed D. discoideum can be reversed by the channel-blocking agent verapamil. Although intravesicular pH levels in D. discoideum show small acidic changes with the expression of different forms of PfCRT, these changes would tend to promote intravesicular trapping of chloroquine ( a weak base) and do not account for reduced drug accumulation in transformed D. discoideum. Our results instead support outward-directed chloroquine efflux for the mechanism of chloroquine resistance by mutant PfCRT. This mechanism shows structural specificity as D. discoideum transformants that expel chloroquine do not expel piperaquine, a bisquinoline analog of chloroquine used frequently against chloroquine-resistant parasites in Southeast Asia. PfCRT, nevertheless, may have some ability to act on quinine and quinidine. Transformed D. discoideum will be useful for further studies of the chloroquine resistance mechanism and may assist in the development and evaluation of new antimalarial drugs.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wellems, TE (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	twellems@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000483, Z01AI000483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER; NIAID NIH HHS [Z01 AI000483-20] Funding Source: Medline; NIDDK NIH HHS [Z01 DK015503-24] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2003, AFR MAL REP 2003; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Ashley EA, 2004, J INFECT DIS, V190, P1773, DOI 10.1086/425015; Basco LK, 2003, ANTIMICROB AGENTS CH, V47, P1391, DOI 10.1128/AAC.47.4.1391-1394.2003; Bennett TN, 2004, MOL BIOCHEM PARASIT, V133, P99, DOI 10.1016/j.molbiopara.2003.09.008; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P301, DOI 10.1016/S0166-6851(01)00403-0; Brzostowski JA, 2002, CURR BIOL, V12, P1199, DOI 10.1016/S0960-9822(02)00953-3; Carter R, 2002, CLIN MICROBIOL REV, V15, P564, DOI 10.1128/CMR.15.4.564-594.2002; CHEN L, 1982, CHINESE MED J-PEKING, V95, P281; Clarke M, 2002, J CELL SCI, V115, P2893; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; DAVIES L, 1993, CELL, V75, P321, DOI 10.1016/0092-8674(93)80073-N; De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Denis MB, 2002, CLIN INFECT DIS, V35, P1469, DOI 10.1086/344647; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; FAIX J, 1992, J CELL SCI, V102, P203; Ferdig MT, 2004, MOL MICROBIOL, V52, P985, DOI 10.1111/j.1365-2958.2004.04035.x; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; Hawley SR, 1996, ANTIMICROB AGENTS CH, V40, P2345, DOI 10.1128/AAC.40.10.2345; Jenne N, 1998, J CELL SCI, V111, P61; Johnson DJ, 2004, MOL CELL, V15, P867, DOI 10.1016/j.molcel.2004.09.012; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KIRK K, 1995, BIOCHEM J, V311, P761, DOI 10.1042/bj3110761; Kreppel L, 2004, NUCLEIC ACIDS RES, V32, pD332, DOI 10.1093/nar/gkh138; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Martin RE, 2004, MOL BIOL EVOL, V21, P1938, DOI 10.1093/molbev/msh205; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; Muller T, 2000, J COMPUT BIOL, V7, P761, DOI 10.1089/10665270050514918; Nessler S, 2004, J BIOL CHEM, V279, P39438, DOI 10.1074/jbc.M404671200; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; Ridley RG, 1998, EXPERT OPIN THER PAT, V8, P121, DOI 10.1517/13543776.8.2.121; Saliba KJ, 1998, BIOCHEM PHARMACOL, V56, P313, DOI 10.1016/S0006-2952(98)00140-3; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; Sanchez CP, 2004, BIOCHEMISTRY-US, V43, P16365, DOI 10.1021/bi048241x; Sanchez CP, 2003, BIOCHEMISTRY-US, V42, P9383, DOI 10.1021/bi034269h; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tran CV, 2004, MICROBIOL-SGM, V150, P1, DOI 10.1099/mic.0.26818-0; Ursos LMB, 2001, MOL BIOCHEM PARASIT, V112, P11, DOI 10.1016/S0166-6851(00)00342-X; Waller KL, 2003, J BIOL CHEM, V278, P33593, DOI 10.1074/jbc.M302215200; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; Wissing F, 2002, J BIOL CHEM, V277, P37747, DOI 10.1074/jbc.M204845200; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784; Zhang HB, 2002, J BIOL CHEM, V277, P49767, DOI 10.1074/jbc.M204005200; Zhang HB, 2004, BIOCHEMISTRY-US, V43, P8290, DOI 10.1021/bi049137i; Zhu G, 2000, INT J SYST EVOL MICR, V50, P1673, DOI 10.1099/00207713-50-4-1673	57	51	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25596	25603		10.1074/jbc.M503227200	http://dx.doi.org/10.1074/jbc.M503227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883156	Green Accepted, hybrid			2022-12-25	WOS:000230207900038
J	Campus, F; Lova, P; Bertoni, A; Sinigaglia, F; Balduini, C; Torti, M				Campus, F; Lova, P; Bertoni, A; Sinigaglia, F; Balduini, C; Torti, M			Thrombopoietin complements G(i)- but not G(q)-dependent pathways for integrin alpha(IIb)beta(3) activation and platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD-PLATELETS; PROTEIN-COUPLED RECEPTORS; C-MPL LIGAND; TYROSINE PHOSPHORYLATION; IN-VITRO; CALCIUM MOBILIZATION; GLYCOPROTEIN-VI; CROSS-TALK; KINASE-C; RAP1B	Binding of thrombopoietin (TPO) to the cMp1 receptor on human platelets potentiates aggregation induced by a number of agonists, including ADP. In this work, we found that TPO was able to restore ADP-induced platelet aggregation upon blockade of the G(q)- coupled P2Y1 purinergic receptor but not upon inhibition of the G(i)-coupled P2Y12 receptor. Moreover, TPO triggered platelet aggregation upon co-stimulation of G(z) by epinephrine but not upon co-timulation of G(q) by the thromboxane analogue U46619. Platelet aggregation induced by TPO and G(i) stimulation was biphasic, and cyclooxygenase inhibitors prevented the second but not the first phase. In contrast to ADP, TPO was unable to induce integrin alpha(IIb)beta(3) activation, as evaluated by binding of both fibrinogen and PAC-1 monoclonal antibody. However, ADP-induced activation of integrin alpha(IIb)beta(3) was blocked by antagonists of the G(q)-coupled P2Y1 receptor but was completely restored by the simultaneous co-stimulation of cMp1 receptor by TPO. Inside- out activation of integrin alpha(IIb)beta(3) induced by TPO and Gi stimulation occurred independently of thromboxane A(2) production and was not mediated by protein kinase C, MAP kinases, or Rho-dependent kinase. Importantly, TPO and Gi activation of integrin alpha(IIb)beta(3) was suppressed by wortmannin and Ly294002, suggesting a critical regulation by phosphatidylinositol 3-kinase. We found that TPO did not activate phospholipase C in human platelets and was unable to restore ADP-induced phospholipase C activation upon blockade of the G(q)-coupled P2Y1 receptor. TPO induced a rapid and sustained activation of the small GTPase Rap1B through a pathway dependent on phosphatidylinositol 3-kinase. In ADP-stimulated platelets, Rap1B activation was reduced, although not abolished, upon blockade of the P2Y1 receptor. However, accumulation of GTP-bound Rap1B in platelets activated by co- stimulation of cMp1 and P2Y12 receptor was identical to that induced by the simultaneous ligation of P2Y1 and P2Y12 receptor by ADP. These results indicate that TPO can integrate G(i), but not G(q), stimulation and can efficiently support integrin alpha(IIb)beta(3) activation platelet aggregation by an alternative signaling pathway independent of phospholipase C but involving the phosphatidylinositol 3-kinase and the small GTPase Rap1B.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ A Avogdro, Dept Med Sci, I-28100 Novara, Italy	University of Pavia; University of Eastern Piedmont Amedeo Avogadro	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 27, I-27100 Pavia, Italy.	mtorti@unipv.it						BALDUINI CL, 1988, BIOCHEM BIOPH RES CO, V156, P823; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973; CRITTENDEN JR, 2004, NAT MED, V9, P982; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; de Bruyn KMT, 2003, J BIOL CHEM, V278, P22412, DOI 10.1074/jbc.M212036200; DEBILI N, 1995, BLOOD, V85, P391, DOI 10.1182/blood.V85.2.391.bloodjournal852391; Eckly A, 2001, THROMB HAEMOSTASIS, V85, P694, DOI 10.1055/s-0037-1615655; Ezumi Y, 1999, BIOCHEM BIOPH RES CO, V261, P58, DOI 10.1006/bbrc.1999.0979; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Fontenay-Roupie M, 1998, THROMB HAEMOSTASIS, V79, P195; Gratacap MP, 2000, BLOOD, V96, P3439, DOI 10.1182/blood.V96.10.3439.h8003439_3439_3446; Hardy AR, 2004, BLOOD, V104, P1745, DOI 10.1182/blood-2004-02-0534; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kauffenstein G, 2001, FEBS LETT, V505, P281, DOI 10.1016/S0014-5793(01)02824-1; Kaushansky K, 2003, J THROMB HAEMOST, V1, P1587, DOI 10.1046/j.1538-7836.2003.00273.x; Kaushansky K, 2002, ONCOGENE, V21, P3359, DOI 10.1038/sj.onc.1205323; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; Kojima H, 2001, EXP HEMATOL, V29, P616, DOI 10.1016/S0301-472X(01)00623-3; Larson MK, 2003, BLOOD, V101, P1409, DOI 10.1182/blood-2002-05-1533; Lova P, 2004, J BIOL CHEM, V279, P25299, DOI 10.1074/jbc.M313199200; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Majka M, 2002, EXP HEMATOL, V30, P751, DOI 10.1016/S0301-472X(02)00810-X; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Oda A, 1999, THROMB HAEMOSTASIS, V82, P377; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; Oda A, 1996, BLOOD, V87, P4664, DOI 10.1182/blood.V87.11.4664.bloodjournal87114664; Pasquet JM, 2000, BLOOD, V95, P3429, DOI 10.1182/blood.V95.11.3429.011k22_3429_3434; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; Pulcinelli FM, 1999, FEBS LETT, V460, P37, DOI 10.1016/S0014-5793(99)01313-7; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; Tulasne D, 2002, EUR J BIOCHEM, V269, P1511, DOI 10.1046/j.1432-1033.2002.02798.x; van Os E, 2003, BRIT J HAEMATOL, V121, P482, DOI 10.1046/j.1365-2141.2003.04292.x; van Willigen G, 2000, THROMB HAEMOSTASIS, V83, P610; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200	47	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24386	24395		10.1074/jbc.M501174200	http://dx.doi.org/10.1074/jbc.M501174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863506	hybrid			2022-12-25	WOS:000230114000013
J	Choudhury, AD; Xu, H; Modi, AP; Zhang, WH; Ludwig, T; Baer, R				Choudhury, AD; Xu, H; Modi, AP; Zhang, WH; Ludwig, T; Baer, R			Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRCA1-BARD1 UBIQUITIN LIGASE; SUSCEPTIBILITY GENE BRCA1; DNA-DAMAGE RESPONSE; IONIZING IRRADIATION; POLYUBIQUITIN CHAINS; CANCER-CELLS; SUBCELLULAR-LOCALIZATION; BRCA1/BARD1 HETERODIMER; NUCLEAR PHOSPHOPROTEIN; MASS-SPECTROMETRY	Although the BRCA1 tumor suppressor has been implicated in a number of cellular processes, it plays an especially important role in the DNA damage response as a regulator of cell cycle checkpoints and DNA repair pathways. In vivo, BRCA1 exists as a heterodimer with the BARD1 protein, and many of its biological functions are mediated by the BRCA1-BARD1 complex. Here, we show that BARD1 is phosphorylated in a cell cycle-dependent manner and that the hyperphosphorylated forms of BARD1 predominate during M phase. By mobility shift analysis and mass spectrometry, we have identified seven sites of mitotic phosphorylation within BARD1. All sites exist within either an SP or TP sequence, and two sites resemble the consensus motif recognized by cyclin-dependent kinases. To examine the functional consequences of BARD1 phosphorylation, we used a gene targeting knock-in approach to generate isogenic cell lines that express either wild-type or mutant forms of the BARD1 polypeptide. Analysis of these lines in clonogenic survival assays revealed that cells bearing phosphorylation site mutations are hypersensitive to mitomycin C, a genotoxic agent that induces interstrand DNA cross-links. These results implicate BARD1 phosphorylation in the cellular response to DNA damage.	Columbia Univ, Ctr Med, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Ctr Med, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Ctr Med, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Baer, R (corresponding author), Columbia Univ, Ctr Med, Inst Canc Genet, 1150 St Nicholas Ave, New York, NY 10032 USA.	rb670@columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585; Choudhury, Atish/0000-0001-9344-6631	NCI NIH HHS [T32-CA009503, CA97403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503, P01CA097403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Gatei M, 2000, CANCER RES, V60, P3299; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hayami R, 2005, CANCER RES, V65, P6; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kalkum M, 2003, P NATL ACAD SCI USA, V100, P2795, DOI 10.1073/pnas.0436605100; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 2001, CANCER RES, V61, P4842; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Qin J, 1997, ANAL CHEM, V69, P4002, DOI 10.1021/ac970489n; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tomlinson GE, 1998, CANCER RES, V58, P3237; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	67	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24669	24679		10.1074/jbc.M502446200	http://dx.doi.org/10.1074/jbc.M502446200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855157	hybrid			2022-12-25	WOS:000230114000047
J	Seo, J; Lozano, MM; Dudley, JP				Seo, J; Lozano, MM; Dudley, JP			Nuclear matrix binding regulates SATB1-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; T-CELL LYMPHOMAS; PROMOTER IN-VIVO; DNA-BINDING; GLUCOCORTICOID-RECEPTOR; ATTACHMENT REGION; PROTEIN SATB1; NEGATIVE REGULATION; GENE-EXPRESSION	Special AT-rich binding protein 1 (SATB1) originally was identified as a protein that bound to the nuclear matrix attachment regions (MARs) of the immunoglobulin heavy chain intronic enhancer. Subsequently, SATB1 was shown to repress many genes expressed in the thymus, including interleukin-2 receptor alpha, c-myc, and those encoded by mouse mammary tumor virus ( MMTV), a glucocorticoid-responsive retrovirus. SATB1 binds to MARs within the MMTV provirus to repress transcription. To address the role of the nuclear matrix in SATB1-mediated repression, a series of SATB1 deletion constructs was used to determine protein localization. Wild-type SATB1 localized to the soluble nuclear, chromatin, and nuclear matrix fractions. Mutants lacking amino acids 224 - 278 had a greatly diminished localization to the nuclear matrix, suggesting the presence of a nuclear matrix targeting sequence (NMTS). Transient transfection experiments showed that NMTS fusions to green fluorescent protein or LexA relocalized these proteins to the nuclear matrix. Difficulties with previous assay systems prompted us to develop retroviral vectors to assess effects of different SATB1 domains on expression of MMTV proviruses or integrated reporter genes. SATB1 overexpression repressed MMTV transcription in the presence and absence of functional glucocorticoid receptor. Repression was alleviated by deletion of the NMTS, which did not affect DNA binding, or by deletion of the MAR-binding domain. Our studies indicate that both nuclear matrix association and DNA binding are required for optimal SATB1-mediated repression of the integrated MMTV promoter and may allow insulation from cellular regulatory elements.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Dudley, JP (corresponding author), 1 Univ Stn,A5000,24th St & Speedway,ESB 226, Austin, TX 78712 USA.	jdudley@uts.cc.utexas.edu			NATIONAL CANCER INSTITUTE [R01CA034780, P01CA077760] Funding Source: NIH RePORTER; NCI NIH HHS [CA34780, CA77760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez JD, 2000, GENE DEV, V14, P521; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Belikov S, 2004, MOL CELL BIOL, V24, P3036, DOI 10.1128/MCB.24.7.3036-3047.2004; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BRAMBLETT D, 1995, J VIROL, V69, P7868, DOI 10.1128/JVI.69.12.7868-7876.1995; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COOK PR, 1982, EMBO J, V1, P447, DOI 10.1002/j.1460-2075.1982.tb01189.x; D'iachenko L B, 1994, Mol Biol (Mosk), V28, P1014; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DENG WP, 1994, MOL CELL BIOL, V14, P391, DOI 10.1128/MCB.14.1.391; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; DUDLEY JP, 1999, ENCY VIROLOGY, P965; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Guerrero-Santoro J, 2004, J CELL BIOCHEM, V92, P810, DOI 10.1002/jcb.20109; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HE WW, 1994, RECEPTOR, V4, P121; HELD W, 1994, J EXP MED, V180, P2347, DOI 10.1084/jem.180.6.2347; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; Kinyamu HK, 2004, BBA-GENE STRUCT EXPR, V1677, P30, DOI 10.1016/j.bbaexp.2003.09.015; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LUKACHER AE, 1995, J EXP MED, V181, P1683, DOI 10.1084/jem.181.5.1683; LUTHER S, 1994, EUR J IMMUNOL, V24, P1757, DOI 10.1002/eji.1830240806; MAKINO Y, 1993, BIOCHEM BIOPH RES CO, V197, P1146, DOI 10.1006/bbrc.1993.2597; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; MATSUZAWA A, 1995, J IMMUNOL, V154, P1644; MICHALIDES R, 1986, VIROLOGY, V154, P76, DOI 10.1016/0042-6822(86)90431-9; Nagaich AK, 2004, MOL CELL, V14, P163, DOI 10.1016/S1097-2765(04)00178-9; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; Namciu SJ, 2004, MOL CELL BIOL, V24, P10236, DOI 10.1128/MCB.24.23.10236-10245.2004; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nourry Claire, 2003, Sci STKE, V2003, pRE7; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; PAYVAR F, 1981, P NATL ACAD SCI-BIOL, V78, P6628, DOI 10.1073/pnas.78.11.6628; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENNINGER JM, 1995, EUR J IMMUNOL, V25, P2115, DOI 10.1002/eji.1830250748; Purdy A, 2003, J EXP MED, V197, P233, DOI 10.1084/jem.20021499; Rabson A. B., 1997, P205; ROMAGNOLO D, 1994, MOL CELL ENDOCRINOL, V102, P131, DOI 10.1016/0303-7207(94)90106-6; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; Rudolph-Owen LA, 1998, MOL BIOL CELL, V9, P421, DOI 10.1091/mbc.9.2.421; SILVER PA, 1986, MOL CELL BIOL, V6, P4763, DOI 10.1128/MCB.6.12.4763; SIMON M, 1994, LEUKEMIA, V8, pS12; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Stein GS, 2003, TRENDS CELL BIOL, V13, P584, DOI 10.1016/j.tcb.2003.09.009; SUNZERI FJ, 1993, CANCER LETT, V74, P57, DOI 10.1016/0304-3835(93)90044-A; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUZUKI S, 1993, BIOCHEM BIOPH RES CO, V197, P1194, DOI 10.1006/bbrc.1993.2603; TAICHMAN RS, 1993, BIOTECHNIQUES, V14, P180; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; TORRES BA, 1993, NATURE, V364, P152, DOI 10.1038/364152a0; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANKLAVEREN P, 1994, ANTICANCER RES, V14, P597; WARRIAR N, 1993, J STEROID BIOCHEM, V46, P699, DOI 10.1016/0960-0760(93)90311-J; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; WINTERSPERGER S, 1995, P NATL ACAD SCI USA, V92, P2745, DOI 10.1073/pnas.92.7.2745; YANG JN, 1992, J IMMUNOL, V149, P1242; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zaidi SK, 2001, J CELL SCI, V114, P3093; Zhu Q, 2000, J VIROL, V74, P6348, DOI 10.1128/JVI.74.14.6348-6357.2000; Zhu Q, 2004, MOL CELL BIOL, V24, P4810, DOI 10.1128/MCB.24.11.4810-4823.2004; Zhu Q, 2002, J VIROL, V76, P2168, DOI 10.1128/JVI.76.5.2168-2179.2002; Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430	81	46	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24600	24609		10.1074/jbc.M414076200	http://dx.doi.org/10.1074/jbc.M414076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851481	hybrid			2022-12-25	WOS:000230114000039
J	Li, XX; Dumont, P; Della Pietra, A; Shetler, C; Murphy, ME				Li, XX; Dumont, P; Della Pietra, A; Shetler, C; Murphy, ME			The codon 47 polymorphism in p53 is functionally significant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTING PROTEIN KINASE-2; P53-DEPENDENT APOPTOSIS; COLORECTAL-CANCER; UV-RADIATION; PUMA; PHOSPHORYLATION; SUSCEPTIBILITY; MEDIATOR; GENE	In addition to a common polymorphism at codon 72, the p53 tumor suppressor gene also contains a rare single nucleotide polymorphism at amino acid 47. Wild type p53 encodes proline at this residue, but in < 5% of African Americans, this amino acid is serine. Notably, phosphorylation of the adjacent serine 46 by the proline-directed kinase p38 MAPK is known to greatly enhance the ability of p53 to induce apoptosis. Here we showed that the serine 47 polymorphic variant, which replaces the proline residue necessary for recognition by proline-directed kinases, is a markedly poorer substrate for phosphorylation on serine 46 by p38 MAPK. Consistent with this finding, we showed that the serine 47 variant has up to 5-fold decreased ability to induce apoptosis compared with wild type p53. Mechanistically,we found that this variant has decreased ability to transactivate two p53 target genes, p53AIP1 and PUMA, but not other p53 response genes; this is the first time that phosphorylation of serine 46 has been implicated in transactivation of PUMA by p53. Down-regulation of PUMA in cells with wild type p53 using short interfering RNAs reduced apoptosis in these cells to a level comparable to that in cells containing the serine 47 variant. The combined data indicated that, like the codon 72 polymorphism, the codon 47 polymorphism of p53 is functionally significant and may play a role in cancer risk, progression, and the efficacy of therapy.	Fox Chase Canc Ctr, Program Cell & Dev Biol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Murphy, ME (corresponding author), Fox Chase Canc Ctr, Program Cell & Dev Biol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Maureen.Murphy@FCCC.edu		Murphy, Maureen/0000-0001-7644-7296				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; Hishida A, 2004, LEUKEMIA LYMPHOMA, V45, P957, DOI 10.1080/10428190310001638878; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jones JS, 2004, CLIN CANCER RES, V10, P5845, DOI 10.1158/1078-0432.CCR-03-0590; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Xi YG, 2004, CARCINOGENESIS, V25, P2201, DOI 10.1093/carcin/bgh229; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	25	87	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24245	24251		10.1074/jbc.M414637200	http://dx.doi.org/10.1074/jbc.M414637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851479	hybrid			2022-12-25	WOS:000229880000101
J	Prade, L; Jones, AF; Boss, C; Bildstein, SR; Meyer, S; Binkert, C; Bur, D				Prade, L; Jones, AF; Boss, C; Bildstein, SR; Meyer, S; Binkert, C; Bur, D			X-ray structure of plasmepsin II complexed with a potent achiral inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM FOOD VACUOLE; PLASMODIUM-FALCIPARUM; ASPARTIC PROTEINASE; ACTIVE-SITE; IN-VITRO; PROTEASE; BINDING; DISRUPTION; DESIGN; FAMILY	The malaria parasite Plasmodium falciparum degrades host cell hemoglobin inside an acidic food vacuole during the blood stage of the infectious cycle. A number of aspartic proteinases called plasmepsins (PMs) have been identified to play important roles in this degradation process and therefore generated significant interest as new antimalarial targets. Several x-ray structures of PMII have been described previously, but thus far, structure-guided drug design has been hampered by the fact that only inhibitors comprising a statine moiety or derivatives thereof have been published. Our drug discovery efforts to find innovative, cheap, and easily synthesized inhibitors against aspartic proteinases yielded some highly potent non-peptidic achiral inhibitors. A highly resolved (1.6 angstrom) x-ray structure of PMII is presented, featuring a potent achiral inhibitor in an unprecedented orientation, contacting the catalytic aspartates indirectly via the "catalytic" water. Major side chain rearrangements in the active site occur, which open up a new pocket and allow a new binding mode of the inhibitor. Moreover, a second inhibitor molecule could be located unambiguously in the active site of PMII. These newly obtained structural insights will further guide our attempts to improve compound properties eventually leading to the identification of molecules suitable as antimalarial drugs.	Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland	Actelion Pharmaceuticals Ltd	Bur, D (corresponding author), Actel Pharmaceut Ltd, Gewerbestr 16, CH-4123 Allschwil, Switzerland.	daniel.bur@actelion.com						Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6; Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bernstein NK, 1999, NAT STRUCT BIOL, V6, P32, DOI 10.1038/4905; Berry C, 1999, FEBS LETT, V447, P149, DOI 10.1016/S0014-5793(99)00276-8; Boss C, 2003, CURR MED CHEM, V10, P883, DOI 10.2174/0929867033457674; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Carcache DA, 2002, CHEMBIOCHEM, V3, P1137, DOI 10.1002/1439-7633(20021104)3:11<1137::AID-CBIC1137>3.0.CO;2-A; Coburn CA, 2004, J MED CHEM, V47, P6117, DOI 10.1021/jm049388p; Erskine PT, 2003, PROTEIN SCI, V12, P1741, DOI 10.1110/ps.0305203; Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g; Fraser ME, 1998, ADV EXP MED BIOL, V436, P355; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; HILL J, 1994, FEBS LETT, V352, P155, DOI 10.1016/0014-5793(94)00940-6; Istvan ES, 2005, J BIOL CHEM, V280, P6890, DOI 10.1074/jbc.M412086200; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z; Oefner C, 1999, CHEM BIOL, V6, P127, DOI 10.1016/S1074-5521(99)89004-8; Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; *WHO, 2004, WHO FACT SHEET	29	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23837	23843		10.1074/jbc.M501519200	http://dx.doi.org/10.1074/jbc.M501519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840589	Green Published, hybrid			2022-12-25	WOS:000229880000056
J	Shin, YG; Klucken, J; Patterson, C; Hyman, BT; McLean, PJ				Shin, YG; Klucken, J; Patterson, C; Hyman, BT; McLean, PJ			The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; E3 UBIQUITIN LIGASE; LEWY BODY DISEASE; PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES; HUNTINGTONS-DISEASE; DROSOPHILA MODEL; IN-VITRO; BODIES; AGGREGATION	alpha-Synuclein is a major component of Lewy bodies, the pathological hallmark of Parkinson disease, dementia with Lewy bodies, and related disorders. Misfolding and aggregation of alpha-synuclein is thought to be a critical cofactor in the pathogenesis of certain neurodegenerative diseases. In the current study, we investigate the role of the carboxyl terminus of Hsp70-interacting protein ( CHIP) in alpha-synuclein aggregation. We demonstrate that CHIP is a component of Lewy bodies in the human brain, where it colocalizes with alpha-synuclein and Hsp70. In a cell culture model, endogenous CHIP colocalizes with alpha-synuclein and Hsp70 in intracellular inclusions, and overexpression of CHIP inhibits alpha-synuclein inclusion formation and reduces alpha-synuclein protein levels. We demonstrate that CHIP can mediate alpha-synuclein degradation by two discrete mechanisms that can be dissected using deletion mutants; the tetratricopeptide repeat domain is critical for proteasomal degradation, whereas the U-box domain is sufficient to direct alpha-synuclein toward the lysosomal degradation pathway. Furthermore, alpha-synuclein, synphilin-1, and Hsp70 all co-immunoprecipitate with CHIP, raising the possibility of a direct alpha-synuclein-CHIP interaction. The fact that the tetratricopeptide repeat domain is required for the effects of CHIP on alpha-synuclein inclusion morphology, number of inclusions, and proteasomal degradation as well as the direct interaction of CHIP with Hsp70 implicates a cooperation of CHIP and Hsp70 in these processes. Taken together, these data suggest that CHIP acts a molecular switch between proteasomal and lysosomal degradation pathways.	Massachusetts Gen Hosp, Dept Neurol, Alzheimer Dis Res Unit, Charlestown, MA 02129 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	McLean, PJ (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Alzheimer Dis Res Unit, 114 16th St, Charlestown, MA 02129 USA.	pmclean@partners.org		McLean, Pamela/0000-0003-4870-5715	NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH068855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005134] Funding Source: NIH RePORTER; NIA NIH HHS [AG05134-20] Funding Source: Medline; NIMH NIH HHS [1R24MH68855] Funding Source: Medline; NINDS NIH HHS [NS 38372] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DICKSON DW, 1989, ACTA NEUROPATHOL, V78, P572, DOI 10.1007/BF00691284; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; KOSAKA K, 1978, ACTA NEUROPATHOL, V42, P127, DOI 10.1007/BF00690978; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2004, BIOCHEM BIOPH RES CO, V321, P665, DOI 10.1016/j.bbrc.2004.07.021; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takahashi R, 2003, J NEUROL, V250, P25, DOI 10.1007/s00415-003-1305-8; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	62	261	277	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23727	23734		10.1074/jbc.M503326200	http://dx.doi.org/10.1074/jbc.M503326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845543	Green Published, hybrid			2022-12-25	WOS:000229880000041
J	Tang, J; Qi, XM; Mercola, D; Han, JH; Chen, G				Tang, J; Qi, XM; Mercola, D; Han, JH; Chen, G			Essential role of p38 gamma in K-ras transformation independent of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; COLON-CANCER; MAP KINASES; VITAMIN-D; C-JUN; PDZ DOMAIN; CELL-DEATH; P38; PATHWAY; EXPRESSION	MAPK cascades play the critical role in regulating Ras oncogene activity by phosphorylation-dependent mechanisms. Whereas the ERK MAPK pathway is required for Ras transformation, our previous works established that the p38 activity is inhibitory to Ras signaling in both experimental and ras-mutated cancer cells ( Chen, G., Hitomi, M., Han, J., and Stacey, D. W. ( 2000) J. Biol. Chem. 275, 38973 - 38980; Qi, X., Tang, J., Pramanik, R., Schultz, R. M., Shirasawa, S., Sasazuki, T., Han, J., and Chen, G. ( 2004) J. Biol. Chem., 279, 22138 - 22144). Here we report that K-Ras activated p38 gamma, a p38 MAPK family member, by inducing its expression without increasing its phosphorylation and that depletion of induced p38 gamma suppressed Ras transformation in rat intestinal epithelial cells. This p38 gamma activity contrasts with that of its family member, p38 gamma, which is activated by Ras through phosphorylation, leading to an inhibition of Ras transformation. Mechanistic analyses showed that unphosphorylated p38 gamma may promote Ras transformation through an increased complex formation with ERK proteins. Significantly, functional p38 gamma protein was expressed only in K-ras-mutated human colon cancer cells, and p38 gamma transcripts were ubiquitously increased in a set of primary human colon cancer tissues. These studies thus demonstrate the essential role of p38 gamma in K-Ras transformation independent of phosphorylation, and elevated p38 gamma may serve as a novel diagnostic marker and therapeutic target for human colon cancer.	Loyola Univ, VA Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA; Loyola Univ, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; Loyola Univ, Program Mol Biol & Biochem, Maywood, IL 60153 USA; Sidney Kimmel Canc Ctr, Dept Canc Gene Therapy, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Scripps Research Institute	Chen, G (corresponding author), Loyola Univ, VA Med Ctr, Dept Radiat Oncol, Bldg 1,B303,2160 S 1st Ave, Maywood, IL 60153 USA.	gchen1@lumc.edu	mercola, dan/L-4182-2013; Han, J/G-4671-2010	mercola, dan/0000-0002-0281-9840; 	NCI NIH HHS [CA91576, U01 CA114810, R01 CA091576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA114810, R01CA091576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi T, 2003, CANCER RES, V63, P4521; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen G, 1999, ONCOGENE, V18, P7149, DOI 10.1038/sj.onc.1203149; Chou FL, 2003, J BIOL CHEM, V278, P52587, DOI 10.1074/jbc.M309322200; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Efimova T, 2004, MOL CELL BIOL, V24, P8167, DOI 10.1128/MCB.24.18.8167-8183.2004; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Ishibe S, 2004, MOL CELL, V16, P257, DOI 10.1016/j.molcel.2004.10.006; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Qi XM, 2004, J BIOL CHEM, V279, P6769, DOI 10.1074/jbc.M311492200; Qi XM, 2002, J BIOL CHEM, V277, P25884, DOI 10.1074/jbc.M203039200; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sabio G, 2004, BIOCHEM J, V380, P19, DOI 10.1042/BJ20031628; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Tang J, 2003, J VIROL, V77, P5975, DOI 10.1128/JVI.77.10.5975-5984.2003; Tortorella LL, 2003, BIOCHEM BIOPH RES CO, V306, P163, DOI 10.1016/S0006-291X(03)00936-7; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	59	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23910	23917		10.1074/jbc.M500699200	http://dx.doi.org/10.1074/jbc.M500699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851477	hybrid, Green Accepted			2022-12-25	WOS:000229880000065
J	Tynan, FE; Borg, NA; Miles, JJ; Beddoe, T; El-Hassen, D; Silins, SL; van Zuylen, WJM; Purcell, AW; Kjer-Nielsen, L; McCluskey, J; Burrows, SR; Rossjohn, J				Tynan, FE; Borg, NA; Miles, JJ; Beddoe, T; El-Hassen, D; Silins, SL; van Zuylen, WJM; Purcell, AW; Kjer-Nielsen, L; McCluskey, J; Burrows, SR; Rossjohn, J			High resolution structures of highly bulged viral Epitopes bound to major histocompatibility complex class I - Implications for T-cell receptor engagement and T-cell immunodominance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CYTOTOXIC LYMPHOCYTES-T; EPSTEIN-BARR-VIRUS; PEPTIDE-BINDING; HLA-B-ASTERISK-3501 MOLECULES; ANTIGEN PRESENTATION; CRYSTAL-STRUCTURES; ANCHOR RESIDUES; ALPHA-BETA; C-TERMINUS	Although HLA class I alleles can bind epitopes up to 14 amino acids in length, little is known about the immunogenicity or the responding T-cell repertoire against such determinants. Here, we describe an HLA-B*3508-restricted cytotoxic T lymphocyte response to a 13-mer viral epitope (LPEPLPQGQLTAY). The rigid, centrally bulged epitope generated a biased T-cell response. Only the N-terminal face of the peptide bulge was critical for recognition by the dominant clonotype SB27. The SB27 public T-cell receptor (TcR) associated slowly onto the complex between the bulged peptide and the major histocompatibility complex, suggesting significant remodeling upon engagement. The broad antigen-binding cleft of HLA-B*3508 represents a critical feature for engagement of the public TcR, as the narrower binding cleft of HLA-B*3501(LPEPLPQGQLTAY), which differs from HLA-B*3508 by a single amino acid polymorphism (Arg(156) -> Leu), interacted poorly with the dominant TcR. Biased TcR usage in this cytotoxic T lymphocyte response appears to reflect a dominant role of the prominent peptide(.)major histocompatibility complex class I surface.	Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia; Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Monash Univ, Sch Biomed Sci, Dept Biochem & Mol Biol, Prot Crystallog Unit, Clayton, Vic 3800, Australia	QIMR Berghofer Medical Research Institute; University of Melbourne; Monash University	Rossjohn, J (corresponding author), Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia.	Jamie.Rossjohn@med.monash.edu.au	Miles, John J/ABC-1105-2020; Rossjohn, Jamie/F-9032-2013; McCluskey, James/A-1291-2007; Purcell, Anthony/AAH-1942-2019; Miles, John/H-4975-2011; Burrows, Scott/G-2050-2011; Beddoe, Travis/F-3415-2014	Miles, John J/0000-0001-5506-6304; Rossjohn, Jamie/0000-0002-2020-7522; McCluskey, James/0000-0002-8597-815X; Purcell, Anthony/0000-0003-0532-8331; Burrows, Scott/0000-0002-1430-0472; Beddoe, Travis/0000-0003-4550-2277; Borg, Natalie/0000-0002-8677-9056	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Androlewicz MJ, 1996, IMMUNITY, V5, P1, DOI 10.1016/S1074-7613(00)80304-0; ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; Bertoni R, 1998, J IMMUNOL, V161, P4447; BLUESTONE JA, 1986, J IMMUNOL, V137, P1244; Borg NA, 2005, NAT IMMUNOL, V6, P171, DOI 10.1038/ni1155; Boulter JM, 2003, PROTEIN ENG, V16, P707, DOI 10.1093/protein/gzg087; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Callan MFC, 2000, J CLIN INVEST, V106, P1251, DOI 10.1172/JCI10590; CALLAN MFC, 1995, ANN NY ACAD SCI, V756, P94, DOI 10.1111/j.1749-6632.1995.tb44488.x; Callan MFC, 1999, SPRINGER SEMIN IMMUN, V21, P37, DOI 10.1007/s002810050051; Callan MFC, 1998, EUR J IMMUNOL, V28, P4382, DOI 10.1002/(SICI)1521-4141(199812)28:12<4382::AID-IMMU4382>3.3.CO;2-Q; CHEN Y, 1994, J IMMUNOL, V152, P2874; Davis MM, 2003, NAT IMMUNOL, V4, P649, DOI 10.1038/ni0703-649; DERES K, 1993, CELL IMMUNOL, V151, P158, DOI 10.1006/cimm.1993.1228; Dyall R, 2000, J IMMUNOL, V164, P1695, DOI 10.4049/jimmunol.164.4.1695; FALK K, 1993, IMMUNOGENETICS, V38, P161, DOI 10.1007/BF00190906; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; Green KJ, 2004, EUR J IMMUNOL, V34, P2510, DOI 10.1002/eji.200425193; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Horig H, 1999, J IMMUNOL, V163, P4434; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kedzierska K, 2004, P NATL ACAD SCI USA, V101, P4942, DOI 10.1073/pnas.0401279101; Khanna R, 1999, EUR J IMMUNOL, V29, P1587, DOI 10.1002/(SICI)1521-4141(199905)29:05<1587::AID-IMMU1587>3.3.CO;2-N; Kjer-Nielsen L, 2003, IMMUNITY, V18, P53, DOI 10.1016/S1074-7613(02)00513-7; Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207; LOMBARDI G, 1991, IMMUNOGENETICS, V34, P149; LOPEZ D, 1994, J IMMUNOL, V152, P5557; Macdonald W, 2002, FEBS LETT, V527, P27, DOI 10.1016/S0014-5793(02)03149-6; Macdonald WA, 2003, J EXP MED, V198, P679, DOI 10.1084/jem.20030066; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARGULIES D, 2003, FUNDAMENTAL IMMUNOLO; Maryanski JL, 1997, HUM IMMUNOL, V54, P117, DOI 10.1016/S0198-8859(97)00082-7; Menssen R, 1999, J MOL BIOL, V285, P645, DOI 10.1006/jmbi.1998.2363; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Mongkolsapaya J, 1999, J VIROL, V73, P67, DOI 10.1128/JVI.73.1.67-71.1999; MURRAY R, 1988, P NATL ACAD SCI USA, V85, P3535, DOI 10.1073/pnas.85.10.3535; NORDA M, 1993, J IMMUNOTHER, V14, P144, DOI 10.1097/00002371-199308000-00010; PANZARA MA, 1992, BIOTECHNIQUES, V12, P728; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; PARHAM P, 1979, J IMMUNOL, V123, P342; Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; SCHONBACH C, 1995, J IMMUNOL, V154, P5951; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sette A, 2003, IMMUNOGENETICS, V54, P830, DOI 10.1007/s00251-002-0530-0; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; SIDNEY J, 1995, J IMMUNOL, V154, P247; Smith KJ, 1996, IMMUNITY, V4, P203, DOI 10.1016/S1074-7613(00)80429-X; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; Steinle A, 1996, IMMUNOGENETICS, V43, P105; Stewart-Jones GBE, 2003, NAT IMMUNOL, V4, P657, DOI 10.1038/ni942; Stryhn A, 2000, EUR J IMMUNOL, V30, P3089, DOI 10.1002/1521-4141(200011)30:11<3089::AID-IMMU3089>3.0.CO;2-5; TAKAMIYA Y, 1994, INT IMMUNOL, V6, P255; Uebel S, 1999, CURR OPIN IMMUNOL, V11, P203, DOI 10.1016/S0952-7915(99)80034-X; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VILLADANGOS JA, 1992, J IMMUNOL, V149, P505; Wilson I A, 1993, Semin Immunol, V5, P75, DOI 10.1006/smim.1993.1011; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Zavala-Ruiz Z, 2004, P NATL ACAD SCI USA, V101, P13279, DOI 10.1073/pnas.0403371101; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	76	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23900	23909		10.1074/jbc.M503060200	http://dx.doi.org/10.1074/jbc.M503060200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849183	hybrid			2022-12-25	WOS:000229880000064
J	Shi, YY; Hong, XG; Wang, CC				Shi, YY; Hong, XG; Wang, CC			The c-terminal (331-376) sequence of Escherichia coli DnaJ is essential for dimerization and chaperone activity - A small angle x-ray scattering study in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE OXIDOREDUCTASE ACTIVITIES; FINGER-LIKE DOMAIN; SHAPE DETERMINATION; CRYSTAL-STRUCTURE; PEPTIDE-BINDING; ZINC FINGERS; PROTEIN; RESOLUTION; HOMOLOG; PURIFICATION	DnaJ, an Escherichia coli Hsp40 protein composed of 376 amino acid residues, is a chaperone with thioldisulfide oxidoreductase activity. We present here for the first time a small angle x-ray scattering study of intact DnaJ and a truncated version, DnaJ (1-330), in solution. The molecular weight of DnaJ and DnaJ (1-330) determined by both small angle x-ray scattering and size-exclusion chromatography provide direct evidence that DnaJ is a homodimer and DnaJ (1-330) is a monomer. The restored models show that DnaJ is a distorted omega-shaped dimeric molecule with the C terminus of each subunit forming the central part of the omega, whereas DnaJ (1-330) exists as a monomer. This indicates that the deletion of the C-terminal 46 residues of DnaJ impairs the association sites, although it does not cause significant conformational changes. Biochemical studies reveal that DnaJ (1-330), while fully retaining its thiol-disulfide oxidoreductase activity, is structurally less stable, and its peptide binding capacity is severely impaired relative to that of the intact molecule. Together, our results reveal that the C-terminal (331-376) residues are directly involved in dimerization, and the dimeric structure of DnaJ is necessary for its chaperone activity but not required for the thiol-disulfide oxidoreductase activity.	Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst High Energy Phys, Beijing 100039, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, CC (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.	chihwang@sun5.ibp.ac.cn		Hong, Xinguo/0000-0001-8994-219X				Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Guinier A., 1955, SMALL ANGLE SCATTERI; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; Izumi Y, 2001, FEBS LETT, V495, P126, DOI 10.1016/S0014-5793(01)02375-4; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Li JZ, 2003, STRUCTURE, V11, P1475, DOI 10.1016/j.str.2003.10.012; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; Linke K, 2003, J BIOL CHEM, V278, P44457, DOI 10.1074/jbc.M307491200; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PIGIET VP, 1986, P NATL ACAD SCI USA, V83, P7643, DOI 10.1073/pnas.83.20.7643; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; SHERMAN MY, 1992, EMBO J, V11, P71; Shi YY, 2005, BIOCHEMISTRY-US, V44, P1683, DOI 10.1021/bi0480943; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Tang W, 2001, BIOCHEMISTRY-US, V40, P14985, DOI 10.1021/bi0107593; Toutain CM, 2003, MOL GENET GENOMICS, V268, P761, DOI 10.1007/s00438-002-0`/93-z; TSOU CL, 1995, BBA-PROTEIN STRUCT M, V1253, P151, DOI 10.1016/0167-4838(95)00172-5; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; Zhao Z, 2003, J BIOL CHEM, V278, P43292, DOI 10.1074/jbc.M306945200; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	43	41	44	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22761	22768		10.1074/jbc.M503643200	http://dx.doi.org/10.1074/jbc.M503643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849180	hybrid			2022-12-25	WOS:000229741800026
J	Swant, JD; Rendon, BE; Symons, M; Mitchell, RA				Swant, JD; Rendon, BE; Symons, M; Mitchell, RA			Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR MIF; FAMILY GTPASES; SMOOTH-MUSCLE; MYOSIN PHOSPHATASE; INVARIANT CHAIN; REGULATORY ROLE; G(1) PHASE; G1 PHASE; IN-VITRO	Our previous studies demonstrated that the proinflammatory peptide, macrophage migration inhibitory factor (MIF), functions as an autocrine mediator of both growth factor- and integrin-dependent sustained ERK MAPK activation, cyclin D1 expression, and cell cycle progression. We now report that MIF promotes the activation of the canonical ERK MAPK cascade and cyclin D1 expression by stimulating the activity of the Rho GTPase and downstream signaling to stress fiber formation. Rho-dependent stress fiber accumulation promotes the sustained activation of ERK and subsequent cyclin D1 expression during G(1)-S phase cell cycle progression. This pathway is reported to be dependent upon myosin light chain (MLC) kinase, integrin clustering, and subsequent activation of focal adhesion kinase, leading to sustained MAPK activity. Our studies reveal that recombinant MIF induces cyclin D1 expression in a Rho-, Rho kinase-, MLC kinase-, and ERK-dependent manner in asynchronous NIH 3T3 fibroblasts. Moreover, MIF-/- murine embryonic fibroblasts display aberrant cyclin D1 expression that is linked to defective Rho activity, stress fiber formation, and MLC phosphorylation. These results suggest that MIF is an integral autocrine mediator of Rho GTPase-dependent signaling events and provide mechanistic insight into how MIF regulates proliferative, migratory, and oncogenic processes.	Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Shore Long Isl Jewish Res Inst, Manhasset, NY 11030 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA	University of Louisville; University of Louisville; Northwell Health; University of Louisville	Mitchell, RA (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Delia Baxter Res Bldg,580 S Preston St, Louisville, KY 40202 USA.	robert.mitchell@louisville.edu			NATIONAL CANCER INSTITUTE [R01CA102285] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102285, CA 102285] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Eto M, 2004, P NATL ACAD SCI USA, V101, P8888, DOI 10.1073/pnas.0307812101; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Kitazawa T, 2003, J PHYSIOL-LONDON, V546, P879, DOI 10.1113/jphysiol.2002.029306; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Liao H, 2003, J BIOL CHEM, V278, P76, DOI 10.1074/jbc.M208820200; Makrydimas G, 2003, IN VIVO, V17, P633; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Meyer-Siegler K, 1998, DIAGN MOL PATHOL, V7, P44, DOI 10.1097/00019606-199802000-00008; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; PETRENKO O, 2003, J BIOL CHEM; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Roovers K, 2003, DEV CELL, V5, P273, DOI 10.1016/S1534-5807(03)00206-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; White ES, 2001, J IMMUNOL, V166, P7549, DOI 10.4049/jimmunol.166.12.7549; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; Zemlickova E, 2004, BIOCHEM BIOPH RES CO, V316, P39, DOI 10.1016/j.bbrc.2004.02.014	53	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23066	23072		10.1074/jbc.M500636200	http://dx.doi.org/10.1074/jbc.M500636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840582	hybrid, Green Accepted			2022-12-25	WOS:000229741800063
J	Grotendorst, GR; Duncan, MR				Grotendorst, GR; Duncan, MR			Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation	FASEB JOURNAL			English	Article						fibrosis; cytokine; cell proliferation	IMMEDIATE-EARLY GENE; TGF-BETA; NRK FIBROBLASTS; CELL-GROWTH; CCN FAMILY; EXPRESSION; CYR61; CANCER; IDENTIFICATION; OVEREXPRESSION	All members of the Ctgf, Cyr61, and Nov (CCN) family share a high degree of sequence homology and conservation of structural motifs and domains. Here, we present data about a structure function analysis of connective tissue growth factor (CTGF), a prototypic member of the CCN family, which has been shown to be a downstream mediator of transforming growth factor-beta activities on fibroblasts. Our findings demonstrate the two domains of CTGF function to mediate two distinct biological effects. The N-terminal domain of CTGF mediates myofibroblast differentiation and collagen synthesis. The C-terminal domain of CTGF mediates fibroblast proliferation. These data provide a molecular basis for the divergence of CTGF actions on connective tissue cell types and suggest a model for functional analysis of all of the CCN family gene products.	Lovelace Resp Res Inst, Albuquerque, NM 87108 USA	Lovelace Respiratory Research Institute	Grotendorst, GR (corresponding author), Lovelace Resp Res Inst, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	ggrotend@lrri.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065603] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 65603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; Ayer-Lelievre C., 2001, Molecular Pathology, V54, P105, DOI 10.1136/mp.54.2.105; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Fan WH, 2000, EUR J CELL BIOL, V79, P915, DOI 10.1078/0171-9335-00122; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grotendorst GR, 2004, FASEB J, V18, P469, DOI 10.1096/fj.03-0699com; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Hishikawa K, 1999, CIRCULATION, V100, P2108, DOI 10.1161/01.CIR.100.20.2108; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; HOLTEN J, 1990, NINA NOTAT, V4, P1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kothapalli D, 2000, J CELL PHYSIOL, V182, P119, DOI 10.1002/(SICI)1097-4652(200001)182:1<119::AID-JCP13>3.0.CO;2-4; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; MURRAY GT, 1993, MATER ENGN, V2, P1; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Roberts AB, 2002, CYTOKINE GROWTH F R, V13, P3, DOI 10.1016/S1359-6101(01)00027-2; Robertson G, 2001, UASGCP REP, V2001, P43; Roestenberg P, 2004, DIABETES CARE, V27, P1164, DOI 10.2337/diacare.27.5.1164; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Yang DH, 1998, J CLIN ENDOCR METAB, V83, P2593, DOI 10.1210/jc.83.7.2593; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	44	163	192	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					729	738		10.1096/fj.04-3217com	http://dx.doi.org/10.1096/fj.04-3217com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857887				2022-12-25	WOS:000229602600029
J	Xie, C; Prahl, A; Ericksen, B; Wu, ZB; Zeng, PY; Li, XQ; Lu, WY; Lubkowski, J; Lu, WY				Xie, C; Prahl, A; Ericksen, B; Wu, ZB; Zeng, PY; Li, XQ; Lu, WY; Lubkowski, J; Lu, WY			Reconstruction of the conserved beta-bulge in mammalian defensins using D-amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-DEFENSINS; ANTIMICROBIAL PEPTIDES; MEMBRANE PERMEABILIZATION; NEUTROPHIL DEFENSINS; DENDRITIC CELLS; PROTEIN; DESIGN; BETA-DEFENSIN-2; SPECIFICITY; DESTABILIZATION	Defensins are cationic antimicrobial mini-proteins that play important roles in the innate immune defense against microbial infection. Six invariant Cys residues in each defensin form three structurally indispensable intramolecular disulfide bridges. The only other residue invariant in all known mammalian defensins is a Gly. Structural studies indicate that the invariant Gly residue is located in an atypical, classic-type beta-bulge with the backbone torsion angles ( phi, psi) disallowed for L-amino acids but permissible for D-enantiomers. We replaced the invariant Gly(17) residue in human neutrophil alpha-defensin 2 (HNP2) by L-Ala or one of the D-amino acids Ala, Glu, Phe, Arg, Thr, Val, or Tyr. Although L-Ala(17)-HNP2 could not be folded, resulting in massive aggregation, all of the D-amino acid-substituted analogs folded with high efficiency. The high resolution x-ray crystal structures of dimeric D-Ala(17)-HNP2 were determined in three different crystal forms, showing a well preserved beta-bulge identical to those found in other defensins. The seven D-analogs of HNP2 exhibited highly variable bactericidal activity against Gram-positive and Gram-negative test strains, consistent with the premise that interplay between charge and hydrophobicity dictates how amphiphilic defensins kill. Further, the bactericidal activity of these D-amino acid analogs of HNP2 correlated well with their ability to induce leakage from large unilamellar vesicles, supporting membrane permeabilization as the lethal event in microbial killing by HNP2. Our findings identify a conformational prerequisite in the beta-bulge of defensins essential for correct folding and native structure, thereby explaining the molecular basis of the Gly-Xaa-Cys motif conserved in all mammalian defensins.	NCI, Macromol Assembly Struct & Cell Signaling Sect, NIH, Frederick, MD 21702 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; Fudan Univ, Sch Pharm, Fudan PharmCo Drug Target Res Ctr, Shanghai 200032, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Fudan University	Lubkowski, J (corresponding author), NCI, Macromol Assembly Struct & Cell Signaling Sect, NIH, Frederick, MD 21702 USA.	jacek@ncifcrf.gov; luw@umbi.umd.edu	Lu, Wuyuan/B-2268-2010; Lu, Weiyue/E-7938-2010; Prahl, Adam/H-7654-2014; Lu, Wuyuan/J-8452-2017; Ericksen, Bryan/F-9047-2012	Lu, Wuyuan/0000-0003-1318-9968; Ericksen, Bryan/0000-0002-8016-8289; Prahl, Adam/0000-0001-7663-6548	NATIONAL CANCER INSTITUTE [Z01SC010386, ZIASC010386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061482, R21AI056264] Funding Source: NIH RePORTER; NIAID NIH HHS [AI061482, AI056264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts B., 1994, MOL BIOL CELL; Axe DD, 1999, J MOL BIOL, V286, P1471, DOI 10.1006/jmbi.1999.2569; Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Blondelle SE, 1999, BBA-BIOMEMBRANES, V1462, P89, DOI 10.1016/S0005-2736(99)00202-3; Brock T.P., 1991, BIOL MICROORGANISMS, V340; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Chen PY, 2001, PROTEIN SCI, V10, P2063, DOI 10.1110/ps.07101; Di Nardo AA, 2004, P NATL ACAD SCI USA, V101, P7954, DOI 10.1073/pnas.0400550101; DionSchultz A, 1997, PROTEIN ENG, V10, P263, DOI 10.1093/protein/10.3.263; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Ericksen B, 2005, ANTIMICROB AGENTS CH, V49, P269, DOI 10.1128/AAC.49.1.269-275.2005; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FAIRMAN R, 1992, J AM CHEM SOC, V114, P5458, DOI 10.1021/ja00039a086; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; IMPERIALI B, 1992, J AM CHEM SOC, V114, P3182, DOI 10.1021/ja00035a002; KEEFE LJ, 1994, PROTEIN SCI, V3, P391; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Krause E, 2000, J AM CHEM SOC, V122, P4865, DOI 10.1021/ja9940524; KREIL G, 1994, SCIENCE, V266, P996, DOI 10.1126/science.7973683; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; Mitchell JBO, 2003, PROTEINS, V50, P563, DOI 10.1002/prot.10320; Ottesen JJ, 2001, NAT STRUCT BIOL, V8, P535, DOI 10.1038/88604; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Struthers MD, 1996, J AM CHEM SOC, V118, P3073, DOI 10.1021/ja954014u; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Tanabe H, 2004, J BIOL CHEM, V279, P11976, DOI 10.1074/jbc.M310251200; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Wu Z, 2004, J PEPT RES, V64, P118, DOI 10.1111/j.1399-3011.2004.00179.x; Wu Z, 2003, J PEPT RES, V62, P53, DOI 10.1034/j.1399-3011.2003.00068.x; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Wu ZB, 2003, J AM CHEM SOC, V125, P2402, DOI 10.1021/ja0294257; Yang D, 2000, J LEUKOCYTE BIOL, V68, P9; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yount NY, 2004, P NATL ACAD SCI USA, V101, P7363, DOI 10.1073/pnas.0401567101	64	63	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32921	32929		10.1074/jbc.M503084200	http://dx.doi.org/10.1074/jbc.M503084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	15894545	hybrid			2022-12-25	WOS:000231920300047
J	Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A				Mirkin, BL; Clark, S; Zheng, X; Chu, F; White, BD; Greene, M; Rebbaa, A			Identification of midkine as a mediator for intercellular transfer of drug resistance	ONCOGENE			English	Article						midkine; drug resistance; apoptosis; senescence; Akt; p21/WAF1	ACID-RESPONSIVE GENE; CLINICAL RESISTANCE; INDUCED APOPTOSIS; CONSTANT LIGHT; CANCER-THERAPY; TUMOR-CELLS; SURVIVAL; DEATH; NEURONS; GROWTH	Resistance to cytotoxic agents is a major limitation for their clinical use to treat human cancers. Tumors become resistant to chemotherapy when a subset of cells undergoes molecular changes leading to overexpression of drug transport proteins, alterations in drug-target interactions or reduced ability to commit apoptosis. However, such changes may not be sufficient to explain why both resistant and nonresistant cells survive drug's action in tumors that ultimately become drug resistant. We hypothesized that, in such tumors, a cytoprotective relationship may exist between drug-resistant and neighboring drug-sensitive cells. The present study addresses the possibility that drug-resistant cells secrete in their culture medium factors able to protect sensitive cells from drug toxicity. A survival molecule, midkine, was identified by cDNA array to be expressed only in drug-resistant cells. Midkine-enriched fractions obtained by affinity chromatography exert a significant cytoprotective effect against doxorubicin in the wild-type drug-sensitive cells. Moreover, transfection of these cells with the midkine gene caused a decreased response to doxorubicin. The underlying mechanism of this cytoprotection appeared to imply activation of the Akt pathway and inhibition of drug-induced proliferation arrest as well as apoptotic cell death. These findings provide evidence for the existence of intercellular cytoprotective signals such as the one mediated by midkine, originating from cells with acquired drug resistance to protect neighboring drug-sensitive cells and thus contribute to development of resistance to chemotherapy.	Childrens Mem Res Ctr, Canc Biol Program, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60614 USA; Univ Washington, Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ Chicago, Ben May Inst, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Washington; University of Washington Seattle; University of Chicago	Rebbaa, A (corresponding author), Childrens Mem Res Ctr, Canc Biol Program, 2430 N Halsted,Box 224, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org			NCI NIH HHS [1R01 CA096616-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Fulda S, 2003, CANCER LETT, V197, P131, DOI 10.1016/S0304-3835(03)00091-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ikematsu S, 2003, BRIT J CANCER, V88, P1522, DOI 10.1038/sj.bjc.6600938; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; MASUDA K, 1995, INVEST OPHTH VIS SCI, V36, P2142; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Owada K, 1999, J NEUROCHEM, V73, P2084; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; Schmitt E, 1997, BIOCHEM CELL BIOL, V75, P301, DOI 10.1139/bcb-75-4-301; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P4063; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009	36	55	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4965	4974		10.1038/sj.onc.1208671	http://dx.doi.org/10.1038/sj.onc.1208671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897897				2022-12-25	WOS:000230646500009
J	Itoh, S; Lemay, S; Osawa, M; Che, W; Duan, YT; Tompkins, A; Brookes, PS; Sheu, SS; Abe, J				Itoh, S; Lemay, S; Osawa, M; Che, W; Duan, YT; Tompkins, A; Brookes, PS; Sheu, SS; Abe, J			Mitochondrial Dok-4 recruits Src kinase and regulates NF-kappa B activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; TYROSINE PHOSPHORYLATION; NITRIC-OXIDE; BINDING DOMAIN; FREE-RADICALS; INSULIN; FAMILY; MECHANISM; ADHESION; P62(DOK)	The downstream of kinase (Dok) family of adapter proteins consists of at least five members structurally characterized by an NH2-terminal tandem of conserved pleckstrin homology and phosphotyrosine binding domains linked to a unique COOH-terminal region. To determine the role of the novel adapter protein Dok-4 in endothelial cells, we first investigated the cell localization of Dok-4. Most surprisingly, immunofluorescence microscopy, cell fractionation studies, and studies with enhanced green fluorescent protein chimeras showed that wild type Dok-4 (Dok-4-WT) specifically localized in mitochondria. An NH2-terminal deletion mutant of Dok-4 (Dok-4-(Delta N11-29)), which lacks the mitochondrial targeting sequence, could not accumulate in mitochondria. Co-immunoprecipitation revealed an interaction of c-Src with Dok-4-WT in endothelial cells. Most interestingly, overexpression of Dok-4-WT, but not Dok-4(Delta N11-29), increased mitochondrial c-Src expression, whereas knock-down of endogenous Dok-4 with a small interfering RNA vector greatly inhibited mitochondrial localization of c-Src, suggesting a unique function for Dok-4 as an anchoring protein for c-Src in mitochondria. Dok-4-WT significantly decreased 39-kDa subunit complex I expression. PP2, a specific Src kinase inhibitor, prevented the Dok-4- mediated complex I decrease, suggesting the involvement of Src kinase in regulation of complex I expression. Dok-4-WT enhanced tumor necrosis factor-alpha (TNF-alpha)-mediated reactive oxygen species (ROS) production, supporting the functional relevance of a Dok-4- Src-complex I/ROS signaling pathway in mitochondria. Finally, Dok-4 enhanced TNF-alpha-mediated NF-kappa B activation, whereas this was inhibited by transfection with Dok-4 small interfering RNA. In addition, Dok-4-induced NF-kappa B activation was also inhibited by transfection of a dominant negative form of c-Src. These data suggest a role for mitochondrial Dok-4 as an anchoring molecule for the tyrosine kinase c-Src, and in turn as a regulator of TNF-alpha-mediated ROS production and NF-kappa B activation.	Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Rochester, NY 14642 USA; McGill Univ, Ctr Hlth, Dept Med, Div Nephrol, Montreal, PQ H3A 2B4, Canada; Univ Rochester, Dept Anesthesiol, Pharmacol & Physiol & Mitochondrial Res Interest, Rochester, NY 14642 USA	University of Rochester; McGill University; University of Rochester	Lemay, S (corresponding author), Univ Rochester, Sch Med & Dent, Cardiovasc Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	serge.lemay@mcgill.ca; jun-ichi_abe@urmc.rochester.edu	Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601; Brookes, Paul/0000-0002-8639-8413; Tompkins, Andrew/0000-0003-1011-5728	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065262, R01HL066919, R01HL033333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33333, HL-66919, HL-65262] Funding Source: Medline; NINDS NIH HHS [NS-37710] Funding Source: Medline; PHS HHS [C017688] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Bedirian A, 2004, J BIOL CHEM, V279, P19335, DOI 10.1074/jbc.M310689200; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Cong F, 1999, MOL CELL BIOL, V19, P8314; Dawn B, 2002, ANN NY ACAD SCI, V962, P18, DOI 10.1111/j.1749-6632.2002.tb04053.x; Esposti MD, 1999, J BIOL CHEM, V274, P29831, DOI 10.1074/jbc.274.42.29831; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hamar P, 2004, P NATL ACAD SCI USA, V101, P14883, DOI 10.1073/pnas.0406421101; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Ide T, 1999, CIRC RES, V85, P357, DOI 10.1161/01.RES.85.4.357; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Lerner-Marmarosh N, 2003, ARTERIOSCL THROM VAS, V23, P1775, DOI 10.1161/01.ATV.0000094432.98445.36; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Marumo T, 1997, CIRCULATION, V96, P2361; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Osawa M, 2004, J BIOL CHEM, V279, P29691, DOI 10.1074/jbc.M309371200; Osawa M, 2002, J CELL BIOL, V158, P773, DOI 10.1083/jcb.200205049; Panduri V, 2004, AM J PHYSIOL-LUNG C, V286, pL1220, DOI 10.1152/ajplung.00371.2003; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; Ramachandran A, 2004, P NATL ACAD SCI USA, V101, P384, DOI 10.1073/pnas.0304653101; Salvi M, 2002, BBA-MOL CELL RES, V1589, P181, DOI 10.1016/S0167-4889(02)00174-X; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Streb JW, 2005, J BIOL CHEM, V280, P4125, DOI 10.1074/jbc.M412466200; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tejedo JR, 2004, ENDOCRINOLOGY, V145, P2319, DOI 10.1210/en.2003-1489; Tsutsui H, 2001, CIRCULATION, V104, P134, DOI 10.1161/01.CIR.104.2.134; Turner CE, 2000, J CELL SCI, V113, P4139; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	40	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26383	26396		10.1074/jbc.M410262200	http://dx.doi.org/10.1074/jbc.M410262200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15855164	hybrid			2022-12-25	WOS:000230386800054
J	Ruthenburg, AJ; Graybosch, DM; Huetsch, JC; Verdine, GL				Ruthenburg, AJ; Graybosch, DM; Huetsch, JC; Verdine, GL			A superhelical spiral in the Escherichia coli DNA gyrase A C-terminal domain imparts unidirectional supercoiling bias	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION DOMAIN; TOPOISOMERASE-IV; NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; STRAND PASSAGE; CLEAVAGE; COMPLEX; PROTECTION; MECHANISM; SEQUENCES	DNA gyrase is unique among type II topoisomerases in that its DNA supercoiling activity is unidirectional. The C-terminal domain of the gyrase A subunit (GyrA-CTD) is required for this supercoiling bias. We report here the x-ray structure of the Escherichia coli GyrA-CTD ( Protein Data Bank code 1ZI0). The E. coli GyrA-CTD adopts a circular-shaped beta-pinwheel fold first seen in the Borrelia burgdorferi GyrA-CTD. However, whereas the B. burgdorferi GyrA-CTD is flat, the E. coli GyrA-CTD is spiral. DNA relaxation assays reveal that the E. coli GyrA-CTD wraps DNA inducing substantial (+) super-helicity, while the B. burgdorferi GyrA-CTD introduces a more modest (+) superhelicity. The observation of a superhelical spiral in the present structure and that of the Bacillus stearothermophilus ParC-CTD structure suggests unexpected similarities in substrate selectivity between gyrase and Topo IV enzymes. We propose a model wherein the right-handed ((+) solenoidal) wrapping of DNA around the E. coli GyrA-CTD enforces unidirectional (+) DNA supercoiling.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	verdine@chemistry.harvard.edu	Ruthenburg, Alexander/F-3992-2015; Ruthenburg, Alexander/C-3941-2008	Ruthenburg, Alexander/0000-0003-2709-4564; Huetsch, John/0000-0003-0045-5833	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051330, T32GM007598, R55GM051330, R01GM044853] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01646] Funding Source: Medline; NIGMS NIH HHS [T32 GM007598, R01 GM044853, GM51330] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bates AD, 1996, BIOCHEMISTRY-US, V35, P1408, DOI 10.1021/bi952433y; Berger JM, 1998, BBA-GENE STRUCT EXPR, V1400, P3, DOI 10.1016/S0167-4781(98)00124-9; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Caron P R, 1994, Adv Pharmacol, V29B, P271; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2003, P NATL ACAD SCI USA, V100, P9820, DOI 10.1073/pnas.1631550100; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CRICK FHC, 1976, P NATL ACAD SCI USA, V73, P2639, DOI 10.1073/pnas.73.8.2639; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x; Heddle JG, 2004, J MOL BIOL, V337, P597, DOI 10.1016/j.jmb.2004.01.049; Hockings SC, 2002, J MOL BIOL, V318, P351, DOI 10.1016/S0022-2836(02)00048-7; Hsieh TJ, 2004, J BIOL CHEM, V279, P55587, DOI 10.1074/jbc.M408934200; Jawad Z, 2002, STRUCTURE, V10, P447, DOI 10.1016/S0969-2126(02)00750-5; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kampranis SC, 1999, P NATL ACAD SCI USA, V96, P8414, DOI 10.1073/pnas.96.15.8414; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; Knight SW, 1999, EMBO J, V18, P4875, DOI 10.1093/emboj/18.17.4875; Knight SW, 2000, J BACTERIOL, V182, P2048, DOI 10.1128/JB.182.7.2048-2051.2000; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Noble CG, 2002, J MOL BIOL, V318, P361, DOI 10.1016/S0022-2836(02)00049-9; ORPHANIDES G, 1994, NUCLEIC ACIDS RES, V22, P1567, DOI 10.1093/nar/22.9.1567; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Petrey D, 2003, METHOD ENZYMOL, V374, P492, DOI 10.1016/S0076-6879(03)74021-X; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Stone MD, 2003, P NATL ACAD SCI USA, V100, P8654, DOI 10.1073/pnas.1133178100; Swofford D. L., 2001, PAUP PHYLOGENETIC AN; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOMSEN B, 1990, J MOL BIOL, V215, P237, DOI 10.1016/S0022-2836(05)80342-0; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Ward D, 1997, MOL MICROBIOL, V26, P897, DOI 10.1046/j.1365-2958.1997.6242005.x; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	53	73	78	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26177	26184		10.1074/jbc.M502838200	http://dx.doi.org/10.1074/jbc.M502838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15897198	hybrid, Green Published			2022-12-25	WOS:000230386800031
J	Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL				Garnis, C; Davies, JJ; Buys, TPH; Tsao, MS; MacAulay, C; Lam, S; Lam, WL			Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression	ONCOGENE			English	Article						array CGH; TRIO; GDNF; 5p; carcinoma in situ; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; ALLELIC DELETION; CARCINOMAS; EXPRESSION; DNA; GENE; 5-ALPHA-REDUCTASE; AMPLIFICATION; FREQUENT; MARKER	Lung cancer is the most widely diagnosed malignancy in the world. Understanding early-stage disease will give insight into its pathogenesis. Despite the fact that pre-invasive lesions are challenging to isolate, and often yield insufficient DNA for the analysis of multiple loci, genomic pro. ling of such lesions will lead to the discovery of causal genetic alterations, which may be otherwise masked by the gross instability associated with tumors. In this study, we report the identification of multiple early genetic events on chromosome 5p in lung cancer progression. Using a high-resolution 5p-specific genomic array, which contains a tiling path of DNA segments for comparative genomic hybridization, nine novel minimal regions of loss and gain were discovered in bronchial carcinoma in situ (CIS) specimens. Within these regions we identified two candidate genes novel to lung cancer. The 0.27 Mbp region at 5p15.2 contains a single gene, Triple Functional Domain, which we determined to be differentially expressed in tumors. The 0.34 Mbp region at 5p13.2 contains Glial Cell Line-Derived Neurotrophic Factor (GDNF), which is a ligand for the RET oncogene product and is normally expressed during lung development (but absent in adult lung tissue). Our data showed not only that GDNF is overexpressed at the transcript level in squamous non-small-cell lung carcinoma, but also that the GDNF protein is present in early-stage lesions. Reactivation of the fetal lung expressed GDNF in early lesions and its amplification in CIS suggests an early role in tumorigenesis. These results highlight the value of examining the genomes of pre-invasive stages of cancer at tiling resolution.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 3L1, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Garnis, C (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 3L1, Canada.	cgarnis@bccrc.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017; Garnis, Cathie/A-3888-2009; MacAulay, Calum/K-1795-2016	Tsao, Ming Sound/0000-0002-9160-5405; MacAulay, Calum/0000-0003-4440-2792				Balsara BR, 1997, CANCER RES, V57, P2116; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fromont-Hankard G, 2002, ARCH PATHOL LAB MED, V126, P432; Garnis C, 2003, CANCER RES, V63, P8582; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9; HARRIS G, 1992, P NATL ACAD SCI USA, V89, P10787, DOI 10.1073/pnas.89.22.10787; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Lam S, 2000, CANCER-AM CANCER SOC, V89, P2468; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; McWilliams A, 2002, ONCOGENE, V21, P6949, DOI 10.1038/sj.onc.1205831; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; RIED T, 1994, CANCER RES, V54, P1801; Saretzki G, 2002, CANCER LETT, V176, P81, DOI 10.1016/S0304-3835(01)00644-9; Siwoski A, 2002, MODERN PATHOL, V15, P889, DOI 10.1097/01.MP.0000024288.63070.4F; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Travis WD, 1999, HISTOLOGICAL TYPING; Ullmann R, 1998, HUM PATHOL, V29, P1145, DOI 10.1016/S0046-8177(98)90428-2; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Wiebe JP, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-9; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	35	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4806	4812		10.1038/sj.onc.1208643	http://dx.doi.org/10.1038/sj.onc.1208643			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870700				2022-12-25	WOS:000230477900007
J	Emiliani, S; Mousnier, A; Busschots, K; Maroun, M; Van Maele, B; Tempe, D; Vandekerckhove, L; Moisant, F; Ben-Slama, L; Witvrouw, M; Christ, F; Rain, JC; Dargemont, C; Debyser, Z; Benarous, R				Emiliani, S; Mousnier, A; Busschots, K; Maroun, M; Van Maele, B; Tempe, D; Vandekerckhove, L; Moisant, F; Ben-Slama, L; Witvrouw, M; Christ, F; Rain, JC; Dargemont, C; Debyser, Z; Benarous, R			Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PREINTEGRATION COMPLEXES; CDNA INTEGRATION; DNA INTEGRATION; HUMAN GENOME; HUMAN-CELLS; IN-VITRO; NUCLEAR-LOCALIZATION; ACUTE INFECTION; EARLY STEPS	The insertion of a DNA copy of its RNA genome into a chromosome of the host cell is mediated by the viral integrase with the help of mostly uncharacterized cellular cofactors. We have recently described that the transcriptional co-activator LEDGF/p75 strongly interacts with HIV-1 integrase. Here we show that interaction of HIV-1 integrase with LEDGF/p75 is important for viral replication. Using multiple approaches including two-hybrid interaction studies, random and directed mutagenesis, we could demonstrate that HIV-1 virus harboring a single mutation that disrupts integraseLEDGF/p75 interaction, resulted in defective HIV-1 replication. Furthermore, we found that LEDGF/p75 tethers HIV-1 integrase to chromosomes and that this interaction may be important for the integration process and the replication of HIV-1.	Univ Paris 06, Inst Cochin, U567, INSERM,UPR8104 CNRS, F-75251 Paris, France; Univ Paris 07, Inst Cochin, U567, INSERM,UPR8104 CNRS, F-75251 Paris, France; Dept Infect Dis, F-75014 Paris, France; Inst Jacques Monod, UMR7592, CNRS, F-75251 Paris, France; KULAK, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Flanders, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Flanders, Belgium; Hybrigen SA, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; KU Leuven	Emiliani, S (corresponding author), Univ Paris 06, Inst Cochin, U567, INSERM,UPR8104 CNRS, Tour 43,2e Etage,Couloir 43-44,2 Pl Jussieu, F-75251 Paris, France.	emiliani@cochin.inserm.fr; zeger.debyser@med.kuleuven.ac.be; benarous@cochin.inserm.fr	Vandekerckhove, Linos/J-6420-2013; Christ, Frauke/H-7513-2018	Vandekerckhove, Linos/0000-0002-8600-1631; Christ, Frauke/0000-0001-9580-3874; Mousnier, Aurelie/0000-0002-7317-1009; RAIN, Jean-Christophe/0000-0001-8110-0641				Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Cherepanov P, 2004, J BIOL CHEM, V279, P48883, DOI 10.1074/jbc.M406307200; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fromont-Racine M, 2002, METHOD ENZYMOL, V350, P513, DOI 10.1016/S0076-6879(02)50982-4; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Ganapathy V, 2003, AUTOIMMUN REV, V2, P290, DOI 10.1016/S1568-9972(03)00063-6; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Li L, 2000, J VIROL, V74, P10965, DOI 10.1128/JVI.74.23.10965-10974.2000; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413	34	191	203	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25517	25523		10.1074/jbc.M501378200	http://dx.doi.org/10.1074/jbc.M501378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15855167	Green Published, hybrid			2022-12-25	WOS:000230207900028
J	Dubreuil, O; Bossus, M; Graille, M; Bilous, M; Savatier, A; Jolivet, M; Menez, A; Stura, E; Ducancel, F				Dubreuil, O; Bossus, M; Graille, M; Bilous, M; Savatier, A; Jolivet, M; Menez, A; Stura, E; Ducancel, F			Fine tuning of the specificity of an anti-progesterone antibody by first and second sphere residue engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; SCANNING SATURATION MUTAGENESIS; IN-VITRO; PHAGE DISPLAY; ESTRADIOL ANTIBODIES; AFFINITY MATURATION; BINDING-AFFINITY; ANTIGEN-BINDING; SITE; FAB	The specificity of anti-progesterone P15G12C12G11 antibody was improved by combination of in vitro scanning saturation mutagenesis and error-prone PCR. The most evolved mutant is able to discriminate against 5 beta-or 5 alpha-dihydroprogesterone, 23 and 15 times better than the starting antibody, while maintaining the affinity for progesterone that remains in the picomolar range. The high level of homology with anti-progesterone monoclonal antibody DB3 allowed the construction of three-dimensional models of P15G12C12G11 based on the structures of DB3 in complex with various steroids. These models together with binding data, derived from site-directed mutagenesis, were used to build a phage library in which five first sphere positions in complementarity-determining regions 2H and 3L were varied. Variants selected by an initial screening in competition against a large excess of 5 beta- or 5 alpha-dihydroprogesterone were characterized by a convergent amino acid signature different from that of the wild-type antibody and had lower cross-reactivity. Binding properties of this first set of mutants were further improved by the addition of second sphere mutations selected independently from an error-prone library. The three-dimensional models of the best variant show changes in the antigen binding site that explain well the increase in selectivity. The improvements are partly linked to a change in the canonical class of the light chain third hypervariable loop.	Ctr Etud Saclay, CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CEA Saclay, CEA, Unite Mixte, F-91191 Gif Sur Yvette, France; Dept Rech & Dev Immunoessais & Proteom, F-69280 Marcy Letoile, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Ducancel, F (corresponding author), Ctr Etud Saclay, CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.	frederic.ducancel@cea.fr	Stura, Enrico A./A-2793-2010; GRAILLE, Marc/D-3242-2014	Stura, Enrico A./0000-0001-6718-2118; GRAILLE, Marc/0000-0002-7853-5852				Adams GP, 1998, CANCER RES, V58, P485; AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Arkin MR, 1998, J MOL BIOL, V284, P1083, DOI 10.1006/jmbi.1998.2234; Bettsworth F, 2001, J MOL RECOGNIT, V14, P99, DOI 10.1002/jmr.525; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Burks EA, 1997, P NATL ACAD SCI USA, V94, P412, DOI 10.1073/pnas.94.2.412; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chames P, 1998, CLIN CHEM LAB MED, V36, P355, DOI 10.1515/CCLM.1998.060; Chames P, 1998, J IMMUNOL, V161, P5421; Chen G, 1999, PROTEIN ENG, V12, P349, DOI 10.1093/protein/12.4.349; Chen JG, 2001, J ORG CHEM, V66, P3021, DOI 10.1021/jo001619m; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Daugherty PS, 2000, P NATL ACAD SCI USA, V97, P2029, DOI 10.1073/pnas.030527597; DUAX WL, 1980, LIPIDS, V15, P783, DOI 10.1007/BF02534032; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Iba Y, 1998, PROTEIN ENG, V11, P361, DOI 10.1093/protein/11.5.361; Korpimaki T, 2003, PROTEIN ENG, V16, P37, DOI 10.1093/proeng/gzg010; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; Lamminmaki U, 1999, J MOL BIOL, V291, P589, DOI 10.1006/jmbi.1999.2981; Lamminmaki U, 2003, PROTEIN SCI, V12, P2549, DOI 10.1110/ps.0353903; Lefranc MP, 2003, NUCLEIC ACIDS RES, V31, P307, DOI 10.1093/nar/gkg085; Merienne K, 1997, J BIOL CHEM, V272, P23775, DOI 10.1074/jbc.272.38.23775; Miyazaki C, 1999, PROTEIN ENG, V12, P407, DOI 10.1093/protein/12.5.407; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Saviranta P, 1998, PROTEIN ENG, V11, P143, DOI 10.1093/protein/11.2.143; SAVOURET JF, 1990, INT J BIOCHEM, V22, P579, DOI 10.1016/0020-711X(90)90033-Y; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200	36	32	37	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24880	24887		10.1074/jbc.M500048200	http://dx.doi.org/10.1074/jbc.M500048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878862	hybrid, Green Published			2022-12-25	WOS:000230114000071
J	Ishida, H; Masuhiro, Y; Fukushima, A; Argueta, JGM; Yamaguchi, N; Shiota, S; Hanazawa, S				Ishida, H; Masuhiro, Y; Fukushima, A; Argueta, JGM; Yamaguchi, N; Shiota, S; Hanazawa, S			Identification and characterization of novel isoforms of human DP-1 - DP-1 alpha regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; EXPRESSION; COMPLEX; REPRESSION; SUGGESTS; PARTNER; BINDING; MEMBER	The cell cycle-regulating transcription factors DP-1 and E2F form a heterodimeric complex and play a central role in cell cycle progression. Two different DP subunits (DP-1 and DP-2) exist in humans. In this study, we identified two novel DP-1 isoforms (DP-1 alpha and DP-1 beta) and characterized their structure and function. DP-1 alpha is composed of 278 amino acids and lacks a portion of the C-terminal heterodimerization domain, whereas DP-1 alpha is composed of 357 amino acids with a frameshift that causes truncation of the C-terminal domain. Yeast two-hybrid and immunoprecipitation assays demonstrated that DP-1 alpha binding to E2F1 was significantly reduced as compared with that of wild-type DP-1 or DP-1 beta. Immunofluorescence analysis revealed that the subcellular localization of both DP-1 isoforms changed from the cytoplasm to the nucleus in HEK 293 cells cotransfected with E2F1 and wild-type DP-1 or DP-1 beta. However, such a translocation for DP-1 alpha was barely observed. Reverse transcription-PCR results showed that the three DP-1 isoforms are expressed ubiquitously at equal levels in several normal human tissues. We also demonstrated the expression of these isoforms at the protein level by Western blotting. Interestingly, we observed a significant decrease in transcriptional activity, a marked delay of cell cycle progression, and an inhibition of cell proliferation in DP-1 alpha-transfected HEK 293 cells. Together, the results of the present study suggest that DP-1 alpha is a novel isoform of DP-1 that acts as a dominant-negative regulator of cell cycle progression.	Kyushu Univ, Fac Dent Sci, Div Oral Infect Dis & Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent Sci, Dept Prevent Dent, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Hanazawa, S (corresponding author), Nihon Univ, Coll Bioresource Sci, Dept Appl Biol Sci, Fujisawa, Kanagawa 2928510, Japan.	hanazawa@brs.nihon-u.ac.jp						Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Dahme T, 2002, EUR J BIOCHEM, V269, P5030, DOI 10.1046/j.1432-1033.2002.03210.x; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GIRLING R, 1993, NATURE, V365, P468, DOI 10.1038/365468d0; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Shenker BJ, 2001, J IMMUNOL, V167, P435, DOI 10.4049/jimmunol.167.1.435; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamada M, 2002, CYTOKINE, V17, P91, DOI 10.1006/cyto.2001.0992; Yamasaki L., 1999, BIOCHIM BIOPHYS ACTA, V1423, P9; ZHANG YH, 1995, ONCOGENE, V10, P2085	32	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24642	24648		10.1074/jbc.M500189200	http://dx.doi.org/10.1074/jbc.M500189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863509	hybrid			2022-12-25	WOS:000230114000044
J	Vishwasrao, HD; Heikal, AA; Kasischke, KA; Webb, WW				Vishwasrao, HD; Heikal, AA; Kasischke, KA; Webb, WW			Conformational dependence of intracellular NADH on metabolic state revealed by associated fluorescence anisotropy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC OPTICAL SIGNALS; RAT HIPPOCAMPAL SLICES; NICOTINAMIDE-ADENINE-DINUCLEOTIDE; REDUCED PYRIDINE NUCLEOTIDE; OXIDATION-REDUCTION; ELECTROCONVULSIVE SEIZURE; SPREADING DEPRESSION; MALATE-DEHYDROGENASE; DECAY; MITOCHONDRIAL	Global analysis of fluorescence and associated anisotropy decays of intrinsic tissue fluorescence offers a sensitive and non-invasive probe of the metabolically critical free/enzyme-bound states of intracellular NADH in neural tissue. Using this technique, we demonstrate that the response of NADH to the metabolic transition from normoxia to hypoxia is more complex than a simple increase in NADH concentration. The concentration of free NADH, and that of an enzyme bound form with a relatively low lifetime, increases preferentially over that of other enzyme bound NADH species. Concomitantly, the intracellular viscosity is reduced, likely due to the osmotic swelling of mitochondria. These conformation and environmental changes effectively decrease the tissue fluorescence average lifetime, causing the usual total fluorescence increase measurements to significantly underestimate the calculated concentration increase. This new discrimination of changes in NADH concentration, conformation, and environment provides the foundation for quantitative functional imaging of neural energy metabolism.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; Columbia Univ, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Columbia University; Howard Hughes Medical Institute	Webb, WW (corresponding author), Cornell Univ, Sch Appl & Engn Phys, 223 Clark Hall, Ithaca, NY 14853 USA.	www2@cornell.edu	Webb, Watt W./B-5905-2011	Kasischke, Karl/0000-0003-0582-4319	NIBIB NIH HHS [9-P41-EB001976] Funding Source: Medline; NIGMS NIH HHS [GM08267] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001976] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AVIDOR Y, 1962, J BIOL CHEM, V237, P2377; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; Bialik CN, 1998, BIOPHYS J, V75, P2564, DOI 10.1016/S0006-3495(98)77701-X; Brumaghim JL, 2003, J BIOL CHEM, V278, P42495, DOI 10.1074/jbc.M306251200; BUCHER T, 1972, EUR J BIOCHEM, V27, P301, DOI 10.1111/j.1432-1033.1972.tb01840.x; CHANCE B, 1958, J BIOL CHEM, V233, P736; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANCE B, 1965, BIOCHEM Z, V341, P357; COUPRIE ME, 1994, REV SCI INSTRUM, V65, P1485, DOI 10.1063/1.1144880; Fayuk D, 2002, J NEUROPHYSIOL, V87, P1924, DOI 10.1152/jn.00231.2001; Fisz JJ, 1996, CHEM PHYS LETT, V259, P579, DOI 10.1016/0009-2614(96)00814-7; GAFNI A, 1976, BIOCHEMISTRY-US, V15, P3165, DOI 10.1021/bi00660a001; Garcia-Perez AI, 1999, ARCH BIOCHEM BIOPHYS, V362, P329, DOI 10.1006/abbi.1998.1051; GAROFALO O, 1988, J NEUROCHEM, V51, P172, DOI 10.1111/j.1471-4159.1988.tb04851.x; Heikal AA, 2001, CHEM PHYS, V274, P37, DOI 10.1016/S0301-0104(01)00486-4; Hess ST, 2003, BIOPHYS J, V85, P2566, DOI 10.1016/S0006-3495(03)74679-7; HONES G, 1986, BIOL CHEM H-S, V367, P103, DOI 10.1515/bchm3.1986.367.1.103; Joubert F, 2004, BIOPHYS J, V86, P629, DOI 10.1016/S0006-3495(04)74141-7; KAO HP, 1993, J CELL BIOL, V120, P175, DOI 10.1083/jcb.120.1.175; Kasischke K, 2001, ACTA NEUROPATHOL, V101, P483; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; KLINGENBERG M, 1960, ANNU REV BIOCHEM, V29, P669, DOI 10.1146/annurev.bi.29.070160.003321; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P357; MERRILL DK, 1976, J NEUROCHEM, V27, P459, DOI 10.1111/j.1471-4159.1976.tb12268.x; MERRILL DK, 1982, BRAIN RES, V239, P71, DOI 10.1016/0006-8993(82)90834-4; Muller M, 1999, J NEUROPHYSIOL, V82, P1818, DOI 10.1152/jn.1999.82.4.1818; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Paul RJ, 1996, NATURWISSENSCHAFTEN, V83, P32, DOI 10.1007/BF01139308; Perez-Pinzon MA, 1998, BRAIN RES, V786, P165, DOI 10.1016/S0006-8993(97)01438-8; Perez-Pinzon MA, 1998, J CEREBR BLOOD F MET, V18, P215, DOI 10.1097/00004647-199802000-00013; SALMON JM, 1982, PHOTOCHEM PHOTOBIOL, V36, P585, DOI 10.1111/j.1751-1097.1982.tb04420.x; SHORE JD, 1979, J BIOL CHEM, V254, P9059; STRICKLER SJ, 1962, J CHEM PHYS, V37, P814, DOI 10.1063/1.1733166; Toptygin D, 2002, J PHYS CHEM B, V106, P3724, DOI 10.1021/jp0133889; VELICK SF, 1961, S LIGHT LIFE, P108; VERKMAN AS, 1991, BIOPHYS CHEM, V40, P117, DOI 10.1016/0301-4622(91)85036-P; VISSER AJWG, 1981, PHOTOCHEM PHOTOBIOL, V33, P35, DOI 10.1111/j.1751-1097.1981.tb04293.x; WAKITA M, 1995, J BIOCHEM-TOKYO, V118, P1151, DOI 10.1093/oxfordjournals.jbchem.a125001; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Zhang QH, 2002, SCIENCE, V295, P1895	44	233	241	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25119	25126		10.1074/jbc.M502475200	http://dx.doi.org/10.1074/jbc.M502475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863500	hybrid			2022-12-25	WOS:000230114000096
J	Wu, XM; Shell, SM; Zou, Y				Wu, XM; Shell, SM; Zou, Y			Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells	ONCOGENE			English	Article						Rad9/Rad1/Hus1; replication protein A ( RPA); interaction of 9-1-1 with RPA; DNA damage checkpiont	SINGLE-STRANDED-DNA; DAMAGE CHECKPOINT; HUMAN RAD9; BINDING PROTEIN; G2/M ARREST; S-PHASE; RPA; PHOSPHORYLATION; ATR; KINASE	Replication protein A (RPA) is a eukaryotic single-stranded DNA-binding protein consisting of three subunits of 70-, 32-, and 14-kDa (RPA70, RPA32, RPA14, respectively). It is a protein essential for most cellular DNA metabolic pathways. Checkpoint proteins Rad9, Rad1, and Hus1 form a clamp-like complex which plays a central role in the DNA damage-induced checkpoint response. In this report, we presented the evidence that Rad9-Rad1-Hus1 (9-1-1) complex directly interacted with RPA in human cells, and this interaction was mediated by the binding of Rad9 protein to both RPA70 and RPA32 subunits. In addition, the cellular interaction of 9-1-1 with RPA or hyperphosphorylated RPA was stimulated by UV irradiation or camptothecin treatment in a dose-dependent manner. Such treatments also resulted in the colocalization of the nuclear foci formed with the two complexes. Consistently, knockdown of the RPA expression in cells by the small interference RNA ( siRNA) blocked the DNA damage-dependent chromatin association of 9-1-1, and also inhibited the 9-1-1 complex formation. Taken together, our results suggest that 9-1-1 and RPA complexes collaboratively function in DNA damage responses, and that the RPA may serve as a regulator for the activity of 9-1-1 complex in the cellular checkpoint network.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NCI NIH HHS [R56 CA086927, R01 CA086927, CA86927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086927, R56CA086927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lindsey-Boltz LA, 2004, NUCLEIC ACIDS RES, V32, P4524, DOI 10.1093/nar/gkh789; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu YY, 2005, BIOCHEM J, V385, P519, DOI 10.1042/BJ20041151; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PARRILLACASTELLAR, 2004, DNA REPAIR, V3, P1009; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	48	86	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4728	4735		10.1038/sj.onc.1208674	http://dx.doi.org/10.1038/sj.onc.1208674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897895	Green Submitted, Green Accepted			2022-12-25	WOS:000230304500011
J	Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O				Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O			Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin	ONCOGENE			English	Article						RALT; MIG-6; ErbB-2; breast cancer; Herceptin; targeted therapies	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; SIGNALING NETWORK; TRANSGENIC MICE; DOWN-REGULATION; CHROMOSOME 1P; CANCER; INHIBITION; PROTEIN; RALT	An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG- 6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB-2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.	Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy; Univ Iceland, Inst Expt Pathol, Reykjavik, Iceland; IDI, Mol Oncol Lab, Rome, Italy; Regina Elena Inst Canc Res, Lab Mol Oncogenesis, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Iceland; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Via Messi Oro,156-158, I-00158 Rome, Italy.	segatto@ifo.it	Sala, Gianluca/C-2056-2017; Ingvarsson, Sigurdur/E-7448-2011; anastasi, sergio/AAB-9585-2020; Caprini, Elisabetta/AAG-8523-2020; Russo, Giandomenico/K-9566-2016	Sala, Gianluca/0000-0002-4494-915X; Ingvarsson, Sigurdur/0000-0003-4125-1714; anastasi, sergio/0000-0003-1009-6117; Russo, Giandomenico/0000-0002-7718-9687; iacovelli, stefano/0000-0003-0806-6365; Segatto, Oreste/0000-0003-2561-1142				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Farabegoli F, 1996, INT J CANCER, V69, P381, DOI 10.1002/(SICI)1097-0215(19961021)69:5<381::AID-IJC5>3.0.CO;2-1; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mincione G, 1996, J CELL BIOCHEM, V60, P437, DOI 10.1002/(SICI)1097-4644(19960315)60:4<437::AID-JCB1>3.0.CO;2-T; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Motoyama AB, 2002, CANCER RES, V62, P3151; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	83	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4540	4548		10.1038/sj.onc.1208658	http://dx.doi.org/10.1038/sj.onc.1208658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856022	Green Published			2022-12-25	WOS:000230157100007
J	Berkowitz, P; Hu, PQ; Liu, Z; Diaz, LA; Enghild, JJ; Chua, MP; Rubenstein, DS				Berkowitz, P; Hu, PQ; Liu, Z; Diaz, LA; Enghild, JJ; Chua, MP; Rubenstein, DS			Desmosome signaling - Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P38 MAP KINASE; HEAT-SHOCK PROTEIN-27; CELL CARCINOMA LINE; INOSITOL 1,4,5-TRISPHOSPHATE; PALMOPLANTAR KERATODERMA; TYROSINE PHOSPHORYLATION; INTRACELLULAR CALCIUM; DJM-1 CELLS; ACTIN; PLAKOGLOBIN	In the human autoimmune blistering disease pemphigus vulgaris (PV) pathogenic antibodies bind the desmosomal cadherin desmoglein-3 (dsg3), causing epidermal cell-cell detachment ( acantholysis). Pathogenic PV dsg3 autoantibodies were used to initiate desmosome signaling in human keratinocyte cell cultures. Heat shock protein 27 (HSP27) and p38MAPK were identified as proteins rapidly phosphorylated in response to PV IgG. Inhibition of p38MAPK activity prevented PV IgG-induced HSP27 phosphorylation, keratin filament retraction, and actin reorganization. These observations suggest that PV IgG binding to dsg3 activates desmosomal signal transduction cascades leading to (i) p38MAPK and HSP27 phosphorylation and (ii) cytoskeletal reorganization, supporting a mechanistic role for signaling in PV IgG-induced acantholysis. Targeting desmosome signaling via inhibition of p38MAPK and HSP27 phosphorylation may provide novel treatments for PV and other desmosome-associated blistering diseases.	Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus, Denmark	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Aarhus University	Rubenstein, DS (corresponding author), Univ N Carolina, Dept Dermatol, Sch Med, Suite 3100,Thurston Bowles Bldg,CB 7287, Chapel Hill, NC 27599 USA.	druben@med.unc.edu		Diaz, Luis/0000-0002-7079-8914; Enghild, Jan Johannes/0000-0001-9292-9172	NIAID NIH HHS [R01 AI49427-01] Funding Source: Medline; NIAMS NIH HHS [R01 AR032081, R01 AR30281, T32 AR07369, R01AR32599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032599, T32AR007369] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anhalt GJ, 2001, JAMA-J AM MED ASSOC, V285, P652, DOI 10.1001/jama.285.5.652; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Ding X, 1997, J INVEST DERMATOL, V109, P592, DOI 10.1111/1523-1747.ep12337524; Duverger O, 2004, J BIOL CHEM, V279, P10252, DOI 10.1074/jbc.M309906200; ESAKI C, 1995, J INVEST DERMATOL, V105, P329, DOI 10.1111/1523-1747.ep12319948; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Feng L, 1999, J CELL SCI, V112, P2081; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Guay J, 1997, J CELL SCI, V110, P357; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hu ED, 2001, EXP NEPHROL, V9, P156; Hu PQ, 2003, J INVEST DERMATOL, V121, P242, DOI 10.1046/j.1523-1747.2003.12376.x; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Karring H, 2004, MOL CELL PROTEOMICS, V3, P660, DOI 10.1074/mcp.M400016-MCP200; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; Panasenko OO, 2003, EUR J BIOCHEM, V270, P892, DOI 10.1046/j.1432-1033.2003.03449.x; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Perng MD, 1999, J CELL SCI, V112, P2099; Reynolds CH, 1997, J NEUROCHEM, V69, P191; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SEISHIMA M, 1995, J INVEST DERMATOL, V104, P33, DOI 10.1111/1523-1747.ep12613469; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909	38	184	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23778	23784		10.1074/jbc.M501365200	http://dx.doi.org/10.1074/jbc.M501365200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840580	hybrid			2022-12-25	WOS:000229880000048
J	Kanski, J; Hong, SJ; Schoneich, C				Kanski, J; Hong, SJ; Schoneich, C			Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; TYROSINE NITRATION; SARCOPLASMIC-RETICULUM; CREATINE-KINASE; OXIDATIVE DAMAGE; PEROXYNITRITE; MITOCHONDRIA; RESTRICTION; DISEASE; INACTIVATION	The nitration of protein tyrosine residues represents an important post-translational modification during development, oxidative stress, and biological aging. To rationalize any physiological changes with such modifications, the actual protein targets of nitration must be identified by proteomic methods. While several studies have used proteomics to screen for 3-nitrotyrosine-containing proteins in vivo, most of these studies have failed to prove nitration unambiguously through the actual localization of 3-nitrotyrosine to specific sequences by mass spectrometry. In this paper we have applied sequential solution isoelectric focusing and SDS-PAGE for the proteomic characterization of specific 3-nitrotyrosine-containing sequences of nitrated target proteins in vivo using nanoelectrospray ionization-tandem mass spectrometry. Specifically, we analyzed proteins from the skeletal muscle of 34-month-old Fisher 344/Brown Norway F1 hybrid rats, a well accepted animal model for biological aging. We identified the 3-nitrotyrosine-containing sequences of 11 proteins, including cytosolic creatine kinase, tropomyosin 1, glyceraldehyde-3-phosphate dehydrogenase, myosin light chain, aldolase A, pyruvate kinase, glycogen phosphorylase, actinin, gamma-actin, ryanodine receptor 3, and neurogenic locus notch homolog. For creatine kinase and neurogenic locus notch homolog, two 3-nitrotyrosine-containing sequences were identified, i.e. at positions 14 and 20 for creatine kinase and at positions 1175 and 1205 for the neurogenic locus notch homolog. The selectivity of the in vivo nitration of creatine kinase at Tyr(14) and Tyr(20) does not correspond to the product selectivity in vitro, where exclusively Tyr(82) was nitrated when creatine kinase was exposed to peroxynitrite. The latter experiments demonstrate that the in vitro exposure of an isolated protein to peroxynitrite may not always be a good model to mimic protein nitration in vivo.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA	University of Kansas	Schoneich, C (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	schoneic@ku.edu			NCI NIH HHS [CA072987] Funding Source: Medline; NIA NIH HHS [AG23551, AG12993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023551, P01AG012993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Casoni F, 2005, J BIOL CHEM, V280, P16295, DOI 10.1074/jbc.M413111200; Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Fernandes G, 1997, J CLIN IMMUNOL, V17, P85, DOI 10.1023/A:1027344730553; Gow AJ, 2004, AM J PHYSIOL-LUNG C, V287, pL262, DOI 10.1152/ajplung.00295.2003; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Guo W, 2003, AM J PHYSIOL-HEART C, V285, pH1396, DOI 10.1152/ajpheart.00096.2003; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; Irie Y, 2003, P NATL ACAD SCI USA, V100, P5634, DOI 10.1073/pnas.1131756100; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kanski J, 2005, AM J PHYSIOL-HEART C, V288, pH371, DOI 10.1152/ajpheart.01030.2003; Kanski J, 2003, FREE RADICAL BIO MED, V35, P1229, DOI 10.1016/S0891-5849(03)00500-8; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Koeck T, 2004, MOL CELL PROTEOMICS, V3, P548, DOI 10.1074/mcp.M300141-MCP200; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lubman DM, 2002, J CHROMATOGR B, V782, P183, DOI 10.1016/S1570-0232(02)00551-2; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Mihm MJ, 2002, BIOCHIMIE, V84, P1013, DOI 10.1016/S0300-9084(02)00005-6; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Molloy MP, 2000, ANAL BIOCHEM, V280, P1, DOI 10.1006/abio.2000.4514; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; Sethuraman M, 2004, MOL CELL PROTEOMICS, V3, P273, DOI 10.1074/mcp.T300011-MCP200; Sharov VS, 2002, ANAL BIOCHEM, V308, P328, DOI 10.1016/S0003-2697(02)00261-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TANZER ML, 1959, J BIOL CHEM, V234, P3201; Toescu EC, 2004, TRENDS NEUROSCI, V27, P614, DOI 10.1016/j.tins.2004.07.010; Turko IV, 2003, J BIOL CHEM, V278, P33972, DOI 10.1074/jbc.M303734200; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wendt S, 2003, J BIOL CHEM, V278, P1125, DOI 10.1074/jbc.M208572200; Xu A, 1998, AM J PHYSIOL-HEART C, V275, pH2087, DOI 10.1152/ajpheart.1998.275.6.H2087; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Yee CS, 2003, BIOCHEMISTRY-US, V42, P14541, DOI 10.1021/bi0352365; Zhan XQ, 2004, BIOCHEM BIOPH RES CO, V325, P1180, DOI 10.1016/j.bbrc.2004.10.169; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4	47	141	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24261	24266		10.1074/jbc.M501773200	http://dx.doi.org/10.1074/jbc.M501773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851474	hybrid			2022-12-25	WOS:000229880000103
J	Gonzalez, CF; Ackerley, DF; Lynch, SV; Matin, A				Gonzalez, CF; Ackerley, DF; Lynch, SV; Matin, A			ChrR, a soluble quinone reductase of Pseudomonas putida that defends against H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-STRESS; ESCHERICHIA-COLI; DT-DIAPHORASE; BIOCHEMICAL-CHARACTERIZATION; BACTERIA INTERACTIONS; CHROMATE REDUCTASE; OXIDOREDUCTASE; ANTIOXIDANT; EXPRESSION; SEQUENCE	Most bacteria contain soluble quinone-reducing flavoenzymes. However, no biological benefit for this activity has previously been demonstrated. ChrR of Pseudomonas putida is one such enzyme that has also been characterized as a chromate reductase; yet we propose that it is the quinone-reducing activity of ChrR that has the greatest biological significance. ChrR reduces quinones by simultaneous two-electron transfer, avoiding formation of highly reactive semiquinone intermediates and producing quinols that promote tolerance of H2O2. Expression of chrR was induced by H2O2, and levels of chrR expression in overexpressing, wild type, and knock-out mutant strains correlated with the H2O2 tolerance and scavenging ability of each strain. The chrR expression level also correlated with intracellular H2O2 levels as measured by protein carbonylation assays and fluorescence-activated cell scanning analysis with the H2O2-responsive dye H(2)DCFDA. Thus, enhancing the activity of ChrR in a chromate-remediating bacterial strain may not only increase the rate of chromate transformation, it may also augment the capacity of these cells to withstand the unavoidable production of H2O2 that accompanies chromate reduction.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Matin, A (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Sherman Fairchild Sci Bldg, Stanford, CA 94305 USA.	a.matin@stanford.edu	Ackerley, David F/B-6325-2015; Matin, AC/A-1315-2007; Lynch, Susan V/B-6272-2009	Matin, AC/0000-0003-4468-980X; Ackerley, David/0000-0002-6188-9902				Ackerley DF, 2004, ENVIRON MICROBIOL, V6, P851, DOI 10.1111/j.1462-2920.2004.00639.x; Ackerley DF, 2004, APPL ENVIRON MICROB, V70, P873, DOI 10.1128/AEM.70.2.873-882.2004; Argyrou A, 2003, BIOCHEMISTRY-US, V42, P2218, DOI 10.1021/bi020654f; Baker CJ, 1997, PHYSIOL MOL PLANT P, V51, P401, DOI 10.1006/pmpp.1997.0132; BAKER CJ, 1991, PHYTOPATHOLOGY, V81, P1504, DOI 10.1094/Phyto-81-1504; Beyer RE, 1997, MOL ASPECTS MED, V18, pS15; Cenas N, 2004, METHOD ENZYMOL, V382, P258; CLARK DP, 1994, FEMS MICROBIOL LETT, V122, P233, DOI 10.1111/j.1574-6968.1994.tb07173.x; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; ISHIBASHI Y, 1990, APPL ENVIRON MICROB, V56, P2268, DOI 10.1128/AEM.56.7.2268-2270.1990; KEYHAN M, 2003, REMEDIATIONA CONTAMI; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; Maruyama A, 2003, MICROBIOL-SGM, V149, P389, DOI 10.1099/mic.0.25796-0; Mazoch J, 2004, EUR J BIOCHEM, V271, P553, DOI 10.1046/j.1432-1033.2003.03957.x; Nelson KE, 2003, ENVIRON MICROBIOL, V5, P630, DOI 10.1046/j.1462-2920.2003.00480.x; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; OHNISHI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P357, DOI 10.1016/0005-2728(69)90132-7; Park CH, 2000, APPL ENVIRON MICROB, V66, P1788, DOI 10.1128/AEM.66.5.1788-1795.2000; Park CH, 2002, REMEDIATION AND BENEFICIAL REUSE OF CONTAMINATED SEDIMENTS, P103; Ross D, 2004, METHOD ENZYMOL, V382, P115; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; Soballe B, 1999, MICROBIOL-SGM, V145, P1817, DOI 10.1099/13500872-145-8-1817; Sparla F, 1999, FEBS LETT, V463, P382, DOI 10.1016/S0014-5793(99)01625-7; SUZUKI T, 1992, J BACTERIOL, V174, P5340, DOI 10.1128/JB.174.16.5340-5345.1992; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; Viamajala S, 2002, BIOTECHNOL PROGR, V18, P290, DOI 10.1021/bp0202968; Wang YT, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P225; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996	30	97	101	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22590	22595		10.1074/jbc.M501654200	http://dx.doi.org/10.1074/jbc.M501654200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840577	hybrid			2022-12-25	WOS:000229741800007
J	Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR				Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR			Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma	ONCOGENE			English	Article						erythropoietin; erythropoietin receptor; head and neck cancer; invasion; HNSCC; JAK-STAT	PLACEBO-CONTROLLED TRIAL; RECEPTOR EXPRESSION; CYTOKINE RECEPTORS; CANCER-PATIENTS; BREAST-CANCER; DOUBLE-BLIND; GROWTH; BIOLOGY; LINES; REQUIREMENT	Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. EPO and the EPO receptor (EPOR) are expressed in nonhematopoietic cells and cancers. However, the role of EPO and EPOR within nonhematopoietic cancer cells remains incompletely understood. Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined. In the present study, we demonstrate the previously unrecognized EPO-mediated invasion by HNSCC cells through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens. Pharmacological doses of EPO also had a limited proliferation effect in these cell lines. These results de. ne a novel role for EPO in mediating tumor cell invasion. Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from HNSCC patients further support the role of EPO/EPOR in HNSCC disease progression and metastasis.	Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lai, SY (corresponding author), Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.	laisy@upmc.edu		Lai, Stephen/0000-0001-8301-7286; Wells, Alan/0000-0002-1637-8150	NIDCD NIH HHS [T32 DC000066-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000066] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBINI A, 1987, CANCER RES, V47, P3239; Arcasoy MO, 2005, CLIN CANCER RES, V11, P20; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Gall RM, 2000, J OTOLARYNGOL, V29, P131; Glaser CM, 2001, INT J RADIAT ONCOL, V50, P705, DOI 10.1016/S0360-3016(01)01488-2; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guo YL, 2004, MOL ENDOCRINOL, V18, P1033, DOI 10.1210/me.2003-0231; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HEO DS, 1989, CANCER RES, V49, P5167; Hwa V, 2004, J BIOL CHEM, V279, P2728, DOI 10.1074/jbc.M310495200; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Lacombe C, 1999, NEPHROL DIAL TRANSPL, V14, P22, DOI 10.1093/ndt/14.suppl_2.22; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu WM, 2004, ONCOGENE, V23, P981, DOI 10.1038/sj.onc.1207294; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Opdam FJM, 2004, ONCOGENE, V23, P6647, DOI 10.1038/sj.onc.1207887; Pajonk F, 2004, ONCOGENE, V23, P8987, DOI 10.1038/sj.onc.1208140; SACKS PG, 1988, CANCER RES, V48, P2858; Shasha D, 2001, SEMIN HEMATOL, V38, P8; TABBARA IA, 1993, ARCH INTERN MED, V153, P298, DOI 10.1001/archinte.153.3.298; Thatcher N, 1998, SEMIN ONCOL, V25, P23; Thomas SM, 2003, CANCER RES, V63, P5629; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xi SC, 2003, CANCER RES, V63, P6763; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yokomizo R, 2002, MOL HUM REPROD, V8, P441, DOI 10.1093/molehr/8.5.441; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719	46	137	150	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4442	4449		10.1038/sj.onc.1208635	http://dx.doi.org/10.1038/sj.onc.1208635			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856028				2022-12-25	WOS:000229976900013
J	Koti, RS; Tsui, JC; Lobos, E; Yang, WX; Seifalian, AM; Davidson, BR				Koti, RS; Tsui, JC; Lobos, E; Yang, WX; Seifalian, AM; Davidson, BR			Nitric oxide synthase distribution and expression with ischemic preconditioning of the rat liver	FASEB JOURNAL			English	Article						isoforms; endothelial; inducible; hepatoprotection; ischemia reperfusion injury	CORONARY-ARTERY-DISEASE; REPERFUSION INJURY; HEPATIC ISCHEMIA; L-ARGININE; TRANSPLANTATION; METABOLISM; MECHANISMS; GENERATION; MANAGEMENT; TOLERANCE	This study was undertaken to identify nitric oxide synthase (NOS) isoforms responsible for the generation of cytoprotective NO during liver ischemic preconditioning (IPC). Sprague-Dawley rats were subjected to 45 min lobar ischemia followed by 2 h reperfusion. L-arginine or NO)nitro-L-arginine methyl ester (L-NAME) was administered to stimulate or block NO synthesis. Study groups (n=6) had 1) sham laparotomy, 2) ischemia reperfusion (IR), 3) IPC with 5 min ischemia and 10 min reperfusion before IR, 4) L-arginine before IR, or 5) L-NAME + IPC before IR. Liver function tests, nitrite + nitrate (NOx) and plasma amino acids were analyzed. The endothelial cell and inducible isoforms of NOS (eNOS and iNOS) were identified using immunohistochemistry and Western blotting. Both IPC and L-arginine treatment increased NOx (P<0.05) and improved serum liver enzymes (P<0.05) when compared with IR. These effects were prevented by L-NAME. Hepatic vein NOx was significantly higher than circulating NOx. iNOS expression was absent within the groups. The preconditioned livers were associated with up-regulation of eNOS expression and also increased L-arginine levels. The effects of L-arginine administration were similar to those evident following IPC. Thus, cytoprotective NO generation during IPC of the liver was a result of increased eNOS expression and increased L-arginine substrate availability.	UCL, Acad Div Surg & Intervent Sci, London NW3 2PF, England; Royal Free Hampstead NHS Trust Hosp, Dept Surg & Liver, Transplantat Unit, London NW3 2QG, England; Univ Leipzig, Inst Anat, D-04103 Leipzig, Germany	University of London; University College London; University of London; University College London; Leipzig University	Seifalian, AM (corresponding author), UCL, Acad Div Surg & Intervent Sci, Rowland Hill St, London NW3 2PF, England.	A.Seifalian@MedSch.UCL.AC.UK	Seifalian, Alexander M/I-6028-2013; Tsui, Janice/T-7858-2019	Seifalian, Alexander M/0000-0002-1180-3322; seifalian, Alexander/0000-0002-8334-9376				Blum A, 2000, CIRCULATION, V101, P2160, DOI 10.1161/01.CIR.101.18.2160; Cottart CH, 1999, HEPATOLOGY, V29, P809, DOI 10.1002/hep.510290317; DELVA E, 1989, ANN SURG, V209, P211, DOI 10.1097/00000658-198902000-00012; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; JAESCHKE H, 1991, AM J PHYSIOL, V260, pG355, DOI 10.1152/ajpgi.1991.260.3.G355; JAESCHKE H, 2003, AM J PHYSL LIVER PHY, V254, pG15; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; Koti RS, 2003, DIGEST SURG, V20, P383, DOI 10.1159/000072064; Koti RS, 2002, LIVER TRANSPLANT, V8, P1182, DOI 10.1053/jlts.2002.36846; Koti RS, 2002, FASEB J, V16, P1654, DOI 10.1096/fj.01-1034fje; Langle F, 1997, TRANSPLANTATION, V63, P1225; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; Napoli C, 2003, P NATL ACAD SCI USA, V100, P2112, DOI 10.1073/pnas.0336359100; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Peralta C, 1999, HEPATOLOGY, V29, P126, DOI 10.1002/hep.510290104; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; Peralta C, 2001, TRANSPLANTATION, V71, P529, DOI 10.1097/00007890-200102270-00008; Redondo J, 2000, CRYOBIOLOGY, V41, P292, DOI 10.1006/cryo.2000.2285; Serafin A, 2002, AM J PATHOL, V161, P587, DOI 10.1016/S0002-9440(10)64214-9; Serracino-Inglott Ferdinand, 2002, BMC Gastroenterol, V2, P22, DOI 10.1186/1471-230X-2-22; Sindram D, 2002, J HEPATOL, V36, P78, DOI 10.1016/S0168-8278(01)00229-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Szabo G, 1998, J CARDIOVASC PHARM, V31, P221, DOI 10.1097/00005344-199802000-00007; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; Wang QD, 1997, J CARDIOVASC PHARM, V29, P291, DOI 10.1097/00005344-199702000-00020; WINDMUELLER HG, 1981, AM J PHYSIOL, V241, pE473, DOI 10.1152/ajpendo.1981.241.6.E473; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Yagnik GP, 2002, HEPATOLOGY, V36, P573, DOI 10.1053/jhep.2002.35058; Yin DP, 1998, TRANSPLANTATION, V66, P152, DOI 10.1097/00007890-199807270-00002; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982	33	46	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1155	+		10.1096/fj.04-3220fje	http://dx.doi.org/10.1096/fj.04-3220fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870170				2022-12-25	WOS:000229602600022
J	Moreno, MC; Sande, P; Marcos, HA; de Zavalia, N; Sarmiento, MIK; Rosenstein, RE				Moreno, MC; Sande, P; Marcos, HA; de Zavalia, N; Sarmiento, MIK; Rosenstein, RE			Effect of glaucoma on the retinal glutamate/glutamine cycle activity	FASEB JOURNAL			English	Article						excitotoxicity; glutamatergic neurons; hyaluronic acid	OPTIC-NERVE TRANSECTION; NITRIC-OXIDE SYNTHASE; GLIAL MULLER CELLS; INTRAOCULAR-PRESSURE; GLUTAMATE TRANSPORTER; OCULAR HYPERTENSION; MEMANTINE TREATMENT; RATS; SYNTHETASE; RECEPTORS	Glutamate-induced excitotoxicity has been proposed to mediate the death of retinal ganglion cells in glaucoma. The metabolic dependence of glutamatergic neurons upon glia via the glutamate/glutamine cycle to provide the precursor for neurotransmitter glutamate is well established. Thus, the aim of the present work was to study the retinal glutamate/glutamine activity in eyes with hypertension induced by intracameral injections of hyaluronic acid (HA). For this purpose, weekly injections of HA were performed unilaterally in the rat anterior chamber, whereas the contralateral eye was injected with saline solution. At 3 or 10 weeks of treatment, glutamate and glutamine uptake and release were assessed using [H-3]-glutamate and [H-3]-glutamine as radioligands, respectively. In addition, glutamine synthetase activity was assessed by a spectrophotometric assay, whereas glutaminase activity was measured through the conversion of [H-3]-glutamine to [H-3]-glutamate. At 3 weeks of treatment with HA, a significant decrease (P<0.01) in glutamate uptake and glutamine synthetase activity was observed. Glutamine uptake and release, as well as glutaminase activity, were significantly increased (P<0.01) in eyes injected with HA for 3 weeks compared with vehicle-injected eyes, whereas [H-3]-glutamate release did not change in hypertensive eyes. Only the changes in glutamine synthetase activity persisted at 10 weeks of treatment with HA. These results indicate a significant alteration in the retinal glutamate/glutamine cycle activity in hypertensive eyes. Since these changes preceded both functional and histological alterations induced by ocular hypertension, these results support the involvement of glutamate in glaucomatous neuropathy.	Univ Buenos Aires, Fac Med, Dept Bioquim Humana,CONICET, Lab Neuroquim Retiniana & Oftalmol Expt, RA-1121 Buenos Aires, DF, Argentina; Univ Moron, Fac Med, Histol Lab, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rosenstein, RE (corresponding author), Univ Buenos Aires, Fac Med, Dept Bioquim Humana,CONICET, Lab Neuroquim Retiniana & Oftalmol Expt, Paraguya 2155,5 P, RA-1121 Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar						ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Benozzi J, 2002, INVEST OPHTH VIS SCI, V43, P2196; Brooks DE, 1997, AM J VET RES, V58, P864; Carter-Dawson L, 2002, INVEST OPHTH VIS SCI, V43, P2633; CULCASI M, 1994, J BIOL CHEM, V269, P12589; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; Dkhissi O, 1999, INVEST OPHTH VIS SCI, V40, P990; Gegelashvili G, 1998, BRAIN RES BULL, V45, P233, DOI 10.1016/S0361-9230(97)00417-6; Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2625, DOI 10.1167/iovs.03-0566; Hare WA, 2004, INVEST OPHTH VIS SCI, V45, P2640, DOI 10.1167/iovs.03-0567; Honkanen RA, 2003, ARCH OPHTHALMOL-CHIC, V121, P183; KALLONIATIS M, 1994, VISUAL NEUROSCI, V11, P793, DOI 10.1017/S0952523800003096; Kaushik S, 2003, J Postgrad Med, V49, P90; KVAMME E, 1985, METHOD ENZYMOL, V113, P241; Lam TT, 2003, INVEST OPHTH VIS SCI, V44, P638, DOI 10.1167/iovs.02-0255; Levkovitch-Verbin H, 2002, J GLAUCOMA, V11, P396, DOI 10.1097/00061198-200210000-00005; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; MOORE CG, 1995, CURR EYE RES, V14, P711, DOI 10.3109/02713689508998499; Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001; MORENO MC, 2005, IN PRESS EXP EYE RES; MORENO MC, 2002, RETINAL DAMAGE CHRON; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; Naskar R, 2000, INVEST OPHTH VIS SCI, V41, P1940; Neufeld AH, 2004, BRAIN RES BULL, V62, P455, DOI 10.1016/j.brainresbull.2003.07.005; Otis TS, 1998, J NEUROSCI, V18, P7099; Poitry S, 2000, J NEUROSCI, V20, P1809; POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; Ritch R, 2000, MED HYPOTHESES, V54, P221, DOI 10.1054/mehy.1999.0025; Saenz DA, 2004, FASEB J, V18, P1912, DOI 10.1096/fj.04-2062fje; Saenz DA, 2002, J PINEAL RES, V33, P31, DOI 10.1034/j.1600-079X.2002.01880.x; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9; Shen F, 2004, INVEST OPHTH VIS SCI, V45, P3107, DOI 10.1167/iovs.03-0948; Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x; Takahata K, 2003, INVEST OPHTH VIS SCI, V44, P1760, DOI 10.1167/iovs.02-0471; TAKATSUNA Y, 1994, CURR EYE RES, V13, P629, DOI 10.3109/02713689408999898; Tanaka K, 2000, NEUROSCI RES, V37, P15, DOI 10.1016/S0168-0102(00)00104-8; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Ueda J, 1998, JPN J OPHTHALMOL, V42, P337, DOI 10.1016/S0021-5155(98)00026-4; Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615; Wamsley S, 2005, ARCH OPHTHALMOL-CHIC, V123, P64, DOI 10.1001/archopht.123.1.64; Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360; Woldemussie E, 2004, GLIA, V47, P109, DOI 10.1002/glia.20000	50	68	71	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1161	+		10.1096/fj.04-3313fje	http://dx.doi.org/10.1096/fj.04-3313fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15870062				2022-12-25	WOS:000229602600023
J	Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR				Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR			Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth	ONCOGENE			English	Article						AKT; mTOR; asbestos; mesothelioma	PROSTATE INTRAEPITHELIAL NEOPLASIA; FACTOR SCATTER FACTOR; HUMAN OVARIAN; PHOSPHATIDYLINOSITOL 3-KINASE; AKT ACTIVATION; KINASE-B; C-MET; CANCER; GENE; EXPRESSION	Malignant mesotheliomas ( MMs) are very aggressive tumors that respond poorly to standard chemotherapeutic approaches. The phosphatidylinositol 3- kinase ( PI3K)/AKT pathway has been implicated in tumor aggressiveness, in part by mediating cell survival and reducing sensitivity to chemotherapy. Using antibodies recognizing the phosphorylated/activated form of AKT kinases, we observed elevated phospho-AKT staining in 17 of 26 ( 65%) human MM specimens. In addition, AKT phosphorylation was consistently observed in MMs arising in asbestos-treated mice and in MM cell xenografts. Consistent with reports implicating hepatocyte growth factor (HGF)/Met receptor signaling in MM, all 14 human and murine MM cell lines had HGF- inducible AKT activity. One of nine human MM cell lines had elevated AKT activity under serum-starvation conditions, which was associated with a homozygous deletion of PTEN, the first reported in MM. Treatment of this cell line with the mTOR inhibitor rapamycin resulted in growth arrest in G1 phase. Treatment of MM cells with the PI3K inhibitor LY294002 in combination with cisplatin had greater efficacy in inhibiting cell proliferation and inducing apoptosis than either agent alone. Collectively, these data indicate that MMs frequently express elevated AKT activity, which may be targeted pharmacologically to enhance chemotherapeutic efficacy. These findings also suggest that mouse models of MM maybe useful for future preclinical studies of pharmaceuticals targeting the PI3K/AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Fox Chase Cancer Center; University of Vermont; Memorial Sloan Kettering Cancer Center; Brown University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jr_testa@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429, R01CA045745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003721] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA045745, CA-06927, P30 CA006927, R01 CA077429, CA-45745, CA-77429] Funding Source: Medline; NIEHS NIH HHS [ES-003721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; BELLACOSA A, IN PRESS CANC RES; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Bowers DC, 2000, CANCER RES, V60, P4277; Britton M, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.30237; Brognard J, 2001, CANCER RES, V61, P3986; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Cao XBX, 2001, AM J RESP CELL MOL, V25, P562, DOI 10.1165/ajrcmb.25.5.4539; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Goodglick LA, 1997, TOXICOL PATHOL, V25, P565, DOI 10.1177/019262339702500605; Harvey P, 2000, BRIT J CANCER, V83, P1147, DOI 10.1054/bjoc.2000.1445; Hu LM, 2002, CANCER RES, V62, P1087; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Liu AX, 1998, CANCER RES, V58, P2973; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Papp T, 2001, ONCOL REP, V8, P1375; Philp AJ, 2001, CANCER RES, V61, P7426; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Rusch VW, 2003, J CLIN ONCOL, V21, P2629, DOI 10.1200/JCO.2003.02.043; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tanno S, 2001, CANCER RES, V61, P589; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	45	136	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6080	6089		10.1038/sj.onc.1208744	http://dx.doi.org/10.1038/sj.onc.1208744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897870				2022-12-25	WOS:000231718100002
J	Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G				Di Stefano, V; Soddu, S; Sacchi, A; D'Orazi, G			HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21(Waf1) after nonapoptotic DNA damage	ONCOGENE			English	Article						HIPK2; p53; acetylation; chromatin immunoprecipitation; DNA damage; PCAF	INTERACTING PROTEIN KINASE-2; APOPTOTIC TARGET GENES; CELL-CYCLE ARREST; INDUCED PHOSPHORYLATION; MUTANT P53; ACTIVATION; INHIBITION; RECRUITMENT; CHECKPOINT; RADIATION	The p53 tumor suppressor gene is activated in response to DNA damage resulting in either growth arrest or apoptosis. We previously demonstrated the specific involvement of homeodomain interacting protein-kinase 2 (HIPK2), a nuclear serine/threonine kinase, in inducing p53-dependent apoptosis through selective p53 phosphorylation at serine 46 after severe genotoxic damage. Here we show that HIPK2 contributes to p53 regulation, independently from serine 46 phosphorylation upon nonapoptotic DNA damage such as that induced by cytostatic doses of cisplatin. We show that HIPK2 depletion by RNA interference inhibits p53 binding to the p21(Waf1) promoter affecting its p53-induced transactivation thereby allowing cell proliferation. We found that nonapoptotic DNA damage induces p53 acetylation mediated by the HAT protein PCAF and this p53 post-translational modification is abolished by HIPK2 depletion. In this regard, we found that HIPK2 cooperates with PCAF to induce selectively p53 transcriptional activity toward the p21(Waf1) promoter while depletion of either HIPK2 or PCAF abolished this function. These data show that HIPK2 regulates the p53 growth arrest function through its PCAF-mediated acetylation.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00185 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Doro 156, I-00185 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; D'Orazi, Gabriella/T-2792-2019	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; D'Orazi, Gabriella/0000-0001-6876-9105				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; EL DW, 1993, CELL, V75, P817; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MIYASHITA T, 1995, CELL, V80, P293; Moller A, 2003, CANCER RES, V63, P4310; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VOGTSIONOV R, 1999, ONCOGENE, V18, P6145; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113	45	54	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5431	5442		10.1038/sj.onc.1208717	http://dx.doi.org/10.1038/sj.onc.1208717			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897882				2022-12-25	WOS:000231222300004
J	Chao, H; Spicer, AP				Chao, H; Spicer, AP			Natural antisense mRNAs to hyaluronan synthase 2 inhibit hyaluronan biosynthesis and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR CHONDROCYTES; C-MYC; DIFFERENTIAL REGULATION; DERMAL FIBROBLASTS; EXPRESSION; SYNTHASES; TRANSCRIPTION; GROWTH; SENSE; HOMEOSTASIS	We report the identification of a natural antisense mRNA of hyaluronan synthase 2 that we have chosen to designate as HASNT ( for HA synthase 2 antisense) in human and mouse. HASNT is transcribed from the opposite strand of the HAS2 gene locus and is represented by several independent expressed sequence tags in human. Portions of the mouse Hasnt gene were identified through an exon-trapping approach. Sequence conservation is extremely low between human and mouse HASNT, and it is not clear whether these mRNAs contain functional open reading frames. HASNT has an alternate splice site in both human and mouse. This splice site is located at an identical position within the gene in both species and results in mRNAs of two different lengths. In each species, the antisense portion of the HASNT gene is complementary to the first exon of HAS2, which represents the 5'-untranslated region. To study the biological activity of HASNT, two human expressed sequence tag clones, representing long and short HASNT splice variants, were cloned into a tetracycline-inducible vector and were stably transfected into human osteosarcoma U2-OS Tet-on cells. The long and short HASNT-expressing cells had a reduction in HAS2 mRNA levels up to 94 and 86%, respectively, whereas hyaluronan biosynthesis was inhibited by 40 and 37%, respectively. Cell proliferation was reduced throughout the time frame of the experiment. Exogenous high molecular mass hyaluronan failed to rescue the suppressed cell proliferation, whereas adenoviral-mediated overexpression of hyaluronan synthase 3, which stimulated endogenous hyaluronan biosynthesis, was able to rescue. Collectively, our data suggest that natural antisense mRNAs of HAS2 are able to regulate HAS2 mRNA levels and hyaluronan biosynthesis in a cell culture model system and may have an important and novel regulatory role in the control of HAS2, HA biosynthesis, and HA-dependent cell functions in vivo.	Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Chao, H (corresponding author), Acorn Sci, 3014 Country Club Dr, Pearland, TX 77030 USA.	acornscientific@yahoo.com						BAI KJ, 2004, IN PRESS AM J RESP C; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dickson G, 2002, NEUROMUSCULAR DISORD, V12, pS67, DOI 10.1016/S0960-8966(02)00085-8; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; FARRELL CM, 1995, J BIOL CHEM, V270, P3400, DOI 10.1074/jbc.270.7.3400; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Good L, 2003, CELL MOL LIFE SCI, V60, P854, DOI 10.1007/s00018-003-3045-4; Hascall VC, 2000, GLYCOCONJUGATE J, V17, P607, DOI 10.1023/A:1011082728155; Herbert A, 2004, NAT GENET, V36, P19, DOI 10.1038/ng1275; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Kaback LA, 1999, J CLIN ENDOCR METAB, V84, P4079, DOI 10.1210/jc.84.11.4079; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON W, 1991, J CELL SCI, V99, P227; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Meyer K, 1934, J BIOL CHEM, V107, P629; Monslow J, 2003, INT J BIOCHEM CELL B, V35, P1272, DOI 10.1016/S1357-2725(03)00048-7; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Recklies AD, 2001, BIOCHEM J, V354, P17, DOI 10.1042/0264-6021:3540017; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; Shendure J, 2002, GENOME BIOL, V3; Spicer A P, 2001, Methods Mol Biol, V171, P373; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SPICER AP, 1995, J IMMUNOL, V155, P3079; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tien JYL, 2005, DEV DYNAM, V233, P130, DOI 10.1002/dvdy.20328; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; TOSIC M, 1990, EMBO J, V9, P401, DOI 10.1002/j.1460-2075.1990.tb08124.x; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yamada Y, 2004, J INVEST DERMATOL, V122, P631, DOI 10.1111/j.0022-202X.2004.22332.x; Yamada Y, 1998, BIOCHEM J, V330, P1223, DOI 10.1042/bj3301223; Zhang W, 2000, BIOCHEM J, V349, P91, DOI 10.1042/0264-6021:3490091; Zimmerman E, 2002, BIOPHYS J, V82, P1848, DOI 10.1016/S0006-3495(02)75535-5	45	54	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27513	27522		10.1074/jbc.M411544200	http://dx.doi.org/10.1074/jbc.M411544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15843373	hybrid			2022-12-25	WOS:000230678600007
J	Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X				Yuan, HD; Fu, FH; Zhuo, JY; Wang, W; Nishitani, J; An, DS; Chen, ISY; Liu, X			Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis	ONCOGENE			English	Article						apoptosis; c-IAP2; upregulation; human papillomavirus; oral keratinocyte	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CELLULAR INHIBITOR; CANCER-CELLS; PROTEIN; DEGRADATION; ACTIVATION; IAPS; DIFFERENTIATION; KERATINOCYTES	Inhibition of apoptosis plays an important role in the cellular immortalization and transformation induced by E6 and E7 oncoproteins of human papillomavirus (HPV). Here, we report that the transcription of the inhibitor of apoptosis gene, cellular inhibitor of apoptosis protein 2, (c-IAP2), is significantly upregulated in HPV16 E6/ E7-immortalized human oral keratinocytes (HOK16E6E7). Overexpression of E6/ E7 from the high-risk HPV16 or 18, but not from the low-risk HPV6, activated c-IAP2 promoter. E6 from HPV16 and 18 played a major role in the activation. In addition, the induction of c- IAP2 transcription required nuclear factor-kappa B activity. Overexpression of c- IAP2 in normal human oral keratinocyte conferred resistance to tumor necrosis factor-alpha ( TNF-alpha)/ cycloheximide (CHX)- induced apoptosis, suggesting the increased c- IAP2 expression in HOK16E6E7 may protect the cells from TNF-alpha- mediated cell death. Moreover, depletion of endogenous c- IAP2 using RNA interference in HOK16E6E7 induced apoptosis, indicating that c- IAP2 is necessary for HPV16 E6/E7-induced resistance to apoptosis and cell survival. Of note, high levels of c- IAP2 transcription were found in several HPV16- or HPV18-positive cancer cells, and depletion of c- IAP2 caused cell death in HPV18- positive HeLa cells. Thus, upregulation of c- IAP2 by E6 and E7 may confer resistance to apoptosis that is necessary for sustained growth of some HPV16- and HPV18- positive cancer cells.	Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90059 USA; Charles R Drew Univ Med & Sci, Dept Otolaryngol, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, AIDS Inst, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	Charles R. Drew University of Medicine & Science; Charles R. Drew University of Medicine & Science; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Liu, X (corresponding author), Charles R Drew Univ Med & Sci, Dept Oral & Maxillofacial Surg, 1621 E 120th St, Los Angeles, CA 90059 USA.	xuliu@cdrewu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K23DE000430] Funding Source: NIH RePORTER; NCRR NIH HHS [G12-RR03026-15] Funding Source: Medline; NIDCR NIH HHS [K23 DE00430] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		An DS, 2003, HUM GENE THER, V14, P1207, DOI 10.1089/104303403322168037; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duffy CL, 2003, VIROLOGY, V314, P196, DOI 10.1016/S0042-6822(03)00390-8; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Finzer P, 2002, CANCER LETT, V188, P15, DOI 10.1016/S0304-3835(02)00431-7; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Havard L, 2002, VIROLOGY, V298, P271, DOI 10.1006/viro.2002.1468; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Hui EKW, 2004, J GEN VIROL, V85, P1877, DOI 10.1099/vir.0.79906-0; Jewett A, 2003, HUM IMMUNOL, V64, P505, DOI 10.1016/S0198-8859(03)00039-9; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Min BM, 1999, EXP CELL RES, V249, P377, DOI 10.1006/excr.1999.4489; Mota F, 1999, CLIN EXP IMMUNOL, V116, P33; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; NISHITANI J, 2002, CELL MOL BIOL, V48, P331; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Thompson DA, 2001, ONCOGENE, V20, P3629, DOI 10.1038/sj.onc.1204483; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200; Yuan HD, 2003, J VIROL, V77, P2063, DOI 10.1128/JVI.77.3.2063-2070.2003; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; zur Hausen H, 1999, EUR J CANCER, V35, P1878, DOI 10.1016/S0959-8049(99)00291-9	50	61	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5069	5078		10.1038/sj.onc.1208691	http://dx.doi.org/10.1038/sj.onc.1208691			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856013				2022-12-25	WOS:000230816900006
J	Liu, X; Shu, S; Kovacs, M; Korn, ED				Liu, X; Shu, S; Kovacs, M; Korn, ED			Biological, biochemical, and kinetic effects of mutations of the cardiomyopathy loop of Dictyostelium myosin II - Importance of ALA(400)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEAVY-CHAIN GENE; REGULATORY LIGHT-CHAIN; BETA-CARDIAC MYOSIN; PHOSPHORYLATION SITE; FUNCTIONAL-ANALYSIS; IN-VITRO; ACANTHAMOEBA MYOSIN; MOTOR-ACTIVITY; TEDS RULE	The cardiomyopathy (CM)-loop of the heavy chain of class-II myosins begins with a highly conserved Arg residue ( whose mutation in human beta-cardiac myosin II results in familial hypertrophic cardiomyopathy). The CM-loop of Dictyostelium myosin II (Arg(397) - Gln(407)) is essential for its biological functions and biochemical activities. We found that the CM-loop of smooth muscle myosin II substituted partially, and the CM-loop of beta-cardiac myosin II less well, for growth, capping of surface receptors and development, and the actin-activated MgATPase and in vitro motility activities of purified myosins. There was little correlation between the biochemical and biological activities of the two chimeras and 19 point mutants, but only the five mutants with k(cat)/K-actin values equivalent to wild-type myosin supported essentially full biological function. The three point mutations of Arg397 equivalent to those that result in hypertrophic cardiomyopathy in humans had minimal biological effects and different biochemical effects. The A400V mutation rendered full-length wild-type myosin almost completely inactive, both in vitro and in vivo, and the reverse V400A mutation in the cardiac CM-loop chimera restored almost full activity, even though the sequence still differed from wild-type in 7 of 11 positions. Transient kinetic studies of acto-subfragment-1 (S1) showed that the chimeras and the Ala/Val, Val/Ala mutations do not affect the equilibrium or the association and dissociation rate constants for either ATP or ADP binding to acto-S1 or the rate of ATP-induced dissociation of acto-S1. We conclude that the Ala/Val, Val/Ala mutations affect the release of Pi from acto-S1 center dot ADP center dot P-i. In addition, Val at position 400 substantially reduces the affinity of actin for S1 in the absence of nucleotide.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2517-8017, Bethesda, MD 20892 USA.	edk@nih.gov	Korn, Edward D/F-9929-2012; Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741; Korn, Edward/0000-0003-3867-6295	NHLBI NIH HHS [Z01 HL000506-30] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000506, Z01HL000506] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Batra R, 1999, BIOCHEMISTRY-US, V38, P6126, DOI 10.1021/bi982251e; Bauer CB, 2000, J BIOL CHEM, V275, P38494, DOI 10.1074/jbc.M005585200; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; Clow PA, 2000, DEVELOPMENT, V127, P2715; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; DAUSSE E, 1993, J CLIN INVEST, V92, P2807, DOI 10.1172/JCI116900; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; DOOLITTLE KW, 1995, DEV BIOL, V167, P118, DOI 10.1006/dbio.1995.1011; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; ELIOTT S, 1993, J CELL SCI, V104, P457; Fujita H, 1997, J CLIN INVEST, V99, P1010, DOI 10.1172/JCI119228; Fujita-Becker S, 2005, J BIOL CHEM, V280, P6064, DOI 10.1074/jbc.M412473200; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Giese KC, 1997, BIOCHEMISTRY-US, V36, P8465, DOI 10.1021/bi963141f; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LEBLANCSTRACESKI JM, 1994, CELL MOTIL CYTOSKEL, V27, P313, DOI 10.1002/cm.970270404; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Liu X, 2000, BIOCHEM BIOPH RES CO, V271, P75, DOI 10.1006/bbrc.2000.2582; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; Palmiter KA, 2000, J MUSCLE RES CELL M, V21, P609, DOI 10.1023/A:1005678905119; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; Robinson DN, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-4; Roopnarine O, 1998, BIOPHYS J, V75, P3023, DOI 10.1016/S0006-3495(98)77743-4; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sasaki N, 1999, J BIOL CHEM, V274, P37840, DOI 10.1074/jbc.274.53.37840; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; Shu S, 2003, P NATL ACAD SCI USA, V100, P6499, DOI 10.1073/pnas.0732155100; Shu S, 2002, J CELL SCI, V115, P4237, DOI 10.1242/jcs.00112; Smith JL, 1996, EMBO J, V15, P6075, DOI 10.1002/j.1460-2075.1996.tb00996.x; SPRINGER ML, 1994, DEVELOPMENT, V120, P2651; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; WANG ZY, 1998, P NATL ACAD SCI USA, V95, P4146; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yamashita H, 2000, J BIOL CHEM, V275, P28045; Yumura S, 1997, MOL BIOL CELL, V8, P2089, DOI 10.1091/mbc.8.10.2089; Zang JH, 1998, P NATL ACAD SCI USA, V95, P13652, DOI 10.1073/pnas.95.23.13652	66	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26974	26983		10.1074/jbc.M504453200	http://dx.doi.org/10.1074/jbc.M504453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15897189	Green Accepted, hybrid			2022-12-25	WOS:000230589500041
J	Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P				Benali-Furet, NL; Chami, M; Houel, L; De Giorgi, F; Vernejoul, F; Lagorce, D; Buscail, L; Bartenschlager, R; Ichas, F; Rizzuto, R; Paterlini-Brechot, P			Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion	ONCOGENE			English	Article						apoptosis; calcium signalling; ER stress; HCV core; liver cancer	ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA; NITRIC-OXIDE; PROTEIN; ACTIVATION; CA2+; LOCALIZATION; MITOCHONDRIA; BAX; TRANSLOCATION	Hepatitis C virus (HCV) core, known to be involved in liver carcinogenesis, is processed in the endoplasmic reticulum (ER). We thus investigated the impact of three HCV core isolates on ER stress, ER calcium signalling and apoptosis. We show that HCV core constructs trigger hyperexpression of Grp78/BiP, Grp 94, calreticulin and sarco/endoplasmic reticulum calcium ATPase, inducing ER stress. By using the ER-targeted aequorin calcium probe, we found that ER calcium depletion follows ER stress in core-expressing cells. HCV core induces apoptosis through overexpression of the CHOP/GADD153 proapoptotic factor, Bax translocation to mitochondria, mitochondrial membrane depolarization, cytochrome c release, caspase-3 and PARP cleavage. Furthermore, reversion of HCV core-induced ER calcium depletion (by transfection of SERCA2) completely abolished mitochondrial membrane depolarization, suggesting that both ER stress (through CHOP overexpression) and calcium signalling play a major role in the HCV core-mediated control of apoptosis. ER stress and apoptosis were also found in a proportion of HCV-full-length replicon-expressing cells and in the liver of HCV core transgenic mice. In conclusion, our data demonstrate that HCV core deregulates the control of apoptosis by inducing ER stress and ER calcium depletion providing new elements to understand the mechanisms involved in HCV-related liver chronic diseases.	Inst Pasteur, INSERM, U370, Dept Liver Canc & Mol Virol, F-75015 Paris, France; Univ Paris 05, CHU Necker, F-75005 Paris, France; Univ Ferrara, Dept Expt Med, I-44100 Ferrara, Italy; INSERM, E347, Inst Europeen Chim & Biol, F-33600 Pessac, France; Inst Louis Bugnard, INSERM, U531, F-31059 Toulouse, France; Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Ferrara; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg	Paterlini-Brechot, P (corresponding author), Fac Necker Enfants Malad, INSERM, U370 Pasteur, 156 Rue Vaugirard, F-75730 Paris, France.	paterlini@necker.fr	Ichas, François/ABD-8277-2020; HOUEL, Ludivine J/E-4151-2016; Rizzuto, Rosario/B-6312-2008; Chami, Mounia/S-6471-2019; Bartenschlager, Ralf/L-2582-2015	Ichas, François/0000-0001-8184-5248; HOUEL, Ludivine J/0000-0003-0218-1418; Chami, Mounia/0000-0003-1498-7187; Bartenschlager, Ralf/0000-0001-5601-9307; Paterlini- Brechot, Patrizia/0000-0001-7981-6325; Rizzuto, Rosario/0000-0001-7044-5097; De Giorgi, Francesca/0000-0003-4850-3582				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200; Bianchi K, 2004, BBA-MOL CELL RES, V1742, P119, DOI 10.1016/j.bbamcr.2004.09.015; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Colombo M, 2003, ANTIVIR RES, V60, P145, DOI 10.1016/j.antiviral.2003.08.010; de Lucas S, 2003, ANTIVIR RES, V60, P117, DOI 10.1016/j.antiviral.2003.08.006; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; Doutheil J, 2000, CELL CALCIUM, V27, P107, DOI 10.1054/ceca.1999.0099; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Martire G, 2001, VIROLOGY, V280, P176, DOI 10.1006/viro.2000.0733; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Minczuk M, 2002, NUCLEIC ACIDS RES, V30, P5074, DOI 10.1093/nar/gkf647; Moorman JP, 2003, VIROLOGY, V312, P320, DOI 10.1016/S0042-6822(03)00208-3; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Pawlotsky JM, 2004, TRENDS MICROBIOL, V12, P96, DOI 10.1016/j.tim.2003.12.005; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Realdon S, 2004, J HEPATOL, V40, P77, DOI 10.1016/j.jhep.2003.09.017; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rodrigues CMP, 2000, J VIRAL HEPATITIS, V7, P175; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Vernejoul F, 2002, CANCER RES, V62, P6124; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	52	216	227	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4921	4933		10.1038/sj.onc.1208673	http://dx.doi.org/10.1038/sj.onc.1208673			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897896				2022-12-25	WOS:000230646500005
J	Felty, Q; Singh, KP; Roy, D				Felty, Q; Singh, KP; Roy, D			Estrogen-induced G(1)/S transition of G(0)-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling	ONCOGENE			English	Article						cell cycle; estradiol; ROS; mitochondria	POLYMERASE CHAIN-REACTION; SUPEROXIDE FORMATION; RECEPTOR-BETA; LEYDIG-CELLS; ER-ALPHA; GROWTH; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	We previously reported that 17-beta-estradiol (E2)-induced mitochondrial reactive oxygen species (mtROS) act as signaling molecules. The purpose of this study was to investigate the effects of E2-induced mtROS on cell cycle progression. E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimic ebselen. Flow cytometry showed that mitochondrial blockers of protein synthesis (chloramphenicol), transcription and replication (ethidium bromide), and function (rotenone, rhodamine 6G) blocked E2-induced G(1) to S transition. Reduction of E2-induced DNA synthesis in the presence of mitochondrial blockers occurred without influencing the level of ATP. Additionally, the mitochondrial blockers inhibited the E2-induced expression of early cell cycle genes such as cyclins D1, D3, E1, E2, and B2. NAC or rotenone reduced E2-induced cyclin D1 expression. Furthermore, E2-induced binding of AP-1 and CREB to the TRE and CRE response sequences, respectively, in the promoter of cyclin D1 was inhibited by NAC or rotenone. In addition, E2-induced expression of PCNA, PRC1, and bcl-2 were inhibited by mitochondrial blockers. These data indicate that E2-induced mtROS are involved in the regulation of early G(1)-phase progression. Since neither antioxidants nor mitochondrial blockers used in this study are reported to bind the estrogen receptor (ER), our findings suggest that E2-induced mtROS modulates G(1) to S transition and some of the early G(1) genes through a nongenomic, ER-independent signaling pathway. Thus, our results suggest (1) a new paradigm that estrogen-induced mitochondrial oxidants control the early stage of cell cycle progression and (2) provide the basis for the discovery of novel antioxidant-based drugs or antioxidant gene therapies for the prevention and treatment of estrogen-dependent breast cancer.	Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Florida Int Univ, Robert Stempel Sch Publ Hlth, Miami, FL 33199 USA	University of Alabama System; University of Alabama Birmingham; State University System of Florida; Florida International University	Roy, D (corresponding author), Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.	Droy@fiu.edu	Singh, Kamaleshwar Prasad/AAE-9166-2020	Felty, Quentin/0000-0002-7151-0441	NCI NIH HHS [CA 4788] Funding Source: Medline; NIEHS NIH HHS [ES10851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arteaga E, 2003, MENOPAUSE, V10, P142, DOI 10.1097/00042192-200310020-00005; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen JQ, 2004, AM J PHYSIOL-ENDOC M, V286, pE1011, DOI 10.1152/ajpendo.00508.2003; Chen JQ, 2004, ANN NY ACAD SCI, V1028, P258, DOI 10.1196/annals.1322.030; Chen JQ, 2004, J CELL BIOCHEM, V93, P358, DOI 10.1002/jcb.20178; Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Du Mond JW, 2001, INT J ONCOL, V18, P623; DuMond JW, 2001, ONCOL REP, V8, P899; Felty Q, 2005, MED HYPOTHESES, V64, P133, DOI 10.1016/j.mehy.2003.12.056; Felty Quentin, 2005, J Carcinog, V4, P1, DOI 10.1186/1477-3163-4-1; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Galli S, 2003, CANCER RES, V63, P6370; Harris RE, 2003, CANCER RES, V63, P6096; HERBER B, 1994, ONCOGENE, V9, P1295; Honore S, 2003, EXP CELL RES, V285, P59, DOI 10.1016/S0014-4827(02)00038-1; *IARC WORK GROUP, 1999, MON EV HORM CONTR PO, P399; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Kim MR, 2003, BIOCHEM BIOPH RES CO, V304, P119, DOI 10.1016/S0006-291X(03)00547-3; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MADDAIAH VT, 1973, J BIOL CHEM, V248, P4263; Maruyama T, 1999, ENDOCRINOLOGY, V140, P365, DOI 10.1210/en.140.1.365; Menon SG, 2003, CANCER RES, V63, P2109; *NAT TOX PROGR, 2002, FED REP CARC, P77283; Pan-Zhou XR, 2000, ANTIMICROB AGENTS CH, V44, P496, DOI 10.1128/AAC.44.3.496-503.2000; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Ramachandran C, 2000, ANTICANCER RES, V20, P3759; Roy D, 2004, CURR GENOMICS, V5, P245, DOI 10.2174/1389202043349471; ROY D, 1988, J BIOL CHEM, V263, P3646; Roy D., 2002, RECENT RES DEV STERO, V3, P1; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965; VANDENBOGERT C, 1986, CANCER LETT, V32, P41, DOI 10.1016/0304-3835(86)90037-6; WANG TTY, 1995, CANCER RES, V55, P2487; Wei QY, 1997, CANCER RES, V57, P1673; Williams AJ, 1999, HUM MOL GENET, V8, P1691, DOI 10.1093/hmg/8.9.1691	49	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4883	4893		10.1038/sj.onc.1208667	http://dx.doi.org/10.1038/sj.onc.1208667			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897899				2022-12-25	WOS:000230646500002
J	Du, WL; Stiber, JA; Rosenberg, PB; Meissner, G; Eu, JP				Du, WL; Stiber, JA; Rosenberg, PB; Meissner, G; Eu, JP			Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY SMOOTH-MUSCLE; CYCLIC-ADP-RIBOSE; CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; BRONCHIAL HYPERRESPONSIVENESS; INOSITOL TRISPHOSPHATE; CONTRACTION; TRACHEAL; VASOCONSTRICTION; MODULATION	Ryanodine receptors (RyRs), intracellular calcium release channels essential for skeletal and cardiac muscle contraction, are also expressed in various types of smooth muscle cells. In particular, recent studies have suggested that in airway smooth muscle cells (ASMCs) provoked by spasmogens, stored calcium release by the cardiac isoform of RyR (RyR2) contributes to the calcium response that leads to airway constriction (bronchoconstriction). Here we report that mouse ASMCs also express the skeletal muscle and brain isoforms of RyRs (RyR1 and RyR3, respectively). In these cells, RyR1 is localized to the periphery near the cell membrane, whereas RyR3 is more centrally localized. Moreover, RyR1 and/or RyR3 in mouse airway smooth muscle also appear to mediate bronchoconstriction caused by the muscarinic receptor agonist carbachol. Inhibiting all RyR isoforms with >= 200 mu M ryanodine attenuated the graded carbachol-induced contractile responses of mouse bronchial rings and calcium responses of ASMCs throughout the range of carbachol used (50 nM to >= 3 mu M). In contrast, inhibiting only RyR1 and RyR3 with 25 mu M dantrolene attenuated these responses caused by high (> 500 nM) but not by low concentrations of carbachol. These data suggest that, as the stimulation of muscarinic receptor in the airway smooth muscle increases, RyR1 and/or RyR3 also mediate the calcium response and thus bronchoconstriction. Our findings provide new insights into the complex calcium signaling in ASMCs and suggest that RyRs are potential therapeutic targets in bronchospastic disorders such as asthma.	Duke Univ, Ctr Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; Duke Univ, Ctr Med, Div Cardiol, Durham, NC 27710 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill	Eu, JP (corresponding author), Duke Univ, Ctr Med, Div Pulm Allergy & Crit Care Med, MSRB 241,Res Dr, Durham, NC 27710 USA.	eu000001@duke.edu		Rosenberg, Paul/0000-0002-5659-160X				Amrani Y, 2004, CURR OPIN PHARMACOL, V4, P230, DOI 10.1016/j.coph.2004.02.004; Ay B, 2004, AM J PHYSIOL-LUNG C, V286, pL909, DOI 10.1152/ajplung.00317.2003; Barata H, 2004, ENDOCRINOLOGY, V145, P881, DOI 10.1210/en.2003-0774; BARNES PJ, 1997, LUNG SCI FDN, P1269; Bergner A, 2002, J GEN PHYSIOL, V119, P187, DOI 10.1085/jgp.119.2.187; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; CABANES LR, 1989, NEW ENGL J MED, V320, P1317, DOI 10.1056/NEJM198905183202005; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; Deshpande DA, 2005, AM J RESP CELL MOL, V32, P149, DOI 10.1165/rcmb.2004-0243OC; Deshpande DA, 2004, AM J RESP CELL MOL, V31, P36, DOI 10.1165/rcmb.2003-0313OC; Deshpande DA, 2003, FASEB J, V17, P452, DOI 10.1096/fj.02-0450fje; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Flucher BE, 1999, J CELL BIOL, V146, P621, DOI 10.1083/jcb.146.3.621; Franzini-Armstrong C, 1998, ANN NY ACAD SCI, V853, P20, DOI 10.1111/j.1749-6632.1998.tb08253.x; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GARSSEN J, 1990, J PHARMACOL METHOD, V24, P209, DOI 10.1016/0160-5402(90)90031-F; Gelband CH, 1997, CIRCULATION, V96, P3647; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; Hyvelin JM, 2000, AM J RESP CRIT CARE, V162, P687, DOI 10.1164/ajrccm.162.2.9911025; Jabr RI, 1997, BRIT J PHARMACOL, V122, P21, DOI 10.1038/sj.bjp.0701326; Jaggar JH, 1998, ACTA PHYSIOL SCAND, V164, P577; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; Janssen LJ, 2001, J APPL PHYSIOL, V91, P1142, DOI 10.1152/jappl.2001.91.3.1142; JANSSEN LJ, 1997, LUNG SCI FDN, P1235; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL659, DOI 10.1152/ajplung.1997.272.4.L659; KATSUYAMA H, 1991, PFLUG ARCH EUR J PHY, V419, P460, DOI 10.1007/BF00370789; KOTLIKOFF MI, 1992, BIOCHEM PHARMACOL, V43, P5, DOI 10.1016/0006-2952(92)90652-Y; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Kuemmerle John F., 1998, Cell Biochemistry and Biophysics, V28, P31, DOI 10.1007/BF02738308; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; Lesh RE, 1998, CIRC RES, V82, P175; Martin C, 1999, BBA-MOL CELL RES, V1451, P343, DOI 10.1016/S0167-4889(99)00104-4; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; NEYLON CB, 1995, BIOCHEM BIOPH RES CO, V215, P814, DOI 10.1006/bbrc.1995.2536; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Protasi F, 2000, BIOPHYS J, V79, P2494, DOI 10.1016/S0006-3495(00)76491-5; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; SATO K, 1994, AM J PHYSIOL-CELL PH, V267, pC1666, DOI 10.1152/ajpcell.1994.267.6.C1666; Sieck GC, 1997, CAN J PHYSIOL PHARM, V75, P878, DOI 10.1139/cjpp-75-7-878; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Sutherland ER, 2004, NEW ENGL J MED, V350, P2689, DOI 10.1056/NEJMra030415; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Sweeney M, 2002, J APPL PHYSIOL, V92, P1594, DOI 10.1152/japplphysiol.00722.2001; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Wang YX, 2004, AM J PHYSIOL-CELL PH, V286, pC538, DOI 10.1152/ajpcell.00106.2003; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; Zhang WM, 2003, AM J PHYSIOL-LUNG C, V285, pL680, DOI 10.1152/ajplung.00067.2003; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	58	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26287	26294		10.1074/jbc.M502905200	http://dx.doi.org/10.1074/jbc.M502905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15894801	hybrid, Green Published			2022-12-25	WOS:000230386800044
J	Goyer, A; Collakova, E; de la Garza, RD; Quinlivan, EP; Williamson, J; Gregory, JF; Shachar-Hill, Y; Hanson, AD				Goyer, A; Collakova, E; de la Garza, RD; Quinlivan, EP; Williamson, J; Gregory, JF; Shachar-Hill, Y; Hanson, AD			5-Formyltetrahydrofolate is an inhibitory but well tolerated metabolite in Arabidopsis leaves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; NITROUS-OXIDE INACTIVATION; METHENYLTETRAHYDROFOLATE SYNTHETASE; SERINE HYDROXYMETHYLTRANSFERASE; GLYCINE DECARBOXYLASE; RAT-LIVER; FOLATE DERIVATIVES; 5,10-METHENYLTETRAHYDROFOLATE; MITOCHONDRIA; ACID	Formyltetrahydrofolate (5-CHO-THF) is formed via a second catalytic activity of serine hydroxymethyltransferase (SHMT) and strongly inhibits SHMT and other folate-dependent enzymes in vitro. The only enzyme known to metabolize 5-CHO-THF is 5-CHO-THF cycloligase (5-FCL), which catalyzes its conversion to 5,10-methenyltetrahydrofolate. Because 5-FCL is mitochondrial in plants and mitochondrial SHMT is central to photorespiration, we examined the impact of an insertional mutation in the Arabidopsis 5-FCL gene (At5g13050) under photorespiratory (30 and 370 mu mol of CO2 mol(-1)) and non-photorespiratory (3200 mu mol of CO2 mol(-1)) conditions. The mutation had only mild visible effects at 370 mu mol of CO2 mol(-1), reducing growth rate by similar to 20% and delaying flowering by 1 week. However, the mutation doubled leaf 5-CHO-THF level under all conditions and, under photorespiratory conditions, quadrupled the pool of 10-formyl-/5,10-methenyltetrahydrofolates (which could not be distinguished analytically). At 370 mu mol of CO2 mol(-1), the mitochondrial 5-CHO-THF pool was 8-fold larger in the mutant and contained most of the 5-CHO-THF in the leaf. In contrast, the buildup of 10-formyl-/5,10-methenyltetrahydrofolates was extramitochondrial. In photorespiratory conditions, leaf glycine levels were up to 46-fold higher in the mutant than in the wild type. Furthermore, when leaves were supplied with 5-CHO-THF, glycine accumulated in both wild type and mutant. These data establish that 5-CHO-THF can inhibit SHMT in vivo and thereby influence glycine pool size. However, the near-normal growth of the mutant shows that even exceptionally high 5-CHO-THF levels do not much affect fluxes through SHMT or any other folate-dependent reaction, i.e. that 5-CHO-THF is well tolerated in plants.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Shachar-Hill, Yair/B-6165-2013; Quinlivan, Eoin P/B-8454-2008; de la Garza, Rocío Isabel Diaz/B-7449-2011; Goyer, Aymeric/AAW-2617-2021; Quinlivan, Eoin/AAJ-1979-2021	Shachar-Hill, Yair/0000-0001-8793-5084; Quinlivan, Eoin P/0000-0002-0908-1762; de la Garza, Rocío Isabel Diaz/0000-0002-0006-5694; Quinlivan, Eoin/0000-0002-0908-1762; Collakova, Eva/0000-0003-3476-6701; Goyer, Aymeric/0000-0003-0714-6750; Gregory, Jesse/0000-0002-9976-2085				Anguera MC, 2003, J BIOL CHEM, V278, P29856, DOI 10.1074/jbc.M302883200; Baggott JE, 2000, BIOCHEMISTRY-US, V39, P14647, DOI 10.1021/bi001362m; BAGGOTT JE, 1995, BIOCHEM J, V308, P1031, DOI 10.1042/bj3081031; Baggott JE, 2003, BIOCHEM J, V374, P773, DOI 10.1042/BJ20021970; Bagley PJ, 2000, CLIN CHEM, V46, P404; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BERTRAND R, 1995, BBA-MOL CELL RES, V1266, P245, DOI 10.1016/0167-4889(95)00020-S; BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; Brookes PS, 2002, BIOCHEMISTRY-US, V41, P5633, DOI 10.1021/bi0120244; Chan SY, 2003, PTERIDINES, V14, P67; Chen LF, 1997, PLANT PHYSIOL, V115, P299, DOI 10.1104/pp.115.1.299; Cossins E, 2000, CAN J BOT, V78, P691, DOI 10.1139/cjb-78-6-691; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Duran AL, 2003, BIOINFORMATICS, V19, P2283, DOI 10.1093/bioinformatics/btg315; Enault F, 2004, NUCLEIC ACIDS RES, V32, pW336, DOI 10.1093/nar/gkh365; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GREGORY JF, 1988, ANAL BIOCHEM, V170, P94, DOI 10.1016/0003-2697(88)90094-2; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2000, TRENDS PLANT SCI, V5, P206, DOI 10.1016/S1360-1385(00)01599-5; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; Horne D W, 1980, Methods Enzymol, V66, P545; HORNE DW, 1992, J NUTR, V122, P2204, DOI 10.1093/jn/122.11.2204; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; Horne DW, 1997, J NUTR, V127, P1772, DOI 10.1093/jn/127.9.1772; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; Lassner MW., 1989, PLANT MOL BIOL REP, V7, P116, DOI DOI 10.1007/BF02669627; Liepman AH, 2003, PLANT PHYSIOL, V131, P215, DOI 10.1104/pp.011460; MARAS B, 1994, J BIOL CHEM, V269, P18429; MAREK LF, 1991, PLANT PHYSIOL, V97, P420, DOI 10.1104/pp.97.1.420; Mouillon JM, 1999, PLANT J, V20, P197, DOI 10.1046/j.1365-313x.1999.00591.x; NAIRN CJ, 1988, J MOL EVOL, V27, P133, DOI 10.1007/BF02138373; Prabhu V, 1998, PLANT PHYSIOL, V116, P137, DOI 10.1104/pp.116.1.137; Roje S, 2002, J BIOL CHEM, V277, P42748, DOI 10.1074/jbc.M205632200; Scott J. M., 1984, FOLATES PTERINS, P307; Sessions A, 2002, PLANT CELL, V14, P2985, DOI 10.1105/tpc.004630; SHIN YS, 1975, CAN J BIOCHEM CELL B, V53, P338, DOI 10.1139/o75-047; SOMERVILLE CR, 1981, PLANT PHYSIOL, V67, P666, DOI 10.1104/pp.67.4.666; SOMERVILLE CR, 1982, BIOCHEM J, V202, P373, DOI 10.1042/bj2020373; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1990, J BIOL CHEM, V265, P14227; TABOR H, 1959, J BIOL CHEM, V234, P1830; TOBIN A, 1980, PLANT PHYSIOL, V66, P225, DOI 10.1104/pp.66.2.225; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935	46	63	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26137	26142		10.1074/jbc.M503106200	http://dx.doi.org/10.1074/jbc.M503106200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888445	hybrid			2022-12-25	WOS:000230386800026
J	Sniegowski, JA; Lappe, JW; Patel, HN; Huffman, HA; Wachter, RM				Sniegowski, JA; Lappe, JW; Patel, HN; Huffman, HA; Wachter, RM			Base catalysis of chromophore formation in Arg(96) and Glu(222) variants of green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ENOLASE SUPERFAMILY; MECHANISM; ACIDS; CYCLIZATION; COMPLEXES; BEHAVIOR; MUTANTS; AMIDE; GFP	In green fluorescent protein (GFP), chromophore biosynthesis is initiated by a spontaneous main-chain condensation reaction. Nucleophilic addition of the Gly(67) amide nitrogen to the Ser(65) carbonyl carbon is catalyzed by the protein fold and leads to a heterocyclic intermediate. To investigate this mechanism, we substituted the highly conserved residues Arg(96) and Glu(222) in enhanced GFP (EGFP). In the R96M variant, the rate of chromophore formation is greatly reduced ( time constant = 7.5 x 10(3) h, pH 7) and exhibits pH dependence. In the E222Q variant, the rate is also attenuated at physiological pH ( 32 h, pH 7) but is accelerated severalfold beyond that of EGFP at pH 9 - 10. In contrast, EGFP maturation is pH-independent and proceeds with a time constant of 1 h ( pH 7 - 10). Mass spectrometric results for R96M and E222Q indicate accumulation of the pre-cyclization state, consistent with rate-limiting backbone condensation. The pH-rate profile implies that the Glu(222) carboxylate titrates with an apparent pK(a) of 6.5 in R96M and that the Gly(67) amide nitrogen titrates with an apparent pK(a) of 9.2 in E222Q. These data suggest a model for GFP chromophore synthesis in which the carboxylate of Glu(222) plays the role of a general base, facilitating proton abstraction from the Gly(67) amide nitrogen or the Tyr(66) alpha-carbon. Arg(96) fulfills the role of an electrophile by lowering the respective pKa values and stabilizing the alpha-enolate. Modulating the base strength of the proton-abstracting group may aid in the design of fast-maturing GFPs with improved characteristics for real-time monitoring of cellular events.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85787 USA	Arizona State University; Arizona State University-Tempe	Wachter, RM (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85787 USA.	RWachter@asu.edu						Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; Barondeau DP, 2003, P NATL ACAD SCI USA, V100, P12111, DOI 10.1073/pnas.2133463100; Barondeau DP, 2005, BIOCHEMISTRY-US, V44, P1960, DOI 10.1021/bi0479205; Bell AF, 2000, BIOCHEMISTRY-US, V39, P4423, DOI 10.1021/bi992675o; Branchini BR, 1998, J AM CHEM SOC, V120, P1, DOI 10.1021/ja973019j; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; JENCKS WP, 1981, CHEM SOC REV, V10, P345, DOI 10.1039/cs9811000345; Jung G, 2005, BIOPHYS J, V88, P1932, DOI 10.1529/biophysj.104.044412; Klenchin VA, 2004, BIOCHEMISTRY-US, V43, P10370, DOI 10.1021/bi049197o; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; MARTIN RB, 1973, J AM CHEM SOC, V95, P4752, DOI 10.1021/ja00795a047; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Matz MV, 2002, BIOESSAYS, V24, P953, DOI 10.1002/bies.10154; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PARSONS SM, 1972, BIOCHEMISTRY-US, V11, P1633, DOI 10.1021/bi00759a015; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Remington S. J., 1992, CURR OPIN STRUC BIOL, V2, P730, DOI 10.1016/0959-440X(92)90208-0; Remington SJ, 2005, BIOCHEMISTRY-US, V44, P202, DOI 10.1021/bi048383r; Rosenow MA, 2004, BIOCHEMISTRY-US, V43, P4464, DOI 10.1021/bi0361315; Siegbahn PEM, 2001, INT J QUANTUM CHEM, V81, P169, DOI 10.1002/1097-461X(2001)81:2<169::AID-QUA9>3.0.CO;2-N; SIGEL H, 1982, CHEM REV, V82, P385, DOI 10.1021/cr00050a003; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Verkhusha VV, 2004, NAT BIOTECHNOL, V22, P289, DOI 10.1038/nbt943; Wachter RM, 1997, BIOCHEMISTRY-US, V36, P9759, DOI 10.1021/bi970563w; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Zabicky J., 1970, CHEM AMIDES	35	104	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26248	26255		10.1074/jbc.M412327200	http://dx.doi.org/10.1074/jbc.M412327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888441	hybrid			2022-12-25	WOS:000230386800040
J	Barfod, ET; Moore, AL; Melnick, RF; Lidofsky, SD				Barfod, ET; Moore, AL; Melnick, RF; Lidofsky, SD			Src regulates distinct pathways for cell volume control through Vav and phospholipase C gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ACTIN CYTOSKELETON; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE PROTRUSION; FOCAL ADHESIONS; STRESS FIBERS; GROWTH-FACTOR; RHO FAMILY; ACTIVATION; RAC	Cell volume recovery in response to swelling requires reorganization of the cytoskeleton and fluid efflux. We have previously shown that electrolyte and fluid efflux via K+ and Cl- channels is controlled by swelling-induced activation of phospholipase C gamma (PLC gamma). Recently, integrin engagement has been suggested to trigger responses to swelling through activation of Rho family GTPases and Src kinases. Because both PLC gamma and Rho GTPases can be regulated by Src during integrin-mediated cytoskeletal reorganization, we sought to identify swelling-induced Src effectors. Upon hypotonic challenge, Src was rapidly activated in transient plasma membrane protrusions, where it colocalized with Vav, an activator of Rho GTPases. Inhibition of Src with PP2 attenuated phosphorylation of Vav. PP2 also attenuated phosphorylation of PLC gamma, and inhibited swelling-mediated activation of K+ and Cl- channels and cell volume recovery. These findings suggest that swelling-induced Src regulates cytoskeletal dynamics, through Vav, and fluid efflux, through PLC gamma, and thus can coordinate structural reorganization with fluid balance to maintain cellular integrity.	Univ Vermont, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05401 USA	University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Dept Med, Burgess 414 MFU, Burlington, VT 05401 USA.	steven.lidofsky@uvm.edu			NCRR NIH HHS [P20 RR16435] Funding Source: Medline; NIDDK NIH HHS [DK56644] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056644, R56DK056644] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Adams JC, 2002, J CELL SCI, V115, P257; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bodily K, 1997, HEPATOLOGY, V25, P403; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carton I, 2003, AM J PHYSIOL-CELL PH, V285, pC935, DOI 10.1152/ajpcell.00069.2003; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; DeMali KA, 2003, J CELL SCI, V116, P2389, DOI 10.1242/jcs.00605; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Haendeler J, 2003, J BIOL CHEM, V278, P49936, DOI 10.1074/jbc.M307317200; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, Prog Liver Dis, V14, P29; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Manabe R, 2002, J CELL SCI, V115, P1497; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Moore AL, 2002, J BIOL CHEM, V277, P34030, DOI 10.1074/jbc.M205945200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Seipel K, 1999, J CELL SCI, V112, P1825; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Volberg T, 2001, J CELL SCI, V114, P2279; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936	62	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25548	25557		10.1074/jbc.M411717200	http://dx.doi.org/10.1074/jbc.M411717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15866884	hybrid			2022-12-25	WOS:000230207900032
J	Finn, PF; Dice, JF				Finn, PF; Dice, JF			Ketone bodies stimulate chaperone-mediated autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; LYSOSOMAL PROTEOLYSIS; PROTEIN-DEGRADATION; LIPID-PEROXIDATION; PEPTIDE SEQUENCES; SELECTIVE PATHWAY; RIBONUCLEASE-A; IN-VITRO; METABOLISM	Chaperone-mediated autophagy (CMA) is a selective lysosomal protein degradative process that is activated in higher organisms under conditions of prolonged starvation and in cell culture by the removal of serum. Ketone bodies are comprised of three compounds (beta-hydroxybutyrate, acetoacetate, and acetone) that circulate during starvation, especially during prolonged starvation. Here we have investigated the hypothesis that ketone bodies induce CMA. We found that physiological concentrations of beta-hydroxybutyrate (BOH) induced proteolysis in cells maintained in media with serum and without serum; however, acetoacetate only induced proteolysis in cells maintained in media with serum. Lysosomes isolated from BOH-treated cells displayed an increased ability to degrade both glyceraldehyde-3-phosphate dehydrogenase and ribonuclease A, substrates for CMA. Isolated lysosomes from cells maintained in media without serum also demonstrated an increased ability to degrade glyceraldehyde-3-phosphate dehydrogenase and ribonuclease A when the reaction was supplemented with BOH. Such treatment did not affect the levels of lysosome-associated membrane protein 2a or lysosomal heat shock cognate protein of 70 kDa, two rate-limiting proteins in CMA. However, pretreatment of glyceraldehyde-3-phosphate and ribonuclease A with BOH increased their rate of degradation by isolated lysosomes. Lysosomes pretreated with BOH showed no increase in proteolysis, suggesting that BOH acts on the substrates to increase their rates of proteolysis. Using OxyBlot (TM) analysis to detect carbonyl formation on proteins, one common marker of protein oxidation, we showed that treatment of substrates with BOH increased their oxidation. Neither glycerol, another compound that increases in circulation during prolonged starvation, nor butanol or butanone, compounds closely related to BOH, had an effect on CMA. The induction of CMA by ketone bodies may provide an important physiological mechanism for the activation of CMA during prolonged starvation.	Tufts Univ, Sch Med, Dept Mol & Cellular Physiol, Boston, MA 02111 USA	Tufts University	Finn, PF (corresponding author), Tufts Univ, Sch Med, Dept Mol & Cellular Physiol, Arnold 809,136 Harrison Ave, Boston, MA 02111 USA.	Patrick.Finn@tufts.edu	Finn, Patrick/AGO-4771-2022					Agarraberes FA, 2001, J CELL SCI, V114, P2491; Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ANIENTO F, 1993, J BIOL CHEM, V268, P10463; AUTERI JS, 1983, J CELL PHYSIOL, V115, P167, DOI 10.1002/jcp.1041150210; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 2000, J CELL SCI, V113, P4441; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Dice J. F., 2000, LYSOSOMAL PATHWAYS P; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1986, J BIOL CHEM, V261, P6853; FELIG P, 1970, NEW ENGL J MED, V282, P166; FERY F, 1985, DIABETES, V34, P326, DOI 10.2337/diabetes.34.4.326; Forsberg H, 1998, DIABETES, V47, P255, DOI 10.2337/diabetes.47.2.255; Hoff Henry, 2004, Methods Mol Biol, V285, P79; Jain SK, 1999, DIABETES, V48, P1850, DOI 10.2337/diabetes.48.9.1850; Jain SK, 1998, FREE RADICAL BIO MED, V25, P1083, DOI 10.1016/S0891-5849(98)00140-3; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kalapos MP, 2003, BBA-GEN SUBJECTS, V1621, P122, DOI 10.1016/S0304-4165(03)00051-5; Kiffin R, 2004, MOL BIOL CELL, V15, P4829, DOI 10.1091/mbc.E04-06-0477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Leung KC, 2004, DNA CELL BIOL, V23, P463, DOI 10.1089/1044549041562285; LOWELL BB, 1987, DIABETES, V36, P14, DOI 10.2337/diabetes.36.1.14; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHSUMI Y, 1983, J BIOCHEM, V93, P547; Olejnicka BT, 1997, REDOX REP, V3, P311, DOI 10.1080/13510002.1997.11747128; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; Persson HL, 2001, REDOX REP, V6, P57, DOI 10.1179/135100001101536049; Russell RR, 1997, J CLIN INVEST, V100, P2892, DOI 10.1172/JCI119838; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Salvador N, 2000, J BIOL CHEM, V275, P27447; SCOTINI E, 1983, LIFE SCI, V32, P2701, DOI 10.1016/0024-3205(83)90363-6; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUMBILLA CM, 1981, BIOCHIM BIOPHYS ACTA, V675, P301, DOI 10.1016/0304-4165(81)90242-7; Takehiro M, 2005, AM J PHYSIOL-ENDOC M, V288, pE372, DOI 10.1152/ajpendo.00157.2004; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Yokoo H, 2003, J PHARMACOL EXP THER, V304, P994, DOI 10.1124/jpet.102.044115; Ziegler A, 2002, NMR BIOMED, V15, P222, DOI 10.1002/nbm.764	44	94	99	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25864	25870		10.1074/jbc.M502456200	http://dx.doi.org/10.1074/jbc.M502456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883160	hybrid			2022-12-25	WOS:000230207900078
J	Cybulsky, AV; Takano, T; Papillon, J; Bijian, K				Cybulsky, AV; Takano, T; Papillon, J; Bijian, K			Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PODOCYTE-SPECIFIC EXPRESSION; OPEN READING FRAMES; COMPLEMENT C5B-9; PHOSPHOLIPASE A(2); TRANSLATIONAL CONTROL; ACTIVATION; KINASE; GENE; MICE; REPERFUSION	C5b-9-induced glomerular epithelial cell (GEC) injury in vivo (in passive Heymann nephritis) and in culture is associated with damage to the endoplasmic reticulum (ER) and increased expression of ER stress proteins. Induction of ER stress proteins is enhanced via cytosolic phospholipase A(2) (cPLA(2)) and limits complement- dependent cytotoxicity. The present study addresses another aspect of the ER unfolded protein response, i.e. activation of protein kinase R-like ER kinase (PERK or pancreatic ER kinase), which phosphorylates eukaryotic translation initiation factor 2-alpha (eIF2 alpha), thereby generally suppressing translation and decreasing the protein load on a damaged ER. Phosphorylation of eIF2 alpha was enhanced significantly in glomeruli of proteinuric rats with passive Heymann nephritis, compared with control. In cultured GECs, complement induced phosphorylation of eIF2 alpha and reduced protein synthesis, and complement-stimulated phosphorylation of eIF2 alpha was enhanced by overexpression of cPLA(2). Ischemia-reperfusion in vitro (deoxyglucose plus antimycin A followed by glucose re-exposure) also stimulated eIF2 alpha phosphorylation and reduced protein synthesis. Complement and ischemia-reperfusion induced phosphorylation of PERK (which correlates with activation), and fibroblasts from PERK knock-out mice were more susceptible to complement-and ischemia-reperfusion-mediated cytotoxicity, as compared with wild type fibroblasts. The GEC protein, nephrin, plays a key role in maintaining glomerular permselectivity. In contrast to a general reduction in protein synthesis, translation regulated by the 5'-end of mouse nephrin mRNA during ER stress was paradoxically maintained, probably due to the presence of short open reading frames in this mRNA segment. Thus, phosphorylation of eIF2 alpha and consequent general reduction in protein synthesis may be a novel mechanism for limiting complement- or ischemia-reperfusion-dependent GEC injury.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University	Cybulsky, AV (corresponding author), Royal Victoria Hosp, Div Nephrol, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	andrey.cybulsky@mcgill.ca	Cybulsky, Andrey V./AAG-8238-2020	Cybulsky, Andrey V./0000-0003-4348-2348				Azuma H, 1997, TRANSPLANTATION, V64, P190, DOI 10.1097/00007890-199707270-00002; Beltcheva O, 2003, J AM SOC NEPHROL, V14, P352, DOI 10.1097/01.ASN.0000043081.65110.C4; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bush KT, 2000, J CLIN INVEST, V106, P621, DOI 10.1172/JCI10968; Coers W, 1996, EXP NEPHROL, V4, P184; Cybulsky AV, 2000, KIDNEY INT, V57, P1052, DOI 10.1046/j.1523-1755.2000.00932.x; Cybulsky AV, 2002, J BIOL CHEM, V277, P41342, DOI 10.1074/jbc.M204694200; CYBULSKY AV, 1995, AM J PHYSIOL-RENAL, V269, pF739, DOI 10.1152/ajprenal.1995.269.5.F739; Cybulsky AV, 1998, KIDNEY INT, V54, P360, DOI 10.1046/j.1523-1755.1998.00013.x; Cybulsky AV, 1999, AM J PATHOL, V155, P1701, DOI 10.1016/S0002-9440(10)65485-5; CYBULSKY AV, 2000, KIDNEY PHYSL PATHOPH, P2645; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; Deng J, 2002, CURR BIOL, V12, P1279, DOI 10.1016/S0960-9822(02)01037-0; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Heymann W, 2000, J AM SOC NEPHROL, V11, P183; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Jousse C, 2001, NUCLEIC ACIDS RES, V29, P4341, DOI 10.1093/nar/29.21.4341; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Little E, 1996, NEUROSCIENCE, V75, P209, DOI 10.1016/0306-4522(96)00267-9; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Michaud JL, 2003, J AM SOC NEPHROL, V14, P1200, DOI 10.1097/01.ASN.0000059864.88610.5E; Moeller MJ, 2000, J AM SOC NEPHROL, V11, P2306, DOI 10.1681/ASN.V11122306; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NICHOLSONWELLER A, 1993, IMMUNOL RES, V12, P244, DOI 10.1007/BF02918256; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Pagtalunan ME, 1999, J AM SOC NEPHROL, V10, P366; Panesar M, 1997, J IMMUNOL, V159, P3584; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Samstein B, 2001, J AM SOC NEPHROL, V12, P182, DOI 10.1681/ASN.V121182; SHIN ML, 1996, BIOMEMBRANE, P119; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smoyer WE, 2000, J AM SOC NEPHROL, V11, P211, DOI 10.1681/ASN.V112211; Valdivielso JM, 2001, AM J PHYSIOL-REG I, V280, pR771, DOI 10.1152/ajpregu.2001.280.3.R771; Wartiovaara J, 2004, J CLIN INVEST, V114, P1475, DOI 10.1172/JCI200422562; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	97	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24396	24403		10.1074/jbc.M500729200	http://dx.doi.org/10.1074/jbc.M500729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863508	hybrid			2022-12-25	WOS:000230114000014
J	Dheur, S; Nykamp, KR; Viphakone, N; Swanson, MS; Minvielle-Sebastia, L				Dheur, S; Nykamp, KR; Viphakone, N; Swanson, MS; Minvielle-Sebastia, L			Yeast mRNA poly(A) tail length control can be reconstituted in vitro in the absence of Pab1p-dependent poly(A) nuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A)-BINDING PROTEIN; BINDING-PROTEIN; POLYMERASE; PAB1; IDENTIFICATION; DEADENYLATION; PURIFICATION; REQUIREMENT; SUBUNIT; ENDS	Regulation of poly( A) tail length during mRNA 3'-end formation requires a specific poly(A)-binding protein in addition to the cleavage/polyadenylation machinery. The mechanism that controls polyadenylation in mammals is well understood and involves the nuclear poly( A)-binding protein PABPN1. In contrast, poly( A) tail length regulation is poorly understood in yeast. Previous studies have suggested that the major cytoplasmic poly( A)-binding protein Pab1p acts as a length control factor in conjunction with the Pab1p-dependent poly( A) nuclease PAN, to regulate poly( A) tail length in an mRNA specific manner. In contrast, we recently showed that Nab2p regulates polyadenylation during de novo synthesis, and its nuclear location is more consistent with a role in 3'-end processing than that of cytoplasmic Pab1p. Here, we investigate whether PAN activity is required for de novo poly( A) tail synthesis. Components required for mRNA 3'-end formation were purified from wild-type and pan mutant cells. In both situations, 3'-end formation could be reconstituted whether Nab2p or Pab1p was used as the poly( A) tail length control factor. However, polyadenylation was more efficient and physiologically more relevant in the presence of Nab2p as opposed to Pab1p. Moreover, cell immunofluorescence studies confirmed that PAN subunits are localized in the cytoplasm which suggests that cytoplasmic Pab1p and PAN may act at a later stage in mRNA metabolism. Based on these findings, we propose that Nab2p is necessary and sufficient to regulate poly( A) tail length during de novo synthesis in yeast.	CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France; Univ Bordeaux 2, F-33076 Bordeaux, France; Univ Florida, Coll Med, Powell Gene Therapy Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; State University System of Florida; University of Florida	Minvielle-Sebastia, L (corresponding author), CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	lionel.minvielle@ibgc.u-bordeaux2.fr	Minvielle-Sebastia, Lionel/M-7154-2014	VIPHAKONE, Nicolas/0000-0001-8219-837X; Swanson, Maurice/0000-0001-6245-5367				Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Amrani N, 1997, MOL CELL BIOL, V17, P3694, DOI 10.1128/MCB.17.7.3694; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; BaudinBaillieu A, 1997, YEAST, V13, P353, DOI 10.1002/(SICI)1097-0061(19970330)13:4<353::AID-YEA86>3.0.CO;2-P; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Brune C, 2005, RNA, V11, P517, DOI 10.1261/rna.7291205; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dunn EF, 2005, GENE DEV, V19, P90, DOI 10.1101/gad.1267005; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hector RE, 2002, EMBO J, V21, P1800, DOI 10.1093/emboj/21.7.1800; Kerwitz Y, 2003, EMBO J, V22, P3705, DOI 10.1093/emboj/cdg347; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Mangus DA, 2004, MOL CELL BIOL, V24, P5521, DOI 10.1128/MCB.24.12.5521-5533.2004; Mangus DA, 2004, MOL CELL BIOL, V24, P4196, DOI 10.1128/MCB.24.10.4196-4206.2004; Minvielle-Sebastia L, 1998, EMBO J, V17, P7454, DOI 10.1093/emboj/17.24.7454; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	37	27	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24532	24538		10.1074/jbc.M504720200	http://dx.doi.org/10.1074/jbc.M504720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15894541	hybrid			2022-12-25	WOS:000230114000030
J	Hong, S; Park, KK; Magae, J; Ando, K; Lee, TS; Kwon, TK; Kwak, JY; Kim, CH; Chang, YC				Hong, S; Park, KK; Magae, J; Ando, K; Lee, TS; Kwon, TK; Kwak, JY; Kim, CH; Chang, YC			Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway - Inhibitory effects of ascochlorin on the invasion of renal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-METALLOPROTEINASES; IV COLLAGENASE; PROTEIN-KINASE; TISSUE INHIBITOR; DOWN-REGULATION; TUMOR INVASION; AP-1; ANTITUMOR; PROMOTER; FRA-1	The expression of matrix metalloproteinases ( MMPs) has been implicated in the invasion and metastasis of cancer cells. Here we examined the effect of ascochlorin, a prenyl-phenol anti-tumor compound from the fungus Ascochyta viciae, on the regulation of signaling pathways that control MMP-9 expression in human renal carcinoma (Caki-1) cells. Ascochlorin reduced the invasive activity of Caki-1 cells and inhibited phorbol 12-myristate 13-acetate-induced increases in MMP-9 expression and activity in a dose-dependent manner. Reporter gene, electrophoretic mobility shift, kinase inhibitor assays, and in vitro kinase assay showed that ascochlorin inhibits MMP-9 gene expression by suppressing activation of the nuclear transcription factor activator protein-1 (AP-1) via the extracellular signal-regulated kinase 1 and 2 pathway. The AP-1 family member most specifically affected by ascochlorin was Fra-1. Ascochlorin did not affect the activation of the c-Jun N-terminal or p38 kinase pathways. Moreover, transfection of Caki-1 cells with AP-1 decoy oligodeoxynucleotides resulted in the suppression of phorbol 12-myristate 13-acetate-induced MMP-9 expression and invasion. In conclusion, ascochlorin represents a unique natural anti-tumor compound that specifically inhibits MMP-9 activity through suppression of AP-1-dependent induction of MMP-9 gene expression.	Catholic Univ Daegu, Coll Med, Dept Pathol, Taegu 705034, South Korea; Catholic Univ Daegu, Coll Med, Dept Obstet & Gynecol, Taegu 705034, South Korea; Inst Res & Innovat, Dept Biotechnol, Kashiwa, Chiba 2770861, Japan; NRL Pharma Inc, Kawasaki, Kanagawa 2130012, Japan; Keimyung Univ, Sch Med, Dept Immunol, Taegu 700712, South Korea; Dong A Univ, Med Res Ctr Canc Mol Therapy, Pusan 602714, South Korea; Dongguk Univ, Coll Oriental Med, Natl Res Lab Gycobiol, Korean Minist Sci & Technol, Kyungbuk 780714, South Korea	Catholic University of Daegu; Catholic University of Daegu; Keimyung University; Dong A University; Dongguk University	Chang, YC (corresponding author), Catholic Univ Daegu, Coll Med, Dept Pathol, 3056-6 Daemyung 4-Dong, Taegu 705034, South Korea.	ycchang@cu.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714				Ahn JD, 2002, GENE THER, V9, P1682, DOI 10.1038/sj.gt.3301849; ANDO M, 1984, ENVIRON RES, V33, P96, DOI 10.1016/0013-9351(84)90011-2; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chae YM, 2004, BIOCHEM BIOPH RES CO, V319, P550, DOI 10.1016/j.bbrc.2004.05.025; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cho NH, 2003, EUR UROL, V44, P560, DOI 10.1016/S0302-2838(03)00362-2; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; HOSOKAWA T, 1985, BIOCHEM BIOPH RES CO, V126, P471, DOI 10.1016/0006-291X(85)90629-1; HOSOKAWA T, 1981, LIPIDS, V16, P433, DOI 10.1007/BF02535011; HOSOKAWA T, 1985, DIABETES, V34, P267, DOI 10.2337/diabetes.34.3.267; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lakka SS, 2003, CANCER RES, V63, P2454; Lein M, 2000, INT J CANCER, V85, P801, DOI 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; MAGAE J, 1986, CANCER RES, V46, P1073; MAGAE J, 1982, J ANTIBIOT, V35, P1547, DOI 10.7164/antibiotics.35.1547; MAGAE J, 1988, J ANTIBIOT, V41, P959, DOI 10.7164/antibiotics.41.959; Moon SK, 2004, J BIOL CHEM, V279, P33063, DOI 10.1074/jbc.M313462200; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; SATO H, 1993, J BIOL CHEM, V268, P23460; SAWADA M, 1973, J ANTIBIOT, V26, P681, DOI 10.7164/antibiotics.26.681; Shiratsuchi T, 2002, J CELL PHYSIOL, V193, P340, DOI 10.1002/jcp.10181; Shishodia S, 2003, CANCER RES, V63, P4375; Simon C, 1998, CANCER RES, V58, P1135; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TAMURA G, 1968, J ANTIBIOT, V21, P539, DOI 10.7164/antibiotics.21.539; Togashi M, 2003, J MED CHEM, V46, P4113, DOI 10.1021/jm0205649; Togashi M, 2002, J ANTIBIOT, V55, P417, DOI 10.7164/antibiotics.55.417; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; WEI L, 1995, MOL BIOL CELL, V15, P1005; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; Woo JH, 2003, CANCER RES, V63, P3430; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; WRANA JL, 1989, J BIOL CHEM, V264, P1860; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; ZUCKER S, 1993, CANCER RES, V53, P140	49	117	125	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25202	25209		10.1074/jbc.M413985200	http://dx.doi.org/10.1074/jbc.M413985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863510	hybrid, Green Published			2022-12-25	WOS:000230114000105
J	Kouno, T; Mizuguchi, M; Tanida, I; Ueno, T; Kanematsu, T; Mori, Y; Shinoda, H; Hirata, M; Kominami, E; Kawano, K				Kouno, T; Mizuguchi, M; Tanida, I; Ueno, T; Kanematsu, T; Mori, Y; Shinoda, H; Hirata, M; Kominami, E; Kawano, K			Solution structure of microtubule-associated protein light chain 3 and identification of its functional subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED PROTEIN; N-15 RESONANCE ASSIGNMENTS; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; BETA-TUBULIN; GABA(A)-RECEPTOR-ASSOCIATED PROTEIN; MAMMALIAN HOMOLOG; BACKBONE DYNAMICS; ACTIVATING ENZYME	Microtubule-associated protein ( MAP) light chain 3 (LC3) is a human homologue of yeast Apg8/Aut7/Cvt5 (Atg8), which is essential for autophagy. MAP-LC3 is cleaved by a cysteine protease to produce LC3-I, which is located in cytosolic fraction. LC3-I, in turn, is converted to LC3-II through the actions of E1- and E2-like enzymes. LC3-II is covalently attached to phosphatidylethanolamine on its C terminus, and it binds tightly to autophagosome membranes. We determined the solution structure of LC3- I and found that it is divided into N- and C-terminal subdomains. Additional analysis using a photochemically induced dynamic nuclear polarization technique also showed that the N- terminal subdomain of LC3- I makes contact with the surface of the C-terminal subdomain and that LC3- I adopts a single compact conformation in solution. Moreover, the addition of dodecylphosphocholine into the LC3- I solution induced chemical shift perturbations primarily in the C-terminal subdomain, which implies that the two subdomains have different sensitivities to dodecylphosphocholine micelles. On the other hand, deletion of the N-terminal subdomain abolished binding of tubulin and microtubules. Thus, we showed that two subdomains of the LC3- I structure have distinct functions, suggesting that MAP-LC3 can act as an adaptor protein between microtubules and autophagosomes.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan; Kyushu Univ, Fac Dent Sci, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka 8128582, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan	University of Toyama; Juntendo University; Kyushu University; Kyushu University; Hokkaido University	Mizuguchi, M (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan.	mineyuki@ms.toyama-mpu.ac.jp; kawano@sci.hokudai.ac.jp	Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009; Shinoda, Hiroyuki/Q-3230-2019; Kawano, Keiichi/F-5265-2011	Tanida, Isei/0000-0001-8999-3990				Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Bavro VN, 2002, EMBO REP, V3, P183, DOI 10.1093/embo-reports/kvf026; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; CROSS D, 1994, MOL CELL BIOCHEM, V132, P81, DOI 10.1007/BF00925677; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dobson CM, 1998, NAT STRUCT BIOL, V5, P504, DOI 10.1038/744; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; Harris R, 2001, J BIOMOL NMR, V21, P185, DOI 10.1023/A:1012473609468; HORE PJ, 1993, PROG NUCL MAG RES SP, V25, P345, DOI 10.1016/0079-6565(93)80002-B; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; KALLICK DA, 1995, J MAGN RESON SER B, V109, P60, DOI 10.1006/jmrb.1995.1146; KAPTEIN R, 1978, NATURE, V274, P293, DOI 10.1038/274293a0; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORDEL J, 1992, BIOCHEMISTRY-US, V31, P4856; Kouno T, 2002, J BIOMOL NMR, V22, P97, DOI 10.1023/A:1013884402033; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MAEDA K, 1985, J MAGN RESON, V63, P199; MANN SS, 1994, J BIOL CHEM, V269, P11492; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; Stangler T, 2002, J BIOL CHEM, V277, P13363, DOI 10.1074/jbc.C200050200; Stangler T, 2001, J BIOMOL NMR, V21, P183, DOI 10.1023/A:1012416810974; Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wolf SG, 1996, J MOL BIOL, V262, P485, DOI 10.1006/jmbi.1996.0530; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	62	87	94	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24610	24617		10.1074/jbc.M413565200	http://dx.doi.org/10.1074/jbc.M413565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15857831	hybrid			2022-12-25	WOS:000230114000040
J	Bairstow, SF; Ling, K; Anderson, RA				Bairstow, SF; Ling, K; Anderson, RA			Phosphatidylinositol phosphate kinase type I gamma directly associates with and regulates Shp-1 tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH-EATEN MICE; ALPHA-ACTININ; NUCLEAR-LOCALIZATION; CATALYTIC-ACTIVITY; DOMAIN; 4,5-BISPHOSPHATE; BINDING; TALIN; MEMBRANE; DEPHOSPHORYLATION	Tyrosine phosphorylation plays a critical role in many regulatory aspects of cellular signaling, and dephosphorylation of phosphotyrosine residues is crucial for termination of signals initiated by tyrosine kinases. Previous work has shown that the tyrosine kinase Src phosphorylates Tyr(644) on phosphatidylinositol phosphate kinase type I (PIPKI) gamma 661 in a focal adhesion kinase-dependent manner. Phosphorylation of this residue is essential for high affinity binding of PIPKI gamma 661 to the focal adhesion protein talin and for targeting of PIPKI gamma 661 to focal adhesions. A yeast two-hybrid screen performed with the C-terminal 178-amino acid tail of PIPKI gamma 661 identified an interaction with the phosphatase domain of the tyrosine phosphatase Shp-1. The interaction between PIPKI gamma 661 and Shp-1 was confirmed via co- immunoprecipitation from HEK293 cell lysates. In addition, Src- phosphorylated PIPKI gamma 661 is a substrate for Shp-1, and Shp-1 modulates both the association between PIPKI gamma 661 and talin and the targeting of PIPKI gamma 661 to focal adhesions in mammalian cells. Finally, we showed that Shp-1 phosphatase activity is inhibited by the product of PIPKI gamma 661, phosphatidylinositol 4,5-bisphosphate, in vitro. These combined results suggest a model in which the reciprocal actions of Src tyrosine kinase and Shp-1 tyrosine phosphatase dynamically regulate the association between PIPKI gamma 661 and talin.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 3750 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	raanders@wisc.edu		Anderson, Richard/0000-0001-6265-8359	NCI NIH HHS [CA104708] Funding Source: Medline; NIGMS NIH HHS [GM57549, GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Baba T, 2003, J IMMUNOL, V170, P3762, DOI 10.4049/jimmunol.170.7.3762; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Doughman RL, 2003, J MEMBRANE BIOL, V194, P77, DOI 10.1007/s00232-003-2027-7; Fraley TS, 2003, J BIOL CHEM, V278, P24039, DOI 10.1074/jbc.M213288200; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Huang ZY, 2003, J LEUKOCYTE BIOL, V73, P823, DOI 10.1189/jlb.0902454; Hunter Tony, 2002, Keio Journal of Medicine, V51, P61; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lin SY, 2004, J BIOL CHEM, V279, P25755, DOI 10.1074/jbc.M314175200; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sechi AS, 2000, J CELL SCI, V113, P3685; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang WT, 2002, BLOOD CELL MOL DIS, V28, P63, DOI 10.1006/bcmd.2002.0485; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Yousefi S, 2003, SEMIN IMMUNOL, V15, P195, DOI 10.1016/S1044-5323(03)00033-2; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	36	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23884	23891		10.1074/jbc.M500576200	http://dx.doi.org/10.1074/jbc.M500576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849189	hybrid			2022-12-25	WOS:000229880000062
J	Pendleton, LC; Goodwin, BL; Solomonson, LP; Eichler, DC				Pendleton, LC; Goodwin, BL; Solomonson, LP; Eichler, DC			Regulation of endothelial argininosuccinate synthase expression and NO production by an upstream open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; L-ARGININE; SYNTHETASE; CELLS; TRANSLATION; DYSFUNCTION; MECHANISMS; INITIATION; VESSELS; ENZYMES	Argininosuccinate synthase ( AS) catalyzes the rate-limiting step in the recycling of citrulline to arginine, which in endothelial cells, is tightly coupled to the production of nitric oxide ( NO). In previous work, we established that endothelial AS mRNA can be initiated from multiple start sites, generating co-expressed mRNA variants with different 5'-untranslated regions (5'-UTRs). One of the 5'-UTRs, the shortest form, represents greater than 90% of the total AS mRNA. Two other extended 5'-UTR forms of AS mRNA, resulting from upstream initiations, contain an out-of-frame, upstream open reading frame (uORF). In this study, the function of the extended 5'-UTRs of AS mRNA was investigated. Single base insertions to place the uORF in-frame, and mutations to extend the uORF, demonstrated functionality, both in vitro with AS constructs and in vivo with luciferase constructs. Overexpression of the uORF suppressed endothelial AS protein expression, whereas specific silencing of the uORF AS mRNAs resulted in the coordinate up-regulation of AS protein and NO production. Expression of the full-length of the uORF was necessary to mediate a trans-suppressive effect on endothelial AS expression, demonstrating that the translation product itself affects regulation. In conclusion, the uORF found in the extended, overlapping 5'-UTR AS mRNA species suppresses endothelial AS expression, providing a novel mechanism for regulating endothelial NO production by limiting the availability of arginine.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Eichler, DC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd,MDC 7, Tampa, FL 33612 USA.	deichler@hsc.usf.edu	Eichler, Duane/A-1906-2012					AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cohen NS, 1996, J CELL BIOCHEM, V60, P334, DOI 10.1002/(SICI)1097-4644(19960301)60:3<334::AID-JCB5>3.3.CO;2-V; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; DENNIS JA, 1989, P NATL ACAD SCI USA, V86, P7947, DOI 10.1073/pnas.86.20.7947; EDDAHIBI S, 1992, AM J PHYSIOL, V263, P194; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Flam BR, 2001, NITRIC OXIDE-BIOL CH, V5, P187, DOI 10.1006/niox.2001.0340; FREYTAG SO, 1984, J BIOL CHEM, V259, P3160; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Goligorsky MS, 2001, DRUG NEWS PERSPECT, V14, P133; Goodwin BL, 2004, J BIOL CHEM, V279, P18353, DOI 10.1074/jbc.M308160200; Gow AJ, 2001, J CELL PHYSIOL, V187, P277, DOI 10.1002/jcp.1085; Hellermann GR, 2000, ARTERIOSCL THROM VAS, V20, P2045, DOI 10.1161/01.ATV.20.9.2045; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Pendleton LC, 2002, J BIOL CHEM, V277, P25363, DOI 10.1074/jbc.M111677200; ROSSITCH E, 1991, J CLIN INVEST, V87, P1295, DOI 10.1172/JCI115132; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; Sharma Rajesh, 2002, Congest Heart Fail, V8, P165, DOI 10.1111/j.1527-5299.2002.00714.x; SU YC, 1995, AM J PHYSIOL-LUNG C, V269, pL581, DOI 10.1152/ajplung.1995.269.5.L581; Vallance P, 2001, HEART, V85, P342, DOI 10.1136/heart.85.3.342; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3	30	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24252	24260		10.1074/jbc.M500106200	http://dx.doi.org/10.1074/jbc.M500106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851478	hybrid			2022-12-25	WOS:000229880000102
J	Rao, A; Chopra, S; Ram, G; Gupta, A; Ranganathan, A				Rao, A; Chopra, S; Ram, G; Gupta, A; Ranganathan, A			Application of the "codon-shuffling" method - Synthesis and selection of de novo proteins as antibacterials	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RESPONSE; ANTIMICROBIAL PEPTIDES; IN-VITRO; EVOLUTION; APTAMERS; SEQUENCE; BINDING; DESIGN; HEPARIN; ACID	Library-based methods of non-rational and part-rational designed de novo peptides are worthy beacons in the search for bioactive peptides and proteins of medicinal importance. In this report, we have used a recently developed directed evolution method called "codon shuffling" for the synthesis and selection of bioactive proteins. The selection of such proteins was based on the creation of an inducible library of "codon-shuffled" genes that are constructed from the ligation-based assembly of judiciously designed hexamer DNA duplexes called dicodons. Upon induction with isopropyl 1-thio-beta-D-galactopyranoside, some library members were found to express dicodon-incorporated proteins. Because of this, the host cells, in our case Escherichia coli, were unable to grow any further. The bactereostatic/ lytic nature of the dicodon proteins was monitored by growth curves as well as by zone clearance studies. Transmission electron microscopy of the affected cells illustrated the extent of cell damage. The proteins themselves were overexpressed as fusion partners and subsequently purified to homogeneity. One such purified protein was found to strongly bind heparin, an indication that the interaction of the de novo proteins may be with the nucleic acids of the host cell, much like many of the naturally occurring antibacterial peptides, e. g. Buforin. Therefore, our approach may help in generating a multitude of finely tuned antibacterial proteins that can potentially be regarded as lead compounds once the method is extended to pathogenic hosts, such as Mycobacteria, for example.	Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Ranganathan, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India.	anand@icgeb.res.in	Chopra, Sidharth/G-1385-2012					Andersson E, 2004, EUR J BIOCHEM, V271, P1219, DOI 10.1111/j.1432-1033.2004.04035.x; Aoki K, 2004, J BIOL CHEM, V279, P39798, DOI 10.1074/jbc.M402677200; Bittker JA, 2002, NAT BIOTECHNOL, V20, P1024, DOI 10.1038/nbt736; Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; Brogden KA, 1998, INFECT IMMUN, V66, P5948, DOI 10.1128/IAI.66.12.5948-5954.1998; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Butz K, 2001, ONCOGENE, V20, P6579, DOI 10.1038/sj.onc.1204805; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chandra BR, 2004, PROTEIN ENG DES SEL, V17, P175, DOI 10.1093/protein/gzh024; Chopra S, 2003, CHEM BIOL, V10, P917, DOI 10.1016/j.chembiol.2003.09.007; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cordes MHJ, 1999, SCIENCE, V284, P325, DOI 10.1126/science.284.5412.325; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; DONG HJ, 1995, J BACTERIOL, V177, P1497, DOI 10.1128/jb.177.6.1497-1504.1995; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Giangaspero A, 2001, EUR J BIOCHEM, V268, P5589; Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; Hong RW, 2003, ANTIMICROB AGENTS CH, V47, P1, DOI 10.1128/AAC.47.1.1-6.2003; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; Klevenz B, 2002, CELL MOL LIFE SCI, V59, P1993, DOI 10.1007/PL00012521; Lai R, 2002, BIOCHEM BIOPH RES CO, V295, P796, DOI 10.1016/S0006-291X(02)00762-3; LEHRER RI, 2004, ADV MOL CELLULAR MIC, P5; Moffet DA, 2001, CHEM REV, V101, P3191, DOI 10.1021/cr000051e; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; Prijambada ID, 1996, FEBS LETT, V382, P21, DOI 10.1016/0014-5793(96)00123-8; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Roberts RW, 1999, CURR OPIN CHEM BIOL, V3, P268, DOI 10.1016/S1367-5931(99)80042-8; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; Rojas NRL, 1997, PROTEIN SCI, V6, P2512; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; Schneider G, 1998, P NATL ACAD SCI USA, V95, P12179, DOI 10.1073/pnas.95.21.12179; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Taylor SV, 2001, P NATL ACAD SCI USA, V98, P10596, DOI 10.1073/pnas.191159298; Tomasinsig L, 2004, ANTIMICROB AGENTS CH, V48, P3260, DOI 10.1128/AAC.48.9.3260-3267.2004; Walker JR, 2003, J PEPT RES, V62, P214, DOI 10.1034/j.1399-3011.2003.00085.x; Wang Z, 2004, NUCLEIC ACIDS RES, V32, pD590, DOI 10.1093/nar/gkh025; Wei YN, 2004, PROTEIN ENG DES SEL, V17, P67, DOI 10.1093/protein/gzh007	43	13	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23605	23614		10.1074/jbc.M503056200	http://dx.doi.org/10.1074/jbc.M503056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843374	hybrid			2022-12-25	WOS:000229880000026
J	Ye, L; Morgenstern, JL; Gee, AD; Hong, GZ; Brown, J; Lockhart, A				Ye, L; Morgenstern, JL; Gee, AD; Hong, GZ; Brown, J; Lockhart, A			Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; PLAQUES; PROBES; DERIVATIVES	A range of imaging agents for use in the positron emission tomography of Alzheimer's disease is currently under development. Each of the main compound classes, derived from thioflavin T (PIB), Congo Red (BSB), and aminonaphthalene (FDDNP) are believed to bind to mutually exclusive sites on the beta-amyloid (A beta) peptide fibrils. We recently reported the presence of three classes of binding sites (BS1, BS2, BS3) on the A beta fibrils for thioflavin T derivatives and now extend these findings to demonstrate that these sites are also able to accommodate ligands from the other chemotype classes. The results from competition assays using [3H]Me-BTA-1 (BS3 probe) indicated that both PIB and FDDNP were able to displace the radioligand with K-i values of 25 and 42 nM, respectively. BSB was unable to displace the radioligand tracer from the A beta fibrils. In contrast, each of the compounds examined were able to displace thioflavin T ( BS1 probe) from the A beta fibrils when evaluated in a fluorescence competition assay with Ki values for PIB, FDDNP, and BSB of 1865, 335, and 600 nM, respectively. Finally, the K-d values for FDDNP and BSB binding to A beta fibrils were directly determined by monitoring the increases in the ligand intrinsic fluorescence, which were 290 and 104 nM, respectively. The results from these assays indicate that (i) the three classes of thioflavin T binding sites are able to accommodate a wide range of chemotype structures, (ii) BSB binds to two sites on the A beta fibrils, one of which is BS2, and the other is distinct from the thioflavin T derivative binding sites, and (iii) there is no independent binding site on the fibrils for FDDNP, and the ligand binds to both the BS1 and BS3 sites with significantly lower affinities than previously reported.	GlaxoSmithKline Res & Dev Ltd, Addenbrookes Hosp, Cambridge CB2 2GG, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge	Lockhart, A (corresponding author), GlaxoSmithKline Res & Dev Ltd, Addenbrookes Hosp, Cambridge CB2 2GG, England.	andrew.2.lockhart@gsk.com		Gee, Antony/0000-0001-8389-9012				Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agdeppa ED, 2003, NEUROSCIENCE, V117, P723, DOI 10.1016/S0306-4522(02)00907-7; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; KOCKHART A, 2004, J BIOL CHEM, V280, P7677; Kung HF, 2001, J AM CHEM SOC, V123, P12740, DOI 10.1021/ja0167147; Kung MP, 2004, BRAIN RES, V1025, P98, DOI 10.1016/j.brainres.2004.08.004; Kung MP, 2002, J MOL NEUROSCI, V19, P7, DOI 10.1007/s12031-002-0003-9; Kung MP, 2002, BRAIN RES, V956, P202, DOI 10.1016/S0006-8993(02)03436-4; Mathis CA, 2003, J MED CHEM, V46, P2740, DOI 10.1021/jm030026b; Mathis CA, 2004, CURR PHARM DESIGN, V10, P1469, DOI 10.2174/1381612043384772; Nordberg A, 2004, LANCET NEUROL, V3, P519, DOI 10.1016/S1474-4422(04)00853-1; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Skovronsky DM, 2000, P NATL ACAD SCI USA, V97, P7609, DOI 10.1073/pnas.97.13.7609; Styren SC, 2000, J HISTOCHEM CYTOCHEM, V48, P1223, DOI 10.1177/002215540004800906; Suemoto T, 2004, NEUROSCI RES, V48, P65, DOI 10.1016/j.neures.2003.09.005; Yang X, 1999, SPECTROCHIM ACTA A, V55, P2719, DOI 10.1016/S1386-1425(99)00161-4; Zhuang ZP, 2001, J MED CHEM, V44, P1905, DOI 10.1021/jm010045q	18	86	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23599	23604		10.1074/jbc.M501285200	http://dx.doi.org/10.1074/jbc.M501285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855161	hybrid			2022-12-25	WOS:000229880000025
J	He, X; Cryle, MJ; De Voss, JJ; de Montellano, PRO				He, X; Cryle, MJ; De Voss, JJ; de Montellano, PRO			Calibration of the channel that determines the omega-hydroxylation regiospecificity of cytochrome P4504A1 - Catalytic oxidation of 12-halododecanoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20-HYDROXYEICOSATETRAENOIC ACID; HEME ALKYLATION; CARBON-MONOXIDE; RAT; INACTIVATION; METABOLISM; PROTEIN; MODEL	The fatty acid omega-hydroxylation regiospecificity of CYP4 enzymes may result from presentation of the terminal carbon to the oxidizing species via a narrow channel that restricts access to the other carbon atoms. To test this hypothesis, the oxidation of 12-iodo-, 12-bromo-, and 12-chlorododecanoic acids by recombinant CYP4A1 has been examined. Although all three 12-halododecanoic acids bind to CYP4A1 with similar dissociation constants, the 12-chloro and 12-bromo fatty acids are oxidized to 12-hydroxydodecanoic acid and 12-oxododecanoic acid, whereas the 12-iodo analogue is very poorly oxidized. Incubations in (H2O)-O-18 show that the 12-hydroxydodecanoic acid oxygen derives from water, whereas that in the aldehyde derives from O-2. The alcohol thus arises from oxidation of the halide to an oxohalonium species that is hydrolyzed by water, whereas the aldehyde arises by a conventional carbon hydroxylation-elimination mechanism. No irreversible inactivation of CYP4A1 is observed during 12-halododecanoic acid oxidation. Control experiments show that CYP2E1, which has an omega-1 regiospecificity, primarily oxidizes 12-halododecanoic acids to the omega-aldehyde rather than alcohol product. Incubation of CYP4A1 with 12,12-[H-2](2)-12-chlorododecanoic acid causes a 2-3-fold increase in halogen versus carbon oxidation. The fact that the order of substrate oxidation (Br > Cl >> I) approximates the inverse of the intrinsic oxidizability of the halogen atoms is consistent with presentation of the halide terminus via a channel that accommodates the chloride and bromide but not iodide atoms, which implies an effective channel diameter greater than 3.90 angstrom but smaller than 4.30 angstrom.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Queensland, Dept Chem, St Lucia, Qld 4072, Australia	University of California System; University of California San Francisco; University of Queensland	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Genetech Hall N572D,600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu	Cryle, Max/H-7656-2017	Cryle, Max/0000-0002-9739-6157	NIGMS NIH HHS [R37 GM025515, GM25515, R01 GM025515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alterman MA, 2002, FEBS LETT, V512, P319, DOI 10.1016/S0014-5793(02)02260-3; APPARU M, 1988, B SOC CHIM FR, P118; Bambal RB, 1996, ARCH BIOCHEM BIOPHYS, V334, P59, DOI 10.1006/abbi.1996.0429; BURKA LT, 1980, J AM CHEM SOC, V102, P7615, DOI 10.1021/ja00545a062; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Capdevila J., 2005, CYTOCHROME P450 STRU, P531; CHAN WK, 1993, CHEM RES TOXICOL, V6, P38, DOI 10.1021/tx00031a006; COREY EJ, 1975, TETRAHEDRON LETT, P2647; CRAMBIE RC, 1980, J CHEM SOC P1, P822; de Visser SP, 2004, J AM CHEM SOC, V126, P8362, DOI 10.1021/ja048528h; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; GUENGERICH FP, 1989, J BIOL CHEM, V264, P17198; GUENGERICH FP, 1980, TOXICOL APPL PHARM, V55, P303, DOI 10.1016/0041-008X(80)90092-7; Hansch C., 1995, EXPLORING QSAR HYDRO, P219; HARADA N, 1984, J BIOL CHEM, V259, P3005; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Holmes VE, 2004, ANAL BIOCHEM, V325, P354, DOI 10.1016/j.ab.2003.10.046; HUNSBERGER JF, 1972, CRC HDB CHEM PHYS, pD111; Imig JD, 1996, AM J PHYSIOL-REG I, V270, pR217, DOI 10.1152/ajpregu.1996.270.1.R217; JOCELYN PC, 1941, ORG SYNTH, V1, P29; KORZEKWA KR, 1990, J AM CHEM SOC, V112, P7042, DOI 10.1021/ja00175a040; KUBIC VL, 1975, DRUG METAB DISPOS, V3, P104; LEWIS DFV, 2002, DRUG METAB REV, V35, P1; LOGEMANN E, 1981, CHEM BER-RECL, V114, P2245, DOI 10.1002/cber.19811140621; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MACDONALD TL, 1980, J AM CHEM SOC, V102, P7760, DOI 10.1021/ja00546a020; MATSUYAMA H, 1989, J ORG CHEM, V54, P5218, DOI 10.1021/jo00283a010; MICO BA, 1983, BIOCHEM PHARMACOL, V32, P2357, DOI 10.1016/0006-2952(83)90188-0; MIRVISS SB, 1989, J ORG CHEM, V54, P1948, DOI 10.1021/jo00269a038; OMURA T, 1964, J BIOL CHEM, V239, P2370; ORRENIUS S, 1972, P55; Ortiz de Montellano P.R., 2005, CYTOCHROME P450 STRU, P183, DOI [10.1007/b139087, DOI 10.1007/B139087]; PAULING L, 1960, NATURE CHEM BOND, P00257; Peyrat JF, 1996, SYNTHETIC COMMUN, V26, P4563, DOI 10.1080/00397919608004780; Schenkman John B., 1998, V107, P25; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; TACHIZAWA H, 1982, MOL PHARMACOL, V22, P745; Verras A, 2004, J MED CHEM, V47, P3572, DOI 10.1021/jm030608t; ZAKHARKIN LI, 1988, ZH ORG KHIM+, V24, P77; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200	44	33	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22697	22705		10.1074/jbc.M502632200	http://dx.doi.org/10.1074/jbc.M502632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849199	Green Accepted, hybrid			2022-12-25	WOS:000229741800019
J	Kim, JA; Yeh, DC; Ver, M; Li, YH; Carranza, A; Conrads, TP; Veenstra, TD; Harrington, MA; Quon, MJ				Kim, JA; Yeh, DC; Ver, M; Li, YH; Carranza, A; Conrads, TP; Veenstra, TD; Harrington, MA; Quon, MJ			Phosphorylation of Ser(24) in the pleckstrin homology domain of insulin receptor substrate-1 by mouse Pelle-like kinase/interleukin-1 receptor-associated kinase - Cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RAT ADIPOSE-CELLS; NF-KAPPA-B; PROTEIN-KINASE; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; TARGETED DISRUPTION; PLASMA-MEMBRANE	Inflammation contributes to insulin resistance in diabetes and obesity. Mouse Pelle-like kinase (mPLK, homolog of human IL-1 receptor-associated kinase (IRAK)) participates in inflammatory signaling. We evaluated IRS-1 as a novel substrate for mPLK that may contribute to linking inflammation with insulin resistance. Wildtype mPLK, but not a kinase-inactive mutant (mPLK-KD), directly phosphorylated full-length IRS-1 in vitro. This in vitro phosphorylation was increased when mPLK was immunoprecipitated from tumor necrosis factor (TNF)-alpha- treated cells. In NIH-3T3(IR) cells, wild-type mPLK (but not mPLK-KD) co-immunoprecipitated with IRS-1. This association was increased by treatment of cells with TNF-alpha. Using mass spectrometry, we identified Ser(24) in the pleckstrin homology (PH) domain of IRS-1 as a specific phosphorylation site for mPLK. IRS-1 mutants S24D or S24E (mimicking phosphorylation at Ser(24)) had impaired ability to associate with insulin receptors resulting in diminished tyrosine phosphorylation of IRS-1 and impaired ability of IRS-1 to bind and activate PI-3 kinase in response to insulin. IRS-1-S24D also had an impaired ability to mediate insulin-stimulated translocation of GLUT4 in rat adipose cells. Importantly, endogenous mPLK/IRAK was activated in response to TNF-alpha or interleukin 1 treatment of primary adipose cells. In addition, using a phospho-specific antibody against IRS-1 phosphorylated at Ser(24), we found that interleukin-1 or TNF-alpha treatment of Fao cells stimulated increased phosphorylation of endogenous IRS-1 at Ser(24). We conclude that IRS-1 is a novel physiological substrate for mPLK. TNF-alpha-regulated phosphorylation at Ser(24) in the pleckstrin homology domain of IRS-1 by mPLK/IRAK represents an additional mechanism for cross-talk between inflammatory signaling and insulin signaling that may contribute to metabolic insulin resistance.	NCCAM, Diabet Unit, NIH, Bethesda, MD 20892 USA; SAIC Frederick Inc, Lab Proteom & Analyt Technol, Mass Spectrometry Ctr, NCI,NIH, Frederick, MD 21702 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quon, MJ (corresponding author), NCCAM, Diabet Unit, NIH, Bldg 10,Rm 6C-205,10 Ctr Dr,MSC 1632, Bethesda, MD 20892 USA.	quonm@nih.gov	Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; Carranza, Andrea/0000-0001-8352-5504; QUON, MICHAEL/0000-0002-5289-3707	NCI NIH HHS [N01-CA-12400] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cozier GE, 2003, J BIOL CHEM, V278, P39489, DOI 10.1074/jbc.M307785200; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delahaye L, 1998, ENDOCRINOLOGY, V139, P4911, DOI 10.1210/en.139.12.4911; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Gao ZG, 2003, J BIOL CHEM, V278, P24944, DOI 10.1074/jbc.M300423200; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Imai S, 2004, BIOCHEM J, V382, P957, DOI 10.1042/BJ20040681; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Maffucci T, 2003, MOL ENDOCRINOL, V17, P1568, DOI 10.1210/me.2001-0211; Mamidipudi V, 2004, J BIOL CHEM, V279, P4161, DOI 10.1074/jbc.C300431200; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Thomas JA, 2003, AM J PHYSIOL-HEART C, V285, pH597, DOI 10.1152/ajpheart.0655.2001; Thomas JA, 1999, J IMMUNOL, V163, P978; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Tuzi S, 2003, J BIOL CHEM, V278, P28019, DOI 10.1074/jbc.M300101200; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Vig E, 2001, J BIOL CHEM, V276, P7859, DOI 10.1074/jbc.M010399200; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	84	63	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23173	23183		10.1074/jbc.M501439200	http://dx.doi.org/10.1074/jbc.M501439200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849359	hybrid			2022-12-25	WOS:000229741800075
J	Park, EY; Rho, YM; Koh, OJ; Ahn, SW; Seong, IS; Song, JJ; Bang, O; Seol, JH; Wang, JM; Eom, SH; Chung, CH				Park, EY; Rho, YM; Koh, OJ; Ahn, SW; Seong, IS; Song, JJ; Bang, O; Seol, JH; Wang, JM; Eom, SH; Chung, CH			Role of the GYVG pore motif of HslU ATPase in protein unfolding and translocation for degradation by HslV peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION INHIBITOR; CATION-PI INTERACTIONS; ESCHERICHIA-COLI; DEPENDENT PROTEASE; EUKARYOTIC PROTEASOME; SULA PROTEIN; CLPB; PROTEOLYSIS; CHAPERONE; COMPLEX	HslVU is an ATP-dependent protease consisting of HslU ATPase and HslV peptidase. In an HslVU complex, the central pores of HslU hexamer and HslV dodecamer are aligned and the proteolytic active sites are sequestered in the inner chamber of HslV. Thus, the degradation of natively folded proteins requires unfolding and translocation processes for their access into the proteolytic chamber of HslV. A highly conserved GYVG(93) sequence constitutes the central pore of HslU ATPase. To determine the role of the pore motif on protein unfolding and translocation, we generated various mutations in the motif and examined their effects on the ability of HslU in supporting the proteolytic activity of HslV against three different substrates: SulA as a natively folded protein, casein as an unfolded polypeptide, and a small peptide. Flexibility provided by Gly residues and aromatic ring structures of the 91st amino acid were essential for degradation of SulA. The same structural features of the GYVG motif were highly preferred, although not essential, for degradation of casein. In contrast, none of the features were required for peptide hydrolysis. Mutations in the GYVG motif of HslU also showed marked influence on its ATPase activity, affinity to ADP, and interaction with HslV. These results suggest that the GYVG motif of HslU plays important roles in unfolding of natively folded proteins as well as in translocation of unfolded proteins for degradation by HslV. These results also implicate a role of the pore motif in ATP cleavage and in the assembly of HslVU complex.	Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500751, South Korea	Seoul National University (SNU); Yale University; Gwangju Institute of Science & Technology (GIST)	Chung, CH (corresponding author), Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea.	chchung@snu.ac.kr	Song, Ji-Joon/C-1721-2011					BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CREAMER LK, 1981, ARCH BIOCHEM BIOPHYS, V211, P689, DOI 10.1016/0003-9861(81)90505-1; DELANO WL, 2002, PYMOL USERS MAN; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Herman C, 2003, MOL CELL, V11, P659, DOI 10.1016/S1097-2765(03)00068-6; Higashitani A, 1997, MOL GEN GENET, V254, P351, DOI 10.1007/s004380050426; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Kang MS, 2001, EMBO J, V20, P734, DOI 10.1093/emboj/20.4.734; Khattar MM, 1997, FEBS LETT, V414, P402, DOI 10.1016/S0014-5793(97)01024-7; Kwon AR, 2003, J MOL BIOL, V330, P185, DOI 10.1016/S0022-2836(03)00580-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; MCKAY DB, 2000, CELL, V103, P633; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Ramachandran R, 2002, P NATL ACAD SCI USA, V99, P7396, DOI 10.1073/pnas.102188799; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SCHOEMAKER JM, 1984, J BACTERIOL, V158, P551, DOI 10.1128/JB.158.2.551-561.1984; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Seong IS, 2000, FEBS LETT, V477, P224, DOI 10.1016/S0014-5793(00)01808-1; Seong IS, 1999, FEBS LETT, V456, P211, DOI 10.1016/S0014-5793(99)00935-7; Seong IS, 2002, J BIOL CHEM, V277, P25976, DOI 10.1074/jbc.M202793200; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Trame CB, 2001, ACTA CRYSTALLOGR D, V57, P1079, DOI 10.1107/S0907444901007673; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Yamada-Inagawa T, 2003, J BIOL CHEM, V278, P50182, DOI 10.1074/jbc.M308327200; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	52	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22892	22898		10.1074/jbc.M500035200	http://dx.doi.org/10.1074/jbc.M500035200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849200	hybrid			2022-12-25	WOS:000229741800042
J	Zhang, LL; Shimizu, S; Tsujimoto, Y				Zhang, LL; Shimizu, S; Tsujimoto, Y			Two distinct Fas-activated signaling pathways revealed by an antitumor drug D609	ONCOGENE			English	Article						apoptosis; Bak; Bax; mitochondria; Fas	CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; NECROSIS-FACTOR RECEPTOR; PHOSPHOLIPASE-C; CELL-DEATH; ACIDIC SPHINGOMYELINASE; CONFORMATIONAL-CHANGE; KINASE ACTIVATION; APOPTOSIS; BAX	During the process of death receptor-mediated apoptosis, Bid is cleaved by activated caspase-8, and then cleaved Bid conveys apoptotic signals to the mitochondria by activating Bax/Bak. In the present study, we found that D609 (an antitumor drug with multiple activities) blocks Fas-induced apoptosis. D609 did not interfere with activation of caspase-8 and cleavage of Bid, whereas it blocked cytochrome c release from the mitochondria by inhibiting the activation of Bax and Bak. D609 had no protective effect against apoptosis of SKW6.4 cells, which are typical type I cells. Studies using permeabilized cells revealed that in addition to activation of caspase-8, Fas activated a distinct and D609-sensitive signaling pathway that transmitted signal(s) sensitizing the mitochondria to apoptotic stimuli, and that D609 itself promoted mitochondrial resistance to apoptotic stimuli.	Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis,Lab Mol Genet, Japan Sci & Technol Corp,SORST, Rm B8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp						AMTMANN E, 1987, CANCER LETT, V35, P237, DOI 10.1016/0304-3835(87)90125-X; Amtmann E, 1996, DRUG EXP CLIN RES, V22, P287; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YH, 1998, P NATL ACAD SCI USA, V95, P7748, DOI 10.1073/pnas.95.13.7748; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Machleidt T, 1996, J EXP MED, V184, P725, DOI 10.1084/jem.184.2.725; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Nomura M, 1999, CANCER RES, V59, P5542; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinohara H, 2000, CANCER RES, V60, P1766; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang LL, 2004, J BIOL CHEM, V279, P33865, DOI 10.1074/jbc.M403499200; Zhou DH, 2001, J PHARMACOL EXP THER, V298, P103	43	5	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2954	2962		10.1038/sj.onc.1208388	http://dx.doi.org/10.1038/sj.onc.1208388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846303				2022-12-25	WOS:000228649500004
J	Rugg, MS; Willis, AC; Mukhopadhyay, D; Hascall, VC; Fries, E; Fulop, C; Milner, CM; Day, AJ				Rugg, MS; Willis, AC; Mukhopadhyay, D; Hascall, VC; Fries, E; Fulop, C; Milner, CM; Day, AJ			Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-STIMULATED GENE-6; NECROSIS-FACTOR-ALPHA; TRYPSIN INHIBITOR; EXTRACELLULAR-MATRIX; CHROMOSOMAL LOCALIZATION; BINDING PROTEIN; SYNOVIAL-FLUID; LINK MODULE; CROSS-LINKS; IN-VIVO	The high molecular mass glycosaminoglycan hyaluronan (HA) can become modified by the covalent attachment of heavy chains (HCs) derived from the serum protein inter-alpha-inhibitor (I alpha I), which is composed of three subunits (HC1, HC2 and bikunin) linked together via a chondroitin sulfate moiety. The formation of HC center dot HA is likely to play an important role in the stabilization of HA-rich extracellular matrices in the context of inflammatory disease (e.g. arthritis) and ovulation. Here, we have characterized the complexes formed in vitro between purified human I alpha I and recombinant human TSG-6 (an inflammation-associated protein implicated previously in this process) and show that these complexes (i.e. TSG-6 center dot HC1 and TSG-6 center dot HC2) act as intermediates in the formation of HC center dot HA. This is likely to involve two transesterification reactions in which an ester bond linking an HC to chondroitin sulfate in intact I alpha I is transferred first onto TSG-6 and then onto HA. The formation of TSG-6 center dot HC1 and TSG-6 center dot HC2 complexes was accompanied by the production of bikunin center dot HC2 and bikunin center dot HC1 by-products, respectively, which were observed to break down, releasing free bikunin and HCs. Both TSG-6 center dot HC formation and the subsequent HC transfer are metal ion-dependent processes; these reactions have a requirement for either Mg2+ or Mn2+ and are inhibited by Co2+. TSG-6, which is released upon the transfer of HCs from TSG-6 onto HA, was shown to combine with I alpha I to form new TSG-6 center dot HC complexes and thus be recycled. The finding that TSG-6 acts as cofactor and catalyst in the production of HC center dot HA complexes has important implications for our understanding of inflammatory and inflammation-like processes.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Cleveland Clin Fdn, Sect Connect Tissue Biol, Dept Biomed Engn, Cleveland, OH 44195 USA; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of Oxford; Cleveland Clinic Foundation; Uppsala University	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	tony.day@bioch.ox.ac.uk	Milner, Caroline M/P-5526-2015; Day, Anthony/O-1658-2015	Milner, Caroline M/0000-0001-7355-9655; Day, Anthony/0000-0002-1415-3134	MRC [MC_U138274352] Funding Source: UKRI; Medical Research Council [MC_U138274352] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; BECKER A, 1971, ARTHRITIS RHEUM, V14, P764, DOI 10.1002/art.1780140613; BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298; BUTLER DM, 1988, ARTHRITIS RHEUM, V31, P1281, DOI 10.1002/art.1780311010; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; CHEN L, 1992, J BIOL CHEM, V267, P12380; Chen L, 1996, J BIOL CHEM, V271, P19409, DOI 10.1074/jbc.271.32.19409; DAY AJ, 2004, HA 2003 P; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; Enghild JJ, 1999, BIOCHEMISTRY-US, V38, P11804, DOI 10.1021/bi9908540; Fujimoto T, 2002, AM J PATHOL, V160, P1495, DOI 10.1016/S0002-9440(10)62575-8; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; HAMERMAN D, 1963, J CLIN INVEST, V42, P1882, DOI 10.1172/JCI104873; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; Jessen TE, 2004, OSTEOARTHR CARTILAGE, V12, P142, DOI 10.1016/j.joca.2003.10.004; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; Kida D, 1999, J RHEUMATOL, V26, P1230; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P11119, DOI 10.1074/jbc.M313471200; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nagyova E, 2004, BIOL REPROD, V71, P1838, DOI 10.1095/biolreprod.104.029595; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P1008, DOI 10.1210/en.2002-220435; Odum L, 2001, ZYGOTE, V9, P283, DOI 10.1017/S0967199401001319; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Sato H, 2001, BIOCHEM BIOPH RES CO, V281, P1154, DOI 10.1006/bbrc.2001.4475; Steinbuch M, 1976, Methods Enzymol, V45, P760; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; Yoshioka S, 2000, ENDOCRINOLOGY, V141, P4114, DOI 10.1210/en.141.11.4114; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	54	140	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25674	25686		10.1074/jbc.M501332200	http://dx.doi.org/10.1074/jbc.M501332200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15840581	hybrid			2022-12-25	WOS:000230207900048
J	Tsuboi, T; Ravier, MA; Xie, H; Ewart, MA; Gould, GW; Baldwin, SA; Rutter, GA				Tsuboi, T; Ravier, MA; Xie, H; Ewart, MA; Gould, GW; Baldwin, SA; Rutter, GA			Mammalian exocyst complex is required for the docking step of insulin vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; PLASMA-MEMBRANE; SEC6/8 COMPLEX; SECRETION; MECHANISMS; EXPRESSION; COMPONENTS; INTERACTS; DYNAMICS; EVENTS	Glucose stimulates insulin secretion from pancreatic beta cells by inducing the recruitment and fusion of insulin vesicles to the plasma membrane. However, little is currently known about the mechanism of the initial docking or tethering of insulin vesicles prior to fusion. Here, we examined the role of the SEC6-SEC8 (exocyst) complex, implicated in trafficking of secretory vesicles to fusion sites in the plasma membrane in yeast and in regulating glucose-stimulated insulin secretion from pancreatic MIN6 beta cells. We show first that SEC6 is concentrated on insulin-positive vesicles, whereas SEC5 and SEC8 are largely confined to the cytoplasm and the plasma membrane, respectively. Overexpression of truncated, dominant-negative SEC8 or SEC10 mutants decreased the number of vesicles at the plasma membrane, whereas expression of truncated SEC6 or SEC8 inhibited overall insulin secretion. When single exocytotic events were imaged by total internal reflection fluorescence microscopy, the fluorescence of the insulin surrogate, neuropeptide Y-monomeric red fluorescent protein brightened, diffused, and then vanished with kinetics that were unaffected by overexpression of truncated SEC8 or SEC10. Together, these data suggest that the exocyst complex serves to selectively regulate the docking of insulin-containing vesicles at sites of release close to the plasma membrane.	Univ Bristol, Dept Biochem, Sch Med Sci, Bristol BS8 1TD, Avon, England; Univ Bristol, Henry Wellcome Labs Integrated Cell Signalling, Sch Med Sci, Bristol BS8 1TD, Avon, England; Univ Glasgow, Henry Wellcome Lab Cell Biol, Div Biochem & Mol Biol, Fac Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Bristol; University of Bristol; University of Glasgow; University of Leeds	Rutter, GA (corresponding author), Univ Bristol, Dept Biochem, Sch Med Sci, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bristol.ac.uk	Gould, Gwyn/AAF-6721-2019; Ravier, Magalie/K-9911-2019; TSUBOI, Takashi/AAD-7976-2019; Ravier, Magalie A/N-6934-2017	Gould, Gwyn/0000-0001-6571-2875; Ravier, Magalie/0000-0001-6607-6559; TSUBOI, Takashi/0000-0001-8290-2021; Ravier, Magalie A/0000-0001-6607-6559; Rutter, Guy/0000-0001-6360-0343	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Bajjalieh SM, 1999, CURR OPIN NEUROBIOL, V9, P321, DOI 10.1016/S0959-4388(99)80047-6; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; Boyd C, 2004, J CELL BIOL, V167, P889, DOI 10.1083/jcb.200408124; Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; BURR IM, 1969, LANCET, V2, P882; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Gut A, 2001, J CELL SCI, V114, P1709; Hazuka CD, 1999, J NEUROSCI, V19, P1324; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rutter GA, 2004, DIABETOLOGIA, V47, P1861, DOI 10.1007/s00125-004-1541-1; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Straub SG, 2004, AM J PHYSIOL-CELL PH, V287, pC565, DOI 10.1152/ajpcell.00079.2004; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; Tsuboi T, 2004, J BIOL CHEM, V279, P47115, DOI 10.1074/jbc.M408179200; Tsuboi T, 2003, J BIOL CHEM, V278, P52042, DOI 10.1074/jbc.M307800200; Tsuboi T, 2003, CURR BIOL, V13, P563, DOI 10.1016/S0960-9822(03)00176-3; Vega IE, 2001, J NEUROSCI, V21, P3839, DOI 10.1523/JNEUROSCI.21-11-03839.2001; Vik-Mo EO, 2003, NEUROSCIENCE, V119, P73, DOI 10.1016/S0306-4522(03)00065-4; Wang L, 2004, J BIOL CHEM, V279, P19875, DOI 10.1074/jbc.M400522200	42	51	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25565	25570		10.1074/jbc.M501674200	http://dx.doi.org/10.1074/jbc.M501674200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878854	hybrid			2022-12-25	WOS:000230207900034
J	Golubovskaya, VM; Finch, R; Cance, WG				Golubovskaya, VM; Finch, R; Cance, WG			Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TUMOR-SUPPRESSOR P53; BREAST-CANCER CELLS; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; P53-MEDIATED APOPTOSIS; GLIOBLASTOMA CELLS; CYCLIN D1; C-JUN; EXPRESSION	Focal adhesion kinase (FAK) is a nonreceptor kinase that is overexpressed in many types of tumors and associates with multiple cell surface receptors and intracellular signaling proteins through which it can play an important role in survival signaling. A link between FAK and p53 in survival signaling has been reported, although the molecular basis of these events has not been described. In the present study, we report that FAK physically and specifically interacts with p53 as demonstrated by pull-down, immunoprecipitation, and co-localization analyses. Using different constructs of N-terminal, central, and C-terminal fragments of FAK and p53 proteins, we determined that the N-terminal fragment of FAK directly interacts with the N-terminal transactivation domain of p53. Inhibition of p53 with small interfering p53 RNA resulted in a decreased complex of FAK and p53 proteins in 293 cells, and induction of p53 with doxorubicin in normal human fibroblasts caused an increase of FAK and p53 interaction. Introduction of the FAK plasmid into p53-null SAOS-2 cells was able to rescue these cells from apoptosis induced by expression of wild type p53. In HCT 116 colon cancer cells, co-transfection of FAK plasmid with p21, MDM-2, and BAX luciferase plasmids resulted in significant inhibition of p53-responsive luciferase activities, demonstrating that FAK can reduce transcriptional activity of p53. The results of the FAK and p53 interaction study strongly support the conclusion that FAK can suppress p53-mediated apoptosis and inhibit transcriptional activity of p53. This provides a novel mechanism for FAK-p53-mediated survival/apoptotic signaling.	Univ Florida, Hlth Sci Ctr, Dept Surg, Sch Med, Gainesville, FL 32610 USA; Univ Florida, Sch Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cance, WG (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, Sch Med, POB 100286,1600 SW Archer Rd, Gainesville, FL 32610 USA.	cance@surgery.ufl.edu						Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Aoto H, 2002, CELL STRUCT FUNCT, V27, P47, DOI 10.1247/csf.27.47; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Beviglia L, 2003, BIOCHEM J, V373, P201, DOI 10.1042/BJ20021846; Cance WG, 2000, CLIN CANCER RES, V6, P2417; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chipuk JE, 2004, CELL CYCLE, V3, P429; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIEDOREK FT, 1995, MAMM GENOME, V6, P123, DOI 10.1007/BF00303256; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Go JH, 2003, MODERN PATHOL, V16, P752, DOI 10.1097/01.MP.0000081728.21368.85; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hauck CR, 2001, CANCER RES, V61, P7079; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Ilic D, 1998, J CELL BIOL, V143, P547; Jiang TY, 2004, J BIOL CHEM, V279, P50181, DOI 10.1074/jbc.M409108200; Jones G, 2004, BIOCHEM BIOPH RES CO, V314, P39, DOI 10.1016/j.bbrc.2003.12.055; Jones G, 2001, CANCER RES, V61, P4978; Kadare G, 2003, J BIOL CHEM, V278, P47434, DOI 10.1074/jbc.M308562200; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lark AL, 2003, CLIN CANCER RES, V9, P215; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lieman JH, 2005, J BIOL CHEM, V280, P10484, DOI 10.1074/jbc.M409371200; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Livasy CA, 2004, APPL IMMUNOHISTO M M, V12, P342, DOI 10.1097/00129039-200412000-00009; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643; Mitaka T, 1997, AM J PATHOL, V150, P267; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIYASHITA T, 1995, CELL, V80, P293; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Ozer E, 2003, TUMORI, V89, P54, DOI 10.1177/030089160308900112; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakuragi N, 2002, GYNECOL ONCOL, V86, P288, DOI 10.1006/gyno.2002.6742; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Song SU, 2001, EXP MOL MED, V33, P46, DOI 10.1038/emm.2001.9; Stewart A, 2002, BIOCHEM BIOPH RES CO, V299, P62, DOI 10.1016/S0006-291X(02)02547-0; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wang JF, 2003, APPL IMMUNOHISTO M M, V11, P206; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zachary I, 1997, INT J BIOCHEM CELL B, V29, P929, DOI 10.1016/S1357-2725(97)00008-3; ZHANG Y, 2004, J BIOL CHEM; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	89	142	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25008	25021		10.1074/jbc.M414172200	http://dx.doi.org/10.1074/jbc.M414172200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855171	hybrid			2022-12-25	WOS:000230114000085
J	Hagihara, Y; Matsuda, T; Yumoto, N				Hagihara, Y; Matsuda, T; Yumoto, N			Cellular quality control screening to identify amino acid pairs for substituting the disulfide bonds in immunoglobulin fold domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; AMYLOID FIBRIL FORMATION; INTRACELLULAR IMMUNIZATION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; VARIABLE DOMAIN; SCFV FRAGMENTS; HEN LYSOZYME; IN-VITRO	We are interested in determining which amino acid pairs can be substituted for the disulfide (S-S) bonds in proteins without disrupting their native structures under physiological conditions. In this study, we focused on the intradomain S-S bonds in Ig fold domains and aimed to determine a simple rule for replacement of their S-S bonds. The cysteines of four different Ig fold domains were mutated randomly, and the amino acid pairs substituted for the S-S bonds were screened by the method utilizing a cellular quality control system. Among the 36 selected mutants, 31 were natively folded without S-S bonds, as judged from the cooperativity of thermal unfolding. In addition, the selected mutant llama heavy chain antibodies retained antigen-binding affinity. At least two of the pairs Ala: Ala, Ala:Val, Val: Ala, and Val: Val were found in the selected mutants for all four different Ig fold domains, and they were stably folded at 30 C. This suggests that examination of these four pairs could be enough to obtain natively folded Ig fold domains without S-S bonds.	Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, Ikeda, Osaka 5638577, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Yumoto, N (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Inst Cell Engn, 1-8-31 Midorigaoka, Ikeda, Osaka 5638577, Japan.	n-yumoto@aist.go.jp	Matsuda, Tomoki/AAE-9910-2019; HAGIHARA, Yoshihisa/K-4996-2016	HAGIHARA, Yoshihisa/0000-0002-5980-1764				BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; Chames P, 2000, FEMS MICROBIOL LETT, V189, P1, DOI 10.1016/S0378-1097(00)00251-2; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FRISCH C, 1994, BIOL CHEM H-S, V375, P353; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; Hagihara Y, 2002, J BIOL CHEM, V277, P51043, DOI 10.1074/jbc.M208893200; Hagihara Y, 2002, P NATL ACAD SCI USA, V99, P6619, DOI 10.1073/pnas.102172099; Hong DP, 2002, J BIOL CHEM, V277, P21554, DOI 10.1074/jbc.M200188200; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; Kjeldsen T, 2002, J BIOL CHEM, V277, P18245, DOI 10.1074/jbc.C200137200; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; Liu Y, 1997, BIOCHEMISTRY-US, V36, P5323, DOI 10.1021/bi962423c; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MAYR LM, 1994, PROTEIN SCI, V3, P227; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Muyldermans S, 2001, J Biotechnol, V74, P277; Nakajima N, 2000, J MOL BIOL, V296, P197, DOI 10.1006/jmbi.1999.3440; Noda Y, 2002, BIOCHEMISTRY-US, V41, P2130, DOI 10.1021/bi0113418; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Ramm K, 1999, J MOL BIOL, V290, P535, DOI 10.1006/jmbi.1999.2854; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RUDIKOFF S, 1986, P NATL ACAD SCI USA, V83, P7875, DOI 10.1073/pnas.83.20.7875; Sambrook J., 2001, MOL CLONING LAB MANU; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; TACHIBANA H, 1994, BIOCHEMISTRY-US, V33, P15008, DOI 10.1021/bi00254a009; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; Wheeler YRY, 2003, MOL THER, V8, P355, DOI 10.1016/S1525-0016(03)00183-7; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 1999, BIOCHEMISTRY-US, V38, P8739, DOI 10.1021/bi9902079; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281; Zavodszky M, 2001, PROTEIN SCI, V10, P149, DOI 10.1110/ps.26801	51	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24752	24758		10.1074/jbc.M503963200	http://dx.doi.org/10.1074/jbc.M503963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870065	hybrid			2022-12-25	WOS:000230114000057
J	Maruyama, M; Ichisaka, T; Nakagawa, M; Yamanaka, S				Maruyama, M; Ichisaka, T; Nakagawa, M; Yamanaka, S			Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX-DETERMINING REGION; SELF-RENEWAL; ES CELLS; EXPRESSION DOMAINS; GENE-EXPRESSION; FAMILY; PROTEIN; OCT-3/4; MEMBER; NANOG	Sox family transcription factors play essential roles in cell differentiation, development, and sex determination. Sox2 was previously thought to be the sole Sox protein expressed in mouse embryonic stem (ES) cells. Sox2 associates with Oct3/4 to maintain self- renewal of ES cells. In the current study, digital differential display identified transcripts for an additional Sox family member, Sox15, enriched in mouse ES cells. Reverse transcription-PCR confirmed that Sox15 expression is highest in undifferentiated ES cells and repressed upon differentiation. Sox15 is expressed at low levels in several tissues, including testis and muscle. In vitro studies showed that Sox15, like Sox2, associated with Oct3/4 on DNA sequences containing the octamer motif and Sox-binding site. Gel mobility shift assays and SELEX analyses showed that Sox15 binds similar DNA sequences as Sox2 but with weaker affinity. In contrast to the early embryonic lethality observed in Sox2-null mice, Sox15-null ES cells and mice were grossly normal. DNA microarray analyses revealed that Otx2, Ctgf, Ebaf, and Hrc are dysregulated in Sox15-null ES cells, however. Chromatin immunoprecipitation showed that Sox15, but not Sox2, bound to a Sox consensus binding site within the Hrc gene. Taken together, these data demonstrate differential roles for Sox15 and Sox2 in transcriptional control in mouse ES cells.	Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; CREST, Japan Sci & Technol Agcy, Kyoto 6068507, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Yamanaka, S (corresponding author), Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Sakyo Ku, 53 Kawaharacho, Kyoto 6068507, Japan.	yamanaka@frontier.kyoto-u.ac.jp						Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Koopman P, 2004, GENE, V328, P177, DOI 10.1016/j.gene.2003.12.008; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Lee HJ, 2004, MOL CELL BIOL, V24, P8428, DOI 10.1128/MCB.24.19.8428-8436.2004; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Murakami A, 2001, NUCLEIC ACIDS RES, V29, P3347, DOI 10.1093/nar/29.16.3347; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Rao M, 2004, DEV BIOL, V275, P269, DOI 10.1016/j.ydbio.2004.08.013; Ridgeway AG, 1999, FEBS LETT, V456, P399, DOI 10.1016/S0014-5793(99)00993-X; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sarraj MA, 2003, GENE EXPR PATTERNS, V3, P413, DOI 10.1016/S1567-133X(03)00085-1; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; VANDEWETERING M, 1993, NUCLEIC ACIDS RES, V21, P1669, DOI 10.1093/nar/21.7.1669; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	44	88	100	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24371	24379		10.1074/jbc.M501423200	http://dx.doi.org/10.1074/jbc.M501423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863505	hybrid			2022-12-25	WOS:000230114000011
J	Yang, CF; Liu, Y; Leskow, FC; Weaver, VM; Kazanietz, MG				Yang, CF; Liu, Y; Leskow, FC; Weaver, VM; Kazanietz, MG			Rac-GAP-dependent inhibition of breast cancer cell proliferation by beta 2-chimerin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTPASE-ACTIVATING PROTEIN; PHORBOL ESTER RECEPTORS; RHO-GTPASES; SUBCELLULAR-LOCALIZATION; N-CHIMAERIN; KAPPA-B; TRANSFORMATION; INVOLVEMENT; EXPRESSION	beta 2-Chimerin is a member of the "non-protein kinase C" intracellular receptors for the second messenger diacylglycerol and the phorbol esters that is yet poorly characterized, particularly in the context of signaling pathways involved in proliferation and cancer progression. beta 2-Chimerin possesses a C-terminal Rac-GAP (GTPase-activating protein) domain that accelerates the hydrolysis of GTP from the Rac GTPase, leading to its inactivation. We found that beta 2-chimerin messenger levels are significantly down-regulated in human breast cancer cell lines as well as in breast tumors. Adenoviral delivery of beta 2-chimerin into MCF-7 breast cancer cells leads to inhibition of proliferation and G(1) cell cycle arrest. Mechanistic studies show that the effect involves the reduction in Rac-GTP levels, cyclin D1 expression, and retinoblastoma dephosphorylation. Studies using the mutated forms of beta 2-chimerin revealed that these effects were entirely dependent on its C-terminal GAP domain and Rac-GAP activity. Moreover, MCF-7 cells stably expressing active Rac (V12Rac1) but not RhoA (V14RhoA) were insensitive to beta 2-chimerin-induced inhibition of proliferation and cell cycle progression. The modulation of G(1)/S progression by beta 2-chimerin not only implies an essential role for Rac in breast cancer cell proliferation but also raises the intriguing possibility that diacylglycerol- regulated non-protein kinase C pathways can negatively impact proliferation mechanisms controlled by Rho GTPases.	Univ Hosp, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Hosp, Dept Pathol, Philadelphia, PA 19104 USA; Univ Hosp, Inst Med & Engn, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu		Weaver, Valerie marie/0000-0003-4786-6752	NCI NIH HHS [R01-CA74197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARECES LB, 1994, J BIOL CHEM, V269, P19553; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Caloca MJ, 2003, BIOCHEM J, V375, P313, DOI 10.1042/BJ20030727; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; Canagarajah B, 2004, CELL, V119, P407, DOI 10.1016/j.cell.2004.10.012; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kazanietz MG, 2002, MOL PHARMACOL, V61, P759, DOI 10.1124/mol.61.4.759; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Leung K, 2003, CELLS TISSUES ORGANS, V175, P72, DOI 10.1159/000073751; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Menna PL, 2003, CANCER RES, V63, P2284; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; YUAN SX, 1995, CANCER RES, V55, P3456; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	47	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24363	24370		10.1074/jbc.M411629200	http://dx.doi.org/10.1074/jbc.M411629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863513	hybrid			2022-12-25	WOS:000230114000010
J	Buhrke, T; Lenz, O; Krauss, N; Friedrich, B				Buhrke, T; Lenz, O; Krauss, N; Friedrich, B			Oxygen tolerance of the H-2-sensing [NiFe] hydrogenase from Ralstonia eutropha H16 is based on limited access of oxygen to the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND HYDROGENASE; NAD-REDUCING HYDROGENASE; X-RAY-ABSORPTION; ALCALIGENES-EUTROPHUS; ALLOCHROMATIUM-VINOSUM; H-2 SENSOR; ACTIVATION; EPR; PURIFICATION; COMPLEX	Hydrogenases, abundant proteins in the microbial world, catalyze cleavage of H-2 into protons and electrons or the evolution of H-2 by proton reduction. Hydrogen metabolism predominantly occurs in anoxic environments mediated by hydrogenases, which are sensitive to inhibition by oxygen. Those microorganisms, which thrive in oxic habitats, contain hydrogenases that operate in the presence of oxygen. We have selected the H-2-sensing regulatory [NiFe] hydrogenase of Ralstonia eutropha H16 to investigate the molecular background of its oxygen tolerance. Evidence is presented that the shape and size of the intramolecular hydrophobic cavities leading to the [NiFe] active site of the regulatory hydrogenase are crucial for oxygen insensitivity. Expansion of the putative gas channel by site-directed mutagenesis yielded mutant derivatives that are sensitive to inhibition by oxygen, presumably because the active site has become accessible for oxygen. The mutant proteins revealed characteristics typical of standard [ NiFe] hydrogenases as described for Desulfovibrio gigas and Allochromatium vinosum. The data offer a new strategy how to engineer oxygen-tolerant hydrogenases for biotechnological application.	Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany; Charite Univ Med Berlin, Inst Biochem, D-10117 Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Friedrich, B (corresponding author), Humboldt Univ, Inst Biol Mikrobiol, Chaussestr 117, D-10115 Berlin, Germany.	baerbel.friedrich@rz.hu-berlin.de	Lenz, Oliver/N-5130-2019; Lenz, Oliver/C-1582-2019	Lenz, Oliver/0000-0003-4550-5128; Lenz, Oliver/0000-0003-4550-5128; Krauss, Norbert/0000-0002-7128-4632				ALBRACHT SPJ, 2001, HYDROGEN FUEL LEARNI, P116; Armstrong FA, 2004, CURR OPIN CHEM BIOL, V8, P133, DOI 10.1016/j.cbpa.2004.02.004; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bernhard M, 1997, EUR J BIOCHEM, V248, P179, DOI 10.1111/j.1432-1033.1997.00179.x; Bernhard M, 2001, J BIOL CHEM, V276, P15592, DOI 10.1074/jbc.M009802200; Bleijlevens B, 2004, J BIOL INORG CHEM, V9, P743, DOI 10.1007/s00775-004-0570-z; Bleijlevens B, 2001, J BIOL INORG CHEM, V6, P763, DOI 10.1007/s007750100252; Bleijlevens B, 2004, J BIOL CHEM, V279, P46686, DOI 10.1074/jbc.M406942200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brecht M, 2003, J AM CHEM SOC, V125, P13075, DOI 10.1021/ja036624x; Buhrke T, 2002, J BIOL INORG CHEM, V7, P897, DOI 10.1007/s00775-002-0379-6; Buhrke T, 2005, J BIOL CHEM, V280, P19488, DOI 10.1074/jbc.M500601200; Buhrke T, 2004, MOL MICROBIOL, V51, P1677, DOI 10.1111/j.1365-2958.2003.03933.x; Burgdorf T, 2005, J AM CHEM SOC, V127, P576, DOI 10.1021/ja0461926; CAMMACK R, 1986, BIOCHIMIE, V68, P85, DOI 10.1016/S0300-9084(86)81072-0; Carepo M, 2002, J AM CHEM SOC, V124, P281, DOI 10.1021/ja010204v; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Cohen J, 2005, BIOCHEM SOC T, V33, P80, DOI 10.1042/BST0330080; Elsen S, 1996, J BACTERIOL, V178, P5174, DOI 10.1128/jb.178.17.5174-5181.1996; Happe RP, 2000, FEBS LETT, V466, P259, DOI 10.1016/S0014-5793(99)01799-8; Haumann M, 2003, BIOCHEMISTRY-US, V42, P11004, DOI 10.1021/bi034804d; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karyakin AA, 2005, BIOCHEM SOC T, V33, P73, DOI 10.1042/BST0330073; Kleihues L, 2000, J BACTERIOL, V182, P2716, DOI 10.1128/JB.182.10.2716-2724.2000; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamle SE, 2004, J AM CHEM SOC, V126, P14899, DOI 10.1021/ja047939v; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lenz O, 1998, P NATL ACAD SCI USA, V95, P12474, DOI 10.1073/pnas.95.21.12474; Melis A, 2001, PLANT PHYSIOL, V127, P740, DOI 10.1104/pp.127.3.740; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Nicolet Y, 2002, J INORG BIOCHEM, V91, P1, DOI 10.1016/S0162-0134(02)00392-6; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Pierik AJ, 1998, FEBS LETT, V438, P231, DOI 10.1016/S0014-5793(98)01306-4; SCHINK B, 1979, BIOCHIM BIOPHYS ACTA, V567, P315, DOI 10.1016/0005-2744(79)90117-7; SCHNEIDER K, 1976, BIOCHIM BIOPHYS ACTA, V452, P66, DOI 10.1016/0005-2744(76)90058-9; Schwartz E, 1998, J BACTERIOL, V180, P3197, DOI 10.1128/JB.180.12.3197-3204.1998; SCHWARTZ E, 2003, PROKARYOTES EVOLVING; Seravalli J, 2000, BIOCHEMISTRY-US, V39, P1274, DOI 10.1021/bi991812e; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Vignais PM, 2004, CURR ISSUES MOL BIOL, V6, P159; Volbeda A, 2002, INT J HYDROGEN ENERG, V27, P1449, DOI 10.1016/S0360-3199(02)00072-1; VOLBEDA A, 1999, ECOLES PHYSIQUE CHIM, V1, P47; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	153	159	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23791	23796		10.1074/jbc.M503260200	http://dx.doi.org/10.1074/jbc.M503260200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849358	hybrid			2022-12-25	WOS:000229880000050
J	Hosokawa, H; Nakanishi-Matsui, M; Kashiwagi, S; Fujii-Taira, I; Hayashi, K; Iwamoto-Kihara, A; Wada, Y; Futai, M				Hosokawa, H; Nakanishi-Matsui, M; Kashiwagi, S; Fujii-Taira, I; Hayashi, K; Iwamoto-Kihara, A; Wada, Y; Futai, M			ATP-dependent rotation of mutant ATP synthases defective in proton transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SUBUNIT OLIGOMER; ESCHERICHIA-COLI F0F1-ATPASE; AQUEOUS ACCESS CHANNELS; ENERGY TRANSDUCTION; MOLECULAR ARCHITECTURE; TORQUE GENERATION; RING ROTATION; ALPHA-SUBUNIT; GAMMA-SUBUNIT; ROTARY MOTOR	During ATP hydrolysis, the gamma epsilon c(10) complex (gamma and epsilon subunits and a c subunit ring formed from 10 monomers) of F0F1 ATPase ( ATP synthase) rotates relative to the alpha(3)beta(3)delta ab(2) complex, leading to proton transport through the interface between the a subunit and the c subunit ring. In this study, we replaced the two pertinent residues for proton transport, cAsp-61 and aArg-210 of the c and a subunits, respectively. The mutant enzymes exhibited lower ATPase activities than that of the wild type but exhibited ATP-dependent rotation in planar membranes, in which their original assemblies are maintained. The mutant enzymes were defective in proton transport, as shown previously. These results suggest that proton transport can be separated from rotation in ATP hydrolysis, although rotation ensures continuous proton transport by bringing the cAsp-61 and aArg-210 residues into the correct interacting positions.	Japan Sci & Technol Agcy, Futai Special Lab, Microbial Chem Res Ctr, Tokyo 1410021, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol Program, Tokyo 1410021, Japan; Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Ibaraki, Osaka 5670047, Japan; Nagahama Inst Biosci & Technol, Dept Biosci, Nagahama, Shiga 5260829, Japan	Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Osaka University	Futai, M (corresponding author), Japan Sci & Technol Agcy, Futai Special Lab, Microbial Chem Res Ctr, Tokyo 1410021, Japan.	mfutai-fsl@bikaken.or.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Aksimentiev A, 2004, BIOPHYS J, V86, P1332, DOI 10.1016/S0006-3495(04)74205-8; Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Gumbiowski K, 2002, J BIOL CHEM, V277, P31287, DOI 10.1074/jbc.M111678200; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; SIGH S, 1996, FEBS LETT, V397, P30; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Sun-Wada G.-H., 2004, HDB ATPASES BIOCH CE, P379; Sun-Wada GH, 2003, J BIOL CHEM, V278, P44843, DOI 10.1074/jbc.M307197200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; TAMURA F, 1981, FEBS LETT, V127, P48, DOI 10.1016/0014-5793(81)80338-9; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; VIK SB, 1994, J BIOL CHEM, V269, P30364; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	48	10	10	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23797	23801		10.1074/jbc.M502650200	http://dx.doi.org/10.1074/jbc.M502650200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849185	hybrid			2022-12-25	WOS:000229880000051
J	Long, XM; Ortiz-Vega, S; Lin, YS; Avruch, J				Long, XM; Ortiz-Vega, S; Lin, YS; Avruch, J			Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; CELL-GROWTH; SIGNALING NETWORK; TUMOR-SUPPRESSOR; RAPTOR; TSC2; PROTEINS; PATHWAY; GAP	The removal of extracellular amino acids or leucine alone inhibits the ability of the mammalian target of rapamycin ( mTOR) to signal to the raptor-dependent substrates, p70 S6 kinase and 4E-BP. This inhibition can be overcome by overexpression of the Rheb GTPase. Rheb binds directly to the amino-terminal lobe of the mTOR catalytic domain, and activates mTOR kinase in a GTP-dependent manner. Herein we show that the binding of Rheb to endogenous and recombinant mTOR is reversibly inhibited by withdrawal of all extracellular amino acids or just leucine. The effect of amino acid withdrawal is not attributable to changes in Rheb-GTP charging; amino acid withdrawal does not alter the GTP charging of recombinant Rheb. Moreover, the binding of mTOR to Rheb mutants that are unable to bind guanyl nucleotide in vivo is also inhibited by amino withdrawal. The inhibitory effect of amino acid withdrawal is exerted through an action on mTOR, at a site largely distinct from that responsible for the binding of Rheb; deletion of the larger, carboxyl-terminal lobe of the mTOR catalytic domain eliminates the inhibitory effect of amino acid withdrawal on Rheb binding, without altering Rheb binding per se. The lesser ability of the mTOR catalytic domain to bind Rheb after amino acid withdrawal does not persist after extraction and purification of the mTOR polypeptide. Amino acid withdrawl may generate an inhibitor of the Rheb-mTOR interaction that interferes with the signaling function of TOR complex 1.	Harvard Univ, Sch Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Avruch, J (corresponding author), Harvard Univ, Sch Med, Diabet Unit, Boston, MA 02114 USA.	avruch@molbio.mgh.harvard.edu	Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232	NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, T32DK007028, R01DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776, DK007028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Findlay GM, 2005, CURR OPIN GENET DEV, V15, P69, DOI 10.1016/j.gde.2004.11.002; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	17	261	275	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23433	23436		10.1074/jbc.C500169200	http://dx.doi.org/10.1074/jbc.C500169200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15878852	Green Published, hybrid			2022-12-25	WOS:000229880000004
J	Mokranjac, D; Popov-Celeketic, D; Hell, K; Neupert, W				Mokranjac, D; Popov-Celeketic, D; Hell, K; Neupert, W			Role of Tim21 in mitochondrial translocation contact sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; OUTER-MEMBRANE; BINDING-SITE; COMPLEX; PRESEQUENCE; INNER; TIM50; SUBUNIT	Translocation of preproteins with N-terminal presequences into mitochondria requires the cooperation of the translocase of the outer membrane (TOM complex) and the presequence translocase of the inner membrane (TIM23 complex). However, the molecular nature of the translocation contact sites is poorly understood. We have identified a novel component of the TIM23 translocase, Tim21, which is involved in their formation. Tim21 is anchored in the mitochondrial inner membrane by a single transmembrane domain and exposes its C-terminal domain into the intermembrane space. The purified C-terminal domain of Tim21 appears not to bind to any of the TIM23 components but rather specifically interacts with the TOM complex. We propose that Tim21 binds to the trans site of the TOM complex thus keeping the two translocases in close contact.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Neupert, W (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.	neupert@med.uni-muenchen.de	Popov-Celeketic, Dusan/O-2371-2016	Popov-Celeketic, Dusan/0000-0002-0512-6900; Mokranjac, Dejana/0000-0002-4005-6979				BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 2004, J BIOL CHEM, V279, P45701, DOI 10.1074/jbc.M404591200; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; Milisav I, 2001, J BIOL CHEM, V276, P25856, DOI 10.1074/jbc.M102132200; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2004, NAT STRUCT MOL BIOL, V11, P1044, DOI 10.1038/nsmb852; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; SIKORSKI RS, 1989, GENETICS, V122, P19; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	23	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23437	23440		10.1074/jbc.C500135200	http://dx.doi.org/10.1074/jbc.C500135200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15878866	hybrid			2022-12-25	WOS:000229880000005
J	Neznanov, N; Chumakov, KM; Neznanova, L; Almasan, A; Banerjee, AK; Gudkov, AV				Neznanov, N; Chumakov, KM; Neznanova, L; Almasan, A; Banerjee, AK; Gudkov, AV			Proteolytic cleavage of the p65-RelA subunit of NF-kappa B during poliovirus infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; ENCODED PROTEASE 3C(PRO); HOST-CELL TRANSCRIPTION; TATA-BINDING PROTEIN; RNA-POLYMERASE-II; IN-VITRO; INDUCED APOPTOSIS; ACTIVATION; EXPRESSION; INHIBITION	Activation of NF-kappa B during viral infection is one of the critical elements in innate immune response. Several virus-specific factors, such as double-stranded RNA, can trigger host defense mechanisms by inducing NF-kappa B-mediated expression of cytokines and interferons. Early stages of poliovirus infection are also associated with degradation of I kappa B alpha and translocation of NF-kappa B into the nucleus. However, at later stages of poliovirus replication the p65-RelA component of the NF-kappa B complex undergoes a specific cleavage that coincides with the onset of intensive poliovirus protein synthesis and the appearance of the activity of poliovirus protease 3C. Indeed, the p65-RelA amino acid sequence contains the recognition site for 3C, and recombinant protein 3C was shown to be capable of proteolytic cleavage of p65-RelA, generating truncated product similar to that observed during poliovirus infection. Cleavage of p65-RelA occurs during replication of ECHO-1 and rhinovirus 14, suggesting that inactivation of NF-kappa B function by proteolytic cleavage of p65-RelA is the common mechanism by which picornaviruses suppress the innate immune response.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; US Food & Drug Administration (FDA)	Neznanov, N (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.	neznann@ccf.org; Gudkov@ccf.org	Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA60730, CA88071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730, R01CA088071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agol VI, 2000, J VIROL, V74, P5534, DOI 10.1128/JVI.74.12.5534-5541.2000; Belov GA, 2003, J VIROL, V77, P45, DOI 10.1128/JVI.77.1.45-56.2003; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Bitko V, 1998, J VIROL, V72, P5610, DOI 10.1128/JVI.72.7.5610-5618.1998; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; Bose S, 2003, P NATL ACAD SCI USA, V100, P10890, DOI 10.1073/pnas.1832775100; Calandria C, 2004, VIRUS RES, V104, P39, DOI 10.1016/j.virusres.2004.02.042; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; EHRENFELD E, 1982, CELL, V28, P435, DOI 10.1016/0092-8674(82)90195-7; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gil J, 2001, J GEN VIROL, V82, P3027, DOI 10.1099/0022-1317-82-12-3027; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Helin E, 2002, ARCH VIROL, V147, P1721, DOI 10.1007/s00705-002-0835-1; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Julkunen I, 2001, CYTOKINE GROWTH F R, V12, P171, DOI 10.1016/S1359-6101(00)00026-5; Kang KH, 2001, J BIOL CHEM, V276, P24638, DOI 10.1074/jbc.M101291200; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001; Neuzil J, 2001, BIOCHEMISTRY-US, V40, P4686, DOI 10.1021/bi002498n; Neznanov N, 2003, J BIOL CHEM, V278, P3809, DOI 10.1074/jbc.M210698200; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; NICKLIN MJH, 1987, P NATL ACAD SCI USA, V84, P4002, DOI 10.1073/pnas.84.12.4002; Ole KL, 2001, VIROLOGY, V288, P175, DOI 10.1006/viro.2001.1090; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Palma JP, 2003, J VIROL, V77, P6322, DOI 10.1128/JVI.77.11.6322-6331.2003; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Sharma R, 2004, VIROLOGY, V320, P195, DOI 10.1016/j.virol.2003.10.020; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taddeo B, 2003, P NATL ACAD SCI USA, V100, P12408, DOI 10.1073/pnas.2034952100; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; TOLSKAYA EA, 1995, J VIROL, V69, P1181, DOI 10.1128/JVI.69.2.1181-1189.1995; TOYODA H, 1986, CELL, V45, P761, DOI 10.1016/0092-8674(86)90790-7; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Yalamanchili P, 1997, J VIROL, V71, P1220, DOI 10.1128/JVI.71.2.1220-1226.1997; Yalamanchili P, 1997, J VIROL, V71, P6881, DOI 10.1128/JVI.71.9.6881-6886.1997; Yalamanchili P, 1996, J VIROL, V70, P2922, DOI 10.1128/JVI.70.5.2922-2929.1996; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000	54	91	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24153	24158		10.1074/jbc.M502303200	http://dx.doi.org/10.1074/jbc.M502303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845545	hybrid			2022-12-25	WOS:000229880000089
J	Piotukh, K; Gu, W; Kofler, M; Labudde, D; Helms, V; Freund, C				Piotukh, K; Gu, W; Kofler, M; Labudde, D; Helms, V; Freund, C			Cyclophilin a binds to linear peptide motifs containing a consensus that is present in many human proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERIZATION; TYROSINE KINASE ITK; PROLYL ISOMERASE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; TERMINAL DOMAIN; CELLS; CATALYSIS; ANTIBODY; FAMILY	Cyclophilin A ( CypA) is a peptidyl-prolyl cis/trans-isomerase that is involved in multiple signaling events of eukaryotic cells. It might either act as a catalyst for prolyl bond isomerization, or it can form stoichiometric complexes with target proteins. We have investigated the linear sequence recognition code for CypA by phage display and found the consensus motif FGPXLp to be selected after five rounds of panning. The peptide FGP-DLPAGD showed inhibition of the isomerase reaction and NMR chemical shift mapping experiments highlight the CypA interaction epitope. Ligand docking suggests that the peptide was able to bind to CypA in the cis- and trans-conformation. Protein Data Bank searches reveal that many human proteins contain the consensus motif, and several of these protein motifs are shown to interact with CypA in vitro. These sequences represent putative target sites for binding of CypA to intracellular proteins.	Free Univ Berlin, Prot Engn Grp, D-13125 Berlin, Germany; Forsch Inst Mol Pharmakol, D-13125 Berlin, Germany; Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany	Free University of Berlin; Saarland University	Freund, C (corresponding author), Free Univ Berlin, Prot Engn Grp, Robert Rossle Str 10, D-13125 Berlin, Germany.	freund@fmp-berlin.de	Gu, Wei/G-4003-2010	Gu, Wei/0000-0003-3951-6680; Helms, Volkhard/0000-0002-2180-9154				BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bosco DA, 2004, BIOCHEMISTRY-US, V43, P6110, DOI 10.1021/bi049841z; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Bruns K, 2003, J BIOL CHEM, V278, P43188, DOI 10.1074/jbc.M305413200; Colgan J, 2004, IMMUNITY, V21, P189, DOI 10.1016/j.immuni.2004.07.005; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; Endrich MM, 1999, J BIOL CHEM, V274, P5326, DOI 10.1074/jbc.274.9.5326; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Goddard T.D., 2004, SPARKY 3; GOLEMIS E, 2001, PROTEIN PROTEIN INTE, P143; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARRISON RK, 1992, J AM CHEM SOC, V114, P3464, DOI 10.1021/ja00035a046; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Howard BR, 2003, NAT STRUCT BIOL, V10, P475, DOI 10.1038/nsb927; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Jin ZG, 2004, ARTERIOSCL THROM VAS, V24, P1186, DOI 10.1161/01.ATV.0000130664.51010.28; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KERN D, 1995, BIOCHEMISTRY-US, V34, P13594, DOI 10.1021/bi00041a039; King PD, 1998, INT IMMUNOL, V10, P1009, DOI 10.1093/intimm/10.7.1009; Kramer A, 1998, METH MOL B, V87, P25; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Maes T, 2002, GENOMICS, V80, P21, DOI 10.1006/geno.2002.6799; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P65, DOI 10.1023/A:1007173329237; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Rucker AL, 2003, PROTEINS, V53, P68, DOI 10.1002/prot.10477; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Wiegers K, 2002, VIROLOGY, V294, P289, DOI 10.1006/viro.2001.1347; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	39	54	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23668	23674		10.1074/jbc.M503405200	http://dx.doi.org/10.1074/jbc.M503405200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845542	hybrid			2022-12-25	WOS:000229880000034
J	Carr, HS; Maxfield, AB; Horng, YC; Winge, DR				Carr, HS; Maxfield, AB; Horng, YC; Winge, DR			Functional analysis of the domains in Cox11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MITOCHONDRIAL INNER MEMBRANE; B SITE FORMATION; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL ACTIVATOR; RHODOBACTER-SPHAEROIDES; YEAST MITOCHONDRIA; PROTEIN; SUBUNIT; SCO1	Cox11 is an intrinsic mitochondrial membrane protein essential for the assembly of an active cytochrome c oxidase complex. Cox11 is tethered to the mitochondrial inner membrane by a single transmembrane helix. Domain mapping was carried out to determine the functional segments of the Cox11 protein. The C-terminal 189 residue Cu(I)-binding domain is shown to be exposed within the mitochondrial intermembrane space. This orientation was demonstrated by the proteolytic susceptibility of a C-terminal Myc epitope tag in mitoplasts but not intact mitochondria. Fusion of the N terminus of Cox11 to the matrix ribosomal protein Rsm22 results in a functional protein capable of suppressing the respiratory defect of both Delta cox11 cells and Delta rsm22 cells. The functionality of the fusion protein suggests that the Cox11 N terminus projects into the matrix. The fusion of the C-terminal segment of Cox11 to Rsm22 resembles a naturally occurring fusion of Cox11 in Schizosaccharomyces pombe to a sequence homologous to the Saccharomyces cerevisiae Rsm22. Studies on a series of SCO1/COX11 chimeras reveal that the matrix domain of Cox11 lacks a specific function, whereas the Cu( I) binding/donating function requires the yeast Cox11 sequence. The Cu(I)-binding domain from human Cox11 cannot functionally replace the yeast sequence. The copper domain of Cox11 may be an important docking motif for Cox1 or a Cox1-associated protein.	Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Winge, Dennis/G-3611-2010; Horng, Yih-Chern/I-6682-2018	Horng, Yih-Chern/0000-0001-9558-3189	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; Banci L, 2004, J BIOL CHEM, V279, P34833, DOI 10.1074/jbc.M403655200; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2002, FEBS LETT, V516, P119, DOI 10.1016/S0014-5793(02)02514-0; Beauvoit B, 1999, EUR J BIOCHEM, V263, P118, DOI 10.1046/j.1432-1327.1999.00475.x; Beinert H, 1995, CHEM BIOL, V2, P781, DOI 10.1016/1074-5521(95)90082-9; Bratton MR, 2000, BIOCHEMISTRY-US, V39, P12989, DOI 10.1021/bi0003083; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Khalimonchuk O, 2005, CURR GENET, V47, P223, DOI 10.1007/s00294-005-0569-1; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Manthey GM, 1998, EUR J BIOCHEM, V255, P156, DOI 10.1046/j.1432-1327.1998.2550156.x; MCMULLIN TW, 1990, MOL CELL BIOL, V10, P4590, DOI 10.1128/MCB.10.9.4590; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Saveanu C, 2001, J BIOL CHEM, V276, P15861, DOI 10.1074/jbc.M010864200; SMITH D, 2002, J BIOL CHEM; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	30	41	41	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22664	22669		10.1074/jbc.M414077200	http://dx.doi.org/10.1074/jbc.M414077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840584	hybrid			2022-12-25	WOS:000229741800015
J	Laroche, G; Rochdi, MD; Laporte, SA; Parent, JL				Laroche, G; Rochdi, MD; Laporte, SA; Parent, JL			Involvement of actin in agonist-induced endocytosis of the G protein-coupled receptor for thromboxane A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; MEDIATED ENDOCYTOSIS; RHOA ACTIVATION; BINDING PROTEIN; ALPHA-ISOFORM; INTERNALIZATION; A(2); TRAFFICKING; PHOSPHORYLATION; BETA-ARRESTIN-1	The role of actin in endocytosis of G protein-coupled receptors is poorly defined. In the present study, we demonstrate that agents that depolymerize (latrunculin B and cytochalasin D) or stabilize (jasplakinolide) the actin cytoskeleton blocked agonist-induced endocytosis of the beta isoform of the thromboxane A(2) receptor (TP beta) in HEK293 cells. This suggests that endocytosis of TP beta requires active remodeling of the actin cytoskeleton. On the other hand, disruption of microtubules with colchicine did not affect endocytosis of the receptor. Expression of wild-type and mutant forms of the small GTPases RhoA and Cdc42 potently inhibited endocytosis of TP beta, further indicating a role for the dynamic regulation of the actin cytoskeleton in this pathway. Agonist treatment of TP beta in HEK293 cells resulted in the formation of actin stress fibers through G alpha(q/11) signaling. Because we previously showed that endocytosis of TP beta is dependent on arrestins, we decided to explore the relation between arrestin-2 and -3 and actin in endocytosis of this receptor. Interestingly, we show that the inhibition of TP beta endocytosis by the actin toxins in HEK293 cells was overcome by the overexpression of arrestin-3, but not of arrestin-2. These results indicate that the actin cytoskeleton is not essential in arrestin-3-mediated endocytosis of TP beta. However, arrestin-3 could not promote endocytosis of the TP beta Y339A and TP beta I343A carboxyl-terminal mutants when the actin cytoskeleton was disrupted. Our data provide new evidence that the actin cytoskeleton plays an essential role in TP beta endocytosis. Furthermore, our work suggests the existence of actin-dependent and -independent arrestin-mediated pathways of endocytosis.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; McGill Univ, Dept Med, Hormones & Canc Res Unit, Montreal, PQ H3A 1A1, Canada	University of Sherbrooke; McGill University	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001,12th N Ave, Sherbrooke, PQ J1H 5N4, Canada.	jean-luc.parent@USherbrooke.ca	Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012	Laporte, Stephane/0000-0002-0633-543X; 				Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ayscough KR, 2000, CURR BIOL, V10, P1587, DOI 10.1016/S0960-9822(00)00859-9; Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; BUBB MR, 1994, J BIOL CHEM, V269, P14869; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Dutt P, 2002, FEBS LETT, V531, P565, DOI 10.1016/S0014-5793(02)03625-6; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Foley JF, 2001, BIOCHEM PHARMACOL, V62, P229, DOI 10.1016/S0006-2952(01)00661-X; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirasawa A, 1998, BRIT J PHARMACOL, V124, P55, DOI 10.1038/sj.bjp.0701795; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; Lunn JA, 2000, AM J PHYSIOL-CELL PH, V279, pC2019, DOI 10.1152/ajpcell.2000.279.6.C2019; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Santini F, 2000, J CELL SCI, V113, P2463; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Shumay E, 2004, J CELL SCI, V117, P593, DOI 10.1242/jcs.00890; Smith PG, 2003, AM J RESP CELL MOL, V28, P436, DOI 10.1165/rcmb.4754; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Theriault C, 2004, BIOCHEMISTRY-US, V43, P5600, DOI 10.1021/bi036268v; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Vogler O, 1999, J PHARMACOL EXP THER, V288, P36; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200; Zaslaver A, 2001, J IMMUNOL, V166, P1272, DOI 10.4049/jimmunol.166.2.1272	58	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23215	23224		10.1074/jbc.M414071200	http://dx.doi.org/10.1074/jbc.M414071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845539	hybrid			2022-12-25	WOS:000229741800079
J	Sakao, S; Taraseviciene-Stewart, L; Lee, JD; Wood, K; Cool, CD; Voelkel, NF				Sakao, S; Taraseviciene-Stewart, L; Lee, JD; Wood, K; Cool, CD; Voelkel, NF			Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells	FASEB JOURNAL			English	Article						pulmonary hypertension; shear stress; VEGF; VEGF receptor blockade	PULMONARY-HYPERTENSION; GROWTH-FACTOR; EXPRESSION; SURVIVIN; RECEPTORS; INHIBITOR; HIERARCHY; PROTEIN; CANCER; GENE	We have demonstrated that VEGF receptor blockade in combination with chronic hypoxia causes in rats severe angioproliferative pulmonary hypertension (SAPH) associated with arterial occlusion by proliferating endothelial cells, and we postulate that the established, lumen-occluding lesions are the result of the emergence of apoptosis-resistant proliferating cells. To study the dependence of exuberant endothelial cell proliferation on initial apoptosis, we adapted the CELLMAX artificial capillary system to analyze the effects of a VEGF receptor antagonist (SU5416) on human pulmonary microvascular endothelial cells under pulsatile shear stress. Immunohistochemical staining for caspase-3 and PCNA and flow cytometry for Annexin-V and BrdU supported our concept, since SU5416 caused initial apoptosis (35.8% at 24 h after the SU5416 addition and 4.8% in control cells) whereas the surviving cells became hyperproliferative ( PCNA positive). Flow cytometry showed that apoptosis inhibition prevented the proliferation following the initial apoptosis. These lumen-filling endothelial cells were apoptosis resistant, grew without serum, and were phenotypically altered in that they express the tumor marker survivin. Hyperproliferative apoptosis-resistant cells were also generated by adding apoptosed cells instead of the VEGF receptor blocker to the CELLMAX system. In conclusion, endothelial cell death resulted in the selection of an apoptosis-resistant, proliferating phenotypically altered endothelial cell phenotype.	Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Voelkel, NF (corresponding author), Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,C272, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu			NHLBI NIH HHS [5P01 HL66254-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066254] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ameshima S, 2003, CIRC RES, V92, P1162, DOI 10.1161/01.RES.0000073585.50092.14; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GOLPON H, 2004, FASEB J         0902; Hirose S, 2000, PATHOL INT, V50, P472, DOI 10.1046/j.1440-1827.2000.01068.x; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Ma JF, 2002, J GASTROINTEST CANC, V32, P73, DOI 10.1385/IJGC:32:2-3:73; Mathew R, 2004, CIRCULATION, V110, P1499, DOI 10.1161/01.CIR.0000141576.39579.23; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Mikami T, 2003, AM J CLIN PATHOL, V119, P723, DOI 10.1309/YLX4L4H36K54X92H; Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rimensberger PC, 2001, CIRCULATION, V103, P544, DOI 10.1161/01.CIR.103.4.544; Sarela AI, 2002, BRIT J CANCER, V86, P886, DOI 10.1038/sj.bjc.6600133; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sitbon O, 2002, J AM COLL CARDIOL, V40, P780, DOI 10.1016/S0735-1097(02)02012-0; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; TARASEVICIENEST.L, 2003, 4 INT C MECH CELL DE; TUDER RM, 1994, AM J PATHOL, V144, P275; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641	27	201	210	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1178	+		10.1096/fj.04-3261fje	http://dx.doi.org/10.1096/fj.04-3261fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15897232				2022-12-25	WOS:000229602600013
J	Akahoshi, T; Tanigawa, T; Sarfeh, IJ; Chiou, SK; Hashizume, M; Maehara, Y; Jones, MK				Akahoshi, T; Tanigawa, T; Sarfeh, IJ; Chiou, SK; Hashizume, M; Maehara, Y; Jones, MK			Selective cyclooxygenase (COX) inhibition causes damage to portal hypertensive gastric mucosa: roles of nitric oxide and NF-kappa B	FASEB JOURNAL			English	Article						celecoxib; indomethacin; NF-kappa B	INCREASED SUSCEPTIBILITY; SYNTHASE EXPRESSION; RAT; ACTIVATION; INJURY; GENE; KEY; LIPOPOLYSACCHARIDE; ERK2	Portal hypertension (PHT) is associated with increased susceptibility of the gastric mucosa to injury by a variety of factors, including nonsteroidal anti-inflammatory drugs (NSAIDs) that nonselectively inhibit both isoforms of cyclooxygenase (COX-1 and -2). PHT gastric mucosa also has excessive nitric oxide (NO) production that contributes to the general increased susceptibility to injury. Using a rat model of PHT, we studied whether selective COX inhibition, which does not damage normal (normotensive) gastric mucosa, is sufficient to cause PHT gastric damage and, if so, whether and how excessive NO is involved. Indomethacin, a nonselective NSAID, caused 2.4-fold more gastric injury to PHT vs. normotensive sham-operated (SO) control rats. Neither NS-398 nor celecoxib, selective COX-2 inhibitors, caused gastric damage in either SO or PHT rats. SC-560, a selective COX-1 inhibitor, did not cause gastric damage in SO rats but dose-dependently caused gastric damage in PHT rats. There was a compensatory increase in COX-2 expression and activity in SC-560-treated SO rats but not SC-560-treated PHT rats. Partial inhibition of NO production restored gastric COX-2 expression and activity levels in SC-560-treated PHT rats to those of SC-560-treated SO rats, by a mechanism consistent with induction of NF-kappa B, and significantly reduced gastric damage. These studies indicate that, in contrast to normotensive gastric mucosa, inhibition of COX-1 alone is sufficient to cause PHT gastric damage as a result of excessive NO that prevents the induction of NF-kappa B and the compensatory increase in COX-2.	Univ Calif Irvine, DVA Med Ctr, Long Beach, CA 90822 USA; Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Disaster & Emergency Med, Fukuoka 812, Japan	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; Kyushu University; Kyushu University	Jones, MK (corresponding author), Univ Calif Irvine, DVA Med Ctr, 5901 E 7th St, Long Beach, CA 90822 USA.	michael.jones4@med.va.gov	Akahoshi, Tomohiko/AAU-4886-2021; Maehara, Yoshihiko/A-4867-2010; Tanigawa, Tetsuya/J-6131-2019	Tanigawa, Tetsuya/0000-0002-9305-1637				Arai K, 2003, GUT, V52, P1242, DOI 10.1136/gut.52.9.1242; Blais V, 2001, J NEUROPATH EXP NEUR, V60, P893, DOI 10.1093/jnen/60.9.893; Boku K, 2001, GASTROENTEROLOGY, V120, P134, DOI 10.1053/gast.2001.20916; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; Gadano AC, 1999, J HEPATOL, V30, P896, DOI 10.1016/S0168-8278(99)80145-7; Habib A, 1997, J IMMUNOL, V158, P3845; Heller J, 1999, HEPATOLOGY, V30, P698, DOI 10.1002/hep.510300301; ICHIKAWA Y, 1994, GASTROENTEROLOGY, V106, P702, DOI 10.1016/0016-5085(94)90705-6; ISHIKAWA T, 1992, SURGERY, V112, P341; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; Kawanaka H, 2001, FASEB J, V15, P574; Liu SF, 1997, J IMMUNOL, V159, P3976; Liu SF, 1999, MOL PHARMACOL, V55, P658; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Muller-Quade J, 2000, APPL ALGEBR ENG COMM, V11, P35, DOI 10.1007/s002000000024; Ohta M, 1998, HEPATOLOGY, V27, P906, DOI 10.1002/hep.510270403; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; Pausawasdi N, 2002, AM J PHYSIOL-GASTR L, V282, pG1069, DOI 10.1152/ajpgi.00164.2001; Pique JM, 1997, BAILLIERE CLIN GASTR, V11, P257, DOI 10.1016/S0950-3528(97)90039-7; Saeki T, 2004, AM J PHYSIOL-GASTR L, V286, pG68, DOI 10.1152/ajpgi.00538.2002; SARFEH IJ, 1991, J CLIN GASTROENTEROL, V13, pS18, DOI 10.1097/00004836-199112001-00003; SARFEH IJ, 1988, SURGERY, V104, P79; SARFEH IJ, 1989, DIGEST DIS SCI, V34, P225, DOI 10.1007/BF01536055; SARFEH IJ, 1982, SURG GYNECOL OBSTET, V155, P167; Takahashi S, 2001, AM J PHYSIOL-GASTR L, V280, pG1296, DOI 10.1152/ajpgi.2001.280.6.G1296; Tanaka A, 2002, ALIMENT PHARM THERAP, V16, P90, DOI 10.1046/j.1365-2036.16.s2.22.x; TARNAWSKI A, 1988, J CLIN GASTROENTEROL, V10, pS35, DOI 10.1097/00004836-198812001-00008; TARNAWSKI AS, 1988, HEPATOLOGY, V8, P1488, DOI 10.1002/hep.1840080604; Tomikawa M, 1999, ANN SURG, V230, P38, DOI 10.1097/00000658-199907000-00006; Tsugawa K, 2003, FASEB J, V17, P2316, DOI 10.1096/fj.02-1107fje; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALLACE JL, 1992, GASTROENTEROL CLIN N, V21, P631; WALLACE JL, 1991, GASTROENTEROLOGY, V100, P878, DOI 10.1016/0016-5085(91)90259-N; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0	39	8	8	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1163	+		10.1096/fj.04-3325fje	http://dx.doi.org/10.1096/fj.04-3325fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15845610				2022-12-25	WOS:000228865300009
J	Joseph, RE; Norris, FA				Joseph, RE; Norris, FA			Substrate specificity and recognition is conferred by the pleckstrin homology domain of the Db1 family guanine nucleotide exchange factor P-rex2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; CRYSTAL-STRUCTURE; ONCOGENIC DBL; PH DOMAINS; RAC; BINDING; ACTIVATION; TIAM1; DH; TRANSFORMATION	Dbl family guanine nucleotide exchange factors ( GEFs) are characterized by the presence of a catalytic Dbl homology domain followed invariably by a lipid-binding pleckstrin homology (PH) domain. To date, substrate recognition and specificity of this family of GEFs has been reported to be mediated exclusively via the Dbl homology domain. Here we report the novel and unexpected finding that, in the Dbl family Rac-specific GEF P-Rex2, it is the PH domain that confers substrate specificity and recognition. Moreover, the beta 3 beta 4 loop of the PH domain of P-Rex2 is the determinant for Rac1 recognition, as substitution of the beta 3 beta 4 loop of the PH domain of Dbs ( a RhoA- and Cdc42-specific GEF) with that of P-Rex2 confers Rac1-specific binding capability to the PH domain of Dbs. The contact interface between the PH domain of P-Rex2 and Rac1 involves the switch loop and helix 3 of Rac1. Moreover, substitution of helix 3 of Cdc42 with that of Rac1 now enables the PH domain of P-Rex2 to bind this Cdc42 chimera. Despite having the ability to recognize this chimeric Cdc42, P-Rex2 is unable to catalyze nucleotide exchange on Cdc42, suggesting that recognition of substrate and catalysis are two distinct events. Thus substrate recognition can now be added to the growing list of functions that are being attributed to the PH domain of Dbl family GEFs.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Lander Univ, Dept Biol, Greenwood, SC 29649 USA	Iowa State University	Norris, FA (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	anorris@lander.edu						Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Blomberg N, 1997, FOLD DES, V2, P343, DOI 10.1016/S1359-0278(97)00048-5; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Dinauer MC, 2003, CURR OPIN HEMATOL, V10, P8, DOI 10.1097/00062752-200301000-00003; Donald S, 2004, FEBS LETT, V572, P172, DOI 10.1016/j.febslet.2004.06.096; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schuebel KE, 1996, ONCOGENE, V13, P363; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	38	7	8	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27508	27512		10.1074/jbc.M412495200	http://dx.doi.org/10.1074/jbc.M412495200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15897194	hybrid			2022-12-25	WOS:000230678600006
J	Bosc, LVG; Layne, JJ; Nelson, MT; Hill-Eubanks, DC				Bosc, LVG; Layne, JJ; Nelson, MT; Hill-Eubanks, DC			Nuclear factor of activated T cells and serum response factor cooperatively regulate the activity of an alpha-actin intronic enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; DEPENDENT TRANSCRIPTIONAL PATHWAY; HEAVY-CHAIN GENE; CARDIAC-HYPERTROPHY; CYCLOSPORINE-A; CARG ELEMENTS; MARKER GENES; IN-VIVO; DIFFERENTIATION; EXPRESSION	Expression of alpha-actin in smooth muscle cells (SMCs) is regulated, in part, by an intronic serum response factor (SRF)-binding CArG element. We have identified a conserved nuclear factor of activated T cells ( NFAT) binding site that overlaps this CArG box and tested the hypothesis that this site plays a previously unrecognized role in regulating alpha-actin expression. A reporter construct prepared using a 56-bp region of the mouse alpha-actin first intron containing SRF, NFAT, and AP-1 sites ( SNAP) acted as an enhancer element in the context of a minimal thymidine kinase promoter. Basal reporter activity following expression in SMCs was robust and sensitive to the calcineurin-NFAT pathway inhibitors cyclosporin A and FK506. Mutating either the NFAT or SRF binding site essentially abolished reporter activity, suggesting that both NFAT and SRF binding are required. Basal activity in non-smooth muscle HEK293 cells was SRF-dependent but NFAT-independent and similar to 8-fold lower than that in SMCs. Activation of NFAT in HEK293 cells induced an similar to 4-fold increase in activity that was dependent on the integrity of both NFAT and SRF binding sites. NFATc3(.)SRF complex formation, demonstrated by co-immunoprecipitation, was facilitated by the presence of SNAP oligonucleotide. Inhibition of the calcineurin-NFAT pathway decreased alpha-actin expression in cultured SMCs, suggesting that the molecular interaction of NFAT and SRF at SNAP may be physiologically relevant. These data provide the first evidence that NFAT and SRF may interact to cooperatively regulate SMC-specific gene expression and support a role for NFAT in the phenotypic maintenance of smooth muscle.	Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Hill-Eubanks, DC (corresponding author), Univ Vermont, Coll Med, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.	David.Hill-Eubanks@uvm.edu		Nelson, Mark/0000-0002-6608-8784	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063722, R01HL044455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK065947, R01DK053832] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44455, HL63722] Funding Source: Medline; NIDDK NIH HHS [DDK065947, DDK53832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amberg GC, 2004, J BIOL CHEM, V279, P47326, DOI 10.1074/jbc.M408789200; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; GONZALEZ BLV, 2004, J BIOL CHEM, V279, P10702; Gorski DH, 2003, TRENDS CARDIOVAS MED, V13, P213, DOI 10.1016/S1050-1738(03)00081-1; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Manabe I, 2001, J BIOL CHEM, V276, P39076, DOI 10.1074/jbc.M105402200; Manabe I, 2001, J CLIN INVEST, V107, P823, DOI 10.1172/JCI11385; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NAKANO Y, 1991, GENE, V99, P285; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PAULETTO P, 1994, AM J HYPERTENS, V7, P661, DOI 10.1093/ajh/7.7.661; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; Schulz RA, 2004, DEV BIOL, V266, P1, DOI 10.1016/j.ydbio.2003.10.008; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wamhoff BR, 2004, CIRC RES, V95, P406, DOI 10.1161/01.RES.0000138582.36921.9e; Wilkins BJ, 2004, CIRC RES, V94, P110, DOI 10.1161/01.RES.0000109415.17511.18; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	52	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26113	26120		10.1074/jbc.M411972200	http://dx.doi.org/10.1074/jbc.M411972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15857835	hybrid			2022-12-25	WOS:000230386800023
J	Ozdemir, A; Spicuglia, S; Lasonder, E; Vermeulen, M; Campsteijn, C; Stunnenberg, HG; Logie, C				Ozdemir, A; Spicuglia, S; Lasonder, E; Vermeulen, M; Campsteijn, C; Stunnenberg, HG; Logie, C			Characterization of lysine 56 of histone H3 as an acetylation site in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE; YEAST; TRANSCRIPTION; H3; METHYLATION; COMPLEXES; CHROMATIN; DOMAIN; IDENTIFICATION; ASSOCIATION	Post-translational histone modifications abound and regulate multiple nuclear processes. Most modifications are targeted to the amino-terminal domains of histones. Here we report the identification and characterization of acetylation of lysine 56 within the core domain of histone H3. In the crystal structure of the nucleosome, lysine 56 contacts DNA. Phenotypic analysis suggests that lysine 56 is critical for histone function and that it modulates formamide resistance, ultraviolet radiation sensitivity, and sensitivity to hydroxyurea. We show that the acetylated form of histone H3 lysine 56 (H3-K56) is present during interphase, metaphase, and S phase. Finally, reverse genetic analysis indicates that none of the known histone acetyltransferases is solely responsible for H3-K56 acetylation in Saccharomyces cerevisiae.	Radboud Univ, NCMLS, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Logie, C (corresponding author), Radboud Univ, NCMLS, Dept Mol Biol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.logie@ncmls.ru.nl	Stunnenberg, Hendrik G./D-6875-2012; Spicuglia, Salvatore/L-2268-2016; Logie, Colin/A-1528-2010; Vermeulen, Michiel/C-8883-2013; Logie, Colin/L-9833-2019	Stunnenberg, Hendrik G./0000-0002-0066-1576; Spicuglia, Salvatore/0000-0002-8101-7108; Logie, Colin/0000-0002-8534-6582; Vermeulen, Michiel/0000-0003-0836-6894; Logie, Colin/0000-0002-8534-6582; Lasonder, Edwin/0000-0003-2582-3444				Ausubel FM, 2003, CURRENT PROTOCOLS MO; Duina AA, 2004, MOL CELL BIOL, V24, P561, DOI 10.1128/MCB.24.2.561-572.2004; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Foss EJ, 2001, GENETICS, V157, P567; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Ye JX, 2005, MOL CELL, V18, P123, DOI 10.1016/j.molcel.2005.02.031; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	22	97	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25949	25952		10.1074/jbc.C500181200	http://dx.doi.org/10.1074/jbc.C500181200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888442	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000230386800002
J	Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R				Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R			Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma	ONCOGENE			English	Article						osteosarcoma; pulmonary metastasis; paxillin; tyrosine phosphorylation; Src family kinase; motility	FOCAL ADHESION KINASE; CELL-MIGRATION; C-SRC; PULMONARY METASTASES; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CRK; BINDING; PROTEIN; ASSOCIATION	To acquire information on signal alteration corresponding to the changes in metastatic potential, we analysed protein tyrosine phosphorylation of low- and high-metastatic human osteosarcoma HuO9 sublines, which were recently established as the first metastatic model of human osteosarcoma. Tyrosine phosphorylation of proteins around 60, 70, and 120 - 130 kDa was enhanced in high-metastatic sublines. Among these proteins, the protein around 70kDa, which was most remarkably phosphorylated, was identified as paxillin, a scaffold protein in integrin signaling. Activity of Src family kinase correlated well with metastatic potential, and a Src family kinase inhibitor, PP2, not only abolished tyrosine phosphorylation of paxillin but also impaired the motility of high-metastatic sublines. The expression of paxillin was also elevated in high-metastatic sublines, and knocking down of paxillin expression by RNAi method resulted in attenuated motility of high-metastatic cells. We also demonstrated that the phosphorylated form of paxillin is essential for the migration-promoting effect in human osteosarcoma. These findings suggest that enhanced activity of Src family kinases and overexpression of paxillin synergistically contribute to the high metastatic potential of human osteosarcoma through the hyperphosphorylation of paxillin.	Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Natl Canc Ctr, Inst Res, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; University of Tokyo; National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; HUTH JF, 1989, ARCH SURG-CHICAGO, V124, P122; Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kimura K, 2002, CLIN EXP METASTAS, V19, P477, DOI 10.1023/A:1020395816633; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuchiya H, 2002, J CLIN ONCOL, V20, P3470, DOI 10.1200/JCO.2002.11.028; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	32	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4754	4764		10.1038/sj.onc.1208654	http://dx.doi.org/10.1038/sj.onc.1208654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870699				2022-12-25	WOS:000230477900002
J	Constantinou, C; Clemens, MJ				Constantinou, C; Clemens, MJ			Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53	ONCOGENE			English	Article						mTOR; p53; polypeptide chain initiation; protein phosphorylation; rapamycin	CYCLE-DEPENDENT PHOSPHORYLATION; MAMMALIAN TARGET; PHAS-I; TRANSCRIPTIONAL TARGET; (S/T)P SITES; S6 KINASE; RAPAMYCIN; CDC2; BINDING; ACTIVATION	Activation of a temperature-sensitive form of mouse p53 in murine erythroleukaemia cells rapidly inhibits protein synthesis and causes early dephosphorylation and cleavage of protein synthesis initiation factor eIF4GI and the eIF4E-binding protein 4E-BP1. Dephosphorylated 4E-BP1 and the cleaved products of 4E-BP1 and eIF4GI associate with eIF4E under these conditions, concomitant with decreased interaction of full-length eIF4GI with eIF4E. These changes may play an important role in preventing formation of the eIF4F complex and thus the initiation of protein synthesis. As observed previously for eIF4GI, the cleavage of 4E-BP1 is insensitive to the general caspase inhibitor z-VAD.FMK, consistent with a caspase-independent mechanism of factor modi. cation and regulation of protein synthesis. Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects. Moreover, p53 activation inhibits rapamycin-insensitive protein kinase activity against 4E-BP1.P53 and rapamycin have additive effects on the inhibition of overall protein synthesis. These data suggest that the inhibition of protein synthesis by p53 is largely independent of the regulation of rapamycin-sensitive mTOR in the system under investigation.	St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, London SW17 0RE, England	St Georges University London	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sghms.ac.uk						Ababneh M, 2001, BIOCHEM BIOPH RES CO, V283, P507, DOI 10.1006/bbrc.2001.4792; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Edinger AL, 2003, CANCER RES, V63, P8451; Ferguson G, 2003, J BIOL CHEM, V278, P47459, DOI 10.1074/jbc.M307949200; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; Marx SO, 1999, MOL CELL BIOL, V19, P6041; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Morley SJ, 1997, RNA, V3, P1085; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Park M, 2000, CANCER RES, V60, P542; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; POON RY, 2006, J BIOL CHEM, V271, P13283; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519	58	40	42	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4839	4850		10.1038/sj.onc.1208648	http://dx.doi.org/10.1038/sj.onc.1208648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897901				2022-12-25	WOS:000230477900011
J	Okabe, M; Yakushi, T; Homma, M				Okabe, M; Yakushi, T; Homma, M			Interactions of MotX with MotY and with the PomA/PomB sodium ion channel complex of the Vibrio alginolyticus polar flagellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED CHARGED RESIDUES; NA+-DRIVEN; ESCHERICHIA-COLI; MEMBRANE TOPOLOGY; CLONING VECTORS; OUTER-MEMBRANE; COMPONENT; PROTEIN; GENE; SEQUENCE	Rotation of the sodium ion-driven polar flagellum of Vibrio alginolyticus requires the inner membrane sodium ion channel complex PomA/PomB and the outer membrane components MotX and MotY. None of the detergents used in this study were able to solubilize MotX when it was expressed alone. However, when co-expressed with MotY, MotX was solubilized by some detergents. The change in the solubility of MotX suggests that MotY interacts with MotX. In agreement with this, a pull-down assay showed the association of MotY with MotX. Solubilized MotX and MotY eluted in the void volume from a gel-filtration column, suggesting that MotX and MotY form a large oligomeric structure(s). In the absence of MotY, MotX affected membrane localization of the PomA/PomB complex and of PomB alone but not of PomA alone, suggesting an interaction between MotX and PomB. We propose that MotX exhibits multiple interactions with the other motor components, first with MotY for its localization to the outer membrane and then with the PomA/PomB complex through PomB for the motor rotation.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University	Okabe, M (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	4juji@cc.nagoya-u.ac.jp						Asai Y, 2000, EMBO J, V19, P3639, DOI 10.1093/emboj/19.14.3639; Asai Y, 2003, J MOL BIOL, V327, P453, DOI 10.1016/S0022-2836(03)00096-2; Asai Y, 1997, J BACTERIOL, V179, P5104, DOI 10.1128/jb.179.16.5104-5110.1997; Asai Y, 1999, J BACTERIOL, V181, P6332, DOI 10.1128/JB.181.20.6332-6338.1999; ATSUMI T, 1992, NATURE, V355, P182, DOI 10.1038/355182a0; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BLAIR DF, 1990, CELL, V60, P439, DOI 10.1016/0092-8674(90)90595-6; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Braun TF, 2004, BIOCHEMISTRY-US, V43, P35, DOI 10.1021/bi035406d; CHUN SY, 1988, SCIENCE, V239, P276, DOI 10.1126/science.2447650; DEAN GE, 1984, J BACTERIOL, V159, P991, DOI 10.1128/JB.159.3.991-999.1984; DEMOT R, 1994, MOL MICROBIOL, V12, P333; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; Doyle TB, 2004, J BACTERIOL, V186, P6341, DOI 10.1128/JB.186.19.6341-6350.2004; Furuno M, 1999, MICROBIOL IMMUNOL, V43, P39, DOI 10.1111/j.1348-0421.1999.tb02370.x; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; KAWAGISHI I, 1995, J BACTERIOL, V177, P5158, DOI 10.1128/jb.177.17.5158-5160.1995; KAWAGISHI I, 1994, MICROBIOL-SGM, V140, P2355, DOI 10.1099/13500872-140-9-2355; Kojima S, 1999, J MOL BIOL, V285, P1537, DOI 10.1006/jmbi.1998.2377; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MCCARTER LL, 1994, J BACTERIOL, V176, P5988, DOI 10.1128/jb.176.19.5988-5998.1994; MCCARTER LL, 1994, J BACTERIOL, V176, P4219, DOI 10.1128/jb.176.14.4219-4225.1994; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Okabe M, 2002, MOL MICROBIOL, V46, P125, DOI 10.1046/j.1365-2958.2002.03142.x; Okabe M, 2001, J BIOCHEM, V130, P879, DOI 10.1093/oxfordjournals.jbchem.a003061; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato K, 2000, J BIOL CHEM, V275, P5718, DOI 10.1074/jbc.275.8.5718; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; STADER J, 1986, J BACTERIOL, V166, P244, DOI 10.1128/jb.166.1.244-252.1986; Stewart BJ, 2003, J BACTERIOL, V185, P4508, DOI 10.1128/JB.185.15.4508-4518.2003; STOLZ B, 1991, J BACTERIOL, V173, P7033, DOI 10.1128/jb.173.21.7033-7037.1991; Yakushi T, 2004, MICROBIOL-SGM, V150, P911, DOI 10.1099/mic.0.26577-0; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yorimitsu T, 2003, J MOL BIOL, V334, P567, DOI 10.1016/j.jmb.2003.09.052; Yorimitsu T, 1999, J BACTERIOL, V181, P5103, DOI 10.1128/JB.181.16.5103-5106.1999; Yorimitsu T, 2002, J MOL BIOL, V320, P403, DOI 10.1016/S0022-2836(02)00426-6; Yorimitsu T, 2001, BBA-BIOENERGETICS, V1505, P82, DOI 10.1016/S0005-2728(00)00279-6; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436; Zhou JD, 1998, J BACTERIOL, V180, P2729, DOI 10.1128/JB.180.10.2729-2735.1998	42	42	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25659	25664		10.1074/jbc.M500263200	http://dx.doi.org/10.1074/jbc.M500263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15866878	Green Submitted, hybrid			2022-12-25	WOS:000230207900046
J	Stapelberg, M; Gellert, N; Swettenham, E; Tomasetti, M; Witting, PK; Procopio, A; Neuzil, J				Stapelberg, M; Gellert, N; Swettenham, E; Tomasetti, M; Witting, PK; Procopio, A; Neuzil, J			alpha-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E SUCCINATE; BREAST-CANCER CELLS; SIGNAL-REGULATED KINASE; RESPONSE FACTOR-I; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; PROTECTS HEPATOCYTES; PROGNOSTIC-FACTORS; HYDROGEN-PEROXIDE; TUMOR PROGRESSION	We have studied the potential effect against human malignant mesotheliomas (MM) of alpha-tocopheryl succinate (alpha-TOS), a redox-silent vitamin E analog with strong pro-apoptotic and anti-cancer activity. alpha-TOS at sub-apoptotic levels inhibited proliferation of MM cell lines, while being nontoxic to nonmalignant mesothelial cells. Because MM cells are typified by a highly metastatic phenotype, we investigated the effect of alpha-TOS on genes playing a major role in MM progression. Of these, alpha-TOS down regulated fibroblast growth factor (FGF)-1 and, in particular, FGF-2 on the transcriptional level in MM cells, and this was not observed in their nonmalignant counterparts. FGF- 2 short interfering RNA suppressed proliferation of MM cells. Down-regulation of FGF-2 was likely because of inhibition of the egr-1 transcription activity that was decreased in MM cells via oxidative stress induced by alpha-TOS, as evidenced by EPR spectroscopy, whereas nonmalignant cells did not show this response. Treatment of MM cells with egr-1 short interfering RNA suppressed proliferation, which was overridden by exogenously added recombinant FGF- 1 and, in particular, FGF-2. An analog of coenzyme Q targeted to mitochondria and superoxide dismutase overrode inhibition of MM cell proliferation by alpha-TOS as well as alpha-TOS-induced inhibition of egr-1-dependent transactivation. Finally, alpha-TOS significantly suppressed experimental MM in immunocompromised mice. Our data suggest that alpha-TOS suppresses MM cell proliferation by disrupting the FGF- FGF receptor autocrine signaling loop by generating oxidative stress and point to the agent as a selective drug against thus far fatal mesotheliomas.	Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Heart Fdn Res Ctr, Southport, Qld 4216, Australia; Univ Sydney, ANZAC Inst, Concord Hosp, Concord, NSW 2139, Australia; Polytech Univ Marche, Dept Mol Pathol, I-60131 Ancona, Italy; Acad Sci Czech Republ, Lab Apoptosis & Cell Signalling, Inst Mol Genet, Prague 14220, Czech Republic	Griffith University; Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute; Marche Polytechnic University; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Neuzil, J (corresponding author), Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Heart Fdn Res Ctr, Gold Coast Campus, Southport, Qld 4216, Australia.	j.neuzil@griffith.edu.au	Ekanayake, Kanchana/P-8817-2016; Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019; Neuzil, Jiri/H-7204-2014; Procopio, Antonio Domenico/AAB-2451-2021; Research Institute, ANZAC/CAE-9030-2022	Witting, Paul/0000-0003-2237-7004; Neuzil, Jiri/0000-0002-2478-2460; Procopio, Antonio Domenico/0000-0001-6897-8724; 				Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; Baas P, 2003, CURR OPIN ONCOL, V15, P127, DOI 10.1097/00001622-200303000-00002; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; BERMUDEZ E, 1990, EXP CELL RES, V190, P91, DOI 10.1016/0014-4827(90)90148-4; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Billottet C, 2004, MOL BIOL CELL, V15, P4725, DOI 10.1091/mbc.E04-04-0336; Birringer M, 2003, BRIT J CANCER, V88, P1948, DOI 10.1038/sj.bjc.6600981; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Dalen H, 2003, BRIT J CANCER, V88, P153, DOI 10.1038/sj.bjc.6600683; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; FARISS MW, 1989, TOXICOL LETT, V47, P61, DOI 10.1016/0378-4274(89)90086-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Jin Y, 2000, MOL PHARMACOL, V57, P984; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kogure K, 2003, CANCER LETT, V192, P19, DOI 10.1016/S0304-3835(02)00683-3; Kogure K, 2002, CANCER LETT, V186, P151, DOI 10.1016/S0304-3835(02)00344-0; Kogure K, 2001, BBA-GEN SUBJECTS, V1528, P25, DOI 10.1016/S0304-4165(01)00168-4; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Malafa MP, 2002, ANN SURG ONCOL, V9, P1023, DOI 10.1245/ASO.2002.03.580; Malafa MP, 2002, SURGERY, V131, P85, DOI 10.1067/msy.2002.119191; Malafa MP, 2000, J SURG RES, V93, P163, DOI 10.1006/jsre.2000.5948; Marzo AL, 1997, CANCER RES, V57, P3200; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neuzil H, 2002, BIOCHEM BIOPH RES CO, V293, P1309, DOI 10.1016/S0006-291X(02)00358-3; Neuzil J, 2004, CURR CANCER DRUG TAR, V4, P355, DOI 10.2174/1568009043332943; Neuzil J, 2003, BRIT J CANCER, V89, P1822, DOI 10.1038/sj.bjc.6601360; Neuzil J, 2001, BIOCHEMISTRY-US, V40, P4686, DOI 10.1021/bi002498n; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; NI J, 2000, BIOCHEM BIOPH RES CO, V300, P357; Nose K, 1996, BIOCHEM J, V316, P381, DOI 10.1042/bj3160381; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Paron I, 2004, BIOCHEM J, V378, P929, DOI 10.1042/BJ20031190; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Polnaszek N, 2003, CANCER RES, V63, P5754; Qian M, 1997, ONCOGENE, V15, P223, DOI 10.1038/sj.onc.1201181; Roberg K, 1998, AM J PATHOL, V152, P1151; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Stapelberg M, 2004, BIOCHEM BIOPH RES CO, V318, P636, DOI 10.1016/j.bbrc.2004.04.072; Steele JPC, 2002, SEMIN ONCOL, V29, P36, DOI 10.1053/sonc.2002.30299; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Strizzi L, 2001, INT J ONCOL, V18, P1093; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Tirmenstein MA, 1999, FREE RADICAL BIO MED, V26, P825, DOI 10.1016/S0891-5849(98)00265-2; Tomasetti M, 2004, BRIT J CANCER, V90, P1644, DOI 10.1038/sj.bjc.6601707; Tomasetti M, 2004, INT J CANCER, V109, P641, DOI 10.1002/ijc.20062; Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673; TURLEY JM, 1995, CELL GROWTH DIFFER, V6, P655; Turley JM, 1997, CANCER RES, V57, P2668; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; WALKER C, 1995, CANCER RES, V55, P530; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Wang XF, 2005, BIOCHEM BIOPH RES CO, V326, P282, DOI 10.1016/j.bbrc.2004.11.028; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; You HH, 2002, MOL CARCINOGEN, V33, P228, DOI 10.1002/mc.10040; Yu WP, 2001, CANCER RES, V61, P6569; Zhang JG, 2001, CHEM-BIOL INTERACT, V138, P267, DOI 10.1016/S0009-2797(01)00278-2; Zhang LR, 1998, CANCER RES, V58, P352; Zhao BH, 1997, MOL CARCINOGEN, V19, P180, DOI 10.1002/(SICI)1098-2744(199707)19:3<180::AID-MC6>3.3.CO;2-O	73	97	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25369	25376		10.1074/jbc.M414498200	http://dx.doi.org/10.1074/jbc.M414498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878867	hybrid			2022-12-25	WOS:000230207900009
J	Yang, JS; Xi, J; Zhuang, ZH; Benkovic, SJ				Yang, JS; Xi, J; Zhuang, ZH; Benkovic, SJ			The oligomeric T4 primase is the functional form during replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE T7 PRIMASE; DNA-REPLICATION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PRIMER SYNTHESIS; GENE-41 PROTEIN; HELICASE GP41; STOICHIOMETRY; SEQUENCE; ARCHITECTURE	Replisome DNA primases are responsible for the synthesis of short RNA primers required for the initiation of repetitive Okazaki fragment synthesis on the lagging strand during DNA replication. In bacteriophage T4, the primase (gp61) interacts with the helicase (gp41) to form the primosome complex, an interaction that greatly stimulates the priming activity of gp61. Because gp41 is hexameric, a question arises as to whether gp61 also forms a hexameric structure during replication. Several results from this study support such a structure. Titration of the primase/single-stranded DNA binding followed by fluorescence anisotropy implicated a 6: 1 stoichiometry. The observed rate constant, k(cat), for priming was found to increase with the primase concentration, implicating an oligomeric form of the primase as the major functional species. The generation of hetero-oligomeric populations of the hexameric primase by controlled mixing of wild type and an inactive mutant primase confirmed the oligomeric nature of the most active primase form. Mutant primases defective in either the N- or C- terminal domains and catalytically inactive could be mixed to create oligomeric primases with restored catalytic activity suggesting an active site shared between subunits. Collectively, these results provide strong evidence for the functional oligomerization of gp61. The potential roles of gp61 oligomerization during lagging strand synthesis are discussed.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	sjb1@psu.edu			NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Jing DH, 1999, J BIOL CHEM, V274, P27287, DOI 10.1074/jbc.274.38.27287; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KKURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; Lee SJ, 2002, P NATL ACAD SCI USA, V99, P12703, DOI 10.1073/pnas.202471499; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; LIU CC, 1981, J BIOL CHEM, V256, P2813; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; MATHEWS CK, 1994, MOL BIOL BACTERIOPHA, P28; Mitkova AV, 2003, J BIOL CHEM, V278, P52253, DOI 10.1074/jbc.M308956200; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; NORUM MT, 2005, P NATL ACAD SCI USA, V102, P3623; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3, pC5; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Trakselis MA, 2003, J BIOL CHEM, V278, P49839, DOI 10.1074/jbc.M307405200; Urlacher TM, 1995, BIOCHEMISTRY-US, V34, P16708, DOI 10.1021/bi00051a020; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	42	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25416	25423		10.1074/jbc.M501847200	http://dx.doi.org/10.1074/jbc.M501847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15897200	hybrid			2022-12-25	WOS:000230207900016
J	Ferraro, P; Pontarin, G; Crocco, L; Fabris, S; Reichard, P; Bianchi, V				Ferraro, P; Pontarin, G; Crocco, L; Fabris, S; Reichard, P; Bianchi, V			Mitochondrial deoxynucleotide pools in quiescent fibroblasts - A possible model for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE 2; DNA DEPLETION; MOLECULAR-CLONING; MAMMALIAN-CELLS; GENE; PHOSPHORYLASE; TRIPHOSPHATE; CDNA; EXPRESSION; NUCLEAR	Mitochondrial (mt) DNA depletion syndromes can arise from genetic deficiencies for enzymes of dNTP metabolism, operating either inside or outside mitochondria. MNGIE is caused by the deficiency of cytosolic thymidine phosphorylase that degrades thymidine and deoxyuridine. The extracellular fluid of the patients contains 10-20 mu M deoxynucleosides leading to changes in dTTP that may disturb mtDNA replication. In earlier work, we suggested that mt dTTP originates from two distinct pathways: (i) the reduction of ribonucleotides in the cytosol ( in cycling cells) and (ii) intra-mt salvage of thymidine ( in quiescent cells). In MNGIE and most other mtDNA depletion syndromes, quiescent cells are affected. Here, we demonstrate in quiescent fibroblasts ( i) the existence of small mt dNTP pools, each usually 3 - 4% of the corresponding cytosolic pool; ( ii) the rapid metabolic equilibrium between mt and cytosolic pools; and (iii) the intra-mt synthesis and rapid turnover of dTTP in the absence of DNA replication. Between 0.1 and 10 mu M extracellular thymidine, intracellular thymidine rapidly approaches the extracellular concentration. We mimic the conditions of MNGIE by maintaining quiescent fibroblasts in 10 - 40 mu M thymidine and/or deoxyuridine. Despite a large increase in intracellular thymidine concentration, cytosolic and mt dTTP increase at most 4-fold, maintaining their concentration for 41 days. Other dNTPs are marginally affected. Deoxyuridine does not increase the normal dNTP pools but gives rise to a small dUTP and a large dUMP pool, both turning over rapidly. We discuss these results in relation to MNGIE.	Univ Padua, Dept Biol, I-35131 Padua, Italy	University of Padua	Bianchi, V (corresponding author), Univ Padua, Dept Biol, Via Trieste 75, I-35131 Padua, Italy.	vbianchi@mail.bio.unipd.it			Telethon [GP0140Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNER S, 1995, PHARMACOL THERAPEUT, V67, P155; Ashihara T, 1979, Methods Enzymol, V58, P248; Balzarini J, 2000, BIOCHEM J, V351, P167, DOI 10.1042/0264-6021:3510167; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BJURSELL G, 1973, J BIOL CHEM, V248, P3904; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; Brown NS, 1998, BIOCHEM J, V334, P1; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; GOULIAN M, 1980, J BIOL CHEM, V255, P630; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; KORNBERG A, 1992, DNA REPLICATION, P680; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Marti R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200; Rampazzo C, 2002, BIOCHEM BIOPH RES CO, V293, P258, DOI 10.1016/S0006-291X(02)00206-1; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192; Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471; Tinkelenberg BA, 2002, CANCER RES, V62, P4909; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2	38	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24472	24480		10.1074/jbc.M502869200	http://dx.doi.org/10.1074/jbc.M502869200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878850	hybrid			2022-12-25	WOS:000230114000023
J	Herman, PL; Behrens, M; Chakraborty, S; Chrastil, BM; Barycki, J; Weeks, DP				Herman, PL; Behrens, M; Chakraborty, S; Chrastil, BM; Barycki, J; Weeks, DP			A three-component dicamba O-demethylase from Pseudomonas maltophilia, strain DI-6 GENE ISOLATION, CHARACTERIZATION, AND HETEROLOGOUS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMONAS SP. RW1; DIOXIN DIOXYGENASE; HERBICIDE DICAMBA; ENZYME-SYSTEM; DEGRADATION; IRON; PURIFICATION; OXYGENASES; GENOME; OPERON	Dicamba O-demethylase is a multicomponent enzyme from Pseudomonas maltophilia, strain DI-6, that catalyzes the conversion of the widely used herbicide dicamba (2-methoxy-3,6-dichlorobenzoic acid) to DCSA ( 3,6-dichlorosalicylic acid). We recently described the biochemical characteristics of the three components of this enzyme ( i.e. reductase(DIC), ferredoxin(DIC), and oxygenase(DIC)) and classified the oxygenase component of dicamba O-demethylase as a member of the Rieske non-heme iron family of oxygenases. In the current study, we used N-terminal and internal amino acid sequence information from the purified proteins to clone the genes that encode dicamba O-demethylase. Two reductase genes (ddmA1 and ddmA2) with predicted amino acid sequences of 408 and 409 residues were identified. The open reading frames encode 43.7- and 43.9-kDa proteins that are 99.3% identical to each other and homologous to members of the FAD-dependent pyridine nucleotide reductase family. The ferredoxin coding sequence (ddmB) specifies an 11.4-kDa protein composed of 105 residues with similarity to the adrenodoxin family of [2Fe-2S] bacterial ferredoxins. The oxygenase gene (ddmC) encodes a 37.3-kDa protein composed of 339 amino acids that is homologous to members of the Phthalate family of Rieske non-heme iron oxygenases that function as monooxygenases. Southern analysis localized the oxygenase gene to a megaplasmid in cells of P. maltophilia. Mixtures of the three highly purified recombinant dicamba O-demethylase components overexpressed in Escherichia coli converted dicamba to DCSA with an efficiency similar to that of the native enzyme, suggesting that all of the components required for optimal enzymatic activity have been identified. Computer modeling suggests that oxygenaseDIC has strong similarities with the core alpha subunits of naphthalene 1,2-dioxygenase. Nonetheless, the present studies point to dicamba O-demethylase as an enzyme system with its own unique combination of characteristics.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Weeks, DP (corresponding author), Univ Nebraska, Dept Biochem, N158 Beadle Ctr, Lincoln, NE 68588 USA.	dweeks@unlnotes.unl.edu		Behrens, Mark/0000-0001-8230-120X				Armengaud J, 1998, J BACTERIOL, V180, P3954, DOI 10.1128/JB.180.15.3954-3966.1998; Armengaud J, 1997, EUR J BIOCHEM, V247, P833, DOI 10.1111/j.1432-1033.1997.00833.x; Armengaud J, 1998, EUR J BIOCHEM, V253, P437, DOI 10.1046/j.1432-1327.1998.2530437.x; Batie C. J., 1991, CHEM BIOCH FLAVOENZY, V3, P543; BUNZ PV, 1993, J BACTERIOL, V175, P6467; Butler CS, 1997, ADV MICROB PHYSIOL, V38, P47; Chakraborty S, 2005, ARCH BIOCHEM BIOPHYS, V437, P20, DOI 10.1016/j.abb.2005.02.024; CHAUDHRY GR, 1991, MICROBIOL REV, V55, P59, DOI 10.1128/MMBR.55.1.59-79.1991; CORK DJ, 1991, ADV APPL MICROBIOL, V36, P1; CORK DJ, 1995, ADV APPL MICROBIOL, V40, P289, DOI 10.1016/S0065-2164(08)70367-8; FOGARTY AM, 1995, J IND MICROBIOL, V14, P365, DOI 10.1007/BF01569952; Furukawa K, 2000, CURR OPIN BIOTECH, V11, P244, DOI 10.1016/S0958-1669(00)00091-4; Gibson DT, 2000, CURR OPIN BIOTECH, V11, P236, DOI 10.1016/S0958-1669(00)00090-2; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Junker F, 1997, J BACTERIOL, V179, P919, DOI 10.1128/jb.179.3.919-927.1997; Karlsson A, 2003, SCIENCE, V299, P1039, DOI 10.1126/science.1078020; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khalil A, 2000, MICROBIOS, V102, P183; KRUEGER JP, 1989, J AGR FOOD CHEM, V37, P534, DOI 10.1021/jf00086a057; KRUEGER JP, 1991, J AGR FOOD CHEM, V39, P995, DOI 10.1021/jf00005a039; NAKATSU CH, 1995, MICROBIOL-UK, V141, P485, DOI 10.1099/13500872-141-2-485; PETERSON JA, 1992, J BIOL CHEM, V267, P14193; Rosche B, 1997, J BACTERIOL, V179, P3549, DOI 10.1128/jb.179.11.3549-3554.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH AE, 1973, J AGR FOOD CHEM, V21, P708, DOI 10.1021/jf60188a050; SMITH AE, 1974, J AGR FOOD CHEM, V22, P601, DOI 10.1021/jf60194a009; TARABAN RH, 1993, APPL ENVIRON MICROB, V59, P2332, DOI 10.1128/AEM.59.7.2332-2334.1993; Timmis KN, 1999, TRENDS BIOTECHNOL, V17, P201, DOI 10.1016/S0167-7799(98)01295-5; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Wackett LP, 2002, ENZYME MICROB TECH, V31, P577, DOI 10.1016/S0141-0229(02)00129-1; Wang XZ, 1997, APPL ENVIRON MICROB, V63, P1623, DOI 10.1128/AEM.63.4.1623-1626.1997; Werlen C, 1996, J BIOL CHEM, V271, P4009; YANG J, 1994, ANAL BIOCHEM, V219, P37, DOI 10.1006/abio.1994.1228	35	83	130	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24759	24767		10.1074/jbc.M500597200	http://dx.doi.org/10.1074/jbc.M500597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855162	hybrid			2022-12-25	WOS:000230114000058
J	Roy, SK; Shuman, JD; Platanias, LC; Shapiro, PS; Reddy, SPM; Johnson, PF; Kalvakolanu, DV				Roy, SK; Shuman, JD; Platanias, LC; Shapiro, PS; Reddy, SPM; Johnson, PF; Kalvakolanu, DV			A role for mixed lineage kinases in regulating transcription factor CCAAT/enhancer-binding protein-beta-dependent gene expression in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-BETA; MAPK PATHWAYS; DNA-BINDING; IFN-GAMMA; PHOSPHORYLATION; ACTIVATION; NF-IL6; DOMAIN; ALPHA; CELLS	Transcription factor CCAAT/enhancer-binding protein-beta(C/EBP-beta) regulates a variety of cellular functions in response to exogenous stimuli. We have reported earlier that C/EBP-beta induces gene transcription through a novel interferon (IFN)- response element called gamma-IFN-activated transcriptional element. We show here that IFN-gamma-induced, C/EBP-beta/gamma-IFN-activated transcriptional element-dependent gene expression is regulated by mixed lineage kinases (MLKs), members of the mitogen-activated protein kinase kinase kinase family. MLK3 appears to activate C/EBP-beta in response to IFN-gamma by a mechanism involving decreased phosphorylation of a specific phosphoacceptor residue, Ser(64), within the transactivation domain. Decreased phosphorylation of Ser64 was independent of IFN-gamma-stimulated ERK1/2 activation and did not require the ERK phosphorylation site Thr(189) located in regulatory domain 2 of C/EBP-beta. Together these studies provide the first evidence that MLK3 is involved in IFN-gamma signaling and identify a novel mechanism of transcriptional activation by IFN-gamma.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA; NCI, Lab Prot Dynam & Signaling, NIH, Frederick, MD 21702 USA; Northwestern Univ, Sch Med, Robert Lurie Canc Ctr, Chicago, IL 60611 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, 665 W Baltimore St,9th Floor, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725; Shuman, Jon/0000-0001-8412-9087	NATIONAL CANCER INSTITUTE [R01CA078282, ZIABC010328, Z01BC010328, R29CA073381, R01CA105005, R01CA077816] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109, R01HL058122, R29HL058122] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005, CA73381, CA78282, CA77816] Funding Source: Medline; NHLBI NIH HHS [HL66109, HL58122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Akbarzadeh S, 2002, J BIOL CHEM, V277, P36280, DOI 10.1074/jbc.M204626200; Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chen XN, 1997, BLOOD, V90, P156; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heda GD, 1996, BLOOD, V87, P2831, DOI 10.1182/blood.V87.7.2831.bloodjournal8772831; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Kalvakolanu DV, 1999, TRENDS MICROBIOL, V7, P166, DOI 10.1016/S0966-842X(99)01476-6; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Morris AC, 2002, MOL CELL BIOL, V22, P4781, DOI 10.1128/MCB.22.13.4781-4791.2002; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; SmithSwintosky VL, 1996, EXP NEUROL, V141, P287, DOI 10.1006/exnr.1996.0163; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Williams BRG, 1997, BIOCHEM SOC T, V25, P509, DOI 10.1042/bst0250509; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	49	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24462	24471		10.1074/jbc.M413661200	http://dx.doi.org/10.1074/jbc.M413661200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878863	hybrid			2022-12-25	WOS:000230114000022
J	Todorov, VT; Volkl, S; Friedrich, R; Kunz-Schughart, LA; Hehlgans, T; Vermeulen, L; Haegeman, G; Schmitz, ML; Kurtz, A				Todorov, VT; Volkl, S; Friedrich, R; Kunz-Schughart, LA; Hehlgans, T; Vermeulen, L; Haegeman, G; Schmitz, ML; Kurtz, A			Role of CREB1 and NF kappa B-p65 in the down-regulation of renin gene expression by tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BINDING PROTEIN CREB; P65 SUBUNIT; TRANSCRIPTION FACTORS; DEPENDENT TRANSCRIPTION; SIGNAL-TRANSDUCTION; RESPONSIVE ELEMENT; ZETA-PKC; KINASE; CAMP	Tumor necrosis factor-alpha( TNF alpha) is a potent inhibitor of renin gene expression in renal juxtaglomerular cells. We have found that TNF alpha suppresses renin transcription via transcription factor NF kappa B, which targets a cAMP responsive element ( CRE) in the renin promoter. Here we aimed to further clarify the role of NF kappa B and the canonical CRE- binding proteins of the CRE- binding protein/ activating transcription factor ( CREB/ ATF) family in the inhibition of renin gene expression by TNF alpha in the juxtaglomerular cell line As4.1. TNF alpha caused a moderate decrease in the binding of CREB1 to its cognate CRE DNA binding site. On the other hand, NF kappa B- p65 transcriptional activity was substantially reduced by TNF alpha, which targeted a trans- activation domain at the very C terminus of the p65 molecule. Our results suggest that TNF alpha inhibits renin gene expression by decreasing the transactivating capacity of NF kappa B- p65 and partially by attenuating CREB1 binding to CRE.	Univ Regensburg, Inst Physiol, D-93040 Regensburg, Germany; Univ Regensburg, Inst Pathol, D-93040 Regensburg, Germany; Univ Regensburg, Dept Immunol, D-93040 Regensburg, Germany; Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Regensburg; University of Regensburg; University of Regensburg; Ghent University; University of Bern	Todorov, VT (corresponding author), Univ Regensburg, Inst Physiol, D-93040 Regensburg, Germany.	vladimir.todorov@vkl.uni-regensburg.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192; Todorov, Vladimir/0000-0002-7011-8130; Kunz-Schughart, Leoni/0000-0003-3912-6594; Volkl, Simon/0000-0003-2193-3048				Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Bader M, 2000, J MOL MED, V78, P130, DOI 10.1007/s001090000089; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dorffel Y, 1999, HYPERTENSION, V34, P113, DOI 10.1161/01.HYP.34.1.113; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Germain S, 1996, BIOCHEM J, V316, P107, DOI 10.1042/bj3160107; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Glenn CL, 2000, HUM MOL GENET, V9, P1943, DOI 10.1093/hmg/9.13.1943; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; Johns DG, 2001, J HYPERTENS, V19, P63, DOI 10.1097/00004872-200101000-00009; Kapadia SR, 1997, CIRC RES, V81, P187, DOI 10.1161/01.RES.81.2.187; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Klar J, 2002, PFLUG ARCH EUR J PHY, V444, P335, DOI 10.1007/s00424-002-0818-9; LALLI E, 1994, J BIOL CHEM, V269, P17359; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Liu XB, 2003, CIRC RES, V92, P1033, DOI 10.1161/01.RES.0000071355.82009.43; Muller MWH, 2002, PFLUG ARCH EUR J PHY, V444, P499, DOI 10.1007/s00424-002-0835-8; Pan L, 2003, BBA-GENE STRUCT EXPR, V1625, P280, DOI 10.1016/S0167-4781(03)00016-2; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shen Z, 2002, BIOTECHNIQUES, V32, P1168, DOI 10.2144/02325dd07; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; Shi Q, 2001, HYPERTENSION, V38, P332, DOI 10.1161/01.HYP.38.3.332; Shi Q, 2001, J BIOL CHEM, V276, P3597, DOI 10.1074/jbc.M008361200; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tamura K, 2000, P NATL ACAD SCI USA, V97, P8513, DOI 10.1073/pnas.100519097; Taugner R, 1984, Contrib Nephrol, V43, P76; Todorov V, 2002, AM J PHYSIOL-REG I, V283, pR1046, DOI 10.1152/ajpregu.00142.2002; Todorov V, 2001, KIDNEY BLOOD PRESS R, V24, P75, DOI 10.1159/000054210; Todorov VT, 2004, J BIOL CHEM, V279, P1458, DOI 10.1074/jbc.M308697200; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wagner C, 1998, CURR OPIN NEPHROL HY, V7, P437, DOI 10.1097/00041552-199807000-00015; Wagner C, 1998, KIDNEY INT, V54, P78; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Ying LH, 1997, J BIOL CHEM, V272, P2412; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	55	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24356	24362		10.1074/jbc.M502968200	http://dx.doi.org/10.1074/jbc.M502968200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15857826	hybrid			2022-12-25	WOS:000230114000009
J	Fiume, R; Faenza, I; Matteucci, A; Astolfi, A; Vitale, M; Martelli, AM; Cocco, L				Fiume, R; Faenza, I; Matteucci, A; Astolfi, A; Vitale, M; Martelli, AM; Cocco, L			Nuclear phospholipase C beta 1 (PLC beta 1) affects CD24 expression in murine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ANTIGEN; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC MARKER; P-SELECTIN; C-BETA; CANCER; LOCALIZATION; GENE; IDENTIFICATION; PROGRESSION	Inositide-specific phospholipase C ( PLC) beta 1 is a key enzyme in nuclear lipid signal transduction affecting cell cycle progression and may be directly involved in regulation of gene expression and hematopoiesis. By microarrays, we compared the effect of nuclear PLC beta 1 overexpression with that of PLC M2b cytoplasmatic mutant, which is exclusively located in the cytoplasm, in murine erythroleukemia cells. Out of 9000 genes analyzed, the CD24 gene, coding for an antigen involved in differentiation and hematopoiesis as well, was up-regulated in cells overexpressing nuclear PLC beta 1 as compared with both cells overexpressing the M2b cytoplasmatic mutant and the wild type cells. Here we show that nuclear PLC beta 1 up-regulated the expression of CD24. The correlation was strengthened by the observation that when PLC beta 1 expression was silenced by means of small interfering RNA, CD24 expression was down-regulated. We also demonstrated that PLC beta 1-dependent up-modulation of CD24 was mediated, at least in part, at the transcriptional level, in that PLC beta 1 affected the CD24 promoter activity. Moreover, the up-regulation of CD24 was higher during erythroid differentiation of murine erythroleukemia cells. Altogether our findings, obtained by combining microarrays, phenotypic analysis, and small interfering RNA technology, identify CD24 as an molecular effector of nuclear PLC beta 1 signaling pathway in murine erythroleukemia cells and strengthen the contention that nuclear PLC beta 1 constitutes a key step in erythroid differentiation in vitro.	Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, I-40126 Bologna, Italy; Univ Bologna, Sch Pharm, I-40126 Bologna, Italy; CNR, ITOI, Unit Bologna, IOR, I-40136 Bologna, Italy; Univ Bologna, Dept Expt Pathol, Canc Res Sect, I-40126 Bologna, Italy; Univ Parma, Human Anat Sect, Dept Anat Pharmacol & Forens Med, I-43100 Parma, Italy	University of Bologna; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); University of Bologna; University of Parma	Cocco, L (corresponding author), Univ Bologna, Dept Anat Sci, Cellular Signaling Lab, Via Irnerio 48, I-40126 Bologna, Italy.	lcocco@biocfarm.unibo.it	Astolfi, Annalisa/K-3034-2016; Vitale, Marco/O-8751-2015; Cocco, Lucio/AAI-2206-2020	Astolfi, Annalisa/0000-0002-2732-0747; Vitale, Marco/0000-0002-3261-6868; Cocco, Lucio/0000-0002-9206-8277; FIUME, ROBERTA/0000-0001-7757-4000				Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ALTEVOGT P, 1994, EUR J IMMUNOL, V24, P731, DOI 10.1002/eji.1830240336; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Belov L, 2001, CANCER RES, V61, P4483; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Cocco L, 2003, ADV ENZYME REGUL, V43, P1, DOI 10.1016/S0065-2571(02)00025-0; DePrimo SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-3; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Faenza I, 2002, BBA-MOL CELL RES, V1589, P305, DOI 10.1016/S0167-4889(02)00192-1; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Friederichs J, 2000, CANCER RES, V60, P6714; Hough MR, 1996, J IMMUNOL, V156, P479; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; KADMON G, 1992, J CELL BIOL, V118, P1245, DOI 10.1083/jcb.118.5.1245; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002-9440(10)64398-2; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; Lo Vasco VR, 2004, LEUKEMIA, V18, P1122, DOI 10.1038/sj.leu.2403368; Martelli AM, 2004, PHARMACOL THERAPEUT, V101, P47, DOI 10.1016/j.pharmthera.2003.10.003; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Osborne SL, 2001, J CELL SCI, V114, P2501; Pass MK, 1998, INT J CANCER, V78, P496, DOI 10.1002/(SICI)1097-0215(19981109)78:4<496::AID-IJC17>3.0.CO;2-4; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; Seeds AM, 2004, J BIOL CHEM, V279, P47222, DOI 10.1074/jbc.M408295200; Strassheim D, 2000, CANCER RES, V60, P2730; Valet G, 2003, CYTOM PART B-CLIN CY, V53B, P4, DOI 10.1002/cyto.b.10028; WENGER RH, 1991, EUR J IMMUNOL, V21, P1039, DOI 10.1002/eji.1830210427; WENGER RH, 1993, J BIOL CHEM, V268, P23345; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X; Zhou QM, 2003, P NATL ACAD SCI USA, V100, P15041, DOI 10.1073/pnas.2533866100	33	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24221	24226		10.1074/jbc.M411833200	http://dx.doi.org/10.1074/jbc.M411833200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849202	hybrid			2022-12-25	WOS:000229880000098
J	Yi, HQ; Gruszczynska-Biegala, J; Wood, D; Zhao, ZF; Zolkiewska, A				Yi, HQ; Gruszczynska-Biegala, J; Wood, D; Zhao, ZF; Zolkiewska, A			Cooperation of the metalloprotease, disintegrin, and cysteine-rich domains of ADAM12 during inhibition of myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASES; 12 MELTRIN ALPHA; CELL-ADHESION; CRYSTAL-STRUCTURE; RESERVE-CELLS; INTEGRIN ALPHA(5)BETA(1); ALPHA-V-BETA-3 INTEGRIN; CATALYTIC DOMAIN; MYOBLAST FUSION; DOWN-REGULATION	The extracellular domain of the mature form of ADAM12 consists of the metalloprotease, disintegrin, cysteine-rich, and epidermal growth factor (EGF)-like domains. The disintegrin, cysteine-rich, and EGF-like fragments have been shown previously to support cell adhesion via activated integrins or proteoglycans. In this study, we report that the entire extracellular domain of mouse ADAM12 produced in Drosophila S2 cells supported efficient adhesion and spreading of C2C12 myoblasts even in the absence of exogenous integrin activators. This adhesion was not mediated by beta(1) integrins or proteoglycans, was myoblast-specific, and required the presence of both the metalloprotease and disintegrin/cysteine-rich domains of ADAM12. Analysis of the recombinant proteins by far-UV circular dichroism suggested that the secondary structures of the autonomously expressed metalloprotease domain and the disintegrin/ cysteine-rich/EGF-like domains differ from the structures present in the intact extracellular domain. Furthermore, the intact extracellular domain ( but not the metalloprotease domain or the disintegrin/ cysteine-rich/ EGF-like fragment alone) decreased the expression of the cell cycle inhibitor p21 and myogenin, two markers of differentiation, and inhibited C2C12 myoblast fusion. Thus, the novel protein-protein interaction reported here involving the extracellular domain of ADAM12 may have important biological consequences during myoblast differentiation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA.	zolkiea@ksu.edu	Gruszczynska-Biegala, Joanna/U-4945-2019	Gruszczynska-Biegala, Joanna/0000-0003-3541-2550; Yi, Haiqing/0000-0003-2254-6226	NCRR NIH HHS [P20 RR017708, P20 RR17708, P20 RR017708-030010] Funding Source: Medline; NIGMS NIH HHS [R01 GM065528-01A2, R01 GM065528-02, R01 GM065528, R01 GM065528-03, R01 GM065528-04, GM065528] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065528] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bax DV, 2004, J BIOL CHEM, V279, P22377, DOI 10.1074/jbc.M400180200; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6; Blaschuk KL, 1997, DEV BIOL, V184, P266, DOI 10.1006/dbio.1997.8527; Bode W, 1996, ADV EXP MED BIOL, V389, P1; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Bridges LC, 2005, BIOCHEM J, V387, P101, DOI 10.1042/BJ20041444; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Calvete JJ, 2003, BIOCHEM J, V372, P725, DOI 10.1042/BJ20021739; Calvete JJ, 2000, PROTEIN SCI, V9, P1365, DOI 10.1110/ps.9.7.1365; Cao Y, 2003, MOL CELL BIOL, V23, P6725, DOI 10.1128/MCB.23.19.6725-6738.2003; Carnac G, 2000, CURR BIOL, V10, P543, DOI 10.1016/S0960-9822(00)00471-1; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jia LG, 1996, TOXICON, V34, P1269, DOI 10.1016/S0041-0101(96)00108-0; Jia LG, 2000, ARCH BIOCHEM BIOPHYS, V373, P281, DOI 10.1006/abbi.1999.1517; JOHNSON WC, 1990, PROTEIN-STRUCT FUNCT, V7, P214; Kamiguti AS, 2003, FEBS LETT, V549, P129, DOI 10.1016/S0014-5793(03)00799-3; Kronqvist P, 2002, AM J PATHOL, V161, P1535, DOI 10.1016/S0002-9440(10)64431-8; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Ly DP, 2003, J BIOL CHEM, V278, P21878, DOI 10.1074/jbc.M212538200; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Moghadaszadeh B, 2003, HUM MOL GENET, V12, P2467, DOI 10.1093/hmg/ddg264; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Orth P, 2004, J MOL BIOL, V335, P129, DOI 10.1016/j.jmb.2003.10.037; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Steele DL, 2000, PROTEIN ENG, V13, P397, DOI 10.1093/protein/13.6.397; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Tomczuk M, 2003, EXP CELL RES, V290, P68, DOI 10.1016/S0014-4827(03)00307-0; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yoshida N, 1998, J CELL SCI, V111, P769; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhao ZF, 2004, EXP CELL RES, V298, P28, DOI 10.1016/j.yexcr.2004.04.005	55	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23475	23483		10.1074/jbc.M413550200	http://dx.doi.org/10.1074/jbc.M413550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849365	Green Accepted, hybrid			2022-12-25	WOS:000229880000010
J	Brady, KL; Ponnampalam, SN; Bumbulis, MJ; Setzer, DR				Brady, KL; Ponnampalam, SN; Bumbulis, MJ; Setzer, DR			Mutations in TFIIIA that increase stability of the TFIIIA-5 S rRNA gene complex - Unusual effects on the kinetics of complex assembly and dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; PROTEIN-DNA COMPLEX; ZINC-FINGER; CRYSTAL-STRUCTURE; 5S RNA; RECOGNITION; SEQUENCE; BINDING; EQUILIBRIUM; INHIBITION	We have identified four mutations in Xenopus TFIIIA that increase the stability of TFIIIA-5 S rRNA gene complexes. In each case, the mutation has a relatively modest effect on equilibrium binding affinity. In three cases, these equilibrium binding effects can be ascribed primarily to decreases in the rate constant for protein-DNA complex dissociation. In the fourth case, however, a substitution of phenylalanine for the wild-type leucine at position 148 in TFIIIA results in much larger compensating changes in the kinetics of complex assembly and dissociation. The data support a model in which a relatively unstable population of complexes with multi-component dissociation kinetics forms rapidly; complexes then undergo a slow conformational change that results in very stable, kinetically homogeneous TFIIIA-DNA complexes. The L148F mutant protein acts as a particularly potent transcriptional activator when it is fused to the VP16 activation domain and expressed in yeast cells. Substitution of L148 to tyrosine or tryptophan produces an equally strong transcriptional activator. Substitution to histidine results in genetic and biochemical effects that are more modest than, but similar to, those observed with the L148F mutation. We propose that an amino acid with a planar side chain at position 148 can intercalate between adjacent base pairs in the intermediate element of the 5 S rRNA gene. Intercalation occurs slowly but results in a very stable DNA-protein complex. These results suggest that transcriptional activation by a cis-acting sequence element is largely dependent on the kinetic, rather than the thermodynamic, stability of the complex formed with an activator protein. Thus, transcriptional activation is dependent in large part on the lifetime of the activator-DNA complex rather than on binding site occupancy at steady state. Introduction of intercalating amino acids into zinc finger proteins may be a useful tool for producing artificial transcription factors with particularly high in vivo activity.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of Missouri System; University of Missouri Columbia; Case Western Reserve University	Setzer, DR (corresponding author), Univ Missouri, Div Biol Sci, 410 Tucker Hall, Columbia, MO 65211 USA.	setzerd@missouri.edu			NIGMS NIH HHS [GM48035] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Bumbulis MJ, 1998, J MOL BIOL, V284, P1307, DOI 10.1006/jmbi.1998.2285; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Hamilton TB, 2001, BIOCHEMISTRY-US, V40, P6093, DOI 10.1021/bi0025215; HANAS JS, 1992, PROG NUCLEIC ACID RE, V43, P205, DOI 10.1016/S0079-6603(08)61048-X; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Kehres DG, 1997, J BIOL CHEM, V272, P20152, DOI 10.1074/jbc.272.32.20152; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lu D, 2003, NATURE, V426, P96, DOI 10.1038/nature02088; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Papworth M, 2003, P NATL ACAD SCI USA, V100, P1621, DOI 10.1073/pnas.252773399; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; Schulman DB, 2002, NUCLEIC ACIDS RES, V30, P2772, DOI 10.1093/nar/gkf385; Setzer DA, 1999, METH MOL B, V118, P115; Setzer DR, 1996, RNA, V2, P1254; Setzer DR, 2000, METH MOL B, V148, P431; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolfe SA, 2003, BIOCHEMISTRY-US, V42, P13401, DOI 10.1021/bi034830b; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291	33	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26743	26750		10.1074/jbc.M502677200	http://dx.doi.org/10.1074/jbc.M502677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15888446	hybrid			2022-12-25	WOS:000230589500015
J	Mohamed, HA; Yao, WZ; Fioravante, D; Smolen, PD; Byrne, JH				Mohamed, HA; Yao, WZ; Fioravante, D; Smolen, PD; Byrne, JH			cAMP-response elements in Aplysia creb1, creb2, and Ap-uch promoters - Implications for feedback loops modulating long term memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SYNAPTIC PLASTICITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MOLECULAR-BIOLOGY; SENSORY NEURONS; C-FOS; FACILITATION; CONSOLIDATION; STORAGE	The Aplysia genes encoding for cAMP-response element-binding protein 1 (CREB1), CREB2, and ubiquitin C-terminal hydrolase (Ap-uch) have been implicated in the formation of long term memory. However, nothing is known about the promoter regions of these genes or the transcription factors that regulate them. We cloned the promoter regions of creb1, creb2, and Ap-uch and identified a canonical cAMP-response element (CRE) in the promoter region of creb1. Variants of the canonical CRE were identified in all three promoters. TATA boxes and C/EBP-binding motifs are also present in the promoter regions of these genes. Promoter immunoprecipitation assays and chromatin immunoprecipitation assays indicated that CREB1 and CREB2 bind to the promoter regions of creb1 and creb2, suggesting that feedback loops modulate the formation of long term memory. In a positive feedback loop, phosphorylated CREB1 might induce its own gene via CREs. In support of this suggestion, treatment with serotonin enhanced binding of CREB1 to its promoter region and increased mRNA levels of creb1. Levels of Ap-uch mRNA also increased in response to serotonin; however, binding of CREB1 or CREB2 to the promoter region of Ap-uch was not detected. The finding that the promoter region of creb2 has a CRE raises the intriguing possibility that its expression is regulated by CREB1 and/or CREB2. CREB2 may repress its own gene, forming a negative feedback loop, and CREB2 up-regulation via CREB1 may limit the activity of the CREB1-mediated positive feedback loop.	Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, Houston, TX 77030 USA	University of Texas System	Byrne, JH (corresponding author), Univ Texas, Sch Med, WM Keck Ctr Neurobiol Learning & Memory, Dept Neurobiol & Anat, POB 20708, Houston, TX 77030 USA.	John.H.Byrne@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019895] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19895] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Barth AL, 2000, J NEUROSCI, V20, P4206; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Bozon B, 2003, PHILOS T R SOC B, V358, P805, DOI 10.1098/rstb.2002.1224; Byrne JH, 1996, J NEUROSCI, V16, P425; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chain DG, 1999, NEURON, V22, P147, DOI 10.1016/S0896-6273(00)80686-8; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Cleary LJ, 1998, J NEUROSCI, V18, P5988; COLE TJ, 1992, GENOMICS, V13, P974, DOI 10.1016/0888-7543(92)90010-P; Craig JC, 2001, J BIOL CHEM, V276, P11719, DOI 10.1074/jbc.M010263200; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; Dash PK, 1996, MOL BRAIN RES, V39, P43, DOI 10.1016/0169-328X(95)00350-2; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; Fleischmann A, 2003, J NEUROSCI, V23, P9116; FOULKES NS, 2002, EUKARYOTIC GENE TRAN, P59; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; Gilchrist Cindy A., 1996, Journal of Biomedical Science, V3, P293, DOI 10.1007/BF02257959; Guan ZH, 2003, J NEUROSCI, V23, P7317; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819; Lamprecht R, 1997, J NEUROSCI, V17, P8443; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mauelshagen J, 1998, LEARN MEMORY, V5, P246; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Patterson SL, 2001, NEURON, V32, P123, DOI 10.1016/S0896-6273(01)00443-3; Pettigrew DB, 2005, J COMPUT NEUROSCI, V18, P163, DOI 10.1007/s10827-005-6557-0; Phares GA, 2003, J NEUROSCI, V23, P8392; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smolen P, 2000, NEURON, V26, P567, DOI 10.1016/S0896-6273(00)81194-0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Wall SM, 2003, AM J PHYSIOL-RENAL, V284, pF229, DOI 10.1152/ajprenal.00147.2002; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Winnepenninckx B, 1998, MOL PHYLOGENET EVOL, V9, P55, DOI 10.1006/mpev.1997.0439; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; Yin LL, 2002, REPROD FERT DEVELOP, V14, P185, DOI 10.1071/RD01028; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318; Zhao YL, 2003, CURR BIOL, V13, P887, DOI 10.1016/S0960-9822(03)00332-4	66	56	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27035	27043		10.1074/jbc.M502541200	http://dx.doi.org/10.1074/jbc.M502541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15888447	hybrid			2022-12-25	WOS:000230589500049
J	Gorovoy, M; Niu, JX; Bernard, O; Profirovic, J; Minshall, R; Neamu, R; Voyno-Yasenetskaya, T				Gorovoy, M; Niu, JX; Bernard, O; Profirovic, J; Minshall, R; Neamu, R; Voyno-Yasenetskaya, T			LIM kinase 1 coordinates microtubule stability and actin polymerization in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-KINASE 1; DEPOLYMERIZING FACTOR; PROTEIN-INTERACTION; RHO-GTPASES; PHOSPHORYLATION; DYNAMICS; DOMAINS; COFILIN; IDENTIFICATION; ORGANIZATION	Microtubule (MT) destabilization promotes the formation of actin stress fibers and enhances the contractility of cells; however, the mechanism involved in the coordinated regulation of MTs and the actin cytoskeleton is poorly understood. LIM kinase 1 (LIMK1) regulates actin polymerization by phosphorylating the actin depolymerization factor, cofilin. Here we report that LIMK1 is also involved in the MT destabilization. In endothelial cells endogenous LIMK1 co-localizes with MTs and forms a complex with tubulin via the PDZ domain. MT destabilization induced by thrombin or nocodazole resulted in a decrease of LIMK1 colocalization with MTs. Overexpression of wild type LIMK1 resulted in MT destabilization, whereas the kinase-dead mutant of LIMK1 (KD) did not affect MT stability. Importantly, down-regulation of endogenous LIMK1 by small interference RNA resulted in abrogation of the thrombin-induced MTs destabilization and the inhibition of thrombin-induced actin polymerization. Expression of Rho kinase 2, which phosphorylates and activates LIMK1, dramatically decreases the interaction of LIMK1 with tubulin but increases its interaction with actin. Interestingly, expression of KD-LIMK1 or small interference RNA-LIMK1 prevents thrombin-induced microtubule destabilization and F-actin formation, suggesting that LIMK1 activity is required for thrombin-induced modulation of microtubule destabilization and actin polymerization. Our findings indicate that LIMK1 may coordinate microtubules and actin cytoskeleton.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA; Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, Melbourne, Vic 3050, Australia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Walter & Eliza Hall Institute	Voyno-Yasenetskaya, T (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu	Bernard, Olivier/J-1133-2014; voyno-yasenetskaya, tatyana/A-3171-2008	Bernard, Olivier/0000-0003-2539-9014; 	NHLBI NIH HHS [R01 HL074948-01A1, HL06078] Funding Source: Medline; NIGMS NIH HHS [R01 GM065160-01A1, GM65160, R01 GM056159-01A2, R55 GM056159, R01 GM065160, R01 GM056159, GM56159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065160, R01GM056159, R55GM056159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Birukova AA, 2004, FASEB J, V18, P1879, DOI 10.1096/fj.04-2328com; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; DANOWSKI BA, 1989, J CELL SCI, V93, P255; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris BZ, 2001, J CELL SCI, V114, P3219; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lee TYJ, 2003, MICROSC RES TECHNIQ, V60, P115, DOI 10.1002/jemt.10250; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Preissner KT, 2000, J PATHOL, V190, P360; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Retaux S, 2002, MOL NEUROBIOL, V26, P269, DOI 10.1385/MN:26:2-3:269; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wittmann T, 2001, J CELL SCI, V114, P3795; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	39	102	109	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26533	26542		10.1074/jbc.M502921200	http://dx.doi.org/10.1074/jbc.M502921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15897190	Green Accepted, hybrid			2022-12-25	WOS:000230386800070
J	Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ				Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ			Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells	ONCOGENE			English	Article						PTTG; thyroid cancer; ISSR-PCR; genetic instability	IN-SITU HYBRIDIZATION; GENOMIC INSTABILITY; CAUSES ANEUPLOIDY; HUMAN SECURIN; FISSR-PCR; EXPRESSION; CANCER; PAPILLARY; GROWTH; HPTTG	Cancer reflects the progressive accumulation of genetic alterations and subsequent genetic instability of cells. Cytogenetic studies have demonstrated the importance of aneuploidy in differentiated thyroid cancer development. The pituitary tumour transforming gene (PTTG), also known as securin, is a mitotic checkpoint protein which inhibits sister chromatid separation during mitosis. PTTG is highly expressed in many cancers and overexpression of PTTG induces aneuploidy in vitro. Using fluorescent intersimple sequence repeat PCR (FISSR-PCR), we investigated the relationship between PTTG expression and the degree of genetic instability in normal and tumorous thyroid samples. The genomic instability index (GI index) was 6.7 - 72.7% higher in cancers than normal thyroid tissues. Follicular thyroid tumours exhibited greater genetic instability than papillary tumours (27.6% (n =9) versus 14.5% (n = 10), P = 0.03). We also demonstrated a strong relationship between PTTG expression and the degree of genetic instability in thyroid cancers (R-2 = 0.80, P = 0.007). To further investigate PTTG's role in genetic instability, we transfected FTC133 thyroid follicular cells and observed increased genetic instability in cells overexpressing PTTG compared with vector-only-transfected controls (n = 3, GI Index VO = 29.7 +/- 5.2 versus PTTG = 63.7 +/- 6.4, P = 0.013). Further, we observed a dose response in genetic instability and PTTG expression ( GI Index low dose (0.5 mu g DNA/ six-well plate) PTTG = 15.3% +/- 1.7 versus high dose (3 mu g DNA) PTTG = 50.8% +/- 3.3, P = 0.006). Overall, we describe the first use of FISSR-PCR in human cancers, and demonstrate that PTTG expression correlates with genetic instability in vivo, and induces genetic instability in vitro. We conclude that PTTG may be an important gene in the mutator phenotype development in thyroid cancer.	Univ Birmingham, Div Med Sci, Birmingham B12 5TT, W Midlands, England	University of Birmingham	Kim, D (corresponding author), Univ Birmingham, Div Med Sci, 2nd Floor IBR, Birmingham B12 5TT, W Midlands, England.	daekim72@yahoo.co.uk						Barril N, 2000, CANCER GENET CYTOGEN, V117, P50, DOI 10.1016/S0165-4608(99)00143-0; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dobosz T, 2000, ONCOLOGY-BASEL, V58, P305, DOI 10.1159/000012117; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Kumar LD, 2001, FORENSIC SCI INT, V116, P63, DOI 10.1016/S0379-0738(00)00350-9; LOEB LA, 1991, CANCER RES, V51, P3075; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Mu YM, 2003, ENDOCR J, V50, P771, DOI 10.1507/endocrj.50.771; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Nagaraju J, 2002, MOL CELL PROBE, V16, P67, DOI 10.1006/mcpr.2001.0404; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 2002, ONCOGENE, V21, P8173, DOI 10.1038/sj.onc.1205954; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Stoler DL, 2002, HEAD NECK-J SCI SPEC, V24, P290, DOI 10.1002/hed.10050; TARUSCIO D, 1994, GENE CHROMOSOME CANC, V9, P180, DOI 10.1002/gcc.2870090306; Viswanathan M, 2003, CLIN CANCER RES, V9, P1057; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P825, DOI 10.1002/hed.10292; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	33	58	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4861	4866		10.1038/sj.onc.1208659	http://dx.doi.org/10.1038/sj.onc.1208659			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897900				2022-12-25	WOS:000230477900013
J	Heine, M; Cramm-Behrens, CI; Ansari, A; Chu, HP; Ryazanov, AG; Naim, HY; Jacob, R				Heine, M; Cramm-Behrens, CI; Ansari, A; Chu, HP; Ryazanov, AG; Naim, HY; Jacob, R			alpha-kinase 1, a new component in apical protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; ELONGATION FACTOR-2 KINASE; GPI-ANCHORED PROTEINS; CANINE KIDNEY-CELLS; BORDER MYOSIN-I; MDCK CELLS; INTRACELLULAR-TRANSPORT; CYTOPLASMIC DOMAIN; ACTIN-FILAMENTS	A key aspect in the structure of epithelial cells is the maintenance of a polarized organization based on a highly specific sorting machinery for cargo destined for the apical or the basolateral membrane domain at the exit site of the trans-Golgi network. We could recently identify two distinct post-trans-Golgi network vesicle populations that travel along separate routes to the plasma membrane, a lipid raft-dependent and a lipid raft-independent pathway. A new component of raft-carrying apical vesicles is alpha-kinase 1 (ALPK1), which was identified in immunoisolated vesicles carrying raft-associated sucrase-isomaltase ( SI). This kinase was absent from vesicles carrying raft-non-associated lactasephlorizin hydrolase. The expression of ALPK1 increases by the time of epithelial cell differentiation, whereas the intracellular localization of ALPK1 on apical transport vesicles was confirmed by confocal analysis. A phosphorylation assay on isolated SI-carrying vesicles revealed the phosphorylation of a protein band of about 105 kDa, which could be identified as the motor protein myosin I. Finally, a specific reduction of ALPK1-expression by RNA interference results in a significant decrease in the apical delivery of SI. Taken together, our data suggest that the phosphorylation of myosin I by ALPK1 is an essential process in the apical trafficking of raft-associated SI.	Univ Marburg, Dept Cell Biol & Cell Pathol, D-35033 Marburg, Germany; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany	Philipps University Marburg; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Veterinary Medicine Hannover, Foundation	Jacob, R (corresponding author), Univ Marburg, Dept Cell Biol & Cell Pathol, Robert Koch Str 6, D-35033 Marburg, Germany.	jacob@staff.uni-marburg.de	Jacob, Ralf/B-8163-2011; ryazanov, alexey/J-8081-2017; Heine, Martin/C-6285-2011	Delebinski, Catharina/0000-0003-2527-4385	NCI NIH HHS [R01 CA81102] Funding Source: Medline; NIGMS NIH HHS [R01 GM57300] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; BETAPUDI V, 2005, MOL BIOL CELL; Brock SC, 2003, P NATL ACAD SCI USA, V100, P15143, DOI 10.1073/pnas.2434327100; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; DeOca GM, 1997, ARCH MED RES, V28, P321; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Durrbach A, 2000, TRAFFIC, V1, P411, DOI 10.1034/j.1600-0854.2000.010506.x; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; Kashina AS, 2004, CURR BIOL, V14, P1877, DOI 10.1016/j.cub.2004.10.003; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Luo X, 2001, J BIOL CHEM, V276, P17836, DOI 10.1074/jbc.M009366200; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Ryazanova LV, 2001, MOL BIOL+, V35, P271, DOI 10.1023/A:1010499720185; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Tyska MJ, 2004, J CELL BIOL, V165, P395, DOI 10.1083/jcb.200310031; VAN ISC, 2000, J CELL PHYSL, V184, P151; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Wollert T, 2002, J CELL BIOL, V159, P571, DOI 10.1083/jcb.200204065; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	44	47	48	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25637	25643		10.1074/jbc.M502265200	http://dx.doi.org/10.1074/jbc.M502265200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883161	hybrid			2022-12-25	WOS:000230207900043
J	Fogelgren, B; Polgar, N; Szauter, KM; Ujfaludi, Z; Laczko, R; Fong, KSK; Csiszar, K				Fogelgren, B; Polgar, N; Szauter, KM; Ujfaludi, Z; Laczko, R; Fong, KSK; Csiszar, K			Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GEL CONTRACTION; ENZYME-ACTIVITY; CROSS-LINKING; GROWTH-FACTOR; GENE-EXPRESSION; IONIC-STRENGTH; PLASMA; PROTEIN; COPPER; METALLOPROTEINASES	Lysyl oxidase (LOX) is a copper-containing amine oxidase known to catalyze the covalent cross-linking of fibrillar collagens and elastin at peptidyl lysine residues. In addition, its involvement in cancer, wound healing, cell motility, chemotaxis, and differentiation reflect a remarkable functional diversity of LOX. To investigate novel mechanisms of LOX regulation and function, we performed a yeast two-hybrid screen to identify LOX-interacting proteins. Three overlapping positive clones were identified as C-terminal fragments of fibronectin (FN). Glutathione S-transferase pull-downs and solid phase binding assays confirmed this interaction. LOX binds to the cellular form of FN (cFN) with a dissociation constant (K-d) of 2.5 nM. This was comparable with our measured Kd of LOX binding to tropoelastin ( 1.9 nM) and type I collagen ( 5.2 nM), but LOX demonstrated a much lower binding affinity for the plasma form of FN (pFN). Immunofluorescent microscopy revealed co-localization of FN and LOX in normal human tissues, where these proteins may interact in vivo. LOX enzymatic activity assays showed that cFN does not seem to be a substrate of LOX. However, cFN can act as a scaffold for enzymatically active 30-kDa LOX. Furthermore, in FN-null mouse embryonic fibroblasts, we observed dramatically decreased proteolytic processing of the 45-kDa LOX proenzyme to the 30-kDa active form, with a corresponding decrease in LOX enzyme activity. Our results suggest that the FN matrix may provide specific microenvironments to regulate LOX catalytic activity.	Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96822 USA	University of Hawaii System	Csiszar, K (corresponding author), Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, 1960 E W Rd,Biomed T311, Honolulu, HI 96822 USA.	Kcsiszar@aol.com	Ujfaludi, Zsuzsanna/AAC-7657-2020; Polgar, Noemi/B-3948-2013	Polgar, Noemi/0000-0002-8400-162X; Ujfaludi Dr., Zsuzsanna/0000-0003-4738-0963; Fong, Keith/0000-0001-6845-1754	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S11AR047713] Funding Source: NIH RePORTER; NCRR NIH HHS [G12RR03961] Funding Source: Medline; NIAMS NIH HHS [AR47713] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASAGA H, 1991, EXP CELL RES, V193, P167, DOI 10.1016/0014-4827(91)90552-6; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CIDADAO AJ, 1989, EUR J CELL BIOL, V48, P303; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; Farhadian F, 1996, CARDIOVASC RES, V32, P433, DOI 10.1016/S0008-6363(96)00119-8; Feres EJ, 1996, J BIOL CHEM, V271, P6411, DOI 10.1074/jbc.271.11.6411; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FushidaTakemura H, 1996, ARCH DERMATOL RES, V288, P7, DOI 10.1007/BF02505035; GACHERU SN, 1990, J BIOL CHEM, V265, P19022; Harlow CR, 2003, ENDOCRINOLOGY, V144, P154, DOI 10.1210/en.2002-220652; He QP, 2003, NEUROBIOL DIS, V12, P25, DOI 10.1016/S0969-9961(02)00006-2; Hong HH, 2002, J PERIODONTOL, V73, P145, DOI 10.1902/jop.2002.73.2.145; Hong HH, 1999, LAB INVEST, V79, P1655; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Hynes RO, 1990, FIBRONECTINS; JOHANSSON S, 1980, BIOCHEM J, V187, P521, DOI 10.1042/bj1870521; Johnson KJ, 1999, J BIOL CHEM, V274, P15473, DOI 10.1074/jbc.274.22.15473; Jung ST, 2003, PROTEIN EXPRES PURIF, V31, P240, DOI 10.1016/S1046-5928(03)00217-1; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KHAN MY, 1990, BIOCHEM J, V270, P33, DOI 10.1042/bj2700033; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; Kosmehl H, 1996, VIRCHOWS ARCH, V429, P311; Kosonen T, 1997, BIOCHEM J, V327, P283, DOI 10.1042/bj3270283; KREBS CJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P7, DOI 10.1016/0167-4838(93)90056-W; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Matsuka YV, 1997, J PROTEIN CHEM, V16, P739, DOI 10.1023/A:1026307731751; Mosher D F, 1978, Ann N Y Acad Sci, V312, P38, DOI 10.1111/j.1749-6632.1978.tb16791.x; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; Mosher DF, 1989, FIBRONECTIN; MOULD P, 2000, EXTRACELLULAR MATRIX, P295; Nakamura Y, 2003, INVEST OPHTH VIS SCI, V44, P4331, DOI 10.1167/iovs.03-0068; Ouzzine M, 1996, FEBS LETT, V399, P215, DOI 10.1016/S0014-5793(96)01323-3; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Ravid K, 1999, J CELL BIOCHEM, V75, P177, DOI 10.1002/(SICI)1097-4644(19991001)75:1<177::AID-JCB18>3.3.CO;2-N; Redden RA, 2003, SKIN RES TECHNOL, V9, P290, DOI 10.1034/j.1600-0846.2003.00023.x; ROCCO M, 1983, J BIOL CHEM, V258, P4545; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Shanley CJ, 1997, J VASC SURG, V25, P446, DOI 10.1016/S0741-5214(97)70254-4; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Taliana L, 2000, INVEST OPHTH VIS SCI, V41, P103; Ugarova TP, 1996, BIOCHEMISTRY-US, V35, P10913, DOI 10.1021/bi960717s; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Uzel MI, 2000, J BONE MINER RES, V15, P1189, DOI 10.1359/jbmr.2000.15.6.1189; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; Ziegler J, 1997, ANAL BIOCHEM, V250, P257, DOI 10.1006/abio.1997.2248	60	139	152	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24690	24697		10.1074/jbc.M412979200	http://dx.doi.org/10.1074/jbc.M412979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15843371	hybrid			2022-12-25	WOS:000230114000049
J	Ohto, T; Uozumi, N; Hirabayashi, T; Shimizu, T				Ohto, T; Uozumi, N; Hirabayashi, T; Shimizu, T			Identification of novel cytosolic phospholipase A(2)s, murine cPLA(2)delta, epsilon, and zeta, which form a gene cluster with cPLA(2)beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHORYLATION SITES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; NUCLEAR-ENVELOPE; THYROID-CELLS; ACTIVATION; DOMAIN; TRANSLOCATION; PURIFICATION	Phospholipase A(2) hydrolyzes the sn-2 ester bond of glycerophospholipids that produce free fatty acids and lysophospholipids. Cytosolic phospholipase A(2)s ( cPLA(2), group IV) are a subgroup of enzymes that act on the intracellular phospholipid membrane. The best investigated cPLA(2)alpha( group IVA) is a key enzyme for lipid mediator production in vivo. Here we report cloning and characterization of novel murine cPLA(2)s: cPLA(2)delta ( group IVD), cPLA(2)epsilon ( group IVE), and cPLA(2)zeta ( group IVF), that form a gene cluster with cPLA(2)beta ( group IVB). The deduced amino acid sequences of cPLA(2)delta, epsilon, and zeta demonstrated a conserved domain structure of cPLA(2), i. e. one C2 domain and one lipase domain. The potential catalytic dyad, Ser and Asp, was conserved for these newly cloned cPLA2s along with relatively high conservation for the surrounding residues. Transcripts of murine cPLA(2)delta, epsilon, and zeta appeared to be enriched in certain organs rather than ubiquitous distribution. Major Northern signals for cPLA(2)delta were detected in placenta, cPLA(2)epsilon in thyroid, heart, and skeletal muscle, and cPLA(2)zeta in thyroid. Recombinant proteins expressed in human embryonic kidney 293 cells demonstrated molecular sizes of about 100 kDa by Western blotting and exhibited Ca2+-dependent PLA(2) activities on 1-palmitoyl-2-[C-14] arachidonoyl-phosphatidylcholine substrate. In contrast to cPLA(2)alpha, cPLA(2)zeta preferred phosphatidylethanolamine to phosphatidylcholine. Intracellular localization was visualized by green fluorescent-tagged proteins. Each molecule showed specific localization, and cPLA(2)delta translocated from the cytosol to the perinuclear region by calcium-ionophore stimulation. We thus discovered these functional novel cPLA2 genes, which cluster on murine chromosome 2E5.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Chem Pharmacol Lab, Chuo Ku, Chiba 2608675, Japan	University of Tokyo; Chiba University	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	tshimizu@m.u-tokyo.ac.jp	Shimizu, Takao/AAV-7052-2021; Uozumi, Nobuyuki/AAG-3252-2019	Hirabayashi, Tetsuya/0000-0001-8099-5367				Asai K, 2003, J BIOL CHEM, V278, P8809, DOI 10.1074/jbc.M212117200; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Di Cerbo A, 1999, J CLIN ENDOCR METAB, V84, P3283, DOI 10.1210/jc.84.9.3283; Diaz BL, 2003, PROSTAG LEUKOTR ESS, V69, P87, DOI 10.1016/S0952-3278(03)00069-3; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NATORI Y, 1983, J BIOCHEM-TOKYO, V93, P631, DOI 10.1093/oxfordjournals.jbchem.a134219; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Six DA, 2003, J BIOL CHEM, V278, P23842, DOI 10.1074/jbc.M301386200; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 2002, PROSTAG OTH LIPID M, V68-9, P59, DOI 10.1016/S0090-6980(02)00021-7; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	52	98	106	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24576	24583		10.1074/jbc.M413711200	http://dx.doi.org/10.1074/jbc.M413711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866882	hybrid			2022-12-25	WOS:000230114000036
J	Sampieri, A; Diaz-Munoz, M; Antaramian, A; Vaca, L				Sampieri, A; Diaz-Munoz, M; Antaramian, A; Vaca, L			The foot structure from the type 1 ryanodine receptor is required for functional coupling to store-operated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CALCIUM-ENTRY; CA2+ ENTRY; CALMODULIN; TRP; DEPLETION; INFLUX; LANTHANIDES; ACTIVATION; PROTEINS	In the present study we have explored structural determinants of the functional interaction between skeletal muscle ryanodine receptor (RyR1) and transient receptor potential channel 1 (TRPC1) channels expressed in Chinese hamster ovary cells. We have illustrated a functional interaction between TRPC1 channels and RyR1 for the regulation of store-operated calcium entry (SOCE) initiated after releasing calcium from a caffeine-sensitive intracellular calcium pool. RNA interference experiments directed to reduce the amount of TRPC1 protein indicate that RyR1 associates to at least two different types of store-operated channels (SOCs), one dependent and one independent of TRPC1. In contrast, bradykinin-induced SOCE is completely dependent on the presence of TRPC1 protein, as we have previously illustrated. Removing the foot structure from RyR1 results in normal caffeine-induced release of calcium from internal stores but abolishes the activation of SOCE, indicating that this structure is require for functional coupling to SOCs. The footless RyR1 protein shows a different cellular localization when compared with wild type RyR1. The later protein shows a higher percentage of colocalization with FM-464, a marker of plasma membrane. The implications of the foot structure for the functional and physical coupling to TRPC and SOCs is discussed.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Neurobiol, Dept Neurobiol Celular & Mol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Vaca, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Ciudad Univ, Mexico City 04510, DF, Mexico.	lvaca@ifc.unam.mx	Sampieri, Alicia/L-3896-2019	Diaz-Munoz, Mauricio/0000-0002-9019-8246; Vaca, Luis/0000-0003-2266-4847				Antaramian A, 2000, REC RES DEV NEUROCH, V3, P47; Antaramian A, 2001, CELL CALCIUM, V30, P9, DOI 10.1054/ceca.2001.0208; BOLOTINA VM, 2004, SCI STKE, V243, P1; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; Harteneck C, 2003, CELL CALCIUM, V33, P303, DOI 10.1016/S0143-4160(03)00043-5; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Huang CL, 2004, J AM SOC NEPHROL, V15, P1690, DOI 10.1097/01.ASN.0000129115.69395.65; Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Protasi F, 2002, FRONT BIOSCI, V7, pD650, DOI 10.2741/protasi; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roderick HL, 2003, CURR BIOL, V13, pR976, DOI 10.1016/j.cub.2003.11.048; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; SEILER S, 1984, J BIOL CHEM, V259, P8550; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Weigl L, 2003, N-S ARCH PHARMACOL, V367, P353, DOI 10.1007/s00210-003-0705-8; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698	38	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24804	24815		10.1074/jbc.M501487200	http://dx.doi.org/10.1074/jbc.M501487200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878845	hybrid			2022-12-25	WOS:000230114000063
J	Alliston, T; Ko, TC; Cao, YN; Liang, YY; Feng, XH; Chang, CB; Derynck, R				Alliston, T; Ko, TC; Cao, YN; Liang, YY; Feng, XH; Chang, CB; Derynck, R			Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; COREPRESSOR CTBP; SMAD4 COOPERATE; EXPRESSION; GENE; BINDING; XENOPUS; ACTIVATION; FAMILY; ACETYLATION	Smads, key effectors of transforming growth factor ( TGF)-beta, activin, and bone morphogenetic protein (BMP) signaling, regulate gene expression and interact with coactivators and corepressors that modulate Smad activity. The corepressor Evi-1 exerts its oncogenic effects by repressing TGF-beta/Smad3-mediated transcription, thereby blocking TGF-beta-induced growth arrest. Because Evi-1 interacts with the highly conserved MH2 domain of Smad3, we investigated the physical and functional interaction of Evi-1 with Smad1 and Smad2, downstream targets of BMP and activin signaling, respectively. Evi-1 interacted with and repressed the receptor-activated transcription through Smad1 and Smad2, similarly to Smad3. In addition, Evi-1 repressed BMP/Smad1- and activin/Smad2-mediated induction of endogenous Xenopus gene expression, suggesting a role of repression of BMP and activin signals by Evi-1 in vertebrate embryogenesis. Evi-1 also repressed the induction of endogenous Smad7 expression by TGF-beta family ligands. In the course of these studies, we observed Evi-1 repression of Smad transactivation even when Smad binding to DNA was kept constant. We therefore explored the mechanism of Evi-1 repression of TGF-beta family-inducible transcription. Evi-1 repression did not result from displacement of Smad binding to DNA or to CREB-binding protein but from the recruitment of Evi-1 by Smad3 and CREB-binding protein to DNA. Following TGF-beta stimulation, Evi-1 and the associated corepressor CtBP were recruited to the endogenous Smad7 promoter. Evi-1 recruitment to the promoter decreased TGF-beta-induced histone acetylation, coincident with its repression of Smad7 gene expression. In this way, Evi-1 acts as a general Smad corepressor to inhibit TGF-beta-, activin-, and BMP-inducible transcription.	Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Texas, Med Branch, Dept Surg, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Baylor Coll Med, Ctr Canc, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Dept Mol & Cellular Biol, Biol Inflammat Ctr, Houston, TX 77030 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine; Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA.	derynck@itsa.ucsf.edu		Alliston, Tamara/0000-0001-9992-2897	NCI NIH HHS [R01-CA63101, R01-CA108454, K08-CA64191] Funding Source: Medline; NICHD NIH HHS [R01-HD43345] Funding Source: Medline; NIDCR NIH HHS [P60 DE13058] Funding Source: Medline; NIDDK NIH HHS [R01-DK60105, P01-DK35608] Funding Source: Medline; NIGMS NIH HHS [R01-GM63773] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043345] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA108454, K08CA064191, R01CA063101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060105, P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Candia AF, 1997, DEVELOPMENT, V124, P4467; Casellas R, 1998, DEV BIOL, V198, P1; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chang CB, 1997, DEVELOPMENT, V124, P827; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FENG XH, 2000, METH MOL B, V177, P221; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Ling L, 2004, J BIOL CHEM, V279, P32737, DOI 10.1074/jbc.M400601200; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; Moustakas A, 2001, J CELL SCI, V114, P4359; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Polesskaya A, 2001, J BIOL CHEM, V276, P44502, DOI 10.1074/jbc.M106501200; Senyuk V, 2003, BIOCHEM BIOPH RES CO, V307, P980, DOI 10.1016/S0006-291X(03)01288-9; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; SU MW, 1991, DEVELOPMENT, V111, P1179; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki A, 1997, DEVELOPMENT, V124, P3037; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Torres-Padilla ME, 2002, J BIOL CHEM, V277, P44677, DOI 10.1074/jbc.M207545200; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	63	66	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24227	24237		10.1074/jbc.M414305200	http://dx.doi.org/10.1074/jbc.M414305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849193	hybrid			2022-12-25	WOS:000229880000099
J	Ching, KH; Kisailus, AE; Burbelo, PD				Ching, KH; Kisailus, AE; Burbelo, PD			The role of SPECs, small Cdc42-binding proteins, in F-actin accumulation at the immunological synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; ANTIGEN-PRESENTING CELLS; APC CONTACT SITE; N-WASP; TYROSINE KINASES; ARP2/3 COMPLEX; GTPASE CDC42; T-CELLS; PALMITOYLATION; ACTIVATION	SPEC1 and SPEC2 are structurally similar Cdc42-binding proteins of 79 and 84 amino acid residues, respectively. We investigated the role of SPEC2 in T cell function due to its high mRNA expression in lymphocytes. Western blot analysis revealed abundant SPEC2 protein in lymphocytes, which in glutathione S-transferase-capture experiments specifically interacted with only GTP-bound Cdc42. Immunofluorescence experiments revealed that the SPEC2 protein was diffusely localized in the cytoplasm and at the cell membrane in unstimulated Jurkat T cells and Raji B cells. Recruitment of SPEC2 within Jurkat T cells to the antigen-presenting cell interface occurred following incubation with staphylococcal enterotoxin E superantigen-loaded B cells and colocalized there with F-actin and Cdc42. T cell receptor (TCR) activation studies using anti-CD3 antibody-coated polystyrene beads showed that SPEC2 was recruited to the site of bead contact, which was not observed with anti-major histocompatibility complex antibody-coated beads. Accumulation of SPEC2 following TCR engagement occurred as early as 5 min, before obvious F-actin accumulation. Biochemical studies with Jurkat T cells demonstrated that N-terminal cysteine residues in SPEC2 were palmitoylated. Overexpression studies of the related SPEC1 showed that it also was recruited to the activated TCR. Mutational analysis revealed that localization of SPEC1 to the TCR required two N-terminal cysteine residues. Furthermore, a SPEC1 Cdc42 Rac-interacting binding mutant, containing an intact N terminus but defective in Cdc42 binding, completely blocked F-actin accumulation at the activated TCR. Taken together these results suggest that SPECs may play important roles in Cdc42-mediated F-actin accumulation at the immunological synapse.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Dept Oncol, Washington, DC 20057 USA	Georgetown University; Georgetown University	Burbelo, PD (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Rm W218 New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	burbelpd@georgetown.edu						Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Badour K, 2003, IMMUNOL REV, V192, P98, DOI 10.1034/j.1600-065X.2003.00031.x; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cannon JL, 2004, J IMMUNOL, V173, P1658, DOI 10.4049/jimmunol.173.3.1658; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Collins TL, 1997, IMMUNOL TODAY, V18, P221; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gauthier-Campbell C, 2004, MOL BIOL CELL, V15, P2205, DOI 10.1091/mbc.E03-07-0493; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Morales-Tirado V, 2004, J IMMUNOL, V173, P726, DOI 10.4049/jimmunol.173.2.726; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Peck JW, 2002, J BIOL CHEM, V277, P43924, DOI 10.1074/jbc.M203569200; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; Prehoda KE, 2002, CURR OPIN CELL BIOL, V14, P149, DOI 10.1016/S0955-0674(02)00307-1; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wulfing C, 2000, P NATL ACAD SCI USA, V97, P10150, DOI 10.1073/pnas.97.18.10150; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zeng R, 2003, J IMMUNOL, V171, P1360, DOI 10.4049/jimmunol.171.3.1360; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	37	8	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23660	23667		10.1074/jbc.M500128200	http://dx.doi.org/10.1074/jbc.M500128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840583	hybrid			2022-12-25	WOS:000229880000033
J	Guo, Y; Wang, HB; Okamoto, Y; Ueda, N; Kingsley, PJ; Marnett, LJ; Schmid, HHO; Das, SK; Dey, SK				Guo, Y; Wang, HB; Okamoto, Y; Ueda, N; Kingsley, PJ; Marnett, LJ; Schmid, HHO; Das, SK; Dey, SK			N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREIMPLANTATION MOUSE EMBRYO; CANNABINOID RECEPTOR; MOLECULAR CHARACTERIZATION; UTERUS; LIGAND; HYDROLASE; ENDOCANNABINOIDS; RECEPTIVITY; ACTIVATION	Implantation requires reciprocal interaction between blastocysts and a receptive uterus. In mice, one important player in this dialogue involves endocannabinoid signaling via cannabinoid receptor CB1. Anandamide is an endogenous cannabinoid ligand, and its levels are spatiotemporally regulated in the uterus during early pregnancy, showing lower levels in the receptive uterus and at the implantation site. However, the mechanism by which differential uterine anandamide gradients are established under different pregnancy status is not clearly understood. Using multiple approaches, we show here that uterine anandamide levels conducive to implantation are primarily regulated by spatiotemporal expression of Nape-Pld, the gene encoding N-acylphosphatidylethanolamine-hydrolyzing phospholipase D that generates anandamide. The expression is well correlated with its activity and anandamide levels. This study is clinically relevant, since elevated anandamide levels in peripheral circulation are associated with spontaneous pregnancy failure in women.	Vanderbilt Univ, Ctr Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Pharmacol, Nashville, TN 37232 USA; Kagawa Univ, Dept Biochem, Kagawa, Japan; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Kagawa University; University of Minnesota System	Dey, SK (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pediat, 221 Kirkland Hall, Nashville, TN 37232 USA.	sk.dey@vanderbilt.edu	OKAMOTO, Yasuo/J-8438-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R37HD012304, R01HD037830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006668, R37DA006668] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12304, HD37830, HD33994] Funding Source: Medline; NIDA NIH HHS [DA06668] Funding Source: Medline; NIEHS NIH HHS [ES07814] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DAS SK, 1994, DEVELOPMENT, V120, P1071; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Kingsley PJ, 2003, ANAL BIOCHEM, V314, P8, DOI 10.1016/S0003-2697(02)00643-7; Maccarrone M, 2004, MOL HUM REPROD, V10, P215, DOI 10.1093/molehr/gah034; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; OKAMOTO Y, 2005, BIOCH J; PARIA BC, 1995, P NATL ACAD SCI USA, V92, P9460, DOI 10.1073/pnas.92.21.9460; Paria BC, 1998, BIOL REPROD, V58, P1490, DOI 10.1095/biolreprod58.6.1490; Paria BC, 1999, BIOL REPROD, V60, P1151, DOI 10.1095/biolreprod60.5.1151; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Paria BC, 2001, J BIOL CHEM, V276, P20523, DOI 10.1074/jbc.M100679200; Paria BC, 2000, CHEM PHYS LIPIDS, V108, P211, DOI 10.1016/S0009-3084(00)00197-3; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; Song H, 2002, DEVELOPMENT, V129, P2879; Wang HB, 2004, NAT MED, V10, P1074, DOI 10.1038/nm1104; Wang HB, 2003, P NATL ACAD SCI USA, V100, P14914, DOI 10.1073/pnas.2436379100; Wang J, 1999, BIOL REPROD, V60, P839, DOI 10.1095/biolreprod60.4.839; Yang ZM, 1996, BIOL REPROD, V55, P756, DOI 10.1095/biolreprod55.4.756	24	93	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23429	23432		10.1074/jbc.C500168200	http://dx.doi.org/10.1074/jbc.C500168200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15890658	hybrid			2022-12-25	WOS:000229880000003
J	Sommer, U; Costello, CE; Hayes, GR; Beach, DH; Gilbert, RO; Lucas, JJ; Singh, BN				Sommer, U; Costello, CE; Hayes, GR; Beach, DH; Gilbert, RO; Lucas, JJ; Singh, BN			Identification of Trichomonas vaginalis cysteine proteases that induce apoptosis in human vaginal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITRICHOMONAS-FETUS; EXTRACELLULAR PROTEASES; IN-VITRO; PROTEINASE; DEATH; MECHANISM; PURIFICATION; ACTIVATION; INVASION	A secreted cysteine protease (CP) fraction from Trichomonas vaginalis is shown here to induce apoptosis in human vaginal epithelial cells (HVEC) and is analyzed by mass spectrometry. The trichomonad parasite T. vaginalis causes one of the most common nonviral sexually transmitted infection in humans, trichomoniasis. The parasite as well as a secreted cysteine protease ( CP) fraction, isolated by affinity chromatography followed by Bio-Gel P-60 column chromatography, are shown to induce HVEC apoptosis, as demonstrated by the Cell Death Detection ELISA(PLUS) assay and annexin V-fluorescein isothiocyanate flow cytometry analyses. Initiation of apoptosis is correlated with protease activity because the specific CP inhibitor E-64 inhibits both activities. SDS-PAGE analysis of the CP fraction reveals triplet bands around 30 kDa, and matrix-assisted laser desorption ionization time-of-flight MS indicates two closely associated peaks of molecular mass 23.6 and 23.8 kDa. Mass spectral peptide sequencing of the proteolytically digested CPs results in matches to previously reported cDNA clones, CP2, CP3, and CP4 ( Mallinson, D. J., Lockwood, B. C., Coombs, G. H., and North, M. J. ( 1994) Microbiology 140, 2725 2735), as well as another sequence with high homology to CP4 (www.tigr.org). These last two species are the most abundant components of the CP fraction. The present results, suggesting that CP-induced programmed cell death may be involved in the pathogenesis of T. vaginalis infection in vivo, may have important implications for therapeutic intervention.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Boston University; Cornell University	Singh, BN (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	singhb@upstate.edu	Gilbert, Robert/J-9107-2012	Gilbert, Robert/0000-0002-1528-243X; Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888, S10RR015942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047334] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR015942, P41-RR10888] Funding Source: Medline; NIAID NIH HHS [AI47334] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIZADEH H, 1994, INFECT IMMUN, V62, P1298, DOI 10.1128/IAI.62.4.1298-1303.1994; Alvarez-Sanchez ME, 2000, MICROB PATHOGENESIS, V28, P193, DOI 10.1006/mpat.1999.0336; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Arroyo R, 1995, Arch Med Res, V26, P279; ARROYO R, 1989, INFECT IMMUN, V57, P2991, DOI 10.1128/IAI.57.10.2991-2997.1989; Bastida-Corcuera F, 2000, J PARASITOL, V86, P328, DOI 10.1645/0022-3395(2000)086[0328:TFECPC]2.0.CO;2; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Budnik BA, 2004, INT J MASS SPECTROM, V234, P203, DOI 10.1016/j.ijms.2004.02.011; COOMBS GH, 1983, PARASITOLOGY, V86, P1, DOI 10.1017/S0031182000057103; Draper D, 1998, J INFECT DIS, V178, P815, DOI 10.1086/515366; Fiori PL, 1996, MICROB PATHOGENESIS, V20, P109, DOI 10.1006/mpat.1996.0010; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; GARBER GE, 1989, J CLIN MICROBIOL, V27, P1548, DOI 10.1128/JCM.27.7.1548-1553.1989; GARBER GE, 1989, CAN J MICROBIOL, V35, P903, DOI 10.1139/m89-150; GARBER GE, 1994, PARASITOL RES, V80, P361, DOI 10.1007/BF00932372; GARBER GE, 1993, APPL PARASITOL, V34, P345; Gilbert RO, 2000, INFECT IMMUN, V68, P4200, DOI 10.1128/IAI.68.7.4200-4206.2000; Huston CD, 2000, CELL MICROBIOL, V2, P617, DOI 10.1046/j.1462-5822.2000.00085.x; Kania SA, 2001, VET IMMUNOL IMMUNOP, V78, P83, DOI 10.1016/S0165-2427(00)00256-7; KRIEGER JN, 1999, SEXUALLY TRANSMITTED, P587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehker MW, 1999, SEX TRANSM INFECT, V75, P231, DOI 10.1136/sti.75.4.231; Leon-Sicairos CD, 2003, J EUKARYOT MICROBIOL, V50, P702, DOI 10.1111/j.1550-7408.2003.tb00695.x; Leon-Sicairos CR, 2004, MICROBIOL-SGM, V150, P1131, DOI 10.1099/mic.0.26927-0; LOCKWOOD BC, 1988, MOL BIOCHEM PARASIT, V30, P135, DOI 10.1016/0166-6851(88)90106-5; LOCKWOOD BC, 1987, MOL BIOCHEM PARASIT, V24, P89, DOI 10.1016/0166-6851(87)90119-8; LOPES MF, 1995, J IMMUNOL, V154, P744; Mallinson DJ, 1995, MICROBIOL-UK, V141, P3077, DOI 10.1099/13500872-141-12-3077; MALLINSON DJ, 1994, MICROBIOL-UK, V140, P2725, DOI 10.1099/00221287-140-10-2725; McCole DF, 2000, INFECT IMMUN, V68, P1710, DOI 10.1128/IAI.68.3.1710-1713.2000; MCLAUGHLIN J, 1979, J BIOL CHEM, V254, P1526; Mendoza-Lopez MR, 2000, INFECT IMMUN, V68, P4907, DOI 10.1128/IAI.68.9.4907-4912.2000; MIN DY, 1998, KOREAN J PARASITOL, V36, P361; Moss JE, 1999, INT REV CYTOL, V187, P203, DOI 10.1016/S0074-7696(08)62419-5; NEALE KA, 1990, INFECT IMMUN, V58, P157, DOI 10.1128/IAI.58.1.157-162.1990; NORTH MJ, 1994, METHOD ENZYMOL, V244, P523; Petrin D, 1998, CLIN MICROBIOL REV, V11, P300, DOI 10.1128/CMR.11.2.300; PROVENZANO D, 1995, INFECT IMMUN, V63, P3388, DOI 10.1128/IAI.63.9.3388-3395.1995; Que XC, 2000, CLIN MICROBIOL REV, V13, P196, DOI 10.1128/CMR.13.2.196-206.2000; Rosset I, 2002, PARASITOL RES, V88, P356, DOI 10.1007/s00436-001-0555-6; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Singh BN, 2004, INFECT IMMUN, V72, P4151, DOI 10.1128/IAI.72.7.4151-4158.2004; Singh BN, 1999, INFECT IMMUN, V67, P3847, DOI 10.1128/IAI.67.8.3847-3854.1999; SINGH BN, IN PRESS AM J VET RE, V66; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Thomford JW, 1996, J PARASITOL, V82, P112, DOI 10.2307/3284125; ToureBalde A, 1996, INFECT IMMUN, V64, P744, DOI 10.1128/IAI.64.3.744-750.1996; Wei S, 2002, INFECT IMMUN, V70, P1750, DOI 10.1128/IAI.70.4.1750-1760.2002; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zieler H, 2000, P NATL ACAD SCI USA, V97, P11516, DOI 10.1073/pnas.97.21.11516; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	51	92	97	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23853	23860		10.1074/jbc.M501752200	http://dx.doi.org/10.1074/jbc.M501752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843376	hybrid			2022-12-25	WOS:000229880000058
J	Tang, H; Hao, Q; Rutherford, SA; Low, B; Zhao, ZJ				Tang, H; Hao, Q; Rutherford, SA; Low, B; Zhao, ZJ			Inactivation of Src family tyrosine kinases by reactive oxygen species in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; ENDOTHELIAL-CELLS; C-SRC; OXIDATIVE STRESS; PROTEIN-KINASE; INTERMOLECULAR AUTOPHOSPHORYLATION; REVERSIBLE INACTIVATION; HYDROGEN-PEROXIDE; ANGIOTENSIN-II	Reactive oxygen species, including H2O2, O-2(.) and OH., are constantly produced in the human body and are involved in the development of cardiovascular diseases. Emerging evidence suggests that reactive oxygen species, besides their deleterious effects at high concentrations, may be protective. However, the mechanism underlying the protective effects of reactive oxygen species is not clear. Here, we reported a novel finding that H2O2 at low to moderate concentrations (50-250 mu M) markedly inactivated Src family tyrosine kinases temporally and spatially in vivo but not in vitro. We further showed that Src family kinases localized to focal adhesions and the plasma membrane were rapidly and permanently inactivated by H2O2, which resulted from a profound reduction in phosphorylation of the conserved tyrosine residue at the activation loop. Interestingly, the cytoplasmic Src family kinases were activated gradually by H2O2, which partially compensated for the loss of total activities of Src family kinases but not their functions. Finally, H2O2 rendered endothelial cells resistant to growth factors and cytokines and protected the cells from inflammatory activation. Because Src family kinases play key roles in cell signaling, the rapid inactivation of Src family kinases by H2O2 may represent a novel mechanism for the protective effects of reactive oxygen species.	Univ Texas Hlth Ctr, Dept Biochem, Tyler, TX 75708 USA; Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University	Tang, H (corresponding author), Univ Texas Hlth Ctr, Dept Biochem, 11937 US Highway 271, Tyler, TX 75708 USA.	hua.tang@uthct.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069806, R01HL076309] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-076309, HL-69806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Ceconi C, 2003, ARCH BIOCHEM BIOPHYS, V420, P217, DOI 10.1016/j.abb.2003.06.002; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Geahlen RL, 2004, ONCOGENE, V23, P8024, DOI 10.1038/sj.onc.1208078; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Huang S, 2003, J BIOL CHEM, V278, P8326, DOI 10.1074/jbc.M208264200; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; Kofler S, 2005, CLIN SCI, V108, P205, DOI 10.1042/CS20040174; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Madamanchi NR, 2005, ARTERIOSCL THROM VAS, V25, P950, DOI 10.1161/01.ATV.0000161050.77646.68; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Petrone A, 2000, J CELL SCI, V113, P2345; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rhee S.G., 2000, SCI STKE; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tang H, 2005, BLOOD, V105, P1977, DOI 10.1182/blood-2004-08-3308; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zahler S, 2000, FASEB J, V14, P555, DOI 10.1096/fasebj.14.3.555; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	56	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23918	23925		10.1074/jbc.M503498200	http://dx.doi.org/10.1074/jbc.M503498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851473	hybrid			2022-12-25	WOS:000229880000066
J	Lin, PC; Puhar, A; Turk, K; Piligkos, S; Bill, E; Neese, F; Steuber, J				Lin, PC; Puhar, A; Turk, K; Piligkos, S; Bill, E; Neese, F; Steuber, J			A vertebrate-type ferredoxin domain in the Na+-translocating NADH dehydrogenase from Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; QUINONE OXIDOREDUCTASE; 2FE-2S FERREDOXIN; GENE; BIOGENESIS; REDUCTION	The Na+-translocating NADH: quinone oxidoreductase from Vibrio cholerae contains a single Fe-S cluster localized in subunit NqrF. Here we study the electronic properties of the Fe-S center in a truncated version of the NqrF subunit comprising only its ferredoxin-like Fe-S domain. Mossbauer spectroscopy of the Fe-S domain in the oxidized state is consistent with a binuclear Fe-S cluster with tetrahedral sulfur coordination by the cysteine residues Cys(70), Cys(76), Cys(79), and Cys(111). Important sequence motifs surrounding these cysteines are conserved in the Fe-S domain and in vertebrate-type ferredoxins. The magnetic circular dichroism spectra of the photochemically reduced Fe-S domain exhibit a striking similarity to the magnetic circular dichroism spectra of vertebrate-type ferredoxins required for the in vivo assembly of iron-sulfur clusters. This study reveals a novel function for vertebrate-type [2Fe-2S] clusters as redox cofactors in respiratory dehydrogenases.	ETH Honggerberg, Inst Mikrobiol, CH-8093 Zurich, Switzerland; Max Planck Inst Bioanorgan Chem, D-45470 Mulheim, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Steuber, J (corresponding author), Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland.	steuber@bioc.unizh.ch	Piligkos, Stergios/C-7409-2013; Neese, Frank/J-4959-2014	Piligkos, Stergios/0000-0002-4011-6476; Neese, Frank/0000-0003-4691-0547; Puhar, Andrea/0000-0002-9915-002X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barquera B, 2002, P NATL ACAD SCI USA, V99, P10322, DOI 10.1073/pnas.162361299; Barquera B, 2004, BIOCHEMISTRY-US, V43, P12322, DOI 10.1021/bi048689y; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1978, Methods Enzymol, V54, P435; Bogachev AV, 2002, BBA-BIOENERGETICS, V1556, P113, DOI 10.1016/S0005-2728(02)00342-0; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; FU WG, 1992, J BIOL CHEM, V267, P15502; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Grinberg AV, 2000, PROTEINS, V40, P590, DOI 10.1002/1097-0134(20000901)40:4<590::AID-PROT50>3.0.CO;2-P; Hase CC, 1999, P NATL ACAD SCI USA, V96, P3183, DOI 10.1073/pnas.96.6.3183; Hayashi M, 2001, FEBS LETT, V488, P5, DOI 10.1016/S0014-5793(00)02404-2; Huynh B H, 1984, Adv Inorg Biochem, V6, P163; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; JOHNSON MK, 1982, IRON SULFUR PROTEINS; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Mansy SS, 2004, ACCOUNTS CHEM RES, V37, P719, DOI 10.1021/ar0301781; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; Mitou G, 2003, BIOCHEMISTRY-US, V42, P1354, DOI 10.1021/bi027116n; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; MUNCK E, 1972, BIOCHEMISTRY-US, V11, P855; Munck E., 2000, PHYS METHODS BIOINOR, P287; PfenningerLi XD, 1996, BIOCHEMISTRY-US, V35, P6233, DOI 10.1021/bi953032l; TA DT, 1992, J BIOL CHEM, V267, P11120; Turk K, 2004, J BIOL CHEM, V279, P21349, DOI 10.1074/jbc.M311692200; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	30	6	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22560	22563		10.1074/jbc.C500171200	http://dx.doi.org/10.1074/jbc.C500171200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15870079	hybrid			2022-12-25	WOS:000229741800003
J	Planaguma, A; Claria, J; Miquel, R; Lopez-Parra, M; Titos, E; Masferrer, JL; Arroyo, V; Rodes, J				Planaguma, A; Claria, J; Miquel, R; Lopez-Parra, M; Titos, E; Masferrer, JL; Arroyo, V; Rodes, J			The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation	FASEB JOURNAL			English	Article						inflammation; liver injury; Kupffer cells; hepatic stellate cells; nuclear receptors	HEPATIC STELLATE CELLS; RECEPTOR-GAMMA; RAT-LIVER; PROSTAGLANDIN E-2; RENAL-FUNCTION; KUPFFER CELLS; IN-VITRO; EXPRESSION; DISEASE; CIRRHOSIS	The importance of inflammation in initiating the sequence of events that lead to liver fibrosis is increasingly recognized. In this study, we tested the effects of SC-236, a selective cyclooxygenase (COX)-2 inhibitor, in rats with carbon tetrachloride (CCl4)-induced liver fibrosis. Livers from CCl4-treated rats showed increased COX-2 expression and 15-deoxyprostaglandin (PG)J(2) (15d-PGJ(2)) formation, as well as decreased peroxisome proliferator-activated receptor (PPAR)gamma expression. In these animals, SC-236 reduced liver fibrosis as revealed by histological analysis and by a reduction in hepatic hydroxyproline levels, metalloproteinase-2 activity, and alpha-smooth muscle actin expression. Interestingly, SC-236 normalized 15d-PGJ(2) levels and restored PPAR gamma expression in the liver Of CCl4-treated rats. In isolated hepatic stellate cells (HSCs)-the major player in liver fibrogenesis-and Kupffer cells-the cell type primarily responsible for increased hepatic COX-2-SC-236 exhibited remarkable pro-apoptotic and growth inhibitory properties. Of interest, SC-236 decreased HSC viability to a similar extent than the PPAR gamma ligand rosiglitazone. Moreover, SC-236 significantly induced PPAR gamma expression in HSCs and acted as a potent PPAR gamma agonist in a luciferase-reporter trans-activation assay. These data indicate that, by mechanisms involving non-parenchymal cell apoptosis and PPAR gamma activation, the selective COX-2 inhibitor SC-236 might have therapeutic potential for prevention of liver fibrosis.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Claria, J (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin, DNA Unit, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019; Arroyo, Vicente/F-9189-2015	Titos, Esther/0000-0002-2543-2243; Arroyo, Vicente/0000-0002-2728-1848; Claria, Joan/0000-0003-4333-7749				Badawi AF, 2004, CANCER RES, V64, P1181, DOI 10.1158/0008-5472.CAN-03-2556; Bataller R, 2001, HEPATOLOGY, V33, P956, DOI 10.1053/jhep.2001.23500; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bosch-Marce M, 1999, GASTROENTEROLOGY, V116, P1167, DOI 10.1016/S0016-5085(99)70020-X; Brenner DA, 2000, J HEPATOL, V32, P32, DOI 10.1016/S0168-8278(00)80413-4; Cheng JD, 2002, HEPATOL RES, V23, P185, DOI 10.1016/S1386-6346(01)00177-2; Claria J, 2003, PROSTAG OTH LIPID M, V72, P19, DOI 10.1016/S1098-8823(03)00075-3; Claria J, 2003, CURR PHARM DESIGN, V9, P2177, DOI 10.2174/1381612033454054; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Deulofeu R, 2000, CLIN SCI, V99, P315, DOI 10.1042/CS20000127; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Efsen E, 2001, HEPATOLOGY, V33, P713, DOI 10.1053/jhep.2001.22761; Endoh T, 1996, CARCINOGENESIS, V17, P467, DOI 10.1093/carcin/17.3.467; Enomoto N, 2000, AM J PHYSIOL-GASTR L, V279, pG100, DOI 10.1152/ajpgi.2000.279.1.G100; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Friedman SL, 2005, J CLIN INVEST, V115, P29, DOI 10.1172/JCI200523928; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; Galli A, 2002, GASTROENTEROLOGY, V122, P1924, DOI 10.1053/gast.2002.33666; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; GEERTS A, 1988, J HEPATOL, V6, P50, DOI 10.1016/S0168-8278(88)80461-6; Hazra S, 2004, J BIOL CHEM, V279, P11392, DOI 10.1074/jbc.M310284200; Hui AY, 2004, J HEPATOL, V41, P251, DOI 10.1016/j.jhep.2004.04.033; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lopez-Parra M, 2005, J HEPATOL, V42, P75, DOI 10.1016/j.jhep.2004.09.011; Lopez-Parra M, 2002, BRIT J PHARMACOL, V135, P891, DOI 10.1038/sj.bjp.0704528; Maddox JF, 2004, TOXICOL SCI, V77, P290, DOI 10.1093/toxsci/kfh028; Marra F, 2000, GASTROENTEROLOGY, V119, P466, DOI 10.1053/gast.2000.9365; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Miyajima A, 2001, J UROLOGY, V166, P1124, DOI 10.1016/S0022-5347(05)65933-2; Mohammed NA, 2004, J CLIN PATHOL, V57, P350, DOI 10.1136/jcp.2003.012120; Nanji AA, 1997, GASTROENTEROLOGY, V112, P943, DOI 10.1053/gast.1997.v112.pm9041257; Nanji AA, 1997, HEPATOLOGY, V26, P1538, DOI 10.1002/hep.510260622; Negishi M, 2002, PROSTAG OTH LIPID M, V68-9, P611, DOI 10.1016/S0090-6980(02)00059-X; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Souto EO, 2001, AM J PHYSIOL-GASTR L, V280, pG805, DOI 10.1152/ajpgi.2001.280.5.G805; Titos E, 2003, FASEB J, V17, P1745, DOI 10.1096/fj.02-1157fje; Tome S, 2004, ALIMENT PHARM THER, V19, P707, DOI 10.1111/j.1365-2036.2004.01881.x; Tsai CH, 2003, J ORAL PATHOL MED, V32, P146, DOI 10.1034/j.1600-0714.2003.00004.x; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wong BCY, 2004, GASTROENTEROLOGY, V126, P136, DOI 10.1053/j.gastro.2003.10.063; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Yamamoto H, 2003, GASTROENTEROLOGY, V125, P556, DOI 10.1016/S0016-5085(03)00904-1	53	116	124	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1120	+		10.1096/fj.04-2753fje	http://dx.doi.org/10.1096/fj.04-2753fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15876570				2022-12-25	WOS:000229602600019
J	Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C				Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C			A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes	ONCOGENE			English	Article						8p11-12 amplicon; breast cancer; array-CGH; minimal region of amplification; candidate oncogene	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CHROMOSOME ARM 8P; CELL-LINES; COLORECTAL-CANCER; HOMOZYGOUS DELETION; DNA AMPLIFICATION; PROGNOSTIC INDEX; BINDING-PROTEIN; MICROARRAYS	Amplification of 8p11-12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11-12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray pro. ling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11-12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplication. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11-12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.	Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, Res Ctr, MRC, Cambridge CB2 2XZ, England; City Hosp NHS Trust, Dept Histopathol, Breast Unit, Nottingham NG5 1PB, England	University of Cambridge; University of Cambridge; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Caldas, C (corresponding author), Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Edwards, Paul A/M-8291-2014; Caldas, Carlos/A-7543-2008; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019; García, María J/G-1361-2016; Özdag, Hilal/C-9929-2009	Edwards, Paul A/0000-0002-4789-3374; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912; Özdag, Hilal/0000-0001-7940-2499; Ellis, Ian/0000-0001-5292-8474; chin, suet-feung/0000-0001-5697-1082; Naderi, Ali/0000-0001-7142-7616				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Agresti A., 2013, CATEGORICAL DATA ANA, V3rd; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bayani J, 2002, CANCER RES, V62, P3466; Bhattacharya N, 2004, EXP MOL PATHOL, V76, P264, DOI 10.1016/j.yexmp.2004.01.002; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; EMI M, 1992, CANCER RES, V52, P5368; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Flanagan JM, 2004, GENE CHROMOSOME CANC, V40, P247, DOI 10.1002/gcc.20039; Forozan F, 2000, CANCER RES, V60, P4519; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Greshock J, 2004, GENOME RES, V14, P179; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hyman E, 2002, CANCER RES, V62, P6240; Ikegawa S, 1999, J HUM GENET, V44, P337, DOI 10.1007/s100380050172; Ikegawa S, 1999, CYTOGENET CELL GENET, V85, P227, DOI 10.1159/000015298; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Ladomery M, 2002, ANN HUM GENET, V66, P331, DOI 10.1017/S0003480002001215; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Parker C, 2001, BRIT J CANCER, V85, P1958, DOI 10.1054/bjoc.2001.2178; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rew DA, 2003, EUR J SURG ONCOL, V29, P764, DOI 10.1016/S0748-7983(03)00083-0; Sambrook J., 2001, MOL CLONING LAB MANU; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	49	123	128	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5235	5245		10.1038/sj.onc.1208741	http://dx.doi.org/10.1038/sj.onc.1208741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897872				2022-12-25	WOS:000230964600010
J	Liebau, E; De Maria, F; Burmeister, C; Perbandt, M; Turella, P; Antonini, G; Federici, G; Giansanti, F; Stella, L; Lo Bello, M; Caccuri, AM; Ricci, G				Liebau, E; De Maria, F; Burmeister, C; Perbandt, M; Turella, P; Antonini, G; Federici, G; Giansanti, F; Stella, L; Lo Bello, M; Caccuri, AM; Ricci, G			Cooperativity and pseudo-cooperativity in the glutathione S-transferase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; IDENTIFICATION; P1-1; RAT; FLUORESCENCE; ENZYME; SITE; IRON; MU	Binding and catalytic properties of glutathione S-transferase from Plasmodium falciparum (PfGST) have been studied by means of fluorescence, steady state and pre-steady state kinetic experiments, and docking simulations. This enzyme displays a peculiar reversible low-high affinity transition, never observed in other GSTs, which involves the G-site and shifts the apparent K-D for glutathione (GSH) from 200 to 0.18 mM. The transition toward the high affinity conformation is triggered by the simultaneous binding of two GSH molecules to the dimeric enzyme, and it is manifested as an uncorrected homotropic behavior, termed "pseudo-cooperativity." The high affinity enzyme is able to activate GSH, lowering its pK(a) value from 9.0 to 7.0, a behavior similar to that found in all known GSTs. Using 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, this enzyme reveals a potential optimized mechanism for the GSH conjugation but a low catalytic efficiency mainly due to a very low affinity for this co-substrate. Conversely, PfGST efficiently binds one molecule of hemin/monomer. The binding is highly cooperative (nH = 1.8) and occurs only when GSH is bound to the enzyme. The thiolate of GSH plays a crucial role in the intersubunit communication because no cooperativity is observed when S-methylglutathione replaces GSH. Docking simulations suggest that hemin binds to a pocket leaning into both the G-site and the H-site. The iron is coordinated by the amidic nitrogen of Asn-115, and the two carboxylate groups are in electrostatic interaction with the is an element of-amino group of Lys-15. Kinetic and structural data suggest that PfGST evolved by optimizing its binding property with the parasitotoxic hemin rather than its catalytic efficiency toward toxic electrophilic compounds.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Bernhard Nocht Inst Trop Med, Dept Biochem, D-20359 Hamburg, Germany; Univ Hamburg, Dept Biochem & Mol Biol, D-20146 Hamburg, Germany; Univ Rome, Dept Biol, I-00146 Rome, Italy; IRCCS, Childrens Hosp, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; Sapienza University Rome	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy.	riccig@uniroma2.it	Perbandt, Markus/K-7603-2018; CACCURI, ANNA MARIA/AFU-2643-2022; Giansanti, Francesco/AAW-7129-2020; Stella, Lorenzo/A-7996-2010	Stella, Lorenzo/0000-0002-5489-7381; Antonini, Giovanni/0000-0002-2115-8961; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846; Giansanti, Francesco/0000-0002-8335-3412				Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; DILLIO C, 1988, BIOCHEM J, V255, P971; DUBOIS VL, 1995, EXP PARASITOL, V81, P117, DOI 10.1006/expr.1995.1099; Egan TJ, 2002, BIOCHEM J, V365, P343, DOI 10.1042/BJ20020793; Famin O, 1999, BIOCHEM PHARMACOL, V58, P59, DOI 10.1016/S0006-2952(99)00059-3; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gryczynski Z, 1997, METHOD ENZYMOL, V278, P538; Harwaldt P, 2002, BIOL CHEM, V383, P821, DOI 10.1515/BC.2002.086; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEBELLO M, 1995, J BIOL CHEM, V270, P1249; Liebau E, 2002, MOL BIOCHEM PARASIT, V124, P85, DOI 10.1016/S0166-6851(02)00160-3; Lien S, 2001, J BIOL CHEM, V276, P35599, DOI 10.1074/jbc.M103789200; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Perbandt M, 2004, J BIOL CHEM, V279, P1336, DOI 10.1074/jbc.M309663200; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 2003, BIOCHEM J, V376, P71, DOI 10.1042/BJ20030860; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; STRIVASTAVA P, 1999, TROP MED INT HEALTH, V4, P251; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	33	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26121	26128		10.1074/jbc.M503889200	http://dx.doi.org/10.1074/jbc.M503889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888443	hybrid			2022-12-25	WOS:000230386800024
J	Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y				Rong, R; Montalbano, J; Jin, WX; Zhang, J; Garling, M; Sheikh, MS; Huang, Y			Oncogenic Ras-mediated downregulation of Gadd153/CHOP is required for Ras-induced cellular transformation	ONCOGENE			English	Article						Ras; Gadd153; gene regulation; transformation	MESSENGER-RNA STABILITY; INTESTINAL EPITHELIAL-CELLS; INDUCED APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; SENSITIZES CELLS; DEATH RECEPTOR-5; GENOTOXIC STRESS; GROWTH ARREST; PROTEIN PAR-4	Oncogenic Ras proteins transform cells via multiple downstream signaling cascades that are important for cell proliferation and survival. Gadd153, also known as CHOP, is a growth inhibitory and proapoptotic protein and its expression is upregulated by many agents that induce apoptosis. Here, we report our novel findings that oncogenic Ras downregulates Gadd153 expression at both protein and mRNA levels and that such downregulation occurs, at least in part, via decreases in GADD153 mRNA stability. Gadd153 downregulation is specific to oncogenic Ras since another oncogenic family member R-Ras2/TC21 does not downregulate Gadd153. W e further demonstrate that the expression of exogenous Gadd153 interferes with Ras-induced oncogenic transformation, which suggests that downregulation of Gadd153 appears to be an important mechanism by which oncogenic Ras promotes cellular transformation. Thus, oncogenic Ras-mediated cellular transformation also involves down-modulation of important molecules such as Gadd153 that negatively regulate cell growth and survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271, R21DK062136] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK067271-01, DK62136-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chen CH, 1996, ONCOGENE, V13, P1659; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Halleck MM, 1997, J BIOL CHEM, V272, P21760, DOI 10.1074/jbc.272.35.21760; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang Y, 2001, CANCER RES, V61, P6918; HUANG Y, 1995, ONCOGENE, V11, P1255; JACKMAN J, 1994, CANCER RES, V54, P5656; Jousse C, 2001, NUCLEIC ACIDS RES, V29, P4341, DOI 10.1093/nar/29.21.4341; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XZ, 1996, MOL CELL BIOL, V16, P4273	53	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4867	4872		10.1038/sj.onc.1208660	http://dx.doi.org/10.1038/sj.onc.1208660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870698				2022-12-25	WOS:000230477900014
J	Sakakibara, K; Kubota, K; Worku, B; Ryer, EJ; Miller, JP; Koff, A; Kent, KC; Liu, B				Sakakibara, K; Kubota, K; Worku, B; Ryer, EJ; Miller, JP; Koff, A; Kent, KC; Liu, B			PDGF-BB regulates p27 expression through ERK-dependent RNA turn-over in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA; INHIBITOR P27(KIP1); DOWN-REGULATION; MICE LACKING; PROLIFERATION; MIGRATION; RAPAMYCIN; TRANSLATION; HYPERPLASIA	Cyclin- dependent kinase inhibitor p27, a critical determinant for cell cycle progression, is an important regulation target of mitogenic signals during arterial injury. In this study, we show in rat aortic smooth muscle cells that PDGF- BB down- regulated p27 protein and mRNA in an ERK- dependent mechanism. Inhibition of ERK, but not other subtypes of the mitogen- activated protein kinase family, prevented the reduction of p27 protein and mRNA. Conversely, direct activation of ERK via adenovirus- mediated expression of a constitutively active form of MEK led to a reduction of p27 protein and mRNA, further supporting the central role of ERK in regulation of p27 expression. Rapamycin, which potently inhibited PDGF- induced activation of p70 S6 kinase as well as proliferation of smooth muscle cells, did not alter the expression of p27. To delineate the molecular mechanism underlying the p27 down- regulation, we examined the effect of PDGF- BB on p27 promoter activity as well as mRNA stability. Stimulation with PDGF- BB significantly shortened the half- life of p27 mRNA without affecting its promoter activity. To further understand the PDGF- stimulated p27 mRNA turnover, we inserted the 5 '- and/ or 3 '- untranslated regions of p27 cDNA into a non- PDGF- responsive luciferase gene. Only those chimeric genes that contained the 3 '- untranslated region responded to PDGF- BB with reduced expression. Moreover, inhibition of ERK completely prevented the effect of PDGF on the chimera expression. In summary, our data suggest that p27 is down- regulated by PDGF- BB in vascular smooth muscle cells through an ERK- dependent posttranscriptional mechanism.	Cornell Univ, Weill Med Coll, Dept Surg, Div Vasc Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Liu, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Surg, Div Vasc Surg, 1300 York Ave,Rm P707, New York, NY 10021 USA.	bol2001@med.cornell.edu		Koff, Andrew/0000-0003-3271-3067	NATIONAL CANCER INSTITUTE [T32CA068971] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068673] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA68971-07] Funding Source: Medline; NHLBI NIH HHS [HL-68673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Boehm M, 2004, J CLIN INVEST, V114, P419, DOI 10.1172/jci200420176; Braun-Dullaeus RC, 1999, J CLIN INVEST, V104, P815, DOI 10.1172/JCI5339; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Gennaro G, 2004, CIRCULATION, V110, P3367, DOI 10.1161/01.CIR.0000147773.86866.CD; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Jiang B, 1996, SURGERY, V120, P427, DOI 10.1016/S0039-6060(96)80319-9; Kavurma MM, 2003, J CELL BIOCHEM, V89, P289, DOI 10.1002/jcb.10497; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kubota K, 2003, J SURG RES, V109, P43, DOI 10.1016/S0022-4804(02)00037-9; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liu B, 2002, SURGERY, V132, P317, DOI 10.1067/msy.2002.125786; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; Marx SO, 2001, CIRCULATION, V104, P852, DOI 10.1161/01.CIR.104.8.852; Mii S, 1996, AM J PHYSIOL-HEART C, V270, pH142, DOI 10.1152/ajpheart.1996.270.1.H142; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nelson PR, 1998, J VASC SURG, V27, P117, DOI 10.1016/S0741-5214(98)70298-8; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shim J, 2002, MOL CELLS, V14, P323; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8	38	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25470	25477		10.1074/jbc.M502320200	http://dx.doi.org/10.1074/jbc.M502320200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15894805	hybrid			2022-12-25	WOS:000230207900021
J	Sauri, A; Saksena, S; Salgado, J; Johnson, AE; Mingarro, I				Sauri, A; Saksena, S; Salgado, J; Johnson, AE; Mingarro, I			Double-spanning plant viral movement protein integration into the endoplasmic reticulum membrane is signal recognition particle-dependent, translocon-mediated, and concerted	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-CELL MOVEMENT; COTRANSLATIONAL INTEGRATION; NASCENT PREPROLACTIN; PURIFIED COMPONENTS; CROSS-LINKING; ER MEMBRANE; AMINO-ACID; POLYPEPTIDE; SEQUENCE; VIRUSES	The current model for cell- to- cell movement of plant viruses holds that transport requires virus- encoded movement proteins that intimately associate with endoplasmic reticulum membranes. We have examined the early stages of the integration into endoplasmic reticulum membranes of a double- spanning viral movement protein using photocross- linking. We have discovered that this process is cotranslational and proceeds in a signal recognition particle- dependent manner. In addition, nascent chain photocross- linking to Sec61 alpha and translocating chain- associated membrane protein reveal that viral membrane protein insertion takes place via the translocon, as with most eukaryotic membrane proteins, but that the two transmembrane segments of the viral protein leave the translocon and enter the lipid bilayer together.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	University of Valencia; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Mingarro, I (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain.	Ismael.Mingarro@uv.es	Salgado, Jesús/A-7759-2013; Johnson, Arthur E/G-3457-2012; Mingarro, Ismael/B-4745-2014	Salgado, Jesús/0000-0002-8537-1550; Mingarro, Ismael/0000-0002-1910-1229	NIGMS NIH HHS [R01 GM26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alder NN, 2004, J BIOL CHEM, V279, P22787, DOI 10.1074/jbc.R400002200; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; de Gier JWL, 2003, EMBO REP, V4, P939, DOI 10.1038/sj.embor.embor921; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Heinrich SU, 2000, CELL, V102, P233, DOI 10.1016/S0092-8674(00)00028-3; Heinrich SU, 2003, EMBO J, V22, P3654, DOI 10.1093/emboj/cdg346; Houben ENG, 2004, EMBO REP, V5, P970, DOI 10.1038/sj.embor.7400261; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; McLean Barbara Gail, 1993, Trends in Microbiology, V1, P105, DOI 10.1016/0966-842X(93)90116-9; Meacock SL, 2002, MOL BIOL CELL, V13, P4114, DOI 10.1091/mbc.E02-04-0198; Mitra R, 2003, VIROLOGY, V312, P35, DOI 10.1016/S0042-6822(03)00180-6; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MUSHEGIAN AR, 1993, ARCH VIROL, V133, P239, DOI 10.1007/BF01313766; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Peremyslov VV, 2004, J VIROL, V78, P3704, DOI 10.1128/JVI.78.7.3704-3709.2004; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Saksena S, 2004, P NATL ACAD SCI USA, V101, P12537, DOI 10.1073/pnas.0404934101; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Vilar M, 2002, J BIOL CHEM, V277, P23447, DOI 10.1074/jbc.M202935200; Vilar M, 2001, J BIOL CHEM, V276, P18122, DOI 10.1074/jbc.M100706200; WALTER P, 1983, METHOD ENZYMOL, V96, P84; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	35	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25907	25912		10.1074/jbc.M412476200	http://dx.doi.org/10.1074/jbc.M412476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888454	hybrid, Green Published			2022-12-25	WOS:000230207900071
J	Smith, KM; Slugoski, MD; Loewen, SK; Ng, AML; Yao, SYM; Chen, XZ; Karpinski, E; Cass, CE; Baldwin, SA; Young, JD				Smith, KM; Slugoski, MD; Loewen, SK; Ng, AML; Yao, SYM; Chen, XZ; Karpinski, E; Cass, CE; Baldwin, SA; Young, JD			The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; NA+ GLUCOSE COTRANSPORTER; NA+/GLUCOSE COTRANSPORTER; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI; VOLTAGE-CLAMP; ELECTROPHYSIOLOGICAL CHARACTERIZATION; ELECTROGENIC PROPERTIES; PYRIMIDINE NUCLEOSIDES; NUCLEOBASE TRANSPORT	The concentrative nucleoside transporter (CNT) protein family in humans is represented by three members, hCNT1, hCNT2, and hCNT3. hCNT3, a Na+/nucleoside symporter, transports a broad range of physiological purine and pyrimidine nucleosides as well as anticancer and antiviral nucleoside drugs, and belongs to a different CNT subfamily than hCNT1/2. H+-dependent Escherichia coli NupC and Candida albicans CaCNT are also CNT family members. The present study utilized heterologous expression in Xenopus oocytes to investigate the specificity, mechanism, energetics, and structural basis of hCNT3 cation coupling. hCNT3 exhibited uniquely broad cation interactions with Na+, H+, and Li+ not shared by Na+ coupled hCNT1/2 or H+ - coupled NupC/CaCNT. Na+ and H+ activated hCNT3 through mechanisms to increase nucleoside apparent binding affinity. Direct and indirect methods demonstrated cation/nucleoside coupling stoichiometries of 2:1 in the presence of Na+ and both Na+ plus H+, but only 1:1 in the presence of H+ alone, suggesting that hCNT3 possesses two Na+- binding sites, only one of which is shared by H+. The H+- coupled hCNT3 did not transport guanosine or 3'-azido-3'-deoxythymidine and 2',3'-dideoxycytidine, demonstrating that Na+- and H+-bound versions of hCNT3 have significantly different conformations of the nucleoside binding pocket and/ or translocation channel. Chimeric studies between hCNT1 and hCNT3 located hCNT3-specific cation interactions to the C-terminal half of hCNT3, setting the stage for site-directed mutagenesis experiments to identify the residues involved.	Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Prot Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	james.young@ualberta.ca						Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P78, DOI 10.1007/BF00378644; CASS E, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; Diez-Sampedro A, 2003, P NATL ACAD SCI USA, V100, P11753, DOI 10.1073/pnas.1733027100; Diez-Sampedro A, 2001, AM J PHYSIOL-RENAL, V280, pF278, DOI 10.1152/ajprenal.2001.280.2.F278; Engel K, 2004, J BIOL CHEM, V279, P50042, DOI 10.1074/jbc.M407913200; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; HANDSCHUMACHER RE, 1993, CANC METABOLISM, P712; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; Hong M, 2001, J PHARMACOL EXP THER, V296, P141; Hong M, 2000, J PHARMACOL EXP THER, V292, P366; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; KRUPKA RM, 1994, BBA-BIOMEMBRANES, V1193, P165, DOI 10.1016/0005-2736(94)90346-8; KRUPKA RM, 1993, BIOCHIM BIOPHYS ACTA, V1183, P105, DOI 10.1016/0005-2728(93)90009-5; Larrayoz IM, 2004, J BIOL CHEM, V279, P8999, DOI 10.1074/jbc.M311940200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Loewen SK, 2004, MOL MEMBR BIOL, V21, P1, DOI 10.1080/0968768031000140836; Loewen SK, 2003, YEAST, V20, P661, DOI 10.1002/yea.1000; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PERIGAUD C, 1994, BIOCHEM PHARMACOL, V48, P11, DOI 10.1016/0006-2952(94)90217-8; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; RITZEL MW, 1997, AM J PHYSIOL, V272, P707; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Segel IH, 1975, ENZYME KINETICS, P346; Seyfang A, 1997, J BIOL CHEM, V272, P24210, DOI 10.1074/jbc.272.39.24210; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Smith KM, 2004, BIOPHYS J, V86, p262A; Smith KM, 2004, J PHYSIOL-LONDON, V558, P807, DOI 10.1113/jphysiol.2004.068189; STEIN WD, 1990, CHANNELS CARRIERS PU, P173; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; WRIGHT EM, 1994, J EXP BIOL, V196, P197; WU XC, 1992, J BIOL CHEM, V267, P8813; Xiao GQ, 2001, MOL PHARMACOL, V59, P339, DOI 10.1124/mol.59.2.339; Yao SY, 2002, AM J PHYSIOL-CELL PH, V283, pC155, DOI 10.1152/ajpcell.00587.2001; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Young JD, 2001, CURR TOP MEMBR, V50, P329	64	64	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25436	25449		10.1074/jbc.M409454200	http://dx.doi.org/10.1074/jbc.M409454200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15870078	hybrid			2022-12-25	WOS:000230207900018
J	Auesukaree, C; Tochio, H; Shirakawa, M; Kaneko, Y; Harashima, S				Auesukaree, C; Tochio, H; Shirakawa, M; Kaneko, Y; Harashima, S			Plc1p, Arg82p, and Kcs1p, enzymes involved in inositol pyrophosphate synthesis, are essential for phosphate regulation and polyphosphate accumulation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; MESSENGER-RNA EXPORT; CYCLIN-CDK COMPLEX; PHOSPHOLIPASE-C; SYNAPTIC-TRANSMISSION; KINASE-ACTIVITY; GENE; YEAST; PROTEIN; ACID	In Saccharomyces cerevisiae, the phosphate signal transduction PHO pathway is involved in regulating several phosphate-responsive genes such as PHO5, which encodes repressible acid phosphatase. In this pathway, a cyclin-dependent kinase inhibitor (Pho81p) regulates the kinase activity of the cyclin-cyclin-dependent kinase complex Pho80p-Pho85p, which phosphorylates the transcription factor Pho4p in response to intracellular phosphate levels. However, how cells sense phosphate availability and transduce the phosphate signal to Pho81p remains unknown. To identify additional components of the PHO pathway, we have screened a collection of yeast deletion strains. We found that disruptants of PLC1, ARG82, and KCS1, which are involved in the synthesis of inositol polyphosphate, and ADK1, which encodes adenylate kinase, constitutively express PHO5. Each of these factors functions upstream of Pho81p and negatively regulates the PHO pathway independently of intracellular orthophosphate levels. Overexpression of KCS1, but not of the other genes, suppressed PHO5 expression in the wild-type strain under low phosphate conditions. These results raise the possibility that diphosphoinositol tetrakisphosphate and/or bisdiphosphoinositol triphosphate may be essential for regulation of the PHO pathway. Furthermore, the Delta plc1, Delta arg82, and Delta kcs1 deletion strains, but not the Delta ipk1 deletion strain, had significantly reduced intracellular polyphosphate levels, suggesting that enzymes involved in inositol pyrophosphate synthesis are also required for polyphosphate accumulation.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Sci Biol Supramol Syst, Yokohama, Kanagawa 2310045, Japan	Osaka University; Yokohama City University	Harashima, S (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	harashima@bio.eng.osaka-u.ac.jp	Tochio, Hidehito/F-6109-2011; Tochio, Hidehito/GWV-0429-2022; Auesukaree, Choowong/J-3484-2016; Auesukaree, Choowong/AAE-8614-2022; Auesukaree, Choowong/V-8254-2019	Tochio, Hidehito/0000-0003-3843-3330; Auesukaree, Choowong/0000-0002-5655-0058; Auesukaree, Choowong/0000-0002-5655-0058				ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Auesukaree C, 2004, J BIOL CHEM, V279, P17289, DOI 10.1074/jbc.M312202200; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Brachmann CB, 1998, YEAST, V14, P115; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; Burke D., 2000, METHODS YEAST GENETI; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; El Alami M, 2003, MOL MICROBIOL, V49, P457, DOI 10.1046/j.1365-2958.2003.03562.x; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GRAF E, 1987, J BIOL CHEM, V262, P11647; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang SD, 2005, GENETICS, V169, P1859, DOI 10.1534/genetics.104.038695; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Knight JP, 2004, CURR GENET, V46, P10, DOI 10.1007/s00294-004-0502-z; Lecoq K, 2001, YEAST, V18, P335, DOI 10.1002/1097-0061(20010315)18:4<335::AID-YEA674>3.0.CO;2-X; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MORTON RK, 1963, NATURE, V200, P429, DOI 10.1038/200429a0; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; Persson BL, 2003, CURR GENET, V43, P225, DOI 10.1007/s00294-003-0400-9; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TOHE A, 1975, MOL GEN GENET, V143, P65, DOI 10.1007/BF00269421; TORRIANIGORINI A, 1994, PHOSPHATE MICROORGAN; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Waters NC, 2004, CURR GENET, V46, P1, DOI 10.1007/s00294-004-0501-0; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	51	79	82	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25127	25133		10.1074/jbc.M414579200	http://dx.doi.org/10.1074/jbc.M414579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866881	hybrid			2022-12-25	WOS:000230114000097
J	Bang, R; Marnell, L; Mold, C; Stein, MP; Du Clos, KT; Chivington-Buck, C; Du Clos, TW				Bang, R; Marnell, L; Mold, C; Stein, MP; Du Clos, KT; Chivington-Buck, C; Du Clos, TW			Analysis of binding sites in human C-reactive protein for Fc gamma RI, Fc gamma RIIA, and C1q by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; CRYSTAL-STRUCTURE; SYNTHETIC PEPTIDE; HUMAN IGG1; C1Q-BINDING SITE; HUMAN MONOCYTES; MOLECULAR-BASIS; RECEPTOR; EXPRESSION; AFFINITY	Human C-reactive protein (CRP) is a classical, acute phase serum protein synthesized by the liver in response to infection, inflammation, or trauma. CRP binds to microbial antigens and damaged cells, opsonizes particles for phagocytosis and regulates the inflammatory response by the induction of cytokine synthesis. These activities of CRP depend on its ability to activate complement and to bind to Fc gamma receptors (Fc gamma R). The goal of this study was to elucidate amino acid residues important for the interaction of CRP with human Fc gamma RI (CD64) and Fc gamma RIIa (CD32). Several mutations of the CRP structure were studied based on the published crystal structure of CRP. Mutant and wild-type recombinant CRP molecules were expressed in the baculovirus system and their interactions with Fc gamma R and C1q were determined. A previous study by our laboratory identified an amino acid position, Leu(176), critical for CRP binding to Fc gamma RI and work by others (Agrawal, A., Shrive, A. K., Greenhough, T. J., and Volanakis, J. E. (2001) J. Immunol. 166, 3998-4004) determined several residues important for C1q binding. The amino acid residues important to CRP binding to Fc gamma RIIa were previously unknown. This study newly identifies residues Thr(173) and Asn(186) as important for the binding of CRP to Fc gamma RIIa and Fc gamma RI. Lys(114), like Leu(176), was implicated in binding to Fc gamma RI, but not Fc gamma RIIa. Single mutations at amino acid positions Lys(114), Asp(169), Thr(173), Tyr(175), and Leu(176) affected C1q binding to CRP. These results further identify amino acids involved in the binding sites on CRP for Fc gamma RI, Fc gamma RIIa, and C1q and indicate that these sites are overlapping.	Dept Vet Affairs Med Ctr, Albuquerque, NM 87108 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico	Du Clos, TW (corresponding author), Vet Adm Med Ctr, Res Serv, 1501 San Pedro SE, Albuquerque, NM 87108 USA.	tduclos@unm.edu		Du Clos, Kevin/0000-0002-3017-7777	NIAID NIH HHS [AI 28358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028358, R29AI028358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998; AGRAWAL A, 1994, J IMMUNOL, V152, P5404; Barna BP, 1996, J LEUKOCYTE BIOL, V59, P397, DOI 10.1002/jlb.59.3.397; BARNA BP, 1994, CANCER IMMUNOL IMMUN, V38, P38, DOI 10.1007/s002620050032; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Bharadwaj D, 2001, J IMMUNOL, V166, P6735, DOI 10.4049/jimmunol.166.11.6735; Bodman-Smith KB, 2004, J LEUKOCYTE BIOL, V75, P1029, DOI 10.1189/jlb.0703306; Bodman-Smith KB, 2002, IMMUNOLOGY, V107, P252, DOI 10.1046/j.1365-2567.2002.01481.x; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CROWELL RE, 1991, J IMMUNOL, V147, P3445; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; Du Clos TW, 2001, J CLIN INVEST, V107, P642; DUCLOS TW, 1991, J BIOL CHEM, V266, P2167; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; GEARHART PJ, 1975, J EXP MED, V141, P56, DOI 10.1084/jem.141.1.56; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Hundt M, 2001, EUR J IMMUNOL, V31, P3475, DOI 10.1002/1521-4141(200112)31:12<3475::AID-IMMU3475>3.0.CO;2-1; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; Iwaki D, 1999, EUR J BIOCHEM, V264, P314, DOI 10.1046/j.1432-1327.1999.00588.x; Kabat EA, 1991, SEQUENCES PROTEINS I; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; LUND J, 1991, J IMMUNOL, V147, P2657; Makunin I. V., 1999, Genetika, V35, P1071; MANOLOV DE, 2004, ATERIOSCLER THROMB V, V24, P1; MARNELL L, 1995, PROTEIN EXPRES PURIF, V6, P439, DOI 10.1006/prep.1995.1059; MARNELL LL, 1995, J IMMUNOL, V155, P2185; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Mold C, 2001, J IMMUNOL, V166, P1200, DOI 10.4049/jimmunol.166.2.1200; NAKAYAMA S, 1982, J IMMUNOL, V128, P2435; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; ROBEY FA, 1981, J BIOL CHEM, V256, P969; Saeland E, 2001, J CLIN INVEST, V107, P641, DOI 10.1172/JCI12418; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Stein MP, 2000, J CLIN INVEST, V105, P369, DOI 10.1172/JCI7817; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9; VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; WOO P, 1985, J BIOL CHEM, V260, P3384; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; YING SC, 1989, J IMMUNOL, V143, P221; ZHOU P, 1995, CLIN IMMUNOL IMMUNOP, V74, P84, DOI 10.1006/clin.1995.1012	52	75	82	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25095	25102		10.1074/jbc.M504782200	http://dx.doi.org/10.1074/jbc.M504782200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878871	hybrid, Green Submitted			2022-12-25	WOS:000230114000093
J	Degerny, C; Monte, D; Beaudoin, C; Jaffray, E; Portois, L; Hay, RT; de Launoit, Y; Baert, JL				Degerny, C; Monte, D; Beaudoin, C; Jaffray, E; Portois, L; Hay, RT; de Launoit, Y; Baert, JL			SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME UBC9; ANDROGEN RECEPTOR; IN-VIVO; HISTONE DEACETYLASE-1; COVALENT ATTACHMENT; FACTOR ER81; PEA3 GROUP; C-JUN; UBIQUITIN; NUCLEAR	A variety of transcription factors are post- translationally modified by SUMO, a 97- residue ubiquitin- like protein bound covalently to the targeted lysine. Here we describe SUMO modification of the Ets family member ERM at positions 89, 263, 293, and 350. To investigate how SUMO modification affects the function of ERM, Ets- responsive intercellular adhesion molecule 1 ( ICAM- 1) and E74 reporter plasmids were employed to demonstrate that SUMO modification causes inhibition of ERM- dependent transcription without affecting the subcellular localization, stability, or DNA- binding capacity of the protein. When the adenoviral protein Gam1 or the SUMO protease SENP1 was used to inhibit the SUMO modification pathway, ERM- dependent transcription was de- repressed. These results demonstrate that ERM is subject to SUMO modification and that this post- translational modification causes inhibition of transcription- enhancing activity.	Univ Lille 1, CNRS, UMR 8117, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France; Univ St Andrews, Sch Biol, St Andrews KY16 9ST, Fife, Scotland; Univ Libre Bruxelles, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of St Andrews; Universite Libre de Bruxelles	de Launoit, Y (corresponding author), Univ Lille 1, CNRS, UMR 8117, Inst Biol Lille,Inst Pasteur Lille, 1 Rue Professeur Calmette, F-59021 Lille, France.	yvan.delaunoit@ibl.fr	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024; monte, didier/0000-0002-0613-6203				Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; BOFFIO R, 2004, MOL CELL, V16, P549; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; DESTERRO JM, 2003, J BIOL CHEM, V278, P31043; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Laget MP, 1996, ONCOGENE, V12, P1325; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; OHagan RC, 1996, ONCOGENE, V13, P1323; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yang SH, 2003, CELL CYCLE, V2, P528, DOI 10.4161/cc.2.6.597	48	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24330	24338		10.1074/jbc.M411250200	http://dx.doi.org/10.1074/jbc.M411250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15857832	hybrid			2022-12-25	WOS:000230114000006
J	Huang, HR; Scherman, MS; D'Haeze, W; Vereecke, D; Holsters, M; Crick, DC; McNeil, MR				Huang, HR; Scherman, MS; D'Haeze, W; Vereecke, D; Holsters, M; Crick, DC; McNeil, MR			Identification and active expression of the Mycobacterium tuberculosis gene encoding 5-phospho-alpha-D-ribose-1-diphosphate: Decaprenyl-phosphate 5-phosphoribosyltransferase, the first enzyme committed to decaprenylphosphoryl-D-arabinose synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS; MEMBRANE-PROTEINS; NOD FACTORS; CELL-WALLS; ARABINOGALACTAN; GROWTH	Decaprenylphosphoryl-D-arabinose, the lipid donor of mycobacterial D-arabinofuranosyl residues, is synthesized from phosphoribose diphosphate rather than from a sugar nucleotide. The first committed step in the process is the transfer of a 5-phosphoribosyl residue from phosphoribose diphosphate to decaprenyl phosphate to form decaprenylphosphoryl-5-phosphoribose via a 5-phospho-alpha-D-ribose-1-diphosphate: decaprenyl-phosphate 5-phospho-ribosyltransferase. A candidate for the gene encoding this enzyme (Rv3806c) was identified in Mycobacterium tuberculosis, primarily via its homology to one of four genes responsible for D-arabinosylation of nodulation factor in Azorhizobium caulinodans. The resulting protein was predicted to contain eight or nine transmembrane domains. The gene was expressed in Escherichia coli, and membranes from the expression strain of E. coli but not from a control strain of E. coli were shown to convert phosphoribose diphosphate and decaprenyl phosphate into decaprenylphosphoryl-5-phosphoribose. Neither UDP-galactose nor GDP-mannose was active as a sugar donor. The enzyme favored polyprenyl phosphate with 50 - 60 carbon atoms, was unable to use C-20 polyprenyl phosphate, and used C-75 polyprenyl phosphate less efficiently than C-50 or C-60. It requires CHAPS detergent and Mg2+ for activity. The Rv3806c gene encoding 5-phospho-alpha-D-ribose-1-diphosphate: decaprenyl-phosphate 5-phosphoribosyltransferase is known to be essential for the growth of M. tuberculosis, and the tuberculosis drug ethambutol inhibits other steps in arabinan biosynthesis. Thus the Rv3806c-encoded enzyme appears to be a good target for the development of new tuberculosis drugs.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Beijing TB & Thorac Tumor Inst, Beijing 101149, Peoples R China; State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	Colorado State University; Flanders Institute for Biotechnology (VIB); Ghent University	McNeil, MR (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	mmcneil@colostate.edu	Crick, Dean/H-8251-2017; McNeil, Michael/G-3325-2019	Crick, Dean/0000-0001-9281-7058; 	FOGARTY INTERNATIONAL CENTER [R03TW006237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706, R56AI049151, R01AI049151] Funding Source: NIH RePORTER; FIC NIH HHS [1 R03 TW006237] Funding Source: Medline; NIAID NIH HHS [AI-49151, AI-33706] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CRICK DC, 2004, TUBERCULOSIS, P115; DAFFE M, 1990, J BIOL CHEM, V265, P6734; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Lee RE, 1998, BIOORG MED CHEM LETT, V8, P951, DOI 10.1016/S0960-894X(98)00147-4; Ma YF, 2002, J BACTERIOL, V184, P3392, DOI 10.1128/JB.184.12.3392-3395.2002; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; Mergaert P, 1996, MOL MICROBIOL, V21, P409, DOI 10.1046/j.1365-2958.1996.6451366.x; Mergaert P, 1997, MOL PLANT MICROBE IN, V10, P683, DOI 10.1094/MPMI.1997.10.5.683; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHERMAN M, 1995, J BACTERIOL, V177, P7125, DOI 10.1128/jb.177.24.7125-7130.1995; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Xin Y, 1997, BBA-GEN SUBJECTS, V1335, P231, DOI 10.1016/S0304-4165(97)00002-0	16	59	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24539	24543		10.1074/jbc.M504068200	http://dx.doi.org/10.1074/jbc.M504068200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878857	hybrid			2022-12-25	WOS:000230114000031
J	Lafaye, A; Junot, C; Pereira, Y; Lagniel, G; Tabet, JC; Ezan, E; Labarre, J				Lafaye, A; Junot, C; Pereira, Y; Lagniel, G; Tabet, JC; Ezan, E; Labarre, J			Combined proteome and metabolite-profiling analyses reveal surprising insights into yeast sulfur metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHILIC INTERACTION CHROMATOGRAPHY; ELECTROSPRAY MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; S-ADENOSYLMETHIONINE; POLAR COMPOUNDS; METABOLOMICS; GLUTATHIONE; TRANSCRIPTOMICS; METABONOMICS; COMBINATION	Metabolomics is considered as an emerging new tool for functional proteomics in the identification of new protein function or in projects aiming at modeling whole cell metabolism. When combined with proteome studies, metabolite-profiling analyses revealed unanticipated insights into the yeast sulfur pathway. In response to cadmium, the observed overproduction of glutathione, essential for the detoxification of the metal, can be entirely accounted for by a marked drop in sulfur-containing protein synthesis and a redirection of sulfur metabolite fluxes to the glutathione pathway. A kinetic analysis showed sequential and dramatic changes in intermediate sulfur metabolite pools within the first hours of the treatment. Strikingly, whereas proteome and metabolic data were positively correlated under cadmium conditions, proteome and metabolic data were negatively correlated during other growth conditions, i.e. methionine supplementation or sulfate starvation. These differences can be explained by alternative mechanisms in the regulation of Met4, the activator of the sulfur pathway. Whereas Met4 activity is controlled by the cellular cysteine content in response to sulfur source and availability, the present study suggests that Met4 activation under cadmium conditions is cysteine-independent. The results clearly indicate that the metabolic state of a cell cannot be safely predicted based solely on proteomic and/or gene expression data. Combined metabolome and proteome studies are necessary to draw a comprehensive and integrated view of cell metabolism.	CEA Saclay, SBGM, DBJC, Lab PhysioGenom, F-91191 Gif Sur Yvette, France; CEA Saclay, DSV, DRM, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Univ Paris 06, CNRS UMR 7613, Lab Chim Struct Organ & Biol, F-75252 Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite	Labarre, J (corresponding author), CEA Saclay, SBGM, DBJC, Lab PhysioGenom, F-91191 Gif Sur Yvette, France.	jean.labarre@cea.fr	Junot, Christophe/AAG-2251-2020					Barbey R, 2005, EMBO J, V24, P521, DOI 10.1038/sj.emboj.7600556; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Coen M, 2004, J PHARMACEUT BIOMED, V35, P93, DOI 10.1016/j.jpba.2003.12.019; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; FERRO AJ, 1973, J BACTERIOL, V116, P812, DOI 10.1128/JB.116.2.812-817.1973; Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; Gangl ET, 2001, ANAL CHEM, V73, P5635, DOI 10.1021/ac010501i; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Lafaye A, 2005, ANAL CHEM, V77, P2026, DOI 10.1021/ac048657g; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; PASZEWSKI A, 2001, RRD MICROBIOL 1, V5, P223; Penninckx M, 2000, ENZYME MICROB TECH, V26, P737, DOI 10.1016/S0141-0229(00)00165-4; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; Strege MA, 1998, ANAL CHEM, V70, P2439, DOI 10.1021/ac9802271; TANG L, 1993, ANAL CHEM, V65, P3654, DOI 10.1021/ac00072a020; ter Kuile BH, 2001, FEBS LETT, V500, P169, DOI 10.1016/S0014-5793(01)02613-8; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; Tolstikov VV, 2002, ANAL BIOCHEM, V301, P298, DOI 10.1006/abio.2001.5513; Verhoeckx KCM, 2004, INT IMMUNOPHARMACOL, V4, P1499, DOI 10.1016/j.intimp.2004.07.008; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; Weckwerth W, 2003, ANNU REV PLANT BIOL, V54, P669, DOI 10.1146/annurev.arplant.54.031902.135014; Yen JL, 2005, MOL BIOL CELL, V16, P1872, DOI 10.1091/mbc.E04-12-1130	30	96	100	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24723	24730		10.1074/JBC.M502285200	http://dx.doi.org/10.1074/JBC.M502285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855158	hybrid			2022-12-25	WOS:000230114000053
J	Milne, GL; Gao, L; Porta, A; Zanoni, G; Vidari, G; Morrow, JD				Milne, GL; Gao, L; Porta, A; Zanoni, G; Vidari, G; Morrow, JD			Identification of the major urinary metabolite of the highly reactive cyclopentenone isoprostane 15-A(2t)-isoprostane in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST TOTAL-SYNTHESIS; LIPID-PEROXIDATION; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GLUTATHIONE TRANSFERASE; FREE-RADICALS; PRODUCT; CYSTEINE; ACID; CONJUGATION; A(2)	The cyclopentenone isoprostanes (A(2)/J(2)-IsoPs) are formed in significant amounts in humans and rodents esterified in tissue phospholipids. Nonetheless, they have not been detected unesterified in the free form, presumably because of their marked reactivity. A(2)/J(2)-IsoPs, similar to other electrophilic lipids such as 15-deoxy-Delta(12,14)-prostaglandin J(2) and 4-hydroxynonenal, contain a highly reactive alpha,beta-unsaturated carbonyl, which allows these compounds to react with thiol-containing biomolecules to produce a range of biological effects. We sought to identify and characterize in rats the major urinary metabolite of 15-A(2t)-IsoP, one of the most abundant A(2)-IsoPs produced in vivo, in order to develop a specific biomarker that can be used to quantify the in vivo production of these molecules. Following intravenous administration of 15-A(2t)-IsoP containing small amounts of [H-3(4)]15-A(2t)-IsoP, 80% of the radioactivity excreted in the urine remained in aqueous solution after extraction with organic solvents, indicating the formation of a polar conjugate(s). Using high pressure liquid chromatography/mass spectrometry, the major urinary metabolite of 15-A(2t)-IsoP was determined to be the mercapturic acid sulfoxide conjugate in which the carbonyl at C9 was reduced to an alcohol. The structure was confirmed by direct comparison to a synthesized standard and via various chemical derivatizations. In addition, this metabolite was found to be formed in significant quantities in urine from rats exposed to an oxidant stress. The identification of this metabolite combined with the finding that these metabolites are produced in in vivo settings of oxidant stress makes it possible to use this method to quantify, for the first time, the in vivo production of cyclopentenone prostanoids.	Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Nashville, TN 37232 USA; Univ Pavia, Dept Organ Chem, I-27100 Pavia, Italy	Vanderbilt University; University of Pavia	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, 526 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu	Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Vidari, Giovanni/0000-0003-4606-2154; PORTA, ALESSIO/0000-0002-2564-9696	NCI NIH HHS [CA77839, CA38079] Funding Source: Medline; NCRR NIH HHS [RR00095] Funding Source: Medline; NHLBI NIH HHS [HL07323] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038079, R55CA038079, P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARY J, 1995, CHEM RES TOXICOL, V8, P34, DOI 10.1021/tx00043a004; Altuntas TG, 2004, CHEM RES TOXICOL, V17, P435, DOI 10.1021/tx034254k; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ATSMON J, 1990, CANCER RES, V50, P1879; ATTALLAH A, 1974, PROSTAG OTH LIPID M, V5, P69, DOI 10.1016/S0090-6980(74)80133-4; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Birner G, 1998, CHEM RES TOXICOL, V11, P750, DOI 10.1021/tx970216n; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chen Y, 1999, BBA-MOL CELL BIOL L, V1436, P550, DOI 10.1016/S0005-2760(98)00168-4; Cox B, 2002, BBA-MOL CELL BIOL L, V1584, P37, DOI 10.1016/S1388-1981(02)00267-6; deZwart LL, 1996, XENOBIOTICA, V26, P1087; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HINCHMAN CA, 1994, J TOXICOL ENV HEALTH, V41, P387, DOI 10.1080/15287399409531852; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; Hubatsch I, 2002, CHEM RES TOXICOL, V15, P1114, DOI 10.1021/tx020027r; JONSSON HT, 1976, J LIPID RES, V17, P1; Krause RJ, 2002, DRUG METAB DISPOS, V30, P1137, DOI 10.1124/dmd.30.10.1137; Landar A, 2003, FREE RADICAL BIO MED, V35, pS106; LEE SC, 1974, J BIOL CHEM, V249, P1369; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; MIDDLEDITCH BS, 1975, PROSTAGLANDINS, V9, P409, DOI 10.1016/0090-6980(75)90147-1; Milne GL, 2004, CHEM RES TOXICOL, V17, P17, DOI 10.1021/tx034213o; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Musiek E, 2003, FREE RADICAL BIO MED, V35, pS56; Seibert K, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P189; SEIBERT K, 1987, P NATL ACAD SCI USA, V84, P256, DOI 10.1073/pnas.84.1.256; Sheffels P, 2004, CHEM RES TOXICOL, V17, P1177, DOI 10.1021/tx049899e; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; WEINANDER R, 1994, J BIOL CHEM, V269, P71; Zanoni G, 2003, J ORG CHEM, V68, P6005, DOI 10.1021/jo034658h; Zanoni G, 2002, J ORG CHEM, V67, P4346, DOI 10.1021/jo025652f	36	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25178	25184		10.1074/jbc.M502891200	http://dx.doi.org/10.1074/jbc.M502891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878849	hybrid			2022-12-25	WOS:000230114000102
J	Schulte, A; Czudnochowski, N; Barboric, M; Schonichen, A; Blazek, D; Peterlin, BM; Geyer, M				Schulte, A; Czudnochowski, N; Barboric, M; Schonichen, A; Blazek, D; Peterlin, BM; Geyer, M			Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ELONGATION-FACTOR-B; IMMUNODEFICIENCY-VIRUS TRANSCRIPTION; DEPENDENT KINASE CDK6; SMOOTH-MUSCLE-CELLS; P-TEFB COMPLEX; POSITIVE TRANSCRIPTION; 7SK SNRNA; CRYSTAL-STRUCTURE; GENE-EXPRESSION	The active form of the positive transcription elongation factor b (P-TEFb) consists of cyclin T and the kinase Cdk9. P-TEFb stimulates transcription by phosphorylating the C-terminal domain of RNA polymerase II. It becomes inactivated when associated in a tetrameric complex with the abundant 7SK small nuclear RNA and the recently identified protein Hexim1. In this study, we identified a stable and soluble C-terminal domain (residues 255-359) in Hexim1 of 12.5-kDa size that binds the cyclin boxes of Cyclin T1. Functional assays in HeLa cells showed that this cyclin T-binding domain (TBD) is required for the binding of Hexim1 to P-TEFb and inhibition of transcriptional activity in vivo. Analytical gel filtration and GST pull-down experiments revealed that both full-length Hexim1 and the TBD are homodimers. Isothermal titration calorimetry yielded a weak multimer for the TBD with a multimerization constant of 1.3 x 10(3) M. The binding affinity between the TBD and cyclin T1 was analyzed with fluorescence spectroscopy methods, using a dansyl-based fluorescence label at position G257C. Equilibrium fluorescence titration and stopped flow fast kinetics yield a dissociation constant of 1.2 mu M. Finally, we tested the effect of the HIV-1 Tat protein on the cyclin T1-TBD complex formation. GST pull-down experiments and size exclusion chromatography exhibit a mutually exclusive binding of the two effectors to cyclin T1. Our data suggest a model where HIV-1 Tat competes with Hexim1 for cyclin T1 binding, thus releasing P-TEFb from the inactive complex to stimulate the transcription of HIV-1 gene expression.	Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Univ Calif San Francisco, Rosalind Russel Med Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russel Med Res Ctr, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russel Med Res Ctr, Dept Immunol, San Francisco, CA 94143 USA	Max Planck Society; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Geyer, M (corresponding author), Max Planck Inst Mol Physiol, Dept Phys Biochem, Otto Hahn Str 11, D-44227 Dortmund, Germany.	matthias.geyer@mpi-dortmund.mpg.de	Barboric, Matjaz/C-9918-2009	Barboric, Matjaz/0000-0002-9715-2291; Blazek, Dalibor/0000-0003-4662-9982; Geyer, Matthias/0000-0002-7718-5002				Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Byers SA, 2005, J BIOL CHEM, V280, P16360, DOI 10.1074/jbc.M500424200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Chen RC, 2004, J BIOL CHEM, V279, P4153, DOI 10.1074/jbc.M310044200; Fujinaga K, 2002, J VIROL, V76, P12934, DOI 10.1128/JVI.76.24.12934-12939.2002; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 2004, GENE, V337, P15, DOI 10.1016/j.gene.2004.05.007; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lacy ER, 2004, NAT STRUCT MOL BIOL, V11, P358, DOI 10.1038/nsmb746; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Napolitano G, 2003, J CELL PHYSIOL, V197, P1, DOI 10.1002/jcp.10376; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Yik JHN, 2005, J BIOL CHEM, V280, P16368, DOI 10.1074/jbc.M500912200; Yik JHN, 2004, MOL CELL BIOL, V24, P5094, DOI 10.1128/MCB.24.12.5094-5105.2004; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200	36	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24968	24977		10.1074/jbc.M501431200	http://dx.doi.org/10.1074/jbc.M501431200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15855166	hybrid			2022-12-25	WOS:000230114000081
J	Xu, XM; Zhou, YQ; Wang, MH				Xu, XM; Zhou, YQ; Wang, MH			Mechanisms of cytoplasmic beta-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY; GROWTH-FACTOR; CYCLIN D1; RON GENE; IDENTIFICATION; ACTIVATION; APC; TARGET	The beta-catenin pathway plays a critical role in the pathogenesis of certain types of cancers. To gain insight into mechanisms by which altered receptor tyrosine kinases regulate cytoplasmic beta-catenin accumulation, the effect of an oncogenic receptor originated from Nantes (RON) variant on beta-catenin accumulation and the role of beta-catenin in RON-mediated tumorigenic activities were studied. In NIH3T3 cells harboring oncogenic variant RON Delta 160, increased beta-catenin accumulation with tyrosine phosphorylation and nuclear translocation was observed. Overexpression of RON Delta 160 also resulted in increased expression of beta-catenin target genes c-myc and cyclin D1. By analyzing cellular proteins that regulate beta-catenin stabilities, it was found that RON Delta 160 activates the protein disheveled (DVL) and inactivates glycogen synthase kinase-3 beta by Ser-9 residue phosphorylation. These effects were channeled by RON Delta 160-activated PI 3-kinase-AKT pathways that are sensitive to specific inhibitors, such as wortmannin, but not to other chemical inhibitors. Silencing RON Delta 160 expression by specific small interfering RNA blocked not only beta-catenin expression but also c-myc and cyclin D1 expression, suggesting that RON expression is required for the activation of the beta-catenin signaling pathway. Moreover, it was found that knockdown of the beta-catenin gene expression by small interfering RNA techniques reduces significantly the RON Delta 160-mediated NIH3T3 cell proliferation, focus-forming activities and anchorage-independent growth. Thus, the oncogenic RON variant regulates beta-catenin stabilities through activation of DVL and inactivation of glycogen synthase kinase-3 beta. The activated beta-catenin cascade is one of the pathways involved in tumorigenic activities mediated by the oncogenic RON variant.	Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Ctr Biol Canc, Amarillo, TX 79106 USA; Zhejiang Univ, Coll Med, Lab Cheung Scholars Program Biomed Sci, Inst Infect Dis, Hangzhou 310027, Peoples R China; Zhejiang Univ, Coll Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310027, Peoples R China	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Zhejiang University; Zhejiang University	Wang, MH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter St, Amarillo, TX 79106 USA.	minghai.wang@ttuhsc.edu			NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91980] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Haraguchi K, 2004, BIOCHEM BIOPH RES CO, V313, P841, DOI 10.1016/j.bbrc.2003.12.021; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Monga SPS, 2002, CANCER RES, V62, P2064; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RONSIN C, 1993, ONCOGENE, V8, P1195; Rubinfeld B, 1997, CANCER RES, V57, P4624; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMIMIZU H, 1997, CELL GROWTH DIFFER, V8, P1349; Sparks AB, 1998, CANCER RES, V58, P1130; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Xu XM, 2004, ONCOGENE, V23, P8464, DOI 10.1038/sj.onc.1207907; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	40	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25087	25094		10.1074/jbc.M414699200	http://dx.doi.org/10.1074/jbc.M414699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878878	hybrid			2022-12-25	WOS:000230114000092
J	Aouida, M; Leduc, A; Poulin, R; Ramotar, D				Aouida, M; Leduc, A; Poulin, R; Ramotar, D			AGP2 encodes the major permease for high affinity polyamine import in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; ACTIN CYTOSKELETON ORGANIZATION; SER/THR PROTEIN-KINASE; K-CL COTRANSPORTER; PLASMA-MEMBRANE; DRUG BLEOMYCIN; SPERMIDINE TRANSPORT; CHOLINE TRANSPORT; YEAST; GENE	Polyamines play essential functions in many aspects of cell biology. Plasma membrane transport systems for the specific uptake of polyamines exist in most eukaryotic cells but have been very recently identified at the molecular level only in the parasite Leishmania. We now report that the high affinity polyamine permease in Saccharomyces cerevisiae is identical to Agp2p, a member of the yeast amino acid transporter family that was previously identified as a carnitine transporter. Deletion of AGP2 dramatically reduces the initial velocity of spermidine and putrescine uptake and confers strong resistance to the toxicity of exogenous polyamines, and transformation with an AGP2 expression vector restored polyamine transport in agp2 Delta mutants. Yeast mutants deficient in polyamine biosynthesis required > 10-fold higher concentrations of exogenous putrescine to restore cell proliferation upon deletion of the AGP2 gene. Disruption of END3, a gene required for an early step of endocytosis, increased the abundance of Agp2p, an effect that was paralleled by a marked up-regulation of spermidine transport velocity. Thus, AGP2 encodes the first eukaryotic permease that preferentially uses spermidine over putrescine as a high affinity substrate and plays a central role in the uptake of polyamines in yeast.	CHU Laval, Med Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Maison Neuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ H1T 2M4, Canada	Laval University; Universite de Montreal	Poulin, R (corresponding author), CHU Laval, Med Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	richard.poulin@crchul.ulaval.ca	Aouida, Mustapha/AEJ-4513-2022	Aouida, Mustapha/0000-0001-7945-5320				Albertsen M, 2003, J BIOL CHEM, V278, P12820, DOI 10.1074/jbc.M210715200; Aoki K, 2001, J BIOL CHEM, V276, P21555, DOI 10.1074/jbc.M101462200; Aouida M, 2004, BIOCHEM J, V384, P47, DOI 10.1042/BJ20040392; Aouida M, 2004, CANCER RES, V64, P1102, DOI 10.1158/0008-5472.CAN-03-2729; BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Brachmann CB, 1998, YEAST, V14, P115; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; Donaton MCV, 2003, MOL MICROBIOL, V50, P911, DOI 10.1046/j.1365-2958.2003.03732.x; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Erez O, 2001, MOL CELL BIOL, V21, P175, DOI 10.1128/MCB.21.1.175-184.2001; Forment J, 2002, BBA-BIOMEMBRANES, V1565, P36, DOI 10.1016/S0005-2736(02)00503-5; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Hasne MP, 2005, J BIOL CHEM, V280, P15188, DOI 10.1074/jbc.M411331200; HOSAKA K, 1981, EUR J BIOCHEM, V116, P1, DOI 10.1111/j.1432-1033.1981.tb05292.x; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; Kaouass M, 1998, J BIOL CHEM, V273, P2109, DOI 10.1074/jbc.273.4.2109; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; Klasson H, 1999, MOL CELL BIOL, V19, P5405; Leduc A, 2003, MOL GENET GENOMICS, V269, P78, DOI 10.1007/s00438-003-0812-8; Lee J, 2002, MOL CELLS, V13, P407; Ludwig A, 2000, PLANT J, V24, P503, DOI 10.1046/j.1365-313x.2000.00900.x; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; Park JH, 1996, J MEMBRANE BIOL, V149, P161, DOI 10.1007/s002329900016; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Poulsen P, 2005, BIOCHEM SOC T, V33, P261, DOI 10.1042/BST0330261; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Sa-Correia I, 2002, J BIOTECHNOL, V98, P215, DOI 10.1016/S0168-1656(02)00133-5; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Schreve JL, 2004, BIOCHEM BIOPH RES CO, V313, P745, DOI 10.1016/j.bbrc.2003.11.172; Seiler N, 2003, CURR DRUG TARGETS, V4, P565, DOI 10.2174/1389450033490876; Sherman F., 1983, METHODS YEAST GENETI; Soksawatmaekhin W, 2004, MOL MICROBIOL, V51, P1401, DOI 10.1046/j.1365-2958.2003.03913.x; Soulet D, 2002, BIOCHEM J, V367, P347, DOI 10.1042/BJ20020764; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Tachihara K, 2005, J BIOL CHEM, V280, P12637, DOI 10.1074/jbc.M410778200; Tang HY, 2000, MOL CELL BIOL, V20, P12, DOI 10.1128/MCB.20.1.12-25.2000; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; Uemura T, 2005, J BIOL CHEM, V280, P9646, DOI 10.1074/jbc.M410274200; Uemura T, 2005, BIOCHEM BIOPH RES CO, V328, P1028, DOI 10.1016/j.bbrc.2005.01.064; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; Vongsamphanh R, 2001, MOL CELL BIOL, V21, P1647, DOI 10.1128/MCB.21.5.1647-1655.2001	61	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24267	24276		10.1074/jbc.M503071200	http://dx.doi.org/10.1074/jbc.M503071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855155	hybrid			2022-12-25	WOS:000229880000104
J	Gruic-Sovulj, I; Uter, N; Bullock, T; Perona, JJ				Gruic-Sovulj, I; Uter, N; Bullock, T; Perona, JJ			tRNA-dependent aminoacyl-adenylate hydrolysis by a nonediting class I aminoacyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-SITE TRANSLOCATION; ELONGATION-FACTOR TU; PROTEIN-SYNTHESIS; STRUCTURAL BASIS; ACID; GLUTAMINYL; DISCRIMINATION; ISOLEUCINE; THREONINE; ERRORS	Glutaminyl-tRNA synthetase generates Gln-tRNA(Gln) 107-fold more efficiently than Glu-tRNA(Gln) and requires tRNA to synthesize the activated aminoacyl adenylate in the first step of the reaction. To examine the role of tRNA in amino acid activation more closely, several assays employing a tRNA analog in which the 2'-OH group at the 3'-terminal A76 nucleotide is replaced with hydrogen (tRNA(2'H)(Gln)) were developed. These experiments revealed a 10(4)-fold reduction in k(cat)/K-m in the presence of the analog, suggesting a direct catalytic role for tRNA in the activation reaction. The catalytic importance of the A76 2'-OH group in aminoacylation mirrors a similar role for this moiety that has recently been demonstrated during peptidyl transfer on the ribosome. Unexpectedly, tracking of Gln-AMP formation utilizing an alpha-P-32-labeled ATP substrate in the presence of tRNA(2'H)(Gln) showed that AMP accumulates 5-fold more rapidly than Gln-AMP. A cold-trapping experiment revealed that the nonenzymatic rate of Gln-AMP hydrolysis is too slow to account for the rapid AMP formation; hence, the hydrolysis of Gln-AMP to form glutamine and AMP must be directly catalyzed by the GlnRS(.)tRNA(2'H)(Gln) complex. This hydrolysis of glutaminyl adenylate represents a novel reaction that is directly analogous to the pre-transfer editing hydrolysis of non-cognate aminoacyl adenylates by editing synthetases such as isoleucyl-tRNA synthetase. Because glutaminyl-tRNA synthetase does not possess a spatially separate editing domain, these data demonstrate that a pre-transfer editing-like reaction can occur within the synthetic site of a class I tRNA synthetase.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Interdept Program Biomol Sci & Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Perona, JJ (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	perona@chem.ucsb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063713] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63713] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agou F, 1998, BIOCHEMISTRY-US, V37, P11309, DOI 10.1021/bi9805590; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Bishop AC, 2003, P NATL ACAD SCI USA, V100, P490, DOI 10.1073/pnas.0237335100; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock TL, 2003, J MOL BIOL, V328, P395, DOI 10.1016/S0022-2836(03)00305-X; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Dale T, 2004, BIOCHEMISTRY-US, V43, P6159, DOI 10.1021/bi036290o; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCHPETERS S, 1991, BIOCHIMIE, V73, P1501; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1978, BIOCHEMISTRY-US, V17, P3740, DOI 10.1021/bi00611a011; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Hendrickson TL, 2003, MOL B INT U, P34; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; HOPFIELD JJ, 1976, P NATL ACAD SCI USA, V73, P1164, DOI 10.1073/pnas.73.4.1164; Hsieh J, 2004, BIOPOLYMERS, V73, P79, DOI 10.1002/bip.10521; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKUBOWSKI H, 1980, BIOCHEMISTRY-US, V19, P5071, DOI 10.1021/bi00563a021; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Kumar RK, 2001, BIOCHEMISTRY-US, V40, P6998, DOI 10.1021/bi010710x; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Lazard M, 2000, J MOL BIOL, V302, P991, DOI 10.1006/jmbi.2000.4102; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; MULVEY RS, 1977, BIOCHEMISTRY-US, V16, P4005, DOI 10.1021/bi00637a011; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nissan TA, 1999, RNA, V5, P434, DOI 10.1017/S1355838299981827; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; PERONA JJ, 2004, AMINOACYL TRNA SYNTH, P73; Persson T, 2003, J BIOL CHEM, V278, P43394, DOI 10.1074/jbc.M305939200; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; Scaringe SA, 2000, METHOD ENZYMOL, V317, P3; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Sherlin LD, 2000, J MOL BIOL, V299, P431, DOI 10.1006/jmbi.2000.3749; Sherlin LD, 2003, STRUCTURE, V11, P591, DOI 10.1016/S0969-2126(03)00074-1; Sherlin LD, 2001, RNA, V7, P1671; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Uter NT, 2005, J BIOL CHEM, V280, P23966, DOI 10.1074/jbc.M414259200; Uter NT, 2004, P NATL ACAD SCI USA, V101, P14396, DOI 10.1073/pnas.0404017101; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799	54	75	76	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23978	23986		10.1074/jbc.M414260200	http://dx.doi.org/10.1074/jbc.M414260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845536	hybrid			2022-12-25	WOS:000229880000072
J	Hang, J; Zemskov, EA; Lorand, L; Belkin, AM				Hang, J; Zemskov, EA; Lorand, L; Belkin, AM			Identification of a novel recognition sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATIN-BINDING DOMAIN; AMINO-ACID SEQUENCE; CELL-ADHESION; CROSS-LINKING; SURFACE TRANSGLUTAMINASE; 3T3 FIBROBLASTS; CDNA-CLONES; EXPRESSION; MATRIX; LOCALIZATION	Tissue transglutaminase belongs to the multigene transglutaminase family of Ca2+-dependent protein cross-linking enzymes. Unlike other transglutaminases, it is involved in cell-matrix interactions and serves as an adhesion co-receptor for fibronectin. Previous work established that the fibronectin-binding motif(s) is located within the NH2-terminal proteolytic fragment of the protein consisting of residues 1-272. Here we identify a novel fibronectin recognition site within this sequence of tissue transglutaminase. Substitution of individual domains of tissue transglutaminase with those from homologous factor XIIIA showed that the major fibronectin-binding site is present within the first beta-sandwich domain of the protein. Experiments with deletion mutants of the first domain revealed that amino acids 81 140 of tissue transglutaminase are involved in fibronectin binding. Using synthetic peptides encompassing this region, we found that the peptide (88)WTATVVDQQDCTLSLQLTT(106) inhibited the interaction of tissue transglutaminase with fibronectin and decreased transglutaminase-dependent cell adhesion and spreading. In the three-dimensional structure of the first domain, amino acids 88-106 comprise an extended hairpin formed by antiparallel beta strands 5 and 6. Mutations of Asp(94) and Asp(97) within the beta 5/beta 6 hairpin to Ala significantly reduced the affinity of tissue transglutaminase for fibronectin, indicating that these residues are critical for fibronectin binding. Identification of the fibronectin-binding site on tissue transglutaminase will help to dissect the role of this protein in cell-matrix interactions.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Rockville, MD 20855 USA; Univ Maryland, Greenebaum Canc Ctr, Rockville, MD 20855 USA; Northwestern Univ, Feinberg Med Sch, Dept Cell & Mol Biol, Chicago, IL 61601 USA	Northwestern University; Feinberg School of Medicine	Belkin, AM (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	abelk001@umaryland.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062895] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02212] Funding Source: Medline; NIGMS NIH HHS [GM62895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; FELLIN FM, 1988, J BIOL CHEM, V263, P1791; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; Gaudry CA, 1999, EXP CELL RES, V252, P104, DOI 10.1006/excr.1999.4633; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grenard P, 2001, J BIOL CHEM, V276, P33066, DOI 10.1074/jbc.M102553200; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Jones RA, 1997, J CELL SCI, V110, P2461; LEMOSY EK, 1992, J BIOL CHEM, V267, P7880; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1988, P NATL ACAD SCI USA, V85, P1057, DOI 10.1073/pnas.85.4.1057; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MENTER DG, 1991, CELL BIOPHYS, V18, P123, DOI 10.1007/BF02989810; Morton TA, 1998, METHOD ENZYMOL, V295, P268; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; RADEK JT, 1993, P NATL ACAD SCI USA, V90, P3152, DOI 10.1073/pnas.90.8.3152; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TURNER PM, 1989, BIOCHEMISTRY-US, V28, P628, DOI 10.1021/bi00428a032; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Verderio EAM, 2003, J BIOL CHEM, V278, P42604, DOI 10.1074/jbc.M303303200; WERAARCHAKULBOONMA, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/PNAS.89.20.9804	36	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23675	23683		10.1074/jbc.M503323200	http://dx.doi.org/10.1074/jbc.M503323200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849356	hybrid			2022-12-25	WOS:000229880000035
J	Mori, S; Kawai, S; Shi, F; Mikami, B; Murata, K				Mori, S; Kawai, S; Shi, F; Mikami, B; Murata, K			Molecular conversion of NAD kinase to NADH kinase through single amino acid residue substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MICROCOCCUS-FLAVUS; BIOSYNTHESIS; PROGRAM; ENZYME; GENE	NAD kinase phosphorylates NAD(+) to form NADP(+) and is strictly specific to NAD(+), whereas NADH kinase phosphorylates both NAD(+) and NADH, thereby showing relaxed substrate specificity. Based on their primary and tertiary structures, the difference in the substrate specificities between NAD and NADH kinases was proposed to be caused by one aligned residue: Gly or polar amino acid (Gln or Thr) in five NADH kinases and a charged amino acid (Arg) in two NAD kinases. The substitution of Arg with Gly in the two NAD kinases relaxed the substrate specificity (i.e. converted the NAD kinases to NADH kinases). The substitution of Arg in one NAD kinase with polar amino acids also relaxed the substrate specificity, whereas substitution with charged and hydrophobic amino acids did not show a similar result. In contrast, the substitution of Gly with Arg in one NADH kinase failed to convert it to NAD kinase. These results suggest that a charged or hydrophobic amino acid residue in the position of interest is crucial for strict specificity of NAD kinases to NAD(+), whereas Gly or polar amino acid residue is not the sole determinant for the relaxed substrate specificity of NADH kinases. The significance of the conservation of the residue at the position in 207 NAD kinase homologues is also discussed.	Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Uji, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Uji, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRANDEN C, 1999, INTRO PROTEIN STRUCT, P4; DAVID EM, 2001, BIOCHEMISTRY-US, P767; ELLEN S, 1974, METHOD ENZYMAT AN, P876; ELLEN S, 1974, METHOD ENZYMAT AN, P650; FOSTER JW, 1980, MICROBIOL REV, V44, P83, DOI 10.1128/MMBR.44.1.83-105.1980; Garavaglia S, 2004, J BIOL CHEM, V279, P40980, DOI 10.1074/jbc.M406586200; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Kawai S, 2003, BIOSCI BIOTECH BIOCH, V67, P1751, DOI 10.1271/bbb.67.1751; Kawai S, 2001, FEMS MICROBIOL LETT, V200, P181, DOI 10.1111/j.1574-6968.2001.tb10712.x; Kornberg A, 1999, Prog Mol Subcell Biol, V23, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGUINNESS ET, 1985, INT J BIOCHEM, V17, P1, DOI 10.1016/0020-711X(85)90079-5; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moat AG, 1987, PYRIDINE NUCLEOTID B, P1; Mori S, 2005, BIOCHEM BIOPH RES CO, V327, P500, DOI 10.1016/j.bbrc.2004.11.163; Ochiai A, 2004, PROTEIN EXPRES PURIF, V36, P124, DOI 10.1016/j.pep.2004.03.012; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	21	32	35	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24104	24112		10.1074/jbc.M502518200	http://dx.doi.org/10.1074/jbc.M502518200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855156	hybrid			2022-12-25	WOS:000229880000084
J	Sonkoly, E; Bata-Csorgo, Z; Pivarcsi, A; Polyanka, H; Kenderessy-Szabo, A; Molnar, G; Szentpali, K; Bari, L; Megyeri, K; Mandi, Y; Dobozy, A; Kemeny, L; Szell, M				Sonkoly, E; Bata-Csorgo, Z; Pivarcsi, A; Polyanka, H; Kenderessy-Szabo, A; Molnar, G; Szentpali, K; Bari, L; Megyeri, K; Mandi, Y; Dobozy, A; Kemeny, L; Szell, M			Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC GENE; HAMSTER HA-1 CELLS; ALPHA-5 INTEGRIN; EXPRESSION; KERATINOCYTES; CANCER; PROLIFERATION; PRODUCT; GROWTH; SKIN	To identify genetic factors contributing to psoriasis susceptibility, gene expression profiles of uninvolved epidermis from psoriatic patients and epidermis from healthy individuals were compared. Besides already characterized genes, we identified a cDNA with yet unknown functions, which we further characterized and named PRINS ( Psoriasis susceptibility-related RNA Gene Induced by Stress). In silico structural and homology studies suggested that PRINS may function as a noncoding RNA. PRINS harbors two Alu elements, it is transcribed by RNA polymerase II, and it is expressed at different levels in various human tissues. Real time reverse transcription-PCR analysis showed that PRINS was expressed higher in the uninvolved epidermis of psoriatic patients compared with both psoriatic lesional and healthy epidermis, suggesting a role for PRINS in psoriasis susceptibility. PRINS is regulated by the proliferation and differentiation state of keratinocytes. Treatment with T-lymphokines, known to precipitate psoriatic symptoms, decreased PRINS expression in the uninvolved psoriatic but not in healthy epidermis. Real time reverse transcription-PCR analysis showed that stress signals such as ultraviolet-B irradiation, viral infection ( herpes simplex virus), and translational inhibition increased the RNA level of PRINS. Gene-specific silencing of PRINS by RNA interference revealed that down-regulation of PRINS impairs cell viability after serum starvation but not under normal serum conditions. Our findings suggest that PRINS functions as a noncoding regulatory RNA, playing a protective role in cells exposed to stress. Furthermore, elevated PRINS expression in the epidermis may contribute to psoriasis susceptibility.	Univ Szeged, Dept Dermatol & Allergol, H-6720 Szeged, Hungary; Univ Szeged, Dept Surg, H-6720 Szeged, Hungary; Univ Szeged, Dept Med Microbiol & Immunol, H-6720 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary; Hungarian Acad Sci, Biol Res Ctr, Dermatol Res Grp, H-6701 Szeged, Hungary	Szeged University; Szeged University; Szeged University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Szell, M (corresponding author), Univ Szeged, Dept Dermatol & Allergol, Koranyi Fasor 6, H-6720 Szeged, Hungary.	szell@mail.derma.szote.u-szeged.hu	Pivarcsi, Andor/J-5801-2017; Kemeny, Lajos/ABF-1339-2021; Mandi, Yvette/AAF-8017-2020; Mandi, Yvette/O-3365-2019	Pivarcsi, Andor/0000-0003-2196-1102; Kemeny, Lajos/0000-0002-2119-9501; Mandi, Yvette/0000-0003-4729-2445; Sonkoly, Eniko/0000-0002-4909-5413; Szentpali, Karoly/0000-0002-3450-3779; Bata-Csorgo, Zsuzsanna/0000-0002-3732-1743				Bata-Csorgo Z, 1998, J CLIN INVEST, V101, P1509, DOI 10.1172/JCI171; BATACSORGO Z, 1995, J CLIN INVEST, V95, P317, DOI 10.1172/JCI117659; Bhalerao J, 1998, HUM MOL GENET, V7, P1537, DOI 10.1093/hmg/7.10.1537; BOS JD, 1983, ARCH DERMATOL RES, V275, P181, DOI 10.1007/BF00510050; Bowcock AM, 2003, J AM ACAD DERMATOL, V49, pS51, DOI 10.1016/S0190-9622(03)01135-6; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Bussemakers MJG, 1999, CANCER RES, V59, P5975; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032; Creamer D., 2002, Angiogenesis, V5, P231, DOI 10.1023/A:1024515517623; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; Erdmann VA, 2001, CELL MOL LIFE SCI, V58, P960, DOI 10.1007/PL00000913; FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; FUNG PA, 1995, SCIENCE, V268, P1036, DOI 10.1126/science.7754381; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; Hollander MC, 1996, NUCLEIC ACIDS RES, V24, P1589, DOI 10.1093/nar/24.9.1589; Jacquot C, 2004, INT J ONCOL, V25, P519; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Klein RJ, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-44; Li TH, 1999, GENE, V239, P367, DOI 10.1016/S0378-1119(99)00384-4; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; Liang P, 1998, MOL BIOTECHNOL, V10, P261, DOI 10.1007/BF02740847; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P11563, DOI 10.1073/pnas.90.24.11563; Mattick JS, 2001, EMBO REP, V2, P986, DOI 10.1093/embo-reports/kve230; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Morey C, 2004, FEBS LETT, V567, P27, DOI 10.1016/j.febslet.2004.03.117; PANNING B, 1995, J MOL BIOL, V248, P513, DOI 10.1006/jmbi.1995.0239; Pivarcsi A, 2001, ARCH DERMATOL RES, V293, P206, DOI 10.1007/s004030100217; ROWDEN G, 1975, J PATHOL, V117, P139, DOI 10.1002/path.1711170303; Rudin CM, 2001, GENE CHROMOSOME CANC, V30, P64, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1066>3.0.CO;2-F; SAMBROOK J, 1989, MOL CLONING, V2, P9; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; STEINBERG TH, 1992, J BIOL CHEM, V267, P20204; Szabo Anna Kenderessy, 2002, Acta Microbiologica et Immunologica Hungarica, V49, P129; Szell M, 2004, J INVEST DERMATOL, V123, P537, DOI 10.1111/j.0022-202X.2004.23224.x; Takeda K, 1998, J BIOL CHEM, V273, P17079, DOI 10.1074/jbc.273.27.17079; Ting KM, 2000, J INVEST DERMATOL, V114, P706, DOI 10.1046/j.1523-1747.2000.00871.x; Wang YH, 1996, ARCH BIOCHEM BIOPHYS, V332, P255, DOI 10.1006/abbi.1996.0340	42	145	165	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24159	24167		10.1074/jbc.M501704200	http://dx.doi.org/10.1074/jbc.M501704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15855153	Green Submitted, hybrid			2022-12-25	WOS:000229880000090
J	Cheng, Y; Chaturvedi, R; Asim, M; Bussiere, FI; Xu, HX; Casero, RA; Wilson, KT				Cheng, Y; Chaturvedi, R; Asim, M; Bussiere, FI; Xu, HX; Casero, RA; Wilson, KT			Helicobacter pylori-induced macrophage apoptosis requires activation of ornithine decarboxylase by c-Myc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PROTEINS; CUTTING EDGE; EXPRESSION; ARGINASE; CELLS; INDUCTION; INFECTION; RELEASE	Helicobacter pylori infection causes chronic inflammation of the gastric mucosa that results from an ineffective immune response. We have demonstrated that one underlying mechanism is induction of macrophage apoptosis mediated by polyamines. The transcription factor c-Myc has been linked to induction of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. We determined whether H. pylori stimulates transcriptional activation of ODC in macrophages, whether this occurs via c-Myc, and whether these events regulate activation of apoptosis. H. pylori induced a significant increase in ODC promoter activity that peaked at 6 h after stimulation and was closely paralleled by similar increases in ODC mRNA, protein, and enzyme activity. By 2 h after stimulation, c-Myc mRNA and protein expression was induced, protein was translocated to the nucleus, and there was specific binding of a consensus probe for c-Myc to nuclear extracts. Both an antennapedia- linked inhibitor of c-Myc binding (Int-H1-S6A, F8A) and transfection of a c-Myc dominant-negative construct significantly attenuated H. pyloriinduced ODC promoter activity, mRNA, enzyme activity, and apoptosis in parallel. Transfection of ODC small interfering RNA inhibited ODC activity and apoptosis to the same degree as inhibition of c-Myc binding. These studies indicate that c-Myc is an important mediator of macrophage activation and may contribute to the mucosal inflammatory response to pathogens such as H. pylori by its effect on ODC.	Univ Maryland, Sch Med, Greenbaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine	Wilson, KT (corresponding author), Univ Maryland, Sch Med, Greenbaum Canc Ctr, 22 S Greene St,Rm N3W62, Baltimore, MD 21201 USA.	kwilson@umaryland.edu		Wilson, Keith/0000-0003-4421-1830; Bussiere, Francoise I/0000-0001-9365-6831; Casero, Robert/0000-0001-5653-3306	NCI NIH HHS [CA 98454, CA 51085] Funding Source: Medline; NIDDK NIH HHS [DK 63626, DK 53620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051085, R01CA098454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, R21DK063626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aziz N, 1999, MOL CELL BIOL, V19, P1101; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bussiere FI, 2005, J BIOL CHEM, V280, P2409, DOI 10.1074/jbc.C400498200; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; FARRAR WL, 1988, J IMMUNOL, V141, P967; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; Gobert AP, 2002, J IMMUNOL, V168, P6002, DOI 10.4049/jimmunol.168.12.6002; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; INTRONA M, 1986, J IMMUNOL, V137, P2711; Keates S, 1999, J IMMUNOL, V163, P5552; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Meyer F, 2003, J IMMUNOL, V171, P3913, DOI 10.4049/jimmunol.171.8.3913; Nardone G, 1999, GUT, V44, P789, DOI 10.1136/gut.44.6.789; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Patchett SE, 1996, GUT, V39, P807, DOI 10.1136/gut.39.6.807; Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110; Varanasi RV, 1998, HELICOBACTER, V3, P188, DOI 10.1046/j.1523-5378.1998.08001.x; Wilson KT, 1996, GASTROENTEROLOGY, V111, P1524, DOI 10.1016/S0016-5085(96)70014-8; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Yang Y, 2003, J CLIN PATHOL-MOL PA, V56, P19, DOI 10.1136/mp.56.1.19; Zhang GX, 2004, WORLD J GASTROENTERO, V10, P1759	25	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 10	2005	280	23					22492	22496		10.1074/jbc.C500122200	http://dx.doi.org/10.1074/jbc.C500122200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	932MN	15843384	hybrid			2022-12-25	WOS:000229557900095
J	Wang, TG; Pei, Z; Zhang, W; Liu, B; Langenbach, R; Lee, C; Wilson, B; Reece, JM; Miller, DS; Hong, JS				Wang, TG; Pei, Z; Zhang, W; Liu, B; Langenbach, R; Lee, C; Wilson, B; Reece, JM; Miller, DS; Hong, JS			MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration	FASEB JOURNAL			English	Article						cyclooxygenase-2; prostaglandin E-2; microglia; neuron; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; PARKINSONS-DISEASE; NITRIC-OXIDE; SUBSTANTIA-NIGRA; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; PROSTAGLANDIN E-2; MOUSE MODEL; MPTP MODEL; CYCLOOXYGENASE	The importance of cyclooxygenase-2 (COX-2) in mediating Parkinson's disease (PD) was suggested in reports, indicating that COX-2 selective inhibitors or genetic knockout reduce 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic (DA) neurotoxicity in a mouse model of PD. However, cell types and mechanisms underlying the activation of COX-2 have not been clearly elucidated in these animal studies. Using primary neuron-glia cultures, we aimed to determine 1) whether microglia participate in 1-methyl-4-phenylpryridinium (MPP)-induced COX-2 activation and 2) whether the activation of COX-2 contributes to subsequent neurotoxicity. MPP+, in a concentration-dependent manner, increased prostaglandin E-2 (PGE(2)) production in mixed neuron-microglia cultures but not in enriched neuron, microglia, or astroglia cultures nor in mixed neuron-astroglia cultures. MPP+-induced PGE2 increase was completely abolished by treatment with DuP697, a COX-2 selective inhibitor. DuP697 also significantly reduced MPP+-induced DA neurotoxicity as determined by DA uptake assay. Immunocytochemistry and confocal microscopy studies showed enhanced COX-2 expression in both microglia and neurons after MPP+ treatment. However, neuronal increase in COX-2 expression was not totally dependent on the production of PGE(2) from microglia, since microglia deficient in COX-2 only attenuated, but did not completely block, MPP+-increased PGE(2) production in mixed neuron-microglia cultures, suggesting that part of PGE(2) production was originated from neurons. Together, these results indicate that MPP+-induced COX-2 expression and subsequent PGE(2) production depend on interactions between neurons and microglia. Microgliosis may also be responsible for the COX-2 activation in neurons, leading to the enhanced DA neurotoxicity, which, in turn, reinforces microgliosis. Thus inhibition of microgliosis and COX-2 activity may stop this vicious circle and be valuable strategies in PD therapy.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Univ Florida, Coll Pharm, Gainesville, FL 32610 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Confocal Microscopy Ctr, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hong, JS (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	hong3@niehs.nih.gov	Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080048, Z01ES090082, Z01ES080048, ZIAES021179, ZIAES090082, Z01ES021179] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banati RB, 1998, MOVEMENT DISORD, V13, P221, DOI 10.1002/mds.870130205; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hoozemans JJM, 2002, BRAIN RES, V951, P218, DOI 10.1016/S0006-8993(02)03164-5; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LEE SH, 1992, J BIOL CHEM, V267, P25934; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Olanow CW, 2004, ANNU REV MED, V55, P41, DOI 10.1146/annurev.med.55.091902.104422; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Sairam K, 2003, BRAIN RES, V966, P245, DOI 10.1016/S0006-8993(02)04174-4; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Teismann P, 2003, ANN NY ACAD SCI, V991, P272; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; UHL GR, 1985, LANCET, V1, P956; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	31	82	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1134	+		10.1096/fj.04-2457fje	http://dx.doi.org/10.1096/fj.04-2457fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15845609				2022-12-25	WOS:000228865300010
J	Doherty, KM; Sharma, S; Uzdilla, LA; Wilson, TM; Cui, S; Vindigni, A; Brosh, RM				Doherty, KM; Sharma, S; Uzdilla, LA; Wilson, TM; Cui, S; Vindigni, A; Brosh, RM			RECQ1 helicase interacts with human mismatch repair factors that regulate genetic recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME HELICASE; WERNER-SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; HETERODUPLEX REJECTION; MITOTIC RECOMBINATION; MUTATION AVOIDANCE; UNWINDING ACTIVITY	Understanding the molecular and cellular functions of RecQ helicases has attracted considerable interest since several human diseases characterized by premature aging and/or cancer have been genetically linked to mutations in genes of the RecQ family. Although a human disease has not yet been genetically linked to a mutation in RECQ1, the prominent roles of RecQ helicases in the maintenance of genome stability suggest that RECQ1 helicase is likely to be important in vivo. To acquire a better understanding of RECQ1 cellular and molecular functions, we have investigated its protein interactions. Using a co-immunoprecipitation approach, we have identified several DNA repair factors that are associated with RECQ1 in vivo. Direct physical interaction of these repair factors with RECQ1 was confirmed with purified recombinant proteins. Importantly, RECQ1 stimulates the incision activity of human exonuclease 1 and the mismatch repair recognition complex MSH2/6 stimulates RECQ1 helicase activity. These protein interactions suggest a role of RECQ1 in a pathway involving mismatch repair factors. Regulation of genetic recombination, a proposed role for RecQ helicases, is supported by the identified RECQ1 protein interactions and is discussed.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Maryland, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; International Center for Genetic Engineering & Biotechnology (ICGEB)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov	Sheng, CUI/M-6405-2013; Sharma, Sudha/AAV-6152-2021; Cui, Sheng/AAQ-1721-2020	Sheng, CUI/0000-0001-6329-3582; Sharma, Sudha/0000-0003-2765-2482; 	NATIONAL CANCER INSTITUTE [R01CA095690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000741, Z01AG000741] Funding Source: NIH RePORTER; NCI NIH HHS [CA095690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Bertuch AA, 2004, GENETICS, V166, P1651, DOI 10.1534/genetics.166.4.1651; Braybrooke JP, 2003, J BIOL CHEM, V278, P48357, DOI 10.1074/jbc.M308838200; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Cui S, 2003, J BIOL CHEM, V278, P1424, DOI 10.1074/jbc.M209407200; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dzantiev L, 2004, MOL CELL, V15, P31, DOI 10.1016/j.molcel.2004.06.016; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Goldfarb T, 2005, GENETICS, V169, P563, DOI 10.1534/genetics.104.035204; Hackett JA, 2003, MOL CELL BIOL, V23, P8450, DOI 10.1128/MCB.23.23.8450-8461.2003; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harrigan JA, 2003, BIOCHIMIE, V85, P1185, DOI 10.1016/j.biochi.2003.10.006; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Johnson FB, 2000, CANCER RES, V60, P1162; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lewis LK, 2002, GENETICS, V160, P49; Mansour AA, 2001, GENETICS, V158, P77; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Maringele L, 2004, GENETICS, V166, P1641, DOI 10.1534/genetics.166.4.1641; McVey M, 2004, GENETICS, V167, P699, DOI 10.1534/genetics.103.025411; Moreau S, 2001, GENETICS, V159, P1423; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakada D, 2004, MOL CELL BIOL, V24, P10016, DOI 10.1128/MCB.24.22.10016-10025.2004; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Pedrazzi G, 2003, BIOL CHEM, V384, P1155, DOI 10.1515/BC.2003.128; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Seki T, 1997, BIOCHEM BIOPH RES CO, V234, P48, DOI 10.1006/bbrc.1997.6535; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Sugawara N, 2004, P NATL ACAD SCI USA, V101, P9315, DOI 10.1073/pnas.0305749101; Surtees JA, 2004, CYTOGENET GENOME RES, V107, P146, DOI 10.1159/000080593; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; von Borstel RC, 1998, GENETICS, V148, P1647; Wang WS, 2003, MOL CELL BIOL, V23, P3527, DOI 10.1128/MCB.23.10.3527-3535.2003; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yang O, 2004, ONCOGENE, V23, P3749, DOI 10.1038/sj.onc.1207462; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269	55	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					28085	28094		10.1074/jbc.M500265200	http://dx.doi.org/10.1074/jbc.M500265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	15886194	hybrid			2022-12-25	WOS:000230678600071
J	Lenertz, LY; Lee, BH; Min, XS; Xu, BE; Wedin, K; Earnest, S; Goldsmith, EJ; Cobb, MH				Lenertz, LY; Lee, BH; Min, XS; Xu, BE; Wedin, K; Earnest, S; Goldsmith, EJ; Cobb, MH			Properties of WNK1 and implications for other family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVOLUTED TUBULE CELLS; INHERITED HYPERTENSION; CALCIUM-TRANSPORT; MUTANT WNK4; KINASE; CL; HYPERKALEMIA; EPITHELIA; MECHANISM; TARGETS	WNKs are large serine/threonine protein kinases structurally distinct from all other members of the protein kinase superfamily. Of the four human WNK family members, WNK1 and WNK4 have been linked to a hereditary form of hypertension, pseudohypoaldosteronism type II. We characterized the biochemical properties and regulation of WNK1 that may contribute to its physiological activities and abnormal function in disease. We showed that WNK1 is activated by hypertonic stress in kidney epithelial cells and in breast and colon cancer cell lines. In addition, hypotonic stress also led to a modest increase in WNK1 activity. Gel filtration suggested that WNK1 exists as a tetramer, and yeast two-hybrid data showed that the N terminus of WNK1 (residues 1-222) interacts with residues 481-660, which includes the WNK1 autoinhibitory domain and a C-terminal coiled-coil domain. Although cell biological studies have suggested a functional interaction between WNK1 and WNK4, we found no evidence of stable interactions between these kinases. However, WNK1 phosphorylated both WNK4 and WNK2. In addition, the WNK1 autoinhibitory domain inhibited the catalytic activity of these WNKs. These findings suggest potential mechanisms for interconnected regulation of WNK family members.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Lee, Byung-Hoon/0000-0002-7101-0471; Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Choate KA, 2003, P NATL ACAD SCI USA, V100, P663, DOI 10.1073/pnas.242728499; Erlich PM, 2003, HYPERTENSION, V41, P1191, DOI 10.1161/01.HYP.0000070025.30572.91; FRIEDMAN PA, 1993, AM J PHYSIOL, V265, pF300, DOI 10.1152/ajprenal.1993.265.2.F300; GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; Kokubo Y, 2004, J HUM GENET, V49, P507, DOI 10.1007/s10038-004-0181-0; Lacroix M, 2004, ONCOL REP, V12, P701; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Wang ZH, 2004, BIOCHEM BIOPH RES CO, V317, P939, DOI 10.1016/j.bbrc.2004.03.132; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2005, CELL RES, V15, P6, DOI 10.1038/sj.cr.7290256; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; XU BE, 2005, IN PRESS P NATL ACAD; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100	27	102	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26653	26658		10.1074/jbc.M502598200	http://dx.doi.org/10.1074/jbc.M502598200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15883153	hybrid			2022-12-25	WOS:000230589500005
J	Zhao, Q; He, ZW; Chen, NY; Cho, YY; Zhu, F; Lu, CR; Ma, WY; Bode, AM; Dong, ZG				Zhao, Q; He, ZW; Chen, NY; Cho, YY; Zhu, F; Lu, CR; Ma, WY; Bode, AM; Dong, ZG			2-arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL CANNABINOID RECEPTOR; SIGNAL-REGULATED KINASE; FACTOR-KAPPA-B; NUCLEAR-FACTOR; PROTEIN-KINASE; CB1 RECEPTOR; AP-1 TRANSACTIVATION; ERK ACTIVATION; INHIBITION; EXPRESSION	2-Arachidonoylglycerol (2-AG) is the most abundant endocannabinoid, and it plays a critical role in cannabinoid receptor-mediated cell signaling. Although 2-AG was shown to induce ERK activation via the cannabinoid receptor 1 (CB1), only a nonspecific CB receptor agonist and antagonist was used in those studies. Whether cannabinoid receptor 2 (CB2) is involved in 2-AG-induced ERK activation is still unclear. Moreover, whether 2-AG is involved in mediation of AP-1 activity and cell transformation is also not known. In the present study, we show that 2-AG stimulates AP-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in mouse epidermal JB6 P+ Cl41 cells. Using JB6 P+ C141 cells, stably transfected with an AP-1 luciferase reporter, we found that 10 mu M 2-AG induced up to a 3-fold stimulation of AP-1 transcriptional activity. The AP-1 stimulation appeared to be mediated by ERK but not JNK or p38 kinase. PD98059, a specific inhibitor of MEK1, almost completely blocked 2-AG-induced ERK phosphorylation and AP-1 activation. Using CB1/2(-/-) murine embryonic fibroblasts, we present the first direct evidence that both cannabinoid receptors 1 and 2 (CB1/2) are involved in 2-AG-induced ERK activation. 2-AG could not stimulate ERK phosphorylation or Fyn kinase activity in dominant negative Fyn. In addition, the Fyn inhibitor PP2 blocked 2-AG-induced Fyn kinase activity and ERK phosphorylation and activity. Small interfering RNA Fyn also suppressed 2-AG-induced ERK phosphorylation. Interestingly, 2-AG enhanced epidermal growth factor-induced AP-1 DNA binding and cell transformation. Taken together, our data provide direct evidence suggesting that 2-AG may have a novel role in cell transformation and carcinogenesis in a signaling pathway involving CB1/2 and activation of Fyn, ERKs, and AP-1.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/G-3567-2010; ZHU, Feng/C-1303-2010	Zhu, Feng/0000-0003-1172-0102; Cho, Yong-Yeon/0000-0003-1107-2651	NCI NIH HHS [CA27502, P01 CA027502, CA88961, CA11135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA088961, P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; Carrier EJ, 2004, MOL PHARMACOL, V65, P999, DOI 10.1124/mol.65.4.999; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; Davis MI, 2003, J BIOL CHEM, V278, P48973, DOI 10.1074/jbc.M305697200; Derkinderen P, 2003, J NEUROSCI, V23, P2371; Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471-4159.2001.00333.x; Dong ZG, 2002, ENVIRON HEALTH PERSP, V110, P757, DOI 10.1289/ehp.02110s5757; Dong ZG, 1997, CANCER RES, V57, P4414; Downer EJ, 2003, BRIT J PHARMACOL, V140, P547, DOI 10.1038/sj.bjp.0705464; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; Gross A, 2003, J IMMUNOL, V170, P5607, DOI 10.4049/jimmunol.170.11.5607; Hashiguchi K, 2002, SOILS FOUND, V42, P107, DOI 10.3208/sandf.42.3_107; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; He ZW, 2005, J BIOL CHEM, V280, P2446, DOI 10.1074/jbc.M402053200; Herring AC, 1998, BIOCHEM PHARMACOL, V55, P1013, DOI 10.1016/S0006-2952(97)00630-8; Herring AC, 2001, CELL SIGNAL, V13, P241, DOI 10.1016/S0898-6568(01)00145-0; Hillard CJ, 2000, J PHARMACOL EXP THER, V294, P27; Huang CS, 2002, CANCER RES, V62, P6857; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Jorda MA, 2004, BLOOD, V104, P526, DOI 10.1182/blood-2003-12-4257; Jorda MA, 2003, BLOOD, V101, P1336, DOI 10.1182/blood-2002-07-2034; Kaminski NE, 1998, J NEUROIMMUNOL, V83, P124, DOI 10.1016/S0165-5728(97)00228-2; Li JJ, 1996, CANCER RES, V56, P483; Li XW, 2003, J BIOL CHEM, V278, P41646, DOI 10.1074/jbc.M306274200; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUO YD, 1992, INT J IMMUNOPHARMACO, V14, P49, DOI 10.1016/0192-0561(92)90104-S; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Maccarrone M, 2003, J BIOL CHEM, V278, P33896, DOI 10.1074/jbc.M303994200; Porcella A, 1998, EUR J NEUROSCI, V10, P1743, DOI 10.1046/j.1460-9568.1998.00175.x; Rayman N, 2004, J IMMUNOL, V172, P2111, DOI 10.4049/jimmunol.172.4.2111; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Schmid HHO, 2002, CHEM PHYS LIPIDS, V121, P111, DOI 10.1016/S0009-3084(02)00157-3; Srivastava MD, 1998, IMMUNOPHARMACOLOGY, V40, P179, DOI 10.1016/S0162-3109(98)00041-1; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; Suzukawa K, 2002, ENVIRON HEALTH PERSP, V110, P865, DOI 10.1289/ehp.02110865; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yea SS, 2000, J PHARMACOL EXP THER, V292, P597	48	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26735	26742		10.1074/jbc.M412828200	http://dx.doi.org/10.1074/jbc.M412828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15886210	Green Accepted, hybrid			2022-12-25	WOS:000230589500014
J	Rotolo, JA; Zhang, JJ; Donepudi, M; Lee, H; Fuks, Z; Kolesnick, R				Rotolo, JA; Zhang, JJ; Donepudi, M; Lee, H; Fuks, Z; Kolesnick, R			Caspase-dependent and -independent activation of acid sphingomyelinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE RAFTS; COLON-CANCER CELLS; B-LYMPHOMA-CELLS; LIPID RAFTS; INDUCED APOPTOSIS; CERAMIDE; DEATH; CD95; FAS; COMPLEX	Recent evidence suggests clustering of plasma membrane rafts into ceramide-enriched platforms serves as a transmembrane signaling mechanism for a subset of cell surface receptors and environmental stresses ( Grassme, H., Jekle, A., Riehle, A., Schwarz, H., Berger, J., Sandhoff, K., Kolesnick, R., and Gulbins, E. ( 2001) J. Biol. Chem. 276, 20589-20596; Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E., and Kolesnick, R. ( 2001) J. Biol. Chem. 276, 23954-23961). Translocation of the secretory form of acid sphingomyelinase ( ASMase) into microscopic rafts generates therein the ceramide that drives raft coalescence. This process serves to feed forward Fas activation, with similar to 2% of full caspase 8 activation sufficient for maximal ASMase translocation, leading to death-inducing signaling complex formation within ceramide-rich platforms, and apoptosis. Here we report that treatment of Jurkat T cells with UV-C also induces ASMase translocation into rafts within 1 min, catalyzing sphingomyelin hydrolysis to ceramide and raft clustering. In contrast to Fas, UV-induced ASMase translocation and activation were caspase-independent. Nonetheless, ceramide-rich platforms promoted UV-C-induced death signaling, because ASMase inhibition or raft disruption inhibited apoptosis, improving clonogenic cell survival. These studies thus define two distinct mechanisms for biologically relevant ASMase activation within rafts; a Fas-mediated mechanism dependent upon caspase 8 and FADD, and a UV-induced mechanism independent of caspase activation. Consistent with this notion, genetic depletion or pharmacologic inhibition of caspase 8 or FADD, which render Jurkat cells incapable of sphingolipid signaling and apoptosis upon Fas ligation, did not impair these events upon UV-C stimulation.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Dept Pharmacol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org		Rotolo, Jim/0000-0003-4195-6167	NATIONAL CANCER INSTITUTE [R01CA085704] Funding Source: NIH RePORTER; NCI NIH HHS [CA85704, CA52462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Bezombes C, 2004, BLOOD, V104, P1166, DOI 10.1182/blood-2004-01-0277; Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819; Bock J, 2003, BIOCHEM BIOPH RES CO, V305, P890, DOI 10.1016/S0006-291X(03)00763-0; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Chung HS, 2003, EXP MOL MED, V35, P181, DOI 10.1038/emm.2003.25; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CURTAIN CC, 1980, BIOCHIM BIOPHYS ACTA, V596, P43, DOI 10.1016/0005-2736(80)90169-8; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; ELKIND MM, 1960, RADIAT RES, V13, P556, DOI 10.2307/3570945; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Garofalo T, 2003, J BIOL CHEM, V278, P8309, DOI 10.1074/jbc.M207618200; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2002, J BIOL CHEM, V277, P30289, DOI 10.1074/jbc.M200494200; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; Ha H, 2003, EXP MOL MED, V35, P279, DOI 10.1038/emm.2003.38; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; He XX, 2003, ANAL BIOCHEM, V314, P116, DOI 10.1016/S0003-2697(02)00629-2; Hillyard DZ, 2004, ATHEROSCLEROSIS, V172, P219, DOI 10.1016/j.atherosclerosis.2003.11.004; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P2459, DOI 10.1016/S0006-3495(00)76790-7; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; Komatsu M, 2001, BBA-MOL CELL BIOL L, V1533, P47, DOI 10.1016/S1388-1981(01)00139-1; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Massey JB, 2001, BBA-BIOMEMBRANES, V1510, P167, DOI 10.1016/S0005-2736(00)00344-8; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scaffidi C, 2000, METHOD ENZYMOL, V322, P363; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schuck S, 2004, J CELL SCI, V117, P5955, DOI 10.1242/jcs.01596; Semac I, 2003, CANCER RES, V63, P534; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921	69	133	144	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26425	26434		10.1074/jbc.M414569200	http://dx.doi.org/10.1074/jbc.M414569200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15849201	hybrid			2022-12-25	WOS:000230386800058
J	Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY				Chae, HD; Choi, TS; Kim, BM; Jung, JH; Bang, YJ; Shin, DY			Oocyte-based screening of cytokinesis inhibitors and identication of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors	ONCOGENE			English	Article						p53; apoptosis; actin inhibitor; chemosensitivity; Bim; Bax	WILD-TYPE P53; Y TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBERS; CELL-LINES; ANTICANCER AGENTS; GENE-EXPRESSION; IN-VIVO; ACTIVATION; CYCLE; ARREST	In this study, we demonstrate that a loss of p53 sensitizes tumor cells to actin damage. Using a novel oocyte-based screening system, we identified natural compounds that inhibit cytokinesis. Among these, pectenotoxin-2 (PTX2), which was first identified as a cytotoxic entity in marine sponges, which depolymerizes actin. laments, was found to be highly effective and more potent to activate an intrinsic pathway of apoptosis in p53-deficient tumor cells compared to those with functional p53 both in vitro and in vivo. Other agents that depolymerize or knot actin. laments were also found to be toxic to p53-deficient tumors. In p53-deficient cells, PTX-2 triggers apoptosis through mitochondrial dysfunction, and this is followed by the release of proapoptotic factors and caspase activation. Furthermore, we observed Bax activation and Bim induction only in p53-deficient cells after PTX-2 treatment. RNA interference of either Bim or Bax resulted in the inhibition of caspases and apoptosis induced by PTX2. However, the small interfering RNAs (SiRNA) of Bim blocked a conformational change of Bax, but Bax SiRNA did not affect Bim expression. Therefore, these results suggest that Bim triggers apoptosis by activating Bax in p53-deficient tumors upon actin damage, and that actin inhibitors may be potent chemotherapeutic agents against p53-deficient tumors.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Seoul Natl Univ, Canc Res Inst, Seoul 110799, South Korea; GenCross Biotech Inst, Anseo 330714, Cheonan, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Dankook University; Seoul National University (SNU); Pusan National University	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Anseo 29, Cheonan 330714, South Korea.	dreamer@dku.edu	Bang, Yung Jue/J-2759-2012; Chae, Hee-Don/D-2620-2011	Bang, Yung Jue/0000-0001-6000-4597; 				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI T, 1991, DEVELOPMENT, V113, P789; Debernardis D, 1997, CANCER RES, V57, P870; Draisci R, 1996, TOXICON, V34, P923, DOI 10.1016/0041-0101(96)00030-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, CLIN CANCER RES, V4, P1047; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hori M, 1999, Nihon Yakurigaku Zasshi, V114 Suppl 1, p225P; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Masui Y, 1996, Prog Cell Cycle Res, V2, P1; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OConnor PM, 1997, CANCER RES, V57, P4285; Park M, 2000, CANCER RES, V60, P542; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valavanis C, 2001, METHOD CELL BIOL, V66, P417; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; YUN J, 2003, J BIOL CHEM; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	42	53	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4813	4819		10.1038/sj.onc.1208640	http://dx.doi.org/10.1038/sj.onc.1208640			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870701				2022-12-25	WOS:000230477900008
J	Knollman, PE; Janovick, JA; Brothers, SP; Conn, PM				Knollman, PE; Janovick, JA; Brothers, SP; Conn, PM			Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GNRH RECEPTOR; HYPOGONADOTROPIC HYPOGONADISM; DISEASE ETIOLOGY; MOLECULAR-BASIS; PHARMACOLOGICAL CHAPERONES; WILD-TYPE; MUTATIONS; EXPRESSION; RESCUE; GENE	Gonadotropin-releasing hormone ( GnRH) receptor mutants from patients with hypogonadotropic hypogonadism are frequently misrouted proteins that exert a dominant-negative ( DN) effect on human ( h) wild-type ( WT) receptor, due to oligomerization and retention in the endoplasmic reticulum. Pharmacologic chaperones restore correct folding, rescuing mutants and WT receptor from this oligomer. Rat WT retains the ability to oligomerize ( since human and mouse mutants exert a DN effect on rat (r) WT sequence) but, unlike human or mouse, escapes the DN effect of GnRH receptor (GnRHR) mutants because rGnRHR mutants route to the plasma membrane with higher efficiency than mouse or human mutants. These distinct behaviors of mouse and rat GnRHRs ( distinguished by only four semi-or nonconservative amino acid differences) led us to assess the role of each amino acid. The difference in both routing and the DN effect appears mediated primarily by Ser(216) in the rGnRHR. The homologous amino acid in the hGnRHR is also Ser and is compensated for by the primate-unique insertion of Lys(191) that, alone, dramatically decreases routing of the receptor. These studies establish the relation between the DN effect and altered receptor trafficking and explain why hGnRHR is more susceptible to defective trafficking by disease-related point mutations than rodent counterparts.	OHSU, ONPRC, Div Neurosci, Beaverton, OR 97006 USA; OHSU, ONPRC, Div Reprod Biol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University	Conn, PM (corresponding author), OHSU, ONPRC, Div Neurosci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	connm@ohsu.edu	Brothers, Shaun/G-8690-2012	Brothers, Shaun/0000-0003-2184-4037	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019899, R37HD019899] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00163] Funding Source: Medline; NICHD NIH HHS [HD-19899, HD-18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bedecarrats GY, 2003, J CLIN ENDOCR METAB, V88, P834, DOI 10.1210/jc.2002-020806; Beranova M, 2001, J CLIN ENDOCR METAB, V86, P1580, DOI 10.1210/jc.86.4.1580; Brothers SP, 2004, MOL ENDOCRINOL, V18, P1787, DOI 10.1210/me.2004-0091; Brothers SP, 2003, J CLIN ENDOCR METAB, V88, P6107, DOI 10.1210/jc.2003-031047; Caron P, 1999, J CLIN ENDOCR METAB, V84, P990, DOI 10.1210/jc.84.3.990; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Castro-Fernandez C, 2005, ENDOCR REV, V26, P479, DOI 10.1210/er.2004-0010; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; Conn P Michael, 2002, Mol Interv, V2, P308, DOI 10.1124/mi.2.5.308; Costa EMF, 2001, J CLIN ENDOCR METAB, V86, P2680, DOI 10.1210/jc.86.6.2680; De Roux N, 1999, J CLIN ENDOCR METAB, V84, P567, DOI 10.1210/jc.84.2.567; deRoux N, 1997, NEW ENGL J MED, V337, P1597, DOI 10.1056/NEJM199711273372205; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HUCKLE WR, 1987, METHOD ENZYMOL, V141, P149; Janovick JA, 2003, ENDOCRINE, V22, P317, DOI 10.1385/ENDO:22:3:317; Janovick JA, 2003, J PHARMACOL EXP THER, V305, P608, DOI 10.1124/jpet.102.048454; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Karges B, 2003, HUM REPROD UPDATE, V9, P523, DOI 10.1093/humupd/dmg040; Karges B, 2003, J CLIN ENDOCR METAB, V88, P1873, DOI 10.1210/jc.2002-020005; KATT JA, 1985, ENDOCRINOLOGY, V116, P2113, DOI 10.1210/endo-116-5-2113; Knobil E, 1980, Recent Prog Horm Res, V36, P53; Knobil E, 1974, Recent Prog Horm Res, V30, P1; KNOBIL E, 1988, HUM REPROD, V3, P469, DOI 10.1093/oxfordjournals.humrep.a136730; Kottler ML, 2000, J CLIN ENDOCR METAB, V85, P3002, DOI 10.1210/jc.85.9.3002; Kottler ML, 1999, ARCH MED RES, V30, P481, DOI 10.1016/S0188-4409(99)00072-7; Layman LC, 2001, FERTIL STERIL, V75, P1148, DOI 10.1016/S0015-0282(01)01782-4; Leanos-Miranda A, 2003, J CLIN ENDOCR METAB, V88, P3360, DOI 10.1210/jc.2003-030084; Leanos-Miranda A, 2002, J CLIN ENDOCR METAB, V87, P4825, DOI 10.1210/jc.2002-020961; Lin XW, 1998, MOL CELL ENDOCRINOL, V146, P27, DOI 10.1016/S0303-7207(98)00204-4; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Maya-Nunez G, 2002, J CLIN ENDOCR METAB, V87, P2144, DOI 10.1210/jc.87.5.2144; Meysing AU, 2004, J CLIN ENDOCR METAB, V89, P3189, DOI 10.1210/jc.2003-031808; Millar RP, 2004, ENDOCR REV, V25, P235, DOI 10.1210/er.2003-0002; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Reinhart GJ, 2004, J BIOL CHEM, V279, P34115, DOI 10.1074/jbc.M404474200; Seminara SB, 2000, J CLIN ENDOCR METAB, V85, P556, DOI 10.1210/jc.85.2.556; Silveira LFG, 2002, J CLIN ENDOCR METAB, V87, P2973, DOI 10.1210/jc.87.6.2973; Silveira LFG, 2002, SEMIN REPROD MED, V20, P327, DOI 10.1055/s-2002-36707; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Ulloa-Aguirre A, 2004, HUM REPROD UPDATE, V10, P177, DOI 10.1093/humupd/dmh015; Ulloa-Aguirre A, 2003, EXPERT OPIN THER TAR, V7, P175, DOI 10.1517/eott.7.2.175.23780; ULLOAAGUIRE A, 1998, HDB PHYSL ENDOCRINOL, V7, P87; WARD CL, 1994, J BIOL CHEM, V269, P25710	43	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24506	24514		10.1074/jbc.M501978200	http://dx.doi.org/10.1074/jbc.M501978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15886197	hybrid			2022-12-25	WOS:000230114000027
J	Murakami, M; Masuda, S; Shimbara, S; Ishikawa, Y; Ishii, T; Kudo, I				Murakami, M; Masuda, S; Shimbara, S; Ishikawa, Y; Ishii, T; Kudo, I			Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE-RELEASING FUNCTION; GROUP-X; GROUP-V; INTESTINAL POLYPOSIS; PROSTAGLANDIN PRODUCTION; ENDOTHELIAL-CELLS; RECEPTOR-BINDING; MAMMALIAN-CELLS; KNOCKOUT MICE; ACID RELEASE	Human group III secreted phospholipase A(2) (sPLA(2)-III) consists of a central group III sPLA(2) domain flanked by unique N- and C-terminal domains. We found that the sPLA(2) domain alone was sufficient for its catalytic activity and for its prostaglandin E-2 (PGE(2))-generating functions in various cell types. In several if not all cell types, the N- and C-terminal domains of sPLA(2)-III were proteolytically removed, leading to the production of the form containing only the sPLA(2) domain, which could be further N- glycosylated at two consensus sites. Immunohistochemistry demonstrated that sPLA(2)-III was preferentially expressed in the microvascular endothelium in human tissues with inflammation, ischemic injury, and cancer. In support of this, sPLA(2)-III was induced in cultured microvascular endothelial cells after stimulation with proinflammatory cytokines. Expression of sPLA(2)-III was also associated with various tumor cells, and colorectal cancer cells transfected with sPLA(2)-III exhibited enhanced PGE(2) production and cell proliferation, which required sPLA(2)-III catalytic activity. When implanted into nude mice, the sPLA(2)-III-transfected cells formed larger solid tumors with increased angiogenesis compared with control cells. Moreover, small interfering RNA for sPLA(2)-III significantly reduced PGE(2) production and proliferation of colorectal cancer cells. Taken together, these results reveal unique cell type-specific processing and N-glycosylation of sPLA(2)-III and the potential role of this enzyme in cancer development by stimulating tumor cell growth and angiogenesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Toho Univ, Sch Med, Dept Pathol, Tokyo 1438540, Japan	Showa University; Tokyo Metropolitan Institute of Medical Science; Toho University	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@pharm.showa-u.ac.jp						Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bollinger JG, 2004, BIOCHEMISTRY-US, V43, P13293, DOI 10.1021/bi049390i; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; CLEGG DO, 1987, SCAND J RHEUMATOL, P3; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hite RD, 2005, AM J PHYSIOL-LUNG C, V288, pL618, DOI 10.1152/ajplung.00274.2004; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kawamori T, 2005, CARCINOGENESIS, V26, P353, DOI 10.1093/carcin/bgh322; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Masuda S, 2005, J BIOL CHEM, V280, P23203, DOI 10.1074/jbc.M500985200; Masuda S, 2005, BIOCHEM J, V387, P27, DOI 10.1042/BJ20041307; Masuda S, 2005, FEBS J, V272, P655, DOI 10.1111/j.1742-4658.2004.04489.x; Masuda S, 2004, BBA-MOL CELL BIOL L, V1686, P61, DOI 10.1016/j.bbalip.2004.08.017; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2003, J BIOL CHEM, V278, P10657, DOI 10.1074/jbc.M211325200; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, EUR J BIOCHEM, V269, P2698, DOI 10.1046/j.1432-1033.2002.02938.x; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Nakashima S, 2004, BRAIN RES, V1015, P207, DOI 10.1016/j.brainres.2004.04.069; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Perrin-Cocon L, 2004, EUR J IMMUNOL, V34, P2293, DOI 10.1002/eji.200324797; Pola R, 2004, J MOL CELL CARDIOL, V36, P363, DOI 10.1016/j.yjmcc.2003.10.016; Rizzo MT, 2000, BLOOD, V96, P3809, DOI 10.1182/blood.V96.12.3809.h8003809_3809_3815; Salcedo R, 2003, BLOOD, V102, P1966, DOI 10.1182/blood-2002-11-3400; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Young M. Rita I., 2004, Angiogenesis, V7, P123, DOI 10.1007/s10456-004-1027-2	46	65	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24987	24998		10.1074/jbc.M502088200	http://dx.doi.org/10.1074/jbc.M502088200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863501	hybrid			2022-12-25	WOS:000230114000083
J	Starita, LM; Horwitz, AA; Keogh, MC; Ishioka, C; Parvin, JD; Chiba, N				Starita, LM; Horwitz, AA; Keogh, MC; Ishioka, C; Parvin, JD; Chiba, N			BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; DNA-REPAIR; LARGE SUBUNIT; PROTEIN LIGASE; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; IN-VITRO; BRCA1; CELLS; BRCA1-BARD1	The breast- and ovarian-specific tumor suppressor BRCA1, when associated with BARD1, is an ubiquitin ligase. We have shown here that this heterodimer ubiquitinates a hyperphosphorylated form of Rpb1, the largest subunit of RNA polymerase II. Two major phosphorylation sites have been identified in the Rpb1 carboxyl terminal domain, serine 2 ( Ser-2) or serine 5 ( Ser-5) of the YSPTSPS heptapeptide repeat. Only the Ser-5 hyperphosphorylated form is ubiquitinated by BRCA1/BARD1. Overexpression of BRCA1 in cells stimulated the DNA damage-induced ubiquitination of Rpb1. Similar to the in vitro reaction, the stimulation of Rpb1 ubiquitination by BRCA1 in cells occurred only on those molecules hyperphosphorylated on Ser-5 of the heptapeptide repeat. In vitro, the carboxyl terminus of BRCA1 ( amino acids 501-1863) was dispensable for the ubiquitination of hyperphosphorylated Rpb1. In cells, however, efficient Rpb1 ubiquitination required the carboxyl terminus of BRCA1, suggesting that interactions mediated by this region were essential in the complex milieu of the nucleus. These results link the BRCA1-dependent ubiquitination of the polymerase with DNA damage.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Tohoku Univ Hosp, Sendai, Miyagi 9808575, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Tohoku University	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu; nchiba@idac.tohoku.ac.jp	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NCI NIH HHS [CA90281] Funding Source: Medline; NIGMS NIH HHS [GM53504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bentley D, 1998, NATURE, V395, P21, DOI 10.1038/25616; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Mondal N, 2001, NATURE, V413, P435, DOI 10.1038/35096590; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Parvin JD, 2001, P NATL ACAD SCI USA, V98, P5952, DOI 10.1073/pnas.121184998; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	61	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24498	24505		10.1074/jbc.M414020200	http://dx.doi.org/10.1074/jbc.M414020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15886201	hybrid			2022-12-25	WOS:000230114000026
J	Fang, HY; Franke, R; Patanavanich, S; Lalvani, A; Powell, NK; Sando, JJ; Kamatchi, GL				Fang, HY; Franke, R; Patanavanich, S; Lalvani, A; Powell, NK; Sando, JJ; Kamatchi, GL			Role of alpha(1) 2.3 subunit I-II linker sites in the enhancement of Ca-v 2.3 current by phorbol 12-myristate 13-acetate and acetyl-beta-methylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEURONAL CALCIUM-CHANNELS; N-TYPE; CA2+ CHANNELS; SYMPATHETIC NEURONS; MODULATION; IDENTIFICATION; SUBUNIT	Potentiation of Ca-v 2.3 currents by phorbol 12-myristate 13-acetate (PMA) or acetyl-beta- methylcholine (MCh) may be due to protein kinase C (PKC)-mediated phosphorylation of the alpha(1) 2.3 subunit. Mutational analysis of potential PKC sites unique to the alpha(1) 2.3 subunit revealed several sites in the II-III linker that are specific to MCh (Kamatchi, G., Franke, R., Lynch, C., III, and Sando, J. ( 2004) J. Biol. Chem. 279, 4102 - 4109). To identify sites responsive to PMA, Ser/Thr -> Ala mutations were made in potential PKC sites homologous to the alpha(1) 2.3 and 2.2 subunits, both of which respond to PMA. Wild type alpha(1) 2.3 or mutants were expressed in Xenopus oocytes in combination with beta 1b and alpha 2/delta subunits and muscarinic M-1 receptors. Inward current (I-Ba) was recorded using Ba2+ as the charge carrier. Thr-365 of the I-II linker was identified as the primary site of PMA action, and this site also was required, along with the previously identified MCh-selective sites, for the MCh response. Ser-369 and Ser-1995 contributed to current enhancement only if Thr-365 also was available. Mutation of the essential sites to Asp increased the basal IBa and caused a corresponding decrease in the PMA or MCh responses, consistent with possible regulation of these sites by phosphorylation. These results suggest that PMA and MCh both activate a pathway that can regulate the common PMA-sensitive sites in the I-II linker but that MCh also activates an additional pathway required for regulation of the MCh-unique sites, especially in the II-III linker.	Univ Virginia, Dept Anesthesiol, Charlottesville, VA 22908 USA	University of Virginia	Kamatchi, GL (corresponding author), Univ Virginia, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	gk3p@virginia.edu			NIGMS NIH HHS [GM65214, GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065214, R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLAND LM, 1993, J NEUROSCI, V13, P516; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; Elmslie KS, 2003, J BIOENERG BIOMEMBR, V35, P477, DOI 10.1023/B:JOBB.0000008021.55853.18; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; HALL KE, 1995, J NEUROSCI, V15, P6069; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Johnson J, 1997, MECH DEVELOP, V67, P215, DOI 10.1016/S0925-4773(97)00122-6; Kamatchi GL, 2004, J BIOL CHEM, V279, P4102, DOI 10.1074/jbc.M308606200; Kamatchi GL, 2003, BRAIN RES, V968, P227, DOI 10.1016/S0006-8993(03)02245-5; Melliti K, 2000, J NEUROSCI, V20, P7167; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; van Koppen CJ, 2003, PHARMACOL THERAPEUT, V98, P197, DOI 10.1016/S0163-7258(03)00032-9; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	17	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23559	23565		10.1074/jbc.M501540200	http://dx.doi.org/10.1074/jbc.M501540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840578	hybrid			2022-12-25	WOS:000229880000020
J	Huang, YP; Norton, DD; Precht, P; Martindale, JL; Burkhardt, JK; Wange, RL				Huang, YP; Norton, DD; Precht, P; Martindale, JL; Burkhardt, JK; Wange, RL			Deficiency of ADAP/Fyb/SLAP-130 destabilizes SKAP55 in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILIZATION; ANTIGEN RECEPTOR; INTERLEUKIN-2 PRODUCTION; INTEGRIN ACTIVATION; MOLECULAR-CLONING; CUTTING EDGE; UV-LIGHT; PROTEIN; BINDING; FYN	ADAP ( adhesion and degranulation-promoting adaptor protein) and SKAP55 (Src kinase-associated phosphoprotein of 55 kDa) are T cell adaptors that mediate inside-out signaling from the T cell antigen receptor to integrins, giving rise to increased integrin affinity/avidity and formation of the immunological synapse between the T cell and the antigen-presenting cell. These two proteins are tightly and constitutively associated with one another, and their ability to interact is required for inside-out signaling. Here we show in an ADAP-deficient Jurkat T cell line that the co-dependence of ADAP and SKAP55 extends beyond their functional and physical interactions and show that SKAP55 protein is unstable in the absence of ADAP. Restoration of ADAP to the ADAP-deficient Jurkat T cell line restores SKAP55 expression by causing a 5-fold decrease in the rate of SKAP55 proteolysis. Inactivation of the Src homology 3 domain of SKAP55, which mediates the association between SKAP55 with ADAP, blocks the protective effect of ADAP. The half-life of SKAP55, in the absence of ADAP, is similar to 15-20 min, increasing to 90 min in the presence of ADAP. This is a remarkably rapid rate of turnover for a signaling protein and suggests the possibility that stimuli that signal for the stabilization of SKAP55 may play an important role in T cell adhesion and conjugate formation.	Childrens Hosp Philadelphia, Abramson Res Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Huang, YP (corresponding author), Childrens Hosp Philadelphia, Abramson Res Ctr, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	HUANGY@email.chop.edu	Martindale, Jennifer Luethy/AAD-1963-2022; Wange, Ronald/AAI-2505-2021	Martindale, Jennifer Luethy/0000-0002-3234-6861; Wange, Ronald/0000-0001-9593-3572				DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dustin ML, 2004, IMMUNITY, V21, P305, DOI 10.1016/j.immuni.2004.08.016; Fujii Y, 2003, FEBS LETT, V540, P111, DOI 10.1016/S0014-5793(03)00234-5; Geng LP, 1999, J IMMUNOL, V163, P5753; Geng LP, 2002, BRIT J HAEMATOL, V116, P19, DOI 10.1046/j.1365-2141.2002.03243.x; Geng LP, 2001, P NATL ACAD SCI USA, V98, P11527, DOI 10.1073/pnas.191378198; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; Hunter AJ, 2000, J IMMUNOL, V164, P1143, DOI 10.4049/jimmunol.164.3.1143; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kellermann SA, 2002, IMMUNOL REV, V186, P172, DOI 10.1034/j.1600-065X.2002.18615.x; Liu J, 1998, P NATL ACAD SCI USA, V95, P8779, DOI 10.1073/pnas.95.15.8779; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Morgan MM, 2001, J IMMUNOL, V167, P5708, DOI 10.4049/jimmunol.167.10.5708; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seminario MC, 2003, ONCOGENE, V22, P8195, DOI 10.1038/sj.onc.1206872; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stewart MP, 1996, J IMMUNOL, V156, P1810; Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003; Veale M, 1999, J BIOL CHEM, V274, P28427, DOI 10.1074/jbc.274.40.28427; Wang HY, 2003, NAT IMMUNOL, V4, P366, DOI 10.1038/ni913; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Wilkinson B, 2004, IMMUNOLOGY, V111, P368, DOI 10.1111/j.0019-2805.2004.01832.x; Wu LT, 2002, J BIOL CHEM, V277, P40420, DOI 10.1074/jbc.M206023200; Wu LT, 2002, MOL CELL BIOL, V22, P2673, DOI 10.1128/MCB.22.8.2673-2686.2002	39	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23576	23583		10.1074/jbc.M413201200	http://dx.doi.org/10.1074/jbc.M413201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849195				2022-12-25	WOS:000229880000022
J	Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M				Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M			Paired-like homeoprotein ESXR1 acts as a sequence-specific transcriptional repressor of the human K-ras gene	ONCOGENE			English	Article						ESXR1; homeoprotein; transcriptional repressor; K-ras gene; cancer gene therapy	ACTIVATION; LUNG; ADENOCARCINOMA; ONCOGENES; PROTEINS; CANCER; MOUSE; TUMORIGENESIS; AMPLIFICATION; REGION	Gain-of-function mutation of the K-ras gene is one of the most common genetic changes in human tumors. In tumors carrying K-ras mutation, the presence of oncogenic K-Ras is necessary for maintenance of the transformed phenotype. ESXR1 is a human paired-like homeodomain-containing protein expressed primarily in the testis. In cells, the 65-kDa full-length ESXR1 protein is proteolytically processed into an N-terminal 45-kDa fragment containing the homeodomain, which localizes exclusively within the nucleus, and a C-terminal 20-kDa fragment consisting of a proline-rich repeat region, which is located in the cytoplasm. In this work, we demonstrated that the N-terminal ESXR1 fragment specifically recognizes the TAATNNNATTA P3 consensus sequence for the paired-like homeodomain and functions as a sequence-specific transcriptional repressor. We also showed that the N-terminal ESXR1 fragment binds to the TAATGTTAT TA sequence present within the first intron of the human K-ras gene and inhibits its expression at both mRNA and protein levels. Ectopic expression of the N-terminal ESXR1 fragment in human carcinoma cells that carry mutated K-ras reduces the level of K-Ras and thereby inhibits the tumor cell proliferation. Identification of ESXR1 as a transcriptional repressor of K-ras has an important implication for the development of cancer therapy that inhibits oncogenic K-Ras expression.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo 1538904, Japan	Hokkaido University; University of Tokyo	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15-Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, GUT, V48, P230, DOI 10.1136/gut.48.2.230; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; JORDANO J, 1988, ONCOGENE, V2, P359; Knudsen S., 2002, BIOL GUIDE ANAL DNA; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; McIntyre A, 2004, ONCOGENE, V23, P9142, DOI 10.1038/sj.onc.1208115; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Ozawa H, 2004, ONCOGENE, V23, P6590, DOI 10.1038/sj.onc.1207884; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	27	7	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5878	5887		10.1038/sj.onc.1208736	http://dx.doi.org/10.1038/sj.onc.1208736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897875				2022-12-25	WOS:000231590400010
J	Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK				Zeisig, DT; Bittner, CB; Zeisig, BB; Garcia-Cuellar, MP; Hess, JL; Slany, RK			The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin	ONCOGENE			English	Article						ENL; MLL; leukemia; histone; chromatin	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION; HISTONE METHYLTRANSFERASE; SWI/SNF COMPLEX; ONCOGENIC ACTIVATION; PAF1 COMPLEX; SET DOMAIN; FAMILY; DIMERIZATION; METHYLATION	Mixed lineage leukemia (MLL) fusion proteins are derived from translocations at 11q23 that occur in aggressive subtypes of leukemia. As a consequence, MLL is joined to different unrelated proteins to form oncogenic transcription factors. Here we demonstrate a direct interaction between several nuclear MLL fusion partners and present evidence for a role of these proteins in histone binding. In two-hybrid studies, ENL interacted with AF4 and AF5q31 as well as with a fragment of AF10. A structure-function analysis revealed that the AF4/AF5q31/AF10 binding domain in ENL coincided with the C-terminus that is essential for transformation by MLL-ENL. The ENL/AF4 association was corroborated by GST-pulldown experiments and by mutual coprecipitation. Both proteins colocalized in vivo in a nuclear speckled pattern. Moreover, AF4 and ENL coeluted on sizing columns together with the known ENL binding partner Polycomb3, suggesting the presence of a multiprotein complex. The overexpression of ENL alone activated a reporter construct and a mutational screen indicated the conserved YEATS domain as essential for this function. Overlay and pulldown-assays finally showed a specific and YEATS domain-dependent association of ENL with histones H3 and H1. In summary, our studies support a common role for nuclear MLL fusion partners in chromatin biology.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Erlangen Nuremberg; University of Pennsylvania	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.	rslany@biologie.uni-erlangen.de		Bittner, Claudia/0000-0002-7641-0351	NATIONAL CANCER INSTITUTE [R01CA078815] Funding Source: NIH RePORTER; NCI NIH HHS [CA92251, CA78815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bittner CB, 2004, EUKARYOT CELL, V3, P976, DOI 10.1128/EC.3.4.976-983.2004; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Erfurth F, 2004, LEUKEMIA, V18, P92, DOI 10.1038/sj.leu.2403200; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Estable MC, 2002, J BIOMED SCI, V9, P234, DOI 10.1007/BF02256070; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferrando AA, 2003, BLOOD, V102, P262, DOI 10.1182/blood-2002-10-3221; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Le Masson I, 2003, MOL CELL BIOL, V23, P6086, DOI 10.1128/MCB.23.17.6086-6102.2003; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MILNE TA, 2005, UNPUB CANC RES; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; Petruk S, 2001, SCIENCE, V294, P1331, DOI 10.1126/science.1065683; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Schreiner S, 2001, CANCER RES, V61, P6480; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Srinivasan RS, 2004, LEUKEMIA, V18, P1364, DOI 10.1038/sj.leu.2403415; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zeisig BB, 2003, ONCOGENE, V22, P1629, DOI 10.1038/sj.onc.1206104; Zeisig BB, 2003, LEUKEMIA, V17, P359, DOI 10.1038/sj.leu.2402804; Zhang HY, 2004, MOL CELL BIOL, V24, P9424, DOI 10.1128/MCB.24.21.9424-9436.2004	40	89	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5525	5532		10.1038/sj.onc.1208699	http://dx.doi.org/10.1038/sj.onc.1208699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856011				2022-12-25	WOS:000231222300013
J	Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S				Taubert, H; Kappler, M; Bache, M; Bartel, F; Kohler, T; Lautenschlager, C; Blumke, K; Wurl, P; Schmidt, H; Meye, A; Hauptmann, S			Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients	ONCOGENE			English	Article						soft-tissue sarcoma; survivin splice variants; prognosis	BREAST-CANCER; SURVIVIN-DELTA-EX3; APOPTOSIS; CARCINOMAS	The aim of this study was to investigate the level and the prognostic value of the expression of different survivin transcript variants - survivin, survivin-Delta Ex3 and survivin-2B - in tumours of 76 soft tissue sarcoma (STS) patients. The expression of survivin transcript variants in STS tissue samples and in 12 nonmalignant control tissues was analysed by quantitative RT-PCRs. Expression levels of all survivin transcript variants were strongly elevated in STS compared to normal tissues. A positive correlation between expression of splice variants and tumour stage was found (P = 0.02; chi(2) test). The multivariate Cox's proportional hazards regression model revealed a 7.3-fold increased risk of tumour-related death for patients with survivin-Delta Ex3 overexpressing tumours (P = 0.007). The effect of surivivin ( wildtype variant) and survivin-2B was less pronounced but still significant (2.2- and 1.9-fold, resp., P < 0.05 each). Our results show for the first time that mRNA expression of survivin-variants is significantly correlated to a poor prognosis for STS patients, and we suggest expression of survivin splice variants together with tumour stage as independent predictor of survival.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Radiotherapy, Halle Saale, Germany; Roboscreen GmbH, Leipzig, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle Saale, Germany; Univ Halle Wittenberg, Dept Urol, D-06097 Halle Saale, Germany; Univ Ulm, Ulm, Germany; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Ulm University; Technische Universitat Dresden	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle Saale, Germany.	helge.taubert@medizin.uni-halle.de	Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271; Taubert, Helge/0000-0002-9077-1727				Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Fangusaro JR, 2005, BRIT J CANCER, V92, P359, DOI 10.1038/sj.bjc.6602317; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Nakagawa Y, 2004, LEUKEMIA RES, V28, P487, DOI 10.1016/j.leukres.2003.10.013; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Yamada Y, 2003, J NEUROSURG, V99, P738, DOI 10.3171/jns.2003.99.4.0738	17	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2005	24	33					5258	5261		10.1038/sj.onc.1208702	http://dx.doi.org/10.1038/sj.onc.1208702			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856009				2022-12-25	WOS:000230964600013
J	Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F				Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F			Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer	ONCOGENE			English	Article						androgens; prostate cancer; six transmembrane; Golgi; transcription	GREEN FLUORESCENT PROTEIN; KALLIKREIN GENE FAMILY; NEOPLASTIC PROSTATE; RESPONSIVE GENES; SERINE-PROTEASE; GOLGI-COMPLEX; HOMEOBOX GENE; IN-VIVO; ANTIGEN; LOCALIZATION	We have identified a novel gene, six transmembrane protein of prostate 2 (STAMP2), named for its high sequence similarity to the recently identified STAMP1 gene. STAMP2 displays a tissue-restricted expression with highest expression levels in placenta, lung, heart, and prostate and is predicted to code for a 459-amino acid six transmembrane protein. Using a form of STAMP2 labeled with green flourescent protein (GFP) in quantitative time-lapse and immuno fluorescence confocal microscopy, we show that STAMP2 is primarily localized to the Golgi complex, trans-Golgi network, and the plasma membrane. STAMP 2 also localizes to vesicular-tubular structures in the cytosol and colocalizes with the Early Endosome Antigen1 (EEA1) suggesting that it may be involved in the secretory/endocytic pathways. STAMP2 expression is exquisitely androgen regulated in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptor-negative prostate cancer cell lines PC-3 and DU145. Analysis of STAMP2 expression in matched normal and tumor samples microdissected from prostate cancer specimens indicates that STAMP2 is overexpressed in prostate cancer cells compared with normal prostate epithelial cells. Further more, ectopic expression of STAMP2 in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation. Taken together, these data suggest that STAMP2 may contribute to the normal biology of the prostate cell, as well as prostate cancer progression.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; Aker Univ Hosp, Dept Pathol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway	University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Dept Mol Biosci, Postboks 1050, N-0316 Oslo, Norway.	fahris@imbv.uio.no	Korkmaz, Kemal Sami/ABI-5112-2020	Korkmaz, Kemal Sami/0000-0003-4040-2568	NATIONAL CANCER INSTITUTE [ZIABC005450, Z01BC005450] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSEBEL FM, 1997, CURR PROTOCLS MOL BI; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; Crawford ED, 1999, UROLOGY, V54, P1, DOI 10.1016/S0090-4295(99)00447-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Deppenmeier U, 2002, CELL MOL LIFE SCI, V59, P1513, DOI 10.1007/s00018-002-8526-3; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HAIGH NG, 2002, PROTEIN TARGETING TR, P74; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Jenster G, 1999, SEMIN ONCOL, V26, P407; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Kokontis JM, 1999, VITAM HORM, V55, P219; Korkmaz KS, 2000, DNA CELL BIOL, V19, P499, DOI 10.1089/10445490050128421; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Korkmaz KS, 2001, DNA CELL BIOL, V20, P435, DOI 10.1089/104454901750361497; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Mellman I, 2000, J CELL BIOL, V149, P529, DOI 10.1083/jcb.149.3.529; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Ordovas JM, 2000, NUTR REV, V58, P76; Passer BJ, 2003, P NATL ACAD SCI USA, V100, P2284, DOI 10.1073/pnas.0530298100; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Ponnambalam S, 1996, CURR BIOL, V6, P1076, DOI 10.1016/S0960-9822(02)70669-6; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; Roy AK, 1999, VITAM HORM, V55, P309; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steiner MS, 2000, CANCER RES, V60, P4419; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stephan C, 2002, UROLOGY, V59, P2, DOI 10.1016/S0090-4295(01)01449-2; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yousef GM, 1999, CANCER RES, V59, P4252	45	103	111	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4934	4945		10.1038/sj.onc.1208677	http://dx.doi.org/10.1038/sj.onc.1208677			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897894	Bronze			2022-12-25	WOS:000230646500006
J	Arias-Barrau, E; Sandoval, N; Naharro, G; Olivera, ER; Luengo, JM				Arias-Barrau, E; Sandoval, N; Naharro, G; Olivera, ER; Luengo, JM			A two-component hydroxylase involved in the assimilation of 3-hydroxyphenyl acetate in Pseudomonas putida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLACETYL-COA LIGASE; ESCHERICHIA-COLI; 4-HYDROXYPHENYLACETATE 3-HYDROXYLASE; HOMOPROTOCATECHUATE 2,3-DIOXYGENASE; MOLECULAR CHARACTERIZATION; DEPENDENT MONOOXYGENASE; AROMATIC-HYDROCARBONS; BACTERIAL-DEGRADATION; CATABOLIC PATHWAY; ACID	The complete catabolic pathway involved in the assimilation of 3-hydroxyphenylacetic acid (3-OH-PhAc) in Pseudomonas putida U has been established. This pathway is integrated by the following: (i) a specific route ( upper pathway), which catalyzes the conversion of 3-OH-PhAc into 2,5-dihydroxyphenylacetic acid (2,5diOH-PhAc) (homogentisic acid, Hmg), and (ii) a central route ( convergent route), which catalyzes the transformation of the Hmg generated from 3-OH-PhAc, L-Phe, and L-Tyr into fumarate and acetoacetate (HmgABC). Thus, in a first step the degradation of 3-OH-PhAc requires the uptake of 3-OH-PhAc by means of an active transport system that involves the participation of a permease (MhaC) together with phosphoenolpyruvate as the energy source. Once incorporated, 3-OH- PhAc is hydroxylated to 2,5-diOH-PhAc through an enzymatic reaction catalyzed by a novel two-component flavoprotein aromatic hydroxylase (MhaAB). The large component (MhaA, 62,719 Da) is a flavoprotein, and the small component (MhaB, 6,348 Da) is a coupling protein that is essential for the hydroxylation of 3-OH-PhAc to 2,5diOH-PhAc. Sequence analyses and molecular biology studies revealed that homogentisic acid synthase (MhaAB) is different from the aromatic hydroxylases reported to date, accounting for its specific involvement in the catabolism of 3-OH-PhAc. Additionally, an ABC transport system (HmgDEFGHI) involved in the uptake of homogentisic acid and two regulatory elements (mhaSR and hmgR) have been identified. Furthermore, the cloning and the expression of some of the catabolic genes in different microbes presented them with the ability to synthesize Hmg (mhaAB) or allowed them to grow in chemically defined media containing 3-OHPhAc as the sole carbon source ( mhaAB and hmgABC).	Univ Leon, Fac Vet, Dept Bioquim & Biol Mol, Leon 24007, Spain; Univ Leon, Fac Vet, Dept Patol Anim Sanidad Anim, Leon 24007, Spain	Universidad de Leon; Universidad de Leon	Luengo, JM (corresponding author), Univ Leon, Fac Vet, Dept Bioquim & Biol Mol, Leon 24007, Spain.	dbbjlr@unileon.es	OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Olivera, Elias Rodriguez/Q-1166-2019; Naharro, Germán/AAA-6572-2019; Luengo, Jose M./E-1935-2016	OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Olivera, Elias Rodriguez/0000-0003-2315-8524; Naharro, Germán/0000-0002-7391-4378; Luengo, Jose M./0000-0002-4984-6256				ANDERSON JJ, 1980, J BACTERIOL, V141, P534, DOI 10.1128/JB.141.2.534-543.1980; Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P150; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P11795; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BLAKLEY ER, 1967, CAN J MICROBIOL, V13, P147, DOI 10.1139/m67-021; Butler CS, 1997, ADV MICROB PHYSIOL, V38, P47; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Chaiyen P, 2001, EUR J BIOCHEM, V268, P5550, DOI 10.1046/j.1432-1033.2001.02490.x; DAGLEY S, 1975, ESSAYS BIOCHEM, V11, P81; DAGLEY S, 1982, FLAVINS FLAVOPROTEIN; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; Diaz E, 2000, CURR OPIN BIOTECH, V11, P467, DOI 10.1016/S0958-1669(00)00126-9; Diaz E, 2004, INT MICROBIOL, V7, P173; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Garcia B, 1999, J BIOL CHEM, V274, P29228, DOI 10.1074/jbc.274.41.29228; Garcia B, 2004, APPL ENVIRON MICROB, V70, P5019, DOI 10.1128/AEM.70.8.5019-5025.2004; GIBSON DT, 1970, BIOCHEMISTRY-US, V9, P1631, DOI 10.1021/bi00809a024; GIBSON DT, 1968, BIOCHEMISTRY-US, V7, P3795, DOI 10.1021/bi00851a003; GIBSON DT, 1984, MICROBIAL DEGRADATIO, P361; GIBSON DT, 1973, BIOCHEMISTRY-US, V12; Gin P, 2003, J BIOL CHEM, V278, P25308, DOI 10.1074/jbc.M303234200; Groce SL, 2003, J AM CHEM SOC, V125, P11780, DOI 10.1021/ja0368103; HARAYAMA S, 1992, ANNU REV MICROBIOL, V46, P565, DOI 10.1146/annurev.micro.46.1.565; HARAYAMA S, 1989, J BIOL CHEM, V264, P15328; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; IKEDA Y, 1983, J ANTIBIOT, V36, P1279, DOI 10.7164/antibiotics.36.1279; Kirchner U, 2003, J BIOL CHEM, V278, P47545, DOI 10.1074/jbc.M307397200; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Leahy JG, 2003, FEMS MICROBIOL REV, V27, P449, DOI 10.1016/S0168-6445(03)00023-8; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; MARTIN M, 1991, J GEN MICROBIOL, V137, P621, DOI 10.1099/00221287-137-3-621; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Miller MA, 1996, J BIOL CHEM, V271, P5524, DOI 10.1074/jbc.271.10.5524; Minambres B, 1996, J BIOL CHEM, V271, P33531, DOI 10.1074/jbc.271.52.33531; NAKAHIGASHI K, 1992, J BACTERIOL, V174, P7352, DOI 10.1128/jb.174.22.7352-7359.1992; Nishijyo T, 2001, MOL MICROBIOL, V40, P917, DOI 10.1046/j.1365-2958.2001.02435.x; Nozaki M, 1979, Top Curr Chem, V78, P145, DOI 10.1007/BFb0048193; O'Connor KE, 2001, J BACTERIOL, V183, P928, DOI 10.1128/JB.183.3.928-933.2001; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Olivera ER, 2001, MOL MICROBIOL, V39, P863, DOI 10.1046/j.1365-2958.2001.02296.x; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; Prieto MA, 2004, FEMS MICROBIOL REV, V28, P503, DOI 10.1016/j.femsre.2004.04.004; PRIETO MA, 1993, J BACTERIOL, V175, P2162, DOI 10.1128/JB.175.7.2162-2167.1993; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Sambrook J., 1989, MOL CLONING, pA1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIASLANI FS, 1974, BIOCHEM J, V140, P31, DOI 10.1042/bj1400031; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SELVARAJ G, 1983, J BACTERIOL, V156, P1292, DOI 10.1128/JB.156.3.1292-1300.1983; SEYFRIED B, 1991, ARCH MICROBIOL, V155, P249, DOI 10.1007/BF00252208; Smith MR, 1990, BIODEGRADATION, V1, P191, DOI 10.1007/BF00058836; Soballe B, 1999, MICROBIOL-SGM, V145, P1817, DOI 10.1099/13500872-145-8-1817; SPARNINS VL, 1974, J BACTERIOL, V120, P159, DOI 10.1128/JB.120.1.159-167.1974; Timmis KN, 1999, TRENDS BIOTECHNOL, V17, P201, DOI 10.1016/S0167-7799(98)01295-5; Tropel D, 2004, MICROBIOL MOL BIOL R, V68, P474, DOI 10.1128/MMBR.68.3.474-500.2004; Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012; van der Meer JR, 2003, CURR OPIN BIOTECH, V14, P248, DOI 10.1016/S0958-1669(03)00058-2; VANBERKEL WJH, 1991, EUR J BIOCHEM, V201, P585; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Wackett LP, 2000, CURR OPIN BIOTECH, V11, P229, DOI 10.1016/S0958-1669(00)00088-4; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	74	29	30	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26435	26447		10.1074/jbc.M501988200	http://dx.doi.org/10.1074/jbc.M501988200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15866873	hybrid			2022-12-25	WOS:000230386800059
J	Sun, LP; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Sun, LP; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL			Ubiquitin-proteasome-mediated degradation, intracellular localization, and protein synthesis of MyoD and Id1 during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS MYOGENIC DIFFERENTIATION; SKELETAL-MUSCLE; DNA-BINDING; MYOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; REGULATORY FACTORS; MESSENGER-RNA; E2A PROTEINS; NUCLEAR; PATHWAY	Mammalian skeletal myogenesis results in the differentiation of myoblasts to mature syncytial myotubes, a process regulated by an intricate genetic network of at least three protein families: muscle regulatory factors, E proteins, and Id proteins. MyoD, a key muscle regulatory factor, and its negative regulator Id1 have both been shown to be degraded by the ubiquitin-proteasome system. Using C2C12 cells and confocal fluorescence microscopy, we showed that MyoD and Id1 co-localize within the nucleus in proliferating myoblasts. In mature myotubes, in contrast, they reside in distinctive subcellular compartments, with MyoD within the nucleus and Id1 exclusively in the cytoplasm. Cellular abundance of Id1 was markedly diminished from the very onset of muscle differentiation, whereas MyoD abundance was reduced to a much lesser extent and only at the later stages of differentiation. These reductions in MyoD and Id1 protein levels seem to result from a change in the rate of protein synthesis rather than the rate of degradation. In vivo protein stability studies revealed that the rates of ubiquitin-proteasome-mediated MyoD and Id1 degradation are independent of myogenic differentiation state. Id1 and MyoD were both rapidly degraded, each with a t(1/ 2) similar or equal to 1 h in myoblasts and in myotubes. Furthermore, relative protein synthesis rates for MyoD and Id1 were significantly diminished during myoblast to myotube differentiation. These results provide insight as to the interaction between MyoD and Id1 in the process of muscle differentiation and have implications for the involvement of the ubiquitin-proteasome-mediated protein degradation and protein synthesis in muscle differentiation and metabolism under abnormal and pathological conditions.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Amack JD, 2002, J CELL BIOL, V159, P419, DOI 10.1083/jcb.200206020; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Braun T, 1996, EMBO J, V15, P310, DOI 10.1002/j.1460-2075.1996.tb00361.x; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ciechanover A, 1999, MOL BIOL REP, V26, P59, DOI 10.1023/A:1006964122190; Cooper RN, 1999, J CELL SCI, V112, P2895; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Di Carlo A, 2004, J BIOL CHEM, V279, P16332, DOI 10.1074/jbc.M313931200; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hatoum Ossama Abu, 1998, Molecular and Cellular Biology, V18, P5670; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Pante N, 2002, MOL BIOL CELL, V13, P425, DOI 10.1091/mbc.01-06-0308; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Yoshida N, 1998, J CELL SCI, V111, P769; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007	37	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26448	26456		10.1074/jbc.M500373200	http://dx.doi.org/10.1074/jbc.M500373200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888449	hybrid			2022-12-25	WOS:000230386800060
J	Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS				Eom, YW; Kim, MA; Park, SS; Goo, MJ; Kwon, HJ; Sohn, S; Kim, WH; Yoon, G; Choi, KS			Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype	ONCOGENE			English	Article						doxorubicin; mitotic catastrophe; apoptosis; senescence-like phenotype; hepatocellular carcinoma cells	TERMINAL PROLIFERATION ARREST; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASE; EPITHELIAL TUMOR-CELLS; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CLONOGENIC SURVIVAL; CHECKPOINT KINASE; GROWTH ARREST; DNA-DAMAGE	Chronic exposure of many human hepatoma cell lines to a low dose (LD) of doxorubicin induced a senescence-like phenotype (SLP) accompanied by enlargement of cells and increased senescence- associated beta-galactosidase activity. LD doxorubicin- induced SLP was preceded by multinucleation and downregulation of multiple proteins with mitotic checkpoint function, including CENP-A, Mad2, BubR1, and Chk1. LD doxorubicin-treated cells eventually underwent cell death through mitotic catastrophe. When we investigated whether LD doxorubicin-induced cell death shares biochemical characteristics with high dose (HD) doxorubicin- induced apoptosis in Huh-7 cells, we observed that externalization of phosphatidyl serine and release of mitochondrial cytochrome c into the cytosol was associated with both types of cell death. However, propidium iodide exclusion assays showed that membrane integrity was lost in the initial phase of LD doxorubicin- induced cell death through mitotic catastrophe, whereas it was lost during the late phase of HD doxorubicin- induced apoptosis. Furthermore, HD doxorubicin-induced apoptosis but not LD doxorubicin-induced mitotic catastrophe led to transient activation of NF-kappa B and strong, sustained activations of p38, c-Jun N-terminal kinase, and caspases. Collectively, these results indicate that different doses of doxorubicin activate different regulatory mechanisms to induce either apoptosis or cell death through mitotic catastrophe.	Ajou Univ, Sch Med, Lab Endocrinol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Cell Biol Lab, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Surg, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 442749, South Korea	Ajou University; Ajou University; Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Lab Endocrinol, San 5,Wonchondong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; 권, 호정/AAS-3642-2021	Kim, Wook Hwan/0000-0003-2820-0154; Eom, Young Woo/0000-0002-5985-6490; Choi, Kyeong Sook/0000-0003-2331-0856				Acunas B, 1999, EUR J RADIOL, V32, P86, DOI 10.1016/S0720-048X(99)00117-5; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Decaudin D, 1998, INT J ONCOL, V12, P141; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; He QY, 2002, INT J ONCOL, V20, P261; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Lock RB, 1996, CANCER RES, V56, P4006; Lu Wei, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P524; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PATT YZ, 1988, CANCER, V61, P1884, DOI 10.1002/1097-0142(19880501)61:9<1884::AID-CNCR2820610927>3.0.CO;2-D; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruth AC, 2000, CANCER RES, V60, P2576; SCIARRINO E, 1985, CANCER, V56, P2751, DOI 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPETH PAJ, 1987, CANCER CHEMOTH PHARM, V20, P305; te Poele RH, 2002, CANCER RES, V62, P1876; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; YAN MH, 1994, NATURE, V372, P798	46	256	266	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4765	4777		10.1038/sj.onc.1208627	http://dx.doi.org/10.1038/sj.onc.1208627			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870702				2022-12-25	WOS:000230477900003
J	Kuzmenko, AI; Wu, HX; Wan, SJ; McCormack, FX				Kuzmenko, AI; Wu, HX; Wan, SJ; McCormack, FX			Surfactant protein A is a principal and oxidation-sensitive microbial permeabilizing factor in the alveolar lining fluid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II CELLS; LOCALIZATION; SECRETION; NITRATION; LUNG	We have reported that surfactant protein A kills some Gram- negative organisms by increasing membrane permeability. In this study, we investigated the physiologic importance of this activity and the effect of oxidative stress on the antimicrobial functions of SP- A in vitro and in vivo. Concentrated bronchoalveolar lavage fluids from SP- A +/ + mice increased the permeability of the Escherichia coli K12 cell membrane to a greater extent than lavage from SP- A -/- animals. Similarly, calcium dependent surfactant- binding proteins of SP- A +/ + mice increased membrane permeability more than those from SP- A +/+ mice and produced greater zonal killing of agar- embedded bacteria in a radial diffusion assay. Exposure of human SP- A to copper- initiated surfactant phospholipid peroxidation or to free radicals generated by human neutrophils in vitro increased the level of SP- A- associated carbonyl moieties and blocked the permeabilizing function of the protein. We also found that exposure of mice to 90% O-2 for 4 days, sufficient to lead to consumption of glutathione, oxidation of protein thiols, and accumulation of airspace protein- associated carbonyl moieties, blocked the permeabilizing activity of lavage fluid from SP- A +/+ mice. We conclude that SP- A is a major microbial permeablizing factor in lavage fluid and that oxidative stress inhibits the antibacterial activity of SP- A by a mechanism that includes oxidative modification and functional inactivation of the protein.	Univ Cincinnati, Div Pulm & Crit Care Med, Dept Internal Med, Sch Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	McCormack, FX (corresponding author), Univ Cincinnati, Div Pulm & Crit Care Med, Dept Internal Med, Sch Med, MSB Rm 6001,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	frank.mccormack@uc.edu	McCormack, Francis X./ABE-8398-2020; Kuzmenko, Oleksandr/P-6059-2016	McCormack, Francis X./0000-0001-7168-9464; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GELVAN D, 1990, BIOCHIM BIOPHYS ACTA, V1035, P353, DOI 10.1016/0304-4165(90)90100-B; GREGORIADIS G, 1972, BIOCHEM J, V129, P123, DOI 10.1042/bj1290123; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kuzmenko AI, 2004, J LIPID RES, V45, P1061, DOI 10.1194/jlr.M300360-JLR200; Levine RL, 2000, METH MOL B, V99, P15; Mark L, 1999, AM J PHYSIOL-LUNG C, V276, pL491, DOI 10.1152/ajplung.1999.276.3.L491; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; NEWMAN SL, 1993, J CLIN INVEST, V92, P624, DOI 10.1172/JCI116630; Saeed FA, 1998, CLIN DIAGN LAB IMMUN, V5, P740, DOI 10.1128/CDLI.5.5.740-743.1998; SUWABE A, 1991, AM J RESP CELL MOL, V5, P80, DOI 10.1165/ajrcmb/5.1.80; Wang GR, 2004, BIOCHEMISTRY-US, V43, P4227, DOI 10.1021/bi036023i; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025	17	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25913	25919		10.1074/jbc.M411344200	http://dx.doi.org/10.1074/jbc.M411344200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15890661	hybrid			2022-12-25	WOS:000230207900072
J	Arima, K; Sato, K; Tanaka, G; Kanaji, S; Terada, T; Honjo, E; Kuroki, R; Matsuo, Y; Izuhara, K				Arima, K; Sato, K; Tanaka, G; Kanaji, S; Terada, T; Honjo, E; Kuroki, R; Matsuo, Y; Izuhara, K			Characterization of the interaction between interleukin-13 and interleukin-13 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; INHIBITORY FACTOR LIF; IL-13 RECEPTOR; SIGNAL-TRANSDUCTION; CODING REGION; BINDING; ALPHA; CLONING; CHAIN; REVEALS	Interleukin-13 (IL-13) possesses two types of receptor: the heterodimer, composed of the IL-13R alpha 1 chain (IL-13R alpha 1) and the IL-4R alpha chain (IL-4R alpha), transducing the IL-13 signals; and the IL-13R alpha 2 chain (IL-13R alpha 2), acting as a nonsignaling "decoy" receptor. Extracellular portions of both IL-13R alpha 1 and IL-13R alpha 2 are composed of three fibronectin type III domains, D1, D2, and D3, of which the last two comprise the cytokine receptor homology modules (CRHs), a common structure of the class I cytokine receptor superfamily. Thus far, there has been no information about the critical amino acids of the CRHs or the role of the D1 domains of IL-13R alpha 1 and IL-13R alpha 2 in binding to IL-13. In this study, we first built the homology modeling of the IL-13(.)hIL-13 receptor complexes and then predicted the amino acids involved in binding to IL-13. By incorporating mutations into these amino acids, we identified Tyr-207, Asp-271, Tyr-315, and Asp-318 in the CRH of human IL-13R alpha 2, and Leu-319 and Tyr-321 in the CRH of human IL-13R alpha 1, as critical residues for binding to IL-13. Tyr-315 in IL-13R alpha 2 and Leu-319 in IL-13R alpha 1 are positionally conserved hydrophobic amino acid residues. Furthermore, by using D1 domain-deleted mutants, we found that the D1 domain is needed for the expression of IL-13R alpha 2, but not IL-13R alpha 1, and that the D1 domain of IL-13R alpha 1 is important for binding to IL-13, but not to IL-4. These results provide the basis for a precise understanding of the interaction between IL-13 and its receptors.	Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan; Saga Med Sch, Ctr Comprehens Community Med, Div Med Res, Saga 8498501, Japan; RIKEN, Genom Sci Ctr, Prot Res Grp, Computat Proteom Team, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2320045, Japan; Univ Tokyo, Fac Agr, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Japan Atom Energy Res Inst, Neutron Sci Res Ctr, Struct Biol Grp, Ibaraki 3191195, Japan	Saga University; Saga University; RIKEN; Yokohama City University; University of Tokyo; Japan Atomic Energy Agency	Izuhara, K (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan.	kizuhara@med.saga-u.ac.jp	Arima, Kazuhiko/I-8962-2014; Terada, Tohru/W-2956-2019	Arima, Kazuhiko/0000-0002-0607-8787; Terada, Tohru/0000-0002-7091-0646				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andrews AL, 2002, J BIOL CHEM, V277, P46073, DOI 10.1074/jbc.M209560200; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bernard J, 2001, LAB INVEST, V81, P1223, DOI 10.1038/labinvest.3780336; Bitard J, 2003, J BIOL CHEM, V278, P16253, DOI 10.1074/jbc.M207193200; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Eisenmesser EZ, 2001, J MOL BIOL, V310, P231, DOI 10.1006/jmbi.2001.4765; Feng NP, 1998, LAB INVEST, V78, P591; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Ishino T, 2004, J BIOL CHEM, V279, P9547, DOI 10.1074/jbc.M309327200; Izuhara K, 2004, DRUG NEWS PERSPECT, V17, P91, DOI 10.1358/dnp.2004.17.2.829041; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; Kurth I, 1999, J IMMUNOL, V162, P1480; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; Letzelter F, 1998, EUR J BIOCHEM, V257, P11, DOI 10.1046/j.1432-1327.1998.2570011.x; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Madhankumar AB, 2002, J BIOL CHEM, V277, P43194, DOI 10.1074/jbc.M205047200; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Moy FJ, 2001, J MOL BIOL, V310, P219, DOI 10.1006/jmbi.2001.4764; Oshima Y, 2001, J BIOL CHEM, V276, P15185, DOI 10.1074/jbc.M010159200; Pagni M, 2004, NUCLEIC ACIDS RES, V32, pW332, DOI 10.1093/nar/gkh479; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schnarr B, 1997, INT IMMUNOL, V9, P861, DOI 10.1093/intimm/9.6.861; Shanafelt AB, 1998, P NATL ACAD SCI USA, V95, P9454, DOI 10.1073/pnas.95.16.9454; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Thompson JP, 1999, J BIOL CHEM, V274, P29944, DOI 10.1074/jbc.274.42.29944; Umeshita-Suyama R, 2000, INT IMMUNOL, V12, P1499, DOI 10.1093/intimm/12.11.1499; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yasunaga S, 2003, CYTOKINE, V24, P293, DOI 10.1016/j.cyto.2003.08.006; Yoon C, 2000, EMBO J, V19, P3530, DOI 10.1093/emboj/19.14.3530	51	62	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24915	24922		10.1074/jbc.M502571200	http://dx.doi.org/10.1074/jbc.M502571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870068	hybrid			2022-12-25	WOS:000230114000075
J	Costa-Rodrigues, J; Carvalho, AF; Fransen, M; Hambruch, E; Schliebs, W; Sa-Miranda, C; Azevedo, JE				Costa-Rodrigues, J; Carvalho, AF; Fransen, M; Hambruch, E; Schliebs, W; Sa-Miranda, C; Azevedo, JE			Pex5p, the peroxisomal cycling receptor, is a monomeric non-globular protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL RECEPTOR; HUMAN PTS1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; BIOGENESIS DISORDERS; LEISHMANIA-DONOVANI; IMPORT MACHINERY; IN-VITRO; MEMBRANE; MATRIX; RECOGNITION	In mammals, targeting of newly synthesized peroxisomal matrix proteins to the organelle requires Pex5p, the peroxisomal cycling receptor. Pex5p is a multidomain protein involved in a complex network of transient protein-protein interactions. Besides interacting directly with most peroxisomal proteins en route to the organelle, Pex5p has also binding domains for several components of the peroxisomal docking/translocation machinery. However, our knowledge of how binding of a cargo protein to Pex5p influences its properties is still rather limited. Here, we describe a protease assay particularly useful for identifying and characterizing protein-protein interactions involving human Pex5p. Binding of a PTS1-containing peptide/ protein to Pex5p as well as the interaction of this peroxin with the Src homology domain 3 of Pex13p could be easily demonstrated using this assay. To address the possible effects of these Pex5p-interacting peptides/proteins on the assumed quaternary structure of Pex5p, we have analyzed the hydrodynamic properties of human Pex5p using size exclusion chromatography, sucrose gradient centrifugation, and sedimentation equilibrium centrifugation. Our results show that Pex5p is a monomeric protein with an abnormal shape. The implications of these findings on current models of protein translocation across the peroxisomal membrane are discussed.	Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, B-3000 Louvain, Belgium; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	Universidade do Porto; Universidade do Porto; KU Leuven; Ruhr University Bochum	Costa-Rodrigues, J (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	jazevedo@ibmc.up.pt	Azevedo, Jorge E/A-4113-2008; sá Miranda, Maria Clara/K-3920-2013; Fransen, Marc/C-6262-2008; Costa-Rodrigues, João/L-1058-2014; Fransen, Marc/ADL-0723-2022; Carvalho, Andreia/J-9013-2015	Azevedo, Jorge E/0000-0001-7714-5302; sá Miranda, Maria Clara/0000-0003-0123-5525; Fransen, Marc/0000-0001-9284-1197; Carvalho, Andreia/0000-0001-8781-5680; Schliebs, Wolfgang/0000-0003-2762-3403; Costa-Rodrigues, Joao/0000-0003-1375-8067				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Azevedo JE, 2004, CELL BIOCHEM BIOPHYS, V41, P451, DOI 10.1385/CBB:41:3:451; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Costa-Rodrigues J, 2004, J BIOL CHEM, V279, P46573, DOI 10.1074/jbc.M406399200; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Harper CC, 2003, J BIOL CHEM, V278, P7897, DOI 10.1074/jbc.M206651200; Jardim A, 2000, J BIOL CHEM, V275, P13637, DOI 10.1074/jbc.275.18.13637; KAIN KC, 1991, BIOTECHNIQUES, V10, P366; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LAURENT TC, 1964, J CHROMATOGR, V14, P217; Madrid KP, 2004, MOL CELL BIOL, V24, P7331, DOI 10.1128/MCB.24.17.7331-7344.2004; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; MIURA S, 1992, J BIOL CHEM, V267, P14405; Oliveira ME, 2003, J BIOL CHEM, V278, P39483, DOI 10.1074/jbc.M305089200; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; Wang DY, 2003, J BIOL CHEM, V278, P43340, DOI 10.1074/jbc.M307789200; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424	48	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24404	24411		10.1074/jbc.M501985200	http://dx.doi.org/10.1074/jbc.M501985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866874	hybrid, Green Published			2022-12-25	WOS:000230114000015
J	Neuspiel, M; Zunino, R; Gangaraju, S; Rippstein, P; McBride, H				Neuspiel, M; Zunino, R; Gangaraju, S; Rippstein, P; McBride, H			Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MAMMALIAN HOMOLOGS; PROTEIN; FISSION; GTPASE; CELLS; MORPHOLOGY; RAB5; DYNAMICS; OUTER	Mitochondrial fusion in higher eukaryotes requires at least two essential GTPases, Mitofusin 1 and Mitofusin 2 (Mfn2). We have created an activated mutant of Mfn2, which shows increased rates of nucleotide exchange and decreased rates of hydrolysis relative to wild type Mfn2. Mitochondrial fusion is stimulated dramatically within heterokaryons expressing this mutant, demonstrating that hydrolysis is not requisite for the fusion event, and supporting a role for Mfn2 as a signaling GTPase. Although steady-state mitochondrial fusion required the conserved intermembrane space tryptophan residue, this requirement was overcome within the context of the hydrolysis-deficient mutant. Furthermore, the punctate localization of Mfn2 is lost in the dominant active mutants, indicating that these sites are functionally controlled by changes in the nucleotide state of Mfn2. Upon staurosporine-stimulated cell death, activated Bax is recruited to the Mfn2-containing puncta; however, Bax activation and cytochrome c release are inhibited in the presence of the dominant active mutants of Mfn2. The dominant active form of Mfn2 also protected the mitochondria against free radical-induced permeability transition. In contrast to staurosporineiinduced outer membrane permeability transition, pore opening induced through the introduction of free radicals was dependent upon the conserved intermembrane space residue. This is the first evidence that Mfn2 is a signaling GTPase regulating mitochondrial fusion and that the nucleotide-dependent activation of Mfn2 concomitantly protects the organelle from permeability transition. The data provide new insights into the critical relationship between mitochondrial membrane dynamics and programmed cell death.	Univ Ottawa, Inst Heart, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute	McBride, H (corresponding author), Univ Ottawa, Inst Heart, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	hmcbride@ottawaheart.ca	McBride, Heidi M/C-1162-2008; McBride, Heidi M./ABD-5774-2021	McBride, Heidi M/0000-0003-4666-2280; McBride, Heidi M./0000-0003-4666-2280				Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Christoforidis S, 2001, METHOD ENZYMOL, V329, P120; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; De Giorgi F, 2000, CELL CALCIUM, V28, P365, DOI 10.1054/ceca.2000.0177; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; Futatsugi N, 2001, BIOPHYS J, V81, P3483, DOI 10.1016/S0006-3495(01)75979-6; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; McQuibban GA, 2003, NATURE, V423, P537, DOI 10.1038/nature01633; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; Rojo M, 2002, J CELL SCI, V115, P1663; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Santel A, 2003, J CELL SCI, V116, P2763, DOI 10.1242/jcs.00479; Santel A, 2001, J CELL SCI, V114, P867; SCHEIDIG AJ, 1995, J MOL BIOL, V253, P132, DOI 10.1006/jmbi.1995.0541; Sesaki H, 2004, J BIOL CHEM, V279, P28298, DOI 10.1074/jbc.M401363200; Sesaki H, 2003, BIOCHEM BIOPH RES CO, V308, P276, DOI 10.1016/S0006-291X(03)01348-2; Sesaki H, 2001, J CELL BIOL, V152, P1123, DOI 10.1083/jcb.152.6.1123; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong ED, 2003, J CELL BIOL, V160, P303, DOI 10.1083/jcb.200209015; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	54	255	271	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25060	25070		10.1074/jbc.M501599200	http://dx.doi.org/10.1074/jbc.M501599200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878861	hybrid			2022-12-25	WOS:000230114000089
J	Saddar, S; Stuart, RA				Saddar, S; Stuart, RA			The yeast F1F0-ATP synthase - Analysis of the molecular organization of subunit G and the importance of a conserved GXXXG motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CRISTAE MORPHOLOGY; ATP SYNTHASE; TRANSMEMBRANE HELIX; SACCHAROMYCES-CEREVISIAE; ROTARY MOTOR; MEMBRANE; COMPLEX; DIMER; IDENTIFICATION; ASSOCIATION	The F1F0-ATP synthase enzyme is located in the inner mitochondrial membrane, where it forms dimeric complexes. Dimerization of the ATP synthase involves the physical association of the neighboring membrane- embedded F-0-sectors. In yeast, the F-0-sector subunits g and e ( Su g and Su e, respectively) play a key role in supporting the formation of ATP synthase dimers. In this study we have focused on Su g to gain a better understanding of the function and the molecular organization of this subunit within the ATP synthase complex. Su g proteins contain a GXXXG motif (G is glycine, and X is any amino acid) in their single transmembrane segment. GXXXG can be a dimerization motif that supports helix-helix interactions between neighboring transmembrane segments. We demonstrate here that the GXXXG motif is important for the function and in particular for the stability of Su g within the ATP synthase. Using site-directed mutagenesis and cross-linking approaches, we demonstrate that Su g and Su e interact, and our findings emphasize the importance of the membrane anchor regions of these proteins for their interaction. Su e also contains a conserved GXXXG motif in its membrane anchor. However, data presented here would suggest that an intact GXXXG motif in Su g is not essential for the Su g-Su e interaction. We suggest that the GXXXG motif may not be the sole basis for a Su g-Su e interaction, and possibly these dimerization motifs may enable both Su g and Su e to interact with another mitochondrial protein.	Marquette Univ, Dept Biol Sci, Milwaukee, WI 53233 USA	Marquette University	Stuart, RA (corresponding author), Marquette Univ, Dept Biol Sci, 530 N 15th St, Milwaukee, WI 53233 USA.	rosemary.stuart@marquette.edu			NIGMS NIH HHS [R01GM61573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Arselin G, 2004, J BIOL CHEM, V279, P40392, DOI 10.1074/jbc.M404316200; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Boyle GM, 1999, EUR J BIOCHEM, V262, P315, DOI 10.1046/j.1432-1327.1999.00345.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner S, 2002, J BIOL CHEM, V277, P48484, DOI 10.1074/jbc.M209382200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; Everard-Gigot V, 2005, EUKARYOT CELL, V4, P346, DOI 10.1128/EC.4.2.346-355.2005; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gavin PD, 2003, BBA-BIOENERGETICS, V1607, P167, DOI 10.1016/j.bbabio.2003.09.013; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Hong SJ, 2004, J BIOENERG BIOMEMBR, V36, P515, DOI 10.1007/s10863-004-8998-y; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Senes A, 2001, P NATL ACAD SCI USA, V98, P9056, DOI 10.1073/pnas.161280798; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Vaillier J, 1999, J BIOL CHEM, V274, P543, DOI 10.1074/jbc.274.1.543; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547	32	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24435	24442		10.1074/jbc.M502804200	http://dx.doi.org/10.1074/jbc.M502804200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15886192	hybrid			2022-12-25	WOS:000230114000019
J	Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN				Harland, M; Taylor, CF; Chambers, PA; Kukalizch, K; Randerson-Moor, JA; Gruis, NA; de Snoo, FA; ter Huurne, JAC; Goldstein, AM; Tucker, MA; Bishop, DT; Bishop, JAN			A mutation hotspot at the p14ARF splice site	ONCOGENE			English	Article						CDKN2A; p14ARF; p16INK4a; melanoma; mutation; splicing	GERMLINE MUTATIONS; MELANOMA FAMILIES; CDKN2A; SENESCENCE; GENE; LOCUS; RECOMBINATION; FIBROBLASTS; EXPRESSION; PROTEINS	Germline mutations of CDKN2A that affect the p16INK4a transcript have been identified in numerous melanoma pedigrees worldwide. In the UK, over 50% of pedigrees with three or more cases of melanoma have been found to carry mutations of CDKN2A. Mutations that affect p14ARF exon 1 beta exclusively are very rare. This has led to the suggestion that it is p16INK4a and not p14ARF that plays the critical role in melanoma predisposition. We report the identification of a cluster of five different germline mutations at the p14ARF exon 1 beta splice donor site in melanoma pedigrees. All the five splice site variants showed evidence of being causal mutations. Three of the variants were demonstrated to result in aberrant splicing of the p14ARF mRNA, confirming their role in melanoma predisposition. No other point mutations were identified in the coding region of p14ARF. The p14ARF transcript of CDKN2A is clearly important in disease predisposition in a subset of melanoma pedigrees. Curiously, the only mutations so far reported to affect p14ARF exon 1 beta exclusively have been knockout mutations. Further investigation into the spectrum of mutations observed in this gene may help clarify the exact role of p14ARF in melanoma predisposition.	St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Clin Ctr, Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England; Leiden Univ, Ctr Med, Dept Dermatol, NL-9600 PB Leiden, Netherlands; Leiden Univ, Ctr Med, Ctr Human & Clin Genet, NL-9600 PB Leiden, Netherlands; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA	Cancer Research UK; Saint James's University Hospital; University of Leeds; Cancer Research UK; Saint James's University Hospital; University of Leeds; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bishop, JAN (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Genet Epidemiol Div, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	j.newton-bishop@cancer.org.uk	Tucker, Margaret A/B-4297-2015	Randerson-Moor, Juliette/0000-0003-0303-0072; Gruis, Nelleke/0000-0002-5210-9150; Newton-Bishop, Julia/0000-0001-9147-6802; Chambers, Philip/0000-0002-0926-717X; Bishop, Tim/0000-0002-8752-8785	NATIONAL CANCER INSTITUTE [Z01CP004410, R01CA083115, ZIACP004410] Funding Source: NIH RePORTER; NCI NIH HHS [IR01 CA083115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Clurman BE, 1998, NEW ENGL J MED, V338, P910, DOI 10.1056/NEJM199803263381312; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Dracopoli NC, 1996, CANCER SURV, V26, P115; Goldstein AM, 2000, J NATL CANCER I, V92, P1006, DOI 10.1093/jnci/92.12.1006; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Harland M, 2005, GENE CHROMOSOME CANC, V43, P128, DOI 10.1002/gcc.20177; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hilleren PJ, 2003, MOL CELL, V12, P1453, DOI 10.1016/S1097-2765(03)00488-X; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Jones AC, 1999, CLIN CHEM, V45, P1133; MEYERHANS A, 1990, NUCLEIC ACIDS RES, V18, P1687, DOI 10.1093/nar/18.7.1687; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PAABO S, 1990, J BIOL CHEM, V265, P4718; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robertson KD, 1999, ONCOGENE, V18, P3810, DOI 10.1038/sj.onc.1202737; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STONE S, 1995, CANCER RES, V55, P2988; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Zaphiropoulos PG, 1998, NUCLEIC ACIDS RES, V26, P2843, DOI 10.1093/nar/26.12.2843; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4604	4608		10.1038/sj.onc.1208678	http://dx.doi.org/10.1038/sj.onc.1208678			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856016				2022-12-25	WOS:000230157100015
J	Hoshino, T; Sakisaka, T; Baba, T; Yamada, T; Kimura, T; Takai, Y				Hoshino, T; Sakisaka, T; Baba, T; Yamada, T; Kimura, T; Takai, Y			Regulation of E-cadherin endocytosis by nectin through afadin, Rap1, and p120(ctn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; SMALL G-PROTEINS; ADHERENS JUNCTIONS; INTERCELLULAR-JUNCTIONS; CYTOPLASMIC DOMAIN; TRANS-INTERACTIONS; C-SRC; CDC42; MOLECULES; RAC	Adherens junctions (AJs) are a major cell-cell adhesion structure in epithelial cells that are formed by two major cell-cell adhesion molecules, E-cadherin and nectin. We have previously shown that nectin first forms cell-cell adhesion and then recruits non-trans-interacting E-cadherin to the nectin-based cell-cell adhesion sites, which gradually trans-interact there, eventually forming AJs. We have examined here the effect of trans-interacting nectin on non-trans-interacting E-cadherin endocytosis. Trans-interacting nectin capable of associating with afadin, but not trans-interacting nectin mutant incapable of associating with afadin, inhibited non-trans-interacting E-cadherin endocytosis in intact cells. Afadin is a nectin- and actin filament-binding protein that connects nectin to the actin cytoskeleton. Studies on the mode of action of the nectin- afadin system using cell-free assay revealed that afadin associated with nectin bound Rap1 activated by trans-interacting nectin, interacted with p120(ctn), and strengthened the binding of p120ctn to E-cadherin, eventually reducing non-trans-interacting E-cadherin endocytosis. Afadin, which did not bind Rap1, was inactive in this capacity. These results indicate that trans-interacting nectin inhibits non-trans-interacting E-cadherin endocytosis through afadin, Rap1, and p120ctn and thereby further accumulates non-trans-interacting E-cadherin to the nectin-based cell-cell adhesion sites for the formation of AJs.	Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Fac Med, Grad Sch Med, Dept Mol Biol & Biochem, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	47	132	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24095	24103		10.1074/jbc.M414447200	http://dx.doi.org/10.1074/jbc.M414447200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15857834	hybrid			2022-12-25	WOS:000229880000083
J	Ziogas, A; Moelling, K; Radziwill, G				Ziogas, A; Moelling, K; Radziwill, G			CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; KINASE ACTIVATION; MAMMALIAN-CELLS; GROWTH-FACTOR; B-RAF; PHOSPHORYLATION; SERINE; MAP; SPECIFICITY; ASSOCIATION	Raf-1 is a regulator of cellular proliferation, differentiation, and apoptosis. Activation of the Raf-1 kinase activity is tightly regulated and involves targeting to the membrane by Ras and phosphorylation by various kinases, including the tyrosine kinase Src. Here we demonstrate that the connector enhancer of Ksr1, CNK1, mediates Src-dependent tyrosine phosphorylation and activation of Raf-1. CNK1 binds preactivated Raf-1 and activated Src and forms a trimeric complex. CNK1 regulates the activation of Raf-1 by Src in a concentration-dependent manner typical for a scaffold protein. Downregulation of endogenously expressed CNK1 by small inhibitory RNA interferes with Src-dependent activation of ERK. Thus, CNK1 allows cross-talk between Src and Raf-1 and is essential for the full activation of Raf-1.	Univ Zurich, Inst Med Virol, CH-8006 Zurich, Switzerland	University of Zurich	Radziwill, G (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30, CH-8006 Zurich, Switzerland.	radziwil@immv.unizh.ch						Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Laberge G, 2005, EMBO J, V24, P487, DOI 10.1038/sj.emboj.7600558; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Rommel C, 1996, ONCOGENE, V12, P609; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stewart M, 2003, HISTOPATHOLOGY, V43, P33, DOI 10.1046/j.1365-2559.2003.01644.x; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Tian XJ, 2001, BIOCHEM BIOPH RES CO, V286, P505, DOI 10.1006/bbrc.2001.5409; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber CK, 2001, CANCER RES, V61, P3595; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yao I, 2000, BIOCHEM BIOPH RES CO, V270, P538, DOI 10.1006/bbrc.2000.2475; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	58	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24205	24211		10.1074/jbc.M413327200	http://dx.doi.org/10.1074/jbc.M413327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845549	hybrid			2022-12-25	WOS:000229880000096
J	Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ				Zhu, YL; Zhong, X; Zheng, S; Du, Q; Xu, WZ			Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway	ONCOGENE			English	Article						Helicobacter pylori; CagA protein; gastric epithelial cell; carcinogenesis; Erk pathway	SIGNAL-REGULATED KINASE; B-RAF; ONCOGENIC MUTATIONS; TUMOR-GROWTH; T-ANTIGEN; INFECTION; CANCER; DETERMINANT; DOWNSTREAM; TELOMERASE	CagA of Helicobacter pylori is a protein that has been closely associated with gastric cancer and that can intervene with signal pathways in cells. Its precise relationship with the occurrence of gastric cancer, however, remains unclear. The purpose of this study is to investigate whether CagA can promote transformation of normal gastric epithelial cells and to consider via what mechanisms CagA may exert its effects. Transformed colonies were merged in soft-agarose medium after immortalized gastric epithelial cells were transfected with recombinant pLHCX retrovirus with cagA and/or dimethylhydrazine. The number of transformed colonies in the group containing cagA/pLHCX retrovirus, combined with a subthreshold dose of dimethylhydrazine, was more than that for cagA/pLHCX retrovirus or dimethylhydrazine at a subthreshold dose alone. For cagA-transfected cells, only IQGAP-2, R-Ras and B-Raf of the Ras/mitogen-activated protein kinase signal pathway were markedly increased, and the activity of extracellular signal-regulated kinase 1/2 (Erk1/2) kinase was significantly higher than that in dimethylhydrazine-transformed cells or control cells. However, no evidence of alteration of any other molecules of the Ras superfamily was observed in cagA-transfected cells. These findings suggest that CagA can transform gastric epithelial cells through activation of the Erk1/2 pathway; this mechanism may, however, be independent of Ras activation.	Zhejiang Univ, Sch Med, Inst Canc, Hangzhou 310009, Zhejiang Prov, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou 310027, Zhejiang Prov, Peoples R China	Zhejiang University; Zhejiang University	Zheng, S (corresponding author), Zhejiang Univ, Sch Med, Inst Canc, Jiefang Rd 88, Hangzhou 310009, Zhejiang Prov, Peoples R China.	zrxhsys@zju.edu.cn						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brill S, 1996, MOL CELL BIOL, V16, P4869; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; COX AD, 1994, ONCOGENE, V9, P3281; Enroth H, 2000, CANCER EPIDEM BIOMAR, V9, P981; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Held M, 2004, HELICOBACTER, V9, P271, DOI 10.1111/j.1083-4389.2004.00222.x; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, P NATL ACAD SCI USA, V99, P14428, DOI 10.1073/pnas.222375399; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hindley A, 2002, J CELL SCI, V115, P1575; Huang RP, 1999, CARCINOGENESIS, V20, P485, DOI 10.1093/carcin/20.3.485; Hubbard SR, 2004, CELL, V116, P764, DOI 10.1016/S0092-8674(04)00256-9; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Keates S, 1999, J IMMUNOL, V163, P5552; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kolb TM, 2004, TOXICOL SCI, V81, P233, DOI 10.1093/toxsci/kfh183; Kwong L, 2003, MOL CELL BIOL, V23, P933, DOI 10.1128/MCB.23.3.933-949.2003; MALE R, 1987, CARCINOGENESIS, V8, P1375, DOI 10.1093/carcin/8.10.1375; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nobuta A, 2004, ALIMENT PHARM THER, V20, P1, DOI 10.1111/j.1365-2036.2004.01976.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Okada T, 1999, MOL CELL BIOL, V19, P6057; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rieder G, 2003, INT J MED MICROBIOL, V293, P403, DOI 10.1078/1438-4221-00280; Rutten Michael J., 1996, Methods in Cell Science, V18, P269, DOI 10.1007/BF00127904; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Shin VY, 2004, CARCINOGENESIS, V25, P2487, DOI 10.1093/carcin/bgh266; Smoot Duane T., 2000, Methods in Cell Science, V22, P133, DOI 10.1023/A:1009846624044; Sugiyama K, 1998, JPN J CANCER RES, V89, P615, DOI 10.1111/j.1349-7006.1998.tb03263.x; TERANO A, 1983, DIGEST DIS SCI, V28, P595, DOI 10.1007/BF01299919; Tokieda M, 1999, CARCINOGENESIS, V20, P1261, DOI 10.1093/carcin/20.7.1261; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zhang Lian, 1998, Zhonghua Yufang Yixue Zazhi, V32, P67; Zhu YL, 2004, CHINESE MED J-PEKING, V117, P1330; Zhu Yong-liang, 2004, Zhejiang Da Xue Xue Bao Yi Xue Ban, V33, P379; Zhu YL, 2005, WORLD J GASTROENTERO, V11, P880, DOI 10.3748/wjg.v11.i6.880	55	54	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3886	3895		10.1038/sj.onc.1208551	http://dx.doi.org/10.1038/sj.onc.1208551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15856031				2022-12-25	WOS:000229435300004
J	York, B; Lou, DY; Panettieri, RA; Krymskaya, VP; Vanaman, TC; Noonan, DJ				York, B; Lou, DY; Panettieri, RA; Krymskaya, VP; Vanaman, TC; Noonan, DJ			Cross-talk between tuberin, calmodulin, and estrogen signaling pathways	FASEB JOURNAL			English	Article						lymphangioleiomyomatosis; tuberous sclerosis; hamartin; estrogen receptor alpha	SCLEROSIS; HAMARTIN; RECEPTOR; GENE; PHOSPHORYLATION; ACTIVATION; PROTEINS; LYMPHANGIOLEIOMYOMATOSIS; KINASE; TSC2	Lymphangioleiomyomatosis (LAM) is a rare disease that occurs primarily in women and has been linked to both estrogen-mediated signaling events and mutations associated with the tuberous sclerosis complex 2 gene product tuberin. These two observations fostered the hypothesis that tuberin's impact on estrogen-mediated signaling might be through a direct interaction with the intracellular receptor for estrogen, estrogen receptor alpha (ER alpha). In the study presented here, tuberin was shown to co-immunoprecipitate and directly bind ER alpha through a domain localized within the carboxyl 73 amino acids of tuberin. This domain had previously been shown to serve as a binding domain for the intracellular calcium signaling molecule calmodulin (CaM). Competition binding studies identified a potential competitive relationship for binding of tuberin by ER alpha and CaM. Additionally, tuberin-ER alpha interactions were found to be modulated by the presence of tuberin's predominant intracellular binding partner hamartin, suggesting that tuberin-hamartin interactions negatively impact the ability of tuberin to modulate ER alpha-mediated gene transcription events. Cumulatively, data presented here support the hypothesis that interactions between tuberin, ER alpha, and CaM may play a critical role in the pathology of LAM disease.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Kentucky; University of Pennsylvania	Noonan, DJ (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dnoonan@pop.uky.edu	panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [R01 HL055301, P50 HL067663, HL64063, HL071106, HL67321, R01 HL071106, HL55301, R01 HL067321, P01 HL067663, HL67663, R01 HL064063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055301, R01HL064063, P01HL067663, R01HL071106, R01HL067321, P50HL067663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; Carafoli E, 1999, CALCIUM CELLULAR REG; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Flores-Delgado G, 2003, MOL CELL ENDOCRINOL, V199, P143, DOI 10.1016/S0303-7207(02)00288-5; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gomez MR, 1988, TUBEROUS SCLEROSIS; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govind AP, 2003, MOL CELL BIOCHEM, V253, P233, DOI 10.1023/A:1026068017309; Henry II Kenneth W, 2003, Nucl Recept, V1, P7, DOI 10.1186/1478-1336-1-7; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; JAMIESON GA, 1979, BIOCHEM BIOPH RES CO, V90, P1048, DOI 10.1016/0006-291X(79)91932-6; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Murthy V, 2000, AM J PHYSIOL-RENAL, V278, pF737; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Pacheco-Rodriguez G, 2002, CHEST, V121, p56S, DOI 10.1378/chest.121.3_suppl.56S; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; ROBERTS PS, 2002, NEW PROSPECTIVES TUB; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; Yamamoto Y, 2002, ARCH BIOCHEM BIOPHYS, V404, P210, DOI 10.1016/S0003-9861(02)00300-4; YU J, 2003, AM J PHYSL LUNG CELL	36	21	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2005	19	6					1202	+		10.1096/fj.04-3142fje	http://dx.doi.org/10.1096/fj.04-3142fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15851513				2022-12-25	WOS:000228865300008
J	Nomura, T; Chang, HY; Lu, R; Hankin, J; Murphy, RC; Schuster, VL				Nomura, T; Chang, HY; Lu, R; Hankin, J; Murphy, RC; Schuster, VL			Prostaglandin signaling in the renal collecting duct - Release, reuptake, and oxidation in the same cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; TRANSPORTER PGT; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; SEROTONIN TRANSPORTER; VASCULAR ENDOTHELIUM; EPITHELIAL-CELLS; GUINEA-PIG; SYNTHASE; EXPRESSION; MDCK	Prostaglandins mediate autacrine and paracrine signaling over short distances. We used the renal collecting duct as a model system to test the hypothesis that local control of prostaglandin signaling is achieved by expressing inactivation in the same cell as synthesis. Immunocytochemical studies demonstrated that renal collecting ducts in situ express the prostaglandin ( PG) synthesis enzyme, cyclooxygenase-1 ( COX-1), as well as both components of prostaglandin metabolic inactivation, i.e. the prostaglandin uptake carrier prostaglandin transporter ( PGT) and the enzyme 15-hydroxyprostaglandin dehydrogenase. We characterized this system further using the collecting duct cell line Madin-Darby canine kidney ( MDCK), which retains COX-2 and prostaglandin dehydrogenase expression but which has lost PGT expression. When we reintroduced PGT, it was correctly sorted to the apical membrane where it altered the sidedness of prostaglandin E2 ( PGE2) release, a process we call "vectorial release via sided reuptake." Importantly, although COX-2 and prostaglandin dehydrogenase are expressed in the same MDCK cell, they must be compartmentalized because even in the presence of excess dehydrogenase newly synthesized PGE2 is released largely un-oxidized. However, when PGE2 undergoes first release and then PGT-mediated reuptake, significant oxidation takes place, suggesting that PGT imports PGE2 into the prostaglandin dehydrogenase compartment. Our data are consistent with a new model that offers significant new mechanisms for the fine control of eicosanoid signaling.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Natl Jewish Med & Res Ctr, Div Cell Biol, Denver, CO 80206 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Jewish Health	Schuster, VL (corresponding author), Albert Einstein Coll Med, Dept Med, Belfer Bldg,Rm 1008,1300 Morris Pk Ave, Bronx, NY 10461 USA.	schuster@aecom.yu.edu			NIDDK NIH HHS [R01DK049688, P50DK064236, R01 DK049688, P50 DK064236] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049688, P50DK064236] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi H, 2003, AM J PHYSIOL-RENAL, V285, pF1188, DOI 10.1152/ajprenal.00402.2002; ANDO Y, 1995, AM J PHYSIOL-RENAL, V268, pF1093, DOI 10.1152/ajprenal.1995.268.6.F1093; Arosh JA, 2004, ENDOCRINOLOGY, V145, P2551, DOI 10.1210/en.2003-1607; Bao Y, 2002, AM J PHYSIOL-RENAL, V282, pF1103, DOI 10.1152/ajprenal.00152.2001; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; Chan BS, 1998, J BIOL CHEM, V273, P6689, DOI 10.1074/jbc.273.12.6689; Chan BS, 2002, BIOCHEMISTRY-US, V41, P9215, DOI 10.1021/bi0203031; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTIZO AM, 1992, PROSTAGLANDINS, V44, P357, DOI 10.1016/0090-6980(92)90008-H; DEVUYST O, 1994, CELL TISSUE RES, V277, P231; Endio S, 2002, AM J PHYSIOL-RENAL, V282, pF618, DOI 10.1152/ajprenal.00150.2001; ENSOR CM, 1995, J LIPID MEDIAT CELL, V12, P313, DOI 10.1016/0929-7855(95)00040-W; ENSOR CM, 1990, J BIOL CHEM, V265, P14888; FARMAN N, 1987, AM J PHYSIOL, V252, pF53, DOI 10.1152/ajprenal.1987.252.1.F53; GSTRAUNTHALER G, 1985, AM J PHYSIOL, V248, pF536, DOI 10.1152/ajprenal.1985.248.4.F536; Han R, 2002, J BIOL CHEM, V277, P36897, DOI 10.1074/jbc.M206949200; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Khan KNM, 1998, TOXICOL PATHOL, V26, P612, DOI 10.1177/019262339802600504; Komhoff M, 1997, AM J PHYSIOL-RENAL, V272, pF460, DOI 10.1152/ajprenal.1997.272.4.F460; LYNCH RM, 1987, AM J PHYSIOL, V253, pC269, DOI 10.1152/ajpcell.1987.253.2.C269; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; MIKKELSEN HB, 1990, HISTOCHEMISTRY, V93, P363, DOI 10.1007/BF00315852; MOORE SA, 1988, AM J PHYSIOL, V254, pC37, DOI 10.1152/ajpcell.1988.254.1.C37; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MORITA I, 1995, BIOCHEMISTRY-US, V34, P7194, DOI 10.1021/bi00021a034; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nomura T, 2004, MOL PHARMACOL, V65, P973, DOI 10.1124/mol.65.4.973; OBERLEITHNER H, 1990, PFLUG ARCH EUR J PHY, V416, P526, DOI 10.1007/BF00382685; PFALLER W, 1989, RENAL PHYSIOL BIOCH, V12, P328; ROSENBERG SO, 1991, AM J PHYSIOL, V260, pC868, DOI 10.1152/ajpcell.1991.260.4.C868; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V269, pF257, DOI 10.1152/ajprenal.1995.269.2.F257; SCHLONDORFF D, 1985, AM J PHYSIOL, V248, pF134, DOI 10.1152/ajprenal.1985.248.1.F134; Schuster VL, 2002, PROSTAG OTH LIPID M, V68-9, P633, DOI 10.1016/S0090-6980(02)00061-8; Schuster VL, 1998, ANNU REV PHYSIOL, V60, P221, DOI 10.1146/annurev.physiol.60.1.221; Serhan CN, 2003, P NATL ACAD SCI USA, V100, P8609, DOI 10.1073/pnas.1733589100; SMITH WL, 1977, PROSTAGLANDINS, V13, P873, DOI 10.1016/0090-6980(77)90217-9; SMITH WL, 1978, AM J PHYSIOL, V235, pF451, DOI 10.1152/ajprenal.1978.235.5.F451; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; Topper JN, 1998, CIRCULATION, V98, P2396, DOI 10.1161/01.CIR.98.22.2396; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Valentich J D, 1981, Ann N Y Acad Sci, V372, P384, DOI 10.1111/j.1749-6632.1981.tb15490.x; WU SM, 1994, ANNU REV PHYSIOL, V56, P141	49	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28424	28429		10.1074/jbc.M408286200	http://dx.doi.org/10.1074/jbc.M408286200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15855165	hybrid			2022-12-25	WOS:000230857300031
J	Clement, M; Martin, SS; Beaulieu, ME; Chamberland, C; Lavigne, P; Leduc, R; Guillemette, G; Escher, E				Clement, M; Martin, SS; Beaulieu, ME; Chamberland, C; Lavigne, P; Leduc, R; Guillemette, G; Escher, E			Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT(1)) receptor using the methionine proximity assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE D2 RECEPTOR; MEMBRANE-SPANNING SEGMENT; AMINO-TERMINAL TAIL; SUBSTANCE-P; TRANSMEMBRANE DOMAIN; COVALENT ATTACHMENT; SPATIAL PROXIMITY; CONTACT POINTS; SIDE-CHAIN; SITE	The peptide hormone angiotensin II (AngII) binds to the AT(1) ((a) under bar ngiotensin (t) under bar ype (1) under bar) receptor within the transmembrane domains in an extended conformation, and its C-terminal residue interacts with transmembrane domain VII at Phe-293/Asn-294. The molecular environment of this binding pocket remains to be elucidated. The preferential binding of benzophenone photolabels to methionine residues in the target structure has enabled us to design an experimental approach called the methionine proximity assay, which is based on systematic mutagenesis and photolabeling to determine the molecular environment of this binding pocket. A series of 44 transmembrane domain III, VI, and VII X -> Met mutants photolabeled either with I-125-[Sar(1), p'-benzoyl-L-Phe(8)] AngII or with I-125-[Sar(1), p ''-methoxy-p'-benzoyl-L-Phe(8)] AngII were purified and digested with cyanogen bromide. Several mutants produced digestion patterns different from that observed with wild type human AT(1), indicating that they had a new receptor contact with position 8 of AngII. The following residues form this binding pocket: L112M and Y113M in transmembrane domain (TMD) III; F249M, W253M, H256M, and T260M in TMD VI; and F293M, N294M, N295M, C296M, and L297M in TMD VII. Homology modeling and incorporation of these contacts allowed us to develop an evidence-based molecular model of interactions with human AT(1) that is very similar to the rhodopsin-retinal interaction.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Escher, E (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	Emanuel.Escher@USherbrooke.ca		Beaulieu, Marie-Eve/0000-0001-5224-8436; Escher, Emanuel/0000-0001-6601-987X				Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BOBROWSKI K, 1992, J AM CHEM SOC, V114, P10279, DOI 10.1021/ja00052a025; BOSSE R, 1993, REGUL PEPTIDES, V44, P215, DOI 10.1016/0167-0115(93)90245-4; Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v; Boucard AA, 2003, J BIOL CHEM, V278, P36628, DOI 10.1074/jbc.M305952200; Boucard AA, 2003, BIOCHEM J, V370, P829, DOI 10.1042/BJ20021566; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; HORNER L, 1952, CHEM BER-RECL, V85, P520, DOI 10.1002/cber.19520850606; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; Inoue Y, 1997, J HYPERTENS, V15, P703, DOI 10.1097/00004872-199715070-00001; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; Kalatskaya I, 2004, J BIOL CHEM, V279, P31268, DOI 10.1074/jbc.M401796200; Karnik SS, 1996, CLIN EXP PHARMACOL P, V23, pS58, DOI 10.1111/j.1440-1681.1996.tb02815.x; Kennedy AP, 1996, MOL PHARMACOL, V50, P789; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laporte SA, 1999, MOL ENDOCRINOL, V13, P578, DOI 10.1210/me.13.4.578; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MARCINIAK B, 1993, J PHYS CHEM-US, V97, P11937, DOI 10.1021/j100148a015; MARIE J, 1994, J BIOL CHEM, V269, P20815; Martin SS, 2004, J BIOL CHEM, V279, P51415, DOI 10.1074/jbc.M407965200; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2003, SEIKAGAKU, V75, P382; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perodin J, 2002, BIOCHEMISTRY-US, V41, P14348, DOI 10.1021/bi0258602; Sachon E, 2003, FEBS LETT, V544, P45, DOI 10.1016/S0014-5793(03)00447-2; Sachon E, 2002, J BIOL CHEM, V277, P50409, DOI 10.1074/jbc.M207242200; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Servant G, 1996, BIOCHEM J, V313, P297, DOI 10.1042/bj3130297; Servant G, 1997, J BIOL CHEM, V272, P8653, DOI 10.1074/jbc.272.13.8653; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; Tan YV, 2003, J BIOL CHEM, V278, P36531, DOI 10.1074/jbc.M304770200; Wu ZP, 2004, J BIOL CHEM, V279, P27357, DOI 10.1074/jbc.M401960200; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	48	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27121	27129		10.1074/jbc.M413653200	http://dx.doi.org/10.1074/jbc.M413653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15890659	hybrid			2022-12-25	WOS:000230589500059
J	Gilquin, B; Braud, S; Eriksson, MAL; Roux, B; Bailey, TD; Priest, BT; Garcia, ML; Menez, A; Gasparini, S				Gilquin, B; Braud, S; Eriksson, MAL; Roux, B; Bailey, TD; Priest, BT; Garcia, ML; Menez, A; Gasparini, S			A variable residue in the pore of Kv1 channels is critical for the high affinity of Blockers from sea anemones and scorpions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; AMINO-ACID-RESIDUES; SHAKER K+ CHANNEL; CONVERGENT EVOLUTION; MOLECULAR-DYNAMICS; BETA-LACTAMASE; BINDING; PEPTIDE; PROTEIN; CHARYBDOTOXIN	Animal toxins are associated with well defined selectivity profiles; however the molecular basis for this property is not understood. To address this issue we refined our previous three-dimensional models of the complex between the sea anemone toxin BgK and the S5-S6 region of Kv1.1 (Gilquin, B., Racape, J., Wrisch, A., Visan, V., Lecoq, A., Grissmer, S., Menez, A., and Gasparini, S. (2002) J. Biol. Chem. 277, 37406-37413) using a docking procedure that scores and ranks the structures by comparing experimental and back-calculated values of coupling free energies Delta Delta G(int) obtained from double-mutant cycles. These models further highlight the interaction between residue 379 of Kv1.1 and the conserved dyad tyrosine residue of BgK. Because the nature of the residue at position 379 varies from one channel subtype to another, we explored how these natural mutations influence the sensitivity of Kv1 channel subtypes to BgK using binding and electrophysiology experiments. We demonstrated that mutations at this single position indeed suffice to abolish or enhance the sensitivity of Kv1 channels for BgK and other sea anemone and scorpion toxins. Altogether, our data suggest that the residue at position 379 of Kv1 channels controls the affinity of a number of blocking toxins.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Cornell University; Merck & Company	Gasparini, S (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.	sylvaine.gasparini@cea.fr	Aguglia, Umberto/AAB-9898-2019	Aguglia, Umberto/0000-0002-4574-2951				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Al-Sabi A, 2004, BIOCHEMISTRY-US, V43, P8625, DOI 10.1021/bi0495681; Beeton C, 2003, J BIOL CHEM, V278, P9928, DOI 10.1074/jbc.M212868200; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Braud S, 2004, PROTEIN EXPRES PURIF, V38, P69, DOI 10.1016/j.pep.2004.07.011; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Claydon TW, 2002, AM J PHYSIOL-CELL PH, V283, pC1114, DOI 10.1152/ajpcell.00542.2001; Claydon TW, 2000, J PHYSIOL-LONDON, V526, P253, DOI 10.1111/j.1469-7793.2000.00253.x; Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Eriksson MAL, 2002, BIOPHYS J, V83, P2595, DOI 10.1016/S0006-3495(02)75270-3; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Gasparini S, 2004, TOXICON, V43, P901, DOI 10.1016/j.toxicon.2004.03.029; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GomezHernandez JM, 1997, PFLUG ARCH EUR J PHY, V434, P661, DOI 10.1007/s004240050449; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; HURST RS, 1991, MOL PHARMACOL, V40, P572; Im W, 1998, COMPUT PHYS COMMUN, V111, P59, DOI 10.1016/S0010-4655(98)00016-2; Kaczorowski GJ, 1999, CURR OPIN CHEM BIOL, V3, P448, DOI 10.1016/S1367-5931(99)80066-0; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; Kuhlmann UC, 2000, J MOL BIOL, V301, P1163, DOI 10.1006/jmbi.2000.3945; Li W, 2004, J MOL BIOL, V337, P743, DOI 10.1016/j.jmb.2004.02.005; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Middleton RE, 2003, BIOCHEMISTRY-US, V42, P13698, DOI 10.1021/bi035209e; Nina M, 1997, J PHYS CHEM B, V101, P5239, DOI 10.1021/jp970736r; Racape J, 2002, J BIOL CHEM, V277, P3886, DOI 10.1074/jbc.M109886200; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schroeder K, 2003, J BIOMOL SCREEN, V8, P50, DOI 10.1177/1087057102239667; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Verdier L, 2005, J BIOL CHEM, V280, P21246, DOI 10.1074/jbc.M502376200; Visan V, 2004, MOL PHARMACOL, V66, P1103, DOI 10.1124/mol.104.002774; Wrisch A, 2000, J BIOL CHEM, V275, P39345, DOI 10.1074/jbc.M006827200; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	43	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27093	27102		10.1074/jbc.M413626200	http://dx.doi.org/10.1074/jbc.M413626200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15890656	hybrid			2022-12-25	WOS:000230589500056
J	Mazharian, A; Roger, S; Maurice, P; Berrou, E; Popoff, MR; Hoylaerts, MF; Fauvel-Lafeve, F; Bonnefoy, A; Bryckaert, M				Mazharian, A; Roger, S; Maurice, P; Berrou, E; Popoff, MR; Hoylaerts, MF; Fauvel-Lafeve, F; Bonnefoy, A; Bryckaert, M			Differential involvement of ERK2 and p38 in platelet adhesion to collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; MAP KINASE; THROMBUS FORMATION; INTEGRIN ALPHA(IIB)BETA(3); P21-ACTIVATED KINASE; BINDING-PROTEIN; FLOW CONDITIONS; CELL-MIGRATION	We investigated the role of two MAP kinases, ERK2 and p38, in platelet adhesion and spreading over collagen matrix in static and blood flow conditions. P38 was involved in collagen-induced platelet adhesion and spreading in static adhesion conditions, whereas ERK2 was not. In blood flow conditions, with shear rates of 300 or 1500 s(-1), ERK2 and p38 displayed differential involvement in platelet adhesion, depending on the presence or absence of the von Willebrand factor (vWF). Low collagen coverage densities (0.04 mu g/cm(2)) did not support vWF binding. During perfusions over this surface, platelet adhesion was not affected by the inhibition of ERK2 phosphorylation by PD 98059. However, abolishing p38 activation by SB 203580 treatment reduced platelet adhesion by 67 +/- 9% at 300 s(-1) and 56 +/- 2% at 1500 s(-1). In these conditions, the p38 activity required for platelet adhesion depends on the alpha 2 beta 1 collagen receptor. At higher collagen coverage densities (0.8 mu g/cm(2)) supporting vWF binding, the inhibition of ERK2 activity by PD 98059 decreased adhesion by 47 +/- 6% at 300 s(-1) and 72 +/- 3% at 1500 s(-1), whereas p38 inhibition had only a small effect. The ERK2 activity required for platelet adhesion was dependent on the interaction of vWF with GPIb. In conclusion, ERK2 and p38 have complementary effects in the control of platelet adhesion to collagen in a shear stress-dependent manner.	Hop Lariboisiere, INSERM, U689E6, F-75010 Paris, France; Hop St Louis, INSERM, U553, IFR105, F-75010 Paris, France; Inst Pasteur, F-75724 Paris, France; Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven	Bryckaert, M (corresponding author), Hop Lariboisiere, INSERM, U689E6, 8 Rue Guy Patin, F-75010 Paris, France.	marijke.bryckaert@larib.inserm.fr	Maurice, Pascal/AAM-9126-2021	Hoylaerts, Marc/0000-0002-6474-3933; MAURICE, Pascal/0000-0003-2167-4808; Mazharian, Alexandra/0000-0002-0204-3325; Bryckaert, Marijke/0000-0003-3398-0976				BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Bernardo A, 2004, J THROMB HAEMOST, V2, P660, DOI 10.1111/j.1538-7836.2004.00661.x; Bonnefoy A, 2003, BLOOD, V101, P1375, DOI 10.1182/blood-2002-06-1818; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Bugaud F, 1999, BLOOD, V94, P3800, DOI 10.1182/blood.V94.11.3800.423k25_3800_3805; Canobbio I, 2004, THROMB HAEMOSTASIS, V91, P102, DOI 10.1160/TH03-02-0083; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Goto SY, 2002, CIRCULATION, V106, P266, DOI 10.1161/01.CIR.0000021427.87256.7E; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; KEHREL B, 1988, BLOOD, V71, P1074; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Li ZY, 2003, CELL, V112, P77, DOI 10.1016/S0092-8674(02)01254-0; Marshall SJ, 2004, BLOOD, V103, P2601, DOI 10.1182/blood-2003-09-3319; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Minuz P, 2002, THROMB HAEMOSTASIS, V87, P888; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; Nadal F, 1997, J BIOL CHEM, V272, P22381, DOI 10.1074/jbc.272.36.22381; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; Rauterberg J, 1993, Curr Top Pathol, V87, P163; Richard J F, 1999, Int Microbiol, V2, P185; Roger S, 2004, FEBS LETT, V556, P227, DOI 10.1016/S0014-5793(03)01430-3; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAELMAN EUM, 1994, BLOOD, V83, P1244; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; Suzuki-Inoue K, 2001, BLOOD, V98, P3708, DOI 10.1182/blood.V98.13.3708; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; Toth-Zsamboki E, 2003, J BIOL CHEM, V278, P46661, DOI 10.1074/jbc.M308452200; Vidal C, 2002, BLOOD, V100, P4462, DOI 10.1182/blood.V100.13.4462; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	46	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26002	26010		10.1074/jbc.M414083200	http://dx.doi.org/10.1074/jbc.M414083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15851480	Green Published, hybrid			2022-12-25	WOS:000230386800008
J	Willoughby, EA; Collins, MK				Willoughby, EA; Collins, MK			Dynamic interaction between the dual specificity phosphatase MKP7 and the JNK3 scaffold protein beta-arrestin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; KINASE PHOSPHATASE; CLATHRIN ADAPTER; ACTIVATION; FAMILY; PHOSPHORYLATION; COMPLEX; ACTS	JNK scaffold proteins bind JNK and upstream kinases to activate subsets of JNK and localize activated JNK to specific subcellular sites. We previously demonstrated that the dual specificity phosphatases (DSPs) MKP7 and M3/6 bind the scaffold JNK-interacting protein-1 (JIP-1) and inactivate the bound subset of JNK (1). The G protein-coupled receptor (GPCR) adaptor beta-arrestin 2 is also a JNK3 scaffold. It binds the upstream kinases ASK1 and MKK4 and couples stimulation of the angiotensin II receptor AT1aR to activation of a cytoplasmic pool of JNK3. Here we report that MKP7 also binds beta-arrestin 2 via amino acids 394-443 of MKP7, the same region that interacts with JIP-1. This region of MKP7 interacts with beta-arrestin 2 at a central region near the JNK binding domain. MKP7 dephosphorylates JNK3 bound to beta-arrestin 2, either following activation by ASK1 overexpression or following AT1aR stimulation. Initial AT1aR stimulation causes a rapid (within 5 min) dissociation of MKP7 from beta-arrestin 2. MKP7 then reassociates with beta-arrestin 2 on endocytic vesicles 30-60 min after initial receptor stimulation. This dynamic interaction between phosphatase and scaffold permits signal transduction through a module that binds both positive and negative regulators.	UCL, Div Infect & Immun, London W1T 4JF, England	University of London; University College London	Collins, MK (corresponding author), UCL, Div Infect & Immun, Windeyer Bldg,46 Cleveland St, London W1T 4JF, England.	mary.collins@ucl.ac.uk						Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou A, 2002, GENOME BIOL, V3; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Wei HJ, 2004, J BIOL CHEM, V279, P48255, DOI 10.1074/jbc.M406205200; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; Willoughby EA, 2003, J BIOL CHEM, V278, P10731, DOI 10.1074/jbc.M207324200; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Xiao KH, 2004, J BIOL CHEM, V279, P55744, DOI 10.1074/jbc.M409785200; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764	49	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25651	25658		10.1074/jbc.M501926200	http://dx.doi.org/10.1074/jbc.M501926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15888437	hybrid			2022-12-25	WOS:000230207900045
J	Kim, HP; Korn, LL; Gamero, AM; Leonard, WJ				Kim, HP; Korn, LL; Gamero, AM; Leonard, WJ			Calcium-dependent activation of interleukin-21 gene expression in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR NFAT; IL-2 MESSENGER-RNA; COMMON GAMMA-CHAIN; FACTOR-ALPHA GENE; CYCLOSPORINE-A; NUCLEAR FACTOR; B-CELLS; LYMPHOCYTES-T; RECEPTOR	Interleukin (IL)-21 is a gamma(c)-dependent cytokine produced by activated T cells with important actions for T, B, and NK cells. The IL-21 gene is adjacent to the IL-2 gene, and like IL-2, IL-21 is strongly induced at the transcriptional level after T cell activation. Interestingly, however, in contrast to the IL-2 gene, a calcium ionophore alone was sufficient to induce IL-21 gene expression in preactivated T cells. Two DNase I hypersensitivity sites were found in the IL-21 gene, corresponding to nucleotide sequences that are conserved in humans and mice. One site is located at the IL-21 promoter region and conferred T cell receptor-mediated IL-21 gene transcription. TCR-induced IL-21 gene expression was inhibited by cyclosporin A and FK506. Correspondingly, the IL-21 5'-regulatory region contains three NFAT binding sites, and induction of IL-21 promoter activity was impaired when these sites were mutated or following treatment with cyclosporin A. Thus, our studies reveal that in contrast to IL-2, a calcium signal alone is sufficient to mediate induction of the IL-21 in preactivated T lymphocytes and that this induction appears to result from specific NFAT binding.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	Kim, Hyoung-Pyo/0000-0003-1441-8822	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005402, ZIAHL005402] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; Campbell PM, 1996, TRANSPLANTATION, V61, P933, DOI 10.1097/00007890-199603270-00016; COCKERILL GW, 1995, BLOOD, V86, P2689; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; JAIN JN, 1993, J IMMUNOL, V151, P837; JUNE CH, 1989, J IMMUNOL, V143, P153; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Mehta DS, 2003, J IMMUNOL, V170, P4111, DOI 10.4049/jimmunol.170.8.4111; Mehta DS, 2005, P NATL ACAD SCI USA, V102, P2016, DOI 10.1073/pnas.0409512102; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Ozaki K, 2004, J IMMUNOL, V173, P5361, DOI 10.4049/jimmunol.173.9.5361; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Perkins D, 1996, J IMMUNOL, V156, P4154; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ragheb JA, 1999, J IMMUNOL, V163, P3321; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; SHAW J, 1988, J IMMUNOL, V140, P2243; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057	43	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25291	25297		10.1074/jbc.M501459200	http://dx.doi.org/10.1074/jbc.M501459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15879595	hybrid			2022-12-25	WOS:000230114000116
J	McLaughlin, JN; Shen, LX; Holinstat, M; Brooks, JD; DiBenedetto, E; Hamm, HE				McLaughlin, JN; Shen, LX; Holinstat, M; Brooks, JD; DiBenedetto, E; Hamm, HE			Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HETEROTRIMERIC G-PROTEINS; PLATELET SHAPE CHANGE; INCREASED ENDOTHELIAL PERMEABILITY; BETA(2) ADRENERGIC-RECEPTOR; GTP-BINDING PROTEIN; LIGHT-CHAIN KINASE; TETHERED LIGAND; DIFFERENTIAL ACTIVATION; MOLECULAR-CLONING; BARRIER FUNCTION	Thrombin activates protease-activated receptor-1 (PAR-1) by cleavage of the amino terminus to unmask a tethered ligand. Although peptide analogs can activate PAR-1, we show that the functional responses mediated via PAR-1 differ between the agonists. Thrombin caused endothelial monolayer permeability and mobilized intracellular calcium with EC50 values of 0.1 and 1.7 nM, respectively. The opposite order of activation was observed for agonist peptide (SFLLRN-CONH2 or TFLL-RNKPDK) activation. The addition of inactivated thrombin did not affect agonist peptide signaling, suggesting that the differences in activation mechanisms are intramolecular in origin. Although activation of PAR-1 or PAR-2 by agonist peptides induced calcium mobilization, only PAR-1 activation affected barrier function. Induced barrier permeability is likely to be G alpha(12/13)-mediated as chelation of G alpha(q)-mediated intracellular calcium with BAPTA-AM, pertussis toxin inhibition of G alpha(i/o), or GM6001 inhibition of matrix metalloproteinase had no effect, whereas Y-27632 inhibition of the G alpha(12/13)-mediated Rho kinase abrogated the response. Similarly, calcium mobilization is G alpha(q)-mediated and independent of G alpha(i/o) and G alpha(12/13) because pertussis toxin and Y-27632 had no effect, whereas U-73122 inhibition of phospholipase C-beta blocked the response. It is therefore likely that changes in permeability reflect G alpha(12/13) activation, and changes in calcium reflect G alpha(q) activation, implying that the pharmacological differences between agonists are likely caused by the ability of the receptor to activate G alpha(12/13) or G alpha(q). This functional selectivity was characterized quantitatively by a mathematical model describing each step leading to Rho activation and/or calcium mobilization. This model provides an estimate that peptide activation alters receptor/G protein binding to favor G alpha(q) activation over G alpha(12/13) by similar to 800-fold.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Dept Math, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Ctr Biomath, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Dept Math, 444 Robinson Res Bldg,23rd Ave S Pierce, Nashville, TN 37232 USA.	heidi.hamm@vanderbilt.edu	Hamm, Heidi E/G-2374-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068953] Funding Source: NIH RePORTER; NHLBI NIH HHS [5P01 HL60678] Funding Source: Medline; NIGMS NIH HHS [5R01 GM068953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelstein R S, 1980, Ann N Y Acad Sci, V356, P142, DOI 10.1111/j.1749-6632.1980.tb29607.x; Ahn HS, 1997, MOL PHARMACOL, V51, P350, DOI 10.1124/mol.51.2.350; Al-Ani B, 2002, J PHARMACOL EXP THER, V302, P1046, DOI 10.1124/jpet.302.3.1046; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Andrade-Gordon P, 2001, J PHARMACOL EXP THER, V298, P34; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bauer M, 2001, THROMB HAEMOSTASIS, V85, P331, DOI 10.1055/s-0037-1615689; Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Bhalla US, 2001, NOVART FDN SYMP, V239, P4; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Blackhart BD, 2000, MOL PHARMACOL, V58, P1178, DOI 10.1124/mol.58.6.1178; Blackhart BD, 1996, J BIOL CHEM, V271, P16466, DOI 10.1074/jbc.271.28.16466; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOEYNAEMS JM, 1977, MOL CELL ENDOCRINOL, V7, P33, DOI 10.1016/0303-7207(77)90074-0; Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324; Bohm SK, 1996, BIOCHEM J, V314, P1009; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; Cupit LD, 1999, TRENDS CARDIOVAS MED, V9, P42, DOI 10.1016/S1050-1738(99)00005-5; de Haen C, 1976, J Theor Biol, V58, P383, DOI 10.1016/S0022-5193(76)80126-9; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; Ebersole BJ, 2003, MOL PHARMACOL, V63, P36, DOI 10.1124/mol.63.1.36; Faraut B, 2003, J CELL PHYSIOL, V196, P105, DOI 10.1002/jcp.10280; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; Gay EA, 2004, MOL PHARMACOL, V66, P97, DOI 10.1124/mol.66.1.97; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goldsack NR, 1998, INT J BIOCHEM CELL B, V30, P641, DOI 10.1016/S1357-2725(98)00011-9; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Hansen KK, 2004, IMMUNOLOGY, V112, P183, DOI 10.1111/j.1365-2567.2004.01870.x; Hao N, 2003, J BIOL CHEM, V278, P46506, DOI 10.1074/jbc.M308432200; Harrell PC, 2005, EXP CELL RES, V303, P308, DOI 10.1016/j.yexcr.2004.09.020; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Hirano Katsuya, 2003, J Atheroscler Thromb, V10, P211; Hofer T, 2002, J NEUROSCI, V22, P4850, DOI 10.1523/JNEUROSCI.22-12-04850.2002; Hollenberg MD, 2000, MOL PHARMACOL, V58, P1175, DOI 10.1124/mol.58.6.1175; Hollenberg MD, 2001, CAN J PHYSIOL PHARM, V79, P439, DOI 10.1139/cjpp-79-5-439; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Ishida A, 2003, PHARMACOL THERAPEUT, V100, P291, DOI 10.1016/j.pharmthera.2003.09.003; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; Kilts JD, 2002, J PHARMACOL EXP THER, V301, P1179, DOI 10.1124/jpet.301.3.1179; Kim JA, 2001, J CELL BIOCHEM, V81, P93, DOI 10.1002/1097-4644(20010401)81:1<93::AID-JCB1026>3.0.CO;2-I; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KRUSE HJ, 1995, AM J PHYSIOL-CELL PH, V268, pC36, DOI 10.1152/ajpcell.1995.268.1.C36; Kurrasch-Orbaugh DM, 2003, J PHARMACOL EXP THER, V304, P229, DOI 10.1124/jpet.102.042184; Lafay M, 1998, THROMB HAEMOSTASIS, V79, P848, DOI 10.1055/s-0037-1615076; Lafleur MA, 2001, BIOCHEM J, V357, P107, DOI 10.1042/0264-6021:3570107; Lemon G, 2003, J THEOR BIOL, V223, P93, DOI 10.1016/S0022-5193(03)00079-1; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; MALIK AB, 1992, SEMIN THROMB HEMOST, V18, P193, DOI 10.1055/s-2007-1002425; Maruyama I, 1994, Rinsho Ketsueki, V35, P234; MCCARTHY SA, 1992, J BIOL CHEM, V267, P21617; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mottola DM, 2002, J PHARMACOL EXP THER, V301, P1166, DOI 10.1124/jpet.301.3.1166; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Otterdal K, 2001, THROMB RES, V103, P411, DOI 10.1016/S0049-3848(01)00334-6; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Preissner KT, 2000, J PATHOL, V190, P360; Quinton TM, 2004, J THROMB HAEMOST, V2, P978, DOI 10.1111/j.1538-7836.2004.00741.x; RABIET MJ, 1994, BRIT MED BULL, V50, P936, DOI 10.1093/oxfordjournals.bmb.a072935; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIEWALD M, 2005, J BIOL CHEM; ROBB S, 1994, EMBO J, V13, P1325, DOI 10.1002/j.1460-2075.1994.tb06385.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Runnels LW, 1998, BIOCHEMISTRY-US, V37, P15563, DOI 10.1021/bi9811258; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Schaeffer P, 1997, BIOCHEM PHARMACOL, V53, P487, DOI 10.1016/S0006-2952(96)00735-6; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Seymour ML, 2003, AM J PHYSIOL-CELL PH, V284, pC1185, DOI 10.1152/ajpcell.00126.2002; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Sower LE, 1999, EXP CELL RES, V247, P422, DOI 10.1006/excr.1998.4372; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stull JT, 1998, ACTA PHYSIOL SCAND, V164, P471, DOI 10.1111/j.1365-201X.1998.tb10699.x; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, P595; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; VERIN AD, 1995, AM J PHYSIOL, V269, P99; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200	112	159	164	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25048	25059		10.1074/jbc.M414090200	http://dx.doi.org/10.1074/jbc.M414090200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878870	hybrid			2022-12-25	WOS:000230114000088
J	Ogawa, T; Ueda, Y; Yoshimura, K; Shigeoka, S				Ogawa, T; Ueda, Y; Yoshimura, K; Shigeoka, S			Comprehensive analysis of cytosolic nudix hydrolases in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCORBATE PEROXIDASE ISOENZYMES; ADP-RIBOSE PYROPHOSPHATASE; HUMAN MUTT HOMOLOG; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MUTAGENIC SUBSTRATE; GUANINE-NUCLEOTIDES; DNA-SYNTHESIS; CLONING; PROTEIN	Nudix hydrolases are a family of proteins that catalyze the hydrolysis of a variety of nucleoside diphosphate derivatives. Twenty-four genes of the Nudix hydrolase homologues (AtNUDTs) with predicted localizations in the cytosol, chloroplasts, and mitochondria exist in Arabidopsis thaliana. Here, we demonstrated the comprehensive analysis of nine types of cytosolic AtNUDT proteins (AtNUDT1, -2, -4, -5, -6, -7, -9, -10, and -11). The recombinant proteins of AtNUDT2, -6, -7, and -10 showed both ADP-ribose and NADH pyrophosphatase activities with significantly high affinities compared with those of animal and yeast enzymes. The expression of each AtNUDT is individually regulated in different tissues. These findings suggest that most cytosolic AtNUDTs may substantially function in the sanitization of potentially hazardous ADP-ribose and the regulation of the cellular NADH/NAD(+) ratio in plant cells. On the other hand, the AtNUDT1 protein had the ability to hydrolyze 8-oxo-dGTP with a K-m value of 6.8 mu M and completely suppress the increased frequency of spontaneous mutations in the Escherichia coli mutT(-) strain, indicating that AtNUDT1 is a functional homologue of E. coli MutT in A. thaliana and is involved in the prevention of spontaneous mutation. The results obtained here suggest that the plant Nudix family has evolved in a specific manner that differs from that of yeast and humans.	Kinki Univ, Fac Agr, Dept Adv Biosci, Nara 6318505, Japan	Kindai University (Kinki University)	Shigeoka, S (corresponding author), Kinki Univ, Fac Agr, Dept Adv Biosci, 3327-204 Nakamachi, Nara 6318505, Japan.	shigeoka@nara.kindai.ac.jp						Abdelraheim SR, 2003, BIOCHEM J, V374, P329, DOI 10.1042/BJ20030441; AbdelRaheim SR, 2001, ARCH BIOCHEM BIOPHYS, V388, P18, DOI 10.1006/abbi.2000.2268; Alscher RG, 1997, PHYSIOL PLANTARUM, V100, P224, DOI 10.1034/j.1399-3054.1997.1000203.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Asada K., 1997, OXIDATIVE STRESS MOL, V34, P715; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Dobrzanska M, 2002, J BIOL CHEM, V277, P50482, DOI 10.1074/jbc.M205207200; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FOYER CH, 1994, PLANT CELL ENVIRON, V17, P507, DOI 10.1111/j.1365-3040.1994.tb00146.x; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; Garcia-Ortiz MV, 2001, PLANT MOL BIOL, V47, P795, DOI 10.1023/A:1013644026132; Gasmi L, 2001, BIOCHEM J, V357, P33, DOI 10.1042/0264-6021:3570033; Hays JB, 2002, DNA REPAIR, V1, P579, DOI 10.1016/S1568-7864(02)00093-9; Ishibashi T, 2003, EMBO REP, V4, P479, DOI 10.1038/sj.embor.embor838; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Klaus SMJ, 2005, J BIOL CHEM, V280, P5274, DOI 10.1074/jbc.M413759200; Kwak YG, 1996, AM J PHYSIOL-CELL PH, V271, pC464, DOI 10.1152/ajpcell.1996.271.2.C464; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; Nunoshiba T, 2004, NUCLEIC ACIDS RES, V32, P5339, DOI 10.1093/nar/gkh868; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Ohtsubo T, 1998, MOL GEN GENET, V259, P577, DOI 10.1007/s004380050851; Okuda K, 2004, BBA-PROTEINS PROTEOM, V1699, P245, DOI 10.1016/j.bbapap.2004.03.004; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Shigeoka S, 2002, J EXP BOT, V53, P1305, DOI 10.1093/jexbot/53.372.1305; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tassotto ML, 2002, J BIOL CHEM, V277, P15807, DOI 10.1074/jbc.M200965200; Xu WL, 2001, MOL MICROBIOL, V39, P286, DOI 10.1046/j.1365-2958.2001.02267.x; Yang HJ, 2000, J BIOL CHEM, V275, P8844, DOI 10.1074/jbc.275.12.8844; Yoshimura K, 1999, BIOCHEM J, V338, P41, DOI 10.1042/0264-6021:3380041	45	108	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25277	25283		10.1074/jbc.M503536200	http://dx.doi.org/10.1074/jbc.M503536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878881	hybrid			2022-12-25	WOS:000230114000114
J	Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J				Dupuy, AG; L'Hoste, S; Cherfils, J; Camonis, J; Gaudriault, G; de Gunzburg, J			Novel Rap1 dominant-negative mutants interfere selectively with C3G and Epac	ONCOGENE			English	Article						Rap; GEF; dominant negative; C3G; Epac	NUCLEOTIDE EXCHANGE FACTOR; CELL-ADHESION; B-RAF; SACCHAROMYCES-CEREVISIAE; 2-HYBRID SYSTEM; IN-VIVO; ACTIVATION; DROSOPHILA; PROTEINS; GTPASE	Rap1 is a Ras-related GTPase that is principally involved in integrin- and E-cadherin-mediated adhesion. Rap1 is transiently activated in response to many incoming signals via a large family of guanine nucleotide exchange factors ( GEFs). The lack of potent Rap1 dominant-negative mutants has limited our ability to decipher Rap1-dependent pathways; we have therefore developed a procedure to generate such mutants consisting in the oligonucleotide-mediated mutagenesis of residues 14-19, selection of mutants presenting an enhanced interaction with Epac2 by yeast two-hybrid screening and counter-screening for mutants still interacting with Rap effectors. In detail analysis of their interaction capacity with various Rap-GEFs in the yeast two-hybrid system revealed that mutants of residues 15 and 16 interacted with Epacs, C3G and CalDAG-GEFI, whereas mutants of position 17 had selectively lost their ability to bind CalDAG-GEFI as well as, for some, C3G. In cellular models where Rap1 is activated via endogenous GEFs, the Rap1[S17A] mutant inhibits both the cAMP-Epac and EGF-C3G pathways, whereas Rap1[G15D] selectively interferes with the latter. Finally, Rap1[S17A] is able to act as a bona. de dominant-negative mutant in vivo since it phenocopies the eye-reducing and lethal effects of D-Rap1 deficiency in Drosophila, effects that are overcome by the overexpression of D-Epac or D-Rap1.	Inst Curie, INSERM, U528, F-75005 Paris, France; CNRS, UPR 9063, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	gunzburg@curie.fr						Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Beranger F, 1997, NUCLEIC ACIDS RES, V25, P2035, DOI 10.1093/nar/25.10.2035; Biou V, 2004, BIOCHEMISTRY-US, V43, P6833, DOI 10.1021/bi049630u; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Karim FD, 1998, DEVELOPMENT, V125, P1; Katagiri K, 2004, NAT IMMUNOL, V5, P1045, DOI 10.1038/ni1111; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; Shi SL, 2004, ONCOGENE, V23, P8711, DOI 10.1038/sj.onc.1208132; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1	59	20	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4509	4520		10.1038/sj.onc.1208647	http://dx.doi.org/10.1038/sj.onc.1208647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856025				2022-12-25	WOS:000230157100004
J	Temes, E; Martin-Puig, S; Acosta-Iborra, B; Castellanos, MC; Feijoo-Cuaresma, M; Olmos, G; Aragones, J; Landazuri, MO				Temes, E; Martin-Puig, S; Acosta-Iborra, B; Castellanos, MC; Feijoo-Cuaresma, M; Olmos, G; Aragones, J; Landazuri, MO			Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; PHOSPHATIDIC-ACID; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; DOWN-REGULATION; PROTEIN-KINASE; LOW-OXYGEN; FACTOR-I; HIF-1-ALPHA	Hypoxia-inducible factors (HIF) are heterodimeric (alpha/beta) transcription factors that play a fundamental role in cellular adaptation to low oxygen tension. In the presence of oxygen, the HIF-alpha subunit becomes hydroxylated at specific prolyl residues by prolyl hydroxylases. This post-translational modification is recognized by the von Hippel-Lindau (VHL) protein, which targets HIF-alpha for degradation. In the absence of oxygen, HIF-alpha hydroxylation is compromised and this subunit is stabilized. We have previously shown that the hypoxia-induced accumulation of HIF-alpha protein is strongly impaired by the inhibitor of diacylglycerol kinase, R59949. Here, we have investigated the mechanisms through which this inhibitor exerts its effect. We found that R59949 inhibits the accumulation of HIF-1/2 alpha protein without affecting the expression of their mRNAs. We also determined that R59949 could only block the accumulation of HIF-alpha in the presence of VHL protein. In agreement with this, the binding of VHL to endogenous HIF-alpha was significantly enhanced after R59949 treatment, even under hypoxic conditions. In addition, we found that R59949 could stimulate prolyl hydroxylase both at 21% O-2 as well as at 1% O-2. Taken together, these results reveal that R59949 is an activator of HIF prolyl hydroxylases. This is of particular interest when we consider that, to date, mainly inhibitors of these enzymes have been described.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego Leon 62, Madrid 28006, Spain.	mortiz.hlpr@salud.madrid.org	Acosta-Iborra, M Bárbara/L-5570-2013	Acosta-Iborra, M Bárbara/0000-0002-1517-114X; Martin-Puig, Silvia/0000-0003-3048-6729; Aragones Lopez, Julian/0000-0002-0193-4679; Olmos Centenera, Gemma/0000-0003-4835-0846				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Knowles HJ, 2003, CANCER RES, V63, P1764; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Naranjo-Suarez S, 2003, J BIOL CHEM, V278, P31895, DOI 10.1074/jbc.M304079200; Preuss I, 2001, EUR J BIOCHEM, V268, P5081, DOI 10.1046/j.0014-2956.2001.02440.x; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Schlemminger I, 2003, BIOORG MED CHEM LETT, V13, P1451, DOI 10.1016/S0960-894X(03)00149-5; Semenza GL, 2004, CANCER CELL, V5, P405, DOI 10.1016/S1535-6108(04)00118-7; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Temes E, 2004, BIOCHEM BIOPH RES CO, V315, P44, DOI 10.1016/j.bbrc.2004.01.015; Um JH, 2004, EXP MOL MED, V36, P233, DOI 10.1038/emm.2004.32; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	56	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24238	24244		10.1074/jbc.M414694200	http://dx.doi.org/10.1074/jbc.M414694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849364	hybrid			2022-12-25	WOS:000229880000100
J	Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C				Mercer, K; Giblett, S; Oakden, A; Brown, J; Marais, R; Pritchard, C			A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression	ONCOGENE			English	Article						A-Raf; Raf-1; knockout; ERK activation; cell cycle; c-Fos; cyclin D1	SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE CASCADE; B-RAF; PROTEIN-KINASE; INDUCED APOPTOSIS; G(1) PHASE; ACTIVATION; EXPRESSION; D1; FIBROBLASTS	The Raf/MEK/ERK ( extracellular regulated kinase) signal transduction pathway controls the ability of cells to respond to proliferative, apoptotic, migratory and differentiation signals. We have investigated the combined contribution of A-Raf and Raf-1 isotypes to signalling through this pathway by generating mice with knockout mutations of both A-raf and raf-1 genes. Double knockout (DKO) mice have a more severe phenotype than single null mutations of either gene, dying in embryogenesis at E10.5. The DKO embryos show no changes in apoptosis, but staining for Ki67 indicates a generalized reduction in proliferation. DKO mouse embryonic fibroblasts (MEFs) exhibit a delayed ability to enter S phase of the cell cycle. This is associated with a reduction in levels of transiently induced MEK and ERK phosphorylation and reduced expression of c-Fos and cyclin Dl. Levels of sustained ERK phosphorylation are not significantly altered. Thus, Raf-1 and A-Raf have a combined role in controlling physiological transient ERK activation and in maintenance of cell cycle progression at its usual rate.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Div Biomed Sci, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England	University of Leicester; University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk		Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; HERBER B, 1994, ONCOGENE, V9, P1295; Hindley A, 2002, J CELL SCI, V115, P1575; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; JIANG W, 1993, ONCOGENE, V8, P3447; KARASARIDES M, 2004, ONCOGENE, V21, P21; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kimura ET, 2003, CANCER RES, V63, P1454; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pritchard CA, 2004, MOL CELL BIOL, V24, P5937, DOI 10.1128/MCB.24.13.5937-5952.2004; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STORM SM, 1990, ONCOGENE, V5, P345; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200	63	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5207	5217		10.1038/sj.onc.1208707	http://dx.doi.org/10.1038/sj.onc.1208707			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856007				2022-12-25	WOS:000230964600007
J	Hu, YP; Venkateswarlu, S; Sergina, N; Howell, G; St Clair, P; Humphrey, LE; Li, WH; Hauser, J; Zborowska, E; Willson, JKV; Brattain, MG				Hu, YP; Venkateswarlu, S; Sergina, N; Howell, G; St Clair, P; Humphrey, LE; Li, WH; Hauser, J; Zborowska, E; Willson, JKV; Brattain, MG			Reorganization of ErbB family and cell survival signaling after knock-down of ErbB2 in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CANCER; CARCINOMA-CELLS; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; POLY(ADP-RIBOSE) POLYMERASE; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; FACTOR INDEPENDENCE	The role of the ErbB family in supporting the malignant phenotype was characterized by stable transfection of a single chain antibody (ScFv5R) against ErbB2 containing a KDEL endoplasmic reticulum retention sequence into GEO human colon carcinoma cells. The antibody traps ErbB2 in the endoplasmic reticulum, thereby down-regulating cell surface ErbB2. The transfected cells showed inactivation of ErbB2 tyrosine phosphorylation and reduced heterodimerization of ErbB2 and ErbB3. This resulted in greater sensitivity to apoptosis induced by growth deprivation and delayed tumorigenicity in vivo. Furthermore, decreased heterodimerization of ErbB2 and ErbB3 led to a reorganization in ErbB function in transfected cells as heterodimerization between epidermal growth factor receptor ( EGFR) and ErbB3 increased, whereas ErbB3 activation remained almost the same. Importantly, elimination of ErbB2 signaling resulted in an increase in EGFR expression and activation in transfected cells. Increased EGFR activation contributed to the sustained cell survival in transfected cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Western Reserve Univ Ireland Canc Ctr, Cleveland, OH 44106 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	Roswell Park Cancer Institute; University of Texas System; University of Texas Health San Antonio; Case Western Reserve University; Case Western Reserve University	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	Michael.brattain@roswellpark.org			NCI NIH HHS [CA54807, CA34432, CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034432, P30CA016056, R01CA054807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Baselga J, 2001, J CLIN ONCOL, V19, p41S; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; DeArmond D, 2003, ONCOGENE, V22, P7781, DOI 10.1038/sj.onc.1206966; DESHANE J, 1994, GENE THER, V1, P332; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottschlich S, 1998, LARYNGOSCOPE, V108, P639, DOI 10.1097/00005537-199805000-00003; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; GULLICK WJ, 1990, INT J CANCER, P55; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; HUANG SS, 1990, J BIOL CHEM, V265, P3340; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIM HH, 1994, J BIOL CHEM, V269, P24747; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; Negro A, 2004, RECENT PROG HORM RES, V59, P1, DOI 10.1210/rp.59.1.1; Nguyen DC, 2003, INT J ONCOL, V22, P1285; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rowinsky EK, 2004, ANNU REV MED, V55, P433, DOI 10.1146/annurev.med.55.091902.104433; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Toi Masakazu, 2004, Breast Cancer, V11, P10, DOI 10.1007/BF02967994; Urano F, 2000, J CELL SCI, V113, P3697; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WANG CY, 1995, CANCER RES, V55, P5101; Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C; Wang JN, 2004, MOL IMMUNOL, V40, P963, DOI 10.1016/j.molimm.2003.09.012; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	70	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27383	27392		10.1074/jbc.M414238200	http://dx.doi.org/10.1074/jbc.M414238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15888451	hybrid			2022-12-25	WOS:000230589500089
J	Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG				Galm, O; Suzuki, H; Akiyama, Y; Esteller, M; Brock, MV; Osieka, R; Baylin, SB; Herman, JG			Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies	ONCOGENE			English	Article						promoter hypermethylation; non-Hodgkin's lymphoma; matrix metalloproteinases; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; CPG ISLAND; METHYLATION; EXPRESSION; TIMP-2; ANGIOGENESIS; PATTERNS; METHYLTRANSFERASE; SURVIVAL	The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2'-deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non- Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.	Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Univ Klinikum Aachen, Med Klin 4, D-52074 Aachen, Germany; Spanish Natl Canc Ctr, Canc Epigenet Lab, Madrid 28029, Spain	Johns Hopkins University; Johns Hopkins Medicine; RWTH Aachen University; RWTH Aachen University Hospital; Centro Nacional de Investigaciones Oncologicas (CNIO)	Herman, JG (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [P50CA096888, U01CA084986] Funding Source: NIH RePORTER; NCI NIH HHS [CA84986, P50 CA96888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Cappabianca L, 2003, EXP CELL RES, V286, P209, DOI 10.1016/S0014-4827(03)00072-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Corn PG, 1999, CANCER RES, V59, P3352; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; Esteller M, 2002, J NATL CANCER I, V94, P26; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hajitou A, 2001, CANCER RES, V61, P3450; Hammani K, 1996, J BIOL CHEM, V271, P25498, DOI 10.1074/jbc.271.41.25498; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; KOSSAKOWSKA AE, 1993, ONCOL RES, V5, P19; List AF, 2001, ONCOLOGIST, V6, P24, DOI 10.1634/theoncologist.6-suppl_5-24; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakopoulou L, 2002, MODERN PATHOL, V15, P26, DOI 10.1038/modpathol.3880486; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; StetlerStevenson M, 1997, BLOOD, V89, P1708, DOI 10.1182/blood.V89.5.1708.1708_1708_1715; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vergani V, 2001, INT J CANCER, V91, P241, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1035>3.3.CO;2-G; Yoshizaki T, 2001, INT J CANCER, V95, P44, DOI 10.1002/1097-0215(20010120)95:1<44::AID-IJC1008>3.3.CO;2-D	37	26	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4799	4805		10.1038/sj.onc.1208599	http://dx.doi.org/10.1038/sj.onc.1208599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870703				2022-12-25	WOS:000230477900006
J	Kim, CH; Braud, S; Isaac, JTR; Roche, KW				Kim, CH; Braud, S; Isaac, JTR; Roche, KW			Protein kinase C phosphorylation of the metabotropic glutamate receptor mGluR5 on serine 839 regulates Ca2+ oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM OSCILLATIONS; GENE-EXPRESSION; DESENSITIZATION; ACTIVATION; FREQUENCY; GLUTAMATE-RECEPTOR-5; DETERMINANTS; SENSITIVITY; PKC	The activation of Group 1 metabotropic glutamate receptors, mGluR5 and mGluR1 alpha, triggers intracellular calcium release; however, mGluR5 activation is unique in that it elicits Ca2+ oscillations. A short region of the mGluR5 C terminus is the critical determinant and differs from the analogous region of mGluR1 alpha by a single amino acid residue, Thr-840, which is an aspartic acid (Asp-854) in mGluR1 alpha. Previous studies show that mGluR5-elicited Ca2+ oscillations require protein kinase C (PKC)-dependent phosphorylation and identify Thr-840 as the phosphorylation site. However, direct phosphorylation of mGluR5 has not been studied in detail. We have used biochemical analyses to directly investigate the phosphorylation of the mGluR5 C terminus. We showed that Ser-839 on mGluR5 is directly phosphorylated by PKC, whereas Thr-840 plays a permissive role. Although Ser-839 is conserved in mGluR1 alpha (Ser-853), it is not phosphorylated, as the adjacent residue (Asp-854) is not permissive; however, mutagenesis of Asp-854 to a permissive alanine residue allows phosphorylation of Ser-853 on mGluR1 alpha. We investigated the physiological consequences of mGluR5 Ser-839 phosphorylation using Ca2+ imaging. Mutations that eliminate Ser-839 phosphorylation prevent the characteristic mGluR5-dependent Ca2+ oscillations. However, mutation of Thr-840 to alanine, which prevents potential Thr-840 phosphorylation but is still permissive for Ser-839 phosphorylation, has no effect on Ca2+ oscillations. Thus, we showed that it is phosphorylation of Ser-839, not Thr-840, that is absolutely required for the unique Ca2+ oscillations produced by mGluR5 activation. The Thr-840 residue is important only in that it is permissive for the PKC-dependent phosphorylation of Ser-839.	NINDS, NIH, Bethesda, MD 20892 USA; Univ Bristol, Dept Anat, Med Res Council Ctr Synap Plast, Bristol BS8 1TD, Avon, England	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Bristol	Roche, KW (corresponding author), NINDS, NIH, Bldg 35,Rm 2C903, Bethesda, MD 20892 USA.	rochek@ninds.nih.gov	Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539; Kim, Chul Hoon/0000-0002-7360-429X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002994, Z01NS003011, Z01NS002994, ZIANS003011] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Ciruela F, 1999, FEBS LETT, V462, P278, DOI 10.1016/S0014-5793(99)01547-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Conn PJ, 2003, ANN NY ACAD SCI, V1003, P12, DOI 10.1196/annals.1300.002; Crawford JH, 2000, NEUROPHARMACOLOGY, V39, P621, DOI 10.1016/S0028-3908(99)00167-7; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kenny PJ, 2004, TRENDS PHARMACOL SCI, V25, P265, DOI 10.1016/j.tips.2004.03.009; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Macek TA, 1998, J NEUROSCI, V18, P6138; Mundell SJ, 2003, J NEUROCHEM, V84, P294, DOI 10.1046/j.1471-4159.2003.01515.x; Nakahara K, 1997, J NEUROCHEM, V69, P1467; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Pellegrini-Giampietro DE, 2003, TRENDS PHARMACOL SCI, V24, P461, DOI 10.1016/S0165-6147(03)00231-1; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; ROCHE KW, 2000, CURRENT PROTOCOLS NE, P1; Rush AM, 2002, J NEUROSCI, V22, P6121; Sato M, 2004, EUR J NEUROSCI, V20, P947, DOI 10.1111/j.1460-9568.2004.03552.x; Sorensen SD, 2003, NEUROPHARMACOLOGY, V44, P699, DOI 10.1016/S0028-3908(03)00053-4; Sosa R, 2002, J NEUROCHEM, V81, P973, DOI 10.1046/j.1471-4159.2002.00883.x; Spooren WPJM, 2001, TRENDS PHARMACOL SCI, V22, P331, DOI 10.1016/S0165-6147(00)01694-1; Uchino M, 2004, J BIOL CHEM, V279, P2254, DOI 10.1074/jbc.M309894200	28	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25409	25415		10.1074/jbc.M502644200	http://dx.doi.org/10.1074/jbc.M502644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15894802	hybrid			2022-12-25	WOS:000230207900015
J	Scaglia, N; Igal, RA				Scaglia, N; Igal, RA			Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG FIBROBLASTS; BREAST-CANCER CELLS; INDUCED APOPTOSIS; FATTY-ACIDS; PHOSPHATIDYLINOSITOL 3-KINASE; TRIGLYCERIDE ACCUMULATION; PHOSPHOLIPID-SYNTHESIS; GENE; EXPRESSION; CHOLESTEROL	Saturated and monounsaturated fatty acids are the most abundant fatty acid species in mammalian organisms, and their distribution is regulated by stearoyl-CoA desaturase, the enzyme that converts saturated into monounsaturated fatty acids. A positive correlation between high monounsaturated fatty acid levels and neoplastic transformation has been reported, but little is still known about the regulation of stearoyl-CoA desaturase in cell proliferation and apoptosis, as well as in cancer development. Here we report that simian virus 40-transformed human lung fibroblasts bearing a knockdown of human stearoyl-CoA desaturase by stable antisense cDNA transfection (hSCDas cells) showed a considerable reduction in monounsaturated fatty acids, cholesterol, and phospholipid synthesis, compared with empty vector transfected-simian virus 40 cell line (control cells). hSCDas cells also exhibited high cellular levels of saturated free fatty acids and triacylglycerol. Interestingly, stearoyl-CoA desaturase-depleted cells exhibited a dramatic decrease in proliferation rate and abolition of anchorage-independent growth. Prolonged exposure to exogenous oleic acid did not reverse either the slower proliferation or loss of anchorage-independent growth of hSCDas cells, suggesting that endogenous synthesis of monounsaturated fatty acids is essential for rapid cell replication and invasiveness, two hallmarks of neoplastic transformation. Moreover, apoptosis was increased in hSCDas cells in a ceramide-independent manner. Finally, stearoyl-CoA desaturase-deficient cells were more sensitive to palmitic acid-induced apoptosis compared with control cells. Our data suggest that, by globally regulating lipid metabolism, stearoyl-CoA desaturase activity modulates cell proliferation and survival and emphasize the important role of endogenously synthesized monounsaturated fatty acids in sustaining the neoplastic phenotype of transformed cells.	Natl Univ La Plata, Inst Invest Bioquim, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Med, RA-1900 La Plata, Argentina; State Univ New Jersey, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of La Plata; Rutgers State University New Brunswick	Igal, RA (corresponding author), Natl Univ La Plata, Inst Invest Bioquim, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Med, RA-1900 La Plata, Argentina.	aigal@atlas.med.unlp.edu.ar						Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Beiraghi S, 2003, GENE, V309, P11, DOI 10.1016/S0378-1119(03)00461-x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; HABIB NA, 1987, BRIT J CANCER, V56, P455, DOI 10.1038/bjc.1987.223; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; Hardy S, 2000, CANCER RES, V60, P6353; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kasai T, 1998, J IMMUNOL, V161, P6469; KHOO DE, 1991, BRIT J CANCER, V63, P97, DOI 10.1038/bjc.1991.20; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Listenberger LL, 2001, J BIOL CHEM, V276, P14890, DOI 10.1074/jbc.M010286200; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Miyazaki M, 2001, J LIPID RES, V42, P1018; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park JY, 2003, BIOCHEM BIOPH RES CO, V303, P891, DOI 10.1016/S0006-291X(03)00436-4; PREISS J, 1986, J BIOL CHEM, V261, P8597; RICHIERI GV, 1995, J LIPID RES, V36, P229; Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200; Samuel W, 2002, J BIOL CHEM, V277, P59, DOI 10.1074/jbc.M108730200; Scaglia N, 2005, BBA-MOL CELL BIOL L, V1687, P141, DOI 10.1016/j.bbalip.2004.11.015; Schaider H, 1998, ANTICANCER RES, V18, P995; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sperling P, 2003, PROSTAG LEUKOTR ESS, V68, P73, DOI 10.1016/S0952-3278(02)00258-2; Sun Y, 2003, J BIOL CHEM, V278, P5813, DOI 10.1074/jbc.M208687200; Thai SF, 2001, CARCINOGENESIS, V22, P1317, DOI 10.1093/carcin/22.8.1317; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wilson R, 2001, J CHROMATOGR A, V905, P251, DOI 10.1016/S0021-9673(00)01006-2; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255; Zhang L, 2001, BIOCHEM J, V357, P183, DOI 10.1042/0264-6021:3570183; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	43	120	127	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25339	25349		10.1074/jbc.M501159200	http://dx.doi.org/10.1074/jbc.M501159200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15851470	Green Published, hybrid			2022-12-25	WOS:000230207900006
J	Vetrivel, KS; Cheng, HP; Kim, SH; Chen, Y; Barnes, NY; Parent, AT; Sisodia, SS; Thinakaran, G				Vetrivel, KS; Cheng, HP; Kim, SH; Chen, Y; Barnes, NY; Parent, AT; Sisodia, SS; Thinakaran, G			Spatial segregation of gamma-secretase and substrates in distinct membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-PRECURSOR-PROTEIN; BETA-SECRETASE; LIPID RAFTS; ALZHEIMERS-DISEASE; PRESENILIN/GAMMA-SECRETASE; NOTCH LIGANDS; CAVEOLAE-LIKE; A-BETA; NICASTRIN; CLEAVAGE	gamma- Secretase facilitates the regulated intramembrane proteolysis of select type I membrane proteins that play diverse physiological roles in multiple cell types and tissue. In this study, we used biochemical approaches to examine the distribution of amyloid precursor protein ( APP) and several additional gamma- secretase substrates in membrane microdomains. We report that APP C- terminal fragments ( CTFs) and gamma- secretase reside in Lubrol WX detergent- insoluble membranes ( DIM) of cultured cells and adult mouse brain. APP CTFs that accumulate in cells lacking gamma- secretase activity preferentially associate with DIM. Cholesterol depletion and magnetic immunoisolation studies indicate recruitment of APP CTFs into cholesterol- and sphingolipid- rich lipid rafts, and co- residence of APP CTFs, PS1, and syntaxin 6 in DIM patches derived from the trans- Golgi network. Photoaffinity cross- linking studies provided evidence for the preponderance of active gamma- secretase in lipid rafts of cultured cells and adult brain. Remarkably, unlike the case of APP, CTFs derived from Notch1, Jagged2, deleted in colorectal cancer ( DCC), and N- cadherin remain largely detergent- soluble, indicative of their spatial segregation in non- raft domains. In embryonic brain, the majority of PS1 and nicastrin is present in Lubrol WXsoluble membranes, wherein the CTFs derived from APP, Notch1, DCC, and N- cadherin also reside. We suggest that gamma- secretase residence in non- raft membranes facilitates proteolysis of diverse substrates during embryonic development but that the translocation of gamma- secretase to lipid rafts in adults ensures processing of certain substrates, including APP CTFs, while limiting processing of other potential substrates.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Chicago	Thinakaran, G (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Knapp R212,924 E 57th St, Chicago, IL 60637 USA.	gopal@uchicago.edu		Young, Natalie/0000-0002-3263-4847	NIA NIH HHS [R01 AG021494, AG021495, AG021494, AG019070, R01 AG021495, R01 AG019070] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019070, R01AG021495, R01AG021494] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abad-Rodriguez J, 2004, J CELL BIOL, V167, P953, DOI 10.1083/jcb.200404149; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Cai DM, 2003, J BIOL CHEM, V278, P3446, DOI 10.1074/jbc.M209065200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DE SB, 1999, NATURE, V398, P518; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074; Lamb BT, 1999, NAT NEUROSCI, V2, P695, DOI 10.1038/11154; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Ma L, 2003, J NEUROSCI, V23, P3164; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Parkin ET, 1997, J NEUROCHEM, V69, P2179; Prinetti A, 2001, J BIOL CHEM, V276, P21136, DOI 10.1074/jbc.M010666200; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wada S, 2003, BIOCHEMISTRY-US, V42, P13977, DOI 10.1021/bi034904j; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	55	186	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25892	25900		10.1074/jbc.M503570200	http://dx.doi.org/10.1074/jbc.M503570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886206	hybrid, Green Accepted			2022-12-25	WOS:000230207900070
J	Felczak, MM; Simmons, LA; Kaguni, JM				Felczak, MM; Simmons, LA; Kaguni, JM			An essential tryptophan of Escherichia coli DnaA protein functions in oligomerization at the E. coli replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; GEL-ELECTROPHORESIS; BINDING DOMAIN; INITIATOR DNAA; ATP BINDING; PLASMID RK2; RECOGNITION; COMPLEXES; GENE; HELICASE	In the initiation of bacterial DNA replication, DnaA protein recruits DnaB helicase to the chromosomal origin, oriC, leading to the assemble of the replication fork machinery at this site. Because a region near the N terminus of DnaA is required for self-oligomerization and the loading of DnaB helicase at oriC, we asked if these functions are separable or interdependent by substituting many conserved amino acids in this region with alanine to identify essential residues. We show that alanine substitutions of leucine 3, phenylalanine 46, and leucine 62 do not affect DnaA function in initiation. In contrast, we find on characterization of a mutant DnaA that tryptophan 6 is essential for DnaA function because its substitution by alanine abrogates self-oligomerization, resulting in the failure to load DnaB at oriC. These results indicate that DnaA bound to oriC forms a specific oligomeric structure, which is required to load DnaB helicase.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	kaguni@msu.edu		Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; Carr KM, 2002, J BIOL CHEM, V277, P39815, DOI 10.1074/jbc.M205031200; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; Felczak MM, 2004, J BIOL CHEM, V279, P51156, DOI 10.1074/jbc.M409695200; FRIED MG, 1994, NUCLEIC ACIDS RES, V22, P5054, DOI 10.1093/nar/22.23.5054; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; HWANG DS, 1988, J BIOL CHEM, V263, P10633; Jakimowicz D, 1998, MICROBIOL-SGM, V144, P1281, DOI 10.1099/00221287-144-5-1281; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KAGUNI JM, 2004, ENCY BIOL CHEM, V1, P761; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Lee YS, 1997, J BIOL CHEM, V272, P83; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MARGULIES CA, 1997, THESIS MICHIGAN STAT; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; McGarry KC, 2004, P NATL ACAD SCI USA, V101, P2811, DOI 10.1073/pnas.0400340101; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Mima S, 2002, BIOCHEM J, V365, P881, DOI 10.1042/BJ20020287; Neuwald AF, 1999, GENOME RES, V9, P27; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; Simmons LA, 2003, MOL MICROBIOL, V47, P755, DOI 10.1046/j.1365-2958.2003.03333.x; Sutton MD, 1997, J MOL BIOL, V271, P693, DOI 10.1006/jmbi.1997.1209; Sutton MD, 1997, J MOL BIOL, V274, P546, DOI 10.1006/jmbi.1997.1425; Sutton MD, 1997, J BIOL CHEM, V272, P23017, DOI 10.1074/jbc.272.37.23017; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Vossen KM, 1997, ANAL BIOCHEM, V245, P85, DOI 10.1006/abio.1996.9944; WAHLE E, 1989, J BIOL CHEM, V264, P2469; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x	44	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24627	24633		10.1074/jbc.M503684200	http://dx.doi.org/10.1074/jbc.M503684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878847	hybrid			2022-12-25	WOS:000230114000042
J	Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Brichta, L; Bloodworth, LM; Li, JH; Wess, J				Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Brichta, L; Bloodworth, LM; Li, JH; Wess, J			Pronounced conformational changes following agonist activation of the M-3 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DISULFIDE CROSS-LINKING; BETA(2) ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT CHANGES; CYTOPLASMIC END; CONSTITUTIVE ACTIVATION; SULFHYDRYL REACTIVITY; PALMITOYLATION SITES; RHODOPSIN STRUCTURE; ALPHA-HELICES	The conformational changes that convert G protein-coupled receptors (GPCRs) activated by diffusible ligands from their resting into their active states are not well understood at present. To address this issue, we used the M-3 muscarinic acetylcholine receptor, a prototypical class A GPCR, as a model system, employing a recently developed disulfide cross-linking strategy that allows the formation of disulfide bonds using Cys-substituted mutant M-3 muscarinic receptors present in their native membrane environment. In the present study, we generated and analyzed 30 double Cys mutant M-3 receptors, all of which contained one Cys substitution within the C-terminal portion of transmembrane domain (TM) VII (Val-541 to Ser-546) and another one within the C-terminal segment of TM I (Val-88 to Phe-92). Following their transient expression in COS-7 cells, all mutant receptors were initially characterized in radioligand binding and second messenger assays (carbachol-induced stimulation of phosphatidylinositol hydrolysis). This analysis showed that all 30 double Cys mutant M-3 receptors were able to bind muscarinic ligands with high affinity and retained the ability to stimulate G proteins with high efficacy. In situ disulfide cross-linking experiments revealed that the muscarinic agonist, carbachol, promoted the formation of cross-links between specific Cys pairs. The observed pattern of disulfide cross-links, together with receptor modeling studies, strongly suggested that M-3 receptor activation induces a major rotational movement of the C-terminal portion of TM VII and increases the proximity of the cytoplasmic ends of TM I and VII. These findings should be of relevance for other family A GPCRs.	NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,8 Ctr Dr,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Han, Sung-Jun/B-9547-2012; Jacobson, Kenneth Alan/A-1530-2009; Li, Jianhua/B-7671-2011	Jacobson, Kenneth Alan/0000-0001-8104-1493; Li, Jianhua/0000-0002-5744-3182	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031115, ZIADK031115, Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foord SM, 2002, CURR OPIN PHARMACOL, V2, P561, DOI 10.1016/S1471-4892(02)00214-X; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Imamoto Y, 2000, BIOCHEMISTRY-US, V39, P15225, DOI 10.1021/bi0018685; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Klein-Seetharaman J, 1999, P NATL ACAD SCI USA, V96, P13744, DOI 10.1073/pnas.96.24.13744; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Mielke T, 2002, BIOCHEMISTRY-US, V41, P7875, DOI 10.1021/bi011862v; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schmidt C, 2003, J BIOL CHEM, V278, P30248, DOI 10.1074/jbc.M304991200; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629; Zhong M, 2004, BIOCHEMISTRY-US, V43, P3490, DOI 10.1021/bi035899m	57	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24870	24879		10.1074/jbc.M500379200	http://dx.doi.org/10.1074/jbc.M500379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870064	hybrid			2022-12-25	WOS:000230114000070
J	Liang, FB; Lee, SY; Liang, J; Lawrence, DS; Zhang, ZY				Liang, FB; Lee, SY; Liang, J; Lawrence, DS; Zhang, ZY			The role of protein-tyrosine phosphatase 1B in integrin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC-FAMILY KINASES; INSULIN SENSITIVITY; CRYSTAL-STRUCTURE; PTP1B INHIBITORS; CELL-MIGRATION; DIRECT BINDING; IN-VIVO; C-SRC; V-SRC	Protein-tyrosine phosphatase 1B (PTP1B) is a key negative regulator of insulin and leptin signaling and a novel therapeutic target for the treatment of type 2 diabetes, obesity, and other associated metabolic syndromes. Because PTP1B regulates multiple signal pathways and it can both enhance and antagonize a cellular event, it is important to establish the physiological relevance of PTP1B in these processes. In this study, we utilize potent and selective PTP1B inhibitors to delineate the role of PTP1B in integrin signaling. We show that down-regulation of PTP1B activity with small molecule inhibitors suppresses cell spreading and migration to fibronectin, increases Tyr(527) phosphorylation in Src, and decreases phosphorylation of FAK, p130(Cas), and ERK1/2. In addition, PTP1B "substrate-trapping" mutants bind Tyr(527)-phosphorylated Src and protect it from dephosphorylation by endogenous PTP1B. These results establish that PTP1B promotes integrin-mediated responses in fibroblasts by dephosphorylating the inhibitory pTyr(527) and thereby activating the Src kinase. We also show that PTP1B forms a complex with Src and p130(Cas), and that the proline-rich motif PPRPPK ( residues 309-314) in PTP1B is essential for the complex formation. We suggest that the specificity of PTP1B for Src pTyr527 is mediated by protein-protein interactions involving the docking protein p130(Cas) with both Src and PTP1B in addition to the interactions between the PTP1B active site and the pTyr(527) motif.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NIDDK NIH HHS [DK68447] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068447] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Cary LA, 1996, J CELL SCI, V109, P1787; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Clampit JE, 2003, BIOCHEM BIOPH RES CO, V300, P261, DOI 10.1016/S0006-291X(02)02839-5; Cuenda A, 2000, METH MOL B, V99, P161; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kumar S, 2005, METHODS, V35, P9, DOI 10.1016/j.ymeth.2004.07.003; LEE SY, 2005, IN PRESS ANGEW CHEM, V44; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; McCormick F, 2000, CURR OPIN BIOTECH, V11, P593, DOI 10.1016/S0958-1669(00)00149-X; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHLAEPFER DD, 1994, NATURE, V372, P786; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Xie LP, 2003, BIOCHEMISTRY-US, V42, P12792, DOI 10.1021/bi035238p; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang ZY, 2003, EXPERT OPIN INV DRUG, V12, P223, DOI 10.1517/eoid.12.2.223.21411; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4	55	78	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24857	24863		10.1074/jbc.M502780200	http://dx.doi.org/10.1074/jbc.M502780200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866871	hybrid			2022-12-25	WOS:000230114000068
J	Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M				Majeed, N; Blouin, MJ; Kaplan-Lefko, PJ; Barry-Shaw, J; Greenberg, NM; Gaudreau, P; Bismar, TA; Pollak, M			A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model	ONCOGENE			English	Article						lit; TRAMP; prostate carcinogenesis; survival	GROWTH-FACTOR-I; HORMONE RECEPTOR; MUTANT MICE; RISK; GHRH; EXPRESSION; PHENOTYPE; SYSTEM; DWARF	Circulating insulin-like growth factor-I (IGF-I) levels have been shown to be related to risk of prostate cancer in epidemiologic studies. While specific genetic loci responsible for interindividual variation in circulating IGF-I levels in normal men have not been identified, candidate genes include those involved in the growth hormone (GH) IGF-I axis such as the hypothalamic factors GH releasing hormone (GHRH) and somatostatin and their receptors. To investigate the role of the GH-IGF-I axis on in vivo prostate carcinogenesis and neoplastic progression, we generated mice genetically predisposed to prostate cancer (the TRAMP model) to be homozygous for lit, a mutation that inactivates the GHRH receptor (GHRH-R) and reduces circulating levels of GH and IGF-I. The lit mutation significantly reduced the percentage of the prostate gland showing neoplastic changes at 35 weeks of age (P = 0.0005) and was also associated with improved survival (P < 0.01). These data provide an example of a germ line mutation that reduces risk in an experimental prostate carcinogenesis model. The results suggest that prostate carcinogenesis and progression may be influenced by germ line variation of genes encoding signalling molecules in the GH-IGF-I axis.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; Univ Montreal, Dept Med, Lab Neuroendocrinol Aging, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; Baylor College of Medicine; Fred Hutchinson Cancer Center; Universite de Montreal; McGill University	Pollak, M (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604				Aleppo G, 1997, ENDOCRINOLOGY, V138, P1058, DOI 10.1210/en.138.3.1058; Arantes-Oliveira N, 2003, SCIENCE, V302, P611, DOI 10.1126/science.1089169; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chandrashekar V, 2004, BIOL REPROD, V71, P17, DOI 10.1095/biolreprod.103.027060; Chopin LK, 2001, PROSTATE, V49, P116, DOI 10.1002/pros.1125; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; CULIG Z, 1994, CANCER RES, V54, P5474; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; Hellawell GO, 2002, CANCER RES, V62, P2942; HOLZENBERGER M, 2002, NATURE, V421, P125; JANSSON JO, 1986, SCIENCE, V232, P511, DOI 10.1126/science.3008329; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Letsch M, 2003, P NATL ACAD SCI USA, V100, P1250, DOI 10.1073/pnas.0337496100; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Maheshwari HG, 1998, J CLIN ENDOCR METAB, V83, P4065, DOI 10.1210/jc.83.11.4065; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Peng XD, 2001, ENDOCRINOLOGY, V142, P1117, DOI 10.1210/en.142.3.1117; Pollak M, 1998, CANCER METAST REV, V17, P383, DOI 10.1023/A:1006154108619; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Stattin P, 2004, J CLIN ONCOL, V22, P3104, DOI 10.1200/JCO.2004.10.105; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Wajnrajch MP, 1996, NAT GENET, V12, P88, DOI 10.1038/ng0196-88; Wang J, 2004, MOL CELL ENDOCRINOL, V219, P171, DOI 10.1016/j.mce.2003.12.018; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911	37	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4736	4740		10.1038/sj.onc.1208572	http://dx.doi.org/10.1038/sj.onc.1208572			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15870705				2022-12-25	WOS:000230304500012
J	Xu, J; Vallejo, AN; Jiang, Y; Weyand, CM; Goronzy, JJ				Xu, J; Vallejo, AN; Jiang, Y; Weyand, CM; Goronzy, JJ			Distinct transcriptional control mechanisms of killer immunoglobulin-like receptors in natural killer (NK) and in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IG-LIKE RECEPTOR; CD28 EXPRESSION; RHEUMATOID-ARTHRITIS; INHIBITORY RECEPTORS; DNA METHYLATION; GENE-EXPRESSION; HLA; ACTIVATION; KIR; MEMORY	Killer immunoglobulin-like receptors (KIR) are expressed by natural killer (NK) cells and by subsets of CD4(+) and CD8(+) T cells, which are therefore thought to be subject to similar regulatory mechanisms. Here, we show that the transcriptional machinery to express KIR is limited to NK and T cells; however, the KIR transcriptional control differs between these two types of lymphocytes. T cells selectively express transcriptional activators binding to positions - 52 to - 61 of the KIR promoter, whereas an AML site around position - 98 is relevant for transcription in NK cells. Although KIR expression is restricted to subsets of memory T cells, our studies demonstrate that transcriptional activators for KIRs are not acquired during T cell differentiation but are already present in naive T cells, suggesting a basic role of KIRs in T cell biology. We suggest that the regulated expression of KIRs in T cells profoundly influences peripheral tolerance and antigen-specific immune responses.	Emory Univ, Sch Med, Kathleen B & Mason I Lowance Ctr Human Immunol, Dept Med, Atlanta, GA 30322 USA; Univ Pittsburgh, Childrens Hosp, Sch Med, Rangos Res Ctr,Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp, Sch Med, Rangos Res Ctr,Dept Immunol, Pittsburgh, PA 15213 USA; Mayo Clin, Div Physiol Imaging, Res Lab, Rochester, MN 55905 USA	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Mayo Clinic	Goronzy, JJ (corresponding author), Emory Univ, Sch Med, Kathleen B & Mason I Lowance Ctr Human Immunol, Dept Med, Rm 1003,Woodruff Mem Res Bldg,101 Woodruff Circle, Atlanta, GA 30322 USA.	jgoronz@emory.edu	Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NIAMS NIH HHS [AR42527, R01 AR041974, AR41974] Funding Source: Medline; NIA NIH HHS [R01 AG015043, R01 AG022379, AG22379, R01 AG022379-03, AG15043] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042527, R01AR041974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022379, R01AG015043] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andre P, 1999, EUR J IMMUNOL, V29, P1076, DOI 10.1002/(SICI)1521-4141(199904)29:04<1076::AID-IMMU1076>3.0.CO;2-Z; Anfossi N, 2001, IMMUNOL REV, V181, P269, DOI 10.1034/j.1600-065X.2001.1810123.x; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Bakker ABH, 1998, J IMMUNOL, V160, P5239; Beelen DW, 2005, BLOOD, V105, P2594, DOI 10.1182/blood-2004-04-1441; Belkin D, 2003, J IMMUNOL, V171, P3056, DOI 10.4049/jimmunol.171.6.3056; Beverley PCL, 2004, SEMIN IMMUNOL, V16, P315, DOI 10.1016/j.smim.2004.08.012; Boucher N, 1998, EXP GERONTOL, V33, P267, DOI 10.1016/S0531-5565(97)00132-0; Chan HW, 2003, J EXP MED, V197, P245, DOI 10.1084/jem.20021127; Glimcher LH, 2004, NAT REV IMMUNOL, V4, P900, DOI 10.1038/nri1490; Goronzy JJ, 2005, IMMUNOL REV, V204, P55, DOI 10.1111/j.0105-2896.2005.00245.x; Groh V, 2003, P NATL ACAD SCI USA, V100, P9452, DOI 10.1073/pnas.1632807100; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; Huard B, 2000, EUR J IMMUNOL, V30, P1665, DOI 10.1002/1521-4141(200006)30:6<1665::AID-IMMU1665>3.0.CO;2-2; KUSNIERCZYK M, 2004, HUM IMMUNOL, V65, P758; LANIER LL, 1992, IMMUNOL TODAY, V13, P392, DOI 10.1016/0167-5699(92)90087-N; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Leibson PJ, 2004, CURR OPIN IMMUNOL, V16, P328, DOI 10.1016/j.coi.2004.03.006; Long EO, 2001, IMMUNOL REV, V181, P223, DOI 10.1034/j.1600-065X.2001.1810119.x; Lopez-Botet M, 1999, CURR OPIN IMMUNOL, V11, P301, DOI 10.1016/S0952-7915(99)80048-X; Luszczek W, 2004, HUM IMMUNOL, V65, P758, DOI 10.1016/j.humimm.2004.05.008; MAndelboim O, 1996, SCIENCE, V274, P2097, DOI 10.1126/science.274.5295.2097; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Martin MP, 2002, J IMMUNOL, V169, P2818, DOI 10.4049/jimmunol.169.6.2818; Miller JS, 2001, BLOOD, V98, P705, DOI 10.1182/blood.V98.3.705; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; Moretta L, 2004, CURR OPIN IMMUNOL, V16, P626, DOI 10.1016/j.coi.2004.07.010; Nakajima T, 2003, CIRC RES, V93, P106, DOI 10.1161/01.RES.0000082333.58263.58; Namekawa T, 2000, J IMMUNOL, V165, P1138, DOI 10.4049/jimmunol.165.2.1138; Nelson GW, 2004, J IMMUNOL, V173, P4273, DOI 10.4049/jimmunol.173.7.4273; Parham P, 2004, IMMUNOL LETT, V92, P11, DOI 10.1016/j.imlet.2003.11.016; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Santourlidis S, 2002, J IMMUNOL, V169, P4253, DOI 10.4049/jimmunol.169.8.4253; Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638; Shilling HG, 2003, BLOOD, V101, P3730, DOI 10.1182/blood-2002-08-2568; Snyder MR, 2004, J IMMUNOL, V173, P3725, DOI 10.4049/jimmunol.173.6.3725; Snyder MR, 2004, TRENDS IMMUNOL, V25, P25, DOI 10.1016/j.it.2003.10.011; Snyder MR, 2003, J EXP MED, V197, P437, DOI 10.1084/jem.20020383; Snyder MR, 2002, J IMMUNOL, V168, P3839, DOI 10.4049/jimmunol.168.8.3839; Stewart CA, 2003, J IMMUNOL, V170, P6073, DOI 10.4049/jimmunol.170.12.6073; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; Trompeter HI, 2005, J IMMUNOL, V174, P4135, DOI 10.4049/jimmunol.174.7.4135; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; Ugolini S, 2001, NAT IMMUNOL, V2, P430, DOI 10.1038/87740; Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5; Uhrberg M, 2001, J IMMUNOL, V166, P3923, DOI 10.4049/jimmunol.166.6.3923; Valiante NM, 1997, IMMUNITY, V7, P739, DOI 10.1016/S1074-7613(00)80393-3; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 2004, TRENDS MOL MED, V10, P119, DOI 10.1016/j.molmed.2004.01.002; Vallejo AN, 2002, J BIOL CHEM, V277, P46940, DOI 10.1074/jbc.M207352200; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; van Bergen J, 2004, J IMMUNOL, V173, P6719, DOI 10.4049/jimmunol.173.11.6719; van der Slik AR, 2003, DIABETES, V52, P2639, DOI 10.2337/diabetes.52.10.2639; Vely F, 2001, J IMMUNOL, V166, P2487, DOI 10.4049/jimmunol.166.4.2487; Vilches C, 2000, J IMMUNOL, V165, P6416, DOI 10.4049/jimmunol.165.11.6416; Warrington KJ, 2001, ARTHRITIS RHEUM, V44, P13, DOI 10.1002/1529-0131(200101)44:1<13::AID-ANR3>3.0.CO;2-6; Yen JH, 2001, J EXP MED, V193, P1159, DOI 10.1084/jem.193.10.1159; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Young NT, 2001, J IMMUNOL, V166, P3933, DOI 10.4049/jimmunol.166.6.3933; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	66	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24277	24285		10.1074/jbc.M500727200	http://dx.doi.org/10.1074/jbc.M500727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15863493	hybrid			2022-12-25	WOS:000229880000105
J	Kubota, K; Lee, DH; Tsuchiya, M; Young, CS; Everett, ET; Martinez-Mier, EA; Snead, ML; Nguyen, L; Urano, F; Bartlett, JD				Kubota, K; Lee, DH; Tsuchiya, M; Young, CS; Everett, ET; Martinez-Mier, EA; Snead, ML; Nguyen, L; Urano, F; Bartlett, JD			Fluoride induces endoplasmic reticulum stress in ameloblasts responsible for dental enamel formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL LUNG-CELLS; INDUCED APOPTOSIS; MESSENGER-RNA; TRANSLATIONAL CONTROL; DNA FRAGMENTATION; GENE-EXPRESSION; CRITICAL PERIOD; RAT INCISOR; PROTEIN; GADD153	mechanism of how fluoride causes fluorosis remains unknown. Exposure to fluoride can inhibit protein synthesis, and this may also occur by agents that cause endoplasmic reticulum (ER) stress. When translated proteins fail to fold properly or become misfolded, ER stress response genes are induced that together comprise the unfolded protein response. Because ameloblasts are responsible for dental enamel formation, we used an ameloblast-derived cell line (LS8) to characterize specific responses to fluoride treatment. LS8 cells were growth-inhibited by as little as 1.9-3.8 ppm fluoride, whereas higher doses induced ER stress and caspase-mediated DNA fragmentation. Growth arrest and DNA damage-inducible proteins (GADD153/CHOP, GADD45 alpha), binding protein (BiP/glucose-responsive protein 78 (GRP78), the non-secreted form of carbonic anhydrase VI (CA-VI), and active X-box-binding protein-1 (Xbp-1) were all induced significantly after exposure to 38 ppm fluoride. Unexpectedly, DNA fragmentation increased when GADD153 expression was inhibited by short interfering RNA treatment but remained unaffected by transient GADD153 overexpression. Analysis of control and GADD153(-/-) embryonic fibroblasts demonstrated that caspase-3 mediated the increased DNA fragmentation observed in the GADD153 null cells. We also demonstrate that mouse incisor ameloblasts are sensitive to the toxic effects of high dose fluoride in drinking water. Activated Ire1 initiates an ER stress response pathway, and mouse ameloblasts were shown to express activated Ire1. Ire1 levels appeared induced by fluoride treatment, indicating that ER stress may play a role in dental fluorosis. Low dose fluoride, such as that present in fluoridated drinking water, did not induce ER stress.	Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, Boston, MA 02115 USA; Tohoku Univ, Grad Sch Dent, Div Aging & Geriatr Dent, Sendai, Miyagi 9808578, Japan; Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med & Dent, Oral Hlth Res Inst, Dept Prevent & Community Dent, Indianapolis, IN 46202 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA; Univ Massachusetts, Sch Med, Program Mol Med, Program Gene Funct & Express, Worcester, MA 01655 USA	Harvard University; Forsyth Institute; Harvard University; Harvard School of Dental Medicine; Tohoku University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; University of Southern California; University of Massachusetts System; University of Massachusetts Worcester	Bartlett, JD (corresponding author), Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA.	jbartlett@forsyth.org	Urano, Fumihiko/AAF-4492-2020; Tsuchiya, Masahiro/C-5553-2018; Everett, Eric/AAP-4459-2021; Bartlett, John/L-9832-2017; Longo, Kenneth A/A-5631-2010	Tsuchiya, Masahiro/0000-0002-7000-4547; 	NCI NIH HHS [CO6RR11244] Funding Source: Medline; NIDCR NIH HHS [R01 DE018106, DE13237, R01 DE014084, DE14084] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013237, R01DE014084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anuradha CD, 2000, ARCH TOXICOL, V74, P226, DOI 10.1007/s002040000132; Aoba T, 2002, CRIT REV ORAL BIOL M, V13, P155, DOI 10.1177/154411130201300206; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BERTRAND R, 1991, BIOCHEM PHARMACOL, V42, P77, DOI 10.1016/0006-2952(91)90683-V; BOIVIN G, 1989, BONE, V10, P89, DOI 10.1016/8756-3282(89)90004-5; Bronckers ALJJ, 1996, EUR J ORAL SCI, V104, P102, DOI 10.1111/j.1600-0722.1996.tb00053.x; Bronckers ALJJ, 2000, HISTOCHEM CELL BIOL, V113, P293, DOI 10.1007/s004180000137; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chen CH, 1996, ONCOGENE, V13, P1659; CHEN LS, 1992, ARCH ORAL BIOL, V37, P771, DOI 10.1016/0003-9969(92)90110-T; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; DenBesten PK, 1999, COMMUNITY DENT ORAL, V27, P41, DOI 10.1111/j.1600-0528.1999.tb01990.x; Elliott J, 2002, J ENDOCRINOL, V172, P137, DOI 10.1677/joe.0.1720137; EVANS RW, 1995, J PUBLIC HEALTH DENT, V55, P238, DOI 10.1111/j.1752-7325.1995.tb02376.x; EVANS RW, 1991, J PUBLIC HEALTH DENT, V51, P251, DOI 10.1111/j.1752-7325.1991.tb02223.x; Everett ET, 2002, J DENT RES, V81, P794, DOI 10.1177/0810794; Guyton KZ, 1996, FREE RADICAL BIO MED, V20, P735, DOI 10.1016/0891-5849(95)02151-5; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hirano S, 1996, ARCH TOXICOL, V70, P249, DOI 10.1007/s002040050268; Hirano S, 1997, ARCH TOXICOL, V72, P52, DOI 10.1007/s002040050468; HOLLAND RI, 1979, ACTA PHARMACOL TOX, V45, P96; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kondo S, 2001, ARCH ORAL BIOL, V46, P557, DOI 10.1016/S0003-9969(00)00139-4; Liu CY, 2003, J CELL SCI, V116, P1861, DOI 10.1242/jcs.00408; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Matsuo S, 1996, ARCH TOXICOL, V70, P420, DOI 10.1007/s002040050294; Mayerhofer T, 2003, BIOCHEM BIOPH RES CO, V310, P115, DOI 10.1016/j.bbrc.2003.08.130; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; National Toxicology Program, 1990, NATL TOXICOL PROGRAM, V393, P1; NISHIKAWA S, 1995, HISTOCHEM CELL BIOL, V104, P151, DOI 10.1007/BF01451574; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRICE BD, 1992, CANCER RES, V52, P3814; Refsnes M, 2002, ANN NY ACAD SCI, V973, P218, DOI 10.1111/j.1749-6632.2002.tb04636.x; Refsnes M, 2003, HUM EXP TOXICOL, V22, P111, DOI 10.1191/0960327103ht322oa; Rojas-Sanchez F, 1999, COMMUNITY DENT ORAL, V27, P288; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SCHOUR I, 1935, J AM DENT ASSOC, P796; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; SMITH CE, 1977, ANAT REC, V187, P63, DOI 10.1002/ar.1091870106; Smith CE, 2005, J BONE MINER RES, V20, P240, DOI 10.1359/JBMR.041002; SMITH CE, 1993, ANAT RECORD, V237, P243, DOI 10.1002/ar.1092370212; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Sok J, 1999, MOL CELL BIOL, V19, P495; Sterling D, 2001, JOP, V2, P165; Sui W, 2003, J DENT RES, V82, P388, DOI 10.1177/154405910308200512; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Thrane EV, 2001, TOXICOL SCI, V61, P83, DOI 10.1093/toxsci/61.1.83; Vieira APGF, 2004, J DENT RES, V83, P76, DOI 10.1177/154405910408300115; VOGEL GL, 1987, J DENT RES, V66, P1691, DOI 10.1177/00220345870660111801; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wang Y, 2000, J BIOL CHEM, V275, P27013; Whitford GM, 1996, MONOGR ORAL SCI, V16, P1; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Young CS, 2005, ARCH ORAL BIOL, V50, P259, DOI 10.1016/j.archoralbio.2004.11.020; Zager RA, 1997, AM J PATHOL, V150, P735; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhou R, 1996, ARCH ORAL BIOL, V41, P739, DOI 10.1016/S0003-9969(96)00078-7	64	130	154	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23194	23202		10.1074/jbc.M503288200	http://dx.doi.org/10.1074/jbc.M503288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849362	Green Submitted, hybrid			2022-12-25	WOS:000229741800077
J	Jung, J; Kim, TG; Lyons, GE; Kim, HRC; Lee, Y				Jung, J; Kim, TG; Lyons, GE; Kim, HRC; Lee, Y			Jumonji regulates cardiomyocyte proliferation via interaction with retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL HEART-DEFECTS; CARDIAC DEVELOPMENT; TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; BINDING-PROTEINS; RXR-ALPHA; FUNCTIONAL INTERACTIONS; REPRESS TRANSCRIPTION; NEUREGULIN RECEPTOR; RETINOIC ACID	Jumonji (JMJ) can function as a transcriptional repressor and plays critical roles in embryonic development including heart development in mice. Although JMJ has been suggested to play a role in cell growth, the molecular mechanisms have not been resolved. The present data demonstrate that JMJ interacts with the retinoblastoma protein (Rb), one of the master regulatory genes of cell cycle. JMJ potentiates the repression function of Rb on E2F activities, leading to reduced cell cycle progression. The transcriptional repression domain of JMJ is critical for the interaction with Rb as well as repression of cell cycle. The physiological relevance of the association between Rb and JMJ was assessed in cardiomyocytes. Primary cardiomyocytes cultured from homozygous jmj knock-out mouse embryos (jmj mutants) show increased cell mitosis in a cardiomyocyte-specific manner. Reporter gene analyses demonstrate that promoter activities of cyclin D1, cyclin D2, and Cdc2 are up-regulated in jmj mutant cardiomyocytes. These data suggest that JMJ down-regulates the cell growth via interaction with Rb, which would provide important insights into the cardiac defects observed in jmj mutant mice.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA	University of Wisconsin System; University of Wisconsin Madison; Wayne State University	Lee, Y (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.	youngsooklee@facstaff.wisc.edu			NCI NIH HHS [CA64139] Funding Source: Medline; PHS HHS [69050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen J, 1998, DEVELOPMENT, V125, P1943; Chen THP, 2002, DEV BIOL, V250, P198, DOI 10.1006/dbio.2002.0796; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gregory SL, 1996, MOL CELL BIOL, V16, P792; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNINK M, 1990, ONCOGENE, V5, P1843; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jung J, 2005, DEV DYNAM, V232, P21, DOI 10.1002/dvdy.20204; Kastner P, 1997, DEVELOPMENT, V124, P4749; Kim TG, 2003, J BIOL CHEM, V278, P42247, DOI 10.1074/jbc.M307386200; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; KWEE L, 1995, DEVELOPMENT, V121, P489; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Li J, 1999, DEVELOPMENT, V126, P2495; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mcfadden DG, 2002, CURR OPIN GENET DEV, V12, P328, DOI 10.1016/S0959-437X(02)00306-4; Motoyama J, 1997, MECH DEVELOP, V66, P27, DOI 10.1016/S0925-4773(97)00082-8; MUNGER K, 1992, CANCER SURV, V12, P197; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Srivastava D, 2000, CIRC RES, V86, P917, DOI 10.1161/01.RES.86.9.917; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Takeuchi T, 1999, MECH DEVELOP, V86, P29, DOI 10.1016/S0925-4773(99)00100-8; TAKEUCHI T, 1995, GENE DEV, V9, P1211, DOI 10.1101/gad.9.10.1211; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Toyoda M, 2003, DEV CELL, V5, P85, DOI 10.1016/S1534-5807(03)00189-8; Volcik KA, 2004, AM J MED GENET A, V126A, P215, DOI 10.1002/ajmg.a.20574; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANG JT, 1995, DEVELOPMENT, V121, P549; Yu JH, 2003, J BIOL CHEM, V278, P49582, DOI 10.1074/jbc.M309986200	56	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 2	2005	280	35					30916	30923		10.1074/jbc.M414482200	http://dx.doi.org/10.1074/jbc.M414482200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	958ZX	15870077	hybrid			2022-12-25	WOS:000231487800033
J	Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM				Yamaguchi, K; Uzzo, RG; Pimkina, J; Makhov, P; Golovine, K; Crispen, P; Kolenko, VM			Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis	ONCOGENE			English	Article						selenium; TRAIL; apoptosis; prostate; cancer	NF-KAPPA-B; DEATH RECEPTOR; BAD PHOSPHORYLATION; SIGNALING COMPLEX; TNF RECEPTOR; LIGAND TRAIL; LINE LNCAP; VITAMIN-E; IN-VIVO; C-FLIP	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytotoxic agent that preferentially induces apoptosis in a variety of human cancer cells. Unfortunately, some tumor cells remain resistant to TRAIL. Therefore, agents that sensitize malignant cells to TRAIL-mediated cell death might be of particular importance for the development of novel antitumor therapeutic regimens. Recent studies establish a critical role of selenium in prostate cancer prevention in vitro and in vivo. Here, we demonstrate that concomitant administration of TRAIL and methylseleninic acid (MSA) produces synergistic effects on the induction of apoptosis in androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells. MSA rapidly and specifically downregulates expression of the cellular FLICE inhibitory protein, a negative regulator of death receptor signaling. In addition, we demonstrate that the synergistic effects of MSA and TRAIL result from the activation of the mitochondrial pathway-mediated amplification loop. Addition of MSA effectively blocked TRAIL-mediated BAD phosphorylation at Ser112 and Ser136 in DU-145 cells and was accompanied by induction of the mitochondrial permeability transition and release of apoptogenic cytochrome c and Smac/DIABLO proteins from the mitochondria and into the cytosol. These results suggest that selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prostate cancer cells.	Fox Chase Canc Ctr, Dept Urol Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kolenko, VM (corresponding author), Fox Chase Canc Ctr, Dept Urol Oncol, 333 Cottman Ave,W329, Philadelphia, PA 19111 USA.	vm_kolenko@fccc.edu	Crispen, Paul/AGE-5677-2022; Uzzo, Robert G./U-5238-2019					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; CHINNAIYAN AM, 1995, CELL, V81, P512; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Deeb D, 2004, MOL CANCER THER, V3, P803; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Dong Y, 2003, CANCER RES, V63, P52; Dong Y, 2002, CANCER RES, V62, P708; Dramsi S, 2002, J BIOL CHEM, V277, P6399, DOI 10.1074/jbc.M109990200; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gupta S, 2003, INT J ONCOL, V22, P15; He Q, 2002, CANCER BIOL THER, V1, P287, DOI 10.4161/cbt.83; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; IP C, 1990, CANCER RES, V50, P1206; Ip C, 2000, CANCER RES, V60, P2882; IP C, 1991, CANCER RES, V51, P595; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang C, 2001, CANCER RES, V61, P3062; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kim T, 2001, CARCINOGENESIS, V22, P559, DOI 10.1093/carcin/22.4.559; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Klein EA, 2003, UROL ONCOL-SEMIN ORI, V21, P59, DOI 10.1016/S1078-1439(02)00301-0; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203; Taghiyev AF, 2003, MOL CANCER RES, V1, P500; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Venkateswaran V, 2002, CANCER RES, V62, P2540; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wu GS, 1999, CANCER RES, V59, P2770; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003; Zu K, 2003, CANCER RES, V63, P6988	57	61	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5868	5877		10.1038/sj.onc.1208742	http://dx.doi.org/10.1038/sj.onc.1208742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897871				2022-12-25	WOS:000231590400009
J	Marinova, Z; Vukojevic, V; Surcheva, S; Yakovleva, T; Cebers, G; Pasikova, N; Usynin, I; Hugonin, L; Fang, WJ; Hallberg, M; Hirschberg, D; Bergman, T; Langel, U; Hauser, KF; Pramanik, A; Aldrich, JV; Terenius, L; Bakalkin, G				Marinova, Z; Vukojevic, V; Surcheva, S; Yakovleva, T; Cebers, G; Pasikova, N; Usynin, I; Hugonin, L; Fang, WJ; Hallberg, M; Hirschberg, D; Bergman, T; Langel, U; Hauser, KF; Pramanik, A; Aldrich, JV; Terenius, L; Bakalkin, G			Translocation of dynorphin neuropeptides across the plasma membrane - A putative mechanism of signal transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; CLATHRIN-MEDIATED ENDOCYTOSIS; RAT HINDLIMB PARALYSIS; DELTA-OPIOID RECEPTORS; DNA-BINDING PROTEINS; TAT-FUSION PROTEINS; SPINAL-CORD INJURY; ENDOPLASMIC-RETICULUM; PHOSPHOLIPID-VESICLES; SUBSTANCE-P	Several peptides, including penetratin and Tat, are known to translocate across the plasma membrane. Dynorphin opioid peptides are similar to cell-penetrating peptides in a high content of basic and hydrophobic amino acid residues. We demonstrate that dynorphin A and big dynorphin, consisting of dynorphins A and B, can penetrate into neurons and non-neuronal cells using confocal fluorescence microscopy/immunolabeling. The peptide distribution was characterized by cytoplasmic labeling with minimal signal in the cell nucleus and on the plasma membrane. Translocated peptides were associated with the endoplasmic reticulum but not with the Golgi apparatus or clathrin-coated endocytotic vesicles. Rapid entry of dynorphin A into the cytoplasm of live cells was revealed by fluorescence correlation spectroscopy. The translocation potential of dynorphin A was comparable with that of transportan-10, a prototypical cell-penetrating peptide. A central big dynorphin fragment, which retains all basic amino acids, and dynorphin B did not enter the cells. The latter two peptides interacted with negatively charged phospholipid vesicles similarly to big dynorphin and dynorphin A, suggesting that interactions of these peptides with phospholipids in the plasma membrane are not impaired. Translocation was not mediated via opioid receptors. The potential of dynorphins to penetrate into cells correlates with their ability to induce non-opioid effects in animals. Translocation across the plasma membrane may represent a previously unknown mechanism by which dynorphins can signal information to the cell interior.	Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Dependence Res, S-17176 Stockholm, Sweden; Med Univ, Fac Med, Dept Pharmacol, Sofia 1431, Bulgaria; Astra Zeneca R&D Sodertalje, Gen Toxicol Sc Safety Assessment, SE-15185 Sodertalje, Sweden; Stockholm Univ, Arrhenius Lab, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Kansas, Sch Pharm, Dept Med Chem, Lawrence, KS 66045 USA; Uppsala Univ, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17176 Stockholm, Sweden; Stockholm Univ, Arrhenius Labs, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Karolinska Institutet; Medical University Sofia; AstraZeneca; Stockholm University; University of Kansas; Uppsala University; Karolinska Institutet; Stockholm University; University of Kentucky	Bakalkin, G (corresponding author), Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Dependence Res, S-17176 Stockholm, Sweden.	Georgy.Bakalkin@cmm.ki.se	Hirschberg, Daniel/J-3133-2014; Vukojevic, Vladana B/AAY-3144-2021; Usynin, Ivan F/A-4945-2017; Pasikova, Natalia/K-2056-2018; Hauser, Kurt/AAX-8361-2020	Hirschberg, Daniel/0000-0002-1136-9802; Vukojevic, Vladana/0000-0003-0873-5653; Langel, Ulo/0000-0001-6107-0844; Bakalkin, Georgy/0000-0002-8074-9833; Usynin, Ivan/0000-0003-1752-9034; Hauser, Kurt/0000-0001-7886-0332				Alford DR, 1996, INT J PEPT PROT RES, V47, P84; Andria ML, 2001, MOL BRAIN RES, V91, P73, DOI 10.1016/S0169-328X(01)00124-3; BAKALKIN GY, 1991, INT J PEPT PROT RES, V38, P505; BAKALKIN GY, 1991, FEBS LETT, V282, P175, DOI 10.1016/0014-5793(91)80471-E; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BURTON PS, 1992, J CONTROL RELEASE, V19, P87, DOI 10.1016/0168-3659(92)90067-2; Cahill CM, 2001, J COMP NEUROL, V440, P65, DOI 10.1002/cne.1370; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; CEBERS G, 1995, EUR J PHARM-MOLEC PH, V290, P105, DOI 10.1016/0922-4106(95)90022-5; CHAHL LA, 1986, EUR J PHARMACOL, V124, P343, DOI 10.1016/0014-2999(86)90237-2; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; CHRISTENSSONNYLANDER I, 1985, REGUL PEPTIDES, V11, P65, DOI 10.1016/0167-0115(85)90032-1; Christiaens B, 2004, EUR J BIOCHEM, V271, P1187, DOI 10.1111/j.1432-1033.2004.04022.x; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; Costigan M, 2002, CELL, V108, P297, DOI 10.1016/S0092-8674(02)00640-2; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P14; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; De Vries TJ, 2002, J NEUROSCI, V22, P3321; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Douliez JP, 2000, BBA-BIOMEMBRANES, V1467, P65, DOI 10.1016/S0005-2736(00)00197-8; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200; Fischer R, 2002, BBA-BIOMEMBRANES, V1564, P365, DOI 10.1016/S0005-2736(02)00471-6; FISCHLI W, 1982, P NATL ACAD SCI-BIOL, V79, P5435, DOI 10.1073/pnas.79.17.5435; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gad H, 1998, NEURON, V21, P607, DOI 10.1016/S0896-6273(00)80570-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hauser KF, 2005, FRONT BIOSCI-LANDMRK, V10, P216, DOI 10.2741/1522; Holt M, 2003, J NEUROSCI, V23, P1329, DOI 10.1523/JNEUROSCI.23-04-01329.2003; Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kim CS, 2004, J BIOL CHEM, V279, P46464, DOI 10.1074/jbc.M403633200; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Kreek MJ, 2001, ANN NY ACAD SCI, V937, P27; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lindhout DA, 2004, BIOPOLYMERS, V75, P367, DOI 10.1002/bip.20150; LONG JB, 1989, BRAIN RES, V497, P155, DOI 10.1016/0006-8993(89)90982-7; Lorenz D, 1998, J GEN PHYSIOL, V112, P577, DOI 10.1085/jgp.112.5.577; Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450; Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; Magzoub M, 2003, BIOPHYS CHEM, V103, P271, DOI 10.1016/S0301-4622(02)00321-6; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P12553, DOI 10.1021/bi00039a009; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Mkrtchian S, 1998, EUR J BIOCHEM, V251, P304, DOI 10.1046/j.1432-1327.1998.2510304.x; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; Mueller VJ, 2004, J NEUROSCI, V24, P2004, DOI 10.1523/JNEUROSCI.4080-03.2004; Naito A, 2004, CURR TOP MED CHEM, V4, P135, DOI 10.2174/1568026043451645; Naito A, 2002, BBA-BIOMEMBRANES, V1558, P34, DOI 10.1016/S0005-2736(01)00420-5; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Oehlke J, 2005, J MOL RECOGNIT, V18, P50, DOI 10.1002/jmr.691; Persson D, 2004, BBA-BIOMEMBRANES, V1665, P142, DOI 10.1016/j.bbamem.2004.07.008; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; Prochiantz A, 2003, NAT REV MOL CELL BIO, V4, P814, DOI 10.1038/nrm1227; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Reznikov K, 2000, FASEB J, V14, P1754, DOI 10.1096/fj.99-0890com; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Saban R, 2002, AM J PHYSIOL-RENAL, V283, pF616, DOI 10.1152/ajprenal.00096.2002; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SHANAHAN F, 1984, J ALLERGY CLIN IMMUN, V74, P499, DOI 10.1016/0091-6749(84)90385-3; SHUKLA VK, 1994, TRENDS PHARMACOL SCI, V15, P420, DOI 10.1016/0165-6147(94)90091-4; SUGIYAMA K, 1984, JPN J PHARMACOL, V35, P247, DOI 10.1254/jjp.35.247; SYDBOM A, 1988, N-S ARCH PHARMACOL, V338, P567, DOI 10.1007/BF00179331; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tan-No K, 2002, BRAIN RES, V952, P7, DOI 10.1016/S0006-8993(02)03180-3; Tan-No K, 2005, PAIN, V113, P301, DOI 10.1016/j.pain.2004.11.004; TAYLOR JW, 1990, BIOCHEMISTRY-US, V29, P5364, DOI 10.1021/bi00474a023; Teng HB, 2000, J NEUROSCI, V20, P7986; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Tessmer MR, 1997, BIOCHEMISTRY-US, V36, P1971, DOI 10.1021/bi961457h; Tessmer MR, 1997, J PEPT RES, V49, P427; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304-3959(96)03225-3; Veach RA, 2004, J BIOL CHEM, V279, P11425, DOI 10.1074/jbc.M311089200; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vukojevic V, 2005, CELL MOL LIFE SCI, V62, P535, DOI 10.1007/s00018-004-4305-7; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wang H, 2001, J NEUROSCI, V21, P3242, DOI 10.1523/JNEUROSCI.21-09-03242.2001; Wang ZJ, 2001, J NEUROSCI, V21, P1779, DOI 10.1523/JNEUROSCI.21-05-01779.2001; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wilkinson RS, 2004, TRENDS NEUROSCI, V27, P171, DOI 10.1016/j.tins.2004.01.011; Wu LG, 2004, TRENDS NEUROSCI, V27, P548, DOI 10.1016/j.tins.2004.07.001; Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004; Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S0006-291X(03)01167-7; Zhang SW, 1998, J PHARMACOL EXP THER, V286, P136	97	46	52	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26360	26370		10.1074/jbc.M412494200	http://dx.doi.org/10.1074/jbc.M412494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15894804	hybrid			2022-12-25	WOS:000230386800052
J	Tahboub, YR; Galijasevic, S; Diamond, MP; Abu-Soud, HM				Tahboub, YR; Galijasevic, S; Diamond, MP; Abu-Soud, HM			Thiocyanate modulates the catalytic activity of mammalian peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EOSINOPHIL PEROXIDASE; RAY CRYSTAL-STRUCTURE; MYELOPEROXIDASE COMPOUNDS I; HYDROGEN-PEROXIDE; NITRIC-OXIDE; ANGSTROM RESOLUTION; MOLECULAR-CLONING; COMPOUND-II; CHLORINATING ACTIVITY; HUMAN LACTOPEROXIDASE	We investigated the potential role of the co-substrate, thiocyanate (SCN-), in modulating the catalytic activity of myeloperoxidase (MPO) and other members of the mammalian peroxidase superfamily ( lactoperoxidase (LPO) and eosinophil peroxidase (EPO)). Pre-incubation of SCN- with MPO generates a more complex biological setting, because SCN- serves as either a substrate or inhibitor, causing diverse impacts on the MPO heme iron microenvironment. Consistent with this hypothesis, the relationship between the association rate constant of nitric oxide binding to MPO-Fe(III) as a function of SCN- concentration is bell-shaped, with a trough comparable with normal SCN- plasma levels. Rapid kinetic measurements indicate that MPO, EPO, and LPO Compound I formation occur at rates slower than complex decay, and its formation serves to simultaneously catalyze SCN- via 1e(-) and 2e(-) oxidation pathways. For the three enzymes, Compound II formation is a fundamental feature of catalysis and allows the enzymes to operate at a fraction of their possible maximum activities. MPO and EPO Compound II is relatively stable and decays gradually within minutes to ground state upon H2O2 exhaustion. In contrast, LPO Compound II is unstable and decays within seconds to ground state, suggesting that SCN- may serve as a substrate for Compound II. Compound II formation can be partially or completely prevented by increasing SCN- concentration, depending on the experimental conditions. Collectively, these results illustrate for the first time the potential mechanistic differences of these three enzymes. A modified kinetic model, which incorporates our current findings with the mammalian peroxidases classic cycle, is presented.	Wayne State Univ, CS Mott Ctr Human Growth & Dev, Dept Obstet & Gynecol, Detroit, MI 48201 USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Abu-Soud, HM (corresponding author), Wayne State Univ, CS Mott Ctr Human Growth & Dev, Dept Obstet & Gynecol, 275 E Hancock, Detroit, MI 48201 USA.	habusoud@med.wayne.edu		Diamond, Michael/0000-0001-6353-4489; Galijasevic, Semira/0000-0001-5799-4219	NHLBI NIH HHS [HL066367] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P10747, DOI 10.1021/bi010478v; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; Adak S, 1997, J BIOL CHEM, V272, P11049; AGNER K, 1963, ACTA CHEM SCAND, V17, pS332; ANDREWS PC, 1982, J BIOL CHEM, V257, P13240; Arlandson M, 2001, J BIOL CHEM, V276, P215, DOI 10.1074/jbc.M004881200; Arnhold J, 2003, REDOX REP, V8, P179, DOI 10.1179/135100003225002664; AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; BARRICK D, 1995, CURR OPIN BIOTECH, V6, P411, DOI 10.1016/0958-1669(95)80070-0; BELDING ME, 1970, SCIENCE, V167, P195, DOI 10.1126/science.167.3915.195; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P189, DOI 10.1016/0167-4838(84)90127-4; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CARLSTROM A, 1969, ACTA CHEM SCAND, V23, P185, DOI 10.3891/acta.chem.scand.23-0185; CAULFIELD JP, 1980, J CELL BIOL, V86, P46, DOI 10.1083/jcb.86.1.46; CHUNG J, 1970, ARCH BIOCHEM BIOPHYS, V141, P73, DOI 10.1016/0003-9861(70)90108-6; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DeGioia L, 1996, J BIOL INORG CHEM, V1, P476; DEMONTELLANO O, 1992, ANN REV PHARM TOXICO, V32, P89; DUGAD LB, 1990, J BIOL CHEM, V265, P7173; DULL TJ, 1990, DNA CELL BIOL, V9, P499, DOI 10.1089/dna.1990.9.499; Dunford HB, 1999, BIOCHEM CELL BIOL, V77, P449, DOI 10.1139/bcb-77-5-449; Ferrari RP, 1997, J INORG BIOCHEM, V68, P17, DOI 10.1016/S0162-0134(97)00003-2; FERRARI RP, 1995, J INORG BIOCHEM, V58, P109, DOI 10.1016/0162-0134(94)00041-8; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Furtmuller PG, 2004, JPN J INFECT DIS, V57, pS30; Furtmuller PG, 2002, BIOCHEMISTRY-US, V41, P11895, DOI 10.1021/bi026326x; Furtmuller PG, 2000, BIOCHEMISTRY-US, V39, P15578, DOI 10.1021/bi0020271; HOOGLAND H, 1988, BIOCHIM BIOPHYS ACTA, V955, P337, DOI 10.1016/0167-4838(88)90213-0; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; HUGHES MN, 1975, CHEM BIOCH THIOCYANI, P1; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P1; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MODI S, 1991, BIOCHEMISTRY-US, V30, P118, DOI 10.1021/bi00215a018; NAUSEEF WM, 1986, BLOOD, V67, P1504; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; Petrides PE, 1998, J MOL MED, V76, P688, DOI 10.1007/s001090050269; PRUITT KM, 1982, BIOCHIM BIOPHYS ACTA, V704, P204, DOI 10.1016/0167-4838(82)90147-9; PRUITT KM, 1982, BIOCHEMISTRY-US, V21, P562, DOI 10.1021/bi00532a023; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; Reiter B., 1991, PEROXIDASES CHEM BIO, P143; Sharonov YA, 1995, FEBS LETT, V377, P512, DOI 10.1016/0014-5793(95)01409-8; STELMASZYNSKA T, 1974, EUR J BIOCHEM, V45, P305, DOI 10.1111/j.1432-1033.1974.tb03555.x; TAYLOR KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P635, DOI 10.1006/abbi.1995.1083; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; THAYER JR, 1980, ANAL BIOCHEM, V102, P110, DOI 10.1016/0003-2697(80)90325-5; THOMAS EL, 1981, BIOCHEMISTRY-US, V20, P3273, DOI 10.1021/bi00514a045; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Ueda T, 1997, EUR J BIOCHEM, V243, P32, DOI 10.1111/j.1432-1033.1997.0032a.x; van Dalen CJ, 2001, BIOCHEM J, V358, P233, DOI 10.1042/0264-6021:3580233; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEVER R, 1981, FEBS LETT, V123, P327, DOI 10.1016/0014-5793(81)80320-1; WOLFSON LM, 1993, J FOOD PROTECT, V56, P887, DOI 10.4315/0362-028X-56.10.887; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZGLICZYNSKI JM, 1977, P SOC EXP BIOL MED, V154, P418	73	51	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26129	26136		10.1074/jbc.M503027200	http://dx.doi.org/10.1074/jbc.M503027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15894800	hybrid			2022-12-25	WOS:000230386800025
J	Zhu, H; Shuman, S				Zhu, H; Shuman, S			Novel 3 '-ribonuclease and 3 '-phosphatase activities of the bacterial non-homologous end-joining protein, DNA ligase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 POLYNUCLEOTIDE KINASE; ACID PHOSPHATASE-EXONUCLEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REPAIR SYSTEM; KU; POLYMERASE; MECHANISM; PRIMASE; ENZYME	Pseudomonas aeruginosa DNA ligase D (PaeLigD) exemplifies a family of bacterial DNA end-joining proteins that consist of a ligase domain fused to a polymerase domain and a putative nuclease module. The LigD polymerase preferentially adds single ribonucleotides at blunt DNA ends and, as we show here, is also capable of adding up to 4 ribonucleotides to a DNA primer-template. We report that PaeLigD has an intrinsic ability to resect the short tract of 3'-ribonucleotides of a primer-template substrate to the point at which the primer strand has a single 3'-ribonucleotide remaining. The failure to digest beyond this point reflects a requirement for a 2'-OH group on the penultimate nucleoside of the primer strand. Replacing the 2'-OH by a 2'-F, 2'-NH2, 2'-OCH3, or 2'-H abolishes the resection reaction. The ribonucleotide resection activity resides within a 187-amino acid N-terminal nuclease domain and is the result of at least two component steps: (i) the 3'-terminal nucleoside is first removed to yield a primer strand with a ribonucleoside 3'-PO4 terminus, and (ii) the 3'-PO4 is hydrolyzed to a 3'-OH. The 3'-ribonuclease and 3'-phosphatase activities are both dependent on a divalent cation, specifically manganese. PaeLigD preferentially remodels the 3'-ends of a duplex primer-template substrate rather than a single strand of identical composition, and it prefers DNA primer strands containing a short 3'-ribonucleotide tract to an all-RNA primer. The nuclease domain of PaeLigD and its bacterial homologs has no apparent structural or mechanistic similarity to previously characterized nucleases. Thus, we surmise that it exemplifies a novel phosphoesterase family, defined in part by conserved residues Asp-50, Arg-52, and His-84, which are essential for the 3'-ribonuclease and 3'-phosphatase reactions.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; Bebenek K, 2005, J BIOL CHEM, V280, P20051, DOI 10.1074/jbc.M501981200; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Cheng Y, 2004, J MOL BIOL, V343, P305, DOI 10.1016/j.jmb.2004.08.055; Cheng ZF, 2002, J BIOL CHEM, V277, P21624, DOI 10.1074/jbc.M202942200; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Doherty AJ, 2001, FEBS LETT, V500, P186, DOI 10.1016/S0014-5793(01)02589-3; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; Ito N, 2003, GENES CELLS, V8, P913, DOI 10.1111/j.1365-2443.2003.00693.x; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lipps G, 2004, NAT STRUCT MOL BIOL, V11, P157, DOI 10.1038/nsmb723; Martins A, 2004, J BIOL CHEM, V279, P18220, DOI 10.1074/jbc.M313386200; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200; Zhu H, 2004, J BIOL CHEM, V279, P26358, DOI 10.1074/jbc.M403200200; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	28	47	48	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					25973	25981		10.1074/jbc.M504002200	http://dx.doi.org/10.1074/jbc.M504002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15897197	hybrid			2022-12-25	WOS:000230386800005
J	Hammond, LE; Neschen, S; Romanelli, AJ; Cline, GW; Ilkayeva, OR; Shulman, GI; Muoio, DM; Coleman, RA				Hammond, LE; Neschen, S; Romanelli, AJ; Cline, GW; Ilkayeva, OR; Shulman, GI; Muoio, DM; Coleman, RA			Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; ELEMENT-BINDING PROTEINS; DIET-INDUCED OBESITY; INSULIN-RESISTANCE; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; ESCHERICHIA-COLI; GENE-EXPRESSION; RAT-TISSUES; MICE	In vitro studies suggest that the mitochondrial glycerol-3-phosphate acyltransferase-1 (mtGPAT1) isoform catalyzes the initial and rate-controlling step in glycerolipid synthesis and aids in partitioning acyl-CoAs toward triacylglycerol synthesis and away from degradative pathways. To determine whether the absence of mtGPAT1 would increase oxidation of acyl-CoAs and restrict the development of hepatic steatosis, we fed wild type and mtGPAT1(-/-) mice a diet high in fat and sucrose (HH) for 4 months to induce the development of obesity and a fatty liver. Control mice were fed a diet low in fat and sucrose (LL). With the HH diet, absence of mtGPAT1 resulted in increased partitioning of acyl-CoAs toward oxidative pathways, demonstrated by 60% lower hepatic triacylglycerol content and 2-fold increases in plasma beta-hydroxybutyrate, acylcarnitines, and hepatic mRNA expression of mitochondrial HMG-CoA synthase. Despite the increase in fatty acid oxidation, liver acyl-CoA levels were 3-fold higher in the mtGPAT1(-/-) mice fed both diets. A lack of difference in CPT1 and FAS mRNA expression between genotypes suggested that the increased acyl-CoA content was not because of increased de novo synthesis, but instead, to an impaired ability to use long-chain acyl-CoAs derived from the diet, even when the dietary fat content was low. Hyperinsulinemia and reduced glucose tolerance on the HH diet was greater in the mtGPAT1(-/-) mice, which did not suppress the expression of the gluconeogenic genes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. This study demonstrates that mtGPAT1 is essential for normal acyl-CoA metabolism, and that the absence of hepatic mtGPAT1 results in the partitioning of fatty acids away from triacylglycerol synthesis and toward oxidation and ketogenesis.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Dept Canc Biol, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Yale University; Howard Hughes Medical Institute; Yale University; Duke University; Duke University	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, 2301 Hooker Res Bldg, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Shulman, Gerald I./P-7176-2019; Adiels, Martin/C-9278-2011; Muoio, Debbie Marie/E-1147-2012	Shulman, Gerald I./0000-0003-1529-5668; Muoio, Deborah/0000-0003-3760-9277	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK056350, U24DK059635, R01DK056598, K01DK067200, P30DK045735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020920] Funding Source: NIH RePORTER; NIDDK NIH HHS [U24 DK59635, P30 DK45735, K01 DK67200, R01 DK040936, DK56350, DK40936, DK56598] Funding Source: Medline; NIGMS NIH HHS [F31 GM20920] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Bell RM, 1983, ENZYMES, V16, P87; Black BL, 1998, METABOLISM, V47, P1354, DOI 10.1016/S0026-0495(98)90304-3; BLACK PN, 1994, BBA-LIPID LIPID MET, V1210, P123, DOI 10.1016/0005-2760(94)90113-9; Bonnefont JP, 1999, MOL GENET METAB, V68, P424, DOI 10.1006/mgme.1999.2938; BREMER J, 1976, MOL CELL BIOCHEM, V12, P113, DOI 10.1007/BF01731557; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; HARDIE DG, 1997, BIOCHEM SOC T, V25, P1226; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; KELKER HC, 1979, J BIOL CHEM, V254, P5364; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; LEWIN TM, 2004, AM J PHYSIOL, V288, pE835; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; MONROY G, 1973, J BIOL CHEM, V248, P2845; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; STEIN TP, 1984, AM J PHYSIOL, V246, P277; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; Thuresson Eva Rupp, 2004, Curr Opin Investig Drugs, V5, P411; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Waters KM, 1997, BBA-LIPID LIPID MET, V1349, P33, DOI 10.1016/S0005-2760(97)00069-6; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029; Zammit VA, 2001, J NUTR, V131, P2074, DOI 10.1093/jn/131.8.2074	46	85	93	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25629	25636		10.1074/jbc.M503181200	http://dx.doi.org/10.1074/jbc.M503181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878874	hybrid			2022-12-25	WOS:000230207900042
J	Eyers, PA; Liu, JJ; Hayashi, NR; Lewellyn, AL; Gautier, J; Maller, JL				Eyers, PA; Liu, JJ; Hayashi, NR; Lewellyn, AL; Gautier, J; Maller, JL			Regulation of the G(2)/M transition in Xenopus oocytes by the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROGESTIN RECEPTOR; MEIOTIC MATURATION; CATALYTIC SUBUNIT; MAMMALIAN OOCYTES; PROMOTING FACTOR; CELL-CYCLE; AURORA-A; IDENTIFICATION; LAEVIS; INHIBITION	Vertebrate oocytes are arrested in G(2) phase of the cell cycle at the prophase border of meiosis I. Progesterone treatment of Xenopus oocytes releases the G(2) block and promotes entry into the M phases of meiosis I and II. Substantial evidence indicates that the release of the G(2) arrest requires a decrease in cAMP and reduced activity of the cAMP- dependent protein kinase ( PKAc). It has been reported and we confirm here that microinjection of either wild type or kinase- dead K72R PKAc inhibits progesterone- dependent release of the G(2) arrest with equal potency and that inhibition can be reversed by a second injection of the heat- stable inhibitor of PKAc, PKI. However, a mutant enzyme predicted to be completely kinase- dead from the crystal structure of PKAc, K72H PKAc, was much less inhibitory when carrying additional mutations that block interaction with either type I or type II regulatory subunit. Moreover, inhibition by K72H PKAc was reversed by PKI at a 30- fold lower concentration and with more rapid kinetics compared with wild type PKAc. K72R PKAc was found to have low but detectable activity after incubation in an oocyte extract. These results indicate that inhibition of the progesterone- dependent G(2)/ M transition in oocytes after microinjection of dead PKAc reflects either low residual activity or binding to regulatory subunits with a resulting net increase in the level of endogenous wild type PKAc. Consistent with this hypothesis, the induction of mitosis in Xenopus egg extracts by the addition of cyclin B was blocked by wild type PKAc but not by K72H PKAc. The identification of substrates for PKAc that maintain cell cycle arrest in G(2) remains an important goal for future work.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Columbia University	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	Jim.Maller@uchsc.edu	Gautier, jean/A-2774-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743, R01GM056781] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56781, GM26743-24] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Cheng XD, 2001, J BIOL CHEM, V276, P4102, DOI 10.1074/jbc.M006447200; DAAR I, 1993, J CELL BIOL, V120, P1197, DOI 10.1083/jcb.120.5.1197; Duckworth BC, 2002, P NATL ACAD SCI USA, V99, P16794, DOI 10.1073/pnas.222661299; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; GIBSON RM, 1997, J BIOL CHEM, V272, P998; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; HUCHON D, 1981, MOL CELL ENDOCRINOL, V22, P211, DOI 10.1016/0303-7207(81)90092-7; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1979, J BIOL CHEM, V254, P579; Maller JL, 2001, P NATL ACAD SCI USA, V98, P8, DOI 10.1073/pnas.98.1.8; MASARACCHIA RA, 1979, ARCH BIOCHEM BIOPHYS, V194, P1, DOI 10.1016/0003-9861(79)90589-7; Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974; MEIJER L, 1989, DEV BIOL, V133, P58, DOI 10.1016/0012-1606(89)90296-0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Schmitt A, 2002, P NATL ACAD SCI USA, V99, P4361, DOI 10.1073/pnas.022056399; SCHULTZ RM, 1983, DEV BIOL, V97, P264, DOI 10.1016/0012-1606(83)90085-4; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; SPEAKER MG, 1977, NATURE, V267, P848, DOI 10.1038/267848a0; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Wang J, 2004, J CELL SCI, V117, P5107, DOI 10.1242/jcs.01383; Zhong N, 2005, J NEUROSCI, V25, P208, DOI 10.1523/JNEUROSCI.3703-04.2005; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	35	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24339	24346		10.1074/jbc.M412442200	http://dx.doi.org/10.1074/jbc.M412442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15860459	hybrid			2022-12-25	WOS:000230114000007
J	Liu, HQ; Du, X; Wang, M; Huang, QL; Ding, LL; McDonald, HW; Yates, JR; Beutler, B; Horwitz, J; Gong, XH				Liu, HQ; Du, X; Wang, M; Huang, QL; Ding, LL; McDonald, HW; Yates, JR; Beutler, B; Horwitz, J; Gong, XH			Crystallin gamma B-I4F mutant protein binds to alpha-crystallin and affects lens transparency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-D-CRYSTALLIN; AUTOSOMAL-DOMINANT CATARACT; CONGENITAL NUCLEAR CATARACT; HEAT-SHOCK PROTEINS; A-CRYSTALLIN; B-CRYSTALLIN; MISSENSE MUTATION; MOUSE LENS; INHERITED CATARACT; CHAPERONE FUNCTION	A new mouse mutant line, Clapper, identified from N-ethyl-N-nitrosurea (ENU)-mutagenized mice, develops a dominant lamellar cataract. The cataract blocks the image of retinal fundus and transmits a fuzzy fluorescein image of retinal vasculature during angiography. The cataractous lens opacity decreases as the mice age. The Clapper mutation has been identified to be a missense mutation of the gamma B-crystallin gene that replaces the 4th isoleucine residue with a phenylalanine (gamma B-I4F). Unlike wild type gamma B, the gamma B-I4F mutant protein binds to alpha-crystallin to form high molecular weight complexes in vivo and in vitro. Circular dichroism measurements indicate that gamma B-I4F protein is less stable than wild type gamma B at high temperature. Darkly stained aggregates, enlarged interfiber spaces, and disorganized and smaller inner mature fibers were found in the regions of the cataract in homozygous Clapper mutant lenses. Thus, the lamellar cataract is likely due to the light-scattering effects of the enlarged interfiber spaces and protein aggregates caused by gamma B-I4F mutant proteins interacting with alpha-crystallin in the lens.	Univ Calif Berkeley, Vision Sci Program, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, Los Angeles, CA 90095 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Los Angeles; Scripps Research Institute; Scripps Research Institute	Gong, XH (corresponding author), Univ Calif Berkeley, Vision Sci Program, 693 Minor Hall,MC 2020, Berkeley, CA 94720 USA.	xgong@berkeley.edu			NATIONAL EYE INSTITUTE [R01EY012808, R37EY003897, R01EY003897, R01EY013849] Funding Source: NIH RePORTER; NEI NIH HHS [EY03897, EY13849, EY12808] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bateman JB, 2000, INVEST OPHTH VIS SCI, V41, P3278; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Chang B, 1996, GENOMICS, V36, P171, DOI 10.1006/geno.1996.0439; Du X, 2004, GENETICS, V166, P331, DOI 10.1534/genetics.166.1.331; Evans P, 2004, J MOL BIOL, V343, P435, DOI 10.1016/j.jmb.2004.08.050; Ferrini W, 2004, INVEST OPHTH VIS SCI, V45, P1436, DOI 10.1167/iovs.03-0760; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; Graw J, 1999, GENOMICS, V62, P67, DOI 10.1006/geno.1999.5974; Graw J, 2001, INVEST OPHTH VIS SCI, V42, P2909; Graw J, 2001, INVEST OPHTH VIS SCI, V42, P1574; Graw JC, 2004, INVEST OPHTH VIS SCI, V45, P1202, DOI 10.1167/iovs.03-0811; Hawes N L, 1999, Mol Vis, V5, P22; Heon E, 1999, AM J HUM GENET, V65, P1261, DOI 10.1086/302619; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; HORWITZ J, 1997, METHOD ENZYMOL, P365; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Klopp N, 1998, GENOMICS, V52, P152, DOI 10.1006/geno.1998.5417; Kmoch S, 2000, HUM MOL GENET, V9, P1779, DOI 10.1093/hmg/9.12.1779; Liang JJN, 2004, PROTEIN SCI, V13, P2476, DOI 10.1110/ps.04815104; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Litt M, 1997, HUM MOL GENET, V6, P665, DOI 10.1093/hmg/6.5.665; LO WK, 1984, J ULTRA MOL STRUCT R, V86, P228, DOI 10.1016/S0022-5320(84)90103-5; LO WK, 1989, P NATL ACAD SCI USA, V86, P9926, DOI 10.1073/pnas.86.24.9926; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; Mackay DS, 2002, AM J HUM GENET, V71, P1216, DOI 10.1086/344212; Mackay DW, 2004, MOL VIS, V10, P155; Mayer Marcus, 2004, Methods Mol Med, V94, P239; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Pande A, 2001, P NATL ACAD SCI USA, V98, P6116, DOI 10.1073/pnas.101124798; Pras E, 2000, INVEST OPHTH VIS SCI, V41, P3511; Qi YH, 2004, HUM GENET, V114, P192, DOI 10.1007/s00439-003-1049-7; Reddy MA, 2004, HUM MOL GENET, V13, P945, DOI 10.1093/hmg/ddh110; Sandilands A, 2002, EMBO J, V21, P6005, DOI 10.1093/emboj/cdf609; Sathish HA, 2004, J BIOL CHEM, V279, P16425, DOI 10.1074/jbc.M313402200; Shentu XC, 2004, MOL VIS, V10, P233; Sinha D, 2001, J BIOL CHEM, V276, P9308, DOI 10.1074/jbc.M010583200; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255	49	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25071	25078		10.1074/jbc.M502490200	http://dx.doi.org/10.1074/jbc.M502490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878859	hybrid			2022-12-25	WOS:000230114000090
J	Kwon, M; Yoon, CS; Jeong, W; Rhee, SG; Waisman, DM				Kwon, M; Yoon, CS; Jeong, W; Rhee, SG; Waisman, DM			Annexin A2-S100A10 heterotetramer, a novel substrate of thioredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; SINGLE-CHAIN UROKINASE; ALPHA-ENOLASE; II TETRAMER; PHOSPHOGLYCERATE KINASE; ANGIOGENESIS INHIBITOR; ENZYMATIC-ACTIVITY; CELLULAR RECEPTOR; NEOPLASTIC-CELLS; BREAST-CANCER	The binding of plasminogen activators and plasminogen to the cell surface results in the rapid generation of the serine protease plasmin. Plasmin is further degraded by an autoproteolytic reaction, resulting in the release of an angiostatin, A(61) (Lys(78)-Lys(468)). Previously, we demonstrated that the annexin A2-S100A10 heterotetramer (AIIt) stimulates the release of A61 from plasmin by promoting the autoproteolytic cleavage of the Lys(468)-Gly(469) bond and reduction of the plasmin Cys(462)-Cys(541) disulfide ( Kwon, M., Caplan, J. F., Filipenko, N. R., Choi, K. S., Fitzpatrick, S. L., Zhang, L., and Waisman, D. M. ( 2002) J. Biol. Chem. 277, 10903-10911). Mechanistically, it was unclear if AIIt promoted a conformational change in plasmin, resulting in contortion of the plasmin disulfide, or directly reduced the plasmin disulfide. In the present study, we show that AIIt thiols are oxidized during the reduction of plasmin disulfides, establishing that AIIt directly participates in the reduction reaction. Incubation of HT1080 cells with plasminogen resulted in the rapid loss of thiol-specific labeling of AIIt by 3-(N-maleimidopropionyl)biocytin. The plasminogen-dependent oxidation of AIIt could be attenuated by thioredoxin. Thioredoxin reductase catalyzed the transfer of electrons from NADPH to the oxidized thioredoxin, thus completing the flow of electrons from NADPH to AIIt. Therefore, we identify AIIt as a substrate of the thioredoxin system and propose a new model for the role of AIIt in the redox-dependent processing of plasminogen and generation of an angiostatin at the cell surface.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Ewha Womans Univ, Div Mol Life, Seoul 120750, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	University of Calgary; Ewha Womans University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Choi KS, 2003, FASEB J, V17, P235, DOI 10.1096/fj.02-0697com; Choi KS, 2003, MOL B INT U, P218; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; Daly EB, 2004, BBA-MOL CELL RES, V1691, P17, DOI 10.1016/j.bbamcr.2003.11.004; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Duffy MJ, 2002, CLIN CHEM, V48, P1194; Ellis V, 2003, CURR TOP DEV BIOL, V54, P263, DOI 10.1016/S0070-2153(03)54012-1; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Filipenko NR, 2003, MOL B INT U, P127; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Fogg DK, 2002, BIOCHEMISTRY-US, V41, P4953, DOI 10.1021/bi012045y; FOLKMAN J, 1976, SCI AM, V234, P58, DOI 10.1038/scientificamerican0576-58; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; GASDASKA PY, 1994, BBA-GENE STRUCT EXPR, V1218, P292, DOI 10.1016/0167-4781(94)90180-5; Gately S, 1996, CANCER RES, V56, P4887; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gonias Steven L., 2001, Frontiers in Bioscience, V6, pd1403, DOI 10.2741/Gonias; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GRIPPO JF, 1983, J BIOL CHEM, V258, P3658; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; Herren T, 2003, FRONT BIOSCI-LANDMRK, V8, pD1, DOI 10.2741/916; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; JESPERSEN J, 1986, THROMB RES, V41, P395, DOI 10.1016/0049-3848(86)90250-1; Jiang XM, 1999, J BIOL CHEM, V274, P2416, DOI 10.1074/jbc.274.4.2416; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kassam G, 2001, J BIOL CHEM, V276, P8924, DOI 10.1074/jbc.M009071200; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; Kralovich KR, 1998, J PROTEIN CHEM, V17, P845, DOI 10.1023/A:1020738620817; Kwon M, 2003, PLASMINOGEN: STRUCTURE, ACTIVATION AND REGULATION, P135; Kwon M, 2002, J BIOL CHEM, V277, P10903, DOI 10.1074/jbc.M111219200; Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Lay AJ, 2002, J BIOL CHEM, V277, P9062, DOI 10.1074/jbc.M111531200; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MacLeod TJ, 2003, J BIOL CHEM, V278, P25577, DOI 10.1074/jbc.M301017200; MACLEOD TJ, 2005, ANNEXINS, V1, P191; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; Miles LA, 2003, THROMB HAEMOSTASIS, V90, P564; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Moriarty-Craige SE, 2004, ANNU REV NUTR, V24, P481, DOI 10.1146/annurev.nutr.24.012003.132208; Myohanen H, 2004, CELL MOL LIFE SCI, V61, P2840, DOI 10.1007/s00018-004-4230-9; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Plow EF, 2004, TRENDS CARDIOVAS MED, V14, P180, DOI 10.1016/j.tcm.2004.04.001; Pluskota E, 2004, J BIOL CHEM, V279, P18063, DOI 10.1074/jbc.M310462200; RAKOCZI I, 1978, BIOCHIM BIOPHYS ACTA, V540, P295, DOI 10.1016/0304-4165(78)90142-3; REDLITZ A, 1995, BAILLIERE CLIN HAEM, V8, P313, DOI 10.1016/S0950-3536(05)80270-7; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; ROUY D, 1990, BIOCHEM J, V271, P51, DOI 10.1042/bj2710051; RUBARTELLI A, 1995, CANCER RES, V55, P675; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; Soderberg A, 2000, CANCER RES, V60, P2281; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; Wang H, 2004, CANCER RES, V64, P162, DOI 10.1158/0008-5472.CAN-03-1862; Williams CH, 2000, EUR J BIOCHEM, V267, P6101, DOI 10.1046/j.1432-1327.2000.01700.x; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	78	28	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23584	23592		10.1074/jbc.M504325200	http://dx.doi.org/10.1074/jbc.M504325200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849182	hybrid			2022-12-25	WOS:000229880000023
J	Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA				Jebar, AH; Hurst, CD; Tomlinson, DC; Johnston, C; Taylor, CF; Knowles, MA			FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma	ONCOGENE			English	Article						bladder cancer; FGFR3; HRAS; NRAS; KRAS2; mutation	GROWTH-FACTOR RECEPTOR-3; HUMAN BLADDER CANCERS; HUMAN URINARY-BLADDER; CODON 12 MUTATION; H-RAS; TISSUE-CULTURE; K-RAS; N-RAS; LINES; ACTIVATION	Fibroblast growth factor receptor 3 (FGFR3) mutations are frequent in superficial urothelial cell carcinoma (UCC). Ras gene mutations are also found in UCC. As oncogenic activation of both FGFR3 and Ras is predicted to result in stimulation of the mitogen-activated protein kinase ( MAPK) pathway, we hypothesized that these might be mutually exclusive events. HRAS mutation has been widely studied in UCC, but all three Ras gene family members have not been screened for mutation in the same sample series. We screened 98 bladder tumours and 31 bladder cell lines for mutations in FGFR3, HRAS, NRAS and KRAS2. FGFR3 mutations were present in 54 tumours (55%) and three cell lines (10%), and Ras gene mutations in 13 tumours (13%) and four cell lines (13%). These included mutations in all three Ras genes; ten in HRAS, four in KRAS2 and four in NRAS and these were not associated with either tumour grade or stage. In no cases were Ras and FGFR3 mutation found together. This mutual exclusion suggests that FGFR3 and Ras gene mutation may represent alternative means to confer the same phenotype on UCC cells. If these events have biological equivalence, Ras mutant invasive UCC may represent a novel subgroup.	St Jamess Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St Jamess Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		/0000-0002-3081-7850; Tomlinson, Darren/0000-0003-4134-7484; Knowles, Margaret/0000-0002-9363-8657				Ayan S., 2001, International Urology and Nephrology, V33, P363, DOI 10.1023/A:1015213713048; Bakkar AA, 2003, CANCER RES, V63, P8108; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CZERNIAK B, 1990, BRIT J CANCER, V62, P762, DOI 10.1038/bjc.1990.374; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIOTT AY, 1974, JNCI-J NATL CANCER I, V53, P1341, DOI 10.1093/jnci/53.5.1341; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; GRIMMOND SM, 1992, UROL RES, V20, P121, DOI 10.1007/BF00296523; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Huang MY, 1997, ONCOL RES, V9, P611; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Knowles MA, 1999, BJU INT, V84, P412; KNOWLES MA, 1993, CANCER RES, V53, P133; KYRIAZIS AA, 1984, CANCER RES, V44, P3997; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; MASTERS JRW, 1986, CANCER RES, V46, P3630; NAYAK SK, 1977, BRIT J CANCER, V35, P142, DOI 10.1038/bjc.1977.21; Olderoy G, 1998, ANTICANCER RES, V18, P2675; OOI A, 1994, INT J ONCOL, V4, P85; OTOOLE C, 1978, BRIT J CANCER, V38, P64, DOI 10.1038/bjc.1978.164; OTOOLE C, 1976, INT J CANCER, V17, P707, DOI 10.1002/ijc.2910170604; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; PAULIE S, 1983, INT J CANCER, V31, P297, DOI 10.1002/ijc.2910310308; Pratsinis H, 1998, IN VITRO CELL DEV-AN, V34, P722; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Przybojewska B, 2000, CANCER GENET CYTOGEN, V121, P73, DOI 10.1016/S0165-4608(00)00223-5; RASHEED S, 1977, J NATL CANCER I, V58, P881, DOI 10.1093/jnci/58.4.881; REZNIKOFF CA, 1993, SEMIN CANCER BIOL, V4, P143; REZNIKOFF CA, 1988, CARCINOGENESIS, V9, P1427, DOI 10.1093/carcin/9.8.1427; RIGBY CC, 1970, BRIT J CANCER, V24, P746, DOI 10.1038/bjc.1970.89; Sarkar S, 2000, CANCER RES, V60, P3862; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; TACHIBANA M, 1995, CANCER RES, V55, P3438; Taylor Claire F, 2004, Methods Mol Med, V92, P9; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Tzeng CC, 1996, ANTICANCER RES, V16, P1797; UCHIDA T, 1995, UROL INT, V55, P63, DOI 10.1159/000282753; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2001, CANCER RES, V61, P1265; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER HE, 1990, ONCOGENE, V5, P557; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS RD, 1980, INVEST UROL, V17, P359; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315	55	248	274	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5218	5225		10.1038/sj.onc.1208705	http://dx.doi.org/10.1038/sj.onc.1208705			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897885				2022-12-25	WOS:000230964600008
J	Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M				Lesca, C; Germanier, M; Raynaud-Messina, B; Pichereaux, C; Etievant, C; Emond, S; Burlet-Schiltz, O; Monsarrat, B; Wright, M; Defais, M			DNA damage induce gamma-tubulin-RAD51 nuclear complexes in mammalian cells	ONCOGENE			English	Article						DNA lesions; Rad51 recombinase complex; gamma-tubulin; nuclear foci	GAMMA-TUBULIN COMPLEXES; STRAND BREAK REPAIR; HUMAN RAD51 PROTEIN; HOMOLOGOUS RECOMBINATION; MICROTUBULE NUCLEATION; MITOTIC SPINDLE; CANCER SUSCEPTIBILITY; IONIZING-RADIATION; CHROMOSOMAL BREAKS; CENTROSOME	Rad51 protein plays an essential role in recombination repair of DNA double-strand breaks and DNA cross-linking adducts. It is part of complexes which can vary with the stage of the cell cycle and the nature of the DNA lesions. During a search for Rad51-associated proteins in CHO nuclear extracts of S-phase cells by mass spectrometry of proteins immunoprecipitated with Rad51 antibodies, we identified a centrosomal protein, c-tubulin. This association was confirmed by the reverse immunoprecipitation with gamma-tubulin antibodies. Both proteins copurified from HeLa cells nuclear extracts following a tandem affinity purification of double-tagged Rad51. Immuno. fluorescence analysis showed colocalization of both Rad51 and gamma-tubulin in discrete foci in mammalian cell nuclei. The number of colocalized foci and their overlapping area increased in the presence of DNA damage produced by genotoxic treatments either during S phase or in exponentially growing cells. These variations did not result from an overall stress because microtubule cytoskeleton poisons devoid of direct interactions with DNA, such as taxol or colcemid, did not lead to an increase of this association. The recruitment of Rad51 and gamma-tubulin in the same nuclear complex suggests a link between DNA recombination repair and the centrosome function during the cell cycle.	Univ Toulouse 3, CNRS, UMR 5089, IPBS, F-31077 Toulouse, France; CNRS, ISTMT, CRPS, UMR2587, F-31400 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Defais, M (corresponding author), Univ Toulouse 3, CNRS, UMR 5089, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.	martine.defais@ipbs.fr		Emond, Stephane/0000-0002-5160-0917; Schiltz, Odile/0000-0002-3606-2356; Pichereaux, Carole/0000-0002-7559-5358				Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Job D, 2003, CURR OPIN CELL BIOL, V15, P111, DOI 10.1016/S0955-0674(02)00003-0; JULIAN M, 1993, J CELL SCI, V105, P145; Korver W, 2003, INT J CANCER, V104, P283, DOI 10.1002/ijc.10945; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Kukharskyy V, 2004, EXP CELL RES, V298, P218, DOI 10.1016/j.yexcr.2004.04.016; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Linke SP, 2003, CANCER RES, V63, P2596; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Maacke H, 2000, INT J CANCER, V88, P907, DOI 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4; MARGULIS TN, 1974, J AM CHEM SOC, V96, P899, DOI 10.1021/ja00810a041; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rios RM, 2004, CELL, V118, P323; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	60	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5165	5172		10.1038/sj.onc.1208723	http://dx.doi.org/10.1038/sj.onc.1208723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897881				2022-12-25	WOS:000230964600003
J	Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N				Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N			Role of type I receptors for anti-Mullerian hormone in the SMAT-1 Sertoli cell line	ONCOGENE			English	Article						anti-Mullerian hormone; Mullerian inhibiting substance; transforming growth factor-beta; receptors; activin-like kinases; Smad	INHIBITING SUBSTANCE; DUCT REGRESSION; TRANSDUCTION PATHWAY; SEXUAL DEVELOPMENT; SMAD PROTEINS; MEMBRANE; DIFFERENTIATION; MECHANISMS; EXPRESSION; MUTATION	Anti-Mullerian hormone (AMH) is a member of the transforming growth factor-beta family responsible for regression of Mullerian ducts during male sexual differentiation and for regulation of gonadal steroidogenesis. AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins, suggesting that AMH and BMPs could also share type I receptors, namely activin-like kinases (ALKs)2, 3 or 6. However, attempts to identify a unique AMH type I receptor among them were unsuccessful. Here, using kinase-deficient type I receptors and small interfering RNA technology, we demonstrate that, in an AMH Sertoli target cell line, ALK3 mediates AMH effects on both Smad1 activation and P450 side-chain cleavage enzyme. In addition, transfecting a combination of normal and kinase-deficient receptors, we show that ALK2 can compensate for the absence of ALK3 and probably acts in synergy with ALK3 at high concentrations of AMH to activate Smad1, whereas ALK6 has a competitive inhibitory effect. These results are a first step in understanding how AMH transduces its effects in immature Sertoli cells.	Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	di Clemente, N (corresponding author), Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, Rue Carnets, F-92140 Clamart, France.	nathalie.diclemente@inserm.ipsc.u-psud.fr	Jamin, Soazik P./K-1507-2019; Jamin, Soazik/F-6796-2015	Jamin, Soazik P./0000-0002-1688-0167; belville, corinne/0000-0002-7841-214X; di Clemente, Nathalie/0000-0001-9087-3486				Allard S, 2000, DEVELOPMENT, V127, P3349; Aoki H, 2001, J CELL SCI, V114, P1483; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dutertre M, 1997, MOL CELL ENDOCRINOL, V136, P57, DOI 10.1016/S0303-7207(97)00214-1; Dutertre M, 2001, ENDOCRINOLOGY, V142, P4040, DOI 10.1210/en.142.9.4040; Faure E, 1996, J BIOL CHEM, V271, P30571, DOI 10.1074/jbc.271.48.30571; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Hay E, 2004, J BIOL CHEM, V279, P1650, DOI 10.1074/jbc.M300969200; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Jamin SP, 2003, MOL CELL ENDOCRINOL, V211, P15, DOI 10.1016/j.mce.2003.09.006; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Josso N, 2003, TRENDS ENDOCRIN MET, V14, P91, DOI 10.1016/S1043-2760(03)00005-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Long WQ, 2000, J CLIN ENDOCR METAB, V85, P540, DOI 10.1210/jc.85.2.540; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Messika-Zeitoun L, 2001, J CLIN ENDOCR METAB, V86, P4390, DOI 10.1210/jc.86.9.4390; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; VIGIER B, 1984, ENDOCRINOLOGY, V114, P1315, DOI 10.1210/endo-114-4-1315; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239	27	35	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4984	4992		10.1038/sj.onc.1208686	http://dx.doi.org/10.1038/sj.onc.1208686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897891				2022-12-25	WOS:000230646500011
J	Chiu, PCN; Chung, MK; Tsang, HY; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB				Chiu, PCN; Chung, MK; Tsang, HY; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB			Glycodelin-S in human seminal plasma reduces cholesterol efflux and inhibits capacitation of spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FOLLICULAR-FLUID; PROTEIN-TYROSINE PHOSPHORYLATION; DEFENSE SYSTEM HYPOTHESIS; ALBUMIN-MEDIATED CHANGES; HUMAN SPERM CAPACITATION; HUMAN CERVICAL-MUCUS; ZONA-PELLUCIDA; BIOLOGICAL-ACTIVITY; BETA-LACTOGLOBULIN; BINDING-PROPERTIES	Tight control of sperm capacitation is important for successful fertilization. Glycodelin-S is one of the most abundant glycoproteins in the human seminal plasma. However, its function is unclear. We investigated the role of glycodelin-S on capacitation of human spermatozoa. Binding kinetics experiments demonstrated the presence of two saturable and reversible binding sites of glycodelin-S on human spermatozoa. Differently glycosylated other isoforms of glycodelin, glycodelin-A and -F, did not compete with glycodelin-S for these binding sites, suggesting that the glycodelin-S binding sites are different from those of the other isoforms. Indirect immunofluorescent staining revealed specific binding of glycodelin-S around the sperm head. This immunoreactivity was greatly reduced in spermatozoa that had migrated through the cervical mucus surrogates. Glycodelin-S at physiological concentrations significantly reduced the bovine serum albumin and cyclodextrin-induced cholesterol efflux and down-regulated the adenylyl cyclase/protein kinase A/tyrosine kinase signaling pathway, resulting in suppression of capacitation. Deglycosylation abolished glycodelin-S binding and the effect of glycodelin-S on bovine serum albumin-induced capacitation. This indicates that the carbohydrate moiety of glycodelin-S is critical for the function of the molecule. It is concluded that glycodelin-S in seminal plasma maintains the uncapacitated state of human spermatozoa.	Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Cent Hosp, Dept Obstet & Gynaecol, Helsinki 00029, Finland; Univ Cent Hosp, Dept Clin Chem, Helsinki 00029, Finland	University of Hong Kong; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Yeung, WSB (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	wsbyeung@hkucc.hku.hk	Chung, Man Kin/B-9613-2012; /C-7476-2009; Chiu, Chi Ngong/C-4245-2009; Koistinen, Hannu/AGU-1279-2022; Seppala, Markku/AAT-6618-2021; Lee, Calvin Kai Fai/C-4328-2009	Chung, Man Kin/0000-0003-4239-4311; Chiu, Chi Ngong/0000-0001-6217-1970; Koistinen, Hannu/0000-0003-0926-3109; Lee, Calvin Kai Fai/0000-0001-5957-439X				AMANN RP, 1993, REPROD FERT DEVELOP, V5, P361, DOI 10.1071/RD9930361; Bajpai M, 2003, REPRODUCTION, V126, P183, DOI 10.1530/rep.0.1260183; BEDFORD JM, 1962, AM J PHYSIOL, V202, P179, DOI 10.1152/ajplegacy.1962.202.1.179; Calogero AE, 1998, HUM REPROD, V13, P911, DOI 10.1093/humrep/13.4.911; Chiu PCN, 2003, BIOL REPROD, V69, P365, DOI 10.1095/biolreprod.102.012658; Chiu PCN, 2003, J BIOL CHEM, V278, P13570, DOI 10.1074/jbc.M212086200; Chiu PCN, 2002, MOL REPROD DEV, V61, P205, DOI 10.1002/mrd.1149; Choi YH, 1998, BIOL REPROD, V59, P1328, DOI 10.1095/biolreprod59.6.1328; Clark GF, 1997, MOL HUM REPROD, V3, P5, DOI 10.1093/molehr/3.1.5; Clark GF, 1996, HUM REPROD, V11, P467, DOI 10.1093/HUMREP/11.3.467; COHENDAYAG A, 1995, P NATL ACAD SCI USA, V92, P11039, DOI 10.1073/pnas.92.24.11039; Cross NL, 1999, MOL REPROD DEV, V53, P92, DOI 10.1002/(SICI)1098-2795(199905)53:1<92::AID-MRD11>3.3.CO;2-H; Cross NL, 1998, BIOL REPROD, V59, P7, DOI 10.1095/biolreprod59.1.7; DAVIS BK, 1980, P NATL ACAD SCI-BIOL, V77, P1546, DOI 10.1073/pnas.77.3.1546; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; Dutta B, 2001, REPROD FERT DEVELOP, V13, P111, DOI 10.1071/RD00119; Feki NC, 2004, MOL HUM REPROD, V10, P137, DOI 10.1093/molehr/gah018; Flesch FM, 2001, J CELL SCI, V114, P3543; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fraser LR, 2004, HUM REPROD, V19, P596, DOI 10.1093/humrep/deh126; Gipson IK, 2001, FRONT BIOSCI-LANDMRK, V6, pD1245, DOI 10.2741/Gipson; GO KJ, 1985, BIOL REPROD, V32, P145, DOI 10.1095/biolreprod32.1.145; Greube A, 2001, BIOCHEMISTRY-US, V40, P8326, DOI 10.1021/bi010552+; Harrison RAP, 2005, THERIOGENOLOGY, V63, P342, DOI 10.1016/j.theriogenology.2004.09.016; Hong SJ, 2004, HUM REPROD, V19, P1562, DOI 10.1093/humrep/deh281; Hong SJ, 2003, FERTIL STERIL, V79, P802, DOI 10.1016/S0015-0282(02)04832-X; Ivic A, 2002, HUM REPROD, V17, P143, DOI 10.1093/humrep/17.1.143; KATZ DF, 1991, AM J OBSTET GYNECOL, V165, P1984, DOI 10.1016/S0002-9378(11)90559-6; Koistinen H, 2000, J ANDROL, V21, P636; Koistinen H, 1999, FEBS LETT, V450, P158, DOI 10.1016/S0014-5793(99)00490-1; Kontopidis G, 2004, J DAIRY SCI, V87, P785, DOI 10.3168/jds.S0022-0302(04)73222-1; KOPF GS, 1991, ELEMENTS MAMMALIAN F, V1, P153; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; Lopes CHGL, 1998, GLYCOCONJUGATE J, V15, P477, DOI 10.1023/A:1006982919464; Martinez P, 1996, FRONT BIOSCI, V1, P103; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; MOTAMED KA, 2000, J ANDROL, V21, P586; NEUWINGER J, 1991, HUM REPROD, V6, P396, DOI 10.1093/oxfordjournals.humrep.a137348; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; Osheroff JE, 1999, MOL HUM REPROD, V5, P1017, DOI 10.1093/molehr/5.11.1017; OVERSTREET JW, 1991, SEMIN PERINATOL, V15, P149; PERRY RL, 1995, FERTIL STERIL, V64, P150; Pockley A G, 1989, Symp Soc Exp Biol, V43, P317; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; Seppala M, 2002, ENDOCR REV, V23, P401, DOI 10.1210/er.2001-0026; SETCHELL BP, 1974, EUR J OBSTET GYN R B, V4, P1, DOI 10.1016/0028-2243(74)90003-3; TANPHAICHITR N, 1988, GAMETE RES, V20, P67, DOI 10.1002/mrd.1120200107; TESARIK J, 1986, J ULTRA MOL STRUCT R, V97, P227, DOI 10.1016/S0889-1605(86)80022-2; Travis AJ, 2002, J CLIN INVEST, V110, P731, DOI [10.1172/JCI200216392, 10.1172/JCI0216392]; Vigne JL, 2001, J BIOL CHEM, V276, P17101, DOI 10.1074/jbc.M010451200; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; WISTROM CA, 1993, DEV BIOL, V159, P679; World Health Organization, 1999, WHO LAB MAN EX HUM S; YANAGIMACHI R, 1994, PHYSL MAMALIAN REPRO, P10; Yao Y, 1999, FERTIL STERIL, V71, P232, DOI 10.1016/S0015-0282(98)00430-0	56	70	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25580	25589		10.1074/jbc.M504103200	http://dx.doi.org/10.1074/jbc.M504103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15883155	hybrid			2022-12-25	WOS:000230207900036
J	El-Mounayri, O; Triplett, JW; Yates, CW; Herring, BP				El-Mounayri, O; Triplett, JW; Yates, CW; Herring, BP			Regulation of smooth muscle-specific gene expression by homeodomain proteins, Hoxa10 and Hoxb8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN EXPRESSION; CELL-DIFFERENTIATION; TELOKIN EXPRESSION; TRANSGENIC MICE; HOMEOBOX GENES; GROWTH-FACTOR; DNA-BINDING; PROMOTER; TRANSCRIPTION	Smooth muscle cells arise from different populations of precursor cells during embryonic development. The mechanisms that specify the smooth muscle cell phenotype in each of these populations of cells are largely unknown. In many tissues and organs, homeodomain transcription factors play a key role in directing cell specification. However, little is known about how these proteins regulate smooth muscle differentiation. Using degenerate reverse transcription- PCR coupled to cDNA library screening we identified two homeodomain proteins, Hoxa10 and Hoxb8, which are expressed in adult mouse smooth muscle tissues. All three of the previously described transcripts of the Hoxa10 gene, Hoxa10- 1, Hoxa10- 2, and Hoxa10- 3, were identified. Hoxa10- 1 directly activated the smooth muscle- specific telokin promoter but did not activate the SM22 alpha, smooth muscle alpha- actin, or smooth muscle myosin heavy chain promoters. Small interfering RNA- mediated knock- down of Hoxa10- 1 demonstrated that Hoxa10- 1 is required for high levels of telokin expression in smooth muscle cells from uterus and colon. On the other hand, Hoxb8 inhibited the activity of the telokin, SM22 alpha, and smooth muscle alpha-actin promoters. Cotransfection of Hoxa10- 1 together with Hoxa10- 2 or Hoxb8 suggested that Hoxa10- 2 and Hoxb8 act as competitive inhibitors of Hoxa10- 1. Results from gel mobility shift assays demonstrated that Hoxa10- 1, Hoxa10- 2, and Hoxb8 bind directly to multiple sites in the telokin promoter. Mutational analysis of telokin promoter reporter genes demonstrated that the three homeodomain protein binding sites located between -80 and -75, +2 and +6, and +14 and +17 were required for maximal promoter activation by Hoxa10- 1 and maximal inhibition by Hoxb8. Together these data demonstrate that the genes encoding smooth muscle restricted proteins are direct transcriptional targets of clustered homeodomain proteins and that different homeodomain proteins have distinct effects on the promoters of these genes.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Herring, BP (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pherring@iupui.edu			NHLBI NIH HHS [HL58571] Funding Source: Medline; NIDDK NIH HHS [DK65644, DK61130] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065644, R01DK061130] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagot CN, 2001, DEV DYNAM, V222, P538, DOI 10.1002/dvdy.1209; BENSON GV, 1995, MOL CELL BIOL, V15, P1591; Bergwerff M, 1998, CIRC RES, V82, P221; Bostrom K, 2000, J CELL BIOCHEM, V78, P210, DOI 10.1002/(SICI)1097-4644(20000801)78:2<210::AID-JCB4>3.0.CO;2-Z; Care A, 1996, MOL CELL BIOL, V16, P4842; Carson JA, 2000, J BIOL CHEM, V275, P39061, DOI 10.1074/jbc.M006532200; Cermik D, 2001, J CLIN ENDOCR METAB, V86, P3387, DOI 10.1210/jc.86.7.3387; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Forlani S, 2003, DEVELOPMENT, V130, P3807, DOI 10.1242/dev.00573; Gorski DH, 2001, CIRC RES, V88, P7, DOI 10.1161/01.RES.88.1.7; Gorski DH, 2000, CIRC RES, V87, P865, DOI 10.1161/01.RES.87.10.865; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Herring BP, 2001, AM J PHYSIOL-CELL PH, V280, pC12, DOI 10.1152/ajpcell.2001.280.1.C12; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Hoggatt AM, 2002, CIRC RES, V91, P1151, DOI 10.1161/01.RES.0000047508.30800.4F; ITO K, 1993, DEV BIOL, V156, P191, DOI 10.1006/dbio.1993.1069; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; Miano JM, 1996, P NATL ACAD SCI USA, V93, P900, DOI 10.1073/pnas.93.2.900; Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Oyama Y, 2004, ARTERIOSCL THROM VAS, V24, P1602, DOI 10.1161/01.ATV.0000138404.17519.45; Pitera JE, 1999, GASTROENTEROLOGY, V117, P1339, DOI 10.1016/S0016-5085(99)70284-2; Qian J, 1996, DEV DYNAM, V207, P135; Roberts DJ, 2000, DEV DYNAM, V219, P109, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1047>3.3.CO;2-Y; Santini S, 2003, GENOME RES, V13, P1111, DOI 10.1101/gr.700503; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Sundberg LJ, 2003, J BIOL CHEM, V278, P29783, DOI 10.1074/jbc.M303771200; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Taylor HS, 1999, HUM REPROD, V14, P1328, DOI 10.1093/humrep/14.5.1328; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; Xu R, 2003, AM J PHYSIOL-HEART C, V284, pH1398, DOI 10.1152/ajpheart.00737.2002; Yin F, 2005, J BIOL CHEM, V280, P4745, DOI 10.1074/jbc.M411585200; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; Zhou JL, 2005, J BIOL CHEM, V280, P10861, DOI 10.1074/jbc.M411586200	45	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25854	25863		10.1074/jbc.M501044200	http://dx.doi.org/10.1074/jbc.M501044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886193	hybrid			2022-12-25	WOS:000230207900067
J	Lookene, A; Beckstead, JA; Nilsson, S; Olivecrona, G; Ryan, RO				Lookene, A; Beckstead, JA; Nilsson, S; Olivecrona, G; Ryan, RO			Apolipoprotein A-V-heparin interactions - Implications for plasma lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; SULFATE PROTEOGLYCANS; LIPASE; GENE; MICE; TRIGLYCERIDES; HYPERTRIGLYCERIDEMIA; HYDROLYSIS	Transgenic and gene disruption experiments in mice have revealed that apolipoprotein (apo) A-V is a potent regulator of plasma triglyceride (TG) levels. To investigate the molecular basis of apoA-V function, the ability of isolated recombinant apoA-V to modulate lipoprotein lipase (LPL) activity was examined in vitro. With three distinct lipid substrate particles, including very low-density lipoprotein (VLDL), a TG/phospholipid emulsion, or dimyristoylphosphatidylcholine liposomes, apoA-V had little effect on LPL activity. In the absence or presence apolipoprotein C-II, apoA-V marginally inhibited LPL activity. On the other hand, apoA-V-dimyristoylphosphatidylcholine disc particles bound to heparin-Sepharose and were specifically eluted upon application of a linear gradient of NaCl. The interaction of apoA-V with sulfated glycosaminoglycans was further studied by surface plasmon resonance spectroscopy. ApoA-V showed strong binding to heparin-coated chips, and binding was competed by free heparin. ApoA-V enrichment enhanced binding of apoC-II-deficient chylomicrons and VLDL to heparin-coated chips. When LPL was first bound to the heparin-coated chip, apoA-V-enriched chylomicrons showed binding. Finally, human pre-and post-heparin plasma samples were subjected to immunoblot analysis with anti- apoA-V IgG. No differences in the amount of apoA-V present were detected. Taken together, the results show that apoA-V lipid complexes bind heparin and, when present on TG-rich lipoprotein particles, may promote their association with cell surface heparan sulfate proteoglycans. Through such interactions, apoA-V may indirectly affect LPL activity, possibly explaining its inverse correlation with plasma TG levels.	Childrens Hosp, Oakland Res Inst, Lipid Biol Hlth & Dis Res Grp, Oakland, CA 94609 USA; Umea Univ, Dept Med Biosci Physiol Chem, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Umea University; Tallinn University of Technology	Ryan, RO (corresponding author), Childrens Hosp, Oakland Res Inst, Lipid Biol Hlth & Dis Res Grp, 747 52nd St, Oakland, CA 94609 USA.	rryan@chori.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073061] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 073061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; Bengtsson-Olivecrona G., 1992, PRACTICAL APPROACH S, P169; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI ZS, 1994, J BIOL CHEM, V269, P2764; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Mahley RW, 1999, J LIPID RES, V40, P1; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; Olivecrona T., 2000, HDB LIPOPROTEIN TEST, P479; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; ROJAS C, 1991, EUR J BIOCHEM, V197, P315, DOI 10.1111/j.1432-1033.1991.tb15913.x; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200	20	101	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25383	25387		10.1074/jbc.M501589200	http://dx.doi.org/10.1074/jbc.M501589200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878877	hybrid			2022-12-25	WOS:000230207900011
J	Togashi, M; Nguyen, P; Fletterick, R; Baxter, JD; Webb, P				Togashi, M; Nguyen, P; Fletterick, R; Baxter, JD; Webb, P			Rearrangements in thyroid hormone receptor charge clusters that stabilize bound 3,5 ',5-triiodo-L-thyronine and inhibit homodimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; RETINOID-X-RECEPTOR; CRYSTAL-STRUCTURE; DNA-BINDING; COREPRESSOR RELEASE; MOLECULAR-BASIS; RESISTANCE; SURFACE; HETERODIMERIZATION; DIMERIZATION	In this study, we investigated how thyroid hormone (3,5', 5-triiodo-L-thyronine, T-3) inhibits binding of thyroid hormone receptor (TR) homodimers, but not TR-retinoid X receptor heterodimers, to thyroid hormone response elements. Specifically we asked why a small subset of TR beta mutations that arise in resistance to thyroid hormone syndrome inhibit both T3 binding and formation of TR beta homodimers on thyroid hormone response elements. We reasoned that these mutations may affect structural elements involved in the coupling of T3 binding to inhibition of TR DNA binding activity. Analysis of TR x-ray structures revealed that each of these resistance to thyroid hormone syndrome mutations affects a cluster of charged amino acids with potential for ionic bond formation between oppositely charged partners. Two clusters (1 and 2) are adjacent to the dimer surface at the junction of helices 10 and 11. Targeted mutagenesis of residues in Cluster 1 (Arg(338), Lys(342), Asp(351), and Asp(355)) and Cluster 2 (Arg(429), Arg(383), and Glu(311)) confirmed that the clusters are required for stable T3 binding and for optimal TR homodimer formation on DNA but also revealed that different arrangements of charged residues are needed for these effects. We propose that the charge clusters are homodimer-specific extensions of the dimer surface and further that T3 binding promotes specific rearrangements of these surfaces that simultaneously block homodimer formation on DNA and stabilize the bound hormone. Our data yield insight into the way that T3 regulates TR DNA binding activity and also highlight hitherto unsuspected T-3-dependent conformational changes in the receptor ligand binding domain.	Univ Calif San Francisco, Sch Med, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Webb, P (corresponding author), Univ Calif San Francisco, Sch Med, Ctr Diabet, HSW1210,513 Parnassus Ave, San Francisco, CA 94143 USA.	webbp@itsa.ucsf.edu	Togashi, Marie/L-3092-2018	Togashi, Marie/0000-0002-0886-8766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51281, DK41482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando S, 1996, J ENDOCRINOL, V151, P293, DOI 10.1677/joe.0.1510293; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; Baxter JD, 2001, J STEROID BIOCHEM, V76, P31, DOI 10.1016/S0960-0760(01)00052-8; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHATTERJEE VKK, 1994, BAILLIERE CLIN ENDOC, V8, P267; Clifton-Bligh RJ, 1998, MOL ENDOCRINOL, V12, P609, DOI 10.1210/me.12.5.609; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Glass CK, 2000, GENE DEV, V14, P121; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huber BR, 2003, MOL ENDOCRINOL, V17, P643, DOI 10.1210/me.2002-0095; Huber BR, 2003, MOL ENDOCRINOL, V17, P107, DOI 10.1210/me.2002-0097; KITAJIMA K, 1995, THYROID, V5, P343, DOI 10.1089/thy.1995.5.343; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; Liang FQ, 2003, J BIOL CHEM, V278, P15073, DOI 10.1074/jbc.M207593200; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PERUTZ MF, 1989, TRENDS BIOCHEM SCI, V14, P42, DOI 10.1016/0968-0004(89)90039-X; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Strop P, 2000, BIOCHEMISTRY-US, V39, P1251, DOI 10.1021/bi992257j; Takeda T, 1999, BIOCHIMIE, V81, P297, DOI 10.1016/S0300-9084(99)80074-1; Takeda T, 2000, THYROID, V10, P11, DOI 10.1089/thy.2000.10.11; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wagner RL, 2001, MOL ENDOCRINOL, V15, P398, DOI 10.1210/me.15.3.398; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Webb P, 2002, J STEROID BIOCHEM, V83, P59, DOI 10.1016/S0960-0760(02)00270-4; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Wondisford FE, 2003, J INVEST MED, V51, P215, DOI 10.1136/jim-51-04-22; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	45	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25665	25673		10.1074/jbc.M501615200	http://dx.doi.org/10.1074/jbc.M501615200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15886199	hybrid, Green Published			2022-12-25	WOS:000230207900047
J	Amstutz, P; Binz, HK; Parizek, P; Stumpp, MT; Kohl, A; Grutter, MG; Forrer, P; Pluckthun, C				Amstutz, P; Binz, HK; Parizek, P; Stumpp, MT; Kohl, A; Grutter, MG; Forrer, P; Pluckthun, C			Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIBIOTIC-RESISTANCE; BINDING-PROTEINS; PEPTIDE INHIBITORS; GENETIC SELECTION; CRYSTAL-STRUCTURE; CHAIN ANTIBODIES; RIBOSOME DISPLAY; PHAGE DISPLAY; IN-VITRO; EXPRESSION	The specific intracellular inhibition of protein activity at the protein level allows the determination of protein function in the cellular context. We demonstrate here the use of designed ankyrin repeat proteins as tailor-made intracellular kinase inhibitors. The target was aminoglycoside phosphotransferase (3')-IIIa (APH), which mediates resistance to aminoglycoside antibiotics in pathogenic bacteria and shares structural homology with eukaryotic protein kinases. Combining a selection and screening approach, we isolated 198 potential APH inhibitors from highly diverse combinatorial libraries of designed ankyrin repeat proteins. A detailed analysis of several inhibitors revealed that they bind APH with high specificity and with affinities down to the subnanomolar range. In vitro, the most potent inhibitors showed complete enzyme inhibition, and in vivo, a phenotype comparable with the gene knockout was observed, fully restoring antibiotic sensitivity in resistant bacteria. These results underline the great potential of designed ankyrin repeat proteins for modulation of intracellular protein function.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Forrer, P (corresponding author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	pforrer@bioc.unizh.ch; plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Forrer, Patrik/0000-0002-9717-0991; Binz, Hans Kaspar/0000-0003-0702-2280				Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Boehr DD, 2001, J BIOL CHEM, V276, P23929, DOI 10.1074/jbc.M100540200; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burk DL, 2002, PHARMACOL THERAPEUT, V93, P283, DOI 10.1016/S0163-7258(02)00197-3; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Colas P, 2000, P NATL ACAD SCI USA, V97, P13720, DOI 10.1073/pnas.97.25.13720; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Daigle DM, 1997, J BIOL CHEM, V272, P24755, DOI 10.1074/jbc.272.40.24755; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Dove A, 2002, NAT BIOTECHNOL, V20, P121, DOI 10.1038/nbt0202-121; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Forrer P, 1998, GENE, V224, P45, DOI 10.1016/S0378-1119(98)00538-1; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; Hanes J, 1998, P NATL ACAD SCI USA, V95, P14130, DOI 10.1073/pnas.95.24.14130; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Huang WZ, 2000, J BIOL CHEM, V275, P14964, DOI 10.1074/jbc.M001285200; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kamb A, 2001, CURR OPIN CHEM BIOL, V5, P74, DOI 10.1016/S1367-5931(00)00160-5; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kohl A, 2003, P NATL ACAD SCI USA, V100, P1700, DOI 10.1073/pnas.0337680100; KOHL A, 2005, IN PRESS STRUCTURE; Koide A, 1998, J MOL BIOL, V284, P1141, DOI 10.1006/jmbi.1998.2238; Koide A, 2002, P NATL ACAD SCI USA, V99, P1253, DOI 10.1073/pnas.032665299; Kotra LP, 2000, ANTIMICROB AGENTS CH, V44, P3249, DOI 10.1128/AAC.44.12.3249-3256.2000; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lobato MN, 2003, TRENDS MOL MED, V9, P390, DOI 10.1016/S1471-4914(03)00163-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1995, J BIOL CHEM, V270, P24686, DOI 10.1074/jbc.270.42.24686; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Nord K, 1997, NAT BIOTECHNOL, V15, P772, DOI 10.1038/nbt0897-772; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAMBROOK J, 1989, MOL CLONING LAB HDB; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stoop AA, 2003, NAT BIOTECHNOL, V21, P1063, DOI 10.1038/nbt860; Sun J, 2003, BIOCHEMISTRY-US, V42, P892, DOI 10.1021/bi026878f; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Visintin M, 2004, J IMMUNOL METHODS, V290, P135, DOI 10.1016/j.jim.2004.04.014; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Xu LH, 2002, CHEM BIOL, V9, P933, DOI 10.1016/S1074-5521(02)00187-4	54	95	106	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24715	24722		10.1074/jbc.M501746200	http://dx.doi.org/10.1074/jbc.M501746200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851475	hybrid			2022-12-25	WOS:000230114000052
J	Gudderra, NP; Ribeiro, JMC; Andersen, JF				Gudderra, NP; Ribeiro, JMC; Andersen, JF			Structural determinants of factor IX(a) binding in nitrophorin 2, a lipocalin inhibitor of the intrinsic coagulation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUG RHODNIUS-PROLIXUS; SURFACE-PLASMON RESONANCE; OXIDE TRANSPORT PROTEIN; BLOOD-FEEDING INSECT; NITRIC-OXIDE; CRYSTAL-STRUCTURE; BLOODSUCKING BUG; HIGH-AFFINITY; HEME PROTEIN; GLA DOMAIN	Nitrophorin 2 (NP2) is a salivary lipocalin from Rhodnius prolixus that binds with coagulation factors IX (fIX) and IXa (fIXa). Binding of NP2 with fIXa results in potent inhibition of the intrinsic factor Xase complex. A panel of site-directed surface mutants of NP2 was generated to locate determinants of high affinity fIX( a) binding. The locations of the mutations were based on comparisons with the related, but less potent, inhibitor nitrophorin 3 (NP3). Three point mutants (K21A, K92A, and V94A) were found that clearly reduced the inhibitory potency as measured by the activity of a reconstituted factor Xase system. Binding of NP2 with fIXa and fIX as measured by surface plasmon resonance and isothermal titration calorimetry was reduced in a similar manner. Of the three mutants, two (K92A and V94A) were located on the loop connecting beta-strands E and F of the lipocalin beta-barrel. The largest changes were seen with the K92A mutation, which lies at the apex of the loop, with a smaller effect being seen with mutation of Val(94). Combination of four E-F loop mutations (K92A, A93K, V94A, E97A) in a single mutant reduced the inhibitory potency and binding to levels similar to those seen with NP3 without affecting heme or histamine binding.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Andersen, JF (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Twinbrook 3 Bldg,12735 Twinbrook Pkwy, Bethesda, MD 20892 USA.	jandersen@niaid.nih.gov	Martinelli, ida/J-2287-2015	Martinelli, ida/0000-0001-9218-3622; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen JF, 2000, BIOCHEMISTRY-US, V39, P10118, DOI 10.1021/bi000766b; Andersen JF, 1997, BIOCHEMISTRY-US, V36, P4423, DOI 10.1021/bi9628883; Andersen JF, 1998, STRUCTURE, V6, P1315, DOI 10.1016/S0969-2126(98)00131-2; Andersen JF, 2000, J BIOL CHEM, V275, P30496, DOI 10.1074/jbc.M002857200; Andersen JF, 2004, BIOCHEMISTRY-US, V43, P6987, DOI 10.1021/bi049655t; Andersen JF, 2003, J BIOL CHEM, V278, P4611, DOI 10.1074/jbc.M211438200; Blostein MD, 2003, J BIOL CHEM, V278, P31297, DOI 10.1074/jbc.M302840200; Disalvo EA, 1996, CHEM PHYS LIPIDS, V84, P35, DOI 10.1016/S0009-3084(96)02617-5; Flower DR, 1996, BIOCHEM J, V318, P1; Francischetti IMB, 2000, J BIOL CHEM, V275, P12639, DOI 10.1074/jbc.275.17.12639; Francischetti IMB, 2002, BIOCHEMISTRY-US, V41, P3810, DOI 10.1021/bi011015s; FREEDMAN SJ, 1995, J BIOL CHEM, V270, P7980, DOI 10.1074/jbc.270.14.7980; Huang MD, 2004, J BIOL CHEM, V279, P14338, DOI 10.1074/jbc.M314011200; Isawa H, 2000, J BIOL CHEM, V275, P6636, DOI 10.1074/jbc.275.9.6636; Jenny NS, 1998, THROMBOSIS HEMORRHAG, P3; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; Montfort WR, 2000, BBA-PROTEIN STRUCT M, V1482, P110, DOI 10.1016/S0167-4838(00)00165-5; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1994, J EXP MED, V180, P2251, DOI 10.1084/jem.180.6.2251; Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P61, DOI 10.1016/j.ibmb.2003.09.004; RIBEIRO JMC, 1995, BIOCHEM J, V308, P243, DOI 10.1042/bj3080243; Roberts SA, 2001, BIOCHEMISTRY-US, V40, P11327, DOI 10.1021/bi0109257; Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; Sun JX, 1996, THROMB HAEMOSTASIS, V75, P573; Weichsel A, 1998, NAT STRUCT BIOL, V5, P304, DOI 10.1038/nsb0498-304; Weichsel A, 2000, NAT STRUCT BIOL, V7, P551, DOI 10.1038/76769; Zhang Y, 1998, BIOCHEMISTRY-US, V37, P10681, DOI 10.1021/bi973050y	29	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25022	25028		10.1074/jbc.M504386200	http://dx.doi.org/10.1074/jbc.M504386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866866	hybrid			2022-12-25	WOS:000230114000086
J	Nanda, N; Bao, M; Lin, H; Clauser, K; Komuves, L; Quertermous, T; Conley, PB; Phillips, DR; Hart, MJ				Nanda, N; Bao, M; Lin, H; Clauser, K; Komuves, L; Quertermous, T; Conley, PB; Phillips, DR; Hart, MJ			Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SCAVENGER RECEPTOR; EXPRESSION; DIMERIZATION; DOMAINS; BINDING; SHC	The present study was designed to identify novel membrane proteins that signal during platelet aggregation. Because one putative mechanism for signaling by a membrane protein involves phosphorylation, we used oligonucleotide-based microarray analyses and mass spectrometric proteomics techniques to specifically discover membrane proteins and also identify those proteins that become phosphorylated on tyrosine, threonine, or serine residues upon platelet aggregation. Surprisingly, both techniques converged to identify a novel membrane protein we have termed PEAR1 ( platelet endothelial aggregation receptor 1). Sequence analysis of PEAR1 predicts a type-1 membrane protein, 15 extracellular epidermal growth factor-like repeats, and multiple cytoplasmic tyrosines. Analysis of the tissue distribution of PEAR1 showed that it was most highly expressed in platelets and endothelial cells. Upon platelet aggregation induced by physiological agonists, PEAR1 became phosphorylated on tyrosine ( Tyr-925), and serine ( Ser-953 and Ser-1029) residues. PEAR1 tyrosine phosphorylation was blocked by eptifibatide, an alpha(IIb)beta(3) antagonist, which inhibits platelet aggregation. Immune clustering of PEAR1 resulted in PEAR1 phosphorylation. Aggregation-induced PEAR1 tyrosine phosphorylation lead to the subsequent association with the ShcB adaptor protein. Platelet proximity induced by centrifugation also induced PEAR1 tyrosine phosphorylation, a reaction not inhibited by eptifibatide. These data suggest that PEAR1 is a novel platelet receptor that signals secondary to alpha(IIb)beta(3)-mediated platelet-platelet contacts.	Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA; Portola Pharmaceut Inc, San Francisco, CA 94080 USA; Millennium Pharmaceut Inc, San Francisco, CA 94080 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Stanford University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Hart, MJ (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Falk Bldg,CV184,300 Pasteur Dr, Stanford, CA 94305 USA.	mhart@cvmed.stanford.edu		Hart, Matthew/0000-0002-2683-480X; Clauser, Karl/0000-0002-1052-9456; Quertermous, Thomas/0000-0002-7645-9067				Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Klein P, 2004, P NATL ACAD SCI USA, V101, P929, DOI 10.1073/pnas.0307285101; Komuves LG, 2000, J HISTOCHEM CYTOCHEM, V48, P821, DOI 10.1177/002215540004800610; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Li R, 2004, BIOCHEM SOC T, V32, P412, DOI 10.1042/BST0320412; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Phillips DR, 1997, AM J CARDIOL, V80, pB11, DOI 10.1016/S0002-9149(97)00572-9; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Prevost N, 2002, P NATL ACAD SCI USA, V99, P9219, DOI 10.1073/pnas.142053899; Prevost N, 2003, J THROMB HAEMOST, V1, P1613, DOI 10.1046/j.1538-7836.2003.00327.x; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Wasserman SM, 2002, PHYSIOL GENOMICS, V12, P13, DOI 10.1152/physiolgenomics.00102.2002; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	27	110	113	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24680	24689		10.1074/jbc.M413411200	http://dx.doi.org/10.1074/jbc.M413411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15851471	hybrid			2022-12-25	WOS:000230114000048
J	Qiu, S; Hua, YL; Yang, F; Chen, YZ; Luo, JH				Qiu, S; Hua, YL; Yang, F; Chen, YZ; Luo, JH			Subunit assembly of N-methyl-d-aspartate receptors analyzed by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-GATED CHANNELS; HETEROMERIC NMDA RECEPTORS; GLYCINE-BINDING-SITE; GLUTAMATE-RECEPTOR; SURFACE EXPRESSION; MOLECULAR DETERMINANTS; TETRAMERIC STRUCTURE; NR2B SUBUNIT; ION CHANNELS; STOICHIOMETRY	N-methyl-D-aspartate (NMDA) receptors play major roles in synaptic transmission and plasticity, as well as excitotoxicity. NMDA receptors are thought to be tetrameric complexes mainly composed of NMDA receptor (NR)1 and NR2 subunits. The NR1 subunits are required for the formation of functional NMDA receptor channels, whereas the NR2 subunits modify channel properties. Biochemical and functional studies indicate that subunits making up NMDA receptors are organized into a dimer of dimers, and the N termini of the subunits are major determinants for receptor assembling. Here we used a biophysical approach, fluorescence resonance energy transfer, to analyze the assembly of intact, functional NMDA receptors in living cells. The results showed that NR1, NR2A, and NR2B subunits could form homodimers when they were expressed alone in HEK293 cells. Subunit homodimers were also found existing in heteromeric NMDA receptors formed between NR1 and NR2 subunits. These findings are consistent with functional NMDA receptors being arranged as a dimer of dimers. In addition, our data indicated that the conformation of NR1 subunit homodimers was affected by the partner NR2 subunits during the formation of heteromeric receptor complexes, which might underlie the mechanism by which NR2 subunits modify NMDA receptor function.	Zhejiang Univ, Sch Med, Dept Neurobiol, Hangzhou 310031, Zhejiang, Peoples R China	Zhejiang University	Luo, JH (corresponding author), Zhejiang Univ, Sch Med, Dept Neurobiol, 353 Yan an Rd, Hangzhou 310031, Zhejiang, Peoples R China.	luojianhong@zju.edu.cn	Yang, Fan/J-4562-2015; Yang, Fan/AAA-6904-2022; Yang, Fan/C-6586-2012; Zhu, Ren-Yuan/V-8966-2019; Yang, Fan/GYU-4249-2022	Yang, Fan/0000-0002-9406-7710; Yang, Fan/0000-0002-0520-5254; Yang, Fan/0000-0002-9406-7710; Zhu, Ren-Yuan/0000-0003-3091-7461; 				Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; Anson LC, 1998, J NEUROSCI, V18, P581; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Brickley SG, 2003, J NEUROSCI, V23, P4958; Chazot PL, 1997, J NEUROCHEM, V69, P2138; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Dingledine R, 1999, PHARMACOL REV, V51, P7; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Flint AC, 1997, J NEUROSCI, V17, P2469; Greger IH, 2003, NEURON, V40, P763, DOI 10.1016/S0896-6273(03)00668-8; Hall RA, 1997, J NEUROCHEM, V68, P625; Hink MA, 2000, J BIOL CHEM, V275, P17556, DOI 10.1074/jbc.M001348200; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kohr G, 2003, J NEUROSCI, V23, P10791; Kuner T, 2003, TRENDS NEUROSCI, V26, P27, DOI 10.1016/S0166-2236(02)00010-3; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Law AJ, 2003, EUR J NEUROSCI, V18, P1197, DOI 10.1046/j.1460-9568.2003.02850.x; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Luo JH, 2002, NEUROPHARMACOLOGY, V42, P306, DOI 10.1016/S0028-3908(01)00188-5; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Matsuda K, 2003, J NEUROSCI, V23, P10064; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nakagawa T, 2005, NATURE, V433, P545, DOI 10.1038/nature03328; Papadakis M, 2004, J BIOL CHEM, V279, P14703, DOI 10.1074/jbc.M313446200; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Perez-Otano I, 2001, J NEUROSCI, V21, P1228; Prybylowski K, 2004, J BIOL CHEM, V279, P9673, DOI 10.1074/jbc.R300029200; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Tu LW, 1999, BIOPHYS J, V76, P2004, DOI 10.1016/S0006-3495(99)77358-3; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; Zheng J, 2004, NEURON, V42, P411, DOI 10.1016/S0896-6273(04)00253-3; Zheng J, 2003, J NEUROSCI, V23, P8167; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1	57	64	71	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24923	24930		10.1074/jbc.M413915200	http://dx.doi.org/10.1074/jbc.M413915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15888440	hybrid			2022-12-25	WOS:000230114000076
J	Usami, H; Kusano, Y; Kumagai, T; Osada, S; Itoh, K; Kobayashi, A; Yamamoto, M; Uchida, K				Usami, H; Kusano, Y; Kumagai, T; Osada, S; Itoh, K; Kobayashi, A; Yamamoto, M; Uchida, K			Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; YA-SUBUNIT GENE; CHEMICAL HEPATOCARCINOGENESIS; INDUCIBLE EXPRESSION; LIPID-PEROXIDATION; PLACENTAL FORM; IDENTIFICATION; DEGRADATION; PI	Exposure of cells to a wide variety of chemoprotective compounds confers resistance to a broad set of carcinogens. For a subset of the chemoprotective compounds, protection is generated by an increase in the abundance of phase 2 detoxification enzymes such as glutathione S-transferases (GSTs). Transcription factor Nrf2, which is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein-1) under unstimulated conditions, regulates the induction of phase 2 enzymes. In this study, to explore the role of the proteasome in the detoxification response, we tested the effect of proteasome inhibitors such as MG132, clasto-lactacystin beta-lactone, and lactacystin on the induction of GST isozymes and found that these inhibitors selectively induced the class Pi GST isozyme (GST P1). Down-regulation of the proteasome by antisense oligonucleotides or RNA interference indeed resulted in significant up-regulation of GST P1, suggesting that a decline in the proteasome activity could be directly or indirectly linked to the induction of GST P1. From the functional analysis of various deletion constructs of the upstream regulatory region of the GST P1 promoter, GST P1 enhancer I was identified as the response element for proteasome inhibition. Overexpression of the wild-type and dominant-negative forms of Nrf2 and Keap1 had little effect on the induction of GST P1 not only by the proteasome inhibitor, but also by phase 2-inducing isothiocyanate, suggesting that there may be a process of GST P1 induction distinct from other phase 2 gene induction mechanisms. Because GST P1 is highly and specifically induced during early hepatocarcinogenesis as well as in hepatocellular carcinoma cells, these data may provide a potential critical role for the proteasome in the induction of a cellular defense program associated with carcinogenesis.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan; Osaka Univ, Grad Sch Pharmacol Sci, Suita, Osaka 5650871, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Nagoya University; Nagoya University; Osaka University; University of Tsukuba; University of Tsukuba	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	Kobayashi, Akira/AAN-8003-2020; Yamamoto, Masayuki/A-4873-2010; Itoh, Ken/B-9506-2013	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; Kobayashi, Akira/0000-0001-9727-1218; Uchida, Koji/0000-0003-3894-5299				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIILIO C, 1987, CARCINOGENESIS, V8, P861, DOI 10.1093/carcin/8.6.861; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Elsby R, 2003, J BIOL CHEM, V278, P22243, DOI 10.1074/jbc.M301211200; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Fukuda A, 1997, BIOCHEM BIOPH RES CO, V236, P505, DOI 10.1006/bbrc.1997.6585; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Ikeda H, 2002, BIOCHEM J, V364, P563, DOI 10.1042/BJ20011756; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KODATE C, 1986, JPN J CANCER RES, V77, P226; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Matsumoto M, 1999, BIOCHEM J, V338, P599, DOI 10.1042/0264-6021:3380599; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Morimitsu Y, 2002, J BIOL CHEM, V277, P3456, DOI 10.1074/jbc.M110244200; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; Osada S, 1995, J BIOL CHEM, V270, P31288, DOI 10.1074/jbc.270.52.31288; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SATO K, 1989, ADV CANCER RES, V52, P205; SATO K, 1984, GANN, V75, P199; Satoh K, 2002, CARCINOGENESIS, V23, P457, DOI 10.1093/carcin/23.3.457; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; SHEA TC, 1988, CANCER RES, V48, P527; Shibata T, 2003, BIOCHEMISTRY-US, V42, P13960, DOI 10.1021/bi035215a; SPENCER SR, 1991, BIOCHEM J, V273, P711, DOI 10.1042/bj2730711; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Tanahashi N, 1999, MOL BIOL REP, V26, P3, DOI 10.1023/A:1006909522731; Tanaka K, 1998, GENES CELLS, V3, P499, DOI 10.1046/j.1365-2443.1998.00207.x; Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195; TATEMATSU M, 1985, CARCINOGENESIS, V6, P1621, DOI 10.1093/carcin/6.11.1621; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WATTENBERG LW, 1985, CANCER RES, V45, P1	49	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25267	25276		10.1074/jbc.M501014200	http://dx.doi.org/10.1074/jbc.M501014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863507	hybrid			2022-12-25	WOS:000230114000113
J	Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D				Mambo, E; Chatterjee, A; de Souza-Pinto, NC; Mayard, S; Hogue, BA; Joque, MO; Dizdaroglu, M; Bohr, VA; Sidransky, D			Oxidized guanine lesions and hOgg1 activity in lung cancer	ONCOGENE			English	Article						hOGG1; lung cancer; 8-oxoG; mitochondria; DNA repair	OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; BASE EXCISION-REPAIR; ESCHERICHIA-COLI; MAMMALIAN-CELLS; NUCLEAR-DNA; P53 GENE; OGG1; MITOCHONDRIAL; 8-OXOGUANINE	In humans, the oxidatively induced DNA lesion 8-hydroxyguanine (8-oxoG) is removed from DNA by hOgg1, a DNA glycosylase/AP lyase that specifically incises 8-oxoG opposite cytosine. We analysed the expression of hOGG1 mRNA in 18 lung cancer and three normal cell lines. Although hOGG1 was overexpressed in most cell lines, 2/18 (11.1%) showed a lower hOGG1 mRNA and protein expression (similar to 80% decrease) relative to normal cell lines. Liquid chromatography/mass spectrometry analysis showed increased levels of 8-oxoG in the two cell lines with the lowest hOGG1 mRNA expression. We examined the ability of nuclear and mitochondrial extracts to incise 8-oxoG lesion in cell lines H1650 and H226 expressing lower hOGG1 mRNA and H1915 and H1975 with higher than normal hOGG1 mRNA expression. Both nuclear and mitochondrial extracts from H1915 and H1975 cells were proficient in 8-oxoG removal. However, both cell lines with the lowest hOGG1 mRNA expression exhibited a severe reduction in 8-oxoG incision in both nuclear and mitochondrial extracts. Under-expression of hOGG1 mRNA and hOgg1 protein was associated with a decrease in mitochondrial DNA repair in response to oxidative damaging agents. These results provide evidence for defective incision of 8-oxoG in both nuclear and mitochondria of H1650 and H226 lung cancer cell lines. These results may implicate 8-oxoG repair defects in certain lung cancers.	Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Dept Otolaryngol Head & Neck Surg, 720 Rutland Ave,818 Ross Res Bldg, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu	Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; Hoque, Mohammad Obaidul/0000-0001-6701-9978	NCI NIH HHS [5 U01 CA084986-04, 5P50CA096784-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084986, P50CA096784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000727, Z01AG000733, ZIAAG000727, ZIAAG000733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arai T, 2002, CARCINOGENESIS, V23, P2005, DOI 10.1093/carcin/23.12.2005; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Audebert M, 2000, CANCER RES, V60, P4740; Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054; Blons H, 1999, MOL CARCINOGEN, V26, P254; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Cherng SH, 2002, J TOXICOL ENV HEAL A, V65, P265, DOI 10.1080/15287390252800855; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; Hashiguchi K, 2004, NUCLEIC ACIDS RES, V32, P5596, DOI 10.1093/nar/gkh863; Hodges NJ, 2002, CARCINOGENESIS, V23, P55, DOI 10.1093/carcin/23.1.55; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu YC, 2005, INT J CANCER, V114, P387, DOI 10.1002/ijc.20730; Hyun JW, 2000, ONCOGENE, V19, P4476, DOI 10.1038/sj.onc.1203787; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Larsen E, 2004, DNA REPAIR, V3, P1457, DOI 10.1016/j.dnarep.2004.06.008; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2003, P NATL ACAD SCI USA, V100, P1838, DOI 10.1073/pnas.0437910100; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Paz-Elizur T, 2003, J NATL CANCER I, V95, P1312, DOI 10.1093/jnci/djg033; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Sakumi K, 2003, CANCER RES, V63, P902; Sava V, 2004, FREE RADICAL BIO MED, V36, P1144, DOI 10.1016/j.freeradbiomed.2004.01.019; Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Vogel U, 2004, BIOCHEM GENET, V42, P453, DOI 10.1023/B:BIGI.0000043957.03420.7e; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Xie YL, 2004, CANCER RES, V64, P3096, DOI 10.1158/0008-5472.CAN-03-3834; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	51	69	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4496	4508		10.1038/sj.onc.1208669	http://dx.doi.org/10.1038/sj.onc.1208669			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856018				2022-12-25	WOS:000230157100003
J	Itoh, S; Ding, B; Bains, CP; Wang, N; Takeishi, Y; Jalili, T; King, GL; Walsh, RA; Yan, C; Abe, J				Itoh, S; Ding, B; Bains, CP; Wang, N; Takeishi, Y; Jalili, T; King, GL; Walsh, RA; Yan, C; Abe, J			Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; VENTRICULAR-MUSCLE; ACTOMYOSIN S-1; MOUSE HEARTS; ACTIVATION; RAS; MGATPASE; ISOFORM; SITES; VIVO	Protein kinase C (PKC)-induced phosphorylation of cardiac troponin I (cTnI) depresses the acto-myosin interaction and may be important during the progression of heart failure. Although both PKC beta II and PKC epsilon can phosphorylate cTnI, only PKC beta expression and activity are elevated in failing human myocardium during end-stage heart failure. Furthermore, although increased cTnI phosphorylation was observed in mice with cardiac-specific PKC beta II overexpression, no differences were observed in cTnI phosphorylation status between wild type and cardiac-specific PKC epsilon overexpression mice. A potentially important downstream effector of PKCs is p90 ribosomal S6 kinase (p90RSK), which plays an important role in cell growth by activating several transcription factors as well as Na+/H+ exchanger. Since both Ser(23) and Ser(24) of cTnI are contained in putative consensus sequences of p90RSK phosphorylation sites, we hypothesized that p90RSK is downstream from PKC beta II and can be a cTnI (Ser(23/24)) kinase. p90RSK, but not ERK1/2 activation, was increased in PKC beta II overexpression mice but not in PKC epsilon overexpression mice. p90RSK could phosphorylate cTnI in vitro with high substrate affinity but not cardiac troponin T (cTnT). To confirm the role of p90RSK in cTnI phosphorylation in vivo, we generated adenovirus containing a dominant negative form of p90RSK (Ad-DN-p90RSK). We found that the inhibition of p90RSK prevented H2O2-mediated cTnI (Ser(23/24)) phosphorylation but not ERK1/2 and PKC alpha/beta II activation. Next, we generated cardiac-specific p90RSK transgenic mice and observed that cTnI (Ser(23/24)) phosphorylation was significantly increased. LY333,531, a specific PKC beta inhibitor, inhibited both p90RSK and cTnI (Ser23/24) phosphorylation by H2O2. Taken together, our data support a new redox-sensitive mechanism regulating cTnI phosphorylation in cardiomyocytes.	Univ Rochester, Sch Med & Dent, Inst Cardiovasc Res, Cardiol Unit, Rochester, NY 14642 USA; Univ Cincinnati, Childrens Hosp, Ctr Med, Cincinnati, OH 45229 USA; Univ Utah, Salt Lake City, UT 84112 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	University of Rochester; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Case Western Reserve University	Abe, J (corresponding author), Univ Rochester, Sch Med & Dent, Inst Cardiovasc Res, Cardiol Unit, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.	jun-ichi_abe@urmc.rochester.edu		Yan, Chen/0000-0002-1397-6358; Wang, Nadan/0000-0002-1682-080X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065262, R01HL066919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-65262, HL-66919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Dhalla NS, 1998, CARDIOVASC RES, V40, P239, DOI 10.1016/S0008-6363(98)00186-2; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Malhotra A, 1997, CARDIOVASC RES, V34, P34, DOI 10.1016/S0008-6363(97)00059-X; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; Noland TA, 1996, BIOCHEMISTRY-US, V35, P14923, DOI 10.1021/bi9616357; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; Reinitz CA, 1997, ARCH BIOCHEM BIOPHYS, V348, P391, DOI 10.1006/abbi.1997.0401; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Saurin AT, 2002, CARDIOVASC RES, V55, P672, DOI 10.1016/S0008-6363(02)00325-5; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takeishi Y, 1998, J CLIN INVEST, V102, P72, DOI 10.1172/JCI2709; Takeishi Y, 2000, CIRC RES, V86, P1218, DOI 10.1161/01.RES.86.12.1218; Takimoto E, 2004, CIRC RES, V94, P496, DOI 10.1161/01.RES.0000117307.57798.F5; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	40	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24135	24142		10.1074/jbc.M413015200	http://dx.doi.org/10.1074/jbc.M413015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840586	hybrid			2022-12-25	WOS:000229880000087
J	Liu, CW; Giasson, BI; Lewis, KA; Lee, VM; DeMartino, GN; Thomas, PJ				Liu, CW; Giasson, BI; Lewis, KA; Lee, VM; DeMartino, GN; Thomas, PJ			A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation - Implications for pathogenesis of Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TRUNCATION; LEWY BODIES; FIBRIL FORMATION; LINKED MUTATIONS; IN-VITRO; INTRANUCLEAR INCLUSIONS; COMMON MECHANISM; DEMENTIA; BRAIN; DEGRADATION	Parkinson disease and other alpha-synucleinopathies are characterized by the deposition of intraneuronal alpha-synuclein (alpha Syn) inclusions. A significant fraction (about 15%) of alpha Syn in these pathological structures are truncated forms that have a much higher propensity than the full-length alpha Syn to form aggregates in vitro. However, little is known about the role of truncated alpha Syn species in pathogenesis or the means by which they are generated. Here, we have provided an in vitro mechanistic study demonstrating that truncated alpha Syns induce rapid aggregation of full- length protein at sub-stoichiometric ratios. Co-overexpression of truncated alpha Syn with full- length protein increases cell vulnerability to oxidative stress in dopaminergic SH-SY5Y cells. These results suggest a precipitating role for truncated alpha Syn in the pathogenesis of diseases involving alpha Syn aggregation. In this regard, the A53T mutation found in some cases of familial Parkinson disease exacerbates the accumulation of insoluble alpha Syns that correlates with the onset of pathology in transgenic mice expressing human alpha Syn-A53T mutant. The caspase-like activity of the 20 S proteasome produces truncated fragments similar to those found in patients and animal models from degradation of unstructured alpha Syn. We propose a model in which incomplete degradation of alpha Syn, especially under overloaded proteasome capacity, produces highly amyloidogenic fragments that rapidly induce the aggregation of full- length protein. These aggregates in turn reduce proteasome activity, leading to further accumulation of fragmented and full- length alpha Syns, creating a vicious cycle of cytotoxicity. This model has parallels in other neurodegenerative diseases, such as Huntington disease, where coaggregation of poly(Q) fragments with full- length protein has been observed.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Lab Med, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA.	philip.thomas@utsouthwestern.edu	Thomas, Philip J/F-7115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R37DK049835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46818, DK 49835] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Baba M, 1998, AM J PATHOL, V152, P879; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Bussell R, 2004, BIOCHEMISTRY-US, V43, P4810, DOI 10.1021/bi036135+; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Li WX, 2005, P NATL ACAD SCI USA, V102, P2162, DOI 10.1073/pnas.0406976102; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Lo BC, 2002, P NATL ACAD SCI USA, V99, P10813; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; Murray IVJ, 2003, BIOCHEMISTRY-US, V42, P8530, DOI 10.1021/bi027363r; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; POYMEROPOULOS MH, 1997, SCIENCE, V276, P2045; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	55	200	210	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22670	22678		10.1074/jbc.M501508200	http://dx.doi.org/10.1074/jbc.M501508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840579	hybrid			2022-12-25	WOS:000229741800016
J	Timmons, JA; Larsson, O; Jansson, E; Fischer, H; Gustafsson, T; Greenhaff, PL; Ridden, P; Rachman, J; Peyrard-Janvid, M; Wahlestedt, C; Sundberg, CJ				Timmons, JA; Larsson, O; Jansson, E; Fischer, H; Gustafsson, T; Greenhaff, PL; Ridden, P; Rachman, J; Peyrard-Janvid, M; Wahlestedt, C; Sundberg, CJ			Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						gene assay; diabetes transcriptome; aerobic training; DMD	HUMAN SKELETAL-MUSCLE; ALPHA-7-BETA-1 INTEGRIN; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; EXERCISE; REGENERATION; ACTIVATION; MICE; NORMALIZATION; PROGRESSION	Global gene expression profiling is used to generate novel insight into a variety of disease states. Such studies yield a bewildering number of data points, making it a challenge to validate which genes specifically contribute to a disease phenotype. Aerobic exercise training represents a plausible model for identification of molecular mechanisms that cause metabolic-related changes in human skeletal muscle. We carried out the first transcriptome-wide characterization of human skeletal muscle responses to 6 wk of supervised aerobic exercise training in 8 sedentary volunteers. Biopsy samples before and after training allowed us to identify similar to 470 differentially regulated genes using the Affymetrix U95 platform (80 individual hybridization steps). Gene ontology analysis indicated that extracellular matrix and calcium binding gene families were most up-regulated after training. An electronic reanalysis of a Duchenne muscular dystrophy (DMD) transcript expression dataset allowed us to identify similar to 90 genes modulated in a nearly identical fashion to that observed in the endurance exercise dataset. Trophoblast noncoding RNA, an interfering RNA species, was the singular exception-being up-regulated by exercise and down-regulated in DMD. The common overlap between gene expression datasets may be explained by enhanced alpha(7)beta(1) integrin signaling, and specific genes in this signaling pathway were up-regulated in both datasets. In contrast to these common features, OXPHOS gene expression is subdued in DMD yet elevated by exercise, indicating that more than one major mechanism must exist in human skeletal muscle to sense activity and therefore regulate gene expression. Exercise training modulated diabetes-related genes, suggesting our dataset may contain additional and novel gene expression changes relevant for the anti-diabetic properties of exercise. In conclusion, gene expression profiling after endurance exercise training identified a range of processes responsible for the physiological remodeling of human skeletal muscle tissue, many of which were similarly regulated in DMD. Furthermore, our analysis demonstrates that numerous genes previously suggested as being important for the DMD disease phenotype may principally reflect compensatory integrin signaling.	Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Lab Med, Div Clin Physiol, SE-17177 Stockholm, Sweden; Univ Med Sch, Ctr Integrated Syst Biol & Med, Nottingham, England	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Nottingham	Timmons, JA (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, SE-17177 Stockholm, Sweden.	Jamie.Timmons@fyfa.ki.se	Gustafsson, Thomas/AAH-1056-2019; Timmons, James A/M-6350-2019; Timmons, James A/J-4698-2014; Sundberg, Carl Johan/B-9356-2013; Larsson, Ola/F-8151-2013; Wahlestedt, Claes/A-7039-2009	Timmons, James A/0000-0002-2255-1220; Timmons, James A/0000-0002-2255-1220; Larsson, Ola/0000-0003-1412-1308; Sundberg, Carl Johan/0000-0002-7000-466X; Gustafsson, Thomas/0000-0002-1559-4206; Greenhaff, Paul/0000-0003-4403-0490				Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bao S, 1998, DIABETES, V47, P1935, DOI 10.2337/diabetes.47.12.1935; Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bogdanovich S, 2004, J MOL MED, V82, P102, DOI 10.1007/s00109-003-0484-1; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Carpentier M, 2000, PROTEIN SCI, V9, P2386, DOI 10.1110/ps.9.12.2386; Carson JA, 2000, J APPL PHYSIOL, V88, P337, DOI 10.1152/jappl.2000.88.1.337; Casar JC, 2004, J CELL SCI, V117, P73, DOI 10.1242/jcs.00828; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Condorelli G, 2001, DIABETES, V50, P1244, DOI 10.2337/diabetes.50.6.1244; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; De Luca A, 2003, J PHARMACOL EXP THER, V304, P453, DOI 10.1124/jpet.102.041343; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Geirsson A, 2003, BIOCHEM BIOPH RES CO, V301, P718, DOI 10.1016/S0006-291X(03)00028-7; Gregorevic P, 2002, AM J PATHOL, V161, P2263, DOI 10.1016/S0002-9440(10)64502-6; Gullberg D, 2003, NATURE, V424, P138, DOI 10.1038/424138a; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Henriquez JP, 2002, J CELL SCI, V115, P2041; Hodges BL, 1997, J CELL SCI, V110, P2873; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Jones SW, 2004, FASEB J, V18, P1025, DOI 10.1096/fj.03-1228fje; Kamanga-Sollo E, 2003, J CELL PHYSIOL, V197, P225, DOI 10.1002/jcp.10362; Kim SS, 2002, J CELL SCI, V115, P2465; Koskinen SOA, 2000, MUSCLE NERVE, V23, P580, DOI 10.1002/(SICI)1097-4598(200004)23:4<580::AID-MUS18>3.0.CO;2-4; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lluis F, 2001, BLOOD, V97, P1703, DOI 10.1182/blood.V97.6.1703; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murakami N, 1999, MUSCLE NERVE, V22, P889, DOI 10.1002/(SICI)1097-4598(199907)22:7<889::AID-MUS12>3.0.CO;2-B; Nagarajan UM, 2002, J IMMUNOL, V169, P5078, DOI 10.4049/jimmunol.169.9.5078; Norrbom J, 2004, J APPL PHYSIOL, V96, P189, DOI 10.1152/japplphysiol.00765.2003; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Pattison JS, 2003, PHYSIOL GENOMICS, V15, P34, DOI 10.1152/physiolgenomics.00040.2003; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Ricort JM, 2004, GROWTH HORM IGF RES, V14, P277, DOI 10.1016/j.ghir.2004.02.002; Rudnicki MA, 2003, NAT MED, V9, P1461, DOI 10.1038/nm1203-1461; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Seibaek M, 2003, CLIN CARDIOL, V26, P515, DOI 10.1002/clc.4960261107; Timmons JA, 1998, J CLIN INVEST, V101, P79, DOI 10.1172/JCI1146; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyni-Lenne R, 2001, EUR J HEART FAIL, V3, P47, DOI 10.1016/S1388-9842(00)00087-8; Uysal KT, 2000, ENDOCRINOLOGY, V141, P3388, DOI 10.1210/en.141.9.3388; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Watchko JF, 2002, J APPL PHYSIOL, V93, P407, DOI 10.1152/japplphysiol.01242.2001; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	58	114	118	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					750	760		10.1096/fj.04-1980com	http://dx.doi.org/10.1096/fj.04-1980com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857889				2022-12-25	WOS:000229602600031
J	van der Stelt, M; Fox, SH; Hill, M; Crossman, AR; Petrosino, S; Di Marzo, V; Brotchie, JM				van der Stelt, M; Fox, SH; Hill, M; Crossman, AR; Petrosino, S; Di Marzo, V; Brotchie, JM			A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTPlesioned non-human primate models of Parkinson's disease	FASEB JOURNAL			English	Article						basal ganglia; anandamide; rimonabant; 2-AG; CB1	GAMMA-AMINOBUTYRIC-ACID; MPTP-LESIONED PRIMATE; CANNABINOID RECEPTOR AGONIST; TREATED RAT MODEL; UNILATERAL 6-HYDROXYDOPAMINE LESIONS; MESSENGER-RNA EXPRESSION; NIGRA PARS RETICULATA; GLOBUS-PALLIDUS; BASAL GANGLIA; L-DOPA	Endocannabinoids and cannabinoid CB1 receptors play a role in the control of movement by modulating GABA,glutamate, and other neurotransmitters throughout the basal ganglia. Roles for abnormalities in endocannabinoid signaling in Parkinson's disease (PD) and the major side effect of current treatments, levodopa-induced dyskinesia (LID), have been suggested by rodent studies. Here we show that signaling by endocannabinoids contributes to the pathophysiology of parkinsonism and LID in MPTP-lesioned, non-human primate models of Parkinson's disease. In MPTP-lesioned marmosets previously treated with levodopa to establish LID,attenuation of CB1 signaling by systemic administration of rimonabant ( 1 and 3 mg/kg) had anti-parkinsonian actions,equivalent to a 71% increase in motor activity at 3 mg/kg. Rimonabant did not elicit dyskinesia. Co-administration of levodopa (8 mg/kg) and rimonabant ( 1 and 3 mg/k g) resulted in significantly less dyskinesia than levodopa alone, without significantly affecting the anti-parkinsonian action of levodopa. These data suggest that enhanced endocannabinoid signaling may be involved in the pathophysiology of both parkinsonism and LID. To define potential mechanisms by which such a role might be mediated, we determined the levels of the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) throughout the basal ganglia in normal and three groups of MPTP-lesioned cynomolgus monkeys (untreated; acutely treated with L-DOPA, non-dyskinetic; long-term treated, with levodopa-induced dyskinesia). In the untreated, MPTP-lesioned primate, parkinsonism was associated with increases in both 2-AG (+88%) and anandamide (+49%) in the striatum, and of 2-AG (+97%) in the substantia nigra, changes that are consistent with the previously suggested role for endocannabinoids in mechanisms attempting to compensate for loss of dopamine in untreated parkinsonism. Increased levels of anandamide (+34%) in the external globus pallidus of MPTP-lesioned animals were normalized by levodopa treatment and may contribute to the generation of parkinsonian symptoms. However, no clear alteration in endocannabinoid levels could be correlated with the expression of LID. These data highlight the potential roles played by endocannabinoids and CB I in PD and LID and suggest the need for further research to pursue the multiple therapeutic opportunities for manipulating this system in movement disorders.	Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; CNR, Ist Chim Biomol, Endocannabinoid Res Grp, Pozzuoli, NA, Italy; Toronto Western Hosp, Movement Disorders Clin, Toronto, ON M5T 2S8, Canada; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester, Lancs, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manchester	Brotchie, JM (corresponding author), Toronto Western Hosp, Toronto Western Res Inst, MC 11-419,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	vdimarzo@icmib.na.cnr.it; brotchie@uhnres.utoronto.ca	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Brotchie, Jonathan/0000-0003-2337-0816				AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Bezard E, 2003, TRENDS NEUROSCI, V26, P215, DOI 10.1016/S0166-2236(03)00038-9; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NAT REV NEUROSCI, V2, P577, DOI 10.1038/35086062; Brotchie JM, 2003, CURR OPIN PHARMACOL, V3, P54, DOI 10.1016/S1471-4892(02)00011-5; Brotchie JM, 1998, MOVEMENT DISORD, V13, P871, DOI 10.1002/mds.870130603; BROTCHIE JM, 2004, IN PRESS J NEURAL TR; Brown TM, 2003, J NEUROSCI, V23, P11073; Calon F, 2003, MOVEMENT DISORD, V18, P241, DOI 10.1002/mds.10343; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; CONSROE P, 1986, INT J NEUROSCI, V30, P277, DOI 10.3109/00207458608985678; Costa B, 1999, ACTA PHARMACOL SIN, V20, P1103; CROSSMAN AR, 1990, MOVEMENT DISORD, V5, P100, DOI 10.1002/mds.870050203; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2000, FASEB J, V14, P1432, DOI 10.1096/fj.14.10.1432; Fernandez-Espejo E, 2004, NEUROPSYCHOPHARMACOL, V29, P1134, DOI 10.1038/sj.npp.1300407; Ferrer B, 2003, EUR J NEUROSCI, V18, P1607, DOI 10.1046/j.1460-9568.2003.02896.x; Fox SH, 2002, MOVEMENT DISORD, V17, P1180, DOI 10.1002/mds.10289; Fox SH, 2002, MOVEMENT DISORD, V17, P145, DOI 10.1002/mds.1280; Fox SH, 2001, MOVEMENT DISORD, V16, P642, DOI 10.1002/mds.1148; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468; Gilgun-Sherki Y, 2003, PHARMACOL TOXICOL, V93, P66, DOI 10.1034/j.1600-0773.2003.930202.x; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, EUR J NEUROSCI, V9, P199, DOI 10.1111/j.1460-9568.1997.tb01390.x; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; Gubellini P, 2002, J NEUROSCI, V22, P6900; Henry B, 2001, EXP NEUROL, V171, P139, DOI 10.1006/exnr.2001.7727; Henry B, 1999, MOVEMENT DISORD, V14, P744, DOI 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7; Hermann H, 2002, NEUROSCIENCE, V109, P451, DOI 10.1016/S0306-4522(01)00509-7; Hill MP, 2004, CLIN NEUROPHARMACOL, V27, P171, DOI 10.1097/01.wnf.0000135478.70905.3d; Hill MP, 2004, J PHARMACOL EXP THER, V310, P386, DOI 10.1124/jpet.104.066191; Hill MP, 2003, MOVEMENT DISORD, V18, P1301, DOI 10.1002/mds.10542; Hille CJ, 2001, EXP NEUROL, V172, P189, DOI 10.1006/exnr.2001.7763; Kanda T, 1998, ANN NEUROL, V43, P507, DOI 10.1002/ana.410430415; Lastres-Becker I, 2001, EUR J NEUROSCI, V14, P1827, DOI 10.1046/j.0953-816x.2001.01812.x; Lees AJ, 2001, NEUROLOGY, V57, P1687, DOI 10.1212/WNL.57.9.1687; Loschmann PA, 2004, EXP NEUROL, V187, P86, DOI 10.1016/j.expneurol.2004.01.018; Maccarrone M, 2003, J NEUROCHEM, V85, P1018, DOI 10.1046/j.1471-4159.2003.01759.x; Maneuf YP, 1996, EUR J PHARMACOL, V308, P161, DOI 10.1016/0014-2999(96)00326-3; Maneuf YP, 1997, EXP NEUROL, V148, P265, DOI 10.1006/exnr.1997.6645; Maneuf YP, 1996, SYNAPSE, V22, P382; MANEUF YP, 1994, EXP NEUROL, V125, P65, DOI 10.1006/exnr.1994.1007; Meschler JP, 2001, NEUROPHARMACOLOGY, V40, P918, DOI 10.1016/S0028-3908(01)00012-0; Meschler JP, 2001, PSYCHOPHARMACOLOGY, V156, P79, DOI 10.1007/s002130100728; Mesnage V, 2004, CLIN NEUROPHARMACOL, V27, P108, DOI 10.1097/00002826-200405000-00003; Metman LV, 2000, MOVEMENT DISORD, V15, P3, DOI 10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E; Millan MJ, 2004, J PHARMACOL EXP THER, V309, P921, DOI 10.1124/jpet.103.062414; Miller AS, 1998, BRAIN RES, V793, P7, DOI 10.1016/S0006-8993(97)01475-3; Muller-Vahl KR, 2002, PHARMACOPSYCHIATRY, V35, P57, DOI 10.1055/s-2002-25028; Nash JE, 2002, MOVEMENT DISORD, V17, P455, DOI 10.1002/mds.10107; Nash JE, 2004, EXP NEUROL, V188, P471, DOI 10.1016/j.expneurol.2004.05.004; Nash JE, 2000, EXP NEUROL, V165, P136, DOI 10.1006/exnr.2000.7444; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; NUTT JG, 1990, NEUROLOGY, V40, P340; Obeso JA, 2000, ANN NEUROL, V47, pS22; Olanow CW, 2003, NEUROLOGY, V61, pS24, DOI 10.1212/WNL.61.6_suppl_3.S24; PAN HS, 1985, J NEUROCHEM, V45, P1396, DOI 10.1111/j.1471-4159.1985.tb07205.x; Pearce RKB, 1995, MOVEMENT DISORD, V10, P731, DOI 10.1002/mds.870100606; Penney J B Jr, 1986, Mov Disord, V1, P3, DOI 10.1002/mds.870010102; PERTWEE RG, 1991, NEUROPHARMACOLOGY, V30, P237, DOI 10.1016/0028-3908(91)90150-A; PERTWEE RG, 1998, PHARMACOL THERAPEUT, V36, P189; Rajput AH, 2002, MOVEMENT DISORD, V17, P289, DOI 10.1002/mds.10031; Rascol O, 2003, ANN NEUROL, V53, pS3, DOI 10.1002/ana.10513; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Richter A, 2002, EUR J PHARMACOL, V454, P145, DOI 10.1016/S0014-2999(02)02477-9; ROBERTSON RG, 1991, BRAIN RES, V563, P278, DOI 10.1016/0006-8993(91)91545-C; ROBERTSON RG, 1990, BRAIN RES, V531, P95, DOI 10.1016/0006-8993(90)90762-Z; de Fonseca FR, 2001, NEUROTOX RES, V3, P23, DOI 10.1007/BF03033228; Romero J, 2002, PHARMACOL THERAPEUT, V95, P137, DOI 10.1016/S0163-7258(02)00253-X; Romero J, 1998, LIFE SCI, V63, P351, DOI 10.1016/S0024-3205(98)00283-5; Romero J, 2000, LIFE SCI, V66, P485, DOI 10.1016/S0024-3205(99)00618-9; Rubino T, 2000, SYNAPSE, V35, P8, DOI 10.1002/(SICI)1098-2396(200001)35:1<8::AID-SYN2>3.0.CO;2-Y; SanudoPena MC, 1998, SYNAPSE, V28, P27, DOI 10.1002/(SICI)1098-2396(199801)28:1<27::AID-SYN4>3.0.CO;2-E; SanudoPena MC, 1997, J NEUROPHYSIOL, V77, P1635, DOI 10.1152/jn.1997.77.3.1635; Savola JM, 2003, MOVEMENT DISORD, V18, P872, DOI 10.1002/mds.10464; Segovia G, 2003, MOVEMENT DISORD, V18, P138, DOI 10.1002/mds.10312; Sieradzan KA, 2001, NEUROLOGY, V57, P2108, DOI 10.1212/WNL.57.11.2108; Silverdale MA, 2004, EXP NEUROL, V188, P128, DOI 10.1016/j.expneurol.2004.03.022; Silverdale MA, 2001, EXP NEUROL, V169, P400, DOI 10.1006/exnr.2001.7649; Steece-Collier K, 2000, EXP NEUROL, V163, P239, DOI 10.1006/exnr.2000.7374; Szabo B, 1999, J NEUROCHEM, V73, P1084, DOI 10.1046/j.1471-4159.1999.0731084.x; Szabo B, 2000, NEUROSCIENCE, V97, P89, DOI 10.1016/S0306-4522(00)00036-1; van der Stelt M, 2003, EUR J PHARMACOL, V480, P133, DOI 10.1016/j.ejphar.2003.08.101; Wallmichrath I, 2002, NEUROSCIENCE, V113, P671, DOI 10.1016/S0306-4522(02)00109-4; Wallmichrath I, 2002, N-S ARCH PHARMACOL, V365, P326, DOI 10.1007/s00210-001-0520-z; WICKENS AP, 1993, EUR J PHARMACOL, V250, P205, DOI 10.1016/0014-2999(93)90646-Y; Zeng BY, 1999, NEUROSCI LETT, V276, P71, DOI 10.1016/S0304-3940(99)00762-4	91	163	167	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1140	+		10.1096/fj.04-3010fje	http://dx.doi.org/10.1096/fj.04-3010fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894565				2022-12-25	WOS:000229602600016
J	Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H				Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H			Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP	ONCOGENE			English	Article						Evi-1; oligomerization; TGF-beta; CtBP; PR domain	T(3/21) FUSION PRODUCT; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTORS; GROWTH-INHIBITION; BLASTIC CRISIS; SMAD PROTEINS; GENE; EXPRESSION; LEUKEMIA; DIMERIZATION	Evi-1 is a transcription factor that is implicated in leukemic transformation of hematopoietic cells. Two distinct alternative forms, Evi-1a and Evi-1c, are generated from the EVI-1 gene. Whereas Evi-1a is widely recognized as an oncoprotein, a role for Evi-1c, which has an additional PR domain in the amino-terminus of Evi-1a, in leukemogenesis, has not been elucidated thus far. Aberrant oligomerization of transcription factors has recently emerged as a prevalent mechanism for activating their oncogenic potential in hematopoietic malignancies. Here, to study the mechanisms that underlie Evi-1 mediated oncogenesis, we investigated formation of oligomeric complexes by the Evi-1 proteins. We show that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer in mammalian cells. Remarkably, Evi-1c has lost the ability to interact with CtBP, a transcriptional corepressor that associates with Evi-1a. As a consequence, the ability of Evi-1c to repress transforming growth factor-beta ( TGF-beta) signaling is significantly abrogated. These results identify a novel function of a PR domain to regulate oligomerization of transcription factors and suggest that homo-oligomerization may play a critical role in corepressor recruitment by the Evi-1 proteins. In addition, we found that the chimeric oncoprotein acute myelocytic leukemia ( AML) 1-Evi-1, generated in t( 3; 21) leukemia, also forms homo-oligomers and hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-beta by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that oligomerization may contribute to the oncogenic potential of Evi-1-containing proteins.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan	University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019; Ogawa, Seishi/AAE-7088-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mizuki M, 2003, CELL MOL BIOL, V49, P907; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; Ogawa S, 1996, Hum Cell, V9, P323; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459	39	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6165	6173		10.1038/sj.onc.1208754	http://dx.doi.org/10.1038/sj.onc.1208754			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897867	Bronze			2022-12-25	WOS:000231718100010
J	Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V				Chien, J; Staub, J; Avula, R; Zhang, HY; Liu, WG; Hartmann, LC; Kaufmann, SH; Smith, DI; Shridhar, V			Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; methylation; tumor suppressor; apoptosis; proliferation	DNA METHYLATION; TUMOR-SUPPRESSOR; CARCINOMA CELLS; X-CHROMOSOME; EARLY-STAGE; EXPRESSION; GENE; PROTEIN; DIFFERENTIATION; IDENTIFICATION	Epigenetic silencing by hypermethylation of CpGs represents a mechanism of inactivation of tumor suppressors. Here we report on the cloning of a novel candidate tumor suppressor gene TCEAL7 inactivated by methylation in ovarian cancer. TCEAL codes for a 1.35 kb transcript that was previously reported to be downregulated in ovarian cancer by cDNA microarray and suppression subtraction cDNA (SSH) analyses. This report focuses on the elucidation of mechanisms associated with TCEAL7 downregulation. Expression of TCEAL7 is downregulated in a majority of ovarian tumors and cancer cell lines but induced by 5-aza-2'- deoxycytidine treatment in a dose-dependant manner, implicating methylation as a mechanism of TCEAL7 inactivation. Sequence analyses of bisufite-modified genomic DNA from somatic cell hybrids with either the active or the inactive human X chromosome reveal that TCEAL7 is subjected to X chromosome inactivation. Loss of TCEAL7 expression in primary tumors and cell lines correlates with methylation of a CpG site within the promoter. In vitro methylation of the CpG site suppresses promoter activity whereas selective demethylation of the SmaI site attenuates the suppression. Finally, re-expression of TCEAL7 in cancer cell lines induces cell death and reduces colony formation effciency. These data implicate TCEAL7 as a cell death regulatory protein that is frequently inactivated in ovarian cancers and suggest that it may function as a tumor suppressor.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Chien, Jeremy/AID-8939-2022	Kaufmann, Scott/0000-0002-4900-7145; Chien, Jeremy/0000-0003-4744-8374				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brown AL, 1999, HUM MOL GENET, V8, P611, DOI 10.1093/hmg/8.4.611; Brown CJ, 1997, AM J HUM GENET, V61, P5, DOI 10.1086/513914; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deng DJ, 2003, WORLD J GASTROENTERO, V9, P26, DOI 10.3748/wjg.v9.i1.26; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 2002, SCIENCE, V297, P1807; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Hatakeyama C, 2004, CLIN GENET, V66, P327, DOI 10.1111/j.1399-0004.2004.00310.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Persengiev SP, 1997, NEUROREPORT, V8, P2091, DOI 10.1097/00001756-199707070-00001; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Saitoh F, 1995, ANTICANCER RES, V15, P2137; Shridhar V, 2001, CANCER RES, V61, P4258; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Song SH, 2001, CANCER RES, V61, P4628; Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Williams JW, 2002, MOL REPROD DEV, V61, P281, DOI 10.1002/mrd.10100; Yang QS, 2002, BIOCHEM GENET, V40, P1, DOI 10.1023/A:1014565320998; YEH CH, 1995, J BIOL CHEM, V270, P15815, DOI 10.1074/jbc.270.26.15815; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	38	51	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5089	5100		10.1038/sj.onc.1208700	http://dx.doi.org/10.1038/sj.onc.1208700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15870691				2022-12-25	WOS:000230816900008
J	Li, GG; Wu, LY; OElschlager, DK; Wan, M; Stockard, CR; Grizzle, WE; Wang, N; Chen, HQ; Sun, Y; Cao, X				Li, GG; Wu, LY; OElschlager, DK; Wan, M; Stockard, CR; Grizzle, WE; Wang, N; Chen, HQ; Sun, Y; Cao, X			Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFICITY; BCL-2 FAMILY; BETA; BIM; MECHANISMS; CARCINOGENESIS; TARGETS; MEMBER; MICE; KEY	Estrogen is a mitogen in most estrogen receptor-alpha (ER alpha)-positive breast cancers. We have found that Smad4, a common signal transducer in the transforming growth factor-beta superfamily, acts as an ER alpha transcriptional corepressor. Here, we show that Smad4 induces apoptosis in ER alpha-positive MCF-7 breast cancer cells, but not in ER alpha-negative MDA-MB-231 cells. Smad4 induced expression of short Bim isoforms ( by alternative splicing) and Bax and release of cytochrome c in ER alpha-positive cells only, and expression of these apoptotic marker genes was reduced when ER alpha small interfering RNA was introduced. Notably, Smad4 was able to induce apoptosis in MDA-231 cells with acquired ER alpha expression. Furthermore, Smad4 inhibited ER alpha-positive tumor growth by inducing apoptosis in tumor xenografts in nude mice. The sizes of tumors expressing Smad4 were only one-tenth the size of those expressing green fluorescent protein, whereas in ER alpha-negative cells, Smad4 did not reduce the tumor size. Notably, Smad4 also promoted short Bim isoform and Bax expression and release of cytochrome c only in ER alpha-positive MCF-7 tumor xenografts. Bim was sufficient for induction of apoptosis, and the short form was the most potent inducer. Our results demonstrate that Smad4 induces apoptosis by regulating Bim splicing as an initial intrinsic signal in ER alpha-positive cells. Smad4-induced apoptosis in ER alpha-positive breast cancer cells may explain the invasive nature of ER alpha-negative breast tumors, thereby providing a potential target for breast cancer intervention.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Urumqi 830011, Peoples R China; W China Ctr Med Sci, Inst Biomed Engn, Chengdu 610041, Sichuan, Peoples R China	University of Alabama System; University of Alabama Birmingham; Chinese Academy of Sciences; Xinjiang Technical Institute of Physics & Chemistry, CAS	Cao, X (corresponding author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,VH G003, Birmingham, AL 35294 USA.	cao@path.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60913] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benson JR, 1996, J MAMMARY GLAND BIOL, V1, P381, DOI 10.1007/BF02017394; Benson JR, 2004, LANCET ONCOL, V5, P229, DOI 10.1016/S1470-2045(04)01426-3; Brooks SC, 2004, STEROIDS, V69, P401, DOI 10.1016/j.steroids.2004.03.014; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buchsbaum DJ, 2002, INT J RADIAT ONCOL, V54, P1180, DOI 10.1016/S0360-3016(02)03788-4; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Ko YJ, 2004, CURR PHARM BIOTECHNO, V5, P459, DOI 10.2174/1389201043376616; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Robertson JFR, 2004, CANCER TREAT REV, V30, P695, DOI 10.1016/j.ctrv.2004.04.003; Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Thomas T, 2004, CURR CANCER DRUG TAR, V4, P483, DOI 10.2174/1568009043332880; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200	31	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27022	27028		10.1074/jbc.M505071200	http://dx.doi.org/10.1074/jbc.M505071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15886208	hybrid			2022-12-25	WOS:000230589500047
J	Poukkula, M; Kaunisto, A; Hietakangas, V; Denessiouk, K; Katajamaki, T; Johnson, MS; Sistonen, L; Eriksson, JE				Poukkula, M; Kaunisto, A; Hietakangas, V; Denessiouk, K; Katajamaki, T; Johnson, MS; Sistonen, L; Eriksson, JE			Rapid turnover of c-FLIP short is determined by its unique C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NF-KAPPA-B; RECEPTOR-MEDIATED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; CASPASE-8 INHIBITOR FLIP; DEATH-EFFECTOR DOMAIN; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; NEURAL-NETWORKS; DOWN-REGULATION	The caspase-8 inhibitor c-FLIP exists as two splice variants, c-FLIPL and c-FLIPS, with distinct roles in death receptor signaling. The mechanisms determining their turnover have not been established. We found that in differentiating K562 erythroleukemia cells both c-FLIP isoforms were inducibly degraded by the proteasome, but c-FLIPS was more prone to ubiquitylation and had a considerably shorter half-life. Analysis of the c-FLIPS-specific ubiquitylation revealed two lysines, 192 and 195, C-terminal to the death effector domains, as principal ubiquitin acceptors in c-FLIPS but not in c-FLIPL. Furthermore the c-FLIPS-specific tail of 19 amino acids, adjacent to the two target lysines, was demonstrated to be the key element determining the isoform-specific instability of c-FLIPS. Molecular modeling in combination with site-directed mutagenesis demonstrated that the C-terminal tail is required for correct positioning and subsequent ubiquitylation of the target lysines. Because the antiapoptotic operation of c-FLIPS was not affected by the tail deletion, the antiapoptotic activity and ubiquitin-mediated degradation of c-FLIPS are functionally and structurally independent processes. The presence of a small destabilizing sequence in c-FLIPS constitutes an important determinant of c-FLIPS/c-FLIPL ratios by allowing differential degradation of c-FLIP isoforms. The conformation-based predisposition of c-FLIPS to ubiquitin-mediated degradation introduces a novel concept to the regulation of the death-inducing signaling complex.	Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, FIN-20521 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland; Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; Abo Akademi University; Abo Akademi University	Eriksson, JE (corresponding author), Univ Turku, Turku Ctr Biotechnol, POB 123, FIN-20521 Turku, Finland.	john.eriksson@utu.fi		Poukkula, Minna Karoliina/0000-0003-4192-2899; Sistonen, Lea/0000-0003-1341-2867; Hietakangas, Ville/0000-0002-9900-7549				Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Fulda S, 2000, CANCER RES, V60, P3947; Hietakangas V, 2003, MOL CELL BIOL, V23, P1278, DOI 10.1128/MCB.23.4.1278-1291.2003; Higuchi H, 2003, J BIOL CHEM, V278, P454, DOI 10.1074/jbc.M209387200; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Karplus K, 1997, PROTEINS, P134; Kataoka T, 2004, MOL CELL BIOL, V24, P2627, DOI 10.1128/MCB.24.7.2627-2636.2004; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Leverkus M, 2000, BLOOD, V96, P2628; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schmitz I, 2004, J IMMUNOL, V172, P2194, DOI 10.4049/jimmunol.172.4.2194; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Song JH, 2003, CLIN CANCER RES, V9, P4255; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795	56	124	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					27345	27355		10.1074/jbc.M504019200	http://dx.doi.org/10.1074/jbc.M504019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15886205	hybrid			2022-12-25	WOS:000230589500085
J	van den Brink, DM; van Miert, JNI; Dacremont, G; Rontani, JF; Wanders, RJA				van den Brink, DM; van Miert, JNI; Dacremont, G; Rontani, JF; Wanders, RJA			Characterization of the final step in the conversion of phytol into phytanic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; CHAIN FATTY-ACIDS; ALPHA-OXIDATION; REFSUMS-DISEASE; IDENTIFICATION; LOCALIZATION; DEFICIENT; PROTEIN	Phytol is a branched-chain fatty alcohol that is a naturally occurring precursor of phytanic acid, a fatty acid involved in the pathogenesis of Refsum disease. The conversion of phytol into phytanic acid is generally believed to take place via three enzymatic steps that involve 1) oxidation to its aldehyde, 2) further oxidation to phytenic acid, and 3) reduction of the double bond at the 2,3 position, yielding phytanic acid. Our recent investigations of this mechanism have elucidated the enzymatic steps leading to phytenic acid production, but the final step of the pathway has not been investigated so far. In this study, we describe the characterization of phytenic acid reduction in rat liver. NADPH-dependent conversion of phytenic acid into phytanic acid was detected, although at a slow rate. However, it was shown that phytenic acid can be activated to its CoA ester and that reduction of phytenoyl-CoA is much more efficient than that of phytenic acid. Furthermore, in rat hepatocytes cultured in the presence of phytol, phytenoyl-CoA could be detected, showing that it is a bona fide intermediate of phytol degradation. Subcellular fractionation experiments revealed that phytenoyl-CoA reductase activity is present in peroxisomes and mitochondria. With these findings, we have accomplished the full elucidation of the mechanism by which phytol is converted into phytanic acid.	Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; State Univ Ghent, B-9000 Ghent, Belgium; Ctr Oceanol Marseille, Lab Microbiol Geochim & Ecol Marines, UMR 6117, F-13288 Marseille, France	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Ghent University	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pediat, Lab Genet Metab Dis F0 224, POB 22700, NL-1100 DE Amsterdam, Netherlands.	R.J.Wanders@amc.uva.nl	van den Brink, Daan/S-7529-2017	van den Brink, Daan/0000-0002-3048-5382				BAXTER JH, 1968, J LIPID RES, V9, P636; BROWN PJ, 1993, J HUM NUTR DIET, V6, P295, DOI 10.1111/j.1365-277X.1993.tb00375.x; Das AK, 2000, J BIOL CHEM, V275, P24333, DOI 10.1074/jbc.M001168200; DOLE VP, 1961, J BIOL CHEM, V236, P3121; Idel S, 2002, J BIOL CHEM, V277, P49319, DOI 10.1074/jbc.M204639200; Jansen GA, 1999, BBA-MOL CELL BIOL L, V1440, P176, DOI 10.1016/S1388-1981(99)00126-2; Jansen GA, 1996, BIOCHEM BIOPH RES CO, V229, P205, DOI 10.1006/bbrc.1996.1781; Monnig G, 2004, J CARDIOVASC ELECTR, V15, P1310, DOI 10.1046/j.1540-8167.2004.03679.x; MURALIDHARAN FN, 1985, BIOCHIM BIOPHYS ACTA, V835, P36; MURALIDHARAN FN, 1986, BIOCHIM BIOPHYS ACTA, V883, P54, DOI 10.1016/0304-4165(86)90134-0; PAHAN K, 1995, J LIPID RES, V36, P986; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Rontani JF, 1999, APPL ENVIRON MICROB, V65, P5484; STEINBERG D, 1966, J LIPID RES, V7, P684; van den Brink DM, 2005, CLIN CHEM, V51, P240; van den Brink DM, 2004, MOL GENET METAB, V82, P33, DOI 10.1016/j.ymgme.2004.01.019; Verhoeven NM, 2001, PROG LIPID RES, V40, P453, DOI 10.1016/S0163-7827(01)00011-X; Vreken P, 1998, J CHROMATOGR B, V713, P281, DOI 10.1016/S0378-4347(98)00186-8; Wanders RJA, 2003, BBA-MOL CELL BIOL L, V1631, P119, DOI 10.1016/S1388-1981(03)00003-9; WANDERS RJA, 2001, METABOLIC MOL BASES, P3303; Watkins PA, 1996, J LIPID RES, V37, P2288; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x; WOLVETANG EJ, 1990, BIOCHIM BIOPHYS ACTA, V1035, P6, DOI 10.1016/0304-4165(90)90166-T	24	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26838	26844		10.1074/jbc.M501861200	http://dx.doi.org/10.1074/jbc.M501861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15866875	hybrid			2022-12-25	WOS:000230589500025
J	Ma, YF; Pitson, S; Hercus, T; Murphy, J; Lopez, A; Woodcock, J				Ma, YF; Pitson, S; Hercus, T; Murphy, J; Lopez, A; Woodcock, J			Sphingosine activates protein kinase A type II by a novel cAMP-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; MOLECULAR-CLONING; PHOSPHORYLATION; MODULATION; GROWTH; N,N-DIMETHYLSPHINGOSINE; APOPTOSIS; ISOFORMS; BRAIN; RAS	Protein kinase A ( PKA) has long been recognized as playing a major role in many regulatory processes in cells through its activation by the ubiquitous second messenger cAMP. We show here a novel mode of activation of PKA type II that is independent of cAMP and is, instead, dependent on sphingosine. PKA type II is specifically activated by sphingosine and its analog, dimethylsphingosine, but not by sphingosine-1-phosphate or other lipids. Like cAMP, sphingosine activates PKA holoenzyme but not the catalytic subunit alone, suggesting that the activation is mediated by the regulatory subunits. However, sphingosine-activated PKA, but not cAMP-activated PKA, is inhibited by phosphatidylserine, suggesting a distinct mechanism of activation. Furthermore, unlike cAMP, sphingosine does not induce the dissociation of PKA holoenzyme into catalytic and regulatory subunits. Modulation of sphingosine levels in vivo results in alteration in basal membrane-associated PKA activity consistent with a direct effect of membrane sphingosine on PKA type II. Importantly, sphingosine-dependent but not cAMP-dependent activation of PKA specifically phosphorylates Ser(58) of the multifunctional adapter protein 14-3-3 zeta, promoting the conversion of dimeric 14-3-3 zeta to a monomeric state, thus potentially modulating several biological functions. These results define a new mode of PKA activation that is sphingosine-dependent and mechanistically different from the classical cAMP-dependent activation of PKA. Furthermore, they suggest that stimuli that induce sphingosine accumulation and modulate phospholipid content at the cell membrane have the potential to activate PKA, thereby inducing the phosphorylation of distinct substrates and biological activities.	Hanson Inst Med & Vet Sci, Div Human Immunol, Cytokine Receptor Lab, Adelaide, SA 5000, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia	Woodcock, J (corresponding author), Hanson Inst Med & Vet Sci, Div Human Immunol, Cytokine Receptor Lab, GPO Box 14 Rundle Mall, Adelaide, SA 5000, Australia.	joanna.woodcock@imvs.sa.gov.au	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; ARAKANE F, 1995, NEUROCHEM INT, V26, P187, DOI 10.1016/0197-0186(94)00102-Z; CIFONE MG, 1993, J EXP MED, V177, P1547; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; HERINGDORF MZ, 2002, BIOCHIM BIOPHYS ACTA, V1582, P178; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; Noguchi K, 1998, EUR J CANCER, V34, P1260, DOI 10.1016/S0959-8049(98)00051-3; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; PUSHKAREVA MY, 1994, BBA-MOL CELL RES, V1221, P54, DOI 10.1016/0167-4889(94)90215-1; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; WALSH DA, 1968, J BIOL CHEM, V243, P3763; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	28	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26011	26017		10.1074/jbc.M409081200	http://dx.doi.org/10.1074/jbc.M409081200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15883165	hybrid			2022-12-25	WOS:000230386800009
J	Robenek, H; Robenek, MJ; Buers, I; Lorkowski, S; Hofnagel, O; Troyer, D; Severs, NJ				Robenek, H; Robenek, MJ; Buers, I; Lorkowski, S; Hofnagel, O; Troyer, D; Severs, NJ			Lipid droplets gain PAT family proteins by interaction with specialized plasma membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; STORAGE; TIP47; EXPRESSION; PERILIPIN; CELLS; ADRP; ACCUMULATION; ADIPOPHILIN; ASSOCIATION	Proteins of the PAT family, named after perilipin, adipophilin, and TIP47 (tail-interacting protein of 47 kDa), are associated with lipid droplets and have previously been localized by immunofluorescence microscopy exclusively to the droplet surface. These proteins are considered not to be present in any other subcellular compartment. By applying the high resolution technique of freeze-fracture electron microscopy combined with immunogold labeling, we now demonstrate that in macrophages and adipocytes PAT family proteins are, first, distributed not only in the surface but also throughout the lipid droplet core and, second, are integral components of the plasma membrane. Under normal culture conditions these proteins are dispersed in the cytoplasmic leaflet of the plasma membrane. Stimulation of lipid droplet formation by incubation of the cells with acetylated low density lipoprotein leads to clustering of the PAT family proteins in raised plasma membrane domains. Fractures penetrating beneath the plasma membrane demonstrate that lipid droplets are closely apposed to these domains. A similar distribution pattern of labeling in the form of linear aggregates within the clusters is apparent in the cytoplasmic monolayer of the plasma membrane and the immediately adjacent outer monolayer of the lipid droplet. The aggregation of the PAT family proteins into such assemblies may facilitate carrier-mediated lipid influx from the extracellular environment into the lipid droplet. Lipid droplets appear to acquire their PAT proteins by interaction with plasma membrane domains enriched in these proteins.	Univ Munster, Leibniz Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, D-48149 Munster, Germany; Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London SW3 6LY, England	University of Munster; Imperial College London	Robenek, H (corresponding author), Univ Munster, Leibniz Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, Domagkstr 3, D-48149 Munster, Germany.	robenek@uni-muenster.de	Lorkowski, Stefan/B-9689-2008	Lorkowski, Stefan/0000-0002-9649-840X				Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; BRANTON D, 1975, SCIENCE, V190, P54, DOI 10.1126/science.1166299; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Dagher G, 2003, J LIPID RES, V44, P1811, DOI 10.1194/jlr.M300267-JLR200; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DiDonato D, 2003, J HISTOCHEM CYTOCHEM, V51, P773, DOI 10.1177/002215540305100608; DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; Fukumoto S, 2002, HISTOCHEM CELL BIOL, V118, P423, DOI 10.1007/s00418-002-0462-7; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Gaus K, 2004, FASEB J, V18, P574, DOI 10.1096/fj.03-0486fje; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; Iwashima Y, 2000, BIOCHEM BIOPH RES CO, V277, P368, DOI 10.1006/bbrc.2000.3685; Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2005, BIOL SCI SER, P1; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Reuter A, 2004, CELL MOL LIFE SCI, V61, P2092, DOI 10.1007/s00018-004-4193-x; Robenek H, 2005, J BIOL CHEM, V280, P5789, DOI 10.1074/jbc.M407194200; Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje; Robenek MJ, 2003, FASEB J, V17, P1940, DOI 10.1096/fj.03-0008fje; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Thyberg J, 2002, J HISTOCHEM CYTOCHEM, V50, P185, DOI 10.1177/002215540205000206; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; Wang SM, 2003, HISTOCHEM CELL BIOL, V120, P285, DOI 10.1007/s00418-003-0575-7; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200	40	90	91	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26330	26338		10.1074/jbc.M413312200	http://dx.doi.org/10.1074/jbc.M413312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15897193	hybrid			2022-12-25	WOS:000230386800049
J	Iverson, HA; Fox, D; Nadler, LS; Klevit, RE; Nathanson, NM				Iverson, HA; Fox, D; Nadler, LS; Klevit, RE; Nathanson, NM			Identification and structural determination of the M-3 muscarinic acetylcholine receptor basolateral sorting signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; MDCK CELLS; EPITHELIAL-CELLS; INTERNALIZATION SIGNAL; XENOPUS OOCYTES; ACINAR-CELLS; FC-RECEPTORS; LDL RECEPTOR; LOCALIZATION; TYROSINE	Muscarinic acetylcholine receptors comprise a family of G-protein- coupled receptors that display differential localization in polarized epithelial cells. We identify a seven-residue sequence, Ala(275)-Val(281), in the third intracellular loop of the M-3 muscarinic receptor that mediates dominant, position-independent basolateral targeting in Madin-Darby canine kidney cells. Mutational analyses identify Glu(276), Phe(280), and Val(281) as critical residues within this sorting motif. Phe(280) and Val(281) comprise a novel dihydrophobic sorting signal as mutations of either residue singly or together with leucine do not disrupt basolateral targeting. Conversely, Glu(276) is required and cannot be substituted with alanine or aspartic acid. A 19-amino acid peptide representing the M-3 sorting signal and surrounding sequence was analyzed via two-dimensional nuclear magnetic resonance spectroscopy. Solution structures show that Glu(276) resides in a type IV beta-turn and the dihydrophobic sequence Phe(280)Val(281) adopts either a type I or IV beta-turn.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, K536A Hlth Sci Bldg,Box 357750,1959 NE Pacific, Seattle, WA 98195 USA.	nathanso@u.washington.edu			NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NIGMS NIH HHS [T32GM008268-17, T32GM07750] Funding Source: Medline; NINDS NIH HHS [R01 NS26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008268, T32GM007750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen NH, 1997, J AM CHEM SOC, V119, P8547, DOI 10.1021/ja963250h; Andersen NH, 1996, FEBS LETT, V399, P47, DOI 10.1016/S0014-5793(96)01279-3; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Bello V, 2001, MOL BIOL CELL, V12, P3004, DOI 10.1091/mbc.12.10.3004; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAVIDSON A, 1991, FEBS LETT, V284, P252, DOI 10.1016/0014-5793(91)80697-2; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Gu HH, 2001, MOL BIOL CELL, V12, P3797, DOI 10.1091/mbc.12.12.3797; Hoekstra D, 2003, J LIPID RES, V44, P869, DOI 10.1194/jlr.R300003-JLR200; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEVEY AI, 1994, NEUROSCIENCE, V63, P207, DOI 10.1016/0306-4522(94)90017-5; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MATUSLEIBOVITCH N, 1990, PFLUG ARCH EUR J PHY, V417, P194, DOI 10.1007/BF00370699; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; Nadler LS, 1999, AM J PHYSIOL-CELL PH, V277, pC1220, DOI 10.1152/ajpcell.1999.277.6.C1220; Nadler LS, 2001, J BIOL CHEM, V276, P10539, DOI 10.1074/jbc.M007190200; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGEER RR, 2004, AM J PHYSIOL-CELL PH, V287, P365; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simmen T, 1999, MOL CELL BIOL, V19, P3136; SIMON SA, 1992, ARCH ORAL BIOL, V37, P685, DOI 10.1016/0003-9969(92)90072-G; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; Wehrle-Haller B, 2001, J BIOL CHEM, V276, P12667, DOI 10.1074/jbc.M008357200; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	45	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24568	24575		10.1074/jbc.M501264200	http://dx.doi.org/10.1074/jbc.M501264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870063	hybrid			2022-12-25	WOS:000230114000035
J	Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y				Yanagida, M; Osato, M; Yamashita, N; Huang, LQ; Jacob, B; Wu, F; Cao, XM; Nakamura, T; Yokomizo, T; Takahashi, S; Yamamoto, M; Shigesada, K; Ito, Y			Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice	ONCOGENE			English	Article						Runx; GATA-1; CBF; down syndrome; megakaryoblastic leukemia	ACUTE MYELOGENOUS LEUKEMIA; DOWN-SYNDROME; CELL-CYCLE; MEGAKARYOBLASTIC LEUKEMIA; GENE; MECHANISMS; TRANSCRIPTION; EXPRESSION; MUTATIONS; GATA-1	The RUNX1/AML1 gene on chromosome 21 is most frequently inactivated in human leukemias. In addition, an increased dose of RUNX1 is suggested as a basis for several kinds of leukemias. Amplifications of chromosome 21 or the RUNX1 gene are shown to be associated with leukemias with lymphoid lineage, whereas its involvement in myeloid lineage remains unclear. In this study, we generated GATA-1 promoter-driven Runx1 transgenic (Tg) mice, which showed a transient mild increase of megakaryocyte marker-positive myeloid cells but no spontaneous leukemia. These mice were then crossed with BXH2 mice, which have a replication-competent retrovirus in the mouse and develop myeloid leukemia due to insertional mutagenesis by random integration of the virus. Overexpressed Runx1 transgene in BXH2 mice resulted in shortening of the latency of leukemia with increased frequency of megakaryoblastic leukemia, suggesting that increased Runx1 dosage is leukemogenic in myeloid lineage. Identifications of retroviral integration sites revealed the genetic alterations that may cooperate with Runx1 overdose in myeloid leukemogenesis. This mouse model may be useful for analysing the pathogenesis of myeloid leukemias with RUNX1 overdose, especially to examine whether an extra-copy of RUNX1 by trisomy 21 is causally related to Down's syndrome-related acute megakaryoblastic leukemia (DS-AMKL).	Inst Mol & Cell Biol, Singapore 138673, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Kyoto University; Japanese Foundation for Cancer Research; University of Tsukuba; University of Tsukuba	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg	Yamamoto, Masayuki/A-4873-2010; Osato, Motomi/N-5056-2014	Yamamoto, Masayuki/0000-0002-9073-9436; Osato, Motomi/0000-0003-3982-9054; Yanagida, Masatoshi/0000-0002-4407-8120				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Antonarakis SE, 1998, GENOMICS, V51, P1, DOI 10.1006/geno.1998.5335; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DUFRESNEZACHARIA MC, 1994, GENOMICS, V19, P462, DOI 10.1006/geno.1994.1095; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Gjertson C, 1999, CLIN IMMUNOL, V91, P50, DOI 10.1006/clim.1998.4685; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Hock H, 2003, IMMUNITY, V18, P109, DOI 10.1016/S1074-7613(02)00501-0; Kirito K, 2002, BLOOD, V99, P3220, DOI 10.1182/blood.V99.9.3220; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McElwaine S, 2004, BRIT J HAEMATOL, V125, P729, DOI 10.1111/j.1365-2141.2004.04982.x; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Niini T, 2000, HAEMATOLOGICA, V85, P362; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Reeves RH, 2001, TRENDS GENET, V17, P83, DOI 10.1016/S0168-9525(00)02172-7; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sui XW, 1999, BLOOD, V93, P2525, DOI 10.1182/blood.V93.8.2525.408k11_2525_2532; Tassone F, 1999, J NEURAL TRANSM-SUPP, P179; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Wotton S, 2002, CANCER RES, V62, P7181; Zhang Y, 2004, BLOOD, V103, P3717, DOI 10.1182/blood-2003-09-3365; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	37	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4477	4485		10.1038/sj.onc.1208675	http://dx.doi.org/10.1038/sj.onc.1208675			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856017				2022-12-25	WOS:000230157100001
J	Fan, RS; Jacamo, RO; Jiang, XH; Sinnett-Smith, J; Rozengurt, E				Fan, RS; Jacamo, RO; Jiang, XH; Sinnett-Smith, J; Rozengurt, E			G protein-coupled receptor activation rapidly stimulates focal adhesion kinase phosphorylation at Ser-843 - Mediation by Ca2+, calmodulin, and Ca2+ calmodulin-dependent kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE-PHOSPHORYLATION; CELL-MIGRATION; SERINE PHOSPHORYLATION; FAK; BOMBESIN; SRC; INHIBITION; CALCIUM; NEUROPEPTIDES	A rapid increase in the tyrosine phosphorylation of focal adhesion kinase (FAK) has been extensively documented in cells stimulated by multiple signaling molecules, but little is known about the regulation of FAK phosphorylation at serine residues. Stimulation of Swiss 3T3 cells with the G protein-coupled receptor agonists bombesin, vasopressin, or bradykinin induced an extremely rapid ( within 5 s) increase in FAK phosphorylation at Ser-843. The phosphorylation of this residue preceded FAK phosphorylation at Tyr-397, the major autophosphorylation site, and FAK phosphorylation at Ser-910. Treatment of intact cells with ionomycin stimulated a rapid increase in FAK phosphorylation at Ser-843, indicating that an increase in intracellular Ca2+ concentration ([Ca2+](i)) is a potential pathway leading to FAK-Ser-843 phosphorylation. Indeed, treatment with agents that prevent an agonist-induced increase in [Ca2+](i) (e.g. thapsigargin or BAPTA (1,2-bis(O-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid)), interfere with calmodulin function ( e. g. trifluoperazine, W13, and W7), or block Ca2+/calmodulin-dependent protein kinase II ( CaMKII) activation (KN93) or expression ( small interfering RNA) abrogated the rapid FAK phosphorylation at Ser-843 induced by bombesin, bradykinin, or vasopressin. Furthermore, activated CaMKII directly phosphorylated the recombinant COOH-terminal region of FAK at a residue equivalent to Ser-843. Thus, our results demonstrate that G protein-coupled receptor activation induces rapid FAK phosphorylation at Ser-843 through Ca2+, calmodulin, and CaMKII.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Ulcer Res & Educ,Digest Dis Re, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Ctr Ulcer Res & Educ,Digest Dis Re, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961	NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTON ES, 1995, J NEUROSCI, V15, P584; BRUNDAGE RA, 1993, AM J PHYSIOL, V265, pC1527, DOI 10.1152/ajpcell.1993.265.6.C1527; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Giannone G, 2004, J BIOL CHEM, V279, P28715, DOI 10.1074/jbc.M404054200; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Hunger-Glaser I, 2004, J CELL PHYSIOL, V200, P213, DOI 10.1002/jcp.20018; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kumada T, 2004, P NATL ACAD SCI USA, V101, P8479, DOI 10.1073/pnas.0401000101; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; Ma A, 2001, MOL BIOL CELL, V12, P1; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; Mukai M, 2002, ANTICANCER RES, V22, P3175; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rozengurt E, 2002, TRENDS ENDOCRIN MET, V13, P128, DOI 10.1016/S1043-2760(01)00544-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1995, CANCER SURV, V24, P81; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sinnett-Smith J, 2004, J BIOL CHEM, V279, P16883, DOI 10.1074/jbc.M313225200; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Withers DJ, 1997, J BIOL CHEM, V272, P2509; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	65	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24212	24220		10.1074/jbc.M500716200	http://dx.doi.org/10.1074/jbc.M500716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15845548	hybrid			2022-12-25	WOS:000229880000097
J	Coombs, PJ; Graham, SA; Drickamer, K; Taylor, ME				Coombs, PJ; Graham, SA; Drickamer, K; Taylor, ME			Selective binding of the scavenger receptor C-type lectin to Lewis(x) trisaccharide and related glycan ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; CARBOHYDRATE-RECOGNITION; STABLE EXPRESSION; STRUCTURAL BASIS; MICE LACKING; PROTEIN; SEQUENCE; DEFICIENCY; MEMBER; SITES	The scavenger receptor C-type lectin (SRCL) is an endothelial receptor that is similar in organization to type A scavenger receptors for modified low density lipoproteins but contains a C-type carbohydrate-recognition domain (CRD). Fragments of the receptor consisting of the entire extracellular domain and the CRD have been expressed and characterized. The extracellular domain is a trimer held together by collagen-like and coiled-coil domains adjacent to the CRD. The amino acid sequence of the CRD is very similar to the CRD of the asialoglycoprotein receptor and other galactose-specific receptors, but SRCL binds selectively to asialo-orosomucoid rather than generally to asialoglycoproteins. Screening of a glycan array and further quantitative binding studies indicate that this selectivity results from high affinity binding to glycans bearing the Lewis(x) trisaccharide. Thus, SRCL shares with the dendritic cell receptor DC-SIGN the ability to bind the Lewis(x) epitope. However, it does so in a fundamentally different way, making a primary binding interaction with the galactose moiety of the glycan rather than the fucose residue. SRCL shares with the asialoglycoprotein receptor the ability to mediate endocytosis and degradation of glycoprotein ligands. These studies suggest that SRCL might be involved in selective clearance of specific desialylated glycoproteins from circulation and/or interaction of cells bearing Lewis(x)-type structures with the vascular endothelium.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Taylor, ME (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, Biochem Bldg, London SW7 2AZ, England.	maureen.taylor@imperial.ac.uk	Graham, Sarah/G-7765-2014	Graham, Sarah/0000-0003-2521-2416; Coombs, Peter/0000-0002-3711-5480	NIGMS NIH HHS [GM62116] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; IOBST ST, 1994, J BIOL CHEM, V269, P15512; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Stambach NS, 2003, GLYCOBIOLOGY, V13, P401, DOI 10.1093/glycob/cwg045; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; TREUHEIT MJ, 1992, BIOCHEM J, V283, P105, DOI 10.1042/bj2830105; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wallis R, 2004, J BIOL CHEM, V279, P14065, DOI 10.1074/jbc.M400171200; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; Yoshida T, 2003, J BIOCHEM, V133, P271, DOI 10.1093/jb/mvg037	37	58	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22993	22999		10.1074/jbc.M504197200	http://dx.doi.org/10.1074/jbc.M504197200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845541	Green Published, hybrid			2022-12-25	WOS:000229741800054
J	Machwe, A; Xiao, LR; Groden, J; Matson, SW; Orren, DK				Machwe, A; Xiao, LR; Groden, J; Matson, SW; Orren, DK			RecQ family members combine strand pairing and unwinding activities to catalyze strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; DNA HELICASE; BIOCHEMICAL-CHARACTERIZATION; SUBSTRATE-SPECIFICITY; HOLLIDAY JUNCTIONS; D-LOOPS; WRN; BLOOMS; BINDING	RecQ helicases are critical for maintaining genomic integrity. In this study, we show that three RecQ members (WRN, deficient in the Werner syndrome; BLM, deficient in the Bloom syndrome; and Drosophila melanogaster RecQ5b (dmRecQ5b)) possess a novel strand pairing activity. Furthermore, each of these enzymes combines this strand pairing activity with its inherent DNA unwinding capability to perform coordinated strand exchange. In this regard, WRN and BLM are considerably more efficient than dmRecQ5b, apparently because dmRecQ5b lacks conserved sequences C-terminal to the helicase domain that contribute to DNA binding, strand pairing, and strand exchange. Based on our findings, we postulate that certain RecQ helicases are structurally designed to accomplish strand exchange on complex replication and recombination intermediates. This is highly consistent with proposed roles for RecQ members in DNA metabolism and the illegitimate recombination and cancer-prone phenotypes associated with RecQ defects.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of Kentucky; University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill	Orren, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 356 Hlth Res Bldg,800 Rose St, Lexington, KY 40536 USA.	dkorre2@uky.edu			NATIONAL CANCER INSTITUTE [R01CA113371] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113371-01, R01 CA113371] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; COX MM, 1982, J BIOL CHEM, V257, P8523; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Garcia PL, 2004, EMBO J, V23, P2882, DOI 10.1038/sj.emboj.7600301; Goto M, 1997, MECH AGEING DEV, V98, P239, DOI 10.1016/S0047-6374(97)00111-5; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Liu Z, 1999, STRUCTURE, V7, P1557, DOI 10.1016/S0969-2126(00)88346-X; Machwe A, 2002, J BIOL CHEM, V277, P4492, DOI 10.1074/jbc.M108880200; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; Ozsoy AZ, 2001, NUCLEIC ACIDS RES, V29, P2986, DOI 10.1093/nar/29.14.2986; SATIGNY Y, 2002, MOL CELL BIOL, V22, P6971; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	37	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23397	23407		10.1074/jbc.M414130200	http://dx.doi.org/10.1074/jbc.M414130200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15845538	Green Published, hybrid			2022-12-25	WOS:000229741800100
J	Kilunga, KB; Inoue, T; Okano, Y; Kabututu, Z; Martin, SK; Lazarus, M; Duszenko, M; Sumii, Y; Kusakari, Y; Matsumura, H; Kai, Y; Sugiyama, S; Inaka, K; Inui, T; Urade, Y				Kilunga, KB; Inoue, T; Okano, Y; Kabututu, Z; Martin, SK; Lazarus, M; Duszenko, M; Sumii, Y; Kusakari, Y; Matsumura, H; Kai, Y; Sugiyama, S; Inaka, K; Inui, T; Urade, Y			Structural and mutational analysis of Trypanosoma brucei prostaglandin H-2 reductase provides insight into the catalytic mechanism of aldo-ketoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE; CRYSTAL-STRUCTURE; F SYNTHASE; LUTEOLYTIC HORMONE; ALDEHYDE REDUCTASE; CORPUS-LUTEUM; ACTIVE-SITE; BOVINE LUNG; SUPERFAMILY; MUTAGENESIS	Trypanosoma brucei prostaglandin F-2 alpha synthase is an aldo-ketoreductase that catalyzes the reduction of prostaglandin H-2 to PGF(2 alpha) in addition to that of 9,10- phenanthrenequinone. We report the crystal structure of TbPGFS.NADP(+).citrate at 2.1 angstrom resolution. TbPGFS adopts a parallel (alpha/beta)(8)-barrel fold lacking the protrudent loops and possesses a hydrophobic core active site that contains a catalytic tetrad of tyrosine, lysine, histidine, and aspartate, which is highly conserved among AKRs. Site-directed mutagenesis of the catalytic tetrad residues revealed that a dyad of Lys(77) and His(110), and a triad of Tyr(52), Lys(77), and His(110) are essential for the reduction of PGH(2) and 9,10- PQ, respectively. Structural and kinetic analysis revealed that His(110), acts as the general acid catalyst for PGH(2) reduction and that Lys(77) facilitates His(110) protonation through a water molecule, while exerting an electrostatic repulsion against His(110) that maintains the spatial arrangement which allows the formation of a hydrogen bond between His(110) and C-11 carbonyl ofPGH(2). We also show that Tyr(52) acts as the general acid catalyst for 9,10- PQ reduction, and thus we not only elucidate the catalytic mechanism of a PGH(2) reductase but also provide an insight into the catalytic specificity of AKRs.	USA, Med Res Unit Kenya, Unit 64109, APO, AE 09831 USA; Osaka Biosci Inst, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan; Osaka Univ, Dept Chem Mat, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Mol Protozool, Suita, Osaka 5650871, Japan; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany; MARUWA Foods Ind Inc, Nara 6391123, Japan; Tsu City Coll, Dept Food & Nutr, Tsu, Mie 5140012, Japan; Japan Sci Technol Agcy, PRESTO, Struct & Funct Biomol Grp, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; Eberhard Karls University of Tubingen; Japan Science & Technology Agency (JST)	Kilunga, KB (corresponding author), USA, Med Res Unit Kenya, Unit 64109, APO, AE 09831 USA.	bkubata@nairobi.mimcom.net	Inui, Takashi/G-1069-2011; Lazarus, Michael/G-3130-2010	Matsumura, Hiroyoshi/0000-0003-0361-3796; Lazarus, Michael/0000-0003-3863-4474; Lazarus, Michael/0000-0003-4700-7894				BARSKI OA, 1995, BIOCHEMISTRY-US, V34, P11264, DOI 10.1021/bi00035a036; BOHREN KM, 1994, J MOL BIOL, V244, P659, DOI 10.1006/jmbi.1994.1762; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BORRAS T, 1989, BIOCHEMISTRY-US, V28, P6133, DOI 10.1021/bi00441a001; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8; BYGDEMAN M, 1970, AM J OBSTET GYNECOL, V106, P567, DOI 10.1016/0002-9378(70)90042-6; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; DEWINTER HL, 1995, BIOCHEMISTRY-US, V34, P8299, DOI 10.1021/bi00026a011; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; ELKABBANI O, 1995, NAT STRUCT BIOL, V2, P687, DOI 10.1038/nsb0895-687; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GLEW RH, 1992, TXB BIOCH CLIN CORRE, P461; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1996, J BIOL CHEM, V271, P30190, DOI 10.1074/jbc.271.47.30190; Jez JM, 2001, CHEM-BIOL INTERACT, V130, P499, DOI 10.1016/S0009-2797(00)00295-7; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Khurana S, 1998, P NATL ACAD SCI USA, V95, P6768, DOI 10.1073/pnas.95.12.6768; Komoto J, 2004, BIOCHEMISTRY-US, V43, P2188, DOI 10.1021/bi036046x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kubata BK, 2000, J EXP MED, V192, P1327, DOI 10.1084/jem.192.9.1327; LEVINE RL, 1977, CLIN CHEM, V23, P2292; MATHE AA, 1977, NEW ENGL J MED, V296, P910, DOI 10.1056/NEJM197704212961605; Matsuura K, 1998, J BIOCHEM-TOKYO, V124, P940, DOI 10.1093/oxfordjournals.jbchem.a022211; MCCRACKEN JA, 1972, NATURE-NEW BIOL, V238, P129, DOI 10.1038/newbio238129a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUTAYOBA BM, 1989, THERIOGENOLOGY, V32, P545, DOI 10.1016/0093-691X(89)90276-8; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okano Y, 2002, J BIOCHEM, V132, P859, DOI 10.1093/oxfordjournals.jbchem.a003298; OLIW E, 1983, PROSTAGLANDINS RELAT, P11; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Penning TM, 1996, STEROIDS, V61, P508, DOI 10.1016/S0039-128X(96)00093-1; PETRASH JM, 1994, DIABETES, V43, P955, DOI 10.2337/diabetes.43.8.955; PRUSCH RD, 1989, CELL TISSUE RES, V255, P553; RAO PV, 1992, J BIOL CHEM, V267, P92; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; ROUSSEL A, 1996, TURBO FRDO GRAPHICS, P81; Samuelsson B, 1979, Harvey Lect, V75, P1; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P11003, DOI 10.1021/bi980475r; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; TARLE I, 1993, J BIOL CHEM, V268, P25687; WATANABE K, 1986, P NATL ACAD SCI USA, V83, P1583, DOI 10.1073/pnas.83.6.1583; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WELLE R, 1991, EUR J BIOCHEM, V196, P423, DOI 10.1111/j.1432-1033.1991.tb15833.x; WILSON DK, 1995, BIOCHEMISTRY-US, V34, P14323, DOI 10.1021/bi00044a009; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WINTERGALEN N, 1995, EUR J BIOCHEM, V234, P264, DOI 10.1111/j.1432-1033.1995.264_c.x; YAMAMOTO S, 1983, PROSTAGLANDINS RELAT, P171; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	54	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26371	26382		10.1074/jbc.M413884200	http://dx.doi.org/10.1074/jbc.M413884200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15845552	hybrid			2022-12-25	WOS:000230386800053
J	Yin, HY; Musiek, ES; Gao, L; Porter, NA; Morrow, JD				Yin, HY; Musiek, ES; Gao, L; Porter, NA; Morrow, JD			Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC ANALYSIS; BICYCLO ENDOPEROXIDES; ALZHEIMERS-DISEASE; ARACHIDONIC-ACID; F-RING; ISOPROSTANES; AUTOXIDATION; F-2-ISOPROSTANES; HYDROPEROXIDES; QUANTIFICATION	Isoprostanes (IsoPs) are isomers of prostaglandins that are generated from the free radical-initiated peroxidation of arachidonic acid (C20.4 omega-6). IsoPs exert potent bioactivity and are regarded as the "gold standard" to assess oxidative stress in various human diseases. Analogously, autoxidation of docosahexaenoic acid (DHA, C22.6 omega-3) generates an array of IsoP-like compounds that are termed neuroprostanes (NPs). A major class of NPs identified in vitro and in vivo contains F-type prostane rings and are know as F-4-NPs. A number of different F-4-NP regioisomers are formed from the peroxidation of DHA. Among the eight possible regioisomeric groups, we hypothesize that 4- and 20-series NPs are generated in greater amounts than other classes because the precursors that lead to regioisomers other than those of the 4- and 20-series can be further oxidized to form novel dioxolane-IsoP-like compounds, analogous to those generated from arachidonate. Various mass spectrometric approaches, including electron capture atmospheric pressure chemical ionization mass spectrometry, were utilized to analyze NPs formed in vitro and in vivo based on their characteristic fragmentation in the gas phase. Experimental results were consistent with our hypothesis that 4- and 20-series NP regioisomers are preferentially generated. The discovery of regioselectivity in the formation of NPs will allow studies of the biological activities of NPs to focus on the more abundantly generated compounds to determine their role in modulating the pathophysiological consequences of DHA oxidation and oxidant stress.	Vanderbilt Univ, Ctr Mol Toxicol, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Div Clin Pharmacol, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Div Clin Pharmacol, Dept Med, Nashville, TN 37235 USA; Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Morrow, JD (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 526 RRB, Nashville, TN 37232 USA.	Jason.morrow@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560; Musiek, Erik/0000-0002-8873-0360	NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL017921, R01HL017921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 77839] Funding Source: Medline; NHLBI NIH HHS [HL17921] Funding Source: Medline; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; PHS HHS [CHE 9996188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gao L, 2003, J BIOL CHEM, V278, P28479, DOI 10.1074/jbc.M303984200; Havrilla CM, 2000, J AM CHEM SOC, V122, P8042, DOI 10.1021/ja001180f; KIEFER H, 1966, TETRAHEDRON LETT, V7, P6163; Kim HY, 2004, BIOCHEMISTRY-US, V43, P1030, DOI 10.1021/bi035197x; Lee SH, 2003, RAPID COMMUN MASS SP, V17, P2168, DOI 10.1002/rcm.1170; Li HW, 1999, P NATL ACAD SCI USA, V96, P13381, DOI 10.1073/pnas.96.23.13381; Montine KS, 2004, CHEM PHYS LIPIDS, V128, P117, DOI 10.1016/j.chemphyslip.2003.10.010; Moriguchi T, 2001, J LIPID RES, V42, P419; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; Murphy RC, 2001, CHEM REV, V101, P479, DOI 10.1021/cr9900883; Musiek ES, 2004, J CHROMATOGR B, V799, P95, DOI 10.1016/j.jchromb.2003.10.036; OCONNOR DE, 1981, J AM CHEM SOC, V103, P223, DOI 10.1021/ja00391a056; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Punta C, 2005, CHEM RES TOXICOL, V18, P349, DOI 10.1021/tx049685x; Quan LG, 2002, J AM CHEM SOC, V124, P12424, DOI 10.1021/ja027451z; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; Seal JR, 2004, ANAL BIOANAL CHEM, V378, P1007, DOI 10.1007/s00216-003-2274-6; Serhan CN, 2004, PROSTAG OTH LIPID M, V73, P155, DOI 10.1016/j.prostaglandins.2004.03.005; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717; VANROLLINS M, 1984, J LIPID RES, V25, P507; Waugh RJ, 1997, FREE RADICAL BIO MED, V23, P943, DOI 10.1016/S0891-5849(97)00133-0; Waugh RJ, 1996, J AM SOC MASS SPECTR, V7, P490, DOI 10.1016/1044-0305(95)00709-1; Yin HY, 2005, ANTIOXID REDOX SIGN, V7, P170, DOI 10.1089/ars.2005.7.170; Yin HY, 2004, J BIOL CHEM, V279, P3766, DOI 10.1074/jbc.M307137200; Yin HY, 2003, J BIOL CHEM, V278, P16720, DOI 10.1074/jbc.M300604200; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092	34	62	67	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26600	26611		10.1074/jbc.M503088200	http://dx.doi.org/10.1074/jbc.M503088200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15894799	hybrid			2022-12-25	WOS:000230386800077
J	Kouadio, JLK; Horn, JR; Pal, G; Kossiakoff, AA				Kouadio, JLK; Horn, JR; Pal, G; Kossiakoff, AA			Shotgun alanine scanning shows that growth hormone can bind productively to its receptor through a drastically minimized interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; HIGH-AFFINITY VARIANT; ESCHERICHIA-COLI; CALORIMETRIC ENTHALPIES; EXTRACELLULAR DOMAIN; CAPACITY CHANGES; REGULATORY STEP; VANT-HOFF; ENERGETICS; MUTAGENESIS	The high affinity binding site (Site1) of the human growth hormone (hGH) binds to its cognate receptor (hGHR) via a concave surface patch containing about 35 residues. Using 167 sequences from a shotgun alanine scanning analysis of Site1, we have determined that over half of these residues can be simultaneously changed to an alanine or a non-isosteric amino acid while still retaining a high affinity interaction. Among these hGH variants the distribution of the mutation is highly variable throughout the interface, although helix 4 is more conserved than the other binding elements. Kinetic and thermodynamic analyses were performed on 11 representative hGH Site1 variants that contained 14-20 mutations. Generally, the tightest binding variants showed similar associated rate constants (kon) as the wild-type (wt) hormone, indicating that their binding proceeds through a similar transition state intermediate. However, calorimetric analyses indicate very different thermodynamic partitioning: wt-hGH binding exhibits favorable enthalpy and entropy contributions, whereas the variants display highly favorable enthalpy and highly unfavorable entropy contributions. The heat capacities (Delta Cp) on binding measured for wt-hGH and its variants are significantly larger than normally seen for typical protein-protein interactions, suggesting large conformational or solvation effects. The multiple Site1 mutations are shown to indirectly affect binding of the second receptor at Site2 through an allosteric mechanism. We show that the stability of the ternary hormone-receptor complex reflects the affinity of the Site2 binding and is surprisingly exempt from changes in Site1 affinity, directly demonstrating that dissociation of the active signaling complex is a stepwise process.	Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, Chicago, IL 60637 USA; Univ Chicago, Inst Biophys Dynam, Cummings Life Sci Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Kossiakoff, AA (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, 920 E 58th St, Chicago, IL 60637 USA.	koss@cummings.uchicago.edu	Horn, James/B-4011-2009; Pal, Gabor/A-6244-2009	Pal, Gabor/0000-0001-7868-7971	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061602] Funding Source: NIH RePORTER; NIDDK NIH HHS [3-R01-DK61602-02S1, DK-61602] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Bernat B, 2004, BIOCHEMISTRY-US, V43, P6076, DOI 10.1021/bi036069b; Bernat B, 2003, P NATL ACAD SCI USA, V100, P952, DOI 10.1073/pnas.0235023100; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHENKO AP, 1986, UNLTRAVIOLET SPECTRO; FUH G, 1990, J BIOL CHEM, V265, P3111; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO;2-F; Gabdoulline RR, 2002, CURR OPIN STRUC BIOL, V12, P204, DOI 10.1016/S0959-440X(02)00311-1; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; Gunasekaran K, 2004, J MOL BIOL, V341, P1327, DOI 10.1016/j.jmb.2004.07.002; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; Horn JR, 2003, J MOL BIOL, V331, P497, DOI 10.1016/S0022-2836(03)00783-6; Horn JR, 2001, BIOCHEMISTRY-US, V40, P1774, DOI 10.1021/bi002408e; Horn JR, 2002, BIOCHEMISTRY-US, V41, P7501, DOI 10.1021/bi025626b; Joss L, 1998, ANAL BIOCHEM, V261, P203, DOI 10.1006/abio.1998.2744; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; Kozlov AG, 2000, PROTEINS, P8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Ladbury JE, 2004, CURR OPIN STRUC BIOL, V14, P562, DOI 10.1016/j.sbi.2004.08.001; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LIN LN, 1993, BIOCHEMISTRY-US, V32, P9398, DOI 10.1021/bi00087a019; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Pal G, 2003, J MOL BIOL, V332, P195, DOI 10.1016/S0022-2836(03)00898-2; Pearce KH, 1996, BIOCHEMISTRY-US, V35, P10300, DOI 10.1021/bi960513b; Protasevich II, 2004, BIOCHEMISTRY-US, V43, P13380, DOI 10.1021/bi0492509; Schiffer C, 2002, J MOL BIOL, V316, P277, DOI 10.1006/jmbi.2001.5348; Skelton NJ, 2003, J BIOL CHEM, V278, P7645, DOI 10.1074/jbc.M209751200; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; ULTSCH M, 1991, J MOL BIOL, V222, P865, DOI 10.1016/0022-2836(91)90578-T; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; Vajdos FF, 2002, J MOL BIOL, V320, P415, DOI 10.1016/S0022-2836(02)00264-4; WALLIS M, 1994, J MOL EVOL, V38, P619, DOI 10.1007/BF00175882; Walsh STR, 2004, P NATL ACAD SCI USA, V101, P17078, DOI 10.1073/pnas.0403336101; Walsh STR, 2003, PROTEIN SCI, V12, P1960, DOI 10.1110/ps.03133903; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Yi SJ, 2002, MOL BIOL EVOL, V19, P1083, DOI 10.1093/oxfordjournals.molbev.a004166	50	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25524	25532		10.1074/jbc.M502167200	http://dx.doi.org/10.1074/jbc.M502167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15857837	hybrid			2022-12-25	WOS:000230207900029
J	Hennecke, G; Nolte, J; Volkmer-Engert, R; Schneider-Mergener, J; Behrens, S				Hennecke, G; Nolte, J; Volkmer-Engert, R; Schneider-Mergener, J; Behrens, S			The periplasmic chaperone SurA exploits two features characteristic of integral outer membrane proteins for selective substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONE; PEPTIDE LIBRARIES; PORINS; PREDICTION; INSERTION; PATHWAY; HSP70; OMPF; SKP	The Escherichia coli periplasmic chaperone and peptidylprolyl isomerase ( PPIase) SurA facilitates the maturation of outer membrane porins. Although the PPIase activity exhibited by one of its two parvulin-like domains is dispensable for this function, the chaperone activity residing in the non-PPIase regions of SurA, a sizable N-terminal domain and a short C-terminal tail, is essential. Unlike most cytoplasmic chaperones SurA is selective for particular substrates and recognizes outer membrane porins synthesized in vitro much more efficiently than other proteins. Thus, SurA may be specialized for the maturation of outer membrane proteins. We have characterized the substrate specificity of SurA based on its natural, biologically relevant substrates by screening cellulose-bound peptide libraries representing outer membrane proteins. We show that two features are critical for peptide binding by SurA: specific patterns of aromatic residues and the orientation of their side chains, which are found more frequently in integral outer membrane proteins than in other proteins. For the first time this sufficiently explains the capability of SurA to discriminate between outer membrane protein and non-outer membrane protein folding intermediates. Furthermore, peptide binding by SurA requires neither an active PPIase domain nor the presence of proline, indicating that the observed substrate specificity relates to the chaperone function of SurA. Finally, we show that SurA is capable of associating with the outer membrane. Together, our data support a model in which SurA is specialized to interact with non-native periplasmic outer membrane protein folding intermediates and to assist in their maturation from early to late outer membrane-associated steps.	Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Genet & Praparat Molekularbiol, D-37077 Gottingen, Germany; Humboldt Univ, Univ Klinikum, Charite, Inst Med Immunol, D-10098 Berlin, Germany	University of Gottingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Behrens, S (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Abt Mol Genet & Praparat Molekularbiol, D-37077 Gottingen, Germany.	sbehren1@gwdg.de		Volkmer, Rudolf/0000-0003-4710-1143				Anantha TP, 2000, J BACTERIOL, V182, P2498, DOI 10.1128/JB.182.9.2498-2506.2000; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bitto E, 2004, FEBS LETT, V568, P94, DOI 10.1016/j.febslet.2004.05.014; Bitto E, 2003, J BIOL CHEM, V278, P49316, DOI 10.1074/jbc.M308853200; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Dutzler R, 1996, STRUCTURE, V4, P127, DOI 10.1016/S0969-2126(96)00016-0; Harms N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/jbc.M011194200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Kleinschmidt JH, 1996, BIOCHEMISTRY-US, V35, P12993, DOI 10.1021/bi961478b; Kluck CJ, 2002, J BIOL CHEM, V277, P41060, DOI 10.1074/jbc.M206520200; Kramer A, 1998, METH MOL B, V87, P25; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; MISRA R, 1991, J BIOL CHEM, V266, P13592; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rizzitello AE, 2001, J BACTERIOL, V183, P6794, DOI 10.1128/JB.183.23.6794-6800.2001; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schafer U, 1999, J BIOL CHEM, V274, P24567, DOI 10.1074/jbc.274.35.24567; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; Seshadri K, 1998, PROTEIN SCI, V7, P2026, DOI 10.1002/pro.5560070919; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; Tamm LK, 2001, J BIOL CHEM, V276, P32399, DOI 10.1074/jbc.R100021200; Webb HM, 2001, J BIOL CHEM, V276, P45622, DOI 10.1074/jbc.M107508200; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x	30	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23540	23548		10.1074/jbc.M413742200	http://dx.doi.org/10.1074/jbc.M413742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15840585	hybrid			2022-12-25	WOS:000229880000018
J	Kim, Y; Ohyama, H; Patel, V; Figueiredo, M; Wong, DT				Kim, Y; Ohyama, H; Patel, V; Figueiredo, M; Wong, DT			Mutation of Cys(105) inhibits dimerization of p12(CDK2-AP1) and its growth suppressor effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACT-INHIBITION; EXPRESSION; P12(DOC-1); ARREST; CELL; ACTIVATION; DOC-1; PHOSPHORYLATION; DIFFERENTIATION; P27(KIP1)	p12(CDK2-AP1) (p12) is a CDK2-associated protein that negatively regulates its kinase activity. Growth arrest of normal diploid cells by contact inhibition resulted in an induction of p27(kip1) and reduction of CDK2 levels. Interestingly, we observed concomitantly in growth-arrested cells, there was a reduction of nuclear p12 and the appearance of a nuclear 25-kDa molecule (p25) recognized by anti-p12 polyclonal antibody. Biochemical analysis showed that bacterial His-tagged p12 could be converted into a dimeric p25 in a reducing agent-dependent manner, and mutating the only cysteine residue of p12 (Cys(105) -> Ala(105)) abolished the dimerization. Transient transfection of wild type p12 into U2OS cells showed a reducing agent-sensitive dimerization that was also abolished by the C105A mutation. Furthermore, reduction of p12 expression by a short interfering RNA resulted in a parallel reduction of p25. These data supports the possibility that p25 is a homodimeric form of p12 through the cysteine residue. More interestingly, transient transfection of p12 ( C105A) into the normal diploid lung fibroblast CCD18LU cells resulted in a reduction of the growth-inhibitory effect of p12 and abolished the inhibitory effect of p12 on CDK2 kinase activity. In addition, we found that the C105A mutation did not alter nuclear localization of p12, but it prevented association with CDK2. Taken together, our data suggest that p12 forms a nuclear homodimers in contact inhibited normal diploid cells and dimerization of p12 is a necessary process for the growth inhibition effect by p12.	Univ Calif Los Angeles, Inst Dent Res, Sch Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Head & Neck Otoaryngol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Harvard University; Harvard School of Dental Medicine	Wong, DT (corresponding author), Univ Calif Los Angeles, Inst Dent Res, Sch Dent, 10833 Le Conte Ave,73-017 CHS, Los Angeles, CA 90095 USA.	dtww@ucla.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007296] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE007296-08] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMSLER K, 1994, J CELL PHYSIOL, V159, P331, DOI 10.1002/jcp.1041590216; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dimberg A, 2000, BLOOD, V96, P2870; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fuse T, 2000, J NEUROCHEM, V74, P1393, DOI 10.1046/j.1471-4159.2000.0741393.x; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kim Y, 2005, ONCOGENE, V24, P407, DOI 10.1038/sj.onc.1208222; Kim Y, 2001, INT J ORAL BIOL  DEC, V2001, P87; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Lundin L, 2003, EXP CELL RES, V287, P190, DOI 10.1016/S0014-4827(03)00125-3; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Modiano JF, 1999, DNA CELL BIOL, V18, P357, DOI 10.1089/104454999315259; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; Taipale M, 2000, EXP CELL RES, V259, P107, DOI 10.1006/excr.2000.4959; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Wieser RJ, 1999, ONCOGENE, V18, P277, DOI 10.1038/sj.onc.1202270; WU F, 1996, AM J PHYSIOL, V270, P879; Yamaguchi S, 1995, Kokubyo Gakkai Zasshi, V62, P78; Yanagisawa K, 1999, J BIOCHEM-TOKYO, V125, P36, DOI 10.1093/oxfordjournals.jbchem.a022265; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	29	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23273	23279		10.1074/jbc.M412929200	http://dx.doi.org/10.1074/jbc.M412929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15840587	hybrid			2022-12-25	WOS:000229741800085
J	Pennathur, S; Ido, Y; Heller, JI; Byun, J; Danda, R; Pergola, P; Willliamson, JR; Heinecke, JW				Pennathur, S; Ido, Y; Heller, JI; Byun, J; Danda, R; Pergola, P; Willliamson, JR; Heinecke, JW			Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species - A potential pathway for oxidative damage of retinal proteins in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MASS-SPECTROMETRIC QUANTIFICATION; AUTOXIDATIVE GLYCOSYLATION; LIPID-PEROXIDATION; MICROVASCULAR COMPLICATIONS; VASCULAR DYSFUNCTIONS; GLUCOSE AUTOXIDATION; NITRATIVE STRESS; ORTHO-TYROSINE; SKIN COLLAGEN	The pattern of oxidized amino acids in aortic proteins of nonhuman primates suggests that a species resembling hydroxyl radical damages proteins when blood glucose levels are high. However, recent studies argue strongly against a generalized increase in diabetic oxidative stress, which might instead be confined to the vascular wall. Here, we describe a pathway for glucose-stimulated protein oxidation and provide evidence of its complicity in diabetic microvascular disease. Low density lipoprotein incubated with pathophysiological concentrations of glucose became selectively enriched in ortho-tyrosine and meta-tyrosine, implicating a hydroxyl radical-like species in protein damage. Model system studies demonstrated that the reaction pathway requires both a reactive carbonyl group and a polyunsaturated fatty acid, involves lipid peroxidation, and is blocked by the carbonyl scavenger aminoguanidine. To explore the physiological relevance of the pathway, we used mass spectrometry and high pressure liquid chromatography to quantify oxidation products in control and hyperglycemic rats. Hyperglycemia raised levels of ortho-tyrosine, meta-tyrosine, and oxygenated lipids in the retina, a tissue rich in polyunsaturated fatty acids. Rats that received aminoguanidine did not show this increase in protein and lipid oxidation. In contrast, rats with diet-induced hyperlipidemia in the absence of hyperglycemia failed to exhibit increased protein and lipid oxidation products in the retina. Our observations suggest that generation of a hydroxyl radical-like species by a carbonyl/polyunsaturated fatty acid pathway might promote localized oxidative stress in tissues vulnerable to diabetic damage. This raises the possibility that antioxidant therapies that specifically inhibit the pathway might delay the vascular complications of diabetes.	Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Rush Univ, Dept Pathol, Chicago, IL 60612 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Rush University; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.	heinecke@u.washington.edu		Ido, Yasuo/0000-0002-3036-9971	NEI NIH HHS [EY06600] Funding Source: Medline; NHLBI NIH HHS [HL39934] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [DK20579, DK02456] Funding Source: Medline; NIEHS NIH HHS [P30ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVELDANO MI, 1972, BIOCHEM BIOPH RES CO, V48, P689, DOI 10.1016/0006-291X(72)90403-2; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BHANDARU R, 1982, ATHEROSCLEROSIS, V42, P263, DOI 10.1016/0021-9150(82)90156-3; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Bucala R, 1992, Adv Pharmacol, V23, P1; Byun J, 1999, FEBS LETT, V455, P243, DOI 10.1016/S0014-5793(99)00893-5; Carr AC, 2000, ARTERIOSCL THROM VAS, V20, P1716, DOI 10.1161/01.ATV.20.7.1716; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; Curtis TM, 2004, DIABETES-METAB RES, V20, P28, DOI 10.1002/dmrr.431; Deen WM, 2002, FASEB J, V16, P1144; Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Ellis EA, 1998, FREE RADICAL BIO MED, V24, P111, DOI 10.1016/S0891-5849(97)00202-5; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Gupta S, 2002, AM J PHYSIOL-CELL PH, V282, pC560, DOI 10.1152/ajpcell.00343.2001; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; Ido Y, 1997, DIABETOLOGIA, V40, pS115, DOI 10.1007/s001250051422; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; Kim IJ, 2003, DIABETES RES CLIN PR, V60, P11, DOI 10.1016/S0168-8227(02)00278-4; King GL, 1997, KIDNEY INT, pS77; Kowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818; Lamharzi N, 2004, DIABETES, V53, P3217, DOI 10.2337/diabetes.53.12.3217; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544; Lyons TJ, 1997, CURR OPIN LIPIDOL, V8, P174, DOI 10.1097/00041433-199706000-00008; Lyons TJ, 2000, INVEST OPHTH VIS SCI, V41, P1176; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; Monnier VM, 2003, ARCH BIOCHEM BIOPHYS, V419, P1, DOI 10.1016/j.abb.2003.08.014; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; Morrow JD, 2003, ARTERIOSCL THROM VAS, V23, P368, DOI 10.1161/01.ATV.0000063107.86298.FD; Mowri HO, 2000, FREE RADICAL BIO MED, V29, P814, DOI 10.1016/S0891-5849(00)00379-8; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Pennathur S, 2004, FRONT BIOSCI-LANDMRK, V9, P565, DOI 10.2741/1257; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; PFEIFFER A, 1995, EXP CLIN ENDOCR DIAB, V103, P7, DOI 10.1055/s-0029-1211323; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Saxena AK, 1999, BIOCHEM BIOPH RES CO, V260, P332, DOI 10.1006/bbrc.1999.0898; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; Semenkovich CF, 1997, DIABETES, V46, P327, DOI 10.2337/diabetes.46.3.327; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sharma K, 1997, SEMIN NEPHROL, V17, P80; Skyler JS, 2001, ENDOCRIN METAB CLIN, V30, P833, DOI 10.1016/S0889-8529(05)70218-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WATKINS NG, 1987, J BIOL CHEM, V262, P7207; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; Zhang SX, 2004, DIABETOLOGIA, V47, P124, DOI 10.1007/s00125-003-1276-4	61	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22706	22714		10.1074/jbc.M500839200	http://dx.doi.org/10.1074/jbc.M500839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15855169	hybrid			2022-12-25	WOS:000229741800020
J	Balasubramanian, S; Chandraratna, RAS; Eckert, RL				Balasubramanian, S; Chandraratna, RAS; Eckert, RL			A novel retinoid-related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis	ONCOGENE			English	Article						pancreatic cancer; retinoids; apoptosis; caspases; cell cycle; AGN193198	OVARIAN-CARCINOMA CELLS; ACID RECEPTOR; SELECTIVE RETINOIDS; PROSTATE-CANCER; LEUKEMIA-CELLS; BREAST-CANCER; X-RECEPTOR; SYNTHETIC RETINOIDS; FENRETINIDE 4-HPR; GROWTH-INHIBITION	Retinoid-related molecules are important potential agents for the treatment of cancer. In the present study, we test the effect of a novel retinoid-related ligand, AGN193198 (4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6- yl)-3-oxo-prophenyl] benzoic acid), on pancreatic cancer cell proliferation and survival. AGN193198 treatment reduces BxPC-3 cell proliferation more efficiently than high-affinity retinoid acid receptor (RAR)- or retinoid X receptor (RXR)- selective retinoids. Moreover, AGN193198 does not activate transcription from RAR or RXR response elements and its effects on cell survival are not reversed by treatment with RAR- or RXR receptor-selective antagonists. These results suggest that the AGN193198-dependent inhibition of BxPC-3 cell function is not mediated via activation of the classical retinoid receptors. Cell cycle analysis of AGN193198-treated BxPC-3 cells indicates that AGN193198 causes accumulation of cells in G2/M. This change is associated with a marked reduction in regulators of S ( cyclin A, cyclin-dependent kinase (cdk) 2), G2/M ( cyclin B1, cdk1, cdc25c) and G1 ( cyclin D1, cyclin E, cdk2, cdk4) phase, and an increase in p21 and p27 level. Kinases assays reveal that cdk1, cdk2 and cdk4 activity are suppressed in AGN193198-treated cells. In addition, reduced cell proliferation is associated with enhanced procaspase ( 3, 8 and 9) and PARP cleavage. Z-VAD-FMK, a pancaspase inhibitor, inhibits AGN193198-dependent caspase activation and attenuates cell death. Z-VAD-FMK inhibits PARP cleavage, but does not alter the AGN193198-dependent reduction in cell cycle regulatory protein expression and activity, suggesting that caspase activation and suppression of cell cycle regulatory protein levels are independent processes. AGN193198 produces similar responses in other pancreatic cancer cell lines including AsPC-1 and MIA PaCa-2. These studies suggest that AGN193198 may be useful for the treatment of pancreatic cancer.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Dept Chem, Irvine, CA 92623 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Case Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrechtsson E, 2002, PANCREAS, V25, P49, DOI 10.1097/00006676-200207000-00013; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ARBUCK SG, 1990, BAILLIERE CLIN GASTR, V4, P953, DOI 10.1016/0950-3528(90)90029-G; Balasubramanian S, 2004, CARCINOGENESIS, V25, P1377, DOI 10.1093/carcin/bgh122; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Benbrook DM, 1998, J MED CHEM, V41, P3753, DOI 10.1021/jm980308p; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brembeck FH, 1998, BRIT J CANCER, V78, P1288, DOI 10.1038/bjc.1998.673; Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P; CHIESA F, 1992, ORAL ONCOL, V28B, P97; Chun KH, 2003, CANCER RES, V63, P3826; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; Dawson MI, 2001, CANCER RES, V61, P4723; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fujimoto K, 1999, INT J CANCER, V81, P637, DOI 10.1002/(SICI)1097-0215(19990517)81:4<637::AID-IJC21>3.0.CO;2-4; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Hammond LA, 2002, ANTI-CANCER DRUG, V13, P781, DOI 10.1097/00001813-200209000-00001; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsieh TC, 1997, PROSTATE, V33, P97; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885; Johnson A, 1999, BRIT J DERMATOL, V140, P12; Kaiser A, 1998, GASTROENTEROLOGY, V115, P967, DOI 10.1016/S0016-5085(98)70269-0; Kawa S, 1997, INT J CANCER, V72, P906, DOI 10.1002/(SICI)1097-0215(19970904)72:5<906::AID-IJC31>3.0.CO;2-3; Keedwell RG, 2004, CANCER RES, V64, P3302, DOI 10.1158/0008-5472.CAN-03-2763; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Liu SQ, 2004, J MED CHEM, V47, P999, DOI 10.1021/jm030346v; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; McGowan Clare H, 2003, Prog Cell Cycle Res, V5, P1; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; Nicoletti VG, 2003, NEUROCHEM RES, V28, P187, DOI 10.1023/A:1022316914492; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Ortiz MA, 2002, DRUG RESIST UPDATE, V5, P162, DOI 10.1016/S1368-7646(02)00050-X; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496; Pettersson F, 2001, PANCREAS, V23, P273, DOI 10.1097/00006676-200110000-00008; Pettersson F, 2000, BRIT J CANCER, V83, P239; PIENTA KJ, 1993, CANCER RES, V53, P224; Rosenberg L, 2003, EXPERT OPIN BIOL TH, V3, P319, DOI 10.1517/14712598.3.2.319; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; SHAO ZM, 1995, ONCOGENE, V11, P493; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SPRUCE LW, 1991, J MED CHEM, V34, P430, DOI 10.1021/jm00105a065; Standeven AM, 2001, BIOCHEM PHARMACOL, V62, P1501, DOI 10.1016/S0006-2952(01)00803-6; STRICKLAND S, 1983, CANCER RES, V43, P5268; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1999, CLIN CANCER RES, V5, P431; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; TEELMANN K, 1993, CANCER RES, V53, P2319; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zuco V, 2004, CELL DEATH DIFFER, V11, P280, DOI 10.1038/sj.cdd.4401304; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	66	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4257	4270		10.1038/sj.onc.1208586	http://dx.doi.org/10.1038/sj.onc.1208586			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15856029				2022-12-25	WOS:000229815300009
J	Sturniolo, MT; Chandraratna, RAS; Eckert, RL				Sturniolo, MT; Chandraratna, RAS; Eckert, RL			A novel transglutaminase activator forms a complex with type 1 transglutaminase	ONCOGENE			English	Article						involucrin; transglutaminase; TIG3; keratinocyte; epidermis	HUMAN EPIDERMAL-KERATINOCYTES; MEMBRANE ANCHORAGE REGION; TUMOR-SUPPRESSOR PROTEIN; INVOLUCRIN CROSS-LINKING; TISSUE TRANSGLUTAMINASE; CALCIUM-IONS; CORNIFIED ENVELOPE; GENE-EXPRESSION; CELL-DIFFERENTIATION; BARRIER FUNCTION	Type I transglutaminase is a plasma membrane-anchored intracellular protein-protein crosslinking enzyme that is responsible for assembly of the keratinocyte cornified envelope during terminal keratinocyte differentiation. We recently described a novel protein, TIG3, that when expressed in keratinocytes causes increased transglutaminase activity and keratinocyte cell death. However, the mechanism of activation of transglutaminase by TIG3 is not known. W e now extend our previous study and show that full-length TIG3 forms a complex with type I transglutaminase that is demonstrated by TIG3-transglutaminase co-precipitation. We also demonstrate that treating TIG3-expressing cells with monodansyl cadaverine, a competitive transglutaminase substrate, attenuates the TIG3-dependent response, suggesting that transglutaminase is an important mediator of TIG3 action. These findings suggest that TIG3 forms a complex with transglutaminase resulting in transglutaminase activation and that transglutaminase activity is required for the TIG3-dependent biological response.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Biol & Chem, Irvine, CA 92713 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NCI NIH HHS [P30 CA134274, P30 CA43703] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA134274, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Broome AM, 2004, J INVEST DERMATOL, V122, P29, DOI 10.1046/j.0022-202X.2003.22105.x; Candi E, 2004, BIOCHEM J, V381, P313, DOI 10.1042/BJ20031474; Casadio R, 1999, EUR J BIOCHEM, V262, P672, DOI 10.1046/j.1432-1327.1999.00437.x; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLINE PR, 1983, CANCER RES, V43, P3203; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Dashti SR, 2001, J BIOL CHEM, V276, P8059, DOI 10.1074/jbc.C000862200; Deucher A, 2000, INT J ONCOL, V17, P1195; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; GOLDSMITH LA, 1975, J INVEST DERMATOL, V64, P316, DOI 10.1111/1523-1747.ep12512262; GORODESKI GI, 1990, J CLIN ENDOCR METAB, V70, P1624, DOI 10.1210/jcem-70-6-1624; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1982, MOL CELL BIOL, V2, P1115, DOI 10.1128/MCB.2.9.1115; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; KASTURI L, 1993, EXP CELL RES, V205, P84, DOI 10.1006/excr.1993.1061; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lambert A, 2000, SKIN PHARMACOL APPL, V13, P17, DOI 10.1159/000029905; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, J BIOL CHEM, V274, P11013, DOI 10.1074/jbc.274.16.11013; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	54	31	31	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2963	2972		10.1038/sj.onc.1208392	http://dx.doi.org/10.1038/sj.onc.1208392			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15846304				2022-12-25	WOS:000228649500005
J	Li, L; Bhatia, M; Zhu, YZ; Zhu, YC; Ramnath, RD; Wang, ZJ; Anuar, FBM; Whiteman, M; Salto-Tellez, M; Moore, PK				Li, L; Bhatia, M; Zhu, YZ; Zhu, YC; Ramnath, RD; Wang, ZJ; Anuar, FBM; Whiteman, M; Salto-Tellez, M; Moore, PK			Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse	FASEB JOURNAL			English	Article						cystathionine-gamma-lyase; H2S	CYSTATHIONINE-GAMMA-LYASE; ACUTE-PANCREATITIS; NITRIC-OXIDE; WHOLE-BLOOD; METABOLISM; CYSTEINE; KINASES; SEPSIS; TISSUE; SHOCK	Hydrogen sulfide (H2S) is synthesized in the body from L-Cysteine by several enzymes including cystathionine-gamma-lyase (CSE). To date, there is little information about the potential role of H2S in inflammation. We have now investigated the part played by H2S in endotoxin-induced inflammation in the mouse. E. coli lipopolysaccharide (LPS) administration produced a dose (10 and 20 mg/kg ip)- and time (6 and 24 h)-dependent increase in plasma H2S concentration. LPS (10 mg/kg ip, 6 h) increased plasma H2S concentration from 34.1 +/- 0.7 mu M to 40.9 +/- 0.6 mu M (n=6, P<0.05) while H2S formation from added L-Cysteine was increased in both liver and kidney. CSE gene expression was also increased in both liver (94.2 +/- 2.7%, n=6, P<0.05) and kidney (77.5 +/- 3.2%, n=6, P<0.05). LPS injection also elevated lung (148.2 +/- 2.6%, n=6, P<0.05) and kidney (78.8 +/- 8.2%, n=6, P<0.05) myeloperoxidase (MPO, a marker of tissue neutrophil infiltration) activity alongside histological evidence of lung, liver, and kidney tissue inflammatory damage. Plasma nitrate/nitrite (NOx) concentration was additionally elevated in a time- and dose-dependent manner in LPS-injected animals. To examine directly the possible proinflammatory effect of H2S, mice were administered sodium hydrosulfide (H2S donor drug, 14 mu mol/kg ip) that resulted in marked histological signs of lung inflammation, increased lung and liver MPO activity, and raised plasma TNF-alpha concentration (4.6 +/- 1.4 ng/ml, n=6). In contrast, DL-propargylglycine (CSE inhibitor, 50 mg/kg ip), exhibited marked anti-inflammatory activity as evidenced by reduced lung and liver MPO activity, and ameliorated lung and liver tissue damage. In separate experiments, we also detected significantly higher (150.5 +/- 43.7 mu M c.f. 43.8 +/- 5.1 mu M, n=5, P<0.05) plasma H2S levels in humans with septic shock. These findings suggest that H2S exhibits proinflammatory activity in endotoxic shock and suggest a new approach to the development of novel drugs for this condition.	Natl Univ Singapore, Dept Pharmacol, Singapore 117597, Singapore; Fudan Univ, Shanghai Med Coll, Minist Educ,Key Lab Mol Med, Dept Physiol & Pathophysiol, Shanghai 200032, Peoples R China; Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore Hosp, Dept Pathol, Singapore 119074, Singapore	National University of Singapore; Fudan University; National University of Singapore; National University of Singapore	Moore, PK (corresponding author), Natl Univ Singapore, Dept Pharmacol, Block MD2,18 Med Dr, Singapore 117597, Singapore.	phchead@nus.edu.sg	Zhu, Yi Zhun/ABG-8449-2021; Whiteman, Matthew/C-6079-2009	Zhu, Yi Zhun/0000-0001-7700-8041; Whiteman, Matthew/0000-0002-6583-6779; Salto-Tellez, Manuel/0000-0001-8586-282X; Ramnath, Raina/0000-0001-8472-5081				AWATA S, 1984, BIOCHEM INT, V8, P171; Bhatia M, 2005, FASEB J, V19, P623, DOI 10.1096/fj.04-3023fje; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Cheng YQ, 2004, AM J PHYSIOL-HEART C, V287, pH2316, DOI 10.1152/ajpheart.00331.2004; Gardiner SM, 1999, BRIT J PHARMACOL, V128, P1772, DOI 10.1038/sj.bjp.0702985; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Haddad JJ, 2002, ANTIOXID REDOX SIGN, V4, P179, DOI 10.1089/152308602753625942; Hui Y, 2003, J INFECTION, V47, P155, DOI 10.1016/S0163-4453(03)00043-4; Ishii I, 2004, BIOCHEM J, V381, P113, DOI 10.1042/BJ20040243; Kamoun P, 2004, AMINO ACIDS, V26, P243, DOI 10.1007/s00726-004-0072-x; Kim SH, 2004, PHARMACOL RES, V49, P433, DOI 10.1016/j.phrs.2003.11.004; KLEBANOFF SJ, 1974, J BIOL CHEM, V249, P3724; KODAMA H, 1983, ARCH BIOCHEM BIOPHYS, V225, P25, DOI 10.1016/0003-9861(83)90003-6; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lyons J, 2001, CRIT CARE MED, V29, P870, DOI 10.1097/00003246-200104000-00036; Malmezat T, 1998, J NUTR, V128, P97, DOI 10.1093/jn/128.1.97; Malmezat T, 2000, AM J PHYSIOL-ENDOC M, V279, pE1391; Mok YYP, 2004, BRIT J PHARMACOL, V143, P881, DOI 10.1038/sj.bjp.0706014; Richardson CJ, 2000, CLIN CHIM ACTA, V293, P115, DOI 10.1016/S0009-8981(99)00245-4; Sorrentino R, 1999, BRIT J PHARMACOL, V127, P1447, DOI 10.1038/sj.bjp.0702666; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Tangerman A, 2002, J CLIN PATHOL, V55, P631, DOI 10.1136/jcp.55.8.631; Thiemermann C, 1997, GEN PHARMACOL-VASC S, V29, P159, DOI 10.1016/S0306-3623(96)00410-7; *US NAT RES COUNC, 1979, HYDR SULF; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; WASHTIEN W, 1977, BIOCHEMISTRY-US, V16, P2485, DOI 10.1021/bi00630a026; Yan H, 2004, BIOCHEM BIOPH RES CO, V313, P22, DOI 10.1016/j.bbrc.2003.11.081; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	34	653	697	1	106	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1196	+		10.1096/fj.04-3583fje	http://dx.doi.org/10.1096/fj.04-3583fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15863703				2022-12-25	WOS:000228865300001
J	Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S				Filipenko, NR; Attwell, S; Roskelley, C; Dedhar, S			Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX	ONCOGENE			English	Article						integrin-linked kinase; Rac; Cdc42; cell spreading; beta-parvin; alpha-PIX	CELL-SUBSTRATE INTERACTION; FOCAL ADHESION PROTEIN; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; RHO-GTPASES; SIGNALING PATHWAYS; BINDING PROTEIN; ADAPTER PROTEIN; CH-ILKBP; ACTIVATION	Cell spreading and migration are regulated in a Rho family GTPase-dependent manner by growth factors and integrin-mediated cell-extracellular matrix (ECM) interactions. The molecular mechanisms involved in the ECM- and growth factor-mediated activation of these small GTPases remain unclear. In the present study, we demonstrate that integrin-linked kinase (ILK), which is a focal adhesion protein activated by both ECM and growth factors, is required for the activation of Rac and Cdc42 in epithelial cells. Ectopic expression of active ILK in mammary epithelial cells induces dramatic reorganization of the actin cytoskeleton and promotes rapid cell spreading on fibronectin. These effects are associated with constitutive activation of both Rac and Cdc42, but not Rho. The use of ILK siRNA or small molecule inhibitors to inhibit ILK expression and kinase activity, respectively, results in diminished cell spreading and actin cytoskeleton reorganization, concomitant with a reduction in Rac and Cdc42 activation. Studies into the mechanism of ILK-mediated Rac activation suggest an important role for the ILK-beta-parvin interaction and the activity of the Rac/Cdc42-specific guanine nucleotide exchange factor alpha-PIX downstream of ILK. Taken together, these data demonstrate an essential role of ILK kinase activity in Rac- and Cdc42-mediated actin cytoskeleton reorganization in epithelial cells, further solidifying a role for ILK in the regulation of cancer cell motility and invasiveness.	British Columbia Canc Agcy, Vancouver, BC, Canada; Univ British Columbia, Dept Anat & Cell Biol, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca	Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Anton IM, 2003, J CELL SCI, V116, P2443, DOI 10.1242/jcs.00433; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Chun SJ, 2003, J CELL BIOL, V163, P397, DOI 10.1083/jcb.200304154; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Li FG, 1999, J CELL SCI, V112, P4589; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Mills J, 2003, J NEUROSCI, V23, P1638; Mishima W, 2004, GENES CELLS, V9, P193, DOI 10.1111/j.1356-9597.2004.00717.x; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; QIAN Y, 2005, ONCOGENE; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosenberger G, 2005, J BIOL CHEM, V280, P6879, DOI 10.1074/jbc.M412119200; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamaji S, 2004, J CELL BIOL, V165, P539, DOI 10.1083/jcb.200308141; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	65	89	92	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5837	5849		10.1038/sj.onc.1208737	http://dx.doi.org/10.1038/sj.onc.1208737			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897874				2022-12-25	WOS:000231590400006
J	Papanikolaou, A; Papafotika, A; Murphy, C; Papamarcaki, T; Tsolas, O; Drab, M; Kurzchalia, TV; Kasper, M; Christoforidis, S				Papanikolaou, A; Papafotika, A; Murphy, C; Papamarcaki, T; Tsolas, O; Drab, M; Kurzchalia, TV; Kasper, M; Christoforidis, S			Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DIPHOSPHOHYDROLASE; MDCK CELLS; TRANSMEMBRANE DOMAINS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; APICAL MEMBRANE; PLASMA-MEMBRANE; CARDIAC-MUSCLE; CAVEOLAE; RAFTS	CD39 ( ecto-nucleoside triphosphate diphosphohydrolase1; E-NTPDase1) is a plasma membrane ecto-enzyme that regulates purinergic receptor signaling by controlling the levels of extracellular nucleotides. In blood vessels this enzyme exhibits a thromboregulatory role through the control of platelet aggregation. CD39 is localized in caveolae, which are plasma membrane invaginations with distinct lipid composition, similar to dynamic lipid microdomains, called rafts. Cholesterol is enriched together with sphingolipids in both rafts and caveolae, as well as in other specialized domains of the membrane, and plays a key role in their function. Here, we examine the potential role of cholesterol-enriched domains in CD39 function. Using polarized Madin-Darby canine kidney ( MDCK) cells and caveolin-1 gene-disrupted mice, we show that caveolae are not essential either for the enzymatic activity of CD39 or for its targeting to plasma membrane. On the other hand, flotation experiments using detergent-free or detergent-based approaches indicate that CD39 associates, at least in part, with distinct lipid assemblies. In the apical membrane of MDCK cells, which lacks caveolae, CD39 is localized in microvilli, which are also cholesterol and raft-dependent membrane domains. Interfering with cholesterol levels using drugs that either deplete or sequester membrane cholesterol results in a strong inhibition of the enzymatic and anti-platelet activity of CD39. The effects of cholesterol depletion are completely reversed by replenishment of membranes with pure cholesterol, but not by cholestenone. These data suggest a functional link between the localization of CD39 in cholesterol-rich domains of the membrane and its role in thromboregulation.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Fdn Res & Technol Hellas, Biomed Res Inst, GR-45110 Ioannina, Greece; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Tech Univ Dresden, Fac Med, Inst Anat, D-01307 Dresden, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Max Planck Society; Technische Universitat Dresden	Christoforidis, S (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	schristo@cc.uoi.gr	Murphy, Carol/ABE-4282-2021; Drab, Marek/J-5196-2013; Drab, Marek/AAQ-1892-2020	Murphy, Carol/0000-0003-1353-8558; Drab, Marek/0000-0002-2771-1692; Christoforidis, Savvas/0000-0002-0210-0713				AMESCH S, 1999, BIOCHEMISTRY-US, V38, P2248; ATAMAN OV, 1991, FIZIOL ZH SSSR, V37, P32; Bhatnagar A, 2004, J BIOL CHEM, V279, P34614, DOI 10.1074/jbc.M404673200; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Breuza L, 2002, EXP CELL RES, V273, P178, DOI 10.1006/excr.2001.5442; CHRISTOFORIDIS S, 1995, EUR J BIOCHEM, V234, P66, DOI 10.1111/j.1432-1033.1995.066_c.x; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dranoff JA, 2002, HEPATOLOGY, V36, P1135, DOI 10.1053/jhep.2002.36823; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Goepfert C, 2001, CIRCULATION, V104, P3109, DOI 10.1161/hc5001.100663; Goepfert C, 2000, MOL MED, V6, P591, DOI 10.1007/BF03401797; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Gratzinger D, 2003, FASEB J, V17, P1458, DOI 10.1096/fj.02-1040com; Grinthal A, 2004, BIOCHEMISTRY-US, V43, P13849, DOI 10.1021/bi048644x; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kittel A, 1999, BIOCHEM BIOPH RES CO, V262, P596, DOI 10.1006/bbrc.1999.1254; Kittel A, 1999, J HISTOCHEM CYTOCHEM, V47, P393, DOI 10.1177/002215549904700313; Kittel A, 2004, EUR J HISTOCHEM, V48, P253; Kittel A, 2004, J HISTOCHEM CYTOCHEM, V52, P861, DOI 10.1369/jhc.3A6167.2004; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Koziak K, 2000, J BIOL CHEM, V275, P2057, DOI 10.1074/jbc.275.3.2057; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lasley RD, 2001, TRENDS CARDIOVAS MED, V11, P259, DOI 10.1016/S1050-1738(01)00120-7; Ledesma MD, 2003, EMBO REP, V4, P1190, DOI 10.1038/sj.embor.7400021; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Marcus AJ, 2003, J THROMB HAEMOST, V1, P2497, DOI 10.1111/j.1538-7836.2003.00479.x; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Matsumoto M, 1999, FEBS LETT, V453, P335, DOI 10.1016/S0014-5793(99)00751-6; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Megias A, 2001, BIOCHEM J, V353, P521, DOI 10.1042/0264-6021:3530521; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Ortega A, 1996, BBA-BIOMEMBRANES, V1283, P45, DOI 10.1016/0005-2736(96)00072-7; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Poole K, 2004, FEBS LETT, V565, P53, DOI 10.1016/j.febslet.2004.03.095; Razani B, 2001, J BIOL CHEM, V276, P38121; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Rhainds D, 2004, J CELL SCI, V117, P3095, DOI 10.1242/jcs.01182; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Sevigny J, 2000, J BIOL CHEM, V275, P5640, DOI 10.1074/jbc.275.8.5640; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Slimane TA, 2003, MOL BIOL CELL, V14, P611, DOI 10.1091/mbc.E02-08-0528; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; Taylor CM, 2002, J NEUROCHEM, V81, P993, DOI 10.1046/j.1471-4159.2002.00884.x; Vogel U, 1998, J CELL SCI, V111, P825; Wang TF, 1998, J BIOL CHEM, V273, P24814, DOI 10.1074/jbc.273.38.24814; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WOOD WG, 1995, BRAIN RES, V683, P36; Zinchuk VS, 1999, CELL TISSUE RES, V298, P499, DOI 10.1007/s004419900105; Zinchuk VS, 2002, MICROSC RES TECHNIQ, V58, P427, DOI 10.1002/jemt.10157	69	66	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26406	26414		10.1074/jbc.M413927200	http://dx.doi.org/10.1074/jbc.M413927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15890655	hybrid			2022-12-25	WOS:000230386800056
J	Sabatino, L; Casamassimi, A; Peluso, G; Barone, MV; Capaccio, D; Migliore, C; Bonelli, P; Pedicini, A; Febbraro, A; Ciccodicola, A; Colantuoni, V				Sabatino, L; Casamassimi, A; Peluso, G; Barone, MV; Capaccio, D; Migliore, C; Bonelli, P; Pedicini, A; Febbraro, A; Ciccodicola, A; Colantuoni, V			A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; MESSENGER-RNA; COLON-CANCER; DIFFERENTIATION; EXPRESSION; PROMOTER; CELLS; ORGANIZATION; INFLAMMATION; TRANSCRIPTS	We examined the peroxisome proliferator-activated receptor gamma ( PPARG) locus in an attempt to identify expressed sequence tags and/or conserved non-coding sequences in the intron sequences containing open reading frames and potentially able to encode new proteins. We identified a new PPARG transcript, defined gamma ORF4, which harbors a readthrough in intron 4. The expected translated protein lacks the ligand-binding domain encoded by exons 5 and 6. We identified the transcript in human tumor cell lines and tissues, synthesized the cDNA, and cloned it in expression vectors. Using transient transfections, we found that gamma ORF4 cDNA is translated into a predominantly nuclear protein that does not transactivate a reporter gene. Moreover, the isoform is dominant negative versus PPAR gamma. Interestingly, gamma ORF4 was expressed in vivo in a series of sporadic colorectal cancers. In some cases, it was expressed, albeit at lower levels, also in the mucosa adjacent to the tumors, suggesting that it may be related to tumorigenesis. A tumorigenic effect of gamma ORF4 is in line with our finding that gamma ORF4 has not only lost the capacity to restrain cell growth but has acquired the potential to stimulate it. In conclusion, this study demonstrates that gamma ORF4 is expressed in vivo, that it has lost some PPAR gamma properties, and that it affects PPAR gamma functioning. The ability to counteract PPAR gamma suggests that gamma ORF4 plays a role in the pathogenesis of colorectal cancers.	CNR, Inst Genet & Biophys Adriano Buzzati Traverso, I-80131 Naples, Italy; Univ Sannio, Dept Biol & Environm Sci, I-82100 Benevento, Italy; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy; Univ Naples Federico II, Dept Pediat, ELFID, I-80131 Naples, Italy; NCI, Fdn G Pascale, Dept Expt Oncol, I-80131 Naples, Italy; Fatebenefratelli Hosp, Div Med Oncol, I-82100 Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Sannio; University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale	Ciccodicola, A (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Via Castellino 111, I-80131 Naples, Italy.	ciccodic@igb.cnr.it; colantuoni@unisannio.it	Bonelli, Patrizia/AAA-5106-2020; Casamassimi, Amelia/AAD-2816-2020	Bonelli, Patrizia/0000-0002-0916-4015; Casamassimi, Amelia/0000-0002-6010-4261; Sabatino, Lina/0000-0001-5341-7430; Ciccodicola, Alfredo/0000-0002-9924-1482; BARONE, Maria Vittoria/0000-0001-6190-4917	Telethon [GP0259Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chew CH, 2003, BIOCHEM BIOPH RES CO, V305, P235, DOI 10.1016/S0006-291X(03)00731-9; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Greene M. E., 1995, Gene Expression, V4, P281; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gupta RA, 2003, J BIOL CHEM, V278, P22669, DOI 10.1074/jbc.M300637200; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hegde P, 2001, CANCER RES, V61, P7792; Ikezoe T, 2001, CANCER RES, V61, P5307; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Larsen LK, 2002, BIOCHEM J, V366, P767, DOI 10.1042/BJ20011821; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; OUDEJANS CBM, 1990, DEVELOPMENT, V108, P471; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804; Saez E, 2003, NAT MED, V9, P1265, DOI 10.1038/nm928; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schutt C, 2000, DEVELOPMENT, V127, P667; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Yoshimura R, 2003, INT J CANCER, V104, P597, DOI 10.1002/ijc.10980	47	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26517	26525		10.1074/jbc.M502716200	http://dx.doi.org/10.1074/jbc.M502716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15857827	hybrid			2022-12-25	WOS:000230386800068
J	Gupta, R; Sharma, S; Sommers, JA; Jin, Z; Cantor, SB; Brosh, RM				Gupta, R; Sharma, S; Sommers, JA; Jin, Z; Cantor, SB; Brosh, RM			Analysis of the DNA substrate specificity of the human BACH1 helicase associated with breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTIONS; ESCHERICHIA-COLI; BRCT DOMAIN; PROTEIN; BINDING; REPAIR; DAMAGE; PHOSPHOPEPTIDE; RECOGNITION; MECHANISM	We have investigated the DNA substrate specificity of BACH1 ( BRCA1- associated C- terminal helicase). The importance of various DNA structural elements for efficient unwinding by purified recombinant BACH1 helicase was examined. The results indicated that BACH1 preferentially binds and unwinds a forked duplex substrate compared with a duplex flanked by only one single-stranded DNA ( ssDNA) tail. In support of its DNA substrate preference, helicase sequestration studies revealed that BACH1 can be preferentially trapped by forked duplex molecules. BACH1 helicase requires a minimal 5' ssDNA tail of 15 nucleotides for unwinding of conventional duplex DNA substrates; however, the enzyme is able to catalytically release the third strand of the homologous recombination intermediate D- loop structure irrespective of DNA tail status. In contrast, BACH1 completely fails to unwind a synthetic Holliday junction structure. Moreover, BACH1 requires nucleic acid continuity in the 5 ' ssDNA tail of the forked duplex substrate within six nucleotides of the ssDNA- dsDNA junction to initiate efficiently DNA unwinding. These studies provide the first detailed information on the DNA substrate specificity of BACH1 helicase and provide insight to the types of DNA structures the enzyme is likely to act upon to perform its functions in DNA repair or recombination.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Massachusetts System; University of Massachusetts Worcester	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	BroshR@grc.nia.nih.gov	Sharma, Sudha/AAV-6152-2021	Sharma, Sudha/0000-0003-2765-2482	NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; Bertram RD, 2002, BIOCHEMISTRY-US, V41, P7725, DOI 10.1021/bi025755s; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Botuyan MVE, 2004, STRUCTURE, V12, P1137, DOI 10.1016/j.str.2004.06.002; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Ding H, 2004, CELL, V117, P873, DOI 10.1016/j.cell.2004.05.026; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hirota Y, 2000, NUCLEIC ACIDS RES, V28, P917, DOI 10.1093/nar/28.4.917; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kawaoka J, 2004, NAT STRUCT MOL BIOL, V11, P526, DOI 10.1038/nsmb771; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakagawa T, 2002, J BIOL CHEM, V277, P28019, DOI 10.1074/jbc.M204165200; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Skibbens RV, 2004, GENETICS, V166, P33, DOI 10.1534/genetics.166.1.33; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004	32	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25450	25460		10.1074/jbc.M501995200	http://dx.doi.org/10.1074/jbc.M501995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878853	hybrid			2022-12-25	WOS:000230207900019
J	Dangi, S; Shapiro, P				Dangi, S; Shapiro, P			Cdc2-mediated inhibition of epidermal growth factor activation of the extracellular signal-regulated kinase pathway during mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTION IN-VITRO; SOMATIC-CELL MITOSIS; RNA-POLYMERASE-II; ACTIVE MAP KINASE; FACTOR RECEPTOR; GOLGI FRAGMENTATION; CANCER-THERAPY; MITOTIC REPRESSION; G(2)/M TRANSITION	Inhibition of general transcription and translation occurs during mitosis to preserve the high energy requirements needed for the dynamic structural changes that are occurring at this time of the cell cycle. Although the mitotic kinase Cdc2 appears to directly phosphorylate and inhibit key proteins directly involved in transcription and translation, the role of Cdc2 in regulating upstream growth factor receptor-mediated signal transduction pathways is limited. In the present study, we examined mechanisms involved in uncoupling receptor-mediated activation of the extracellular signal-regulated (ERK) signaling pathway in mitotic cells. Treatment with epidermal growth factor (EGF) failed to activate the ERK pathway in mitotic cells, although partial activation of ERK could be achieved in mitotic cells treated with phorbol 12-myristate 13-acetate (PMA). The discrepancy between EGF and PMA-mediated ERK activation suggested that multiple events in the ERK pathway were regulated during mitosis. We show that Cdc2 inhibits EGF-mediated ERK activation through direct interaction and phosphorylation of several ERK pathway proteins, including the guanine nucleotide exchange factor, Sos-1, and Raf-1 kinase. Inhibition of Cdc2 activity with roscovitine in mitotic cells restored ERK activation by EGF and PMA. Similarly, mitotic inhibition of ERK activity in cells expressing active mutants of H-Ras and Raf-1 kinase could also be reversed following Cdc2 inhibition. In contrast, ERK activation in cells expressing active MEK1 was not inhibited during mitosis or affected by roscovitine. These data suggest that Cdc2 inhibits growth factor receptor-mediated ERK activation during mitosis by primarily targeting signaling proteins that are upstream of MEK1.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Shapiro, P (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	pshapiro@rx.umaryland.edu						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Albanell J, 1999, J MAMMARY GLAND BIOL, V4, P337, DOI 10.1023/A:1018762216147; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Brose MS, 2002, CANCER RES, V62, P6997; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Drevs J, 2003, CURR DRUG TARGETS, V4, P113, DOI 10.2174/1389450033346885; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Gomez-Cambronero J, 1999, FEBS LETT, V443, P126, DOI 10.1016/S0014-5793(98)01685-8; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; KASZKIN M, 1991, CANCER RES, V51, P4328; King C R, 1990, Semin Cancer Biol, V1, P329; KINZEL V, 1990, CANCER RES, V50, P7932; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; Kiyokawa N, 1997, ONCOGENE, V15, P2633, DOI 10.1038/sj.onc.1201442; Klein S, 1997, BIOCHEM J, V322, P937, DOI 10.1042/bj3220937; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Leresche A, 1996, EXP CELL RES, V229, P282, DOI 10.1006/excr.1996.0373; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; NEWBERRY EP, 1995, BIOCHEM BIOPH RES CO, V208, P253, DOI 10.1006/bbrc.1995.1331; Nigg E A, 1992, Semin Cell Biol, V3, P245, DOI 10.1016/1043-4682(92)90026-R; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; NORBURY C, 1990, CIBA F SYMP, V150, P168; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Shah OJ, 2003, J BIOL CHEM, V278, P16433, DOI 10.1074/jbc.M300435200; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Tebar F, 2002, FEBS LETT, V517, P206, DOI 10.1016/S0014-5793(02)02624-8; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Xie SQ, 2004, ONCOGENE, V23, P3822, DOI 10.1038/sj.onc.1207479; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yun C, 2004, MOL CANCER RES, V2, P159; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	64	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24524	24531		10.1074/jbc.M414079200	http://dx.doi.org/10.1074/jbc.M414079200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15888452	hybrid			2022-12-25	WOS:000230114000029
J	Gurung, B; Yu, L; Xia, D; Yu, CA				Gurung, B; Yu, L; Xia, D; Yu, CA			The iron-sulfur cluster of the Rieske iron-sulfur protein functions as a proton-exiting gate in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; DOMAIN MOVEMENT; BOVINE HEART; BC1 COMPLEX; RHODOBACTER-SPHAEROIDES; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; QUINONE REDUCTION; TETHER REGION; B(6)F COMPLEX	The destruction of the Rieske iron-sulfur cluster ([2Fe-2S]) in the bc(1) complex by hematoporphyrin-promoted photoinactivation resulted in the complex becoming proton-permeable (Miki, T., Yu, L., and Yu, C.-A. ( 1991) Biochemistry 30, 230-238). To study further the role of this [2Fe-2S] cluster in proton translocation of the bc(1) complex, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes with mutations at the histidine ligands of the [2Fe-2S] cluster were generated and characterized. These mutants lacked the [2Fe-2S] cluster and possessed no bc(1) activity. When the mutant complex was co-inlaid in phospholipid vesicles with intact bovine mitochondrial bc(1) complex or cytochrome c oxidase, the proton ejection, normally observed in intact reductase or oxidase vesicles during the oxidation of their corresponding substrates, disappeared. This indicated the creation of a proton-leaking channel in the mutant complex, whose [2Fe-2S] cluster was lacking. Insertion of the bc(1) complex lacking the head domain of the Rieske iron-sulfur protein, removed by thermolysin digestion, into PL vesicles together with mitochondrial bc(1) complex also rendered the vesicles proton-permeable. Addition of the excess purified head domain of the Rieske iron-sulfur protein partially restored the proton-pumping activity. These results indicated that elimination of the [2Fe-2S] cluster in mutant bc(1) complexes opened up an otherwise closed proton channel within the bc(1) complex. It was speculated that in the normal catalytic cycle of the bc(1) complex, the [2Fe-2S] cluster may function as a proton-exiting gate.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; NCI, Lab Cell Biol Ctr, NIH, Bethesda, MD 20892 USA	Oklahoma State University System; Oklahoma State University - Stillwater; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 255 NRC, Stillwater, OK 74078 USA.	cayuq@okstate.edu			NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010319, ZIABC010319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; COCCO T, 1992, EUR J BIOCHEM, V209, P475, DOI 10.1111/j.1432-1033.1992.tb17312.x; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; CROFTS AR, 2004, BIOCHIM BIOPHYS ACTA, V1665, P77; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; Esser L, 2004, J MOL BIOL, V341, P281, DOI 10.1016/j.jmb.2004.05.065; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gennis RB, 1999, SCIENCE, V286, P252, DOI 10.1126/science.286.5438.252; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GUNER S, 1991, BIOCHIM BIOPHYS ACTA, V1058, P269, DOI 10.1016/S0005-2728(05)80247-6; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P50703, DOI 10.1074/jbc.M208556200; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENNER ER, 1973, Patent No. 3737516; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; Kannt A, 1998, FEBS LETT, V434, P17, DOI 10.1016/S0014-5793(98)00942-9; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LORUSSO M, 1983, EUR J BIOCHEM, V137, P413, DOI 10.1111/j.1432-1033.1983.tb07844.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MIKI T, 1991, BIOCHEMISTRY-US, V30, P230, DOI 10.1021/bi00215a033; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Obungu VH, 2000, BBA-BIOENERGETICS, V1457, P36, DOI 10.1016/S0005-2728(99)00116-4; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; Valkova-Valchanova M, 2000, BIOCHEMISTRY-US, V39, P15484, DOI 10.1021/bi000751d; Wikstrom M, 2003, BBA-BIOENERGETICS, V1604, P61, DOI 10.1016/S0005-2728(03)00041-0; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2004, BIOCHEMISTRY-US, V43, P1488, DOI 10.1021/bi035378z; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	53	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24895	24902		10.1074/jbc.M503319200	http://dx.doi.org/10.1074/jbc.M503319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878858	hybrid			2022-12-25	WOS:000230114000073
J	Hertz, R; Kalderon, B; Byk, T; Berman, I; Za'tara, G; Mayer, R; Bar-Tana, J				Hertz, R; Kalderon, B; Byk, T; Berman, I; Za'tara, G; Mayer, R; Bar-Tana, J			Thioesterase activity and acyl-CoA/fatty acid cross-talk of hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-BINDING PROTEIN; GENE-EXPRESSION; LIGAND SPECIFICITY; MASS-SPECTROMETRY; HNF-4-ALPHA; ACTIVATION; RECEPTORS; CRYSTAL; RESCUE; DOMAIN	Hepatocyte nuclear factor-4 alpha ( HNF-4 alpha) activity is modulated by natural and xenobiotic fatty acid and fatty acyl-CoA ligands as a function of their chain length, unsaturation, and substitutions. The acyl-CoA site of HNF-4 alpha is reported here to consist of the E-F domain, to bind long-chain acyl-CoAs but not the respective free acids, and to catalyze the hydrolysis of bound fatty acyl-CoAs. The free acid pocket, previously reported in the x-ray structure of HNF-4 alpha E-domain, entraps fatty acids but excludes acyl-CoAs. The acyl-CoA and free acid sites are distinctive and noncongruent. Free fatty acid products of HNF-4 alpha thioesterase may exchange with free acids entrapped in the fatty acid pocket of HNF-4 alpha. Cross-talk between the acyl-CoA and free fatty acid binding sites is abrogated by high affinity, nonhydrolyzable acyl-CoA ligands of HNF-4 alpha that inhibit its thioesterase activity. Hence, HNF-4 alpha transcriptional activity is controlled by its two interrelated acyl ligands and two binding sites interphased in tandem by the thioesterase activity. The acyl-CoA/ free-acid and receptor/enzyme duality of HNF-4 alpha extends the paradigm of nuclear receptors.	Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel; Quark Biotech Inc, IL-70400 Ness Ziona, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, POB 12272, IL-91120 Jerusalem, Israel.	bartanaj@cc.huji.ac.il						BARTANA J, 1985, J BIOL CHEM, V260, P8404; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Duda K, 2004, J BIOL CHEM, V279, P23311, DOI 10.1074/jbc.M400864200; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; Duncan SA, 1997, DEVELOPMENT, V124, P279; Elholm M, 2000, J LIPID RES, V41, P538; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Hamilton JA, 2004, PROG LIPID RES, V43, P177, DOI 10.1016/j.plipres.2003.09.002; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; Kalderon B, 2002, J LIPID RES, V43, P1125, DOI 10.1194/jlr.M200060-JLR200; KAWAGUCHI A, 1981, J BIOCH JAPAN, V89, P2337; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; Malik S, 1996, MOL CELL BIOL, V16, P1824; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Petrescu AD, 2005, J BIOL CHEM, V280, P16714, DOI 10.1074/jbc.M405906200; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Potier N, 2003, PROTEIN SCI, V12, P725, DOI 10.1110/ps.0232503; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Sladek F. M., 2001, HEPATOCYTE NUCL FACT, P309; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P233; WALSH C, 1979, ENZYMATIC REACTION M, P94; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	31	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24451	24461		10.1074/jbc.M500732200	http://dx.doi.org/10.1074/jbc.M500732200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870076	hybrid			2022-12-25	WOS:000230114000021
J	Siu, MKY; Wong, CH; Lee, WM; Cheng, CY				Siu, MKY; Wong, CH; Lee, WM; Cheng, CY			Sertoli-germ cell anchoring junction dynamics in the testis are regulated by an interplay of lipid and protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; RAT TESTIS; P21-ACTIVATED KINASE; SEMINIFEROUS EPITHELIUM; TIGHT JUNCTION; EXTRACELLULAR-MATRIX; AKT PHOSPHORYLATION; SIGNALING PATHWAYS	When Sertoli and germ cells were co-cultured in vitro in serum-free chemically defined medium, functional anchoring junctions such as cell-cell intermediate filament-based desmosome-like junctions and cell-cell actin-based adherens junctions (e.g. ectoplasmic specialization (ES)) were formed within 1-2 days. This event was marked by the induction of several protein kinases such as phosphatidylinositol 3-kinase (PI3K), phosphorylated protein kinase B (PKB; also known as Akt), p21-activated kinase-2 (PAK-2), and their downstream effector (ERK) as well as an increase in PKB intrinsic activity. PI3K, phospho (p)-PKB, and PAK were co-localized to the site of apical ES in the seminiferous epithelium of the rat testis in immunohistochemistry studies. Furthermore, PI3K also co-localized with p-PKB to the same site in the epithelium as determined by fluorescence microscopy, consistent with their localization at the ES. These kinases were shown to associate with ES-associated proteins such as beta 1-integrin, phosphorylated focal adhesion kinase, and c-Src by co-immunoprecipitation, suggesting that the integrin(.)laminin protein complex at the apical ES likely utilizes these protein kinases as regulatory proteins to modulate Sertoli-germ cell adherens junction dynamics via the ERK signaling pathway. To validate this hypothesis further, an in vivo model using AF-2364 (1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide) to perturb Sertoli-germ cell anchoring junction function, inducing germ cell loss from the epithelium in adult rats, was used in conjunction with specific inhibitors. Interestingly, the event of germ cell loss induced by AF-2364 in vivo was also associated with induction of PI3K, p-PKB, PAK-2, and p-ERK as well as a surge in intrinsic PKB activity. Perhaps the most important of all, pretreatment of rats with wortmannin (a PI3K inhibitor) or anti-beta 1-integrin antibody via intratesticular injection indeed delayed AF-2364-induced spermatid loss from the epithelium. In summary, these results illustrate that Sertoli-germ cell anchoring junction dynamics in the testis are regulated, at least in part, via the beta 1-integrin/PI3K/PKB/ERK signaling pathway.	Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong, Peoples R China	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, Ctr Biomed Res, 1230 York Ave, New York, NY 10021 USA.	Y-Cheng@popcbr.rockefeller.edu	Lee, Will M/D-2357-2009	Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U01 HD045908, U54 HD029990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMLANI S, 1988, ANAT REC, V220, P143, DOI 10.1002/ar.1092200206; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Chapin RE, 2001, J ANDROL, V22, P1030; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; CHENG CY, 1986, ENDOCRINOLOGY, V118, P480, DOI 10.1210/endo-118-2-480; Cheng CY, 2001, BIOL REPROD, V65, P449, DOI 10.1095/biolreprod65.2.449; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CRANS DC, 1989, J AM CHEM SOC, V111, P7597, DOI 10.1021/ja00201a049; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; Crepieux P, 2002, ARCH BIOCHEM BIOPHYS, V399, P245, DOI 10.1006/abbi.2002.2773; Crepieux P, 2001, ONCOGENE, V20, P4696, DOI 10.1038/sj.onc.1204632; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; de Kretser D.M., 1988, P837; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; GALDIERI M, 1981, J ANDROL, V2, P249; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Grima J, 1998, J BIOL CHEM, V273, P21040, DOI 10.1074/jbc.273.33.21040; Grima J, 2001, BIOL REPROD, V64, P1500, DOI 10.1095/biolreprod64.5.1500; Guttman JA, 2002, J CELL SCI, V115, P499; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Khan SA, 2002, ENDOCRINOLOGY, V143, P2259, DOI 10.1210/en.143.6.2259; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; KUSTIN K, 1973, J AM CHEM SOC, V95, P3564, DOI 10.1021/ja00792a017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lee NPY, 2003, BIOL REPROD, V68, P489, DOI 10.1095/biolreprod.102.005793; Lee NPY, 2005, J CELL PHYSIOL, V202, P344, DOI 10.1002/jcp.20119; Lee NPY, 2003, ENDOCRINOLOGY, V144, P3114, DOI 10.1210/en.2002-0167; Lui WY, 2003, BIOL REPROD, V68, P1087, DOI 10.1095/biolreprod.102.010371; Marino M, 2003, MOL BIOL CELL, V14, P2583, DOI 10.1091/mbc.E02-09-0621; MATHER JP, 1982, ANN NY ACAD SCI, V383, P44, DOI 10.1111/j.1749-6632.1982.tb23161.x; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Meroni SB, 2004, J ENDOCRINOL, V180, P257, DOI 10.1677/joe.0.1800257; Meroni SB, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740195; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mruk D, 1997, J ANDROL, V18, P612; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 1999, J BIOL CHEM, V274, P27056, DOI 10.1074/jbc.274.38.27056; Munshi HG, 2002, J BIOL CHEM, V277, P38159, DOI 10.1074/jbc.M202384200; Ohtakara K, 2000, BIOCHEM BIOPH RES CO, V272, P712, DOI 10.1006/bbrc.2000.2854; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; PRZYBOROWSKI L, 1965, HELV CHIM ACTA, V48, P1556, DOI 10.1002/hlca.19650480716; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Santini CL, 2001, J BIOL CHEM, V276, P8159, DOI 10.1074/jbc.C000833200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Siu MKY, 2004, BIOESSAYS, V26, P978, DOI 10.1002/bies.20099; Siu MKY, 2004, BIOL REPROD, V71, P375, DOI 10.1095/biolreprod.104.028225; Siu MKY, 2004, BIOL REPROD, V70, P945, DOI 10.1095/biolreprod.103.023606; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; Strege PR, 2003, AM J PHYSIOL-CELL PH, V284, pC60, DOI 10.1152/ajpcell.00532.2001; Toyama Yoshiro, 2003, Anatomical Science International, V78, P1, DOI 10.1046/j.0022-7722.2003.00034.x; VOGL AW, 1989, INT REV CYTOL, V119, P1; Vogl AW, 2000, ARCH HISTOL CYTOL, V63, P1, DOI 10.1679/aohc.63.1; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003; ZWAIN IH, 1994, MOL CELL ENDOCRINOL, V104, P213, DOI 10.1016/0303-7207(94)90124-4	79	143	153	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25029	25047		10.1074/jbc.M501049200	http://dx.doi.org/10.1074/jbc.M501049200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870075	Green Published, hybrid			2022-12-25	WOS:000230114000087
J	Smith, AC; Cirulis, JT; Casanova, JE; Scidmore, MA; Brumell, JH				Smith, AC; Cirulis, JT; Casanova, JE; Scidmore, MA; Brumell, JH			Interaction of the Salmonella-containing vacuole with the endocytic recycling system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III SECRETION SYSTEM; TYPHIMURIUM-CONTAINING VACUOLES; ENTERICA SEROVAR TYPHIMURIUM; SURFACE-ANTIGEN PARTICLES; PATHOGENICITY ISLAND 2; RIBOSYLATION FACTOR 6; PLASMA-MEMBRANE; INTRACELLULAR PROLIFERATION; ACTIN CYTOSKELETON; CELL-SURFACE	Upon entry of the pathogen Salmonella enterica serovar Typhimurium into host cells, the majority of bacteria reside in a membrane-bound compartment called the Salmonella-containing vacuole (SCV). Previous studies have established that the SCV transiently interacts with early endosomes but only acquires a subset of late endosomal/lysosomal proteins. However, the complete set of interactions between the SCV and the endocytic machinery has yet to be characterized. In this study, we have shown that four characterized regulators of endocytic recycling were present on the SCV after invasion. Interaction kinetics were different for each of the regulators; ARF6 and Rab4 associated immediately, but their presence was diminished 60 min post-infection, whereas syntaxin13 and Rab11 association peaked at 60 min. Using a dominant negative approach, we determined that Rab11 regulates the recycling of CD44 from the vacuole but had no effect on major histocompatibility complex (MHC) class I recycling. In contrast, syntaxin13 regulated the recycling of MHC class I but not of CD44. We also determined that maturation of the SCV, measured by the acquisition of lysosomal associated membrane protein-1, slowed when recycling was impaired. These findings suggest that protein movement through the endocytic recycling system is regulated through at least two concurrent pathways and that efficient interaction with these pathways is necessary for maturation of the Salmonella-containing vacuole. We also demonstrate the utility of using Salmonella invasion as a model of endosomal recycling events.	Hosp Sick Children, IIIR Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A1, Canada; Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA; Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Virginia; Cornell University	Brumell, JH (corresponding author), Hosp Sick Children, IIIR Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	john.brumell@sickkids.ca						Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; Birmingham CL, 2005, INFECT IMMUN, V73, P1204, DOI 10.1128/IAI.73.2.1204-1208.2005; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Brumell JH, 1999, CURR BIOL, V9, pR277, DOI 10.1016/S0960-9822(99)80178-X; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Brumell JH, 2004, CURR OPIN MICROBIOL, V7, P78, DOI 10.1016/j.mib.2003.12.005; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cirillo DM, 1998, MOL MICROBIOL, V30, P175, DOI 10.1046/j.1365-2958.1998.01048.x; Collins RF, 2002, J IMMUNOL, V169, P3250, DOI 10.4049/jimmunol.169.6.3250; Criss AK, 2001, J BIOL CHEM, V276, P48431, DOI 10.1074/jbc.M106969200; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Damiani MT, 2004, TRAFFIC, V5, P785, DOI 10.1111/j.1600-0854.2004.00220.x; DELPORTILLO FG, 1995, J CELL BIOL, V129, P81; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; GARCIADELPORTILLO F, 1994, J CELL SCI, V107, P2005; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; Harrison RE, 2004, MOL BIOL CELL, V15, P3146, DOI 10.1091/mbc.E04-02-0092; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; HOCHMAN JH, 1991, J IMMUNOL, V146, P1862; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Hurley BP, 2003, TRENDS MICROBIOL, V11, P562, DOI 10.1016/j.tim.2003.10.002; Johnson AO, 1998, J BIOL CHEM, V273, P17968, DOI 10.1074/jbc.273.28.17968; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; LIU TM, 1995, J IMMUNOL, V154, P3147; Martinez-Lorenzo MJ, 2001, CELL MICROBIOL, V3, P407, DOI 10.1046/j.1462-5822.2001.00123.x; MARTINEZKINADER B, 1995, IMMUNOLOGY, V86, P287; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Prigent M, 2003, J CELL BIOL, V163, P1111, DOI 10.1083/jcb.200305029; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Roberts RL, 2000, J LEUKOCYTE BIOL, V68, P627; Rzomp KA, 2003, INFECT IMMUN, V71, P5855, DOI 10.1128/IAI.71.10.5855-5870.2003; SCHIRMBECK R, 1995, EUR J IMMUNOL, V25, P1063, DOI 10.1002/eji.1830250431; Schirmbeck R, 1996, EUR J IMMUNOL, V26, P2812, DOI 10.1002/eji.1830261204; Segura I, 2004, J MICROBIOL METH, V56, P83, DOI 10.1016/j.mimet.2003.09.004; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Song R, 1996, J IMMUNOL, V156, P4182; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Stryhn A, 1996, J IMMUNOL, V156, P4191; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; Trischler M, 1999, J CELL SCI, V112, P4773; Tsolis RM, 1999, ADV EXP MED BIOL, V473, P261; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wick MJ, 1996, EUR J IMMUNOL, V26, P2790, DOI 10.1002/eji.1830261135; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	64	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24634	24641		10.1074/jbc.M500358200	http://dx.doi.org/10.1074/jbc.M500358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15886200	hybrid			2022-12-25	WOS:000230114000043
J	Ohya, K; Handa, Y; Ogawa, M; Suzuki, M; Sasakawa, C				Ohya, K; Handa, Y; Ogawa, M; Suzuki, M; Sasakawa, C			IpgB1 is a novel Shigella effector protein involved in bacterial invasion of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ESCHERICHIA-COLI K-12; III SECRETION SYSTEM; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; RHO-GTPASES; INFECTED MACROPHAGES; FLEXNERI; PLASMID; VIRULENCE	Shigella, the causative agent of bacillary dysentery, is capable of inducing the large scale membrane ruffling required for the bacterial invasion of host cells. Shigella secrete a subset of effectors via the type III secretion system (TTSS) into the host cells to induce membrane ruffling. Here, we show that IpgB1 is secreted via the TTSS into epithelial cells and plays a major role in producing membrane ruffles via stimulation of Rac1 and Cdc42 activities, thus promoting bacterial invasion of epithelial cells. The invasiveness of the ipgB1 mutant was decreased to less than 50% of the wild-type level (100%) in a gentamicin protection or plaque forming assay. HeLa cells infected with the wild-type or a IpgB1-hyperproducing strain developed membrane ruffles, with the invasiveness and the scale of membrane ruffles being comparable with the level of IpgB1 production in bacteria. Upon expression of EGFP-IpgB1 in HeLa cells, large membrane ruffles are extended, where the EGFP-IpgB1 was predominantly associated with the cytoplasmic membrane. The IpgB1-mediated formation of ruffles was significantly diminished by expressing Rac1 small interfering RNA and Cdc42 small interfering RNA or by treatment with GGTI-298, an inhibitor of the geranylgeranylation of Rho GTPases. When IpgB1 was expressed in host cells or wild-type Shigella-infected host cells, Rac1 and Cdc42 were activated. The results thus indicate that IpgB1 is a novel Shigella effector involved in bacterial invasion of epithelial cells via the activation of Rho GTPases.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Suzuki, Masato/B-7568-2013	Suzuki, Masato/0000-0001-8975-2193; Ohya, Kenji/0000-0002-8867-3618				Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bougneres L, 2004, J CELL BIOL, V166, P225, DOI 10.1083/jcb.200402073; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dumenil G, 2000, J CELL SCI, V113, P71; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; Forsberg M, 2003, J LEUKOCYTE BIOL, V74, P620, DOI 10.1189/jlb.1202586; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kitamura T, 1998, INT J HEMATOL, V67, P351; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mounier J, 1999, J CELL SCI, V112, P2069; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ogawa M, 2003, MOL MICROBIOL, V48, P913, DOI 10.1046/j.1365-2958.2003.03489.x; Page AL, 1999, CELL MICROBIOL, V1, P183, DOI 10.1046/j.1462-5822.1999.00019.x; Page AL, 2002, MOL MICROBIOL, V43, P1533, DOI 10.1046/j.1365-2958.2002.02835.x; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; SASAKAWA C, 1986, INFECT IMMUN, V54, P32, DOI 10.1128/IAI.54.1.32-36.1986; SASAKAWA C, 2004, BACTERIAL INVASION, V5, P25; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Skoudy A, 2000, CELL MICROBIOL, V2, P19, DOI 10.1046/j.1462-5822.2000.00028.x; SMALL PLC, 1987, INFECT IMMUN, V55, P1674, DOI 10.1128/IAI.55.7.1674-1679.1987; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Suzuki T, 2005, J BIOL CHEM, V280, P14042, DOI 10.1074/jbc.M414671200; Tafazoli F, 2003, INFECT IMMUN, V71, P872, DOI 10.1128/IAI.71.2.872-881.2003; TOBE T, 1991, MOL MICROBIOL, V5, P887, DOI 10.1111/j.1365-2958.1991.tb00762.x; Tran Van Nhieu G., 1997, EMBO J, V16, P2717; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van der Goot FG, 2004, J BIOL CHEM, V279, P47792, DOI 10.1074/jbc.M406824200; Van Nhieu GT, 2005, CURR OPIN MICROBIOL, V8, P16, DOI 10.1016/j.mib.2004.12.006; Van Nhieu GT, 1999, EMBO J, V18, P3249, DOI 10.1093/emboj/18.12.3249; Vogt A, 1996, ONCOGENE, V13, P1991; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; Yoshida S, 2003, TRENDS MICROBIOL, V11, P139, DOI 10.1016/S0966-842X(03)00023-4; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	51	78	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24022	24034		10.1074/jbc.M502509200	http://dx.doi.org/10.1074/jbc.M502509200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849186	hybrid			2022-12-25	WOS:000229880000076
J	Gotoh, K; Fukagawa, K; Fukagawa, T; Noguchi, H; Kakuma, T; Sakata, T; Yoshimatsu, H				Gotoh, K; Fukagawa, K; Fukagawa, T; Noguchi, H; Kakuma, T; Sakata, T; Yoshimatsu, H			Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine interact in the leptin-signaling pathway to regulate feeding behavior	FASEB JOURNAL			English	Article						exendin(9-39); tele-methyl histamine; nucleus of the solitary tract	RAT HYPOTHALAMUS; FOOD-INTAKE; RECEPTOR; MICE; NUCLEUS; BRAIN; CELLS	Glucagon-like peptide-1 (GLP-1), corticotropin-releasing hormone (CRH), and hypothalamic neuronal histamine suppress food intake,a target of leptin action in the brain. This study examined the interactions of GLP-1, CRH, and histamine downstream from the leptin-signaling pathway in regulating feeding behavior. Infusion of GLP-1 into the third cerebral ventricle (i3vt) at a dose of 1 mu g significantly decreased the initial 1 h cumulative food intake in rats as compared with phosphate-buffered saline (PBS) controls. The GLP-1-induced suppression of feeding was partially attenuated by intraperitoneal pretreatment with alpha-fluoromethylhistidine (FMH), a specific suicide inhibitor of histidine decarboxylase, which depletes hypothalamic neuronal histamine. Pretreatment with alpha-helical CRH (10 mu g/rat, i3vt), a nonselective CRH antagonist, abolished the GLP-1-induced suppression of feeding completely. I3vt infusion of GLP-1 increased the CRH content and histamine turnover assessed using the pargyline-induced accumulation of tele-methyl histamine(t-MH), a major metabolite of neuronal histamine,in the hypothalamus. The central infusion of CRH also induced the increase of histamine turnover and CRH receptor type 1 was localized on the cell body of histamine neuron. Pretreatment with exendin(9-39), a GLP-1 receptor ant agonist, attenuated the leptin-induced increase in CRH content of the hypothalamus. Finally,i3vt infusion of leptin also increased histamine turnover in the hypothalamus. Pretreatment with exendin(9-39), alpha-helical CRH or both antagonists attenuated the leptin-induced responses of t-MH levels in the hypothalamus. These results suggest that CRH or hypothalamic neuronal histamine mediates the GLP-1-induced suppression of feeding behavior, that CRH mediates GLP-1 signaling to neuronal histamine and that a functional link from GLP-1 to neuronal histamine via CRH constitutes the leptin-signaling pathway regulating feeding behavior.	Oita Univ, Fac Med, Dept Internal Med 1, Oita 8795593, Japan	Oita University	Yoshimatsu, H (corresponding author), Oita Univ, Fac Med, Dept Internal Med 1, Oita 8795593, Japan.	hiroy@med.oita-u.ac.jp						ENG J, 1992, MT SINAI J MED, V59, P147; FUKAGAWA K, 1989, AM J PHYSIOL, V256, pR605, DOI 10.1152/ajpregu.1989.256.3.R605; GOKE R, 1993, J BIOL CHEM, V268, P19650; Goldstone AP, 1997, FEBS LETT, V415, P134, DOI 10.1016/S0014-5793(97)01103-4; Gunn I, 1996, BIOCHEM SOC T, V24, P581, DOI 10.1042/bst0240581; Huang QL, 1998, ENDOCRINOLOGY, V139, P1524, DOI 10.1210/en.139.4.1524; Itateyama E, 2003, EXP BIOL MED, V228, P1132; Larsen PJ, 1997, NEUROSCIENCE, V77, P257, DOI 10.1016/S0306-4522(96)00434-4; Larsen PJ, 1997, ENDOCRINOLOGY, V138, P4445, DOI 10.1210/en.138.10.4445; MacLusky NJ, 2000, ENDOCRINOLOGY, V141, P752, DOI 10.1210/en.141.2.752; Masaki T, 2003, ENDOCRINOLOGY, V144, P2741, DOI 10.1210/en.2003-0031; Navarro M, 1996, J NEUROCHEM, V67, P1982; OISHI R, 1987, J NEUROCHEM, V49, P541, DOI 10.1111/j.1471-4159.1987.tb02898.x; OOHARA A, 1994, J NEUROCHEM, V63, P677; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Ryan AS, 1998, J CLIN ENDOCR METAB, V83, P2399, DOI 10.1210/jc.83.7.2399; SAKATA T, 1981, PHYSIOL BEHAV, V27, P401, DOI 10.1016/0031-9384(81)90323-1; SAKATA T, 1982, NEURAL BASIS FEEDING, P339; Sarkar S, 2003, BRAIN RES, V985, P163, DOI 10.1016/S0006-8993(03)03117-2; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; vanDijk G, 1996, AM J PHYSIOL-REG I, V271, pR1096, DOI 10.1152/ajpregu.1996.271.4.R1096; Yoshimatsu K, 1999, DIABETES, V48, P2286, DOI 10.2337/diabetes.48.12.2286	27	41	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1131	+		10.1096/fj.04-2384fje	http://dx.doi.org/10.1096/fj.04-2384fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894564				2022-12-25	WOS:000229602600015
J	Griol-Charhbili, V; Messadi-Laribi, E; Bascands, JL; Heudes, D; Meneton, P; Giudicelli, JF; Alhenc-Gelas, F; Richer, C				Griol-Charhbili, V; Messadi-Laribi, E; Bascands, JL; Heudes, D; Meneton, P; Giudicelli, JF; Alhenc-Gelas, F; Richer, C			Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia	FASEB JOURNAL			English	Article						myocardial infarction; angiotensin-converting enzyme inhibitor; kallikrein-kinin system; mice	ANGIOTENSIN-CONVERTING ENZYME; BRADYKININ B-2 RECEPTOR; FLOW-DEPENDENT DILATION; GENE KNOCKOUT MICE; NITRIC-OXIDE; ISCHEMIA/REPERFUSION INJURY; INFARCT SIZE; IN-VIVO; CORONARY-OCCLUSION; SIGNALING PATHWAYS	Tissue kallikrein (TK), a major kinin-forming enzyme, is synthesized in the heart and arteries. We tested the hypothesis that TK plays a protective role in myocardial ischemia by performing ischemia-reperfusion (IR) injury, with and without ischemic preconditioning (IPC) or ACE inhibitor (ramiprilat) pretreatment, in vivo in littermate wild-type (WT) or TK-deficient (TK-/-) mice. IR induced similar infarcts in WT and TK-/- IPC reduced infarct size by 65% in WT, and by 40% in TK-/- (P<0.05, TK-/- vs WT). Ramiprilat also reduced infarct size by 29% in WT, but in TK-/- its effect was completely suppressed. Pretreatment of WT with a B2, but not a B1, kinin receptor antagonist reproduced the effects of TK deficiency. However, B2 receptor-deficient mice (B2(-/-)) unexpectedly responded to IPC or ramiprilat like WT mice. But pretreatment of the B2(-/-) mice with a B1 antagonist suppressed the cardioprotective effects of IPC and ramiprilat. In B2(-/-), B1 receptor gene expression was constitutively high. In WT and TK-/- mice, both B2 and B1 mRNA levels increased several fold during IR, and even more during IPC+IR. Thus TK and the B2 receptor play a critical role in the cardioprotection afforded by two experimental maneuvers of potential clinical relevance, IPC and ACE inhibition, during ischemia.	INSERM, U652 367, F-75270 Paris, France; Fac Med Paris Sud, Dept Pharmacol, F-94276 Le Kremlin Bicetre, France; Inst Louis Bugnard, INSERM, U388, IFR31, F-31432 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)	Richer, C (corresponding author), INSERM, U652, 15 Rue Ecole Med, F-75270 Paris, France.	christine.giudicelli@kb.u-psud.fr	Meneton, Pierre/T-1216-2019; Bascands, Jean-loup/G-3260-2013; Alhenc-Gelas, Francois/F-9511-2017	Bascands, Jean-loup/0000-0002-1667-5913				Bergaya S, 2004, CIRC RES, V94, P1623, DOI 10.1161/01.RES.0000131497.73744.1a; Bergaya S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Brown NJ, 2000, CIRCULATION, V102, P2190; COHEN MV, 1991, CIRCULATION, V84, P341, DOI 10.1161/01.CIR.84.1.341; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; Gougat J, 2004, J PHARMACOL EXP THER, V309, P661, DOI 10.1124/jpet.103.059527; Guo YR, 1998, AM J PHYSIOL-HEART C, V275, pH1375; HARTMAN JC, 1995, ANN THORAC SURG, V60, P789, DOI 10.1016/0003-4975(95)00192-N; HARTMAN JC, 1993, J CARDIOVASC PHARM, V21, P996, DOI 10.1097/00005344-199306000-00022; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; KITAKAZE M, 1995, CIRCULATION, V92, P950, DOI 10.1161/01.CIR.92.4.950; Laude K, 2002, CARDIOVASC RES, V55, P466, DOI 10.1016/S0008-6363(02)00277-8; Linz W, 1996, DIABETES, V45, pS51, DOI 10.2337/diab.45.1.S51; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Murphy E, 2004, CIRC RES, V94, P7, DOI 10.1161/01.RES.0000108082.76667.F4; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakano A, 2000, PHARMACOL THERAPEUT, V86, P263, DOI 10.1016/S0163-7258(00)00058-9; NOLLY H, 1994, HYPERTENSION, V23, P919, DOI 10.1161/01.HYP.23.6.919; Oldenburg O, 2004, AM J PHYSIOL-HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003; Pan HL, 2000, AM J PHYSIOL-HEART C, V279, pH116; PEARSON PJ, 1990, CIRCULATION, V81, P1921, DOI 10.1161/01.CIR.81.6.1921; Pinto YM, 2000, FASEB J, V14, P1861; Schulz R, 2004, CARDIOVASC RES, V61, P402, DOI 10.1016/j.cardiores.2003.09.019; Slim R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134968; Trabold F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Tschope C, 2004, CARDIOVASC RES, V61, P559, DOI 10.1016/j.cardiores.2003.10.018; Tschope C, 2000, BRAZ J MED BIOL RES, V33, P701, DOI 10.1590/S0100-879X2000000600011; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; WALL TM, 1994, J PHARMACOL EXP THER, V270, P681; Weidenbach R, 2000, BRIT J PHARMACOL, V131, P138, DOI 10.1038/sj.bjp.0703544; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; Yang XP, 1997, HYPERTENSION, V30, P735, DOI 10.1161/01.HYP.30.3.735; Yang XP, 1999, HYPERTENSION, V34, P24, DOI 10.1161/01.HYP.34.1.24; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759; Zhu BQ, 2000, J AM COLL CARDIOL, V35, P787, DOI 10.1016/S0735-1097(99)00592-6	45	55	60	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1172	+		10.1096/fj.04-3508fje	http://dx.doi.org/10.1096/fj.04-3508fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15860541				2022-12-25	WOS:000228865300003
J	Trivedi, V; Chand, P; Srivastava, K; Puri, SK; Maulik, PR; Bandyopadhyay, U				Trivedi, V; Chand, P; Srivastava, K; Puri, SK; Maulik, PR; Bandyopadhyay, U			Clotrimazole inhibits hemoperoxidase of Plasmodium falciparum and induces oxidative stress - Proposed antimalarial mechanism of clotrimazole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MALARIA PARASITES; HORSERADISH-PEROXIDASE; CELL-PROLIFERATION; THYROID PEROXIDASE; PROSTHETIC HEME; IN-VITRO; MERCAPTOMETHYLIMIDAZOLE; LACTOPEROXIDASE; INACTIVATION; RESISTANCE	The mechanism of antimalarial activity of clotrimazole was studied placing emphasis on its role in inhibiting hemoperoxidase for inducing oxidative stress in Plasmodium falciparum. Clotrimazole, in the presence of H2O2, causes irreversible inactivation of the enzyme, and the inactivation follows pseudo-first order kinetics, consistent with a mechanism-based (suicide) mode. The pseudofirst order kinetic constants are k(i) = 2.85 mu M, k(inact) = 0.9 min(-1), and t(1/2) = 0.77 min. The one-electron oxidation product of clotrimazole has been identified by EPR spectroscopy as the 5,5'-dimethyl-1-pyrroline N-oxide (DMPO) adduct of the nitrogen-centered radical (a(N) = 15 G), and as DMPO protects against inactivation, this radical is involved in the inactivation process. Binding studies indicate that the clotrimazole oxidation product interacts at the heme moiety, and the heme-clotrimazole adduct has been dissociated from the inactivated enzyme and identified (m/z 1363) by mass analysis. We found that the inhibition of hemoperoxidase increases the accumulation of H2O2 in P. falciparum and causes oxidative stress. Furthermore, the inhibition of hemoperoxidase correlates well with the inhibition of parasite growth. The results described herein indicate that the antimalarial activity of clotrimazole might be due to the inhibition of hemoperoxidase and subsequent development of oxidative stress in P. falciparum.	Cent Drug Res Inst, Drug Target Discovery & Dev Div, Lucknow 226001, Uttar Pradesh, India; Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Cent Drug Res Inst, Div Parasitol, Lucknow 226001, Uttar Pradesh, India; Indian Inst Technol, Dept Phys, Kanpur 208016, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Bandyopadhyay, U (corresponding author), Cent Drug Res Inst, Drug Target Discovery & Dev Div, Chatter Manzil Palace,Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India.	ubandyo_1964@yahoo.com						Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; ATOR MA, 1987, J BIOL CHEM, V262, P14954; Bandyopadhyay U, 2002, LIFE SCI, V71, P2845, DOI 10.1016/S0024-3205(02)02143-4; BANDYOPADHYAY U, 1995, BIOCHEM J, V306, P751, DOI 10.1042/bj3060751; BANDYOPADHYAY U, 1992, BIOCHEM J, V284, P305, DOI 10.1042/bj2840305; Bandyopadhyay U, 1997, BIOCHEM PHARMACOL, V54, P241, DOI 10.1016/S0006-2952(97)00156-1; Becker K, 2004, INT J PARASITOL, V34, P163, DOI 10.1016/j.ijpara.2003.09.011; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; Biswas K, 2003, J BIOL CHEM, V278, P10993, DOI 10.1074/jbc.M210328200; Bossche H. V. d., 1983, BIOCHEM SOC T, V11, P665; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P404, DOI 10.1016/0003-9861(52)90469-4; Chen YR, 1999, J BIOL CHEM, V274, P24611, DOI 10.1074/jbc.274.35.24611; CLARK IA, 1983, INFECT IMMUN, V39, P1; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1988, BIOCHEMISTRY-US, V27, P5470, DOI 10.1021/bi00415a013; DOERGE DR, 1986, BIOCHEMISTRY-US, V25, P4724, DOI 10.1021/bi00364a041; Dunford H. B., 1991, PEROXIDASES CHEM BIO, P1; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ENGLER H, 1982, BIOCHEM PHARMACOL, V31, P3801, DOI 10.1016/0006-2952(82)90296-9; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; FRIEDMAN MJ, 1979, NATURE, V280, P245, DOI 10.1038/280245a0; HOSOYA T, 1989, BIOCHEMISTRY-US, V28, P2639, DOI 10.1021/bi00432a042; HSIAO LL, 1991, BIOCHEM J, V274, P121, DOI 10.1042/bj2740121; Huy N, 2002, J BIOCHEM, V131, P437, DOI 10.1093/oxfordjournals.jbchem.a003119; Huy NT, 2004, BIOL PHARM BULL, V27, P361, DOI 10.1248/bpb.27.361; Huy NT, 2002, J BIOL CHEM, V277, P4152, DOI 10.1074/jbc.M107285200; Ito C, 2002, LEUKEMIA, V16, P1344, DOI 10.1038/sj.leu.2402510; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; JUNG MJ, 1975, BIOCHEM BIOPH RES CO, V67, P301, DOI 10.1016/0006-291X(75)90316-2; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Klokouzas A, 2001, EUR J BIOCHEM, V268, P6569, DOI 10.1046/j.0014-2956.2001.02611.x; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; McLean KJ, 2002, MICROBIOL-SGM, V148, P2937, DOI 10.1099/00221287-148-10-2937; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; MURPHY MJ, 1974, P NATL ACAD SCI USA, V71, P612, DOI 10.1073/pnas.71.3.612; Natarajan A, 2004, J MED CHEM, V47, P1882, DOI 10.1021/jm0499716; NOLLIN S, 1977, ANTIMICROBIAL AGENTS, V11, P500; OCKENHOUSE CF, 1984, J IMMUNOL, V133, P1601; OHTAKI S, 1982, J BIOL CHEM, V257, P761; Penso J, 2002, EUR J PHARMACOL, V451, P227, DOI 10.1016/S0014-2999(02)02103-9; PRUITT KM, 1985, LACTOPEROXIDASE SYST; Rosenthal Philip J., 1998, P145; Saliba KJ, 1998, T ROY SOC TROP MED H, V92, P666, DOI 10.1016/S0035-9203(98)90805-7; SAWYER PR, 1975, DRUGS, V9, P424, DOI 10.2165/00003495-197509060-00003; Sennequier N, 1999, J BIOL CHEM, V274, P930, DOI 10.1074/jbc.274.2.930; Takei S, 2003, INT J UROL, V10, P78, DOI 10.1046/j.1442-2042.2003.00575.x; Tiffert T, 2000, P NATL ACAD SCI USA, V97, P331, DOI 10.1073/pnas.97.1.331; Tiffert T, 2000, J PHYSIOL-LONDON, V525, P125, DOI 10.1111/j.1469-7793.2000.00125.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trivedi V, 2005, PROTEIN EXPRES PURIF, V41, P154, DOI 10.1016/j.pep.2004.12.016; Turan VK, 2001, DRUG METAB DISPOS, V29, P837; WOZENCRAFT AO, 1984, INFECT IMMUN, V43, P664, DOI 10.1128/IAI.43.2.664-669.1984; Wright AD, 2001, J MED CHEM, V44, P873, DOI 10.1021/jm0010724; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	57	47	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2005	280	50					41129	41136		10.1074/jbc.M501563200	http://dx.doi.org/10.1074/jbc.M501563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	992EJ	15863504	hybrid			2022-12-25	WOS:000233866900003
J	Bebrone, C; Anne, C; De Vriendt, K; Devreese, B; Rossolini, GM; Van Beeumen, J; Frere, JM; Galleni, M				Bebrone, C; Anne, C; De Vriendt, K; Devreese, B; Rossolini, GM; Van Beeumen, J; Frere, JM; Galleni, M			Dramatic broadening of the substrate profile of the Aeromonas hydrophila CphA metallo-beta-lactamase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STANDARD NUMBERING SCHEME; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; ACTIVE-SITE; D-CAPTOPRIL; BACTEROIDES-FRAGILIS; ANGSTROM RESOLUTION; COMPLEX; BINDING; ENZYME	Among class B beta-lactamases, the subclass B2 CphA enzyme is characterized by a unique specificity profile. CphA efficiently hydrolyzes only carbapenems. In this work, we generated site-directed mutants that possess a strongly broadened activity spectrum when compared with the WT CphA. Strikingly, the N116H/N220G double mutant exhibits a substrate profile close to that observed for the broad spectrum subclass B1 enzymes. The double mutant is significantly activated by the binding of a second zinc ion under conditions where the WT enzyme is non-competitively inhibited by the same ion.	Univ Liege, Ctr Ingn Prot, B-4000 Liege, Belgium; Univ Ghent, Lab Eiwitbiochem & Eiwitengineering, B-9000 Ghent, Belgium; Univ Siena, Policlin Le Scotte, Dipartimento Biol Mol, Sez Microbiol, I-53100 Siena, Italy	University of Liege; Ghent University; University of Siena	Galleni, M (corresponding author), Univ Liege, Ctr Ingn Prot, Allee 6 Aout B6, B-4000 Liege, Belgium.	mgalleni@ulg.ac.be	Devreese, Bart/B-2011-2009; Anne-Longin, Christine/M-4902-2017; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Anne-Longin, Christine/0000-0003-0103-4272; Devreese, Bart/0000-0002-9764-2581; ROSSOLINI, Gian Maria/0000-0002-9386-0434				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Dal Peraro M, 2002, J BIOL INORG CHEM, V7, P704, DOI 10.1007/s00775-002-0346-2; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DEMEESTER F, 1987, BIOCHEM PHARMACOL, V36, P2393, DOI 10.1016/0006-2952(87)90609-5; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garau G, 2004, ANTIMICROB AGENTS CH, V48, P2347, DOI 10.1128/AAC.48.7.2347-2349.2004; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Heinz U, 2003, J BIOL CHEM, V278, P20659, DOI 10.1074/jbc.M212581200; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; MATAGNE A, 1993, EUR J BIOCHEM, V217, P61, DOI 10.1111/j.1432-1033.1993.tb18218.x; MATAGNE A, 1990, BIOCHEM J, V265, P131, DOI 10.1042/bj2650131; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Rasia RM, 2003, PROTEIN SCI, V12, P1538, DOI 10.1110/ps.0301603; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; SEGATORE B, 1993, ANTIMICROB AGENTS CH, V37, P1324, DOI 10.1128/AAC.37.6.1324; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; Vanhove M, 2003, CELL MOL LIFE SCI, V60, P2501, DOI 10.1007/s00018-003-3092-x; Villadares MH, 1996, MICROB DRUG RESIST, V2, P253, DOI 10.1089/mdr.1996.2.253	28	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28195	28202		10.1074/jbc.M414052200	http://dx.doi.org/10.1074/jbc.M414052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	15863831	hybrid, Green Submitted			2022-12-25	WOS:000230857300005
J	Grm, HS; Massimi, P; Gammoh, N; Banks, L				Grm, HS; Massimi, P; Gammoh, N; Banks, L			Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein	ONCOGENE			English	Article						HPV E6; HPV E2; replication; transactivation	DNA-BINDING DOMAIN; UBIQUITIN-PROTEIN LIGASE; CERVICAL-CARCINOMA CELLS; DISCS LARGE PROTEIN; P53 IN-VITRO; HPV-18 E6; HIGH-RISK; MEDIATED DEGRADATION; HUMAN KERATINOCYTES; TYPE-16 DNA	Human papillomaviruses are the causative agents of cervical cancer. Previous studies have shown that loss of the viral E2 protein during malignant progression is an important feature of HPV-induced malignancy due to the resulting uncontrolled expression of the viral oncoproteins E6 and E7. We now show however that the viral E2 and E6 proteins are both capable of regulating each other's activity. When coexpressed, E2 and E6 induce marked changes in the pattern of each other's expression, with preferential accumulation in nuclear speckles. The two proteins interact directly, resulting in changes in the substrate specificities of E6 and the biochemical activities of E2. Thus, while E6 efficiently degrades its PDZ domain-containing substrates in the absence of E2, this activity is greatly diminished when E2 is present. Likewise, E2 alone drives both viral DNA replication and viral gene expression. However, in the presence of E6, viral DNA replication is inhibited while the transcriptional activity of E2 is elevated. These studies de. ne a far more complex pattern of interaction between E2 and E6 than was previously thought and redefines the possible consequences of loss of E2 with respect to uncontrolled E6 activity and consequent malignant progression.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bechtold V, 2003, J VIROL, V77, P2021, DOI 10.1128/JVI.77.3.2021-2028.2003; BEDROSIAN CL, 1990, VIROLOGY, V174, P557, DOI 10.1016/0042-6822(90)90109-5; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CRUM CP, 1989, AM J PATHOL, V134, P1183; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; DELMARPENA L, 2002, PERSPECTIVES MED VIR, V8, P31; Demeret C, 2003, ONCOGENE, V22, P168, DOI 10.1038/sj.onc.1206108; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Guccione E, 2004, INT J CANCER, V110, P928, DOI 10.1002/ijc.20184; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; HIGGINS GD, 1992, J GEN VIROL, V73, P2047, DOI 10.1099/0022-1317-73-8-2047; Howley PM, 2001, VIROLOGY, P2197; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; LIU JS, 2002, PERSP MED V, V8, P53; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Okoye A, 2005, VIRUS RES, V108, P1, DOI 10.1016/j.virusres.2004.07.004; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PICCINI A, 1995, J GEN VIROL, V76, P2909, DOI 10.1099/0022-1317-76-11-2909; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stein GS, 2000, J CELL SCI, V113, P2527; STOLER MH, 1989, VIROLOGY, V172, P331, DOI 10.1016/0042-6822(89)90135-9; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; TAURINA M, 1993, ONCOGENE, V8, P3165; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1996, ONCOGENE, V13, P471; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	78	43	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5149	5164		10.1038/sj.onc.1208701	http://dx.doi.org/10.1038/sj.onc.1208701			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15856010				2022-12-25	WOS:000230964600002
J	Javanbakht, H; Diaz-Griffero, F; Stremlau, M; Si, ZH; Sodroski, J				Javanbakht, H; Diaz-Griffero, F; Stremlau, M; Si, ZH; Sodroski, J			The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SIMIAN CELLS; POSTENTRY RESTRICTION; REVERSE TRANSCRIPTION; B30.2(SPRY) DOMAIN; OLD-WORLD; HIV-1; REPLICATION; PROTEIN; REF1	TRIM5 alpha is a cytoplasmic protein that mediates a post-entry block to infection by some retroviruses. TRIM5 alpha contains a tripartite motif ( TRIM), which includes RING, B-box 2, and coiled-coil domains, and a C-terminal B30.2 ( SPRY) domain. We investigated the contribution of the RING and B- box 2 domains to the antiretroviral activity of rhesus monkey TRIM5 alpha (TRIM5 alpha(rh)), which potently restricts infection by human immunodeficiency virus, type 1 (HIV-1) and simian immunodeficiency virus of African green monkeys (SIVagm). Disruption of the RING domain caused mislocalization of TRIM5 alpha(rh) so that the cytoplasmic level of the protein was decreased compared with that of the wild-type protein. Nonetheless, partial ability to restrict HIV-1 and SIVagm was retained by the RING domain mutants. By contrast, although TRIM5 alpha(rh) mutants with disrupted B- box 2 domains were efficiently expressed and correctly localized to the cytoplasm, antiretroviral activity was absent. The B- box 2 mutants colocalized and associated with wild-type TRIM5 alpha(rh) and exerted dominant-negative effects on the antiretroviral activity of the wild-type protein. Taken together with other data, these results indicate that functionally defective TRIM5 alpha(rh) molecules that retain a coiled coil can act as dominant-negative inhibitors of wild-type TRIM5 alpha(rh) function. The RING domain of TRIM5 alpha(rh) is not absolutely required for retrovirus restriction.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Sodroski, J (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St,JFB 824, Boston, MA 02115 USA.	joseph_sodroski@dfci.harvard.edu	Liu, FL/D-1795-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, R01AI063987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54785] Funding Source: Medline; NIAID NIH HHS [AI28691, AI063987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arts EJ, 1996, ADV VIRUS RES, V46, P97, DOI 10.1016/S0065-3527(08)60071-8; Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Bieniasz PD, 2003, TRENDS MICROBIOL, V11, P286, DOI 10.1016/S0966-842X(03)00123-9; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Diaz-Griffero F, 2002, J VIROL, V76, P12866, DOI 10.1128/JVI.76.24.12866-12876.2002; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Hatziioannou T, 2004, P NATL ACAD SCI USA, V101, P10774, DOI 10.1073/pnas.0402361101; Hatziioannou T, 2004, J VIROL, V78, P6005, DOI 10.1128/JVI.78.11.6005-6012.2004; Hatziioannou T, 2003, EMBO J, V22, P385, DOI 10.1093/emboj/cdg042; Himathongkham S, 1996, VIROLOGY, V219, P485, DOI 10.1006/viro.1996.0276; Hofmann W, 1999, J VIROL, V73, P10020, DOI 10.1128/JVI.73.12.10020-10028.1999; Keckesova Z, 2004, P NATL ACAD SCI USA, V101, P10780, DOI 10.1073/pnas.0402474101; Kootstra NA, 2003, P NATL ACAD SCI USA, V100, P1298, DOI 10.1073/pnas.0337541100; Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099; Owens CA, 2003, J VIROL, V77, P726, DOI 10.1128/JVI.77.1.726-731.2003; Owens CM, 2004, J VIROL, V78, P5423, DOI 10.1128/JVI.78.10.5423-5437.2004; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Perron MJ, 2004, P NATL ACAD SCI USA, V101, P11827, DOI 10.1073/pnas.0403364101; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sawyer SL, 2005, P NATL ACAD SCI USA, V102, P2832, DOI 10.1073/pnas.0409853102; SHIBATA R, 1995, J GEN VIROL, V76, P2723, DOI 10.1099/0022-1317-76-11-2723; Shoham NG, 2003, P NATL ACAD SCI USA, V100, P13501, DOI 10.1073/pnas.2135380100; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Song B, 2005, J VIROL, V79, P3930, DOI 10.1128/JVI.79.7.3930-3937.2005; Song BW, 2005, J VIROL, V79, P6111, DOI 10.1128/JVI.79.10.6111-6121.2005; Stremlau M, 2005, J VIROL, V79, P3139, DOI 10.1128/JVI.79.5.3139-3145.2005; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Towers G, 2002, J VIROL, V76, P2548, DOI 10.1128/JVI.76.5.2548-2550.2002; Towers G, 2000, P NATL ACAD SCI USA, V97, P12295, DOI 10.1073/pnas.200286297; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Xu LX, 2003, EXP CELL RES, V288, P84, DOI 10.1016/S0014-4827(03)00187-3; Yap MW, 2005, CURR BIOL, V15, P73, DOI 10.1016/j.cub.2004.12.042; Yap MW, 2004, P NATL ACAD SCI USA, V101, P10786, DOI 10.1073/pnas.0402876101	35	149	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 22	2005	280	29					26933	26940		10.1074/jbc.M502145200	http://dx.doi.org/10.1074/jbc.M502145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	946RI	15897199	hybrid			2022-12-25	WOS:000230589500037
J	Moog-Lutz, C; Degoutin, J; Gouzi, JY; Frobert, Y; de Carvalhoo, NB; Bureau, J; Creminon, C; Vigny, M				Moog-Lutz, C; Degoutin, J; Gouzi, JY; Frobert, Y; de Carvalhoo, NB; Bureau, J; Creminon, C; Vigny, M			Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; SIGNAL TRANSDUCER; PROTEIN-KINASE; ALK; CELLS; STAT3; GENE; TRANSFORMATION; IDENTIFICATION; FUSION	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is transiently expressed in specific regions of the central and peripheral nervous systems, suggesting a role in its normal development and function. The nature of the cognate ligands of ALK in vertebrate is still a matter of debate. We produced a panel of monoclonal antibodies (mAbs) directed against the extracellular domain of the human receptor. Two major species of ALK (220 and 140 kDa) were identified in transfected cells, and the use of our mAbs established that the 140-kDa species results from a cleavage of the 220-kDa form. Two mAbs, in the nM range, induced the differentiation of PC12 cells transiently transfected with ALK. In human embryonic kidney 293 cells stably expressing ALK, these two mAbs strongly activated the receptor and subsequently the mitogen-activated protein kinase pathway. We further showed for the first time that activation of ALK also resulted in a specific activation of STAT3. In contrast, other mAbs presented the characteristics of blocking antibodies. Finally, in these cell systems, a mitogenic form of pleiotrophin, a proposed ligand of ALK, failed to activate this receptor. Thus, in the absence of clearly established ligand(s) in vertebrates, the availability of mAbs allowing the activation or the inhibition of the receptor will be essential for a better understanding of the biological roles of ALK.	Univ Paris 06, INSERM, Inst Fer Moulin, U706, F-75005 Paris, France; CEA Saclay, Direct Rech Med, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Vigny, M (corresponding author), Univ Paris 06, INSERM, Inst Fer Moulin, U706, 17 Rue Fer Moulin, F-75005 Paris, France.	vigny@fer-a-moulin.inserm.fr	MOOG-LUTZ, Christel/F-1975-2011	GOUZI, Jean Y./0000-0002-8853-1564				Armstrong F, 2004, ONCOGENE, V23, P6071, DOI 10.1038/sj.onc.1207813; ASHMAN LK, 1994, J CELL PHYSIOL, V158, P545, DOI 10.1002/jcp.1041580321; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cussac D, 2004, BLOOD, V103, P1464; Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; GRASSI J, 1989, J IMMUNOL METHODS, V123, P193, DOI 10.1016/0022-1759(89)90223-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kunioku H, 2001, NEUROSCI LETT, V309, P13, DOI 10.1016/S0304-3940(01)02012-2; Lai R, 2004, AM J PATHOL, V164, P2251, DOI 10.1016/S0002-9440(10)63781-9; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; LeSauteur L, 1996, J NEUROSCI, V16, P1308; Liao EH, 2004, NATURE, V430, P345, DOI 10.1038/nature02647; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Prat M, 1998, J CELL SCI, V111, P237; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; RUSSO C, 1983, J IMMUNOL METHODS, V65, P269, DOI 10.1016/0022-1759(83)90324-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009; Selo I, 1996, J IMMUNOL METHODS, V199, P127, DOI 10.1016/S0022-1759(96)00173-1; Serresi M, 2004, ONCOGENE, V23, P1098, DOI 10.1038/sj.onc.1207227; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Slupianek A, 2001, CANCER RES, V61, P2194; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	57	116	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26039	26048		10.1074/jbc.M501972200	http://dx.doi.org/10.1074/jbc.M501972200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15886198	hybrid			2022-12-25	WOS:000230386800013
J	Zhang, XF; Wang, JF; Chandran, B; Persaud, K; Pytowski, B; Fingeroth, J; Groopman, JE				Zhang, XF; Wang, JF; Chandran, B; Persaud, K; Pytowski, B; Fingeroth, J; Groopman, JE			Kaposi's sarcoma-associated herpesvirus activation of vascular endothelial growth factor receptor 3 alters endothelial function and enhances infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; LYMPHATIC ENDOTHELIUM; LYTIC REPLICATION; FIBROBLAST CELLS; DISINTEGRIN-LIKE; HEPARAN-SULFATE; TARGET-CELLS; HUMAN-HERPESVIRUS-8; INTEGRIN	Kaposi's sarcoma-associated herpesvirus ( KSHV; also known as human herpesvirus 8) is the etiologic agent of Kaposi's sarcoma, an endothelial neoplasm. This gamma-herpesvirus encodes for several unique proteins that alter target cell function, including the virion envelope-associated glycoprotein B (gB). Glycoprotein B has an RGD (Arg-Gly-Asp) motif at the extracellular amino terminus region and binds to the alpha(3)beta(1) surface integrin, which enhances virus entry. We now report that gB can activate the vascular endothelial growth factor receptor 3 (VEGFR-3) on the surface of microvascular endothelial cells and trigger receptor signaling, which can modulate endothelial migration and proliferation. Furthermore, we observed that VEGFR-3 expression and activation enhance KSHV infection and participate in KSHV-mediated transformation. These functional changes in the endothelium may contribute to the pathogenesis of Kaposi's sarcoma and suggest that interventions that inhibit gB activation of VEGFR-3 could be useful in the treatment of this neoplasm.	Harvard Univ, Beth Israel Deaconess Med Ctr,Sch Med, Dept Med, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr,Sch Med, Dept Med, Div Infect Dis, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr,Sch Med, Dept Surg, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr,Sch Med, Dept Surg, Div Infect Dis, Boston, MA 02115 USA; Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; ImClone Syst, Dept Mol & Cellular Biol, New York, NY 10014 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Kansas; University of Kansas Medical Center; Eli Lilly	Groopman, JE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr,Sch Med, Dept Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu			NCI NIH HHS [CA 75911] Funding Source: Medline; NIDA NIH HHS [1R01 DA15008-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; Akula SM, 2001, VIROLOGY, V282, P245, DOI 10.1006/viro.2000.0851; Akula SM, 2001, VIROLOGY, V284, P235, DOI 10.1006/viro.2001.0921; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Baker CH, 2002, AM J PATHOL, V161, P929, DOI 10.1016/S0002-9440(10)64253-8; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Bohling T, 1996, J NEUROPATH EXP NEUR, V55, P522; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Feire AL, 2004, P NATL ACAD SCI USA, V101, P15470, DOI 10.1073/pnas.0406821101; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1993, ONCOGENE, V8, P1233; Glaunsinger B, 2004, MOL CELL, V13, P713, DOI 10.1016/S1097-2765(04)00091-7; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; GUO CH, 1995, ENDOCRINOLOGY, V136, P3031, DOI 10.1210/en.136.7.3031; Iivanainen E, 2003, MICROSC RES TECHNIQ, V60, P13, DOI 10.1002/jemt.10238; Inoue N, 2003, J VIROL, V77, P8147, DOI 10.1128/JVI.77.14.8147-8152.2003; Jacobson LP, 2000, J INFECT DIS, V181, P1940, DOI 10.1086/315503; Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kim TA, 2003, J IMMUNOL, V170, P2629, DOI 10.4049/jimmunol.170.5.2629; Komatsu T, 2001, VIRAL IMMUNOL, V14, P311, DOI 10.1089/08828240152716565; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Krishnan HH, 2004, J VIROL, V78, P3601, DOI 10.1128/JVI.78.7.3601-3620.2004; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Liu ZY, 1997, BLOOD, V90, P2253, DOI 10.1182/blood.V90.6.2253.2253_2253_2259; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Luciani F, 2004, CELL DEATH DIFFER, V11, P574, DOI 10.1038/sj.cdd.4401374; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Malnati M, 2002, BLOOD, V100, P1575, DOI 10.1182/blood.V100.5.1575.h81702001575_1575_1578; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Muralidhar S, 2000, J CLIN VIROL, V16, P203, DOI 10.1016/S1386-6532(99)00081-5; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Naranatt PP, 2003, J VIROL, V77, P1524, DOI 10.1128/JVI.77.2.1524-1539.2003; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138; Pertel PE, 2002, J VIROL, V76, P4390, DOI 10.1128/JVI.76.9.4390-4400.2002; Reed JA, 1998, BLOOD, V91, P3825, DOI 10.1182/blood.V91.10.3825.3825_3825_3832; Renne R, 1998, J VIROL, V72, P5182, DOI 10.1128/JVI.72.6.5182-5188.1998; Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schraufstatter IU, 2002, J IMMUNOL, V169, P2102, DOI 10.4049/jimmunol.169.4.2102; Sharma-Walia N, 2004, J VIROL, V78, P4207, DOI 10.1128/JVI.78.8.4207-4223.2004; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Stebbing J, 2003, CURR OPIN INFECT DIS, V16, P25, DOI 10.1097/00001432-200302000-00005; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Vieira J, 2001, J VIROL, V75, P1378, DOI 10.1128/JVI.75.3.1378-1386.2001; Wang FZ, 2003, J VIROL, V77, P3131, DOI 10.1128/JVI.77.5.3131-3147.2003; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; Wang JF, 2001, J BIOL CHEM, V276, P41950, DOI 10.1074/jbc.M101370200; WU CY, 1995, J CELL SCI, V108, P2511; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Zhang XF, 2005, J CELL PHYSIOL, V202, P205, DOI 10.1002/jcp.20106; Zhou FC, 2002, J VIROL, V76, P6185, DOI 10.1128/JVI.76.12.6185-6196.2002	80	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26216	26224		10.1074/jbc.M411392200	http://dx.doi.org/10.1074/jbc.M411392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15878864	hybrid			2022-12-25	WOS:000230386800036
J	Magee, C; Nurminskaya, M; Faverman, L; Galera, P; Linsenmayer, TF				Magee, C; Nurminskaya, M; Faverman, L; Galera, P; Linsenmayer, TF			SP3/SP1 transcription activity regulates specific expression of collagen type X in hypertrophic chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION IN-VITRO; GENE-EXPRESSION; SPONDYLOMETAPHYSEAL DYSPLASIA; ARTICULAR CHONDROCYTES; CHICK TIBIOTARSUS; FAMILY PROTEINS; DOWN-REGULATION; MICE LACKING; C-FOS; SP3	Previously, we have shown that two non-canonical specificity protein (SP)-binding sites within the proximal promoter (nucleotide (nt) -139 to +5) of the chicken Col10a1 gene are involved in conferring tissue-specific expression of type X collagen to hypertrophic chondrocytes. In the present study, we examined the role of SP3/SP1 transcription factors in the regulation of the Col10a1 promoter. The SP3/SP1 ratio is higher in hypertrophic versus non-hypertrophic chondrocytes, due to the significant decrease in SP1 in hypertrophic cells detected by real-time PCR and Western blot analyses. Functional analyses by transfection-mediated overexpression of SP1 and SP3 suggest that SP1 inhibits the Col10a1 promoter. This effect is negated by an interaction with SP3 in hypertrophic chondrocytes. Additionally, mutation analysis showed that the 40-bp intervening sequence (nt -115 to -75) is required for expression of the Col10a1 gene. In this sequence, a binding site for Dlx5/6 transcription factors (nt -99 to -87) retards a protein specific for hypertrophic chondrocytes in electrophoretic mobility shift assay. Endogenous levels of Dlx5 are 3-fold higher in hypertrophic versus non-hypertrophic cells by real-time PCR analysis, and overexpression of Dlx5 in non-hypertrophic chondrocytes activates the proximal Col10a1 promoter 3-fold. These results indicate that the SP3/SP1 ratio and Dlx5 are important regulators of the proximal Col10a1 promoter in hypertrophic cartilage and suggest that interactions between SP3 and SP1 regulate expression of different types of collagen during chondrocyte differentiation.	Tufts Univ, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Univ Caen, Fac Med, F-14032 Caen, France	Tufts University; Universite de Caen Normandie	Linsenmayer, TF (corresponding author), Tufts Univ, Dept Anat & Cellular Biol, 135 Harrison Ave,J-333, Boston, MA 02111 USA.	thomas.linsenmayer@tufts.edu	Nurminskaya, Maria/GQH-4607-2022		NICHD NIH HHS [HD-23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; ARIAS JL, 1992, ARCH BIOCHEM BIOPHYS, V298, P293, DOI 10.1016/0003-9861(92)90126-H; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; Campbell MR, 2004, AM J PATHOL, V164, P487, DOI 10.1016/S0002-9440(10)63139-2; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Dourado G, 1998, J CELL BIOCHEM, V70, P507, DOI 10.1002/(SICI)1097-4644(19980915)70:4<507::AID-JCB7>3.0.CO;2-N; Ferrari D, 2002, DEV BIOL, V252, P257, DOI 10.1006/dbio.2002.0862; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; Gress CJ, 2000, J CELL BIOL, V149, P983, DOI 10.1083/jcb.149.4.983; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harada S, 1997, MOL ENDOCRINOL, V11, P1832, DOI 10.1210/me.11.12.1832; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Ikegawa S, 1998, AM J HUM GENET, V63, P1659, DOI 10.1086/302158; Jacenko O, 1996, ANN NY ACAD SCI, V785, P278, DOI 10.1111/j.1749-6632.1996.tb56283.x; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; Jacenko O, 2001, AM J PATHOL, V159, P2257, DOI 10.1016/S0002-9440(10)63076-3; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kavurma MM, 2003, J BIOL CHEM, V278, P32537, DOI 10.1074/jbc.M305650200; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; Long FX, 1995, J BIOL CHEM, V270, P31310, DOI 10.1074/jbc.270.52.31310; Long FX, 1998, J BIOL CHEM, V273, P6542, DOI 10.1074/jbc.273.11.6542; LUVALLE P, 1989, DEV BIOL, V133, P613, DOI 10.1016/0012-1606(89)90065-1; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Milona M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-43; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Riemer S, 2002, J CELL BIOCHEM, V86, P688, DOI 10.1002/jcb.10260; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Thomas DP, 2000, J CELL SCI, V113, P439; Volk SW, 1998, J BONE MINER RES, V13, P1521, DOI 10.1359/jbmr.1998.13.10.1521; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WU Q, 2002, T ORTHOP RES SOC, V27, pPA34; Zhang JH, 2003, INT J ONCOL, V23, P1043; ZHAO GQ, 1994, DEV BIOL, V164, P37, DOI 10.1006/dbio.1994.1178	43	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25331	25338		10.1074/jbc.M412549200	http://dx.doi.org/10.1074/jbc.M412549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15849196	hybrid			2022-12-25	WOS:000230207900005
J	Zhou, XF; Taghizadeh, K; Dedon, PC				Zhou, XF; Taghizadeh, K; Dedon, PC			Chemical and biological evidence for base propenals as the major source of the endogenous M(1)dG adduct in cellular DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; LINOLEIC-ACID; MALONDIALDEHYDE; BLEOMYCIN; DEOXYGUANOSINE; DAMAGE; PYRIMIDOPURINONE	The endogenous DNA adduct, M(1)dG, has been shown to arise in vitro in reactions of dG with malondialdehyde (MDA), a product of both lipid peroxidation and 4'-oxidation of deoxyribose in DNA, and with base propenals also derived from deoxyribose 4'-oxidation. We now report the results of cellular studies consistent with base propenals, and not MDA, as the major source of M(1)dG under biological conditions. As a foundation for cellular studies, M(1)dG, base propenals, and MDA were quantified in purified DNA treated with oxidizing agents known to produce deoxyribose 4'-oxidation. The results revealed a consistent pattern; Fe2+-EDTA and gamma-radiation generated MDA but not base propenals or M(1)dG, whereas bleomycin and peroxynitrite (ONOO-) both produced M(1)dG as well as base propenals with no detectable MDA. These observations were then assessed in Escherichia coli with controlled membrane levels of polyunsaturated fatty acids (PUFA). ONOO- treatment (2 mM) of cells containing no PUFA (defined medium with 18:0/stearic acid) produced 6.5 M(1)dG/10(7) deoxynucleotides and no detectable lipid peroxidation products, including MDA, as compared with 3.8 M(1)dG/10(7) deoxynucleotides and 0.07 mu g/ ml lipid peroxidation products with control cells grown in a mixture of fatty acids (0.5% PUFA) mimicking Luria-Bertani medium. In cells grown with linoleic acid (18:2), the level of PUFA rose to 54% and the level of MDA rose to 0.14 mu g/ml, whereas M(1)dG fell to 1.4/10(7) deoxynucleotides. Parallel studies with gamma- radiation revealed levels of MDA similar to those produced by ONOO- but no detectable M(1)dG. These results are consistent with base propenals as the major source of M(1)dG in this model cell system.	MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Dedon, PC (corresponding author), MIT, Biol Engn Div, NE47-277, Cambridge, MA 02139 USA.	pcdedon@mit.edu		Dedon, Peter/0000-0003-0011-3067	NATIONAL CANCER INSTITUTE [R01CA103146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059790] Funding Source: NIH RePORTER; NCI NIH HHS [CA103146, CA26735] Funding Source: Medline; NIEHS NIH HHS [ES002109] Funding Source: Medline; NIGMS NIH HHS [GM59790] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avery SV, 1996, APPL ENVIRON MICROB, V62, P3960, DOI 10.1128/AEM.62.11.3960-3966.1996; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BASU AK, 1988, CHEM RES TOXICOL, V1, P53, DOI 10.1021/tx00001a010; BASU AK, 1984, CANCER RES, V44, P2848; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Byrns MC, 2002, CHEM RES TOXICOL, V15, P373, DOI 10.1021/tx0101402; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; Cline SD, 2004, P NATL ACAD SCI USA, V101, P7275, DOI 10.1073/pnas.0402252101; Collins C, 2003, CHEM RES TOXICOL, V16, P1560, DOI 10.1021/tx0341198; CRONAN JE, 1994, J BACTERIOL, V176, P3069, DOI 10.1128/JB.176.10.3069-3071.1994; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Dedon PC, 1998, P NATL ACAD SCI USA, V95, P11113, DOI 10.1073/pnas.95.19.11113; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; EZE MO, 1981, J GEN MICROBIOL, V124, P299; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Frelon S, 2002, J CHEM SOC PERK T 1, P2866, DOI 10.1039/b207532f; Gingipalli L, 2001, J AM CHEM SOC, V123, P2664, DOI 10.1021/ja0056421; HARLEY JB, 1978, J BACTERIOL, V134, P808, DOI 10.1128/JB.134.3.808-820.1978; Howlett NG, 1997, APPL ENVIRON MICROB, V63, P2971, DOI 10.1128/AEM.63.8.2971-2976.1997; JOHNSON F, 1984, J MED CHEM, V27, P954, DOI 10.1021/jm00374a004; Kadlubar FF, 1998, MUTAT RES-FUND MOL M, V405, P125, DOI 10.1016/S0027-5107(98)00129-8; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; Ohshima H, 2003, TOXICOL LETT, V140, P99, DOI 10.1016/S0378-4274(02)00506-4; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Plastaras JP, 2002, BIOCHEMISTRY-US, V41, P5033, DOI 10.1021/bi0113059; Plastaras JP, 2000, CHEM RES TOXICOL, V13, P1235, DOI 10.1021/tx0001631; Pogozelski WK, 1998, CHEM REV, V98, P1089, DOI 10.1021/cr960437i; PRYOR WA, 1976, LIPIDS, V11, P370, DOI 10.1007/BF02532843; RABINOWITCH HD, 1993, J BACTERIOL, V175, P5324, DOI 10.1128/JB.175.17.5324-5328.1993; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Rashid R, 1999, INT J RADIAT BIOL, V75, P101, DOI 10.1080/095530099140852; Rouzer CA, 1997, CHEM RES TOXICOL, V10, P181, DOI 10.1021/tx9601216; Rubio J, 1996, PORTL PR P, V10, P34; Sevilla CL, 1997, CHEM RES TOXICOL, V10, P172, DOI 10.1021/tx960120d; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Sharma RA, 2001, CARCINOGENESIS, V22, P1557, DOI 10.1093/carcin/22.9.1557; Sheu JY, 2003, ANAL SCI, V19, P621, DOI 10.2116/analsci.19.621; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; VanderVeen LA, 2003, P NATL ACAD SCI USA, V100, P14247, DOI 10.1073/pnas.2332176100; Vanderwall DE, 1997, CHEM BIOL, V4, P373, DOI 10.1016/S1074-5521(97)90128-9; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Yermilov V, 1996, FEBS LETT, V399, P67, DOI 10.1016/S0014-5793(96)01288-4	52	64	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2005	280	27					25377	25382		10.1074/jbc.M503079200	http://dx.doi.org/10.1074/jbc.M503079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941IG	15878883	hybrid			2022-12-25	WOS:000230207900010
J	Dhami, GK; Babwah, AV; Sterne-Marr, R; Ferguson, SSG				Dhami, GK; Babwah, AV; Sterne-Marr, R; Ferguson, SSG			Phosphorylation-independent regulation of metabotropic glutamate receptor 1 signaling requires G protein-coupled receptor kinase 2 binding to the second intracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; RAPID DESENSITIZATION; SPLICE VARIANTS; INTERNALIZATION; ACTIVATION; AGONIST; 1A; SPECIFICITY; ENDOCYTOSIS; INHIBITION	Metabotropic glutamate receptors (mGluRs) are members of a unique class of G protein-coupled receptors (class III) that include the calcium-sensing and gamma-aminobutyric acid type B receptors. The activity of mGluRs is regulated by second messenger-dependent protein kinases and G protein-coupled receptor kinases (GRKs). The attenuation of both mGluR1a and mGluR1b signaling by GRK2 is phosphorylation- and beta-arrestin-independent and requires the concomitant association of GRK2 with both the receptor and G alpha(q/11). G protein interactions are mediated, in part, by the mGluR1 intracellular second loop, but the domains required for GRK2 binding are unknown. In the present study, we showed that GRK2 binds to the second intracellular loop of mGluR1a and mGluR1b and also to the mGluR1a carboxyl-terminal tail. Alanine scanning mutagenesis revealed a discrete domain within loop 2 that contributes to GRK2 binding, and the mutation of either lysine 691 or 692 to an alanine within this domain resulted in a loss of GRK2 binding to both mGluR1a and mGluR1b. Mutation of either Lys(691) or Lys(692) prevented GRK2- mediated attenuation of mGluR1b signaling, whereas the mutation of only Lys692 prevented GRK2-mediated inhibition of mGluR1a signaling. Thus, the mGluR1a carboxyl-terminal tail may also be involved in regulating the signaling of the mGluR1a splice variant. Taken together, our findings indicated that kinase binding to an mGluR1 domain involved in G protein- coupling is essential for the phosphorylation-independent attenuation of signaling by GRK2.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; Siena Coll, Dept Biol, Loudonville, NY 12211 USA	Western University (University of Western Ontario); Western University (University of Western Ontario)	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca						Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Francesconi A, 2002, J NEUROSCI, V22, P2196, DOI 10.1523/JNEUROSCI.22-06-02196.2002; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Gan XQ, 2004, J BIOL CHEM, V279, P49741, DOI 10.1074/jbc.M407570200; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; Iacovelli L, 2003, J BIOL CHEM, V278, P12433, DOI 10.1074/jbc.M203992200; ISHII K, 1994, J BIOL CHEM, V269, P1125; Iwata K, 2005, J BIOL CHEM, V280, P2197, DOI 10.1074/jbc.M408834200; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Mary S, 1997, EUR J PHARMACOL, V335, P65, DOI 10.1016/S0014-2999(97)01155-2; Mundell SJ, 2002, MOL PHARMACOL, V61, P1114, DOI 10.1124/mol.61.5.1114; Mundell SJ, 2004, MOL PHARMACOL, V65, P1507, DOI 10.1124/mol.65.6.1507; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Pao CS, 2005, J BIOL CHEM, V280, P11052, DOI 10.1074/jbc.M412996200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; Reiter E, 2001, BIOCHEM BIOPH RES CO, V282, P71, DOI 10.1006/bbrc.2001.4534; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com	35	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24420	24427		10.1074/jbc.M501650200	http://dx.doi.org/10.1074/jbc.M501650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15870073	hybrid			2022-12-25	WOS:000230114000017
J	Frank, M; Thumer, L; Lohse, MJ; Bunemann, M				Frank, M; Thumer, L; Lohse, MJ; Bunemann, M			G protein activation without subunit dissociation depends on a G alpha(i)-specific region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ACTIVATION; FLUORESCENT PROTEIN; GIRK CHANNELS; LIVING CELLS; K+ CHANNEL; EXPRESSION; VARIANT; FRET	G proteins transmit a variety of extracellular signals into intracellular responses. The G alpha and G beta gamma subunits are both known to regulate effectors. Interestingly, the G alpha subunit also determines subtype specificity of G beta gamma effector interactions. However, in light of the common paradigm that G alpha and G beta gamma subunits dissociate during activation, a plausible mechanism of how this subtype specificity is generated was lacking. Using a fluorescence resonance energy transfer ( FRET)-based assay developed to directly measure mammalian G protein activation in intact cells, we demonstrate that fluorescent G alpha(i1,2,3), G alpha(z), and G beta(1)gamma(2) subunits do not dissociate during activation but rather undergo subunit rearrangement as indicated by an activation-induced increase in FRET. In contrast, fluorescent G alpha(0) subunits exhibited an activation-induced decrease in FRET, reflecting subunit dissociation or, alternatively, a distinct subunit rearrangement. The alpha(B/C)-region within the alpha-helical domain, which is much more conserved within G alpha(i1,2,3) and G alpha(z) as compared with that in G alpha(0), was found to be required for exhibition of an activation-induced increase in FRET between fluorescent G alpha and G beta gamma subunits. However, the alpha(B/C)-region of G alpha(i1) alone was not sufficient to transfer the activation pattern of G alpha(i) to the G alpha(o) subunit. Either residues in the first 91 amino acids or in the C-terminal remainder (amino acids 93-354) of G alpha(i1) together with the alpha(B/C)-helical region of G alpha(i1) were needed to transform the G alpha(o)-activation pattern into a G alpha(i1)-type of activation. The discovery of subtype-selective mechanisms of G protein activation illustrates that G protein subfamilies have specific mechanisms of activation that may provide a previously unknown basis for G protein signaling specificity.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany	University of Wurzburg	Bunemann, M (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacherstr 9, D-97078 Wurzburg, Germany.	m-buenemann@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				Azpiazu I, 2004, J BIOL CHEM, V279, P27709, DOI 10.1074/jbc.M403712200; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOURNE HR, 1989, NATURE, V337, P504, DOI 10.1038/337504a0; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Klein S, 2000, P NATL ACAD SCI USA, V97, P3219, DOI 10.1073/pnas.050015797; Levitzki A, 2002, CHEMBIOCHEM, V3, P815, DOI 10.1002/1439-7633(20020902)3:9<815::AID-CBIC815>3.0.CO;2-E; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Sadja R, 2003, NEURON, V39, P9, DOI 10.1016/S0896-6273(03)00402-1; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yi TM, 2003, P NATL ACAD SCI USA, V100, P10764, DOI 10.1073/pnas.1834247100	22	126	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24584	24590		10.1074/jbc.M414630200	http://dx.doi.org/10.1074/jbc.M414630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866880	hybrid			2022-12-25	WOS:000230114000037
J	Inomata, K; Hammam, MAS; Kinoshita, H; Murata, Y; Khawn, H; Noack, S; Michael, N; Lamparter, T				Inomata, K; Hammam, MAS; Kinoshita, H; Murata, Y; Khawn, H; Noack, S; Michael, N; Lamparter, T			Sterically locked synthetic bilin derivatives and phytochrome Agp1 from Agrobacterium tumefaciens form photoinsensitive Pr- and Pfr-like adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; CYANOBACTERIUM SYNECHOCYSTIS; SPECTRAL PROPERTIES; CPH1 PHYTOCHROME; EFFICIENT METHOD; CHROMOPHORE; RING; PHOTOTRANSFORMATION; PHYCOCYANOBILIN; COMPONENT	Phytochrome photoreceptors undergo reversible photoconversion between the red-absorbing form, Pr, and the far-red-absorbing form, Pfr. The first step in the conversion from Pr to Pfr is a Z to E isomerization around the C15 = C16 double bond of the bilin chromophore. We prepared four synthetic biliverdin ( BV) derivatives in which rings C and D are sterically locked by cyclizing with an additional carbon chain. In these chromophores, which are termed 15Za, 15Zs, 15Ea, and 15Es, the C15 = C16 double bond is in either the Z or E configuration and the C14-C15 single bond in either the syn or anti conformation. The chromophores were assembled with Agrobacterium phytochrome Agp1, which incorporates BV as natural chromophore. All locked BV derivatives bound covalently to the protein and formed adducts with characteristic spectral properties. The 15Za adduct was spectrally similar to the Pr form and the 15Ea adduct similar to the Pfr form of the BV adduct. Thus, the chromophore of Agp1 adopts a C15 = C16 Z configuration and a C14-C15 anti conformation in the Pr form and a C15 = C16 E configuration and a C14-C15 anti conformation in the Pfr form. Both the 15Zs and the 15Es adducts absorbed only in the blue region of the visible spectra. All chromophore adducts were analyzed by size exclusion chromatography and histidine kinase activity to probe for protein conformation. In either case, the 15Za adduct behaved like the Pr and the 15Ea adduct like the Pfr form of Agp1. Replacing the natural chromophore by a locked 15Ea derivative can thus bring phytochrome holoprotein in the Pfr form in darkness. In this way, physiological action of Pfr can be studied in vivo and separated from Pr/Pfr cycling and other light effects.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan; Free Univ Berlin, D-14195 Berlin, Germany	Kanazawa University; Free University of Berlin	Inomata, K (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan.	inomata@cacheibm.s.kanazawa-u.ac.jp; lamparte@zedat.fu-berlin.de	Lamparter, Tilman/E-4421-2013; Hammam, Mostafa/M-6126-2016	Lamparter, Tilman/0000-0003-4327-9737; Hammam, Mostafa/0000-0003-4299-2231				Andel F, 2000, BIOCHEMISTRY-US, V39, P2667, DOI 10.1021/bi991688z; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Borucki B, 2003, BIOCHEMISTRY-US, V42, P13684, DOI 10.1021/bi035511n; Chen EF, 1997, BIOCHEMISTRY-US, V36, P4903, DOI 10.1021/bi9627065; Esteban B, 2005, BIOCHEMISTRY-US, V44, P450, DOI 10.1021/bi0484365; Falk H., 1989, CHEM LINEAR OLIGOPYR; Hammam MAS, 2004, CHEM LETT, V33, P1258, DOI 10.1246/cl.2004.1258; Hanzawa H, 2002, P NATL ACAD SCI USA, V99, P4725, DOI 10.1073/pnas.062713399; Hanzawa H, 2001, P NATL ACAD SCI USA, V98, P3612, DOI 10.1073/pnas.051629698; Heyne K, 2002, BIOPHYS J, V82, P1004, DOI 10.1016/S0006-3495(02)75460-X; HOLZWARTH AR, 1992, BIOCHIM BIOPHYS ACTA, V1140, P59, DOI 10.1016/0005-2728(92)90020-3; Hubschmann T, 2001, EUR J BIOCHEM, V268, P3383, DOI 10.1046/j.1432-1327.2001.02229.x; Hubschmann T, 2001, EUR J BIOCHEM, V268, P2055, DOI 10.1046/j.1432-1327.2001.02083.x; Kakiuchi T, 1998, CHEM LETT, P1001, DOI 10.1246/cl.1998.1001; Kakiuchi T, 1999, SYNLETT, P901; KINOSHITA H, 2005, IN PRESS CHEM LETT, V34; Kneip C, 1999, BIOCHEMISTRY-US, V38, P15185, DOI 10.1021/bi990688w; LAGARIAS JC, 1985, J BIOL CHEM, V260, P2415; Lamparter T, 2004, FEBS LETT, V573, P1, DOI 10.1016/j.febslet.2004.07.050; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 1996, PLANT CELL ENVIRON, V19, P560, DOI 10.1111/j.1365-3040.1996.tb00389.x; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Lamparter T, 2001, EUR J BIOCHEM, V268, P4720, DOI 10.1046/j.1432-1327.2001.02395.x; LAMPARTER T, 2005, IN PRESS BIOCHEMISTR; Lindner I, 1998, ANGEW CHEM INT EDIT, V37, P1843, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1843::AID-ANIE1843>3.0.CO;2-W; MIZUTANI Y, 1994, BIOCHEMISTRY-US, V33, P153, DOI 10.1021/bi00167a020; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; Otto H, 2003, BIOCHEMISTRY-US, V42, P5885, DOI 10.1021/bi026946y; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Rudiger W., 1994, PHOTOMORPHOGENESIS P, V2nd, P51; Ryu JS, 2005, CELL, V120, P395, DOI 10.1016/j.cell.2004.12.019; Sawamoto D, 2001, CHEM LETT, P588, DOI 10.1246/cl.2001.588; Takeda S, 2001, CHEM LETT, P590, DOI 10.1246/cl.2001.590; TOKUTOMI S, 1992, PHOTOCHEM PHOTOBIOL, V56, P545, DOI 10.1111/j.1751-1097.1992.tb02199.x; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; ZHANG CF, 1992, J AM CHEM SOC, V114, P4569, DOI 10.1021/ja00038a019	41	78	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24491	24497		10.1074/jbc.M504710200	http://dx.doi.org/10.1074/jbc.M504710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878872	hybrid			2022-12-25	WOS:000230114000025
J	Jungmann, RA; Kiryukhina, O				Jungmann, RA; Kiryukhina, O			Cyclic AMP and AKAP-mediated targeting of protein kinase a regulates lactate dehydrogenase subunit A mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; 3'-UNTRANSLATED REGION; ANCHORING PROTEINS; NUCLEAR-PROTEIN; LLC-PK1 CELLS; RICH DOMAIN; BINDING; GENE; EXPRESSION; ELEVATION	Expression of the lactate dehydrogenase A subunit (ldh-A) gene is controlled through transcriptional as well as post-transcriptional mechanisms. Both mechanisms involve activation of protein kinase A (PKA) into its sub-units and subsequent phosphorylation and activation of several key regulatory factors. In rat C6 glioma cells, post-transcriptional gene regulation occurs through PKA-mediated stabilization of LDH-A mRNA and subsequent increase of intracellular LDH-A mRNA levels. Previous studies (Tian, D., Huang, D., Short, S., Short, M. L., and Jungmann, R. A. (1998) J. Biol. Chem. 273, 24861-24866) have demonstrated a cAMP-stabilizing region (CSR) located in the LDH-A 3'-untranslated region which, in combination with several phosphorylated CSR-binding proteins (CSR-BP), regulates the PKA-mediated stabilization of LDH-A mRNA. However, the mechanistic details of interaction of CSR with proteins as they pertain to mRNA stabilization by PKA are so far largely unknown. In this study we tested the hypothesis that ribosomal protein extracts (RSW) from glioma cells contain PKA regulatory (RII) and catalytic (C) subunits that, in combination with a protein kinase A anchoring protein (AKAP 95) and CSR-BPs participate in forming CSR-protein complexes that are responsible for mRNA stability regulation. To demonstrate the importance of CSR-protein complex formation, the PKA subunits and AKAP 95 were removed from the RSW by immunoprecipitation, and the antigen-deleted RSW were subjected to CSR binding analysis using gel mobility shift and UV cross-linking. It was shown that AKAP 95 as well as RII formed a direct linkage with CSR during CSR-protein complex formation. In contrast, the catalytic subunit formed part of the CSR-protein complex but did not bind to CSR directly in a covalent linkage. To determine whether formation of CSR complexes that included C, RII, and AKAP 95 constituted a functional event and was necessary for mRNA stabilization, cell-free decay reactions were carried out with RSW extracts, and the kinetics of decay of LDH-A mRNA was determined. Depletion of PKA subunits and AKAP 95 from RSW extracts by immunoprecipitation resulted in a marked loss of mRNA stabilization activity indicating that the presence of the PKA regulatory and catalytic subunits as well as AKAP 95 in the CSR-protein complexes was absolutely necessary to achieve LDH-A mRNA stabilization.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Jungmann, RA (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	rjungman@northwestern.edu		Kiryukhina, Olga/0000-0001-5962-8423	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053115] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53115] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1976, CELL, V8, P495, DOI 10.1016/0092-8674(76)90217-8; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHEN M, 1993, J BIOL CHEM, V268, P24138; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DERDA DF, 1980, J BIOL CHEM, V255, P1112; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; HUANG D, 1995, MOL CELL ENDOCRINOL, V108, P87, DOI 10.1016/0303-7207(94)03459-7; HUANG DL, 1995, MOL ENDOCRINOL, V9, P994, DOI 10.1210/me.9.8.994; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; Kapiloff MS, 1999, J CELL SCI, V112, P2725; LAKS MS, 1981, J BIOL CHEM, V256, P8775; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI SSL, 1989, CELL BIOL INT REP, V13, P619, DOI 10.1016/0309-1651(89)90112-4; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PENG H, 1995, J BIOL CHEM, V270, P20536, DOI 10.1074/jbc.270.35.20536; PENG H, 1995, J BIOL CHEM, V270, P23996, DOI 10.1074/jbc.270.41.23996; Ranganathan G, 2002, J BIOL CHEM, V277, P43281, DOI 10.1074/jbc.M202560200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1994, RNA PROCESSING PRACT, V2, P107; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAUE M, 1991, J BIOL CHEM, V266, P5743; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SMITH JD, 1988, EMBO J, V7, P3711, DOI 10.1002/j.1460-2075.1988.tb03254.x; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tian D, 1998, J BIOL CHEM, V273, P28454, DOI 10.1074/jbc.273.43.28454; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747	35	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25170	25177		10.1074/jbc.M502514200	http://dx.doi.org/10.1074/jbc.M502514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15878851	hybrid			2022-12-25	WOS:000230114000101
J	Kappler, U; Bailey, S				Kappler, U; Bailey, S			Molecular basis of intramolecular electron transfer in sulfite-oxidizing enzymes is revealed by high resolution structure of a heterodimeric complex of the catalytic molybdopterin subunit and a c-type cytochrome subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOBACILLUS-NOVELLUS; OXIDASE; DEHYDROGENASE; MOLYBDENUM; OXIDATION; COFACTOR; PURIFICATION; TYROSINE-343; REFINEMENT; DEFICIENCY	Sulfite-oxidizing molybdoenzymes convert the highly reactive and therefore toxic sulfite to sulfate and have been identified in insects, animals, plants, and bacteria. Although the well studied enzymes from higher animals serve to detoxify sulfite that arises from the catabolism of sulfur-containing amino acids, the bacterial enzymes have a central role in converting sulfite formed during dissimilatory oxidation of reduced sulfur compounds. Here we describe the structure of the Starkeya novella sulfite dehydrogenase, a heterodimeric complex of the catalytic molybdopterin subunit and a c-type cytochrome subunit, that reveals the molecular mechanism of intramolecular electron transfer in sulfite-oxidizing enzymes. The close approach of the two redox centers in the protein complex (Mo-Fe distance 16.6 angstrom) allows for rapid electron transfer via tunnelling or aided by the protein environment. The high resolution structure of the complex has allowed the identification of potential through-bond pathways for electron transfer including a direct link via Arg-55A and/or an aromatic-mediated pathway. A potential site of electron transfer to an external acceptor cytochrome c was also identified on the SorB subunit on the opposite side to the interaction with the catalytic SorA subunit.	Res Councils Daresbury Lab, Council Cent Lab, Warrington WA4 4AD, Cheshire, England; Univ Queensland, Ctr Met Biol, Brisbane, Qld 4072, Australia	STFC Daresbury Laboratory; University of Queensland	Bailey, S (corresponding author), Res Councils Daresbury Lab, Council Cent Lab, Warrington WA4 4AD, Cheshire, England.	s.bailey@dl.ac.uk	Kappler, Ulrike/A-9483-2013	Kappler, Ulrike/0000-0002-2642-1319				Arnoux P, 2003, NAT STRUCT BIOL, V10, P928, DOI 10.1038/nsb994; Cowtan K, 2001, ACTA CRYSTALLOGR D, V57, P1435, DOI 10.1107/S0907444901010812; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; Feng CJ, 2003, J AM CHEM SOC, V125, P14696, DOI 10.1021/ja038197t; Feng CJ, 2003, BIOCHEMISTRY-US, V42, P12235, DOI 10.1021/bi0350194; Feng CJ, 2003, J BIOL CHEM, V278, P2913, DOI 10.1074/jbc.M210374200; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; Gray HB, 2003, Q REV BIOPHYS, V36, P341, DOI 10.1017/S0033583503003913; Jones S, 1997, J MOL BIOL, V272, P121, DOI 10.1006/jmbi.1997.1234; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Kappler U, 2004, ACTA CRYSTALLOGR D, V60, P2070, DOI 10.1107/S0907444904022395; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MCEWAN AG, 2004, RESPIRATION ARCHAEA, P175; MIZE C, 1995, J INHERIT METAB DIS, V18, P283, DOI 10.1007/BF00710416; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Pacheco A, 1999, J BIOL INORG CHEM, V4, P390, DOI 10.1007/s007750050325; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAJAGOPALAN KV, 1980, MOLYBDENUM MOLYBDENU, P243; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; Wilson HL, 2004, J BIOL CHEM, V279, P15105, DOI 10.1074/jbc.M314288200; YAMANAKA T, 1981, PLANT CELL PHYSIOL, V22, P613; 1994, ACTA CRYSTALLOGR SD, V50, P760	34	108	114	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24999	25007		10.1074/jbc.M503237200	http://dx.doi.org/10.1074/jbc.M503237200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15863498	hybrid			2022-12-25	WOS:000230114000084
J	Clark, DE; Williams, CC; Duplessis, TT; Moring, KL; Notwick, AR; Long, WW; Lane, WS; Beuvink, I; Hynes, NE; Jones, FE				Clark, DE; Williams, CC; Duplessis, TT; Moring, KL; Notwick, AR; Long, WW; Lane, WS; Beuvink, I; Hynes, NE; Jones, FE			ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-GLAND; SIGNAL TRANSDUCER; DNA-BINDING; ACTIVATION; DIFFERENTIATION; KINASE; CELLS; GAMMA; P21-ACTIVATED-KINASE-1; RESPONSES	The epidermal growth factor receptor family member ERBB4 is required for mammary gland development and lactation. ERBB4 activities in the breast are mediated through the signal transducer and activator of transcription ( STAT) family member STAT5A, and ERBB4 directly activates STAT5A, in part, through phosphorylation of STAT5A at the regulatory Tyr-694. Here we show that STAT5A regulation by ERBB4 is also mediated through STAT5A serine phosphorylation. Using a reverse-phase high performance liquid chromatography tandem mass spectrometry analysis of proteolytically digested STAT5A coexpressed with ERBB4, we identified STAT5A serine phosphorylations at the previously described Ser-779 and at the novel Ser-127/Ser128. Immunohistochemistry of wild-type and ERBB4-null mammary glands at late pregnancy showed that ERBB4 expression was required for STAT5A phosphorylation at Ser-779. Independent serine-to-alanine residue substitutions in full-length STAT5A revealed that although STAT5A Ser-779 phosphorylation was dispensable for phosphorylation of STAT5A at Tyr-694 and subsequent DNA binding, Ser-779 was required to stabilize an interaction with ERBB4 and mediate ERBB4-induced STAT5A stimulation of gene expression. STAT5A Ser127/ Ser-128, on the other hand, was required for ERBB4-induced phosphorylation of Tyr-694, whereas Ser-779 and as yet unidentified tyrosine residues were phosphorylated in the absence of Ser-127/Ser-128. In addition, STAT5A S127A/S128A remained associated with ERBB4 but failed to bind DNA or activate transcription in response to ERBB4 coexpression. Our studies demonstrate that phosphorylation of STAT5A at Ser-127/Ser128 and Ser-779 are obligatory events regulating ERBB4-mediated activation of STAT5A.	Tulane Univ, Ctr Hlth Sci, Ctr Canc, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Ctr Hlth Sci, Ctr Canc, Dept Pathol, New Orleans, LA 70112 USA; Tulane Univ, Ctr Hlth Sci, Ctr Canc, Dept Struct & Cellular Biol, New Orleans, LA 70112 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Tulane University; Tulane University; Tulane University; Harvard University; Friedrich Miescher Institute for Biomedical Research	Jones, FE (corresponding author), Tulane Univ, Ctr Hlth Sci, Ctr Canc, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	fjones@tulane.edu			NCI NIH HHS [R01CA95783, R01CA96717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095783, R01CA096717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Burow ME, 2001, J STEROID BIOCHEM, V78, P409, DOI 10.1016/S0960-0760(01)00117-0; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	31	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24175	24180		10.1074/jbc.M414044200	http://dx.doi.org/10.1074/jbc.M414044200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15863494	hybrid			2022-12-25	WOS:000229880000092
J	Doyle, SL; Jefferies, CA; O'Neill, LA				Doyle, SL; Jefferies, CA; O'Neill, LA			Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NF kappa B activation by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BINDING PROTEIN; IKK-BETA; SUBUNIT; BTK; PATHWAYS; MUTATION; FAMILY; DOMAIN; ALPHA	Bruton's tyrosine kinase (Btk) has recently been shown to participate in the induction of nuclear factor kappa B (NF kappa B)-dependent gene expression by the lipopolysaccharide (LPS) receptor Toll-like receptor-4 (TLR4). In this study we have examined the mechanism whereby Btk participates in this response. Treatment of the murine monocytic cell line Raw264.7 with LFM-A13, a specific Btk inhibitor, blocked LPS-induced NF kappa B-dependent reporter gene expression but not I kappa B alpha degradation. Transient transfection of HEK293 cells with Btk had no effect on NF kappa B-dependent reporter gene expression but strongly promoted transactivation of a reporter gene by a p65-Gal4 fusion protein. I kappa B alpha degradation activated by LPS was intact in macrophages from X-linked immunodeficiency (Xid) mice, which contain inactive Btk. Transfection of cells with a dominant negative form of Btk (BtkK430R) inhibited LPS-driven p65 mediated transactivation. Additionally LFM-A13 impaired phosphorylation of serine 536 on p65 induced by LPS in HEK293-TLR4 cells, and in Xid macrophages this response was impaired. This study therefore reveals a novel function for Btk. It is required for the signaling pathway activated by TLR4, which culminates in phosphorylation of p65 on serine 536 promoting transactivation by NF kappa B.	Trinity Coll Dublin, Dept Biochem & Biotechnol Inst, Dublin 2, Ireland	Trinity College Dublin	O'Neill, LA (corresponding author), Trinity Coll Dublin, Dept Biochem & Biotechnol Inst, Dublin 2, Ireland.	laoneill@tcd.ie	Doyle, Sarah/C-1453-2014; Jefferies, Caroline/AAI-1543-2021	Jefferies, Caroline/0000-0002-8879-6722; O'Neill, Luke/0000-0002-4333-2748; Doyle, Sarah/0000-0002-6294-9380				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY LAD, 1994, HUM MOL GENET, V3, P79, DOI 10.1093/hmg/3.1.79; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Jiang X, 2003, BIOCHEM BIOPH RES CO, V301, P583, DOI 10.1016/S0006-291X(03)00011-1; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Mansell A, 2004, J BIOL CHEM, V279, P37227, DOI 10.1074/jbc.C400289200; McGettrick AF, 2004, MOL IMMUNOL, V41, P577, DOI 10.1016/j.molimm.2004.04.006; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Mukhopadhyay S, 2001, J CELL BIOCHEM, V81, P659, DOI 10.1002/jcb.1088; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SMITH CIE, 1994, J IMMUNOL, V152, P557; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Yang EJ, 2004, J BIOL CHEM, V279, P1827, DOI 10.1074/jbc.M308722200; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306	30	125	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23496	23501		10.1074/jbc.C500053200	http://dx.doi.org/10.1074/jbc.C500053200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849198	hybrid, Green Published			2022-12-25	WOS:000229880000013
J	Haslbeck, M; Miess, A; Stromer, T; Walter, S; Buchner, J				Haslbeck, M; Miess, A; Stromer, T; Walter, S; Buchner, J			Disassembling protein aggregates in the yeast cytosol - The cooperation of Hsp26 with SSA1 and Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONE; ALPHA-CRYSTALLIN; CITRATE SYNTHASE; DISAGGREGATION; EXPRESSION; SUBSTRATE; SYSTEM; DNAK	In all organisms studied, elevated temperatures induce the expression of a variety of stress proteins, among them small Hsps (sHsp). sHsps are chaperones that prevent the unspecific aggregation of proteins by forming stable complexes with unfolded polypeptides. Reactivation of captured proteins requires the assistance of other ATP-dependent chaperones. How sHsps and ATP-dependent chaperones work together is poorly understood. Here, we analyzed the interplay of chaperones present in the cytosol of Saccharomyces cerevisiae. Specifically, we characterized the influence of Hsp104 and Ssa1 on the disassembly of Hsp26(.)substrate complexes in vitro and in vivo. We show that recovery of proteins from aggregates in the cell requires the chaperones to work together with defined but overlapping functions. During reactivation, proteins are transferred from a stable complex with Hsp26 to Hsp104 and Hsp70. The need for ATP-dependent chaperones depends on the type of sHsp(.)substrate complex. Although Ssa1 is able to release substrate proteins from soluble Hsp26(.)substrate complexes, Hsp104 is essential to dissociate substrate proteins from aggregates with incorporated sHsps. Our results are consistent with a model of several interrelated defense lines against protein aggregation.	Tech Univ Munich, Dept Chem, D-88747 Garching, Germany	Technical University of Munich	Buchner, J (corresponding author), Tech Univ Munich, Dept Chem, D-88747 Garching, Germany.	johannes.buchner@ch.tum.de	Haslbeck, Martin/A-4413-2013; Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Cashikar AG, 2005, J BIOL CHEM, V280, P23869, DOI 10.1074/jbc.M502854200; COXON A, 1995, CHEM BIOL, V2, P119, DOI 10.1016/1074-5521(95)90011-X; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; Dumitru GL, 2004, J MOL BIOL, V339, P1179, DOI 10.1016/j.jmb.2004.04.052; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; Grallert H, 1999, J BIOL CHEM, V274, P20171, DOI 10.1074/jbc.274.29.20171; Grallert H, 1998, J BIOL CHEM, V273, P33305, DOI 10.1074/jbc.273.50.33305; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck M, 2003, J CHROMATOGR B, V786, P127, DOI 10.1016/S1570-0232(02)00716-X; Haslbeck M, 2004, EMBO J, V23, P638, DOI 10.1038/sj.emboj.7600080; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee S, 2004, J STRUCT BIOL, V146, P99, DOI 10.1016/j.jsb.2003.11.016; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Mogk A, 2004, J STRUCT BIOL, V146, P90, DOI 10.1016/j.jsb.2003.10.009; Mogk A, 2004, CURR BIOL, V14, pR78, DOI 10.1016/j.cub.2003.12.051; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Schafer H, 2001, ELECTROPHORESIS, V22, P2955, DOI 10.1002/1522-2683(200108)22:14<2955::AID-ELPS2955>3.0.CO;2-U; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SRERE PA, 1966, J BIOL CHEM, V241, P2157; STEGE GJJ, 1995, J CELL PHYSIOL, V164, P579, DOI 10.1002/jcp.1041640316; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Wegele H, 2003, J CHROMATOGR B, V786, P109, DOI 10.1016/S1570-0232(02)00724-9; Weibezahn J, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-1	52	169	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23861	23868		10.1074/jbc.M502697200	http://dx.doi.org/10.1074/jbc.M502697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15843375	hybrid			2022-12-25	WOS:000229880000059
J	Nandakumar, J; Shuman, S				Nandakumar, J; Shuman, S			Dual mechanisms whereby a broken RNA end assists the catalysis of its repair by T4 RNA ligase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-DNA-LIGASE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; BOND FORMATION; ENZYME; NICK; INTERMEDIATE	T4 RNA ligase 2 ( Rnl2) efficiently seals 3'-OH/5'-PO4 RNA nicks via three nucleotidyl transfer steps. Here we show that the terminal 3'-OH at the nick accelerates the second step of the ligase pathway (adenylylation of the 5'-PO4 strand) by a factor of 1000, even though the 3'-OH is not chemically transformed during the reaction. Also, the terminal 2'-OH at the nick accelerates the third step ( attack of the 3'-OH on the 5'-adenylated strand to form a phosphodiester) by a factor of 25-35, even though the 2'-OH is not chemically reactive. His-37 of Rnl2 is uniquely required for step 3, providing a similar to 10(2) rate acceleration. Biochemical epistasis experiments show that His-37 and the RNA 2'-OH act independently. We conclude that the broken RNA end promotes catalysis of its own repair by Rnl2 via two mechanisms, one of which ( enhancement of step 3 by the 2'-OH) is specific to RNA ligation. Substrate-assisted catalysis provides a potential biochemical checkpoint during nucleic acid repair.	Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Mol Biol Program, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Nandakumar, Jayakrishnan/0000-0001-9146-2785	NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanc V, 1999, J BIOL CHEM, V274, P24289, DOI 10.1074/jbc.274.34.24289; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; Deng JP, 2004, J MOL BIOL, V343, P601, DOI 10.1016/j.jmb.2004.08.041; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Jiang YL, 2003, BIOCHEMISTRY-US, V42, P1922, DOI 10.1021/bi027014x; Kosloff M, 2001, TRENDS BIOCHEM SCI, V26, P161, DOI 10.1016/S0968-0004(00)01748-5; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LEHMAN IR, 1974, SCIENCE, V186, P790; Martins A, 2004, J BIOL CHEM, V279, P50654, DOI 10.1074/jbc.M407657200; MODRICH P, 1973, J BIOL CHEM, V248, P7502; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Nandakumar J, 2004, J BIOL CHEM, V279, P31337, DOI 10.1074/jbc.M402394200; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Palazzo SS, 2003, MOL BIOCHEM PARASIT, V127, P161, DOI 10.1016/S0166-6851(02)00333-X; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2004, CURR OPIN STRUC BIOL, V14, P757, DOI 10.1016/j.sbi.2004.10.006; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; YANG SW, 1992, J BIOL CHEM, V267, P8117; Yin SM, 2004, VIROLOGY, V319, P141, DOI 10.1016/j.virol.2003.10.037; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200	25	20	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23484	23489		10.1074/jbc.M500831200	http://dx.doi.org/10.1074/jbc.M500831200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15851476	hybrid			2022-12-25	WOS:000229880000011
J	Poon, CJ; Plaas, AH; Keene, DR; McQuillan, DJ; Last, K; Fosang, AJ				Poon, CJ; Plaas, AH; Keene, DR; McQuillan, DJ; Last, K; Fosang, AJ			N-Linked keratan sulfate in the aggrecan interglobular domain potentiates aggrecanase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN-BINDING REGION; HUMAN SYNOVIAL-FLUID; ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; CLEAVAGE-SITE; LARGER OLIGOSACCHARIDES; BOVINE KERATOCYTES; MOLECULAR-CLONING; PIVOTAL ROLE; IN-VIVO	Keratan sulfate is thought to influence the cleavage of aggrecan by metalloenzymes. We have therefore produced a recombinant substrate, substituted with keratan sulfate, suitable for the study of aggrecanolysis in vitro. Recombinant human G1-G2 was produced in primary bovine keratocytes using a vaccinia virus expression system. Following purification and digestion with specific hydrolases, fluorophore-assisted carbohydrate electrophoresis was used to confirm the presence of the monosulfated Gal-GlcNAc6S and GlcNAc6s- Gal disaccharides and the disulfated Gal6S-GlcNAc6S disaccharides of keratan sulfate. Negligible amounts of fucose or sialic acid were detected, and the level of unsulfated disaccharides was minimal. Treatment with keratanases reduced the size of the recombinant G1-G2 by similar to 5 kDa on SDS-PAGE. Treatment with N-glycosidase F also reduced the size of G1-G2 by similar to 5 kDa and substantially reduced G1-G2 immunoreactivity with monoclonal antibody 5-D-4, indicating that keratan sulfate on the recombinant protein is N-linked. Cleavage of G1-G2 by aggrecanase was markedly reduced when keratan sulfate chains were removed by treatment with keratanase, keratanase II, endo-beta-galactosidase, or N-glycosidase F. These results indicate that modification of oligosaccharides in the aggrecan interglobular domain with keratan sulfate, most likely at asparagine residue 368, potentiates aggrecanase activity in this part of the core protein.	Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Arthritis Res Grp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.	amanda.fosang@mcri.edu.au		Last, Karena/0000-0002-4396-8404; Fosang, Amanda/0000-0002-5523-5427				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; Brown GM, 1998, J BIOL CHEM, V273, P26408, DOI 10.1074/jbc.273.41.26408; CATERSON B, 1986, ARTICULAR CARTILAGE, P59; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; DICKENSON JM, 1992, BIOCHEM J, V282, P267, DOI 10.1042/bj2820267; DICKENSON JM, 1991, BIOCHEM J, V278, P779, DOI 10.1042/bj2780779; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; Fosang AJ, 2000, J BIOL CHEM, V275, P33027, DOI 10.1074/jbc.M910207199; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FOSANG AJ, 2004, T ORTHOP RES SOC, V29, P232; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Habuchi O, 1996, GLYCOBIOLOGY, V6, P51, DOI 10.1093/glycob/6.1.51; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HOUNSELL EF, 1986, EUR J BIOCHEM, V157, P375, DOI 10.1111/j.1432-1033.1986.tb09679.x; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; Little CB, 2005, MOL CELL BIOL, V25, P3388, DOI 10.1128/MCB.25.8.3388-3399.2005; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; McQuillan D J, 2001, Methods Mol Biol, V171, P201; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Mercuri FA, 1999, J BIOL CHEM, V274, P32387, DOI 10.1074/jbc.274.45.32387; Munteanu SE, 2000, ARTHRITIS RHEUM, V43, P2211, DOI 10.1002/1529-0131(200010)43:10<2211::AID-ANR8>3.0.CO;2-D; Munteanu SE, 2002, MATRIX BIOL, V21, P429, DOI 10.1016/S0945-053X(02)00034-3; Nakazawa K, 1998, ARCH BIOCHEM BIOPHYS, V359, P269, DOI 10.1006/abbi.1998.0897; Plaas A H, 2001, Methods Mol Biol, V171, P117; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Singer II, 1997, OSTEOARTHR CARTILAGE, V5, P407, DOI 10.1016/S1063-4584(97)80045-3; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; TAI GH, 1994, CARBOHYD RES, V255, P303, DOI 10.1016/S0008-6215(00)90987-X; Tai GH, 1997, J BIOL CHEM, V272, P28227, DOI 10.1074/jbc.272.45.28227; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; TAI GH, 1991, BIOCHEM J, V273, P307, DOI 10.1042/bj2730307; TAI GH, 1993, BIOCHEM J, V291, P889, DOI 10.1042/bj2910889; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; TODA N, 1970, BIOCHIM BIOPHYS ACTA, V208, P227, DOI 10.1016/0304-4165(70)90241-2; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; van Meurs J, 1999, ARTHRITIS RHEUM-US, V42, P2074, DOI 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5; van Meurs J, 1999, J IMMUNOL, V163, P5633; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x	65	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23615	23621		10.1074/jbc.M412145200	http://dx.doi.org/10.1074/jbc.M412145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849197	hybrid			2022-12-25	WOS:000229880000027
J	Wen, KK; Rubenstein, PA				Wen, KK; Rubenstein, PA			Acceleration of yeast actin polymerization by yeast Arp2/3 complex does not require an Arp2/3-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; F-ACTIN; CONFORMATIONAL-CHANGES; BINDING-ACTIVITY; IN-VITRO; NUCLEATION; DYNAMICS; NUCLEOTIDE; MOTILITY; WASP	The Arp2/3 complex creates filament branches leading to an enhancement in the rate of actin polymerization. Work with Arp complexes from different sources indicated that it was inactive by itself, required an activating factor such as the Wiskott-Aldrich syndrome protein ( WASP), and might exhibit a preference for ATP or ADP-P-i actin. However, with yeast actin, Pi release is almost concurrent with polymerization, eliminating the presence of an ADP-P-i cap. We thus investigated the ability of the yeast Arp2/3 complex (yArp2/3) to facilitate yeast actin polymerization in the presence and absence of the Arp2/3-activating factor Las17p WA. yArp2/3 significantly accelerates yeast actin but not muscle actin polymerization in the absence of Las17p WA. The addition of Las17p WA further enhances yeast actin polymerization by yArp2/3 and allows the complex to now assist muscle actin polymerization. This actin isoform difference is not observed with bovine Arp2/3 complex, because the neural WASP VCA fragment is required for polymerization of both actins. Observation of individual branching filaments showed that Las17p WA increased the persistence of filament branches. Compared with wild type actin, the V159N mutant actin, proposed to be more ATP-like in behavior, exhibited an enhanced rate of polymerization in the presence of the yArp2/3 complex. yArp2/3 caused a significant rate of Pi release prior to observation of an increase in filament mass but while branched structures were present. Thus, yeast F-actin can serve as a primary yArp2/3-activating factor, indicating that a newly formed yeast actin filament has a topology, unlike that of muscle actin, that is recognized specifically by yArp2/3.	Univ Iowa, Roy A & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Roy A & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Belmont LD, 1998, J CELL BIOL, V142, P1289, DOI 10.1083/jcb.142.5.1289; Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; Bryan KE, 2005, J BIOL CHEM, V280, P1696, DOI 10.1074/jbc.M410180200; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; CARLIER MT, 1986, INT J GYNECOL PATHOL, V5, P69, DOI 10.1097/00004347-198603000-00008; COOK RK, 1992, J BIOL CHEM, V267, P9430; Dayel MJ, 2001, P NATL ACAD SCI USA, V98, P14871, DOI 10.1073/pnas.261419298; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; Nolen BJ, 2004, P NATL ACAD SCI USA, V101, P15627, DOI 10.1073/pnas.0407149101; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; Pan F, 2004, J BIOL CHEM, V279, P54629, DOI 10.1074/jbc.M402357200; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SYITKINA TM, 1999, J CELL BIOL, V145, P1009; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	43	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					24168	24174		10.1074/jbc.M502024200	http://dx.doi.org/10.1074/jbc.M502024200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15857833	hybrid			2022-12-25	WOS:000229880000091
J	Luk, E; Yang, M; Jensen, LT; Bourbonnais, Y; Culotta, VC				Luk, E; Yang, M; Jensen, LT; Bourbonnais, Y; Culotta, VC			Manganese activation of superoxide dismutase 2 in the mitochondria of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER/ZINC SUPEROXIDE-DISMUTASE; IN-VIVO; METAL TRANSPORTERS; YEAST MITOCHONDRIA; PHYSIOLOGICAL-ROLE; PROTEIN IMPORT; CHAPERONE; GENE; BINDING; FAMILY	Manganese-dependent superoxide dismutase 2 (SOD2) in the mitochondria plays a key role in protection against oxidative stress. Here we probed the pathway by which SOD2 acquires its manganese catalytic cofactor. We found that a mitochondrial localization is essential. A cytosolic version of Saccharomyces cerevisiae Sod2p is largely apo for manganese and is only efficiently activated when cells accumulate toxic levels of manganese. Furthermore, Candida albicans naturally produces a cytosolic manganese SOD (Ca SOD3), yet when expressed in the cytosol of S. cerevisiae, a large fraction of Ca SOD3 also remained manganese-deficient. The cytosol of S. cerevisae cannot readily support activation of Mn-SOD molecules. By monitoring the kinetics for metalation of S. cerevisiae Sod2p in vivo, we found that prefolded Sod2p in the mitochondria cannot be activated by manganese. Manganese insertion is only possible with a newly synthesized polypeptide. Furthermore, Sod2p synthesis appears closely coupled to Sod2p import. By reversibly blocking mitochondrial import in vivo, we noted that newly synthesized Sod2p can enter mitochondria but not a Sod2p polypeptide that was allowed to accumulate in the cytosol. We propose a model in which the insertion of manganese into eukaryotic SOD2 molecules is driven by the protein unfolding process associated with mitochondrial import.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Univ Laval, Dept Biochim & Microbiol, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Ctr Rech Fonct, CREFSIP, Ste Foy, PQ G1K 7P4, Canada	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Laval University; Laval University	Culotta, VC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm E7626, Baltimore, MD 21205 USA.	vculotta@jhsph.edu		Bourbonnais, Yves/0000-0002-8130-6612; Jensen, Laran/0000-0003-3199-1743; Luk, Ed/0000-0002-6619-2258	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074402] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07141, ES 08996] Funding Source: Medline; NIGMS NIH HHS [F32 GM 074402] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartnikas TB, 2003, J BIOL CHEM, V278, P33602, DOI 10.1074/jbc.M305435200; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BOWLER C, 1990, J BACTERIOL, V172, P1539, DOI 10.1128/jb.172.3.1539-1546.1990; Brouwer M, 2003, BIOCHEM J, V374, P219, DOI 10.1042/BJ20030272; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Duttaroy A, 2003, GENETICS, V165, P2295; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Ginsberg MD, 2003, J MOL BIOL, V327, P885, DOI 10.1016/S0022-2836(03)00173-6; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Keller JN, 1998, J NEUROSCI, V18, P687; Kirby K, 2002, P NATL ACAD SCI USA, V99, P16162, DOI 10.1073/pnas.252342899; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Lamarre C, 2001, J BIOL CHEM, V276, P43784, DOI 10.1074/jbc.M108095200; Leveque VJP, 2000, BIOCHEMISTRY-US, V39, P7131, DOI 10.1021/bi9929958; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu G, 2004, CANCER LETT, V214, P69, DOI 10.1016/j.canlet.2004.06.027; Luk E, 2003, P NATL ACAD SCI USA, V100, P10353, DOI 10.1073/pnas.1632471100; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; MacKenzie JA, 2004, J BIOL CHEM, V279, P9803, DOI 10.1074/jbc.M307167200; Marc P, 2002, EMBO REP, V3, P159, DOI 10.1093/embo-reports/kvf025; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; Martin J, 1997, J BIOENERG BIOMEMBR, V29, P35, DOI 10.1023/A:1022407705182; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mizuno K, 2004, J BIOL CHEM, V279, P27339, DOI 10.1074/jbc.M400813200; Mukhopadhyay A, 2004, BIOCHEM J, V382, P385, DOI 10.1042/BJ20040065; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RAVINDRANATH SD, 1975, J BIOL CHEM, V250, P6107; REID GA, 1982, J BIOL CHEM, V257, P3056; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Sherman F., 1978, METHODS YEAST GENETI; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; Wei JPJ, 2001, J BIOL CHEM, V276, P44798, DOI 10.1074/jbc.M104708200; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Whittaker JW, 2003, BIOCHEM SOC T, V31, P1318; Whittaker MM, 1999, J BIOL CHEM, V274, P34751, DOI 10.1074/jbc.274.49.34751; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477	50	95	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					22715	22720		10.1074/jbc.M504257200	http://dx.doi.org/10.1074/jbc.M504257200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15851472	hybrid			2022-12-25	WOS:000229741800021
J	Takeda, DY; Parvin, JD; Dutta, A				Takeda, DY; Parvin, JD; Dutta, A			Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; LICENSING FACTOR CDT1; EUKARYOTIC DNA-REPLICATION; RE-REPLICATION; MULTIPLE MECHANISMS; GEMININ BINDING; INHIBITION; MITOSIS; XENOPUS; REREPLICATION	Previous reports have shown that the N terminus of Cdt1 is required for its degradation during S phase (Li, X., Zhao, Q., Liao, R., Sun, P., and Wu, X. (2003) J. Biol. Chem. 278, 30854-30858; Nishitani, H., Lygerou, Z., and Nishimoto, T. (2004) J. Biol. Chem. 279, 30807-30816). The stabilization was attributed to deletion of the cyclin binding motif (Cy motif), which is required for its phosphorylation by cyclin-dependent kinases. Phosphorylated Cdt1 is subsequently recognized by the F-box protein Skp2 and targeted for proteasomal mediated degradation. Using phosphopeptide mapping and mutagenesis studies, we found that threonine 29 within the N terminus of Cdt1 is phosphorylated by Cdk2 and required for interaction with Skp2. However, threonine 29 and the Cy motif are not necessary for proteolysis of Cdt1 during S phase. Mutants of Cdt1 that do not stably associate with Skp2 or cyclins are still degraded in S phase to the same extent as wild type Cdt1, indicating that other determinants within the N terminus of Cdt1 are required for degrading Cdt1. We localized the region necessary for Cdt1 degradation to the first 32 residues. Overexpression of stable forms of Cdt1 significantly delayed entry into and completion of S phase, suggesting that failure to degrade Cdt1 prevents normal progression through S phase. In contrast, Cdt1 mutants that fail to interact with Skp2 and cyclins progress through S phase with similar kinetics as wild type Cdt1 but stimulate the re-replication caused by overexpressing Cdt1. Therefore, a Skp2-independent pathway that requires the N-terminal 32 residues of Cdt1 is critical for the degradation of Cdt1 in S phase, and this degradation is necessary for the optimum progression of cells through S phase.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Parvin, Jeffrey D/C-8955-2009	Dutta, Anindya/0000-0002-4319-0073; Takeda, David/0000-0002-5986-1169	NCI NIH HHS [CA90281, CA89406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406, R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200; Ferenbach A, 2005, NUCLEIC ACIDS RES, V33, P316, DOI 10.1093/nar/gki176; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Maiorano D, 2004, EXP CELL RES, V295, P138, DOI 10.1016/j.yexcr.2003.11.018; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Thomer M, 2004, DEVELOPMENT, V131, P4807, DOI 10.1242/dev.01348; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wilmes GM, 2004, GENE DEV, V18, P981, DOI 10.1101/gad.1202304; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	37	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23416	23423		10.1074/jbc.M501208200	http://dx.doi.org/10.1074/jbc.M501208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15855168	hybrid			2022-12-25	WOS:000229741800102
J	Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H				Erkan, M; Kleeff, J; Esposito, I; Giese, T; Ketterer, K; Buchler, MW; Giese, NA; Friess, H			Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis	ONCOGENE			English	Article						hypoxia; apoptosis; PanIN; Bcl-2; chemoresistance; TGF-beta	HYPOXIC CELL-DEATH; PHASE-III TRIAL; PROTEIN BNIP3; CURATIVE RESECTION; BH3 DOMAIN; MITOCHONDRIAL; CARCINOMA; APOPTOSIS; BCL-2; 5-FLUOROURACIL	Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma. In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cyclers quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens. Modulation of BNIP3 expression was achieved using specific siRNA molecules. The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide assays. BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively. Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells. By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas. Interestingly, while BNIP3 was undetectable in the cancer cells of 59% of the cases, 75-100% of PanIN2/3 lesions displayed BNIP3 immunoreactivity. Loss of BNIP3 expression correlated with poorer survival of patients (8 vs 14 months for BNIP3 negative vs positive tumors). Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four. Downregulation of BNIP3 resulted in increased resistance to 5-fluoro-uracil and gemcitabine. In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, con tributes to resistance to chemotherapy, and correlates with a worsened prognosis.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bani MR, 2004, MOL CANCER THER, V3, P111; Bold RJ, 1999, ANN SURG ONCOL, V6, P279, DOI 10.1007/s10434-999-0279-x; Brandt R, 2004, PANCREATOLOGY, V4, P587, DOI 10.1159/000082241; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; CROWN J, 1991, J CLIN ONCOL, V9, P1682, DOI 10.1200/JCO.1991.9.9.1682; CULLINAN S, 1990, CANCER, V65, P2207, DOI 10.1002/1097-0142(19900515)65:10<2207::AID-CNCR2820651007>3.0.CO;2-Y; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; De Angelis PM, 2004, INT J ONCOL, V24, P1279; Friess H, 1998, GASTROENTEROLOGY, V115, P1018, DOI 10.1016/S0016-5085(98)70278-1; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graber HU, 1999, J GASTROINTEST SURG, V3, P74, DOI 10.1016/S1091-255X(99)80012-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Guo JC, 2004, ONCOGENE, V23, P71, DOI 10.1038/sj.onc.1206926; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1999, DIGEST DIS SCI, V44, P1793, DOI 10.1023/A:1018882320500; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Monti P, 2004, VIRCHOWS ARCH, V445, P236, DOI 10.1007/s00428-004-1053-x; Moskaluk CA, 1997, CANCER RES, V57, P2140; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Reynolds TY, 1996, CANCER RES, V56, P5754; Richter A, 2003, WORLD J SURG, V27, P324, DOI 10.1007/s00268-002-6659-z; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Takaori K, 2004, PANCREAS, V28, P257, DOI 10.1097/00006676-200404000-00008; Tenedini E, 2004, BLOOD, V104, P3126, DOI 10.1182/blood-2003-07-2597; Tracey L, 2004, J INTERF CYTOK RES, V24, P185, DOI 10.1089/107999004322917034; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilentz RE, 2000, CANCER RES, V60, P2002; Xu ZW, 2002, CANCER CHEMOTH PHARM, V49, P504, DOI 10.1007/s00280-002-0435-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144	61	171	181	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4421	4432		10.1038/sj.onc.1208642	http://dx.doi.org/10.1038/sj.onc.1208642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856026				2022-12-25	WOS:000229976900011
J	Sakurai, T; Fujita, Y; Ohto, E; Oguro, A; Atomi, Y				Sakurai, T; Fujita, Y; Ohto, E; Oguro, A; Atomi, Y			The decrease of the cytoskeleton tubulin follows the decrease of the associating molecular chaperone alpha B-crystallin in unloaded soleus muscle atrophy without stretch	FASEB JOURNAL			English	Article						microtubule; small heat shock protein; hindlimb suspension; mechanical stress	HEAT-SHOCK PROTEINS; SKELETAL-MUSCLE; RAT SOLEUS; INTERMEDIATE-FILAMENT; PROTEOMIC ANALYSIS; GENE-EXPRESSION; MESSENGER-RNA; MICROTUBULE; ACTIN; TURNOVER	The cytoskeletal component tubulin/microtubule commonly allows the cell to respond mechanically to the environment. The concentration of free tubulin dimer is autoregulated in the balance of free dimer and polymeric forms of microtubule (MT) protein, having an intrinsic property of "dynamic instability", and through cotranslational beta-tubulin mRNA degradation. Recently, we have demonstrated that alpha B-crystallin is a key molecule of muscle atrophy, since alpha B-crystallin has a chaperone-like-activity that suppresses tubulin aggregation and protects the MT disassembly against both Ca2+ and depolymelizing alkaloid in vitro. Most of the small heat-shock proteins (sHsps), including alpha B-crystallin, are expressed in skeletal muscle. However, no report to date has studied the changes of tubulin/MT during muscle adaptation. Here, we examined changes in tubulin content in rat soleus muscles after hindlimb suspension (HS) with/without passive stretch and the recovery. HS induced rapid decreases of soleus muscle mass, most Hsps ( alpha B-crystallin, Hsp90, Hsp70, Hsp27, and p20) and tubulin contents in soleus muscle, while heat-shock cognate 70-kDa protein (Hsc70) did not decrease. Soleus muscle mass, most Hsps, and tubulin were maintained with passive stretch. After 5 days' recovery, the levels of tubulin and Hsps, but not Hsc70, were restored to control levels. The interactions of alpha B-crystallin and tubulin/MT were observed with immunoprecipitation with an anti-alpha-tubulin antibody and taxol-dependent MT assembly. Other sHsps were also associated with alpha B-crystallin and MT, whereas Hsp90 and Hsp70 did not co-precipitate with them. These data imply an interaction and close relationship between alpha B-crystallin and tubulin/MTs in muscle tissues. The amount of mRNA of alpha B-crystallin decreased with the muscle atrophy level, whereas the gene expression level of beta I-tubulin was maintained during HS. This means a significant role of post-transcriptional regulation in tubulin/MT system in muscle adaptation, whereas alpha B-crystallin and most sHsps are regulated at the transcriptional level. Additional functional contribution of alpha B-crystallin to tubulin/MTs during myotube formation was examined using C2C12 myoblast cultured cells, the alpha B-crystallin expression of which was decreased or increased. It indicated the necessity of alpha B-crystallin during microtubule reorganization. In conclusion, tubulin/MTs were revealed to be early soleus muscle atrophy suggest that the chaperone effect of alpha B-crystallin on the cytoskeleton, which may be also dynamically regulated in the muscle cell, is a key mechanism for muscle adaptation and protection of the atrophy and also muscle differentiation.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	University of Tokyo	Atomi, Y (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan.	atomi@idaten.c.u-tokyo.ac.jp	Atomi, Yoriko/AAF-4783-2019	Atomi, Yoriko/0000-0003-3808-6543; Oguro-Ando, Asami/0000-0003-4029-3250				ANTIN PB, 1981, J CELL BIOL, V90, P300, DOI 10.1083/jcb.90.2.300; Appaix F, 2003, EXP PHYSIOL, V88, P175, DOI 10.1113/eph8802511; Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; ATOMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1323, DOI 10.1016/0006-291X(91)92083-V; Atomi Y, 2000, J APPL PHYSIOL, V88, P1355, DOI 10.1152/jappl.2000.88.4.1355; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; BOOTH FW, 1982, J APPL PHYSIOL, V52, P1113; BOOTH FW, 1983, MED SCI SPORT EXER, V15, P415; BOUDRIAU S, 1993, J HISTOCHEM CYTOCHEM, V41, P1013, DOI 10.1177/41.7.8515044; Chang W, 2002, J BIOL CHEM, V277, P30690, DOI 10.1074/jbc.M204930200; Desplanches D, 1997, INT J SPORTS MED, V18, pS259, DOI 10.1055/s-2007-972722; Fujita Y, 2004, J CELL SCI, V117, P1719, DOI 10.1242/jcs.01021; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GOLDSPINK DF, 1977, J PHYSIOL-LONDON, V264, P267, DOI 10.1113/jphysiol.1977.sp011667; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GUNDERSEN GG, 1989, J CELL BIOL, V109, P2275, DOI 10.1083/jcb.109.5.2275; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Isfort RJ, 2002, J CHROMATOGR B, V769, P323, DOI 10.1016/S1570-0232(02)00021-1; Isfort RJ, 2002, PROTEOMICS, V2, P543, DOI 10.1002/1615-9861(200205)2:5<543::AID-PROT543>3.0.CO;2-K; Isfort RJ, 2000, ELECTROPHORESIS, V21, P2228, DOI 10.1002/1522-2683(20000601)21:11<2228::AID-ELPS2228>3.0.CO;2-V; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; LETERME D, 1994, PFLUG ARCH EUR J PHY, V429, P274, DOI 10.1007/BF00374323; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOUGHNA P, 1986, J APPL PHYSIOL, V61, P173, DOI 10.1152/jappl.1986.61.1.173; McElhinny AS, 2004, J CELL SCI, V117, P3175, DOI 10.1242/jcs.01158; McKoy G, 1999, J PHYSIOL-LONDON, V516, P583, DOI 10.1111/j.1469-7793.1999.0583v.x; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MOREY ER, 1979, BIOSCIENCE, V29, P168, DOI 10.2307/1307797; Mounier N, 2002, CELL STRESS CHAPERON, V7, P167, DOI 10.1379/1466-1268(2002)007<0167:ACASHS>2.0.CO;2; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03-0419fje; OTEY CA, 1988, CELL MOTIL CYTOSKEL, V9, P337, DOI 10.1002/cm.970090406; Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Perng MD, 1999, J CELL SCI, V112, P2099; Putnam AJ, 2003, AM J PHYSIOL-CELL PH, V284, pC627, DOI 10.1152/ajpcell.00137.2002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; Stromer MH, 1998, HISTOL HISTOPATHOL, V13, P283, DOI 10.14670/HH-13.283; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; TSUTSUI H, 1994, CIRCULATION, V90, P533, DOI 10.1161/01.CIR.90.1.533; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; Yoshioka M, 2003, FASEB J, V17, P1812, DOI 10.1096/fj.02-1200com	48	47	53	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2005	19	7					1199	+		10.1096/fj.04-3060fje	http://dx.doi.org/10.1096/fj.04-3060fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15894563				2022-12-25	WOS:000229602600014
J	Andi, B; Cook, PF				Andi, B; Cook, PF			Regulatory mechanism of histidine-tagged homocitrate synthase from Saccharomyces cerevisiae - II. Theory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME-CATALYZED REACTIONS; LYSINE	In this study, rate equations that predict the regulatory kinetic behavior of homocitrate synthase were derived, and simulation of the predicted behavior was carried out over a range of values for the kinetic parameters. The data obtained allow application of the resulting expressions to enzyme systems that exhibit activation and inhibition as a result of the interaction of effectors at multiple sites in the free enzyme. Homocitrate synthase was used as an example in terms of its activation by Na+ binding to the active enzyme conformer at an allosteric site, inhibition by binding to the active site, and inhibition by lysine binding to the less active enzyme conformer.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Cook, PF (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	pcook@chemdept.chem.ou.edu		Andi, Babak/0000-0002-7666-639X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 071417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andi B, 2005, J BIOL CHEM, V280, P31624, DOI 10.1074/jbc.M502846200; Andi B, 2004, BIOCHEMISTRY-US, V43, P11790, DOI 10.1021/bi048766p; Andi B, 2004, ARCH BIOCHEM BIOPHYS, V421, P243, DOI 10.1016/j.abb.2003.11.005; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BHATTACHARJEE JK, 1992, EVOLUTION METABOLIC, P47; CHA S, 1968, J BIOL CHEM, V243, P820; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; Ramos F, 1996, YEAST, V12, P1315, DOI 10.1002/(SICI)1097-0061(199610)12:13<1315::AID-YEA20>3.3.CO;2-H; TRACY JW, 1975, P NATL ACAD SCI USA, V72, P1802, DOI 10.1073/pnas.72.5.1802; UMBARGER HE, 1987, ANNU REV BIOCHEM, V47, P532; VOGEL HJ, 1960, BIOCHIM BIOPHYS ACTA, V41, P172, DOI 10.1016/0006-3002(60)90392-9	11	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31633	31640		10.1074/jbc.M502847200	http://dx.doi.org/10.1074/jbc.M502847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	15897191	hybrid			2022-12-25	WOS:000231665200038
J	Li, JP; Wang, EF; Rinaldo, F; Datta, K				Li, JP; Wang, EF; Rinaldo, F; Datta, K			Upregulation of VEGF-C by androgen depletion: the involvement of IGFIR-FOXO pathway	ONCOGENE			English	Article						VEGF-C; prostate cancer; metastasis; androgen; IGF-IR	ENDOTHELIAL-GROWTH-FACTOR; LYMPH-NODE METASTASIS; REFRACTORY PROSTATE-CANCER; FACTOR RECEPTOR-3; TRANSCRIPTION FACTORS; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; TYROSINE KINASES; FAMILY-MEMBER; CELL-DEATH	Androgen ablation therapy is eventually followed by a more metastatic and androgen-refractory stage of prostate cancer. The detailed molecular mechanism of this gradual transition is not clearly understood. Recent reports correlate the high abundance of vascular endothelial growth factor-C (VEGF-C) to the lymph node metastasis seen in human prostate cancer (Tsurusaki et al., 1999). In this study, we report that androgen ablation in LNCaP cells augment the transcriptional upregulation of VEGF-C and the downregulation of the IGF-IR pathway, due to androgen withdrawal, is a potential mechanism for this observed VEGF-C transcription. Forkhead transcription factor FOXO-1, activated by SIRT-1, was identified as the downstream molecule within this pathway. Furthermore, the VEGF-C-induced increase of Bag-IL expression in LNCaP cells suggests that VEGF-C plays a role in the androgen-independent reactivation of the androgen receptor, resulting in androgen-refractory prostate cancer growth.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Datta, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,Gugg 1401B, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu			NCHHSTP CDC HHS [1 PSOCA91956-3] Funding Source: Medline	NCHHSTP CDC HHS		Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Arnold JT, 2005, AM J PHYSIOL-ENDOC M, V288, pE573, DOI 10.1152/ajpendo.00454.2004; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Clarijs R, 2001, INVEST OPHTH VIS SCI, V42, P1422; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; DeMeyts P, 1995, ANN NY ACAD SCI, V766, P388, DOI 10.1111/j.1749-6632.1995.tb26688.x; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145; Hashimoto I, 2001, BRIT J CANCER, V85, P93, DOI 10.1054/bjoc.2001.1846; HATVA E, 1995, AM J PATHOL, V146, P368; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kang HY, 2004, J BONE MINER RES, V19, P1181, DOI 10.1359/JBMR.040306; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; Kimura Y, 2003, ONCOL REP, V10, P1747; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kubo H, 2000, BLOOD, V96, P546; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Nicholson B, 2004, J CELL BIOCHEM, V91, P125, DOI 10.1002/jcb.10772; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olofsson B, 1999, CURR OPIN BIOTECH, V10, P528, DOI 10.1016/S0958-1669(99)00024-5; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033; Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095; Tang YC, 2003, CANCER RES, V63, P1166; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Veikkola T, 2000, CANCER RES, V60, P203; Wang Zhong-liang, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P47; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zeng YP, 2004, CLIN CANCER RES, V10, P5137, DOI 10.1158/1078-0432.CCR-03-0434	70	49	51	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5510	5520		10.1038/sj.onc.1208693	http://dx.doi.org/10.1038/sj.onc.1208693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15897888				2022-12-25	WOS:000231222300011
J	Hsu, HL; Shi, B; Gartenhaus, RB				Hsu, HL; Shi, B; Gartenhaus, RB			The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells	ONCOGENE			English	Article						transformation; cell cycle	DOUBLE-STRAND BREAKS; HISTONE H2AX; GENOMIC INSTABILITY; CANDIDATE ONCOGENE; IONIZING-RADIATION; PROTEIN 53BP1; DNA-DAMAGE; ATM; PHOSPHORYLATION; ACTIVATION	Multiple copies in T-cell maligancy (MCT-1) is a putative oncogene initially identified in a human T-cell lymphoma. Forced expression of MCT-1 has recently been shown to induce cell transformation and proliferation, as well as to activate survival-related PI-3K/AKT pathways protecting cells from apoptosis. MCT-1 protein is stabilized in response to DNA damage. The impact of MCT-1 overexpression on DNA damage response remains unknown. Here, we show that MCT-1 deregulates cell cycle checkpoints. The phosphorylation of genomic stabilizers H2AX and NBS1 are enhanced in MCT-1-overexpressing cells. Forced expression of MCT-1 significantly increases the number of DNA damage-induced foci involving gamma-H2AX and 53BP1. In MCT-1-overexpressing cells, the proportion of S-phase cell population is preferentially increased after exposure to gamma-irradiation compared to controls. Knockdown of endogenous MCT-1 using an siRNA approach attenuates the H2AX phosphorylation and the G1/S checkpoint defect. Furthermore, MCT-1 is capable of transforming immortalized human mammary epithelial cells and promoting genomic instability. These data shed light on the role of MCT-1 in the cellular response to DNA damage and its involvement in malignant transformation.				rgartenhaus@som.umaryland.edu	Hsu, Hsin-Ling/E-3672-2010	Shi, Bo/0000-0002-0780-0372				Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Prosniak M, 1998, CANCER RES, V58, P4233; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200	26	33	34	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4956	4964		10.1038/sj.onc.1208680	http://dx.doi.org/10.1038/sj.onc.1208680			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897892				2022-12-25	WOS:000230646500008
J	Grassme, H; Riehle, A; Wilker, B; Gulbins, E				Grassme, H; Riehle, A; Wilker, B; Gulbins, E			Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICYCLIC ANTIDEPRESSANT DESIPRAMINE; ACID SPHINGOMYELINASE; INDUCED APOPTOSIS; RAFTS; RECEPTOR; ENTRY; FAS; MECHANISMS; PATHWAY; VIRUS	The cell membrane contains very small distinct membrane domains enriched of sphingomyelin and cholesterol that are named rafts. We have shown that the formation of ceramide via activation of the acid sphingomyelinase transforms rafts into ceramide-enriched membrane platforms. These platforms are required for infection of mammalian cells with Pseudomonas aeruginosa, Staphylococcus aureus, or Neisseriae gonorrhoeae. In the present study we determined whether the acid sphingomyelinase, ceramide, and ceramide-enriched membrane platforms are also involved in the infection of human cells with pathogenic rhinoviruses. We demonstrate that infection of human epithelial cells with several rhinovirus strains triggers a rapid activation of the acid sphingomyelinase correlating with microtubules- and microfilament-mediated translocation of the enzyme from an intracellular compartment onto the extracellular leaflet of the cell membrane. The activity of the acid sphingomyelinase results in the formation of ceramide in the cell membrane and, finally, large ceramide-enriched membrane platforms. Rhinoviruses colocalize with ceramide-enriched membrane platforms during the infection. The significance of ceramide-enriched membrane platforms for rhinoviral uptake is demonstrated by the finding that genetic deficiency or pharmacological inhibition of the acid sphingomyelinase prevented infection of human epithelial cells by rhinoviruses. The data identify the acid sphingomyelinase and ceramide as key molecules for the infection of human cells with rhinoviruses.	Univ Duisberg Essen, Dept Mol Biol, D-45122 Essen, Germany	University of Duisburg Essen	Gulbins, E (corresponding author), Univ Duisberg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Snyers L, 2003, J VIROL, V77, P5360, DOI 10.1128/JVI.77.9.5360-5369.2003; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	35	155	162	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2005	280	28					26256	26262		10.1074/jbc.M500835200	http://dx.doi.org/10.1074/jbc.M500835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	943WT	15888438	hybrid			2022-12-25	WOS:000230386800041
J	Lee, PCW; Sever, N; DeBose-Boyd, RA				Lee, PCW; Sever, N; DeBose-Boyd, RA			Isolation of sterol-resistant Chinese hamster ovary cells with genetic deficiencies in both Insig-1 and Insig-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; COENZYME-A REDUCTASE; HMG COA REDUCTASE; SENSING DOMAIN; FEEDBACK-REGULATION; COMPETITIVE INHIBITOR; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; LIPID-SYNTHESIS	Insig-1 and Insig-2, a pair of endoplasmic reticulum (ER) membrane proteins, mediate feedback control of cholesterol synthesis through their sterol-dependent binding to the following two polytopic ER membrane proteins: sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Sterol-induced binding of Insigs to SCAP prevents the proteolytic processing of SREBPs, membrane-bound transcription factors that enhance the synthesis of cholesterol, by retaining complexes between SCAP and SREBP in the ER. Sterol-induced binding of Insigs to reductase leads to the ubiquitination and ER-associated degradation of the enzyme, thereby slowing a rate-controlling step in cholesterol synthesis. Here we report the isolation of a new line of mutant Chinese hamster ovary cells, designated SRD-15, deficient in both Insig-1 and Insig-2. The SRD-15 cells were produced by gamma-irradiation of Insig-1 deficient SRD-14 cells, followed by selection in high levels of the oxysterol, 25-hydroxycholesterol. Sterols neither inhibit SREBP processing nor promote reductase ubiquitination/degradation in SRD-15 cells. Sterol regulation of SREBP processing and reductase ubiquitination/degradation is fully restored in SRD-15 cells when they are transfected with expression plasmids encoding either Insig-1 or Insig-2. These results demonstrate an absolute requirement for Insig proteins in the regulatory system that mediates lipid homeostasis in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeBose-Boyd, RA (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	Russell.DeBose-Boyd@utsouthwestern.edu	Sever, Navdar/AAB-7906-2022	Sever, Navdar/0000-0001-9462-7979	NHLBI NIH HHS [HL70441, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL070441, P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J LIPID RES, V21, P505; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1983, J BIOL CHEM, V258, P8450; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	32	57	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					25242	25249		10.1074/jbc.M502989200	http://dx.doi.org/10.1074/jbc.M502989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866869	hybrid			2022-12-25	WOS:000230114000110
J	Li, CH; Salvucci, ME; Portis, AR				Li, CH; Salvucci, ME; Portis, AR			Two residues of rubisco activase involved in recognition of the rubisco substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; ARABIDOPSIS-THALIANA; SUBUNIT INTERACTIONS; ATP HYDROLYSIS; ANTISENSE RNA; PHOTOSYNTHESIS; CHAPERONE; ATPASES; CARBAMYLATION	Rubisco activase is an AAA(+) protein, a superfamily with members that use a "Sensor 2" domain for substrate recognition. To determine whether the analogous domain of activase is involved in recognition of ribulose-1,5- bisphosphate carboxylase/oxygenase ( Rubisco, EC 4.1.1.39), two chimeric activases were constructed, interchanging a Sensor 2-containing region between activases from spinach and tobacco. Spinach chimeric activase was a poor activator of both spinach and tobacco Rubisco. In contrast, tobacco chimeric activase activated spinach Rubisco far better than tobacco Rubisco, similar to spinach activase. A point mutation, K311D, in the Sensor 2 domain of the tobacco chimeric activase abolished its ability to better activate spinach Rubisco. The opposite mutation, D311K, in wild type tobacco activase produced an enzyme that activated both spinach and tobacco Rubisco, whereas a second mutation, D311K/L314V, shifted the activation preference toward spinach Rubisco. The involvement of these two residues in substrate selectivity was confirmed by introducing the analogous single and double mutations in cotton activase. The ability of the two tobacco activase mutants to activate wild type and mutant Chlamydomonas Rubiscos was also examined. Tobacco D311K activase readily activated wild type and P89R but not D94K Rubisco, whereas the tobacco L314V activase only activated D94K Rubisco. The tobacco activase double mutant D311K/L314V activated wild type Chlamydomonas Rubisco better than either the P89R or D94K Rubisco mutants, mimicking activation by spinach activase. The results identified a substrate recognition region in activase in which two residues may directly interact with two residues in Rubisco.	USDA ARS, Photosynth Res Unit, Western Cotton Res Lab, Urbana, IL 61801 USA; Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; USDA ARS, Photosynth Res Unit, Urbana, IL 61801 USA	United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Portis, AR (corresponding author), USDA ARS, Photosynth Res Unit, Western Cotton Res Lab, Urbana, IL 61801 USA.	arportis@uiuc.edu						BUTZ ND, 1989, PLANT PHYSIOL, V89, P735, DOI 10.1104/pp.89.3.735; Crafts-Brandner SJ, 2000, P NATL ACAD SCI USA, V97, P13430, DOI 10.1073/pnas.230451497; DEJIMENEZ ES, 1995, BIOCHEMISTRY-US, V34, P2826, DOI 10.1021/bi00009a012; Duff AP, 2000, J MOL BIOL, V298, P903, DOI 10.1006/jmbi.2000.3724; Eckardt NA, 1997, PLANT PHYSIOL, V113, P575, DOI 10.1104/pp.113.2.575; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; Esau BD, 1998, PHOTOSYNTH RES, V58, P175, DOI 10.1023/A:1006133212261; Esau BD, 1996, ARCH BIOCHEM BIOPHYS, V326, P100, DOI 10.1006/abbi.1996.0052; Larson EM, 1997, J BIOL CHEM, V272, P17033, DOI 10.1074/jbc.272.27.17033; Lilley RM, 1997, PLANT PHYSIOL, V114, P605, DOI 10.1104/pp.114.2.605; MATE CJ, 1993, PLANT PHYSIOL, V102, P1119, DOI 10.1104/pp.102.4.1119; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ogura T, 2004, J STRUCT BIOL, V146, P106, DOI 10.1016/j.jsb.2003.11.008; Ott CM, 2000, J BIOL CHEM, V275, P26241, DOI 10.1074/jbc.M004580200; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Portis AR, 2003, PHOTOSYNTH RES, V75, P11, DOI 10.1023/A:1022458108678; ROBINSON SP, 1988, PLANT PHYSIOL, V88, P1008, DOI 10.1104/pp.88.4.1008; SALVUCCI ME, 1992, ARCH BIOCHEM BIOPHYS, V298, P688, DOI 10.1016/0003-9861(92)90467-B; Salvucci ME, 1996, PHOTOSYNTH RES, V47, P1, DOI 10.1007/BF00017748; Salvucci ME, 2004, PLANT PHYSIOL, V134, P1460, DOI 10.1104/pp.103.038323; Salvucci ME, 2003, PLANTA, V216, P736, DOI 10.1007/s00425-002-0923-1; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; SOMERVILLE CR, 1982, PLANT PHYSIOL, V70, P381, DOI 10.1104/pp.70.2.381; vandeLoo FJ, 1996, BIOCHEMISTRY-US, V35, P8143, DOI 10.1021/bi9604901; von Caemmerer S, 2005, PLANT PHYSIOL, V137, P747, DOI 10.1104/pp.104.056077; WANG ZY, 1992, PLANT PHYSIOL, V99, P1348, DOI 10.1104/pp.99.4.1348; WANG ZY, 1992, PLANT PHYSIOL, V100, P1858, DOI 10.1104/pp.100.4.1858; WANG ZY, 1993, BIOCHIM BIOPHYS ACTA, V1202, P47, DOI 10.1016/0167-4838(93)90061-U; WERNEKE JM, 1988, PLANT PHYSIOL, V87, P917, DOI 10.1104/pp.87.4.917; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; Wickner S, 1999, P NATL ACAD SCI USA, V96, P8318, DOI 10.1073/pnas.96.15.8318; YOKOTA A, 1992, EUR J BIOCHEM, V204, P901, DOI 10.1111/j.1432-1033.1992.tb16710.x; Zhang N, 1999, P NATL ACAD SCI USA, V96, P9438, DOI 10.1073/pnas.96.16.9438; Zhang N, 2002, P NATL ACAD SCI USA, V99, P3330, DOI 10.1073/pnas.042529999; Zhang ZL, 2000, J BIOCHEM-TOKYO, V128, P383, DOI 10.1093/oxfordjournals.jbchem.a022765	37	42	44	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 1	2005	280	26					24864	24869		10.1074/jbc.M503547200	http://dx.doi.org/10.1074/jbc.M503547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	939ZT	15866868	hybrid			2022-12-25	WOS:000230114000069
J	Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N				Radhika, V; Ha, JH; Jayaraman, M; Tsim, ST; Dhanasekaran, N			Mitogenic signaling by lysophosphatidic acid (LPA) involves G alpha(12)	ONCOGENE			English	Article						G protein; LPA; G alpha(13); cell-proliferation; oncogene; transformation	INDUCED CELL-PROLIFERATION; PROTEIN-COUPLED RECEPTORS; OVARIAN-CANCER CELLS; N-TERMINAL KINASE; NEURITE RETRACTION; G(12) FAMILY; 3T3 CELLS; ACTIVATION; IDENTIFICATION; TRANSFORMATION	Lysophosphatidic acid (LPA), a major G protein coupled receptor(GPCR)-activating ligand present in serum, elicits growth factor like responses by stimulating specific GPCRs coupled to heterotrimeric G proteins such as G(i), G(q), and G(12/13). Previous studies have shown that the overexpression of wild-type G alpha(12) (G alpha 12WT) results in the oncogenic transformation of NIH3T3 cells (G alpha 12WT-NIH3T3) in a serum-dependent manner. Based on the potent growth-stimulating activity of LPA and the presence of LPA and LPA-like molecules in the serum, we hypothesized that the serum-dependent neoplastic transformation of G alpha 12WT-NIH3T3 cells was mediated by the stimulation of LPA-receptors (LPARs) by LPA in the serum. In the present study, using guanine nucleotide exchange assay and GST-TPR binding assay, we show that the treatment of G alpha 12WT-NIH3T3 with 2 mu M LPA leads to the activation of G alpha(12). Stimulation of these cells with LPA promotes JNK-activation, a critical component of G alpha(12)-response and cell proliferation. We also show that LPA can substitute for serum in stimulating JNK-activity, DNA synthesis, and proliferation of G alpha 12WT-NIH3T3 cells. LPA-mediated proliferative response in NIH3T3 cells involves G alpha(12), but not the closely related G alpha(13). Pretreatment of G alpha 12WT-NIH3T3 cells with suramin (100 mu M), a receptor-uncoupling agent, inhibited LPA-stimulated proliferation of these cells by 55% demonstrating the signal coupling between cell surface LPAR and Ga-12 in the neoplastic proliferation of NIH3T3 cells. As LPA and LPAR mediated mitogenic pathways have been shown to play a major role in tumor genesis and progression, a mechanistic understanding of the signal coupling between LPAR, Ga-12, and the downstream effectors is likely to unravel additional targets for novel cancer chemotherapies.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu	Jayaraman, Muralidharan/H-8563-2019	Jayaraman, Muralidharan/0000-0003-3274-877X; HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Barr AJ, 1997, J BIOL CHEM, V272, P2223; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 1998, MOL PHARMACOL, V54, P979, DOI 10.1124/mol.54.6.979; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Furui T, 1999, CLIN CANCER RES, V5, P4308; Goetzl EJ, 1999, CANCER RES, V59, P5370; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P70, DOI 10.1016/S1388-1981(02)00138-5; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Windh RT, 2002, METHOD ENZYMOL, V344, P3; WONG YH, 1995, ONCOGENE, V10, P1927; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yuan JZ, 2003, J BIOL CHEM, V278, P4882, DOI 10.1074/jbc.M211175200	42	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4597	4603		10.1038/sj.onc.1208665	http://dx.doi.org/10.1038/sj.onc.1208665			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856019				2022-12-25	WOS:000230157100014
J	Park, WH; Margossian, S; Horwitz, AA; Simons, AM; D'Andrea, AD; Parvin, JD				Park, WH; Margossian, S; Horwitz, AA; Simons, AM; D'Andrea, AD; Parvin, JD			Direct DNA binding activity of the Fanconi anemia D2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; BRANCH MIGRATION; FANCD2; BRCA2; DEFICIENT; GENE; MONOUBIQUITINATION; RECOMBINATION; BRCA2/FANCD1; INSTABILITY	It is known that the Fanconi anemia D2 protein is vital for protecting the genome from DNA damage, but what activities this protein has are unknown. In these experiments we purified full-length Fanconi anemia protein D2 (FANCD2), and we found that FANCD2 bound to DNA with specificity for certain structures: double strand DNA ends and Holliday junctions. Proteins containing patient-derived mutations or artificial variants of the FANCD2 protein were similarly expressed and purified, and each variant bound to the Holliday junction DNA with similar affinity as did the wild-type protein. There was no single discrete domain of FANCD2 protein that bound to DNA, but rather the full-length protein was required for structure-specific DNA binding. This finding of DNA binding is the first biochemical activity identified for this key protein in the Fanconi anemia pathway.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	JParvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER; NCI NIH HHS [CA090281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1989, BLOOD, V73, P391; Bagby GC, 2003, CURR OPIN HEMATOL, V10, P68, DOI 10.1097/00062752-200301000-00011; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou Angelos, 2004, Methods Mol Biol, V262, P239; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Oca RM, 2005, BLOOD, V105, P1003, DOI 10.1182/blood-2003-11-3997; Donahue SL, 2004, NUCLEIC ACIDS RES, V32, P3248, DOI 10.1093/nar/gkh649; Donahue SL, 2002, J BIOL CHEM, V277, P46243, DOI 10.1074/jbc.M207937200; Escarceller M, 1997, SOMAT CELL MOLEC GEN, V23, P401, DOI 10.1007/BF02673750; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Hirsch B, 2004, BLOOD, V103, P2554, DOI 10.1182/blood-2003-06-1970; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; KWEE ML, 1983, HUM GENET, V64, P384, DOI 10.1007/BF00292372; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Lundberg R, 2001, J BIOL CHEM, V276, P9543, DOI 10.1074/jbc.M008634200; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pfeiffer P, 2004, CYTOGENET GENOME RES, V104, P7, DOI 10.1159/000077460; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van den Bosch M, 2002, BIOL CHEM, V383, P873; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005	39	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2005	280	25					23593	23598		10.1074/jbc.M503730200	http://dx.doi.org/10.1074/jbc.M503730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	936UD	15849361	hybrid, Green Published			2022-12-25	WOS:000229880000024
J	Bao, XF; Pavao, MSG; dos Santos, JC; Sugahara, K				Bao, XF; Pavao, MSG; dos Santos, JC; Sugahara, K			A functional dermatan sulfate epitope containing iduronate(2-O-sulfate) alpha 1-3GalNAc(6-O-sulfate) disaccharide in the mouse brain - Demonstration using a novel monoclonal antibody raised against dermatan sulfate of ascidian Ascidia nigra	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING GROWTH-FACTOR; OUTGROWTH-PROMOTING ACTIVITY; EMBRYONIC PIG BRAIN; CHONDROITIN-SULFATE; NEURITE OUTGROWTH; HYBRID CHAINS; ZETA/RPTP-BETA; HIGH-AFFINITY; NEURITOGENIC ACTIVITY; NEUROTROPHIC FACTORS	Oversulfated chondroitin sulfate (CS), dermatan sulfate (DS), and CS/DS hybrid structures bind growth factors, promote the neurite outgrowth of hippocampal neurons in vitro, and have been implicated in the development of the brain. To investigate the expression of functional oversulfated DS structures in the brain, a novel monoclonal antibody (mAb), 2A12, was generated against DS (An-DS) from ascidian Ascidia nigra, which contains a unique iD disaccharide unit, iduronic acid (2-O-sulfate) alpha 1 -> 3GalNAc(6-O-sulfate), as a predominant disaccharide. mAb 2A12 specifically reacted with the immunogen, and recognized iD-enriched decasaccharides as minimal structures. The 2A12 epitope was specifically observed in the hippocampus and cerebellum of the mouse brain on postnatal day 7, and the expression in the cerebellum disappeared in the adult brain, suggesting a spatiotemporally regulated expression of this epitope. Embryonic hippocampal neurons were immunopositive for 2A12, and the addition of the antibody to the culture medium significantly reduced the neurite growth of hippocampal neurons. In addition, two minimum 2A12-reactive decasaccharide sequences with multiple consecutive iD units were isolated from the An-DS chains, which exhibited stronger inhibitory activity against the binding of various growth factors and neurotrophic factors to immobilized embryonic pig brain CS/DS chains (E-CS/DS) than the intact E-CS/DS, suggesting that the 2A12 epitope at the neuronal surface acts as a receptor or co-receptor for these molecules. Thus, we have selected a unique antibody that recognizes iD-enriched oversulfated DS structures, which are implicated in the development of the hippocampus and cerebellum in the central nervous system. The antibody will also be applicable for investigating structural alterations in CS/DS in aging and pathological conditions.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Lab Tecido Conjuntivo, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Programa Glicobiol, Inst Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Kobe Pharmaceutical University; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1,Motoyama Kita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Pavao, Mauro Sergio Goncalves/B-1979-2010	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271	FOGARTY INTERNATIONAL CENTER [R03TW005775] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW05775] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Barnett MW, 2002, J CELL SCI, V115, P4495, DOI 10.1242/jcs.00114; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Catlow K, 2003, BIOCHEM SOC T, V31, P352, DOI 10.1042/BST0310352; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; ITO Y, 2005, IN PRESS GLYCOBIOLOG; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; KJELLEN L, 1991, ANNU REV BIOCHEM, V47, P385; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nandini CD, 2005, J BIOL CHEM, V280, P4058, DOI 10.1074/jbc.M412074200; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RHOMBERG AJ, 1997, LAB GUIDE GLYCOCONJU, P77; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SAITO H, 1968, J BIOL CHEM, V243, P1536; Schwartz NB, 2004, GLYCOCONJUGATE J, V21, P329, DOI 10.1023/B:GLYC.0000046278.34016.36; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Tiedemann K, 2001, ARCH BIOCHEM BIOPHYS, V391, P65, DOI 10.1006/abbi.2001.2376; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Wilson MT, 2000, J COMP NEUROL, V424, P532, DOI 10.1002/1096-9861(20000828)424:3<532::AID-CNE10>3.0.CO;2-Z; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; Zhang JY, 2000, EUR J NEUROSCI, V12, P4171, DOI 10.1046/j.1460-9568.2000.01312.x; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	53	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 17	2005	280	24					23184	23193		10.1074/jbc.M503036200	http://dx.doi.org/10.1074/jbc.M503036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	934XB	15849184	hybrid			2022-12-25	WOS:000229741800076
J	Barnes, BR; Glnnd, S; Long, YC; Hjalm, G; Andersson, L; Zierath, JR				Barnes, BR; Glnnd, S; Long, YC; Hjalm, G; Andersson, L; Zierath, JR			5 '-AMP-activated protein kinase regulates skeletal muscle glycogen content and ergogenics	FASEB JOURNAL			English	Article						muscle ergogenics; AALPK activity; allosteric regulation; FDL; glycogen supercompensation	GLUCOSE-TRANSPORT; SYNTHASE ACTIVITY; EXERCISE; CONTRACTION; METABOLISM; RATS; ACTIVATION; ISOFORM; INSULIN; PHOSPHORYLATION	5'-AMP-activated protein kinase (AMPK) activity is increased during exercise in an intensity- and glycogen-dependent manner. We previously reported that a mutation in the AMPK gamma 3 subunit (prkag3(225Q)) increases AMPK activity and skeletal muscle glycogen content. Transfection experiments revealed the R225Q mutation is associated with high basal AMPK activity and diminished AMP dependence. Thus, the R225Q mutation can be considered a loss-of-function mutation that abolished allosteric regulation by AMP/ATP, causing increased basal AMPK activity. We used AMPK gamma 3 transgenic (Tg-Prkag3(225Q)) and knockout (Prkag3(-/-)) mice to determine the relationship between AMPK activity, glycogen content, and ergogenics (ability to perform work) in isolated extensor digitorum. longus skeletal muscle after contractions induced by electrical stimulation. Contraction-induced AMPK activity was inversely coupled to glycogen content in wild-type and Tg-Prkag3(225Q) mice, but not in Prkag3(-/-) mice, highlighting a partial feedback control of glycogen on contraction-induced AMPK activity in the presence of a functional AMPK gamma 3 isoform. Skeletal muscle glycogen content was positively correlated to work performance, regardless of genotype. Thus, chronic activation of AMPK by the Prkag-3(225Q) mutation directly influences skeletal muscle ergogenics by enhancing glycogen content. In conclusion, functional studies of the AAPK gamma 3 isoform further support the close connection between glycogen content and exercise performance in skeletal muscle.	Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Mol Biosci, Uppsala, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Swedish Univ Agr Sci, Dept Med Biochem & Microbiol, Uppsala, Sweden; Uppsala Univ, Uppsala Biomed Ctr, Swedish Univ Agr Sci, Dept Anim Breeding & Genet, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences; Uppsala University; Swedish University of Agricultural Sciences; Uppsala University	Zierath, JR (corresponding author), Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, Von Eulers Vag 4,4th Floor, S-17177 Stockholm, Sweden.	Juleen.Zierath@fyfa.ki.se		Zierath, Juleen/0000-0001-6891-7497				Barnes BR, 2002, DIABETES, V51, P2703, DOI 10.2337/diabetes.51.9.2703; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CONLEE RK, 1978, AM J PHYSIOL, V235, pR145, DOI 10.1152/ajpregu.1978.235.3.R145; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; Derave W, 2000, DIABETES, V49, P1281, DOI 10.2337/diabetes.49.8.1281; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; Fogt DL, 2004, AM J PHYSIOL-ENDOC M, V286, pE363, DOI 10.1152/ajpendo.00115.2003; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hutber CA, 1997, AM J PHYSIOL-ENDOC M, V272, pE262, DOI 10.1152/ajpendo.1997.272.2.E262; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Jorgensen SB, 2004, DIABETES, V53, P3074, DOI 10.2337/diabetes.53.12.3074; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Mu J, 2003, BIOCHEM SOC T, V31, P236, DOI 10.1042/bst0310236; Nielsen JN, 2004, P NUTR SOC, V63, P233, DOI 10.1079/PNS2004348; Nielsen JN, 2002, J PHYSIOL-LONDON, V541, P979, DOI 10.1113/jphysiol.2002.018044; Pascoe DD, 1996, SPORTS MED, V21, P98, DOI 10.2165/00007256-199621020-00003; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; SAHLIN K, 1978, ACTA PHYSIOL SCAND, V104, P370, DOI 10.1111/j.1748-1716.1978.tb06289.x; Song XM, 2002, DIABETOLOGIA, V45, P56, DOI 10.1007/s125-002-8245-8; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; Wojtaszewski JFP, 2003, BIOCHEM SOC T, V31, P1290; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; YOUNG DA, 1990, DIABETES, V39, P1408, DOI 10.2337/diabetes.39.11.1408	31	56	62	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2005	19	7					773	779		10.1096/fj.04-3221com	http://dx.doi.org/10.1096/fj.04-3221com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	933CU	15857891				2022-12-25	WOS:000229602600033
J	Sandona, D; Danieli-Betto, D; Germinario, E; Biral, D; Martinello, T; Lioy, A; Tarricone, E; Gastaldello, S; Betto, R				Sandona, D; Danieli-Betto, D; Germinario, E; Biral, D; Martinello, T; Lioy, A; Tarricone, E; Gastaldello, S; Betto, R			The T-tubule membrane ATP-operated P2X(4) receptor influences contractility of skeletal muscle	FASEB JOURNAL			English	Article						extracellular ATP signaling; ATP release; slow- and fast-twitch muscles; twitch potentiation; muscle fatigue	EXTRACELLULAR ATP; P2X(4) RECEPTOR; SARCOPLASMIC-RETICULUM; NUCLEOTIDE RECEPTORS; EXPRESSION; P2Y; ACTIVATION; ADENOSINE; CLONING; RELEASE	Evidence indicates that extracellular ATP may have relevant functions in skeletal muscle, even though the physiological role and distribution of specific signaling pathway elements are not well known. The present work shows that P2X(4) receptor, an extracellular ATP-regulated cell membrane channel permeable to Ca2+, is expressed in several tissues of the rat, including skeletal muscle. A specific antibody detected a protein band of similar to 60 kDa. Immunofluorescence demonstrated that P2X(4) has an intracellular localization, and confocal analysis revealed that the receptor colocalizes with the T-tubule membrane DHP receptor. Considering that the natural agonist of P2X(4) is ATP, we explored if changes of extracellular ATP levels could occur in contracting skeletal muscle to regulate the channel. In vitro experiments showed that substantial ATP is released and rapidly hydrolyzed after electrical stimulation of rat muscle fibers. Results show that the presence of ATP-degrading enzymes (hexokinase/apyrase), inhibitors of P2X receptors or Ca2+-free conditions, all abolished the progressive twitch tension potentiation produced in soleus muscle by low-frequency (0.05 Hz) stimulation. These data reveal that ATP-mediated Ca2+ entry, most likely through P2X(4) receptor, may play an important role in modulating the contractility of skeletal muscle.	CNR, Inst Neurosci, Lab Muscle Biol & Physiopathol, I-35121 Padua, Italy; Univ Padua, Dept Biomed & Expt Sci, I-35100 Padua, Italy; Univ Padua, Dept Human Anat & Physiol, I-35100 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Betto, R (corresponding author), CNR, Inst Neurosci, Lab Muscle Biol & Physiopathol, Viale G Colombo 3, I-35121 Padua, Italy.	romeo.betto@bio.unipd.it	Gastaldello, Stefano/AAM-6768-2020; sandona, dorianna/AAB-9480-2020; Gastaldello, Stefano/AAD-3788-2020	Gastaldello, Stefano/0000-0001-7369-8452; DANIELI, DANIELA/0000-0002-6186-8327; Martinello, Tiziana/0000-0002-5949-6261	NHLBI NIH HHS [HL63903] Funding Source: Medline; Telethon [1286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063903] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bogdanov Y, 1998, LIFE SCI, V62, P697, DOI 10.1016/S0024-3205(97)01168-5; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P341, DOI 10.1113/jphysiol.1994.sp020254; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; Carpenter D, 1999, NEUROSCI LETT, V273, P183, DOI 10.1016/S0304-3940(99)00653-9; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; Collet C, 2002, PFLUG ARCH EUR J PHY, V443, P771, DOI 10.1007/s00424-001-0758-9; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; CUNHA RA, 1993, PFLUG ARCH EUR J PHY, V424, P503, DOI 10.1007/BF00374914; Danieli-Betto D, 2000, J APPL PHYSIOL, V89, P891, DOI 10.1152/jappl.2000.89.3.891; Delgado J, 1997, BIOCHEM J, V327, P899, DOI 10.1042/bj3270899; Dhulipala PDK, 1998, GENE, V207, P259, DOI 10.1016/S0378-1119(97)00647-1; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Egan TM, 2004, J NEUROSCI, V24, P3413, DOI 10.1523/JNEUROSCI.5429-03.2004; FORRESTER T, 1972, J PHYSIOL-LONDON, V224, P611, DOI 10.1113/jphysiol.1972.sp009915; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; HENNING RH, 1993, BRIT J PHARMACOL, V110, P133, DOI 10.1111/j.1476-5381.1993.tb13782.x; Hong SJ, 1998, J NEUROPHYSIOL, V80, P2550, DOI 10.1152/jn.1998.80.5.2550; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Irwin W, 2002, J BIOL CHEM, V277, P12221, DOI 10.1074/jbc.M108938200; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kim MS, 2002, ARCH BIOCHEM BIOPHYS, V401, P205; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Le KT, 1998, J NEUROSCI, V18, P7152; LI CY, 1993, P NATL ACAD SCI USA, V90, P8264, DOI 10.1073/pnas.90.17.8264; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; MARGRETH A, 1993, BIOCHEM BIOPH RES CO, V197, P1303, DOI 10.1006/bbrc.1993.2619; Meyer MP, 1999, DEV DYNAM, V216, P442, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<442::AID-DVDY12>3.0.CO;2-Z; Michel AD, 1997, MOL PHARMACOL, V51, P524; Midrio M, 1997, PFLUG ARCH EUR J PHY, V434, P398, DOI 10.1007/s004240050413; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025; Ryten M, 2001, DEV DYNAM, V221, P331, DOI 10.1002/dvdy.1147; RYTEN M, 2004, FASEB J, V21, P163; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; Sandona D, 2004, BIOCHEM J, V381, P105, DOI 10.1042/BJ20031644; Schiaffino S, 2002, TRENDS PHARMACOL SCI, V23, P569, DOI 10.1016/S0165-6147(02)02111-9; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SEGUELA P, 1996, NEUROSCIENCE, V16, P448; Soto F, 2003, FEBS LETT, V533, P54, DOI 10.1016/S0014-5793(02)03751-1; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Townsend-Nicholson A, 1999, MOL BRAIN RES, V64, P246, DOI 10.1016/S0169-328X(98)00328-3; Urano T, 1997, CANCER RES, V57, P3281; Vizi ES, 2000, J AUTONOM NERV SYST, V81, P278, DOI 10.1016/S0165-1838(00)00129-6; Wells DG, 1995, DEV BIOL, V172, P585, DOI 10.1006/dbio.1995.8062; Yang A, 2004, AM J PHYSIOL-HEART C, V287, pH1096, DOI 10.1152/ajpheart.00079.2004; Zhong Y, 1998, BRIT J PHARMACOL, V125, P771, DOI 10.1038/sj.bjp.0702118; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	61	36	40	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1184	+		10.1096/fj.04-3333fje	http://dx.doi.org/10.1096/fj.04-3333fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15857823				2022-12-25	WOS:000228865300007
J	Kim, K; Ren, J; Jiang, Y; Ebrahem, Q; Tipps, R; Cristina, K; Xiao, Y; Qiao, J; Taylor, KL; Lum, H; Anand-Apte, B; Xu, Y				Kim, K; Ren, J; Jiang, Y; Ebrahem, Q; Tipps, R; Cristina, K; Xiao, Y; Qiao, J; Taylor, KL; Lum, H; Anand-Apte, B; Xu, Y			GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine	FASEB JOURNAL			English	Article						angiogenesis; G protein coupled receptor; SPC	PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; LOW-DENSITY-LIPOPROTEIN; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; ACTIVATION; MIGRATION; LIGAND; APOPTOSIS; OVARIAN	Angiogenesis is critical for many physiological and pathological processes. We show here that the lipid sphingosylphosphorylcholine (SPC) induces angiogenesis in vivo and GPR4 is required for the biological effects of SPC on endothelial cells (EC). In human umbilical vein EC, down-regulation of GPR4 specifically inhibits SPC-, but not sphingosine-1-phosphate-, or vascular endothelial growth factor (VEGF)-induced tube formation. Re-introduction of GPR4 fully restores the activity of SPC. In microvascular EC, GPR4 plays a pivotal role in cell survival, growth, migration, and tube formation through both SPC-dependent and -independent pathways. The biological effects resulting from SPC/GPR4 interactions involve the activation of both phosphatidylinositol-3 kinase and Akt. Moreover, the effects of SPC on EC require SPC induced trans-phosphorylation and activation of the VEGF receptor 2. These results identify SPC and its receptor, GPR4, as critical regulators of the angiogenic potential of EC.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA; Rush Univ, Med Ctr, Dept Pharmacol, Chicago, IL 60612 USA; Cleveland Clin Fdn, Ctr Drug Dev & Discovery, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Rush University; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org			NCI NIH HHS [R01-CA89228-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY016490] Funding Source: Medline; NHLBI NIH HHS [R01 HL68804-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089228] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY016490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ADES EW, 1992, J VIROL METHODS, V39, P83, DOI 10.1016/0166-0934(92)90127-Y; Baudhuin LM, 2003, FASEB J, V17, P341, DOI 10.1096/fj.03-0302fje; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; BERGER A, 1995, P NATL ACAD SCI USA, V92, P5885, DOI 10.1073/pnas.92.13.5885; Boguslawski G, 2000, BIOCHEM BIOPH RES CO, V272, P603, DOI 10.1006/bbrc.2000.2822; Boguslawski G, 2002, EXP CELL RES, V274, P264, DOI 10.1006/excr.2002.5472; BROOKS PC, 1999, METHODS MOL BIOL, V129; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Dart AM, 1999, CARDIOVASC RES, V43, P308, DOI 10.1016/S0008-6363(99)00150-9; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; Karman RJ, 1997, PROSTAG LEUKOTR ESS, V56, P345, DOI 10.1016/S0952-3278(97)90582-2; Kim JH, 2000, IUBMB LIFE, V50, P119, DOI 10.1080/713803698; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Lu J, 2002, J LIPID RES, V43, P463; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Lum H, 2003, AM J PHYSIOL-HEART C, V285, pH1786, DOI 10.1152/ajpheart.00359.2003; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; Niedernberg A, 2003, BRIT J PHARMACOL, V138, P481, DOI 10.1038/sj.bjp.0705055; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sin WC, 2004, ONCOGENE, V23, P6299, DOI 10.1038/sj.onc.1207838; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; STRASBERG PM, 1988, BIOCHEM CELL BIOL, V66, P1322, DOI 10.1139/o88-153; Sun LY, 1996, J INVEST DERMATOL, V106, P232, DOI 10.1111/1523-1747.ep12340570; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Zhong B, 2003, BLOOD, V101, P3240, DOI 10.1182/blood-2001-12-0180; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	46	57	66	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2005	19	2					819	+		10.1096/fj.04-2988fje	http://dx.doi.org/10.1096/fj.04-2988fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	905TE	15857892				2022-12-25	WOS:000227591900027
J	Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM				Layland, J; Cave, AC; Warren, C; Grieve, DJ; Sparks, E; Kentish, JC; Solaro, RJ; Shah, AM			Protection against endotoxemia-induced contractile dysfunction in mice with cardiac-specific expression of slow skeletal troponin I	FASEB JOURNAL			English	Article						myocardial contractility; myofilament Ca2+ responsiveness	CALCIUM SENSITIVITY; VENTRICULAR MYOCYTES; MYOFILAMENT RESPONSE; NITRIC-OXIDE; PHOSPHORYLATION; CA2+; RELAXATION; ACTIVATION; PROTEINS; HEARTS	Gram negative endotoxemia is associated with an intrinsic impairment of cardiomyocyte contraction, in part due to a reduction in myofilament Ca2+ responsiveness. Endotoxemic rat hearts show increased cardiac troponin I (cTnI) phosphorylation at serines 23 and 24, residues required for the protein kinase A (PKA)-dependent reduction of myofilament Ca2+ sensitivity after beta-adrenoceptor stimulation. To investigate the functional significance of increased TnI phosphorylation in endotoxemia, we studied the contractile effects of systemic bacterial lipopolysaccharide (LPS) treatment in transgenic mice (TG) with cardiac-specific replacement of cTnI by slow skeletal TnI (ssTnI, which lacks the PKA phosphorylation sites) and matched nontransgenic littermates (NTG) on a CD1 background. In wild-type CD1 mice treated with LPS (6 mg/kg ip), after 16-18 h there was a significant reduction in the maximum rates of left ventricular pressure development and pressure decline in isolated Langendorff-perfused hearts compared with saline-treated controls and a decrease in isolated myocyte unloaded sarcomere shortening from 6.1 +/- 0.2 to 3.9 +/- 0.2% (1 Hz, 32 degrees C, P<0.05). Similarly, in NTG myocytes, endotoxemia reduced myocyte shortening by 42% from 6.7 0.2 to 3.9 +/- 0.1% (P<0.05) with no change in intracellular Ca2+ transients. However, in the TG group, LPS reduced myocyte shortening by only 13% from 7.5 +/- 0.2 to 6.5 +/- 0.2% (P<0.05). LPS treatment significantly reduced the positive inotropic effect of isoproterenol in NTG myocytes but not in TG myocytes, even though isoproterenol-induced increases in Ca2+ transient amplitude were similar in both groups. Only LPS-treated NTG hearts showed a significant increase in cTnI phosphorylation. Investigation of the sarcomere shortening-Ca2+ relationship in Triton-skinned cardiomyocytes revealed a significant reduction in myofilament Ca2+ sensitivity after LPS treatment in NTG myocytes, an effect that was substantially attenuated in TG myocytes. In conclusion, the replacement of cTnI with ssTnI in the heart provides significant protection against endotoxemia-induced cardiac contractile dysfunction, most probably by preserving myofilament Ca2+ responsiveness due to prevention of phosphorylation of TnI at PKA-sensitive sites.	Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, London SE5 9PJ, England; Univ Illinois, Chicago, IL USA	University of London; King's College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Div Cardiovasc, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Warren, Gordon/A-9794-2008; Grieve, David/F-5035-2010	Warren, Gordon/0000-0002-7073-8524; Shah, Ajay/0000-0002-6547-0631	NHLBI NIH HHS [R37 HL-22231] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1985, J MOL CELL CARDIOL, V17, P821, DOI 10.1016/S0022-2828(85)80097-3; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Kaye DM, 1999, BIOCHEM BIOPH RES CO, V256, P398, DOI 10.1006/bbrc.1999.0346; KENTISH JC, 1991, PFLUG ARCH EUR J PHY, V419, P310, DOI 10.1007/BF00371112; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Khadour FH, 2002, AM J PHYSIOL-HEART C, V283, pH1108, DOI 10.1152/ajpheart.00549.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Layland J, 2002, J PHYSIOL-LONDON, V540, P457, DOI 10.1113/jphysiol.2001.014126; Layland J, 2004, J PHYSIOL-LONDON, V556, P835, DOI 10.1113/jphysiol.2004.061176; Lim CC, 2001, AM J PHYSIOL-HEART C, V281, pH969, DOI 10.1152/ajpheart.2001.281.2.H969; LINCOLN TM, 1978, J BIOL CHEM, V253, P337; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pena JR, 2004, CARDIOVASC RES, V61, P756, DOI 10.1016/j.cardiores.2003.12.019; PFITZER G, 1982, FEBS LETT, V149, P171, DOI 10.1016/0014-5793(82)81095-8; Powers FM, 1998, J MOL CELL CARDIOL, V30, P967, DOI 10.1006/jmcc.1998.0661; Rigby SL, 1998, AM J PHYSIOL-HEART C, V274, pH580, DOI 10.1152/ajpheart.1998.274.2.H580; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; SOLARO RJ, 2001, HDB PHYSL, P264; STAHL TJ, 1990, AM J PHYSIOL, V258, pH625, DOI 10.1152/ajpheart.1990.258.3.H625; Tavernier B, 2001, FASEB J, V15, P294, DOI 10.1096/fj.00-0433fje; Tavernier B, 2001, AM J RESP CRIT CARE, V163, P362, DOI 10.1164/ajrccm.163.2.2002128; Tavernier B, 1998, CARDIOVASC RES, V38, P472, DOI 10.1016/S0008-6363(98)00028-5; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wu LL, 2001, AM J PHYSIOL-REG I, V281, pR408, DOI 10.1152/ajpregu.2001.281.2.R408; Yasuda S, 1997, CIRC RES, V81, P1011; YATES LD, 1983, J MOL BIOL, V168, P123, DOI 10.1016/S0022-2836(83)80326-X; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; ZHONG JM, 1997, AM J PHYSIOL-HEART C, V273, pH2312	36	126	128	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2005	19	6					1137	+		10.1096/fj.04-2519fje	http://dx.doi.org/10.1096/fj.04-2519fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	922UP	15601671				2022-12-25	WOS:000228865300006
